PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Chapline, C; Cottom, J; Tobin, H; Hulmes, J; Crabb, J; Jaken, S				Chapline, C; Cottom, J; Tobin, H; Hulmes, J; Crabb, J; Jaken, S			A major, transformation-sensitive PKC-binding protein is also a PKC substrate involved in cytoskeletal remodeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C SUBSTRATE; RAT EMBRYO FIBROBLASTS; REF52 CELLS; IDENTIFICATION; FAMILY; SRC	Protein kinase C (PKC) plays a major role in regulating cell growth, transformation, and gene expression; however, identifying phosphorylation events that mediate these responses has been difficult. We expression-cloned a group of PKC-binding proteins and identified a high molecular weight, heat-soluble protein as the major PKC-binding protein in REF52 fibroblasts (Chapline, C., Mousseau, B., Ramsay, K., Duddy, S., Li, Y., Kiley, S. C., and Jaken, S. (1996) J. Biol. Chem. 271, 6417-6422). In this study, we demonstrate that this PKC-binding protein, clone 72, is also a PKC substrate in vitro and in vivo. Using a combination of phosphopeptide mapping, Edman degradation, and electrospray mass spectrometry, serine residues 283, 300, 507, and 515 were identified as the major in vitro PKC phosphorylation sites in clone 72. Phosphorylation state-selective antibodies were raised against phosphopeptides encompassing each of the four phosphorylation sites. These antibodies were used to determine that phorbol esters stimulate phosphorylation of serines 283, 300, 507, and 515 in cultured cells, indicating that clone 72 is directly phosphorylated by PKC in living cells. Phosphorylated clone 72 preferentially accumulates in membrane protrusions and ruffles, indicating that PKC activation and clone 72 phosphorylation are involved in membrane-cytoskeleton remodeling. These data lend further evidence to the model that PKCs directly interact with, phosphorylate, and modify the functions of a group of substrate proteins, STICKs (substrates that interact with C-kinase).	Adirondack Biomed Res Inst, Lake Placid, NY 12946 USA		Jaken, S (corresponding author), Adirondack Biomed Res Inst, 10 Old Barn Rd, Lake Placid, NY 12946 USA.				NCI NIH HHS [CA53841, CA/GM50152] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053841] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; BIEMANN K, 1990, METHOD ENZYMOL, V193, P886, DOI 10.1016/0076-6879(90)93460-3; CHAPLINE C, 1993, J BIOL CHEM, V268, P6858; Chapline C, 1996, J BIOL CHEM, V271, P6417, DOI 10.1074/jbc.271.11.6417; CRABB JW, 1991, J BIOL CHEM, V266, P16674; DONG LQ, 1995, J BIOL CHEM, V270, P25534, DOI 10.1074/jbc.270.43.25534; ESCRIBANO J, 1994, J CELL PHYSIOL, V160, P511, DOI 10.1002/jcp.1041600314; Fowler L, 1998, CELL GROWTH DIFFER, V9, P177; Fowler L, 1998, CELL GROWTH DIFFER, V9, P405; FUJISE A, 1994, J BIOL CHEM, V269, P31642; HUDDLESTON MJ, 1993, J AM SOC MASS SPECTR, V4, P710, DOI 10.1016/1044-0305(93)80049-5; HYATT SL, 1994, BIOCHEMISTRY-US, V33, P1223, DOI 10.1021/bi00171a023; HYATT SL, 1994, CELL GROWTH DIFFER, V5, P495; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; LIAO L, 1994, BIOCHEMISTRY-US, V33, P1229, DOI 10.1021/bi00171a024; Lin XY, 1997, CANCER RES, V57, P2304; Lin XY, 1996, J BIOL CHEM, V271, P28430, DOI 10.1074/jbc.271.45.28430; LIN XY, 1995, MOL CELL BIOL, V15, P2754; Mochly-Rosen D, 1998, FASEB J, V12, P35; Nauert JB, 1997, CURR BIOL, V7, P52, DOI 10.1016/S0960-9822(06)00027-3; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Staudinger J, 1997, J BIOL CHEM, V272, P32019, DOI 10.1074/jbc.272.51.32019; Wertz SL, 1996, BIOCHEMISTRY-US, V35, P11104, DOI 10.1021/bi961248x; West K.A., 1992, TXB APPL AUTOMATIC P, P233, DOI [10.1016/B978-0-12-058756-8.50029-8, DOI 10.1016/B978-0-12-058756-8.50029-8]	24	66	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19482	19489		10.1074/jbc.273.31.19482	http://dx.doi.org/10.1074/jbc.273.31.19482			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677369	hybrid			2022-12-25	WOS:000075125200021
J	Ordentlich, A; Barak, D; Kronman, C; Ariel, N; Segall, Y; Velan, B; Shafferman, A				Ordentlich, A; Barak, D; Kronman, C; Ariel, N; Segall, Y; Velan, B; Shafferman, A			Functional characteristics of the oxyanion hole in human acetylcholinesterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION-STATE; SUBSTRATE-SPECIFICITY; SERINE PROTEASES; SUBTILISIN BPN'; ANIONIC SITE; ACTIVE-SITE; RESIDUES; INHIBITION; BINDING; MUTAGENESIS	The contribution of the oxyanion hole to the functional architecture and to the hydrolytic efficiency of human acetylcholinesterase (HuAChE) was investigated through single replacements of its elements, residues Gly-121, Gly-122 and the adjacent residue Gly-120, by alanine, All three substitutions resulted in about 100-fold decrease of the bimolecular rate constants for hydrolysis of acetylthiocholine; however, whereas replacements of Gly-120 and Gly-121 affected only the turnover number, mutation of residue Gly-122 had an effect also on the Michaelis constant. The differential behavior of the G121A and G122A enzymes was manifested also toward the transition state analog m-(N,N,N-trimethylammonio)trifluoroacetophenone (TMTFA), organophosphorous inhibitors, carbamates, and toward selected noncovalent active center ligands, Reactivity of both mutants toward TMTFA was 2000-11,000-fold lower than that of the wild type HuAChE; however, the G121A enzyme exhibited a rapid inhibition pattern, as opposed to the slow binding kinetics shown by the G122A enzyme. For both phosphates (diethyl phosphorofluoridate, diisopropyl phosphorofluoridate, and paraoxon) and phosphonates (sarin and soman), the decrease in inhibitory activity toward the G121A enzyme was very substantial (2000-6700-fold), irrespective of size of the alkoxy substituents on the phosphorus atom, On the other hand, for the G122A HuAChE the relative decline in reactivity toward phosphonates (500-460-fold) differed from that toward the phosphates (12-95-fold). Although formation of Michaelis complexes with substrates does not seem to involve significant interaction with the oxyanion hole, interactions with this motif are a major stabilizing element in accommodation of covalent inhibitors like organophosphates or carbamates. These observations and molecular modeling suggest that replacements of residues Gly-120 or Gly-121 by alanine alter the structure of the oxyanion hole motif, abolishing the H-bonding capacity of residue at position 121. These mutations weaken the interaction between HuA-ChE and the various ligands by 2.7-5.0 kcal/mol. In contrast, variations in reactivity due to replacement of residue Gly-122 seem to result from steric hindrance at the active center acyl pocket.	Israel Inst Biol Res, Dept Biochem & Mol Biol, IL-70450 Ness Ziona, Israel; Israel Inst Biol Res, Dept Organ Chem, IL-70450 Ness Ziona, Israel		Shafferman, A (corresponding author), Israel Inst Biol Res, Dept Biochem & Mol Biol, IL-70450 Ness Ziona, Israel.							ALDRICH WN, 1972, ENZYME INHIBITORS SU, P245; ASHANI Y, 1994, MOL PHARMACOL, V45, P555; BARAK D, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P195; BARAK D, 1994, J BIOL CHEM, V269, P6296; BOURNE N, 1984, J AM CHEM SOC, V106, P7591, DOI 10.1021/ja00336a046; BRADY K, 1990, BIOCHEMISTRY-US, V29, P7608, DOI 10.1021/bi00485a010; BRAXTON S, 1991, J BIOL CHEM, V266, P11797; BRODBECK U, 1979, BIOCHIM BIOPHYS ACTA, V567, P357, DOI 10.1016/0005-2744(79)90122-0; CARTER P, 1990, PROTEINS, V7, P335, DOI 10.1002/prot.340070405; Cousin X, 1998, NUCLEIC ACIDS RES, V26, P226, DOI 10.1093/nar/26.1.226; Cygler M, 1997, METHOD ENZYMOL, V284, P3; DEREWENDA U, 1992, BIOCHEMISTRY-US, V31, P1532, DOI 10.1021/bi00120a034; DING XC, 1994, BIOCHEMISTRY-US, V33, P9285, DOI 10.1021/bi00197a032; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FORSBERG A, 1984, EUR J BIOCHEM, V140, P153, DOI 10.1111/j.1432-1033.1984.tb08079.x; Fuxreiter M, 1998, J AM CHEM SOC, V120, P183, DOI 10.1021/ja972326m; GERLT JA, 1993, BIOCHEMISTRY-US, V32, P11943, DOI 10.1021/bi00096a001; GIBNEY G, 1990, P NATL ACAD SCI USA, V87, P7546, DOI 10.1073/pnas.87.19.7546; GRAY PJ, 1987, TOXICOL APPL PHARM, V91, P140, DOI 10.1016/0041-008X(87)90201-8; GROCHULSKI P, 1994, BIOCHEMISTRY-US, V33, P3494, DOI 10.1021/bi00178a005; Harel M, 1996, J AM CHEM SOC, V118, P2340, DOI 10.1021/ja952232h; HAREL M, 1993, P NATL ACAD SCI USA, V90, P9031, DOI 10.1073/pnas.90.19.9031; HAREL M, 1992, P NATL ACAD SCI USA, V89, P10827, DOI 10.1073/pnas.89.22.10827; HENDERSON R, 1970, Journal of Molecular Biology, V54, P341, DOI 10.1016/0022-2836(70)90434-1; HOSEA NA, 1995, BIOCHEMISTRY-US, V34, P11528, DOI 10.1021/bi00036a028; JACKSON SE, 1993, BIOCHEMISTRY-US, V32, P13909, DOI 10.1021/bi00213a021; KEMP JR, 1990, TOXICOL APPL PHARM, V104, P264; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; KRONMAN C, 1992, GENE, V121, P29; LoewensteinLichtenstein Y, 1996, MOL PHARMACOL, V50, P1423; MASSOULLIE J, 1992, MULTIDISCIPLINARY AP, P286; MENARD R, 1992, BIOL CHEM H-S, V373, P393, DOI 10.1515/bchm3.1992.373.2.393; Millard CB, 1995, BIOCHEMISTRY-US, V34, P15925, DOI 10.1021/bi00049a007; Monard C., 1961, B SOC CHIM FR, P1084; NAIR HK, 1994, BIOCHEMISTRY-US, V33, P8566, DOI 10.1021/bi00194a023; NAIR HK, 1993, J AM CHEM SOC, V115, P9939, DOI 10.1021/ja00075a009; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Ordentlich A, 1996, J BIOL CHEM, V271, P11953, DOI 10.1074/jbc.271.20.11953; ORDENTLICH A, 1995, J BIOL CHEM, V270, P2082, DOI 10.1074/jbc.270.5.2082; ORDENTLICH A, 1993, J BIOL CHEM, V268, P17083; Raves ML, 1997, NAT STRUCT BIOL, V4, P57, DOI 10.1038/nsb0197-57; RICH DH, 1989, COMPUTER AIDED DRUG, P185; RYU SM, 1991, CHEM RES TOXICOL, V4, P517, DOI 10.1021/tx00023a004; SAUNDERS BC, 1948, J CHEM SOC, P695, DOI 10.1039/jr9480000695; SHAFFERMAN A, 1992, EMBO J, V11, P3561, DOI 10.1002/j.1460-2075.1992.tb05439.x; SHAFFERMAN A, 1992, J BIOL CHEM, V267, P17640; SOREQ H, 1990, P NATL ACAD SCI USA, V87, P9688, DOI 10.1073/pnas.87.24.9688; Stojan J, 1997, BBA-PROTEIN STRUCT M, V1337, P75, DOI 10.1016/S0167-4838(96)00154-9; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAYLOR P, 1994, ANNU REV PHARMACOL, V34, P281, DOI 10.1146/annurev.pa.34.040194.001433; VASILYEV VV, 1994, J MOL STRUC-THEOCHEM, V304, P129; VELAN B, 1991, J BIOL CHEM, V266, P23977; VELLOM DC, 1993, BIOCHEMISTRY-US, V32, P12, DOI 10.1021/bi00052a003; WARSHEL A, 1989, BIOCHEMISTRY-US, V28, P3629, DOI 10.1021/bi00435a001; WELLS JA, 1986, PHILOS T R SOC A, V317, P415, DOI 10.1098/rsta.1986.0051; Wlodek ST, 1997, J AM CHEM SOC, V119, P8159, DOI 10.1021/ja970395v	56	119	123	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19509	19517		10.1074/jbc.273.31.19509	http://dx.doi.org/10.1074/jbc.273.31.19509			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677373	hybrid			2022-12-25	WOS:000075125200025
J	Chandok, MR; Sopory, SK				Chandok, MR; Sopory, SK			ZmcPKC70, a protein kinase C-type enzyme from maize - Biochemical characterization, regulation by phorbol 12-myristate 13-acetate and its possible involvement in nitrate reductase gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; ESTER RECEPTOR; CALCIUM; PHOSPHORYLATION; CALMODULIN; PLANTS; DIACYLGLYCEROL; PURIFICATION; PROTOPLASTS	The crucial enzyme in diacylglycerol-mediated signaling is protein kinase C (PKC). In this paper we provide evidence for the existence and role of PKC in maize. A protein of an apparent molecular mass of 70 kDa was purified. The protein showed kinase activity that was stimulated by phosphatidylserine and oleyl acetyl glycerol (OAG) in the presence of Ca(2+). Phorbol 12-myristate 13-acetate (PMA) replaced the requirement of GAG. [(3)H]PMA. binding to the 70-kDa protein was competed by unlabeled PMA and OAG but not by 4 alpha-PMA, an inactive analog. The kinase phosphorylates histone H1 at serine residue(s), and this activity was inhibited by H-7 and staurosporine. These properties suggest that the 70-kDa protein is a conventional serine/threonine protein kinase C (cPKC). Polyclonal antibodies raised against the polypeptide precipitate the enzyme activity and immunostained the protein on Western blots. The antibodies also cross-reacted with a protein of expected size from sorghum, rice, and tobacco. A rapid increase in the protein level was observed in maize following PMA treatments. In order to assign a possible role of PKC in gene regulation, the nitrate reductase transcript level was investigated. The transcript level increased by PMA, not by 4 alpha-PMA treatments, and the increase wa.s inhibited by H-7 but not by okadaic acid. The data sham the existence and possible function of PKC in higher plants.	Jawaharlal Nehru Univ, Sch Life Sci, Ctr Plant Mol Biol, New Delhi 110067, India; Int Ctr Genet Engn & Biotechnol, New Delhi 110067, India	Jawaharlal Nehru University, New Delhi; Department of Biotechnology (DBT) India; International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB), New Delhi	Chandok, MR (corresponding author), Univ Munich, Inst Bot, Menzinger Str 67, D-80638 Munich, Germany.							ASAOKA Y, 1992, TRENDS BIOCHEM SCI, V17, P414, DOI 10.1016/0968-0004(92)90011-W; BAZZI MD, 1989, BIOCHEMISTRY-US, V28, P3577, DOI 10.1021/bi00434a064; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BOSSEN ME, 1990, PHYSIOL PLANTARUM, V80, P55; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREVIARIO D, 1995, PLANT MOL BIOL, V27, P953, DOI 10.1007/BF00037023; Chandok MR, 1996, MOL GEN GENET, V251, P599, DOI 10.1007/BF02173650; CHANDOK MR, 1992, PHYTOCHEMISTRY, V31, P2255, DOI 10.1016/0031-9422(92)83259-2; Chandok MR, 1996, J PLANT BIOCHEM BIOT, V5, P7, DOI 10.1007/BF03262971; CHANDOK MR, 1994, FEBS LETT, V356, P39, DOI 10.1016/0014-5793(94)01213-X; CHEN ZT, 1994, PLANT J, V6, P729, DOI 10.1046/j.1365-313X.1994.6050729.x; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DASGUPTA M, 1994, PLANT PHYSIOL, V104, P961, DOI 10.1104/pp.104.3.961; DROBAK BK, 1996, MEMBRANES SPECIALIZE, P195; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; ELLIOTT DC, 1987, BIOCHEM BIOPH RES CO, V145, P1043, DOI 10.1016/0006-291X(87)91541-5; ELLIOTT DC, 1987, PHYTOCHEMISTRY, V26, P2929, DOI 10.1016/S0031-9422(00)84565-3; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; HARMON AC, 1990, PLANT BIOL, V9, P319; HARMON AC, 1987, PLANT PHYSIOL, V83, P830, DOI 10.1104/pp.83.4.830; HARMON AC, 1996, MEMBRANES SPECIALIZE, P137; HARPER JF, 1991, SCIENCE, V252, P951, DOI 10.1126/science.1852075; HARPER JF, 1994, BIOCHEMISTRY-US, V33, P7267, DOI 10.1021/bi00189a031; HASS BCJ, 1991, J PLANT PHYSL, V138, P350; HEPLER PK, 1985, ANNU REV PLANT PHYS, V36, P397, DOI 10.1146/annurev.pp.36.060185.002145; HUANG KP, 1988, J BIOL CHEM, V263, P14839; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; JACON S, 1987, P NATL ACAD SCI USA, V84, P4418; Katagiri T, 1996, PLANT MOL BIOL, V30, P647, DOI 10.1007/BF00049339; KAWASAKI T, 1993, GENE, V129, P183, DOI 10.1016/0378-1119(93)90267-7; KOMATSU S, 1993, PLANT SCI, V94, P127, DOI 10.1016/0168-9452(93)90014-Q; KOSAKA Y, 1988, BIOCHEM BIOPH RES CO, V151, P973, DOI 10.1016/S0006-291X(88)80461-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE Y, 1991, P NATL ACAD SCI USA, V88, P2127, DOI 10.1073/pnas.88.6.2127; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; LONGERAN TA, 1990, PLANT PHYSIOL, V93, P110; MA H, 1993, TRENDS GENET, V9, P228, DOI 10.1016/0168-9525(93)90075-S; Marks F., 1996, PROTEIN PHOSPHORYLAT; MARKS R, 1996, PROTEIN PHOSPHORYLAT, P81; Martell A. E., 1971, SPECIAL PUBLICATION, V17; MERRIL CR, 1983, METHOD ENZYMOL, V96, P230; MORELLO L, 1993, BIOCHEM BIOPH RES CO, V197, P55, DOI 10.1006/bbrc.1993.2440; MUTO S, 1985, FEBS LETT, V193, P88, DOI 10.1016/0014-5793(85)80085-5; NAMORI T, 1994, BIOCHEM BIOPH RES CO, V203, P311; NEUFELD E, 1989, ANAL BIOCHEM, V177, P138, DOI 10.1016/0003-2697(89)90028-6; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OLAH Z, 1986, FEBS LETT, V195, P33, DOI 10.1016/0014-5793(86)80124-7; PARK MH, 1990, BIOCHEM BIOPH RES CO, V169, P1185, DOI 10.1016/0006-291X(90)92021-Q; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PEARS C, 1995, J BIOSCIENCE, V20, P311, DOI 10.1007/BF02703836; POLYA GM, 1993, PLANT PHYSIOL, V101, P545, DOI 10.1104/pp.101.2.545; POOVAIAH BW, 1987, CRC CR REV PLANT SCI, V6, P47, DOI 10.1080/07352688709382247; PUTNAMEVANS CL, 1990, BIOCHEMISTRY-US, V29, P2488, DOI 10.1021/bi00462a008; RAGHURAM N, 1995, PLANT MOL BIOL, V29, P25, DOI 10.1007/BF00019116; RANJEVA R, 1987, ANNU REV PLANT PHYS, V38, P73, DOI 10.1146/annurev.pp.38.060187.000445; Roberts DM, 1993, CURR OPIN CELL BIOL, V5, P242, DOI 10.1016/0955-0674(93)90110-C; ROBERTS DM, 1992, ANNU REV PLANT PHYS, V43, P375, DOI 10.1146/annurev.pp.43.060192.002111; SASAKI T, 1994, PLANT J, V6, P615, DOI 10.1046/j.1365-313X.1994.6040615.x; SATIEL AR, 1987, BIOCHEM J, V241, P759; SCHAAP D, 1989, FEBS LETT, V243, P351, DOI 10.1016/0014-5793(89)80160-7; SCHAAP D, 1990, EUR J BIOCHEM, V191, P431, DOI 10.1111/j.1432-1033.1990.tb19139.x; SCHAFER A, 1998, FEBS LETT, V187, P35; SCHALLER GE, 1992, BIOCHEMISTRY-US, V31, P1721, DOI 10.1021/bi00121a020; SHARKEY NA, 1984, P NATL ACAD SCI-BIOL, V81, P607, DOI 10.1073/pnas.81.2.607; SIMPSON GG, 1994, BBA-MOL CELL RES, V1222, P306, DOI 10.1016/0167-4889(94)90183-X; Sopory S K, 1996, Subcell Biochem, V26, P345; STONE JM, 1995, PLANT PHYSIOL, V108, P451, DOI 10.1104/pp.108.2.451; Subramaniam R, 1997, PLANT CELL, V9, P653, DOI 10.1105/tpc.9.4.653; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UCHIDA T, 1984, J BIOL CHEM, V259, P2311; URAO T, 1994, PLANT PHYSIOL, V105, P1461, DOI 10.1104/pp.105.4.1461; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572	75	33	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19235	19242		10.1074/jbc.273.30.19235	http://dx.doi.org/10.1074/jbc.273.30.19235			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668112	hybrid			2022-12-25	WOS:000074974700079
J	Fernandez, CJ; Warren, G				Fernandez, CJ; Warren, G			In vitro synthesis of sulfated glycosaminoglycans coupled to inter-compartmental Golgi transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							CELL-FREE SYSTEM; GDP-DISSOCIATION INHIBITOR; EMBRYO EPIPHYSEAL CARTILAGE; MOUSE MASTOCYTOMA-CELLS; ADP-RIBOSYLATION FACTOR; COP-COATED VESICLES; BETA-D-XYLOSIDES; RAT-LIVER GOLGI; ENDOPLASMIC-RETICULUM; CHONDROITIN SULFATE	We have used isolated rat liver Gels membranes to reconstitute the synthesis of sulfated glycosaminoglycans (GAGs) onto the membrane-permeable, external acceptor xyloside. Biosynthetic labeling of GAGs with [S-35]sulfate in vitro is shown to have an absolute requirement for ATP and cytosolic proteins and is inhibited by dismantling the Golgi apparatus with okadaic acid or under mitotic conditions suggesting that intercompartmental transport between Golgi cisternae is a prerequisite for the successful completion of the initiation, polymerization, and sulfation of GAGs. Accordingly, we show that in vitro synthesis of S-35-GAGs utilizes the same machinery employed in Golgi transport events in terms of vesicle budding (ADP-ribosylation factor and coatomer), docking (Rabs), targeting (SNAREs), and fusion (N-ethylmaleimide-sensitive factor). This provides compelling evidence that GAGs synthesis is linked to Golgi membrane traffic and suggests that it can be used as a complementation-independent method to study membrane transport in Golgi preparations from any source. We have applied this system to show that intra-Golgi traffic requires the function of the Golgi target-SNARE, syntaxin 5.	Imperial Canc Res Fund, Cell Biol Lab, London WC2A 3PX, England	Cancer Research UK	Warren, G (corresponding author), Imperial Canc Res Fund, Cell Biol Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	g.warren@icrf.icnet.uk						ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BAME KJ, 1991, J BIOL CHEM, V266, P10287; BANFIELD DK, 1995, NATURE, V375, P806, DOI 10.1038/375806a0; BANFIELD DK, 1994, J CELL BIOL, V127, P357, DOI 10.1083/jcb.127.2.357; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Beeley J. G., 1985, GLYCOPROTEIN PROTEOG; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BREWER CB, 1995, J CELL SCI, V108, P789; CALABRO A, 1994, J BIOL CHEM, V269, P22764; CARRINO DA, 1994, MATRIX BIOL, V14, P121, DOI 10.1016/0945-053X(94)90002-7; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; COLLINS RN, 1992, J BIOL CHEM, V267, P24906; DASCHER C, 1994, J BIOL CHEM, V269, P29363; DAVIDSON HW, 1992, J CELL BIOL, V116, P1343, DOI 10.1083/jcb.116.6.1343; ELAZAR Z, 1994, J BIOL CHEM, V269, P794; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; ETCHISON JR, 1995, J BIOL CHEM, V270, P756, DOI 10.1074/jbc.270.2.756; Fernandez CJ, 1997, MOL BIOL CELL, V8, P2171, DOI 10.1091/mbc.8.11.2171; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; FRANSSON L, 1995, GLYCOBIOLOGY, V5, P407, DOI 10.1093/glycob/5.4.407; FRANSSON LA, 1992, BIOCHIM BIOPHYS ACTA, V1137, P287, DOI 10.1016/0167-4889(92)90149-6; GALLIGANI L, 1975, J BIOL CHEM, V250, P5400; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; Hay JC, 1997, CELL, V89, P149, DOI 10.1016/S0092-8674(00)80191-9; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; HOPPE W, 1985, EUR J BIOCHEM, V152, P91, DOI 10.1111/j.1432-1033.1985.tb09167.x; Hui N, 1997, MOL BIOL CELL, V8, P1777, DOI 10.1091/mbc.8.9.1777; HUMPHRIES DE, 1988, BIOCHEM BIOPH RES CO, V154, P365, DOI 10.1016/0006-291X(88)90694-8; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOBAYASHI T, 1989, J BIOL CHEM, V264, P5966; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; KREINER T, 1990, CELL REGUL, V1, P415, DOI 10.1091/mbc.1.5.415; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Lewis MJ, 1996, CELL, V85, P205, DOI 10.1016/S0092-8674(00)81097-1; LIDHOLT K, 1989, BIOCHEM J, V261, P999, DOI 10.1042/bj2610999; LIDHOLT K, 1988, BIOCHEM J, V254, P571, DOI 10.1042/bj2540571; LINDAHL U, 1986, TRENDS BIOCHEM SCI, V11, P221, DOI 10.1016/0968-0004(86)90011-3; LUCOCQ J, 1991, J CELL SCI, V100, P753; LUCOCQ JM, 1987, EMBO J, V6, P3239, DOI 10.1002/j.1460-2075.1987.tb02641.x; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MILLER SG, 1992, METHOD ENZYMOL, V219, P234; MISTELI T, 1994, J CELL BIOL, V125, P269, DOI 10.1083/jcb.125.2.269; Nagahama M, 1996, J CELL BIOL, V133, P507, DOI 10.1083/jcb.133.3.507; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; NUWAYHID N, 1986, J BIOL CHEM, V261, P2936; OKAYAMA M, 1973, J BIOCHEM-TOKYO, V74, P1069; PEREZ M, 1986, BIOCHIM BIOPHYS ACTA, V864, P213, DOI 10.1016/0304-4157(86)90012-2; PETER F, 1994, J CELL BIOL, V126, P1393, DOI 10.1083/jcb.126.6.1393; PEVSNER J, 1994, CURR OPIN CELL BIOL, V6, P555, DOI 10.1016/0955-0674(94)90076-0; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; PRESTON SF, 1985, J CELL BIOL, V101, P1086, DOI 10.1083/jcb.101.3.1086; PRINZ R, 1980, BIOCHIM BIOPHYS ACTA, V630, P402, DOI 10.1016/0304-4165(80)90289-5; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; Rabouille C, 1998, CELL, V92, P603, DOI 10.1016/S0092-8674(00)81128-9; RATCLIFFE A, 1985, J CELL BIOL, V101, P2355, DOI 10.1083/jcb.101.6.2355; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ROTHMAN JE, 1987, J BIOL CHEM, V262, P12502; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHWANINGER R, 1991, J BIOL CHEM, V266, P13055; SCHWARTZ NB, 1977, J BIOL CHEM, V252, P6316; SCHWARTZ NB, 1974, P NATL ACAD SCI USA, V71, P4047, DOI 10.1073/pnas.71.10.4047; SCOTT J. E., 1960, METHODS BIOCHEM ANAL, V8, P145; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; Silbert JE, 1995, BBA-REV BIOMEMBRANES, V1241, P371, DOI 10.1016/0304-4157(95)00011-9; SLUSAREWICZ P, 1994, CELL BIOL LAB HDB, V1, P509; SOLDATI T, 1994, NATURE, V369, P76, DOI 10.1038/369076a0; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SPIRO RC, 1991, J CELL BIOL, V115, P1463, DOI 10.1083/jcb.115.5.1463; STEIN GS, 1994, CELL BIOL LAB HDB, V1, P282; STUART RA, 1993, J BIOL CHEM, V268, P4050; Subramaniam VN, 1996, SCIENCE, V272, P1161, DOI 10.1126/science.272.5265.1161; SUGUMARAN G, 1992, J BIOL CHEM, V267, P8802; SUGUMARAN G, 1992, BIOCHEM BIOPH RES CO, V183, P357, DOI 10.1016/0006-291X(92)90488-7; SUGUMARAN G, 1991, J BIOL CHEM, V266, P9565; SUGUMARAN G, 1990, J BIOL CHEM, V265, P18284; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; Tang BL, 1997, MOL CELL BIOL, V17, P256, DOI 10.1128/MCB.17.1.256; UHLINHANSEN L, 1993, J BIOL CHEM, V268, P17370; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; VELASCO A, 1988, EUR J CELL BIOL, V47, P241; vonMollard GF, 1997, J CELL BIOL, V137, P1511, DOI 10.1083/jcb.137.7.1511; WARREN G, 1989, NATURE, V342, P857, DOI 10.1038/342857a0; WARREN G, 1993, ANNU REV BIOCHEM, V62, P323, DOI 10.1146/annurev.bi.62.070193.001543; WARREN G, 1985, TRENDS BIOCHEM SCI, V10, P439, DOI 10.1016/0968-0004(85)90027-1; WATERS MG, 1992, METHOD ENZYMOL, V219, P331; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WEI Z, 1993, P NATL ACAD SCI USA, V90, P3885, DOI 10.1073/pnas.90.9.3885; WEISS O, 1989, J BIOL CHEM, V264, P21066; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; WONGPALMS S, 1995, ARCH BIOCHEM BIOPHYS, V319, P383, DOI 10.1006/abbi.1995.1308; Yang DH, 1996, HISTOCHEM J, V28, P33, DOI 10.1007/BF02331425; Yoshimori T, 1996, J CELL BIOL, V133, P247, DOI 10.1083/jcb.133.2.247; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	104	12	13	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19030	19039		10.1074/jbc.273.30.19030	http://dx.doi.org/10.1074/jbc.273.30.19030			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668084	hybrid			2022-12-25	WOS:000074974700051
J	Grothe, K; Hanke, C; Momayezi, M; Kissmehl, R; Plattner, H; Schultz, JE				Grothe, K; Hanke, C; Momayezi, M; Kissmehl, R; Plattner, H; Schultz, JE			Functional characterization and localization of protein phosphatase type 2C from Paramecium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; COMPLEX; CALCINEURIN; CLONING; CELLS	me cloned a protein phosphatase 2C gene from Paramecium (PtPP2C), which codes for one of the smallest PP2C isoforms (Klumpp, S,, Hanke, C,, Donella-Deana, A., Beyer, A., Kellner, R., Pinna, L. A., and Schultz, J. E. (1994) J. Biol. Chem. 269, 32774-32780). After mutation of 9 ciliate Q codons (TAA) to CAA PtPP2C was expressed as an active protein in Escherichia coli, The catalytic core region contains 284 amino acids as defined by C- and N-terminal deletions, The C terminus from amino acid 200-300 of PP2C isoforms has only about 20% similarity, To demonstrate that the carboxy end is in fact needed for activity, we generated an enzymatically active PtPP2C containing a C-terminally located tobacco etch virus-protease site. Upon proteolytic truncation enzyme activity was lost, i.e. the C terminus of PP2C is indispensable for enzyme activity. During these experiments isoleucine 214 was fortuitously identified to be essential for PP2C catalysis, Mutation of the hydrophobic amino acid to glycine in the ciliate or bovine isoforms resulted in inactive protein. Because Ile(214) is in a loop region without defined secondary structure, our data clearly go beyond the x-ray structure, The functional equivalence of the 180 amino acid long C terminus from the bovine PP2C with the 100 amino acid long carboxy end of the PtPP2C was demonstrated by producing an active chimera, i,e, the PP2C from Paramecium has no obvious regions which may be specifically involved in subcellular localization or substrate recognition. Using antibodies against recombinant PtPP2C we localized the enzyme by immunogold labeling in the cytosol and nucleus and very distinctly on the ciliary microtubule/dynein complex, The data suggest a role for PtPP2C in the regulation of dyneins, i,e, in cellular cargo transport and ciliary motility.	Univ Tubingen, Inst Pharmazeut, D-72076 Tubingen, Germany; Univ Konstanz, Fak Biol, D-78434 Constance, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Konstanz	Schultz, JE (corresponding author), Univ Tubingen, Inst Pharmazeut, Morgenstelle 8, D-72076 Tubingen, Germany.	Joachim.Schultz@uni-tuebingen.de						Bork P, 1996, PROTEIN SCI, V5, P1421, DOI 10.1002/pro.5560050720; Cohen PTW, 1997, TRENDS BIOCHEM SCI, V22, P245, DOI 10.1016/S0968-0004(97)01060-8; Das AK, 1996, EMBO J, V15, P6798, DOI 10.1002/j.1460-2075.1996.tb01071.x; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Dick T, 1997, GENE, V199, P139, DOI 10.1016/S0378-1119(97)00359-4; EGLOFF MP, 1995, J MOL BIOL, V254, P942, DOI 10.1006/jmbi.1995.0667; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Jung G., 1985, ANGEW CHEM, V97, P883, DOI 10.1002/ange.19850971032; KANESHIRO ES, 1979, J PROTOZOOL, V26, P147, DOI 10.1111/j.1550-7408.1979.tb02754.x; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; KISSMEHL R, 1998, IN PRESS HISTOCHEM C; Klumpp S, 1998, J NEUROSCI RES, V51, P328, DOI 10.1002/(SICI)1097-4547(19980201)51:3<328::AID-JNR6>3.0.CO;2-I; KLUMPP S, 1994, J BIOL CHEM, V269, P32774; MANN DJ, 1992, BIOCHIM BIOPHYS ACTA, V1130, P100, DOI 10.1016/0167-4781(92)90471-B; Marley AE, 1996, BIOCHEM J, V320, P801, DOI 10.1042/bj3200801; MCGOWAN CH, 1988, METHOD ENZYMOL, V159, P416; Momayezi M, 1996, J HISTOCHEM CYTOCHEM, V44, P891, DOI 10.1177/44.8.8756761; ROBINSON MK, 1994, MOL CELL BIOL, V14, P3634, DOI 10.1128/MCB.14.6.3634; SCHLECHT S, 1993, NATURWISSENSCHAFTEN, V80, P9, DOI 10.1007/BF01139751; SCHROEDER CC, 1990, J CELL BIOL, V111, P2553, DOI 10.1083/jcb.111.6.2553	22	11	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19167	19172		10.1074/jbc.273.30.19167	http://dx.doi.org/10.1074/jbc.273.30.19167			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668103	Green Published, hybrid			2022-12-25	WOS:000074974700070
J	Stancato, LF; Yu, CR; Petricoin, EF; Larner, AC				Stancato, LF; Yu, CR; Petricoin, EF; Larner, AC			Activation of Raf-1 by interferon gamma and oncostatin M requires expression of the Stat1 transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; ALPHA-INTERFERON; GENE-EXPRESSION; ACTIVE STAT1; RECEPTOR; PROTEIN; PATHWAY	A primary signaling cascade responsible for the ex pression of cytokine-stimulated immediate early genes involves the activation of the Jak/Stat pathway. In addition to being tyrosine-phosphorylated, several signal transducers and activators of transcription (Stats), including Stat1 alpha, Stat3, and Stat4, are phosphorylated on a conserved serine residue, which is a consensus phosphorylation site for mitogen-activated protein kinases (MAPKs), Serine phosphorylation of Stat1 alpha is required for maximal transcriptional activation of early response genes by interferon gamma (IFN gamma) as well as the antiviral and antigrowth actions of this cytokine. Incubation of cells with either IFN gamma or oncostatin M (OSM) activates Raf-1, a serine/threonine kinase responsible for the ultimate activation of p42 MAPK. To examine whether any of the signaling components that are required for activation of the Jak/Stat pathway are also necessary for activation of Raf-1 by IFNs and OSM, we examined activation of Raf-1 in cell lines that are deficient in either Stat1 alpha or Stat2. Unexpectedly, incubation of Stat1-deficient, but not Stat2-deficient cells with IFN gamma or OSM for 5 min displayed no increase in Raf-1 activity. In peripheral blood lymphocytes Raf-1 was associated with Stat1, and this interaction was disrupted after incubation of cells with IFN gamma, Stat1-negative cells reconstituted with either Stat1 alpha or Stat1 alpha with a point mutation in the site where it is serine-phosphorylated displayed normal activation of Raf-1 by IFN gamma and OSM, However, activation of Raf-1 was not observed in lines that expressed Stat1 alpha containing a mutation in its tyrosine phosphorylation site or in its SH2 domain. These results provide the first example of a novel role of Stat1 alpha not as a transcription factor, but as a protein which may function to scaffold signaling components required for activation of the distinct Raf/MEK/MAPK signaling cascade.	NCI, Mol & Cellular Biol Lab, NIH, Bethesda, MD 20892 USA; NCI, Expt Immunol Lab, NIH, Frederick, MD 21701 USA; Ctr Biol Evaluat & Res, Div Cytokine Biol, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA)	Larner, AC (corresponding author), Cleveland Clin Fdn, Dept Immunol, 9500 Euclid Ave, Cleveland, OH 44195 USA.			Yu, Cheng-Rong/0000-0001-7246-0362	NATIONAL CANCER INSTITUTE [R01CA077366] Funding Source: NIH RePORTER; NCI NIH HHS [CA77366] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; BUSCHER D, 1995, MOL CELL BIOL, V15, P466; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DAVID M, 1995, MOL CELL BIOL, V15, P7050; David M, 1996, J BIOL CHEM, V271, P15862, DOI 10.1074/jbc.271.27.15862; DENT P, 1995, MOL CELL BIOL, V15, P4125; Horvath CM, 1996, J VIROL, V70, P647, DOI 10.1128/JVI.70.1.647-650.1996; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; LARNER AC, 1995, BBA-MOL CELL RES, V1266, P278, DOI 10.1016/0167-4889(95)00015-K; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; Sakatsume M, 1996, J IMMUNOL, V156, P4160; Sakatsume M, 1998, J BIOL CHEM, V273, P3021, DOI 10.1074/jbc.273.5.3021; Stancato LF, 1997, MOL CELL BIOL, V17, P3833, DOI 10.1128/MCB.17.7.3833; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	20	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18701	18704		10.1074/jbc.273.30.18701	http://dx.doi.org/10.1074/jbc.273.30.18701			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668040	hybrid			2022-12-25	WOS:000074974700007
J	Grkovic, S; Brown, MH; Roberts, MJ; Paulsen, IT; Skurray, RA				Grkovic, S; Brown, MH; Roberts, MJ; Paulsen, IT; Skurray, RA			QacR is a repressor protein that regulates expression of the Staphylococcus aureus multidrug efflux pump QacA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RESISTANCE GENE; KANAMYCIN RESISTANCE; THERMAL INACTIVATION; TRANSPORT PROTEINS; LAC REPRESSOR; BINDING; VECTORS; TRANSCRIPTION; PLASMID	The Staphylococcus aureus QacA protein is a multidrug transporter that confers resistance to a broad range of antimicrobial agents via proton motive force dependent efflux of the compounds. Primer extension analysis was performed to map the transcription start points of the qacA and divergently transcribed qacR mRNAs. Each gene utilized a single promoter element, the locations of which were confirmed by site-directed mutagenesis. Fusions of the qacA and qacR promoters to a chloramphenicol acetyl transferase reporter gene were used to demonstrate that QacR is a trans-acting repressor of qacA transcription that does not autoregulate its own expression. An inverted repeat overlapping the qacA transcription start site was shown to be the operator sequence for control of qacA gene expression. Removal of one half of the operator prevented QacR-mediated repression of the qacA promoter. Purified QacR protein bound specifically to this operator sequence in DNase I-footprinting experiments. Importantly, addition of diverse QacA substrates was shown to induce qacA expression in vivo, as well as inhibit binding of QacR to operator DNA in vitro, by using gel-mobility shift assays. QacR therefore appears to interact directly with structurally dissimilar inducing compounds that are substrates of the QacA multidrug efflux pump.	Univ Sydney, Sch Biol Sci, Sydney, NSW 2006, Australia	University of Sydney	Skurray, RA (corresponding author), Univ Sydney, Sch Biol Sci, Macleay Bldg A12, Sydney, NSW 2006, Australia.		Paulsen, Ian T/K-3832-2012; Brown, Melissa/V-2296-2017	Paulsen, Ian T/0000-0001-9015-9418; Brown, Melissa/0000-0001-6461-7550				AHMED M, 1993, J BIOL CHEM, V268, P11086; AHMED M, 1994, J BIOL CHEM, V269, P28506; ARAMAKI H, 1995, J BACTERIOL, V177, P3120, DOI 10.1128/jb.177.11.3120-3127.1995; Aramaki H, 1995, PROTEIN ENG, V8, P1259, DOI 10.1093/protein/8.12.1259; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROSIUS J, 1984, GENE, V27, P151, DOI 10.1016/0378-1119(84)90136-7; CHAUDHARY PM, 1993, J NATL CANCER I, V85, P632, DOI 10.1093/jnci/85.8.632; Doran JL, 1997, CLIN DIAGN LAB IMMUN, V4, P23, DOI 10.1128/CDLI.4.1.23-32.1997; ENGLEKA KA, 1992, J BIOL CHEM, V267, P11307; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GUILFOILE PG, 1992, J BACTERIOL, V174, P3659, DOI 10.1128/JB.174.11.3659-3666.1992; HAGMAN KE, 1995, MICROBIOL-SGM, V141, P611, DOI 10.1099/13500872-141-3-611; Hames B. D., 1981, GEL ELECTROPHORESIS; HILLEN W, 1994, ANNU REV MICROBIOL, V48, P345, DOI 10.1146/annurev.mi.48.100194.002021; HINRICHS W, 1994, SCIENCE, V264, P418, DOI 10.1126/science.8153629; JOBLING MG, 1990, NUCLEIC ACIDS RES, V18, P5315, DOI 10.1093/nar/18.17.5315; KARTNER N, 1983, SCIENCE, V221, P1285, DOI 10.1126/science.6137059; KATO S, 1992, FEBS LETT, V308, P175, DOI 10.1016/0014-5793(92)81269-R; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZER M, 1988, P NATL ACAD SCI USA, V85, P8973, DOI 10.1073/pnas.85.23.8973; LEWIS K, 1994, TRENDS BIOCHEM SCI, V19, P119, DOI 10.1016/0968-0004(94)90204-6; LI XZ, 1995, ANTIMICROB AGENTS CH, V39, P1948, DOI 10.1128/AAC.39.9.1948; LOMOVSKAYA O, 1995, J BACTERIOL, V177, P2328, DOI 10.1128/jb.177.9.2328-2334.1995; Lucas CE, 1997, J BACTERIOL, V179, P4123, DOI 10.1128/jb.179.13.4123-4128.1997; LYON BR, 1984, MOL GEN GENET, V193, P554, DOI 10.1007/BF00382099; Markham PN, 1996, J BACTERIOL, V178, P1473, DOI 10.1128/jb.178.5.1473-1475.1996; Miller J.H., 1972, EXPT MOL GENETICS; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; Paulsen IT, 1996, MICROBIOL REV, V60, P575, DOI 10.1128/MMBR.60.4.575-608.1996; Paulsen IT, 1996, P NATL ACAD SCI USA, V93, P3630, DOI 10.1073/pnas.93.8.3630; PERRY LJ, 1987, PROTEIN ENG, V1, P101, DOI 10.1093/protein/1.2.101; Record Jr MT, 1996, ESCHERICHIA COLI SAL, P792; ROUCH DA, 1990, MOL MICROBIOL, V4, P2051, DOI 10.1111/j.1365-2958.1990.tb00565.x; Sambrook J., 2002, MOL CLONING LAB MANU; Shaw W V, 1975, Methods Enzymol, V43, P737; SHEWCHUK LM, 1989, BIOCHEMISTRY-US, V28, P6140, DOI 10.1021/bi00441a002; SHEWCHUK LM, 1989, BIOCHEMISTRY-US, V28, P2331, DOI 10.1021/bi00431a052; Shi WP, 1996, J BIOL CHEM, V271, P9291, DOI 10.1074/jbc.271.16.9291; STARK MJR, 1987, GENE, V51, P255, DOI 10.1016/0378-1119(87)90314-3; STRANEY SB, 1987, CELL, V51, P699, DOI 10.1016/0092-8674(87)90093-6; TENNENT JM, 1985, ANTIMICROB AGENTS CH, V27, P79, DOI 10.1128/AAC.27.1.79; TOMAZIC SJ, 1988, J BIOL CHEM, V263, P3086; Volkin D B, 1995, Methods Mol Biol, V40, P35; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Zheleznova EE, 1997, PROTEIN SCI, V6, P2465	49	152	161	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18665	18673		10.1074/jbc.273.29.18665	http://dx.doi.org/10.1074/jbc.273.29.18665			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660841	hybrid			2022-12-25	WOS:000074828500096
J	Parker, AE; Van de Weyer, I; Laus, MC; Oostveen, I; Yon, J; Verhasselt, P; Luyten, WHML				Parker, AE; Van de Weyer, I; Laus, MC; Oostveen, I; Yon, J; Verhasselt, P; Luyten, WHML			A human homologue of the Schizosaccharomyces pombe rad1(+) checkpoint gene encodes an exonuclease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CHECKPOINT; WILD-TYPE P53; DNA-DAMAGE; USTILAGO-MAYDIS; REC1 GENE; SACCHAROMYCES-CEREVISIAE; FISSION YEAST; INSITU HYBRIDIZATION; ALLELIC DELETION; REPAIR	In the fission yeast Schizosaccharomyces pombe the rad1(+) gene is required for both the DNA damage-dependent and the DNA replication-dependent cell cycle checkpoints. We have identified a human homologue of the S. pombe rad1(+) gene, designated Hrad1, as well as a mouse homologue: Mrad1. Two Hrad1 alternative splice variants with different open reading frames have been identified; one codes for a long form, Hrad1A, and the other encodes a short form because of N-terminal truncation, Hrad1B. Hrad1A has 60% identity to the S. pombe rad1(+) sequence at the DNA level and 49% identity and 72% similarity at the amino acid level. Northern blot analysis indicates elevated levels of expression in testis and cancer cell lines. Chromosomal localization by fluorescence in situ hybridization indicates that Hrad1 is located on chromosome 5p13.2-13.3. This region is subject to loss of heterozygosity in several human cancers. Hrad1 also shares homology with the Saccharomyces cerevisiae RAD17 and Ustilago maydis REC1 proteins. REC1 has previously been characterized as a 3' --> 5' exonuclease with a C-terminal domain essential for cell cycle checkpoint function. We have expressed and purified polyhistidine-tagged fusions of Rrad1A and Hrad1B and show that HisHrad1A has 3' --> 5' exonuclease activity, whereas HisHrad1B lacks such activity. The biological functions of the two proteins remain to be determined.	Janssen Res Fdn, Dept Expt Mol Biol, B-2340 Beerse, Belgium; Janssen Res Fdn, Dept Appl Mol Biol, B-2340 Beerse, Belgium	Johnson & Johnson; Johnson & Johnson	Luyten, WHML (corresponding author), Janssen Res Fdn, Dept Expt Mol Biol, Turnhoutseweg 30, B-2340 Beerse, Belgium.	wluyten@janbe.jnj.com						ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; Altschul Stephen F., J MOL BIOL, V215, P403, DOI [10.1016/S0022-2836(05)80360-2, DOI 10.1016/S0022-2836(05)80360-2]; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; BHAT KM, 1991, BIOCHEM BIOPH RES CO, V176, P371, DOI 10.1016/0006-291X(91)90934-Y; CARR AM, 1995, TRENDS CELL BIOL, V5, P32, DOI 10.1016/S0962-8924(00)88934-5; CARR AM, 1994, INT J RAD BIOL S, V66, P133; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; Demetrick DJ, 1996, CYTOGENET CELL GENET, V73, P104, DOI 10.1159/000134318; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HAWN MT, 1995, CANCER RES, V55, P3721; Heng H H, 1994, Methods Mol Biol, V33, P35; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HOLDEN DW, 1991, CURR GENET, V20, P145, DOI 10.1007/BF00312777; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KANTERSMOLER G, 1995, MOL BIOL CELL, V6, P1793, DOI 10.1091/mbc.6.12.1793; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KATO R, 1994, NUCLEIC ACIDS RES, V22, P3104, DOI 10.1093/nar/22.15.3104; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; Leupold U., 1970, METHODS CELL PHYSL, V4, P169; Lieberman HB, 1996, P NATL ACAD SCI USA, V93, P13890, DOI 10.1073/pnas.93.24.13890; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LONG KE, 1994, GENE, V148, P155, DOI 10.1016/0378-1119(94)90250-X; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; NASIM A, 1975, GENETICS, V79, P573; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; ONEL K, 1995, MOL CELL BIOL, V15, P5329; Onel K, 1996, GENETICS, V143, P165; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; ROWLEY R, 1992, EMBO J, V11, P1335, DOI 10.1002/j.1460-2075.1992.tb05178.x; SANDHEZ Y, 1997, SCIENCE, V277, P1497; Siede W, 1996, NUCLEIC ACIDS RES, V24, P1669, DOI 10.1093/nar/24.9.1669; SUNNERHAGEN P, 1990, MOL CELL BIOL, V10, P3750, DOI 10.1128/MCB.10.7.3750; THELEN MP, 1994, J BIOL CHEM, V269, P747; WEINERT TA, 1990, MOL CELL BIOL, V10, P6554, DOI 10.1128/MCB.10.12.6554; Wieland I, 1996, ONCOGENE, V12, P97; WIELAND I, 1994, CANCER RES, V54, P1772; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	49	92	97	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18332	18339		10.1074/jbc.273.29.18332	http://dx.doi.org/10.1074/jbc.273.29.18332			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660799	hybrid			2022-12-25	WOS:000074828500054
J	Saharinen, J; Taipale, J; Monni, O; Keski-Oja, J				Saharinen, J; Taipale, J; Monni, O; Keski-Oja, J			Identification and characterization of a new latent transforming growth factor-beta-binding protein, LTBP-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX MICROFIBRILS; SMOOTH-MUSCLE CELLS; TGF-BETA; PERICELLULAR MATRIX; MOLECULAR-CLONING; 8-CYSTEINE REPEAT; ENDOTHELIAL-CELLS; MARFAN-SYNDROME; MESSENGER-RNA; FIBRILLIN	Transforming growth factor beta (TGF-beta s) are secreted by most cell types as latent high molecular weight complexes consisting of TGF-beta and its latency associated peptide (LAP) propeptide dimers, covalently linked to latent TGF-beta-binding proteins (LTBPs), Currently, three different LTBPs are known (LTBPs 1, 2, and 3), all with highly similar protein domain structure consisting of epidermal growth factor-like and 8-Cys repeats. The 3rd 8-Cys repeat of LTBP-1 mediates its association with TGF-beta 1 . LAP. By using an expressed sequence tag homologous to the 3rd 8-Cys repeat of human LTBP-1 as a probe, a novel cDNA similar to known LTBPs was cloned from human heart cDNA Library. This cDNA was named LTBP-4 and found to exist in at least four different forms, generated by alternative splicing at the amino terminus and at the central epidermal growth factor repeat domain. One of the alternative amino-terminal forms contained an RGD sequence, indicating possible cell-surface interactions with integrins. LTBP-4 gene was localized to chromosomal position 19q13.1-19q13.2. The major LTBP-4 mRNA form is about 5.1 kilobase pairs in size and is predominantly expressed in the heart, aorta, uterus, and small intestine. Immunoblotting analysis indicated that LTBP-4 was secreted from cultured human lung fibroblasts both in a free form and in a disulfide bound complex with a TGF-beta.LAP-like protein. Both LTBP-4 forms were also found to be deposited in the extracellular matrix. The matrix-associated LTBP-4 was susceptible to proteolytic release with plasmin. LTBP-4 is a new member of the growing LTBP-fibrillin family of proteins and offers an alternative means for the secretion and targeted matrix deposition of TGF-beta s or related proteins.	Univ Helsinki, Haartman Inst, Dept Virol, FIN-00014 Helsinki, Finland; Univ Helsinki, Haartman Inst, Dept Med Genet, FIN-00014 Helsinki, Finland; Univ Helsinki, Dept Dermatol & Venereol, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki; University of Helsinki	Keski-Oja, J (corresponding author), Univ Helsinki, Haartman Inst, Dept Virol, POB 21,Haartmaninkatu 3, FIN-00014 Helsinki, Finland.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; APPELLA E, 1988, FEBS LETT, V231, P1, DOI 10.1016/0014-5793(88)80690-2; BENEZRA M, 1993, BLOOD, V81, P3324; Bonfield JK, 1995, NUCLEIC ACIDS RES, V23, P4992, DOI 10.1093/nar/23.24.4992; CORSON GM, 1993, GENOMICS, V17, P476, DOI 10.1006/geno.1993.1350; DAVIS C G, 1990, New Biologist, V2, P410; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; EKLOV S, 1993, CANCER RES, V53, P3193; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FLAUMENHAFT R, 1993, J CELL BIOL, V120, P995, DOI 10.1083/jcb.120.4.995; GIBSON MA, 1995, MOL CELL BIOL, V15, P6932; Gleizes PE, 1996, J BIOL CHEM, V271, P29891, DOI 10.1074/jbc.271.47.29891; HEDMAN K, 1979, J CELL BIOL, V81, P83, DOI 10.1083/jcb.81.1.83; Hyytiainen M, 1998, J BIOL CHEM, V273, P20669, DOI 10.1074/jbc.273.32.20669; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; KEENE DR, 1991, J HISTOCHEM CYTOCHEM, V39, P441, DOI 10.1177/39.4.2005373; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LYONS RM, 1988, J CELL BIOL, V106, P1659, DOI 10.1083/jcb.106.5.1659; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MCCARTNEYFRANCIS NL, 1994, J LEUKOCYTE BIOL, V55, P401, DOI 10.1002/jlb.55.3.401; MIYAZONO K, 1992, J BIOL CHEM, V267, P5668; MIYAZONO K, 1991, EMBO J, V10, P1091, DOI 10.1002/j.1460-2075.1991.tb08049.x; MOREN A, 1994, J BIOL CHEM, V269, P32469; Olofsson A, 1995, J BIOL CHEM, V270, P31294, DOI 10.1074/jbc.270.52.31294; OLOFSSON A, 1992, J BIOL CHEM, V267, P19482; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; Pfaff M, 1996, FEBS LETT, V384, P247, DOI 10.1016/0014-5793(96)00325-0; Ramirez F, 1996, CURR OPIN GENET DEV, V6, P309, DOI 10.1016/S0959-437X(96)80007-4; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; SAARINEN J, 1994, J BIOL CHEM, V269, P18134; Saharinen J, 1996, EMBO J, V15, P245, DOI 10.1002/j.1460-2075.1996.tb00355.x; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; Sakamoto H, 1996, J BIOL CHEM, V271, P4916; Sambrook J., 2002, MOL CLONING LAB MANU; SATO Y, 1993, J CELL BIOL, V123, P1249, DOI 10.1083/jcb.123.5.1249; TAIPALE J, 1995, J BIOL CHEM, V270, P4689, DOI 10.1074/jbc.270.9.4689; Taipale J, 1996, J HISTOCHEM CYTOCHEM, V44, P875, DOI 10.1177/44.8.8756760; TAIPALE J, 1994, J CELL BIOL, V124, P171, DOI 10.1083/jcb.124.1.171; TAIPALE J, 1992, J BIOL CHEM, V267, P25378; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; TSUJI T, 1990, P NATL ACAD SCI USA, V87, P8835, DOI 10.1073/pnas.87.22.8835; YIN WS, 1995, J BIOL CHEM, V270, P10147, DOI 10.1074/jbc.270.17.10147; ZHANG H, 1995, J CELL BIOL, V129, P1165, DOI 10.1083/jcb.129.4.1165; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855	45	108	115	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18459	18469		10.1074/jbc.273.29.18459	http://dx.doi.org/10.1074/jbc.273.29.18459			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660815	hybrid			2022-12-25	WOS:000074828500070
J	Weng, YM; Siciliano, SJ; Waldburger, KE; Sirotina-Meisher, A; Staruch, MJ; Daugherty, BL; Gould, SL; Springer, MS; DeMartino, JA				Weng, YM; Siciliano, SJ; Waldburger, KE; Sirotina-Meisher, A; Staruch, MJ; Daugherty, BL; Gould, SL; Springer, MS; DeMartino, JA			Binding and functional properties of recombinant and endogenous CXCR3 chemokine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INTERLEUKIN-8 RECEPTOR; EOTAXIN RECEPTOR; EXPRESSION; CLONING; LESTR/FUSIN; CYTOKINES; LIGAND; MEMBER; FAMILY; SDF-1	IP10 and MIG are two members of the CXC branch of the chemokine superfamily whose expression is dramatically up-regulated by interferon (lFN)-gamma, The proteins act largely on natural killer (NK)-cells and activated T-cells and have been implicated in mediating some of the effects of IFN-gamma and Lipopolysaccharides (LPSs), as well as T-cell-dependent anti-tumor responses. Recently both chemokines have been shown to be functional agonists of the same G-protein-coupled receptor, CXCR3, We now report the pharmacological characterization of CXCR3 and find that, when heterologously expressed, CXCR3 binds IP10 and MIG with K-i values of 0.14 and 4.9 nm, respectively. The receptor has very modest affinity for SDF-1 alpha and little or no affinity for other CXC-chemokines, The properties of the endogenous receptor expressed on activated T-cells are similar. Surprisingly, several CC-chemokines, particularly eotaxin and MCP-4, also compete with moderate affinity for the binding of IP10 to CXCR3, Eotaxin does not activate CXCR3 but, in CXCR3-transfected cells, can block IP10-mediated receptor activation. Eotaxin, therefore, may be a natural CXCR3 antagonist.	Merck Res Labs, Dept Immunol Res, Rahway, NJ 07065 USA; Merck Res Labs, Dept Inflammat Res, Rahway, NJ 07065 USA	Merck & Company; Merck & Company	DeMartino, JA (corresponding author), Merck Res Labs, Dept Immunol Res, 126 E Lincoln Ave, Rahway, NJ 07065 USA.	julie_demartino@merck.com						Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; DEMARTINO JA, 1994, J BIOL CHEM, V269, P14446; FARBER JM, 1993, BIOCHEM BIOPH RES CO, V192, P223, DOI 10.1006/bbrc.1993.1403; FARBER JM, 1990, P NATL ACAD SCI USA, V87, P5238, DOI 10.1073/pnas.87.14.5238; Farber JM, 1997, J LEUKOCYTE BIOL, V61, P246, DOI 10.1002/jlb.61.3.246; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; HORUK R, 1993, SCIENCE, V261, P1182, DOI 10.1126/science.7689250; Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963; LUSTER AD, 1993, J EXP MED, V178, P1057, DOI 10.1084/jem.178.3.1057; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; MCCONNELL HM, 1992, SCIENCE, V257, P1906, DOI 10.1126/science.1329199; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; PITCHFORD S, 1995, AM J PHYSIOL-CELL PH, V268, pC936, DOI 10.1152/ajpcell.1995.268.4.C936; Ploix C, 1998, DIABETES, V47, P39, DOI 10.2337/diabetes.47.1.39; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; STREITER RM, 1995, J LEUKOCYTE BIOL, V57, P752; SZABO MC, 1995, J BIOL CHEM, V270, P25348, DOI 10.1074/jbc.270.43.25348; VANRIPER G, 1993, J EXP MED, V177, P851, DOI 10.1084/jem.177.3.851; WEINER HL, 1994, ANNU REV IMMUNOL, V12, P809, DOI 10.1146/annurev.immunol.12.1.809	25	171	178	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18288	18291		10.1074/jbc.273.29.18288	http://dx.doi.org/10.1074/jbc.273.29.18288			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660793	hybrid			2022-12-25	WOS:000074828500048
J	Zwollo, P; Rao, S; Wallin, JJ; Gackstetter, ER; Koshland, ME				Zwollo, P; Rao, S; Wallin, JJ; Gackstetter, ER; Koshland, ME			The transcription factor NF-kappa B/p50 interacts with the blk gene during B cell activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; FACTOR BSAP; 3'ALPHA ENHANCER; CHAIN GENE; DIFFERENTIATION; PROTEIN; BINDING; PROMOTER; SUBUNIT; PROLIFERATION	The B cell-specific transcription factor Pax-5 has been shown previously to interact with the promoter of the blk gene in vitro, blk encodes a tyrosine kinase associated with the B cell receptor, which is expressed during the early but not the final stages of B cell development. To investigate whether Pax-5 regulates expression of the blk gene in vivo during B cell development and/or activation, Pax-5a was overexpressed in B cell lines. Increases in blk promoter activity using a chloramphenicol acetyltransferase reporter gene system suggested a role for Pax-5a as a transcriptional activator. Subsequent site-specific mutagenesis studies showed that mutations of the Pax-5 binding site on blk significantly alter promoter activity, although results suggested that other factors could bind to this region as well. Using mobility shift assays, we detected an inducible transcription factor that interacts strongly with a sequence overlapping the Pax-5 site on the blk promoter and identified this as a homodimer of NF-kappa B/p50, a member of the NF-kappa B/Rel family of transcription factors. This factor was present at high levels in lipopolysaccharide-activated normal B cells and in plasma cell lines but either at low levels or undetectable levels in resting normal B cells or pre-B or mature B cell lines. In contrast, lipopolysaccharide induction of a pre B cell line (703/Z) induced a complex that contained both NF-kappa B/p50 and p65. These studies suggest that different NF-kappa B complexes are able to interact with a sequence overlapping the Pax-5 site on the blk promoter and that the relative levels of "bound" factor influence levels of bit expression. Since p50 homodimers and p50/p65 heterodimers of the NF-kappa B complex should have opposing effects on blk transcription, this could provide a mechanism to differentially regulate blk expression during B cell development and activation.	Coll William & Mary, Dept Biol, Williamsburg, VA 23187 USA; Univ Calif Berkeley, Dept Mol & Cellular Biol, Berkeley, CA 94720 USA	William & Mary; University of California System; University of California Berkeley	Zwollo, P (corresponding author), Coll William & Mary, Dept Biol, Millington Hall, Williamsburg, VA 23187 USA.			Wallin, Jeffrey/0000-0002-5952-3813				ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; DYMECKI SM, 1992, J BIOL CHEM, V267, P4815; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HAGMAN J, 1994, CURR OPIN IMMUNOL, V6, P222, DOI 10.1016/0952-7915(94)90095-7; HAGMAN J, 1996, GENE DEV, V7, P2198; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KEHRL JH, 1994, IMMUNOL TODAY, V15, P432, DOI 10.1016/0167-5699(94)90273-9; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; Michaelson JS, 1996, J IMMUNOL, V156, P2349; NEURATH MF, 1995, P NATL ACAD SCI USA, V92, P5336, DOI 10.1073/pnas.92.12.5336; NEURATH MF, 1995, IMMUNOL TODAY, V16, P564, DOI 10.1016/0167-5699(95)80078-6; OKABE T, 1992, EUR J IMMUNOL, V22, P37, DOI 10.1002/eji.1830220107; Rinkenberger JL, 1996, IMMUNITY, V5, P377, DOI 10.1016/S1074-7613(00)80263-0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; Sha WC, 1998, J EXP MED, V187, P143, DOI 10.1084/jem.187.2.143; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SINGH M, 1993, MOL CELL BIOL, V13, P3611, DOI 10.1128/MCB.13.6.3611; Snapper CM, 1996, J IMMUNOL, V156, P183; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; Usui T, 1997, J IMMUNOL, V158, P3197; WAKATSUKI Y, 1994, J EXP MED, V179, P1099, DOI 10.1084/jem.179.4.1099; Wallin JJ, 1998, SCIENCE, V279, P1961, DOI 10.1126/science.279.5358.1961; XU LZ, 1992, INT IMMUNOL, V4, P875, DOI 10.1093/intimm/4.8.875; YAO XR, 1993, P NATL ACAD SCI USA, V90, P7946, DOI 10.1073/pnas.90.17.7946; ZWOLLO P, 1994, J BIOL CHEM, V269, P15310; Zwollo P, 1997, J BIOL CHEM, V272, P10160, DOI 10.1074/jbc.272.15.10160	31	27	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18647	18655		10.1074/jbc.273.29.18647	http://dx.doi.org/10.1074/jbc.273.29.18647			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660839	hybrid			2022-12-25	WOS:000074828500094
J	Kardassis, D; Sacharidou, E; Zannis, VI				Kardassis, D; Sacharidou, E; Zannis, VI			Transactivation of the human apolipoprotein CII promoter by orphan and ligand-dependent nuclear receptors - The regulatory element CIIC is a thyroid hormone response element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTORS; ACTIVATION FUNCTION AF-2; C-II GENE; TRANSCRIPTIONAL ACTIVATION; COUP-TF; SUPERFAMILY; PROTEIN; HNF-4; ARP-1; IDENTIFICATION	The regulatory elements CIIC (-159/-116) and CIIB (-102-81) of the apolipoprotein CP (apoCII) promoter have distinct specificities for orphan nuclear receptors (Vorgia, P., Zannis, V. I., and Kardassis, D. (1998) J. Biol. Chem. 273, 4188-4199), In this communication we investigated the contribution of Ligand-dependent and orphan nuclear receptors on the transcriptional regulation of the human apoCII gene. It was found that element CIIC in addition to ARP-1 and EAR-2 binds RXR alpha/T3R beta heterodimers strongly, whereas element CITE binds hepatic nuclear factor 4 (HNF-4) exclusively. Binding is abolished by mutations that alter the HRE binding motifs, Transient cotransfection experiments showed that in the presence of T3, RXR alpha/T3R beta heterodimers transactivated the -205/+18 apoCII promoter 1.6- and 11-fold in HepG2 and COS-l respectively. No transactivation was observed in the presence of 9-cis-retinoic acid. Transactivation requires the regulatory element CIIC, suggesting that this element contains a thyroid hormone response element. HNF-4 did not affect the apoCII promoter activity in HepG2 cells. However, mutations in the HNF-4 binding site on element CIIB and inhibition of HNF-4 synthesis in HepG2 cells by antisense HNF-4 constructs decreased the apoCII promoter activity to 25-40% of the control, indicating that HNF-4 is a positive regulator of the apoCII gene. ARP-1 repressed the -205/+18 but not the -104/+18 apoCII promoter activity in HepG2 cells, indicating that the repression depends on the regulatory element CIIC. In contrast, combination of ARP-I and HNF-4 transactivated different apoCII promoter segments as well as a minimal adenovirus major late promoter driven by the regulatory element CIIB, Mutagenesis or deletion of elements CIIB or CIIC established that the observed transactivation requires DNA binding of one of the two factors and may result from HNF-4-ARP-1 interactions that elicit the transactivation functions of HNF-4. The combined data indicate that RXR alpha/T3R beta in the presence of T3 and HNF-4 can upregulate the apoCII promoter activity by binding to the regulatory elements CIIC and CIIB, respectively. In addition, ARP-1 can either hare inhibitory or stimulatory effects on the apoCII promoter activity via different mechanisms.	Univ Crete, Dept Med, Div Basic Sci, Biochem Sect, Heraklion, Crete, Greece; Inst Mol Biol & Biotechnol, Heraklion, Crete, Greece	University of Crete	Kardassis, D (corresponding author), Univ Crete, Dept Med, Div Basic Sci, Biochem Sect, Heraklion, Crete, Greece.				NHLBI NIH HHS [HL-33952] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033952] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAN CM, 1995, GENOMICS, V28, P291, DOI 10.1006/geno.1995.1144; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BRECKENRIDGE WC, 1978, NEW ENGL J MED, V298, P1265, DOI 10.1056/NEJM197806082982301; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; Brunzell JD, 1989, METABOLIC BASIS INHE, P1165; BURRIS TP, 1995, P NATL ACAD SCI USA, V92, P9525, DOI 10.1073/pnas.92.21.9525; CASANOVA J, 1994, MOL CELL BIOL, V14, P5756, DOI 10.1128/MCB.14.9.5756; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; Drewes T, 1996, MOL CELL BIOL, V16, P925; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GLASS CK, 1990, BIOCHIM BIOPHYS ACTA, V1032, P157, DOI 10.1016/0304-419X(90)90002-I; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUERRA MJMD, 1993, MOL CELL BIOL, V13, P7725, DOI 10.1128/MCB.13.12.7725; HadzopoulouCladaras M, 1997, J BIOL CHEM, V272, P539; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JACKSON RL, 1977, P NATL ACAD SCI USA, V74, P1942, DOI 10.1073/pnas.74.5.1942; Kardassis D, 1996, HYPERTENSION, V27, P980, DOI 10.1161/01.HYP.27.4.980; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KIMURA A, 1993, J BIOL CHEM, V268, P11125; Ktistaki E, 1997, MOL CELL BIOL, V17, P2790, DOI 10.1128/MCB.17.5.2790; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LEBLANC BP, 1995, GENE DEV, V9, P1811, DOI 10.1101/gad.9.15.1811; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; Leng X, 1996, MOL CELL BIOL, V16, P2332; LUSIS AJ, 1986, P NATL ACAD SCI USA, V83, P3929, DOI 10.1073/pnas.83.11.3929; Malik S, 1996, MOL CELL BIOL, V16, P1824; MALIK S, 1995, NUCLEIC ACIDS RES, V23, P1536, DOI 10.1093/nar/23.9.1536; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; METZGER S, 1993, J BIOL CHEM, V268, P16831; MILLER AL, 1973, J BIOL CHEM, V248, P3359; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NAKSHATRI H, 1994, J BIOL CHEM, V269, P890; NILSSONEHLE P, 1980, ANNU REV BIOCHEM, V49, P667, DOI 10.1146/annurev.bi.49.070180.003315; NITSCH D, 1993, P NATL ACAD SCI USA, V90, P5479, DOI 10.1073/pnas.90.12.5479; OGAMI K, 1990, J BIOL CHEM, V265, P9808; Rassoul F, 1988, Dtsch Z Verdau Stoffwechselkr, V48, P104; SAGAMI I, 1986, MOL CELL BIOL, V6, P4259, DOI 10.1128/MCB.6.12.4259; SAYER F, 1995, SCIENCE, V270, P1825; SAYER F, 1995, SCIENCE, V270, P1783; SLADEK FM, 1994, LIVER GENE EXPRESSIO, P127; TABLER M, 1994, NUCLEIC ACIDS RES, V22, P3958, DOI 10.1093/nar/22.19.3958; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; Tzameli I, 1996, J BIOL CHEM, V271, P8402, DOI 10.1074/jbc.271.14.8402; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Vorgia P, 1998, J BIOL CHEM, V273, P4188, DOI 10.1074/jbc.273.7.4188; WEI CF, 1985, J BIOL CHEM, V260, P5211; ZANNIS VI, 1993, ADV HUM GENET, V21, P145	57	30	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17810	17816		10.1074/jbc.273.28.17810	http://dx.doi.org/10.1074/jbc.273.28.17810			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651383	hybrid			2022-12-25	WOS:000074816100076
J	Lam, M; Bhat, MB; Nunez, G; Ma, JJ; Distelhorst, CW				Lam, M; Bhat, MB; Nunez, G; Ma, JJ; Distelhorst, CW			Regulation of Bcl-xl channel activity by calcium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; ENDOPLASMIC-RETICULUM; APOPTOSIS; CA2+; ONCOPROTEIN; MEMBRANE; PROTEIN; NUCLEAR	Recent studies have demonstrated that the anti-apoptotic proteins, Bcl-2 and Bcl-xl, with the carboxyl terminal hydrophobic domain removed, form cation-selective channels in the lipid bilayer reconstitution system. However, the regulatory properties of these channels are unknown. In this study, we investigated the ion-conducting properties of full length Bcl-xl in the lipid bilayer reconstitution system. Our findings indicate that Bcl-xl forms a cation-selective channel that conducts sodium but not calcium and that Bcl-xl channel activity is reversibly inhibited by luminal calcium with a half-dissociation constant of similar to 60 mu M This calcium-de pendent regulation of the Bcl-xl channel provides new insights into the roles of calcium and Bcl-2-related proteins in the programmed cell death pathway.	Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; University of Michigan System; University of Michigan	Ma, JJ (corresponding author), Case Western Reserve Univ, Dept Physiol & Biophys, 10900 Euclid Ave, Cleveland, OH 44106 USA.	jxm63@po.cwru.edu; cwd@po.cwru.edu	Nuñez, Gabriel/A-7160-2014		NCI NIH HHS [R01 CA42755] Funding Source: Medline; NIA NIH HHS [AG-15556] Funding Source: Medline; NIDDK NIH HHS [5T32DK07319] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042755] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007319] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015556] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BAFFY G, 1993, J BIOL CHEM, V268, P6511; Barrero MJ, 1997, J BIOL CHEM, V272, P27694, DOI 10.1074/jbc.272.44.27694; BATY D, 1987, P NATL ACAD SCI USA, V84, P1152, DOI 10.1073/pnas.84.5.1152; Bhat MB, 1997, BIOPHYS J, V73, P1329, DOI 10.1016/S0006-3495(97)78166-9; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BROSTROM CO, 1990, ANNU REV PHYSIOL, V52, P577; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; DEJONG D, 1994, CANCER RES, V54, P256; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; Hidalgo C, 1995, BIOSCIENCE REP, V15, P387, DOI 10.1007/BF01788370; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Klaerke DA, 1997, COMP BIOCHEM PHYS A, V118, P215, DOI 10.1016/S0300-9629(97)00070-4; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LODISH HF, 1992, J BIOL CHEM, V267, P12753; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; MAGNELLI L, 1994, BIOCHEM BIOPH RES CO, V204, P84, DOI 10.1006/bbrc.1994.2429; Marin MC, 1996, ONCOGENE, V12, P2259; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MIYATA H, 1991, AM J PHYSIOL, V261, pH1123, DOI 10.1152/ajpheart.1991.261.4.H1123; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; Triggle DJ, 1997, J HYPERTENS, V15, pS9, DOI 10.1097/00004872-199715055-00003; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	35	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17307	17310		10.1074/jbc.273.28.17307	http://dx.doi.org/10.1074/jbc.273.28.17307			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651311	hybrid			2022-12-25	WOS:000074816100004
J	Leung, SM; Chen, D; DasGupta, BR; Whiteheart, SW; Apodaca, G				Leung, SM; Chen, D; DasGupta, BR; Whiteheart, SW; Apodaca, G			SNAP-23 requirement for transferrin recycling in streptolysin-O-permeabilized Madin-Darby canine kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR MEMBRANE-FUSION; PROTEIN-PROTEIN INTERACTIONS; NEUROTOXIN TYPE-A; BOTULINUM NEUROTOXIN; MDCK CELLS; VESICULAR TRANSPORT; CA2+-DEPENDENT EXOCYTOSIS; CLOSTRIDIAL NEUROTOXINS; SYNTAXIN-BINDING; PC12 CELLS	Fusion of recycling and transcytotic vesicles with the apical and basolateral plasma membrane domains of Madin-Darby canine kidney (MDCK) cells requires the N-ethylmaleimide-sensitive factor and is sensitive to botulinum neurotoxin serotype E (BoNT/E). BoNT/E is thought to selectively proteolyze the 25,000-dalton synaptosomal associated protein (SNAP-25), a protein found in neurons or cells of neuroendocrine origin. However, SNAP-25 is not found in MDCK cells. One possible target for BoNT/E in MDCK cells is SNAP-23, a newly described SNAP-25 homolog that is found in several organs including kidney. Currently, the function of SNAP-23 is unknown. We have reconstituted transferrin recycling in permeabilized MDCK cells to assess the role of SNAP-23 in the endocytic traffic of this protein. We find that: (i) SNAP-23 is expressed in MDCK cells and is found both at the basolateral plasma membrane and associated with apical and basolateral vesicles, (ii) canine SNAP-23 is cleaved by BoNT/E, (iii) transferrin recycling is N-ethylmaleimide-sensitive factor-dependent and BoNT/E-sensitive, and (iv) addition of either exogenous SNAP-23 or anti-SNAP-23 antibodies inhibits ligand recycling. Our observations suggest that SNAP-23 may be required for fusion of recycling vesicles with the basolateral membrane of polarized MDCK cells.	Univ Pittsburgh, Renal Electroelyte Div, Dept Med, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Lab Epithelial Cell Biol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA; Univ Kentucky, Dept Biochem, Lexington, KY 40536 USA; Univ Wisconsin, Dept Food Microbiol & Toxicol, Madison, WI 53706 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Kentucky; University of Wisconsin System; University of Wisconsin Madison	Apodaca, G (corresponding author), Univ Pittsburgh, Renal Electroelyte Div, Dept Med, 982 Scaife Hall, Pittsburgh, PA 15261 USA.	gla6@pop.pitt.edu	Apodaca, Gerard/HCJ-0048-2022	Whiteheart, Sidney/0000-0001-5577-0473	NIAID NIH HHS [R01 AI25144, AI36953] Funding Source: Medline; NIDDK NIH HHS [R01DK51970-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025144, R01AI036953] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051970] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Apodaca G, 1996, EMBO J, V15, P1471, DOI 10.1002/j.1460-2075.1996.tb00491.x; APODACA G, 1994, J CELL BIOL, V125, P67, DOI 10.1083/jcb.125.1.67; Araki S, 1997, BIOCHEM BIOPH RES CO, V234, P257, DOI 10.1006/bbrc.1997.6560; BANERJEE A, 1993, NEUROSCI LETT, V164, P93, DOI 10.1016/0304-3940(93)90865-I; Banerjee A, 1996, J BIOL CHEM, V271, P20227, DOI 10.1074/jbc.271.34.20227; BARROSO M, 1994, J CELL BIOL, V124, P83, DOI 10.1083/jcb.124.1.83; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BREITFELD PP, 1989, METHOD CELL BIOL, V32, P329; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DASGUPTA BR, 1990, J PHYSIOL-PARIS, V84, P220; DASGUPTA BR, 1983, TOXICON, V21, P535, DOI 10.1016/0041-0101(83)90131-9; Gaisano HY, 1997, FEBS LETT, V414, P298, DOI 10.1016/S0014-5793(97)01013-2; Gaisano HY, 1996, MOL BIOL CELL, V7, P2019, DOI 10.1091/mbc.7.12.2019; GALLI T, 1994, J CELL BIOL, V125, P1015, DOI 10.1083/jcb.125.5.1015; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GUMBINER B, 1986, J CELL BIOL, V102, P457, DOI 10.1083/jcb.102.2.457; GUTIERREZ LM, 1995, FEBS LETT, V372, P39, DOI 10.1016/0014-5793(95)00944-5; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; JAHN R, 1994, ANN NY ACAD SCI, V733, P245, DOI 10.1111/j.1749-6632.1994.tb17274.x; LOMNETH R, 1991, J NEUROCHEM, V57, P1413, DOI 10.1111/j.1471-4159.1991.tb08308.x; Low SH, 1996, MOL BIOL CELL, V7, P2007, DOI 10.1091/mbc.7.12.2007; Low SH, 1998, J BIOL CHEM, V273, P3422, DOI 10.1074/jbc.273.6.3422; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; Macaulay SL, 1997, BIOCHEM BIOPH RES CO, V237, P388, DOI 10.1006/bbrc.1997.7143; MARTYS JL, 1995, J BIOL CHEM, V270, P25976, DOI 10.1074/jbc.270.43.25976; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MILLER SG, 1991, J CELL BIOL, V112, P39, DOI 10.1083/jcb.112.1.39; MOSTOV KE, 1995, BIOESSAYS, V17, P129, DOI 10.1002/bies.950170208; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Peng XR, 1997, MOL BIOL CELL, V8, P399, DOI 10.1091/mbc.8.3.399; PEVSNER J, 1994, CURR OPIN CELL BIOL, V6, P555, DOI 10.1016/0955-0674(94)90076-0; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PIMPLIKAR SW, 1994, J CELL BIOL, V125, P1025, DOI 10.1083/jcb.125.5.1025; PODBILEWICZ B, 1990, EMBO J, V9, P3477, DOI 10.1002/j.1460-2075.1990.tb07556.x; PROTOPOPOV V, 1993, CELL, V74, P855, DOI 10.1016/0092-8674(93)90465-3; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; Rothman JE, 1997, SCIENCE, V276, P1212, DOI 10.1126/science.276.5316.1212; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; SATHYAMOORTHY V, 1985, J BIOL CHEM, V260, P461; SCHIAVO G, 1993, FEBS LETT, V335, P99, DOI 10.1016/0014-5793(93)80448-4; Schmidt JJ, 1995, J PROTEIN CHEM, V14, P703, DOI 10.1007/BF01886909; SHONE CC, 1993, EUR J BIOCHEM, V217, P965, DOI 10.1111/j.1432-1033.1993.tb18327.x; SIMPSON LL, 1983, J PHARMACOL EXP THER, V224, P135; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; Ungermann C, 1998, J CELL BIOL, V140, P61, DOI 10.1083/jcb.140.1.61; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; Wang GY, 1997, J CELL SCI, V110, P505; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; WHITEHEART SW, 1995, TRENDS CELL BIOL, V5, P64, DOI 10.1016/S0962-8924(00)88948-5; WILSON DW, 1991, TRENDS BIOCHEM SCI, V16, P334, DOI 10.1016/0968-0004(91)90138-L; WILSON KL, 1995, CELL, V81, P475, DOI 10.1016/0092-8674(95)90067-5; Wong PPC, 1997, BIOCHEM BIOPH RES CO, V230, P64, DOI 10.1006/bbrc.1996.5884	60	57	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17732	17741		10.1074/jbc.273.28.17732	http://dx.doi.org/10.1074/jbc.273.28.17732			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651373	hybrid			2022-12-25	WOS:000074816100066
J	Peng, Y; Genin, A; Spinner, NB; Diamond, RH; Taub, R				Peng, Y; Genin, A; Spinner, NB; Diamond, RH; Taub, R			The gene encoding human nuclear protein tyrosine phosphatase, PRL-1 - Cloning, chromosomal localization, and identification of an intron enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGENERATING LIVER; HEPATOCYTES; SEQUENCE; GROWTH; DNA	Expression of the rat PRL I gene, which encodes a unique nuclear protein tyrosine phosphatase, is positively associated with cellular growth during liver development, regeneration, and oncogenesis but with differentiation in intestine and other tissues. Here, we analyzed the structure of the human PRL-I gene and localized it to chromosome 6 within band q12, Human, rat, and mouse PRL-1 are 100% conserved at the amino acid level and 55% identical to a newly identified Caenorhabditis elegans PRL-I, The presence of two promoter activities, P1 and P2, in the human PRL-I gene were identified by primer extension and RNase protection assays. A functional TATA box was identified in promoter P1 upstream of the non-coding first exon, A non-canonical internal promoter, P2, was found in the first intron that results in PRL-I transcripts beginning 8 base pairs downstream of the 5'-end of exon 2 and causes no alteration in the encoded protein. The first 200-base pair region of either promoter P1 or P2 conferred high basal transcriptional activity. An enhancer that bound a developmentally regulated factor, PRL-I intron enhancer complex (PIEC), was localized to the first intron of the human PRL-1 gene. The presence of PIEC correlated with the ability of the intron enhancer to confer transcriptional activation in HepG2 and F9 cells. The intron enhancer contributed significantly to PRL I promoter activity in HepG2 cells which contain PIEC but not to NIH 3T3 cells which do not.	Univ Penn, Sch Med, Dept Genet, Div Gastroenterol, Philadelphia, PA 19104 USA; Childrens Hosp, Dept Genet, Div Genet, Philadelphia, PA 19104 USA; Childrens Hosp, Dept Pediat, Div Genet, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Taub, R (corresponding author), Univ Penn, Sch Med, Dept Genet, Div Gastroenterol, 705A Stellar Chance,422 Curie Blvd, Philadelphia, PA 19104 USA.				NIDDK NIH HHS [DK44237, DK49629] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044237, R01DK049629] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Cates CA, 1996, CANCER LETT, V110, P49, DOI 10.1016/S0304-3835(96)04459-X; CRESSMAN DE, 1994, J BIOL CHEM, V269, P30429; DIAMOND HR, 1996, AM J PHYSIOL, V271, pG121; DIAMOND RH, 1994, MOL CELL BIOL, V14, P3752, DOI 10.1128/MCB.14.6.3752; Du KY, 1997, MOL CELL BIOL, V17, P4096, DOI 10.1128/MCB.17.7.4096; GREENBAUM LE, 1995, J CLIN INVEST, V96, P1351, DOI 10.1172/JCI118170; LICHTER P, 1992, HUMAN CYTOGENETICS P; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MOHN KL, 1990, J BIOL CHEM, V265, P21914; MONTAGNA M, 1995, HUM GENET, V96, P532; Moore DD, 1995, GLOB MOB SURV; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; Peng Y, 1997, GENOMICS, V43, P278, DOI 10.1006/geno.1997.4821; RODRIGUEZ E, 1994, CANCER RES, V54, P3398; SEAL SN, 1991, MOL CELL BIOL, V11, P2704, DOI 10.1128/MCB.11.5.2704; Suh E, 1996, MOL CELL BIOL, V16, P619; TAUB R, 1996, PROTEIN PHOSPHORYLAT, P59; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	18	24	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17286	17295		10.1074/jbc.273.27.17286	http://dx.doi.org/10.1074/jbc.273.27.17286			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642300	hybrid			2022-12-25	WOS:000074545200090
J	Saito, K; Nishijima, M; Kuge, O				Saito, K; Nishijima, M; Kuge, O			Genetic evidence that phosphatidylserine synthase II catalyzes the conversion of phosphatidylethanolamine to phosphatidylserine in Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOSYNTHESIS; MUTANT; PHOSPHATIDYLCHOLINE; KINASE	Phosphatidylserine (PS) in mammalian cells is synthesized through the exchange of free L-serine with the base moiety of phosphatidylcholine or phosphatidylethanolamine (PE), The serine base exchange in Chinese hamster ovary (CHO) cells is catalyzed by at least two enzymes, PS synthase (PSS) I and II. A PSS I-lacking mutant of CHO-III cells, PSA-S, which exhibits similar to 2-fold lower serine base exchange activity than CHO-K1, is defective in the conversion of phosphatidylcholine to PS but has the ability to convert PE to PS. The PSA-3 mutant requires exogenous PS or PE for cell growth. In the present study, from PSA-3 mutant cells, we isolated a mutant, named PSB-2, with a further decrease in the serine base exchange activity. The activity in the homogenate of PSB-2 mutant cells was similar to 10% that of PSA-3 mutant cells and similar to 5% that of CHO-K1 cells. The PSB-2 mutant exhibited an similar to 80% reduction in the PSS II mRNA level relative to that in PSA-3 mutant and CHO-K1 cells. These results showed that the PSB-2 mutant is defective in PSS II. Like the PSA-S mutant, the PSB-2 mutant grew well in medium supplemented with PS, However, in the medium supplemented with PE, the PSB-2 mutant was incapable of growth, in contrast to the PSA-3 mutant. In the medium with exogenous PE, the PSB-2 mutant was defective in PS biosynthesis, whereas the PSA-3 mutant synthesized a normal amount of PS, A metabolic labeling experiment with exogenous [P-32]PE revealed that the PSB-2 mutant was defective in the conversion of exogenous PE to PS, This defect and the growth and PS biosynthetic defects of the PSB-2 mutant cultivated with exogenous PE were complemented by the PSS II cDNA In addition, the cDNA of the other PS synthase, PSS I, was shown not to complement the defect in the conversion of exogenous PE to PS of the PSB-2 mutant, implying that PSS I negligibly contributes to the conversion of PE to PS in CHO-K1 cells. These results indicated that PSS LI is critical for the growth and PS biosynthesis of PSA-3 mutant cells cultivated with exogenous PE and suggested that most of the PS formation from PE in CHO-gl cells is catalyzed by PSS II.	Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, Tokyo 162, Japan	National Institute of Infectious Diseases (NIID)	Kuge, O (corresponding author), Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, Toyama 1-23-1, Tokyo 162, Japan.			Kuge, Osamu/0000-0003-4962-3519				BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BORKENHAGEN L, 1961, J BIOL CHEM, V236, pPC28; ESKO JD, 1978, P NATL ACAD SCI USA, V75, P1190, DOI 10.1073/pnas.75.3.1190; HASEGAWA K, 1989, J BIOL CHEM, V264, P19887; KUGE O, 1986, J BIOL CHEM, V261, P5790; KUGE O, 1986, J BIOL CHEM, V261, P5795; Kuge O, 1998, P NATL ACAD SCI USA, V95, P4199, DOI 10.1073/pnas.95.8.4199; Kuge O, 1997, BBA-LIPID LIPID MET, V1348, P151, DOI 10.1016/S0005-2760(97)00137-9; KUGE O, 1991, J BIOL CHEM, V266, P24184; Kuge O, 1997, J BIOL CHEM, V272, P19133, DOI 10.1074/jbc.272.31.19133; KUGE O, 1985, P NATL ACAD SCI USA, V82, P1926, DOI 10.1073/pnas.82.7.1926; KUGE O, 1989, BIOCHIM BIOPHYS ACTA, V986, P61, DOI 10.1016/0005-2736(89)90272-1; LEWIS WH, 1980, SOMAT CELL GENET, V6, P333, DOI 10.1007/BF01542787; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARGGRAF WD, 1974, H-S Z PHYSIOL CHEM, V355, P1299, DOI 10.1515/bchm2.1974.355.2.1299; MILLER MA, 1986, J BIOL CHEM, V261, P9753; NISHIJIMA M, 1986, J BIOL CHEM, V261, P5784; NISHIJIMA M, 1984, J BIOL CHEM, V259, P7101; RAETZ CRH, 1982, P NATL ACAD SCI-BIOL, V79, P3223, DOI 10.1073/pnas.79.10.3223; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; Saito K, 1996, FEBS LETT, V395, P262, DOI 10.1016/0014-5793(96)01049-6; Sambrook J., 2002, MOL CLONING LAB MANU; VOELKER DR, 1984, P NATL ACAD SCI-BIOL, V81, P2669, DOI 10.1073/pnas.81.9.2669	23	52	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17199	17205		10.1074/jbc.273.27.17199	http://dx.doi.org/10.1074/jbc.273.27.17199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642289	hybrid			2022-12-25	WOS:000074545200079
J	Walker, LA; Gailly, P; Jensen, PE; Somlyo, AV; Somlyo, AP				Walker, LA; Gailly, P; Jensen, PE; Somlyo, AV; Somlyo, AP			The unimportance of being (protein kinase C) epsilon	FASEB JOURNAL			English	Article						calcium sensitization; PKC; myosin light chain kinase; phosphorylation	MYOSIN LIGHT-CHAIN; VASCULAR SMOOTH-MUSCLE; PHORBOL ESTER; SIGNAL-TRANSDUCTION; REGULATORY DOMAIN; 2ND MESSENGERS; CALYCULIN-A; PHOSPHORYLATION; CALCIUM; CONTRACTION	The purpose of our study was to determine the mechanism through which phorbol esters and smooth muscle myosin phosphatase inhibitors can induce contraction of smooth muscle in the absence of Ca2+. Protein kinase C-epsilon (PKC-epsilon) was previously implicated in this process based largely on its supposed absence in the ferret portal vein, and a correlation was drawn between the presence of this isoform and the ability of smooth muscle to contract independently of Ca2+ and phosphorylation of the 20 kDa regulatory light chains of myosin (MLC20). We demonstrate here, with two antibodies, one to the NH2 terminus and the other to the COOH terminus of PKC-epsilon, that Eis present in both ferret portal vein and rabbit portal vein smooth muscle, neither of which exhibits phorbol ester-induced contraction in the absence of Ca2+, However, in the presence of clamped submaximal Ca2+, phorbol ester increased MLC20, phosphorylation from 17.7 +/- 1.7% to 46.4 +/- 3.6% in ferret portal vein smooth muscle and evoked an increase in force, Prolonged (48 h) incubation of ferret portal vein with phorbol esters completely down-regulated PKC-epsilon, as shown by Western blots, and abolished the phorbol ester-evoked contraction at submaximal Ca2+, but not Ca2+-independent, contractions induced by the phosphatase inhibitor microcystin, Contractions induced by microcystin in Ca2+-free solution were associated with increased phosphorylation of myosin light chain kinase (MLCK), Activation of MLCK by autophosphorylation in the absence of Ca2+ occurs in vitro (1). We conclude that PKC-epsilon is neither necessary nor sufficient for Ca2+-independent regulation of myosin II in smooth muscle, but contractions induced by agents: that inhibit smooth muscle myosin phosphatase in the absence of Ca2+ may be mediated by MLCK autophosphorylated or activated by another Ca2+-independent kinase.-Walker, L. A., Gailly, P., Jensen, P. E., Somlyo, A. V., Somlyo, A. P. The unimportance of being (protein kinase C) epsilon.	Univ Virginia, Hlth Sci Ctr, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22906 USA; Univ Virginia, Hlth Sci Ctr, Dept Med, Charlottesville, VA 22906 USA; Univ Virginia, Hlth Sci Ctr, Dept Pathol, Charlottesville, VA 22906 USA; Catholic Univ Louvain, Dept Physiol, Brussels, Belgium; Sch Nursing, Aarhus, Denmark	University of Virginia; University of Virginia; University of Virginia; Universite Catholique Louvain	Somlyo, AP (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Mol Physiol & Biol Phys, POB 10011, Charlottesville, VA 22906 USA.	aps2n@aemsun.med.virginia.edu	Walker, Lori/J-7098-2013	Walker, Lori/0000-0003-2556-8076	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048807] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL48807] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARANY K, 1992, BIOCHIM BIOPHYS ACTA, V1134, P233, DOI 10.1016/0167-4889(92)90181-A; BIALOJAN C, 1988, J PHYSIOL-LONDON, V398, P81, DOI 10.1113/jphysiol.1988.sp017030; CHATTERJEE M, 1986, AM J PHYSIOL, V251, pC356, DOI 10.1152/ajpcell.1986.251.3.C356; COLLINS EM, 1992, AM J PHYSIOL, V262, pH754, DOI 10.1152/ajpheart.1992.262.3.H754; DEKKER LV, 1995, CURR OPIN STRUC BIOL, V5, P396, DOI 10.1016/0959-440X(95)80103-0; ETO M, 1995, J BIOCHEM, V118, P1104, DOI 10.1093/oxfordjournals.jbchem.a124993; Fujihara H, 1997, MOL BIOL CELL, V8, P2437, DOI 10.1091/mbc.8.12.2437; FULGINITI J, 1993, J VASC RES, V30, P315, DOI 10.1159/000159012; Gailly P, 1997, J PHYSIOL-LONDON, V500, P95, DOI 10.1113/jphysiol.1997.sp022002; Gong MC, 1997, MOL BIOL CELL, V8, P279, DOI 10.1091/mbc.8.2.279; GONG MC, 1992, J BIOL CHEM, V267, P14662; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P423; Herring BP, 1996, AM J PHYSIOL-CELL PH, V270, pC1656, DOI 10.1152/ajpcell.1996.270.6.C1656; HIMPENS B, 1989, J PHYSIOL-LONDON, V413, P489, DOI 10.1113/jphysiol.1989.sp017665; HORI M, 1993, BRIT J PHARMACOL, V110, P1527, DOI 10.1111/j.1476-5381.1993.tb13996.x; Horowitz A, 1996, AM J PHYSIOL-CELL PH, V271, pC589, DOI 10.1152/ajpcell.1996.271.2.C589; Horowitz A, 1996, PHYSIOL REV, V76, P967, DOI 10.1152/physrev.1996.76.4.967; ISHIHARA H, 1989, J PHARMACOL EXP THER, V250, P388; Jensen PE, 1996, BIOCHEM J, V318, P469, DOI 10.1042/bj3180469; JIANG MJ, 1989, PFLUG ARCH EUR J PHY, V413, P637, DOI 10.1007/BF00581814; KAMM KE, 1989, ANNU REV PHYSIOL, V51, P299; KHALIL RA, 1992, J PHYSIOL-LONDON, V455, P585, DOI 10.1113/jphysiol.1992.sp019317; KHALIL RA, 1992, AM J PHYSIOL, V263, pC714, DOI 10.1152/ajpcell.1992.263.3.C714; KITAZAWA T, 1991, P NATL ACAD SCI USA, V88, P9307, DOI 10.1073/pnas.88.20.9307; KITAZAWA T, 1991, ADV EXP MED BIOL, V304, P97; KITAZAWA T, 1989, J BIOL CHEM, V264, P5330; LEE MW, 1994, AM J PHYSIOL, V267, pC659, DOI 10.1152/ajpcell.1994.267.3.C659; NAKABAYASHI H, 1991, FEBS LETT, V294, P144, DOI 10.1016/0014-5793(91)81362-C; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NIXON GF, 1995, J PHYSIOL-LONDON, V487, P283, DOI 10.1113/jphysiol.1995.sp020879; PEARS C, 1991, BIOCHEM J, V276, P257, DOI 10.1042/bj2760257; Pettitt TR, 1997, J BIOL CHEM, V272, P17354, DOI 10.1074/jbc.272.28.17354; SANDO JJ, 1992, CELL SIGNAL, V4, P595, DOI 10.1016/0898-6568(92)90041-6; SATO K, 1992, J PHARMACOL EXP THER, V261, P497; SINGER HA, 1987, J PHARMACOL EXP THER, V243, P814; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; SUZUKI A, 1993, BRIT J PHARMACOL, V109, P703, DOI 10.1111/j.1476-5381.1993.tb13631.x; Takuwa Y, 1996, JPN HEART J, V37, P793; TOKUI T, 1995, BIOCHEMISTRY-US, V34, P5173, DOI 10.1021/bi00015a031; WALSH MP, 1994, CAN J PHYSIOL PHARM, V72, P1392, DOI 10.1139/y94-201; Wu XQ, 1998, J BIOL CHEM, V273, P11362, DOI 10.1074/jbc.273.18.11362	42	30	30	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1998	12	10					813	821		10.1096/fasebj.12.10.813	http://dx.doi.org/10.1096/fasebj.12.10.813			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZY035	9657521				2022-12-25	WOS:000074580100006
J	Lee, KK; Murakawa, M; Nishida, E; Tsubuki, S; Kawashima, S; Sakamaki, K; Yonehara, S				Lee, KK; Murakawa, M; Nishida, E; Tsubuki, S; Kawashima, S; Sakamaki, K; Yonehara, S			Proteolytic activation of MST/Krs, STE20-related protein kinase, by caspase during apoptosis	ONCOGENE			English	Article						Fas (Apo-1/CD95); apoptosis; caspase; protein kinase; signal transduction	TUMOR-NECROSIS-FACTOR; INDUCED CELL-DEATH; MONOCLONAL-ANTIBODY; FAS; PROTEASES; CLONING; DOMAIN; INTERACTS; CONTAINS; RECEPTOR	The Fas system has been extensively investigated as a model of apoptosis and the caspase cascade has been shown to be a characteristic mechanism of signaling of apoptosis. We have identified and purified a kinase that was activated after the stimulation of Fas on human thymoma-derived HPB-ALL cells. Partial amino acid sequencing of the purified kinase revealed it to be MST/ Krs, member of the yeast STE20 family of protein kinases. MST/Krs was activated by proteolytic cleavage and proteolytic activation was blocked by the caspase inhibitor, Z-VAD-FK. A mutant MST with Asp-->Asn replacement at a putative caspase cleavage site was resistant to either the proteolytic cleavage or the activation of the kinase activity. These findings suggest that proteolytic activation is one activation mechanism of MST and plays a role in apoptosis.	Kyoto Univ, Inst Virus Res, Kyoto 60601, Japan; Tokyo Metropolitan Inst Med Sci, Tokyo 113, Japan; Kyoto Univ, Fac Sci, Dept Biophys, Kyoto 60601, Japan	Kyoto University; Tokyo Metropolitan Institute of Medical Science; Kyoto University	Yonehara, S (corresponding author), Kyoto Univ, Inst Virus Res, Kyoto 60601, Japan.			Sakamaki, Kazuhiro/0000-0002-7072-9628				Abbas AK, 1996, CELL, V84, P655, DOI 10.1016/S0092-8674(00)81042-9; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cahill MA, 1996, ONCOGENE, V13, P2087; CASCIOLA RL, 1995, J EXP MED, V12, P1625; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Creasy CL, 1996, J BIOL CHEM, V271, P21049, DOI 10.1074/jbc.271.35.21049; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; Creasy CL, 1995, GENE, V167, P303, DOI 10.1016/0378-1119(95)00653-2; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; FRIESEN H, 1994, GENE DEV, V8, P2162, DOI 10.1101/gad.8.18.2162; Furukawa Y, 1996, J BIOL CHEM, V271, P28469, DOI 10.1074/jbc.271.45.28469; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Lu ML, 1996, P NATL ACAD SCI USA, V93, P8977, DOI 10.1073/pnas.93.17.8977; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Taylor LK, 1996, P NATL ACAD SCI USA, V93, P10099, DOI 10.1073/pnas.93.19.10099; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; Yuan JY, 1997, CURR OPIN CELL BIOL, V9, P247, DOI 10.1016/S0955-0674(97)80069-5	35	116	119	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 11	1998	16	23					3029	3037		10.1038/sj.onc.1201840	http://dx.doi.org/10.1038/sj.onc.1201840			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZT782	9662336				2022-12-25	WOS:000074125300010
J	Wellbrock, C; Geissinger, E; Gomez, A; Fischer, P; Friedrich, K; Schartl, M				Wellbrock, C; Geissinger, E; Gomez, A; Fischer, P; Friedrich, K; Schartl, M			Signalling by the oncogenic receptor tyrosine kinase Xmrk leads to activation of STAT5 in Xiphophorus melanoma	ONCOGENE			English	Article						receptor tyrosine kinase; melanoma; STAT5; signal transduction	EPIDERMAL GROWTH-FACTOR; DNA-BINDING ACTIVITY; COLONY-STIMULATING FACTOR; GENE-EXPRESSION; BETA-CHAIN; TRANSCRIPTIONAL ACTIVATION; CELL-PROLIFERATION; ONCOSTATIN-M; ERYTHROPOIETIN; INTERLEUKIN-2	Overexpression of the mutationally activated Xmrk receptor initiates the formation of hereditary malignant melanoma in the fish Xiphophorus, In addition to transcriptional overexpression a cell-type specific signal transduction is essential for Xmrk mediated tumor formation. To elucidate the consequence of Xmrk signalling and to identify target proteins that characterize the tumor phenotype, we analysed proteins that are strongly tyrosine phosphorylated in the fish melanoma cell line PSM, One of the most prominent phosphotyrosine proteins was found to be the signal transducer and activator of transcription STAT5. In a heterologous cell system (murine pro B-cells), activation of the Xmrk kinase in a chimeric receptor induced tyrosine phosphorylation, nuclear translocation and DNA binding of STAT5. Following receptor stimulation, expression of the STAT5 specific target genes cis, osm and pim-1 was induced, In Xiphophorus PSM cells STAT5 was found to be preferentially localized in the nucleus, but treatment with tyrphostin AG555, a specific Xmrk kinase-inhibitor, blocked nuclear localization. In these cells as well as in Xiphophorus melanoma expression of pim-1 and constitutive DNA-binding activity of STATS was detectable. This constitutive activity was higher in malignant than in benign melanomas, indicating that STATS activation is correlated with the malignancy of these tumors.	Univ Wurzburg, Theodor Boveri Inst, Bioctr, Dept Physiol Chem 1, D-97074 Wurzburg, Germany; Univ Wurzburg, Theodor Boveri Inst, Bioctr, Dept Phys Chem 2, D-97074 Wurzburg, Germany	University of Wurzburg; University of Wurzburg	Schartl, M (corresponding author), Univ Wurzburg, Theodor Boveri Inst, Bioctr, Dept Physiol Chem 1, Am Hubland, D-97074 Wurzburg, Germany.		Gómez, Ana/K-6998-2014	Gómez, Ana/0000-0003-4714-8064; Wellbrock, Claudia/0000-0002-3825-6381; Schartl, Manfred/0000-0001-9882-5948				ADAM D, 1993, SCIENCE, V259, P816, DOI 10.1126/science.8430335; ADAM D, 1991, ONCOGENE, V6, P73; Beadling C, 1996, EMBO J, V15, P1902, DOI 10.1002/j.1460-2075.1996.tb00541.x; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Chretien S, 1996, EMBO J, V15, P4174, DOI 10.1002/j.1460-2075.1996.tb00792.x; COFFER PJ, 1995, BIOCHEM BIOPH RES CO, V210, P74, DOI 10.1006/bbrc.1995.1629; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; David M, 1996, J BIOL CHEM, V271, P9185, DOI 10.1074/jbc.271.16.9185; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DOMEN J, 1993, LEUKEMIA S2, V7, P108; FENDLY BM, 1990, CANCER RES, V50, P1550; Friedman MC, 1996, P NATL ACAD SCI USA, V93, P2077, DOI 10.1073/pnas.93.5.2077; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; GAFFEN SL, 1995, P NATL ACAD SCI USA, V92, P7192, DOI 10.1073/pnas.92.16.7192; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; GouilleuxGruart V, 1996, BLOOD, V87, P1692; HOOVER D, 1991, J BIOL CHEM, V266, P14018; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KUHN C, 1979, IN VITRO CELL DEV B, V15, P537, DOI 10.1007/BF02618156; Leaman DW, 1996, MOL CELL BIOL, V16, P369; LILLY M, 1992, ONCOGENE, V7, P727; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; MALITSCHEK B, 1994, J BIOL CHEM, V14, P10423; MAUELER W, 1993, INT J CANCER, V55, P288, DOI 10.1002/ijc.2910550220; Meinke A, 1996, MOL CELL BIOL, V16, P6937; Mellitzer G, 1996, P NATL ACAD SCI USA, V93, P9600, DOI 10.1073/pnas.93.18.9600; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PALLARD C, 1995, J BIOL CHEM, V270, P15942, DOI 10.1074/jbc.270.27.15942; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SCHARTL M, 1995, TRENDS GENET, V11, P185, DOI 10.1016/S0168-9525(00)89041-1; SELTEN G, 1986, CELL, V46, P603, DOI 10.1016/0092-8674(86)90886-X; Shuai K, 1996, ONCOGENE, V13, P247; STEWART BE, 1995, J INVEST DERMATOL, V105, P699, DOI 10.1111/1523-1747.ep12324482; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VIELKIND U, 1976, J EXP ZOOL, V196, P197, DOI 10.1002/jez.1401960207; VIGNAIS ML, 1996, MOL CELL BIOL, V16, P17759; WAKAMATSU Y, 1981, CANCER RES, V41, P679; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Wang DM, 1996, MOL CELL BIOL, V16, P6141; WELLBROCK C, 1995, ONCOGENE, V10, P2135; WELLBROCK C, 1998, IN PRESS INT J CANC; WINKLER C, 1994, ONCOGENE, V9, P1517; WITTBRODT J, 1992, EMBO J, V11, P4239, DOI 10.1002/j.1460-2075.1992.tb05518.x; WITTBRODT J, 1989, NATURE, V341, P415, DOI 10.1038/341415a0; Xu BXC, 1996, J BIOL CHEM, V271, P19768, DOI 10.1074/jbc.271.33.19768; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	61	30	32	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 11	1998	16	23					3047	3056		10.1038/sj.onc.1201844	http://dx.doi.org/10.1038/sj.onc.1201844			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZT782	9662338	Bronze			2022-12-25	WOS:000074125300012
J	Cabibbo, A; Consalez, GG; Sardella, M; Sitia, R; Rubartelli, A				Cabibbo, A; Consalez, GG; Sardella, M; Sitia, R; Rubartelli, A			Changes in gene expression during the growth arrest of HepG2 hepatoma cells induced by reducing agents or TGF beta 1	ONCOGENE			English	Article						redox regulation; redox signalling; proliferation; RNA fingerprinting; placental type alkaline phosphatase; Cytokeratin K17	DNA-BINDING ACTIVITY; DIFFERENTIAL DISPLAY; REDOX REGULATION; CYSTEINE RESIDUES; FACTOR-I; IDENTIFICATION; RECEPTOR; INVITRO; LINE; TRANSCRIPTION	The growth of hepatoma cells can be inhibited by treatment with TGF beta 1 or with exogenous reducing agents. To gain information on the molecular mechanisms underlying growth arrest, we visualized and compared gene expression profiles of proliferating ver sus non proliferating HepG2 cells by computer-assisted gene fishing, an improved technique of RNA fingerprinting that allows the selective amplification of coding regions within transcripts. While many transcripts are selectively regulated by either treatment, a set of bands appear to be coordinately regulated by 2ME and TGF beta 1, suggesting their possible involvement in the mechanisms of growth arrest. Display tags corresponding to 18 differentially expressed genes were cloned and, in most cases, identified as known genes or, more frequently, as their homospecific/cross-specific homologues. A novel member of the kinesin superfamily was identified amongst the genes induced by both 2ME and TGF beta 1. This gene, KIF3C, is upregulated in several cell lines undergoing growth arrest. Taken together, our findings show that computer-assisted gene fishing is a powerful tool for the identification and cloning of genes involved in the control of cell proliferation and indicate that extracellular reducing agents can regulate cell growth through modulation of gene expression.	Hosp San Raffaele, San Raffaele Sci Inst, Dept Biol & Technol Res, DIBIT, I-20132 Milan, Italy; Ist Nazl Ric Canc, I-16132 Genoa, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Genoa; IRCCS AOU San Martino IST	Cabibbo, A (corresponding author), Hosp San Raffaele, San Raffaele Sci Inst, Dept Biol & Technol Res, DIBIT, Via Olgettina 58, I-20132 Milan, Italy.		Consalez, Giacomo/AAA-2146-2019; Sitia, Roberto/AAB-5005-2019; Rubartelli, Anna/AAA-1259-2021	Consalez, Giacomo/0000-0003-4594-6273; Sitia, Roberto/0000-0001-7086-4152; 				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; AIZENMAN E, 1989, NEURON, V2, P1257, DOI 10.1016/0896-6273(89)90310-3; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARNONE MI, 1995, J BIOL CHEM, V270, P12048, DOI 10.1074/jbc.270.20.12048; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; COLLINS SJ, 1987, BLOOD, V70, P1233; Consalez GG, 1996, TRENDS GENET, V12, P455; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; Francia G, 1996, CANCER RES, V56, P3855; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hamm HE, 1996, CURR OPIN CELL BIOL, V8, P189, DOI 10.1016/S0955-0674(96)80065-2; HUANG LE, 1994, J BIOL CHEM, V269, P30718; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; IWATA S, 1994, J IMMUNOL, V152, P5633; JACKSON A, 1995, J BIOL CHEM, V270, P33, DOI 10.1074/jbc.270.1.33; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1995, METHOD ENZYMOL, V254, P304; LIANG P, 1992, CANCER RES, V52, P6966; LIN JK, 1992, CANCER RES, V52, P385; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; NARAYANAN S, 1983, ANN CLIN LAB SCI, V13, P133; RUBARTELLI A, 1995, CANCER RES, V55, P675; SALESIOTIS AN, 1995, CANCER LETT, V91, P47, DOI 10.1016/0304-3835(95)03717-B; Sambrook J., 2002, MOL CLONING LAB MANU; Sardella M, 1998, GENOMICS, V47, P405, DOI 10.1006/geno.1997.5123; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SIDELL N, 1982, J NATL CANCER I, V68, P589; SULLIVAN JM, 1994, NEURON, V13, P929, DOI 10.1016/0896-6273(94)90258-5; Vignali G, 1996, EUR J NEUROSCI, V8, P536, DOI 10.1111/j.1460-9568.1996.tb01238.x; Wang FL, 1996, CANCER RES, V56, P3634; Wu XS, 1996, MOL CELL BIOL, V16, P1035; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	36	15	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 4	1998	16	22					2935	2943		10.1038/sj.onc.1201825	http://dx.doi.org/10.1038/sj.onc.1201825			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZR544	9671414				2022-12-25	WOS:000073988200012
J	Connolly, JA; Morgan, IM; Jackson, ME; Campo, MS				Connolly, JA; Morgan, IM; Jackson, ME; Campo, MS			The BPV-4 co-carcinogen quercetin induces cell cycle arrest and up-regulates transcription from the LCR of BPV-4	ONCOGENE			English	Article						BPV-4; cell transformation; transcriptional regulation; transcription factors; quercetin; co-carcinogens	BOVINE PAPILLOMAVIRUS TYPE-4; LONG CONTROL REGION; ESTROGEN-BINDING SITES; COLON-CANCER; TRANSFORMATION INVITRO; TUMOR PROMOTION; PROTEIN; DNA; INHIBITION; COMPLEX	Bracken fern is the environmental co-carcinogen of BPV-4 in the induction of neoplasias of the upper alimentary canal of cattle. The flavonoid quercetin is one of the most potent and best characterised mutagens present in the fern. We have shown that transfection with BPV-4 DNA and exposure to a single dose of quercetin leads to tumorigenic transformation of primary bovine cells. We now show that quercetin induces cell cycle arrest and up-regulates transcription from the BPV-4 long control region (LCR). This up-regulation is mediated by a 21 nucleotide-long cis-element in the LCR, designated QRE-1, which is located immediately downstream of the TATA box. Cellular proteins bind to QRE-1 and removal or substitution of QRE-1 lead to the abrogation of the response to quercetin. As expression of the viral oncogenes is controlled by the LCR, perturbation in this control and increased oncoprotein expression are likely to contribute to fully malignant cell transformation by overcoming the cell cycle arrest induced by quercetin, thus forcing damaged cells to proliferate.	Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute	Campo, MS (corresponding author), Beatson Inst Canc Res, Garscube Estate, Glasgow G61 1BD, Lanark, Scotland.							AHMED MS, 1994, CARCINOGENESIS, V15, P1627, DOI 10.1093/carcin/15.8.1627; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AVILA MA, 1994, CANCER RES, V54, P2425; BJIELDANES LF, 1977, SCIENCE, V197, P577; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CAIRNEY M, 1995, CARCINOGENESIS, V16, P1997, DOI 10.1093/carcin/16.8.1997; CAMPO MS, 1994, CARCINOGENESIS, V15, P1597, DOI 10.1093/carcin/15.8.1597; CONNOLLY JA, 1997, THESIS U GLASGOW GLA; CUTHILL S, 1993, MOL CARCINOGEN, V8, P96, DOI 10.1002/mc.2940080206; DOEBERITZ MV, 1994, J VIROL, V68, P2811; FAZAL F, 1990, CARCINOGENESIS, V11, P2005, DOI 10.1093/carcin/11.11.2005; GRAZIANI Y, 1983, EUR J BIOCHEM, V135, P583, DOI 10.1111/j.1432-1033.1983.tb07692.x; GSCHWENDT M, 1984, BIOCHEM BIOPH RES CO, V124, P63, DOI 10.1016/0006-291X(84)90916-1; HOSOKAWA N, 1990, INT J CANCER, V45, P1119, DOI 10.1002/ijc.2910450622; JACKSON ME, 1993, CRIT REV ONCOGENESIS, V4, P277; JACKSON ME, 1991, J GEN VIROL, V72, P877, DOI 10.1099/0022-1317-72-4-877; JACKSON ME, 1995, J VIROL, V69, P6038, DOI 10.1128/JVI.69.10.6038-6046.1995; JAGGAR RT, 1990, J GEN VIROL, V71, P3041, DOI 10.1099/0022-1317-71-12-3041; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KATO R, 1983, CARCINOGENESIS, V4, P1301, DOI 10.1093/carcin/4.10.1301; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; Knowles G, 1996, J VIROL, V70, P8451, DOI 10.1128/JVI.70.12.8451-8458.1996; MATTER WF, 1992, BIOCHEM BIOPH RES CO, V186, P624, DOI 10.1016/0006-291X(92)90792-J; MCCAFFERY RE, 1994, J GEN VIROL, V75, P3047, DOI 10.1099/0022-1317-75-11-3047; NAKAYASU M, 1986, MUTAT RES, V174, P79, DOI 10.1016/0165-7992(86)90081-3; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; Novina CD, 1996, TRENDS GENET, V12, P351, DOI 10.1016/0168-9525(96)10034-2; PENNIE WD, 1993, VIROLOGY, V193, P614, DOI 10.1006/viro.1993.1169; PENNIE WD, 1992, VIROLOGY, V190, P861, DOI 10.1016/0042-6822(92)90926-G; Pereira MA, 1996, CARCINOGENESIS, V17, P1305, DOI 10.1093/carcin/17.6.1305; PIANTELLI M, 1995, J INVEST DERMATOL, V105, P248, DOI 10.1111/1523-1747.ep12317599; Plaumann B, 1996, ONCOGENE, V13, P1605; RAHMAN A, 1990, CARCINOGENESIS, V11, P2001, DOI 10.1093/carcin/11.11.2001; RANELLETTI FO, 1992, INT J CANCER, V50, P486, DOI 10.1002/ijc.2910500326; SAKAI A, 1990, TERATOGEN CARCIN MUT, V10, P333, DOI 10.1002/tcm.1770100406; SCAMBIA G, 1990, Anti-Cancer Drugs, V1, P45, DOI 10.1097/00001813-199010000-00008; SCAMBIA G, 1993, INT J CANCER, V54, P462, DOI 10.1002/ijc.2910540318; SMITH KT, 1987, CANC CELLS PAPILLOMA, P267; Trujillo JM, 1996, VIROLOGY, V220, P1, DOI 10.1006/viro.1996.0279; VANWARTHOOD JE, 1989, ONCOGENE, V4, P1267; WITHAM SE, 1986, BIOCHEM J, V240, P913	41	18	18	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	1998	16	21					2739	2746		10.1038/sj.onc.1201796	http://dx.doi.org/10.1038/sj.onc.1201796			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ013	9652740				2022-12-25	WOS:000073812200005
J	Ottini, L; Falchetti, M; D'Amico, C; Amorosi, A; Saieva, C; Masala, G; Frati, L; Cama, A; Palli, D; Mariani-Costantini, R				Ottini, L; Falchetti, M; D'Amico, C; Amorosi, A; Saieva, C; Masala, G; Frati, L; Cama, A; Palli, D; Mariani-Costantini, R			Mutations at coding mononucleotide repeats in gastric cancer with the microsatellite mutator phenotype	ONCOGENE			English	Article						gastric cancer; microsatellite instability; TGF beta-RII; IGFIIR; BAX; hMSH3; hMSH6; BRCA2; mutation	II RECEPTOR GENE; BETA RECEPTOR; INSTABILITY; COLON; CELLS; BAX	We analysed 50 gastric carcinomas (GCs) to verify whether mutations at coding repeats were associated with microsatellite instability (MSI), The tumors included: ten cases with no MSI, 14 cases with MSI=1 locus, 13 cases with MSI=two loci and 13 cases with MSI greater than or equal to 3 loci, We investigated coding repeats within the TGF-beta RII, IGFIIR, BAX, hMSH6, AMSH3 and BRCA2 genes. The TGF-beta RII, IGIIR, BAX, hMSH6 and hMSH3 repeats were altered in 11 (22%), five (10%), four (8%), 16 (32%) and five (10%) cases respectively. Mutations occurred only in MSI-positive (MSI+) tumors and correlated with increasing MSI levels. No alterations of the BRCA2 repeat were found. Mutations in genes other than hMSH6 were strongly associated to kMSH6 mutations, suggesting a key role of this gene. The non-coding BAT-26 and E-Cadherin 3' UTR poly(A)8/(T)15 repeats were analysed in 44 of the 50 cases. Novel tumor-associated alleles were observed only in MSI-positive GCs and were in most cases associated with mutations at coding repeats. Further investigations with BAT-40 confirmed that four cases manifested mononucleotide repeat alterations restricted to hMSH6 and one case to TGF-beta XII. A subset of tumors,vith MSI at two or more dinucleotide loci resulted negative for mutations at coding and non-coding mononucleotide repeats.	Univ Gabriele DAnnunzio, Dept Oncol & Neurosci, I-66013 Chieti, Italy; Univ La Sapienza, Dept Expt Med & Pathol, Rome, Italy; Careggi Hosp, CSPO, Epidemiol Unit, Florence, Italy; Univ Florence, Dept Pathol, Florence, Italy; CSPO, IST, Epidemiol Satellite Unit, Florence, Italy; IMNS, Isernia, Italy	G d'Annunzio University of Chieti-Pescara; Sapienza University Rome; University of Florence; Azienda Ospedaliero Universitaria Careggi; University of Florence	Mariani-Costantini, R (corresponding author), Univ Gabriele DAnnunzio, Dept Oncol & Neurosci, I-66013 Chieti, Italy.		Mariani-Costantini, Renato/B-6637-2012; CAMA, Alessandro/J-3964-2018; Frati, Luigi/ABI-7437-2020; Saieva, Calogero/AAC-2611-2019; Masala, Giovanna/AAC-5474-2022	Mariani-Costantini, Renato/0000-0002-4440-1848; CAMA, Alessandro/0000-0003-3647-1368; Saieva, Calogero/0000-0002-0117-1608; Masala, Giovanna/0000-0002-5758-9069; PALLI, Domenico/0000-0002-5558-2437; OTTINI, LAURA/0000-0001-8030-0449; tumino, rosario/0000-0003-2666-414X				Akiyama Y, 1997, CANCER RES, V57, P3920; Arnheim N, 1997, CURR OPIN GENET DEV, V7, P364, DOI 10.1016/S0959-437X(97)80150-5; BUIATTI E, 1991, INT J CANCER, V48, P369, DOI 10.1002/ijc.2910480310; Casey Graham, 1997, Current Opinion in Oncology, V9, P88; Chung YJ, 1996, CANCER RES, V56, P4662; Chung YJ, 1997, ONCOGENE, V15, P1719, DOI 10.1038/sj.onc.1201343; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; Hoang JM, 1997, CANCER RES, V57, P300; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MIYASHITA T, 1995, CELL, V80, P293; MYEROFF LL, 1995, CANCER RES, V55, P5545; Ohue M, 1996, INT J CANCER, V68, P203, DOI 10.1002/(SICI)1097-0215(19961009)68:2<203::AID-IJC11>3.0.CO;2-B; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OTTINI L, 1995, CANCER RES, V55, P5677; Ottini L, 1997, CANCER RES, V57, P4523; Ouyang H, 1997, CANCER RES, V57, P1851; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1995, CANCER RES, V55, P5548; Perucho M, 1996, NAT MED, V2, P630, DOI 10.1038/nm0696-630; Prolla TA, 1996, SEMIN CANCER BIOL, V7, P241, DOI 10.1006/scbi.1996.0032; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; Stratton MR, 1996, CURR OPIN GENET DEV, V6, P93, DOI 10.1016/S0959-437X(96)90017-9; Takahashi H, 1996, CANCER RES, V56, P2738; Zhou XP, 1997, ONCOGENE, V15, P1713, DOI 10.1038/sj.onc.1201337	28	45	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	1998	16	21					2767	2772		10.1038/sj.onc.1201816	http://dx.doi.org/10.1038/sj.onc.1201816			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ013	9652743	Green Published			2022-12-25	WOS:000073812200008
J	Lee, Y; Sayre, LM				Lee, Y; Sayre, LM			Reaffirmation that metabolism of polyamines by bovine plasma amine oxidase occurs strictly at the primary amino termini	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-AMINOPROPIONITRILE; MONOAMINE-OXIDASE; SPERMIDINE; MODEL	Oxidation of the biologically important polyamines spermine and spermidine by plasma amine oxidase (PAO) was specified many years ago to occur at the terminal primary rather than internal secondary amine positions. However, the finding of sequential enzymatic conversion of spermine to spermidine and then to putrescine (1,4-butanediamine) is superficially suggestive of metabolism at the secondary amine positions, and a recent publication (Houen, G., Beck, K., and Jensen, A. L. (1994) Acta Chem. Scand 48, 52-60) claimed that the original interpretation of preferential "terminal" deamination does not stand up to scrutiny with modern methods of analysis. We herein demonstrate that the findings cited in support of secondary amine deamination can arise artifactually from spontaneous elimination/addition reactions following initial metabolism at the terminal positions of 3-(aminopropyl)amines. We further find no evidence for the ability of PAO to metabolize the secondary amine position in homospermidine, which is devoid of such complicating side reactions. Our results support the original claimed specificity of PAO for the primary amino termini of polyamines, all of which are consistent with the general finding that the quinone-dependent copper amine oxidases specifically metabolize primary amines.	Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA	Case Western Reserve University	Sayre, LM (corresponding author), Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA.		Sayre, Lawrence M/C-8224-2011		NIGMS NIH HHS [GM 48812] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048812] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI O, 1966, AGR BIOL CHEM TOKYO, V30, P1202, DOI 10.1080/00021369.1966.10858750; ANTHONY DC, 1989, J NEUROPATH EXP NEUR, V48, P348, DOI 10.1097/00005072-198905000-00148; BACHRACH U, 1960, BIOCHIM BIOPHYS ACTA, V40, P545, DOI 10.1016/0006-3002(60)91401-3; BACHRACH U, 1986, ANAL BIOCHEM, V152, P423, DOI 10.1016/0003-2697(86)90429-X; BERGERON RJ, 1981, SYNTHESIS-STUTTGART, P732; DING CZ, 1993, J MED CHEM, V36, P1711, DOI 10.1021/jm00064a004; FERNANDEZ S, 1991, SYNTHESIS-STUTTGART, P713; HASSE K, 1963, BIOCHEM Z, V337, P69; HOUEN G, 1994, ACTA CHEM SCAND, V48, P52, DOI 10.3891/acta.chem.scand.48-0052; JAKOBY WB, 1959, J BIOL CHEM, V234, P2145; Klinman JP, 1996, J BIOL CHEM, V271, P27189, DOI 10.1074/jbc.271.44.27189; KUTTAN R, 1971, BIOCHEMISTRY-US, V10, P361, DOI 10.1021/bi00779a001; LEE YH, 1995, J AM CHEM SOC, V117, P3096, DOI 10.1021/ja00116a014; Lee YH, 1996, J AM CHEM SOC, V118, P7241, DOI 10.1021/ja9543210; MONDOVI B, 1983, METHOD ENZYMOL, V94, P314; RAIMONDI L, 1985, AGENTS ACTIONS, V16, P95, DOI 10.1007/BF01983110; TABOR CW, 1956, J PHARMACOL EXP THER, V116, P139; TABOR CW, 1970, J BIOL CHEM, V245, P5424; TABOR CW, 1964, FED PROC, V23, P385; TABOR CW, 1964, J BIOL CHEM, V239, P2194; TABOR H, 1972, ADV ENZYMOL RAMB, V36, P203; TANG SS, 1983, J BIOL CHEM, V258, P4331; Wilce MCJ, 1997, BIOCHEMISTRY-US, V36, P16116, DOI 10.1021/bi971797i; WILMARTH KR, 1991, J TOXICOL ENV HEALTH, V32, P415, DOI 10.1080/15287399109531493	24	37	39	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19490	19494		10.1074/jbc.273.31.19490	http://dx.doi.org/10.1074/jbc.273.31.19490			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677370	hybrid			2022-12-25	WOS:000075125200022
J	Short, DB; Trotter, KW; Reczek, D; Kreda, SM; Bretscher, A; Boucher, RC; Stutts, MJ; Milgram, SL				Short, DB; Trotter, KW; Reczek, D; Kreda, SM; Bretscher, A; Boucher, RC; Stutts, MJ; Milgram, SL			An apical PDZ protein anchors the cystic fibrosis transmembrane conductance regulator to the cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNEL; GUANYLATE KINASES; EPITHELIAL-CELLS; EXPRESSION; DOMAIN; FAMILY; EZRIN; TIGHT; GENE; ZO-1	The function of the cystic fibrosis transmembrane conductance regulator (CFTR) as a Cl- channel in the apical membrane of epithelial cells is extensively documented. However, less is known about the molecular determinants of CFTR residence in the apical membrane, basal regulation of its Cl- channel activity, and its reported effects on the function of other transporters. These aspects of CFTR function likely require specific interactions between CFTR and unknown proteins in the apical compartment of epithelial cells. Here we report that CFTR interacts with the recently discovered protein, EBP50 GERM-binding phosphoprotein 50). EBP50 is concentrated at the apical membrane in human airway epithelial cells, in vivo, and CFTR and EBP50 associate in in vitro binding assays. The CFTR-EBP50 interaction requires the COOH-terminal DTRL sequence of CFTR and utilizes either PDZ1 or PDZ2 of EBP50, although binding to PDZ1 is of greater affinity. Through formation of a complex, the intel action between CFTR and EBP50 may influence the stability and/or regulation of CFTR Cl- channel function in the cell membrane and provides a potential mechanism through which CFTR can affect the activity of other apical membrane proteins.	Univ N Carolina, Dept Physiol, Chapel Hill, NC 27599 USA; Univ N Carolina, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA; Cornell Univ, Biochem Mol & Cell Biol Sect, Ithaca, NY 14853 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Cornell University	Milgram, SL (corresponding author), Univ N Carolina, Dept Physiol, CB 7545, Chapel Hill, NC 27599 USA.	milg@med.unc.edu			NHLBI NIH HHS [P50 HL42384] Funding Source: Medline; NIDDK NIH HHS [R29DK50744] Funding Source: Medline; NIGMS NIH HHS [GM36652] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042384] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK050744] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036652] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS ME, 1995, J BIOL CHEM, V270, P25859, DOI 10.1074/jbc.270.43.25859; ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; BECQ F, 1994, P NATL ACAD SCI USA, V91, P9160, DOI 10.1073/pnas.91.19.9160; BERRYMAN M, 1993, J CELL SCI, V105, P1025; BRANT SR, 1995, AM J PHYSIOL, V269, P198; Bretscher A, 1997, J CELL SCI, V110, P3011; Cantiello HF, 1996, EXP PHYSIOL, V81, P505, DOI 10.1113/expphysiol.1996.sp003953; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CLARKE LL, 1996, AM J PHYSIOL, V270, P259; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; GABRIEL SE, 1993, NATURE, V363, P263, DOI 10.1038/363263a0; Gee SH, 1998, J NEUROSCI, V18, P128; GRAY MA, 1989, AM J PHYSIOL, V257, pC240, DOI 10.1152/ajpcell.1989.257.2.C240; Greger R, 1996, J MOL MED-JMM, V74, P527; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hanrahan JW, 1996, J EXP ZOOL, V275, P283; HARRIS A, 1995, QJM-INT J MED, V88, P229; Ismailov II, 1997, AM J PHYSIOL-CELL PH, V272, pC1077, DOI 10.1152/ajpcell.1997.272.4.C1077; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; Jia YL, 1997, J BIOL CHEM, V272, P4978, DOI 10.1074/jbc.272.8.4978; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Kornau HC, 1997, CURR OPIN NEUROBIOL, V7, P368, DOI 10.1016/S0959-4388(97)80064-5; KUVER R, 1994, BIOCHEM BIOPH RES CO, V203, P1457, DOI 10.1006/bbrc.1994.2348; MCNICHOLAS CM, 1997, AM J PHYSIOL, V273, P843; MILGRAM SL, 1992, J CELL BIOL, V117, P717, DOI 10.1083/jcb.117.4.717; MORELOCK MM, 1995, J MED CHEM, V38, P1309, DOI 10.1021/jm00008a009; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; Myszka DG, 1996, PROTEIN SCI, V5, P2468, DOI 10.1002/pro.5560051209; Naren AP, 1997, NATURE, V390, P302, DOI 10.1038/36882; Niethammer M, 1996, J NEUROSCI, V16, P2157; ORAT AG, 1995, AM J PHYSIOL, V268, pC1552; Ponting CP, 1997, PROTEIN SCI, V6, P464; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; RECZEK D, 1998, J BIOL CHEM, V273, P18378; RIORDAN JR, 1989, SCIENCE, V245, P1066; SARKADI B, 1992, J BIOL CHEM, V267, P2087; Sheng M, 1996, CURR OPIN NEUROBIOL, V6, P602, DOI 10.1016/S0959-4388(96)80091-2; SONGYANG Z, 1997, SCIENCE, V275, P7376; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; Stutts MJ, 1997, J BIOL CHEM, V272, P14037, DOI 10.1074/jbc.272.22.14037; Vaheri A, 1997, CURR OPIN CELL BIOL, V9, P659, DOI 10.1016/S0955-0674(97)80119-6; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; WILLOTT E, 1992, AM J PHYSIOL, V262, pC1119, DOI 10.1152/ajpcell.1992.262.5.C1119; WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7; Xia XM, 1998, J NEUROSCI, V18, P2360; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010	50	393	398	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19797	19801		10.1074/jbc.273.31.19797	http://dx.doi.org/10.1074/jbc.273.31.19797			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677412	Green Published, hybrid			2022-12-25	WOS:000075125200064
J	Weitkamp, B; Jurk, K; Beinbrech, G				Weitkamp, B; Jurk, K; Beinbrech, G			Projectin-thin filament interactions and modulation of the sensitivity of the actomyosin ATPase to calcium by projectin kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONNECTIN-LIKE PROTEINS; CRAYFISH CLAW MUSCLE; SKELETAL-MUSCLE; INSECT FLIGHT; MOLLUSCAN TWITCHIN; STRIATED-MUSCLE; BINDING PROTEIN; LIGHT-CHAIN; TROPONIN-I; MYOSIN	The insect muscle protein projectin (900 kDa) belongs to a novel family of cytoskeleton-associated protein kinases (titin, twitchin, and projectin) that are members of the immunoglobulin superfamily, The functions of these kinases are still unknown although recent data suggest a role in modulating muscle activity and generating passive elasticity, An important question is what are the in vivo substrates for these enzymes. We found a thin filament-associated 30 kDa protein that acts as an in vitro substrate for projectin kinase from Locusta migratoria, However, we did not find activators for projectin kinase, Neither calcium, calcium with calmodulin, nor cAMP activated the in vitro activity of projectin kinase, Binding studies revealed a strong interaction between projectin and thin filaments comparable with that of the projectin-myosin interaction. That an interaction might be possible in vivo is suggested by immunological studies showing that projectin is attached to the surface of myosin filaments. Since the molecular weights indicate that the 30 kDa protein might be troponin I, which is known to play a central role in modulating cardiac contractile activity, we studied whether phosphorylation of this protein by projectin changes the calcium sensitivity of the actomyosin ATPase. We found a significant increase in the calcium sensitivity. Thus, our results indicate the existence of a novel mechanism of regulation of muscle activity by a cytoskeleton-associated kinase.	Univ Munster, Inst Anim Physiol, D-48143 Munster, Germany	University of Munster	Weitkamp, B (corresponding author), Inst Arterioskleroseforsch, Domagkstr 3, D-48149 Munster, Germany.	jurk162@uni-muenster.de	Jurk, Kerstin/AAT-7768-2020					AYMESOUTHGATE A, 1995, J CELL BIOL, V128, P393, DOI 10.1083/jcb.128.3.393; BARBAS JA, 1991, GENE DEV, V5, P132, DOI 10.1101/gad.5.1.132; BEALL CJ, 1991, J CELL BIOL, V114, P941, DOI 10.1083/jcb.114.5.941; BENIAN GM, 1989, NATURE, V342, P45, DOI 10.1038/342045a0; BUSS JE, 1977, FEBS LETT, V73, P101, DOI 10.1016/0014-5793(77)80025-2; COHEN P, 1988, PROC R SOC SER B-BIO, V234, P115, DOI 10.1098/rspb.1988.0040; ETLINGER JD, 1976, J CELL BIOL, V68, P123, DOI 10.1083/jcb.68.1.123; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; GAUTEL M, 1995, EUR J BIOCHEM, V230, P752; GAUTEL M, 1995, EMBO J, V14, P1952, DOI 10.1002/j.1460-2075.1995.tb07187.x; GRANGE RW, 1993, CAN J APPL PHYSIOL, V18, P229, DOI 10.1139/h93-020; HEIERHORST J, 1994, J BIOL CHEM, V269, P21086; HEIERHORST J, 1995, EUR J BIOCHEM, V233, P426, DOI 10.1111/j.1432-1033.1995.426_2.x; Heierhorst J, 1996, NATURE, V380, P636, DOI 10.1038/380636a0; HEROLD PE, 1994, P NATL ACAD SCI USA, V91, P10144; HOROWITS R, 1986, NATURE, V323, P160, DOI 10.1038/323160a0; HOROWITS R, 1989, J CELL BIOL, V109, P2169, DOI 10.1083/jcb.109.5.2169; HU DH, 1990, J MUSCLE RES CELL M, V11, P497, DOI 10.1007/BF01745217; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; HUXELY HE, 1965, SCI AM, V213, P18; KATO M, 1992, BIOCHEM J, V281, P339, DOI 10.1042/bj2810339; KAWAMURA Y, 1994, J MUSCLE RES CELL M, V15, P623, DOI 10.1007/BF00121070; KELLER CS, 1995, CURR OPIN CELL BIOL, V7, P32, DOI 10.1016/0955-0674(95)80042-5; Kellermayer MSZ, 1996, FEBS LETT, V380, P281, DOI 10.1016/0014-5793(96)00055-5; KENDRICK-JONES J, 1970, Journal of Molecular Biology, V54, P313, DOI 10.1016/0022-2836(70)90432-8; KOLSCH B, 1995, NATURWISSENSCHAFTEN, V82, P239; LABEIT S, 1992, EMBO J, V11, P1711, DOI 10.1002/j.1460-2075.1992.tb05222.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKEY A, 1990, EMBO J, V9, P3459, DOI 10.1002/j.1460-2075.1990.tb07554.x; LEHMAN W, 1975, J GEN PHYSIOL, V66, P1, DOI 10.1085/jgp.66.1.1; LEHMAN W, 1974, J GEN PHYSIOL, V63, P553, DOI 10.1085/jgp.63.5.553; LEI JY, 1994, J BIOL CHEM, V269, P21078; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANABE T, 1993, J MUSCLE RES CELL M, V14, P654, DOI 10.1007/BF00141562; MAROTO M, 1992, J MOL BIOL, V224, P287, DOI 10.1016/0022-2836(92)90994-U; NISHITA K, 1990, J BIOCHEM-TOKYO, V108, P677, DOI 10.1093/oxfordjournals.jbchem.a123262; Ohtani Y, 1996, TISSUE CELL, V28, P1, DOI 10.1016/S0040-8166(96)80038-3; OJIMA T, 1995, FISHERIES SCI, V61, P871, DOI 10.2331/fishsci.61.871; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P2284, DOI 10.1073/pnas.87.6.2284; PORTZEHL H, 1964, BIOCHIM BIOPHYS ACTA, V79, P581, DOI 10.1016/0926-6577(64)90224-4; PROBST WC, 1994, P NATL ACAD SCI USA, V91, P8487, DOI 10.1073/pnas.91.18.8487; ROCKSTEIN M, 1951, ANAL CHEM, V23, P1500, DOI 10.1021/ac60058a044; SZENTGYO.AG, 1973, J MOL BIOL, V74, P179, DOI 10.1016/0022-2836(73)90106-X; TOHTONG R, 1995, NATURE, V374, P650, DOI 10.1038/374650a0; VANDENBOOM R, 1995, AM J PHYSIOL, V37, P596; VIBERT P, 1993, J MUSCLE RES CELL M, V14, P598, DOI 10.1007/BF00141557; VIGOREAUX JO, 1991, J MUSCLE RES CELL M, V12, P340, DOI 10.1007/BF01738589; ZIEGLER C, 1994, COMP BIOCHEM PHYS A, V109, P823, DOI 10.1016/0300-9629(94)90230-5	48	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19802	19808		10.1074/jbc.273.31.19802	http://dx.doi.org/10.1074/jbc.273.31.19802			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677413	hybrid			2022-12-25	WOS:000075125200065
J	Andersen, CB; Roth, RA; Conti, M				Andersen, CB; Roth, RA; Conti, M			Protein kinase B/Akt induces resumption of meiosis in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-I; CYCLIC-AMP PHOSPHODIESTERASE; MOLECULAR-CLONING; PHOSPHATIDYLINOSITOL 3-KINASE; CAMP-PHOSPHODIESTERASE; SER/THR KINASE; INSULIN; AKT; PHOSPHORYLATION; ADIPOCYTES	The activation of protein kinase B/Akt is thought to be a critical step in the phosphoinositide 3-kinase pathway that regulates cell growth and differentiation. Because insulin-like growth factor 1 stimulates the resumption of meiosis in Xenopus laevis oocytes via phosphoinositide 3-kinase activation, we investigated the Akt involvement in this process. Injection of mRNA coding for a constitutively active Akt in Xenopus oocytes induced germinal vesicle breakdown (GVBD) to the same extent as progesterone or insulin treatment. Injection of mRNA coding for the wild type Akt kinase was less effective in stimulating GVBD, whereas Akt bearing a lysine mutation in the catalytic domain that abolishes the kinase activity had no effect, A mutant Akt lacking a membrane-targeting sequence did not induce GVBD, despite high levels of expression and activity, As previously reported for insulin, induction of GVBD by Akt was prevented by incubating the oocytes with cilostamide, an inhibitor specific for the type 3 phosphodiesterase (PDE8), suggesting that the activity of a PDE is required for Akt action. That an increase in PDE activity in the oocyte is sufficient to induce meiotic resumption was demonstrated by expression of an active PDE protein. In addition, the constitutively active Akt caused a S-fold increase in the activity of the endogenous PDE. These data demonstrate that Akt is in the pathway controlling resumption of meiosis in the Xenopus oocyte and that regulation of the activity of a PDE3 is a step distal to the kinase activation.	Stanford Univ, Sch Med, Dept Gynecol & Obstet, Div Reprod Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA	Stanford University; Stanford University	Conti, M (corresponding author), Stanford Univ, Sch Med, Dept Gynecol & Obstet, Div Reprod Biol, Stanford, CA 94305 USA.				NICHD NIH HHS [P50 HD31398, HD20788] Funding Source: Medline; NIDDK NIH HHS [DK34976] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD031398, R01HD020788] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALESSI BR, 1997, CURR BIOL, V7, P261; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEGERMAN E, 1990, P NATL ACAD SCI USA, V87, P533, DOI 10.1073/pnas.87.2.533; Degerman E, 1996, BIOCHEM SOC T, V24, P1010, DOI 10.1042/bst0241010; DEUTERREINHARD M, 1997, MOL CELL BIOL, V17, P2259; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; Hemmings BA, 1997, SCIENCE, V277, P534, DOI 10.1126/science.277.5325.534; HU Q, 1995, SCIENCE, V268, P1008; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; LIU XJ, 1995, MOL CELL BIOL, V15, P3563; MALLER JL, 1986, J CYCLIC NUCL PROT, V11, P543; MALLER JL, 1979, J BIOL CHEM, V254, P579; Rahn T, 1996, J BIOL CHEM, V271, P11575, DOI 10.1074/jbc.271.19.11575; RAHN T, 1994, FEBS LETT, V350, P314, DOI 10.1016/0014-5793(94)00797-7; SADLER SE, 1991, MOL ENDOCRINOL, V5, P1939, DOI 10.1210/mend-5-12-1939; SADLER SE, 1989, J BIOL CHEM, V264, P856; SADLER SE, 1987, J BIOL CHEM, V262, P10644; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SETTE C, 1994, J BIOL CHEM, V269, P18271; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Tsafriri A, 1996, DEV BIOL, V178, P393, DOI 10.1006/dbio.1996.0226; Walter SA, 1997, MOL BIOL CELL, V8, P2157, DOI 10.1091/mbc.8.11.2157; WIERSMA A, 1998, 11 INT WORKSH DEV FU, P15; Wijkander J, 1998, ENDOCRINOLOGY, V139, P219, DOI 10.1210/en.139.1.219	35	71	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18705	18708		10.1074/jbc.273.30.18705	http://dx.doi.org/10.1074/jbc.273.30.18705			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668041	hybrid			2022-12-25	WOS:000074974700008
J	Beau, I; Groyer-Picard, MT; Le Bivic, A; Vannier, B; Loosfelt, H; Milgrom, E; Misrahi, M				Beau, I; Groyer-Picard, MT; Le Bivic, A; Vannier, B; Loosfelt, H; Milgrom, E; Misrahi, M			The basolateral localization signal of the follicle-stimulating hormone receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE KIDNEY-CELLS; POLYMERIC IMMUNOGLOBULIN RECEPTOR; LYSOSOMAL ACID-PHOSPHATASE; TRANSFECTED MDCK CELLS; GROWTH-FACTOR RECEPTOR; CYTOPLASMIC DOMAIN; EPITHELIAL-CELLS; ALPHA(2A)-ADRENERGIC RECEPTOR; INTERNALIZATION SIGNAL; THYROTROPIN RECEPTOR	The follicle-stimulating hormone receptor (FSHR) is physiologically localized in the basolateral compartment of the membrane of Sertoli cells. This localization is also observed when the receptor is experimentally expressed in Madin-Darby canine kidney cells. We thus used in vitro mutagenesis and transfection into these polarized cells to delineate the basolateral localization signal of the receptor. The signal was localized in the C-terminal tail of the intracellular domain (amino acids 678-691) at a marked distance of the membrane. Mutation of individual amino acids highlighted the importance of Tyr(684) and Leu(689). The 14-amino acid sequence was grafted onto the p75 neurotrophin receptor and redirected this apical protein to the basolateral cell membrane compartment, Deletion of amino acids 677-695 did not modify the internalization of the FSHR, showing that the basolateral localization signal of the FSHR is not colinear with its internalization signal.	Assistance Publ Hop Paris, Hop Bicetre, Inst Federat Rech 21, INSERM,U135,Unite Hormones Genes & Reprod, F-94275 Le Kremlin Bicetre, France; Fac Sci Luminy, Lab Genet & Physiol Dev, Unite Mixte Rech 9943, F-13288 Marseille, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Saclay; UDICE-French Research Universities; Aix-Marseille Universite	Misrahi, M (corresponding author), Assistance Publ Hop Paris, Hop Bicetre, Inst Federat Rech 21, INSERM,U135,Unite Hormones Genes & Reprod, 3Eme Niveau,78 Rue Gen Leclerc, F-94275 Le Kremlin Bicetre, France.		Beau, Isabelle/M-4423-2017	Beau, Isabelle/0000-0002-3352-6813; Vannier, Brigitte/0000-0002-6870-507X				AROETI B, 1993, J CELL BIOL, V123, P1149, DOI 10.1083/jcb.123.5.1149; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; Beau I, 1997, J BIOL CHEM, V272, P5241, DOI 10.1074/jbc.272.8.5241; BREITFELD PP, 1990, J BIOL CHEM, V265, P13750; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; Dym M, 1970, Biology Reprod., V3, P308; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; GEFFEN I, 1993, J BIOL CHEM, V268, P20772; GHINEA N, 1994, J CELL BIOL, V125, P87, DOI 10.1083/jcb.125.1.87; GHINEA N, 1992, J CELL BIOL, V118, P1347, DOI 10.1083/jcb.118.6.1347; HEMPSTEAD BL, 1990, J BIOL CHEM, V265, P9595; Hobert ME, 1997, J BIOL CHEM, V272, P32901, DOI 10.1074/jbc.272.52.32901; HONING S, 1995, J CELL BIOL, V128, P321, DOI 10.1083/jcb.128.3.321; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; KAUFMANN M, 1994, ENDOCRINOLOGY, V134, P1173, DOI 10.1210/en.134.3.1173; KEEFER JR, 1993, J BIOL CHEM, V268, P11340; KEEFER JR, 1994, J BIOL CHEM, V269, P16425; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; LEBIVIC A, 1989, P NATL ACAD SCI USA, V86, P9313; LeGall AH, 1997, J BIOL CHEM, V272, P4559, DOI 10.1074/jbc.272.7.4559; Lin S, 1997, J BIOL CHEM, V272, P26300, DOI 10.1074/jbc.272.42.26300; LOOSFELT H, 1992, P NATL ACAD SCI USA, V89, P3765, DOI 10.1073/pnas.89.9.3765; LUO H, 1993, AM J PHYSIOL, V265, pC193, DOI 10.1152/ajpcell.1993.265.1.C193; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MCGREGOR MJ, 1989, PROTEIN ENG, V2, P521, DOI 10.1093/protein/2.7.521; MEDURI G, 1992, ENDOCRINOLOGY, V131, P366, DOI 10.1210/en.131.1.366; Meduri G, 1996, J ENDOCRINOL, V148, P435, DOI 10.1677/joe.0.1480435; MISRAHI M, 1997, PHARMACOTHERAPEUTICS, V128, P33; MISRAHI M, 1998, IN PRESS BAILLIERES; MONLAUZEUR L, 1995, J BIOL CHEM, V270, P12219, DOI 10.1074/jbc.270.20.12219; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; Odorizzi G, 1997, J CELL BIOL, V137, P1255, DOI 10.1083/jcb.137.6.1255; PRILL V, 1993, EMBO J, V12, P2181, DOI 10.1002/j.1460-2075.1993.tb05866.x; RAYMOND JR, 1993, AM J PHYSIOL, V264, pF9, DOI 10.1152/ajprenal.1993.264.1.F9; RODRIGUEZBOULAN E, 1993, J CELL SCI, P9; Sands JM, 1997, J CLIN INVEST, V99, P1399, DOI 10.1172/JCI119299; Saunders C, 1996, J BIOL CHEM, V271, P995, DOI 10.1074/jbc.271.2.995; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; Sheikh H, 1996, J BIOL CHEM, V271, P12185, DOI 10.1074/jbc.271.21.12185; Simoni M, 1997, ENDOCR REV, V18, P739, DOI 10.1210/er.18.6.739; Song Y, 1997, FASEB J, V11, P93, DOI 10.1096/fasebj.11.1.9034171; STULTZ CM, 1993, PROTEIN SCI, V2, P305; TALOR Z, 1982, J CLIN INVEST, V69, P1136, DOI 10.1172/JCI110549; THOMAS DC, 1994, J BIOL CHEM, V269, P15732; THOMAS DC, 1993, J BIOL CHEM, V268, P3313; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735; Vannier B, 1996, BIOCHEMISTRY-US, V35, P1358, DOI 10.1021/bi952290f; VASSART G, 1994, ENDOCRINE REV MONOGR, V3, P77; Wozniak M, 1996, J BIOL CHEM, V271, P5017; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929; YEH TC, 1994, DIABETES, V43, P1297, DOI 10.2337/diabetes.43.11.1297	54	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18610	18616		10.1074/jbc.273.29.18610	http://dx.doi.org/10.1074/jbc.273.29.18610			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660834	hybrid			2022-12-25	WOS:000074828500089
J	Du, SY; Bird, TH; Bauer, CE				Du, SY; Bird, TH; Bauer, CE			DNA binding characteristics of RegA - A constitutively active anaerobic activator of photosynthesis gene expression in Rhodobacter capsulatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PUF OPERON; RHIZOBIUM-MELILOTI; OXYGEN REGULATION; PHOSPHORYLATION; PROTEIN; PROMOTER; SYSTEM; OMPR; IDENTIFICATION	In the purple non-sulfur bacterium Rhodobacter capsulatus, RegA and RegB comprise a two-component regulatory system that is required for maximal anaerobic transcription of key photosynthesis genes. RegB is a sensor kinase that uses ATP to phosphorylate its cognate response regulator, RegA, The mechanism under which RegA similar to P influences transcription of target genes has been unclear given that past attempts to demonstrate DNA binding activity by isolated RegA have failed. This led to a model invoking a role for RegA similar to P as an intermediate in a more complex multicomponent phosphoryl transfer cascade. In the present study, we describe the isolation of a mutant version of RegA (RegA*) which promotes high level expression of photosynthesis genes independent of RegB. DNase I footprint analyses show that purified RegA* binds to the promoters of the puf and puc operons at locations that are consistent with RegA functioning as a transcriptional activator for these operons. We conclude that RegA functions, like most members of the response regulator family, as a DNA-binding protein that directly affects the expression of its target genes.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA	Indiana University System; Indiana University Bloomington	Bauer, CE (corresponding author), Indiana Univ, Dept Biol, Jordan Hall, Bloomington, IN 47405 USA.	cbauer@bio.indiana.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040941, R29GM040941, K04GM000618, R37GM040941] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40941, GM00618, R01 GM040941, R37 GM040941] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIBA H, 1989, J BIOCHEM-TOKYO, V106, P5, DOI 10.1093/oxfordjournals.jbchem.a122817; ALEXEYEV MF, 1995, BIOTECHNIQUES, V18, P52; BAILALOV I, 1996, BIOCHEMISTRY-US, V35, P11053; BAUER C, 1993, TRENDS GENET, V9, P56, DOI 10.1016/0168-9525(93)90188-N; BAUER CE, 1988, J BIOL CHEM, V263, P4820; Bauer CE, 1996, CELL, V85, P5, DOI 10.1016/S0092-8674(00)81074-0; BAUER CE, 1995, ANOXYGENIC PHOTOSYNT, P1221; BAUER CE, 1987, PROGR PHOTOSYNTHESIS, V4, P699; Bird TH, 1996, J MOL BIOL, V256, P436, DOI 10.1006/jmbi.1996.0099; BRENNAN RG, 1989, J BIOL CHEM, V264, P1903; COHENBAZIRE G, 1957, J CELL COMPAR PHYSL, V49, P25, DOI 10.1002/jcp.1030490104; ERASO JM, 1994, J BACTERIOL, V176, P32, DOI 10.1128/JB.176.1.32-43.1994; HAN DC, 1994, MOL MICROBIOL, V12, P23, DOI 10.1111/j.1365-2958.1994.tb00991.x; INOUE K, 1995, BIOCHEMISTRY-US, V34, P391, DOI 10.1021/bi00002a002; Jiang ZY, 1997, J BACTERIOL, V179, P5720, DOI 10.1128/jb.179.18.5720-5727.1997; KLUG G, 1991, MOL GEN GENET, V226, P167, DOI 10.1007/BF00273600; MARRS BL, 1980, METHOD ENZYMOL, V69, P29; Maxam A M, 1980, Methods Enzymol, V65, P499; MOSLEY CS, 1994, J BACTERIOL, V176, P7566, DOI 10.1128/JB.176.24.7566-7573.1994; NAKASHIMA K, 1991, J BIOL CHEM, V266, P10775; NARRO ML, 1990, J BACTERIOL, V172, P4549, DOI 10.1128/jb.172.8.4549-4554.1990; PONNAMPALAM SN, 1995, J BACTERIOL, V177, P2990, DOI 10.1128/jb.177.11.2990-2997.1995; Ponnampalam SN, 1997, J BIOL CHEM, V272, P18391, DOI 10.1074/jbc.272.29.18391; Qian YL, 1996, J BACTERIOL, V178, P12, DOI 10.1128/jb.178.1.12-18.1996; RE SD, 1994, NUCLEIC ACIDS RES, V22, P1555; ROGGIANI M, 1993, J BACTERIOL, V175, P3181; SCOLNIK PA, 1984, NATURE, V307, P289, DOI 10.1038/307289a0; SGANGA MW, 1992, CELL, V68, P945, DOI 10.1016/0092-8674(92)90037-D; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; STRAUCH MA, 1995, J BACTERIOL, V177, P4532, DOI 10.1128/jb.177.15.4532-4536.1995; STUDIER FW, 1990, METHOD ENZYMOL, V53, P450; Tiwari RP, 1996, MICROBIOL-UK, V142, P1693, DOI 10.1099/13500872-142-7-1693; TSUZUKI M, 1994, J MOL BIOL, V242, P607, DOI 10.1006/jmbi.1994.1610; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; VOLZ K, 1991, J BIOL CHEM, V266, P15511; VOLZ K, 1993, BIOCHEMISTRY-US, V32, P11741, DOI 10.1021/bi00095a001; WEINSTEIN M, 1993, GENE, V134, P145, DOI 10.1016/0378-1119(93)90088-K; WEISS V, 1992, P NATL ACAD SCI USA, V89, P5088, DOI 10.1073/pnas.89.11.5088; Xu K, 1996, MOL MICROBIOL, V19, P145, DOI 10.1046/j.1365-2958.1996.358882.x; YOUNG DA, 1989, MOL GEN GENET, V218, P1, DOI 10.1007/BF00330558	40	70	72	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18509	18513		10.1074/jbc.273.29.18509	http://dx.doi.org/10.1074/jbc.273.29.18509			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660820	hybrid			2022-12-25	WOS:000074828500075
J	Kiselev, SL; Kustikova, OS; Korobko, EV; Prokhortchouk, EB; Kabishev, AA; Lukanidin, EM; Georgiev, GP				Kiselev, SL; Kustikova, OS; Korobko, EV; Prokhortchouk, EB; Kabishev, AA; Lukanidin, EM; Georgiev, GP			Molecular cloning and characterization of the mouse tag7 gene encoding a novel cytokine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; DOMAIN-CONTAINING RECEPTOR; MESSENGER-RNA EXPRESSION; DEATH-DOMAIN; FACTOR-ALPHA; FACTOR-BETA; CELL-LINES; TNF-ALPHA; LYMPHOTOXIN	Cloning of the mouse tag7 gene encoding a novel cytokine is described. The Tag7 protein consists of 182 amino acids. Genomic organization of the tag7 gene and its promoter region remind those of the genes of the tumor necrosis factor locus, although the tag7 gene is not linked to this locus. The gene is located on chromosome 7 at the area that corresponds to band 7A3, which has genetic linkage with lupus-like disease in mouse models, tag7 transcription is essential for lymphoid organs, It is also detected in certain areas of lungs, brain, and intestine and in some tumors. Tag7 protein is detectable in both cell-associated and soluble forms. The soluble form of Tag7 triggers apoptosis in mouse L929 cells in vitro and does not involve NF-kappa B activation. The relationship between Tag7 and tumor necrosis factor family of ligands is discussed.	Inst Gene Biol, Moscow 117334, Russia; Danish Canc Soc, DK-2100 Copenhagen, Denmark	Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences; Danish Cancer Society	Kiselev, SL (corresponding author), Inst Gene Biol, 3415 Vavilova St, Moscow 117334, Russia.		Prokhortchouk, Egor/I-9108-2014; Korobko, Elena/AAP-1193-2021; Kiselev, Sergey/AAO-1247-2020	Korobko, Elena/0000-0002-9752-9714; kiselev, sergey/0000-0001-7921-6987				AGGARWAL BB, 1985, J BIOL CHEM, V260, P2334; ARMITAGE RJ, 1992, EUR J IMMUNOL, V22, P2071, DOI 10.1002/eji.1830220817; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; COLOMBO MP, 1992, CANCER RES, V52, P4853; DEKOSSODO S, 1992, J EXP MED, V176, P1259, DOI 10.1084/jem.176.5.1259; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GARDNER SM, 1987, J IMMUNOL, V139, P476; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; ISHIBASHI K, 1991, BLOOD, V77, P2451; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; KLAUS GGB, 1988, LYMPHOCYTES PRACTICA, P15; KONO DH, 1994, P NATL ACAD SCI USA, V91, P10168, DOI 10.1073/pnas.91.21.10168; KOROBKO EV, IN PRESS CELL DEATH; Kruger-Krasagakes S, 1995, Recent Results Cancer Res, V139, P155; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; MOREL L, 1994, IMMUNITY, V1, P219, DOI 10.1016/1074-7613(94)90100-7; NEDOSPASOV SA, 1986, NUCLEIC ACIDS RES, V14, P7713, DOI 10.1093/nar/14.19.7713; OKA M, 1995, J INTERF CYTOK RES, V15, P1005, DOI 10.1089/jir.1995.15.1005; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; PAUL NL, 1988, ANNU REV IMMUNOL, V6, P407, DOI 10.1146/annurev.iy.06.040188.002203; PEKAREK LA, 1993, CANCER RES, V53, P1978; POKHOLOK DK, 1995, P NATL ACAD SCI USA, V92, P674, DOI 10.1073/pnas.92.3.674; RUBIN BY, 1986, J EXP MED, V164, P1350, DOI 10.1084/jem.164.4.1350; Sambrook J., 1990, MOL CLONING LAB MANU, V2nd; SENIN VM, 1984, VESTNIK USSR ACAD ME, V5, P85; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SPIES T, 1986, P NATL ACAD SCI USA, V83, P8699, DOI 10.1073/pnas.83.22.8699; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; SPRIGGS DR, 1988, J CLIN INVEST, V81, P455, DOI 10.1172/JCI113341; TAKASUKA N, 1991, J IMMUNOL, V146, P3824; TAKASUKA N, 1995, J IMMUNOL, V154, P4803; TIAN QS, 1991, CELL, V67, P629, DOI 10.1016/0092-8674(91)90536-8; VAN MEIR EG, 1995, GLIA, V15, P264, DOI 10.1002/glia.440150308; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211	38	61	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18633	18639		10.1074/jbc.273.29.18633	http://dx.doi.org/10.1074/jbc.273.29.18633			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660837	hybrid			2022-12-25	WOS:000074828500092
J	Yang, PR; Kansra, S; Pimental, RA; Gilbreth, M; Marcus, S				Yang, PR; Kansra, S; Pimental, RA; Gilbreth, M; Marcus, S			Cloning and characterization of shk2 a gene encoding a novel p21-activated protein kinase from fission yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDRICH SYNDROME PROTEIN; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; CELL-GROWTH; RHO-FAMILY; SEXUAL-DIFFERENTIATION; SIGNAL TRANSDUCTION; SMALL GTPASES; HOMOLOG; CDC42	We describe the characterization of a novel gene, shk2, encoding a second p21(cdc42/rac)-activated protein kinase (PAK) homolog in fission yeast. Like other known PAKs, Shk2 binds to Cdc42 in vivo and in vitro. While overexpression of either shk2 or cdc42 alone does not impair growth of wild type fission yeast cells, cooverexpression of the two genes is toxic and leads to highly aberrant cell morphology, providing evidence for functional interaction between Cdc42 and Shk2 proteins in vivo. Fission yeast shk2 null mutants are viable and exhibit no obvious phenotypic defects, Overexpression of shk2 restores viability and normal morphology but not full mating competence to fission yeast cells carrying a shk1 null mutation. Additional genetic data suggest that Shk2, like Cdc42 and Shk1, participates in Ras-dependent morphological control and mating response pathways in fission yeast. We also show that overexpression of byr2, a gene encoding a Stell/MAPK kinase kinase homolog, suppresses the mating defect of cells partially defective for shk1 function, providing evidence of a link between PAKs and mitogen-activated protein kinase signaling in fission yeast. Taken together, our results suggest that Shk2 is partially overlapping in function with Shk1, with Shk1 being the dominant protein in function.	Univ Texas, Md Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Marcus, S (corresponding author), Univ Texas, Md Anderson Canc Ctr, Dept Mol Genet, 1515 Holcombe Blvd, Houston, TX 77030 USA.	smarcus@mdacc.tmc.edu			NCI NIH HHS [T32CA09299, P30CA16672] Funding Source: Medline; NIGMS NIH HHS [R01GM53239] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009299, P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053239] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alfa C, 1993, EXPT FISSION YEAST L; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; CHEN WN, 1993, J BIOL CHEM, V268, P13280; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; Gilbreth M, 1996, P NATL ACAD SCI USA, V93, P13802, DOI 10.1073/pnas.93.24.13802; Hotchin NA, 1996, CANCER SURV, V27, P311; HUGHES DA, 1993, NATURE, V364, P349, DOI 10.1038/364349a0; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; Kolluri R, 1996, P NATL ACAD SCI USA, V93, P5615, DOI 10.1073/pnas.93.11.5615; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Leberer E, 1997, CURR OPIN GENET DEV, V7, P59, DOI 10.1016/S0959-437X(97)80110-4; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MARCUS S, 1995, P NATL ACAD SCI USA, V92, P6180, DOI 10.1073/pnas.92.13.6180; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; Martin H, 1997, MOL MICROBIOL, V23, P431, DOI 10.1046/j.1365-2958.1997.d01-1870.x; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MILLER PJ, 1994, MOL CELL BIOL, V14, P1075, DOI 10.1128/MCB.14.2.1075; Mosch HU, 1996, P NATL ACAD SCI USA, V93, P5352, DOI 10.1073/pnas.93.11.5352; MUNDER T, 1992, MOL CELL BIOL, V12, P2091, DOI 10.1128/MCB.12.5.2091; NEIMAN AM, 1993, MOL BIOL CELL, V4, P107, DOI 10.1091/mbc.4.1.107; OTTILIE S, 1995, EMBO J, V14, P5908, DOI 10.1002/j.1460-2075.1995.tb00278.x; Peter M, 1996, EMBO J, V15, P7046, DOI 10.1002/j.1460-2075.1996.tb01096.x; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; Rose MD., 1990, METHODS YEAST GENETI; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; Sipiczki M, 1989, MOL BIOL FISSION YEA, P431; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG Y, 1991, MOL CELL BIOL, V11, P3554, DOI 10.1128/MCB.11.7.3554; WU CL, 1995, J BIOL CHEM, V270, P15984, DOI 10.1074/jbc.270.27.15984; XU HP, 1992, MOL BIOL CELL, V3, P721, DOI 10.1091/mbc.3.7.721; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	47	35	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18481	18489		10.1074/jbc.273.29.18481	http://dx.doi.org/10.1074/jbc.273.29.18481			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660817	hybrid			2022-12-25	WOS:000074828500072
J	Duncan, EA; Dave, UP; Sakai, J; Goldstein, JL; Brown, MS				Duncan, EA; Dave, UP; Sakai, J; Goldstein, JL; Brown, MS			Second-site cleavage in sterol regulatory element-binding protein occurs at transmembrane junction as determined by cysteine panning	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; SYNTHASE GENE; EXPRESSION; ACTIVATION; PROMOTER; SREBP-2; DIFFERENTIATION; REDUCTASE	In response to sterol deprivation, two sequential proteolytic cleavages release the NH2-terminal fragments of sterol regulatory element-binding proteins (SREBPs) from cell membranes, The fragments translocate to the nucleus where they activate genes involved in cholesterol and fatty acid metabolism. The SREBPs are bound to membranes in a hairpin fashion. The NH2-terminal and COOH-terminal domains face the cytoplasm, separated by two membrane spanning segments and a short lumenal loop. The first cleavage occurs at Site-1 in the lumenal loop. The NH2-terminal fragment is then released by cleavage at Site-2, which is believed to lie within the first transmembrane segment. Here, we use a novel cysteine panning method to identify the second cleavage site (Site-2) in human SREBP-2 as the Leu(484) Cys(485) bond that lies at the junction between the cytoplasmic NH2-terminal fragment and the first transmembrane segment. We transfected cells with cDNAs encoding fusion proteins with single cysteine residues at positions to the NH2-terminal and COOH-terminal sides of cysteine 485. The NH2-terminal fragments were tested for susceptibility to modification with N-alpha-(3-maleimidylpropionyl)biocytin, which attaches a biotin group to cysteine sulfhydryls, Cysteines to the NH2-terminal side of cysteine 485 were retained on the NH2-terminal fragment, but cysteines to the COOH-terminal side of leucine 484 were lost. Leucine 484 is three residues to the COOH-terminal side of the tetrapeptide Asp-Arg-Ser-Arg, which immediately precedes the first transmembrane segment and is required for Site-2 cleavage.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Duncan, EA (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.			Sakai, Juro/0000-0003-4043-1035	NHLBI NIH HHS [HL20948] Funding Source: Medline; NIGMS NIH HHS [GM08014] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKUSJARVI G, 1987, MOL CELL BIOL, V7, P549, DOI 10.1128/MCB.7.1.549; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; BOLLAG DM, 1991, PROTEIN METHODS, P100; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; DEISENHOFER J, 1989, CHEM SCRIPTA, V29, P205; Duncan EA, 1997, J BIOL CHEM, V272, P12778, DOI 10.1074/jbc.272.19.12778; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GUAN GM, 1995, J BIOL CHEM, V270, P21958, DOI 10.1074/jbc.270.37.21958; HASAN MT, 1994, SOMAT CELL MOLEC GEN, V20, P183, DOI 10.1007/BF02254759; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; HUA XX, 1995, J BIOL CHEM, V270, P29422, DOI 10.1074/jbc.270.49.29422; ISOLA VJ, 1989, J VIROL, V63, P2325, DOI 10.1128/JVI.63.5.2325-2334.1989; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; MOCCHETTI I, 1986, P NATL ACAD SCI USA, V83, P7221, DOI 10.1073/pnas.83.19.7221; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Sakai J, 1998, J BIOL CHEM, V273, P5785, DOI 10.1074/jbc.273.10.5785; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Sakai J, 1997, J BIOL CHEM, V272, P20213, DOI 10.1074/jbc.272.32.20213; SATO R, 1994, J BIOL CHEM, V269, P17267; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Theopold U, 1996, P NATL ACAD SCI USA, V93, P1195, DOI 10.1073/pnas.93.3.1195; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; Vallett SM, 1996, J BIOL CHEM, V271, P12247, DOI 10.1074/jbc.271.21.12247; YANG JX, 1994, GENE DEV, V8, P1910, DOI 10.1101/gad.8.16.1910	30	122	128	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17801	17809		10.1074/jbc.273.28.17801	http://dx.doi.org/10.1074/jbc.273.28.17801			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651382	hybrid			2022-12-25	WOS:000074816100075
J	Nassir, F; Bonen, DK; Davidson, NO				Nassir, F; Bonen, DK; Davidson, NO			Apolipoprotein(a) synthesis and secretion from hepatoma cells is coupled to triglyceride synthesis and secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA LIPOPROTEIN(A) CONCENTRATIONS; APO-B SECRETION; HEP G2 CELLS; INTRACELLULAR DEGRADATION; BABOON HEPATOCYTES; TRANSLOCATION; PROTEIN; GENE; MUTAGENESIS; PHENOTYPES	Apolipoprotein(a) (apo(a)) is synthesized and secreted from liver cells and represents one of the two major protein components of the atherogenic lipoprotein, Lp(a), Little is known, however, of the factors that regulate the secretion of this protein. We have undertaken an analysis of the response to oleate supplementation in stable clones of HepG2 and McA-RH7777 cells express ing either a 6 K-IV or 17 K-IV isoform of apo(a), These cell lines were examined by pulse chase analysis and each demonstrated an increase (range 2-6-fold) in apo(a) secretion following supplementation with 0.8 mM oleate, Microsomal membranes, prepared from HepG2 cells expressing a 6 K-TV apo(a) isoform, demonstrated that oleate supplementation increased the apparent protection of apo(a) from protease digestion, suggesting that alterations in the translocation efficiency of apo(a) may accompany the addition of oleate, Cells incubated with brefeldin A demonstrated increased recovery of the precursor form of apo(a) with oleate supplementation, suggesting that alterations in post-translational degradation may also contribute to the observed in crease in apo(a) secretion following oleate addition. To further characterize the oleate-dependent increase in apo(a) secretion, cells were incubated with an inhibitor of the microsomal triglyceride transfer protein. These experiments demonstrated a dose dependent decrease in apo(a) secretion from both cell lines. Furthermore, addition of either the microsomal triglyceride transfer protein inhibitor or triacsin C, an inhibitor of acyl-CoA synthase, completely abrogated the oleate-dependent increase in apo(a) secretion. Taken together, these data provide evidence that apo(a) secretion from hepatoma cells may be linked to elements of cellular triglyceride assembly and secretion.	Univ Chicago, Dept Med, Chicago, IL 60637 USA	University of Chicago	Davidson, NO (corresponding author), Univ Chicago, Dept Med, 5841 S Maryland Ave,MC 4076, Chicago, IL 60637 USA.	ndavidso@medicine.bsd.uchicago.edu		Nassir, Fatiha/0000-0002-3653-3621	NHLBI NIH HHS [HL-38180, HL-18577] Funding Source: Medline; NIDDK NIH HHS [DK42030] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038180, P01HL018577, R37HL038180] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Angelin B, 1997, CURR OPIN LIPIDOL, V8, P337, DOI 10.1097/00041433-199712000-00003; Benoist F, 1997, J BIOL CHEM, V272, P20435, DOI 10.1074/jbc.272.33.20435; BOERWINKLE E, 1992, J CLIN INVEST, V90, P52, DOI 10.1172/JCI115855; Bonen DK, 1997, J BIOL CHEM, V272, P5659, DOI 10.1074/jbc.272.9.5659; BONEN DK, 1998, IN PRESS J LIPID RES; BONNARDEL JA, 1995, J BIOL CHEM, V270, P28892, DOI 10.1074/jbc.270.48.28892; BROUSSEAU ME, 1994, ATHEROSCLEROSIS, V106, P109, DOI 10.1016/0021-9150(94)90087-6; Brunner C, 1996, J BIOL CHEM, V271, P32403, DOI 10.1074/jbc.271.50.32403; CALLOW MJ, 1995, J BIOL CHEM, V270, P23914, DOI 10.1074/jbc.270.41.23914; DAVIDSON NO, 1985, J LIPID RES, V26, P368; DIXON JL, 1991, J BIOL CHEM, V266, P5080; EDELSTEIN C, 1994, CHEM PHYS LIPIDS, V67-8, P135, DOI 10.1016/0009-3084(94)90132-5; FRAZER KA, 1995, NAT GENET, V9, P424, DOI 10.1038/ng0495-424; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; Gaw Allan, 1994, Current Opinion in Lipidology, V5, P149, DOI 10.1097/00041433-199404000-00012; Gordon DA, 1996, J BIOL CHEM, V271, P33047, DOI 10.1074/jbc.271.51.33047; Hoppichler F, 1996, ATHEROSCLEROSIS, V122, P127, DOI 10.1016/0021-9150(96)05803-0; Igal RA, 1997, BIOCHEM J, V324, P529, DOI 10.1042/bj3240529; Ingram MF, 1996, J LIPID RES, V37, P2202; Jamil H, 1996, P NATL ACAD SCI USA, V93, P11991, DOI 10.1073/pnas.93.21.11991; KOSCHINSKY ML, 1991, BIOCHEMISTRY-US, V30, P5044, DOI 10.1021/bi00234a029; KOSCHINSKY ML, 1993, J BIOL CHEM, V268, P19819; KRAFT HG, 1989, J CLIN INVEST, V83, P137, DOI 10.1172/JCI113849; MANCINI FP, 1995, ARTERIOSCL THROM VAS, V15, P1911, DOI 10.1161/01.ATV.15.11.1911; MCCORMICK SPA, 1995, P NATL ACAD SCI USA, V92, P10147, DOI 10.1073/pnas.92.22.10147; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MENZEL HJ, 1990, J BIOL CHEM, V265, P981; Mooser V, 1996, J CLIN INVEST, V98, P2414, DOI 10.1172/JCI119055; RADER DJ, 1994, J CLIN INVEST, V93, P2758, DOI 10.1172/JCI117292; RADER DJ, 1993, J CLIN INVEST, V91, P443, DOI 10.1172/JCI116221; Rouy D, 1998, J BIOL CHEM, V273, P1247, DOI 10.1074/jbc.273.2.1247; SAKATA N, 1993, J BIOL CHEM, V268, P22967; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; Scanu AM, 1997, J LIPID RES, V38, P2193; SCANU AM, 1992, METABOLISM, V41, P1361, DOI 10.1016/0026-0495(92)90108-M; SHELNESS GS, 1994, J BIOL CHEM, V269, P9310; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; Wang YW, 1997, J BIOL CHEM, V272, P12272, DOI 10.1074/jbc.272.19.12272; WHITE AL, 1994, J BIOL CHEM, V269, P9060; WHITE AL, 1993, J LIPID RES, V34, P509; WHITE AL, 1994, J BIOL CHEM, V269, P28716; White AL, 1997, J BIOL CHEM, V272, P5048, DOI 10.1074/jbc.272.8.5048; Wu XJ, 1996, J LIPID RES, V37, P1198; Wu XJ, 1997, J BIOL CHEM, V272, P11575; Wu XJ, 1997, ARTERIOSCL THROM VAS, V17, P3347, DOI 10.1161/01.ATV.17.11.3347; ZHOU MY, 1995, J BIOL CHEM, V270, P25220, DOI 10.1074/jbc.270.42.25220; Zysow BR, 1997, ARTERIOSCL THROM VAS, V17, P1741, DOI 10.1161/01.ATV.17.9.1741	47	43	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17793	17800		10.1074/jbc.273.28.17793	http://dx.doi.org/10.1074/jbc.273.28.17793			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651381	hybrid			2022-12-25	WOS:000074816100074
J	Takahashi, H; Asano, K; Kinouchi, M; Ishida-Yamamoto, A; Wuepper, KD; Iizuka, H				Takahashi, H; Asano, K; Kinouchi, M; Ishida-Yamamoto, A; Wuepper, KD; Iizuka, H			Structure and transcriptional regulation of the human cystatin A gene - The 12-O-tetradecanoylphorbol-13-acetate (TPA) responsive element-2 site (-272 to -278) on cystatin A gene is critical for TPA-dependent regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HUMAN INVOLUCRIN GENE; CORNIFIED CELL-ENVELOPE; KERATINOCYTE DIFFERENTIATION; TERMINAL DIFFERENTIATION; EXPRESSION; CYSTEINE; INHIBITOR; EPIDERMIS; PROMOTER	Cystatin A, a cysteine proteinase inhibitor, is one of the precursor proteins of cornified cell envelope of keratinocytes and is expressed during the late stage of keratinocyte differentiation. We have isolated and characterized the human cystatin A gene. The cystatin A gene consists of three exons and two introns, The first, the second, and the third exons consist of coding sequences that are 66, 102, and 126 base pairs in length, respectively. The first and the second introns consist of 14 and 3.6 kilobase pairs, respectively. The transcription initiation site was located 55 base pairs upstream from the first translation site. The fragment, +77 to -2595 in the 5'-flanking region of the human cystatin A gene, was subcloned into a chloramphenicol acetyltransferase (CAT) reporter vector. The expression vector, p2672CAT, produced a significant CAT activity in transiently transfected SV40-transformed human keratinocytes (SVHK cells), that were further stimulated by 12-O-tetradecanoylphorbol-13-acetate (TPA), a potent protein kinase C activator. Sequence analysis of the gene detected three TPA responsive elements (TRE-1, TRE-2, and TRE-3) and one AP-2 site on the 5' upstream promoter region, Deletion analyses of the p2672CAT vector demonstrated that TRE-2, which was located bet ween -272 and -278, was critical for the regulation by TPA Gel shift analyses revealed that c-Jun, JunD, and c-Fos bound to the TRE-2 region and that the p2672CAT activity level was elevated by co-transfection with c-Jun and c-Fos or with JunD and c-Fos expression vectors. Furthermore, co-transfection of SVHK cells with the protein kinase C-alpha expression vector and the p2672CAT expression vector also resulted in an increased CAT activity. These results indicate that the 5'-flanking region of the human cystatin A gene confers promoter activity and contains a TRE (TRE-2) that mediates, at least in part, the enhanced expression of this gene by TPA.	Asahikawa Med Coll, Dept Dermatol, Asahikawa, Hokkaido 078, Japan; Oregon Hlth Sci Univ, Dept Dermatol, Portland, OR 97201 USA	Asahikawa Medical College; Oregon Health & Science University	Takahashi, H (corresponding author), Asahikawa Med Coll, Dept Dermatol, 3-11 Nishikagura, Asahikawa, Hokkaido 078, Japan.	ht@asakikawa-med.ac.jp						ABRAHAMSON M, 1990, BIOCHEM J, V268, P287, DOI 10.1042/bj2680287; BARRETT AJ, 1987, TRENDS BIOCHEM SCI, V12, P193, DOI 10.1016/0968-0004(87)90092-2; BRZIN J, 1982, FEBS LETT, V138, P193, DOI 10.1016/0014-5793(82)80439-0; BRZIN J, 1983, H-S Z PHYSIOL CHEM, V364, P1475, DOI 10.1515/bchm2.1983.364.2.1475; DISEPIO D, 1995, J BIOL CHEM, V270, P10792, DOI 10.1074/jbc.270.18.10792; DLUGOSZ AA, 1992, MOL CARCINOGEN, V5, P286, DOI 10.1002/mc.2940050409; ECKERT RL, 1993, J INVEST DERMATOL, V100, P613, DOI 10.1111/1523-1747.ep12472288; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FREIJE JP, 1991, J BIOL CHEM, V266, P20538; GREEN GDJ, 1984, BIOCHEM J, V218, P939, DOI 10.1042/bj2180939; HAWLEYNELSON P, 1982, EXP CELL RES, V137, P155, DOI 10.1016/0014-4827(82)90017-9; HOHL D, 1990, DERMATOLOGICA, V180, P201, DOI 10.1159/000248031; HOHL D, 1991, J BIOL CHEM, V266, P6626; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; IshidaYamamoto A, 1997, J INVEST DERMATOL, V108, P12, DOI 10.1111/1523-1747.ep12285611; JARVINEN M, 1978, J INVEST DERMATOL, V71, P114, DOI 10.1111/1523-1747.ep12546165; KARTASOVA T, 1988, MOL CELL BIOL, V8, P2195, DOI 10.1128/MCB.8.5.2195; KOIZUMI H, 1993, J INVEST DERMATOL, V101, P858, DOI 10.1111/1523-1747.ep12371707; LEIBERSPERGER H, 1991, J BIOL CHEM, V266, P14778; LopezBayghen E, 1996, J BIOL CHEM, V271, P512, DOI 10.1074/jbc.271.1.512; MAFSON RA, 1982, CANCER RES, V42, P4600; MANIATIS T, 1989, MOL CLONING LAB MANU, pCH13; NEUMAN JR, 1987, BIOTECHNIQUES, V5, P441; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; Pennacchio LA, 1996, SCIENCE, V271, P1731, DOI 10.1126/science.271.5256.1731; Ruhrberg C, 1996, J CELL BIOL, V134, P715, DOI 10.1083/jcb.134.3.715; SAITOH E, 1987, GENE, V61, P329, DOI 10.1016/0378-1119(87)90196-X; SHAW PA, 1988, J BIOL CHEM, V263, P18133; SIMON M, 1994, KERATINOCYTE HDB, P275; Stanwell C, 1996, J INVEST DERMATOL, V106, P482, DOI 10.1111/1523-1747.ep12343690; STEINBERG ML, 1983, J INVEST DERMATOL, V81, pS131, DOI 10.1111/1523-1747.ep12540905; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; Takahashi H, 1997, J INVEST DERMATOL, V108, P843, DOI 10.1111/1523-1747.ep12292575; TAKAHASHI H, 1993, J INVEST DERMATOL, V100, P10, DOI 10.1111/1523-1747.ep12349867; TAKAHASHI H, 1995, ARCH DERMATOL RES, V287, P740, DOI 10.1007/BF01105799; TAKAHASHI H, 1990, Journal of Dermatology (Tokyo), V17, P457; TEZUKA T, 1994, DERMATOLOGY, V188, P21, DOI 10.1159/000247079; Welter JF, 1995, ONCOGENE, V11, P2681; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; WEVERS A, 1992, ARCH DERMATOL RES, V284, P5, DOI 10.1007/BF00371918; YAMADA H, 1987, ARCH DERMATOL RES, V279, P194, DOI 10.1007/BF00413257; YAMANISHI K, 1992, J BIOL CHEM, V267, P17858	44	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17375	17380		10.1074/jbc.273.28.17375	http://dx.doi.org/10.1074/jbc.273.28.17375			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651321	hybrid			2022-12-25	WOS:000074816100014
J	Ankoma-Sey, V; Matli, M; Chang, KB; Lalazar, A; Donner, DB; Wong, L; Warren, RS; Friedman, SL				Ankoma-Sey, V; Matli, M; Chang, KB; Lalazar, A; Donner, DB; Wong, L; Warren, RS; Friedman, SL			Coordinated induction of VEGF receptors in mesenchymal cell types during rat hepatic wound healing	ONCOGENE			English	Article						hepatic stellate cells; sinusoidal endothelium; hepatic fibrosis; receptor tyrosine kinases	ENDOTHELIAL GROWTH-FACTOR; HUMAN HEPATOCELLULAR-CARCINOMA; FACTOR-BETA-RECEPTOR; HUMAN COLON-CANCER; FAT-STORING CELLS; TYROSINE KINASE; GENE-EXPRESSION; IN-VIVO; LIVER; LIPOCYTES	Homology PCR has been used to identify receptor tyrosine kinases (RTKs) expressed during activation of rat hepatic stellate cells, the key fibrogenic mesenchymal element in the liver. Partial cDNAs encoding several RTKs were cloned from stellate cells activated in vivo, including those of Flt-1, Flk-1, c-met, PDGFR, and Tyro10/DDR2, RNAse protection from cells activated in vivo demonstrated biphasic induction of flt-1 and flk-1 mRNAs, receptors for vascular endothelial growth factor (VEGF), Culture-activation of stellate cells was associated with increased [I-125]VEGF binding and Flt-1 and Flk-1 receptor protein. Induction of VEGF binding sites correlated with an 2.5-fold increase in DNA synthesis in response to VEGF, but only if cells were activated by growth on collagen I, whereas cells maintained in a quiescent state on a basement membrane-like substratum (EHS matrix) were nonproliferative, In both stellate and endothelial cells VEGF-induced mitogenesis was augmented by co-incubation with basic fibroblast growth factor (bFGF), a cytokine with known synergy with VEGF, These findings suggest that the cellular targets of VEGF in liver may not be confined to sinusoidal endothelial cells, and that VEGF responses reflect combined effects on both hepatic stellate cells and sinusoidal endothelium.	Univ Calif San Francisco, Ctr Liver, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Indiana Univ, Sch Med, Dept Physiol & Biophys, Indianapolis, IN 46202 USA; Indiana Univ, Walther Oncol Ctr, Indianapolis, IN 46202 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Friedman, SL (corresponding author), CUNY Mt Sinai Sch Med, Div Liver Dis, Box 1123,1425 Madison Ave,Room 11-70F, New York, NY 10029 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743, T32DK007007, R01DK037340] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK26743, DK 07007, DK37340] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Batard P, 1996, BLOOD, V87, P2212, DOI 10.1182/blood.V87.6.2212.bloodjournal8762212; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; DAVIS BH, 1988, J CELL PHYSIOL, V136, P547, DOI 10.1002/jcp.1041360323; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DUMONT DJ, 1993, ONCOGENE, V8, P1293; ENZAN H, 1994, HEPATOLOGY, V19, P895, DOI 10.1016/0270-9139(94)90289-5; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; Friedman S L, 1996, Prog Liver Dis, V14, P101; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; FRIEDMAN SL, 1989, J BIOL CHEM, V264, P10756; FRIEDMAN SL, 1994, J BIOL CHEM, V269, P10551; FRIEDMAN SL, 1985, P NATL ACAD SCI USA, V82, P8681, DOI 10.1073/pnas.82.24.8681; FRIEDMAN SL, 1993, METHODS TOXICOL, V1, P292; GEERTS A, 1991, HEPATOLOGY, V13, P1193, DOI 10.1002/hep.1840130628; GRESSNER AM, 1995, J HEPATOL, V22, P28; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hioki O, 1996, J HEPATOL, V24, P217, DOI 10.1016/S0168-8278(96)80032-8; Ikeda H., 1996, Hepatology, V24, p460A; JARNAGIN WR, 1994, J CELL BIOL, V127, P2037, DOI 10.1083/jcb.127.6.2037; JOHNSON JD, 1993, P NATL ACAD SCI USA, V90, P5677, DOI 10.1073/pnas.90.12.5677; KAWADA N, 1992, BIOCHEM J, V285, P367, DOI 10.1042/bj2850367; LAI C, 1994, ONCOGENE, V9, P877; Lalazar A, 1997, GENE, V195, P235, DOI 10.1016/S0378-1119(97)00159-5; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Levi E, 1996, P NATL ACAD SCI USA, V93, P7069, DOI 10.1073/pnas.93.14.7069; MAHER JJ, 1990, J CLIN INVEST, V86, P1641, DOI 10.1172/JCI114886; Mise M, 1996, HEPATOLOGY, V23, P455; Mochida S, 1996, BIOCHEM BIOPH RES CO, V226, P176, DOI 10.1006/bbrc.1996.1329; MORI S, 1991, J BIOL CHEM, V266, P21158; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; MYOKEN Y, 1991, P NATL ACAD SCI USA, V88, P5819, DOI 10.1073/pnas.88.13.5819; NOMURA M, 1995, J BIOL CHEM, V270, P28316; PEPPER MS, 1991, BIOCHEM BIOPH RES CO, V181, P9082; PROCTOR E, 1982, GASTROENTEROLOGY, V83, P1183; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; RAZ V, 1991, ONCOGENE, V6, P753; ROCKEY DC, 1993, J CLIN INVEST, V92, P1795, DOI 10.1172/JCI116769; Rodewald HR, 1996, ONCOGENE, V12, P397; ROSENBAUM J, 1995, GASTROENTEROLOGY, V109, P1986, DOI 10.1016/0016-5085(95)90767-X; Sankar S, 1996, J CLIN INVEST, V97, P1436, DOI 10.1172/JCI118565; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Schlessinger J, 1993, Harvey Lect, V89, P105; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; STAVRI GT, 1995, CIRCULATION, V92, P11, DOI 10.1161/01.CIR.92.1.11; Suzuki K, 1996, CANCER RES, V56, P3004; TAKAHASHI Y, 1995, CANCER RES, V55, P3964; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; UNEMORI EN, 1992, J CELL PHYSIOL, V153, P557, DOI 10.1002/jcp.1041530317; Vlodavsky I, 1996, CANCER METAST REV, V15, P177, DOI 10.1007/BF00437470; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; WARREN RS, 1995, J CLIN INVEST, V95, P1789, DOI 10.1172/JCI117857; WONG L, 1994, J CLIN INVEST, V94, P1563, DOI 10.1172/JCI117497; Xu JH, 1996, J CELL BIOL, V132, P239, DOI 10.1083/jcb.132.1.239; YAMANE A, 1994, ONCOGENE, V9, P2683	54	102	112	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 9	1998	17	1					115	121		10.1038/sj.onc.1201912	http://dx.doi.org/10.1038/sj.onc.1201912			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZY936	9671320	Bronze			2022-12-25	WOS:000074677800013
J	Matsumoto, Y; Kosugi, S; Shinbo, T; Chou, DZ; Ohashi, M; Wakabayashi, Y; Sakai, K; Okumoto, M; Mori, N; Aizawa, S; Niwa, O; Kominami, R				Matsumoto, Y; Kosugi, S; Shinbo, T; Chou, DZ; Ohashi, M; Wakabayashi, Y; Sakai, K; Okumoto, M; Mori, N; Aizawa, S; Niwa, O; Kominami, R			Allelic loss analysis of gamma-ray-induced mouse thymic lymphomas: two candidate tumor suppressor gene loci on chromosomes 12 and 16	ONCOGENE			English	Article						tumor suppressor gene; allelic loss (or LOH) analysis; thymic lymphoma; gamma-ray irradiation; p53	RADIATION-INDUCED APOPTOSIS; P53 MUTATIONS; P53-DEFICIENT MICE; FREQUENT LOSS; CANCER; IRRADIATION; HETEROZYGOSITY; DEFICIENCY; RESISTANCE; SUSCEPTIBILITY	A total of 429 gamma-ray-induced thymic lymphomas were obtained from F-1 and backcross mice between BALB/c and MSM strains, about a half of which carried a p53-deficient allele. A genome-wide allelic loss analysis has revealed two loci exhibiting frequent alleLic losses but no allelic preference, one is localized within a 2.9 cM region between D12Mit53 and D12Mit279 loci on chromosome 12, and the other is near the D16Mit122/D16Mit162 loci on chromosome 16, The frequency of allelic loss in the D12Mit279 region is 62% and does not differ in tumors between the presence and absence of the p53-deficient allele, In contrast, the loss frequency of D16Mit122 is raised by the existence of p53-deficient allele: 62% for p63(-/+) and 13% for p53(+/+), suggesting cooperative function of the two losses. The D12Mit279 and D16Mit122 regions probably harbor different types of tumor suppressor gene that play key roles in lymphoma development.	Niigata Univ, Sch Med, Dept Biochem, Niigata 951, Japan; Niigata Univ, Sch Med, Dept Radiat Med, Niigata 951, Japan; Univ Osaka Prefecture, Adv Sci & Technol Res Inst, Sakai, Osaka 593, Japan; Kyoto Univ, Ctr Radiat Biol, Sakyo Ku, Kyoto 60601, Japan; Kumamoto Univ, Dept Morphogenesis, Inst Mol Embryol & Genet, Kumamoto 860, Japan	Niigata University; Niigata University; Japan Advanced Institute of Science & Technology (JAIST); Osaka Metropolitan University; Kyoto University; Kumamoto University	Kominami, R (corresponding author), Niigata Univ, Sch Med, Dept Biochem, Asahimachi 1-757, Niigata 951, Japan.		Kosugi, S./K-5142-2019	Kosugi, Shin-ichi/0000-0002-6602-7412				BONHOMME F, 1989, GENETIC VARIANTS STR, P658; BRATHWAITE O, 1992, CANCER RES, V52, P3791; CHANG WYH, 1995, CANCER RES, V55, P3246; DIETRICH WF, 1994, P NATL ACAD SCI USA, V91, P9451, DOI 10.1073/pnas.91.20.9451; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HALEVY O, 1991, ONCOGENE, V6, P1593; Hamatani K, 1996, IMMUNOGENETICS, V45, P1, DOI 10.1007/s002510050159; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HAYASHI T, 1993, GENOMICS, V17, P490, DOI 10.1006/geno.1993.1352; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KNUDSON AG, 1985, CANCER RES, V45, P1437; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEE JM, 1994, ONCOGENE, V9, P3731; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LIEBERMAN M, 1992, J EXP MED, V176, P399, DOI 10.1084/jem.176.2.399; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MAFUNE Y, 1994, ONCOGENE, V9, P2191; MILLER RD, 1995, P NATL ACAD SCI USA, V92, P10792, DOI 10.1073/pnas.92.23.10792; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MORI N, 1995, GENOMICS, V25, P609, DOI 10.1016/0888-7543(95)80001-3; Ohashi M, 1996, JPN J CANCER RES, V87, P696, DOI 10.1111/j.1349-7006.1996.tb00280.x; OKUMOTO M, 1989, J RADIAT RES, V30, P135, DOI 10.1269/jrr.30.135; OKUMOTO M, 1990, CANCER RES, V50, P3848; OOTSUYAMA A, 1994, MOL CARCINOGEN, V11, P236, DOI 10.1002/mc.2940110409; SAEZ GT, 1994, MOL CARCINOGEN, V9, P40, DOI 10.1002/mc.2940090108; Santos J, 1996, ONCOGENE, V12, P669; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Suda T, 1994, DNA Res, V1, P169, DOI 10.1093/dnares/1.4.169; SUZUKI T, 1989, CANCER RES, V49, P1095; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TSUKADA T, 1993, ONCOGENE, V8, P3313; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; YOUNG J, 1993, ONCOGENE, V8, P671; Zhuang SM, 1996, CANCER RES, V56, P3338	40	60	61	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	1998	16	21					2747	2754		10.1038/sj.onc.1201810	http://dx.doi.org/10.1038/sj.onc.1201810			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ013	9652741				2022-12-25	WOS:000073812200006
J	Gueckel, R; Enenkel, C; Wolf, DH; Hilt, W				Gueckel, R; Enenkel, C; Wolf, DH; Hilt, W			Mutations in the yeast proteasome beta-type subunit pre3 uncover position-dependent effects on proteasomal peptidase activity and in vivo function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE COMPLEX; SACCHAROMYCES-CEREVISIAE; CATABOLITE INACTIVATION; MULTIFUNCTIONAL PROTEINASE; HYDROLYZING ACTIVITY; UBIQUITIN PATHWAY; INVIVO FUNCTION; CELL-DIVISION; DEGRADATION; PROTEOLYSIS	Proteasomes are highly complex proteases responsible for selective protein degradation in the eukaryotic cell. 26 S proteasomes consist of two regulatory 19 S cap complexes and the 20 S proteasome, which acts as the proteolytic core module. We isolated six mutants of the yeast Saccharomyces cerevisiae containing mutations in the 20 S proteasome P-type subunit Pre3. Three mutations (pre3-2, pre3-3, and pre3-5) which reside at the active site cleft of the Pre3 subunit solely caused reduction of the proteasomal peptidylglutamyl peptide-hydrolyzing activity but did not lead to detectable defects in protein degradation nor to any other phenotype. However, the pre3-2 mutation strengthened phenotypes induced by other 20 S proteasomal mutations, indicating that the peptidylglutamyl peptide-hydrolyzing activity has to fulfill some rescue functions. The other three mutations (pre3-1,pre3-4 and pre3-6) are located at diverse sites of the Pre3 protein and caused multiple defects in proteasomal peptide cleaving activities. pre3-1 and pre3-6 mutants exhibited significant defects in proteasomal protein degradation; they accumulated ubiquitinated proteins and stabilized defined substrate proteins as, e.g. fructose-1,6-bisphosphatase. In addition, pre3-1 and pre3-6 mutant cells exhibited pleiotropic phenotypes as temperature sensitivity and cell cycle-related effects.	Univ Stuttgart, Inst Biochem, D-70569 Stuttgart, Germany; Humboldt Univ, Inst Biochem, D-10117 Berlin, Germany	University of Stuttgart; Humboldt University of Berlin	Hilt, W (corresponding author), Univ Stuttgart, Inst Biochem, Pfaffenwaldring 55, D-70569 Stuttgart, Germany.	hilt@po.uni-stuttgart.de						Arendt CS, 1997, P NATL ACAD SCI USA, V94, P7156, DOI 10.1073/pnas.94.14.7156; Ausubel FA, 1990, CURRENT PROTOCOLS MO; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BARRAL Y, 1995, GENE DEV, V9, P399, DOI 10.1101/gad.9.4.399; CENTOLA M, 1994, MOL CELL BIOL, V14, P1510, DOI 10.1128/MCB.14.2.1510; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; CROSS FR, 1993, MOL CELL BIOL, V13, P3266, DOI 10.1128/MCB.13.6.3266; DESHAIES RJ, 1995, TRENDS CELL BIOL, V5, P428, DOI 10.1016/S0962-8924(00)89102-3; Deshaies RJ, 1997, CURR OPIN GENET DEV, V7, P7, DOI 10.1016/S0959-437X(97)80103-7; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; ENENKEL C, 1994, FEBS LETT, V341, P193, DOI 10.1016/0014-5793(94)80455-9; FRIEDMAN H, 1994, P NATL ACAD SCI USA, V91, P2031, DOI 10.1073/pnas.91.6.2031; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; Gerlinger UM, 1997, MOL BIOL CELL, V8, P2487, DOI 10.1091/mbc.8.12.2487; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Guthrie C, 1991, METHODS ENZYMOL, V194; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hilt W, 1996, TRENDS BIOCHEM SCI, V21, P96, DOI 10.1016/S0968-0004(96)10012-8; HILT W, 1993, J BIOL CHEM, V268, P3479; Hoyt MA, 1997, CELL, V91, P149, DOI 10.1016/S0092-8674(00)80396-7; JOHNSTON GC, 1980, MOL GEN GENET, V178, P357, DOI 10.1007/BF00270484; Juang YL, 1997, SCIENCE, V275, P1311, DOI 10.1126/science.275.5304.1311; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; LEW DJ, 1993, J CELL BIOL, V120, P1305, DOI 10.1083/jcb.120.6.1305; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MCCUSKER JH, 1988, GENETICS, V119, P303; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; ORLOWSKI M, 1993, BIOCHEMISTRY-US, V32, P1563, DOI 10.1021/bi00057a022; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; RICHTERRUOFF B, 1994, FEBS LETT, V354, P50, DOI 10.1016/0014-5793(94)01085-4; RICHTERRUOFF B, 1992, FEBS LETT, V302, P192, DOI 10.1016/0014-5793(92)80438-M; RIVETT AJ, 1989, J BIOL CHEM, V264, P12215; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHORK SM, 1995, J BIOL CHEM, V270, P26446, DOI 10.1074/jbc.270.44.26446; SCHORK SM, 1994, FEBS LETT, V349, P270, DOI 10.1016/0014-5793(94)00668-7; SCHORK SM, 1994, NATURE, V369, P283, DOI 10.1038/369283a0; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; SENGSTAG C, 1987, NUCLEIC ACIDS RES, V15, P233, DOI 10.1093/nar/15.1.233; SEUFERT W, 1992, EMBO J, V11, P3077, DOI 10.1002/j.1460-2075.1992.tb05379.x; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; WAGNER JC, 1992, EUR J BIOCHEM, V203, P571, DOI 10.1111/j.1432-1033.1992.tb16585.x; YAGLOM J, 1995, MOL CELL BIOL, V15, P731	58	20	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19443	19452		10.1074/jbc.273.31.19443	http://dx.doi.org/10.1074/jbc.273.31.19443			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677364	hybrid			2022-12-25	WOS:000075125200016
J	Matsuguchi, T; Lilly, MB; Kraft, AS				Matsuguchi, T; Lilly, MB; Kraft, AS			Cytoplasmic domains of the human granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor beta chain (h beta c) responsible for human GM-CSF-induced myeloid cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE KINASE; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; EXPRESSION CLONING; NEURITE OUTGROWTH; GROWTH-FACTOR; STEEL FACTOR; ACTIVATION; INTERLEUKIN-6; SUBUNIT	Granulocyte-macrophage colony-stimulating factor (GM-CSF) regulates differentiation, survival, and proliferation of myeloid progenitor cells. The biologic actions; of GM-CSF are mediated by its binding to the alpha and beta subunits of the GM-CSF receptor (GM-CSFR alpha and beta c, respectively). To determine whether identical regions of the beta c protein mediate both cell growth and differentiation, we expressed cDNA constructs encoding the human wild-type (897 amino acids) and truncated beta c (h beta c) subunits along with the wild-type human GM-CSFR alpha subunit in the murine WT19 cell line, an FDC-P1-derived cell line that differentiates toward the monocytic lineage in response to murine GM-CSF. Whereas the WT19 cell line carrying the C-terminal deleted h beta c subunit of 627 amino acids was still able to grow in human GM-CSF (hGM-CSF), 681 amino acids of the hpc were necessary for cell differentiation. The addition of hGM-CSF to WT19 cell lines containing the h beta c627 subunit stimulated the phosphorylation of ERK (extracellular signal-regulated kinase) and induced the tyrosine-phosphorylation of SHP-2 and STAT5, suggesting that the activation of these molecules is insufficient to mediate the induction of differentiation. A point mutation of tyrosine 628 to phenylalanine (Y628F) within h beta c681 abolished the ability of hGM-CSF to induce differentiation. Our results indicate that the signals required for hGM-CSF-induced differentiation and cell growth are mediated by different regions of the h beta c subunit.	Univ Colorado, Hlth Sci Ctr, Div Med Oncol, Denver, CO 80262 USA; Univ Washington, Div Med Oncol, Seattle, WA 98108 USA; Vet Affairs Med Ctr, Seattle, WA 98108 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Kraft, AS (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Med Oncol, 4200 E 9th Ave, Denver, CO 80262 USA.				NCI NIH HHS [CA45672] Funding Source: Medline; NIDDK NIH HHS [DK44741] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA045672, R01CA045672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044741] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; BALDWIN GC, 1992, DEV BIOL, V151, P352, DOI 10.1016/0012-1606(92)90175-G; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Bone H, 1997, J BIOL CHEM, V272, P14470, DOI 10.1074/jbc.272.22.14470; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOURETTE RP, 1995, CELL GROWTH DIFFER, V6, P631; Bourette RP, 1997, EMBO J, V16, P5880, DOI 10.1093/emboj/16.19.5880; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DRANOFF G, 1994, SCIENCE, V264, P713, DOI 10.1126/science.8171324; EMERSON SG, 1989, BLOOD, V74, P49; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; GASSON JC, 1991, BLOOD, V77, P1131, DOI 10.1182/blood.V77.6.1131.1131; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; HALLEK M, 1994, LEUKEMIA, V8, P740; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; Ihara S, 1997, EMBO J, V16, P5345, DOI 10.1093/emboj/16.17.5345; Ihara S, 1996, J BIOCHEM, V120, P865; ISHIZAKAIKEDA E, 1993, P NATL ACAD SCI USA, V90, P123, DOI 10.1073/pnas.90.1.123; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; Matsuguchi T, 1997, J BIOL CHEM, V272, P17450, DOI 10.1074/jbc.272.28.17450; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Melemed AS, 1997, BLOOD, V90, P3462, DOI 10.1182/blood.V90.9.3462; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; OCHI A, 1983, P NATL ACAD SCI-BIOL, V80, P6351, DOI 10.1073/pnas.80.20.6351; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Piekorz RP, 1997, CYTOKINE, V9, P639, DOI 10.1006/cyto.1997.0221; PIESS M, 1997, BLOOD, V89, P3175; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; Schultz H, 1997, J CELL PHYSIOL, V173, P310, DOI 10.1002/(SICI)1097-4652(199712)173:3<310::AID-JCP2>3.0.CO;2-Q; Shimozaki K, 1997, J BIOL CHEM, V272, P25184, DOI 10.1074/jbc.272.40.25184; Smith A, 1997, EMBO J, V16, P451, DOI 10.1093/emboj/16.3.451; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STANLEY E, 1994, P NATL ACAD SCI USA, V91, P5592, DOI 10.1073/pnas.91.12.5592; VAILLANCOURT RR, 1995, MOL CELL BIOL, V15, P3644; Wakao H, 1997, BIOCHEM BIOPH RES CO, V234, P198, DOI 10.1006/bbrc.1997.6486; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; Woldman I, 1997, J IMMUNOL, V159, P877; Wu YY, 1996, J BIOL CHEM, V271, P13023, DOI 10.1074/jbc.271.22.13023; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	42	15	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19411	19418		10.1074/jbc.273.31.19411	http://dx.doi.org/10.1074/jbc.273.31.19411			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677359	hybrid			2022-12-25	WOS:000075125200011
J	Nikolic, Z; Laube, B; Weber, RG; Lichter, P; Kioschis, P; Poustka, A; Mulhardt, C; Becker, CM				Nikolic, Z; Laube, B; Weber, RG; Lichter, P; Kioschis, P; Poustka, A; Mulhardt, C; Becker, CM			The human glycine receptor subunit alpha 3 - GLRA3 gene structure, chromosomal localization, and functional characterization of alternative transcripts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; BETA-SUBUNIT; ACETYLCHOLINE-RECEPTORS; BINDING SUBUNIT; SPASMODIC MOUSE; SPASTIC MOUSE; MUTATION; HYPEREKPLEXIA; EXPRESSION; PHOSPHORYLATION	The neuronal glycine receptor is a ligand-gated chloride channel composed of ligand binding cu and structural beta polypeptides. Homology screening of a human fetal brain cDNA library resulted in the identification of two alternative splice variants of the glycine receptor alpha 3 subunit, The amino acid sequence predicted for the alpha 3L variant was largely identical to the corresponding rat subunit, In contrast, the novel splice variant alpha 3K lacked the coding sequence for 15 amino acids located within the cytoplasmic loop connecting transmembrane spanning region 3 (TM3) and TM4, Using P1 artificial chromosome (PAC) clones, the structure of the GLRA3 gene was elucidated and its locus assigned to human chromosomal bands 4q33-q34 by fluorescence in situ hybridization. Two transcripts of 2.4 and 9 kilobases, corresponding to alpha 3L and alpha 3K, respectively, were identified and found to be widely distributed throughout the human central nervous system. Structural analysis of the GLRAB gene revealed that the alpha 3K transcript resulted from a complex splice event where excision of the novel exon 8A comprising the alternative sequence of 45 base pairs coincides with the persistence of a large intronic sequence in the S'-untranslated region. Functional expression in KEK 293 cells of alpha 3L and alpha 3K subunits resulted in the formation of glycine-gated chloride channels that differed significantly in desensitization behavior, thus defining the cytoplasmic loop as an important determinant of channel inactivation kinetics.	Univ Erlangen Nurnberg, Inst Biochem, D-91054 Erlangen, Germany; Max Planck Inst Hirnforsch, D-60528 Frankfurt, Germany; Deutsch Krebsforschungszentrum, Abt Org Komplexer Genome, D-69120 Heidelberg, Germany; Deutsch Krebsforschungszentrum, Abt Mol Genomanalyse, D-69120 Heidelberg, Germany	University of Erlangen Nuremberg; Max Planck Society; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Becker, CM (corresponding author), Univ Erlangen Nurnberg, Inst Biochem, Fahrstr 17, D-91054 Erlangen, Germany.		Weber, Ruthild/E-2906-2015	Weber, Ruthild/0000-0001-6610-1080				Becker C. M., 1995, NEUROSCIENTIST, V1, P130; BECKER CM, 1988, EMBO J, V7, P3717, DOI 10.1002/j.1460-2075.1988.tb03255.x; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Brune W, 1996, AM J HUM GENET, V58, P989; Buckanovich RJ, 1997, MOL CELL BIOL, V17, P3194, DOI 10.1128/MCB.17.6.3194; BUCKWALTER MS, 1994, HUM MOL GENET, V3, P2025, DOI 10.1093/hmg/3.11.2025; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DERRY JMJ, 1991, GENOMICS, V10, P593, DOI 10.1016/0888-7543(91)90441-G; GRENNINGLOH G, 1987, NATURE, V328, P215, DOI 10.1038/328215a0; GRENNINGLOH G, 1990, EMBO J, V9, P771, DOI 10.1002/j.1460-2075.1990.tb08172.x; Handford CA, 1996, MOL BRAIN RES, V35, P211; HOFFMAN PW, 1994, J NEUROSCI, V14, P4185; HUGANIR RL, 1986, NATURE, V321, P774, DOI 10.1038/321774a0; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; KINGSMORE SF, 1994, MAMM GENOME, V5, P831, DOI 10.1007/BF00292030; KINGSMORE SF, 1994, NAT GENET, V7, P136, DOI 10.1038/ng0694-136; Kling C, 1997, NEUROSCIENCE, V78, P411, DOI 10.1016/S0306-4522(96)00567-2; KUHSE J, 1991, FEBS LETT, V283, P73, DOI 10.1016/0014-5793(91)80557-J; KUHSE J, 1990, J BIOL CHEM, V265, P22317; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; MALOSIO ML, 1991, J BIOL CHEM, V266, P2048; MALOSIO ML, 1991, EMBO J, V10, P2401, DOI 10.1002/j.1460-2075.1991.tb07779.x; MATZENBACH B, 1994, J BIOL CHEM, V269, P2607; Milani N, 1996, AM J HUM GENET, V58, P420; MILANI N, 1998, IN PRESS GENOMICS; Monani U, 1996, GENOME RES, V6, P1200, DOI 10.1101/gr.6.12.1200; MULHARDT C, 1994, NEURON, V13, P1003, DOI 10.1016/0896-6273(94)90265-8; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; REES MI, 1994, HUM MOL GENET, V3, P2175, DOI 10.1093/hmg/3.12.2175; RUIZGOMEZ A, 1991, J BIOL CHEM, V266, P559; RYAN SG, 1994, NAT GENET, V7, P131, DOI 10.1038/ng0694-131; Sambrook J., 2002, MOL CLONING LAB MANU; SAUL B, 1994, FEBS LETT, V350, P71, DOI 10.1016/0014-5793(94)00736-5; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; SHIANG R, 1995, ANN NEUROL, V38, P85, DOI 10.1002/ana.410380115; SHIANG R, 1993, NAT GENET, V5, P351, DOI 10.1038/ng1293-351; SONTHEIMER H, 1989, NEURON, V2, P1491, DOI 10.1016/0896-6273(89)90195-5; UETZ P, 1994, FEBS LETT, V339, P302, DOI 10.1016/0014-5793(94)80435-4; VAELLO ML, 1994, J BIOL CHEM, V269, P2002; VANDENBERG RJ, 1992, NEURON, V9, P491, DOI 10.1016/0896-6273(92)90186-H	40	85	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19708	19714		10.1074/jbc.273.31.19708	http://dx.doi.org/10.1074/jbc.273.31.19708			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677400	hybrid			2022-12-25	WOS:000075125200052
J	Barber, LA; Spandau, DF; Rathman, SC; Murphy, RC; Johnson, CA; Kelley, SW; Hurwitz, SA; Travers, JB				Barber, LA; Spandau, DF; Rathman, SC; Murphy, RC; Johnson, CA; Kelley, SW; Hurwitz, SA; Travers, JB			Expression of the platelet-activating factor receptor results in enhanced ultraviolet B radiation-induced apoptosis in a human epidermal cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; FACTOR PAF; HUMAN KERATINOCYTES; HUMAN NEUTROPHILS; RELEASE; ACETYLHYDROLASE; IDENTIFICATION; STIMULATION; ENDOTOXIN	Recent studies have demonstrated that ultraviolet B radiation (UVB) damages human keratinocytes in part by inducing oxidative stress and cytokine production. Severe UVB damage to the keratinocyte can also result in apoptosis or programmed cell death, Although the lipid mediator platelet-activating factor (PAF) is synthesized in response to epidermal cell damage and epidermal cells express PAF receptors, it is not known whether PAF is involved in UVB-induced epidermal cell apoptosis, These studies examined the role of the PAF system in UVB-induced epidermal cell apoptosis using a novel model system created by retroviral-mediated transduction of the PAF receptor-negative human epidermal cell line KB with the human PAF receptor (PAF-R). Expression of the PAF-R in KB cells did not affect base-line growth or apoptosis, yet resulted in a decrease in the lag time between treatment of the cells and the induction of apoptosis following irradiation with 400 J/m(2) UVB, This effect was inhibited by pretreatment with the PAF-R antagonists WEB 2086 and A-85783, confirming involvement of the PAF-R in this process, At lower doses (100-200 J/m(2)) of UVB, only RR cells that expressed the PAF-R became apoptotic. Treatment of PAF-R-expressing EB clones with the metabolically stable PAF-R agonist 1-hexadexyl-2-N-methylcarbamoyl-3-gIycerophosphocholine (CPAF) alone did not induce apoptosis but augmented the degree of apoptosis observed if CPAF was used in combination with lower doses (200 J/m(2)) of UVB irradiation. interestingly, UVB irradiation was found to stimulate PAF synthesis only in PAF-R-expressing KB cell clones. The antioxidants N-acetyl cysteine, 1,1,3,3-tetramethyl-2-thiourea, and vitamin E inhibited both WE-induced PAF biosynthesis as well as the augmentation of WE-induced apoptosis in PAF-R-expressing HE clones, suggesting the possibility that UVB stimulates the production of oxidized lipid species with PAF-R agonistic activity in this model system. Thus, these studies indicate that a component of UVB-induced epidermal cell cytotoxicity can be modulated by PAF-R activation through the production of PAF and PAF-like species.	Indiana Univ, Sch Med, Dept Dermatol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Pediat, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, HB Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; National Jewish Health	Travers, JB (corresponding author), Indiana Univ, James Whitcomb Riley Hosp Children, Sch Med, HB Wells Ctr Pediat Res, Rm 2659,702 Barnhill Dr, Indianapolis, IN 46202 USA.	jtravers@wpo.iupui.edu	Murphy, Robert/AAO-5349-2020	Murphy, Robert/0000-0002-9430-6515; Travers, Jeffrey/0000-0001-7232-1039	NHLBI NIH HHS [HL43403] Funding Source: Medline; NIAMS NIH HHS [K08AR1993] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR001993] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALLOATTI G, 1994, J PHARMACOL EXP THER, V269, P766; AMBROSIO G, 1994, J CLIN INVEST, V93, P2408, DOI 10.1172/JCI117248; ARENDS MJ, 1990, AM J PATHOL, V136, P593; AZZOUZI BE, 1993, BIOCHEM BIOPH RES CO, V190, P320; BAULDRY SA, 1991, BIOCHIM BIOPHYS ACTA, V1084, P178; CAMUSSI G, 1987, J EXP MED, V166, P1390, DOI 10.1084/jem.166.5.1390; CASALSTENZEL J, 1987, BRIT J DERMATOL, V118, P475; Cotton J, 1997, RADIAT RES, V147, P148, DOI 10.2307/3579415; CUNDELL DR, 1995, NATURE, V377, P435, DOI 10.1038/377435a0; EAGLE H, 1955, P SOC EXP BIOL MED, V89, P362; FARR RS, 1980, CLIN IMMUNOL IMMUNOP, V15, P318, DOI 10.1016/0090-1229(80)90044-6; Ferro TJ, 1997, AM J PHYSIOL-LUNG C, V272, pL979, DOI 10.1152/ajplung.1997.272.5.L979; GRANDEL KE, 1985, NEW ENGL J MED, V313, P405, DOI 10.1056/NEJM198508153130702; GREWE M, 1993, J INVEST DERMATOL, V101, P528, DOI 10.1111/1523-1747.ep12365904; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; Izumi T, 1995, BBA-LIPID LIPID MET, V1259, P317, DOI 10.1016/0005-2760(95)00171-9; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KERR JFR, 1965, J PATHOL BACTERIOL, V90, P419, DOI 10.1002/path.1700900210; KOCK A, 1990, J EXP MED, V172, P1609, DOI 10.1084/jem.172.6.1609; Lehr HA, 1997, J CLIN INVEST, V99, P2358, DOI 10.1172/JCI119417; LEVESQUE JP, 1986, P NATL ACAD SCI USA, V83, P6494, DOI 10.1073/pnas.83.17.6494; LEWIS MS, 1988, J CLIN INVEST, V82, P2045, DOI 10.1172/JCI113825; MALLET AI, 1985, BIOCHEM BIOPH RES CO, V126, P192, DOI 10.1016/0006-291X(85)90590-X; MATSUMOTO K, 1995, BLOOD, V86, P1437, DOI 10.1182/blood.V86.4.1437.bloodjournal8641437; Matsuzawa A, 1997, J BIOL CHEM, V272, P32315, DOI 10.1074/jbc.272.51.32315; MIWA M, 1988, J CLIN INVEST, V82, P1983, DOI 10.1172/JCI113818; Murphy RC, 1996, ADV EXP MED BIOL, V416, P51; NAKAMURA M, 1992, FEBS LETT, V314, P125, DOI 10.1016/0014-5793(92)80957-I; OFLAHERTY JT, 1994, BBA-LIPID LIPID MET, V1210, P209, DOI 10.1016/0005-2760(94)90123-6; PEI Y, 1998, IN PRESS J IMMUNOL; Pinckard RN, 1996, J LEUKOCYTE BIOL, V59, P219, DOI 10.1002/jlb.59.2.219; Porter AG, 1997, BIOESSAYS, V19, P501, DOI 10.1002/bies.950190609; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; Roth M, 1996, J EXP MED, V184, P191, DOI 10.1084/jem.184.1.191; SANCHEZ Y, 1995, BIOESSAYS, V17, P545, DOI 10.1002/bies.950170611; SHENG YH, 1995, CURR EYE RES, V14, P341, DOI 10.3109/02713689508999931; SHEPPARD GS, 1994, J MED CHEM, V37, P2011, DOI 10.1021/jm00039a015; SMILEY PL, 1991, J BIOL CHEM, V266, P11104; Stewart MS, 1996, J INVEST DERMATOL, V106, P1086, DOI 10.1111/1523-1747.ep12339344; STOLL LL, 1993, AM J PHYSIOL, V264, pC885, DOI 10.1152/ajpcell.1993.264.4.C885; TESSNER TG, 1989, J BIOL CHEM, V264, P4794; Toledano BJ, 1997, J IMMUNOL, V158, P3705; TRAVERS JB, 1990, BIOCHIM BIOPHYS ACTA, V1042, P193, DOI 10.1016/0005-2760(90)90007-K; TRAVERS JB, 1995, J INVEST DERMATOL, V105, P816, DOI 10.1111/1523-1747.ep12326581; Travers JB, 1996, J INVEST DERMATOL, V107, P88, DOI 10.1111/1523-1747.ep12298295; TRIGGIANI M, 1991, BIOCHIM BIOPHYS ACTA, V1084, P41, DOI 10.1016/0005-2760(91)90053-K; WILCOX RW, 1987, LIPIDS, V22, P800, DOI 10.1007/BF02535534; ZIMMERMAN GA, 1995, J NUTR, V125, P16615	49	64	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18891	18897		10.1074/jbc.273.30.18891	http://dx.doi.org/10.1074/jbc.273.30.18891			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668065	hybrid			2022-12-25	WOS:000074974700032
J	Duina, AA; Kalton, HM; Gaber, RF				Duina, AA; Kalton, HM; Gaber, RF			Requirement for Hsp90 and a CyP-40-type cyclophilin in negative regulation of the heat shock response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL REGULATION; STEROID-RECEPTOR; BINDING-PROTEIN; HSP70; THERMOTOLERANCE; GROWTH; INVIVO; KINASE; GENES	The heat shock response is a highly conserved mechanism that allows cells to withstand a variety of stress conditions. Activation of this response is characterized by increased synthesis of heat shock proteins (HSPs), which protect cellular proteins from stress-induced denaturation, Heat shock transcription factors (HSFs) are required for increased expression of HSPs during stress conditions and can be found in complexes containing components of the Hsp90 molecular chaperone machinery, raising the possibility that Hsp90 is involved in regulation of the heat shock response. To test this, we have assessed the effects of mutations that impair activity of the Hsp90 machinery on heat shock related events in Saccharomyces cerevisiae. Mutations that either reduce the level of Hsp90 protein or eliminate Cpr7, a CyP-40-type cyclophilin required for full Hsp90 function, resulted in increased HSF-dependent activities. Genetic tests also revealed that Hsp90 and Cpr7 function synergistically to repress gene expression from HSF-dependent promoters. Conditional loss of Hsp90 activity resulted in both increased HSF-dependent gene expression and acquisition of a thermotolerant phenotype. Our results reveal that Hsp90 and Cpr7 are required for negative regulation of the heat shock response under both stress and nonstress conditions and establish a specific endogenous role for the Hsp90 machinery in S. cerevisiae.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Northwestern University	Gaber, RF (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, 2153 Sheridan Rd, Evanston, IL 60208 USA.	r-gaber@nwu.edu						BARNES CA, 1990, J BACTERIOL, V172, P4352, DOI 10.1128/jb.172.8.4352-4358.1990; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; Chang HCJ, 1997, MOL CELL BIOL, V17, P318, DOI 10.1128/MCB.17.1.318; CHENG LI, 1993, BIOCHEM BIOPH RES CO, V195, P201, DOI 10.1006/bbrc.1993.2030; CRAIG EA, 1984, CELL, V38, P841, DOI 10.1016/0092-8674(84)90279-4; CRAIG EA, 1994, CELL, V78, P365, DOI 10.1016/0092-8674(94)90416-2; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; CRAIG EA, 1985, CRC CR REV BIOCH MOL, V18, P239, DOI 10.3109/10409238509085135; Duina AA, 1996, YEAST, V12, P943, DOI 10.1002/(SICI)1097-0061(199608)12:10<943::AID-YEA997>3.0.CO;2-3; Duina AA, 1996, SCIENCE, V274, P1713, DOI 10.1126/science.274.5293.1713; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; GIARDINA C, 1995, MOL CELL BIOL, V15, P2737; HALLADAY JT, 1995, MOL CELL BIOL, V15, P4890; JAKOBSEN BK, 1988, MOL CELL BIOL, V8, P5040, DOI 10.1128/MCB.8.11.5040; Jurivich D.A., 1994, BIOL HEAT SHOCK PROT, P417; Kaiser C., 1994, METHODS YEAST GENETI; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; Lindquist S, 1996, P NATL ACAD SCI USA, V93, P5301, DOI 10.1073/pnas.93.11.5301; MAGER WH, 1993, BIOCHEM J, V290, P1; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; NADEAU K, 1993, J BIOL CHEM, V268, P1479; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; Nathan DF, 1997, P NATL ACAD SCI USA, V94, P12949, DOI 10.1073/pnas.94.24.12949; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; Parsell D.A., 1994, BIOL HEAT SHOCK PROT, P457; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; SEWELL AK, 1995, J BIOL CHEM, V270, P25079, DOI 10.1074/jbc.270.42.25079; Shi YH, 1998, GENE DEV, V12, P654, DOI 10.1101/gad.12.5.654; SLATER MR, 1987, MOL CELL BIOL, V7, P1906, DOI 10.1128/MCB.7.5.1906; SORGER PK, 1990, CELL, V62, P793, DOI 10.1016/0092-8674(90)90123-V; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; SORGER PK, 1987, EMBO J, V6, P3035, DOI 10.1002/j.1460-2075.1987.tb02609.x; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; WERNERWASHBURNE M, 1987, MOL CELL BIOL, V7, P2568, DOI 10.1128/MCB.7.7.2568; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074	39	119	123	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18974	18978		10.1074/jbc.273.30.18974	http://dx.doi.org/10.1074/jbc.273.30.18974			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668076	hybrid			2022-12-25	WOS:000074974700043
J	Fay, PJ; Koshibu, K				Fay, PJ; Koshibu, K			The A2 subunit of factor VIIIa modulates the active site of factor IXa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE FACTOR-VIII; COAGULATION FACTOR-X; A1/A3-C1-C2 DIMER; CATALYZED PROTEOLYSIS; PROCOAGULANT ACTIVITY; BINDING-SITE; FACTOR XASE; PROTEIN-C; A2-SUBUNIT; ACTIVATION	Factor VIIIa, the protein cofactor for factor Ma, is comprised of Al, A2, and A3-C1-C2 subunits. Isolated subunits of factor VIIIa were examined for their ability to accelerate the factor IXa-catalyzed activation of factor X. The A2 subunit enhanced the k(cat) for this conversion by 100-fold whereas the K-m for factor X was unaffected. The apparent K-d for the interaction of A2 subunit with factor Ma was similar to 300 nM. Similar results were obtained using purified A2 expressed as the isolated domain in Chinese hamster ovary cells, although this material was less stable than the factor VIIIa-derived material. Isolated Al and A3-C1-C2 subunits showed no effect on the rate of factor X conversion. A2 subunit increased the fluorescence anisotropy of fluorescein-Phe-Phe-Arg-factor IXa (Delta r = 0.015) and markedly increased anisotropy in the presence of factor X (Delta r = 0.057), suggesting that it contributes to the orientation of the factor Ma active site and its relation to substrate. A synthetic peptide to A2 residues 558-565 inhibited the A2-dependent enhancement of factor X activation with an IC50 = 40 mu M, a value similar to its K-i for inhibition of the intrinsic factor Xase (105 mu M). These results indicate that the isolated A2 subunit modulates the active site of factor Ma and identifies a functional role for this subunit in factor VIIIa.	Univ Rochester, Med Ctr, Vasc Med Unit, Sch Med & Dent,Dept Med, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Fay, PJ (corresponding author), Univ Rochester, Med Ctr, Vasc Med Unit, Sch Med & Dent,Dept Med, POB 610,601 Elmwood Ave, Rochester, NY 14642 USA.			Koshibu, Kyoko/0000-0002-9809-0299	NHLBI NIH HHS [HL 38199, HL 30616] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038199, P01HL030616] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amano K, 1998, BLOOD, V91, P538, DOI 10.1182/blood.V91.2.538.538_538_548; Boedeker Berthold G. D., 1992, Transfusion Medicine Reviews, V6, P256, DOI 10.1016/S0887-7963(92)70177-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASILLAS G, 1971, COAGULATION, V4, P107; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; FAY PJ, 1993, J BIOL CHEM, V268, P17861; FAY PJ, 1994, J BIOL CHEM, V269, P20522; Fay PJ, 1996, J BIOL CHEM, V271, P6027, DOI 10.1074/jbc.271.11.6027; FAY PJ, 1992, J BIOL CHEM, V267, P13246; FAY PJ, 1991, J BIOL CHEM, V266, P8957; Gilbert GE, 1997, BIOCHEMISTRY-US, V36, P10768, DOI 10.1021/bi970537y; JESTY J, 1990, J BIOL CHEM, V265, P17539; KAUFMAN RJ, 1988, J BIOL CHEM, V263, P6352; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1992, BLOOD, V80, P3120; LAMPHEAR BJ, 1992, J BIOL CHEM, V267, P3725; Lapan KA, 1997, J BIOL CHEM, V272, P2082; Lenting PJ, 1996, J BIOL CHEM, V271, P1935, DOI 10.1074/jbc.271.4.1935; LENTING PJ, 1994, J BIOL CHEM, V269, P7150; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1993, METHOD ENZYMOL, V222, P128; LOLLAR P, 1984, BLOOD, V63, P1303; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; LOLLAR P, 1994, J CLIN INVEST, V93, P2497, DOI 10.1172/JCI117259; LOLLAR P, 1991, J BIOL CHEM, V266, P12481; LOLLAR P, 1992, J BIOL CHEM, V267, P23652; MANN KG, 1990, BLOOD, V76, P1; Mathur A, 1997, J BIOL CHEM, V272, P23418, DOI 10.1074/jbc.272.37.23418; MERTENS K, 1985, THROMB HAEMOSTASIS, V54, P654; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; OBRIEN DP, 1992, BIOCHEMISTRY-US, V31, P2805, DOI 10.1021/bi00125a022; OBrien LM, 1997, BLOOD, V90, P3943, DOI 10.1182/blood.V90.10.3943; OBRIEN LM, 1995, J BIOL CHEM, V270, P27087, DOI 10.1074/jbc.270.45.27087; PAN Y, 1995, NAT STRUCT BIOL, V2, P740, DOI 10.1038/nsb0995-740; Pemberton S, 1997, BLOOD, V89, P2413, DOI 10.1182/blood.V89.7.2413; PITTMAN DD, 1992, BLOOD, V79, P389; RAWALASHEIKH R, 1990, BIOCHEMISTRY-US, V29, P2606, DOI 10.1021/bi00462a025; Regan LM, 1996, J BIOL CHEM, V271, P3982; REGAN LM, 1994, J BIOL CHEM, V269, P9445; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433	40	94	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19049	19054		10.1074/jbc.273.30.19049	http://dx.doi.org/10.1074/jbc.273.30.19049			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668086	hybrid			2022-12-25	WOS:000074974700053
J	Foos, G; Garcia-Ramirez, JJ; Galang, CK; Hauser, CA				Foos, G; Garcia-Ramirez, JJ; Galang, CK; Hauser, CA			Elevated expression of Ets2 or distinct portions of Ets2 can reverse Ras-mediated cellular transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; GENE-EXPRESSION; ONCOGENIC ACTIVITY; DOMAIN PROTEIN; NUCLEAR TARGET; BINDING-SITES; MAP KINASE; CELLS; ACTIVATION; PROMOTER	Ets transcription factors are important downstream targets of oncogenic Ras. The transcriptional activity of several Ets family members is regulated by Ras, and interfering with Ets-dependent transcription by expression of just the Ets2 DNA binding domain can inhibit or reverse Ras-mediated cellular transformation. To better understand the role of Ets proteins in Ras transformation, we have now analyzed the effects of stably expressing a variety of Ets2 constructs in Ras-transformed NIH3T3 (DT) cells. Expression of only the Ets2 transactivation domains, which also inhibits Ras or Neu/ErbB-2-mediated activation of Ets-dependent transcription, strongly inhibited anchorage-independent growth, but did not revert the transformed DT cell morphology, Unexpectedly, high expression of full-length Ets2, a transcriptional activator, broadly reversed the transformed properties of DT cells, including anchorage-independent growth, transformed morphology, and tumorigenicity, but did not impair attached cell growth. Increasing full-length Ets2 transcriptional activity by fusing it to the VP16 transactivation domain enhanced its ability to reverse DT cell transformation. Mutational analysis revealed that the mitogen-activated protein kinase phosphorylation site required for Ras-mediated activation, Ets2(T72), was not essential for Ets2 reversion activity. The distinct reversion activities of the highly expressed Ets2 transactivation domains or full-length Ets2, along with the specific reversion activity by Ets2 constructs that either inhibit or activate Ets-dependent transcription, suggests multiple roles for Ets factors in cellular transformation. These results indicate that several distinct approaches for modulating Ets activity may be useful for intervention in human cancers.	Burnham Inst, La Jolla Canc Res Ctr, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Hauser, CA (corresponding author), Burnham Inst, La Jolla Canc Res Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Garcia-Ramirez, Jose J/L-2153-2014	Garcia-Ramirez, Jose J/0000-0002-8348-3727	NATIONAL CANCER INSTITUTE [R01CA063130] Funding Source: NIH RePORTER; NCI NIH HHS [CA63130] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; AOYAMA A, 1993, CRIT REV ONCOGENESIS, V4, P53; ARTELT P, 1991, GENE, V99, P249, DOI 10.1016/0378-1119(91)90134-W; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; Basuyaux JP, 1997, J BIOL CHEM, V272, P26188, DOI 10.1074/jbc.272.42.26188; BORTNER DM, 1993, CRIT REV ONCOGENESIS, V4, P137; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; CHAMBERS AF, 1993, CRIT REV ONCOGENESIS, V4, P95; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; Funaoka K, 1997, BIOCHEM BIOPH RES CO, V236, P79, DOI 10.1006/bbrc.1997.6909; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; GALANG CK, 1994, ONCOGENE, V9, P2913; GHYSDAEL J, 1997, ONCOGENES TRANSCRIPT, P29; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; Giovane A, 1997, MOL CELL BIOL, V17, P5667, DOI 10.1128/MCB.17.10.5667; HAUSER CA, 1995, METHOD ENZYMOL, V255, P412; HAUSER CA, 1994, METHOD ENZYMOL, V238, P271; Janknecht R, 1996, ONCOGENE, V13, P1745; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KIVINEN L, 1993, ONCOGENE, V8, P2703; KLAMBT C, 1993, DEVELOPMENT, V117, P163; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LI C, 1992, GENOMICS, V13, P658, DOI 10.1016/0888-7543(92)90138-I; Liu AY, 1997, PROSTATE, V30, P145, DOI 10.1002/(SICI)1097-0045(19970215)30:3<145::AID-PROS1>3.0.CO;2-L; LJUNGDAHL S, 1997, FEBS LETT, V249, P648; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; Michieli P, 1996, ONCOGENE, V12, P775; MIN SY, 1994, CELL GROWTH DIFFER, V5, P563; Neznanov N, 1997, J BIOL CHEM, V272, P27549, DOI 10.1074/jbc.272.44.27549; NEZNANOV NS, 1993, MOL CELL BIOL, V13, P1815, DOI 10.1128/MCB.13.3.1815; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; OHagan RC, 1996, ONCOGENE, V13, P1323; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; REBAY I, 1995, CELL, V81, P857, DOI 10.1016/0092-8674(95)90006-3; Rees S, 1996, BIOTECHNIQUES, V20, P102; REUTER CWM, 1995, METHOD ENZYMOL, V255, P245; SAVOYSKY E, 1994, ONCOGENE, V9, P1839; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SETH A, 1990, ONCOGENE, V5, P1761; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; SUZUKI H, 1995, P NATL ACAD SCI USA, V92, P4442, DOI 10.1073/pnas.92.10.4442; Venanzoni MC, 1996, ONCOGENE, V12, P1199; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WASYLYK C, 1994, ONCOGENE, V9, P3665; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; Yang BS, 1996, MOL CELL BIOL, V16, P538	60	46	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18871	18880		10.1074/jbc.273.30.18871	http://dx.doi.org/10.1074/jbc.273.30.18871			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668063	hybrid			2022-12-25	WOS:000074974700030
J	Liu, XP; Miller, MJS; Joshi, MS; Sadowska-Krowicka, H; Clark, DA; Lancaster, JR				Liu, XP; Miller, MJS; Joshi, MS; Sadowska-Krowicka, H; Clark, DA; Lancaster, JR			Diffusion-limited reaction of free nitric oxide with erythrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-BLOOD-CELLS; OXYGEN-UPTAKE; HEMOGLOBIN; COEFFICIENTS; RATS	Concentration changes of nitric oxide (NO) were monitored using an NO-sensitive electrode in phosphate-buffered saline (PBS) with either free oxyhemoglobin (oxyHb) or red blood cells (RBCs), In aerated PBS, the half-life of 0.9 mu M NO is greater than 4 min. NO is undetectable (<50 nM) when added to a solution of oxyHb because the reaction of NO with oxyHb is rapid. The disappearance rate of NO in PBS containing RBCs is rapid, compared with PBS, but it is much slower (by a factor of approximately 650) than with an equivalent solution of free oxyHb, The half-life of NO is inversely proportional to the concentration of RBCs, independent of oxyHb concentration inside RBCs, and the disappearance rate of NO is first order in NO concentration and first order in the concentration of RBCs, After all the oxyHb reacts with NO to form methemoglobin, the disappearance rate of NO slows greatly, These data indicate that the reaction of NO with oxyhemoglobin within RBCs is limited by the diffusion of NO into the cell, which has also been shown previously for the reaction of O-2 with deoxyhemoglobin, Experimental data show that the half-life of NO in the presence of 2.1 x 10(6) RBCs/ml is 4.2 s, From this value, we estimate that the half-life of NO in whole blood (5 x 10(9) RBCs/ml) will be 1.8 ms, A simple analytical expression for the half-life of NO in PBS with RBCs was derived in this study based on a spherical diffusion model. The calculated half-life of NO from the expression is in good agreement with the experimental values.	Louisiana State Univ, Sch Med, Dept Physiol, New Orleans, LA 70112 USA; Louisiana State Univ, Sch Med, Dept Pediat, New Orleans, LA 70112 USA; Louisiana State Univ, Sch Med, Dept Med, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University System; Louisiana State University System	Lancaster, JR (corresponding author), Louisiana State Univ, Sch Med, Dept Physiol, 1901 Perdido St, New Orleans, LA 70112 USA.	jlanca@lsumc.edu	Liu, Xiaoping/A-4516-2008	Liu, Xiaoping/0000-0002-7516-382X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD031885] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA028842] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA28842] Funding Source: Medline; NICHD NIH HHS [HD31885] Funding Source: Medline; NIDDK NIH HHS [DK46995] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abassi Z, 1997, J LAB CLIN MED, V129, P603, DOI 10.1016/S0022-2143(97)90194-3; Bard A. J., 1980, ELECTROCHEMICAL METH; CARLSEN E, 1958, J GEN PHYSIOL, V42, P83, DOI 10.1085/jgp.42.1.83; CHIEN JCW, 1969, J AM CHEM SOC, V91, P2166, DOI 10.1021/ja01036a085; COIN JT, 1979, J BIOL CHEM, V254, P1178; Eich RF, 1996, BIOCHEMISTRY-US, V35, P6976, DOI 10.1021/bi960442g; FARMER MC, 1988, BIOMATER ARTIF CELL, V16, P289, DOI 10.3109/10731198809132578; GILLESPIE JS, 1989, BRIT J PHARMACOL, V98, P445, DOI 10.1111/j.1476-5381.1989.tb12616.x; Hakim TS, 1996, PHYSIOL MEAS, V17, P267, DOI 10.1088/0967-3334/17/4/004; Hartridge H, 1927, J PHYSIOL-LONDON, V52, P232, DOI 10.1113/jphysiol.1927.sp002354; Hermann L, 1865, ARCH ANAT PHYSL LPZ, P469; HUXLEY VH, 1983, MICROVASC RES, V26, P89, DOI 10.1016/0026-2862(83)90058-4; HUXLEY VH, 1981, J PHYSIOL-LONDON, V316, P75, DOI 10.1113/jphysiol.1981.sp013773; JAFFE ER, 1964, RED BLOOD CELL, P397; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; KILBOURN RG, 1994, BIOCHEM BIOPH RES CO, V199, P155, DOI 10.1006/bbrc.1994.1208; KOSAKA H, 1994, AM J PHYSIOL, V266, pC1400, DOI 10.1152/ajpcell.1994.266.5.C1400; LANCASTER JR, 1992, AM SCI, V80, P248; Lancaster JR, 1997, NITRIC OXIDE-BIOL CH, V1, P18, DOI 10.1006/niox.1996.0112; LANCASTER JR, 1994, P NATL ACAD SCI USA, V91, P8137, DOI 10.1073/pnas.91.17.8137; LIU XP, 1990, J ELECTROANAL CHEM, V294, P289, DOI 10.1016/0022-0728(90)87152-A; Loscalzo J, 1997, J LAB CLIN MED, V129, P580, DOI 10.1016/S0022-2143(97)90191-8; Malinski T, 1996, METHOD ENZYMOL, V268, P58; MALINSKI T, 1993, BIOCHEM BIOPH RES CO, V193, P1076, DOI 10.1006/bbrc.1993.1735; MEULEMANS A, 1994, NEUROSCI LETT, V171, P89, DOI 10.1016/0304-3940(94)90612-2; MULDOON S, 1996, ARTIF CELL BLOOD SUB, V24, P392; NICOLSON P, 1951, PROC R SOC SER B-BIO, V138, P241, DOI 10.1098/rspb.1951.0020; NORTON JM, 1990, BIORHEOLOGY, V27, P21; RABINOVICI R, 1995, CRIT CARE MED, V23, P801, DOI 10.1097/00003246-199505000-00004; Rudolph AS, 1997, J APPL PHYSIOL, V82, P1826, DOI 10.1152/jappl.1997.82.6.1826; Sandoval M, 1997, GASTROENTEROLOGY, V113, P1480, DOI 10.1053/gast.1997.v113.pm9352850; SCHULTZ SC, 1993, J LAB CLIN MED, V122, P301; SHAW AW, 1977, J CHEM SOC FARAD T 1, V73, P1239, DOI 10.1039/f19777301239; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; VANASSENDELFT OW, 1975, ANAL BIOCHEM, V69, P43, DOI 10.1016/0003-2697(75)90563-1; VANDEGRIFF KD, 1984, BIOPHYS J, V45, P825, DOI 10.1016/S0006-3495(84)84226-5; WADE RS, 1990, CHEM RES TOXICOL, V3, P289, DOI 10.1021/tx00016a002; WESTENBERGER U, 1990, FREE RADICAL RES COM, V11, P167, DOI 10.3109/10715769009109680; ZUCK TF, 1994, CRIT REV CL LAB SCI, V31, P295, DOI 10.3109/10408369409084678	39	403	410	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18709	18713		10.1074/jbc.273.30.18709	http://dx.doi.org/10.1074/jbc.273.30.18709			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668042	hybrid			2022-12-25	WOS:000074974700009
J	Kingma, PS; Osheroff, N				Kingma, PS; Osheroff, N			Topoisomerase II-mediated DNA cleavage and religation in the absence of base pairing - Abasic lesions as a tool to dissect enzyme mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA-MELANOGASTER; ANTINEOPLASTIC DRUGS; SITE; REQUIREMENTS; COMPLEX; FORM; NMR	The interaction of topoisomerase II with its DNA cleavage site is critical to the physiological functions of the enzyme. Despite this importance, the specific enzyme-DNA interactions that drive topoisomerase II-mediated DNA cleavage and religation are poorly understood. Therefore, to dissect interactions between the enzyme and its cleavage site, abasic DNA lesions were incorporated into a bilaterally symmetrical and identical cleavage site, Results indicate that topoisomerase II has unique interactions with each position of the 4-base overhang generated by enzyme-mediated DNA cleavage. Lesions located 2 bases 3' to the point of scission stimulated cleavage the most, whereas those 3 bases from the point of scission stimulated cleavage the least. Moreover, an additive and in some cases synergistic cleavage enhancement was observed in oligonucleotides that contained multiple DNA lesions, with levels reaching >60-fold higher than the wild-type substrate. Finally, topoisomerase II efficiently cleaved and religated a DNA substrate in which apyrimidinic sites were simultaneously incorporated at every position on one strand of the 4-base overhang. Therefore, unlike classical DNA ligases in which base pairing is the driving force behind closure of the DNA break, it appears that for topoisomerase II, the enzyme is responsible for the spatial orientation of the DNA termini for ligation.	Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Med Oncol, Sch Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Osheroff, N (corresponding author), Vanderbilt Univ, Dept Biochem, Sch Med, 654 Med Res Bldg 1, Nashville, TN 37232 USA.	osheron@ctrvax.vanderbilt.edu			NIGMS NIH HHS [GM33944, GM53960] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033944] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bigioni M, 1996, BIOCHEMISTRY-US, V35, P153, DOI 10.1021/bi951736p; CAPRANICO G, 1992, EUR J CANCER, V28A, P2055, DOI 10.1016/0959-8049(92)90255-Z; CAPRANICO G, 1990, NUCLEIC ACIDS RES, V18, P6611, DOI 10.1093/nar/18.22.6611; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; CORBETT AH, 1993, CHEM RES TOXICOL, V6, P585, DOI 10.1021/tx00035a001; Cozzarelli N.R., 1990, DNA TOPOLOGY ITS BIO; FELIX CA, 1995, CANCER RES, V55, P4287; FREUDENREICH CH, 1993, EMBO J, V12, P2085, DOI 10.1002/j.1460-2075.1993.tb05857.x; FREUDENREICH CH, 1994, P NATL ACAD SCI USA, V91, P11007, DOI 10.1073/pnas.91.23.11007; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; GU Y, 1994, CANCER RES, V54, P2326; Kingma PS, 1997, BIOCHEMISTRY-US, V36, P5934, DOI 10.1021/bi970507v; Kingma PS, 1997, J BIOL CHEM, V272, P1148, DOI 10.1074/jbc.272.2.1148; Kingma PS, 1997, J BIOL CHEM, V272, P7488, DOI 10.1074/jbc.272.11.7488; LIU LF, 1983, J BIOL CHEM, V258, P5365; Nitiss JL, 1996, EUR J CANCER, V32A, P958, DOI 10.1016/0959-8049(96)00056-1; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P4303, DOI 10.1021/bi00388a018; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P6402, DOI 10.1021/bi00394a015; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; Pommier Y., 1996, CANC CHEMOTHERAPY BI, P435; RAAP J, 1987, J BIOMOL STRUCT DYN, V5, P219, DOI 10.1080/07391102.1987.10506391; ROBINSON MJ, 1991, BIOCHEMISTRY-US, V30, P1807, DOI 10.1021/bi00221a012; ROWE TC, 1986, CANCER RES, V46, P2021; SANDER M, 1983, J BIOL CHEM, V258, P8421; SCHMIDT VK, 1994, J MOL BIOL, V241, P18, DOI 10.1006/jmbi.1994.1469; SINGH MP, 1994, BIOCHEMISTRY-US, V33, P10271, DOI 10.1021/bi00200a007; VESNAVER G, 1989, P NATL ACAD SCI USA, V86, P3614, DOI 10.1073/pnas.86.10.3614; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681	30	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					17999	18002		10.1074/jbc.273.29.17999	http://dx.doi.org/10.1074/jbc.273.29.17999			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660751	hybrid			2022-12-25	WOS:000074828500006
J	Wakeman, JA; Walsh, J; Andrews, PW				Wakeman, JA; Walsh, J; Andrews, PW			Human Wnt-13 is developmentally regulated during the differentiation of NTERA-2 pluripotent human embryonal carcinoma cells	ONCOGENE			English	Article						Wnt-13; teratocarcinoma; human; neuron	PROTO-ONCOGENE INT-1; RETINOIC ACID; XENOPUS EMBRYOS; EXPRESSION; GENE; TERATOCARCINOMA; DROSOPHILA; LINES; POLARITY; HOMOLOG	The Wnt gene family encodes a series of conserved glycoproteins that regulate pattern formation during embryogenesis, in a variety of tissues including the nervous system. As with other genes that control embryonic cell differentiation, members of the Wnt family have also been implicated in tumourigenesis, To search for Wnt genes involved in human teratocarcinomas, with a possible role in human embryogenesis, we used RT-PCR primed with degenerate oligonucleotides to analyse mRNA from differentiating cultures of the pluripotent human embryonal carcinoma (EC) cell line NTERA-2, NTERA-2 EC cells differentiate into neurons and other cell types when induced with retinoic acid. Wnt gene expression was not detected in the undifferentiated EC cells, but Wnt-related PCR fragments were amplified from differentiating cultures, 4-14 days after induction with retinoic acid, The RT-PCR products were composed primarily of DNA fragments corresponding to the recently identified human Wnt-13 gene, No other Wnt-related genes were identified. Northern analysis confirmed induction of Wnt-13 as a 2.4 kb mRNA during the early phases of retinoic acid-induced differentiation, and during differentiation along a non-neural pathway induced by hexamethylene bisacetamide (HMBA), but not in the terminally differentiated neurons, Wnt-13 remained expressed in non-neural differentiated NTERA-2 cells, even several weeks after the induction of differentiation. The time course of induction, its induction by HMBA, and its persistence in differentiated cells indicate that Wnt-13 expression is not dependent upon direct activation by retinoic acid. Wnt-13 was not detected, or only detected at low levels, in other human EC cells, However, it was found to be expressed at a high level in one malignant teratoma cell line, 577MF, that does not exhibit an EC phenotype although it was derived from a testicular teratocarcinoma. At least two members of the human frizzled gene family, thought to encode receptors for Wnt proteins, were also expressed in the NTERA-2 cells, suggesting the presence of a mechanism by which endogenously expressed Wnt-13 could modulate the histogenesis of teratocarcinomas by mediating interactions between subpopulations of differentiating EC cells. We note that Wnt-13 maps to chromosome 1p13, a region reported to be subject to relatively frequent loss of heterozygosity in germ cell tumours, Further analysis indicated that 465 bp of the published Wnt-13 sequence, within the predicted 5' UTR, is incorrect and is possibly derived from a human mitochondrial DNA sequence.	Univ Sheffield, Dept Biomed Sci, Sheffield S10 2TN, S Yorkshire, England	University of Sheffield	Andrews, PW (corresponding author), Univ Sheffield, Dept Biomed Sci, Western Bank, Sheffield S10 2TN, S Yorkshire, England.			Wakeman, Jane/0000-0002-7561-634X; Andrews, Peter/0000-0001-7215-4410	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ACKERMAN SL, 1994, MOL BRAIN RES, V25, P157, DOI 10.1016/0169-328X(94)90293-3; ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; ANDREWS PW, 1980, INT J CANCER, V26, P269, DOI 10.1002/ijc.2910260304; ANDREWS PW, 1988, BIOCHIM BIOPHYS ACTA, V948, P17, DOI 10.1016/0304-419X(88)90003-0; ANDREWS PW, 1984, LAB INVEST, V50, P147; ANDREWS PW, 1990, DIFFERENTIATION, V43, P131, DOI 10.1111/j.1432-0436.1990.tb00439.x; Andrews PW, 1996, INT J CANCER, V66, P806, DOI 10.1002/(SICI)1097-0215(19960611)66:6<806::AID-IJC17>3.0.CO;2-0; ANDREWS PW, 1997, IN PRESS ACTA PATH M; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BROWN AMC, 1987, MOL CELL BIOL, V7, P3971, DOI 10.1128/MCB.7.11.3971; DEALY CN, 1993, MECH DEVELOP, V43, P175, DOI 10.1016/0925-4773(93)90034-U; DICKINSON ME, 1994, DEVELOPMENT, V120, P1453; FENDERSON BA, 1987, DEV BIOL, V122, P21, DOI 10.1016/0012-1606(87)90328-9; Fogh J., 1975, HUMAN TUMOR CELLS IN, VVolume 1, P115, DOI [10.1007/978-1-4757-1647-4_5, DOI 10.1007/978-1-4757-1647-4_5]; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; HUGUET EL, 1994, CANCER RES, V54, P2615; Katoh M, 1996, ONCOGENE, V13, P873; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MARTIN GR, 1980, SCIENCE, V209, P768, DOI 10.1126/science.6250214; MATHEW S, 1994, CANCER RES, V54, P6265; MATTHAEI KI, 1983, EXP CELL RES, V143, P471, DOI 10.1016/0014-4827(83)90076-9; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MILLER JM, 1996, GENE DEV, V10, P257; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PAPKOFF J, 1989, MOL CELL BIOL, V9, P3377, DOI 10.1128/MCB.9.8.3377; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978; PARR BA, 1993, DEVELOPMENT, V119, P247; PATTILLO RA, 1971, IN VITRO CELL DEV B, V6, P398; PATTILLO RA, 1968, CANCER RES, V28, P1231; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; RAMAKRISHNA NR, 1993, DEVELOPMENT S, V119, P95; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; THOMAS KR, 1991, CELL, V67, P969, DOI 10.1016/0092-8674(91)90369-A; THOMSON JA, 1995, P NATL ACAD SCI USA, V92, P7844, DOI 10.1073/pnas.92.17.7844; Vider BZ, 1996, ONCOGENE, V12, P153; Wang YS, 1996, J BIOL CHEM, V271, P4468; WOLDA SL, 1992, ONCOGENE, V7, P1941; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; ZHAO ZY, 1995, GENOMICS, V27, P370, DOI 10.1006/geno.1995.1060	45	27	29	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 16	1998	17	2					179	186		10.1038/sj.onc.1201942	http://dx.doi.org/10.1038/sj.onc.1201942			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZZ211	9674702				2022-12-25	WOS:000074706700006
J	Al-Hasani, H; Kinck, CS; Cushman, SW				Al-Hasani, H; Kinck, CS; Cushman, SW			Endocytosis of the glucose transporter GLUT4 is mediated by the GTPase dynamin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADIPOSE-CELLS; TEMPERATURE-SENSITIVE MUTANT; COATED VESICLE FORMATION; PHOSPHATIDYLINOSITOL 3-KINASE; PLASMA-MEMBRANE; BREFELDIN-A; 1-PHOSPHATIDYLINOSITOL 3-KINASE; SUBCELLULAR TRAFFICKING; 3T3-L1 ADIPOCYTES; INSULIN-RECEPTOR	To study the role of the GTPase dynamin in GLUT4 intracellular recycling, we have overexpressed dynamin-1 wild type and a GTPase-negative mutant (K44A) in primary rat adipose cells. Transfection was accomplished by electroporation using an hemagglutinin (HA)-tagged GLUT4 as a reporter protein. In cells expressing HA GLUT4 alone, insulin results in an approximate to 7-fold increase in cell surface anti-HA antibody binding. Studies with wortmannin indicate that the kinetics of HA-GLUT4-trafficking parallel those of the native GLUT4 and in addition, that newly synthesized HA-GLUT4 goes to the plasma membrane before being sorted into the insulin responsive compartments. Short term (4 h) coexpression of dynamin-K44A and HA-GLUT4 increases the amount of cell surface HA-GLUT4 in both the basal and insulin-stimulated states. Under conditions of maximal expression of dynamin-K44A (24 h), most or all of the intracellular HA-GLUT4 appears to be present on the cell surface in the basal state, and insulin has no further effect. Measurements of the kinetics of HA-GLUT4 endocytosis show that dynamin-K44A blocks internalization of the glucose transporters. In contrast, expression of dynamin wild type decreases the amount of cell surface HA-GLUT4 in both the basal and insulin stimulated states. These data demonstrate that the endocytosis of GLUT4 is largely mediated by processes which require dynamin.	NIDDK, EDMNS, DB, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Al-Hasani, H (corresponding author), NIDDK, EDMNS, DB, NIH, Bldg 10,Rm 5N102,10 Ctr Dr,MSC 1420, Bethesda, MD 20892 USA.	hadi@helix.nih.gov						BAO SC, 1995, J BIOL CHEM, V270, P30199; CARPENTIER JL, 1995, J BIOL CHEM, V270, P5001, DOI 10.1074/jbc.270.10.5001; CHAKRABARTI R, 1994, J BIOL CHEM, V269, P7926; Cheatham B, 1996, P NATL ACAD SCI USA, V93, P15169, DOI 10.1073/pnas.93.26.15169; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; COOK TA, 1994, P NATL ACAD SCI USA, V91, P644, DOI 10.1073/pnas.91.2.644; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; FAN JY, 1983, J CELL SCI, V61, P219; FUTTER CE, 1995, J BIOL CHEM, V270, P10999, DOI 10.1074/jbc.270.18.10999; Gustavsson J, 1996, MOL MED, V2, P367, DOI 10.1007/BF03401634; Hamer I, 1997, J BIOL CHEM, V272, P21685, DOI 10.1074/jbc.272.35.21685; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; Henley JR, 1996, J CELL BIOL, V133, P761, DOI 10.1083/jcb.133.4.761; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HOLMAN GD, 1994, J BIOL CHEM, V269, P17516; Jones SM, 1998, SCIENCE, V279, P573, DOI 10.1126/science.279.5350.573; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; KANDROR KV, 1995, J CELL BIOL, V129, P999, DOI 10.1083/jcb.129.4.999; KESSELL I, 1989, P NATL ACAD SCI USA, V86, P4968, DOI 10.1073/pnas.86.13.4968; KONO T, 1981, J BIOL CHEM, V256, P6400; KonoSugita E, 1996, EUR J BIOCHEM, V236, P1033, DOI 10.1111/j.1432-1033.1996.01033.x; KOSAKA T, 1983, J CELL BIOL, V97, P499, DOI 10.1083/jcb.97.2.499; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; LEITINGER B, 1995, P NATL ACAD SCI USA, V92, P10109, DOI 10.1073/pnas.92.22.10109; Maier O, 1996, BIOCHEM BIOPH RES CO, V223, P229, DOI 10.1006/bbrc.1996.0876; Malide D, 1997, J HISTOCHEM CYTOCHEM, V45, P1083, DOI 10.1177/002215549704500806; Malide D, 1997, FEBS LETT, V409, P461, DOI 10.1016/S0014-5793(97)00563-2; Malide D, 1997, J CELL SCI, V110, P2795; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; NAKATA T, 1993, J CELL SCI, V105, P1; NISHIMURA H, 1993, J BIOL CHEM, V268, P19246; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; OKADA T, 1994, J BIOL CHEM, V269, P3568; Olson AL, 1997, MOL CELL BIOL, V17, P2425, DOI 10.1128/MCB.17.5.2425; Omata W, 1997, BIOCHEM BIOPH RES CO, V241, P401, DOI 10.1006/bbrc.1997.7810; PACCAUD JP, 1992, J BIOL CHEM, V267, P13101; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; Quon MJ, 1996, BIOCHEM BIOPH RES CO, V226, P587, DOI 10.1006/bbrc.1996.1400; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; QUON MJ, 1994, P NATL ACAD SCI USA, V91, P587; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SATOH S, 1993, J BIOL CHEM, V268, P17820; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SHEPHERD PR, 1993, J BIOL CHEM, V268, P22243; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; Shpetner HS, 1996, J BIOL CHEM, V271, P13, DOI 10.1074/jbc.271.1.13; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; Timmers KI, 1996, BIOCHEM J, V320, P429, DOI 10.1042/bj3200429; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Wang K, 1997, J BIOL CHEM, V272, P17055, DOI 10.1074/jbc.272.27.17055; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Warnock DE, 1997, MOL BIOL CELL, V8, P2553, DOI 10.1091/mbc.8.12.2553; WEBER TM, 1988, INSULIN RECEPTOR, V2, P171; Yang J, 1996, BIOCHEM J, V313, P125, DOI 10.1042/bj3130125; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	60	87	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17504	17510		10.1074/jbc.273.28.17504	http://dx.doi.org/10.1074/jbc.273.28.17504			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651341	hybrid			2022-12-25	WOS:000074816100034
J	Heraud, JM; Racaud-Sultan, C; Gironcel, D; Albiges-Rizo, C; Giacomini, T; Roques, S; Martel, V; Breton-Douillon, M; Perret, B; Chap, H				Heraud, JM; Racaud-Sultan, C; Gironcel, D; Albiges-Rizo, C; Giacomini, T; Roques, S; Martel, V; Breton-Douillon, M; Perret, B; Chap, H			Lipid products of phosphoinositide 3-kinase and phosphatidylinositol 4 ',5 '-bisphosphate are both required for ADP-dependent platelet spreading	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; FOCAL ADHESION KINASE; LIGHT CHAIN KINASE; GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; THROMBIN RECEPTOR; PHOSPHOLIPASE-C; ACTIVATION; INTEGRIN; WORTMANNIN	We have shown previously that ADP released upon platelet adhesion mediated by alpha(IIb)beta(3) integrin triggers accumulation of phosphatidylinositol 3',4'-bisphosphate (PtdIns-3,4-P-2) (Gironcel, D., Racaud-Sultan, C., Payrastre, B., Haricot, RI., Borchert, G., Kieffer, N., Breton, RI., and Chap, H. (1996) FEES Lett. 389, 253-256). ADP has also been involved in platelet spreading. Therefore, in order to study a possible role of phosphoinositide 3-kinase in platelet morphological changes following adhesion, human platelets were pretreated with specific phosphoinositide 3-kinase inhibitors LY294002 and wortmannin. Under conditions where PtdIns-3,4-P-2 synthesis was totally inhibited (25 mu M LY294002 or 100 nM wortmannin), platelets adhered to the fibrinogen matrix, extended pseudopodia, but did not spread. Moreover, addition of ADP to the medium did not reverse the inhibitory effects of phosphoinositide 3-kinase inhibi tors on platelet spreading. Although synthetic dipalmitoyl PtdIns-3,4-P-2 and dipalnitoyl phosphatidylinositol 3',4',5'-trisphosphate restored only partially platelet spreading, phosphatidylinositol 4',5'-bisphosphate (PtdIns-4,5-P-2) was able to trigger full spreading of wortmannin-treated adherent platelets. Following P-32 labeling of intact platelets, the recovery of [P-32]PtdIns 4,5-P-2 in anti-talin immunoprecipitates from adherent plate lets was found to be decreased upon treatment by wortmannin. These results suggest that the lipid products of phosphoinositide S-kinase are required but not sufficient for ADP-induced spreading of adherent platelets and that PtdIns-4,5-P-2 could be a downstream messenger of this signaling pathway.	Hop Purpan, Inst Federat Rech Immunol Cellulaire & Mol, INSERM, U326, F-31059 Toulouse, France; Fac Med, Inst Albert Bonniot, Lab Etud Differenciat & Adherenee Cellulaires, Unite Mixte Rech CNRS Univ Joseph Fourier 5538, F-38706 La Tronche, France; Ecole Natl Super Aeronaut & Espace, F-31055 Toulouse, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Universite de Toulouse; Institut Superieur de l'Aeronautique et de l'Espace (ISAE-SUPAERO)	Racaud-Sultan, C (corresponding author), Hop Purpan, Inst Federat Rech Immunol Cellulaire & Mol, INSERM, U326, F-31059 Toulouse, France.		Albiges-Rizo, Corinne/M-2568-2013; Heraud, Jean-Michel/O-1464-2013; Frachet, Véronique/B-8418-2018; Martel-Frachet, Veronique/B-8657-2014	Heraud, Jean-Michel/0000-0003-1107-0859; Frachet, Véronique/0000-0001-6739-7901; Racaud-Sultan, Claire/0000-0002-6549-1088; ALBIGES-RIZO, Corinne/0000-0002-6333-4150				ALBIGESRIZO C, 1995, J CELL SCI, V108, P3317; Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Chung J, 1997, J BIOL CHEM, V272, P14740, DOI 10.1074/jbc.272.23.14740; Cichowski K, 1996, J BIOL CHEM, V271, P7544, DOI 10.1074/jbc.271.13.7544; Derman MP, 1997, J BIOL CHEM, V272, P6465, DOI 10.1074/jbc.272.10.6465; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FUKAMI K, 1994, J BIOL CHEM, V269, P1518; Gironcel D, 1996, FEBS LETT, V389, P253, DOI 10.1016/0014-5793(96)00595-9; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; Haimovich B, 1996, BLOOD, V87, P152, DOI 10.1182/blood.V87.1.152.bloodjournal871152; Hartwig JH, 1996, J BIOL CHEM, V271, P32986, DOI 10.1074/jbc.271.51.32986; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Isenberg G, 1998, INT REV CYTOL, V178, P73; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; KOCHS G, 1993, BIOCHEM J, V291, P627, DOI 10.1042/bj2910627; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V208, P985, DOI 10.1006/bbrc.1995.1431; KOVACSOVICS TJ, 1995, J BIOL CHEM, V270, P11358, DOI 10.1074/jbc.270.19.11358; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; Meyers R, 1997, J BIOL CHEM, V272, P4384, DOI 10.1074/jbc.272.7.4384; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; NUCKOLLS GH, 1992, J CELL SCI, V102, P753; PIGNATARO OP, 1990, J BIOL CHEM, V265, P1718; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SAITOH M, 1987, J BIOL CHEM, V262, P7796; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; SULTAN C, 1990, BIOCHEM J, V269, P831, DOI 10.1042/bj2690831; Symes K, 1996, P NATL ACAD SCI USA, V93, P9641, DOI 10.1073/pnas.93.18.9641; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Vignoud L, 1997, J CELL SCI, V110, P1421; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WENNSTROM S, 1994, ONCOGENE, V9, P651; WITKE W, 1995, CELL, V81, P41, DOI 10.1016/0092-8674(95)90369-0; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Zhang J, 1996, J BIOL CHEM, V271, P6265, DOI 10.1074/jbc.271.11.6265; ZHANG J, 1995, BIOCHEM BIOPH RES CO, V211, P484, DOI 10.1006/bbrc.1995.1839	43	49	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17817	17823		10.1074/jbc.273.28.17817	http://dx.doi.org/10.1074/jbc.273.28.17817			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651384	Green Published, hybrid			2022-12-25	WOS:000074816100077
J	Kwiatkowski, BA; Bastian, LS; Bauer, TR; Tsai, S; Zielinska-Kwiatkowska, AG; Hickstein, DD				Kwiatkowski, BA; Bastian, LS; Bauer, TR; Tsai, S; Zielinska-Kwiatkowska, AG; Hickstein, DD			The ets family member Tel binds to the Fli-1 oncoprotein and inhibits its transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; GENE; FUSION; LEUKEMIA; ERYTHROLEUKEMIA; TRANSLOCATION; PROTOONCOGENE; ACTIVATION; PROMOTER; RECEPTOR	The tel gene, recently shown to be translocated in a spectrum of acute and chronic human leukemias, be longs to the ets family of sequence specific transcription factors. To determine the role of Tel in normal hematopoietic development, we used the tel gene as the bait in the yeast two hybrid system to screen a hematopoietic stem cell library. Two partners were identified: Tel binds to itself, and Tel binds to the ets family member Fli-1. In vitro and in vivo assays confirmed these inter actions. In transient transfection assays, Fli-1 transactivates megakaryocytic specific promoters, and Tel inhibits this effect of Fli-1, Transactivation studies using deletion mutants of Tel, and the Tel-AML-1 fusion protein, indicate that the helix-loop-helix domain of Tel only partially inhibits transactivation and that complete inhibition requires the full-length Tel molecule, including the DNA binding domain. The Tel and Fli-1 proteins are expressed early in hematopoiesis, and the inability of Tel fusion proteins such as Tel-AML-1 to counteract Fli-1 mediated transactivation may contribute to the malignant phenotype in human leukemias where this fusion protein is present.	Vet Affairs Paget Sound Hlth Care Syst, Med Res Serv, Seattle, WA 98108 USA; Fred Hutchinson Canc Res Ctr, Div Mol Med, Seattle, WA 98109 USA; Univ Washington, Sch Med, Dept Med, Div Hematol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Med, Div Oncol, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Hickstein, DD (corresponding author), Vet Affairs Paget Sound Hlth Care Syst, Med Res Serv, 1660 S Columbian Way, Seattle, WA 98108 USA.							Bastian LS, 1996, J BIOL CHEM, V271, P18554, DOI 10.1074/jbc.271.31.18554; Bauer TR, 1997, HUM GENE THER, V8, P243, DOI 10.1089/hum.1997.8.3-243; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; HASHIMOTO Y, 1995, J BIOL CHEM, V270, P24532, DOI 10.1074/jbc.270.41.24532; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P38113; HROMAS R, 1994, INT J HEMATOL, V59, P257; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RAO VN, 1993, ONCOGENE, V8, P2167; RICARDO R, 1996, BRIT J HAEMATOL, V95, P673; Sambrook J., 2002, MOL CLONING LAB MANU; SETH A, 1990, ONCOGENE, V5, P1761; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; ZHANG LQ, 1993, ONCOGENE, V8, P1621	19	109	109	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17525	17530		10.1074/jbc.273.28.17525	http://dx.doi.org/10.1074/jbc.273.28.17525			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651344	hybrid			2022-12-25	WOS:000074816100037
J	Tan, PK; Waites, C; Liu, YJ; Krantz, DE; Edwards, RH				Tan, PK; Waites, C; Liu, YJ; Krantz, DE; Edwards, RH			A leucine-based motif mediates the endocytosis of vesicular monoamine and acetylcholine transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSE CORE VESICLES; SYNAPTIC VESICLE; CYTOPLASMIC DOMAIN; MOLECULAR-CLONING; FUNCTIONAL IDENTIFICATION; INTERNALIZATION MOTIF; CHROMAFFIN GRANULES; CARBOXYL-TERMINUS; TARGETING SIGNAL; MEMBRANE-PROTEIN	Specific transport proteins mediate the packaging of neurotransmitters into secretory vesicles and consequently require targeting to the appropriate intracellular compartment, To identify residues in the neuron-specific vesicular monoamine transporter (VMAT2) responsible for endocytosis, we examined the effect of amino (NH2-) and carboxyl (COOH-)-terminal mutations on steady state distribution and internalization. Deletion of a critical COOH terminal domain sequence (AKEEKMAIL) results in accumulation of VMAT2 at the plasma membrane and a 50% reduction in endocytosis. Site directed mutagenesis shows that replacement of the isoleucine-leucine pair within this sequence by alanine-alanine alone reduces endocytosis by 50% relative to wild type VMAT2. Furthermore, the KEEKMAIL se quence functions as an internalization signal when transferred to the plasma membrane protein Tac, and the mutation of the isoleucine-leucine pair also abolishes internalization of this protein. The closely related vesicular acetylcholine transporter (VAChT) contains a similar di leucine sequence within the cytoplasmic COOH-terminal domain that when mutated results in accumulation of VAChT at the plasma membrane. The VAChT di-leucine sequence also confers internalization when appended to two other proteins and in one of these chimeras, conversion of the di-leucine sequence to dialanine reduces the internalization rate by 50%. Both VMAT2 and VAChT thus use leucine-based signals for efficient endocytosis and as such are the first synaptic vesicle proteins known to use this motif for trafficking.	Univ Calif San Francisco, Sch Med, Dept Neurol, Grad Program Neurosci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Dept Physiol, Grad Program Cell Biol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Edwards, RH (corresponding author), Univ Calif San Francisco, Sch Med, Dept Neurol, Grad Program Neurosci, 3rd & Parnassus Ave, San Francisco, CA 94143 USA.	edwards@itsa.ucsf.edu	Liu, Yongjian/J-7852-2018					BREMNES B, 1994, J CELL SCI, V107, P2021; Cowles CR, 1997, CELL, V91, P109, DOI 10.1016/S0092-8674(01)80013-1; CUTLER DF, 1990, J CELL BIOL, V110, P721, DOI 10.1083/jcb.110.3.721; DAVIS CG, 1986, CELL, V45, P15, DOI 10.1016/0092-8674(86)90533-7; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; Dietrich J, 1996, J BIOL CHEM, V271, P11441, DOI 10.1074/jbc.271.19.11441; Dietrich J, 1997, J CELL BIOL, V138, P271, DOI 10.1083/jcb.138.2.271; Dittrich E, 1996, J BIOL CHEM, V271, P5487, DOI 10.1074/jbc.271.10.5487; ERICKSON JD, 1993, J NEUROCHEM, V61, P2314, DOI 10.1111/j.1471-4159.1993.tb07476.x; ERICKSON JD, 1994, J BIOL CHEM, V269, P21929; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; Finn JP, 1997, J BIOL CHEM, V272, P16301, DOI 10.1074/jbc.272.26.16301; Garippa RJ, 1996, J BIOL CHEM, V271, P20660, DOI 10.1074/jbc.271.34.20660; Gilmor ML, 1996, J NEUROSCI, V16, P2179; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GonzalezGaitan M, 1997, CELL, V88, P767, DOI 10.1016/S0092-8674(00)81923-6; GROTE E, 1995, CELL, V81, P581, DOI 10.1016/0092-8674(95)90079-9; Grote E, 1996, J CELL BIOL, V132, P537, DOI 10.1083/jcb.132.4.537; HAFT CR, 1994, J BIOL CHEM, V269, P26286; Hao JC, 1997, J NEUROSCI, V17, P1596; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; HOWELL M, 1994, FEBS LETT, V338, P16, DOI 10.1016/0014-5793(94)80108-8; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; JOHNSTON PA, 1989, EMBO J, V8, P2863, DOI 10.1002/j.1460-2075.1989.tb08434.x; KOENIG JH, 1989, J NEUROSCI, V9, P3844; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; Krantz DE, 1997, J BIOL CHEM, V272, P6752, DOI 10.1074/jbc.272.10.6752; KREJCI E, 1993, FEBS LETT, V335, P27, DOI 10.1016/0014-5793(93)80432-T; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lamaze C, 1997, J BIOL CHEM, V272, P20332, DOI 10.1074/jbc.272.33.20332; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; Liu YJ, 1997, ANNU REV NEUROSCI, V20, P125; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; LIU YJ, 1994, J CELL BIOL, V127, P1419, DOI 10.1083/jcb.127.5.1419; Martin Thomas F. J., 1994, Current Opinion in Neurobiology, V4, P626, DOI 10.1016/0959-4388(94)90002-7; MATTEOLI M, 1992, J CELL BIOL, V117, P849, DOI 10.1083/jcb.117.4.849; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; NIRENBERG MJ, 1995, P NATL ACAD SCI USA, V92, P8773, DOI 10.1073/pnas.92.19.8773; Nirenberg MJ, 1996, J NEUROSCI, V16, P4135; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Ooi CE, 1997, EMBO J, V16, P4508; PATZAK A, 1986, J CELL BIOL, V102, P510, DOI 10.1083/jcb.102.2.510; PEARSON RB, 1991, METHOD ENZYMOL, V200, P63; PETER D, 1995, J NEUROSCI, V15, P6179; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; REAVES B, 1993, MOL BIOL CELL, V4, P93, DOI 10.1091/mbc.4.1.93; REGNIERVIGOUROUX A, 1991, EMBO J, V10, P3589, DOI 10.1002/j.1460-2075.1991.tb04925.x; ROGHANI A, 1994, P NATL ACAD SCI USA, V91, P10620, DOI 10.1073/pnas.91.22.10620; RUBIN LA, 1985, HYBRIDOMA, V4, P91, DOI 10.1089/hyb.1985.4.91; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SCHELLER RH, 1995, NEURON, V14, P893; SCHULDINER S, 1995, PHYSIOL REV, V75, P369, DOI 10.1152/physrev.1995.75.2.369; SHIN JY, 1991, J BIOL CHEM, V266, P10658; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; Simpson F, 1996, J CELL BIOL, V133, P749, DOI 10.1083/jcb.133.4.749; SMYTHE E, 1992, METHOD ENZYMOL, V219, P223; Solimena M, 1996, EMBO J, V15, P2102, DOI 10.1002/j.1460-2075.1996.tb00564.x; SOLLNER T, 1994, TRENDS NEUROSCI, V17, P344, DOI 10.1016/0166-2236(94)90178-3; Stenius K, 1995, J CELL BIOL, V131, P1801, DOI 10.1083/jcb.131.6.1801; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Tan PK, 1996, J CELL BIOL, V135, P1789, DOI 10.1083/jcb.135.6.1789; TOOZE SA, 1993, MECHANISMS INTRACELL, P157; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VORHEES P, 1995, EMBO J, V14, P4961	68	101	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17351	17360		10.1074/jbc.273.28.17351	http://dx.doi.org/10.1074/jbc.273.28.17351			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651318	hybrid			2022-12-25	WOS:000074816100011
J	Vinogradova, O; Carlin, C; Sonnichsen, FD; Sanders, CR				Vinogradova, O; Carlin, C; Sonnichsen, FD; Sanders, CR			A membrane setting for the sorting motifs present in the adenovirus E3-13.7 protein which down-regulates the epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERIC IMMUNOGLOBULIN RECEPTOR; SELF-DIFFUSION MEASUREMENTS; LYSOSOMAL ACID-PHOSPHATASE; DI-LEUCINE MOTIF; CYTOPLASMIC TAIL; INTERNALIZATION SIGNAL; ENDOCYTIC PATHWAY; II RECEPTOR; TYROSINE; SYSTEMS	The adenovirus E3-13.7 protein interferes with endo somal protein sorting to down-regulate the epidermal growth factor receptor and related tyrosine kinase receptors. The cytoplasmic C terminus of this protein contains three protein sorting motifs which are related to the function of E3-13.7, In this study, the structure of a 23-residue polypeptide corresponding to this domain was examined using solution NMR and CD spectroscopic methods. The peptide was observed to exist in a mostly random structural state in aqueous solution but underwent high affinity association with dodecylphosphocholine micelles, where it adopted an ordered structure. The affinity of this peptide for the micellar surface and the structure of the bound peptide were independent of pH variation, surface charge, or attachment of a myristoyl anchor to the N-terminal. Studies with phospholipid vesicles suggested that the micellar structural results can be extrapolated to a true lipid bilayer. On the micellar surface all three sorting motifs are closely associated with the water/apolar interface: 72-YLRH and 87-LL lie within interfacial amphipathic helices, while 76-HPQY is non-helical and dimples just above the surface. These results contribute to the development of an understanding of the basis for specificity in recognition of sorting motifs by components of the cellular protein trafficking machinery.	Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr Canc, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Sanders, CR (corresponding author), Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA.	crs4@po.cwru.edu	Sönnichsen, Frank D/D-8408-2011; Vinogradova, Olga/ABE-8367-2020	Sönnichsen, Frank D/0000-0002-4539-3755; Vinogradova, Olga/0000-0001-5101-7361	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007653] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047485, R29GM047485] Funding Source: NIH RePORTER; NCI NIH HHS [CA49650] Funding Source: Medline; NHLBI NIH HHS [T32 HL07653] Funding Source: Medline; NIGMS NIH HHS [GM47485] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTIERI AS, 1995, J AM CHEM SOC, V117, P7566, DOI 10.1021/ja00133a039; AMESON LS, 1995, J CELL BIOL, V129, P1217; AROETI B, 1993, J CELL BIOL, V123, P1149, DOI 10.1083/jcb.123.5.1149; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BREITFELD PP, 1990, J BIOL CHEM, V265, P13750; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CHANG CP, 1993, J BIOL CHEM, V268, P19312; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; Gao XF, 1998, BIOPHYS J, V74, P1871, DOI 10.1016/S0006-3495(98)77897-X; Gennis R.B., 1989, BIOMEMBRANES; HOFFMAN P, 1992, J BIOL CHEM, V267, P13480; HOFFMAN P, 1994, MOL CELL BIOL, V14, P3996; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; JONSSON B, 1986, COLLOID POLYM SCI, V264, P77, DOI 10.1007/BF01410310; KIM YM, 1989, J MAGN RESON, V84, P9, DOI 10.1016/0022-2364(89)90003-6; KIRCHHAUSEN T, 1993, CURR OPIN STRUC BIOL, V3, P182, DOI 10.1016/S0959-440X(05)80150-2; Kroenke CD, 1997, BIOCHEMISTRY-US, V36, P8145, DOI 10.1021/bi9705669; KUIVINEN E, 1993, J CELL BIOL, V120, P1271, DOI 10.1083/jcb.120.5.1271; LAUTERWEIN J, 1979, BIOCHIM BIOPHYS ACTA, V556, P244, DOI 10.1016/0005-2736(79)90046-4; LEHMANN LE, 1992, EMBO J, V11, P4391, DOI 10.1002/j.1460-2075.1992.tb05539.x; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Rohrer J, 1996, J CELL BIOL, V132, P565, DOI 10.1083/jcb.132.4.565; SANDOVAL IV, 1994, J BIOL CHEM, V269, P6622; SODERMAN O, 1994, PROG NUCL MAG RES SP, V26, P445, DOI 10.1016/0079-6565(94)80013-8; STILBS P, 1982, J COLLOID INTERF SCI, V87, P385, DOI 10.1016/0021-9797(82)90335-6; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VINOGRADOVA O, 1998, IN PRESS J BIOMOL NM; WILDE A, 1994, J BIOL CHEM, V269, P7131; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955	34	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17343	17350		10.1074/jbc.273.28.17343	http://dx.doi.org/10.1074/jbc.273.28.17343			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651317	hybrid			2022-12-25	WOS:000074816100010
J	Vallian, S; Gaken, JA; Gingold, EB; Kouzarides, T; Chang, KS; Farzaneh, F				Vallian, S; Gaken, JA; Gingold, EB; Kouzarides, T; Chang, KS; Farzaneh, F			Modulation of Fos-mediated AP-1 transcription by the promyelocytic leukemia protein	ONCOGENE			English	Article						AP-1; PML; Fos; APL; transcription	RETINOIC ACID RECEPTOR; PML-RAR-ALPHA; CBP-INDUCED STIMULATION; C-FOS; DNA-BINDING; IN-VITRO; ACTIVATION DOMAIN; NUCLEAR RECEPTORS; JUN; GENE	The growth and transformation suppressor function of promyelocytic leukemia (PML) protein are disrupted in acute promyelocytic leukemia (APL) as a result of its fusion to the RAR alpha gene by t(15;17) translocation. There is significant sequence homology between the dimerization domain of PML and the Fos family of proteins, which imply that PML may be involved in AP-1 activity. Here we show that PML can cooperate with Fos to stimulate its AP-1-mediated transcriptional activity. Cotransfection of PML with GAL4/Fos strongly induced Fos-mediated activation of GAL4-responsive reporters, indicating a functional interaction between Fos and PML in vivo. Deletion analysis of Fos and PML demonstrated that the intact C-terminal domain of Fos (containing the dimerization domain), and the RING-finger, B1 box and nuclear localization domains of PML are involved in the cooperative activity of Fos and PML. Immunoprecipitation and electrophoretic mobility shift assay showed that PML is associated with the AP-1 complex. PMLRAR alpha was also found to enhance the transcriptional activity of GAL4/Fos. The addition of retinoic acid abrogated the PMLRAR alpha, but not PML-induced stimulation of GAL4/Fos activity in a dose-dependent manner. This study demonstrated that PML is involved in the AP-1 complex and can modulate Fos-mediated transcriptional activity, which may contribute to its growth suppressor function.	Univ Texas, MD Anderson Cancer Ctr, Div Lab Med, Houston, TX 77030 USA; Univ London Kings Coll, Sch Med & Dent, Dept Mol Med, London SE5 9NU, England; Univ Cambridge, Wellcome CRC Inst, Cambridge CB2 1QR, England	University of Texas System; UTMD Anderson Cancer Center; University of London; King's College London; University of Cambridge	Chang, KS (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Div Lab Med, Houston, TX 77030 USA.		Farzaneh, Farzin/B-4902-2009; Vallian, Sadeq/AAA-7085-2020	Farzaneh, Farzin/0000-0002-9275-2415; Vallian, Sadeq/0000-0002-5151-5923; Kouzarides, Tony/0000-0002-8918-4162	NATIONAL CANCER INSTITUTE [R01CA055577] Funding Source: NIH RePORTER; NCI NIH HHS [CA55577] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Wellcome Trust(Wellcome TrustEuropean Commission)		Altabef M, 1996, EMBO J, V15, P2707, DOI 10.1002/j.1460-2075.1996.tb00631.x; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bannister AJ, 1995, ONCOGENE, V11, P2509; Boddy MN, 1996, ONCOGENE, V13, P971; Borden KLB, 1996, P NATL ACAD SCI USA, V93, P1601, DOI 10.1073/pnas.93.4.1601; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; BROWN HJ, 1995, EMBO J, V14, P124, DOI 10.1002/j.1460-2075.1995.tb06982.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; COUSENS DJ, 1989, EMBO J, V8, P2337, DOI 10.1002/j.1460-2075.1989.tb08361.x; CURRAN T, 1996, ONCOGENE, V9, P675; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Doucas V, 1996, BBA-REV CANCER, V1288, pM25, DOI 10.1016/S0304-419X(96)00028-5; DOUCAS V, 1993, P NATL ACAD SCI USA, V90, P9345, DOI 10.1073/pnas.90.20.9345; Doyle GAR, 1997, J BIOL CHEM, V272, P11840, DOI 10.1074/jbc.272.18.11840; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Early E, 1996, P NATL ACAD SCI USA, V93, P7900, DOI 10.1073/pnas.93.15.7900; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GUIOCHONMANTEL A, 1995, MOL ENDOCRINOL, V9, P1791, DOI 10.1210/me.9.12.1791; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; He DL, 1997, CANCER RES, V57, P1868; HIRAI SI, 1990, ONCOGENE, V5, P39; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KOLLA SS, 1993, J CELL PHYSIOL, V156, P63, DOI 10.1002/jcp.1041560110; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; Le XF, 1996, J BIOL CHEM, V271, P130, DOI 10.1074/jbc.271.1.130; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; MULLER R, 1985, NATURE, V314, P546, DOI 10.1038/314546a0; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; Sambrook J., 1989, MOL CLONING LAB MANU, P655; Stadler M, 1995, ONCOGENE, V11, P2565; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810; TEURICH S, 1995, CHEM SENSES, V20, P251, DOI 10.1093/chemse/20.2.251; Vallian S, 1997, EXP CELL RES, V237, P371, DOI 10.1006/excr.1997.3801; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; YANG-YEN H-F, 1990, New Biologist, V2, P351; Yoshida H, 1996, CANCER RES, V56, P2945	53	44	45	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 4	1998	16	22					2843	2853		10.1038/sj.onc.1201837	http://dx.doi.org/10.1038/sj.onc.1201837			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZR544	9671405				2022-12-25	WOS:000073988200003
J	Mills, JJ; Falls, JG; De Souza, AT; Jirtle, RL				Mills, JJ; Falls, JG; De Souza, AT; Jirtle, RL			Imprinted M6p/Igf2 receptor is mutated in rat liver tumors	ONCOGENE			English	Article						M6p/Igf2r; genomic imprinting; liver cancer; tumor suppressor	FACTOR-II RECEPTOR; FACTOR TYPE-2 RECEPTOR; GROWTH-FACTOR-BETA; MOUSE; GENE; LOCUS; IGF2R; HETEROZYGOSITY; BINDING	We have previously shown that inactivation of mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/ IGF2R) is a common early event in both human liver and breast carcinogenesis. The M6p/Igf2r is imprinted in mice while expression is biallelic in most humans. In this investigation the M6p/Igf2r gene is shown to also be imprinted in the liver of Fischer 344, Lewis and Brown Norway rats. In addition, we have identified mutations in the expressed allele of the M6p/Igf2r in 40% of diethylnitrosamine-initiated rat liver tumors. These results provide further evidence that the M6P/IGF2R functions as a liver tumor suppressor gene. They also suggest that mice and rats would be more sensitive than humans to those hepatocarcinogens in which the M6p/ Igf2r is mechanistically involved in transformation since one rather than two alleles would need to be inactivated.	Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA; Zeneca Pharmaceut, Dept Safety Med, Macclesfield SK10 4TG, Cheshire, England	Duke University	Jirtle, RL (corresponding author), Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA.			Mills, Jeremy James/0000-0003-1719-9047	NATIONAL CANCER INSTITUTE [R01CA025951] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008823] Funding Source: NIH RePORTER; NCI NIH HHS [CA25951] Funding Source: Medline; NIEHS NIH HHS [ES08823] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BARLOW DP, 1995, SCIENCE, V270, P1610, DOI 10.1126/science.270.5242.1610; Dahms NM, 1996, BIOCHEM SOC T, V24, P136, DOI 10.1042/bst0240136; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; DESOUZA AT, 1995, ONCOGENE, V10, P1725; deSouza AT, 1997, FASEB J, V11, P60, DOI 10.1096/fasebj.11.1.9034167; Franklin GC, 1996, PLACENTA, V17, P3, DOI 10.1016/S0143-4004(05)80638-1; Hankins GR, 1996, ONCOGENE, V12, P2003; HASEMAN JK, 1987, ENVIRON HEALTH PERSP, V74, P229, DOI 10.2307/3430453; JIRTLE RL, 1994, CARCINOGENESIS, V15, P1473, DOI 10.1093/carcin/15.8.1473; KALSCHEUER VM, 1993, NAT GENET, V5, P74, DOI 10.1038/ng0993-74; Kang JX, 1997, P NATL ACAD SCI USA, V94, P13671, DOI 10.1073/pnas.94.25.13671; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; Ludwig T, 1996, DEV BIOL, V177, P517, DOI 10.1006/dbio.1996.0182; MILLS JJ, 1995, LIVER REGENERATION C, P199; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; Moser GJ, 1996, CARCINOGENESIS, V17, P1835, DOI 10.1093/carcin/17.9.1835; Ouyang H, 1997, CANCER RES, V57, P1851; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; SZEBENYI G, 1994, GENOMICS, V19, P120, DOI 10.1006/geno.1994.1021; Wutz A, 1997, NATURE, V389, P745, DOI 10.1038/39631; XU YQ, 1993, BIOCHEM BIOPH RES CO, V197, P747, DOI 10.1006/bbrc.1993.2542; Yamada T, 1997, P NATL ACAD SCI USA, V94, P10351, DOI 10.1073/pnas.94.19.10351	25	46	46	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	1998	16	21					2797	2802		10.1038/sj.onc.1201801	http://dx.doi.org/10.1038/sj.onc.1201801			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ013	9652747	Green Submitted			2022-12-25	WOS:000073812200012
J	Chandra, NC; Spiro, MJ; Spiro, RG				Chandra, NC; Spiro, MJ; Spiro, RG			Identification of a glycoprotein from rat liver mitochondrial inner membrane and demonstration of its origin in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-D-MANNOSIDASE; N-LINKED OLIGOSACCHARIDES; FRACTION; PROTEINS; PATHWAY; CELLS; GRADIENT; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLSERINE; LOCALIZATION	Employing antisera against various subfractions of rat liver mitochondria (mitoplast, inner membrane, intermembrane, and matrix) as well as metabolically radiolabeled BRL-3A rat liver cells, we undertook a search for the presence of glycoproteins in this major cellular compartment for which little information in regard to glycoconjugates was available. Subsequent to [S-35]methionine labeling of BRL-3A cells, a peptide:N-glycosidase-sensitive protein (45 kDa) was observed by SDS-polyacrylamide gel electrophoresis of the inner membrane immunoprecipitate, which was reduced to a molecular mass of 42 kDa by this enzyme. The 45-kDa protein was readily labeled with [2-H-3]mannose, and indeed the radioactivity of the inner membrane immunoprecipitate was almost exclusively present in this component. Moreover, antisera directed against mitochondrial NADH-ubiquinone oxidoreductase (complex I) or F1F0-ATPase (complex V) also precipitated a 45-kDa protein from BRL-3A cell lysates as the predominant mannose-radiolabeled constituent. Endo-beta-N-acetylglu-cosaminidase completely removed the radiolabel hom this glycoprotein, and the released oligosaccharides were of the partially trimmed polymannose type (Glc(1)Man(9)GlcNAc to Man(8)GlcNAc). Cycloheximide as well as tunicamycin resulted in total inhibition of radiolabeling of the inner membrane glycoprotein and moreover, pulse-chase studies employing metrizamide density gradient centrifugation demonstrated that the glycoprotein was initially present in the endoplasmic reticulum (ER) and subsequently appeared in a mitochondrial location. Early movement of the glycoprotein to the mitochondria after synthesis in the;ER was also evident from the limited processing undergone by its N-linked oligosaccharides; this stood in contrast to lysosomal glycoproteins in which we noted extensive conversion to complex oligosaccharides. Our findings suggest that the 45-kDa glycoprotein migrates from ER to mitochondria by the previously observed contact sites between the two organelles. Furthermore, the presence of this glycoprotein in at least two major mitochondrial multienzyme complexes would be consistent with a role in mitochondrial translocations.	Joslin Diabet Ctr, Elliott P Joslin Res Lab, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Biol Chem, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Spiro, RG (corresponding author), Joslin Diabet Ctr, Elliott P Joslin Res Lab, 1 Joslin Pl, Boston, MA 02215 USA.				NIDDK NIH HHS [DK17325, DK17477] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017325, R01DK017477] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arnold I, 1997, FEBS LETT, V411, P195, DOI 10.1016/S0014-5793(97)00691-1; Baginski ES, 1974, METH ENZYMOL; BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; BERGMEYER HU, 1974, METHOD ENZYMAT AN, V1, P485; Bharadwaj M, 1996, BIOCHEM J, V313, P193, DOI 10.1042/bj3130193; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRILES EB, 1977, J BIOL CHEM, V252, P1107; Camici O, 1997, MOL CELL BIOCHEM, V175, P71, DOI 10.1023/A:1006889328983; CHAN TL, 1970, J CELL BIOL, V45, P291, DOI 10.1083/jcb.45.2.291; CRETIN F, 1991, BIOCHIM BIOPHYS ACTA, V1058, P141, DOI 10.1016/S0005-2728(05)80230-0; DANIEL PF, 1994, GLYCOBIOLOGY, V4, P551, DOI 10.1093/glycob/4.5.551; DePierre J., 1976, BIOCH ANAL MEMBRANES, P79; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; GLEW RH, 1973, J BIOL CHEM, V248, P3137; GLOVER LA, 1992, BIOCHEM J, V284, P609, DOI 10.1042/bj2840609; GODELAINE D, 1981, J BIOL CHEM, V256, P161; Greenawalt J W, 1974, Methods Enzymol, V31, P310; HAN AL, 1989, ARCH BIOCHEM BIOPHYS, V275, P166, DOI 10.1016/0003-9861(89)90360-3; Hart GW, 1997, ANNU REV BIOCHEM, V66, P315, DOI 10.1146/annurev.biochem.66.1.315; Haucke V, 1997, MOL CELL BIOL, V17, P4024, DOI 10.1128/MCB.17.7.4024; KATZ J, 1983, BIOCHEM J, V214, P795, DOI 10.1042/bj2140795; KNECHT E, 1988, J HISTOCHEM CYTOCHEM, V36, P1433, DOI 10.1177/36.11.3171166; KOLDOVSKY O, 1971, BIOCHEM J, V125, P697, DOI 10.1042/bj1250697; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEELAVATHI DE, 1970, BIOCHIM BIOPHYS ACTA, V211, P124, DOI 10.1016/0005-2736(70)90087-8; LUBAS WA, 1987, J BIOL CHEM, V262, P3775; MEIER PJ, 1981, BIOCHIM BIOPHYS ACTA, V646, P283, DOI 10.1016/0005-2736(81)90335-7; MOHAN PS, 1986, J BIOL CHEM, V261, P4328; MOORE SEH, 1990, J BIOL CHEM, V265, P13104; MOORE SEH, 1994, J BIOL CHEM, V269, P12715; MOREMEN KW, 1994, GLYCOBIOLOGY, V4, P113, DOI 10.1093/glycob/4.2.113; PENNINGTON R, 1961, BIOCHEM J, V80, P649, DOI 10.1042/bj0800649; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.biochem.59.1.331; RABOUILLE C, 1992, J BIOL CHEM, V267, P11573; RICKWOOD D, 1975, FEBS LETT, V50, P102, DOI 10.1016/0014-5793(75)80467-4; Romisch K, 1997, P NATL ACAD SCI USA, V94, P6730, DOI 10.1073/pnas.94.13.6730; ROTH J, 1983, J HISTOCHEM CYTOCHEM, V31, P987, DOI 10.1177/31.8.6190857; RUSINOL AE, 1994, J BIOL CHEM, V269, P27494; SCHNAITMAN C, 1967, J CELL BIOL, V32, P719, DOI 10.1083/jcb.32.3.719; SCHNAITMAN C, 1968, J CELL BIOL, V38, P158, DOI 10.1083/jcb.38.1.158; SHIAO YJ, 1995, J BIOL CHEM, V270, P11190, DOI 10.1074/jbc.270.19.11190; SOTTOCASA G, 1972, BIOCHEM BIOPH RES CO, V47, P808, DOI 10.1016/0006-291X(72)90564-5; SOTTOCASA GL, 1971, FEBS LETT, V17, P100, DOI 10.1016/0014-5793(71)80574-4; SPIRO MJ, 1985, J BIOL CHEM, V260, P5808; Tokatlidis K, 1996, NATURE, V384, P585, DOI 10.1038/384585a0; TOLLESHAUG H, 1985, EUR J BIOCHEM, V153, P223, DOI 10.1111/j.1432-1033.1985.tb09290.x; TOMITA Y, 1985, BIOCHIM BIOPHYS ACTA, V842, P176, DOI 10.1016/0304-4165(85)90200-4; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TULSIANI DRP, 1977, J BIOL CHEM, V252, P3227; Vaitukaitis J L, 1981, Methods Enzymol, V73, P46; VANCE JE, 1991, J BIOL CHEM, V266, P89; WATTIAUX R, 1978, J CELL BIOL, V78, P349, DOI 10.1083/jcb.78.2.349; WENG SA, 1993, J BIOL CHEM, V268, P25656; Wieme R.J., 1974, METHOD ENZYMAT AN, V2, P618; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; WONG TK, 1982, J BIOL CHEM, V257, P6614	58	55	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19715	19721		10.1074/jbc.273.31.19715	http://dx.doi.org/10.1074/jbc.273.31.19715			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677401	hybrid			2022-12-25	WOS:000075125200053
J	Kawai, H; Sango, K; Mullin, KA; Proia, RL				Kawai, H; Sango, K; Mullin, KA; Proia, RL			Embryonic stem cells with a disrupted GD3 synthase gene undergo neuronal differentiation in the absence of b-series gangliosides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO DIFFERENTIATION; NERVOUS-SYSTEM; EXPRESSION; METABOLISM; BRAIN	The dramatic changes in the expression of GD3 and other b-series gangliosides during neuronal development and morphogenesis have led to a widely held belief that these gangliosides may be necessary for neuronal differentiation. To determine directly if GD3 and b-series gangliosides are required for neuronal differentiation, we have produced embryonic stem (ES) cells with both alleles of the GD3 synthase gene (GD3S) disrupted by successive rounds of gene targeting. The double-targeted ES cells were deficient in GD3 synthase activity and did not synthesize b-series gangliosides. Despite this deficit, the GD3S(-/-) ES cells could be induced to undergo neuronal differentiation. Neuronally differentiated wild-type and GD3S(-/-) ES cells formed a complex neurite network around the embryoid bodies, Both types of neuronal cells expressed the axon-specific cytoskeletal proteins, neurofilament-M, and growth-associated protein-43 as well as the dendrite-specific marker, microtubule-associated protein-a. Our results indicate that GD3 synthase and b-series gangliosides are not necessary for the neuronal differentiation of uncommitted precursor cells.	NIDDK, Sect Biochem Genet, Genet & Biochem Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Proia, RL (corresponding author), NIDDK, Sect Biochem Genet, Genet & Biochem Branch, NIH, Bldg 10,Rm 9D-20,10 Ctr Dr,MSC 1810, Bethesda, MD 20892 USA.	proia@nih.gov	Proia, Richard L/A-7908-2012	Proia, Richard/0000-0003-0456-1270				ARIGA T, 1995, BIOCHEMISTRY-US, V34, P11500, DOI 10.1021/bi00036a024; BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085; BOUVIER JD, 1989, J NEUROCHEM, V52, P460, DOI 10.1111/j.1471-4159.1989.tb09143.x; Brigande JV, 1998, J NEUROCHEM, V70, P871; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; Datta AK, 1998, J BIOL CHEM, V273, P9608, DOI 10.1074/jbc.273.16.9608; FRAICHARD A, 1995, J CELL SCI, V108, P3181; GOLDMAN JE, 1984, J NEUROIMMUNOL, V7, P179, DOI 10.1016/S0165-5728(84)80017-X; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HAREL R, 1993, J BIOL CHEM, V268, P14476; Hirschberg K, 1996, J BIOL CHEM, V271, P14876, DOI 10.1074/jbc.271.25.14876; IRVINE RA, 1994, COMP BIOCHEM PHYS B, V109, P603, DOI 10.1016/0305-0491(94)90123-6; KASAHARA K, 1994, ANAL BIOCHEM, V218, P224, DOI 10.1006/abio.1994.1164; KELLER GM, 1995, CURR OPIN CELL BIOL, V7, P862, DOI 10.1016/0955-0674(95)80071-9; KOJIMA N, 1994, J BIOL CHEM, V269, P30451; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; Li RX, 1997, J BIOL CHEM, V272, P1349, DOI 10.1074/jbc.272.2.1349; Liu H, 1997, GLYCOBIOLOGY, V7, P1067, DOI 10.1093/glycob/7.8.1067; Okabe S, 1996, MECH DEVELOP, V59, P89, DOI 10.1016/0925-4773(96)00572-2; Osanai T, 1997, BIOCHEM BIOPH RES CO, V241, P327, DOI 10.1006/bbrc.1997.7817; PENG I, 1986, J CELL BIOL, V102, P252, DOI 10.1083/jcb.102.1.252; PERCY AK, 1991, J NEUROCHEM, V56, P1461, DOI 10.1111/j.1471-4159.1991.tb02038.x; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROSNER H, 1985, DEV BRAIN RES, V18, P85, DOI 10.1016/0165-3806(85)90252-4; ROSNER H, 1992, NEUROCHEM INT, V20, P339, DOI 10.1016/0197-0186(92)90048-V; SANDBERG PO, 1980, EXP CELL RES, V130, P393, DOI 10.1016/0014-4827(80)90017-8; SCHNAAR R L, 1991, Glycobiology, V1, P477, DOI 10.1093/glycob/1.5.477; STRUBING C, 1995, MECH DEVELOP, V53, P275, DOI 10.1016/0925-4773(95)00446-8; SVENNERHOLM L, 1964, J LIPID RES, V5, P145; Takamiya K, 1996, P NATL ACAD SCI USA, V93, P10662, DOI 10.1073/pnas.93.20.10662; TETTAMANTI G, 1993, ADV LIPID RES, V25, P235; Tsuji S, 1996, J BIOCHEM-TOKYO, V120, P1; TSUJI S, 1985, J BIOCHEM-TOKYO, V97, P969, DOI 10.1093/oxfordjournals.jbchem.a135140; VANDEURSEN J, 1992, NUCLEIC ACIDS RES, V20, P3815, DOI 10.1093/nar/20.15.3815; VANECHTEN G, 1993, J BIOL CHEM, V268, P5341; Yamamoto A, 1996, J NEUROCHEM, V66, P26; YU RK, 1994, PROG BRAIN RES, V101, P31	37	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19634	19638		10.1074/jbc.273.31.19634	http://dx.doi.org/10.1074/jbc.273.31.19634			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677390	hybrid			2022-12-25	WOS:000075125200042
J	Bemark, M; Olsson, H; Heinegard, D; Leanderson, T				Bemark, M; Olsson, H; Heinegard, D; Leanderson, T			Purification and characterization of a protein binding to the SP6 Kappa promoter - A potential role for CArG-box binding factor-A in Kappa transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; ALPHA-ACTIN GENE; SINGLE-STRAND; FACTOR BSAP; ATTACHMENT REGIONS; UPSTREAM ELEMENT; 3'ALPHA ENHANCER; NUCLEAR MATRIX; C-MYC; NF-HB	A protein interacting with an AT-rich region that is a positive control element within the SP6 kappa promoter was purified and identified as CArG-box binding factor-A The purified protein was shown to interact specifically with the coding strand of single-stranded DNA and, with lower affinity, with double-stranded DNA.A mutation that inhibited binding of the protein to the AT-rich region also aborted the transcriptional stimulatory effect of the region. Two Ets proteins, PU.1 and elf-1, that have previously been shown to bind to an adjacent DNA element were shown to physically interact with CArG-box binding factor-A An antiserum raised against the protein recognized two different forms indicating either that different splice-forms of CArG-box binding factor-A are expressed, or that the protein is subject to post-translational modification.	Lund Univ, Dept Cellular & Mol Biol, Immunol Grp, S-22007 Lund, Sweden; Lund Univ, Dept Cellular & Mol Biol, Connect Tissue Biol Grp, S-22007 Lund, Sweden	Lund University; Lund University	Leanderson, T (corresponding author), Lund Univ, Dept Cellular & Mol Biol, Immunol Grp, POB 7031, S-22007 Lund, Sweden.	Tomas.Leandersson@immuno.lu.se	Bemark, Mats/B-2578-2019	Bemark, Mats/0000-0001-7416-9819; Olsson, Henric/0000-0002-5101-8871				ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; ANDRAKE M, 1988, P NATL ACAD SCI USA, V85, P7942, DOI 10.1073/pnas.85.21.7942; ATCHISON ML, 1990, EMBO J, V9, P3109, DOI 10.1002/j.1460-2075.1990.tb07508.x; Bemark M, 1998, IMMUNOGENETICS, V47, P183, DOI 10.1007/s002510050347; Bemark M, 1997, EUR J IMMUNOL, V27, P1308, DOI 10.1002/eji.1830270603; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; BOULIKAS T, 1993, J CELL BIOCHEM, V52, P14, DOI 10.1002/jcb.240520104; CALVIO C, 1995, RNA, V1, P724; COGAN JG, 1995, J BIOL CHEM, V270, P11310, DOI 10.1074/jbc.270.19.11310; Davie JR, 1995, INT REV CYTOL, V162A, P191; DAYN A, 1992, NUCLEIC ACIDS RES, V20, P5991, DOI 10.1093/nar/20.22.5991; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIGNAM JD, 1990, METHOD ENZYMOL, V182, P194; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; FALKNER FG, 1984, NATURE, V310, P71, DOI 10.1038/310071a0; FORRESTER WC, 1994, SCIENCE, V265, P1221, DOI 10.1126/science.8066460; FREEMAN L A, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P165; GAILLARD C, 1990, J MOL BIOL, V215, P245, DOI 10.1016/S0022-2836(05)80343-2; GIARDINA C, 1992, GENE DEV, V6, P2190, DOI 10.1101/gad.6.11.2190; GORLACH M, 1992, EMBO J, V11, P3289, DOI 10.1002/j.1460-2075.1992.tb05407.x; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; HOGBOM E, 1991, NUCLEIC ACIDS RES, V19, P4347, DOI 10.1093/nar/19.16.4347; Jenuwein T, 1997, NATURE, V385, P269, DOI 10.1038/385269a0; KADONAGA JT, 1991, METHOD ENZYMOL, V208, P10; KAMADA S, 1992, GENE, V119, P229, DOI 10.1016/0378-1119(92)90276-U; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; LARSEN A, 1982, CELL, V29, P609, DOI 10.1016/0092-8674(82)90177-5; Lau PP, 1997, J BIOL CHEM, V272, P1452, DOI 10.1074/jbc.272.3.1452; LEONARD MW, 1991, MOL CELL BIOL, V11, P6128, DOI 10.1128/MCB.11.12.6128; LOU Y, 1995, MOL CELL BIOL, V15, P4115; MACDONALD GH, 1995, J BIOL CHEM, V270, P3527, DOI 10.1074/jbc.270.8.3527; MICHELOTTI GA, 1996, MOL CELL BIOL, V16, P1656; NELSEN B, 1992, INT REV CYTOL, V133, P121, DOI 10.1016/S0074-7696(08)61859-8; NESBITT SA, 1992, ANAL BIOCHEM, V206, P267, DOI 10.1016/0003-2697(92)90365-E; NEURATH MF, 1994, J IMMUNOL, V153, P730; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; PELHAM HRB, 1980, P NATL ACAD SCI-BIOL, V77, P4170, DOI 10.1073/pnas.77.7.4170; PONTIUS BW, 1990, P NATL ACAD SCI USA, V87, P8403, DOI 10.1073/pnas.87.21.8403; Sambrook L., 1989, MOL CLONING LAB MANU; SCHABLE KF, 1993, BIOL CHEM H-S, V374, P1001; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHWARZENBACH H, 1995, J BIOL CHEM, V270, P898, DOI 10.1074/jbc.270.2.898; SIGVARDSSON M, 1995, MOL CELL BIOL, V15, P1343; Sigvardsson M, 1996, J IMMUNOL, V156, P3788; SIGVARDSSON M, 1995, EUR J IMMUNOL, V25, P298, DOI 10.1002/eji.1830250150; SIGVARDSSON M, 1994, MOL IMMUNOL, V31, P1005, DOI 10.1016/0161-5890(94)90095-7; SINGH M, 1993, MOL CELL BIOL, V13, P3611, DOI 10.1128/MCB.13.6.3611; SMIDT MP, 1995, NUCLEIC ACIDS RES, V23, P2389, DOI 10.1093/nar/23.13.2389; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; SUN SQ, 1995, MOL CELL BIOL, V15, P2429; Tansey WP, 1997, CELL, V88, P729, DOI 10.1016/S0092-8674(00)81916-9; TAY N, 1992, J VIROL, V66, P6841, DOI 10.1128/JVI.66.12.6841-6848.1992; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875; Werner MH, 1997, CELL, V88, P733, DOI 10.1016/S0092-8674(00)81917-0; WITTIG B, 1992, EMBO J, V11, P4653, DOI 10.1002/j.1460-2075.1992.tb05567.x; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371	57	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18881	18890		10.1074/jbc.273.30.18881	http://dx.doi.org/10.1074/jbc.273.30.18881			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668064	hybrid			2022-12-25	WOS:000074974700031
J	Davletov, B; Perisic, O; Williams, RL				Davletov, B; Perisic, O; Williams, RL			Calcium-dependent membrane penetration is a hallmark of the C2 domain of cytosolic phospholipase A2 whereas the C2A domain of synaptotagmin binds membranes electrostatically	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-ENVELOPE; TRANSLOCATION; DELTA; A(2)	C2 domains have been identified in a wide range of intracellular proteins, including lipid modifying enzymes, protein kinases, GTPases, and proteins involved int membrane trafficking.Many C2 domains bind membranes in a calcium-dependent manner. The first C2 domain from synaptotagmin I (SytIC2A) and the C2 domain from cytosolic phospholipase A2 (cPLA2C2) are among the best characterized C2 domains in terms of their structures and calcium binding. Here we demonstrate that the protein-lipid interaction is dramatically different for these two domains. Photolabeling with 3-(trifluoromethyl)-3-(m-[I-125]iodophenyl)diazirine ([I-125]TID) in the presence of phospholipid vesicles indicates that cPLA2C2 penetrates into the hydrophobic region of the membrane. Hydrophobic surfaces on cPLA2C2 are exposed even in the absence of calcium, but only in its presence does the domain penetrate into the nonpolar core of the membrane. The interaction of SytIC2A with phospholipid membranes is primarily electrostatic with binding being abolished in 500 mM NaCl. Because soluble phospholipid head group analogues do not compete with binding of either SytIC2A or cPLA2C2 to vesicles, it is likely that membrane binding by these domains involves multiple interactions.	Univ Cambridge, Ctr Mrc, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology; University of Cambridge	Davletov, B (corresponding author), Univ Cambridge, Ctr Mrc, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.		Davletov, Bazbek/ABA-8569-2021	Davletov, Bazbek/0000-0003-4658-3275; Perisic, Olga/0000-0002-3842-2896; Williams, Roger/0000-0001-7754-4207	Medical Research Council [MC_U105184308] Funding Source: Medline; MRC [MC_U105184308] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRUNNER J, 1993, ANNU REV BIOCHEM, V62, P483, DOI 10.1146/annurev.bi.62.070193.002411; CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; Edwards AS, 1997, BIOCHEMISTRY-US, V36, P15615, DOI 10.1021/bi9718752; Essen LO, 1997, BIOCHEMISTRY-US, V36, P2753, DOI 10.1021/bi962466t; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; Grobler JA, 1996, NAT STRUCT BIOL, V3, P788, DOI 10.1038/nsb0996-788; Grobler JA, 1998, BIOCHEMISTRY-US, V37, P5020, DOI 10.1021/bi972952w; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; Nalefski EA, 1998, J BIOL CHEM, V273, P1365, DOI 10.1074/jbc.273.3.1365; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Nalefski EA, 1997, BIOCHEMISTRY-US, V36, P12011, DOI 10.1021/bi9717340; NEWTON AC, 1994, BIOCHEMISTRY-US, V33, P6651, DOI 10.1021/bi00187a035; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; Ponting CP, 1996, PROTEIN SCI, V5, P162; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; Shao XG, 1997, NEURON, V18, P133, DOI 10.1016/S0896-6273(01)80052-0; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; SWAIRJO MA, 1995, NAT STRUCT BIOL, V2, P968, DOI 10.1038/nsb1195-968	22	102	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19093	19096		10.1074/jbc.273.30.19093	http://dx.doi.org/10.1074/jbc.273.30.19093			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668093	hybrid			2022-12-25	WOS:000074974700060
J	Naver, H; Scott, MP; Golbeck, JH; Olsen, CE; Scheller, HV				Naver, H; Scott, MP; Golbeck, JH; Olsen, CE; Scheller, HV			The eight-amino acid internal loop of PSI-C mediates association of low molecular mass iron-sulfur proteins with the P700-F-X core in photosystem I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNECHOCOCCUS-SP PCC-6301; CLOSTRIDIUM-PASTEURIANUM FERREDOXIN; REACTION-CENTER COMPLEX; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; MODIFIED LIGANDS; 8-KDA SUBUNIT; CENTER-A; CENTER-B; F-A	The PSI-C subunit of photosystem I (PS I) shows similarity to soluble 2[4Fe-4S] ferredoxins. PSI-C contains an eight residue internal loop and a 15 residue C-terminal extension which are absent in the ferredoxins. The eight-residue loop has been shown to interact with PSI-A/PSI-B (Naver, H., Scott, M. P., Golbeck, J. H., Moller, B. L., and Scheller, H. V. (1996) J. Biol. Chem. 271, 8996-9001). Four mutant proteins were constructed. Two were modified barley PSI-C proteins, one lacking the loop and the C terminus (PSI-C-core) and one where the loop replace the C-terminal extension (PSI-CcoreLc-term). Two were modified Clostridium pasteurianum ferredoxins, one with the loop of barley PSI-C and one with both the loop and the C terminus of PSI-C. Wild-type proteins and the mutants were used to reconstitute barley P700-F-X cores lacking PSI-C, -D, and-E. Western blotting showed that PSI-CcoreLc-term binds to PS I, whereas PSI-C-core does not. Without PSI-D the PSI-CcoreLc-term mutant accepts electrons from F-X in contrast to PSI-C mutants without the loop. Flash photolysis of P700-F, cores reconstituted with C. pasteurianum ferredoxin showed that only the ferredoxin mutants with the loop accepted electrons from F-X. From this, it is concluded that the loop of PSI-C is necessary and sufficient for the association between PS I and PSI-C, and that the loop is functional as an interaction domain even when positioned at the C terminus of PSI-C or on a low molecular mass, soluble ferredoxin.	Royal Vet & Agr Univ, Dept Plant Biol, Plant Biochem Lab, DK-1871 Frederiksberg C, Denmark; Royal Vet & Agr Univ, Dept Chem, DK-1871 Frederiksberg, Denmark; Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA	University of Copenhagen; University of Copenhagen; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Nebraska System; University of Nebraska Lincoln	Scheller, HV (corresponding author), Royal Vet & Agr Univ, Dept Plant Biol, Plant Biochem Lab, 40 Thorvaldsensvej, DK-1871 Frederiksberg C, Denmark.	scheller@biobase.dk	Scheller, Henrik/AAH-4770-2020; Olsen, Carl E/H-3031-2014; Scheller, Henrik V/A-8106-2008	Scheller, Henrik/0000-0002-6702-3560; Olsen, Carl E/0000-0002-2275-0596; Scheller, Henrik V/0000-0002-6702-3560; Naver, Helle/0000-0002-7364-3862				ADMAN FT, 1972, J BIOL CHEM, V248, P3987; ALIVERTI A, 1995, FEBS LETT, V368, P220, DOI 10.1016/0014-5793(95)00648-S; ANDERSEN B, 1993, PIGMENT PROTEIN COMP, P383; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; Brettel K, 1997, BBA-BIOENERGETICS, V1318, P322, DOI 10.1016/S0005-2728(96)00112-0; Buchanan BB, 1971, METHOD ENZYMOL, V23, P413, DOI [10.1016/S0076-6879(71)23115-3, DOI 10.1016/S0076-6879(71)23115-3]; CHITNIS PR, 1995, PHOTOSYNTH RES, V44, P23, DOI 10.1007/BF00018294; CHITNIS PR, 1989, J BIOL CHEM, V264, P18374; DIAZQUINTANA, 1998, BIOCHEMISTRY, V37, P3429; DUNN PPJ, 1988, PLANT MOL BIOL, V11, P311, DOI 10.1007/BF00027388; ELLEFSON WL, 1980, METHOD ENZYMOL, V69, P223; Fischer N, 1998, EMBO J, V17, P849, DOI 10.1093/emboj/17.4.849; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; Fromme P, 1996, CURR OPIN STRUC BIOL, V6, P473, DOI 10.1016/S0959-440X(96)80112-6; GOLBECK JH, 1986, BIOCHIM BIOPHYS ACTA, V849, P16, DOI 10.1016/0005-2728(86)90091-5; GOLBECK JH, 1987, BIOCHIM BIOPHYS ACTA, V895, P167, DOI 10.1016/S0304-4173(87)80002-2; Golbeck JH, 1994, MOL BIOL CYANOBACTER, P319; GRAVES MC, 1985, P NATL ACAD SCI USA, V82, P1653, DOI 10.1073/pnas.82.6.1653; HERMAN PL, 1994, PLANT PHYSIOL, V104, P1459, DOI 10.1104/pp.104.4.1459; HOJ PB, 1987, J BIOL CHEM, V262, P12676; HOJ PB, 1986, J BIOL CHEM, V261, P14292; Jung YS, 1996, J BIOL CHEM, V271, P31135, DOI 10.1074/jbc.271.49.31135; Jung YS, 1997, J BIOL CHEM, V272, P8040, DOI 10.1074/jbc.272.12.8040; Jung YS, 1995, PHOTOSYNTH RES, V46, P249, DOI 10.1007/BF00020437; Kamlowski A, 1997, BBA-BIOENERGETICS, V1319, P199, DOI 10.1016/S0005-2728(96)00162-4; Kjaer B, 1996, PHOTOSYNTH RES, V47, P33, DOI 10.1007/BF00017751; Krauss N, 1996, NAT STRUCT BIOL, V3, P965, DOI 10.1038/nsb1196-965; LI N, 1991, BIOCHEMISTRY-US, V30, P7863, DOI 10.1021/bi00245a028; MEHARI T, 1995, J BIOL CHEM, V270, P28108; Moulis JM, 1995, BIOCHEMISTRY-US, V34, P16781, DOI 10.1021/bi00051a028; Naver H, 1996, J BIOL CHEM, V271, P8996, DOI 10.1074/jbc.271.15.8996; NAVER H, 1995, PHYSIOL PLANTARUM, V95, P19, DOI 10.1111/j.1399-3054.1995.tb00802.x; NAVER H, 1995, PHOTOSYNTHESIS LIGHT, V2, P155; OHOKA H, 1988, J BIOCHEM-TOKYO, V103, P962, DOI 10.1093/oxfordjournals.jbchem.a122394; PARRETT KG, 1989, BIOCHIM BIOPHYS ACTA, V973, P324, DOI 10.1016/S0005-2728(89)80439-6; PARRETT KG, 1990, BIOCHIM BIOPHYS ACTA, V1015, P341, DOI 10.1016/0005-2728(90)90039-7; Rodday SM, 1996, BIOCHEMISTRY-US, V35, P11832, DOI 10.1021/bi9612834; ROUSSEAU F, 1993, EMBO J, V12, P1755, DOI 10.1002/j.1460-2075.1993.tb05823.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHELLER HV, 1989, CARLSBERG RES COMMUN, V54, P11, DOI 10.1007/BF02910468; Scheller HV, 1997, PHYSIOL PLANTARUM, V100, P842, DOI 10.1034/j.1399-3054.1997.1000410.x; SCOTT MP, 1992, RES PHOTOSYNTHESIS, V1, P593; SCROFANI SDB, 1994, BIOCHEMISTRY-US, V33, P14486, DOI 10.1021/bi00252a015; SERRANO A, 1982, ANAL BIOCHEM, V126, P109, DOI 10.1016/0003-2697(82)90115-4; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Tjus SE, 1998, PLANT PHYSIOL, V116, P755, DOI 10.1104/pp.116.2.755; ZANETTI G, 1987, EUR J BIOCHEM, V169, P143, DOI 10.1111/j.1432-1033.1987.tb13591.x; ZHAO JD, 1992, BIOCHEMISTRY-US, V31, P5093, DOI 10.1021/bi00137a001; ZHAO JD, 1990, FEBS LETT, V276, P175, DOI 10.1016/0014-5793(90)80536-R	49	11	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18778	18783		10.1074/jbc.273.30.18778	http://dx.doi.org/10.1074/jbc.273.30.18778			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668051	hybrid			2022-12-25	WOS:000074974700018
J	Balch, SG; McKnight, AJ; Seldin, MF; Gordon, S				Balch, SG; McKnight, AJ; Seldin, MF; Gordon, S			Cloning of a novel C-type lectin expressed by murine macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE-BINDING PROTEIN; CA2+-DEPENDENT ANIMAL LECTINS; NATURAL-KILLER-CELL; SITE-DIRECTED MUTAGENESIS; ACTIVATION ANTIGEN CD69; IMMUNOGLOBULIN-E; MESSENGER-RNA; SUGAR LIGANDS; GENE FAMILIES; MOUSE NKR-P1	We report the cloning of a novel macrophage-restricted C-type lectin by differential display polymerase chain reaction. This molecule, named mouse macrophage C-type lectin, is a 219-amino acid, type II transmembrane protein with a single extracellular C-type lectin domain. Northern blot analysis indicates that it is expressed in cell lines and normal mouse tissues in a macrophage-restricted manner. The cDNA and genomic sequences of mouse macrophage C-type lectin indicate that it is related to the Group II animal C-type lectins. The mel gene locus has been mapped between the genes for the interleukin-17 receptor and CD4 on mouse chromosome 6, the same chromosome as the mouse natural killer cell gene complex.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Univ Calif Davis, Dept Biol Chem, Rowe Program Genet, Davis, CA 95616 USA; Univ Calif Davis, Dept Med, Davis, CA 95616 USA	University of Oxford; University of California System; University of California Davis; University of California System; University of California Davis	Balch, SG (corresponding author), Kansas State Univ, Coll Vet Med, 101 Trotter Hall, Manhattan, KS 66506 USA.				NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000734] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00734] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Alschul S F, 1990, J Mol Biol, V215, P403; BEZOUSKA K, 1991, J BIOL CHEM, V266, P11604; BISHOP D T, 1985, Genetic Epidemiology, V2, P349, DOI 10.1002/gepi.1370020404; BLACKBURN CC, 1983, J BIOL CHEM, V258, P1180; Brown MG, 1997, GENOMICS, V42, P16, DOI 10.1006/geno.1997.4721; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; DRICKAMER K, 1993, PROG NUCLEIC ACID RE, V45, P207, DOI 10.1016/S0079-6603(08)60870-3; Elgavish S, 1997, TRENDS BIOCHEM SCI, V22, P462, DOI 10.1016/S0968-0004(97)01146-8; Gabius HJ, 1997, EUR J BIOCHEM, V243, P543, DOI 10.1111/j.1432-1033.1997.t01-1-00543.x; Genetic Computer Group, 1994, PROGR MAN WISC PACK; GIORDA R, 1991, J IMMUNOL, V147, P1701; GORDON S, 1996, WEIERS HDB EXPT IMMU, V4, P153; GORDON S, 1997, LUNG MACROPHAGES DEN, P3; GORDON S, 1996, OXFORD TXB MED, V1, P84; GUMPERZ JE, 1995, NATURE, V378, P245, DOI 10.1038/378245a0; HAMANN J, 1993, J IMMUNOL, V150, P4920; HOYLE GW, 1991, J BIOL CHEM, V266, P1850; HU ZZ, 1994, BBA-MOL CELL RES, V1220, P333, DOI 10.1016/0167-4889(94)90158-9; IOBST ST, 1994, J BIOL CHEM, V269, P15512; IOBST ST, 1994, J BIOL CHEM, V269, P15505; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE SH, 1985, J EXP MED, V161, P475, DOI 10.1084/jem.161.3.475; LEENEN PJ, 1993, MACROPHAGES RELATED, P29; LEUNG JO, 1985, J BIOL CHEM, V260, P2523; LEWIS CE, 1992, MACROPHAGE NATURAL I; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Lin HH, 1997, GENOMICS, V41, P301, DOI 10.1006/geno.1997.4674; McKnight AJ, 1996, J BIOL CHEM, V271, P486, DOI 10.1074/jbc.271.1.486; McKnight AJ, 1998, ADV IMMUNOL, V68, P271, DOI 10.1016/S0065-2776(08)60562-3; ODA S, 1989, J BIOCHEM-TOKYO, V105, P1040, DOI 10.1093/oxfordjournals.jbchem.a122763; ODA S, 1988, J BIOCHEM-TOKYO, V104, P600, DOI 10.1093/oxfordjournals.jbchem.a122518; RICE P, 1996, PROGRAM MANUAL EGCG; RINI JM, 1995, ANNU REV BIOPH BIOM, V24, P551, DOI 10.1146/annurev.biophys.24.1.551; RUSSELL ME, 1994, J CLIN INVEST, V94, P722, DOI 10.1172/JCI117391; SAKAMAKI T, 1995, J LEUKOCYTE BIOL, V57, P407, DOI 10.1002/jlb.57.3.407; SANTIS AG, 1994, EUR J IMMUNOL, V24, P1692, DOI 10.1002/eji.1830240735; SELDIN MF, 1988, J EXP MED, V167, P688, DOI 10.1084/jem.167.2.688; SPILSBURY K, 1995, BLOOD, V85, P1620, DOI 10.1182/blood.V85.6.1620.bloodjournal8561620; SUTER U, 1987, NUCLEIC ACIDS RES, V15, P7295, DOI 10.1093/nar/15.18.7295; VERCELLI D, 1989, NATURE, V338, P649, DOI 10.1038/338649a0; WATSON ML, 1994, METH MOL G, V5, P369; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; WONG S, 1991, J IMMUNOL, V147, P1417; YOKOYAMA WM, 1991, J IMMUNOL, V147, P3229; YOKOYAMA WM, 1993, ANNU REV IMMUNOL, V11, P613, DOI 10.1146/annurev.iy.11.040193.003145; Yokoyama WM, 1997, J EXP MED, V186, P1803, DOI 10.1084/jem.186.11.1803	52	61	65	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18656	18664		10.1074/jbc.273.29.18656	http://dx.doi.org/10.1074/jbc.273.29.18656			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660840	hybrid			2022-12-25	WOS:000074828500095
J	DiCiommo, DP; Bremner, R				DiCiommo, DP; Bremner, R			Rapid, high level protein production using DNA-based semliki forest virus vectors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINDBIS-VIRUS; EXPRESSION VECTORS; RNA; PARTICLES; GENE; RECOMBINATION; SYSTEM; CELLS	Semliki Forest virus (SFV) vectors can be produced faster, and have a wider host range, than baculovirus vectors, However, the original SFV system requires in vitro manipulation of RNA. me have generated a system that is wholly DNA-based, Both the replicon vector, encoding SFV polymerase and the protein of interest, and the helper vector, encoding viral structural proteins, were modified so that expression was RNA polymerase II-dependent. Transfection of the modified replicon plasmid alone generated 20-30-fold more protein than obtained from a simple expression vector, Expression required the SFV replicase, which amplifies replicon RNA. The SFV-based vector generated 10-20-fold more protein than a plasmid based on Sindbis virus. Cotransfection of SFV replicon and helper vectors generated viral titers of around 10(6) infectious particles/ml. A single electroporation, plated on one IO-cm plate, generated enough virus (10(7) particles) to produce >500 mu g of protein, mild type, replication proficient virus was not detected in three tests utilizing almost 10(8) viral particles, a distinct advantage over a DNA Sindbis-based system in which over half the virus particles generated are fully infectious. The new SFV vectors significantly enhance the utility of this expression system.	Eye Res Inst Canada, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Ophthalmol, Toronto, ON M5G 1L5, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1L5, Canada	University of Toronto; University of Toronto	Bremner, R (corresponding author), Eye Res Inst Canada, 399 Bathurst St, Toronto, ON M5T 2S8, Canada.		Bremner, Rod/I-6490-2012	Bremner, Rod/0000-0001-9184-7212				BERGLUND P, 1993, BIO-TECHNOL, V11, P916, DOI 10.1038/nbt0893-916; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; Cook DG, 1996, P NATL ACAD SCI USA, V93, P9223, DOI 10.1073/pnas.93.17.9223; Couffinhal T, 1997, HUM GENE THER, V8, P929, DOI 10.1089/hum.1997.8.8-929; Dubensky TW, 1996, J VIROL, V70, P508, DOI 10.1128/JVI.70.1.508-519.1996; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Forman MS, 1997, J BIOL CHEM, V272, P32247, DOI 10.1074/jbc.272.51.32247; FROLOV I, 1994, J VIROL, V68, P8111, DOI 10.1128/JVI.68.12.8111-8117.1994; Frolov I, 1996, P NATL ACAD SCI USA, V93, P11371, DOI 10.1073/pnas.93.21.11371; Frolova E, 1997, J VIROL, V71, P248, DOI 10.1128/JVI.71.1.248-258.1997; HERWEIJER H, 1995, HUM GENE THER, V6, P1161, DOI 10.1089/hum.1995.6.9-1161; JALANKO A, 1985, VIROLOGY, V141, P257, DOI 10.1016/0042-6822(85)90256-9; Jones I, 1996, CURR OPIN BIOTECH, V7, P512, DOI 10.1016/S0958-1669(96)80054-1; Li KJ, 1996, P NATL ACAD SCI USA, V93, P11658, DOI 10.1073/pnas.93.21.11658; LILJESTROM P, 1991, J VIROL, V65, P4107; LILJESTROM P, 1991, BIO-TECHNOL, V9, P1356, DOI 10.1038/nbt1291-1356; LILJESTROM P, 1994, CURRENT PROTOCOLS MO, V2; Liljestrom Peter, 1994, Current Opinion in Biotechnology, V5, P495, DOI 10.1016/0958-1669(94)90063-9; MOSS B, 1991, SCIENCE, V252, P1662, DOI 10.1126/science.2047875; Netzer WJ, 1997, NATURE, V388, P343, DOI 10.1038/41024; RAJU R, 1995, J VIROL, V69, P7391, DOI 10.1128/JVI.69.12.7391-7401.1995; ROLLS MM, 1994, CELL, V79, P497, DOI 10.1016/0092-8674(94)90258-5; Sambrook J, 1987, MOL CLONING LAB MANU; STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994; THOMSON M, 1994, VIROLOGY, V199, P354, DOI 10.1006/viro.1994.1133; Tubulekas I, 1997, GENE, V190, P191, DOI 10.1016/S0378-1119(96)00679-8; WEISS BG, 1991, J VIROL, V65, P4017, DOI 10.1128/JVI.65.8.4017-4025.1991	28	91	110	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18060	18066		10.1074/jbc.273.29.18060	http://dx.doi.org/10.1074/jbc.273.29.18060			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660762	hybrid			2022-12-25	WOS:000074828500017
J	Furukawa, T; Miura, R; Mori, Y; Strobeck, M; Suzuki, K; Ogihara, Y; Asano, T; Morishita, R; Hashii, M; Higashida, H; Yoshii, M; Nukada, T				Furukawa, T; Miura, R; Mori, Y; Strobeck, M; Suzuki, K; Ogihara, Y; Asano, T; Morishita, R; Hashii, M; Higashida, H; Yoshii, M; Nukada, T			Differential interactions of the C terminus and the cytoplasmic I-II loop of neuronal Ca2+ channels with G-protein alpha and beta gamma subunits - II. Evidence for direct binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELTA-OPIOID RECEPTORS; CALCIUM-CHANNEL; FUNCTIONAL EXPRESSION; PERTUSSIS TOXIN; NG108-15 CELLS; INHIBITION; MODULATION; BRAIN; CURRENTS; PURIFICATION	The present study was designed to obtain evidence for direct interactions of G-protein alpha (G alpha) and beta gamma subunits (G beta gamma) with N- (alpha(1B)) and P/Q-type (alpha(1A)) Ca2+ channels, using synthetic peptides and fusion proteins derived from loop 1 (cytoplasmic loop between repeat I and II) and the C terminus of these channels. For N-type, prepulse facilitation as mediated by G beta gamma was impaired when a synthetic loop 1 peptide was applied intracellulary. Receptor agonist-induced inhibition of N-type as mediated by G alpha was also impaired by the loop 1 peptide but only when applied in combination with a C-terminal peptide. For P/Q-type channels, by contrast, the G alpha-mediated inhibition was diminished by application of a C-terminal peptide alone. Moreover, in vitro binding analysis for N- and P/Q-type channels revealed direct interaction of G alpha with C-terminal fusion proteins as well as direct interaction of G beta gamma with loop 1 fusion proteins. These findings define loop 1 of N- and P/Q-type Ca2+ channels as an interaction site for G beta gamma and the C termini for G alpha.	Tokyo Inst Psychiat, Dept Neurochem, Setagaya Ku, Tokyo 156, Japan; Tokyo Inst Psychiat, Dept Neurophysiol, Setagaya Ku, Tokyo 156, Japan; Teikyo Univ, Fac Med, Dept Internal Med, Itabashi Ku, Tokyo 173, Japan; Natl Inst Physiol Sci, Dept Informat Physiol, Okazaki, Aichi 444, Japan; Univ Cincinnati, Coll Med, Inst Mol Pharmacol & Biophys, Cincinnati, OH 45267 USA; Daiichi Pharmaceut Co Ltd, Tokyo R&D Ctr, New Prod Res Labs 3, Edogawa Ku, Tokyo 134, Japan; Aichi Human Serv Ctr, Inst Dev Res, Dept Biochem, Kasugai, Aichi 48003, Japan; Kanazawa Univ, Sch Med, Neuroinformat Res Inst, Dept Biophys, Kanazawa, Ishikawa 920, Japan	Tokyo Institute of Psychiatry; Tokyo Institute of Psychiatry; Teikyo University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); University System of Ohio; University of Cincinnati; Daiichi Sankyo Company Limited; Kanazawa University	Nukada, T (corresponding author), Tokyo Inst Psychiat, Dept Neurochem, Setagaya Ku, 2-1-8 Kamikitazawa, Tokyo 156, Japan.		higashida, haruhiro/L-3773-2015	higashida, haruhiro/0000-0002-1779-0606				ASANO T, 1988, J BIOCHEM-TOKYO, V103, P950, DOI 10.1093/oxfordjournals.jbchem.a122392; ASANO T, 1993, J BIOL CHEM, V268, P20512; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; DeWaard M, 1997, NATURE, V385, P446, DOI 10.1038/385446a0; DUNLAP K, 1978, NATURE, V276, P837, DOI 10.1038/276837a0; EWALD DA, 1988, P NATL ACAD SCI USA, V85, P3633, DOI 10.1073/pnas.85.10.3633; FUJITA Y, 1993, NEURON, V10, P585, DOI 10.1016/0896-6273(93)90162-K; Furukawa T, 1998, J BIOL CHEM, V273, P17585, DOI 10.1074/jbc.273.28.17585; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRIECO F, 1992, BIOTECHNIQUES, V13, P856; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; HESCHELER J, 1987, NATURE, V325, P445, DOI 10.1038/325445a0; HIGASHIDA H, 1990, P ROY SOC B-BIOL SCI, V242, P68, DOI 10.1098/rspb.1990.0105; HILLE B, 1994, TRENDS NEUROSCI, V17, P531, DOI 10.1016/0166-2236(94)90157-0; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; ITOH H, 1986, P NATL ACAD SCI USA, V83, P3776, DOI 10.1073/pnas.83.11.3776; KASAI H, 1992, J PHYSIOL-LONDON, V448, P161, DOI 10.1113/jphysiol.1992.sp019035; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KOBILKA BK, 1987, P NATL ACAD SCI USA, V84, P46, DOI 10.1073/pnas.84.1.46; LAUGWITZ KL, 1993, NEURON, V10, P233, DOI 10.1016/0896-6273(93)90314-H; LIPSCOMBE D, 1989, NATURE, V340, P639, DOI 10.1038/340639a0; MCFADZEAN I, 1989, NEURON, V3, P177, DOI 10.1016/0896-6273(89)90030-5; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NAKAMURA F, 1991, J BIOL CHEM, V266, P12676; NAKAMURA K, 1994, J PHYSIOL-LONDON, V474, P35, DOI 10.1113/jphysiol.1994.sp020000; NIRENBERG M, 1983, SCIENCE, V222, P794, DOI 10.1126/science.6314503; NUKADA T, 1987, FEBS LETT, V211, P5, DOI 10.1016/0014-5793(87)81263-2; OHARAIMAIZUMI M, 1992, J NEUROCHEM, V58, P2275, DOI 10.1111/j.1471-4159.1992.tb10974.x; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; PRATHER PL, 1994, J BIOL CHEM, V269, P21293; Qin N, 1997, P NATL ACAD SCI USA, V94, P8866, DOI 10.1073/pnas.94.16.8866; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SOEJIMA M, 1984, PFLUG ARCH EUR J PHY, V400, P424, DOI 10.1007/BF00587544; TAKAO K, 1994, NEURON, V13, P747, DOI 10.1016/0896-6273(94)90041-8; TAUSSIG R, 1992, NEURON, V8, P799, DOI 10.1016/0896-6273(92)90100-R; TSUNOO A, 1986, P NATL ACAD SCI USA, V83, P9832, DOI 10.1073/pnas.83.24.9832; WAKAMORI M, 1994, RECEPTOR CHANNEL, V2, P303; YOSHII M, 1994, BRAIN RES, V642, P123, DOI 10.1016/0006-8993(94)90913-X; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0; Zhang JF, 1996, NEURON, V17, P991, DOI 10.1016/S0896-6273(00)80229-9; ZHU Y, 1994, NEURON, V13, P657, DOI 10.1016/0896-6273(94)90033-7	43	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17595	17603		10.1074/jbc.273.28.17595	http://dx.doi.org/10.1074/jbc.273.28.17595			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651354	hybrid			2022-12-25	WOS:000074816100047
J	Uhlmann, EJ; Subramanian, T; Vater, CA; Lutz, R; Chinnadurai, G				Uhlmann, EJ; Subramanian, T; Vater, CA; Lutz, R; Chinnadurai, G			A potent cell death activity associated with transient high level expression of BCL-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLLICULAR LYMPHOMA; SOMATIC MUTATION; HOMOLOG BAK; GENE; APOPTOSIS; PROTEIN; INDUCTION; DISTINCT; SURVIVAL; BH1	The BCL-2 proto-oncogene contains unusually long untranslated 5' and 3' sequences. Deletion of the sequences flanking the BCL-2 open reading frame dramatically increases the level of protein expression. Transient high level BCL-2 protein expression mediated by plasmid transfection or by infection with recombinant adenovirus results in potent apoptosis of several cell lines. Detailed mutational (deletion and add-back) analysis reveals that both 5'- and 3'-flanking sequences con tribute to the negative modulation of protein expression from the BCL-2 open reading frame. It appears that these sequences exert the negative regulatory effect in an orientation-dependent manner. Analysis of BCL-2 RNA levels indicate that elevated levels of mRNA may be the primary cause of elevated levels of protein expression. Apoptosis induced by adenovirus vectors expressing elevated levels of BCL-2 can be readily inhibited by the caspase inhibitor z-VAD-fmk, suggesting that high levels of BCL-2 expression induce apoptosis via the caspase cascade. Mutational analysis of BCL-2 indicates that its pro-apoptotic activity is separable from its antiapoptosis activity. Our results raise the possibility that oncogenic conversion of BCL-2 may require somatic mutations in the pro-apoptotic activity, in addition to other activating mutations that result in enhanced expression. Consistent with this hypothesis, a somatic mutation of BCL-2 observed in multiple human tumors results in reduced apoptosis activity.	St Louis Univ, Hlth Sci Ctr, Inst Mol Virol, St Louis, MO 63110 USA; Apoptosis Technol Inc, Cambridge, MA 02139 USA	Saint Louis University	Chinnadurai, G (corresponding author), St Louis Univ, Hlth Sci Ctr, Inst Mol Virol, 3681 Pk Ave, St Louis, MO 63110 USA.				NATIONAL CANCER INSTITUTE [R01CA073803, R01CA033616] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA033616, CA-73803, CA-33616] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEY MC, 1988, CANCER RES, V48, P589; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BETT AJ, 1994, P NATL ACAD SCI USA, V91, P8802, DOI 10.1073/pnas.91.19.8802; Borner C, 1996, J BIOL CHEM, V271, P12695, DOI 10.1074/jbc.271.22.12695; BOYD JM, 1995, ONCOGENE, V11, P1921; Chen DF, 1997, NATURE, V385, P434, DOI 10.1038/385434a0; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; Evan G, 1997, INT J CANCER, V71, P709, DOI 10.1002/(SICI)1097-0215(19970529)71:5<709::AID-IJC2>3.0.CO;2-V; FU LN, 1997, EMBO J, V16, P5117; Harigai M, 1996, ONCOGENE, V12, P1369; Hengartner MO, 1997, NATURE, V388, P714, DOI 10.1038/41873; HENGARTNER MO, 1994, NATURE, V369, P319; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KORSMEYER SJ, 1992, BLOOD, V80, P879; Matolcsy A, 1996, BLOOD, V88, P3937, DOI 10.1182/blood.V88.10.3937.bloodjournal88103937; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; Oh JH, 1997, NEUROREPORT, V8, P1851, DOI 10.1097/00001756-199705260-00012; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; PIETENPOL JA, 1994, CANCER RES, V54, P3714; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Rokhlin OW, 1997, CANCER RES, V57, P1758; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; Skowronski EW, 1996, CELL DEATH DIFFER, V3, P171; SUBRAMANIAN T, 1995, CELL GROWTH DIFFER, V6, P131; TANAKA S, 1992, BLOOD, V79, P229; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Uhlmann EJ, 1996, CANCER RES, V56, P2506; Vairo G, 1996, ONCOGENE, V13, P1511; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Vaux DL, 1997, CELL, V90, P389, DOI 10.1016/S0092-8674(00)80497-3; VENKATESH LK, 1990, P NATL ACAD SCI USA, V87, P8746, DOI 10.1073/pnas.87.22.8746; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	47	54	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17926	17932		10.1074/jbc.273.28.17926	http://dx.doi.org/10.1074/jbc.273.28.17926			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651399	hybrid			2022-12-25	WOS:000074816100092
J	Yang, MZ; Kurkinen, M				Yang, MZ; Kurkinen, M			Cloning and characterization of a novel matrix metalloproteinase (MMP), CMMP, from chicken embryo fibroblasts - CMMP, Xenopus XMMP, and human MMP19 have a conserved unique cysteine in the catalytic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHIL COLLAGENASE; EXTRACELLULAR-MATRIX; INTERSTITIAL COLLAGENASE; GELATINASE-B; DEVELOPMENTAL EXPRESSION; MESSENGER-RNAS; IV COLLAGENASE; CDNA LIBRARY; GENE FAMILY; IDENTIFICATION	We cloned a novel matrix metalloproteinase (MMP) called CMMP from cultured primary chicken embryo fibroblasts. The cDNA-derived CMMP sequence contains 472 amino acids including a putative 19-residue signal peptide and a unique cysteine in the catalytic domain, an insertion in a sequence motif that binds the structural (noncatalytic) zinc of MMPs. Strikingly, a homologously inserted cysteine is also found in Xenopus XMMP and human MMP19, two recently cloned novel members of the MMP family. Phylogenetic analysis suggest that XMMP and MMP19 represent founding members of the MMP family, whereas CMMP is related to collagenase MMPs. Bacterially produced recombinant CMMP (without the amino-terminal inhibition domain), which was autoproteolyzed at the carboxyl-terminal domain, digested casein and gelatin. As shown by Northern blotting, CMMP mRNA of 1.8 kilobase pairs was constitutively expressed in cultured primary chicken embryo fibroblasts and up-regulated by tumor necrosis factor-alpha and the phorbol ester 12-O-tetradecanoylphorbol-13-acetate, but it was not regulated by interleukin-1, basic fibroblast growth factor, or retinoic acid. CMMP mRNA of 1.8 kb was also detected in the head and body of 8-day-old chicken embryos and dramatically up-regulated in 9-day-old embryos.	Wayne State Univ, Sch Med, Ctr Mol Med & Genet, Detroit, MI 48202 USA; Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48202 USA	Wayne State University; Wayne State University	Kurkinen, M (corresponding author), Wayne State Univ, Sch Med, Ctr Mol Med & Genet, 5125 Biol Sci Bldg,5047 Gullen Mall, Detroit, MI 48202 USA.	markku@cmb.biosci.wayne.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024442] Funding Source: NIH RePORTER; NICHD NIH HHS [HD24442] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALTSHUL SF, 1997, INPRESS NUCL ACIDS R, V25; AMES RT, 1994, BIOCHEM J, V300, P729, DOI 10.1042/bj3000729; APTE AN, 1993, BIOTECHNIQUES, V15, P890; BARRETT AJ, 1986, RES MONOG CELL TISSU, V12, P515; Bartlett JD, 1996, GENE, V183, P123, DOI 10.1016/S0378-1119(96)00525-2; BELAAOUAJ A, 1995, J BIOL CHEM, V270, P14568, DOI 10.1074/jbc.270.24.14568; Benbow U, 1996, J BIOL CHEM, V271, P10715, DOI 10.1074/jbc.271.18.10715; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; BODE W, 1994, EMBO J, V13, P1263, DOI 10.1002/j.1460-2075.1994.tb06378.x; BONASSAR LJ, 1995, ARTHRITIS RHEUM, V38, P173, DOI 10.1002/art.1780380205; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BRENNER CA, 1989, GENE DEV, V3, P848, DOI 10.1101/gad.3.6.848; CANETESOLER R, 1995, DEV DYNAM, V204, P30, DOI 10.1002/aja.1002040105; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cole AA, 1996, J BIOL CHEM, V271, P11023, DOI 10.1074/jbc.271.18.11023; Cossins J, 1996, BIOCHEM BIOPH RES CO, V228, P494, DOI 10.1006/bbrc.1996.1688; GACK S, 1995, CELL GROWTH DIFFER, V6, P759; HASTY KA, 1990, J BIOL CHEM, V265, P11421; HIROSE T, 1993, P NATL ACAD SCI USA, V90, P2569, DOI 10.1073/pnas.90.7.2569; IMAI K, 1995, J BIOL CHEM, V270, P6691, DOI 10.1074/jbc.270.12.6691; KNAUPER V, 1993, BIOCHEM J, V295, P581; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Kokorine I, 1996, J CELL SCI, V109, P2151; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEPAGE T, 1990, EMBO J, V9, P3003, DOI 10.1002/j.1460-2075.1990.tb07493.x; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; LOVEJOY B, 1994, SCIENCE, V263, P375, DOI 10.1126/science.8278810; MacDougall JR, 1995, CANCER METAST REV, V14, P351, DOI 10.1007/BF00690603; MARTIN GR, 1988, ADV PROTEIN CHEM, V39, P1; MATRISIAN LM, 1992, BIOESSAYS, V6, P121; Matsumoto SI, 1997, BBA-GENE STRUCT EXPR, V1354, P159, DOI 10.1016/S0167-4781(97)00120-6; MATTOT V, 1995, J CELL SCI, V108, P529; MERTZ LM, 1994, ANAL BIOCHEM, V221, P160, DOI 10.1006/abio.1994.1392; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; MURPHY G, 1987, BIOCHEM J, V248, P265, DOI 10.1042/bj2480265; NEWMAN KM, 1994, ARTERIOSCLER THROMB, V14, P1315, DOI 10.1161/01.ATV.14.8.1315; OGATA Y, 1992, J BIOL CHEM, V267, P3581; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Okada A, 1997, J CELL BIOL, V137, P67, DOI 10.1083/jcb.137.1.67; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; Okamoto T, 1997, J BIOL CHEM, V272, P6059, DOI 10.1074/jbc.272.9.6059; Otter M, 1995, BIOCHEM MOL BIOL INT, V37, P563; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Pendas AM, 1997, J BIOL CHEM, V272, P4281, DOI 10.1074/jbc.272.7.4281; Puente XS, 1996, CANCER RES, V56, P944; REPONEN P, 1994, J CELL BIOL, V124, P1091, DOI 10.1083/jcb.124.6.1091; RODGERS WH, 1994, J CLIN INVEST, V94, P946, DOI 10.1172/JCI117461; Sang QXA, 1996, J PROTEIN CHEM, V15, P137, DOI 10.1007/BF01887395; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato T, 1997, J CELL SCI, V110, P589; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; STOCKER W, 1995, PROTEIN SCI, V4, P823; Stolow MA, 1996, MOL BIOL CELL, V7, P1471, DOI 10.1091/mbc.7.10.1471; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; VINCENTI MP, 1994, ARTHRITIS RHEUM, V37, P1115, DOI 10.1002/art.1780370802; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; WERB Z, 1994, TXB RHEUMATOLOGY, P248; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; WITTY EP, 1995, MOL BIOL CELL, V6, P1287, DOI 10.1091/mbc.6.10.1287; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Yang MZ, 1997, J BIOL CHEM, V272, P13527, DOI 10.1074/jbc.272.21.13527; YANG MZ, 1994, EUR J BIOCHEM, V222, P651, DOI 10.1111/j.1432-1033.1994.tb18909.x; Yang MZ, 1996, J BIOL CHEM, V271, P25548, DOI 10.1074/jbc.271.41.25548; Ye S, 1996, J BIOL CHEM, V271, P13055, DOI 10.1074/jbc.271.22.13055; Zhang YN, 1996, J BIOL CHEM, V271, P8015, DOI 10.1074/jbc.271.14.8015	68	49	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17893	17900		10.1074/jbc.273.28.17893	http://dx.doi.org/10.1074/jbc.273.28.17893			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651395	hybrid			2022-12-25	WOS:000074816100088
J	Nohturfft, A; Brown, MS; Goldstein, JL				Nohturfft, A; Brown, MS; Goldstein, JL			Topology of SREBP cleavage-activating protein, a polytopic membrane protein with a sterol-sensing domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; ENDOPLASMIC-RETICULUM; DEGRADATION; GLYCOPROTEIN; RECEPTOR; ENZYME; GENE	The NH2-terminal fragments of sterol regulatory element-binding proteins (SREBPs) are released from endoplasmic reticulum membranes by proteases whose activities depend upon SREBP cleavage-activating protein (SCAP), a polytopic endoplasmic reticulum membrane protein. The activity of SCAP is inhibited by sterols, which appear to interact with the polytopic membrane domain of SCAP. Here, we use protease protection and N-linked glycosylation site-mapping techniques to define the topology of the eight membrane-spanning domains of SCAP, The data indicate that the NH,terminus and COOH terminus of SCAP face the cytosol, The long intralumenal loops after membrane-spanning segments I and 7 are glycosylated, confirming their lumenal location. The region comprising membrane-spanning segments 2-6 shows sequence resemblance to putative sterol-sensing domains in three other proteins: 3-hydroxy-3-methylglutaryl CoA reductase (HMG-CoA reductase), the Niemann-Pick CI protein, and the morphogen receptor Patched. The orientation of the eight membrane-spanning segments in SCAP is consistent with the model proposed for HMG-CoA reductase (Olender, E, H,, and Simoni, R. D, (1992) J. Biol. Chem. 267, 4223-4235), The membrane-spanning domains of SCAP and HMG-CoA reductase confer sterol sensitivity upon the functional activities of the two molecules. The common membrane topology of the two proteins is consistent with the notion that sterols regulate both proteins by a common mechanism.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Nohturfft, A (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA.			Nohturfft, Axel/0000-0001-9484-3209	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Duncan EA, 1997, J BIOL CHEM, V272, P12778, DOI 10.1074/jbc.272.19.12778; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; HUA XX, 1995, J BIOL CHEM, V270, P29422, DOI 10.1074/jbc.270.49.29422; INOUE S, 1992, J BIOL CHEM, V267, P9080; ISOLA VJ, 1989, J VIROL, V63, P2325, DOI 10.1128/JVI.63.5.2325-2334.1989; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; KOCH GLE, 1988, J CELL SCI, V90, P485; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LISCUM L, 1985, J BIOL CHEM, V260, P522; LISCUM L, 1995, J BIOL CHEM, V270, P15443, DOI 10.1074/jbc.270.26.15443; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; Nohturfft A, 1996, P NATL ACAD SCI USA, V93, P13709, DOI 10.1073/pnas.93.24.13709; OLENDER EH, 1992, J BIOL CHEM, V267, P4223; Osborne TF, 1995, CRIT REV EUKAR GENE, V5, P317, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.50; Pentchev P. G., 1995, METABOLIC MOL BASES, P2625; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; Sakai J, 1998, J BIOL CHEM, V273, P5785, DOI 10.1074/jbc.273.10.5785; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Sakai J, 1997, J BIOL CHEM, V272, P20213, DOI 10.1074/jbc.272.32.20213; Tabin CJ, 1997, TRENDS CELL BIOL, V7, P442, DOI 10.1016/S0962-8924(97)01159-8; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	37	157	168	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17243	17250		10.1074/jbc.273.27.17243	http://dx.doi.org/10.1074/jbc.273.27.17243			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642295	Green Published, hybrid			2022-12-25	WOS:000074545200085
J	Sweeney, KJ; Swarbrick, A; Sutherland, RL; Musgrove, EA				Sweeney, KJ; Swarbrick, A; Sutherland, RL; Musgrove, EA			Lack of relationship between CDK activity and G(1) cyclin expression in breast cancer cells	ONCOGENE			English	Article						cyclin D1; cyclin E; CDK; CKI; breast cancer; kinase activity	DEPENDENT KINASES; INHIBITS GROWTH; D1; OVEREXPRESSION; LINE; PROTEINS; PRB; DIFFERENTIATION; PROLIFERATION; AMPLIFICATION	The G(1) cyclins, cyclin D1 and E, are rate limiting for progression through G(1) phase of the cell cycle in breast epithelial cells and are oncogenic when expressed in the mammary epithelium of transgenic mice. These genes are frequently overexpressed in clinical breast cancer where overexpression appears to be associated with specific disease phenotypes, altered responsiveness to therapeutic intervention and patient survival. In order to investigate the functional correlates of cyclin D1 and cyclin E overexpression we employed a panel of normal, immortalized and neoplastic breast epithelial cell lines to examine the relationships between cyclin gene expression, cyclin-CDK complex formation and CDK activity. In agreement with earlier studies cyclin D1 and E expression varied over an approximately tenfold range among the 18 cell lines studied. There was no apparent relationship, however, between cyclin D1 expression and the in vitro activity of its major kinase partner, Cdk4, although MDA-MB-134 cells displayed the highest level of both cyclin D1 expression and Cdk4 activity. Similarly, there was no significant relationship between cyclin E expression and cyclin E-Cdk2 activity. Fractionation of whole cell lysates by gel filtration chromatography revealed that similar to 90% of the cyclin E protein was present in inactive complexes containing the CDK inhibitors p21 and p27. Much of the small fraction of active cyclin E protein was of very high apparent molecular mass, >400 kDa, suggesting that formation of these complexes is a more important determinant of cyclin E-Cdk2 activity than cyclin E abundance. These data suggest that properties of cyclins D1 and E in addition to their ability to activate Cdk4 and Cdk2 may contribute to the effects of overexpression on the breast cancer phenotype.	St Vincents Hosp, Gardiner Inst, Canc Res Program, Sydney, NSW 2010, Australia	St Vincents Hospital Sydney	Musgrove, EA (corresponding author), St Vincents Hosp, Gardiner Inst, Canc Res Program, Sydney, NSW 2010, Australia.		Swarbrick, Alexander/E-6107-2010; Sutherland, Robert L/A-8378-2008	Swarbrick, Alexander/0000-0002-3051-5676; 				ALLE KM, 1997, IN PRESS CLIN CANC R; Bartkova J, 1996, INT J CANCER, V65, P323, DOI 10.1002/(SICI)1097-0215(19960126)65:3<323::AID-IJC8>3.0.CO;2-1; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; DESAI D, 1995, MOL CELL BIOL, V15, P345, DOI 10.1128/MCB.15.1.345; DUTTA A, 1995, P NATL ACAD SCI USA, V92, P5386, DOI 10.1073/pnas.92.12.5386; Florenes VA, 1996, ONCOGENE, V13, P2447; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; Gillett C, 1996, INT J CANCER, V69, P92, DOI 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.3.CO;2-I; GILLETT C, 1994, CANCER RES, V54, P1812; GrayBablin J, 1996, P NATL ACAD SCI USA, V93, P15215, DOI 10.1073/pnas.93.26.15215; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HAN EKH, 1995, ONCOGENE, V10, P953; Han EKH, 1996, CELL GROWTH DIFFER, V7, P699; Higashi H, 1996, EUR J BIOCHEM, V237, P460, DOI 10.1111/j.1432-1033.1996.0460k.x; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Hiyama H, 1997, ONCOGENE, V14, P2533, DOI 10.1038/sj.onc.1201080; Hui R, 1996, CLIN CANCER RES, V2, P923; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KEYOMARSI K, 1994, CANCER RES, V54, P380; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KRANENBURG O, 1995, ONCOGENE, V10, P87; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MCINTOSH GG, 1995, ONCOGENE, V11, P885; Michalides R, 1996, BRIT J CANCER, V73, P728, DOI 10.1038/bjc.1996.128; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Musgrove EA, 1996, J CELL BIOCHEM, V60, P363; MUSGROVE EA, 1989, CANCER RES, V49, P2398; MUSGROVE EA, 1995, INT J CANCER, V63, P584, DOI 10.1002/ijc.2910630420; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Nielsen NH, 1996, BRIT J CANCER, V74, P874, DOI 10.1038/bjc.1996.451; Nielsen NH, 1997, ONCOGENE, V14, P295, DOI 10.1038/sj.onc.1200833; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PARGE HE, 1993, SCIENCE, V262, P387, DOI 10.1126/science.8211159; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Sarcevic B, 1997, J BIOL CHEM, V272, P33327, DOI 10.1074/jbc.272.52.33327; Sgambato A, 1996, CANCER RES, V56, P1389; Sgambato A, 1997, CELL GROWTH DIFFER, V8, P393; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sidle A, 1996, CRIT REV BIOCHEM MOL, V31, P237, DOI 10.3109/10409239609106585; SoferLevi Y, 1996, ONCOGENE, V13, P2431; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; Sweeney KJ, 1997, ONCOGENE, V14, P1329, DOI 10.1038/sj.onc.1200951; Tan P, 1997, CANCER RES, V57, P1259; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	59	68	69	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 4	1998	16	22					2865	2878		10.1038/sj.onc.1201814	http://dx.doi.org/10.1038/sj.onc.1201814			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZR544	9671407				2022-12-25	WOS:000073988200005
J	Aberdam, E; Bertolotto, C; Sviderskaya, EV; de Thillot, V; Hemesath, TJ; Fisher, DE; Bennett, DC; Ortonne, JP; Ballotti, R				Aberdam, E; Bertolotto, C; Sviderskaya, EV; de Thillot, V; Hemesath, TJ; Fisher, DE; Bennett, DC; Ortonne, JP; Ballotti, R			Involvement of microphthalmia in the inhibition of melanocyte lineage differentiation and of melanogenesis by agouti signal protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATING-HORMONE-RECEPTOR; TRANSCRIPTION FACTOR; HUMAN HOMOLOG; MELANOCORTIN RECEPTORS; INVERSE AGONISTS; TYROSINASE GENE; IN-VITRO; MOUSE; LOCUS; MICE	In mouse follicular melanocytes, production of eumelanins (brown-black pigments) and pheomelanins (yellow-brownish pigments) is under the control of two intercellular signaling molecules that exert opposite actions, alpha-melanocyte-stimulating hormone (alpha MSH) which preferentially increases the synthesis of eumelanins, and agouti signal protein (ASP) whose expression favors the production of hair containing pheomelanins. In this study, we report that ASP does not only affect mature melanocytes but can also inhibit the differentiation of melanoblasts. We show that both alpha MSH and forskolin promote the differentiation of murine melanoblasts into mature melanocytes and that ASP inhibits this process. We present evidence that the expression of a specific melanogenic transcription factor, microphthalmia, and its binding to an M box regulatory element, is inhibited by ASP. We also show that, in B16 murine melanoma cells, ASP inhibits alpha MSH-stimulated expression of tyrosinase, tyrosine-related proteins 1 and 2 through an inhibition of the transcription activity of their respective promoters. Further, ASP inhibits alpha MSH-induced expression of the microphthalmia gene and reduces the level of microphthalmia in the cells. Our data demonstrate that ASP can regulate both melanoblast differentiation and melanogenesis, pointing out the key role of microphthalmia in the control of these processes.	Fac Med, INSERM, U385, F-06107 Nice 2, France; Harvard Univ, Sch Med, Childrens Hosp, Div Pediat Hematol Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Univ London St Georges Hosp, Sch Med, London SW17 0RE, England	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; St Georges University London	Ballotti, R (corresponding author), Fac Med, INSERM, U385, Ave Valombrose, F-06107 Nice 2, France.		Sviderskaya, Elena V/D-2419-2009; Bertolotto-Ballotti, Corine/O-2155-2016; Bertolotto, Corine/AAF-6634-2021; Bennett, Dorothy C/C-2418-2008; BALLOTTI, Robert/F-8825-2013	Bertolotto, Corine/0000-0001-6971-7753; Bennett, Dorothy C/0000-0002-3639-7527; BALLOTTI, Robert/0000-0002-7322-4908				ABDELMALEK Z, 1995, P NATL ACAD SCI USA, V92, P1789, DOI 10.1073/pnas.92.5.1789; BENNETT DC, 1993, INT REV CYTOL, V146, P191, DOI 10.1016/S0074-7696(08)60383-6; Bertolotto C, 1996, J CELL BIOL, V134, P747, DOI 10.1083/jcb.134.3.747; Bertolotto C, 1998, MOL CELL BIOL, V18, P694, DOI 10.1128/MCB.18.2.694; BLANCHARD SG, 1995, BIOCHEMISTRY-US, V34, P10406, DOI 10.1021/bi00033a012; BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; BURCHILL SA, 1986, J ENDOCRINOL, V109, P15, DOI 10.1677/joe.0.1090015; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fuse N, 1996, BIOCHEM BIOPH RES CO, V219, P702, DOI 10.1006/bbrc.1996.0298; Graham A, 1997, PIGM CELL RES, V10, P298, DOI 10.1111/j.1600-0749.1997.tb00689.x; HEARING VJ, 1987, INT J BIOCHEM, V19, P1141, DOI 10.1016/0020-711X(87)90095-4; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; HUGHES AE, 1994, NAT GENET, V7, P509, DOI 10.1038/ng0894-509; HUGHES MJ, 1993, J BIOL CHEM, V268, P20687; HUNT G, 1994, J ENDOCRINOL, V140, pR1, DOI 10.1677/joe.0.140R001; HUNT G, 1995, J ENDOCRINOL, V147, pR1, DOI 10.1677/joe.0.147R001; JACKSON IJ, 1992, EMBO J, V11, P527, DOI 10.1002/j.1460-2075.1992.tb05083.x; JIMENEZCERVANTES C, 1994, J BIOL CHEM, V269, P17993; JIMENEZCERVANTES C, 1993, PIGM CELL RES, V6, P394, DOI 10.1111/j.1600-0749.1993.tb00621.x; KOBAYASHI T, 1995, J CELL SCI, V108, P2301; KWON HY, 1994, P NATL ACAD SCI USA, V91, P9760, DOI 10.1073/pnas.91.21.9760; LEDOUARIN NM, 1992, INT REV CYTOL, V138, P269, DOI 10.1016/S0074-7696(08)61591-0; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; MILLER MW, 1993, GENE DEV, V7, P454, DOI 10.1101/gad.7.3.454; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; Pozvek G, 1997, MOL PHARMACOL, V51, P658, DOI 10.1124/mol.51.4.658; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; Sakai C, 1997, EMBO J, V16, P3544, DOI 10.1093/emboj/16.12.3544; Siegrist W, 1996, BIOCHEM BIOPH RES CO, V218, P171, DOI 10.1006/bbrc.1996.0030; STEINGRIMSSON E, 1994, NAT GENET, V8, P50; Suzuki I, 1996, ENDOCRINOLOGY, V137, P1627, DOI 10.1210/en.137.5.1627; Suzuki I, 1997, J INVEST DERMATOL, V108, P838, DOI 10.1111/1523-1747.ep12292572; TAKEUCHI T, 1989, Journal of Investigative Dermatology, V92, p239S, DOI 10.1111/1523-1747.ep13075730; TAMATE HB, 1984, SCIENCE, V224, P1241, DOI 10.1126/science.6328651; TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194-251; Weilbaecher KN, 1998, J EXP MED, V187, P775, DOI 10.1084/jem.187.5.775; WESTPHAL RS, 1994, MOL PHARMACOL, V46, P937; WILLARD DH, 1995, BIOCHEMISTRY-US, V34, P12341, DOI 10.1021/bi00038a030; WILSON BD, 1995, HUM MOL GENET, V4, P223, DOI 10.1093/hmg/4.2.223; YASUMOTO KI, 1994, MOL CELL BIOL, V14, P8058, DOI 10.1128/MCB.14.12.8058; YAVUZER U, 1995, ONCOGENE, V10, P123; YEN TT, 1994, FASEB J, V8, P479, DOI 10.1096/fasebj.8.8.8181666; ZEMEL MB, 1995, P NATL ACAD SCI USA, V92, P4733, DOI 10.1073/pnas.92.11.4733	43	64	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19560	19565		10.1074/jbc.273.31.19560	http://dx.doi.org/10.1074/jbc.273.31.19560			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677380	hybrid			2022-12-25	WOS:000075125200032
J	Andersson, L; Freeman, MW				Andersson, L; Freeman, MW			Functional changes in scavenger receptor binding conformation are induced by charge mutants spanning the entire collagen domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HELICAL PEPTIDE MODEL; HAMSTER OVARY CELLS; ALZHEIMERS-DISEASE; LIGAND-BINDING; IN-VITRO; EXPRESSION; PROTEINS; SITE; DEGRADATION	Macrophage scavenger receptors are trimeric integral membrane proteins that bind a diverse array of negatively charged ligands, They have been shown to play a role in the pathogenesis of atherosclerosis and in host responses to microbial infections. Earlier mutational studies demonstrated that the distal segment of the collagen domain of the receptor was critically important for high affinity ligand binding activity. In this study, mutations spanning the entire collagen domain were generated and binding was assayed in transfected cells, as well as in assays employing a secreted, receptor fusion protein, Many of the distal, positively charged C-terminal residues in the type II collagen domain of the receptor, previously reported to be essential for binding at 37 degrees C, were found not to be critical for binding at 4 degrees C, Conversely, more proximally charged residues of the collagen receptor that have not been previously mutated were shown to have substantial effects on binding that were also temperature-dependent. These data suggest that scavenger receptor ligand recognition depends on more complex conformational interactions, involving charged residues throughout the entire collagen domain, than was previously recognized.	Massachusetts Gen Hosp, Lipid Metab Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Nessel Gene Therapy Ctr, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Freeman, MW (corresponding author), Massachusetts Gen Hosp, Lipid Metab Unit, GRJ 1328, Boston, MA 02114 USA.				NHLBI NIH HHS [HL 45098] Funding Source: Medline; NIDDK NIH HHS [DK50305] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL145098, R01HL045098] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050305] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACTON S, 1993, J BIOL CHEM, V268, P3530; ANACHI RB, 1995, FEBS LETT, V368, P551, DOI 10.1016/0014-5793(95)00738-U; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; ASHKENAS J, 1993, J LIPID RES, V34, P983; BICKEL PE, 1992, J CLIN INVEST, V90, P1450, DOI 10.1172/JCI116012; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BROWN MS, 1980, J SUPRAMOL STR CELL, V13, P67, DOI 10.1002/jss.400130107; Christie RH, 1996, AM J PATHOL, V148, P399; DANIEL TO, 1983, J BIOL CHEM, V258, P4606; DEJAGER S, 1993, J CLIN INVEST, V92, P894, DOI 10.1172/JCI116664; DOI T, 1993, J BIOL CHEM, V268, P2126; FRASER I, 1993, NATURE, V364, P343, DOI 10.1038/364343a0; FREEMAN M, 1990, P NATL ACAD SCI USA, V87, P8810, DOI 10.1073/pnas.87.22.8810; FREEMAN M, 1991, P NATL ACAD SCI USA, V88, P4931, DOI 10.1073/pnas.88.11.4931; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; Harlow E, 1988, ANTIBODIES LAB MANUA; HODGES RS, 1988, J BIOL CHEM, V263, P11768; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KRIEGER M, 1983, CELL, V33, P413, DOI 10.1016/0092-8674(83)90423-3; KRIEGER M, 1993, J BIOL CHEM, V268, P4569; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MATSUMOTO A, 1990, P NATL ACAD SCI USA, V87, P9133, DOI 10.1073/pnas.87.23.9133; MAYER WE, 1995, GENE, V164, P267, DOI 10.1016/0378-1119(95)94092-Z; Mielewczyk SS, 1996, BIOCHEMISTRY-US, V35, P11396, DOI 10.1021/bi960706z; Paresce DM, 1996, NEURON, V17, P553, DOI 10.1016/S0896-6273(00)80187-7; PENMAN M, 1991, J BIOL CHEM, V266, P23985; RESNICK D, 1993, J BIOL CHEM, V268, P3538; Resnick D, 1996, J BIOL CHEM, V271, P26924, DOI 10.1074/jbc.271.43.26924; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; Starling GC, 1997, TISSUE ANTIGENS, V49, P1, DOI 10.1111/j.1399-0039.1997.tb02702.x; Tanaka T, 1996, PROTEIN ENG, V9, P307, DOI 10.1093/protein/9.3.307; Yamamoto K, 1997, FEBS LETT, V414, P182, DOI 10.1016/S0014-5793(97)01006-5	33	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19592	19601		10.1074/jbc.273.31.19592	http://dx.doi.org/10.1074/jbc.273.31.19592			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677385	hybrid			2022-12-25	WOS:000075125200037
J	Gervais, JLM; Seth, P; Zhang, H				Gervais, JLM; Seth, P; Zhang, H			Cleavage of CDK inhibitor p21(Cip1/Waf1) by caspases is an early event during DNA damage-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; CELL-CYCLE; S-PHASE; ICE/CED-3 PROTEASE; GROWTH ARREST; P21; PCNA; DEATH; SUPPRESSION; REPLICATION	Activation of the p53-mediated DNA dams.ge response induces either G(1) cell cycle arrest or apoptosis. The Gr, cell cycle arrest is in part caused by the p53-dependent transcriptional activation of the CDK inhibitor, p21(Cip1/)Waf1. We report here that human p21 protein is rapidly induced but selectively cleaved during the apoptotic response to gamma-irradiation. Such an event occurred early, well before the morphological appearance of apoptosis. Ectopical expression of p53 in tumor cells alone could induce p21 expression, followed by p21 cleavage and apoptosis, The cleavage of pal could be reproduced in extracts prepared from irradiated cells or by recombinant caspase-3, suggesting that a caspase-like activity is responsible for this cleavage, p21 binds independently to both CDK2 and proliferation cell nuclear antigen (PCNA). Our studies indicated that p21 cleavage by the caspase-like activity specifically abolished its interaction with PCNA, suggesting that p21 cleavage may interfere with normal PCNA-dependent repair. Our data suggest that pal may serve as a critical checkpoint regulator for both cell cycle arrest and apoptosis during the p53-mediated DNA damage response. Manipulation of the checkpoint regulators involved in cell cycle arrest and apoptosis may thus provide a novel strategy to cancer therapy.	Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA; NCI, Med Breast Canc Sect, Med Branch, NIH, Bethesda, MD 20892 USA	Yale University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Zhang, H (corresponding author), Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA.	hui.zhang@yale.edu						Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Alnemri ES, 1997, J CELL BIOCHEM, V64, P33, DOI 10.1002/(SICI)1097-4644(199701)64:1<33::AID-JCB6>3.0.CO;2-0; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CANMAN CE, 1995, SEMIN CANCER BIOL, V6, P17, DOI 10.1006/scbi.1995.0003; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; DEN C, 1995, CELL, V82, P675; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; HARPER JW, 1993, CELL, V75, P805; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; KASTAN MB, 1991, CANCER RES, V51, P6304; KATAYOSE D, 1995, BIOCHEM BIOPH RES CO, V215, P446, DOI 10.1006/bbrc.1995.2485; KATAYOSE D, 1995, CELL GROWTH DIFFER, V6, P1207; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li R, 1996, CURR BIOL, V6, P189, DOI 10.1016/S0960-9822(02)00452-9; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	34	200	206	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19207	19212		10.1074/jbc.273.30.19207	http://dx.doi.org/10.1074/jbc.273.30.19207			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668108	hybrid			2022-12-25	WOS:000074974700075
J	Liu, Y; Ray, SK; Yang, XQ; Luntz-Leybman, V; Chiu, IM				Liu, Y; Ray, SK; Yang, XQ; Luntz-Leybman, V; Chiu, IM			A splice variant of E2-2 basic helix-loop-helix protein represses the brain-specific fibroblast growth factor 1 promoter through the binding to an imperfect E-box	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR MESSENGER-RNA; DEVELOPING NERVOUS-SYSTEM; TRANSCRIPTION FACTOR; RAT-BRAIN; MOLECULAR-CLONING; GENE-EXPRESSION; PRONEURAL GENE; TISSUES; LOCALIZATION; ENHANCERS	We previously demonstrated that a cis-element (-489 to -467) in the brain-specific fibroblast growth factor (FGF)-1 promoter (FGF-1.B) binds multiple nuclear factors, and this binding enhances transcriptional activity of this promoter. Here we report the isolation of three cDNA clones, VL1, VL2 and VL3, from a human brain stem cDNA expression library using four tandem repeats of the 26-base pair sequence (-492 to -467) as the probe. These cDNA clones represent the variant of bHLH protein E2-2/SEF2-1 in having 12 additional nucleotides encoding the amino acids RSRS, The glutathione S-transferase (GST) fusion proteins of VL1, VL2, and VL3 immunologically react with anti-E2-2 antibody and anti-GST-VL2 antibody. Electrophoretic mobility shift assay and methylation interference assay revealed that the GST fusion proteins specifically bind to an imperfect E-box sequence (GACCTG) present in the :26-base pair sequence, Transient expression of the full-length E2-2 without RSRS in U1240MG glioblastoma cells resulted in repression of FGF-I,B promoter activity. We further showed a significant repression of promoter activity (>40 fold) by E2-2 (lacking the amino acid sequence RSRS) when the E47 reporter construct, containing a hexameric E-box site, was used. In contrast, the E2-2 variant containing the RSRS sequence has no significant effect on either the FGF-1 promoter or E47 promoter, These results suggest that the relative abundance of the two splice variants of E2-2 in brain could be an important determinant for the expression of FGF-1.	Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Chiu, IM (corresponding author), Ohio State Univ, Dept Internal Med, 480 W 9th Ave, Columbus, OH 43210 USA.		Yang, Xiaoqi/E-2070-2011; Chiu, Ing-Ming/B-1534-2008; yang, xin/HGU-9981-2022		NATIONAL CANCER INSTITUTE [R01CA045611] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA45611] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKAZAWA C, 1995, J BIOL CHEM, V270, P8730, DOI 10.1074/jbc.270.15.8730; Alam KY, 1996, J BIOL CHEM, V271, P30263, DOI 10.1074/jbc.271.47.30263; BAIN G, 1993, MOL CELL BIOL, V13, P3522, DOI 10.1128/MCB.13.6.3522; BEAN AJ, 1991, P NATL ACAD SCI USA, V88, P10237, DOI 10.1073/pnas.88.22.10237; BEGLEY CG, 1992, P NATL ACAD SCI USA, V89, P38, DOI 10.1073/pnas.89.1.38; CHIU IM, 1990, ONCOGENE, V5, P755; CHOTANI MA, 1995, NUCLEIC ACIDS RES, V23, P434, DOI 10.1093/nar/23.3.434; CORNELIUSSEN B, 1991, J VIROL, V65, P6084, DOI 10.1128/JVI.65.11.6084-6093.1991; CORNELIUSSEN B, 1994, NATURE, V368, P760, DOI 10.1038/368760a0; DU XY, 1994, J NEUROSCI, V14, P7688; ECKENSTEIN FP, 1994, BIOCHEM PHARMACOL, V47, P103, DOI 10.1016/0006-2952(94)90442-1; GOBEL V, 1992, CELL GROWTH DIFFER, V3, P143; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HARA Y, 1994, BRAIN RES, V664, P101, DOI 10.1016/0006-8993(94)91959-3; Harlow E., 1988, ANTIBODIES LAB MANUA; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; JARMAN AP, 1993, CELL, V73, P1307, DOI 10.1016/0092-8674(93)90358-W; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LOGAN A, 1988, MOL CELL ENDOCRINOL, V58, P275, DOI 10.1016/0303-7207(88)90164-5; MYERS RL, 1995, ONCOGENE, V11, P785; MYERS RL, 1995, J BIOL CHEM, V270, P8257, DOI 10.1074/jbc.270.14.8257; MYERS RL, 1993, ONCOGENE, V8, P341; PAYSON RA, 1993, NUCLEIC ACIDS RES, V21, P489, DOI 10.1093/nar/21.3.489; Pscherer A, 1996, EMBO J, V15, P6680, DOI 10.1002/j.1460-2075.1996.tb01058.x; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; Ray SK, 1997, J BIOL CHEM, V272, P7546, DOI 10.1074/jbc.272.11.7546; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; Skerjanc IS, 1996, J BIOL CHEM, V271, P3555, DOI 10.1074/jbc.271.7.3555; Smallwood PM, 1996, P NATL ACAD SCI USA, V93, P9850, DOI 10.1073/pnas.93.18.9850; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STOCK A, 1992, J NEUROSCI, V12, P4688; TAKAHASHI JA, 1990, P NATL ACAD SCI USA, V87, P5710, DOI 10.1073/pnas.87.15.5710; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; WANG WP, 1991, ONCOGENE, V6, P1521; WANG WP, 1991, DNA CELL BIOL, V10, P771, DOI 10.1089/dna.1991.10.771; WANG WP, 1989, MOL CELL BIOL, V9, P2387, DOI 10.1128/MCB.9.6.2387; WEINER HL, 1989, P NATL ACAD SCI USA, V86, P2683, DOI 10.1073/pnas.86.8.2683; WILCOX BJ, 1991, NEURON, V6, P397, DOI 10.1016/0896-6273(91)90248-X	42	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19269	19276		10.1074/jbc.273.30.19269	http://dx.doi.org/10.1074/jbc.273.30.19269			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668116	hybrid			2022-12-25	WOS:000074974700083
J	Matsuo, E; Mori, H; Shimoike, T; Ito, K				Matsuo, E; Mori, H; Shimoike, T; Ito, K			Syd, a SecY-interacting protein, excludes SecA from, the SecYE complex with an altered secY24 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI PREPROTEIN TRANSLOCASE; ESCHERICHIA-COLI; MEMBRANE; MACHINERY; RECONSTITUTION; COMPONENTS; EXPORT; ATP; OVERPRODUCTION; MUTATIONS	Syd is an Escherichia coli cytosolic protein that interacts with SecY, Overproduction of this protein causes a number of protein translocation-related phenotypes, including the strong toxicity against the secY24 mutant cells. Previously, this mutation was shown to impair the interaction between SecY and SecE, the two fundamental subunits of the membrane-embedded part of protein translocase. We have now studied in vitro the mechanisms of the Syd-directed inhibition of protein translocation, Pro-OmpA translocation into inverted membrane vesicles (IMVs) prepared from the secY24 mutant cells as well as the accompanied translocation ATPase activity of SecA were rapidly inhibited by purified Syd protein. In the course of protein translocation, high affinity binding of preprotein-bearing SecA to the translocase on the IMV is followed by ATP-driven insertion of the 80-kDa SecA segment into the membrane. Our experiments using I-125-labeled SecA and the secY24 mutant IMV showed that Syd abolished both the high affinity SecA binding and the SecA insertion. Syd was even able to release the inserted form of SecA that had been stabilized by a nonhydrolyzable ATP analog. Syd affected markedly the proteolytic digestion pattern of the IMV-integrated SecY24 protein, suggesting that Syd exerts its inhibitory effect by interacting directly with the SecY24 protein. In accordance with this notion, a SecY24 variant with a second site mutation (secY249) resisted the Syd action both in vivo and in vitro. Thus, Syd acts against the SecY24 form of translocase, in which SecY-SecE interaction has been compromised, to exclude the SecA motor protein from the SecYE channel complex.	Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Ito, K (corresponding author), Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan.	kito@virus.kyoto-u.ac.jp		Mori, Hiroyuki/0000-0002-0429-1269				AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; AKIYAMA Y, 1990, BIOCHEM BIOPH RES CO, V167, P711, DOI 10.1016/0006-291X(90)92083-C; AKIYAMA Y, 1994, J BIOL CHEM, V269, P5218; BABA T, 1994, P NATL ACAD SCI USA, V91, P4539, DOI 10.1073/pnas.91.10.4539; BABA T, 1990, J BACTERIOL, V172, P7005, DOI 10.1128/jb.172.12.7005-7010.1990; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; BRUNDAGE L, 1992, J BIOL CHEM, V267, P4166; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; Duong F, 1997, EMBO J, V16, P2756, DOI 10.1093/emboj/16.10.2756; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; HANADA M, 1994, J BIOL CHEM, V269, P23625; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; Homma T, 1997, FEBS LETT, V408, P11, DOI 10.1016/S0014-5793(97)00376-1; Ito K, 1996, GENES CELLS, V1, P337, DOI 10.1046/j.1365-2443.1996.34034.x; JOLY JC, 1994, P NATL ACAD SCI USA, V91, P4703, DOI 10.1073/pnas.91.11.4703; KIHARA A, 1995, P NATL ACAD SCI USA, V92, P4532, DOI 10.1073/pnas.92.10.4532; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; Matsumoto G, 1997, EMBO J, V16, P6384, DOI 10.1093/emboj/16.21.6384; Matsuo E, 1998, MOL GEN GENET, V258, P240, DOI 10.1007/s004380050728; MATSUYAMA S, 1992, BIOCHIM BIOPHYS ACTA, V1122, P77, DOI 10.1016/0167-4838(92)90130-6; MATSUYAMA S, 1990, FEBS LETT, V269, P96, DOI 10.1016/0014-5793(90)81128-B; NISHIYAMA K, 1993, EMBO J, V12, P3409, DOI 10.1002/j.1460-2075.1993.tb06015.x; Pohlschroder M, 1996, J BIOL CHEM, V271, P19908, DOI 10.1074/jbc.271.33.19908; Sato K, 1997, J BIOL CHEM, V272, P20082, DOI 10.1074/jbc.272.32.20082; SHIBA K, 1984, EMBO J, V3, P631, DOI 10.1002/j.1460-2075.1984.tb01859.x; SHIMOIKE T, 1995, J BIOL CHEM, V270, P5519, DOI 10.1074/jbc.270.10.5519; SHIMOIKE T, 1992, MOL MICROBIOL, V6, P1205, DOI 10.1111/j.1365-2958.1992.tb01559.x; TAURA T, 1993, J BACTERIOL, V175, P7771, DOI 10.1128/JB.175.24.7771-7775.1993; TAURA T, 1994, MOL GEN GENET, V243, P261, DOI 10.1007/BF00301061; Taura T, 1997, BIOCHIMIE, V79, P517, DOI 10.1016/S0300-9084(97)82744-7; Wickner W, 1996, J BIOL CHEM, V271, P29514, DOI 10.1074/jbc.271.47.29514; Yoshihisa T, 1996, J BIOL CHEM, V271, P9429, DOI 10.1074/jbc.271.16.9429	34	26	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18835	18840		10.1074/jbc.273.30.18835	http://dx.doi.org/10.1074/jbc.273.30.18835			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668058	hybrid			2022-12-25	WOS:000074974700025
J	Michaelson, LV; Lazarus, CM; Griffiths, G; Napier, JA; Stobart, AK				Michaelson, LV; Lazarus, CM; Griffiths, G; Napier, JA; Stobart, AK			Isolation of a Delta(5)-fatty acid desaturase gene from Mortierella alpina	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROSOMAL PREPARATIONS; HISTIDINE-RESIDUES; SYNECHOCYSTIS; CYTOCHROME-B5; ARABIDOPSIS; TEMPERATURE; EXPRESSION; CLONING; ENZYME	Arachidonic acid (C20:4 Delta(5,8,11,14)) is a polyunsaturated fatty acid synthesized by the Delta(6)-fatty acid desaturation of di-homo-gamma-linolenic acid (C20:3 Delta(8,11,14)). I, mammals, it is known to be a precursor of the prostaglandins and the leukotrienes but it is also accumulated. by the filamentous fungus Mortierella alpina. We have isolated a cDNA encoding the Delta(5)-fatty acid desaturase from M. alpina via a polymerase chain reaction-based strategy using primers designed to the conserved histidine box regions of microsomal desaturases, and confirmed its function by expression in the yeast Saccharomyces cerevisiae. Analysis of the lipids from the transformed yeast demonstrated the accumulation of arachidonic acid. The M. alpina Delta(5)-desaturase is the first example of a cloned Delta(5)-desaturase, and differs from other fungal desaturases previously characterized by the presence of an N-terminal domain related to cytochrome b(5).	Univ Bristol, Sch Biol Sci, Bristol BS8 1UG, Avon, England; Hort Res Int, Wellesbourne CV35 9EF, Warwick, England; Univ Bristol, Dept Agr Sci, Inst Arable Crops Res, Long Ashton Res Stn, Bristol BS41 9AF, Avon, England	University of Bristol; University of Warwick; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Rothamsted Research; University of Bristol	Michaelson, LV (corresponding author), Univ Bristol, Sch Biol Sci, Woodland Rd, Bristol BS8 1UG, Avon, England.	louise.michaelson@bristol.ac.uk	Lazarus, Colin M/B-9474-2011	Griffiths, Gareth/0000-0002-7507-6945; Napier, Johnathan/0000-0003-3580-3607; Michaelson, Louise/0000-0001-5621-4495				Anamnart S, 1997, GENE, V184, P299, DOI 10.1016/S0378-1119(96)00621-X; ARONDEL V, 1992, SCIENCE, V258, P1353, DOI 10.1126/science.1455229; AVELANGEMACHEREL MH, 1995, FEBS LETT, V361, P111, DOI 10.1016/0014-5793(95)00163-4; DAILEY HA, 1980, J BIOL CHEM, V255, P5184; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; Gill I, 1997, TRENDS BIOTECHNOL, V15, P470, DOI 10.1016/S0167-7799(97)01077-9; Horrobin D.F., 1990, REV CONT PHYSL, V1, P1; HORROBIN DF, 1992, PROG LIPID RES, V31, P167; Jackson FM, 1998, EUR J BIOCHEM, V252, P513, DOI 10.1046/j.1432-1327.1998.2520513.x; JACKSON FM, 1998, IN PRESS J GEN MICRO; Mitchell AG, 1997, J BIOL CHEM, V272, P28281, DOI 10.1074/jbc.272.45.28281; MITCHELL AG, 1995, J BIOL CHEM, V270, P29766; Napier JA, 1998, BIOCHEM J, V330, P611; Napier JA, 1997, BIOCHEM J, V328, P717; OKULEY J, 1994, PLANT CELL, V6, P147, DOI 10.1105/tpc.6.1.147; REDDY AS, 1993, PLANT MOL BIOL, V22, P293, DOI 10.1007/BF00014936; Sambrook J., 2002, MOL CLONING LAB MANU; Sayanova O, 1997, P NATL ACAD SCI USA, V94, P4211, DOI 10.1073/pnas.94.8.4211; SCHMIDT H, 1994, PLANT MOL BIOL, V26, P631, DOI 10.1007/BF00013749; SHANKLIN J, 1994, BIOCHEMISTRY-US, V33, P12787, DOI 10.1021/bi00209a009; SHIMIZU S, 1988, BIOCHEM BIOPH RES CO, V150, P335, DOI 10.1016/0006-291X(88)90525-6; SMITH MA, 1994, PLANT MOL BIOL, V25, P527, DOI 10.1007/BF00043880; SMITH MA, 1990, BIOCHEM J, V272, P23, DOI 10.1042/bj2720023; SMITH MA, 1992, BIOCHEM J, V287, P141, DOI 10.1042/bj2870141; SPERLING P, 1995, EUR J BIOCHEM, V232, P798, DOI 10.1111/j.1432-1033.1995.0798a.x; Tanaka T, 1996, LIPIDS, V31, P1173, DOI 10.1007/BF02524292	27	136	170	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19055	19059		10.1074/jbc.273.30.19055	http://dx.doi.org/10.1074/jbc.273.30.19055			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668087	Green Published, Green Accepted, hybrid			2022-12-25	WOS:000074974700054
J	Raben, N; Nagaraju, K; Lee, E; Kessler, P; Byrne, B; Lee, L; LaMarca, M; King, C; Ward, J; Sauer, B; Plotz, P				Raben, N; Nagaraju, K; Lee, E; Kessler, P; Byrne, B; Lee, L; LaMarca, M; King, C; Ward, J; Sauer, B; Plotz, P			Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; CELLS; EXPRESSION; THERAPY; MODELS; ENZYME; MOUSE; HEART; CDNA; SITE	We have used gene targeting to create a mouse model of glycogen storage disease type II, a disease in which distinct clinical phenotypes present at different ages. As in the severe human infantile disease (Pompe Syndrome), mice homozygous for disruption of the acid alpha-glucosidase gene (6(neo)/6(neo)) lack enzyme activity and begin to accumulate glycogen in cardiac and skeletal muscle lysosomes by 3 weeks of age, with a progressive increase thereafter. By 3.5 weeks of age, these mice have markedly reduced mobility and strength. They grow normally, however, reach adulthood, remain fertile, and, as in the human adult disease, older mice accumulate glycogen in the diaphragm. By 8-9 months of age animals develop obvious muscle wasting and a weak, waddling gait. This model, therefore, recapitulates critical features of both the infantile and the adult forms of the disease at a pace suitable for the evaluation of enzyme or gene replacement. In contrast, in a second model, mutant mice with deletion of exon 6 (Delta 6/Delta 6), like the recently published acid cu-glucosidase knockout with disruption of exon 13 (Bijvoet, A. G., van de Kamp, E. H., Kroos, M., Ding, J. H., Yang, B. Z., Visser, P., Bakker, C. E., Verbeet, M. P., Oostra, B. A., Reuser, A. J. J., and van der Ploeg, A. T. (1998) Hum. Mel. Genet. 7, 53-62), have unimpaired strength and mobility (up to 6.5 months of age) despite indistinguishable biochemical and pathological changes. The genetic background of the mouse strains appears to contribute to the differences among the three models.	NIAMS, Arthrit & Rheumatism Branch, NIH, Bethesda, MD 20892 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21218 USA; Univ Miami, Sch Med, Dept Mol Genet & Microbiol, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Pediat, Miami, FL 33101 USA; NIMH, Clin Neurosci Branch, Bethesda, MD 20892 USA; NCI, Anim Sci Branch, Off Lab Anim Resources, NIH, Bethesda, MD 20892 USA; NIDDK, Biochem & Metab Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Johns Hopkins University; University of Miami; University of Miami; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Raben, N (corresponding author), NIAMS, Arthrit & Rheumatism Branch, NIH, Bldg 10,Rm 9N244,9000 Rockville Pike, Bethesda, MD 20892 USA.	rabenn@arb.niams.nih.gov	Nagaraju, Kanneboyina/AAV-7684-2021; Nagaraju, Kanneboyina/ABA-6525-2021					Adams EM, 1997, HUM MUTAT, V10, P128, DOI 10.1002/(SICI)1098-1004(1997)10:2<128::AID-HUMU5>3.0.CO;2-G; Bijvoet AGA, 1996, BBA-GENE STRUCT EXPR, V1308, P93, DOI 10.1016/0167-4781(96)00093-0; Bijvoet AGA, 1998, HUM MOL GENET, V7, P53, DOI 10.1093/hmg/7.1.53; Erickson RP, 1996, BIOESSAYS, V18, P993, DOI 10.1002/bies.950181209; HERMANS MMP, 1991, J BIOL CHEM, V266, P13507; Hirschhorn R., 1995, METABOLIC MOL BASES, P2443; Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082; Kikuchi T, 1998, J CLIN INVEST, V101, P827, DOI 10.1172/JCI1722; KROOS MA, 1995, J MED GENET, V32, P836, DOI 10.1136/jmg.32.10.836-a; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; MARTINIUK F, 1986, P NATL ACAD SCI USA, V83, P9641, DOI 10.1073/pnas.83.24.9641; NEUFELD EF, 1991, ANNU REV BIOCHEM, V60, P257, DOI 10.1146/annurev.biochem.60.1.257; Pauly DF, 1998, GENE THER, V5, P473, DOI 10.1038/sj.gt.3300609; RABEN N, 1995, MUSCLE NERVE, pS70; REUSER AJJ, 1995, MUSCLE NERVE, pS61; SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166; VANDERPLOEG AT, 1988, PEDIATR RES, V24, P90, DOI 10.1203/00006450-198807000-00021; VANDERPLOEG AT, 1988, J NEUROL, V235, P392; VANDERPLOEG AT, 1991, J CLIN INVEST, V87, P513, DOI 10.1172/JCI115025; VanHove JLK, 1996, P NATL ACAD SCI USA, V93, P65, DOI 10.1073/pnas.93.1.65; Wilson JM, 1996, J CLIN INVEST, V97, P1138, DOI 10.1172/JCI118527; YAMANAKA S, 1994, P NATL ACAD SCI USA, V91, P9975, DOI 10.1073/pnas.91.21.9975; Zaretsky JZ, 1997, HUM GENE THER, V8, P1555, DOI 10.1089/hum.1997.8.13-1555	23	212	237	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19086	19092		10.1074/jbc.273.30.19086	http://dx.doi.org/10.1074/jbc.273.30.19086			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668092	hybrid			2022-12-25	WOS:000074974700059
J	Schmidt, C; Stehling, P; Schnitzer, J; Reutter, W; Horstkorte, R				Schmidt, C; Stehling, P; Schnitzer, J; Reutter, W; Horstkorte, R			Biochemical engineering of neural cell surfaces by the synthetic N-propanoyl-substituted neuraminic acid precursor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY A2B5; SIALIC ACIDS; NEURITE OUTGROWTH; GROWTH-FACTOR; RAT; DIFFERENTIATION; LINE; TRANSPLANTATION; MIGRATION; INTEGRIN	Sialylation of glycoproteins and glycolipids plays an important role during development, regeneration, and pathogenesis of diseases, During times of intense plasticity within the nervous system, such as development and regeneration, sialylation of neural cells is distinct from the time of its maintenance, In this study, a synthetic precursor of neuraminic acid, N-propanoylmannosamine (N-propanoyl neuraminic acid precursor (P-NAP)), is applied to the culture medium of oligodendrocyte progenitor cells, microglia, astrocytes, and neurons from neonatal rat brains to alter sialylation of glycoconjugates within these cells. P-NAP is metabolized and incorporated as N-propanoyl neuraminic acid into glycoproteins of the cell membrane. P-NAP stimulates the proliferation of astrocytes and microglia but not of oligodendrocyte progenitor in vitro. However, P-NAP increases the number of oligodendrocyte progenitor cells expressing the early oligodendroglial surface marker A2B5 epitope. In the presence of P-NAP, cerebellar neurons (but not astrocytes) in microexplant cultures start to express the oligodendroglial progenitor marker A2B5 epitope, which is normally undetectable on these cells. The controls, which were performed in the absence of any additive or in the presence of the physiological precursor of neuraminic acid, N-acetylmannosamine, did not show any increase in A2B5 expression.	Free Univ Berlin, Inst Mol Biol & Biochem, D-14195 Berlin, Germany; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany	Free University of Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Horstkorte, R (corresponding author), Free Univ Berlin, Inst Mol Biol & Biochem, Arnimallee 22, D-14195 Berlin, Germany.		Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763				ASHTON FA, 1990, BRAIN RES, V529, P349, DOI 10.1016/0006-8993(90)90850-B; BOGLER O, 1990, P NATL ACAD SCI USA, V87, P6368, DOI 10.1073/pnas.87.16.6368; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; CAMERON RS, 1991, GLIA, V4, P124, DOI 10.1002/glia.440040204; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DUBOIS C, 1990, J BIOL CHEM, V265, P2797; EISENBARTH GS, 1984, P NATL ACAD SCI USA, V75, P4913; FISCHER G, 1986, J NEUROSCI, V6, P605; FRANK MM, 1992, CURR OPIN IMMUNOL, V4, P14, DOI 10.1016/S0952-7915(92)90117-W; FREDMAN P, 1984, ARCH BIOCHEM BIOPHYS, V233, P661, DOI 10.1016/0003-9861(84)90492-2; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HARA S, 1987, ANAL BIOCHEM, V164, P138, DOI 10.1016/0003-2697(87)90377-0; KAYSER H, 1992, FEBS LETT, V301, P137, DOI 10.1016/0014-5793(92)81233-C; KAYSER H, 1992, J BIOL CHEM, V267, P16934; KEPPLER OT, 1995, J BIOL CHEM, V270, P1308, DOI 10.1074/jbc.270.3.1308; KLUGE A, 1992, EUR J CELL BIOL, V59, P12; LILLIEN LE, 1990, NEURON, V5, P111, DOI 10.1016/0896-6273(90)90301-U; Mahal LK, 1997, SCIENCE, V276, P1125, DOI 10.1126/science.276.5315.1125; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MERI S, 1994, BIOCHEM BIOPH RES CO, V198, P52, DOI 10.1006/bbrc.1994.1008; NOBLE M, 1988, NATURE, V333, P560, DOI 10.1038/333560a0; Park TU, 1997, BIOCHEM BIOPH RES CO, V234, P686, DOI 10.1006/bbrc.1997.6700; PILATTE Y, 1993, GLYCOBIOLOGY, V3, P201, DOI 10.1093/glycob/3.3.201; RATHJEN FG, 1984, EMBO J, V3, P1; SCHAUER R, 1982, ADV CARBOHYD CHEM BI, V40, P131, DOI 10.1016/S0065-2318(08)60109-2; Schmidt C, 1997, GLIA, V20, P284; Schmidt C, 1996, J NEUROSCI RES, V43, P12, DOI 10.1002/jnr.490430103; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; VIGNAIS L, 1993, INT J DEV NEUROSCI, V11, P603, DOI 10.1016/0736-5748(93)90049-J; WARRINGTON AE, 1993, J NEUROSCI RES, V34, P1, DOI 10.1002/jnr.490340102; Wieser JR, 1996, FEBS LETT, V395, P170, DOI 10.1016/0014-5793(96)01029-0; Wolswijk Guus, 1995, P149	32	72	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19146	19152		10.1074/jbc.273.30.19146	http://dx.doi.org/10.1074/jbc.273.30.19146			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668100	hybrid			2022-12-25	WOS:000074974700067
J	Wu, HH; Momand, J				Wu, HH; Momand, J			Pyrrolidine dithiocarbamate prevents p53 activation and promotes p53 cysteine residue oxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; PROTEIN S-THIOLATION; DNA-BINDING FUNCTION; CELL-CYCLE; NUCLEAR-LOCALIZATION; GROWTH ARREST; DIHYDRORHODAMINE 123; E6 ONCOPROTEIN; INTACT-CELLS; WILD-TYPE	Pyrrolidine dithiocarbamate (PDTC) is a thiol compound widely used to study the activation of redox-sensitive transcription factors. Although normally used as an antioxidant, PDTC has been shown to exert pro oxidant activity on proteins both in vitro and in vivo. Be cause p53 redox status has been shown to alter its DNA binding capability, we decided to test the effect of PDTC on p53 activation. In this communication, we report that PDTC inhibits the activation of temperature sensitive murine p53(Val-135) (TSp53) in the transformed rat embryo fibroblast line, Al-5, as well as wild-type human p53 in the normal diploid fibroblast line, WS1neo. In A1-5 cells, PDTC abrogated UV- and temperature shift-induced TSp53 nuclear translocation and p53-mediated transactivation of MDM2. PDTC also blocked UV-induced accumulation of wild-type p53 in WS1neo cells. Continual presence of PDTC was required for its effect as both W-induced nuclear translocation and accumulation resumed after PDTC removal. We next investigated whether PDTC treatment altered the p53 redox state. We found that PDTC increased p53 cysteine residue oxidation in vivo. This represents the first direct evidence showing that the p53 redox state can be altered in vivo and that increased oxidation correlates with its inability to perform its downstream functions.	City Hope Natl Med Ctr, Beckman Res Inst, Dept Cell & Tumor Biol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	Momand, J (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Cell & Tumor Biol, Duarte, CA 91010 USA.		Momand, Jamil/F-8154-2012					BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BAYER EA, 1987, ANAL BIOCHEM, V161, P262, DOI 10.1016/0003-2697(87)90450-7; Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; Dasgupta G, 1997, EXP CELL RES, V237, P29, DOI 10.1006/excr.1997.3766; DOVER R, 1994, J CELL SCI, V107, P1181; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GERWECK LG, 1984, ADV EXP MED BIOL, V180, P269; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; Gorman A, 1997, FEBS LETT, V404, P27, DOI 10.1016/S0014-5793(97)00069-0; HAINAUT P, 1993, CANCER RES, V53, P4469; HAINAUT P, 1995, ONCOGENE, V10, P27; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HENDERSON LM, 1993, EUR J BIOCHEM, V217, P973, DOI 10.1111/j.1432-1033.1993.tb18328.x; HEYDUK T, 1986, BIOCHIM BIOPHYS ACTA, V874, P337, DOI 10.1016/0167-4838(86)90033-6; Huang RP, 1996, J CELL BIOL, V133, P211, DOI 10.1083/jcb.133.1.211; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LEONARDO AD, 1994, GENE DEV, V8, P2540; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALZMAN W, 1984, MOL CELL BIOL, V4, P1689; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Martinez JD, 1997, CELL GROWTH DIFFER, V8, P941; MATTHEWS BW, 1967, NATURE, V214, P652, DOI 10.1038/214652a0; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1997, J CELL BIOCHEM, V64, P343; NOBEL CSI, 1995, J BIOL CHEM, V270, P26202, DOI 10.1074/jbc.270.44.26202; Orrenius S, 1996, BIOCHEM SOC T, V24, P1032, DOI 10.1042/bst0241032; Pearson GD, 1998, J BIOL CHEM, V273, P5431, DOI 10.1074/jbc.273.10.5431; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; RENZING J, 1995, ONCOGENE, V10, P1865; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; Saucedo LJ, 1998, CELL GROWTH DIFFER, V9, P119; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; Schlamp CL, 1997, J NATL CANCER I, V89, P1530, DOI 10.1093/jnci/89.20.1530; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; Sepehrnia B, 1996, J BIOL CHEM, V271, P15084, DOI 10.1074/jbc.271.25.15084; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SUGANO T, 1995, JPN J CANCER RES, V86, P415, DOI 10.1111/j.1349-7006.1995.tb03072.x; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; THOMAS JA, 1986, ANAL BIOCHEM, V157, P32, DOI 10.1016/0003-2697(86)90192-2; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; Verhaegh GW, 1997, MOL CELL BIOL, V17, P5699, DOI 10.1128/MCB.17.10.5699; Vichi P, 1997, EMBO J, V16, P7444, DOI 10.1093/emboj/16.24.7444; WINTERBOURN CC, 1993, FREE RADICAL BIO MED, V14, P85, DOI 10.1016/0891-5849(93)90512-S; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	68	67	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18898	18905		10.1074/jbc.273.30.18898	http://dx.doi.org/10.1074/jbc.273.30.18898			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668066	Green Published, hybrid			2022-12-25	WOS:000074974700033
J	Yeagley, D; Agati, JM; Quinn, PG				Yeagley, D; Agati, JM; Quinn, PG			A tripartite array of transcription factor binding sites mediates cAMP induction of phosphoenolpyruvate carboxykinase gene transcription and its inhibition by insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTER-REGULATORY REGION; PROTEIN-KINASE-A; GLYCOGEN-SYNTHASE KINASE-3-BETA; RESPONSE ELEMENT; GTP GENE; FACTOR CREB; PHOSPHATIDYLINOSITOL 3'-KINASE; MULTIHORMONAL REGULATION; PHOSPHORYLATED CREB; CELL-CYCLE	Transcription of the phosphoenolpyruvate carboxykinase (PEPCH) gene is induced upon activation of protein kinase A by cAMP and phosphorylation of Ser-133 in the transcription factor, cAMP-response element binding protein (CREB), and this induction is inhibited by insulin, We show here that insulin does not act by dephosphorylating CREB or by affecting heterologous kinases that phosphorylate Ser-129 or Ser-142 in CREB, In addition, insulin inhibition of minimal PEPCK promoter activity induced by CREB-GAL4 + protein kinase A was equivalent to inhibition of basal transcription, and thus cAMP-independent. On the other hand, nearly complete insulin inhibition is observed with the full PEPCK promoter (-600/+69), indicating that other factors are involved, The additional promoter elements required for induction by protein kinase A lie within -271 nucleotides of the start site and correspond to putative binding sites for activator protein-1 and CAAT/enhancer-binding protein (C/EBP), first identified by Roesler et al. (Roesler, W. J., McFie, P. J., and Puttick, D. M., (1993) J. Biol. Chem, 268, 3791-3796), This tripartite array of binding sites for CREB, C/EBP, and activator protein-1 (AP-1) factors forms a cAMP response unit that, together with the minimal promoter, can mediate both induction by cAMP and inhibition by insulin, Thus, for the PEPCH gene with a single CREB site, the CREB.CBP.RNA polymerase II complex cannot mediate either induction by cAMP or inhibition by insulin.	Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Quinn, PG (corresponding author), Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, 500 Univ Dr, Hershey, PA 17033 USA.				NIDDK NIH HHS [DK49600] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049600] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agati JM, 1998, J BIOL CHEM, V273, P18751, DOI 10.1074/jbc.273.30.18751; ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; ALBERTS AS, 1993, MOL CELL BIOL, V13, P2104, DOI 10.1128/MCB.13.4.2104; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BEGUM N, 1995, J BIOL CHEM, V270, P709, DOI 10.1074/jbc.270.2.709; Budworth PR, 1997, MOL ENDOCRINOL, V11, P1669, DOI 10.1210/me.11.11.1669; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; Carlone DL, 1997, MOL ENDOCRINOL, V11, P292, DOI 10.1210/me.11.3.292; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CHU DTW, 1986, J BIOL CHEM, V261, P6848; CHU DTW, 1988, J BIOL CHEM, V263, P13007; COHEN P, 1992, TRENDS BIOCHEM SCI, V17, P408, DOI 10.1016/0968-0004(92)90010-7; COHEN P, 1992, BIOCHEM SOC T, V20, P671, DOI 10.1042/bst0200671; CORBIN JD, 1978, J BIOL CHEM, V253, P3997; CORBIN JD, 1988, ADV SEC MESS PHOSPH, V21, P75; Cross DAE, 1997, FEBS LETT, V406, P211, DOI 10.1016/S0014-5793(97)00240-8; DENTON RM, 1992, BIOCHEM SOC T, V20, P659, DOI 10.1042/bst0200659; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; GRANNER D, 1990, J BIOL CHEM, V265, P10173; HADARI YR, 1992, J BIOL CHEM, V267, P17483; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HANSON RW, 1972, AM J CLIN NUTR, V25, P1010; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HURST HC, 1990, MOL CELL BIOL, V10, P6192, DOI 10.1128/MCB.10.12.6192; Klemm DJ, 1998, J BIOL CHEM, V273, P917, DOI 10.1074/jbc.273.2.917; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LIU J, 1991, MOL CELL BIOCHEM, V104, P89; LIU JS, 1991, J BIOL CHEM, V266, P19095; LUCAS PC, 1991, P NATL ACAD SCI USA, V88, P2184, DOI 10.1073/pnas.88.6.2184; MAGNUSON MA, 1987, J BIOL CHEM, V262, P14917; MAURER RA, 1989, J BIOL CHEM, V264, P6870; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; Mendez R, 1997, MOL CELL BIOL, V17, P5184, DOI 10.1128/MCB.17.9.5184; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PRICE DJ, 1990, P NATL ACAD SCI USA, V87, P7944, DOI 10.1073/pnas.87.20.7944; QUINN PG, 1994, J BIOL CHEM, V269, P14375; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; QUINN PG, 1993, J BIOL CHEM, V268, P16999; ROESLER WJ, 1995, J BIOL CHEM, V270, P8225, DOI 10.1074/jbc.270.14.8225; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; ROESLER WJ, 1993, J BIOL CHEM, V268, P3791; Roesler WJ, 1996, J BIOL CHEM, V271, P8068, DOI 10.1074/jbc.271.14.8068; ROESLER WJ, 1994, J BIOL CHEM, V269, P14276; RUTTER GA, 1995, CURR BIOL, V5, P890, DOI 10.1016/S0960-9822(95)00179-5; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SHORT JM, 1986, J BIOL CHEM, V261, P9721; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; WALKER DH, 1992, MOL BIOL CELL, V3, P687, DOI 10.1091/mbc.3.6.687; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; WHITE MF, 1994, J BIOL CHEM, V269, P1; WYNSHAWBORIS A, 1986, J BIOL CHEM, V261, P9714; XING LP, 1995, J BIOL CHEM, V270, P17488, DOI 10.1074/jbc.270.29.17488; XING LP, 1993, MOL ENDOCRINOL, V7, P1484, DOI 10.1210/me.7.11.1484; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597	72	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18743	18750		10.1074/jbc.273.30.18743	http://dx.doi.org/10.1074/jbc.273.30.18743			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668047	hybrid			2022-12-25	WOS:000074974700014
J	Cens, T; Restituito, S; Vallentin, A; Charnet, P				Cens, T; Restituito, S; Vallentin, A; Charnet, P			Promotion and inhibition of L-type Ca2+ channel facilitation by distinct domains of the beta subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; NEURONAL CALCIUM CHANNELS; RAT VENTRICULAR MYOCYTES; SKELETAL-MUSCLE; SMOOTH-MUSCLE; CELLS; POTENTIATION; EXPRESSION; PHOSPHORYLATION; ACTIVATION	Ca2+ current potentiation by conditioning depolarization is a general mechanism by which excitable cells can control the level of Ca2+ entry during repetitive depolarizations. Several types of Ca2+ channels are sensitive to conditioning depolarization, however, using clearly distinguishable mechanisms. In the case of L-type Ca2+ channels, prepulse-induced current facilitation can only be recorded when the pore-forming alpha(1C) subunit is coexpressed with the auxiliary beta(1), beta(3), or beta(4), but not beta(2), subunit, These four beta subunits are composed of two conserved domains surrounded by central, N-terminal, and C-terminal variable regions. Using different deleted and chimeric forms of the beta(1) and beta(2) subunits, we have mapped essential sequences for L-type Ca2+ channel facilitation. A first sequence, located in the second conserved domain of all beta subunits, is responsible for the promotion of current facilitation by the beta subunit. A second sequence of 16 amino acids, located on the N-terminal tail of the beta(2) subunit, induces a transferable block of L-type current facilitation. Site-specific mutations reveal the essential inhibitory role played by three positive charges on this segment. The lack of prepulse-induced current facilitation recorded with some truncated forms of the beta(2) subunit suggests the existence of an additional inhibitory sequence in the beta(2) subunit.	Ctr Rech Biochim Macromol, CNRS, Unite Propre Rech 1086, F-34033 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Charnet, P (corresponding author), Ctr Rech Biochim Macromol, CNRS, Unite Propre Rech 1086, 1919 Route Mende,BP 5051, F-34033 Montpellier, France.	charnet@xerxes.crbm.cnrs-mop.fr	Cens, Thierry/M-3337-2017	Cens, Thierry/0000-0002-4109-2779; Charnet, Pierre/0000-0003-4692-528X				AdachiAkahane S, 1996, J GEN PHYSIOL, V108, P435, DOI 10.1085/jgp.108.5.435; ARTALEJO CR, 1990, NATURE, V348, P239, DOI 10.1038/348239a0; BOURINET E, 1994, EMBO J, V13, P5032, DOI 10.1002/j.1460-2075.1994.tb06832.x; Bourinet E, 1996, P NATL ACAD SCI USA, V93, P1486, DOI 10.1073/pnas.93.4.1486; Cens T, 1996, PFLUG ARCH EUR J PHY, V431, P771, DOI 10.1007/BF02253842; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; DEWAARD M, 1995, J BIOL CHEM, V270, P12056, DOI 10.1074/jbc.270.20.12056; Dolphin AC, 1996, TRENDS NEUROSCI, V19, P35, DOI 10.1016/0166-2236(96)81865-0; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; Fleig A, 1996, J PHYSIOL-LONDON, V496, P339, DOI 10.1113/jphysiol.1996.sp021689; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; JOHNSON BD, 1994, P NATL ACAD SCI USA, V91, P11492, DOI 10.1073/pnas.91.24.11492; KLEPPISCH T, 1994, EMBO J, V13, P2502, DOI 10.1002/j.1460-2075.1994.tb06538.x; MCCARRON JG, 1992, NATURE, V357, P74, DOI 10.1038/357074a0; McCleskey Edwin W., 1994, Current Opinion in Neurobiology, V4, P304, DOI 10.1016/0959-4388(94)90090-6; OLCESE R, 1994, NEURON, V13, P1433, DOI 10.1016/0896-6273(94)90428-6; Parri HR, 1996, J NEUROSCI, V16, P4890; PELZER D, 1990, REV PHYSIOL BIOCH P, V114, P107; PEREZREYES E, 1995, KIDNEY INT, V48, P1111, DOI 10.1038/ki.1995.395; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; PIETROBON D, 1990, NATURE, V346, P651, DOI 10.1038/346651a0; PRAGNELL M, 1991, FEBS LETT, V291, P253, DOI 10.1016/0014-5793(91)81296-K; RICHARD S, 1990, AM J PHYSIOL, V258, pH1872, DOI 10.1152/ajpheart.1990.258.6.H1872; RICHARD S, 1993, J PHYSIOL-LONDON, V462, P197, DOI 10.1113/jphysiol.1993.sp019551; SCULPTOREANU A, 1995, AM J PHYSIOL-CELL PH, V269, pC725, DOI 10.1152/ajpcell.1995.269.3.C725; SCULPTOREANU A, 1993, NATURE, V364, P240, DOI 10.1038/364240a0; SCULPTOREANU A, 1993, P NATL ACAD SCI USA, V90, P10135, DOI 10.1073/pnas.90.21.10135; Snutch T P, 1992, Curr Opin Neurobiol, V2, P247, DOI 10.1016/0959-4388(92)90111-W; Stanley EF, 1997, NATURE, V385, P340, DOI 10.1038/385340a0; TOMLINSON WJ, 1993, NEUROPHARMACOLOGY, V32, P1117, DOI 10.1016/0028-3908(93)90006-O; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; WEI XY, 1994, J BIOL CHEM, V269, P1635; WEI XY, 1994, BIOPHYS J, V66, pA128	33	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18308	18315		10.1074/jbc.273.29.18308	http://dx.doi.org/10.1074/jbc.273.29.18308			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660796	hybrid			2022-12-25	WOS:000074828500051
J	Currie, RA				Currie, RA			Biochemical characterization of the NF-Y transcription factor complex during B lymphocyte development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-II GENES; CCAAT-BINDING PROTEIN; DNA-BINDING; HETEROLOGOUS SUBUNITS; SEQUENCE IDENTITY; MOLECULAR-CLONING; HUMAN COACTIVATOR; NUCLEAR FACTORS; PLASMA-CELLS; DRA PROMOTER	The transcription factor, NF-Y, plays a critical role in tissue-specific major histocompatibility complex class II gene transcription. In this report the biochemical properties of the heterotrimeric NF-Y complex have been characterized during stage-specific B-cell development, and in several class II- mutant B-cell lines, which represent distinct bare lymphocyte syndrome class II genetic complementation groups. The NF-Y complex derived from class II+ mature B-cells bound with high affinity to anion exchangers, and eluted as an intact trimeric complex, whereas, NF-Y derived from class II plasma B-cells, and from bare lymphocyte syndrome group II cell lines, RJ2.2.5 and RM3, dissociated into discrete NF-YA and NF-YB:C subunit fractions. Recombination of the MPC11 plasma B-cell derived NF-P A:B:C complex with the low molecular mass protein fraction, NF-Y-associated factors (YAFs), derived from mature A20 B cell nuclei, conferred high affinity anion exchange binding to NF-Y as an intact trimeric complex. Recombination of the native NF-YA:B:C complex with the transcriptional cofactor, PC4, likewise conferred high affinity NF-Y binding to anion exchangers, and stabilized NF-Y interaction with CCAAT-box DNA motifs in vitro. Interaction between PC4 and NF-Y was mapped to the C-terminal region of PC4, and the subunit interaction subdomain of the highly conserved DNA binding-subunit interaction domain (DBD) of NF-YA. These results suggest that in class II+ mature B-cells NF-Y is associated with the protein cofactor, PC4, which may play an important role in NF-Y-mediated transcriptional control of class II genes.	Wheeler Inst Biomed Res, Lab Gene Regulat, Huntington, NY 11743 USA		Currie, RA (corresponding author), Wheeler Inst Biomed Res, Lab Gene Regulat, Huntington, NY 11743 USA.				NIAID NIH HHS [AI37686] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI037686] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALLARD DW, 1988, J BIOL CHEM, V263, P8450; BECKER DM, 1991, P NATL ACAD SCI USA, V88, P1968, DOI 10.1073/pnas.88.5.1968; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; Boss JM, 1997, CURR OPIN IMMUNOL, V9, P107, DOI 10.1016/S0952-7915(97)80166-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG CH, 1994, J EXP MED, V180, P1367, DOI 10.1084/jem.180.4.1367; CHODOSH LA, 1988, CELL, V53, P25, DOI 10.1016/0092-8674(88)90484-9; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CRESSWELL P, 1994, CURR BIOL, V4, P541, DOI 10.1016/S0960-9822(00)00119-6; Currie RA, 1997, J BIOL CHEM, V272, P30880, DOI 10.1074/jbc.272.49.30880; DANILITION SL, 1991, NUCLEIC ACIDS RES, V19, P6913, DOI 10.1093/nar/19.24.6913; DEDRICK RL, 1990, MOL CELL BIOL, V10, P593, DOI 10.1128/MCB.10.2.593; DELLABONA P, 1989, J IMMUNOL, V142, P2902; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dooley KA, 1998, J BIOL CHEM, V273, P1349, DOI 10.1074/jbc.273.3.1349; DORN A, 1987, P NATL ACAD SCI USA, V84, P6249, DOI 10.1073/pnas.84.17.6249; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; Fontes JD, 1996, J EXP MED, V183, P2517, DOI 10.1084/jem.183.6.2517; GE H, 1994, P NATL ACAD SCI USA, V91, P12691, DOI 10.1073/pnas.91.26.12691; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GUARENTE L, 1993, TRANSCRIPTIONAL REGU, V2, P1007; HATAMOCHI A, 1988, J BIOL CHEM, V263, P5940; KAISER K, 1995, EMBO J, V14, P3520, DOI 10.1002/j.1460-2075.1995.tb07358.x; KARA CJ, 1990, MOL CELL BIOL, V10, P1347, DOI 10.1128/MCB.10.4.1347; Knaus R, 1996, EMBO J, V15, P1933, DOI 10.1002/j.1460-2075.1996.tb00544.x; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LATRON F, 1988, P NATL ACAD SCI USA, V85, P2229, DOI 10.1073/pnas.85.7.2229; LI XY, 1992, NUCLEIC ACIDS RES, V20, P1087, DOI 10.1093/nar/20.5.1087; LIOU HC, 1990, SCIENCE, V247, P1581, DOI 10.1126/science.2321018; Mach B, 1996, ANNU REV IMMUNOL, V14, P301, DOI 10.1146/annurev.immunol.14.1.301; MAITY SN, 1990, P NATL ACAD SCI USA, V87, P5378, DOI 10.1073/pnas.87.14.5378; MAITY SN, 1992, J BIOL CHEM, V267, P8286; MAITY SN, 1992, J BIOL CHEM, V267, P16574; Malik S, 1998, P NATL ACAD SCI USA, V95, P2192, DOI 10.1073/pnas.95.5.2192; MCNABB DS, 1995, GENE DEV, V9, P47, DOI 10.1101/gad.9.1.47; MILOS PM, 1992, GENE DEV, V6, P991, DOI 10.1101/gad.6.6.991; MIWA K, 1987, P NATL ACAD SCI USA, V84, P4939, DOI 10.1073/pnas.84.14.4939; PARKER RC, 1977, P NATL ACAD SCI USA, V74, P851, DOI 10.1073/pnas.74.3.851; REITH W, 1994, MOL CELL BIOL, V14, P1230, DOI 10.1128/MCB.14.2.1230; REITH W, 1994, P NATL ACAD SCI USA, V91, P554, DOI 10.1073/pnas.91.2.554; REITH W, 1994, P NATL ACAD SCI USA, V91, P20020; Sambrook J., 2002, MOL CLONING LAB MANU; SCHROTER H, 1985, EMBO J, V4, P3867, DOI 10.1002/j.1460-2075.1985.tb04159.x; SILACCI P, 1994, J EXP MED, V180, P1329, DOI 10.1084/jem.180.4.1329; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; SOMA GI, 1984, BIOCHEM BIOPH RES CO, V124, P164, DOI 10.1016/0006-291X(84)90931-8; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1995, GENE DEV, V9, P1021, DOI 10.1101/gad.9.9.1021; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; TSANG SY, 1990, MOL CELL BIOL, V10, P711, DOI 10.1128/MCB.10.2.711; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; VILEN BJ, 1991, MOL CELL BIOL, V11, P2406, DOI 10.1128/MCB.11.5.2406; VIVILLE S, 1991, J IMMUNOL, V146, P3211; VUORIO T, 1990, J BIOL CHEM, V265, P22480; Werten S, 1998, J MOL BIOL, V276, P367, DOI 10.1006/jmbi.1997.1534; WRIGHT KL, 1995, J BIOL CHEM, V270, P20978, DOI 10.1074/jbc.270.36.20978; XING YY, 1994, P NATL ACAD SCI USA, V91, P3009, DOI 10.1073/pnas.91.8.3009	60	17	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18220	18229		10.1074/jbc.273.29.18220	http://dx.doi.org/10.1074/jbc.273.29.18220			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660784	hybrid			2022-12-25	WOS:000074828500039
J	Dufour, C; Weinberger, RP; Schevzov, G; Jeffrey, PL; Gunning, P				Dufour, C; Weinberger, RP; Schevzov, G; Jeffrey, PL; Gunning, P			Splicing of two internal and four carboxyl-terminal alternative exons in nonmuscle tropomyosin 5 pre-mRNA is independently regulated during development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; CYTOSKELETAL TROPOMYOSIN; FUNCTIONAL DOMAINS; PREMESSENGER RNA; GENE-EXPRESSION; SR PROTEINS; CDNA CLONES; ISOFORMS; FIBROBLAST; MUSCLE	Four nonmuscle tropomyosin isoforms have been reported to be produced from the rat Tm5 gene by alternative splicing (Beisel, K, W., and Kennedy, J. E, (1994) Gene (Amst,) 145, 251-256), In order to detect additional isoforms that might be expressed from that gene, we used reverse transcriptase-polymerase chain reaction assays and evaluated the presence of all product combinations of two alternative internal exons (6a and 6b) and four carboxyl-terminal exons (9a, 9b, 9c, and 9d) in developing and adult rat brain. We identified five different combinations for exon 9 (9a + 9b, 9a + 9c, 9a + 9d, 9c, and 9d), and the exon combinations 9a + 9c and 9a + 9d were previously unreported. Each of these combinations existed with both exon 6a and exon 6b, Thus, the rat brain generates at least 10 different isoforms from the Tm5 gene. Northern blot hybridization with alternative exon specific probes revealed that these isoforms were also expressed in a number of different adult rat tissues, although some exons are preferentially expressed in particular tissues. Studies of regulation of the 10 different Tm5 isoform mRNAs during rat brain development indicated that no two isoforms are coordinately accumulated. Furthermore, there is a developmental switch in the use of exon 6a to exon 6b from embryonic to adult isoforms, TM5 protein isoforms show a differential localization in the adult cerebellum.	New Childrens Hosp, Oncol Res Unit, Parramatta, NSW 2124, Australia; Childrens Med Res Inst, Cell Biol Unit, Wentworthville, NSW 2145, Australia; Childrens Med Res Inst, Dev Neurobiol Unit, Wentworthville, NSW 2145, Australia; Univ Sydney, Dept Paediat & Child Hlth, Sydney, NSW 2006, Australia	Children's Medical Research Institute - Australia; Children's Medical Research Institute - Australia; University of Sydney	Gunning, P (corresponding author), New Childrens Hosp, Oncol Res Unit, Clin Sci Bldg,POB 3515, Parramatta, NSW 2124, Australia.		Schevzov, Galina/G-5117-2013; Gunning, Peter W/E-9058-2010	Schevzov, Galina/0000-0002-0793-2279; Gunning, Peter/0000-0003-0833-3128				BEISEL NW, 1994, GENE, V145, P251; BOYD J, 1995, P NATL ACAD SCI USA, V92, P11534, DOI 10.1073/pnas.92.25.11534; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; CHO YJ, 1991, P NATL ACAD SCI USA, V88, P10153, DOI 10.1073/pnas.88.22.10153; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAYTON L, 1988, J MOL BIOL, V201, P507, DOI 10.1016/0022-2836(88)90633-X; ERDELYI M, 1995, NATURE, V377, P524, DOI 10.1038/377524a0; FU XD, 1995, RNA, V1, P663; GALLEGO ME, 1992, MOL CELL BIOL, V12, P5415, DOI 10.1128/MCB.12.12.5415; Gallego ME, 1997, EMBO J, V16, P1772, DOI 10.1093/emboj/16.7.1772; GIMONA M, 1995, P NATL ACAD SCI USA, V92, P9776, DOI 10.1073/pnas.92.21.9776; GOODWIN LO, 1991, J BIOL CHEM, V266, P8408; GOUXPELLETAN M, 1990, EMBO J, V9, P241, DOI 10.1002/j.1460-2075.1990.tb08101.x; GRAHAM IR, 1992, MOL CELL BIOL, V12, P3872, DOI 10.1128/MCB.12.9.3872; GUNNING P, 1990, DEV BIOL, V138, P443, DOI 10.1016/0012-1606(90)90210-A; Gunning P, 1997, ANAT EMBRYOL, V195, P311, DOI 10.1007/s004290050050; HAILSTONES D, 1994, THESIS U SYDNEY SYDN; Hammell RL, 1996, J BIOL CHEM, V271, P4236; Hammell RL, 1997, J BIOL CHEM, V272, P22409, DOI 10.1074/jbc.272.36.22409; HANNAN AJ, 1995, MOL CELL NEUROSCI, V6, P397, DOI 10.1006/mcne.1995.1030; HARADA Y, 1995, J BIOCHEM-TOKYO, V118, P780, DOI 10.1093/oxfordjournals.jbchem.a124980; HELFMAN DM, 1986, MOL CELL BIOL, V6, P3582, DOI 10.1128/MCB.6.11.3582; ISHAKAWA R, 1989, J BIOL CHEM, V264, P7490; Kislauskis EH, 1997, J CELL BIOL, V136, P1263, DOI 10.1083/jcb.136.6.1263; LEAVITT J, 1987, MOL CELL BIOL, V7, P2467, DOI 10.1128/MCB.7.7.2467; LEESMILLER JP, 1991, BIOESSAYS, V13, P429, DOI 10.1002/bies.950130902; LEESMILLER JP, 1990, MOL CELL BIOL, V10, P1729, DOI 10.1128/MCB.10.4.1729; LIN CH, 1995, RNA, V1, P234; LIN JJC, 1988, J CELL BIOL, V107, P563, DOI 10.1083/jcb.107.2.563; MACLEOD AR, 1988, MOL CELL BIOL, V8, P433, DOI 10.1128/MCB.8.1.433; MACLEOD AR, 1986, NUCLEIC ACIDS RES, V14, P8413, DOI 10.1093/nar/14.21.8413; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; MUTHUCHAMY M, 1993, MOL CELL BIOL, V13, P3311, DOI 10.1128/MCB.13.6.3311; NOVY RE, 1993, CELL MOTIL CYTOSKEL, V25, P267, DOI 10.1002/cm.970250307; PITTENGER MF, 1995, J CELL SCI, V108, P3253; PITTENGER MF, 1992, J CELL BIOL, V118, P841, DOI 10.1083/jcb.118.4.841; PITTENGER MF, 1994, CURR OPIN CELL BIOL, V6, P96, DOI 10.1016/0955-0674(94)90122-8; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; RIO DC, 1993, CURR OPIN GENET DEV, V3, P574, DOI 10.1016/0959-437X(93)90093-5; RUIZOPAZO N, 1987, J BIOL CHEM, V262, P4755; Sambrook J., 2002, MOL CLONING LAB MANU; Schevzov G, 1997, MOL CELL NEUROSCI, V8, P439, DOI 10.1006/mcne.1997.0599; SCHEVZOV G, 1993, J CELL BIOL, V121, P811, DOI 10.1083/jcb.121.4.811; SINGER RH, 1993, CURR BIOL, V3, P719, DOI 10.1016/0960-9822(93)90079-4; TAKENAGA K, 1990, BIOCHIM BIOPHYS ACTA, V1087, P101, DOI 10.1016/0167-4781(90)90129-P; TemmGrove CJ, 1996, CELL MOTIL CYTOSKEL, V33, P223, DOI 10.1002/(SICI)1097-0169(1996)33:3<223::AID-CM6>3.0.CO;2-B; Tetzlaff MT, 1996, EMBO J, V15, P1247, DOI 10.1002/j.1460-2075.1996.tb00466.x; WANG YC, 1992, J BIOL CHEM, V267, P2728; WANG YC, 1992, J BIOL CHEM, V267, P12004; WARREN KS, 1995, J CELL BIOL, V129, P697, DOI 10.1083/jcb.129.3.697; Weinberger R, 1996, J NEUROSCI, V16, P238; YAMAWAKIKATAOKA Y, 1987, J BIOL CHEM, V262, P10791; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799	53	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18547	18555		10.1074/jbc.273.29.18547	http://dx.doi.org/10.1074/jbc.273.29.18547			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660825	hybrid			2022-12-25	WOS:000074828500080
J	Habib, T; Hejna, JA; Moses, RE; Decker, SJ				Habib, T; Hejna, JA; Moses, RE; Decker, SJ			Growth factors and insulin stimulate tyrosine phosphorylation of the 51C/SHIP2 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; KINASE; RECEPTOR; WORTMANNIN; ACTIVATION; INHIBITOR; CELLS; GRB2; SHC	Antibodies raised against the 51C/SHIP2 inositol polyphosphate 5'-phosphatase were used to examine the effects of growth factors and insulin on the metabolism of this protein. Immunoblot analysis revealed that the 51C/SHIP2 protein was widely expressed in fibroblast and nonhematopoietic tumor cell lines, unlike the SHIP protein, which was found only in cell lines of hematopoietic origin. The 51C/SHIP2 antiserum precipitated a protein of approximately 145 kDa along with an activity which hydrolyzed phosphatidylinositol 3,4,5-trisphosphate to phosphatidylinositol 3,4-bisphosphate. Tyrosine phosphorylation of the 51C/SHIP2 protein occurred in response to treatment of cells with epidermal growth (EGF), platelet-derived growth factor (PDGF), nerve growth factor (NGF), insulin-like growth factor-1 (IGF-1), or insulin. EGF and PDGF induced transient tyrosine phosphorylation of 51C/SHIP2, with maximal tyrosine phosphorylation occurring at 5-10 min following treatment and returning to near basal levels within 20 min, In contrast, treatment of cells with NGF, IGF-1, or insulin resulted in prolonged tyrosine phosphorylation of 51C/SHIP2 protein, with 40-80% maximal phosphorylation sustained for up to 2 h following agonist treatment. The kinetics of activation of the Akt/PKB protein kinase by the various factors correlated well with the kinetics of tyrosine phosphorylation of 51C/SHIP2, EGF, NGF, and PDGF stimulated the association of 51C/SHIP2 protein with the Shc adapter protein; however, no Shc could be detected in 51C/SHIP2-immune precipitates from cells treated with IGF-1 or insulin. The data suggest that 51C/SHIP2 may play a significant role in regulation of phosphatidylinositol 3'-kinase signaling by growth factors and insulin.	Parke Davis Pharmaceut Res Div, Dept Cell Biol, Ann Arbor, MI 48105 USA; Oregon Hlth Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA	Pfizer; Oregon Health & Science University	Decker, SJ (corresponding author), Parke Davis Pharmaceut Res Div, Dept Cell Biol, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.	deckers@aa.wl.com						Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Barthel A, 1998, BIOCHEM BIOPH RES CO, V243, P509, DOI 10.1006/bbrc.1998.8134; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DECKER SJ, 1984, MOL CELL BIOL, V4, P571, DOI 10.1128/MCB.4.4.571; DeuterReinhard M, 1997, MOL CELL BIOL, V17, P2559, DOI 10.1128/MCB.17.5.2559; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; FUKUI Y, 1991, ONCOGENE, V6, P407; GIRUIATO S, 1997, J BIOL CHEM, V272, P26857; GUINEBAULT C, 1995, J BIOL CHEM, V268, P13773; HANSEN SH, 1995, J BIOL CHEM, V270, P28425; HEJNA JA, 1995, GENOMICS, V29, P285, DOI 10.1006/geno.1995.1247; HU Q, 1995, SCIENCE, V370, P527; Jefferson AB, 1997, J BIOL CHEM, V272, P5983, DOI 10.1074/jbc.272.9.5983; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Liu L, 1997, J BIOL CHEM, V272, P10998; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; Liu L, 1997, J BIOL CHEM, V272, P8983; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Okada S, 1997, J BIOL CHEM, V272, P28042, DOI 10.1074/jbc.272.44.28042; OKADA T, 1994, J BIOL CHEM, V269, P3568; Osborne MA, 1996, J BIOL CHEM, V271, P29271, DOI 10.1074/jbc.271.46.29271; Pesesse X, 1997, BIOCHEM BIOPH RES CO, V239, P697, DOI 10.1006/bbrc.1997.7538; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; RUBIN CS, 1977, J BIOL CHEM, V252, P3554; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; TOKER A, 1994, J BIOL CHEM, V269, P32358; TOKER A, 1997, SCIENCE, V387, P673; Vanhaesebroeck B, 1996, CANCER SURV, V27, P249; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0	41	107	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18605	18609		10.1074/jbc.273.29.18605	http://dx.doi.org/10.1074/jbc.273.29.18605			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660833	hybrid			2022-12-25	WOS:000074828500088
J	Leenders, F; Vater, J; Stein, T; Franke, P				Leenders, F; Vater, J; Stein, T; Franke, P			Characterization of the binding site of the tripeptide intermediate D-phenylalanyl-L-prolyl-L-valine in gramicidin S biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHETASE; PEPTIDE	The tripeptide intermediate D-Phe-Pro-Val in the biosynthesis of gramicidin S was labeled by incorporation of either L-[C-14]phenylalanine or L-[C-14]valine in an in vitro biosynthetic assay. The gramicidin S synthetase S-tripeptide complex was first digested with CNBr and subsequently by Staphylococcus aureus V8 protease, The active site peptide carrying the radioactively labeled tripeptide was isolated in pure form by reversed phase high performance liquid chromatography technology and analyzed by liquid phase sequencing, mass spectrometry, and amino acid analysis, It was demonstrated that D-Phe-Pro-Val is attached to the 4'-phosphopantetheine cofactor at the thiolation center for valine of gramicidin S synthetase 2, In this way the attachment site of a peptide intermediate in nonribosomal peptide biosynthesis was identified for the first time. Our results are in full agreement with the multiple carrier model of nonribosomal peptide biosynthesis (Stein, T., Vater, J., Kruft, V., Otto, A., Wittmann-Liebold, B., Franke, P., Panico, M., McDowell, R., and Morris, H. R. (1996) J. Biol. Chem, 271, 15426-15435), which predicts that the growing peptide chain in the elongation process should always be bound to the thiotemplate site specific for its C-terminal amino acid component.	Tech Univ Berlin, Max Volmer Inst Biophys Chem & Biochem, D-10587 Berlin, Germany; Frei Univ Berlin, Inst Biochem, D-14195 Berlin, Germany	Technical University of Berlin; Free University of Berlin	Vater, J (corresponding author), Tech Univ Berlin, Max Volmer Inst Biophys Chem & Biochem, Franklinstr 29, D-10587 Berlin, Germany.			Vater, Joachim/0000-0002-4478-4244				BIEMANN K, 1990, METHOD ENZYMOL, V193, P455, DOI 10.1016/0076-6879(90)93433-L; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIU CW, 1984, THESIS TU BERLIN; GADOW A, 1983, EUR J BIOCHEM, V132, P229, DOI 10.1111/j.1432-1033.1983.tb07352.x; GEVERS W, 1969, P NATL ACAD SCI USA, V63, P1335, DOI 10.1073/pnas.63.4.1335; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; Kleinkauf H, 1996, EUR J BIOCHEM, V236, P335, DOI 10.1111/j.1432-1033.1996.00335.x; KURAHASHI K, 1974, ANNU REV BIOCHEM, V43, P445, DOI 10.1146/annurev.bi.43.070174.002305; Laland S G, 1973, Essays Biochem, V9, P31; LALAND SG, 1972, NATURE-NEW BIOL, V239, P43, DOI 10.1038/newbio239043a0; LIPMANN F, 1973, ACCOUNTS CHEM RES, V6, P361, DOI 10.1021/ar50071a001; Marahiel MA, 1997, CHEM REV, V97, P2651, DOI 10.1021/cr960029e; MORRIS HR, 1982, NATURE, V300, P643, DOI 10.1038/300643a0; MORRIS HR, 1981, BIOCHEM BIOPH RES CO, V101, P623, DOI 10.1016/0006-291X(81)91304-8; SCHLUMBOHM W, 1991, J BIOL CHEM, V266, P23135; STEIN T, 1994, FEBS LETT, V340, P39, DOI 10.1016/0014-5793(94)80169-X; STEIN T, 1996, J BIOL CHEM, V271, P15426; TURGAY K, 1992, MOL MICROBIOL, V6, P529, DOI 10.1111/j.1365-2958.1992.tb01498.x; VATER J, 1987, EUR J BIOCHEM, V163, P297, DOI 10.1111/j.1432-1033.1987.tb10800.x; Vater J, 1997, J PROTEIN CHEM, V16, P557, DOI 10.1023/A:1026386100259; VATER J, 1985, BIOCHEMISTRY-US, V24, P2022, DOI 10.1021/bi00329a033; VATER J, 1990, BIOCH PEPTIDE ANTIBI, P33; vonDohren H, 1997, CHEM REV, V97, P2675, DOI 10.1021/cr9600262; VONDOHREN H, 1982, PEPTIDE ANTIBIOTCS B, P169	24	4	4	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18011	18014		10.1074/jbc.273.29.18011	http://dx.doi.org/10.1074/jbc.273.29.18011			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660754	hybrid			2022-12-25	WOS:000074828500009
J	Mamane, Y; Hellauer, K; Rochon, MH; Turcotte, B				Mamane, Y; Hellauer, K; Rochon, MH; Turcotte, B			A linker region of the yeast zinc cluster protein Leu3p specifies binding to everted repeat DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZN(2)CYS(6) BINUCLEAR CLUSTER; UPSTREAM ACTIVATION SITES; SACCHAROMYCES-CEREVISIAE; CYC7 GENE; HAP1; SEQUENCE; TRANSCRIPTION; ELEMENTS; COMPLEX; GAL4	Feast zinc cluster proteins form a major class of yeast transcriptional regulators. They usually bind as homodimers to target DNA sequences, with each monomer recognizing a CGG triplet, Orientation and spacing between the CGG triplet specifies the recognition sequence for a given zinc cluster protein. For instance, Gal4p binds to inverted CGG triplets spaced by 11 base pairs whereas Ppr1p recognizes a similar motif but with a spacing of 6 base pairs. Hap1p, another member of this family, binds to a direct repeat consisting of two CGG triplets. Other members of this family, such as Leu3p, also recognize CGG triplets but when oriented in opposite directions, an everted repeat. This implies that the two zinc clusters of Leu3p bound to an everted repeat must be oriented in opposite directions to those of Gal4p or Ppr1p bound to inverted repeats. In order to map the domain responsible for proper orientation of the zinc clusters of Leu3p, we constructed chimeric proteins between Leu3p and Ppr1p and tested their binding to a Leu3p and a Ppr1p site, Our results show that the linker region, which bridges the zinc cluster to the dimerization domain, specifies binding of Leu3p to an everted repeat. We propose that the Leu3p linker projects the two zinc clusters of a Leu3p homodimer in opposite directions allowing binding to everted repeats.	McGill Univ, Royal Victoria Hosp, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 1A1, Canada	McGill University; Royal Victoria Hospital; McGill University	Turcotte, B (corresponding author), McGill Univ, Royal Victoria Hosp, Dept Med, 687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.							BAXEVANIS AD, 1993, CURR OPIN GENET DEV, V3, P278, DOI 10.1016/0959-437X(93)90035-N; BRAM RJ, 1986, EMBO J, V5, P603, DOI 10.1002/j.1460-2075.1986.tb04253.x; FRIDEN P, 1987, MOL CELL BIOL, V7, P2708, DOI 10.1128/MCB.7.8.2708; Gray WM, 1996, MOL CELL BIOL, V16, P347; GRONEMEYER H, 1987, EMBO J, V6, P3985, DOI 10.1002/j.1460-2075.1987.tb02741.x; Ha N, 1996, NUCLEIC ACIDS RES, V24, P1453, DOI 10.1093/nar/24.8.1453; HALVORSEN YDC, 1991, MOL CELL BIOL, V11, P1777, DOI 10.1128/MCB.11.4.1777; HARADA R, 1995, MOL CELL BIOL, V15, P129, DOI 10.1128/MCB.15.1.129; Hellauer K, 1996, MOL CELL BIOL, V16, P6096; Holmberg S, 1996, GENETICS, V144, P467; KAMMERER B, 1984, J MOL BIOL, V180, P239, DOI 10.1016/S0022-2836(84)80002-9; Karpichev IV, 1997, MOL CELL BIOL, V17, P69, DOI 10.1128/MCB.17.1.69; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lenouvel F, 1997, J BIOL CHEM, V272, P15521, DOI 10.1074/jbc.272.24.15521; Liang SD, 1996, MOL CELL BIOL, V16, P3773; LODI T, 1991, MOL CELL BIOL, V11, P3762, DOI 10.1128/MCB.11.7.3762; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MARMORSTEIN R, 1994, GENE DEV, V8, P2504, DOI 10.1101/gad.8.20.2504; Noel J, 1998, J BIOL CHEM, V273, P17463, DOI 10.1074/jbc.273.28.17463; Ozcan S, 1996, MOL CELL BIOL, V16, P5536; PFEIFER K, 1987, CELL, V49, P19, DOI 10.1016/0092-8674(87)90751-3; PREZANT T, 1987, MOL CELL BIOL, V7, P3252, DOI 10.1128/MCB.7.9.3252; REECE RJ, 1993, SCIENCE, V261, P909, DOI 10.1126/science.8346441; REMBOUTSIKA E, 1994, MOL CELL BIOL, V14, P5547, DOI 10.1128/MCB.14.8.5547; ROY A, 1990, MOL CELL BIOL, V10, P5257, DOI 10.1128/MCB.10.10.5257; Schjerling P, 1996, NUCLEIC ACIDS RES, V24, P4599, DOI 10.1093/nar/24.23.4599; SCHNEIDER JC, 1991, MOL CELL BIOL, V11, P4934, DOI 10.1128/MCB.11.10.4934; Schwabe JWR, 1997, NAT STRUCT BIOL, V4, P680, DOI 10.1038/nsb0997-680; Seraphin B, 1996, NUCLEIC ACIDS RES, V24, P3276, DOI 10.1093/nar/24.16.3276; SIDDIQUI AH, 1989, MOL CELL BIOL, V9, P4706, DOI 10.1128/MCB.9.11.4706; SIKORSKI RS, 1989, GENETICS, V122, P19; Swaminathan K, 1997, NAT STRUCT BIOL, V4, P751, DOI 10.1038/nsb0997-751; TINI M, 1993, GENE DEV, V7, P295, DOI 10.1101/gad.7.2.295; Todd RB, 1997, FUNGAL GENET BIOL, V21, P388, DOI 10.1006/fgbi.1997.0993; VALLEE BL, 1991, P NATL ACAD SCI USA, V88, P999, DOI 10.1073/pnas.88.3.999; VASHEE S, 1993, J BIOL CHEM, V268, P24699; WINKLER H, 1988, EMBO J, V7, P1799, DOI 10.1002/j.1460-2075.1988.tb03011.x; Zhang L, 1996, EMBO J, V15, P4676, DOI 10.1002/j.1460-2075.1996.tb00844.x; ZHANG L, 1994, GENE DEV, V8, P2110, DOI 10.1101/gad.8.17.2110; ZITOMER RS, 1987, MOL CELL BIOL, V7, P2212, DOI 10.1128/MCB.7.6.2212	41	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18556	18561		10.1074/jbc.273.29.18556	http://dx.doi.org/10.1074/jbc.273.29.18556			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660826	hybrid			2022-12-25	WOS:000074828500081
J	Siddhanta, A; Shields, D				Siddhanta, A; Shields, D			Secretory vesicle budding from the trans-Golgi network is mediated by phosphatidic acid levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; PHOSPHATIDYLINOSITOL TRANSFER PROTEIN; PLECKSTRIN-HOMOLOGY DOMAINS; PHOSPHOLIPASE-D; CELLS; PHOSPHOINOSITIDES; ACTIVATION; MEMBRANES; COMPLEX; KINASE	Phospholipid metabolism plays a central role in regulating vesicular traffic in the secretory pathway. In mammalian cells, activation of a Golgi-associated phospholipase D activity by ADP-ribosylation factor results in hydrolysis of phosphatidylcholine to phosphatidic acid (PA). This reaction has been proposed to stimulate nascent secretory vesicle budding from the trans-Golgi network. It is unclear whether PA itself or diacylglycerol (DAG), a metabolite implicated in yeast secretory vesicle formation, regulates budding. To distinguish between these possibilities we have used a permeabilized cell system supplemented with phospholipid-modifying enzymes that generate either DAG or PA. The data demonstrate that in mammalian cells accumulation of PA rather than DAG is a key step in regulating budding of secretory vesicles from the trans-Golgi network.	Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Shields, D (corresponding author), Albert Einstein Coll Med, Dept Dev & Mol Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021860, R37DK021860] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA13330] Funding Source: Medline; NIDDK NIH HHS [DK21860] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Austin CD, 1996, J CELL BIOL, V135, P1471, DOI 10.1083/jcb.135.6.1471; BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Chen YG, 1997, J CELL BIOL, V138, P495, DOI 10.1083/jcb.138.3.495; Chen YG, 1996, J BIOL CHEM, V271, P5297, DOI 10.1074/jbc.271.10.5297; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; Henderson RJ, 1992, LIPID ANAL PRACTICAL, P65; Herman Paul K., 1992, Trends in Cell Biology, V2, P363, DOI 10.1016/0962-8924(92)90048-R; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; Jones SM, 1997, J CELL BIOL, V139, P339, DOI 10.1083/jcb.139.2.339; Jones SM, 1998, SCIENCE, V279, P573, DOI 10.1126/science.279.5350.573; Kearns BG, 1997, NATURE, V387, P101, DOI 10.1038/387101a0; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; KTISTAKIS NT, 1995, P NATL ACAD SCI USA, V92, P4952, DOI 10.1073/pnas.92.11.4952; Martin TFJ, 1997, TRENDS CELL BIOL, V7, P271, DOI 10.1016/S0962-8924(97)01060-X; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; OHASHI M, 1995, NATURE, V377, P544, DOI 10.1038/377544a0; PERTILE P, 1995, J BIOL CHEM, V270, P5130, DOI 10.1074/jbc.270.10.5130; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; STACK JH, 1993, EMBO J, V12, P2195, DOI 10.1002/j.1460-2075.1993.tb05867.x; Tuscher O, 1997, FEBS LETT, V419, P271, DOI 10.1016/S0014-5793(97)01471-3; XU HX, 1993, J CELL BIOL, V122, P1169, DOI 10.1083/jcb.122.6.1169	26	124	125	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					17995	17998		10.1074/jbc.273.29.17995	http://dx.doi.org/10.1074/jbc.273.29.17995			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660750	hybrid			2022-12-25	WOS:000074828500005
J	Tang, H; Kerins, DM; Hao, Q; Inagami, T; Vaughan, DE				Tang, H; Kerins, DM; Hao, Q; Inagami, T; Vaughan, DE			The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; CELLULAR RECEPTOR; GROWTH-FACTOR; IN-VIVO; BINDING; SURFACE; SRC; EXPRESSION; INDUCTION; MIGRATION	Urokinase-type plasminogen activator (uPA) binds to cells via a specific glycosylphosphatidyilinositol-anchored receptor. Although occupancy of the uPA receptor (uPAR) has been shown to alter cellular function and to induce gene expression, the signaling mechanism has not been characterized. Urokinase induced an increase in the tyrosine phosphorylation of multiple proteins in bovine aortic endothelial cells. In contrast, low molecular weight uPA did not induce this response. Analysis by immunoblotting demonstrated tyrosine phosphorylation of focal adhesion kinase (FAK), the focal adhesion-associated proteins paxillin and p130(cas), and mitogen-activated protein kinase (MAPK) following the occupancy of the uPAR by uPA Treatment of cells with phosphatidylinositol-specific phospholipase C, which cleaves glycosylphosphatidylinositol-linked proteins from the cell surface, blocked the uPA-induced tyrosine phosphorylation of FAK, indicating the requirement of an intact uPAR on the cell surface. The uPA-induced activation of MAPK was completely inhibited by genistein, but not by 4-amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine, a specific inhibitor of Src family kinases, Thus, this study demonstrates a novel role for the uPAR in endothelial cell signal transduction that invoices the activation of FAK and MAPK, which are mediated by the receptor-binding domain of uPA. This may have important implications for the mechanism through which uPA influences cell migration and differentiation.	Vanderbilt Univ, Med Ctr, Sch Med, Dept Biochem,Div Cardiol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Vet Affairs Med Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Vaughan, DE (corresponding author), Vanderbilt Univ, Med Ctr, Sch Med, Dept Biochem,Div Cardiol, Rm 315 MRBII, Nashville, TN 37232 USA.	doug.vaughan@mcmail.vanderbilt.edu	Kerins, David/AAE-5692-2020		NHLBI NIH HHS [HL35323, HL14192, HL51387] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035323, R01HL051387, P50HL014192] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson R G, 1994, Semin Immunol, V6, P89, DOI 10.1006/smim.1994.1013; BARAK LS, 1980, P NATL ACAD SCI-BIOL, V77, P980, DOI 10.1073/pnas.77.2.980; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; BUSSO N, 1994, J CELL BIOL, V126, P259, DOI 10.1083/jcb.126.1.259; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CONESE M, 1995, BIOL CHEM H-S, V376, P143; DELROSSO M, 1993, BIOCHEM BIOPH RES CO, V190, P347, DOI 10.1006/bbrc.1993.1054; DUMLER I, 1993, FEBS LETT, V322, P37, DOI 10.1016/0014-5793(93)81106-A; Dumler I, 1998, J BIOL CHEM, V273, P315, DOI 10.1074/jbc.273.1.315; GYETKO MR, 1994, J CLIN INVEST, V93, P1380, DOI 10.1172/JCI117114; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; ILLC D, 1995, NATURE, V377, P539; Koshelnick Y, 1997, J BIOL CHEM, V272, P28563, DOI 10.1074/jbc.272.45.28563; KRATZSCHMAR J, 1993, GENE, V125, P177, DOI 10.1016/0378-1119(93)90325-W; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; LEWIS JM, 1995, MOL BIOL CELL, V6, P151, DOI 10.1091/mbc.6.2.151; Li CH, 1995, J BIOL CHEM, V270, P30282, DOI 10.1074/jbc.270.51.30282; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MCNEILL H, 1990, CELL REGUL, V1, P843, DOI 10.1091/mbc.1.11.843; MIGNATTI P, 1991, J CELL BIOL, V113, P1193, DOI 10.1083/jcb.113.5.1193; MYOHANEN HT, 1993, J HISTOCHEM CYTOCHEM, V41, P1291; ODEKON LE, 1992, J CELL PHYSIOL, V150, P258, DOI 10.1002/jcp.1041500206; PARK DJ, 1991, J BIOL CHEM, V266, P24237; PEPPER MS, 1987, J CELL BIOL, V105, P2535, DOI 10.1083/jcb.105.6.2535; PLOUG M, 1991, J BIOL CHEM, V266, P1926; POLLANEN J, 1988, J CELL BIOL, V106, P87, DOI 10.1083/jcb.106.1.87; RABBANI SA, 1992, J BIOL CHEM, V267, P14151; REUNING U, 1993, THROMB RES, V72, P59, DOI 10.1016/0049-3848(93)90173-L; REUNING U, 1992, ARTERIOSCLER THROMB, V12, P1161, DOI 10.1161/01.ATV.12.10.1161; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHLAEPFER DD, 1994, NATURE, V372, P786; Simon DI, 1996, BLOOD, V88, P3185, DOI 10.1182/blood.V88.8.3185.bloodjournal8883185; STAHL A, 1995, J CELL BIOL, V129, P335, DOI 10.1083/jcb.129.2.335; STEFANOVA I, 1991, J IMMUNOL, V147, P1587; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TAKAHASHI K, 1990, THROMB RES, P55; TESFAIGZI J, 1994, BIOTECHNIQUES, V17, P268; TURNER CE, 1993, J CELL SCI, V105, P637; VAUGHAN DE, 1995, J CLIN INVEST, V95, P995, DOI 10.1172/JCI117809; WALTZ DA, 1993, J CLIN INVEST, V91, P1541, DOI 10.1172/JCI116360; WEI Y, 1994, J BIOL CHEM, V269, P32380; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551	46	154	162	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18268	18272		10.1074/jbc.273.29.18268	http://dx.doi.org/10.1074/jbc.273.29.18268			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660790	hybrid			2022-12-25	WOS:000074828500045
J	Yuan, CS; Wnuk, SF; Robins, MJ; Borchardt, RT				Yuan, CS; Wnuk, SF; Robins, MJ; Borchardt, RT			A novel mechanism-based inhibitor (6 '-bromo-5 ',6 '-didehydro-6 '-deoxy-6 '-fluorohomoadenosine) that covalently modifies human placental S-adenosylhomocysteine hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-HOMOCYSTEINE HYDROLASE; SPECTRUM ANTIVIRAL AGENTS; NEPLANOCIN-A; INACTIVATION; NUCLEOSIDES; DESIGN; TARGET; METHYLTRANSFERASES; CHEMOTHERAPY; ANALOGS	Most inhibitors of S-adenosylhomocysteine (AdoHcy) hydrolase function as substrates for the "3'-oxidative activity" of the enzyme and convert the enzyme from its active form (NAD(+)) to its inactive form (NADH) (Liu, S,, Wolfe, M. S., and Borchardt, R. T. (1992) Antivir. Res. 19, 247-265), In this study, we describe the effects of a mechanism-based inhibitor, 6'-bromo-5',6'-didehydro-6'-deoxy-6'-fluorohomoadenosine (BDDFHA), which functions as a substrate for the "6'-hydrolytic activity" of the enzyme with subsequent formation of a covalent linkage with the enzyme. Incubation of human placental AdoHcy hydrolase with BDDFHA results in a maximum inactivation of 83% with the remaining enzyme activity exhibiting one-third of the k(cat) value of the native enzyme. This partial inactivation is concomitant with the release of both Br- and F- ions and the formation of adenine (Ade). The enzyme can be covalently labeled with [8-H-3]BDDFHA, resulting in a stoichiometry of 2 mol of BDDFHA/mol of the tetrameric enzyme. The H-3-labeled enzyme retains its original NAD(+)/NADH content. Tryptic digestion and subsequent protein sequencing of the [8-H-3]BDDFHA-labeled enzyme revealed that Arg(196) is the residue that is associated with the radiolabeled inhibitor. The partition ratio of the Ade formation (nonlethal event) to covalent acylation (lethal event) is approximately 1:1. From these experimental results, a possible mechanism by which BDDFHA inactivates AdoHcy hdyrolase is proposed: enzyme-mediated water addition at the C-6' position of BDDFHA followed by elimination of Br- ion results in the formation of homoAdo 6'-carboxyl fluoride (HACF). HACF then partitions in two ways: (a) attack by a proximal nucleophile (Arg196) to form an amide bond after expulsion of F- ion (lethal event) or (b) depurination to form Ade and hexose-derived 6-carboxyl fluoride (HDCF), which is further hydrolyzed to hexose-derived B-carboxylic acid (HDCA) and F- ion (nonlethal event).	Univ Kansas, Dept Biochem, Lawrence, KS 66047 USA; Brigham Young Univ, Dept Chem & Biochem, Provo, UT 84602 USA	University of Kansas; Brigham Young University	Borchardt, RT (corresponding author), Univ Kansas, Dept Pharmaceut Chem, Simons Res Labs, 2095 Constant Ave, Lawrence, KS 66047 USA.	borchardt@smissman.hbc.ukans.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029332] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-29332] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABELES RH, 1982, BIOCHEMISTRY-US, V21, P5557, DOI 10.1021/bi00265a027; BORCHARDT RT, 1980, J MED CHEM, V23, P347, DOI 10.1021/jm00178a001; BORCHERDING DR, 1988, J MED CHEM, V31, P1729, DOI 10.1021/jm00117a011; BORCHERDING DR, 1987, J ORG CHEM, V52, P5457, DOI 10.1021/jo00233a029; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COULTERKARIS DE, 1989, ANN HUM GENET, V53, P169, DOI 10.1111/j.1469-1809.1989.tb01781.x; DECLERCQ E, 1987, BIOCHEM PHARMACOL, V36, P2567, DOI 10.1016/0006-2952(87)90533-8; DELAHABA G, 1959, J BIOL CHEM, V234, P603; GLAZER RI, 1986, BIOCHEM PHARMACOL, V35, P4523, DOI 10.1016/0006-2952(86)90774-4; GUPTA RA, 1995, ARCH BIOCHEM BIOPHYS, V319, P365, DOI 10.1006/abbi.1995.1306; HASOBE M, 1989, ANTIMICROB AGENTS CH, V33, P828, DOI 10.1128/AAC.33.6.828; HENDERSON DM, 1992, MOL BIOCHEM PARASIT, V53, P169, DOI 10.1016/0166-6851(92)90019-G; HUGGING JW, 1995, 8 INT C ANT RES APR; JARVI ET, 1991, J MED CHEM, V34, P647, DOI 10.1021/jm00106a028; Keller B. T., 1988, ANTIVIRAL DRUG DEV M, P123; KITZ R, 1962, J BIOL CHEM, V237, P3245; LIU S, 1992, ANTIVIR RES, V19, P247, DOI 10.1016/0166-3542(92)90083-H; LIU SM, 1992, BIOORG MED CHEM LETT, V2, P1741, DOI 10.1016/S0960-894X(00)80467-9; MADHAVAN GVB, 1988, J MED CHEM, V31, P1798, DOI 10.1021/jm00117a021; MCCARTHY JR, 1989, J AM CHEM SOC, V111, P1127, DOI 10.1021/ja00185a052; PALMER JL, 1979, J BIOL CHEM, V254, P1217; PARRY RJ, 1991, BIOCHEMISTRY-US, V30, P9988, DOI 10.1021/bi00105a025; ROBINS MJ, 1992, J MED CHEM, V35, P2283, DOI 10.1021/jm00090a020; SILVERMAN RB, 1988, MECHANISM BASED ENZY, V1, P3; Wnuk SF, 1997, J MED CHEM, V40, P1608, DOI 10.1021/jm960828p; WOLFE MS, 1991, J MED CHEM, V34, P1521, DOI 10.1021/jm00109a001; WOLOS JA, 1993, CELL IMMUNOL, V149, P402, DOI 10.1006/cimm.1993.1165; WOLOS JA, 1993, J IMMUNOL, V151, P526; Yuan CS, 1996, J BIOL CHEM, V271, P28009, DOI 10.1074/jbc.271.45.28009; YUAN CS, 1995, J BIOL CHEM, V270, P16140, DOI 10.1074/jbc.270.27.16140; YUAN CS, 1993, J BIOL CHEM, V268, P17030; YUAN CS, 1994, BIOCHEMISTRY-US, V33, P3758, DOI 10.1021/bi00178a036; YUAN CS, 1994, BIOCHEMISTRY-US, V33, P12305, DOI 10.1021/bi00206a038	34	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18191	18197		10.1074/jbc.273.29.18191	http://dx.doi.org/10.1074/jbc.273.29.18191			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660780	hybrid			2022-12-25	WOS:000074828500035
J	Kunimura, C; Kikuchi, K; Ahmed, N; Shimizu, A; Yasumoto, S				Kunimura, C; Kikuchi, K; Ahmed, N; Shimizu, A; Yasumoto, S			Telomerase activity in a specific cell subset co-expressing integrin beta 1/EGFR but not p75(NGFR)/bcl2/integrin beta 4 in normal human epithelial cells	ONCOGENE			English	Article						bcl-2; epithelial cells; integrin beta 1, beta 4; p75(NGFR); telomerase regulation	GROWTH-FACTOR RECEPTOR; STEM-CELLS; IMMORTAL CELLS; HUMAN FIBROBLASTS; HUMAN SKIN; INTEGRIN; DIFFERENTIATION; ALPHA-6-BETA-4; HEMIDESMOSOMES; KERATINOCYTES	Telomerase activity is correlated with the immortality of various cultured cells and cancer cells. The activity, however, is also demonstrated in various normal regenerating cells which normally have a finite life span in vivo and in vitro, though its biological implication remains unclear. Using cultured normal human epithelial cells, we show that telomerase activity is associated with epithelial cell subsets which actively proliferate in vitro. Unlike in most cancer cell lines, telomerase activity was evidently up-regulated when the cells entered into S phase in primary human epithelial cells. To characterize the cells which have telomerase activity, the primary human epithelial cell population of uterine cervix was dissociated into several distinctive cellular subsets by means of immunocytochemical cell fractionation. Telomerase activity was found to be closely associated with the subset which expressed predominantly integrin pi and epidermal growth factor receptor. We further identified the telomerase-negative subpopulation which contained a small subset that strongly coexpresses p75(NGFR) low affinity nerve growth factor receptor, integrin beta 4 and bcl-2 protein. The location of the p75(NGFR)-expressing cells contrasts to that of the Ki-67 positive cells in vivo and is distinctive of telomerase positive cycling cells, indicating that these cells remain at the G0 phase, The present study supports the notion that telomerase activity is linked to cell cycle regulation, implying that telomerase is activated upon cell proliferation in regenerating normal human epithelial cells.	Kanagawa Canc Ctr, Res Inst, Lab Mol Cell Biol, Asahi Ku, Yokohama, Kanagawa 241, Japan	Kanagawa Prefectural Cancer Center	Yasumoto, S (corresponding author), Kanagawa Canc Ctr, Res Inst, Lab Mol Cell Biol, Asahi Ku, 1-1-2 Nakao, Yokohama, Kanagawa 241, Japan.							Albanell J, 1996, CANCER RES, V56, P1503; ALLSHIRE RC, 1988, NATURE, V332, P656, DOI 10.1038/332656a0; ALLSHIRE RC, 1989, NUCLEIC ACIDS RES, V17, P4611, DOI 10.1093/nar/17.12.4611; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; BARRANDON Y, 1987, P NATL ACAD SCI USA, V84, P2302, DOI 10.1073/pnas.84.8.2302; Bestilny LJ, 1996, CANCER RES, V56, P3796; BUCK CR, 1987, P NATL ACAD SCI USA, V84, P3060, DOI 10.1073/pnas.84.9.3060; CARTER WG, 1990, J CELL BIOL, V111, P3141, DOI 10.1083/jcb.111.6.3141; Chiu CP, 1996, STEM CELLS, V14, P239, DOI 10.1002/stem.140239; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; Dowling J, 1996, J CELL BIOL, V134, P559, DOI 10.1083/jcb.134.2.559; Harada H, 1998, J ORAL PATHOL MED, V27, P11; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HARLEY CB, 1995, TELOMERES, P247; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Holt SE, 1997, P NATL ACAD SCI USA, V94, P10687, DOI 10.1073/pnas.94.20.10687; Holt SE, 1996, MOL CELL BIOL, V16, P2932; JONES JCR, 1991, CELL REGUL, V2, P427, DOI 10.1091/mbc.2.6.427; JONES PH, 1995, CELL, V80, P83, DOI 10.1016/0092-8674(95)90453-0; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; KAJIJI S, 1989, EMBO J, V8, P673, DOI 10.1002/j.1460-2075.1989.tb03425.x; Kikuchi K, 1997, CELL GROWTH DIFFER, V8, P571; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; KRUK PA, 1995, P NATL ACAD SCI USA, V92, P258, DOI 10.1073/pnas.92.1.258; Kyo S, 1997, CANCER RES, V57, P610; LAVKER RM, 1991, ANN NY ACAD SCI, V642, P214; LAVKER RM, 1982, SCIENCE, V215, P1239, DOI 10.1126/science.7058342; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; Loeffler Markus, 1997, P1, DOI 10.1016/B978-012563455-7/50002-7; Mandal M, 1997, J BIOL CHEM, V272, P14183, DOI 10.1074/jbc.272.22.14183; Morrison SJ, 1996, IMMUNITY, V5, P207, DOI 10.1016/S1074-7613(00)80316-7; Morrison SJ, 1996, NAT MED, V2, P1011, DOI 10.1038/nm0996-1011; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; Ohta Y, 1997, JPN J CANCER RES, V88, P644, DOI 10.1111/j.1349-7006.1997.tb00432.x; POLAKOWSKA RR, 1994, DEV DYNAM, V199, P176, DOI 10.1002/aja.1001990303; POTTEN CS, 1988, J CELL SCI, P45; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SARIOLA H, 1991, SCIENCE, V254, P571, DOI 10.1126/science.1658930; Sharma HW, 1995, P NATL ACAD SCI USA, V92, P12343, DOI 10.1073/pnas.92.26.12343; SONNENBERG A, 1991, J CELL BIOL, V113, P907, DOI 10.1083/jcb.113.4.907; STEPP MA, 1990, P NATL ACAD SCI USA, V87, P8970, DOI 10.1073/pnas.87.22.8970; TSUTSUMI K, 1993, AM J PATHOL, V143, P1150; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; WILKIE AOM, 1990, NATURE, V346, P868, DOI 10.1038/346868a0; YASUMOTO S, 1991, J VIROL, V65, P2000, DOI 10.1128/JVI.65.4.2000-2009.1991; Yasumoto S, 1996, ONCOGENE, V13, P433; YASUMOTO S, 1992, TISSUE CULT RES COMM, V11, P13; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; Zhu XL, 1996, P NATL ACAD SCI USA, V93, P6091, DOI 10.1073/pnas.93.12.6091	59	42	43	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 16	1998	17	2					187	197		10.1038/sj.onc.1201916	http://dx.doi.org/10.1038/sj.onc.1201916			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZZ211	9674703				2022-12-25	WOS:000074706700007
J	Baker, LP; Nielsen, MD; Impey, S; Metcalf, MA; Poser, SW; Chan, G; Obrietan, K; Hamblin, MW; Storm, DR				Baker, LP; Nielsen, MD; Impey, S; Metcalf, MA; Poser, SW; Chan, G; Obrietan, K; Hamblin, MW; Storm, DR			Stimulation of type 1 and type 8 Ca2+/calmodulin-sensitive adenylyl cyclases by the G(s)-coupled 5-hydroxytryptamine subtype 5-HT7A receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN CIRCADIAN CLOCK; SEROTONIN RECEPTOR; RAT-BRAIN; MOLECULAR-CLONING; INTRACELLULAR CALCIUM; PERTUSSIS-TOXIN; MESSENGER-RNA; HIGH-AFFINITY; CELLS; EXPRESSION	The neurotransmitter serotonin (5-hydroxytryptamine, 5-HT) plays an important regulatory role in developing and adult nervous systems, With the exception of the 5-HT3 receptor, all of the cloned serotonin receptors belong to the G protein-coupled receptor superfamily, Subtypes 5 HT6 and 5-HT7 couple to stimulation of adenylyl cyclases through G(s) and display high affinities for antipsychotic and antidepressant drugs. In the brain, mRNA for 5-HT6 is found at high levels in the hippocampus, striatum, and nucleus accumbens, 5-HT7 mRNA is most abundant in the hippocampus, neocortex, and hypothalamus. To better understand how serotonin might control cAMP levels in the brain, we coexpressed 5-HT6 or 5-HT7A receptors with specific isoforms of adenylyl cyclase in HEK 293 cells. The 5-HT6 receptor functioned as a typical G(s)-coupled receptor in that it stimulated AC5, a G(s)-sensitive adenylyl cyclase, but not AC1 or AC8, calmodulin (CaM)-stimulated adenylyl cyclases that are not activated by G(s) coupled receptors in vivo. Surprisingly, serotonin activation of 5-HT7A stimulated AC1 and AC8 by increasing intracellular Ca2+. 5-HT also increased intracellular Ca2+ in primary neuron cultures. These data define a novel mechanism for the regulation of intracellular cAMP by serotonin.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; Vet Affairs Med Ctr, Seattle, WA 98108 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Storm, DR (corresponding author), Univ Washington, Dept Pharmacol, Box 357280, Seattle, WA 98195 USA.		Chan, Guy/B-1862-2009		PHS HHS [20498] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADHAM N, 1993, N-S ARCH PHARMACOL, V348, P566, DOI 10.1007/BF00167231; AKIYOSHI J, 1995, J NEUROCHEM, V64, P2473; Bachus SE, 1996, J CLIN PSYCHIAT, V57, P72; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BARD JA, 1993, J BIOL CHEM, V268, P23422; Beeckmans K, 1996, ACTA NEUROL BELG, V96, P35; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Contesse V, 1996, MOL PHARMACOL, V49, P481; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; DICKENSON JM, 1995, BRIT J PHARMACOL, V116, P2889, DOI 10.1111/j.1476-5381.1995.tb15941.x; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; Graeff FG, 1996, PHARMACOL BIOCHEM BE, V54, P129, DOI 10.1016/0091-3057(95)02135-3; Heidmann DEA, 1997, J NEUROCHEM, V68, P1372; Hirst WD, 1997, BRIT J PHARMACOL, V120, P509, DOI 10.1038/sj.bjp.0700921; HOYER D, 1994, PHARMACOL REV, V46, P157; IMPEY S, 1994, MOL CELL BIOL, V14, P8272, DOI 10.1128/MCB.14.12.8272; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; Jasper JR, 1997, BRIT J PHARMACOL, V122, P126, DOI 10.1038/sj.bjp.0701336; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; Kohen R, 1996, J NEUROCHEM, V66, P47; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; Lembo PMC, 1997, MOL PHARMACOL, V52, P164, DOI 10.1124/mol.52.1.164; Leonard BE, 1996, PSYCHOTHER PSYCHOSOM, V65, P66, DOI 10.1159/000289049; LOVENBERG TW, 1993, NEURON, V11, P449, DOI 10.1016/0896-6273(93)90149-L; MARTIN GR, 1994, PHARMACOL THERAPEUT, V62, P283, DOI 10.1016/0163-7258(94)90048-5; MASTERS SB, 1985, BIOCHEM J, V227, P933, DOI 10.1042/bj2270933; MESTON CM, 1992, J PSYCHOACTIVE DRUGS, V24, P1; Miller JD, 1996, SLEEP, V19, P641, DOI 10.1093/sleep/19.8.641; MILLIGAN G, 1993, TRENDS PHARMACOL SCI, V14, P239, DOI 10.1016/0165-6147(93)90019-G; MONS N, 1994, MOL BRAIN RES, V22, P236, DOI 10.1016/0169-328X(94)90052-3; MONSMA FJ, 1993, MOL PHARMACOL, V43, P320; MORK A, 1990, EUR J PHARMACOL, V175, P237, DOI 10.1016/0014-2999(90)90560-S; Nibuya M, 1996, J NEUROSCI, V16, P2365; Nielsen MD, 1996, J BIOL CHEM, V271, P33308, DOI 10.1074/jbc.271.52.33308; Obrietan K, 1998, J NEUROPHYSIOL, V79, P1360, DOI 10.1152/jn.1998.79.3.1360; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; Premont RT, 1996, J BIOL CHEM, V271, P13900, DOI 10.1074/jbc.271.23.13900; PROSSER RA, 1994, BRAIN RES, V644, P67, DOI 10.1016/0006-8993(94)90348-4; PROSSER RA, 1989, J NEUROSCI, V9, P1073; ROTH BL, 1994, J PHARMACOL EXP THER, V268, P1403; RUAT M, 1993, P NATL ACAD SCI USA, V90, P8547, DOI 10.1073/pnas.90.18.8547; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Schoeffter P, 1996, BRIT J PHARMACOL, V117, P993, DOI 10.1111/j.1476-5381.1996.tb16687.x; SHEN Y, 1993, J BIOL CHEM, V268, P18200; Shimizu M, 1996, J PHARMACOL EXP THER, V279, P1551; Simansky KJ, 1996, BEHAV BRAIN RES, V73, P37, DOI 10.1016/0166-4328(96)00066-6; Soares JC, 1997, BIOL PSYCHIAT, V41, P86, DOI 10.1016/S0006-3223(96)00006-6; Stam NJ, 1997, FEBS LETT, V413, P489, DOI 10.1016/S0014-5793(97)00964-2; SUBERS EM, 1988, J MOL CELL CARDIOL, V20, P131, DOI 10.1016/S0022-2828(88)80026-9; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; Ullmer C, 1996, BRIT J PHARMACOL, V117, P1081, DOI 10.1111/j.1476-5381.1996.tb16700.x; WARD RP, 1995, NEUROSCIENCE, V64, P1105, DOI 10.1016/0306-4522(94)00439-C; WATSON PA, 1994, J BIOL CHEM, V269, P28893; WAYMAN GA, 1994, J BIOL CHEM, V269, P25400; WAYMAN GA, 1995, J BIOL CHEM, V270, P24108, DOI 10.1074/jbc.270.41.24108; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; XIA ZG, 1993, J NEUROCHEM, V60, P305, DOI 10.1111/j.1471-4159.1993.tb05852.x; XIA ZG, 1991, NEURON, V6, P431, DOI 10.1016/0896-6273(91)90251-T; ZGOMBICK JM, 1993, MOL PHARMACOL, V44, P575	62	82	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17469	17476		10.1074/jbc.273.28.17469	http://dx.doi.org/10.1074/jbc.273.28.17469			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651336	hybrid			2022-12-25	WOS:000074816100029
J	Chaudhary, D; O'Rourke, K; Chinnaiyan, AM; Dixit, VM				Chaudhary, D; O'Rourke, K; Chinnaiyan, AM; Dixit, VM			The death inhibitory molecules CED-9 and CED-4L use a common mechanism to inhibit the CED-3 death protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; CAENORHABDITIS-ELEGANS; APOPTOSIS; ENCODES; BCL-2	The apoptotic machinery of Caenorhabditis elegans includes three core interacting components: CED-3, CED-4, and CED-9, CED-3 is a death protease composed of a prodomain and a protease domain. CED-4 is a P-loop-containing, nucleotide-binding molecule that complexes with the single polypeptide zymogen form of CED-3, promoting its activation by autoprocessing, CED-9 blocks death by complexing with CED-4 and suppressing its ability to promote CED-3 activation. A naturally occurring alternatively spliced form of CED-4 that contains an insertion within the nucleotide-binding region (CED-4L) functions as a dominant negative inhibitor of CED-3 processing and attenuates cell death. Domain mapping studies revealed that distinct regions within CED-4 bind to the CED-3 prodomain and protease domain. Importantly, the CED-4 P-loop was involved in prodomain binding, Disruption of P-loop geometry because of mutation of a critical lysine (K165R) or insertional inactivation (CED-4L) abolished prodomain binding. Regardless, K165R and CED-4L still retained CED-3 binding through the protease domain but were unable to initiate CED-3 processing. Therefore, the P-loop-prodomain interaction is critical for triggering CED-4-mediated CED-3 processing. Underscoring the importance of this interaction was the finding that CED-9 contacted the P-loop and selectively inhibited its interaction with the CED-3 prodomain. These results provide a simple mechanism for how CED-9 functions to block CED-4-mediated CED-3 processing and cell death.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Dixit, VM (corresponding author), Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.		dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326	PHS HHS [7863] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bauer MKA, 1997, FEBS LETT, V402, P256, DOI 10.1016/S0014-5793(96)01497-4; Boise L H, 1995, Curr Top Microbiol Immunol, V200, P107; Chinnaiyan AM, 1997, NATURE, V388, P728, DOI 10.1038/41913; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Farrow SN, 1996, CURR OPIN GENET DEV, V6, P45, DOI 10.1016/S0959-437X(96)90009-X; Hawkins C J, 1997, Semin Immunol, V9, P25, DOI 10.1006/smim.1996.0052; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; Hengartner MO, 1997, NATURE, V388, P714, DOI 10.1038/41873; Hengartner MO, 1996, CURR OPIN GENET DEV, V6, P34, DOI 10.1016/S0959-437X(96)90007-6; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Hugunin M, 1996, J BIOL CHEM, V271, P3517, DOI 10.1074/jbc.271.7.3517; Irmler M, 1997, FEBS LETT, V406, P189, DOI 10.1016/S0014-5793(97)00271-8; JACOBSON MD, 1997, CURR BIOL, V7, P277; James C, 1997, CURR BIOL, V7, P246, DOI 10.1016/S0960-9822(06)00120-5; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; McKenna SL, 1997, ADV CANCER RES, V71, P121, DOI 10.1016/S0065-230X(08)60098-6; MOUNTZ JD, 1996, J CLIN IMMUNOL IMM S, V80, P2; Nagata S, 1996, CURR BIOL, V6, P1241, DOI 10.1016/S0960-9822(02)70706-9; Osborne BA, 1996, CURR OPIN IMMUNOL, V8, P245, DOI 10.1016/S0952-7915(96)80063-X; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Seshagiri S, 1997, CURR BIOL, V7, P455, DOI 10.1016/S0960-9822(06)00216-8; Shaham S, 1996, CELL, V86, P201, DOI 10.1016/S0092-8674(00)80092-6; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; Vaux DL, 1997, CELL, V90, P389, DOI 10.1016/S0092-8674(00)80497-3; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Wu DY, 1997, J BIOL CHEM, V272, P21449, DOI 10.1074/jbc.272.34.21449; Xue D, 1997, NATURE, V390, P305, DOI 10.1038/36889; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	36	31	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17708	17712		10.1074/jbc.273.28.17708	http://dx.doi.org/10.1074/jbc.273.28.17708			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651369	hybrid			2022-12-25	WOS:000074816100062
J	Dizhoor, AM; Boikov, SG; Olshevskaya, EV				Dizhoor, AM; Boikov, SG; Olshevskaya, EV			Constitutive activation of photoreceptor guanylate cyclase by Y99C mutant of GCAP-1 - Possible role in causing human autosomal dominant cone degeneration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-CHARACTERIZATION; MOLECULAR-CLONING; EXPRESSION; PROTEIN; RETINA; PHOSPHODIESTERASE; RETGC	Photoreceptor membrane guanylate cyclases (RetGC) are regulated by calcium-binding proteins, GCAP-1 and GCAP-2. At Ca2+ concentrations below 100 nM, characteristic of light adapted photoreceptors, guanylate cyclase-activating protein (GCAPs) activate RetGC, and at free Ca2+ concentrations above 500 nM, characteristic of dark-adapted photoreceptors, GCAPs inhibit RetGC. A mutation, Y99C, in human GCAP-1 was recently found to be linked to autosomal dominant cone dystrophy in a British family (Payne, A. M., Downes, S. M., Bessant, D. A. R., Taylor, R., Holder, G. E., Warren, M. J., Bird, A. C., and Bhattachraya, S. S. (1998) Hum. Mol. Genet. 7, 273-277). We produced recombinant Y99C GCAP-1 mutant and tested its ability to activate RetGC in vitro at various free Ca2+ concentrations. The Y99C mutation does not decrease the ability of GCAP-1 to activate RetGC. However, RetGC stimulated by the Y99C GCAP-1 remains active even at Ca2+ concentration above 1 mu M. Hence, the cyclase becomes constitutively active within the whole physiologically relevant range of free Ca2+ concentrations. We have also found that the Y99C GCAP-1 can activate RetGc even in the presence of Ca2+ loaded nonmutant GCAPs. This is consistent with the fact that cone degeneration was dominant in human patients who carried such mutation (Payne, A. M., Downes, S. M., Bessant, D. A. R., Taylor, R., Holder, G. E., Warren, M. J., Bird, A. C., and Bhattachraya, S. S. (1998) Hum. Mol. Genet. 7, 273-277). A similar mutation, Y104C, in GCAP-2 results in a different phenotype. This mutation apparently does not affect Ca2+ sensitivity of GCAP-S. Instead, the Y104C GCAP-2 stimulates RetGC less efficiently than the wild-type GCAP-2. Our data indicate that cone degeneration associated with the Y99C mutation in GCAP-1 can be a result of constitutive acti vation of cGMP synthesis.	Wayne State Univ, Sch Med, Kresge Eye Inst, Dept Ophthalmol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA	Wayne State University; Wayne State University	Dizhoor, AM (corresponding author), Wayne State Univ, Sch Med, Kresge Eye Inst, Dept Ophthalmol, 4717 St Antoine, Detroit, MI 48201 USA.	adizhoor@med.wayne.edu		Dizhoor, Alexander/0000-0001-6770-9186	NEI NIH HHS [EY11522] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011522] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Baylor D, 1996, P NATL ACAD SCI USA, V93, P560, DOI 10.1073/pnas.93.2.560; Cuenca N., 1997, Investigative Ophthalmology and Visual Science, V38, pS21; DIZHOOR AM, 1995, J BIOL CHEM, V270, P25200, DOI 10.1074/jbc.270.42.25200; DIZHOOR AM, 1994, NEURON, V12, P1345, DOI 10.1016/0896-6273(94)90449-9; Dizhoor AM, 1996, J BIOL CHEM, V271, P19346, DOI 10.1074/jbc.271.32.19346; FARBER DB, 1992, NEURON, V9, P349, DOI 10.1016/0896-6273(92)90173-B; Frins S, 1996, J BIOL CHEM, V271, P8022, DOI 10.1074/jbc.271.14.8022; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; GORACZNIAK RM, 1994, BIOCHEM J, V302, P455, DOI 10.1042/bj3020455; GORCZYCA WA, 1995, J BIOL CHEM, V270, P22029, DOI 10.1074/jbc.270.37.22029; HAYASHI F, 1991, P NATL ACAD SCI USA, V88, P4746, DOI 10.1073/pnas.88.11.4746; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; Howes K, 1998, INVEST OPHTH VIS SCI, V39, P867; Kachi S., 1998, IOVS, V39, pS1051; LOWE DG, 1995, P NATL ACAD SCI USA, V92, P5535, DOI 10.1073/pnas.92.12.5535; Olshevskaya EV, 1997, J BIOL CHEM, V272, P14327, DOI 10.1074/jbc.272.22.14327; OttoBruc A, 1997, P NATL ACAD SCI USA, V94, P4727, DOI 10.1073/pnas.94.9.4727; PALCZEWSKI K, 1994, NEURON, V13, P395, DOI 10.1016/0896-6273(94)90355-7; Payne AM, 1998, HUM MOL GENET, V7, P273, DOI 10.1093/hmg/7.2.273; Perrault I, 1996, NAT GENET, V14, P461, DOI 10.1038/ng1296-461; PITTLER SJ, 1991, P NATL ACAD SCI USA, V88, P322; Pugh EN, 1997, BIOSCIENCE REP, V17, P429; ROCQUE WJ, 1993, J BIOL CHEM, V268, P9964; SempleRowland SL, 1996, FEBS LETT, V385, P47, DOI 10.1016/0014-5793(96)00345-6; SHYJAN AW, 1992, NEURON, V9, P727, DOI 10.1016/0896-6273(92)90035-C; SITARAMAYYA A, 1995, MOL CELL BIOCHEM, V148, P139, DOI 10.1007/BF00928151; Surguchov A, 1997, GENOMICS, V39, P312, DOI 10.1006/geno.1996.4513; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; YANG RB, 1995, P NATL ACAD SCI USA, V92, P602, DOI 10.1073/pnas.92.2.602	29	136	140	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17311	17314		10.1074/jbc.273.28.17311	http://dx.doi.org/10.1074/jbc.273.28.17311			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651312	hybrid			2022-12-25	WOS:000074816100005
J	Hsieh, TY; Matsumoto, M; Chou, HC; Schneider, R; Hwang, SB; Lee, AS; Lai, MMC				Hsieh, TY; Matsumoto, M; Chou, HC; Schneider, R; Hwang, SB; Lee, AS; Lai, MMC			Hepatitis C virus core protein interacts with heterogeneous nuclear ribonucleoprotein K	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-EFFICIENCY TRANSFORMATION; TRANSCRIPTIONAL REGULATION; HEPATOCELLULAR-CARCINOMA; MAMMALIAN-CELLS; GENE-PRODUCTS; BINDING; INFECTION; PROMOTER; DNA; EXPRESSION	Hepatitis C virus (HCV) core protein, a component of viral nucleocapsid, has been shown to modulate cellular and viral promoter activities. To identify potential cellular targets for HCV core protein, a human liver cDNA library was screened for core-interacting proteins using the yeast two-hybrid system. Among the proteins identified was heterogeneous nuclear ribonucleoprotein K (hnRNP K), which has been demonstrated to be a transcriptional regulator. The interaction of HCV core protein with hnRNP K was confirmed by glutathione transferase fusion protein binding assay, protein-protein blotting assay, and coimmunoprecipitation in vitro and in vivo. Additionally, these two proteins were shown to be partially colocalized in the nucleus. The hnRNP K-binding site in HCV core protein was mapped to the region from amino acid residues 25-91, a hydrophilic area near the N terminus. The HCV core protein-binding domain was located within amino acid residues 250 to 392, which contain the three proline-rich domains, of hnRNP K. Furthermore, HCV core protein relieved the suppression effect of hnRNP K on the activity of the human thymidine kinase gene promoter. The specific binding of HCV core protein to hnRNP K suggests that multiple functions of hnRNP K may be disrupted by the core protein during HCV infection and thus explains, in part, the pathogenesis of HCV.	Univ So Calif, Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Howard Hughes Med Inst, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Biochem, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Norris Canc Res Inst, Los Angeles, CA 90033 USA; Hallym Univ, Hallym Acad Sci, Inst Environm & Life Sci, Chuncheon 200702, South Korea	University of Southern California; Howard Hughes Medical Institute; University of Southern California; University of Southern California; University of Southern California; Hallym University	Lai, MMC (corresponding author), Univ So Calif, Sch Med, Dept Mol Microbiol & Immunol, 2011 Zonal Ave,HMR-401, Los Angeles, CA 90033 USA.		Lai, Michael M. C./I-7001-2012	Lee, Amy/0000-0002-0378-5443	NATIONAL CANCER INSTITUTE [R37CA027607, R01CA027607] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI040038] Funding Source: NIH RePORTER; NCI NIH HHS [CA27607] Funding Source: Medline; NIAID NIH HHS [AI40038] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; AGNELLO V, 1992, NEW ENGL J MED, V327, P1490, DOI 10.1056/NEJM199211193272104; ALMASIO P, 1992, LANCET, V339, P989, DOI 10.1016/0140-6736(92)91563-N; ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; Barba G, 1997, P NATL ACAD SCI USA, V94, P1200, DOI 10.1073/pnas.94.4.1200; Bomsztyk K, 1997, FEBS LETT, V403, P113, DOI 10.1016/S0014-5793(97)00041-0; Buchenau P, 1997, J CELL BIOL, V137, P291, DOI 10.1083/jcb.137.2.291; BUSTELO XR, 1995, MOL CELL BIOL, V15, P1324; CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245; CHANG SC, 1994, BIOCHEM BIOPH RES CO, V205, P1284, DOI 10.1006/bbrc.1994.2804; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN PJ, 1992, VIROLOGY, V188, P102, DOI 10.1016/0042-6822(92)90739-C; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; COLLETT MS, 1992, COMP IMMUNOL MICROB, V15, P145, DOI 10.1016/0147-9571(92)90087-8; CUTHBERT JA, 1994, CLIN MICROBIOL REV, V7, P505, DOI 10.1128/CMR.7.4.505-532.1994; Denisenko ON, 1996, J BIOL CHEM, V271, P27701, DOI 10.1074/jbc.271.44.27701; DIBISCEGLIE AM, 1994, J CLIN GASTROENTEROL, V19, P222, DOI 10.1097/00004836-199410000-00011; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; HARTMANN H, 1995, Z GASTROENTEROL, V33, P643; HOBERT O, 1994, J BIOL CHEM, V269, P20225; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hussy P, 1996, VIROLOGY, V224, P93, DOI 10.1006/viro.1996.0510; Hwang Soon B., 1995, Journal of Biomedical Science, V2, P227, DOI 10.1007/BF02253382; JOHNSON RJ, 1993, NEW ENGL J MED, V328, P465, DOI 10.1056/NEJM199302183280703; Kai N, 1997, J NEUROSCI RES, V48, P407, DOI 10.1002/(SICI)1097-4547(19970601)48:5<407::AID-JNR3>3.3.CO;2-F; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; KIM YK, 1992, J BIOL CHEM, V267, P2723; LANFORD RE, 1993, VIROLOGY, V197, P225, DOI 10.1006/viro.1993.1583; LI LJ, 1993, P NATL ACAD SCI USA, V90, P3554, DOI 10.1073/pnas.90.8.3554; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; Liu QY, 1997, J VIROL, V71, P657, DOI 10.1128/JVI.71.1.657-662.1997; LO SY, 1994, VIROLOGY, V199, P124, DOI 10.1006/viro.1994.1104; LO SY, 1995, VIROLOGY, V213, P455, DOI 10.1006/viro.1995.0018; Matsumoto M, 1996, VIROLOGY, V218, P43, DOI 10.1006/viro.1996.0164; Matsumoto M, 1997, J VIROL, V71, P1301, DOI 10.1128/JVI.71.2.1301-1309.1997; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; Moriya K, 1997, J GEN VIROL, V78, P1527, DOI 10.1099/0022-1317-78-7-1527; Okada K, 1996, CLIN NEPHROL, V45, P71; RAY RB, 1995, VIRUS RES, V37, P209, DOI 10.1016/0168-1702(95)00034-N; Ray RB, 1996, J VIROL, V70, P4438, DOI 10.1128/JVI.70.7.4438-4443.1996; Ray RB, 1997, J BIOL CHEM, V272, P10983; RUGGIERI A, 1997, VIROLOGY, V64, P73; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTOLINI E, 1994, J VIROL, V68, P3631, DOI 10.1128/JVI.68.6.3631-3641.1994; SHIH CM, 1993, J VIROL, V67, P5823, DOI 10.1128/JVI.67.10.5823-5832.1993; SHIH CM, 1995, J VIROL, V69, P1160, DOI 10.1128/JVI.69.2.1160-1171.1995; Shimotohno K, 1995, INTERVIROLOGY, V38, P162, DOI 10.1159/000150427; SUZUKI R, 1995, J GEN VIROL, V76, P53, DOI 10.1099/0022-1317-76-1-53; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875; Tomonaga T, 1996, P NATL ACAD SCI USA, V93, P5830, DOI 10.1073/pnas.93.12.5830; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; Zhu NL, 1998, J VIROL, V72, P3691, DOI 10.1128/JVI.72.5.3691-3697.1998	62	126	137	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17651	17659		10.1074/jbc.273.28.17651	http://dx.doi.org/10.1074/jbc.273.28.17651			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651361	hybrid			2022-12-25	WOS:000074816100054
J	Karuppayil, SM; Moran, E; Das, GM				Karuppayil, SM; Moran, E; Das, GM			Differential regulation of p53-dependent and -independent proliferating cell nuclear antigen gene transcription by 12 S E1A oncoprotein requires CBP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E1A-ASSOCIATED PROTEIN P300; BASAL PROMOTER ELEMENTS; ADENOVIRUS E1A; P53; ACTIVATION; BINDING; COACTIVATOR; REPRESSION; PRODUCTS; FAMILY	The tumor suppressor protein p53 and the adenoviral 12 S E1A oncoprotein are both known to elicit their biological effects mainly by regulating the transcription of important cellular genes. The human proliferating cell nuclear antigen (PCNA) gene is a transcriptional target of both p53 and E1A. We have analyzed the effects of p53 and 12 S E1A, separately as well as together, on PCNA gene transcription. Our results showed that whereas both p53 and 12 S E1A separately activated PCNA transcription, 12 S E1A repressed p53-mediated transcriptional activation. Thus, 12 S E1A uses a dual strategy of transcriptional activation and repression to take control of the cellular PCNA gene regulation. The cyclic AMP-response element in the PCNA core promoter, besides being crucial for basal transcription, synergizes with p53 to activate transcription. The cyclic AMP response element-binding protein (CREB)-binding protein (CBP) is an essential component of both the transcriptional activation and repression by E1A. Our data demonstrate for the first time that E1A can modulate CBP function to activate PCNA transcription, while at the same time repressing p53-mediated activation by disrupting CBP interaction with p53, thereby uncoupling PCNA transcription from the regulatory effects of p53.	Univ Texas, Hlth Sci Ctr, Canc Therapy & Res Ctr, Gene Regulat Lab, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Cancer Therapy & Research Center; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Das, GM (corresponding author), Univ Texas, Hlth Sci Ctr, Canc Therapy & Res Ctr, Gene Regulat Lab, 8122 Datapoint Dr,Suite 700, San Antonio, TX 78229 USA.		Das, Gokul M/A-5772-2013	Das, Gokul M/0000-0003-2937-8093	NCI NIH HHS [P30 CA54174] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA054174] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COLGAN J, 1995, P NATL ACAD SCI USA, V92, P1955, DOI 10.1073/pnas.92.6.1955; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; DAS G, 1995, NATURE, V374, P657, DOI 10.1038/374657a0; DAS G, 1993, J BIOL CHEM, V268, P25026; ENAMI KH, 1995, MOL CELL BIOL, V15, P5906; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LABRIE C, 1993, MOL CELL BIOL, V13, P1697, DOI 10.1128/MCB.13.3.1697; Lee BH, 1997, P NATL ACAD SCI USA, V94, P4481, DOI 10.1073/pnas.94.9.4481; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MORRIS GF, 1990, J BIOL CHEM, V265, P16116; Morris GF, 1996, P NATL ACAD SCI USA, V93, P895, DOI 10.1073/pnas.93.2.895; Pengue G, 1996, P NATL ACAD SCI USA, V93, P1015, DOI 10.1073/pnas.93.3.1015; Scolnick DM, 1997, CANCER RES, V57, P3693; Shen WC, 1997, CELL, V90, P615, DOI 10.1016/S0092-8674(00)80523-1; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; Steegenga WT, 1996, MOL CELL BIOL, V16, P2101; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821	34	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17303	17306		10.1074/jbc.273.28.17303	http://dx.doi.org/10.1074/jbc.273.28.17303			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651310	hybrid			2022-12-25	WOS:000074816100003
J	Lacaille, VG; Androlewicz, MJ				Lacaille, VG; Androlewicz, MJ			Herpes simplex virus inhibitor ICP47 destabilizes the transporter associated with antigen processing (TAP) heterodimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I MOLECULES; PEPTIDE-BINDING-SITE; EXPRESSION; PROTEIN; REGION; GENE; SPECIFICITY; PATHWAY; CELLS	Chemical cross-linking of the transporter associated with antigen processing (TAP) heterodimer was used to determine whether the herpes simplex virus inhibitor of TAP, ICP47, induces a conformational change in TAP. Cross-linking of TAP in cellular membranes produced a major species of similar to 220 kDa which was comprised solely of TAP.1 and TAP.2 and most Likely represents the TAP heterodimer. Interestingly, prior treatment of TAP-containing membranes with TAP peptide substrates stimulated the formation of the cross-linked TAP heterodimer, whereas pretreatment of membranes with ICP47 completely blocked the formation of the crosslinked heterodimer. These data suggest that suitable substrates for TAP stabilize the TAP heterodimer, whereas ICP47 destabilizes the heterodimer. The results indicate that subtle conformational changes occur in the TBP heterodimer upon the binding of peptides and the inhibitor ICP47 and that ICP47 has a deleterious effect on TAP heterodimer structure, in addition to its role as a potent blocker of substrate binding to TAP.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Program Immunol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Androlewicz, MJ (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Program Immunol, 12902 Magnolia Dr, Tampa, FL 33612 USA.	androlma@moffitt.usf.edu			NATIONAL CANCER INSTITUTE [R01CA069115] Funding Source: NIH RePORTER; NCI NIH HHS [CA69115] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn K, 1996, EMBO J, V15, P3247, DOI 10.1002/j.1460-2075.1996.tb00689.x; ANDROLEWICZ MJ, 1994, P NATL ACAD SCI USA, V91, P12716, DOI 10.1073/pnas.91.26.12716; ANDROLEWICZ MJ, 1994, IMMUNITY, V1, P7, DOI 10.1016/1074-7613(94)90004-3; ANDROLEWICZ MJ, 1993, P NATL ACAD SCI USA, V90, P9130, DOI 10.1073/pnas.90.19.9130; DEMARS R, 1985, P NATL ACAD SCI USA, V82, P8183, DOI 10.1073/pnas.82.23.8183; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; FRUH K, 1995, NATURE, V375, P415, DOI 10.1038/375415a0; Galocha B, 1997, J EXP MED, V185, P1565, DOI 10.1084/jem.185.9.1565; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GRANDEA AG, 1995, SCIENCE, V270, P105, DOI 10.1126/science.270.5233.105; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HILL A, 1995, NATURE, V375, P411, DOI 10.1038/375411a0; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KOENIG S, 1990, J IMMUNOL, V145, P127; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; Lehner PJ, 1998, IMMUNITY, V8, P221, DOI 10.1016/S1074-7613(00)80474-4; Li SL, 1997, P NATL ACAD SCI USA, V94, P8708, DOI 10.1073/pnas.94.16.8708; MEYER TH, 1994, FEBS LETT, V351, P443, DOI 10.1016/0014-5793(94)00908-2; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; Neumann L, 1997, J MOL BIOL, V272, P484, DOI 10.1006/jmbi.1997.1282; Ortmann B, 1997, SCIENCE, V277, P1306, DOI 10.1126/science.277.5330.1306; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; PULVERTAFT RJV, 1964, LANCET, V1, P238; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; SCOTT JE, 1995, J IMMUNOL, V155, P143; SEONG RH, 1988, J EXP MED, V167, P288, DOI 10.1084/jem.167.2.288; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; Stephens DB, 1997, FEBS LETT, V416, P353, DOI 10.1016/S0014-5793(97)01221-0; SUH WK, 1994, SCIENCE, V264, P1322, DOI 10.1126/science.8191286; Tomazin R, 1996, EMBO J, V15, P3256, DOI 10.1002/j.1460-2075.1996.tb00690.x; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VANENDERT PM, 1994, IMMUNITY, V1, P491, DOI 10.1016/1074-7613(94)90091-4	33	47	51	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17386	17390		10.1074/jbc.273.28.17386	http://dx.doi.org/10.1074/jbc.273.28.17386			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651323	hybrid			2022-12-25	WOS:000074816100016
J	Shen, ZC; Jacobs-Lorena, M				Shen, ZC; Jacobs-Lorena, M			A type I peritrophic matrix protein from the malaria vector Anopheles gambiae binds to chitin - Cloning, expression, and characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARASITE CHITINASE; LUCILIA-CUPRINA; BLOOD MEAL; MEMBRANE; SEQUENCE; CLEAVAGE; CDNA; DNA; GUT	Upon feeding, mosquito midguts secrete the peritrophic matrix (PM), an extracellular chitin-containing envelope that completely surrounds the blood meal. Because the malaria parasite must cross the PM to complete its life cycle in the mosquito, the PM is a potential barrier for malaria transmission. By antibody screening of an expression library we have identified and partially characterized a cDNA encoding a putative PM protein, termed Anopheles gambiae adult peritrophin 1 (Ag-Aper1). Ag-Aper1 is the first cloned PM gene from a disease vector. Northern analysis detected an abundant Ag-Aper1 transcript only in the adult gut, and not in any other tissues or at any other stages of development. The predicted amino acid sequence indicates that it has two tandem chitin-binding domains that share high sequence similarity with each other and also with the chitin-binding domain of an adult gut-specific chitinase from the same organism. The presumed ability of Ag-Aper1 to bind chitin was verified by a functional assay with the baculovirus-expressed recombinant protein. Ag-Aper1 did bind to chitin but not to cellulose, indicating that Ag-Aper1 binds chitin specifically. The double chitin-binding domain organization of Ag-Aper1 suggests that each protein molecule is able to link two chitin polymer chains. Hence, this protein is likely to act as a molecular linker that connects PM chitin fibrils into a three-dimensional network.	Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA	Case Western Reserve University	Jacobs-Lorena, M (corresponding author), Case Western Reserve Univ, Sch Med, Dept Genet, 10900 Euclid Ave, Cleveland, OH 44106 USA.							ALTSCHUL T, 1990, J MOL BIOL, V215, P401; BILLINGSLEY PF, 1992, J PARASITOL, V78, P430, DOI 10.2307/3283640; CAMPBELL BC, 1992, INSECT BIOCHEM MOLEC, V22, P415, DOI 10.1016/0965-1748(92)90136-3; Casu R, 1997, P NATL ACAD SCI USA, V94, P8939, DOI 10.1073/pnas.94.17.8939; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAMPTON JM, 1994, ANN TROP MED PARASIT, V88, P3, DOI 10.1080/00034983.1994.11812828; EAST IJ, 1993, INT J PARASITOL, V23, P221, DOI 10.1016/0020-7519(93)90144-N; Edwards MJ, 1997, INSECT BIOCHEM MOLEC, V27, P1063, DOI 10.1016/S0965-1748(97)00093-3; Elvin CM, 1996, J BIOL CHEM, V271, P8925, DOI 10.1074/jbc.271.15.8925; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Freyvogel T. A., 1965, Acta Tropica Basle, V22, P148; FREYVOGEL THIERRY A., 1965, ACTA TROP, V22, P118; FUHRMAN JA, 1992, P NATL ACAD SCI USA, V89, P1548, DOI 10.1073/pnas.89.5.1548; HUBER M, 1991, P NATL ACAD SCI USA, V88, P2807, DOI 10.1073/pnas.88.7.2807; Jacobs-Lorena Marcelo, 1996, P318; Jasinskiene N, 1998, P NATL ACAD SCI USA, V95, P3743, DOI 10.1073/pnas.95.7.3743; KRAMER KJ, 1993, INSECT BIOCHEM MOLEC, V23, P691, DOI 10.1016/0965-1748(93)90043-R; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lehane MJ, 1997, ANNU REV ENTOMOL, V42, P525, DOI 10.1146/annurev.ento.42.1.525; Lemos FJA, 1996, INSECT BIOCHEM MOLEC, V26, P651, DOI 10.1016/S0965-1748(96)00014-8; Moskalyk LA, 1996, INSECT MOL BIOL, V5, P261, DOI 10.1111/j.1365-2583.1996.tb00100.x; Muller H.M., 1993, Parassitologia (Rome), V35, P73; Muller HM, 1995, EXP PARASITOL, V81, P371, DOI 10.1006/expr.1995.1128; MULLER HM, 1993, EMBO J, V12, P2891, DOI 10.1002/j.1460-2075.1993.tb05951.x; PETERS W, 1992, ZOOPHYSIOLOGY PERITR, V130; RAMOS A, 1994, J EXP ZOOL, V268, P269, DOI 10.1002/jez.1402680403; REGEV A, 1996, APPL ENVIRON MICROB, V62, P381; SHAHABUDDIN M, 1993, P NATL ACAD SCI USA, V90, P4266, DOI 10.1073/pnas.90.9.4266; Shen ZC, 1997, J BIOL CHEM, V272, P28895, DOI 10.1074/jbc.272.46.28895; Tellam R. L., 1996, P86; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Wang P, 1997, J BIOL CHEM, V272, P16663, DOI 10.1074/jbc.272.26.16663; Watanabe T, 1996, MOL MAR BIOL BIOTECH, V5, P299; WILLADSEN P, 1993, PARASITOL TODAY, V9, P132, DOI 10.1016/0169-4758(93)90177-H	34	139	161	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17665	17670		10.1074/jbc.273.28.17665	http://dx.doi.org/10.1074/jbc.273.28.17665			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651363	hybrid			2022-12-25	WOS:000074816100056
J	Shrikumar, A; Cooperman, BS				Shrikumar, A; Cooperman, BS			Antichymotrypsin interaction with chymotrypsin - Reactions following encounter complex formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; SERPIN; THROMBIN; ALPHA-1-ANTICHYMOTRYPSIN; ANTITHROMBIN; EXPRESSION; INHIBITION; MECHANISM; FORM	Serpins, serine proteinase inhibitors, form enzymatically inactive, 1:1 complexes (denoted E*I*) with their target proteinases, that only slowly release I*, in which the P1-P1' linkage is cleaved. Recently we presented evidence that the serpin antichymotrypsin (ACT, I) reacts with the serine proteinase chymotrypsin (Chtr, E) to form an E*I* complex via a three-step mechanism, E + I reversible arrow E .I reversible arrow EI' reversible arrow E*I* in which EI', which retains the P1-P1' linkage, is formed in a partly or largely rate-determining step, depending on temperature (O'Malley, K. H, Nair, S, A., Rubin, H., and Cooperman, B, S, (1997) J. Biol. Chem. 272, 5354-5359). Here we extend these studies through the introduction of a new assay for the formation of the postcomplex fragment, corresponding to ACT residues 359 (the P1' residue) to 398 (the C ter minus), coupled with rapid quench flow kinetic analysis. We show that the E I encounter complex of wild type-rACT and Chtr forms both E*I* and postcomplex fragment with the same rate constant, so that both spe cies arise from EI' conversion to E*I*. These results sup port our earlier conclusion that the P1-P1' linkage is preserved in EI' and imply that E*I* corresponds to a covalent adduct of E and I, either acyl enzyme or the tetrahedral intermediate formed by water attack on acyl enzyme. Furthermore, we show that the A347R (P12) variant of rACT, which is a substrate rather than an inhibitor of Chtr, has a rate constant for postcomplex fragment formation from the E I complex very similar to that observed for WT-rACT, implying that EI' is the common intermediate from which partitioning to inhibitor and substrate pathways occurs. These results are used to elaborate a proposed scheme for ACT interaction with Chtr that is considered in the light of relevant results from studies of other serpin-serine proteinase pairs.	Univ Penn, Dept Chem, Philadelphia, PA 19104 USA	University of Pennsylvania	Cooperman, BS (corresponding author), Univ Penn, Dept Chem, Philadelphia, PA 19104 USA.	cooprman@pobox.upenn.edu			NATIONAL INSTITUTE ON AGING [R01AG010599] Funding Source: NIH RePORTER; NIA NIH HHS [AG10599] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAUMANN U, 1991, J MOL BIOL, V218, P595, DOI 10.1016/0022-2836(91)90704-A; BJORK I, 1982, J BIOL CHEM, V257, P2406; BJORK I, 1982, J BIOL CHEM, V257, P9487; BUCK MA, 1989, ANAL BIOCHEM, V182, P295, DOI 10.1016/0003-2697(89)90597-6; COOPERMAN BS, 1993, J BIOL CHEM, V268, P23616; DAS S, 1995, NEURON, V14, P447, DOI 10.1016/0896-6273(95)90300-3; GETTINS P, 1993, BIOESSAYS, V15, P461, DOI 10.1002/bies.950150705; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LIEBERMAN J, 1995, NEUROBIOL AGING, V16, P747, DOI 10.1016/0197-4580(95)00056-K; Lukacs CM, 1996, NAT STRUCT BIOL, V3, P888, DOI 10.1038/nsb1096-888; MATHESON NR, 1991, J BIOL CHEM, V266, P13489; OLSON ST, 1995, J BIOL CHEM, V270, P30007; OLSON ST, 1982, J BIOL CHEM, V257, P4891; OMalley KM, 1997, J BIOL CHEM, V272, P5354, DOI 10.1074/jbc.272.8.5354; PEEHL DM, 1995, CANCER-AM CANCER SOC, V75, P2021, DOI 10.1002/1097-0142(19950401)75:7+<2021::AID-CNCR2820751644>3.0.CO;2-R; Plotnick MI, 1996, BIOCHEMISTRY-US, V35, P7586, DOI 10.1021/bi960233w; RUBIN H, 1990, J BIOL CHEM, V265, P1199; SASAGAWA T, 1982, J CHROMATOGR, V240, P329, DOI 10.1016/S0021-9673(00)99612-2; SCALIA R, 1995, SHOCK, V4, P251, DOI 10.1097/00024382-199510000-00004; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Schechter NM, 1997, J BIOL CHEM, V272, P24499, DOI 10.1074/jbc.272.39.24499; Stavridi ES, 1996, BIOCHEMISTRY-US, V35, P10608, DOI 10.1021/bi9605806; Stone SR, 1997, J MOL BIOL, V265, P344, DOI 10.1006/jmbi.1996.0727; Stratikos E, 1997, P NATL ACAD SCI USA, V94, P453, DOI 10.1073/pnas.94.2.453; WEI A, 1994, NAT STRUCT BIOL, V1, P250; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652; Wilczynska M, 1997, NAT STRUCT BIOL, V4, P354, DOI 10.1038/nsb0597-354; ZHONG JQ, 1996, THESIS U PENNSYLVANI	29	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17459	17462		10.1074/jbc.273.28.17459	http://dx.doi.org/10.1074/jbc.273.28.17459			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651334	hybrid			2022-12-25	WOS:000074816100027
J	Su, J; Chai, XY; Kahn, B; Napoli, JL				Su, J; Chai, XY; Kahn, B; Napoli, JL			cDNA cloning, tissue distribution, and substrate characteristics of a cis-retinol/3 alpha-hydroxysterol short-chain dehydrogenase isozyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTORS; RAT VENTRAL PROSTATE; BETA-CAROTENE; ALCOHOL-DEHYDROGENASE; METABOLIZING ENZYMES; ISOMERS; SEPARATION; VEGETABLES; EXPRESSION; ANDROGENS	We report here a mouse cDNA that encodes a 316-amino acid short chain dehydrogenase that prefers NAD(+) as its cofactor and recognizes as substrates androgens and retinols, i.e. has steroid 3 alpha- and 17 beta-dehydrogenase and cis/trans-retinol catalytic activities. This (c) under bar is-(r) under bar etinol/(a) under bar ndrogen dehydrogenase type (2) under bar (CRAD2) shares close amino acid similarity with mouse retinol dehydrogenase isozyme types 1 and 2 and CRAD1 (86, 84, and 87%, respectively). CRAD2 exhibits cooperative kinetics with 3 alpha-adiol (3 alpha-hydroxysteroid dehydrogenase activity) and testosterone (17 beta-hydroxysteroid dehydrogenase activity), but Michaelis-Menten kinetics with androsterone (3 alpha-hydroxysteroid dehydrogenase activity), 11-cis-retinol, all-trans-retinol, and 9-cis-retinol, with V/K-0.5 values of 1.6, 0.2, 0.1, 0.04, 0.005, and not saturated, respectively. Carbenoxolone (IC50 = 2 mu M) and 4-methylpyrazole (IC50 = 5 mM) inhibited CRAD2, but neither ethanol nor phosphatidylcholine had marked effects on its activity. Liver expressed CRAD2 mRNA intensely, with expression in lung, eye, kidney, and brain (2.9, 2, 1.6, and 0.6% of liver mRNA respectively). CRAD2 represents the fifth isozyme in a group of short chain dehydrogenase/reductase isozymes (retinol dehydrogenases 1-3 and CRAD1), closely related in primary amino acid sequence (similar to 85%), that are expressed in different quantities in various tissues, have different substrate specificities, and may serve different physiological functions. CRAD2 may alter the amounts of active and inactive androgens and/or convert retinols into retinals. These data expand insight into the multifunctional nature of short-chain dehydrogenases/reductases and into the enzymology of steroid and retinoid metabolism.	SUNY Buffalo, Sch Med & Biomed Sci, Dept Biochem, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Napoli, JL (corresponding author), SUNY Buffalo, Sch Med & Biomed Sci, Dept Biochem, 140 Farber Hall,3435 Main St, Buffalo, NY 14214 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047839] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47839] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKER ME, 1994, STEROIDS, V59, P248, DOI 10.1016/0039-128X(94)90109-0; BAKER ME, 1991, MOL CELL ENDOCRINOL, V78, pC99, DOI 10.1016/0303-7207(91)90178-U; Beaulieu M, 1996, J BIOL CHEM, V271, P22855, DOI 10.1074/jbc.271.37.22855; Biswas MG, 1997, J BIOL CHEM, V272, P15959, DOI 10.1074/jbc.272.25.15959; BOERMAN MHEM, 1995, BIOCHEMISTRY-US, V34, P7027, DOI 10.1021/bi00021a014; BOUDOU P, 1994, J CLIN ENDOCR METAB, V78, P1064, DOI 10.1210/jc.78.5.1064; BOUDOU P, 1995, J CLIN ENDOCR METAB, V80, P1158, DOI 10.1210/jc.80.4.1158; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN PS, 1959, NATURE, V184, P1377, DOI 10.1038/1841377a0; BRUCHOVSKY N, 1971, ENDOCRINOLOGY, V89, P1212, DOI 10.1210/endo-89-5-1212; BUSHWAY RJ, 1985, J LIQ CHROMATOGR, V8, P1527, DOI 10.1080/01483918508067163; Chai XY, 1996, GENE, V169, P219, DOI 10.1016/0378-1119(95)00833-0; CHAI XY, 1995, J BIOL CHEM, V270, P3900, DOI 10.1074/jbc.270.8.3900; CHAI XY, 1995, J BIOL CHEM, V270, P28408, DOI 10.1074/jbc.270.47.28408; Chai XY, 1997, J BIOL CHEM, V272, P33125, DOI 10.1074/jbc.272.52.33125; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHANDLER LA, 1987, J FOOD SCI, V52, P669, DOI 10.1111/j.1365-2621.1987.tb06700.x; Clinton SK, 1996, CANCER EPIDEM BIOMAR, V5, P823; DANIELPOUR D, 1994, CANCER RES, V54, P3413; DeCoster R, 1996, J STEROID BIOCHEM, V56, P133, DOI 10.1016/0960-0760(95)00230-8; DRIESSEN CAGG, 1995, INVEST OPHTH VIS SCI, V36, P1988; EDWARDS CRW, 1993, J STEROID BIOCHEM, V45, P1, DOI 10.1016/0960-0760(93)90114-C; GIFFIN JE, 1995, METABOLIC MOL BASIS, P2967; HUANG HFS, 1994, BIOL REPROD, V51, P541, DOI 10.1095/biolreprod51.3.541; Huang HFS, 1997, ENDOCRINOLOGY, V138, P553, DOI 10.1210/en.138.2.553; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; KRIEG M, 1995, J STEROID BIOCHEM, V53, P395, DOI 10.1016/0960-0760(95)00085-E; KROOK M, 1990, BIOCHEMISTRY-US, V29, P738, DOI 10.1021/bi00455a021; Leatherbarrow R.J, 1987, ENZFITTER NONLINEAR; Lin HK, 1997, MOL ENDOCRINOL, V11, P1971, DOI 10.1210/me.11.13.1971; Lotan R, 1988, Prog Clin Biol Res, V259, P261; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; Mahendroo MS, 1996, MOL ENDOCRINOL, V10, P380, DOI 10.1210/me.10.4.380; MARKS AR, 1992, J BIOL CHEM, V267, P15459; Mertz JR, 1997, J BIOL CHEM, V272, P11744, DOI 10.1074/jbc.272.18.11744; MOORE RJ, 1973, ENDOCRINOLOGY, V93, P581, DOI 10.1210/endo-93-3-581; NAGAO A, 1994, FASEB J, V8, P968, DOI 10.1096/fasebj.8.12.8088462; Napoli JL, 1996, FASEB J, V10, P993, DOI 10.1096/fasebj.10.9.8801182; OLSON JA, 1995, NUTR BLINDNESS; ONEIL CA, 1992, J CHROMATOGR, V624, P235, DOI 10.1016/0021-9673(92)85682-J; OPPERMAN UCT, 1996, ENZYMOL MOL BIOL CAR, V6, P403; RUSSELL DW, 1994, ANNU REV BIOCHEM, V63, P25, DOI 10.1146/annurev.bi.63.070194.000325; SCHULTZ FM, 1974, ENDOCRINOLOGY, V94, P979; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; STAHL W, 1992, ARCH BIOCHEM BIOPHYS, V294, P173, DOI 10.1016/0003-9861(92)90153-N; STAHL W, 1993, CLIN CHEM, V39, P810; SUCOV HM, 1995, MOL NEUROBIOL, V10, P169, DOI 10.1007/BF02740674; TAUROG JD, 1975, BIOCHEMISTRY-US, V14, P810, DOI 10.1021/bi00675a026; Wilson J D, 1970, Recent Prog Horm Res, V26, P309; WU L, 1993, J BIOL CHEM, V268, P12964; Yeum KJ, 1996, AM J CLIN NUTR, V64, P594, DOI 10.1093/ajcn/64.4.594; YOUNG CYF, 1994, PROSTATE, V25, P39, DOI 10.1002/pros.2990250106	52	68	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17910	17916		10.1074/jbc.273.28.17910	http://dx.doi.org/10.1074/jbc.273.28.17910			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651397	hybrid			2022-12-25	WOS:000074816100090
J	Zeng, HW; Jackson, DA; Oshima, H; Simons, SS				Zeng, HW; Jackson, DA; Oshima, H; Simons, SS			Cloning and characterization of a novel binding factor (GMEB-2) of the glucocorticoid modulatory element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE AMINOTRANSFERASE GENE; TRANSCRIPTION FACTORS; RESPONSE ELEMENT; RECEPTOR; CELL; EXPRESSION; INDUCTION; ACTIVATION; SUPPRESSIN; UPSTREAM	The 21-base pair glucocorticoid modulatory element (GME) of the rat tyrosine aminotransferase gene is the only cis-acting element known to modulate the transcriptional activity of receptors bound to glucocorticoid response elements. Specifically, the GME increases the activity of complexes bound both by physiological concentrations of glucocorticoids, due to a left shift in the dose-response curve, and by saturating concentrations of anti-glucocorticoids. For this reason, the nuclear protein(s) that has been demonstrated to bind to the GME is of major interest as a possible transcription factor with hitherto undescribed properties. Subsequent studies indicated that not one but two proteins of 88 and 67 kDa (= GMEB-1 and -2, respectively) formed a heteromeric complex with double-stranded GME oligonucleotides in gel shift assays and participated in the expression of GME activity (Oshima, H., Szapary, D., and Simons, S. S., Jr. (1995) J. Biol. Chem. 270, 21895-21910). Here, we report the use of polymerase chain reaction of degenerate oligonucleotides and 5'- and 3'-rapid amplification of cDNA ends to clone two cDNAs of 2.0 and 1.9 kilobase pairs that probably result hom alternative splicing. Both cDNAs encoded open reading frames containing all four previously sequenced peptides. The longer 2.0-kilobase pair cDNA encoded an open reading frame for an acidic, 529-amino acid protein and afforded a major 67-kDa and a minor 58-kDa protein after in vitro transcription/translation. Both proteins were recognized by a mono-epitopic antibody raised against a peptide of GMEB-2. The in vitro translated protein bound to GME DNA in gel shift assays. However, the binding to GME DNA increased markedly after mixing with authentic GMEB-1 to give a gel-shifted complex that was similar to that derived hom HTC cell cytosol. GMEB-2 shares a unique domain (KDWKR) with proteins derived from diverse organisms as follows: Drosophila (DEAF-I), rat (Suppressin), and Caenorhabditis elegans (three unknown open reading frames). Collectively, these data suggest that the 67-kDa GMEB-2 not only is an important factor for the modulation of glucocorticoid receptor bound to glucocorticoid response elements but also may belong to a novel family of transcription factors.	NIDDK, LMCB, Steroid Hormone Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Simons, SS (corresponding author), NIDDK, LMCB, Steroid Hormone Sect, NIH, Bldg 8,Rm B2A-07, Bethesda, MD 20892 USA.	steroids@helix.nih.gov	Jackson, David/E-9984-2014					ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; BAN EMH, 1994, IMMUNOL RES, V13, P1, DOI 10.1007/BF02918219; BOSHART M, 1990, CELL, V61, P905, DOI 10.1016/0092-8674(90)90201-O; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Collier CD, 1996, MOL ENDOCRINOL, V10, P463, DOI 10.1210/me.10.5.463; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; ESPINAS ML, 1994, MOL CELL BIOL, V14, P4116, DOI 10.1128/MCB.14.6.4116; GRANGE T, 1989, NUCLEIC ACIDS RES, V17, P8695, DOI 10.1093/nar/17.21.8695; GRANGE T, 1991, NUCLEIC ACIDS RES, V19, P131, DOI 10.1093/nar/19.1.131; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; Gross CT, 1996, EMBO J, V15, P1961, DOI 10.1002/j.1460-2075.1996.tb00547.x; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HUTCHISON KA, 1993, J STEROID BIOCHEM, V46, P681, DOI 10.1016/0960-0760(93)90309-K; JACKSON DA, 1998, IN PRESS J STEROID B; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LeBoeuf R D, 1994, Immunomethods, V5, P79, DOI 10.1006/immu.1994.1040; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MERCIER L, 1983, ENDOCRINOLOGY, V112, P601, DOI 10.1210/endo-112-2-601; MERCIER L, 1986, J STEROID BIOCHEM, V25, P11, DOI 10.1016/0022-4731(86)90275-X; MODARRESS KJ, 1994, J BIOL CHEM, V269, P25621; Montano MM, 1997, MOL ENDOCRINOL, V11, P330, DOI 10.1210/me.11.3.330; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; NITSCH D, 1993, P NATL ACAD SCI USA, V90, P5479, DOI 10.1073/pnas.90.12.5479; NITSCH D, 1990, MOL CELL BIOL, V10, P3334, DOI 10.1128/MCB.10.7.3334; OSHIMA H, 1995, J BIOL CHEM, V270, P21893, DOI 10.1074/jbc.270.37.21893; OSHIMA H, 1993, J BIOL CHEM, V268, P26858; OSHIMA H, 1992, MOL ENDOCRINOL, V6, P416, DOI 10.1210/me.6.3.416; OSHIMA H, 1992, ENDOCRINOLOGY, V130, P2106, DOI 10.1210/en.130.4.2106; REICHMAN ME, 1984, BIOCHEMISTRY-US, V23, P5376, DOI 10.1021/bi00317a042; RIGAUD G, 1991, CELL, V67, P977, DOI 10.1016/0092-8674(91)90370-E; SCHMID E, 1987, EUR J BIOCHEM, V165, P499, DOI 10.1111/j.1432-1033.1987.tb11467.x; SCHWEIZERGROYER G, 1992, J STEROID BIOCHEM, V41, P747, DOI 10.1016/0960-0760(92)90416-G; SIMONS SS, 1992, MOL ENDOCRINOL, V6, P995, DOI 10.1210/me.6.7.995; SIMONS SS, 1989, CANCER RES, V49, pS2244; SIMONS SS, 1983, J STEROID BIOCHEM, V31, P1; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; SZAPARY D, 1992, ENDOCRINOLOGY, V130, P3492, DOI 10.1210/en.130.6.3492; SZAPARY D, 1993, MOL ENDOCRINOL, V7, P941, DOI 10.1210/me.7.8.941; THOMPSON EB, 1979, GLUCOCORTICOID HORMO, P203; TOMKINS GM, 1970, COLD SPRING HARB SYM, V35, P635, DOI 10.1101/SQB.1970.035.01.078; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; WASNER G, 1988, MOL ENDOCRINOL, V2, P1009, DOI 10.1210/mend-2-11-1009; ZARET KS, 1992, P NATL ACAD SCI USA, V89, P6540, DOI 10.1073/pnas.89.14.6540	47	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17756	17762		10.1074/jbc.273.28.17756	http://dx.doi.org/10.1074/jbc.273.28.17756			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651376	hybrid			2022-12-25	WOS:000074816100069
J	Tisdale, EJ; Jackson, MR				Tisdale, EJ; Jackson, MR			Rab2 protein enhances coatomer recruitment to pre-Golgi intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; GTP-BINDING PROTEIN; ENDOPLASMIC-RETICULUM; KINASE-C; BETA-COP; DEPENDENT FORMATION; TRANSPORT VESICLES; COATED VESICLES; CELL-SURFACE; MEMBRANES	The Rab2 protein is a resident of pre-Golgi intermediates and required for vesicular transport in the early secretory pathway. We have previously shown that a peptide corresponding to the amino terminus of Rab2 (residues 2-14) arrests protein traffic prior to a rate-limiting event in VSV-G movement through pre-GoIgi structures (Tisdale, E. J., and Balch, W. E. (1996) J. Biol, Chem. 271, 29372-29379). To determine the mechanism by which this peptide inhibits transport, we investigated the effect of the Rab2 peptide on the distribution of the beta-COP subunit of coatomer because COPI partially localizes to pre-Golgi intermediates, We found that the peptide caused a dramatic change in the distribution of pre-Golgi intermediates containing beta-COP. A quantitative binding assay was employed to measure recruitment of beta-COP to membrane when incubated with the Rab2 (13-mer). Peptide-treated microsomes showed a 25-70% increase in the level of membrane-associated beta-COP. The enhanced recruitment of coatomer to membrane was specific to the Rab2 (13-mer) and required guanosine 5'-3-O-(thio)triphosphate, ADP ribosylation factor, and protein kinase C-like activity. The ability to enhance beta-COP membrane binding was not limited to the peptide. Similarly, the addition of recombinant Rab2 protein to the assay promoted beta-COP membrane association. Our results suggest that the Rab2 peptide causes the persistent recruitment of COPI to pre-Golgi intermediates which ultimately arrests protein transport due to the inability of membranes to uncoat.	Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA; RW Johnson Pharmaceut Res Inst, San Diego, CA 92121 USA	Wayne State University; Johnson & Johnson; Johnson & Johnson USA	Tisdale, EJ (corresponding author), Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA.	etisdale@med.wayne.edu						ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BRUNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288, DOI 10.1016/0006-291X(91)90922-T; BUCCIONE R, 1994, BIOCHEM J, V298, P149, DOI 10.1042/bj2980149; CARDONE MH, 1994, J CELL BIOL, V124, P717, DOI 10.1083/jcb.124.5.717; CAVENAGH M, 1996, J BIOL CHEM, V36, P21767; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; FABBRI M, 1994, J BIOL CHEM, V269, P26848; GOODNIGHT J, 1995, J BIOL CHEM, V270, P991; HALLER H, 1994, ANN NY ACAD SCI, V733, P313, DOI 10.1111/j.1749-6632.1994.tb17281.x; HARAKUGE S, 1994, J CELL BIOL, V124, P883, DOI 10.1083/jcb.124.6.883; HENDRICKS LC, 1993, MOL BIOL CELL, V4, P413, DOI 10.1091/mbc.4.4.413; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OPRINS A, 1993, J CELL BIOL, V121, P49, DOI 10.1083/jcb.121.1.49; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; PELHAM H R B, 1991, Current Opinion in Cell Biology, V3, P585, DOI 10.1016/0955-0674(91)90027-V; PELHAM HRB, 1995, CURR OPIN CELL BIOL, V7, P530, DOI 10.1016/0955-0674(95)80010-7; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; RANDAZZO PA, 1992, METHOD ENZYMOL, V219, P362; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SARASTE J, 1991, J CELL SCI, V100, P415; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; Simon JP, 1996, J CELL BIOL, V135, P355, DOI 10.1083/jcb.135.2.355; Tisdale EJ, 1996, J BIOL CHEM, V271, P29372, DOI 10.1074/jbc.271.46.29372; Tisdale EJ, 1997, J CELL BIOL, V137, P581, DOI 10.1083/jcb.137.3.581; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WEISS O, 1989, J BIOL CHEM, V264, P21066; WHITNEY JA, 1995, CELL, V83, P703; Yedovitzky M, 1997, J BIOL CHEM, V272, P1417, DOI 10.1074/jbc.272.3.1417	46	42	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17269	17277		10.1074/jbc.273.27.17269	http://dx.doi.org/10.1074/jbc.273.27.17269			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642298	hybrid			2022-12-25	WOS:000074545200088
J	Lanyi, A; Deb, D; Seymour, RC; Ludes-Meyers, JH; Subler, MA; Deb, S				Lanyi, A; Deb, D; Seymour, RC; Ludes-Meyers, JH; Subler, MA; Deb, S			'Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain	ONCOGENE			English	Article						mutant p53; transcriptional activation, domain	FACTOR RECEPTOR PROMOTER; WILD-TYPE P53; TRANSCRIPTIONAL ACTIVATION; DNA-BINDING; TRANSFORMING MUTANTS; FUNCTION MUTATIONS; SUPPRESSOR GENE; MDR1 GENE; PROTEIN; CELLS	Tumor-derived p53 mutants can transcriptionally activate a number of promoters of genes involved in cellular proliferation. For this transactivation, mutant p53 does not use the wild-type p53 DNA-binding site, suggesting a mechanism of transactivation that is independent of direct DNA binding. Here me describe our analysis of the domain requirements for mutant p53 to transactivate promoters of the human epidermal growth factor receptor (EGFR), human multiple drug resistance 1 (MDR-1) and human proliferating cell nuclear antigen (PCNA) genes. We also report the identification of a structural domain required for the 'Gain of function' property of mutant p53-281G, 'Gain of function' is measured as the tumorigenicity (in nude mice) of 10(3) murine cells expressing mutant p53 constitutively. We have generated internal deletion mutants of p53-281G deleting conserved domains I, II, III, IV and V, individually. We have also generated one deletion mutant eliminating amino acids 100 through 300 that removes four of the five conserved domains (II-V); another mutant, p53-281G del 393-327, deletes the oligomerization and nonsequence-specific nucleic acid-binding domains of p53, For the EGFR and MDR-1 promoters, all these mutants have significantly lower transactivation ability than intact p53-281G, These deletion mutants, however, significantly activated the pCNA promoter, suggesting that the mechanism of transactivation of the PCNA promoter is different from that of the EGFR and MDR-I promoters, When expressed constitutively in 10(3) cells, p53-281G del 393-327 was found to be defective in inducing tumor formation in nude mice although intact p53-281G was very efficient. Thus, our results suggest that structural domains near the C-terminus are needed for 'gain of function'.	Univ Texas, Hlth Sci Ctr, Dept Microbiol, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio	Deb, S (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Microbiol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.				NATIONAL CANCER INSTITUTE [R01CA070712] Funding Source: NIH RePORTER; NCI NIH HHS [CA70712] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; CHEN CJ, 1990, J BIOL CHEM, V265, P506; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DEB SP, 1994, ONCOGENE, V9, P1341; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GRUDA MC, 1993, MOL CELL BIOL, V13, P961, DOI 10.1128/MCB.13.2.961; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSIAO M, 1994, AM J PATHOL, V145, P702; KIESER A, 1994, ONCOGENE, V9, P963; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LANE DP, 1994, BRIT MED BULL, V50, P582, DOI 10.1093/oxfordjournals.bmb.a072911; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LEE W, 1994, STRUCT BIOL, V1, P877; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN JY, 1995, ONCOGENE, V10, P2387; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; MARGULIES L, 1993, J BIOL CHEM, V268, P15096; Muller BF, 1996, ONCOGENE, V12, P1941; OROURKE RW, 1990, ONCOGENE, V5, P1829; OZBUN MA, 1995, ADV CANCER RES, V66, P71, DOI 10.1016/S0065-230X(08)60252-3; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SHALUSKI G, 1991, CANCER RES, V51, P5232; SOUSSI T, 1990, ONCOGENE, V5, P945; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1994, ONCOGENE, V9, P1351; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; SUBLER MA, 1994, J VIROL, V68, P103, DOI 10.1128/JVI.68.1.103-110.1994; TSUTSUMIISHII Y, 1995, CELL GROWTH DIFFER, V6, P1; UEBA T, 1994, P NATL ACAD SCI USA, V91, P9009, DOI 10.1073/pnas.91.19.9009; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WOLF D, 1984, MOL CELL BIOL, V4, P552, DOI 10.1128/MCB.4.3.552; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529	47	74	75	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 18	1998	16	24					3169	3176		10.1038/sj.onc.1201857	http://dx.doi.org/10.1038/sj.onc.1201857			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671396				2022-12-25	WOS:000074261300010
J	Landesman-Bollag, E; Channavajhala, PL; Cardiff, RD; Seldin, DC				Landesman-Bollag, E; Channavajhala, PL; Cardiff, RD; Seldin, DC			p53 deficiency and misexpression of protein kinase CK2 alpha collaborate in the development of thymic lymphomas in mice	ONCOGENE			English	Article						casein kinase II; lymphoma; oncogene; protein kinase; p53; transgenic mice	TUMOR SUPPRESSOR PROTEIN; STRANDED-DNA ENDS; C-TERMINAL DOMAIN; T-CELL TUMORS; WILD-TYPE P53; TRANSGENIC MICE; CASEIN KINASE-2; PHOSPHORYLATION SITE; CONSENSUS SEQUENCES; P53-DEFICIENT MICE	Protein kinase CK2 (casein kinase II) is a serine-threonine protein kinase with many substrates, some of which are involved in cell cycle regulation. CK2 activity is elevated in human solid tumors and leukemia, and dysregulated expression of CK2 induces lymphoma in transgenic mice. Mice that are deficient in p53 also develop lymphomas, and p53 activity may be regulated by CK2 phosphorylation, Here we demonstrate that CK2 alpha transgenic mice partially or completely deficient in p53 develop thymic lymphomas at a markedly accelerated rate when compared to p53-deficient mice lacking the transgene, Lymphomas originating from CK2 alpha transgenic mice that are heterozygous for p53 generally Lose the wild type p53 allele, indicating that loss of p53 is an important step in tumor progression. Moreover, though lymphomas occur as early as 3 weeks of age in the transgenic mice that are nullizygous for p53, they are still monoclonal, indicating that additional stochastic mutations are required for their development. These lymphomas express high levels of myc mRNA and frequently ectopically express Lmo-2, a transcription factor involved in human T cell acute lymphocytic leukemia. The p53-null CK2 alpha transgenic lymphomas grow rapidly but are highly prone to apoptosis, suggesting that transformation occurs through synergistic dysregulation of cell cycle control induced by misexpression of CK2 and loss of function of p53.	Boston Univ, Med Ctr, Dept Med, Boston, MA 02118 USA; Boston Univ, Med Ctr, Dept Microbiol, Boston, MA 02118 USA; Boston Univ, Med Ctr, Dept Pathol, Boston, MA 02118 USA; Univ Calif Davis, Dept Pathol, Davis, CA 95616 USA	Boston University; Boston University; Boston University; University of California System; University of California Davis	Seldin, DC (corresponding author), Boston Univ, Med Ctr, Dept Med, Boston, MA 02118 USA.			Seldin, David C/0000-0003-0168-2333	NCI NIH HHS [CA71796] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071796] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; APPEL K, 1995, ONCOGENE, V11, P1971; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLYTH K, 1995, ONCOGENE, V10, P1717; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; BOUSSET K, 1993, ONCOGENE, V8, P3211; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Condorelli GL, 1996, CANCER RES, V56, P5113; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DAYAMAKIN M, 1994, CANCER RES, V54, P2262; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, MOL CARCINOGEN, V14, P16, DOI 10.1002/mc.2940140105; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELSON A, 1995, ONCOGENE, V11, P181; Faust RA, 1996, CANCER LETT, V101, P31, DOI 10.1016/0304-3835(96)04110-9; FILHOL O, 1992, J BIOL CHEM, V267, P20577; Filhol O, 1996, BIOCHEM J, V316, P331, DOI 10.1042/bj3160331; FISCELLA M, 1994, ONCOGENE, V9, P3249; FISCH P, 1992, ONCOGENE, V7, P2389; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; FRIEDRICH TD, 1989, BIOCHIM BIOPHYS ACTA, V992, P41, DOI 10.1016/0304-4165(89)90048-2; FUKASAWA K, 1996, SCIENCE, V271, P174; GAPANY M, 1995, MOL MED, V1, P659, DOI 10.1007/BF03401606; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HRUBEY TW, 1990, BIOCHEM BIOPH RES CO, V172, P190, DOI 10.1016/S0006-291X(05)80192-5; HSU B, 1995, ONCOGENE, V11, P175; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; HWANG LY, 1995, CURR OPIN IMMUNOL, V7, P659, DOI 10.1016/0952-7915(95)80074-3; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JOHNSON GG, 1988, J BIOL CHEM, V263, P9079; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; Jones JM, 1997, CELL GROWTH DIFFER, V8, P829; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; LARSON RC, 1994, ONCOGENE, V9, P3675; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LITCHFIELD DW, 1990, FEBS LETT, V261, P117, DOI 10.1016/0014-5793(90)80650-8; Lowsky R, 1997, BLOOD, V89, P2276, DOI 10.1182/blood.V89.7.2276; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARIN O, 1992, FEBS LETT, V301, P111, DOI 10.1016/0014-5793(92)80221-2; Matthews DE, 1996, USING UNDERSTANDING; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MEGGIO F, 1991, FEBS LETT, V279, P307, DOI 10.1016/0014-5793(91)80174-2; MESTRES P, 1994, ACTA ANAT, V149, P13; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MIYASHITA T, 1995, CELL, V80, P293; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; NEALE GAM, 1995, BLOOD, V86, P3060; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; PERICH JW, 1992, BIOCHEMISTRY-US, V31, P5893, DOI 10.1021/bi00140a027; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PURDIE CA, 1994, ONCOGENE, V9, P603; ROLIEY N, 1994, ONCOGENE, V9, P3067; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SELDIN DC, 1995, CURR OPIN IMMUNOL, V7, P665, DOI 10.1016/0952-7915(95)80075-1; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; SIU G, 1984, CELL, V37, P393, DOI 10.1016/0092-8674(84)90369-6; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0	78	140	143	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 11	1998	16	23					2965	2974		10.1038/sj.onc.1201854	http://dx.doi.org/10.1038/sj.onc.1201854			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZT782	9662328				2022-12-25	WOS:000074125300002
J	Schmidt-Kastner, PK; Jardine, K; Cormier, M; McBurney, MW				Schmidt-Kastner, PK; Jardine, K; Cormier, M; McBurney, MW			Absence of p53-dependent cell cycle regulation in pluripotent mouse cell lines	ONCOGENE			English	Article						embryonal carcinoma; stem cells; insertional mutation; DNA methylation	EMBRYONAL CARCINOMA-CELLS; WILD-TYPE P53; MURINE LEUKEMIA-VIRUS; DNA-DAMAGE; GENE-EXPRESSION; INDUCED APOPTOSIS; STEM-CELLS; TUMOR SUPPRESSORS; FACTOR FAMILY; MUTANT P53	We examined the expression of p53 in three lines of pluripotent embryonal carcinoma (EC) and ES cells, p53 mRNA and protein levels were constitutively high in two lines but absent from one. In the P19 line of EC cells neither p53 protein nor mRNA was detected. The first intron of the p53 gene in these cells had been invaded by murine leukemia virus and there was extensive hypermethylation of the p53 gene accompanying its inactivation. In all three cell lines, irradiation resulted in arrest of the cells in the G2 but not in the G1 phase of the cell cycle despite the induction of p21(cip1) in the cell lines expressing p53. Thus, the chromosomal stability of EC and ES cells appears to be not dependent on the p53 protein and we interpret our results to suggest that these cells may require the deletion of p53 dependent cell cycle regulation in order to become immortalized.	Univ Ottawa, Ottawa Reg Canc Ctr, Ottawa, ON K1H 8L6, Canada; Univ Ottawa, Dept Med, Ottawa, ON K1H 8L6, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa	McBurney, MW (corresponding author), Univ Ottawa, Ottawa Reg Canc Ctr, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.							AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; BELL JC, 1986, MOL CELL BIOL, V6, P617, DOI 10.1128/MCB.6.2.617; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; BOND JA, 1994, ONCOGENE, V9, P1885; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; CZOSNEK HH, 1984, MOL CELL BIOL, V4, P1638, DOI 10.1128/MCB.4.8.1638; DAVID YB, 1988, ONCOGENE, V3, P179; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Fu LN, 1996, EMBO J, V15, P4392, DOI 10.1002/j.1460-2075.1996.tb00812.x; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GAUTSCH JW, 1983, NATURE, V301, P32, DOI 10.1038/301032a0; GUILLOUF C, 1995, ONCOGENE, V10, P2263; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; HAGGARTY A, 1991, CELL GROWTH DIFFER, V2, P503; Hall PA, 1997, CURR BIOL, V7, pR144, DOI 10.1016/S0960-9822(97)70074-5; HARPER JW, 1993, CELL, V75, P805; HARTUNG S, 1986, NATURE, V320, P365, DOI 10.1038/320365a0; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hawley RS, 1996, GENE DEV, V10, P2383, DOI 10.1101/gad.10.19.2383; HUPPI K, 1994, ONCOGENE, V9, P3017; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; MCBURNEY MW, 1982, DEV BIOL, V89, P503, DOI 10.1016/0012-1606(82)90338-4; MCBURNEY MW, 1993, INT J DEV BIOL, V37, P135; MCBURNEY MW, 1976, J CELL PHYSIOL, V89, P441, DOI 10.1002/jcp.1040890310; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; MITREITER K, 1994, VIROLOGY, V200, P837, DOI 10.1006/viro.1994.1253; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; NELSON N, 1993, MOL CELL BIOL, V13, P588, DOI 10.1128/MCB.13.1.588; NICOLAS JF, 1975, ANN INST PASTEUR MIC, VA126, P3; Okazawa H, 1996, J CELL BIOL, V132, P955, DOI 10.1083/jcb.132.5.955; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PENNICA D, 1984, VIROLOGY, V134, P477, DOI 10.1016/0042-6822(84)90316-7; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; Sabapathy K, 1997, EMBO J, V16, P6217, DOI 10.1093/emboj/16.20.6217; Sambrook J., 2002, MOL CLONING LAB MANU; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SITHANANDAM G, 1988, J VIROL, V62, P932, DOI 10.1128/JVI.62.3.932-943.1988; SLACK RS, 1995, J CELL BIOL, V129, P779, DOI 10.1083/jcb.129.3.779; SLACK RS, 1993, ONCOGENE, V8, P1585; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; Staines WA, 1996, NEUROSCIENCE, V71, P845, DOI 10.1016/0306-4522(95)00494-7; Stevens L C, 1967, Adv Morphog, V6, P1; STEWART N, 1995, ONCOGENE, V10, P109; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WOLF D, 1984, MOL CELL BIOL, V4, P1402, DOI 10.1128/MCB.4.7.1402; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yamagata T, 1996, MOL CELL BIOL, V16, P1283; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	60	42	43	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 11	1998	16	23					3003	3011		10.1038/sj.onc.1201835	http://dx.doi.org/10.1038/sj.onc.1201835			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZT782	9662333				2022-12-25	WOS:000074125300007
J	Blattner, C; Bender, K; Herrlich, P; Rahmsdorf, HJ				Blattner, C; Bender, K; Herrlich, P; Rahmsdorf, HJ			Photoproducts in transcriptionally active DNA induce signal transduction to the delayed U.V.-responsive genes for collagenase and metallothionein	ONCOGENE			English	Article						ultraviolet irradiation; p53 stabilization; collagenase 1; metallothionein; transcription-coupled repair; pyrimidine dimers	IMMUNODEFICIENCY VIRUS TYPE-1; CYCLOBUTANE PYRIMIDINE DIMERS; RECEPTOR TYROSINE KINASES; GROUP-C FIBROBLASTS; XERODERMA-PIGMENTOSUM; UV-LIGHT; PLASMINOGEN-ACTIVATOR; EXTRACELLULAR FACTOR; NONIRRADIATED CELLS; ULTRAVIOLET-LIGHT	Mammalian cells in culture react to ultraviolet irradiation with the massive transcriptional activation of several genes and with the stabilization of the p53 protein. While U.V.-induced transcription of several immediate-response genes depends on U.V.-induced activation of signal transduction generated by non-nuclear mechanisms, stabilization of p53 and the transcription of several delayed-response genes are triggered by U.V.-induced DNA damage. By comparing dose responses for the activation by U.V. of delayed-responsive genes (collagenase 1, metallothionein IIA) in cells from patients with different DNA repair deficiencies (complementation groups of Xeroderma pigmentosum, Cockayne's syndrome and Trichothiodystrophy), we show here that U.V.-induced transcription of these genes does depend on pyrimidine dimers in transcribed regions of the genome (but not on damage in its silent part). Since all cells with defects in DNA repair that had been tested and which lack different enzymes, respond to U.V. with expression of these same genes, functional repair does not appear to be required for the induction of expression, and repair intermediates (which would not be identical in cells of different repair deficiency) cannot be responsible for signal generation.	Forschungszentrum Karlsruhe, Inst Genet, D-76021 Karlsruhe, Germany	Helmholtz Association; Karlsruhe Institute of Technology	Herrlich, P (corresponding author), Forschungszentrum Karlsruhe, Inst Genet, POB 3640, D-76021 Karlsruhe, Germany.		Blattner, Christine/ABI-2152-2020; Blattner, Christine/H-2105-2013	Blattner, Christine/0000-0002-7250-5273; Blattner, Christine/0000-0002-7250-5273				ANGEL P, 1986, MOL CELL BIOL, V6, P1760, DOI 10.1128/MCB.6.5.1760; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; [Anonymous], 1985, DNA REPAIR; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BERNDER K, 1997, J PHOTOCH PHOTOBIO B, V37, P1; BLATTNER C, 1994, ENVIRON MOL MUTAGEN, V24, P3, DOI 10.1002/em.2850240103; BOOTSMA D, 1994, MUTAT RES, V307, P15, DOI 10.1016/0027-5107(94)90273-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROUGHTON BC, 1994, NAT GENET, V7, P189, DOI 10.1038/ng0694-189; BROUGHTON BC, 1990, MUTAT RES, V235, P33, DOI 10.1016/0921-8777(90)90020-6; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DRAPKIN R, 1994, CELL, V77, P9, DOI 10.1016/0092-8674(94)90228-3; EVENO E, 1995, CANCER RES, V55, P4325; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HANAWALT PC, 1995, MUTAT RES-DNA REPAIR, V336, P101, DOI 10.1016/0921-8777(94)00061-A; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HERRLICH P, 1997, MOL BIOL TOXICOLOGY, pCH31; HOEIJMAKERS JHJ, 1994, EUR J CANCER, V30A, P1912, DOI 10.1016/0959-8049(94)00381-E; Huang CS, 1997, ONCOGENE, V14, P1945, DOI 10.1038/sj.onc.1201056; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; Isaacs JS, 1997, ONCOGENE, V14, P1669, DOI 10.1038/sj.onc.1201001; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; KRAMER M, 1993, J BIOL CHEM, V268, P6734; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LEHMANN AR, 1988, CANCER RES, V48, P6090; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MISKIN R, 1981, P NATL ACAD SCI-BIOL, V78, P6236, DOI 10.1073/pnas.78.10.6236; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RAHMSDORF HJ, 1987, NUCLEIC ACIDS RES, V15, P1643, DOI 10.1093/nar/15.4.1643; RENZING J, 1995, ONCOGENE, V10, P1865; ROTEM N, 1987, MOL CELL BIOL, V7, P622, DOI 10.1128/MCB.7.2.622; SACHSENMAIER C, 1994, BIOCHEM PHARMACOL, V47, P129, DOI 10.1016/0006-2952(94)90446-4; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHORPP M, 1984, CELL, V37, P861, DOI 10.1016/0092-8674(84)90421-5; SIEGEL J, 1995, ONCOGENE, V11, P1363; STEFANINI M, 1993, CARCINOGENESIS, V14, P1101, DOI 10.1093/carcin/14.6.1101; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; STEIN B, 1989, J VIROL, V63, P4540, DOI 10.1128/JVI.63.11.4540-4544.1989; Tolmie J L, 1994, Clin Dysmorphol, V3, P1; VANHOFFEN A, 1995, EMBO J, V14, P360, DOI 10.1002/j.1460-2075.1995.tb07010.x; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; VENEMA J, 1990, NUCLEIC ACIDS RES, V18, P443, DOI 10.1093/nar/18.3.443; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; Weeda G, 1997, AM J HUM GENET, V60, P320; Wilhelm D, 1997, MOL CELL BIOL, V17, P4792, DOI 10.1128/MCB.17.8.4792; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; YAROSH DB, 1993, J INVEST DERMATOL, V100, P790, DOI 10.1111/1523-1747.ep12476573	57	33	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 4	1998	16	22					2827	2834		10.1038/sj.onc.1201827	http://dx.doi.org/10.1038/sj.onc.1201827			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZR544	9671403				2022-12-25	WOS:000073988200001
J	Poirel, H; Lacronique, V; Mauchauffe, M; Le Coniat, M; Raffoux, E; Daniel, MT; Erickson, P; Drabkin, H; MacLeod, RAF; Drexler, HG; Ghysdael, J; Berger, R; Bernard, OA				Poirel, H; Lacronique, V; Mauchauffe, M; Le Coniat, M; Raffoux, E; Daniel, MT; Erickson, P; Drabkin, H; MacLeod, RAF; Drexler, HG; Ghysdael, J; Berger, R; Bernard, OA			Analysis of TEL proteins in human leukemias	ONCOGENE			English	Article						TEL/ETV6 proteins; AML1 proteins; t(12;21) translocation; acute leukemias; gene inactivation	ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; CELL-LINE; TRANSCRIPTIONAL ACTIVATION; MYELOMONOCYTIC LEUKEMIA; AML1 GENE; FUSION; TRANSLOCATION; T(12-21); DELETION	Chromosomal translocations involving the human 12p13 band frequently affect the TEL gene, usually resulting in gene fusion between TEL and genes encoding proteins of various types. The most frequent 12p13 translocation is the t(12;21)(p13;q22), which recombines TEL with the AMI;I gene on chromosome 21 and is frequently associated with deletion of the untranslocated TEL allele. Using antisera against different parts of TEL and against the AML1 proteins, we undertook Western blot and immunofluorescence analyses of leukemic samples with and without 12p13 abnormalities. In t(12;21) samples, TEL-AML1 was detected as several protein species in the nuclei, whereas the AML1-TEL protein, was inconsistently expressed. AML1 was found to be expressed but no normal TEL proteins were detected. A survey of the TEL proteins in a panel of human leukemic samples without t(12;21) revealed a variation in the ratio of TEL protein isoforms. We also analysed a leukemic cell line bearing a t(12;22)(p13;q11) that was found to affect the 5' untranslated CUT) region of TEL and to be associated with inactivation of the untranslocated TEL allele. No MN1-TEL fusion could be detected upon RT-PCR analysis, in contrast to the previously investigated t(12;22). Strikingly, extremely low levels of apparently normal TEL proteins, expressed from the translocated allele, were detected by Western blot analysis. These results suggest that the level of TEL expression can be important for leukemogenesis.	INSERM, U301, F-75010 Paris, France; Inst Genet Mol, CNRS, SD 301, F-75010 Paris, France; Hop St Louis, Cent Hematol Lab, Paris, France; Univ Colorado, Hlth Sci Ctr, Div Med Oncol, Denver, CO 80262 USA; Deutsch Sammlung Mikroorganism Zellkultur GmbH, German Collect Microorganisms & Cell Cultures, Braunschweig, Germany; Ctr Univ, Inst Curie, Sect Rech, CNRS,UMR 146, F-91405 Orsay, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Leibniz Institut fur Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Bernard, OA (corresponding author), INSERM, U301, 27 Rue Juliette Dodu, F-75010 Paris, France.		Penard-Lacronique, Virginie/R-1938-2019; Bernard, Olivier A./E-5721-2016; GHYSDAEL, Jacques/F-3377-2013; Penard-Lacronique, Virginie/E-5729-2016	Penard-Lacronique, Virginie/0000-0001-9435-7331; Penard-Lacronique, Virginie/0000-0001-9435-7331; Bernard, Olivier/0000-0002-0463-9747				Andreasson P, 1997, GENE CHROMOSOME CANC, V19, P77, DOI 10.1002/(SICI)1098-2264(199706)19:2<77::AID-GCC2>3.0.CO;2-X; Baens M, 1996, GENOME RES, V6, P404, DOI 10.1101/gr.6.5.404; Bernard OA, 1996, LEUKEMIA LYMPHOMA, V23, P459, DOI 10.3109/10428199609054854; BUIJS A, 1995, ONCOGENE, V10, P1511; CAVE H, 1995, BLOOD, V86, P3869, DOI 10.1182/blood.V86.10.3869.bloodjournal86103869; Erickson PF, 1996, BLOOD, V88, P1813; GOLUB T, 1996, BIOCHIM BIOPHYS ACTA, V1288, P7; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Kim DH, 1996, BLOOD, V88, P785, DOI 10.1182/blood.V88.3.785.bloodjournal883785; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; LANOTTE M, 1991, BLOOD, V77, P1080; MacLeod RAF, 1996, GENE CHROMOSOME CANC, V16, P144; McLean TW, 1996, BLOOD, V88, P4252; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; Peeters P, 1997, CANCER RES, V57, P564; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; Poirel H, 1997, ONCOGENE, V14, P349, DOI 10.1038/sj.onc.1200829; Raynaud S, 1996, BLOOD, V87, P2891, DOI 10.1182/blood.V87.7.2891.bloodjournal8772891; Raynaud SD, 1996, BLOOD, V88, P682, DOI 10.1182/blood.V88.2.682.bloodjournal882682; Romana SP, 1996, LEUKEMIA, V10, P167; ROMANA SP, 1994, GENE CHROMOSOME CANC, V9, P186, DOI 10.1002/gcc.2870090307; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; ROSENFELD C, 1977, NATURE, V267, P841, DOI 10.1038/267841a0; Stegmaier K, 1996, CANCER RES, V56, P1413; Suto Y, 1997, GENE CHROMOSOME CANC, V18, P254, DOI 10.1002/(SICI)1098-2264(199704)18:4<254::AID-GCC3>3.0.CO;2-#; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; Tanaka T, 1996, MOL CELL BIOL, V16, P3967	34	34	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 4	1998	16	22					2895	2903		10.1038/sj.onc.1201817	http://dx.doi.org/10.1038/sj.onc.1201817			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZR544	9671410				2022-12-25	WOS:000073988200008
J	Li, JJ; Rhim, JS; Schlegel, R; Vousden, KH; Colburn, NH				Li, JJ; Rhim, JS; Schlegel, R; Vousden, KH; Colburn, NH			Expression of dominant negative Jun inhibits elevated AP-1 and NF-kappa B transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes	ONCOGENE			English	Article						dominant negative c-Jun; transcription factor; HPV; transformation; human keratinocytes	HUMAN PAPILLOMAVIRUS TYPE-16; PROMOTER-INDUCED TRANSFORMATION; TRANSGENIC MICE; GENE-PRODUCT; C-JUN; MULTISTAGE CARCINOGENESIS; TRANSCRIPTION FACTORS; RESISTANT VARIANTS; EPIDERMAL-CELLS; JB6 CELLS	AP-1 transactivation appears to be required for mouse JB6 cell neoplastic transformation induced by the tumor promoter TPA or epidermal growth factor (EGF). Exposure to AP-1 transrepressing retinoids and glucocorticoids and expression of a dominant negative c-jun (TAM67) blocked tumor promoter-induced AP-1 transactivation and neoplastic transformation. The aim of the present study was to extend the inquiry of the role of AP-1 and other transcription factors to human neoplastic progression. Expression of human papilloma-virus (HPV) 16 or 18 E6 and E7 immortalizes human keratinocytes and inhibits serum/calcium-stimulated differentiation. Further transformation by v-fos coexpression renders these keratinocytes tumorigenic in nude mice. We have analysed two series of E6/E7 immortalized human keratinocyte cell lines that show progressing phenotypes ranging from differentiation sensitive to anchorage-independent to tumorigenic in nude mice. We analysed the activities of AP-1 and NF-kappa B which may 'cross-talk'. Both DNA binding and transactivation of AP-1 and NF-kappa B transcription factors showed elevation in the anchorage-independent (16RH) and tumorigenic (18 v-fos) keratinocyte lines compared to the less progressed but immortalized cell lines. HPV E7 was expressed at a constant level shown by quantitative RT-PCR in both the more and the less progressed lines, indicating that E7 is not the factor limiting this progression. Blocked shift/supershift analysis indicates that Fos family member proteins especially Fra-1 and Fra-2 are related to progression and no changes found in the Jun family member proteins although they are present in the AP-1/DNA binding complex. When a dominant negative mutant c-jun driven by a human keratin 14 promoter was cotransfected with AP-1 or NF-kappa B reporters, both AP-1 and NF-kappa B activities were suppressed in the more progressed cell lines 16RH add 18 v-fos but not in the less progressed 16RL or 18 cell lines. Overexpression of the same dominant negative c-jun did not inhibit p53 dependent reporter transactivation, indicating the specificity of inhibition of AP-1 and NF-kappa B transactivation in the HPV-immortalized cells. Stable transfectants of this mutant c-jun in the two more progressed cell lines 16RH and 18 v-fos showed reduced AP-1 and NF-kappa B activation and reduced anchorage-independent growth. Together, these results indicate that activation of AP-1, NF-kappa B or both may contribute to neoplastic progression in HPV immortalized human keratinocytes and that specific targeting of the elevated levels seen in benign or malignant tumors might be effective for prevention or treatment of human cancer.	NCI, Frederick Canc Res & Dev Ctr, Lab Biochem Physiol, Frederick, MD 21702 USA; Georgetown Univ, Washington, DC USA; NCI, Frederick Canc Res & Dev Ctr, ABL, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Li, JJ (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Lab Biochem Physiol, Frederick, MD 21702 USA.			Li, Jian Jian/0000-0003-3694-9675				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Antinore MJ, 1996, EMBO J, V15, P1950, DOI 10.1002/j.1460-2075.1996.tb00546.x; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEAUPARLANT P, 1994, ONCOGENE, V9, P3189; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; CARROLL R, 1991, J VIROL, V65, P3460, DOI 10.1128/JVI.65.7.3460-3467.1991; CHEN TM, 1993, CANCER RES, V53, P1167; CHENG J, 1992, GENE DEV, V6, P1444, DOI 10.1101/gad.6.8.1444; COLBURN NH, 1982, J CELL BIOCHEM, V18, P261, DOI 10.1002/jcb.1982.240180302; COLBURN NH, 1981, P NATL ACAD SCI-BIOL, V78, P6912, DOI 10.1073/pnas.78.11.6912; COLBURN NH, 1979, NATURE, V281, P589, DOI 10.1038/281589a0; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; CZEGLEDY J, 1994, INT J CANCER, V56, P182, DOI 10.1002/ijc.2910560206; Dong ZG, 1997, MOL CARCINOGEN, V19, P204, DOI 10.1002/(SICI)1098-2744(199707)19:3<204::AID-MC8>3.0.CO;2-D; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; DRINKWATER NR, 1989, GENES SIGNAL TRANSDU, P3; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GREENHALGH DA, 1995, CELL GROWTH DIFFER, V6, P579; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; Joseloff E, 1997, MOL CARCINOGEN, V18, P26, DOI 10.1002/(SICI)1098-2744(199701)18:1<26::AID-MC4>3.0.CO;2-P; KEMP CJ, 1994, COLD SPRING HARB SYM, V59, P427, DOI 10.1101/SQB.1994.059.01.048; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; Li JJ, 1996, CANCER RES, V56, P483; Li JJ, 1997, CANCER RES, V57, P3569; LI JJ, 1995, ONCOGENE, V10, P1989; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; PEI XF, 1993, VIROLOGY, V196, P855, DOI 10.1006/viro.1993.1546; Rosenberger SF, 1996, ONCOGENE, V12, P2301; SCHLEGEL R, 1988, EMBO J, V7, P3181, DOI 10.1002/j.1460-2075.1988.tb03185.x; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STELLMACH V, 1991, P NATL ACAD SCI USA, V88, P4582, DOI 10.1073/pnas.88.11.4582; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; WATTS RG, 1995, MOL CARCINOGEN, V13, P27, DOI 10.1002/mc.2940130106; WEINBERG RA, 1989, CANCER RES, V49, P3713; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Wilding J, 1996, CANCER RES, V56, P5285; Yamagata T, 1997, MOL CELL BIOL, V17, P4272, DOI 10.1128/MCB.17.8.4272	49	101	104	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	1998	16	21					2711	2721		10.1038/sj.onc.1201798	http://dx.doi.org/10.1038/sj.onc.1201798			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ013	9652737				2022-12-25	WOS:000073812200002
J	Burgers, PMJ; Gerik, KJ				Burgers, PMJ; Gerik, KJ			Structure and processivity of two forms of Saccharomyces cerevisiae DNA polymerase delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; REPLICATION FACTOR-C; S-PHASE; EPSILON; PURIFICATION; TEMPLATE; ANALOG; ORIGIN; ERRORS	Yeast DNA polymerase delta (Pol delta) consists of three subunits encoded by the POL3, POL31, and POL32 genes. Each of these genes was cloned under control of the galactose-inducible GAL1-10 promoter and overexpressed in various combinations. Overexpression of all three genes resulted in a 30-fold overproduction of Pol delta, which was identical in enzymatic properties to Pol delta isolated from a wild-type yeast strain. Whereas overproduction of POL3 together with POL32 did not lead to an identifiable Pol3p.Pol32p complex, a chromatographically distinct and novel complex was identified upon overproduction of POL3 and POL31, This two-subunit complex, designated Pol delta*:, is structurally and functionally analogous to mammalian Pol delta. The properties of Pol delta* and Pol delta were compared. A gel filtration analysis showed that Pol delta* is a heterodimer (Pol3p.Pol31p) and Pol delta a dimer of a heterotrimer, (Pol3p.Pol31p.Pol32p)(2). In the absence of proliferating cell nuclear antigen (PCNA), Pol delta* showed a processivity of 2-3 on poly(dA) oligo(dT) compared with 5-10 for Pol delta. In the presence of PCNA, both enzymes were fully processive on this template. DNA replication by Pol delta* on a natural DNA template was dependent on PCNA and on replication factor C. However, Pol delta*-mediated DNA synthesis proceeded inefficiently and was characterized by frequent pause sites. Reconstitution of Pol delta was achieved upon addition of Pol32p to Pol delta.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Burgers, PMJ (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA.		Burgers, Peter M/AAW-6621-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032431] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32431, R01 GM032431] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; BAUER GA, 1988, P NATL ACAD SCI USA, V85, P7506, DOI 10.1073/pnas.85.20.7506; BAUER GA, 1988, J BIOL CHEM, V263, P917; BUDD ME, 1993, MOL CELL BIOL, V13, P496, DOI 10.1128/MCB.13.1.496; BURGERS PMJ, 1988, J BIOL CHEM, V263, P925; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; BURGERS PMJ, 1993, J BIOL CHEM, V268, P19923; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; DOWNEY KM, 1990, BIOESSAYS, V12, P231, DOI 10.1002/bies.950120507; Eissenberg JC, 1997, MOL CELL BIOL, V17, P6367, DOI 10.1128/MCB.17.11.6367; FERGUSON BM, 1991, CELL, V65, P507, DOI 10.1016/0092-8674(91)90468-E; Gerik KJ, 1998, J BIOL CHEM, V273, P19747, DOI 10.1074/jbc.273.31.19747; Giot L, 1997, GENETICS, V146, P1239; GOULIAN M, 1990, J BIOL CHEM, V265, P16402; Hindges R, 1997, BIOL CHEM, V378, P345; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; MacNeill SA, 1996, EMBO J, V15, P4613, DOI 10.1002/j.1460-2075.1996.tb00839.x; MORRISON A, 1994, MOL GEN GENET, V242, P289, DOI 10.1007/BF00280418; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; MURAKAMI Y, 1993, J BIOL CHEM, V268, P11008; NG L, 1993, J BIOL CHEM, V268, P13571; PODUST LM, 1994, NUCLEIC ACIDS RES, V22, P2970, DOI 10.1093/nar/22.15.2970; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P5003, DOI 10.1021/bi00015a011; RIVIN CJ, 1980, J CELL BIOL, V85, P108, DOI 10.1083/jcb.85.1.108; Shcherbakova PV, 1996, GENETICS, V142, P717; SUGIMOTO K, 1995, NUCLEIC ACIDS RES, V23, P3493, DOI 10.1093/nar/23.17.3493; Sun YB, 1997, J BIOL CHEM, V272, P13013, DOI 10.1074/jbc.272.20.13013; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; YODER BL, 1991, J BIOL CHEM, V266, P22689; Zhou JQ, 1997, NUCLEIC ACIDS RES, V25, P1094, DOI 10.1093/nar/25.6.1094; Zlotkin T, 1996, EMBO J, V15, P2298, DOI 10.1002/j.1460-2075.1996.tb00583.x; Zuo SJ, 1997, P NATL ACAD SCI USA, V94, P11244, DOI 10.1073/pnas.94.21.11244	34	153	159	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19756	19762		10.1074/jbc.273.31.19756	http://dx.doi.org/10.1074/jbc.273.31.19756			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677406	hybrid			2022-12-25	WOS:000075125200058
J	Zhang, CJ; Cavenagh, MM; Kahn, RA				Zhang, CJ; Cavenagh, MM; Kahn, RA			A family of Arf effectors defined as suppressors of the loss of Arf function in the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; GTPASE-ACTIVATING PROTEIN; STATIONARY-PHASE; CHOLERA-TOXIN; TRANSPORT; COFACTOR; REENTRY; DNA	Arf proteins are ubiquitous, eukaryotic regulators of virtually every step of vesicular membrane traffic. ADP-ribosylation factors are essential in yeast and the lethality resulting from either overexpression or underexpression (deletion) of Arf genes has previously been ascribed to dysregulation of the secretory process. We have identified a family of four genes (Suppressors of Arf t(s), SAT) as high copy suppressors of a loss of function allele of ARF1 (arf1-3), Those proteins with SAT activity were found to contain a minimal consensus motif, including a C2C2H2 cluster with a novel and specific spacing. Genetic interactions between members of this family and with ARF1 are consistent with each sharing a common cellular pathway, Included in this family is Gcs1, a protein previously described (Poon, P. P., Wang, X., Rotman, M., Huber, I., Cukierman, E., Cassel, D., Singer, R. A. and Johnston, G. C. (1996) Proc. Natl. Acad, Sci. U. S. A. 93, 10074-10077) to possess Arf GTPase-activating protein (GAP) activity, demonstrating a direct interaction between Arf and at least one of these suppressors, The suppression of the loss of Arf function by overexpression of Gcs1 and demonstration of direct, preferential binding of Gcs1 to the activated form of Arf (Arf GTP) lead us to conclude that the biological role of Gcs1 is as an effector of the essential function of Arf in mitotic growth, rather than a down-regulator as implied by the biochemical (Arf GAP) activity. Suppression of the growth defect of al arf1(-3) cells was observed under conditions that did not alter the secretory defect associated with arf1(-) mutation, indicating that the essential role of Arf in eukaryotes can be distinguished from role(s) in the secretory pathway and appear to employ distinct pathways and effectors.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA	Emory University	Kahn, RA (corresponding author), Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA.	rkahn@bimcore.emory.edu	Kahn, Richard/ABD-2666-2020	Kahn, Richard/0000-0002-0259-0601	NIGMS NIH HHS [GM55823] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055823] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; Cross FR, 1997, YEAST, V13, P647, DOI 10.1002/(SICI)1097-0061(19970615)13:7<647::AID-YEA115>3.0.CO;2-#; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; DREBOT MA, 1987, P NATL ACAD SCI USA, V84, P7948, DOI 10.1073/pnas.84.22.7948; FILIPAK M, 1992, CURR GENET, V22, P471, DOI 10.1007/BF00326412; HammondsOdie LP, 1996, J BIOL CHEM, V271, P18859, DOI 10.1074/jbc.271.31.18859; IRELAND LS, 1994, EMBO J, V13, P3812, DOI 10.1002/j.1460-2075.1994.tb06692.x; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KAHN RA, 1995, J BIOL CHEM, V270, P143, DOI 10.1074/jbc.270.1.143; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; Leung DW, 1989, TECHNIQUE, V1, P11; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; PHILIPPSEN P, 1991, METHOD ENZYMOL, V194, P169; Poon PP, 1996, P NATL ACAD SCI USA, V93, P10074, DOI 10.1073/pnas.93.19.10074; Roth MG, 1997, CURR OPIN CELL BIOL, V9, P519, DOI 10.1016/S0955-0674(97)80028-2; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; RUDGE SA, 1998, IN PRESS MOL BIOL CE; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Sherman F., 1974, METHODS YEAST GENETI; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	28	72	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19792	19796		10.1074/jbc.273.31.19792	http://dx.doi.org/10.1074/jbc.273.31.19792			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677411	hybrid			2022-12-25	WOS:000075125200063
J	Khwaja, A; Lehmann, K; Marte, BM; Downward, J				Khwaja, A; Lehmann, K; Marte, BM; Downward, J			Phosphoinositide 3-kinase induces scattering and tubulogenesis in epithelial cells through a novel pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; MET RECEPTOR; C-MET; R-RAS; PROTEIN CAUSES; MDCK CELLS; TRANSFORMATION; MORPHOGENESIS	Hepatocyte growth factor/scatter factor (HGF/SF) treatment of the Madin-Darby canine kidney epithelial cell line causes scattering of cells grown in monolayer culture and the formation of branching tubules by cells grown in collagen gels. HGF/SF causes prolonged activation of both the mitogen-activated protein (MAP) kinase extracellular signal-regulated kinase 2 (ERK2) and the phosphoinositide 3-OH kinase (PI 3-kinase) target protein kinase B (PKB)/ Akt; inhibition of either the MAP kinase pathway by the MAP kinase/ERK kinase inhibitor PD98059 or the PI 3-kinase pathway by LY294002 blocks HGF/SF induction of scattering, although in morphologically distinct ways. Expression of constitutively activated PI 3-kinase, Pas, or R-Ras will cause scattering, but activated Raf will not, indicating that activation of the MAP kinase pathway is not sufficient for this response. Downstream of PI 3-kinase, activated PKB/Akt and Pac are both unable to induce scattering, implicating a novel pathway. Scattering induced by Pas or PI 3-kinase is sensitive to PD98059, as well as to LY294002, suggesting that basal MAP kinase activity is required, but not sufficient, for the scattering response. Induction of MDCk cell tubulogenesis in collagen gels by HGF/SF is inhibited by PD98059; expression of activated Pas and Raf causes disorganized growth in this system, but activated PI 3-kinase or R-Ras causes branching tubule formation similar to that seen with HGF/SF treatment. These data indicate that multiple signaling pathways acting downstream of Met and Pas are needed for these morphological effects; scattering is induced primarily by the PI 3-kinase pathway, which acts through effecters, other than PKB/Akt or Pac and requires at least basal MAP kinase function. Elevated PI 3-kinase activity induces tubulogenesis, but total inhibition and excess activation of the MAP kinase pathway both oppose this effect.	Imperial Canc Res Fund, London WC2A 3PX, England	Cancer Research UK	Downward, J (corresponding author), Imperial Canc Res Fund, 44 Lincolns Inn Fields, London WC2A 3PX, England.	downward@icrf.icnet.uk	Khwaja, Asim/C-1509-2008	Downward, Julian/0000-0002-2331-4729				BARDELLI A, 1992, ONCOGENE, V7, P1973; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CLARK P, 1994, J CELL SCI, V107, P1265; COX AD, 1994, ONCOGENE, V9, P3281; Fialka I, 1996, J CELL BIOL, V132, P1115, DOI 10.1083/jcb.132.6.1115; Fourier TM, 1996, J BIOL CHEM, V271, P22211, DOI 10.1074/jbc.271.36.22211; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Huff SY, 1997, ONCOGENE, V14, P133, DOI 10.1038/sj.onc.1200815; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Klinghoffer RA, 1996, MOL CELL BIOL, V16, P5905; LU PJ, 1995, J CELL BIOL, V129, P1363, DOI 10.1083/jcb.129.5.1363; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, ONCOGENE, V6, P501; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Rubio I, 1997, BIOCHEM J, V326, P891, DOI 10.1042/bj3260891; SAELMAN EUM, 1995, J CELL SCI, V108, P3531; SAEZ R, 1994, ONCOGENE, V9, P2977; SCHOENENBERGER CA, 1991, J CELL BIOL, V112, P873, DOI 10.1083/jcb.112.5.873; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3	52	200	201	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18793	18801		10.1074/jbc.273.30.18793	http://dx.doi.org/10.1074/jbc.273.30.18793			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668053	hybrid			2022-12-25	WOS:000074974700020
J	Zhang, ZS; Devarajan, P; Dorfman, AL; Morrow, JS				Zhang, ZS; Devarajan, P; Dorfman, AL; Morrow, JS			Structure of the ankyrin-binding domain of alpha-Na,K-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B PROTEINS; ALPHA-SUBUNIT; PLASMA-MEMBRANE; MOLECULAR-CLONING; SPECTRIN; RECEPTOR; IDENTIFICATION; NA,K-ATPASE; BETA; NA+,K+-ATPASE	The ankyrin 33-residue repeating motif, an L-shaped structure with protruding beta-hairpin tips, mediates specific macromolecular interactions with cytoskeletal, membrane, and regulatory proteins. The association between ankyrin and alpha-Na,K-ATPase, a ubiquitous membrane protein critical to vectorial transport of ions and nutrients, is required to assemble and stabilize Na,K-ATPase at the plasma membrane. alpha-Na,K-ATPase binds both red cell ankyrin (Ank(R) a product of the ANK1 gene) and Madin-Darby canine kidney cell ankyrin (Ank(G), a product of the ANK3 gene) utilizing residues 142-166 (SYYQEAKSSKIMESFK NMVPQQALV) in its second cytoplasmic domain Fusion peptides of glutathione S-transferase incorporating these 25 amino acids bind specifically to purified ankyrin (K-d = 118 +/- 50 nM). The three-dimensional structure (2.6 Angstrom) of this minimal ankyrin-binding motif, crystallized as the fusion protein, reveals a 7-residue loop with one charged hydrophilic face capping a double beta-strand, Comparison with ankyrin-binding sequences in p53, CD44, neurofascin/L1, and the inositol 1,4,5-trisphosphate receptor suggests that the valency and specificity of ankyrin binding is achieved by the interaction of 5-7-residue surface loops with the beta-hairpin tips of multiple ankyrin repeat units.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA	Yale University; Yale University	Morrow, JS (corresponding author), Yale Univ, Sch Med, Dept Pathol, 333 Cedar St, New Haven, CT 06510 USA.							[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Beck KA, 1997, J CELL SCI, V110, P1239; BENNETT V, 1992, J BIOL CHEM, V267, P8703; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BOURGUIGNON LYW, 1995, J BIOL CHEM, V270, P7257, DOI 10.1074/jbc.270.13.7257; BOURGUIGNON LYW, 1993, J IMMUNOL, V151, P6634; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; DAVIS JQ, 1990, J BIOL CHEM, V265, P17252; DAVIS JQ, 1993, J CELL BIOL, V121, P121, DOI 10.1083/jcb.121.1.121; Devarajan P, 1997, P NATL ACAD SCI USA, V94, P10711, DOI 10.1073/pnas.94.20.10711; Devarajan P, 1996, J CELL BIOL, V133, P819, DOI 10.1083/jcb.133.4.819; DEVARAJAN P, 1994, P NATL ACAD SCI USA, V91, P2965, DOI 10.1073/pnas.91.8.2965; DEVARAJAN P, 1996, MEMBRANE PROTEIN CYT, P97; DEVARAJAN P, 1997, MOL BIOL CELL S, V8, P305; DIEDERICH RJ, 1994, DEVELOPMENT, V120, P473; DONAHUE JP, 1994, P NATL ACAD SCI USA, V91, P12178, DOI 10.1073/pnas.91.25.12178; FERRANTE AW, 1995, P NATL ACAD SCI USA, V92, P1911, DOI 10.1073/pnas.92.6.1911; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; GREGORIO CC, 1994, J CELL BIOL, V125, P345, DOI 10.1083/jcb.125.2.345; GUNDERSEN D, 1991, J CELL BIOL, V112, P863, DOI 10.1083/jcb.112.5.863; INOUE J, 1993, ONCOGENE, V8, P2067; JONES TA, 1996, MANUAL O VERSION 5 1; JORDAN C, 1995, J BIOL CHEM, V270, P29971; KENNEDY SP, 1991, J CELL BIOL, V115, P267, DOI 10.1083/jcb.115.1.267; KERR L D, 1992, Current Opinion in Cell Biology, V4, P496, DOI 10.1016/0955-0674(92)90017-7; Leveillard Thierry, 1993, Gene Expression, V3, P135; LOKESHWAR VB, 1994, J CELL BIOL, V126, P1099, DOI 10.1083/jcb.126.4.1099; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MCTIGUE MA, 1995, J MOL BIOL, V246, P21, DOI 10.1006/jmbi.1994.0061; MICHAELY P, 1993, J BIOL CHEM, V268, P22703; Michaely P, 1992, Trends Cell Biol, V2, P127, DOI 10.1016/0962-8924(92)90084-Z; MORROW JS, 1989, J CELL BIOL, V108, P455, DOI 10.1083/jcb.108.2.455; MORROW JS, 1997, HDB PHYSIOL 14, P485; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nelson W J, 1990, Semin Cell Biol, V1, P359; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; SMITH PR, 1993, AM J PHYSIOL, V264, pC63, DOI 10.1152/ajpcell.1993.264.1.C63; ZHANG H, 1992, PLANT CELL, V4, P1575, DOI 10.1105/tpc.4.12.1575; ZHANG Z, 1997, AM CRYSTAL ASS NEWSL, V24, P129	43	76	77	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18681	18684		10.1074/jbc.273.30.18681	http://dx.doi.org/10.1074/jbc.273.30.18681			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668035	hybrid			2022-12-25	WOS:000074974700002
J	Phi-van, L; Sellke, C; von Bodenhausen, A; Stratling, WH				Phi-van, L; Sellke, C; von Bodenhausen, A; Stratling, WH			An initiation zone of chromosomal DNA replication at the chicken lysozyme gene locus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; XENOPUS EGG EXTRACT; MAMMALIAN-CELLS; RIBOSOMAL DNA; BROAD ZONE; ORIGIN; DOMAIN; SITES; EXPRESSION; REGION	The chicken lysozyme gene domain is distinguished by a broad knowledge of how its expression is regulated. Here, we examined the in vivo replication of the lysozyme gene locus using polymerase chain reaction amplification and competitive polymerase chain reaction of size-fractionated, nascent DNA strands. We found that DNA replication initiates at multiple sites within a broad initiation zone spanning at least 20 kilobases, which includes most of the lysozyme gene domain, The 5' border of this zone is probably located downstream of the lysozyme 5' nuclear matrix attachment region. Preferred initiation occurs in a 3'-located subzone. The initiation zone at the lysozyme gene locus is also active in nonexpressing Liver DU249 cells. Furthermore, examining the timing of DNA replication at the lysozyme gene locus revealed that the gene locus replicates early during S phase in both HD11 and DU249 cells, irrespective of its transcriptional activity.	Bundesforsch Anstalt Landwirtschaft, Inst Tierzucht & Tierverhalten, D-29223 Celle, Germany; Univ Hamburg, Inst Physiol Chem, D-20246 Hamburg, Germany	University of Hamburg	Phi-van, L (corresponding author), Bundesforsch Anstalt Landwirtschaft, Inst Tierzucht & Tierverhalten, Dornbergstr 25-27, D-29223 Celle, Germany.							ALADJEM MI, 1995, SCIENCE, V270, P815, DOI 10.1126/science.270.5237.815; ARIIZUMI K, 1993, P NATL ACAD SCI USA, V90, P3695, DOI 10.1073/pnas.90.8.3695; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BLOW JJ, 1990, J CELL SCI, V95, P383; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BURHANS WC, 1990, CELL, V62, P955, DOI 10.1016/0092-8674(90)90270-O; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COVERLEY D, 1994, ANNU REV BIOCHEM, V63, P745, DOI 10.1146/annurev.bi.63.070194.003525; DEPAMPHILIS ML, 1993, ANNU REV BIOCHEM, V62, P29; Dhar SK, 1996, MOL CELL BIOL, V16, P2314; DIJKWEL PA, 1991, MOL CELL BIOL, V11, P3850, DOI 10.1128/MCB.11.8.3850; DIJKWEL PA, 1992, MOL CELL BIOL, V12, P3715, DOI 10.1128/MCB.12.9.3715; DIJKWEL PA, 1988, MOL CELL BIOL, V8, P29; DIVIACCO S, 1992, GENE, V122, P313, DOI 10.1016/0378-1119(92)90220-J; DUBEY DD, 1994, EMBO J, V13, P3638, DOI 10.1002/j.1460-2075.1994.tb06671.x; EDENBERG HJ, 1975, ANNU REV GENET, V9, P245, DOI 10.1146/annurev.ge.09.120175.001333; ERISMAN MD, 1988, ONCOGENE HDB, P341; FANGMAN WL, 1992, CELL, V71, P363, DOI 10.1016/0092-8674(92)90505-7; GIACCA M, 1994, P NATL ACAD SCI USA, V91, P7119, DOI 10.1073/pnas.91.15.7119; GILBERT DM, 1995, MOL CELL BIOL, V15, P2942; GOETHE R, 1994, J BIOL CHEM, V269, P31302; GOLDMAN MA, 1984, SCIENCE, V224, P686, DOI 10.1126/science.6719109; HAHN M, 1988, MOL CELL BIOL, V8, P2659, DOI 10.1128/MCB.8.6.2659; HANDELI S, 1989, CELL, V57, P909, DOI 10.1016/0092-8674(89)90329-2; HATTON KS, 1988, MOL CELL BIOL, V8, P2149, DOI 10.1128/MCB.8.5.2149; HECK MMS, 1990, J CELL BIOL, V110, P903, DOI 10.1083/jcb.110.4.903; HEINTZ NH, 1982, P NATL ACAD SCI-BIOL, V79, P4083, DOI 10.1073/pnas.79.13.4083; HOLMQUIST GP, 1987, AM J HUM GENET, V40, P151; HOZAK P, 1993, CELL, V73, P361, DOI 10.1016/0092-8674(93)90235-I; HUBERMAN JA, 1968, J MOL BIOL, V32, P327, DOI 10.1016/0022-2836(68)90013-2; IKEGAMI S, 1978, NATURE, V275, P458, DOI 10.1038/275458a0; JACKSON DA, 1986, EMBO J, V5, P1403, DOI 10.1002/j.1460-2075.1986.tb04374.x; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; JANTZEN K, 1986, NUCLEIC ACIDS RES, V14, P6085, DOI 10.1093/nar/14.15.6085; JUNG A, 1980, P NATL ACAD SCI-BIOL, V77, P5759, DOI 10.1073/pnas.77.10.5759; KELLY RE, 1995, MOL CELL BIOL, V15, P4136; KITSBERG D, 1993, NATURE, V366, P588, DOI 10.1038/366588a0; Kumar S, 1996, NUCLEIC ACIDS RES, V24, P3289, DOI 10.1093/nar/24.17.3289; LANGLOIS AJ, 1974, CANCER RES, V34, P1457; LITTLE RD, 1993, MOL CELL BIOL, V13, P6600, DOI 10.1128/MCB.13.10.6600; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NEWPORT JW, 1990, J CELL BIOL, V111, P2247, DOI 10.1083/jcb.111.6.2247; Pelizon C, 1996, MOL CELL BIOL, V16, P5358; PHIVAN L, 1988, EMBO J, V7, P655, DOI 10.1002/j.1460-2075.1988.tb02860.x; PhiVan L, 1996, BIOCHEMISTRY-US, V35, P10735, DOI 10.1021/bi9603783; RAHMSDORF HJ, 1987, NUCLEIC ACIDS RES, V15, P1643, DOI 10.1093/nar/15.4.1643; SHINOMIYA T, 1993, MOL CELL BIOL, V13, P4098, DOI 10.1128/MCB.13.7.4098; SHINOMIYA T, 1994, MOL CELL BIOL, V14, P7394, DOI 10.1128/MCB.14.11.7394; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STRATLING WH, 1986, BIOCHEMISTRY-US, V25, P495, DOI 10.1021/bi00350a033; VASSILEV L, 1990, MOL CELL BIOL, V10, P4899, DOI 10.1128/MCB.10.9.4899; VASSILEV L, 1989, NUCLEIC ACIDS RES, V17, P7693, DOI 10.1093/nar/17.19.7693; VASSILEV LT, 1992, CRIT REV BIOCHEM MOL, V27, P445, DOI 10.3109/10409239209082569; VASSILEV LT, 1990, MOL CELL BIOL, V10, P4685, DOI 10.1128/MCB.10.9.4685; VAUGHN JP, 1990, CELL, V61, P1075, DOI 10.1016/0092-8674(90)90071-L; VITRAPERLMAN VJ, 1993, MOL CELL BIOL, V13, P5931; Wang ST, 1998, MOL CELL BIOL, V18, P39, DOI 10.1128/MCB.18.1.39; YOON Y, 1995, MOL CELL BIOL, V15, P2482; ZHU J, 1992, CHROMOSOMA, V102, P7	59	23	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18300	18307		10.1074/jbc.273.29.18300	http://dx.doi.org/10.1074/jbc.273.29.18300			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660795	hybrid			2022-12-25	WOS:000074828500050
J	Price, ER; Ding, HF; Badalian, T; Bhattacharya, S; Takemoto, C; Yao, TP; Hemesath, TJ; Fisher, DE				Price, ER; Ding, HF; Badalian, T; Bhattacharya, S; Takemoto, C; Yao, TP; Hemesath, TJ; Fisher, DE			Lineage-specific signaling in melanocytes - c-Kit stimulation recruits p300/CBP to microphthalmia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RUBINSTEIN-TAYBI-SYNDROME; RECEPTOR TYROSINE KINASE; NUCLEAR-PROTEIN CBP; TRANSCRIPTION FACTOR; GENE-PRODUCT; IN-VIVO; HISTONE ACETYLTRANSFERASE; CONSERVED FAMILY; PHOSPHATASE SHP1; MAST-CELLS	During melanocyte development, the cytokine Steel factor activates its receptor c-Kit, initiating a signal transduction cascade, which is vital for lineage determination via unknown downstream nuclear targets. c-Kit has recently been found to trigger mitogen-activated protein kinase-mediated phosphorylation of Microphthalmia (Mi), a lineage-restricted transcription factor, which, like Steel factor and c-Kit, is essential for melanocyte development. This cascade results in increased Mi-dependent transcriptional reporter activity, Here we examine the mechanism by which Mi is activated by this pathway. Phosphorylation does not significantly alter Mi's nuclear localization, DNA binding, or dimerization, However, the transcriptional coactivator p300/CBP selectively associates with mitogen-activated protein kinase-phosphorylated Mi, even under conditions in which non-MAPK phospho-Mi is more abundant. Moreover, p300/CBP coactivates Mi transcriptional activity in a manner dependent upon this phosphorylation, Mi thus joins CREB as a transcription factor whose signal-responsive phosphorylation regulates coactivator recruitment, in this case modulating lineage development in melanocytes.	Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Fisher, DE (corresponding author), Dana Farber Canc Inst, Boston, MA 02115 USA.		Takemoto, Clifford M/Y-7558-2018; Bhattacharya, Shoumo/F-4127-2010	Bhattacharya, Shoumo/0000-0002-5571-0478; Ding, Han-Fei/0000-0001-5702-3439				ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bannister AJ, 1995, ONCOGENE, V11, P2509; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENTLEY NJ, 1994, MOL CELL BIOL, V14, P7996, DOI 10.1128/MCB.14.12.7996; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; Bertolotto C, 1996, J CELL BIOL, V134, P747, DOI 10.1083/jcb.134.3.747; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; Costa JJ, 1996, J EXP MED, V183, P2681, DOI 10.1084/jem.183.6.2681; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DUBREUIL P, 1991, P NATL ACAD SCI USA, V88, P2341, DOI 10.1073/pnas.88.6.2341; ECKNER R, 1994, COLD SPRING HARB SYM, V59, P85, DOI 10.1101/SQB.1994.059.01.012; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FLEISCHMAN RA, 1992, J CLIN INVEST, V89, P1713, DOI 10.1172/JCI115772; FRYNS JP, 1995, J MED GENET, V32, P668, DOI 10.1136/jmg.32.8.668; Halaban R, 1996, J INVEST DERMATOL, V106, P1266, DOI 10.1111/1523-1747.ep12348972; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; Hemesath TJ, 1998, NATURE, V391, P298, DOI 10.1038/34681; HERRANZ P, 1994, CLIN EXP DERMATOL, V19, P170, DOI 10.1111/j.1365-2230.1994.tb01152.x; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Hurlin PJ, 1995, ONCOGENE, V11, P2487; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lenormand JL, 1997, MOL CELL BIOL, V17, P584, DOI 10.1128/MCB.17.2.584; Lorenz U, 1996, J EXP MED, V184, P1111, DOI 10.1084/jem.184.3.1111; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOGHAL N, 1995, MOL CELL BIOL, V15, P3945; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Paulson RF, 1996, NAT GENET, V13, P309, DOI 10.1038/ng0796-309; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Sato S, 1997, ONCOGENE, V14, P3083, DOI 10.1038/sj.onc.1201298; SVIDERSKAYA EV, 1995, DEVELOPMENT, V121, P1547; TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194-251; Tsujimura T, 1996, BLOOD, V88, P1225, DOI 10.1182/blood.V88.4.1225.bloodjournal8841225; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YASUMOTO KI, 1994, MOL CELL BIOL, V14, P8058, DOI 10.1128/MCB.14.12.8058; YAVUZER U, 1995, ONCOGENE, V10, P123; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	50	152	152	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					17983	17986		10.1074/jbc.273.29.17983	http://dx.doi.org/10.1074/jbc.273.29.17983			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660747	hybrid			2022-12-25	WOS:000074828500002
J	Yue, CP; Dodge, KL; Weber, G; Sanborn, BM				Yue, CP; Dodge, KL; Weber, G; Sanborn, BM			Phosphorylation of serine 1105 by protein kinase A inhibits phospholipase C beta(3) stimulation by G alpha(q)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT MYOMETRIAL CELLS; CYCLIC-AMP; ALPHA-SUBUNITS; SMOOTH-MUSCLE; C ACTIVITY; ACTIVATION; ADENOSINE-3',5'-MONOPHOSPHATE; PURIFICATION; CALCIUM; CONTRACTION	The mechanism by which protein kinase A (PKA) inhibits G alpha(q)-stimulated phospholipase C activity of the beta subclass (PLC beta) is unknown. We present evidence that phosphorylation of PLC beta(3) by PKA results in inhibition of G alpha(q)-stimulated PLC beta(3) activity, and we identify the site of phosphorylation. Two-dimensional phosphoamino acid analysis of in vitro phosphorylated PLC beta(3) revealed a single phosphoserine as the putative PKA site, and peptide mapping yielded one phosphopeptide. The residue was identified as Ser(1105) by direct sequencing of reverse-phase high pressure liquid chromatography-isolated phosphopeptide and by site-directed mutagenesis. Overexpression of G alpha(q) with PLC beta(3) or PLCP, (Serll05 --> Ala) mutant in COSM6 cells resulted in a 5-fold increase in [H-3]phosphatidylinositol 1,4,5trisphosphate formation compared with expression of G alpha(q), PLC beta(3), or PLC beta(3), (Ser(1105) --> Ala) mutant alone. Whereas G alpha(q)-stimulated PLC beta(3) activity was inhibited by 58-71% by overexpression of PKA catalytic subunit, G alpha(q)-stimulated PLC beta(3) (Ser(1105) --> Ala) mutant activity was not affected. Furthermore, phosphatidylinositide turnover stimulated by presumably G alpha(q)-coupled M1 muscarinic and oxytocin receptors was completely inhibited by pretreating cells with 8-[4-chlorophenythio]cAMP in RBL-2H3 cells expressing only PLCP beta(3). These data establish that direct phosphorylation by PKA of Ser(1105) in the putative G-box of PLC beta(3) inhibits G alpha(q)-stimulated PLC beta(3) activity. This can at least partially explain the inhibitory effect of PKA on G alpha(q)-stimulated phosphatidylinositide turnover observed in a variety of cells and tissues.	Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77225 USA; Karolinska Hosp, Dept Mol Med, Clin Genet Unit, CMM, S-17176 Stockholm, Sweden	University of Texas System; Karolinska Institutet; Karolinska University Hospital	Sanborn, BM (corresponding author), Univ Texas, Sch Med, Dept Biochem & Mol Biol, POB 20708, Houston, TX 77225 USA.	bsanborn@bmb.med.uth.tmc.edu	Weber, Günther/F-3410-2016	Weber, Gunther/0000-0002-3861-808X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD009618, R01HD009618, T32HD007325] Funding Source: NIH RePORTER; NICHD NIH HHS [T32 HD07325, HD09618] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ali H, 1997, J BIOL CHEM, V272, P11706, DOI 10.1074/jbc.272.18.11706; ARNAUDEAU S, 1994, PFLUG ARCH EUR J PHY, V428, P51, DOI 10.1007/BF00374751; BLACKMORE PF, 1986, J BIOL CHEM, V261, P1056; Dodge KL, 1998, ENDOCRINOLOGY, V139, P2265, DOI 10.1210/en.139.5.2265; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; Hoiting BH, 1996, BRIT J PHARMACOL, V117, P419, DOI 10.1111/j.1476-5381.1996.tb15207.x; HSU CJ, 1985, ENDOCRINOLOGY, V116, P2029, DOI 10.1210/endo-116-5-2029; JHON DY, 1993, J BIOL CHEM, V268, P6654; Jiang HP, 1996, J BIOL CHEM, V271, P13430, DOI 10.1074/jbc.271.23.13430; Kim CG, 1996, J BIOL CHEM, V271, P21187, DOI 10.1074/jbc.271.35.21187; KOZASA T, 1993, P NATL ACAD SCI USA, V90, P9176, DOI 10.1073/pnas.90.19.9176; KU CY, 1995, ENDOCRINOLOGY, V136, P1509, DOI 10.1210/en.136.4.1509; LAGERCRANTZ J, 1995, GENOMICS, V26, P467, DOI 10.1016/0888-7543(95)80164-H; Laglia G, 1996, ENDOCRINOLOGY, V137, P3170, DOI 10.1210/en.137.8.3170; Liu MY, 1996, NATURE, V382, P83, DOI 10.1038/382083a0; LOUNSBURY KM, 1993, J BIOL CHEM, V268, P3494; MCATEE P, 1990, J BIOL CHEM, V265, P6788; Meij JTA, 1996, BIOCHEM BIOPH RES CO, V225, P705, DOI 10.1006/bbrc.1996.1239; PITTNER RA, 1989, BIOCHEM J, V257, P455, DOI 10.1042/bj2570455; RAO MR, 1986, ENDOCRINOLOGY, V119, P435; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Richardson RM, 1998, J BIOL CHEM, V273, P10690, DOI 10.1074/jbc.273.17.10690; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; TACHADO SD, 1992, CELL SIGNAL, V4, P61, DOI 10.1016/0898-6568(92)90008-V; TAGUCHI M, 1988, ENDOCRINOLOGY, V123, P2019, DOI 10.1210/endo-123-4-2019; WEN YS, 1992, ENDOCRINOLOGY, V131, P1377, DOI 10.1210/en.131.3.1377; WU DQ, 1995, J BIOL CHEM, V270, P16008, DOI 10.1074/jbc.270.27.16008; WU DQ, 1993, J BIOL CHEM, V268, P3704; WU DQ, 1992, J BIOL CHEM, V267, P1811; YADA Y, 1989, FEBS LETT, V242, P368, DOI 10.1016/0014-5793(89)80503-4	30	90	92	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18023	18027		10.1074/jbc.273.29.18023	http://dx.doi.org/10.1074/jbc.273.29.18023			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660757	hybrid			2022-12-25	WOS:000074828500012
J	Kaur, P; Russell, J				Kaur, P; Russell, J			Biochemical coupling between the DrrA and DrrB proteins of the doxorubicin efflux pump of Streptomyces peucetius	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPORT; CELLS	The drrAB operon of Streptomyces peucetius encodes for resistance to the antibiotics doxorubicin and daunorubicin, Subcloning of the drrAB genes in Escherichia coli has previously been shown to result in expression of DrrA and DrrB proteins and resistance to doxorubicin in a sensitive strain of E, coli, DrrA, a peripheral membrane protein, binds ATP in a UV-catalyzed reaction in a doxorubicin-dependent manner; DrrB, a hydrophobic protein, is localized to the inner membrane of E, coli (Kaur, P, (1997) J, Bacteriol. 179, 569-575), The present study provides evidence that DrrB, the membrane component of the complex, is stably maintained in the cell only if DrrA is present. Furthermore, it was found that the catalytic component DrrA is in an active conformation only when it is in a complex with DrrB, In a subclone containing the drrB gene by itself, no DrrB protein could be detected, although a translational fusion of the first 15 amino acids of DrrB to beta-galactosidase indicated that DrrB is translated in the absence of DrrA, Upon co-transformation with a plasmid containing the drrA gene in trans, DrrB could again be detected in these cells. UV cross-linking studies with [alpha-P-32]ATP showed that only the membrane bound form of DrrA in cells containing both DrrA and DrrB was in a conformation competent to bind ATP, Chemical cross linking studies also provided direct evidence for interaction between the two proteins. Based on these analyses, a model for interaction between DrrA and DrrB proteins is presented.	Georgia State Univ, Dept Biol, Atlanta, GA 30303 USA	University System of Georgia; Georgia State University	Kaur, P (corresponding author), Georgia State Univ, Dept Biol, 24 Peachtree Ctr Ave, Atlanta, GA 30303 USA.				NIGMS NIH HHS [R29 GM51981-02] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM051981] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GUILFOILE PG, 1991, P NATL ACAD SCI USA, V88, P8553, DOI 10.1073/pnas.88.19.8553; Hwang JW, 1997, J BACTERIOL, V179, P6264, DOI 10.1128/jb.179.20.6264-6270.1997; KAUR P, 1993, J BACTERIOL, V175, P351, DOI 10.1128/JB.175.2.351-357.1993; Kaur P, 1997, J BACTERIOL, V179, P569, DOI 10.1128/jb.179.3.569-575.1997; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; Miller JH., 1992, EXPT MOL GENETICS; REIZER J, 1992, PROTEIN SCI, V1, P1326, DOI 10.1002/pro.5560011012; Sambrook J., 2002, MOL CLONING LAB MANU; SENIOR AE, 1995, J BIOENERG BIOMEMBR, V27, P31, DOI 10.1007/BF02110328; YUE VT, 1977, BIOCHEMISTRY-US, V16, P4678, DOI 10.1021/bi00640a023	12	41	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17933	17939		10.1074/jbc.273.28.17933	http://dx.doi.org/10.1074/jbc.273.28.17933			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651400	hybrid			2022-12-25	WOS:000074816100093
J	Tzingounis, AV; Lin, CL; Rothstein, JD; Kavanaugh, MP				Tzingounis, AV; Lin, CL; Rothstein, JD; Kavanaugh, MP			Arachidonic acid activates a proton current in the rat glutamate transporter EAAT4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR PURKINJE-CELLS; GATED CHLORIDE CHANNEL; SYNAPTIC TRANSMISSION; INTRACELLULAR PH; GLIAL-CELLS; ION FLUXES; SALAMANDER; SYNAPTOSOMES; MODULATION; SYNAPSES	The excitatory amino acid transporter EAAT4 is expressed predominantly in Purkinje neurons in the rat cerebellum (1-3), and it participates in postsynaptic reuptake of glutamate released at the climbing fiber syn apse (4). Transporter-mediated currents in Purkinje neurons are increased more than 3-fold by arachidonic acid, a second messenger that is liberated following de polarization-induced Ca2+ activation of phospholipase A(2) (5). In this study we demonstrate that application of arachidonic acid to oocytes expressing rat EAAT4 increased glutamate-induced currents to a similar extent. However, arachidonic acid did not cause an increase in the rate of glutamate transport or in the chloride current associated with glutamate transport but rather activated a proton-selective conductance. These data reveal a novel action of arachidonate on a glutamate transporter and suggest a mechanism by which synaptic activity may decrease intracellular pH in neurons where this transporter is localized.	Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA; Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21205 USA	Oregon Health & Science University; Johns Hopkins University	Kavanaugh, MP (corresponding author), Oregon Hlth Sci Univ, Vollum Inst, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	kavanaug@ohsu.edu	rothstein, jeffrey d/C-9470-2013; Lin, Chien-liang G/E-3513-2011		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033270] Funding Source: NIH RePORTER; NINDS NIH HHS [NS33270] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARBOUR B, 1989, NATURE, V342, P918, DOI 10.1038/342918a0; BARBOUR B, 1994, NEURON, V12, P1331, DOI 10.1016/0896-6273(94)90448-0; Bergles DE, 1997, P NATL ACAD SCI USA, V94, P14821, DOI 10.1073/pnas.94.26.14821; Billups B, 1996, J NEUROSCI, V16, P6722; Cao YW, 1997, J NEUROSCI, V17, P2257; CHAN PH, 1983, J NEUROCHEM, V40, P309, DOI 10.1111/j.1471-4159.1983.tb11284.x; Clark BA, 1997, J PHYSIOL-LONDON, V502, P335, DOI 10.1111/j.1469-7793.1997.335bk.x; DUMUIS A, 1988, NATURE, V336, P68, DOI 10.1038/336068a0; Eliasof S, 1998, J NEUROSCI, V18, P698; Fairman W. A., 1997, Society for Neuroscience Abstracts, V23, P1790; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; Furuta A, 1997, NEUROSCIENCE, V81, P1031, DOI 10.1016/S0306-4522(97)00252-2; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P279; Kataoka Y, 1997, J NEUROSCI, V17, P7017; LEHRE KP, 1995, J NEUROSCI, V15, P1835; Linden DJ, 1995, NEURON, V15, P1393, DOI 10.1016/0896-6273(95)90017-9; Malandro MS, 1996, ANNU REV BIOCHEM, V65, P305; Nagao S, 1997, NEUROSCIENCE, V78, P929; Otis TS, 1997, SCIENCE, V277, P1515, DOI 10.1126/science.277.5331.1515; PICAUD SA, 1995, J NEUROPHYSIOL, V74, P1760, DOI 10.1152/jn.1995.74.4.1760; RHOADS DE, 1982, J NEUROCHEM, V38, P1255, DOI 10.1111/j.1471-4159.1982.tb07898.x; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; SCHWARTZ EA, 1990, J PHYSIOL-LONDON, V426, P43, DOI 10.1113/jphysiol.1990.sp018126; Sonders MS, 1997, J NEUROSCI, V17, P960; Takahashi KI, 1996, NEUROSCI RES, V24, P109, DOI 10.1016/0168-0102(95)00989-2; Takahashi M, 1997, J EXP BIOL, V200, P401; Takahashi M, 1996, J PHYSIOL-LONDON, V497, P523, DOI 10.1113/jphysiol.1996.sp021785; TAKAHASHI M, 1995, J NEUROSCI, V15, P5693; VANDENBERG RJ, 1995, J BIOL CHEM, V270, P17668, DOI 10.1074/jbc.270.30.17668; VOLTERRA A, 1992, J NEUROCHEM, V59, P600, DOI 10.1111/j.1471-4159.1992.tb09411.x; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; WEBB DJ, 1981, J CELL BIOL, V91, P562, DOI 10.1083/jcb.91.2.562; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0; Yamada K, 1996, NEUROREPORT, V7, P2013, DOI 10.1097/00001756-199608120-00032; ZERANGUE N, 1995, J BIOL CHEM, V270, P6433, DOI 10.1074/jbc.270.12.6433; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0	36	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17315	17317		10.1074/jbc.273.28.17315	http://dx.doi.org/10.1074/jbc.273.28.17315			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651313	Green Published, hybrid			2022-12-25	WOS:000074816100006
J	Doza, YN; Hall-Jackson, CA; Cohen, P				Doza, YN; Hall-Jackson, CA; Cohen, P			Arsenite blocks growth factor induced activation of the MAP kinase cascade, upstream of Ras and downstream of Grb2-Sos	ONCOGENE			English	Article						Raf; MAP kinase kinase (MKK); p70 S6 kinase; mSos; EGF-receptor; stress	MITOGENIC SIGNAL-TRANSDUCTION; PROTEIN-TYROSINE-PHOSPHATASE; L6 MUSCLE-CELLS; NUCLEOTIDE EXCHANGE; PLASMA-MEMBRANE; PC12 CELLS; DOWN-REGULATION; HEAT-SHOCK; RECEPTOR; PATHWAY	Pretreatment of cells with 0.5 mM sodium arsenite (but not other activators of stress-activated MAP kinase cascades) prevents the activation of p21Ras and strongly suppresses the activation of c-Raf and the MAP kinase cascade by a variety of growth factors. Arsenite appears to exert its effect by preventing the guanine nucleotide exchange factor mSos from converting Pas to its active GTP-bound state. Exposure to arsenite may be a simple way of assessing whether Pas plays an essential role in mediating activation of the MAP kinase cascade by extracellular signals.	Univ Dundee, Inst Med Sci, Dept Biochem, MRC Prot Phosphorylat Unit, Dundee DD1 4HN, Scotland	University of Dundee	Cohen, P (corresponding author), Univ Dundee, Inst Med Sci, Dept Biochem, MRC Prot Phosphorylat Unit, Dundee DD1 4HN, Scotland.							ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Ali S, 1996, EMBO J, V15, P135, DOI 10.1002/j.1460-2075.1996.tb00341.x; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BAXTER RM, 1995, EUR J BIOCHEM, V234, P84, DOI 10.1111/j.1432-1033.1995.084_c.x; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1995, ONCOGENE, V11, P1327; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; CorbalanGarcia S, 1996, ONCOGENE, V12, P1063; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; DOWNWARD J, 1995, METHOD ENZYMOL, V255, P110; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; HUNDAL HS, 1992, ENDOCRINOLOGY, V131, P1165, DOI 10.1210/en.131.3.1165; JOHNSTON D, 1980, J BIOL CHEM, V255, P6975; KLARLUND JK, 1995, J BIOL CHEM, V270, P23421, DOI 10.1074/jbc.270.40.23421; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MITSUMOTO Y, 1992, J BIOL CHEM, V267, P4957; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; ROSSOMANDO AJ, 1994, MOL CELL BIOL, V14, P1594, DOI 10.1128/MCB.14.3.1594; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; TANGUAY RM, 1983, CAN J BIOCHEM CELL B, V61, P414, DOI 10.1139/o83-056; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TRAVERSE S, 1993, ONCOGENE, V8, P3175; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; XIAO S, 1994, J BIOL CHEM, V269, P21244	41	22	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 9	1998	17	1					19	24		10.1038/sj.onc.1202168	http://dx.doi.org/10.1038/sj.onc.1202168			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZY936	9671310				2022-12-25	WOS:000074677800003
J	Barnache, S; Wendling, F; Lacombe, C; Denis, N; Titeux, M; Vainchenker, W; Moreau-Gachelin, F				Barnache, S; Wendling, F; Lacombe, C; Denis, N; Titeux, M; Vainchenker, W; Moreau-Gachelin, F			Spi-1 transgenic mice develop a clonal erythroleukemia which does not depend on p53 mutation	ONCOGENE			English	Article						Spi-1/PU.1; p53; transgenic; leukemia; Friend	VIRUS-INDUCED ERYTHROLEUKEMIA; FOCUS-FORMING VIRUS; FRIEND-VIRUS; ERYTHROPOIETIN RECEPTOR; TRANSCRIPTION FACTOR; TUMORIGENIC CELLS; PUTATIVE ONCOGENE; LEUKEMIA-VIRUS; GENE; ACTIVATION	Spi-1 transcriptional activation and wild-type p53 extinction are two oncogenic alterations involved in the malignant transformation of erythroblasts during the Friend acute erythroleukemia, To dissect the contribution of these alterations in the deregulation of the differentiation and proliferation of erythroblasts, we generated spi-1 transgenic mice. Analysis of these animals revealed that Spi-1 overexpression was directly involved in the block of proerythroblast differentiation. However, the erythroleukemia that develops in these animals evolved in two steps. During the early step (HS1 step), non tumorigenic proerythroblasts remained strictly dependent upon erythropoietin (Epo) for their survival and proliferation. Later on, Epo-independent and tumorigenic proerythroblasts emerged (HS2 step) suggesting that other oncogenes cooperate with Spi-1 to lead to a fully malignant phenotype, By provirus tagging, we demonstrate that the HS1 step was clonal indicating that a cell selection must occur in vivo. Analysis of the nature of p53 in both the in vivo HS1 and HS2 proerythroblasts and in cultured erythroblastic cell lines showed that-p53 was normal in the HS1 primary tissues but was mutated in the HS1 cultured cell lines-p53 was frequently altered in HS2 primary tissues but was found normal in some mice. These data indicate that (1) the blockage of the erythroblast differentiation by Spi-1 occurs independently of p53 alteration (ii) p53 alteration is not necessary to confer Epo independence and tumorigenicity to spi-1 transgenic proerythroblasts.	Inst Curie, INSERM U248, F-75005 Paris, France; Inst Gustave Roussy, INSERM U362, F-94800 Villejuif, France; Hop Cochin, ICGM, INSERM U363, F-75014 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier	Moreau-Gachelin, F (corresponding author), Inst Curie, INSERM U248, 26 Rue Ulm, F-75005 Paris, France.			Vainchenker, William/0000-0003-4705-202X				AIZAWA S, 1990, EMBO J, V9, P2107, DOI 10.1002/j.1460-2075.1990.tb07379.x; BASSIN RH, 1971, NATURE, V229, P564, DOI 10.1038/229564b0; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVID YB, 1988, ONCOGENE, V3, P179; ELIYAHU D, 1988, ONCOGENE, V3, P313; ELLIOTT JI, 1995, EMBO J, V14, P575, DOI 10.1002/j.1460-2075.1995.tb07033.x; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Hallier M, 1998, J BIOL CHEM, V273, P4838, DOI 10.1074/jbc.273.9.4838; HICKS GG, 1988, J VIROL, V62, P4752, DOI 10.1128/JVI.62.12.4752-4755.1988; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LAVIGUEUR A, 1991, ONCOGENE, V6, P2197; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LONGMORE GD, 1991, CELL, V67, P1089, DOI 10.1016/0092-8674(91)90286-8; MAGER DL, 1981, P NATL ACAD SCI-BIOL, V78, P1703, DOI 10.1073/pnas.78.3.1703; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Milot E, 1996, CELL, V87, P105, DOI 10.1016/S0092-8674(00)81327-6; MOREAUGACHELIN F, 1986, J VIROL, V57, P349, DOI 10.1128/JVI.57.1.349-352.1986; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1985, J VIROL, V53, P292, DOI 10.1128/JVI.53.1.292-295.1985; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOREAUGACHELIN F, 1983, BIOCHIMIE, V65, P259, DOI 10.1016/S0300-9084(83)80277-6; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; MUNROE DG, 1988, ONCOGENE, V2, P621; PAUL R, 1989, J VIROL, V63, P4958, DOI 10.1128/JVI.63.11.4958-4961.1989; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; Quang CT, 1997, EMBO J, V16, P5639, DOI 10.1093/emboj/16.18.5639; SCHUETZE S, 1992, MOL CELL BIOL, V12, P2967, DOI 10.1128/MCB.12.7.2967; Scott EW, 1997, IMMUNITY, V6, P437, DOI 10.1016/S1074-7613(00)80287-3; SITBON M, 1986, CELL, V47, P851, DOI 10.1016/0092-8674(86)90800-7; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; WENDLING F, 1981, P NATL ACAD SCI-BIOL, V78, P3614, DOI 10.1073/pnas.78.6.3614; WENDLING F, 1983, TUMOR VIRUSES DIFFER, P357; WOLFF L, 1985, SCIENCE, V228, P1549, DOI 10.1126/science.2990034	46	20	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 11	1998	16	23					2989	2995		10.1038/sj.onc.1202095	http://dx.doi.org/10.1038/sj.onc.1202095			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZT782	9662331				2022-12-25	WOS:000074125300005
J	Liu, NS; Lucibello, FC; Engeland, K; Muller, R				Liu, NS; Lucibello, FC; Engeland, K; Muller, R			A new model of cell cycle-regulated transcription: Repression of the cyclin A promoter by CDF-1 and anti-repression by E2F	ONCOGENE			English	Article						cyclin A; CDF; E2F; transcriptional repression	B-MYB TRANSCRIPTION; CDC25C TRANSCRIPTION; IN-VIVO; A GENE; SITE; EXPRESSION; INITIATION; ELEMENT; COMPLEX	Cell cycle regulation of the cyclin A gene is determined by a bipartite repressor binding site in the region of the basal promoter, termed CDE-CHR, which also controls the expression of cell cycle genes upregulated in S or G(2) (such as cdc25C). The CDE-CHR in the cyclin A promoter is recognized by both E2F complexes and CDF-1, but the contribution of each of these factors in cell cycle regulation is unknown. In the present study, we have introduced mutations into the cyclin A promoter which lead to either a loss or enhancement of E2F binding, while having only marginal effects on the interaction with CDF-1. Unlike mutants deficient for CDF-1 binding, promoter variants lacking E2F binding showed an unchanged repression in G(0), thus identifying CDF-1 as the principal repressor of the cyclin A gene. The same mutants did show, however, a delayed derepression while a mutation leading to increased E2F binding resulted in premature up-regulation. These findings clearly suggest that E2F contributes to the correct timing of cyclin A transcription, presumably by acting as an anti-repressor. In agreement with this conclusion, we find that the cyclin A promoter only poorly interacts with E2F-4, which is the major E2F family member in G, cells, while a clear binding is seen with E2F-1 and -3, which are up-regulated in late G(1).	Univ Marburg, Inst Molekularbiol & Tumorforsch, D-35033 Marburg, Germany	Philipps University Marburg	Muller, R (corresponding author), Univ Marburg, Inst Molekularbiol & Tumorforsch, Emil Mannkopff Str 2, D-35033 Marburg, Germany.		Müller, Rolf/L-4997-2016; Engeland, Kurt/AAW-9965-2020	Müller, Rolf/0000-0003-3339-4248; Engeland, Kurt/0000-0003-3525-0440				DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Huet X, 1996, MOL CELL BIOL, V16, P3789; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LaThangue NB, 1996, BIOCHEM SOC T, V24, P54; Liu NS, 1996, NUCLEIC ACIDS RES, V24, P2905, DOI 10.1093/nar/24.15.2905; Liu NS, 1997, NUCLEIC ACIDS RES, V25, P4915, DOI 10.1093/nar/25.24.4915; LUCIBELLO FC, 1995, EMBO J, V14, P132, DOI 10.1002/j.1460-2075.1995.tb06983.x; Muller H, 1997, MOL CELL BIOL, V17, P5508; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; NAKAMURA T, 1995, EXP CELL RES, V216, P422, DOI 10.1006/excr.1995.1053; NEVINS JR, 1992, SCIENCE, V258, P424; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; Oswald F, 1996, MOL CELL BIOL, V16, P1889; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; YOSHIZUMI M, 1995, MOL CELL BIOL, V15, P3266; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; ZHU LG, 1995, MOL CELL BIOL, V15, P3552; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1; ZWICKER J, 1995, NUCLEIC ACIDS RES, V23, P3822, DOI 10.1093/nar/23.19.3822; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	31	75	75	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 11	1998	16	23					2957	2963		10.1038/sj.onc.1201838	http://dx.doi.org/10.1038/sj.onc.1201838			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZT782	9662327				2022-12-25	WOS:000074125300001
J	Zachos, G; Spandidos, DA				Zachos, G; Spandidos, DA			Transcriptional regulation of the c-H-ras1 gene by the P53 protein is implicated in the development of human endometrial and ovarian tumours	ONCOGENE			English	Article						H-ras proto-oncogene; P53 protein; DNA binding; endometrial tumours; ovarian tumours	H-RAS PROTOONCOGENE; WILD-TYPE P53; ESTROGEN-RECEPTORS; CARCINOMA; EXPRESSION; SEQUENCE; ONCOGENE; CELLS; OVEREXPRESSION; SUPPRESSOR	The human c-H-ras1 gene contains within the first intron a p53 element, which functions as a transcriptional enhancer. Using nuclear extracts from human endometrial and ovarian tumours in gel retardation assays, we examined the binding levels of the P53 protein to the H-ras element in tumour versus the adjacent normal tissue. Elevated P53 binding in the tumour tissue was found in 5/12 (42%) endometrial and in 2/5 (40%) ovarian specimens and these cases were found to overexpress wild-type P53, Loss of P53 binding to the H-l as element due to p53 mutations, was observed in 3/12 (25%) endometrial and in 1/5 (20%) ovarian cases, Similar P53 binding levels to the H-uas element were found in 4/12 (33%) endometrial and in 2/5 (40%) ovarian pairs showing normal expression of wild-type P53, Overexpression of the Ras p21 protein correlated with elevated binding and increased nuclear levels of wildtype P53. Our results suggest that P53 protein alterations, participate in the development of human gynecological neoplasias through aberrant transcriptional regulation of the H-ras proto-oncogene.	Univ Crete, Sch Med, Div Virol, Heraklion 71409, Greece; Natl Hellen Res Fdn, Inst Biol Res & Biotechnol, Athens 11635, Greece	University of Crete; National Hellenic Research Foundation	Spandidos, DA (corresponding author), Univ Crete, Sch Med, Div Virol, Heraklion 71409, Greece.			Spandidos, Demetrios/0000-0002-1146-931X				Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Hurd C, 1997, ONCOGENE, V15, P991, DOI 10.1038/sj.onc.1201233; Hwang DY, 1997, J VIROL, V71, P6416, DOI 10.1128/JVI.71.9.6416-6426.1997; JUVEN T, 1993, ONCOGENE, V8, P3411; KIHANA T, 1995, CANCER, V76, P72, DOI 10.1002/1097-0142(19950701)76:1<72::AID-CNCR2820760110>3.0.CO;2-3; KLEMI PJ, 1995, CANCER, V76, P1201, DOI 10.1002/1097-0142(19951001)76:7<1201::AID-CNCR2820760716>3.0.CO;2-L; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVESQUE MA, 1995, CANCER-AM CANCER SOC, V75, P1327, DOI 10.1002/1097-0142(19950315)75:6<1327::AID-CNCR2820750615>3.0.CO;2-P; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Liloglou T, 1997, BRIT J CANCER, V75, P1119, DOI 10.1038/bjc.1997.193; LONG CA, 1988, AM J OBSTET GYNECOL, V159, P1512, DOI 10.1016/0002-9378(88)90586-8; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Maniatis T., 1989, MOL CLONING LAB MANU; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; Miturski R, 1996, ACTA HISTOCHEM, V98, P411, DOI 10.1016/S0065-1281(96)80008-0; Scambia G, 1997, BRIT J CANCER, V75, P1547, DOI 10.1038/bjc.1997.264; SCAMBIA G, 1993, AM J OBSTET GYNECOL, V168, P71, DOI 10.1016/S0002-9378(12)90888-1; Soong R, 1996, BRIT J CANCER, V74, P562, DOI 10.1038/bjc.1996.401; SPANDIDOS DA, 1995, INT J ONCOL, V7, P1029; Varras MN, 1996, ONCOLOGY-BASEL, V53, P505; Zachos G, 1997, CRIT REV ONCOL HEMAT, V26, P65, DOI 10.1016/S1040-8428(97)00013-9; Zachos G, 1996, J Exp Ther Oncol, V1, P335; Zachos G, 1996, JPN J CANCER RES, V87, P916, DOI 10.1111/j.1349-7006.1996.tb02120.x; ZACHOS G, 1995, INT J ONCOL, V6, P595; ZOUMPOURLIS V, 1995, INT J ONCOL, V7, P1035	29	17	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 11	1998	16	23					3013	3017		10.1038/sj.onc.1201836	http://dx.doi.org/10.1038/sj.onc.1201836			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZT782	9662334				2022-12-25	WOS:000074125300008
J	Chen, Y; Shyu, JF; Santhanagopal, A; Inoue, D; David, JP; Dixon, SJ; Horne, WC; Baron, R				Chen, Y; Shyu, JF; Santhanagopal, A; Inoue, D; David, JP; Dixon, SJ; Horne, WC; Baron, R			The calcitonin receptor stimulates Shc tyrosine phosphorylation and Erk1/2 activation - Involvement of G(i), protein kinase C, and calcium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3',5'-CYCLIC ADENOSINE-MONOPHOSPHATE; HETEROTRIMERIC G-PROTEINS; CYTOSOLIC-FREE CALCIUM; BETA-GAMMA-SUBUNITS; MAP KINASE; SIGNAL-TRANSDUCTION; PARATHYROID-HORMONE; PHOSPHOLIPASE-C; RAT OSTEOCLASTS; PATHWAY	While it is web established that adenylyl cyclase and phospholipase C-beta are two proximal signal effecters for the calcitonin receptor, the more distal signaling pathways are less well characterized. G protein-coupled receptors can activate Erk1/2 by G(s)-, G(i)-, or G(q)-dependent signaling pathways, depending on the specific receptor and cell type examined. Since the calcitonin receptor can couple to all three of these G proteins, the ability of calcitonin to activate Erk1/2 was investigated. Calcitonin induced time- and concentration-dependent increases in Shc tyrosine phosphorylation, Shc-Grb2 association and Erk1/2 phosphorylation and activation in a HEK 293 cell line that stably expresses the rabbit calcitonin receptor Cia isoform. Pertussis toxin, which inactivates G(i), and calphostin C, a protein kinase C inhibitor, each partially inhibited calcitonin-induced Shc tyrosine phosphorylation, Shc-Grb2 association, and Erk1/2 phosphorylation. In contrast, neither forskolin nor H89, a protein kinase A inhibitor, had a significant effect on basal or calcitonin-stimulated Erk1/2 phosphorylation. Our results suggest that the calcitonin receptor induces Shc phosphorylation and Erk1/2 activation in HEK293 cells by parallel G(i)- and PRO-dependent mechanisms. The calcitonin-induced elevation of cytosolic free Ca2+ was required for Erk1/2 phosphorylation, since preventing any change in cytosolic free Ca2+ by chelating both cytosolic and extracellular Ca2+ abolished the response. However, the change in Ca2+ that is induced by calcitonin is not sufficient to account for the calcitonin-induced Erk1/2 phosphorylation, since treatment with 100 nM ionomycin or 10 mu M thapsigargin, each of which induced elevations of Ca2+ comparable to those induced by calcitonin, induced significantly less Erk1/2 phosphorylation than that induced by calcitonin. Erk1/2 may have important roles as downstream effecters mediating cellular responses to calcitonin stimulation.	Yale Univ, Sch Med, Dept Orthoped, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT 06520 USA; Univ Western Ontario, Fac Med & Dent, Div Oral Biol, London, ON N6A 5C1, Canada; Univ Western Ontario, Fac Med & Dent, Dept Physiol, London, ON N6A 5C1, Canada	Yale University; Yale University; Yale University; Western University (University of Western Ontario); Western University (University of Western Ontario)	Horne, WC (corresponding author), Yale Univ, Sch Med, Dept Orthoped, POB 208044, New Haven, CT 06520 USA.		Dixon, S. Jeffrey/G-3657-2013	Dixon, S. Jeffrey/0000-0001-9162-1686	NIDCR NIH HHS [DE-04724] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE004724, R01DE004724] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; Azria M., 1989, CALCITONINS PHYSL PH; CAZAUBON SM, 1994, J BIOL CHEM, V269, P24805; CHABRE O, 1992, MOL ENDOCRINOL, V6, P551, DOI 10.1210/me.6.4.551; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; FAURE M, 1994, J BIOL CHEM, V269, P7851; FORCE T, 1992, AM J PHYSIOL, V262, pF1110, DOI 10.1152/ajprenal.1992.262.6.F1110; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3450; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HORNE WC, 1994, TRENDS ENDOCRIN MET, V5, P395, DOI 10.1016/1043-2760(95)92521-J; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; MALGAROLI A, 1989, J BIOL CHEM, V264, P14342; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; MorishimaKawashima M, 1996, MOL BIOL CELL, V7, P893, DOI 10.1091/mbc.7.6.893; Offermanns S, 1996, CANCER SURV, V27, P177; Parrizas M, 1997, J BIOL CHEM, V272, P154; PEREZ M, 1997, J BONE MINER RES, V12, pS323; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rosen LB, 1996, P NATL ACAD SCI USA, V93, P1113, DOI 10.1073/pnas.93.3.1113; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SCHLESSINGER J, 1994, COLD SPRING HARB SYM, V59, P173, DOI 10.1101/SQB.1994.059.01.021; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SHAH GV, 1994, ENDOCRINOLOGY, V134, P596, DOI 10.1210/en.134.2.596; Shyu JF, 1996, J BIOL CHEM, V271, P31127, DOI 10.1074/jbc.271.49.31127; SU YJ, 1992, ENDOCRINOLOGY, V131, P1497, DOI 10.1210/en.131.3.1497; TETI A, 1995, J BIOL CHEM, V270, P16666, DOI 10.1074/jbc.270.28.16666; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANDERKUUR J, 1995, J BIOL CHEM, V270, P7587, DOI 10.1074/jbc.270.13.7587; VERHEIJEN MHG, 1995, ENDOCRINOLOGY, V136, P3331, DOI 10.1210/en.136.8.3331; Verheijen MHG, 1997, J BIOL CHEM, V272, P3423, DOI 10.1074/jbc.272.6.3423; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; ZAIDI M, 1990, J ENDOCRINOL, V126, P473, DOI 10.1677/joe.0.1260473	46	76	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19809	19816		10.1074/jbc.273.31.19809	http://dx.doi.org/10.1074/jbc.273.31.19809			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677414	hybrid			2022-12-25	WOS:000075125200066
J	Huang, Y; Putney, JW				Huang, Y; Putney, JW			Relationship between intracellular calcium store depletion and calcium release-activated calcium current in a mast cell line (RBL-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTRY	The kinetic relationship between depletion of endoplasmic reticulum calcium stores and the activation of a calcium release-activated calcium current (I-crac) was investigated in the RBL-1 mast cell line. The inositol trisphosphate receptor activator, inositol 2,4,5-trisphosphate ((2,4,5)IP3), the sarcoplasmic-endoplasmic reticulum calcium ATPase inhibitor, thapsigargin, and the calcium ionophore, ionomycin, were used to deplete stored calcium. For (2,4,5)IP3 and thapsigargin, a significant delay was observed between the initiation of calcium store depletion and the activation of I-crac. However, for ionomycin, little or no delay was observed. This may indicate that a specialized subcompartment of the endoplasmic reticulum functions as a regulator of calcium entry and that this compartment is relatively resistant to depletion by (2,4,5)IP3 and thapsigargin but not to depletion by ionomycin. For all three calcium-depleting agents, the rate of development of I-crac. once initiated, was relatively constant, suggesting an all-or-none mechanism. However, there were also clear experimental situations in which submaximal, graded depletion of stored calcium resulted in submaximal activation of I-crac. This complex behavior could also result from the existence of a specific subcompartment of endoplasmic reticulum regulating I-crac. The kinetic behavior of this compartment may not be accurately reflected by the kinetics of calcium changes in the bulk of endoplasmic reticulum. These findings add to the growing body of evidence suggesting specialization of the endoplasmic reticulum calcium stores with regard to the control of capacitative calcium entry.	NIEHS, Calcium Regulat Sect, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Putney, JW (corresponding author), NIEHS, Calcium Regulat Sect, Lab Signal Transduct, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.		Putney, James W/F-7247-2019	Putney, James W/0000-0002-3379-4789				BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; CLAPHAM DE, 1995, NATURE, V375, P634, DOI 10.1038/375634a0; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; MCDONALD TV, 1993, J BIOL CHEM, V268, P3889; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Parekh AB, 1997, CELL, V89, P973, DOI 10.1016/S0092-8674(00)80282-2; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Putney JW, 1997, CELL CALCIUM, V21, P257, DOI 10.1016/S0143-4160(97)90050-6; Ribeiro CMP, 1996, J BIOL CHEM, V271, P21522, DOI 10.1074/jbc.271.35.21522; THASTRUP O, 1994, AGENTS ACTIONS, V43, P187, DOI 10.1007/BF01986687; WHITE RE, 1991, NATURE, V351, P570, DOI 10.1038/351570a0	14	67	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19554	19559		10.1074/jbc.273.31.19554	http://dx.doi.org/10.1074/jbc.273.31.19554			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677379	hybrid			2022-12-25	WOS:000075125200031
J	Renn, SCP; Tomkinson, B; Taghert, PH				Renn, SCP; Tomkinson, B; Taghert, PH			Characterization and cloning of tripeptidyl peptidase II from the fruit fly, Drosophila melanogaster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUST SCHISTOCERCA-GREGARIA; NUCLEOTIDE-SEQUENCE; MUSCA-DOMESTICA; DYE-BINDING; NEUROPEPTIDES; ENDOPEPTIDASE; PURIFICATION; SUBTILISIN; PROTEINS; CDNA	We describe the characterization, cloning, and genetic analysis of tripeptidyl peptidase II (TPP II) from Drosophila melanogaster. Mammalian TPP II removes N-terminal tripeptides, has wide distribution, and has been identified as the cholecystokinin-degrading peptidase in rat brain. Size exclusion and ion exchange chromatography produced a 70-fold purification; of dTPP II activity from Drosophila tissue extracts. The substrate specificity and the inhibitor sensitivity of dTPP II is comparable to that of the human enzyme. In. particular, dTPP II is sensitive to butabindide, a specific inhibitor of the rat cholecystokinin-inactivating activity. We isolated a 4309-base pair dTPP II cDNA which predicts a 1354-amino acid protein. The deduced human and Drosophila TPP II proteins display 38% overall identity. The catalytic triad, its spacing, and the sequences that surround it are highly conserved; the C-terminal end of dTPP II contains a 100-amino acid insert not found in the mammalian proteins. Recombinant dTPP II displays the predicted activity following expression in HEK cells. TPP II maps to cytological position 49F4-7; animals deficient for this interval show reduced TPP II activity.	Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA; Swedish Univ Agr Sci, Ctr Biomed, Dept Vet Med Chem, S-75123 Uppsala, Sweden	Washington University (WUSTL); Swedish University of Agricultural Sciences	Taghert, PH (corresponding author), Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA.				NINDS NIH HHS [NS-21749] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021749] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ashburner M., 1989, DROSOPHILA LAB MANUA, P37; BALOW RM, 1983, J BIOL CHEM, V258, P1622; BALOW RM, 1986, J BIOL CHEM, V261, P2409; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNK BP, 1991, NATURE, V353, P351, DOI 10.1038/353351a0; BULL AL, 1956, J EXP ZOOL, V132, P467, DOI 10.1002/jez.1401320306; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CORNEL MJ, 1995, J BIOL CHEM, V270, P13613, DOI 10.1074/jbc.270.23.13613; Csuhai E, 1995, PROG BRAIN RES, V104, P131; DOEBBER TW, 1978, ENDOCRINOLOGY, V103, P1794, DOI 10.1210/endo-103-5-1794; Duronio RJ, 1998, MOL CELL BIOL, V18, P141, DOI 10.1128/MCB.18.1.141; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; ISAAC RE, 1987, BIOCHEM J, V245, P365, DOI 10.1042/bj2450365; ISAAC RE, 1988, BIOCHEM J, V255, P843, DOI 10.1042/bj2550843; Kolhekar AS, 1997, J NEUROSCI, V17, P1363, DOI 10.1523/jneurosci.17-04-01363.1997; LAMANGO NS, 1994, BIOCHEM J, V299, P651, DOI 10.1042/bj2990651; LAMANGO NS, 1993, INSECT BIOCHEM MOLEC, V23, P801, DOI 10.1016/0965-1748(93)90068-4; LASKO PF, 1988, GENETICS, V120, P495; MATSAS R, 1984, BIOCHEM J, V223, P433, DOI 10.1042/bj2230433; MORGAN TH, 1938, CARNEGIE I WASH YB, V37, P298; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Nassel DR, 1996, CURR OPIN NEUROBIOL, V6, P842, DOI 10.1016/S0959-4388(96)80036-5; OBRIEN MA, 1994, ZOOL SCI, V11, P633; ONDETTI MA, 1982, ANNU REV BIOCHEM, V51, P283, DOI 10.1146/annurev.bi.51.070182.001435; PAGE AE, 1993, ARCH BIOCHEM BIOPHYS, V306, P354, DOI 10.1006/abbi.1993.1523; PETERS K, 1989, CURR MICROBIOL, V18, P171, DOI 10.1007/BF01569566; READ SM, 1981, ANAL BIOCHEM, V116, P53, DOI 10.1016/0003-2697(81)90321-3; REALINI C, 1994, FEBS LETT, V348, P109, DOI 10.1016/0014-5793(94)00569-9; Rose C, 1996, NATURE, V380, P403, DOI 10.1038/380403a0; ROSEN J, 1991, J BIOL CHEM, V266, P3827; Sambrook J., 2002, MOL CLONING LAB MANU; SMOLLER DA, 1991, CHROMOSOMA, V100, P487, DOI 10.1007/BF00352199; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOMKINSON B, 1991, BIOMED BIOCHIM ACTA, V50, P727; TOMKINSON B, 1987, P NATL ACAD SCI USA, V84, P7508, DOI 10.1073/pnas.84.21.7508; TOMKINSON B, 1994, BIOCHEM J, V304, P517, DOI 10.1042/bj3040517; Tomkinson B, 1995, NEUROCHEM RES, V20, P1443, DOI 10.1007/BF00970592; Tomkinson B, 1997, FEBS LETT, V405, P277, DOI 10.1016/S0014-5793(97)00173-7; TOMKINSON B, 1990, BIOCHEM J, V267, P149, DOI 10.1042/bj2670149; TOMKINSON B, 1991, BIOCHEMISTRY-US, V30, P168, DOI 10.1021/bi00215a025; TURNER AJ, 1985, BIOCHEM PHARMACOL, V34, P1347, DOI 10.1016/0006-2952(85)90669-0; Voorhorst WGB, 1996, J BIOL CHEM, V271, P20426, DOI 10.1074/jbc.271.34.20426; WILSON C, 1993, NEUROCHEM RES, V18, P743, DOI 10.1007/BF00966768; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WU CT, 1989, MOL GEN GENET, V218, P559, DOI 10.1007/BF00332424; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1	46	32	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19173	19182		10.1074/jbc.273.30.19173	http://dx.doi.org/10.1074/jbc.273.30.19173			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668104	hybrid, Green Submitted			2022-12-25	WOS:000074974700071
J	Roos, J; Kelly, RB				Roos, J; Kelly, RB			Dap160, a neural-specific Eps15 homology and multiple SH3 domain-containing protein that interacts with Drosophila dynamin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLES; NERVE-TERMINALS; COATED PITS; AMPHIPHYSIN; POLYPEPTIDES; TRANSMISSION; PURIFICATION; ENDOCYTOSIS; BINDING; TARGETS	The discovery of overlapping hot spots of dynamin (Estes, P. S., Roos, J., van der Bliek, A., Kelly, R. B., Krishnan, K. S., and Ramaswami, M. (1996) J. Neurosci. 16, 5443-5456) and the heterotetrameric adaptor 2 complex (Gonzalez-Gaitan, M,, and Jackle, H. (1997) Cell 88, 767-776) in Drosophila nerve terminals led to the concept of zones of active endocytosis close to sites of active exocytosis. The proline-rich domain of Drosophila dynamin was used to identify and purify a third component of the endocytosis zones. Dap160 (dynamin-associated protein 160 kDa) is a membrane-associated, dynamin-binding protein of 160 kDa that has four putative src homology 3 domains and an Eps15 homology domain, motifs frequently found in proteins associated with endocytosis, The binding capacities of the four putative src homology 3 domains were examined individually and in combination and shown to bind known proteins that contained proline-rich domains. Each binding site, however, was different in its preference for binding partners. We suggest that Dap160 is a scaffolding protein that helps anchor proteins required for endocytosis at sites where they are needed in the Drosophila nerve terminal.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Hormone Res Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Kelly, RB (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015927] Funding Source: NIH RePORTER; NINDS NIH HHS [NS15927] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andrews J, 1996, GENETICS, V143, P1699; BETZ WJ, 1995, CURR BIOL, V5, P1098, DOI 10.1016/S0960-9822(95)00220-X; BETZ WJ, 1992, J NEUROSCI, V12, P363, DOI 10.1523/jneurosci.12-02-00363.1992; Chien CT, 1998, MOL CELL BIOL, V18, P598, DOI 10.1128/MCB.18.1.598; DAVID C, 1994, FEBS LETT, V351, P73, DOI 10.1016/0014-5793(94)00826-4; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; DOYLE K, 1996, PROMEGA PROTOCOLS AP, P184; Estes PS, 1996, J NEUROSCI, V16, P5443; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; GASS GV, 1996, J NEUROGENET, V10, P169; GonzalezGaitan M, 1997, CELL, V88, P767, DOI 10.1016/S0092-8674(00)81923-6; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; GRIECO F, 1992, BIOTECHNIQUES, V13, P856; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Hosaka M, 1998, J BIOL CHEM, V273, P1425, DOI 10.1074/jbc.273.3.1425; Iannolo G, 1997, CANCER RES, V57, P240; ITO N, 1985, DROSOPHILA INFORMATI, V69, P81; KLEID DG, 1981, SCIENCE, V214, P1125, DOI 10.1126/science.6272395; Koenig JH, 1996, J CELL BIOL, V135, P797, DOI 10.1083/jcb.135.3.797; KOENIG JH, 1989, J NEUROSCI, V9, P3844; LICHTE B, 1992, EMBO J, V11, P2521, DOI 10.1002/j.1460-2075.1992.tb05317.x; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Mellman I, 1996, CURR OPIN CELL BIOL, V8, P497, DOI 10.1016/S0955-0674(96)80026-3; Micheva KD, 1997, J BIOL CHEM, V272, P27239, DOI 10.1074/jbc.272.43.27239; Nemoto Y, 1997, J BIOL CHEM, V272, P30817, DOI 10.1074/jbc.272.49.30817; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; RAMASWAMI M, 1994, NEURON, V13, P363, DOI 10.1016/0896-6273(94)90353-0; REICHMUTH C, 1995, MOL BRAIN RES, V32, P45, DOI 10.1016/0169-328X(95)00058-Z; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; Shpetner HS, 1996, J BIOL CHEM, V271, P13, DOI 10.1074/jbc.271.1.13; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; Stewart BA, 1996, J NEUROSCI, V16, P3877; Tang HY, 1997, MOL CELL BIOL, V17, P4294, DOI 10.1128/MCB.17.8.4294; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDEGOOR J, 1995, P NATL ACAD SCI USA, V92, P5739, DOI 10.1073/pnas.92.12.5739	45	175	180	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19108	19119		10.1074/jbc.273.30.19108	http://dx.doi.org/10.1074/jbc.273.30.19108			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668096	hybrid			2022-12-25	WOS:000074974700063
J	Urbani, A; Bazzo, R; Nardi, MC; Cicero, DO; De Francesco, R; Steinkuhler, C; Barbato, G				Urbani, A; Bazzo, R; Nardi, MC; Cicero, DO; De Francesco, R; Steinkuhler, C; Barbato, G			The metal binding site of the hepatitis C virus NS3 protease - A spectroscopic investigation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; N-15 NMR-SPECTROSCOPY; HYDROGEN-BONDING INTERACTIONS; ALPHA-LYTIC PROTEASE; NON-B-HEPATITIS; SERINE-PROTEASE; ACTIVE-SITE; NON-A; TAUTOMERIC EQUILIBRIA; HETERONUCLEAR NMR	The NS3 region of the hepatitis C virus encodes for a serine protease activity, which is necessary for the processing of the nonstructural region of the viral polyprotein, The minimal domain with proteolytic activity resides in the N terminus, where a structural tetradentate zinc binding site is located. The ligands being been identified by x-ray crystallography as being three cysteines (Cys(97), Cys(99), and Cys(145)) and one histidine residue (His(149)), which is postulated to coordinate the metal through a water molecule. In this article, we present an analysis of the role of metal coordination with respect to enzyme activity and folding. Using NMR spectroscopy, the resonances of His149 were assigned based on their isotropic shift in a Co(II)-substituted protein. Data obtained with N-15-labeled NS3 protease were compatible with the involvement of the delta-N of His(149) in metal coordination. pH titration experiments showed that the cooperative association of at least two protons is required in the protonation process of His149. Changes in the NMR signals of this residue between pH 7 and 5 are interpreted as evidence for a structural change at the metal binding site, which switches from a "closed" to an "open" conformation. Site-directed mutagenesis of His149 has shown the importance of this residue in the metal incorporation pathway and for achieving an active fold. The metal coordination of the protease was also investigated by circular dichroism and electronic absorption spectroscopies using a Co(II)-substituted enzyme. We show evidence for rearrangements of the metal coordination geometry induced by complex formation with an NS4A peptide cofactor. No such changes were observed upon binding to a substrate peptide. Also, CN- and N-3(-) induced Co(II) ligand field perturbations, which went along with an 1.5-fold enhancement of protease activity.	Ist Ric Biol Mol P Angeletti, I-00040 Pomezia, Rome, Italy	Merck & Company	Steinkuhler, C (corresponding author), Ist Ric Biol Mol P Angeletti, Via Pontina Km 30600, I-00040 Pomezia, Rome, Italy.	Steinkuhler@irbm.it	Cicero, Daniel/AAV-5203-2021; Barbato, Gaetano/G-4904-2011; De Francesco, Raffaele/J-6003-2012	Barbato, Gaetano/0000-0001-9840-6858; De Francesco, Raffaele/0000-0001-8754-5123				BACHOVCHIN WW, 1986, BIOCHEMISTRY-US, V25, P7751, DOI 10.1021/bi00371a070; BACHOVCHIN WW, 1988, BIOCHEMISTRY-US, V27, P7689, DOI 10.1021/bi00420a018; BACHOVCHIN WW, 1978, J AM CHEM SOC, V100, P8041, DOI 10.1021/ja00494a001; BALACCO G, 1994, J CHEM INF COMP SCI, V34, P1235, DOI 10.1021/ci00022a003; BARTENSCHLAGER R, 1994, J VIROL, V68, P5045, DOI 10.1128/JVI.68.8.5045-5055.1994; BERTINI I, 1993, CHEM REV, V93, P2833, DOI 10.1021/cr00024a009; BERTINI I, 1978, J AM CHEM SOC, V100, P4873, DOI 10.1021/ja00483a038; Bertini I, 1984, Adv Inorg Biochem, V6, P71; BERTINI I, 1981, J AM CHEM SOC, V103, P7784, DOI 10.1021/ja00416a016; Bianchi E, 1997, BIOCHEMISTRY-US, V36, P7890, DOI 10.1021/bi9631475; BLOMBERG F, 1977, J AM CHEM SOC, V99, P8149, DOI 10.1021/ja00467a005; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CLORE GM, 1991, J AM CHEM SOC, V113, P4350, DOI 10.1021/ja00011a059; CLORE GM, 1992, BIOCHEMISTRY-US, V21, P4048; DeFrancesco R, 1996, BIOCHEMISTRY-US, V35, P13282, DOI 10.1021/bi9616458; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; FAILLA C, 1995, J VIROL, V69, P1769, DOI 10.1128/JVI.69.3.1769-1777.1995; FAILLA C, 1994, J VIROL, V68, P3753, DOI 10.1128/JVI.68.6.3753-3760.1994; FESHT A, 1985, ENZYME STRUCTURE MEC, P143; GOOLEY PR, 1993, BIOCHEMISTRY-US, V32, P13098, DOI 10.1021/bi00211a020; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; HIJIKATA M, 1993, J VIROL, V67, P4665, DOI 10.1128/JVI.67.8.4665-4675.1993; HIJIKATA M, 1991, P NATL ACAD SCI USA, V88, P5547, DOI 10.1073/pnas.88.13.5547; HIROMI I, 1979, KINETICS FAST ENZYME, P99; HOLMQUIST B, 1986, METHOD ENZYMOL, V130, P270; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; Kim JL, 1996, CELL, V87, P343, DOI 10.1016/S0092-8674(00)81351-3; KRIZEK BA, 1991, J AM CHEM SOC, V113, P4518, DOI 10.1021/ja00012a021; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; Landro JA, 1997, BIOCHEMISTRY-US, V36, P9340, DOI 10.1021/bi963054n; Lesk AM, 1996, J MOL BIOL, V258, P501, DOI 10.1006/jmbi.1996.0264; Lian L. Y., 1993, NMR MACROMOLECULES P, P153; LIN C, 1995, J VIROL, V69, P4373, DOI 10.1128/JVI.69.7.4373-4380.1995; Love RA, 1996, CELL, V87, P331, DOI 10.1016/S0092-8674(00)81350-1; MARET W, 1993, METHOD ENZYMOL, V226, P52; MENGLI C, 1997, NAT STRUCT BIOL, V7, P567; MERKLE DL, 1991, J AM CHEM SOC, V113, P5450, DOI 10.1021/ja00014a045; Mori A, 1997, BIOCHEM BIOPH RES CO, V231, P738, DOI 10.1006/bbrc.1997.6180; MUNOWITZ M, 1982, J AM CHEM SOC, V104, P1192, DOI 10.1021/ja00369a007; OTTING G, 1989, J AM CHEM SOC, V111, P1871, DOI 10.1021/ja00187a050; PELTON JG, 1993, PROTEIN SCI, V2, P543; Pieroni L, 1997, J VIROL, V71, P6373, DOI 10.1128/JVI.71.9.6373-6380.1997; ROBERTS JD, 1982, J AM CHEM SOC, V104, P3945, DOI 10.1021/ja00378a027; Schmiedeskamp M, 1997, PROTEIN SCI, V6, P1835, DOI 10.1002/pro.5560060904; SCHUSTER II, 1979, J ORG CHEM, V44, P3864, DOI 10.1021/jo01336a025; SHUYUARN F, 1992, VIROLOGY, V186, P725; SOMMERGRUBER W, 1989, VIROLOGY, V169, P68, DOI 10.1016/0042-6822(89)90042-1; Steinkuhler C, 1996, J VIROL, V70, P6694; Stempniak M, 1997, J VIROL, V71, P2881, DOI 10.1128/JVI.71.4.2881-2886.1997; Taliani M, 1996, ANAL BIOCHEM, V240, P60, DOI 10.1006/abio.1996.0331; TOMEI L, 1993, J VIROL, V67, P4017, DOI 10.1128/JVI.67.7.4017-4026.1993; Tomei L, 1996, J GEN VIROL, V77, P1065, DOI 10.1099/0022-1317-77-5-1065; Urbani A, 1997, J BIOL CHEM, V272, P9204; VANDIJK AA, 1990, BIOCHEMISTRY-US, V29, P8164, DOI 10.1021/bi00487a026; VANDIJK AA, 1992, BIOCHEMISTRY-US, V31, P9063, DOI 10.1021/bi00152a050; Vila AJ, 1996, J AM CHEM SOC, V118, P7291, DOI 10.1021/ja9601346; WITANOWSKI M, 1972, TETRAHEDRON, V28, P637, DOI 10.1016/0040-4020(72)84027-4	58	55	59	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18760	18769		10.1074/jbc.273.30.18760	http://dx.doi.org/10.1074/jbc.273.30.18760			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668049	hybrid, Green Published			2022-12-25	WOS:000074974700016
J	Hansen, PA; Wang, WC; Marshall, BA; Holloszy, JO; Mueckler, M				Hansen, PA; Wang, WC; Marshall, BA; Holloszy, JO; Mueckler, M			Dissociation of GLUT4 translocation and insulin-stimulated glucose transport in transgenic mice overexpressing GLUT1 in skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3T3-L1 ADIPOCYTES; PLASMA-MEMBRANE; HEXOSAMINE BIOSYNTHESIS; RESPONSIVE TISSUES; PROTEIN; RESISTANCE; CLONING; IDENTIFICATION; ACTIVATION; WORTMANNIN	Overexpression of the human GLUT1 glucose transporter protein in skeletal muscle of transgenic mice results in large increases in basal glucose transport and metabolism, but impaired stimulation of glucose transport by insulin, contractions, or hypoxia (Gulve, E, A., Ren, J,-M,, Marshall, B, A., Gao, J,, Hansen, P, A., Holloszy, J. O., and Mueckler, M. (1994) J, Biol, Chem, 269, 18366-18370). This study examined the relationship between glucose transport and cell-surface glucose transporter content in isolated skeletal muscle from wild-type and GLUT1-overexpressing mice using 2-deoxyglucose, 3-O-methylglucose, and the 2-N-[4-(1-azi-2,2,2-trifluoroethyl)benzoyl]-1,3-bis (D-mannos-4-yloxy)-2-propylamine exofacial photolabeling technique. Insulin (2 milliunits/ml) stimulated a 3-fold increase in a-deoxyglucose uptake in extensor digitorum longus muscles of control mice (0.47 +/- 0.07 mu mol/ml/20 min in basal muscle versus 1.44 mu mol/ml/20 min in insulin-stimulated muscle; mean +/- S.E.), Insulin failed to increase a-deoxyglucose uptake above basal rates in muscles overexpressing GLUT1 (4.00 +/- 0.40 mu mol/ml/20 min in basal muscle versus 3.96 +/- 0.37 mu mol/ml/20 min in insulin-stimulated muscle). A similar lack of insulin stimulation in muscles overexpressing GLUT1 was observed using 3-O-methylglucose. However, the magnitude of the insulin-stimulated increase in cell-surface GLUT4 photolabeling was nearly identical (similar to 3-fold) in wild-type and GLUT1-overexpressing muscles. This apparently normal insulin-stimulated translocation of GLUT4 in GLUT1-overexpressing muscle was confirmed by immunoelectron microscopy. Our findings suggest that GLUT4 activity at the plasma membrane can be dissociated from the plasma membrane content of GLUT4 molecules and thus suggest that the intrinsic activity of GLUT4 is subject to regulation.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Mueckler, M (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	mike@cellbio.wustl.edu	Mueckler, Mike M/F-6115-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050332, R01DK038495, R01DK018986] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK50332, DK38495, DK18986] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baron AD, 1995, J CLIN INVEST, V96, P2792, DOI 10.1172/JCI118349; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; Buse MG, 1996, J BIOL CHEM, V271, P23197, DOI 10.1074/jbc.271.38.23197; CARTEE GD, 1991, J APPL PHYSIOL, V70, P1593, DOI 10.1152/jappl.1991.70.4.1593; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; CLANCY BM, 1991, J BIOL CHEM, V266, P10122; DOUEN AG, 1990, J BIOL CHEM, V265, P13427; DUDEK RW, 1994, FEBS LETT, V339, P205, DOI 10.1016/0014-5793(94)80416-8; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; GARVEY WT, 1987, J BIOL CHEM, V262, P189; GOODYEAR LJ, 1991, AM J PHYSIOL, V261, pE795, DOI 10.1152/ajpendo.1991.261.6.E795; GULVE EA, 1994, J BIOL CHEM, V269, P18366; HANEY PM, 1995, J CELL BIOL, V129, P641, DOI 10.1083/jcb.129.3.641; HANSEN P, 1995, AM J PHYSIOL-CELL PH, V268, pC30, DOI 10.1152/ajpcell.1995.268.1.C30; HANSEN PA, 1994, J APPL PHYSIOL, V76, P979, DOI 10.1152/jappl.1994.76.2.979; HANSEN PA, 1995, J BIOL CHEM, V270, P1679; Hansen PA, 1997, AM J PHYSIOL-ENDOC M, V273, pE28, DOI 10.1152/ajpendo.1997.273.1.E28; HARRISON SA, 1992, J BIOL CHEM, V267, P3783; HENRIKSEN EJ, 1991, ACTA PHYSIOL SCAND, V143, P381, DOI 10.1111/j.1748-1716.1991.tb09249.x; HIRSHMAN MF, 1990, J BIOL CHEM, V265, P987; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; LEE AD, 1995, FEBS LETT, V361, P51, DOI 10.1016/0014-5793(95)00147-2; LUND S, 1993, FEBS LETT, V330, P312, DOI 10.1016/0014-5793(93)80895-2; LUND S, 1995, P NATL ACAD SCI USA, V92, P5817, DOI 10.1073/pnas.92.13.5817; MARETTE A, 1992, DIABETES, V41, P1562, DOI 10.2337/diabetes.41.12.1562; MARSHALL BA, 1993, J BIOL CHEM, V268, P18442; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; MUNOZ P, 1995, BIOCHEM J, V312, P393, DOI 10.1042/bj3120393; PAREKH B S, 1989, Peptide Research, V2, P249; REN JM, 1993, J BIOL CHEM, V268, P16113; TREADWAY JL, 1994, J BIOL CHEM, V269, P29956; VANNUCCI SJ, 1992, BIOCHEM J, V288, P325, DOI 10.1042/bj2880325; Wang WC, 1996, J CELL BIOL, V135, P415, DOI 10.1083/jcb.135.2.415; WILSON CM, 1994, BIOCHEM J, V299, P755, DOI 10.1042/bj2990755; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107; YOUNG DA, 1986, J BIOL CHEM, V261, P6049	40	60	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18173	18179		10.1074/jbc.273.29.18173	http://dx.doi.org/10.1074/jbc.273.29.18173			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660777	hybrid			2022-12-25	WOS:000074828500032
J	Rockman, HA; Choi, DJ; Akhter, SA; Jaber, M; Giros, B; Lefkowitz, RJ; Caron, MG; Koch, WJ				Rockman, HA; Choi, DJ; Akhter, SA; Jaber, M; Giros, B; Lefkowitz, RJ; Caron, MG; Koch, WJ			Control of myocardial contractile function by the level of beta-adrenergic receptor kinase 1 in gene-targeted mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAILING HUMAN HEART; GAMMA-SUBUNITS; G-PROTEINS; EXPRESSION; DESENSITIZATION; ACTIVATION	We studied the effect of alterations in the level of myocardial beta-adrenergic receptor kinase (beta ARK1) in two types of genetically altered mice. The first group is heterozygous for beta ARK1 gene ablation, beta ARK1(+/-), and the second is not only heterozygous for beta AR1 gene ablation but is also transgenic for cardiac-specific overexpression of a beta ARK1 COOH-terminal inhibitor pep tide, beta ARK1(+/-)/beta ARKct. In contrast to the embryonic lethal phenotype of the homozygous beta ARK1 knockout (Jaber, M., Koch, W. J., Rockman, H. A., Smith, B., Bond, R. A., Sulik, K., Ross, J., Jr., Lefkowitz, R. J., Caron, M. G,, and Giros, B. (1996) Proc. Natl. Acad Sci. U.S.A. 93, 12974-12979), beta ARK1(+/-) mice develop normally. Cardiac catheterization was performed in mice and showed a stepwise increase in contractile function in the beta ARK1(+/-) and beta ARK1(+/-)/beta ARKct mice with the greatest level observed in the beta ARK1(+/-)/beta ARKct animals. Contractile parameters were measured in adult myocytes isolated from both groups of gene-targeted animals. A significantly greater increase in percent cell shortening and rate of cell shortening following isoproterenol stimulation was observed in the beta ARK1(+/-) and beta ARK1(+/-)/beta ARKct myocytes compared with wild-type cells, indicating a progressive increase in intrinsic contractility. These data demonstrate that contractile function can be modulated by the level of beta ARK1 activity. This has important implications in disease states such as heart failure (in which beta ARK1 activity is increased) and suggests that beta ARK1 should be considered as a therapeutic target in this situation. Even partial inhibition of beta ARK1 activity enhances beta-adrenergic receptor signaling leading to improved functional catecholamine responsiveness.	Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Duke Univ, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Dept Med, Durham, NC 27710 USA; Duke Univ, Howard Hughes Med Inst, Durham, NC 27710 USA	Duke University; University of North Carolina; University of North Carolina Chapel Hill; Duke University; Duke University; Duke University; Howard Hughes Medical Institute	Koch, WJ (corresponding author), Duke Univ, Med Ctr, Dept Surg, Box 2606,Room 472 MSRB, Durham, NC 27710 USA.		GIROS, Bruno/ABD-5790-2021; Lefkowitz, Robert/AAW-2649-2021	GIROS, Bruno/0000-0001-5876-9822; Jaber, Mohamed/0000-0003-2536-1913	NHLBI NIH HHS [HL 16037, HL 56687] Funding Source: Medline; NINDS NIH HHS [NS 19576] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037, R01HL056687] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019576] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akhter SA, 1997, P NATL ACAD SCI USA, V94, P12100, DOI 10.1073/pnas.94.22.12100; ANZAI T, 1996, CIRCULATION, V94, P643; BRODDE OE, 1993, PHARMACOL THERAPEUT, V60, P405, DOI 10.1016/0163-7258(93)90030-H; Choi DJ, 1997, J BIOL CHEM, V272, P17223, DOI 10.1074/jbc.272.27.17223; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; Gros R, 1997, J CLIN INVEST, V99, P2087, DOI 10.1172/JCI119381; He HP, 1997, J CLIN INVEST, V100, P380, DOI 10.1172/JCI119544; INGLESE J, 1993, J BIOL CHEM, V268, P23735; Jaber M, 1996, P NATL ACAD SCI USA, V93, P12974, DOI 10.1073/pnas.93.23.12974; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; Korzick DH, 1997, AM J PHYSIOL-HEART C, V272, pH590, DOI 10.1152/ajpheart.1997.272.1.H590; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LITTLE WC, 1985, CIRC RES, V56, P808, DOI 10.1161/01.RES.56.6.808; Lohse MJ, 1996, KIDNEY INT, V49, P1047, DOI 10.1038/ki.1996.153; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; Palakodeti V, 1997, AM J PHYSIOL-HEART C, V273, pH1283, DOI 10.1152/ajpheart.1997.273.3.H1283; PING PP, 1995, J CLIN INVEST, V95, P1271, DOI 10.1172/JCI117777; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; Rockman HA, 1997, AM J PHYSIOL-HEART C, V272, pH1553, DOI 10.1152/ajpheart.1997.272.4.H1553; Rockman HA, 1998, P NATL ACAD SCI USA, V95, P7000, DOI 10.1073/pnas.95.12.7000; Rockman HA, 1996, P NATL ACAD SCI USA, V93, P9954, DOI 10.1073/pnas.93.18.9954; UNGERER M, 1993, CIRCULATION, V87, P454, DOI 10.1161/01.CIR.87.2.454; UNGERER M, 1994, CIRC RES, V74, P206, DOI 10.1161/01.RES.74.2.206; Ungerer M, 1996, CIRC RES, V79, P455, DOI 10.1161/01.RES.79.3.455; Wolska BM, 1996, AM J PHYSIOL-HEART C, V271, pH1250, DOI 10.1152/ajpheart.1996.271.3.H1250	26	139	146	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18180	18184		10.1074/jbc.273.29.18180	http://dx.doi.org/10.1074/jbc.273.29.18180			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660778	hybrid			2022-12-25	WOS:000074828500033
J	Holmberg, C; Helin, K; Sehested, M; Karlstrom, O				Holmberg, C; Helin, K; Sehested, M; Karlstrom, O			E2F-1-induced p53-independent apoptosis in transgenic mice	ONCOGENE			English	Article						E2F; p53; apoptosis; testis; transgenic mice	RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F; S-PHASE ENTRY; UBIQUITIN-PROTEASOME PATHWAY; CELL-CYCLE REGULATION; TUMOR-SUPPRESSOR; BINDING PROTEIN; IN-VIVO; DEREGULATED EXPRESSION; FIBROBLASTS LEADS	The E2F transcription factors are keg targets for the retinoblastoma protein, pRB, By inactivation of E2Fs, PRE prevents progression to the S phase. To test proliferative functions of E2F, we generated transgenic mice expressing human E2F-1 and/or human DP-1. When the hydroxymethyl glutaryl coenzyme A reductase promoter was used to express DP-1, overexpression occurred in a variety of tissues and did not confer phenotypic changes. In contrast, expression of E2F-1 from the same promoter was obtained only in testicles, in which E2F-1 overexpression caused atrophy and sterility through a process involving increased apoptosis in the germinal epithelium. This effect was potentiated by simultaneous overexpression of DP-1. Testicular atrophy as a result of overexpression of E2F-1 and DP-1 is independent of functional p53, since p53-nullizygous transgenic mice overexpressing E2F-1 and DP-1 also suffered testicular atrophy.	Univ Copenhagen, Inst Mol Biol, Dept Mol Cell Biol, DK-1353 Copenhagen K, Denmark; European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Rigshosp, Dept Pathol, DK-2100 Copenhagen O, Denmark	University of Copenhagen; IRCCS European Institute of Oncology (IEO); Rigshospitalet	Karlstrom, O (corresponding author), Univ Copenhagen, Inst Mol Biol, Dept Mol Cell Biol, Oster Farimagsgade 2A, DK-1353 Copenhagen K, Denmark.		Helin, Kristian/K-2526-2019; Helin, Kristian/HDM-8306-2022; Holmberg, Christian/L-8011-2014	Helin, Kristian/0000-0003-1975-6097; Holmberg, Christian/0000-0001-9224-0543				Asano M, 1996, GENE DEV, V10, P1422, DOI 10.1101/gad.10.11.1422; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BRADL M, 1991, P NATL ACAD SCI USA, V88, P6447, DOI 10.1073/pnas.88.15.6447; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; Dobie K, 1997, TRENDS GENET, V13, P127, DOI 10.1016/S0168-9525(97)01097-4; Dobie KW, 1996, P NATL ACAD SCI USA, V93, P6659, DOI 10.1073/pnas.93.13.6659; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Du W, 1996, EMBO J, V15, P3684, DOI 10.1002/j.1460-2075.1996.tb00738.x; DYSON N, 1993, J VIROL, V67, P7641, DOI 10.1128/JVI.67.12.7641-7647.1993; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; GAUTIER C, 1989, NUCLEIC ACIDS RES, V17, P8389, DOI 10.1093/nar/17.20.8389; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; Guy CT, 1996, MOL CELL BIOL, V16, P685; Harlow E., 1988, ANTIBODIES LAB MANUA; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; HOGAN B, 1986, MANIPULATING MOUSE E; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KASTAN MB, 1991, CANCER RES, V51, P6304; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LOWE SW, 1993, NATURE, V362, P2847; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; MEHTALI M, 1990, GENE, V91, P179, DOI 10.1016/0378-1119(90)90086-7; MELLILO RM, 1994, MOL CELL BIOL, V14, P8241; Moberg K, 1996, MOL CELL BIOL, V16, P1436; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; ORMONDROYD E, 1995, ONCOGENE, V11, P1437; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; PURDIE CA, 1994, ONCOGENE, V9, P603; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; ROBERTSON G, 1995, P NATL ACAD SCI USA, V92, P5371, DOI 10.1073/pnas.92.12.5371; SAITO M, 1995, GENOMICS, V25, P130, DOI 10.1016/0888-7543(95)80118-6; Sambrook J., 2002, MOL CLONING LAB MANU; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; STEVENS LC, 1973, J NATL CANCER I, V50, P235, DOI 10.1093/jnci/50.1.235; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WU CL, 1995, MOL CELL BIOL, V15, P2536; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4	90	98	103	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 16	1998	17	2					143	155		10.1038/sj.onc.1201915	http://dx.doi.org/10.1038/sj.onc.1201915			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZZ211	9674698				2022-12-25	WOS:000074706700002
J	Anderson, VE; Gootz, TD; Osheroff, N				Anderson, VE; Gootz, TD; Osheroff, N			Topoisomerase IV catalysis and the mechanism of quinolone action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED DNA CLEAVAGE; DRUG-INTERACTION DOMAINS; II-TARGETED DRUGS; ESCHERICHIA-COLI; EUKARYOTIC TOPOISOMERASE; STREPTOCOCCUS-PNEUMONIAE; DROSOPHILA-MELANOGASTER; STAPHYLOCOCCUS-AUREUS; ANTINEOPLASTIC DRUGS; IN-VITRO	Topoisomerase IV is.bacterial type II topoisomerase that is essential for proper chromosome segregation and is a target for quinolone-based antimicrobial agents. Despite the importance of this enzyme to the survival of prokaryotic cells and to the treatment of bacterial infections, relatively little is known about the details of its catalytic mechanism or the basis by which quinolones alter its enzymatic functions. Therefore, a series of experiments that analyzed individual steps of the topoisomerase IV catalytic cycle were undertaken to address these critical mechanistic issues. The following conclusions were drawn, First, equilibrium levels of DNA cleavage mediated by the bacterial enzyme were considerably (>10-fold) higher than those observed with its eukaryotic counterparts. To a large extent, this reflected decreased rates of DNA religation. Second, the preference of topoisomerase TV for catalyzing DNA decatenation over relaxation reflects increased rates of strand passage and enzyme recycling rather than a heightened recognition of intermolecular DNA helices, Third, quinolones stimulate topoisomerase IV-mediated DNA cleavage both by increasing rates of DNA scission and by inhibiting religation of cleaved DNA. Finally, quinolones inhibit the overall catalytic activity of topoisomerase TV primarily by interfering with enzyme-ATP interactions.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med Oncol, Nashville, TN 37232 USA; Pfizer Inc, Pfizer Cent Res, Dept Canc Immunol & Infect Dis, Groton, CT 06340 USA	Vanderbilt University; Vanderbilt University; Pfizer	Osheroff, N (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 654 Med Res Bldg I, Nashville, TN 37232 USA.				NATIONAL CANCER INSTITUTE [T32CA009385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033944] Funding Source: NIH RePORTER; NCI NIH HHS [5 T32 CA09385] Funding Source: Medline; NIGMS NIH HHS [GM33944] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS DE, 1992, CELL, V71, P277, DOI 10.1016/0092-8674(92)90356-H; BARRETT JF, 1989, ANTIMICROB AGENTS CH, V33, P1697, DOI 10.1128/AAC.33.10.1697; Blanche F, 1996, ANTIMICROB AGENTS CH, V40, P2714, DOI 10.1128/AAC.40.12.2714; CORBETT AH, 1991, J BIOL CHEM, V266, P19666; CORBETT AH, 1993, J BIOL CHEM, V268, P14394; CORBETT AH, 1993, ANTIMICROB AGENTS CH, V37, P2599, DOI 10.1128/AAC.37.12.2599; CORBETT AH, 1993, CHEM RES TOXICOL, V6, P585, DOI 10.1021/tx00035a001; Drlica K, 1997, MICROBIOL MOL BIOL R, V61, P377, DOI 10.1128/.61.3.377-392.1997; Elsea SH, 1997, BIOCHEMISTRY-US, V36, P2919, DOI 10.1021/bi962488f; ELSEA SH, 1993, ANTIMICROB AGENTS CH, V37, P2179, DOI 10.1128/AAC.37.10.2179; ENGLUND PT, 1978, CELL, V14, P157, DOI 10.1016/0092-8674(78)90310-0; FERRERO L, 1994, MOL MICROBIOL, V13, P641, DOI 10.1111/j.1365-2958.1994.tb00458.x; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P14998, DOI 10.1074/jbc.270.25.14998; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P3872, DOI 10.1073/pnas.73.11.3872; GELLERT M, 1977, P NATL ACAD SCI USA, V74, P4772, DOI 10.1073/pnas.74.11.4772; GILLIGAN PJ, 1986, Patent No. 4623650; Gootz TD, 1996, ANTIMICROB AGENTS CH, V40, P2691, DOI 10.1128/AAC.40.12.2691; Gootz TD, 1996, MED RES REV, V16, P433, DOI 10.1002/(SICI)1098-1128(199609)16:5<433::AID-MED3>3.0.CO;2-W; Gootz Thomas D., 1993, P139; HIROTA Y, 1968, COLD SPRING HARB SYM, V33, P677, DOI 10.1101/SQB.1968.033.01.077; Hooper D., 1993, QUINOLONE ANTIMICROB, Vsecond; HOOPER DC, 1991, NEW ENGL J MED, V324, P384, DOI 10.1056/NEJM199102073240606; HOSHINO K, 1953, ANTIMICROB AGENTS CH, V3826, P94; HSIUNG YC, 1995, J BIOL CHEM, V270, P20359, DOI 10.1074/jbc.270.35.20359; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; KATO J, 1992, J BIOL CHEM, V267, P25676; KATO JI, 1988, J BACTERIOL, V170, P3967, DOI 10.1128/jb.170.9.3967-3977.1988; KHODURSKY AB, 1995, P NATL ACAD SCI USA, V92, P11801, DOI 10.1073/pnas.92.25.11801; Kingma PS, 1997, BIOCHEMISTRY-US, V36, P5934, DOI 10.1021/bi970507v; KREUZER KN, 1979, J BACTERIOL, V140, P424, DOI 10.1128/JB.140.2.424-435.1979; LIU LF, 1983, J BIOL CHEM, V258, P5365; Marians KJ, 1997, J BIOL CHEM, V272, P9401; MAXWELL A, 1992, J ANTIMICROB CHEMOTH, V30, P409, DOI 10.1093/jac/30.4.409; Maxwell A, 1997, TRENDS MICROBIOL, V5, P102, DOI 10.1016/S0966-842X(96)10085-8; Menzel R, 1994, Adv Pharmacol, V29A, P39; Munoz R, 1996, ANTIMICROB AGENTS CH, V40, P2252, DOI 10.1128/AAC.40.10.2252; Ng EY, 1996, ANTIMICROB AGENTS CH, V40, P1881, DOI 10.1128/AAC.40.8.1881; OSHEROFF N, 1989, BIOCHEMISTRY-US, V28, P6157, DOI 10.1021/bi00441a005; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P4303, DOI 10.1021/bi00388a018; OSHEROFF N, 1989, PHARMACOL THERAPEUT, V41, P223, DOI 10.1016/0163-7258(89)90108-3; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; OSHEROFF N, 1994, CANC CHEMOTHER PHARM, V34, P19; Pan XS, 1996, ANTIMICROB AGENTS CH, V40, P2321, DOI 10.1128/AAC.40.10.2321; PENG H, 1993, P NATL ACAD SCI USA, V90, P8571, DOI 10.1073/pnas.90.18.8571; PENG H, 1993, J BIOL CHEM, V268, P24481; PRUSS GJ, 1982, CELL, V31, P35, DOI 10.1016/0092-8674(82)90402-0; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; ROBINSON MJ, 1993, BIOCHEMISTRY-US, V32, P3638, DOI 10.1021/bi00065a016; ROBINSON MJ, 1992, ANTIMICROB AGENTS CH, V36, P751, DOI 10.1128/AAC.36.4.751; ROBINSON MJ, 1991, BIOCHEMISTRY-US, V30, P1807, DOI 10.1021/bi00221a012; ROBINSON MJ, 1990, BIOCHEMISTRY-US, V29, P2511, DOI 10.1021/bi00462a012; ROBINSON MJ, 1991, J BIOL CHEM, V266, P14585; Sambrook J., 1989, MOL CLONING LAB MANU, V1; SANDER M, 1983, J BIOL CHEM, V258, P8421; SHELTON ER, 1983, J BIOL CHEM, V258, P9530; SORENSEN BS, 1992, J MOL BIOL, V228, P778, DOI 10.1016/0022-2836(92)90863-F; SUGINO A, 1977, P NATL ACAD SCI USA, V74, P4767, DOI 10.1073/pnas.74.11.4767; Ullsperger C, 1996, J BIOL CHEM, V271, P31549, DOI 10.1074/jbc.271.49.31549; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WASSERMAN RA, 1993, CANCER RES, V53, P3591; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; WORLAND ST, 1989, J BIOL CHEM, V264, P4412; ZECHIEDRICH EL, 1990, EMBO J, V9, P4555, DOI 10.1002/j.1460-2075.1990.tb07908.x; Zechiedrich EL, 1997, GENE DEV, V11, P2580, DOI 10.1101/gad.11.19.2580; ZECHIEDRICH EL, 1995, GENE DEV, V9, P2859, DOI 10.1101/gad.9.22.2859; ZIMMER C, 1990, J BASIC MICROB, V30, P209, DOI 10.1002/jobm.3620300312	69	59	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17879	17885		10.1074/jbc.273.28.17879	http://dx.doi.org/10.1074/jbc.273.28.17879			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651393	hybrid			2022-12-25	WOS:000074816100086
J	Ikebe, M; Kambara, T; Stafford, WF; Sata, M; Katayama, E; Ikebe, R				Ikebe, M; Kambara, T; Stafford, WF; Sata, M; Katayama, E; Ikebe, R			A hinge at the central helix of the regulatory light chain of myosin is critical for phosphorylation-dependent regulation of smooth muscle myosin motor activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN GIZZARD-MUSCLE; 3-DIMENSIONAL STRUCTURE; ENZYMATIC-PROPERTIES; 2-HEADED STRUCTURE; BOUNDARY ANALYSIS; PEPTIDE COMPLEX; CONFORMATION; CALMODULIN; KINASE; PROTEOLYSIS	The motor function of smooth muscle myosin is activated by phosphorylation of the regulatory light chain (RLC) at Ser(19). However, the molecular mechanism by which the phosphorylation activates the motor function is not yet understood. In the present study, we focused our attention on the role of the central helix of RLC for regulation. The flexible region at the middle of the central helix (Gly(95)-Pro(98)) was substituted or deleted to various extents, and the effects of the deletion or substitution on the regulation of the motor activity of myosin were examined. Deletion of Gly(95)-Asp(97), Gly(95)-Thr(96), or Thr(96)-Asp(97) decreased the actin-translocating activity of myosin a Little, but the phosphorylation-dependent regulation of the motor activity was not disrupted. In contrast, the deletion of Gly(95)-Pro(98) Of RLC completely abolished the actin translocating activity of phosphorylated myosin. However, the unregulated myosin long subfragment 1 containing this RLC mutant showed motor activity the same as that containing the wild type RLC, Since long subfragment 1 motor activity is unregulated by phosphorylation, i.e. constitutively active, these results suggest that the deletion of these residues at the central helix of RLC disrupts the phosphorylation-mediated activation mechanism but not the motor function of myosin itself. On the other hand, the elimination of Pro(98) or substitution of Gly(95)-Pro(98) by Ala resulted in the activation of actin translocating activity of dephosphorylated myosin, whereas it did not affect the motor activity of phosphorylated myosin, Together, these results clearly indicate the importance of the hinge at the central helix of RLC on the phosphorylation-mediated regulation of smooth muscle myosin.	Univ Massachusetts, Med Ctr, Dept Physiol, Worcester, MA 01655 USA; Boston Biomed Res Inst, Muscle Res Grp, Boston, MA 02114 USA; Univ Tokyo, Inst Med Sci, Minato Ku, Tokyo 108, Japan	University of Massachusetts System; University of Massachusetts Worcester; Boston Biomedical Research Institute; University of Tokyo	Ikebe, M (corresponding author), Univ Massachusetts, Med Ctr, Dept Physiol, 55 Lake Ave N, Worcester, MA 01655 USA.		Stafford, Walter/ABC-6553-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047530, R01HL056218] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041653] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47530, HL 56218] Funding Source: Medline; NIAMS NIH HHS [AR 41653] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; CHIEN YH, 1984, MOL CELL BIOL, V4, P507, DOI 10.1128/MCB.4.3.507; CRAIG R, 1983, NATURE, V302, P436, DOI 10.1038/302436a0; CREMO CR, 1995, J BIOL CHEM, V270, P2171, DOI 10.1074/jbc.270.5.2171; Cuda G, 1997, BIOPHYS J, V72, P1767, DOI 10.1016/S0006-3495(97)78823-4; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, V2, P423; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; IKEBE M, 1994, J BIOL CHEM, V269, P28165; IKEBE M, 1983, BIOCHEMISTRY-US, V22, P4580, DOI 10.1021/bi00288a036; IKEBE M, 1984, J BIOL CHEM, V259, P1639; IKEBE M, 1985, J BIOL CHEM, V260, P3146; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; IKEBE M, 1987, J BIOL CHEM, V262, P13828; IKEBE M, 1986, J BIOL CHEM, V261, P36; IKEBE M, 1985, J BIOL CHEM, V260, P27; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JAKES R, 1976, FEBS LETT, V70, P229, DOI 10.1016/0014-5793(76)80763-6; KAMISOYAMA H, 1994, BIOCHEMISTRY-US, V33, P840, DOI 10.1021/bi00169a027; KAMM KE, 1989, ANNU REV PHYSIOL, V51, P299; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAITA T, 1981, EUR J BIOCHEM, V117, P417, DOI 10.1111/j.1432-1033.1981.tb06354.x; MATSUURA M, 1995, FEBS LETT, V363, P246, DOI 10.1016/0014-5793(95)00326-5; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MORITA JI, 1991, BIOCHEMISTRY-US, V30, P9539, DOI 10.1021/bi00103a022; ONISHI H, 1984, J BIOCHEM, V95, P899, DOI 10.1093/oxfordjournals.jbchem.a134685; ONISHI H, 1983, J BIOCHEM-TOKYO, V94, P1147, DOI 10.1093/oxfordjournals.jbchem.a134459; ONISHI H, 1982, J BIOCHEM-TOKYO, V92, P871, DOI 10.1093/oxfordjournals.jbchem.a134001; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Sata M, 1997, P NATL ACAD SCI USA, V94, P91, DOI 10.1073/pnas.94.1.91; Sata M, 1996, BIOCHEMISTRY-US, V35, P11113, DOI 10.1021/bi960435s; Sellers JR, 1991, CURR OPIN CELL BIOL, V3, P98, DOI 10.1016/0955-0674(91)90171-T; Sellers JR, 1987, ENZYMES, V18, ppp381, DOI 10.1016/S1874-6047(08)60264-4; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; STAFFORD WF, 1994, METHOD ENZYMOL, V240, P478; SUZUKI H, 1978, J BIOCHEM, V84, P1529, DOI 10.1093/oxfordjournals.jbchem.a132278; SWEENEY HL, 1994, P NATL ACAD SCI USA, V91, P1490, DOI 10.1073/pnas.91.4.1490; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; Trybus KM, 1991, CURR OPIN CELL BIOL, V3, P105, DOI 10.1016/0955-0674(91)90172-U; TRYBUS KM, 1994, J CELL BIOL, V124, P963, DOI 10.1083/jcb.124.6.963; TRYBUS KM, 1982, P NATL ACAD SCI-BIOL, V79, P6151, DOI 10.1073/pnas.79.20.6151; TRYBUS KM, 1993, J BIOL CHEM, V268, P4412; TRYBUS KM, 1984, J BIOL CHEM, V259, P8564; VANBERKUM MFA, 1990, J BIOL CHEM, V265, P3750; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0; YANO K, 1993, BIOCHEMISTRY-US, V32, P12054, DOI 10.1021/bi00096a016; Yphantis D, 1994, MODERN ANAL ULTRACEN, P209	50	49	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17702	17707		10.1074/jbc.273.28.17702	http://dx.doi.org/10.1074/jbc.273.28.17702			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651368	hybrid			2022-12-25	WOS:000074816100061
J	Li, QS; Das Gupta, J; Hunt, AG				Li, QS; Das Gupta, J; Hunt, AG			Polynucleotide phosphorylase is a component of a novel plant poly(A) polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPLAST MESSENGER-RNA; ESCHERICHIA-COLI; BINDING PROTEINS; DEGRADATION; GENE; SEQUENCE; DECAY	We have isolated cDNA clones encoding a novel RNA-binding protein that is a component of a multisubunit poly(A) polymerase from pea seedlings. The encoded protein bears a significant resemblance to polynucleotide phosphorylases (PNPases) from bacteria and chloroplasts, More significantly, this RNA-binding protein is able to degrade RNAs with the resultant production of nucleotide diphosphates, and it can add extended polyadenylate tracts to RNAs using ADP as a donor for adenylate moieties, These activities are characteristic of PNPase, Antibodies raised against the cloned protein simultaneously immunoprecipitate both poly(A) polymerase and PNPase activity. We conclude from these studies that PNPase is the RNA-binding cofactor for this poly(A) polymerase and is an integral player in the reaction catalyzed by this enzyme. The identification of this RNA-binding protein as PNPase, which is a chloroplast-localized enzyme known to be involved in mRNA 3'-end determination and turnover (Hayes, R., Kudla, J., Schuster, G., Gabay, L., Maliga, P., and Gruissem, W. (1996) EMBO J, 15, 1132-1141), raises interesting questions regarding the subcellular location of the poly(A) polymerase under study, We have reexamined this issue, and we find that this enzyme can be detected in chloroplast extracts. The involvement of PNPase in poly adenylation in vitro provides a biochemical rationale for the link between chloroplast RNA polyadenylation and RNA turnover which has been noted by others (Lisitsky, I., Klaff, P,, and Schuster, G, (1996) Proc. Natl, Acad, Sci, U. S. A. 93, 13398-13403).	Univ Kentucky, Dept Agron, Plant Physiol Biochem Mol Biol Program, Lexington, KY 40546 USA	University of Kentucky	Hunt, AG (corresponding author), Univ Kentucky, Dept Agron, Plant Physiol Biochem Mol Biol Program, N212A Agr Sci Ctr N, Lexington, KY 40546 USA.		Hunt, Arthur/A-8040-2009; Li, Qingshun/C-5603-2009	Li, Qingshun/0000-0003-4105-1480; Hunt, Arthur/0000-0002-0008-4158				Bycroft M, 1997, CELL, V88, P235, DOI 10.1016/S0092-8674(00)81844-9; DASGUPTA J, 1995, PLANT SCI, V110, P215; GANTT JS, 1986, MOL GEN GENET, V202, P186, DOI 10.1007/BF00331635; HAJNSDORF E, 1995, P NATL ACAD SCI USA, V92, P3973, DOI 10.1073/pnas.92.9.3973; Hayes R, 1996, EMBO J, V15, P1132, DOI 10.1002/j.1460-2075.1996.tb00451.x; KARLINNEUMANN GA, 1986, EMBO J, V5, P9, DOI 10.1002/j.1460-2075.1986.tb04170.x; Kudla J, 1996, EMBO J, V15, P7137, DOI 10.1002/j.1460-2075.1996.tb01105.x; Li QS, 1996, J BIOL CHEM, V271, P19831, DOI 10.1074/jbc.271.33.19831; Lisitsky I, 1996, P NATL ACAD SCI USA, V93, P13398, DOI 10.1073/pnas.93.23.13398; MCCLAREN RS, 1991, J MOL BIOL, V220, P81; MOGEN BD, 1992, MOL CELL BIOL, V12, P5406, DOI 10.1128/MCB.12.12.5406; OHARA EB, 1995, P NATL ACAD SCI USA, V92, P1807, DOI 10.1073/pnas.92.6.1807; OJALA D, 1981, NATURE, V290, P470, DOI 10.1038/290470a0; OROZCO EM, 1986, METHOD ENZYMOL, V118, P232; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; Py B, 1996, NATURE, V381, P169, DOI 10.1038/381169a0; REGNIER P, 1987, J BIOL CHEM, V262, P63; REINER AM, 1969, J BACTERIOL, V97, P1437, DOI 10.1128/JB.97.3.1437-1443.1969; SACHS A, 1993, J BIOL CHEM, V268, P22955; Sambrook J., 2002, MOL CLONING LAB MANU; XU FF, 1995, NATURE, V374, P180, DOI 10.1038/374180a0; XU FF, 1993, P NATL ACAD SCI USA, V90, P6756, DOI 10.1073/pnas.90.14.6756; YANG JJ, 1994, PLANT SCI, V99, P161, DOI 10.1016/0168-9452(94)90173-2	23	31	32	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17539	17543		10.1074/jbc.273.28.17539	http://dx.doi.org/10.1074/jbc.273.28.17539			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651346	hybrid			2022-12-25	WOS:000074816100039
J	Marekov, LN; Steinert, PM				Marekov, LN; Steinert, PM			Ceramides are bound to structural proteins of the human foreskin epidermal cornified cell envelope	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLINE-RICH PROTEIN-1; STRATUM-CORNEUM; CROSS-LINKING; LIPIDS; TRANSGLUTAMINASES; CORNEOCYTE; INVOLUCRIN; LORICRIN	An important component of barrier function in human epidermis is contributed by ceramides that are bound by ester linkages to undefined proteins of the cornified cell envelope (CE), In this paper, we have examined the protein targets for the ceramide attachment. By partial saponification of isolated foreskin epidermal CEs followed by limited proteolysis, we have recovered several lipopeptides. Biochemical and mass spectroscopic characterization revealed that all contained near stoichiometric amounts of ceramides of masses ranging from about 690 to 890 atomic mass units, of which six quantitatively major species were common. The array of ceramides was similar to that obtained from pig skin, the composition of which is known, thereby providing strong indirect data for their fatty acid and sphingosine compositions, The recovered peptides accounted for about 20% of the total foreskin CE ceramides, By amino acid sequencing, about 35% of the peptides were derived from ancestral glutamine glutamate-rich regions of involucrin, an important CE structural protein. Another 18% derived from rod domain sequences of periplakin and envoplakin, which are also known or suspected CE proteins. Other peptides were too short for unequivocal identification. Together, these data indicate that involucrin, envoplakin, periplakin, and possibly other structural proteins serve as substrates for the attachment of ceramides by ester linkages to the CE for barrier function in human epidermis.	NIAMSD, Lab Shin Biol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Steinert, PM (corresponding author), NIAMSD, Lab Shin Biol, NIH, Bldg 6,Rm 425, Bethesda, MD 20892 USA.	pemast@helix.nih.gov						DOWNING DT, 1993, DERMATOLOGY GEN MED, P210; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; Elias Peter M., 1996, Journal of Dermatology (Tokyo), V23, P756; ELIAS PM, 1991, ADV LIPID RES, V24, P1; FOLK JE, 1985, METHOD ENZYMOL, V113, P358; FOLK JE, 1983, ADV ENZYMOL RAMB, V54, P1; GREEN H, 1992, MOL BIOL EVOL, V9, P977; GREEN KJ, 1990, J BIOL CHEM, V265, P2603; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; GROSS M, 1974, J BIOL CHEM, V249, P3021; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HOHL D, 1990, DERMATOLOGICA, V180, P201, DOI 10.1159/000248031; Holbrook K.A., 1993, DERMATOLOGY GEN MED, P97; Jarnik M, 1998, J CELL SCI, V111, P1051; Jarnik M, 1996, J CELL SCI, V109, P1381; LAZO ND, 1995, J INVEST DERMATOL, V105, P296, DOI 10.1111/1523-1747.ep12318985; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; MARTINET N, 1990, BIOCHEM J, V271, P305, DOI 10.1042/bj2710305; PONEC M, 1994, KERATINOCYTE HDB, P351; Reichert Uwe, 1993, P107; Robinson NA, 1997, J BIOL CHEM, V272, P12035, DOI 10.1074/jbc.272.18.12035; Ruhrberg C, 1996, J CELL BIOL, V134, P715, DOI 10.1083/jcb.134.3.715; SCHURER NY, 1991, ADV LIPID RES, V24, P27; SIMON M, 1994, KERATINOCYTE HDB, P275; Steinert P M, 1995, Cell Death Differ, V2, P33; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; Steinert PM, 1997, J BIOL CHEM, V272, P2021, DOI 10.1074/jbc.272.3.2021; STEVEN AC, 1994, J CELL SCI, V107, P693; SWARTZENDRUBER DC, 1987, J INVEST DERMATOL, V88, P709, DOI 10.1111/1523-1747.ep12470383; WERTZ PW, 1987, J INVEST DERMATOL, V89, P419, DOI 10.1111/1523-1747.ep12471781; WERTZ PW, 1989, COMP BIOCHEM PHYS B, V93, P265, DOI 10.1016/0305-0491(89)90080-1; WERTZ PW, 1989, J INVEST DERMATOL, V93, P169, DOI 10.1111/1523-1747.ep12277394; WERTZ PW, 1989, J INVEST DERMATOL, V92, P109, DOI 10.1111/1523-1747.ep13071317; WERTZ PW, 1983, J LIPID RES, V24, P759; WERTZ PW, 1991, PHYSL BIOCH MOL BIOL, P205; YAFFE MB, 1992, J BIOL CHEM, V267, P12233; YONEDA K, 1993, P NATL ACAD SCI USA, V90, P10754, DOI 10.1073/pnas.90.22.10754	37	157	166	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17763	17770		10.1074/jbc.273.28.17763	http://dx.doi.org/10.1074/jbc.273.28.17763			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651377	hybrid			2022-12-25	WOS:000074816100070
J	Solomon, C; Sebag, M; White, JH; Rhim, J; Kremer, R				Solomon, C; Sebag, M; White, JH; Rhim, J; Kremer, R			Disruption of vitamin D receptor-retinoid X receptor heterodimer formation following ras transformation of human keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR HORMONE RECEPTORS; D RESPONSE ELEMENT; THYROID-HORMONE; ACID RECEPTORS; CO-REPRESSOR; DIFFERENTIATION; BINDING; 1,25-DIHYDROXYVITAMIN-D3; CELLS; GENE	A partial resistance to the growth inhibitory influence of 1,25-dihydroxyvitamin D-3 is apparent when immortalized keratinocytes are transformed by the ras oncogene. The vitamin D receptor (VDR) was isolated, analyzed, and found to be identical in normal, immortalized, and ras-transformed keratinocytes. Subsequently, nuclear extracts from immortalized and ras-transformed keratinocytes were analyzed in gel mobility shift assays utilizing labeled vitamin D response elements or thyroid hormone response elements. A specific protein DNA complex that was shown to contain VDR using an anti-VDR antibody was identified in both types of extracts; however, the addition of an anti-retinoid X receptor (RXR) antibody identified RXR in the complex of both normal and immortalized keratinocyte cell extracts, but not in ras-transformed keratinocytes. Furthermore, transfection of ras-transformed keratinocytes with wild-type human RXR alpha rescued VDR.RXR and thyroid hormone receptor.RXR complexes as demonstrated by a supershift in the presence of the anti-RXR antibody. Both cell lines were found to express RXR alpha message in equal amounts. Western blot analysis revealed that RXR alpha protein from ras-transformed keratinocytes was indistinguishable from that from immortalized keratinocytes and from control cells. These results suggest a causal relationship between resistance to the growth inhibitory influences of 1,25-dihydroxyvitamin D-3 and disruption of the VDR.RXR complex in malignant keratinocytes.	McGill Univ, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Physiol, Montreal, PQ H3A 1A1, Canada; NCI, Mol Oncol Lab, Frederick Canc Res & Dev Ctr, NIH, Frederick, MD 21702 USA	McGill University; McGill University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Kremer, R (corresponding author), Royal Victoria Hosp, Calcium Res Lab, Rm H4-67,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.		white, john h/N-9782-2013	white, john h/0000-0002-4785-2687; Kremer, Richard/0000-0002-7053-2139				Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Arbelle JE, 1996, ENDOCRINOLOGY, V137, P786, DOI 10.1210/en.137.2.786; BIKLE DD, 1986, BIOCHEMISTRY-US, V25, P1545, DOI 10.1021/bi00355a013; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; DURST M, 1987, ONCOGENE, V1, P251; ELDER JT, 1992, J INVEST DERMATOL, V98, pS36, DOI 10.1111/1523-1747.ep12462180; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FERRARA J, 1994, J BIOL CHEM, V269, P2971; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FREEDMAN LP, 1994, MOL ENDOCRINOL, V8, P265, DOI 10.1210/me.8.3.265; HAUSSLER MR, 1986, ANNU REV NUTR, V6, P527, DOI 10.1146/annurev.nu.06.070186.002523; HOLLENBERG AN, 1995, MOL ENDOCRINOL, V9, P540, DOI 10.1210/me.9.5.540; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; HOSOMI J, 1983, ENDOCRINOLOGY, V113, P1950, DOI 10.1210/endo-113-6-1950; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; Jin CH, 1996, MOL ENDOCRINOL, V10, P196, DOI 10.1210/me.10.2.196; Kephart DD, 1996, MOL ENDOCRINOL, V10, P408, DOI 10.1210/me.10.4.408; Mackey SL, 1996, MOL ENDOCRINOL, V10, P298, DOI 10.1210/me.10.3.298; OMALLEY BW, 1984, J CLIN INVEST, V74, P307, DOI 10.1172/JCI111425; OZONO K, 1990, J BIOL CHEM, V265, P21881; PILLAI S, 1988, J BIOL CHEM, V263, P5390; SEBAG M, 1994, J INVEST DERMATOL, V103, P323, DOI 10.1111/1523-1747.ep12394802; SEBAG M, 1992, J BIOL CHEM, V267, P12162; SMITH EL, 1986, J INVEST DERMATOL, V86, P709, DOI 10.1111/1523-1747.ep12276343; SONE T, 1990, MOL ENDOCRINOL, V4, P623, DOI 10.1210/mend-4-4-623; XIAO JH, 1995, J BIOL CHEM, V270, P3001, DOI 10.1074/jbc.270.7.3001; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	29	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17573	17578		10.1074/jbc.273.28.17573	http://dx.doi.org/10.1074/jbc.273.28.17573			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651351	hybrid			2022-12-25	WOS:000074816100044
J	El-Naggar, AK; Coombes, MM; Batsakis, JG; Hong, WK; Goepfert, H; Kagan, J				El-Naggar, AK; Coombes, MM; Batsakis, JG; Hong, WK; Goepfert, H; Kagan, J			Localization of chromosome 8p regions involved in early tumorigenesis of oral and laryngeal squamous carcinoma	ONCOGENE			English	Article						oral and laryngeal; chromosome 8p; squamous carcinoma; microsatellite; loss of heterozygosity	TUMOR-SUPPRESSOR GENES; PROSTATIC INTRAEPITHELIAL NEOPLASIA; CELL CARCINOMAS; ALLELIC LOSS; FREQUENT LOSS; SHORT ARM; HEPATOCELLULAR-CARCINOMA; COLORECTAL-CANCER; BREAST-CANCER; NECK-CANCER	We analysed 30 primary invasive oral and laryngeal squamous carcinomas (SC), with concurrent dysplastic Lesions, for genetic alterations at 15 microsatellite loci on the short arm of chromosome 8. Overall, loss of heterozygosity (LOH) was observed, in at least one informative locus, in 27% of the dysplastic lesions and in 67% of the invasive carcinomas. The highest frequency of allele tosses in dysplasia (20% and 17%), and invasive carcinoma (40% and 48%) were detected in the same D8S298 and LPL-tet loci located on chromosomes 8p21 and 8p22 respectively. The minimal region with LOH was limited to 4.6 megaBases (mBs) at 8p22 and 7.1 mBs at 8p21. In addition, allelic losses in both dysplastic and corresponding invasive specimens were noted at the same loci in some tumors suggesting their emergence from a common preneoplastic clone. Allele losses correlated significantly with male gender, oral and laryngeal sites and high proliferative index. The data suggest that inactivation of tumor suppressor gene(s), within these loci, may constitute an early event in the evolution of oral and laryngeal SC.	Univ Texas, MD Anderson Cancer Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Lab Med, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	El-Naggar, AK (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Pathol, Houston, TX 77030 USA.				NIH HHS [1P5ODE11906-01] Funding Source: Medline	NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ALSEE KW, 1994, CANCER RES, V54, P1617; Bockmuhl U, 1996, CANCER RES, V56, P5325; Bova GS, 1996, GENOMICS, V35, P46, DOI 10.1006/geno.1996.0321; BRZOSKA PM, 1995, CANCER RES, V55, P3055; Califano J, 1996, CANCER RES, V56, P2488; CHANG M, 1994, AM J PATHOL, V144, P1; Collins A, 1996, P NATL ACAD SCI USA, V93, P14771, DOI 10.1073/pnas.93.25.14771; COWAN JM, 1992, J NATL CANCER I, V84, P793, DOI 10.1093/jnci/84.10.793; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; ELNAGGAR AK, 1995, CANCER RES, V55, P2656; EMI M, 1992, CANCER RES, V52, P5368; EMMERTBUCK MR, 1995, CANCER RES, V55, P2959; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIELD JK, 1995, BRIT J CANCER, V72, P1180, DOI 10.1038/bjc.1995.483; FUJIWARA Y, 1995, ONCOGENE, V10, P891; Gustafson CE, 1996, CANCER RES, V56, P5238; ICHIKAWA T, 1994, CANCER RES, V54, P2299; JIN YS, 1995, CANCER RES, V55, P3204; KAGAN J, 1995, ONCOGENE, V11, P2121; KERANGUEVEN F, 1995, ONCOGENE, V10, P1023; KERANGUEVEN F, 1994, ONCOL REP, V1, P393; KIARIS H, 1994, INT J ONCOL, V5, P1243; Kishimoto Y, 1996, J CANCER RES CLIN, V122, P585, DOI 10.1007/BF01221189; KNOWLES MA, 1993, ONCOGENE, V8, P1357; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; LEVINE AJ, 1992, CANC SURVEYS, V12; LI XH, 1994, J NATL CANCER I, V86, P1524, DOI 10.1093/jnci/86.20.1524; MacGrogan D, 1996, GENOMICS, V35, P55, DOI 10.1006/geno.1996.0322; MACGROGAN D, 1994, GENE CHROMOSOME CANC, V10, P151, DOI 10.1002/gcc.2870100302; MERLO GR, 1992, AM J PATHOL, V140, P215; NAWROZ H, 1994, CANCER RES, V54, P1617; OHATA H, 1993, GENE CHROMOSOME CANC, V7, P85, DOI 10.1002/gcc.2870070204; RADFORD DM, 1995, CANCER RES, V55, P5180; RAO PH, 1994, CANCER GENET CYTOGEN, V77, P60, DOI 10.1016/0165-4608(94)90150-3; SAKR WA, 1994, IN VIVO, V8, P439; Scholnick SB, 1996, J NATL CANCER I, V88, P1676, DOI 10.1093/jnci/88.22.1676; Scully C, 1997, INT J ONCOL, V10, P5; SPEICHER MR, 1995, CANCER RES, V55, P1010; SREEKANTAIAH C, 1994, GENE CHROMOSOME CANC, V11, P29, DOI 10.1002/gcc.2870110106; Sunwoo JB, 1996, GENE CHROMOSOME CANC, V16, P164, DOI 10.1002/(SICI)1098-2264(199607)16:3<164::AID-GCC2>3.0.CO;2-X; SUZUKI H, 1995, GENE CHROMOSOME CANC, V13, P168, DOI 10.1002/gcc.2870130306; TAMAKO K, 1996, ONCOGENE, V12, P405; TRAGANOS F, 1977, J HISTOCHEM CYTOCHEM, V25, P46, DOI 10.1177/25.1.64567; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WOOD S, 1994, GENOMICS, V24, P597, DOI 10.1006/geno.1994.1673; YAREMKO ML, 1995, GENE CHROMOSOME CANC, V13, P186, DOI 10.1002/gcc.2870130308; YAREMKO ML, 1994, GENE CHROMOSOME CANC, V10, P1, DOI 10.1002/gcc.2870100102	47	64	65	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 11	1998	16	23					2983	2987		10.1038/sj.onc.1201808	http://dx.doi.org/10.1038/sj.onc.1201808			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZT782	9662330				2022-12-25	WOS:000074125300004
J	Fan, SJ; Wang, JA; Yuan, RQ; Ma, YX; Meng, QH; Erdos, MR; Brody, LC; Goldberg, ID; Rosen, EM				Fan, SJ; Wang, JA; Yuan, RQ; Ma, YX; Meng, QH; Erdos, MR; Brody, LC; Goldberg, ID; Rosen, EM			BRCA1 as a potential human prostate tumor suppressor: modulation of proliferation, damage responses and expression of cell regulatory proteins	ONCOGENE			English	Article						prostate cancer; DU-145; BRCA1; DNA damage; apoptosis; p300	OVARIAN-CANCER; GENE BRCA1; TRANSCRIPTIONAL ACTIVATION; BREAST-CANCER; MUTATIONS; REGION; P53; FRAGMENTS; CARRIERS; FAMILIES	In addition to breast and ovarian cancer in women, recent evidence suggests that germ-line mutations of the breast cancer susceptibility gene-1 (BRCA1) also confer an increased life-time risk for prostate cancer in male probands, However, it is not known if and how BRCA1 functions in prostate cancer, We stably expressed wildtype (wt) and tumor-associated mutant BRCA1 transgenes in DU-145, a human prostate cancer cell line with low endogenous expression of BRCA1, As compared with parental cells and vector transfected clones, wtBRCA1 clones exhibited: (1) a slightly decreased proliferation rate (doubling time = 25 h as compared with 22 h for control cells); (2) a (3-6)-fold increase in sensitivity to chemotherapy drugs (adriamycin, camptothecin, and taxol); (3) increased susceptibility to drug-induced apoptosis; (4) reduced repair of single-strand DNA strand breaks; and (5) alterations in expression of key cellular regulatory proteins (including BRCA2, p300, Mdm-2, p21(WAF1/CIP1), Bcl-2 and Bar). Clones transfected with the 5677insA breast cancer-associated mutant BRCA1 (insBRCA1) displayed a similar phenotype to wtBRCA1 clones, except that insBRCA1 clones had a significantly decreased proliferation rate (doubling time=42 h), On the other hand, cells transfected with with 185delAG mutant BRCA1 showed no obvious phenotype as compared with parental or vector transfected cells, These findings suggest that BRCA1 may function as a human prostate tumor suppressor by virtue of its ability to modulate proliferation and various components of the cellular damage response. They also suggest several potential target gene products for a BRCA1 prostate tumor suppressor function.	Long Isl Jewish Med Ctr, Albert Einstein Coll Med, Dept Radiat Oncol, New Hyde Park, NY 11040 USA; Natl Human Genome Res Inst, Genet & Mol Biol Branch, NIH, Bethesda, MD 20892 USA	Northwell Health; Yeshiva University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Fan, SJ (corresponding author), Long Isl Jewish Med Ctr, Albert Einstein Coll Med, Dept Radiat Oncol, Long Isl Campus,270-05 76th Ave, New Hyde Park, NY 11040 USA.		Meng, Q./GSI-6185-2022					ALLEY MC, 1988, CANCER RES, V48, P589; ANDRES JL, IN PRESS ONCOGENE; BERTRAND R, 1995, CELL GROWTH APOPTOSI, P97; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; Cobrinik D, 1996, CURR TOP MICROBIOL, V208, P31; DubsPoterszman MC, 1995, ONCOGENE, V11, P2445; EASTON DF, 1995, AM J HUM GENET, V56, P265; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; GAO X, 1995, ONCOGENE, V11, P1241; Garnick MB, 1996, ANN INTERN MED, V125, P205, DOI 10.7326/0003-4819-125-3-199608010-00009; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; JISHI MF, 1995, CANCER, V76, P1416, DOI 10.1002/1097-0142(19951015)76:8<1416::AID-CNCR2820760818>3.0.CO;2-D; Karp JE, 1996, CANCER RES, V56, P5547; Langston AA, 1996, AM J HUM GENET, V58, P881; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; MURAKAMI YS, 1995, CANCER RES, V55, P3389; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Rao VN, 1996, ONCOGENE, V12, P523; Samuelson AV, 1997, P NATL ACAD SCI USA, V94, P12094, DOI 10.1073/pnas.94.22.12094; SANCHEZPRIETO R, 1995, ONCOGENE, V11, P675; SARKAR FH, 1992, PROSTATE, V21, P145, DOI 10.1002/pros.2990210207; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Shao NS, 1996, ONCOGENE, V13, P1; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; STREUWING JP, 1997, NEW ENGL J MED, V336, P1401; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Tirkkonen M, 1997, CANCER RES, V57, P1222; Trouche D, 1996, NUCLEIC ACIDS RES, V24, P4139, DOI 10.1093/nar/24.21.4139; TULINIUS H, 1992, BRIT MED J, V305, P855, DOI 10.1136/bmj.305.6858.855; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; Webber MM, 1997, PROSTATE, V30, P58; Williams BJ, 1996, J UROLOGY, V155, P720, DOI 10.1016/S0022-5347(01)66509-1; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Zhang H, 1997, J BIOL CHEM, V272, P17416, DOI 10.1074/jbc.272.28.17416	47	93	97	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 11	1998	16	23					3069	3082		10.1038/sj.onc.1202116	http://dx.doi.org/10.1038/sj.onc.1202116			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZT782	9662340				2022-12-25	WOS:000074125300014
J	Mizutani, S; Koide, H; Kaziro, Y				Mizutani, S; Koide, H; Kaziro, Y			Isolation of a new protein factor required for activation of Raf-1 by Ha-Ras: partial purification from rat brain cytosols	ONCOGENE			English	Article						Ras; Raf; reconstitution; cell-free system	SIGNAL-TRANSDUCTION PATHWAY; KINASE KINASE KINASE; KSR-1 GENE ENCODES; PLASMA-MEMBRANE; IN-VITRO; TYROSINE PHOSPHORYLATION; C-ELEGANS; B-RAF; CASCADE; 14-3-3-PROTEINS	Ras-mediated signaling pathways play a critical role in cellular proliferation and differentiation. Although it has been demonstrated that Ras interacts with Raf-1 to stimulate the serine/threonine kinase activity of Raf-1, the precise mechanism by which Ras activates Raf-1 remains obscure. To address this question, we developed a cell-free system in which the activated form of H-Ras can induce Raf-1 activation. Using this system, we found the presence of a new protein factor, in cytosolic fractions of both human embryonic kidney 293 cells and rat brain tissues, that is required for Ras-dependent activation of Raf-1. The factor was purified from rat brain cytosols through successive column chromatographies on DEAE Sephacel, SP Sepharose and Sephacryl S-300, The approximate molecular weight of the activator was estimated as 400000 by gel filtration. Its activity was sensitive to heat and trypsin treatments. The purified activator did not contain Src, 14-3-3, protein kinase C, JAK2 or Ksr-1, as judged by immunoblotting, Further characterization of the activator is underway.	Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 227, Japan	Tokyo Institute of Technology	Kaziro, Y (corresponding author), Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 227, Japan.		Koide, Hiroshi/E-9000-2011	Koide, Hiroshi/0000-0001-5916-3179				AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; DENT P, 1994, P NATL ACAD SCI USA, V91, P9544, DOI 10.1073/pnas.91.20.9544; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; GOTOH Y, 1994, ONCOGENE, V9, P1891; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; Kuroda S, 1996, J BIOL CHEM, V271, P14680, DOI 10.1074/jbc.271.25.14680; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; Miyake M, 1996, FEBS LETT, V378, P15, DOI 10.1016/0014-5793(95)01416-0; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Stokoe D, 1997, EMBO J, V16, P2384, DOI 10.1093/emboj/16.9.2384; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; SUNDARAM M, 1995, CELL, V83, P889, DOI 10.1016/0092-8674(95)90205-8; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; TRAVERSE S, 1993, ONCOGENE, V8, P3175; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; YAMAMORI B, 1995, J BIOL CHEM, V270, P11723, DOI 10.1074/jbc.270.20.11723; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	45	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	1998	16	21					2781	2786		10.1038/sj.onc.1201806	http://dx.doi.org/10.1038/sj.onc.1201806			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ013	9652745				2022-12-25	WOS:000073812200010
J	Gjoerup, O; Lukas, J; Bartek, J; Willumsen, BM				Gjoerup, O; Lukas, J; Bartek, J; Willumsen, BM			Rac and Cdc42 are potent stimulators of E2F-dependent transcription capable of promoting retinoblastoma susceptibility gene product hyperphosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CELL-CYCLE PROGRESSION; ABL TYROSINE KINASE; ACTIN STRESS FIBERS; S-PHASE ENTRY; DEREGULATED EXPRESSION; ONCOGENIC RAS; TRANSFORMATION; G(1); RHO	The Rho family of GTPases plays an important and diverse role in reorganization of the actin cytoskeleton, transcriptional regulation, and multiple aspects of cell growth. Our study has examined their potential links to the cell cycle machinery. We find that constitutively active mutants of Rac and Cdc42, but not Rho, are potent inducers of E2F transcriptional activity in NIH 3T3 fibroblasts. Furthermore, activated Rac and Cdc42, but again not Rho, are capable of inducing cyclin D1 accumulation and pRB hyperphosphorylation in serum-deprived cells, outlining one route leading to enhanced E2F-mediated transcription. The inhibitory effect of the cyclin-dependent kinase inhibitors, p16(ink4), p21(cip1), and p27(cip) on Rac/Cdc42-mediated E2F transcription corroborates a role for PRE family members and their functional inactivation by cyclin dependent kinases in generating E2F activity. While the up-regulation of E2F transcriptional activity by Rac or Cdc42, not Rho, suffices for entry into S phase and DNA synthesis in Rat-1 R12 cells, this is clearly not the case in NIH 3T3, where additional requirements must exist.	Univ Copenhagen, Dept Cellular & Mol Biol, DK-1353 Copenhagen K, Denmark; Danish Canc Soc, Div Canc Biol, DK-2100 Copenhagen, Denmark	University of Copenhagen; Danish Cancer Society	Willumsen, BM (corresponding author), Univ Copenhagen, Dept Cellular & Mol Biol, Oster Farimagsgade 2A, DK-1353 Copenhagen K, Denmark.		Willumsen, Berthe M/H-1903-2012; Bartek, Jiri/G-5870-2014	Willumsen, Berthe M/0000-0002-2277-6999; Lukas, Jiri/0000-0001-9087-506X				Afshari CA, 1997, ONCOGENE, V14, P3029, DOI 10.1038/sj.onc.1201157; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen Y, 1996, J BIOL CHEM, V271, P19637, DOI 10.1074/jbc.271.33.19637; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DIMRI GP, 1994, J BIOL CHEM, V269, P16180; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fan JG, 1997, ONCOGENE, V14, P2595, DOI 10.1038/sj.onc.1201105; FILMUS J, 1994, ONCOGENE, V9, P3627; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hofmann F, 1996, GENE DEV, V10, P851, DOI 10.1101/gad.10.7.851; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Lukas J, 1996, MOL CELL BIOL, V16, P6917; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Michieli P, 1996, ONCOGENE, V12, P775; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Molnar A, 1997, J BIOL CHEM, V272, P13229, DOI 10.1074/jbc.272.20.13229; NEVINS JR, 1992, SCIENCE, V258, P424; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Renshaw MW, 1996, CURR BIOL, V6, P76, DOI 10.1016/S0960-9822(02)00424-4; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Roux P, 1997, CURR BIOL, V7, P629, DOI 10.1016/S0960-9822(06)00289-2; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Urich M, 1997, ONCOGENE, V14, P1235, DOI 10.1038/sj.onc.1200982; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WILLUMSEN BM, 1995, METHOD ENZYMOL, V250, P269; Winston JT, 1996, ONCOGENE, V12, P127; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	54	65	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18812	18818		10.1074/jbc.273.30.18812	http://dx.doi.org/10.1074/jbc.273.30.18812			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668055	hybrid			2022-12-25	WOS:000074974700022
J	Huijbregts, RPH; de Kroon, AIPM; de Kruijff, B				Huijbregts, RPH; de Kroon, AIPM; de Kruijff, B			Rapid transmembrane movement of newly synthesized phosphatidylethanolamine across the inner membrane of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORT-SYSTEM; AMINO-ACIDS; PHOSPHATIDYLSERINE DECARBOXYLASE; ASYMMETRIC DISTRIBUTION; ENDOPLASMIC-RETICULUM; ACTIVE-TRANSPORT; PLASMA-MEMBRANE; PHOSPHOLIPIDS; PROTEIN; VESICLES	For the first time the transmembrane movement of an endogenously synthesized phospholipid across the inner membrane of E. coli is reported. [C-14]phosphatidylethanolamine (PE) was biosynthetically introduced into inner membrane vesicles from the PE deficient strain AD93, by reconstitution with the enzyme phosphatidylserine (PS) synthetase, Upon addition of wild type cell lysate containing PS synthetase, and the metabolic substrates CTP and [C-14]serine to inside-out vesicles from AD93, [C-14]PS was synthesized, which was for the most part converted into [C-14]PE. [C-14]PE was introduced in right-side out vesicles by enclosing PS synthetase and CTP in the vesicle lumen and adding [C-14]serine. The newly synthesized [C-14]PE immediately equilibrated over both membrane leaflets (t(1/2) less than one min), as determined by its accessibility toward the amino-reactive chemical fluorescamine. In both inside-out and right-side out vesicles, a 35-65% distribution was found of the newly synthesized PE over the cytoplasmic and periplasmic leaflet, respectively, The transport process of PE was not influenced by the presence of ATP or the proton motive force in inside out vesicles. Pretreatment of both types of vesicles with sulfhydryl reagents, or of right-side out vesicles with proteinase K, did not affect the rate and extent of the transmembrane distribution of the newly synthesized PE.	Univ Utrecht, Ctr Biomembranes & Lipid Enzymol, Inst Biomembranes, Dept Biochem Membranes, NL-3584 CH Utrecht, Netherlands	Utrecht University	Huijbregts, RPH (corresponding author), Univ Utrecht, Ctr Biomembranes & Lipid Enzymol, Inst Biomembranes, Dept Biochem Membranes, Padualaan 8, NL-3584 CH Utrecht, Netherlands.		de Kroon, Anton I/O-4119-2016	de Kroon, Anton/0000-0003-1209-756X				BISHOP DG, 1977, EUR J BIOCHEM, V80, P381, DOI 10.1111/j.1432-1033.1977.tb11893.x; BISHOP WR, 1985, CELL, V42, P51, DOI 10.1016/S0092-8674(85)80100-8; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bogdanov M, 1996, J BIOL CHEM, V271, P11615, DOI 10.1074/jbc.271.20.11615; BOGDANOV M, 1995, J BIOL CHEM, V270, P732, DOI 10.1074/jbc.270.2.732; CARTER JR, 1968, J LIPID RES, V9, P748; CHEN CC, 1986, J BIOL CHEM, V261, P2599; CHEN L, 1985, J BACTERIOL, V161, P973, DOI 10.1128/JB.161.3.973-980.1985; COLLEAU M, 1991, CHEM PHYS LIPIDS, V57, P29, DOI 10.1016/0009-3084(91)90046-E; DECHAVIGNY A, 1991, J BIOL CHEM, V266, P5323; deCock H, 1996, EMBO J, V15, P5567, DOI 10.1002/j.1460-2075.1996.tb00941.x; DEVRIJE T, 1987, BIOCHIM BIOPHYS ACTA, V900, P63, DOI 10.1016/0005-2736(87)90278-1; DONOHUEROLFE AM, 1980, P NATL ACAD SCI-BIOL, V77, P1867, DOI 10.1073/pnas.77.4.1867; Dowhan W, 1997, ANNU REV BIOCHEM, V66, P199, DOI 10.1146/annurev.biochem.66.1.199; DOWHAN W, 1992, METHOD ENZYMOL, V209, P348; DOWHAN W, 1974, J BIOL CHEM, V249, P3079; GELDWERTH D, 1993, J CLIN INVEST, V92, P308, DOI 10.1172/JCI116568; HAMA H, 1988, J BACTERIOL, V170, P2236, DOI 10.1128/jb.170.5.2236-2239.1988; HAMA H, 1987, BIOCHIM BIOPHYS ACTA, V905, P231, DOI 10.1016/0005-2736(87)90451-2; HERRMANN A, 1990, BIOCHEMISTRY-US, V29, P2023, DOI 10.1021/bi00460a010; Hrafnsdottir S, 1997, BIOCHEMISTRY-US, V36, P4969, DOI 10.1021/bi962513h; Huijbregts RPH, 1996, BBA-BIOMEMBRANES, V1280, P41, DOI 10.1016/0005-2736(95)00272-3; Huijbregts RPH, 1997, MOL MEMBR BIOL, V14, P35, DOI 10.3109/09687689709048168; KANFER J, 1964, J BIOL CHEM, V239, P1720; KONINGS WN, 1971, J BIOL CHEM, V246, P5857; KREBS JJR, 1979, J BIOL CHEM, V254, P5308; LANGLEY KE, 1979, P NATL ACAD SCI USA, V76, P6245, DOI 10.1073/pnas.76.12.6245; LARSON TJ, 1976, BIOCHEMISTRY-US, V15, P5212, DOI 10.1021/bi00669a003; Letain TE, 1997, MOL MICROBIOL, V24, P271, DOI 10.1046/j.1365-2958.1997.3331703.x; LOMBARDI FJ, 1972, J BIOL CHEM, V247, P7844; MUHLRADT PF, 1975, EUR J BIOCHEM, V51, P343, DOI 10.1111/j.1432-1033.1975.tb03934.x; MULLER M, 1984, P NATL ACAD SCI-BIOL, V81, P7421, DOI 10.1073/pnas.81.23.7421; OSBORN MJ, 1972, J BIOL CHEM, V247, P3062; Possot OM, 1997, MOL MICROBIOL, V24, P457, DOI 10.1046/j.1365-2958.1997.3451726.x; RAETZ CRH, 1972, J BIOL CHEM, V247, P2008; RAETZ CRH, 1990, J BIOL CHEM, V265, P1235; RAETZ CRH, 1978, MICROBIOL REV, V42, P614, DOI 10.1128/MMBR.42.3.614-659.1978; RAETZ CRH, 1974, J BIOL CHEM, V249, P5038; RAWYLER A, 1984, BIOCHIM BIOPHYS ACTA, V769, P330, DOI 10.1016/0005-2736(84)90314-6; RIETVELD AG, 1993, J BIOL CHEM, V268, P12427; RIETVELD AG, 1994, J BIOL CHEM, V269, P28670; RIETVELD AG, 1995, EMBO J, V14, P5506, DOI 10.1002/j.1460-2075.1995.tb00237.x; Rilfors L, 1984, MEMBRANE FLUIDITY, P205; ROSEMAN M, 1975, BIOCHEMISTRY-US, V14, P4826, DOI 10.1021/bi00693a008; ROTHMAN JE, 1977, P NATL ACAD SCI USA, V74, P1821, DOI 10.1073/pnas.74.5.1821; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; Saha SK, 1996, BIOSCI BIOTECH BIOCH, V60, P111; SEIGNEURET M, 1984, P NATL ACAD SCI-BIOL, V81, P3751, DOI 10.1073/pnas.81.12.3751; Tang XJ, 1996, SCIENCE, V272, P1495, DOI 10.1126/science.272.5267.1495; TAVERNIER E, 1995, BIOCHIMIE, V77, P174, DOI 10.1016/0300-9084(96)88122-3; UDENFRIEND S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871; VANCE DE, 1991, BIOCH LIPIDS LIPOPRO, P205; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; ZACHOWSKI A, 1993, BIOCHEM J, V294, P1	54	40	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18936	18942		10.1074/jbc.273.30.18936	http://dx.doi.org/10.1074/jbc.273.30.18936			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668071	hybrid			2022-12-25	WOS:000074974700038
J	Porter, DJT; Short, SA; Hanlon, MH; Preugschat, F; Wilson, JE; Willard, DH; Consler, TG				Porter, DJT; Short, SA; Hanlon, MH; Preugschat, F; Wilson, JE; Willard, DH; Consler, TG			Product release is the major contributor to k(cat) for the hepatitis C virus helicase-catalyzed strand separation of short duplex DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI REP HELICASE; ADENINE-NUCLEOTIDE BINDING; INDUCED DIMERIZATION; KINETIC MECHANISM; NS3 PROTEIN; NUCLEIC-ACID; GP41 FORMS; ASSAY; HYDROLYSIS; ENZYME	Hepatitis C virus (HCV) helicase catalyzes the ATP-dependent strand separation of duplex RNA and DNA containing a 3' single-stranded tail. Equilibrium and velocity sedimentation centrifugation experiments demonstrated that the enzyme was monomeric in the presence of DNA and ATP analogues. Steady-state and pre-steady-state kinetics for helicase activity were monitored by the fluorescence changes associated with strand separation of F21:HF31 that was formed from a 5'-hexachlorofluorescein-tagged 31-mer (HF31) and a complementary 3'-fluorescein-tagged 21-mer (F21). k(cat) for this reaction was 0.12 s(-1). The fluorescence change associated with strand separation of F21:HF31 by excess enzyme and ATP was a biphasic process. The time course of the early phase (duplex unwinding) suggested only a few base pairs (similar to 2) were disrupted concertedly. The maximal value of the rate constant (k(eff)) describing the late phase of the reaction (strand separation) was 0.5 s(-1), which was 4-fold greater than k(cat). Release of HF31 from E.HF31 in the presence of ATP (0.21 s(-1)) was the major contributor to k(cat). At saturating ATP and competitor DNA concentrations, the enzyme unwound 44% of F21:HF31 that was initially bound to the enzyme (low processivity). These results are consistent with a passive mechanism for strand separation of F21:HF31 by HCV helicase.	Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA	GlaxoSmithKline	Porter, DJT (corresponding author), Glaxo Wellcome Inc, 5 Moore Dr, Res Triangle Pk, NC 27709 USA.							ABDELMONEM M, 1976, EUR J BIOCHEM, V65, P441, DOI 10.1111/j.1432-1033.1976.tb10359.x; Ali JA, 1997, SCIENCE, V275, P377, DOI 10.1126/science.275.5298.377; AMARATUNGA M, 1993, BIOCHEMISTRY-US, V32, P6815, DOI 10.1021/bi00078a003; BJORNSON KP, 1994, BIOCHEMISTRY-US, V33, P14306, DOI 10.1021/bi00251a044; Bjornson KP, 1996, BIOCHEMISTRY-US, V35, P2268, DOI 10.1021/bi9522763; Bjornson KP, 1996, J MOL BIOL, V263, P411, DOI 10.1006/jmbi.1996.0585; BUJALOWSKI W, 1995, BIOCHEMISTRY-US, V34, P8513, DOI 10.1021/bi00027a001; BUKH J, 1994, P NATL ACAD SCI USA, V91, P8239, DOI 10.1073/pnas.91.17.8239; CHAO KL, 1991, J MOL BIOL, V221, P1165, DOI 10.1016/0022-2836(91)80119-F; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; Cohn E., 1943, PROTEINS AMINO ACIDS, P157; DONG F, 1995, J BIOL CHEM, V270, P7462, DOI 10.1074/jbc.270.13.7462; Dong F, 1996, J BIOL CHEM, V271, P19625, DOI 10.1074/jbc.271.32.19625; DURSCHLAG H, 1986, THERMODYNAMIC DATA B, P45; Eggleston AK, 1996, NUCLEIC ACIDS RES, V24, P1179, DOI 10.1093/nar/24.7.1179; GRAKOUI A, 1993, J VIROL, V67, P2832, DOI 10.1128/JVI.67.5.2832-2843.1993; Gwack Y, 1996, BIOCHEM BIOPH RES CO, V225, P654, DOI 10.1006/bbrc.1996.1225; HOUSTON P, 1994, P NATL ACAD SCI USA, V91, P5471, DOI 10.1073/pnas.91.12.5471; KIM DW, 1995, BIOCHEM BIOPH RES CO, V215, P160, DOI 10.1006/bbrc.1995.2447; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; MAGRIN S, 1994, HEPATOLOGY, V19, P273; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MOORE KJM, 1994, BIOCHEMISTRY-US, V33, P14565, DOI 10.1021/bi00252a024; MOORE KJM, 1994, BIOCHEMISTRY-US, V33, P14550, DOI 10.1021/bi00252a023; Preugschat F, 1996, J BIOL CHEM, V271, P24449, DOI 10.1074/jbc.271.40.24449; Raney KD, 1996, J BIOL CHEM, V271, P14074, DOI 10.1074/jbc.271.24.14074; RANEY KD, 1994, P NATL ACAD SCI USA, V91, P6644, DOI 10.1073/pnas.91.14.6644; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2863, DOI 10.1021/bi00433a018; SEGL IH, 1993, ENZYME KINETICS, P564; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; SUZICH JA, 1993, J VIROL, V67, P6152, DOI 10.1128/JVI.67.10.6152-6158.1993; Tai CL, 1996, J VIROL, V70, P8477, DOI 10.1128/JVI.70.12.8477-8484.1996; WONG I, 1992, J BIOL CHEM, V267, P7596; Wong I, 1996, BIOCHEMISTRY-US, V35, P5726, DOI 10.1021/bi952959i; YO N, 1997, NAT STRUCT BIOL, V4, P463	39	61	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18906	18914		10.1074/jbc.273.30.18906	http://dx.doi.org/10.1074/jbc.273.30.18906			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668067	hybrid			2022-12-25	WOS:000074974700034
J	Venkatachalam, KV; Akita, H; Strott, CA				Venkatachalam, KV; Akita, H; Strott, CA			Molecular cloning, expression, and characterization of human bifunctional 3 '-phosphoadenosine 5 '-phosphosulfate synthase and its functional domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATED ENZYME INTERMEDIATE; SULFATE ACTIVATION LOCUS; ATP SULFURYLASE; SACCHAROMYCES-CEREVISIAE; PENICILLIUM-CHRYSOGENUM; ARABIDOPSIS-THALIANA; NUCLEOTIDE-SEQUENCE; RAT CHONDROSARCOMA; ESCHERICHIA-COLI; APS KINASE	The universal sulfonate donor, 3'-phosphoadenosine 5'-phosphosulfate (PAPS), is synthesized by the concerted action of ATP sulfurylase and adenosine 5'-phosphosulfate (APS) kinase, which in animals ale fused into a bifunctional protein. The cDNA for human PAPS synthase (hPAPSS) along with polymerase chain reaction products corresponding to several NH2- and COOH-terminal fragments were cloned and expressed in COS-l cells. A 1-268-amino acid fragment expressed APS kinase activity, whereas a 220-623 fragment evinced ATP sulfurylase activity. The 1-268 fragment and full-length hPAPSS (1-623) exhibited hyperbolic responses against APS substrate with equivalent K-m values (0.6 and 0.4 mu M, respectively). The 1-268 fragment demonstrated Michaelis-Menten kinetics against ATP as substrate (K-m 0.26 mM); however, full-length hPAPSS exhibited a sigmoidal response (apparent K-m 1.5 mM) suggesting cooperative binding. Catalytic efficiency (V-mac/K-m) of the 1-268 fragment was 64-fold higher than. full-length hPAPSS for ATP, The kinetic data suggest that the COOH-terminal domain of hPAPSS exerts a regulatory role over APS kinase activity located in that NH2-terminal domain of this bifunctional protein. In addition, the 1-268 fragment and full-length hPAPSS were overexpressed in Escherichia coli and column purified, Purified full-length hPAPSS, in contrast to the! COS-l cell-expressed cDNA construct, exhibited a hyperbolic response curve against ATP suggesting that hPAPSS is perhaps modified in vivo.	NICHD, Sect Steroid Regulat Endocrinol & Reprod, Res Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Strott, CA (corresponding author), NICHD, Sect Steroid Regulat Endocrinol & Reprod, Res Branch, NIH, Bldg 49,Rm 6A36, Bethesda, MD 20892 USA.	cheastro@box-c.nih.gov		Venkatachalam, K.V./0000-0001-6692-9099				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ADAMS MD, 1993, NAT GENET, V4, P373, DOI 10.1038/ng0893-373; ARZ HE, 1994, BBA-GENE STRUCT EXPR, V1218, P447, DOI 10.1016/0167-4781(94)90203-8; BANDURSKI RS, 1956, J AM CHEM SOC, V78, P6408, DOI 10.1021/ja01605a028; BORGESWALMSLEY MI, 1995, MOL GEN GENET, V247, P423; CHEREST H, 1987, MOL GEN GENET, V210, P307, DOI 10.1007/BF00325699; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; FAROOQUI AA, 1980, INT J BIOCHEM, V12, P529, DOI 10.1016/0020-711X(80)90003-8; FOSTER BA, 1994, J BIOL CHEM, V269, P19777; GREGORY JD, 1960, ANNU REV BIOCHEM, V29, P347, DOI 10.1146/annurev.bi.29.070160.002023; Harlow E., 1988, ANTIBODIES LAB MANUA; Huxtable RJ, 1986, BIOCH SULFUR, P293; KITAGAWA T, 1976, J BIOCH, V79, P223; KORCH C, 1991, MOL GEN GENET, V229, P96, DOI 10.1007/BF00264218; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEUSTEK T, 1994, PLANT PHYSIOL, V105, P897, DOI 10.1104/pp.105.3.897; LEYH TS, 1988, J BIOL CHEM, V263, P2409; LEYH TS, 1992, J BIOL CHEM, V267, P10405; LEYH TS, 1993, CRIT REV BIOCHEM MOL, V28, P515, DOI 10.3109/10409239309085137; LI H, 1995, J BIOL CHEM, V270, P29453, DOI 10.1074/jbc.270.49.29453; LYLE S, 1994, BIOCHEMISTRY-US, V33, P5920, DOI 10.1021/bi00185a032; LYLE S, 1994, BIOCHEMISTRY-US, V33, P6822, DOI 10.1021/bi00188a010; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; RENOSTO F, 1989, J BIOL CHEM, V264, P9433; ROBBINS PW, 1956, J AM CHEM SOC, V78, P6409, DOI 10.1021/ja01605a029; ROBBINS PW, 1958, J BIOL CHEM, V233, P681; ROSENTHAL E, 1995, GENE, V165, P243, DOI 10.1016/0378-1119(95)00450-K; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SATISHCHANDRAN C, 1992, BIOCHEMISTRY-US, V31, P11684, DOI 10.1021/bi00162a003; SATISHCHANDRAN C, 1989, J BIOL CHEM, V264, P15012; SCHWEDOCK JS, 1994, J BACTERIOL, V176, P7055, DOI 10.1128/JB.176.22.7055-7064.1994; SEGAL IH, 1987, METHOD ENZYMOL, V143, P334; SERE PA, 1987, ANNU REV BIOCHEM, V56, P89; Vaitukaitis J L, 1981, Methods Enzymol, V73, P46; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VIEILLE C, 1990, MOL PLANT MICROBE IN, V3, P389, DOI 10.1094/MPMI-3-389; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	37	51	56	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19311	19320		10.1074/jbc.273.30.19311	http://dx.doi.org/10.1074/jbc.273.30.19311			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668121	hybrid			2022-12-25	WOS:000074974700088
J	Chinpaisal, C; Lee, CH; Wei, LN				Chinpaisal, C; Lee, CH; Wei, LN			Mechanisms of the mouse orphan nuclear receptor TR2-11-mediated gene suppression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; RETINOID-X RECEPTOR; TATA-BINDING PROTEIN; MOLECULAR-CLONING; RESPONSE ELEMENT; ACID RECEPTORS; CO-REPRESSOR; BETA-GENE; ACTIVATION; IDENTIFICATION	The mouse orphan nuclear receptor TR2-11 functions as a repressor for reporter genes containing a direct repeat-5 or direct repeat-4 hormone response element. The functional domains responsible for its suppressive activity are defined, including the DNA-binding domain and the ligand-binding domain. The C-terminal 30 amino acid residues can be deleted without compromising its suppressive activity, whereas a deletion for 40 amino acids completely abolishes the suppressive activity and receptor dimerization, and reduces the DNA binding affinity. Point mutation at three conserved leucine residues located on the predicted dimer interface abolishes the suppressive activity, receptor dimerization and its DNA binding property. However, mutation at two consecutive glutamate residues located within the hinge between the last two helices of the ligand-binding domain (helix 10 and helix 11 according to the human retinoid receptor X alpha structure) drastically reduces its DNA binding affinity and abrogates the suppressive activity without compromising its ability to dimerize, indicating that receptor dimerization property can be functionally uncoupled from its suppressive activity. A transferable, active silencing activity is encoded within the DEF segment of the receptor molecule, as evidenced by the suppression of a GAL4 reporter by a chimeric protein containing the DNA-binding domain of GAL4 and the DEF segment of TR2-11, Moreover, the C-terminal 49 amino acid sequence is required for this trans-suppressive activity. It is suggested that TR2-11 functions as a repressor, mediated by mechanisms requiring high affinity DNA binding, receptor dimerization, and active silencing.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Wei, LN (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, 3-249 Millard Hall,435 Delaware St SE, Minneapolis, MN 55455 USA.	weixx009@maroon.tc.umn.edu			NIDA NIH HHS [DA11190] Funding Source: Medline; NIDDK NIH HHS [DK46866] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046866] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA011190] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P5725, DOI 10.1128/MCB.13.9.5725; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; BAURGUET W, 1995, NATURE, V375, P377; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; CHANG C, 1989, BIOCHEM BIOPH RES CO, V165, P735, DOI 10.1016/S0006-291X(89)80028-2; Chang LM, 1997, J BIOL CHEM, V272, P10144; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Chinpaisal C, 1997, BIOCHEMISTRY-US, V36, P14088, DOI 10.1021/bi971598z; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Fondell JD, 1996, MOL CELL BIOL, V16, P281; Gaemers IC, 1997, ENDOCRINOLOGY, V138, P1544, DOI 10.1210/en.138.4.1544; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Joyeux A, 1997, MOL ENDOCRINOL, V11, P193, DOI 10.1210/me.11.2.193; Lee CH, 1996, MOL REPROD DEV, V44, P305, DOI 10.1002/(SICI)1098-2795(199607)44:3&lt;305::AID-MRD4&gt;3.0.CO;2-Q; Lee CH, 1997, J ENDOCRINOL, V152, P245, DOI 10.1677/joe.0.1520245; LEE CH, 1995, GENOMICS, V30, P46, DOI 10.1006/geno.1995.0007; LEE HJ, 1995, J BIOL CHEM, V270, P5434, DOI 10.1074/jbc.270.10.5434; Lee HJ, 1996, J BIOL CHEM, V271, P10405, DOI 10.1074/jbc.271.17.10405; LEHMANN JM, 1993, MOL CELL BIOL, V13, P7698, DOI 10.1128/MCB.13.12.7698; Lin BC, 1997, MOL CELL BIOL, V17, P6131, DOI 10.1128/MCB.17.10.6131; LIN TM, 1995, J BIOL CHEM, V270, P30121; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Perlmann T, 1996, MOL ENDOCRINOL, V10, P958, DOI 10.1210/me.10.8.958; SCHULMAN IG, 1995, P NATL ACAD SCI USA, V92, P8288, DOI 10.1073/pnas.92.18.8288; SUCOV HM, 1995, MOL NEUROBIOL, V10, P169, DOI 10.1007/BF02740674; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; Thenot S, 1997, J BIOL CHEM, V272, P12062, DOI 10.1074/jbc.272.18.12062; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; WU R, 1995, RECOMBINANT DNA METH, V2, P323; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; ZHANG XK, 1994, MOL CELL BIOL, V14, P4311, DOI 10.1128/MCB.14.6.4311; ZHANG XK, 1993, TRENDS ENDOCRIN MET, V4, P156, DOI 10.1016/1043-2760(93)90105-N	39	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18077	18085		10.1074/jbc.273.29.18077	http://dx.doi.org/10.1074/jbc.273.29.18077			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660764	hybrid			2022-12-25	WOS:000074828500019
J	Gerke, C; Kraft, A; Sussmuth, R; Schweitzer, O; Gotz, F				Gerke, C; Kraft, A; Sussmuth, R; Schweitzer, O; Gotz, F			Characterization of the N-acetylglucosaminyltransferase activity involved in the biosynthesis of the Staphylococcus epidermidis polysaccharide intercellular adhesin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULASE-NEGATIVE STAPHYLOCOCCI; AZORHIZOBIUM-CAULINODANS; SACCHAROMYCES-CEREVISIAE; TRANSPOSON MUTANTS; ESCHERICHIA-COLI; SYNTHASE GENE; PROTEIN; IDENTIFICATION; STREPTOCOCCUS; ACCUMULATION	The polysaccharide intercellular adhesin (PIA) is an important factor in the colonization of medical devices by Staphylococcus epidermidis. The genes encoding PIA production are organized in the icaADBC (intercellular adhesion) operon. To study the function of the individual genes, we have established an in vitro assay with UDP-N-acetylglucosamine, the substrate for PIA biosynthesis, and analyzed the products by thin-layer chromatography and mass spectrometry. IcaA alone exhibited a low N-acetylglucosaminyltransferase activity and represents the catalytic enzyme. Coexpression of icaA with icaD led to a significant increase in activity. The newly identified icaD gene is located between icaA and icaB and overlaps both genes, N-Acetylglucosamine oligomers produced by IcaAD reached a maximal length of 20 residues. Only when icaA and icaD were expressed together with icaC were oligomer chains that react with PIA-specific antiserum synthesized. IcaA and IcaD are located in the cytoplasmic membrane, and IcaC also has all the structural features of an integral membrane protein. These results indicate a close interaction between IcaA, IcaD, and IcaC. Tunicamycin and bacitracin did not affect the in vitro synthesis of PIA intermediates or the complete PIA biosynthesis in vivo, suggesting that a undecaprenyl phosphate carrier is not involved. IcaAD represents a novel protein combination among P-glycosyltransferases.	Univ Tubingen, Inst Organ Chem, D-72076 Tubingen, Germany; Max Planck Inst Entwicklungsbiol, Biochem Abt, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Max Planck Society	Gotz, F (corresponding author), Univ Tubingen, Inst Organ Chem, Waldhauser Str 7018, D-72076 Tubingen, Germany.	friedrich.goetz@uni-tuebingen.de		Sussmuth, Roderich/0000-0001-7027-2069; Gerke, Christiane/0000-0001-9446-8031				ARAKI Y, 1980, J BIOCHEM-TOKYO, V88, P469, DOI 10.1093/oxfordjournals.jbchem.a132994; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUGG TDH, 1994, FEMS MICROBIOL LETT, V119, P255; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; Din AB, 1996, MOL GEN GENET, V250, P214; GEREMIA RA, 1994, P NATL ACAD SCI USA, V91, P2669, DOI 10.1073/pnas.91.7.2669; GOTZ F, 1987, FEMS MICROBIOL LETT, V40, P285, DOI 10.1016/0378-1097(87)90391-0; GOTZ F, 1990, J APPL BACTERIOL S, P49; Heilmann C, 1996, INFECT IMMUN, V64, P277, DOI 10.1128/IAI.64.1.277-282.1996; Heilmann C, 1996, MOL MICROBIOL, V20, P1083, DOI 10.1111/j.1365-2958.1996.tb02548.x; Heilmann C, 1997, MOL MICROBIOL, V24, P1013, DOI 10.1046/j.1365-2958.1997.4101774.x; Heilmann C, 1998, ZBL BAKT-INT J MED M, V287, P69; HOLTJE JV, 1975, J BACTERIOL, V124, P1067; Hussain M, 1997, INFECT IMMUN, V65, P519, DOI 10.1128/IAI.65.2.519-524.1997; JOHN M, 1993, P NATL ACAD SCI USA, V90, P625, DOI 10.1073/pnas.90.2.625; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUDWICKA A, 1984, ZBL BAKT-INT J MED M, V258, P256, DOI 10.1016/S0176-6724(84)80043-7; LUDWICKA A, 1984, ZBL BAKT-INT J MED M, V256, P479, DOI 10.1016/S0174-3031(84)80024-4; LUGTENBE.EJ, 1972, J BACTERIOL, V109, P326, DOI 10.1128/JB.109.1.326-335.1972; MACK D, 1994, INFECT IMMUN, V62, P3244, DOI 10.1128/IAI.62.8.3244-3253.1994; Mack D, 1996, J BACTERIOL, V178, P175, DOI 10.1128/jb.178.1.175-183.1996; MARMUR J, 1961, J MOL BIOL, V3, P202; MERGAERT P, 1995, J BIOL CHEM, V270, P29217, DOI 10.1074/jbc.270.49.29217; MULLER E, 1993, INFECT IMMUN, V61, P551, DOI 10.1128/IAI.61.2.551-558.1993; NAGAHASHI S, 1995, J BIOL CHEM, V270, P13961, DOI 10.1074/jbc.270.23.13961; *NEW ENGL BIOL, 1990, PROT FUS PUR SYST MA; ORLEAN P, 1987, J BIOL CHEM, V262, P5732; PASCUAL A, 1986, EUR J CLIN MICROBIOL, V5, P518, DOI 10.1007/BF02017694; Peschel A, 1996, J BACTERIOL, V178, P531, DOI 10.1128/jb.178.2.531-536.1996; PETERS G, 1981, ZBL BAKT MIK HYG B, V173, P293; ROSS P, 1991, MICROBIOL REV, V55, P35, DOI 10.1128/MMBR.55.1.35-58.1991; RUPP ME, 1994, CLIN INFECT DIS, V19, P231, DOI 10.1093/clinids/19.2.231; Sambrook J., 2002, MOL CLONING LAB MANU; SAXENA IM, 1995, J BACTERIOL, V177, P1419, DOI 10.1128/jb.177.6.1419-1424.1995; SCHUMACHERPERDREAU F, 1994, FEMS MICROBIOL LETT, V117, P71; SEMINO CE, 1995, P NATL ACAD SCI USA, V92, P3498, DOI 10.1073/pnas.92.8.3498; SPAINK HP, 1994, MOL MICROBIOL, V13, P821, DOI 10.1111/j.1365-2958.1994.tb00474.x; SUGAHARA K, 1979, J BIOL CHEM, V254, P6252; TIMMERMAN CP, 1991, INFECT IMMUN, V59, P4187, DOI 10.1128/IAI.59.11.4187-4192.1991; TOJO M, 1988, J INFECT DIS, V157, P713, DOI 10.1093/infdis/157.4.713; Tokuyasu K, 1996, BIOSCI BIOTECH BIOCH, V60, P1598, DOI 10.1271/bbb.60.1598; Veenstra GJC, 1996, J BACTERIOL, V178, P537, DOI 10.1128/jb.178.2.537-541.1996; WIELAND KP, 1995, GENE, V158, P91, DOI 10.1016/0378-1119(95)00137-U; WONG HC, 1990, P NATL ACAD SCI USA, V87, P8130, DOI 10.1073/pnas.87.20.8130; Ziebuhr W, 1997, INFECT IMMUN, V65, P890, DOI 10.1128/IAI.65.3.890-896.1997; [No title captured]	47	341	361	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18586	18593		10.1074/jbc.273.29.18586	http://dx.doi.org/10.1074/jbc.273.29.18586			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660830	hybrid			2022-12-25	WOS:000074828500085
J	Gesbert, F; Guenzi, C; Bertoglio, J				Gesbert, F; Guenzi, C; Bertoglio, J			A new tyrosine-phosphorylated 97-kDa adaptor protein mediates interleukin-2-induced association of SHP-2 with p85-phosphatidylinositol 3-kinase in human T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR SUBSTRATE-1; SRC HOMOLOGY-2 DOMAINS; PHOSPHATIDYLINOSITOL 3-KINASE; IL-2 RECEPTOR; PHOSPHOTYROSINE PHOSPHATASE; GAMMA-CHAIN; SH2 DOMAINS; BETA-CHAIN; ACTIVATION; BINDING	Interleukin (IL)-2 is a major cytokine that controls differentiation and proliferation of T lymphocytes. In this report we characterize an as yet unidentified 97-kDa protein that is a major tyrosine kinase substrate in IL-2-stimulated cells. pp97 was found to associate with the p85.p110 phosphatidylinositol 3-kinase complex, the Src homology 2 (SH2) domain-containing tyrosine phosphatase SHP-2, and the adaptor molecules CrkL and Grb2. We demonstrate that these interactions are directly mediated through the SH2 domains of CrkL, p85, and SHP-2 and through the SH3 domains of Grb2. pp97 was found to mediate the IL-2-induced interaction between p85 and both a phosphorylated and a non-phosphorylated form of SHP-2. In this study we show that pp97 behaves as a docking protein and associates with at least CrkL, p85, and SHP-2 in the same multimolecular complex. We thus characterized pp97 as a new tyrosine kinase substrate in human T lymphocytes which might play a central role in the regulation of several pathways activated by IL-2.	Fac Pharm Paris 11, INSERM, U461, F-92296 Chatenay Malabry, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Bertoglio, J (corresponding author), Fac Pharm Paris 11, INSERM, U461, 5 Rue Jean Baptiste Clement, F-92296 Chatenay Malabry, France.	j.bertoglio@cep.u-psud.fr		Gesbert, Franck/0000-0002-5800-8385				Adachi M, 1997, ONCOGENE, V14, P1629, DOI 10.1038/sj.onc.1200981; ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; ASAO H, 1992, FEBS LETT, V304, P141, DOI 10.1016/0014-5793(92)80605-G; ASAO H, 1990, J EXP MED, V171, P637, DOI 10.1084/jem.171.3.637; AUGUSTINE JA, 1991, MOL CELL BIOL, V11, P4431, DOI 10.1128/MCB.11.9.4431; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; Carlberg K, 1997, J BIOL CHEM, V272, P15943, DOI 10.1074/jbc.272.25.15943; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COHEN B, 1990, P NATL ACAD SCI USA, V87, P4458, DOI 10.1073/pnas.87.12.4458; Craddock BL, 1997, J BIOL CHEM, V272, P29281, DOI 10.1074/jbc.272.46.29281; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Gesbert F, 1998, J BIOL CHEM, V273, P3986, DOI 10.1074/jbc.273.7.3986; GOBERT S, 1995, BLOOD, V86, P598, DOI 10.1182/blood.V86.2.598.bloodjournal862598; Gu HH, 1997, J BIOL CHEM, V272, P16421, DOI 10.1074/jbc.272.26.16421; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HORI T, 1987, BLOOD, V70, P1069; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MERIDA I, 1991, J IMMUNOL, V147, P2202; MINAMI Y, 1995, IMMUNITY, V2, P89, DOI 10.1016/1074-7613(95)90081-0; MINAMI Y, 1993, EMBO J, V12, P759, DOI 10.1002/j.1460-2075.1993.tb05710.x; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; Nelson BH, 1997, P NATL ACAD SCI USA, V94, P1878, DOI 10.1073/pnas.94.5.1878; Noguchi T, 1996, J BIOL CHEM, V271, P27652, DOI 10.1074/jbc.271.44.27652; Ravichandran KS, 1996, P NATL ACAD SCI USA, V93, P5275, DOI 10.1073/pnas.93.11.5275; Reif K, 1997, J BIOL CHEM, V272, P14426, DOI 10.1074/jbc.272.22.14426; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; SALEEM A, 1995, J BIOL CHEM, V270, P10380, DOI 10.1074/jbc.270.18.10380; SALTZMAN EM, 1988, J BIOL CHEM, V263, P6956; Sattler M, 1997, J BIOL CHEM, V272, P14320, DOI 10.1074/jbc.272.22.14320; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TENHOEVE J, 1993, ONCOGENE, V8, P2469; TRUITT KE, 1994, J BIOL CHEM, V269, P5937; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WANG J, 1995, J BIOL CHEM, V270, P12774, DOI 10.1074/jbc.270.21.12774; WHITE MF, 1987, J BIOL CHEM, V262, P9769; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHU XY, 1994, J BIOL CHEM, V269, P5518	53	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18273	18281		10.1074/jbc.273.29.18273	http://dx.doi.org/10.1074/jbc.273.29.18273			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660791	hybrid			2022-12-25	WOS:000074828500046
J	Vassylyev, DG; Tomitori, H; Kashiwagi, K; Morikawa, K; Igarashi, K				Vassylyev, DG; Tomitori, H; Kashiwagi, K; Morikawa, K; Igarashi, K			Crystal structure and mutational analysis of the Escherichia coli putrescine receptor - Structural basis for substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY STRUCTURE; PREFERENTIAL UPTAKE SYSTEM; ORNITHINE-BINDING PROTEIN; D-ASPARTATE RECEPTOR; SALMONELLA-TYPHIMURIUM; POLYAMINE TRANSPORT; ACTIVE-TRANSPORT; HYDROGEN-BONDS; POTD PROTEIN; SPERMIDINE	PotF protein is a periplasmic substrate-binding protein of the putrescine transport system in Escherichia coli. We hare determined the crystal structure of PotF protein in complex with the substrate at 2.3-Angstrom resolution, The PotF molecule has dimensions of 54 x 42 x 30 A and consists of two similar globular domains. The PotF structure is reminiscent of other periplasmic receptors with a highest structural homology to another polyamine-binding protein, PotD. Putrescine is tightly bound in the deep cleft between the two domains of PotF through 12 hydrogen bonds and 36 van der Waals interactions. The comparison of the PotF structure with that of PotD provides the insight into the differences in the specificity between the two proteins. The PotF structure, in combination with the mutational analysis, revealed the residues crucial for putrescine binding (Trp-37, Ser-85, Glu-185, Trp-244, Asp-247, and Asp-278) and the importance of water molecules for putrescine recognition.	Biomol Engn Res Inst, Osaka 5650874, Japan; Chiba Univ, Fac Pharmaceut Sci, Inage Ku, Chiba 2638522, Japan	Chiba University	Vassylyev, DG (corresponding author), Matsushita Elect Ind Co Ltd, Int Inst Adv Res, 3-4 Hikaridai, Kyoto 6190222, Japan.		Vassylyev, Dmitry/A-9005-2008	Igarashi, Kazuei/0000-0003-3751-3187				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1992, XPLOR VERSION 3 1 MA; Chao J, 1997, MOL PHARMACOL, V51, P861, DOI 10.1124/mol.51.5.861; FLOCCO MM, 1994, J BIOL CHEM, V269, P8931; FURUCHI T, 1991, J BIOL CHEM, V266, P20928; Hsiao CD, 1996, J MOL BIOL, V262, P225, DOI 10.1006/jmbi.1996.0509; Johnson TD, 1996, TRENDS PHARMACOL SCI, V17, P22, DOI 10.1016/0165-6147(96)81566-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KANG CH, 1991, J BIOL CHEM, V266, P23893; KASHIWAGI K, 1990, J BIOL CHEM, V265, P8387; KASHIWAGI K, 1990, J BIOL CHEM, V265, P20893; KASHIWAGI K, 1993, J BIOL CHEM, V268, P19358; Kashiwagi K, 1997, J BIOL CHEM, V272, P6318, DOI 10.1074/jbc.272.10.6318; Kashiwagi K, 1996, J BIOL CHEM, V271, P12205, DOI 10.1074/jbc.271.21.12205; KASHIWAGI K, 1986, J BACTERIOL, V165, P972, DOI 10.1128/jb.165.3.972-977.1986; Kashiwagi K, 1996, MOL PHARMACOL, V49, P1131; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUECKE H, 1990, NATURE, V347, P402, DOI 10.1038/347402a0; Maniatis T., 1982, MOL CLONING LAB MANU, P250; MOWBRAY SL, 1992, J MOL BIOL, V225, P155, DOI 10.1016/0022-2836(92)91033-L; Nickitenko AV, 1995, BIOCHEMISTRY-US, V34, P16585, DOI 10.1021/bi00051a006; OH BH, 1993, J BIOL CHEM, V268, P11348; OH BH, 1994, J BIOL CHEM, V269, P4135; OLIVER DB, 1982, CELL, V30, P311, DOI 10.1016/0092-8674(82)90037-X; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; PARK MH, 1993, TRENDS BIOCHEM SCI, V18, P475, DOI 10.1016/0968-0004(93)90010-K; PEGG AE, 1988, CANCER RES, V48, P759; PFLUGRATH JW, 1985, NATURE, V314, P257, DOI 10.1038/314257a0; PISTOCCHI R, 1993, J BIOL CHEM, V268, P146; Quiocho FA, 1997, STRUCTURE, V5, P997, DOI 10.1016/S0969-2126(97)00253-0; QUIOCHO FA, 1989, NATURE, V340, P404, DOI 10.1038/340404a0; Quiocho FA, 1996, MOL MICROBIOL, V20, P17, DOI 10.1111/j.1365-2958.1996.tb02484.x; QUIOCHO FA, 1984, NATURE, V310, P381, DOI 10.1038/310381a0; SACK JS, 1989, J MOL BIOL, V206, P171, DOI 10.1016/0022-2836(89)90531-7; SACK JS, 1989, J MOL BIOL, V206, P193, DOI 10.1016/0022-2836(89)90532-9; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO, P10; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAYERS JR, 1992, BIOTECHNIQUES, V13, P592; Seiler N, 1996, INT J BIOCHEM CELL B, V28, P843, DOI 10.1016/1357-2725(96)00021-0; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; Sugiyama S, 1996, J BIOL CHEM, V271, P9519, DOI 10.1074/jbc.271.16.9519; Sugiyama S, 1996, PROTEIN SCI, V5, P1984, DOI 10.1002/pro.5560051004; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TAME JRH, 1994, SCIENCE, V264, P1578, DOI 10.1126/science.8202710; Vassylyev DG, 1998, ACTA CRYSTALLOGR D, V54, P132, DOI 10.1107/S0907444997009049; VYAS MN, 1994, BIOCHEMISTRY-US, V33, P4762, DOI 10.1021/bi00182a003; VYAS NK, 1988, SCIENCE, V242, P1290, DOI 10.1126/science.3057628; Williams K, 1997, BIOCHEM J, V325, P289, DOI 10.1042/bj3250289; Williams K, 1995, MOL PHARMACOL, V48, P1087; YAMAGUCHI K, 1985, MOL GEN GENET, V200, P362, DOI 10.1007/BF00425718; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YAO NH, 1994, BIOCHEMISTRY-US, V33, P4769, DOI 10.1021/bi00182a004; ZOU JY, 1993, J MOL BIOL, V233, P739, DOI 10.1006/jmbi.1993.1549	56	58	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17604	17609		10.1074/jbc.273.28.17604	http://dx.doi.org/10.1074/jbc.273.28.17604			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651355	hybrid, Green Submitted			2022-12-25	WOS:000074816100048
J	Virolle, T; Monthouel, MN; Djabari, Z; Ortonne, JP; Meneguzzi, G; Aberdam, D				Virolle, T; Monthouel, MN; Djabari, Z; Ortonne, JP; Meneguzzi, G; Aberdam, D			Three activator protein-1-binding sites bound by the Fra-2 center dot JunD complex cooperate for the regulation of murine laminin alpha 3A (lama3A) promoter activity by transforming growth factor-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL EPIDERMOLYSIS-BULLOSA; HOMOZYGOUS NONSENSE MUTATION; PLASMINOGEN-ACTIVATOR; GENE-EXPRESSION; CHAIN GENE; HUMAN KERATINOCYTES; BASEMENT-MEMBRANES; AP1 SITES; BINDING; ADHESION	Several lines of evidence suggest a role for laminin 5 in skin wound healing. We report here that transforming growth factor-beta (TGF-beta), which elicits various responses during cutaneous healing, stimulates transcription of the mouse laminin alpha 3A (lama3A) gene. To identify the TGF-beta-responsive elements (TGF beta-REs) on the lama3A promoter, we have generated a series of 5'-deletions of the promoter upstream of the beta-galactosidase reporter gene. Transient cell transfection assays using mouse PAM212 keratinocytes revealed that TGF beta-REs lie between nucleotides -297 and -54 relative to the transcription start site. Insertion of the TGF beta-RE in front of the unresponsive minimal SV40 promoter conferred TGF-beta inducibility. Computer analysis of the promoter sequence identified three canonical activator protein-1 (AP-1) sites located at nucleotides -277 (AP-1A), -125 (AP-1B), and -69 (AP-1C). Site-directed mutagenesis of either the AP-1A or AP-1C site did not drastically alter the basal activity of the lama3A promoter, but reduced TGF-beta responsiveness by 50%. Simultaneous mutation of these two AP-1 sites resulted in a 65% decline in the response to TGF-beta, suggesting a cooperative contribution of each site to the overall promoter activity. In contrast, mutation of the AP-1B site markedly reduced the basal activity of the lama3A promoter, indicating that this AP-1 site is essential for gene expression. Mobility shift assays demonstrated specific binding of Fra-2 and JunD to the AP-1 sites, suggesting for the first time a possible regulatory function for the Fra-2 JunD AP-1 complex in a basal keratinocyte-specific gene.	Fac Med Nice, UFR Med, INSERM, U385, F-06107 Nice 2, France; Hop Archet, Serv Dermatol, F-06002 Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice	Aberdam, D (corresponding author), Fac Med Nice, UFR Med, INSERM, U385, Av Valombrose, F-06107 Nice 2, France.		Aberdam, Daniel/G-3299-2013; Virolle, Thierry/E-5838-2016	Aberdam, Daniel/0000-0002-4019-5418; Meneguzzi, Guerrino/0000-0002-1609-6540				ABERDAM D, 1994, NAT GENET, V6, P299, DOI 10.1038/ng0394-299; ABERDAM D, 1994, CELL ADHES COMMUN, V2, P115, DOI 10.3109/15419069409004431; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; Bahadoran P, 1997, BRIT J DERMATOL, V136, P35, DOI 10.1111/j.1365-2133.1997.tb08743.x; Banerjee C, 1996, ENDOCRINOLOGY, V137, P1991, DOI 10.1210/en.137.5.1991; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; CARTER WG, 1990, J CELL BIOL, V111, P3141, DOI 10.1083/jcb.111.6.3141; Chen Y, 1996, J BIOL CHEM, V271, P31602, DOI 10.1074/jbc.271.49.31602; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Eckert RL, 1997, J INVEST DERMATOL, V109, P501, DOI 10.1111/1523-1747.ep12336477; Ferrigno O, 1997, J BIOL CHEM, V272, P20502, DOI 10.1074/jbc.272.33.20502; GALLIANO MF, 1995, J BIOL CHEM, V270, P21820, DOI 10.1074/jbc.270.37.21820; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; Iozzo RV, 1997, J BIOL CHEM, V272, P5219, DOI 10.1074/jbc.272.8.5219; Jang SI, 1996, J BIOL CHEM, V271, P24105, DOI 10.1074/jbc.271.39.24105; Jin G, 1997, J BIOL CHEM, V272, P26620, DOI 10.1074/jbc.272.42.26620; Kagami S, 1996, EXP CELL RES, V229, P1, DOI 10.1006/excr.1996.0336; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KESKIOJA J, 1992, J INVEST DERMATOL, V99, P193, DOI 10.1111/1523-1747.ep12616826; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KORANG K, 1995, FEBS LETT, V368, P556, DOI 10.1016/0014-5793(95)00740-Z; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; LARJAVA H, 1993, J CLIN INVEST, V92, P1425, DOI 10.1172/JCI116719; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; MARINKOVICH MP, 1992, J BIOL CHEM, V267, P17900; MARINKOVICH MP, 1992, J CELL BIOL, V119, P695, DOI 10.1083/jcb.119.3.695; Mauviel A, 1996, J BIOL CHEM, V271, P10917, DOI 10.1074/jbc.271.18.10917; McGrath JA, 1996, J INVEST DERMATOL, V106, P781, DOI 10.1111/1523-1747.ep12346349; Miner JH, 1997, J CELL BIOL, V137, P685, DOI 10.1083/jcb.137.3.685; NAGLE RB, 1995, AM J PATHOL, V146, P1498; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; PULKKINEN L, 1994, NAT GENET, V6, P293, DOI 10.1038/ng0394-293; PULKKINEN L, 1994, GENOMICS, V24, P357, DOI 10.1006/geno.1994.1627; PYKE C, 1995, CANCER RES, V55, P4132; ROBERTS AB, 1996, MOL CELLULAR BIOL WO, P275; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; Rutberg SE, 1996, ONCOGENE, V13, P167; RYAN MC, 1994, J BIOL CHEM, V269, P22779; THIERRY F, 1992, J VIROL, V66, P3740, DOI 10.1128/JVI.66.6.3740-3748.1992; VAILLY J, 1995, J INVEST DERMATOL, V104, P462, DOI 10.1111/1523-1747.ep12605898; VERRANDO P, 1987, EXP CELL RES, V170, P116, DOI 10.1016/0014-4827(87)90121-2; VERRANDO P, 1993, J INVEST DERMATOL, V101, P738, DOI 10.1111/1523-1747.ep12371685; VIDAL F, 1995, GENOMICS, V30, P273, DOI 10.1006/geno.1995.9877; VOLLBERG TM, 1991, EXP CELL RES, V193, P93, DOI 10.1016/0014-4827(91)90542-3; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; WIKNER NE, 1990, J INVEST DERMATOL, V95, P607, DOI 10.1111/1523-1747.ep12505603; ZWAIN IH, 1994, MOL CELL NEUROSCI, V5, P229, DOI 10.1006/mcne.1994.1027	49	41	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17318	17325		10.1074/jbc.273.28.17318	http://dx.doi.org/10.1074/jbc.273.28.17318			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651314	hybrid			2022-12-25	WOS:000074816100007
J	Snyers, L; Umlauf, E; Prohaska, R				Snyers, L; Umlauf, E; Prohaska, R			Oligomeric nature of the integral membrane protein stomatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BAND 7.2B; ORGANIZATION; CAVEOLAE; GENE; ERYTHROCYTES; EXPRESSION	The 32-kDa integral membrane protein stomatin (protein 7.2b) is not only an important component of the red cell membrane but can also be found in abundance in different tissues and cell lines. The protein is thought to be anchored to the membrane by a hydrophobic domain while both N and C termini are exposed to the cytoplasm. We have previously shown in the human cell line UAC that stomatin concentrates preferentially in plasma membrane folds and protrusions. There is also evidence that stomatin is linked to the cortical actin cytoskeleton, suggesting a role in cortical morphogenesis of the cell. In this study, we demonstrate that the fundamental structure of stomatin is oligomeric, Whereas interaction of stomatin with itself was suggested by cross-linking experiments, we show by density gradient centrifugation analysis that soluble homo-oligomeric complexes of this protein are present in Triton X-100 extracts of UAC cells. We also show the existence of these oligomers by co-immunoprecipitation of the endogenous stomatin and a recombinantly expressed myc-tagged stomatin, using an anti-myc antibody. The data indicate that these complexes comprise between 9 and 12 monomers of stomatin, Two C-terminally truncated forms of stomatin do not incorporate into these oligomers, suggesting an involvement of the C terminus in the homo-oligomeric interaction.	Univ Vienna, Inst Biochem, Bioctr, A-1030 Vienna, Austria	University of Vienna	Prohaska, R (corresponding author), Univ Vienna, Inst Biochem, Bioctr, Dr Bohr Gasse 9-3, A-1030 Vienna, Austria.	prohaska@bch.univie.ac.at						ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; Barnes TM, 1996, J NEUROCHEM, V67, P46; BERRYMAN M, 1995, J CELL BIOL, V131, P1231, DOI 10.1083/jcb.131.5.1231; BUTLER AJ, 1991, J BIOL CHEM, V266, P18250; Desneves J, 1996, BIOCHEM BIOPH RES CO, V224, P108, DOI 10.1006/bbrc.1996.0992; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; GALLAGHER PG, 1995, J BIOL CHEM, V270, P26358, DOI 10.1074/jbc.270.44.26358; HIEBLDIRSCHMIED CM, 1991, BIOCHIM BIOPHYS ACTA, V1065, P195, DOI 10.1016/0005-2736(91)90230-6; HIEBLDIRSCHMIED CM, 1991, BIOCHIM BIOPHYS ACTA, V1090, P123, DOI 10.1016/0167-4781(91)90047-P; HUANG MX, 1995, NATURE, V378, P292, DOI 10.1038/378292a0; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; LANDE WM, 1982, J CLIN INVEST, V70, P1273, DOI 10.1172/JCI110726; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; SALZER U, 1993, BIOCHIM BIOPHYS ACTA, V1151, P149, DOI 10.1016/0005-2736(93)90098-K; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; Snyers L, 1997, EUR J CELL BIOL, V73, P281; SNYERS L, 1994, EUR J BIOCHEM, V223, P411, DOI 10.1111/j.1432-1033.1994.tb19008.x; Song KS, 1997, J BIOL CHEM, V272, P4398, DOI 10.1074/jbc.272.7.4398; STEWART GW, 1993, BIOCHIM BIOPHYS ACTA, V1225, P15, DOI 10.1016/0925-4439(93)90116-I; STEWART GW, 1992, BLOOD, V79, P1593, DOI 10.1182/blood.V79.6.1593.bloodjournal7961593; Tavernarakis N, 1997, ANNU REV PHYSIOL, V59, P659, DOI 10.1146/annurev.physiol.59.1.659; Unfried I, 1995, GENOMICS, V30, P521, DOI 10.1006/geno.1995.1273; Vaheri A, 1997, CURR OPIN CELL BIOL, V9, P659, DOI 10.1016/S0955-0674(97)80119-6	25	111	114	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17221	17226		10.1074/jbc.273.27.17221	http://dx.doi.org/10.1074/jbc.273.27.17221			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642292	hybrid			2022-12-25	WOS:000074545200082
J	Heist, EK; Srinivasan, M; Schulman, H				Heist, EK; Srinivasan, M; Schulman, H			Phosphorylation at the nuclear localization signal of Ca2+/calmodulin-dependent protein kinase II blocks its nuclear targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-DEPENDENT KINASE; MULTIFUNCTIONAL CAM KINASE; CENTRAL-NERVOUS-SYSTEM; CELL-CYCLE; TRANSCRIPTION FACTOR; HIPPOCAMPAL SLICES; FOS TRANSCRIPTION; RAT-BRAIN; EXPRESSION; ACTIVATION	Translocation of protein kinases with broad: substrate specificities between different subcellular compartments by activation of signaling pathways is an established mechanism to direct the activity of these enzymes toward particular substrates. Recently, we identified two isoforms of Ca2+/calmodulin-dependent protein kinase II (CaM kinase II), which are targeted to the nucleus by an alternatively spliced nuclear localization signal (NLS). Here we report that cotransfection with constitutively active mutants of CaM kinase I or CaM kinase IV specifically blocks nuclear targeting of CaM kinase II as a result of phosphorylation of a Ser immediately adjacent to the NLS of CaM kinase II. Both CaM kinase I and CaM kinase IV are able to phosphorylate this Ser residue in vitro, and mutagenesis studies suggest that this phosphorylation is both necessary and sufficient to block nuclear targeting. Furthermore, we provide experimental evidence that introduction of a negatively charged residue at this phosphorylation site reduces; binding of the kinase to an NLS receptor in vitro, thus providing a mechanism that may explain the blockade of nuclear targeting that me have observed in situ.	Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA	Stanford University	Schulman, H (corresponding author), Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA.	schulman@cmgm.stanford.edu			NIGMS NIH HHS [GM40600, 5T32 GM07365, GM 30179] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040600, T32GM007365, R37GM030179, R01GM030179] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE H, 1993, EXP CELL RES, V206, P1, DOI 10.1006/excr.1993.1113; BACSKAI BJ, 1993, SCIENCE, V260, P222, DOI 10.1126/science.7682336; BAITINGER C, 1990, J CELL BIOL, V111, P1763, DOI 10.1083/jcb.111.5.1763; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; BROCKE L, 1995, J NEUROSCI, V15, P6797; Chi NC, 1997, MOL BIOL CELL, V8, P945, DOI 10.1091/mbc.8.6.945; CHIDA K, 1992, P NATL ACAD SCI USA, V89, P4290, DOI 10.1073/pnas.89.10.4290; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; EDMAN CF, 1994, BIOCHIM BIOPHYS ACTA, V1221, P90; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; HENNEKES H, 1993, J CELL BIOL, V120, P1293, DOI 10.1083/jcb.120.6.1293; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hubner S, 1997, J BIOL CHEM, V272, P17191, DOI 10.1074/jbc.272.27.17191; JANS DA, 1995, J BIOL CHEM, V270, P17064, DOI 10.1074/jbc.270.29.17064; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; KANASEKI T, 1991, J CELL BIOL, V115, P1049, DOI 10.1083/jcb.115.4.1049; KURET J, 1984, BIOCHEMISTRY-US, V23, P5495, DOI 10.1021/bi00318a018; LEE JC, 1994, P NATL ACAD SCI USA, V91, P6413, DOI 10.1073/pnas.91.14.6413; Linden D J, 1993, Curr Opin Neurobiol, V3, P401, DOI 10.1016/0959-4388(93)90133-J; LLEDO PM, 1995, P NATL ACAD SCI USA, V92, P11175, DOI 10.1073/pnas.92.24.11175; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; MACNICOL M, 1990, J BIOL CHEM, V265, P18055; MACNICOL M, 1992, J BIOL CHEM, V267, P12197; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MIYANO O, 1992, J BIOL CHEM, V267, P1198; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; MOLLOY SS, 1991, P NATL ACAD SCI USA, V88, P4756, DOI 10.1073/pnas.88.11.4756; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; NAKAMURA Y, 1995, NEUROSCIENCE, V68, P181, DOI 10.1016/0306-4522(95)00092-W; Nakamura Y, 1996, NEUROSCI LETT, V204, P61, DOI 10.1016/0304-3940(96)12317-X; NGHIEM P, 1994, NATURE, V371, P347, DOI 10.1038/371347a0; OCORR KA, 1991, NEURON, V6, P907, DOI 10.1016/0896-6273(91)90231-N; OHTA Y, 1989, J BIOL CHEM, V264, P16143; ONEILL RE, 1995, VIROLOGY, V206, P116, DOI 10.1016/S0042-6822(95)80026-3; PICCIOTTO MR, 1995, SYNAPSE, V20, P75, DOI 10.1002/syn.890200111; PLANASSILVA MD, 1992, EMBO J, V11, P507, DOI 10.1002/j.1460-2075.1992.tb05081.x; Ramirez MT, 1997, J BIOL CHEM, V272, P31203, DOI 10.1074/jbc.272.49.31203; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SCHILLING K, 1991, P NATL ACAD SCI USA, V88, P5665, DOI 10.1073/pnas.88.13.5665; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; Shimomura A, 1996, J BIOL CHEM, V271, P17957, DOI 10.1074/jbc.271.30.17957; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SRINIVASAN M, 1994, J CELL BIOL, V126, P839, DOI 10.1083/jcb.126.4.839; Strack S, 1997, J BIOL CHEM, V272, P13467, DOI 10.1074/jbc.272.21.13467; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Sun PQ, 1996, J BIOL CHEM, V271, P3066, DOI 10.1074/jbc.271.6.3066; TAGAWA T, 1995, J CELL BIOL, V130, P255, DOI 10.1083/jcb.130.2.255; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; WALDMANN R, 1990, BIOCHEMISTRY-US, V29, P1679, DOI 10.1021/bi00459a002; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2	63	94	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19763	19771		10.1074/jbc.273.31.19763	http://dx.doi.org/10.1074/jbc.273.31.19763			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677407	hybrid			2022-12-25	WOS:000075125200059
J	Sakai, T; Peyruchaud, O; Fassler, R; Mosher, DF				Sakai, T; Peyruchaud, O; Fassler, R; Mosher, DF			Restoration of beta(1)A integrins is required for lysophosphatidic acid-induced migration of beta(1)-null mouse fibroblastic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; ADHESION; FIBRONECTIN; PROLIFERATION; MODULATION; INVASION; BINDING; ENCODES; GENE	Cells lacking the beta(1) integrin subunit or expressing beta(1)A with certain cytoplasmic mutations have poor directed cell migration to platelet-derived growth factor or epidermal growth factor, ligands of receptor tyrosine kinases (Sakai, T., Zhang, Q., FHssler, 8, and Mosher, D. F, (1998) J. Cebl Biol. 141, 527-538). We investigated the effect of expression of beta(1)A integrins on lysophosphatidic acid (LPA)-induced migration of fibroblastic cells derived from beta(1)-null mouse embryonic stem cells. These cells expressed edg-2, a G-protein-linked receptor for LPA, as well as the related edg-1 receptor. Cells expressing wild type beta(1)A demonstrated enhanced cell migration across filters coated with gelatin or adhesive proteins in response to LPA, whereas beta(1)-deficient cells lacked LPAinduced cell migratory ability. Checkerboard analyses indicated that LPA causes both chemotaxis and chemokinesis of beta(1)-replete cells. Cells expressing beta(1)A with mutations of prolines or tyrosines in conserved cytoplasmic NPXY motifs, threonine in the inter-motif sequence, or a critical aspartic acid in the extracellular domain had low migratory responses to LPA. These findings indicate that active beta(1)A integrin is required for cell migration induced by LPA and that the cytoplasmic domain of ligated beta(1)A interacts with pathways that are common to both receptor tyrosine kinase and G-protein-linked receptor signaling.	Univ Wisconsin, Dept Med, Med Sci Ctr, Madison, WI 53706 USA; Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA; Lund Univ, Dept Expt Pathol, S-22185 Lund, Sweden	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Lund University	Mosher, DF (corresponding author), Univ Wisconsin, Dept Med, Med Sci Ctr, 1300 Univ Ave,4285B, Madison, WI 53706 USA.	dfmosher@facstaff.wisc.edu		Peyruchaud, Olivier/0000-0002-5393-4945	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021644, R01HL054462] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54462, HL21644] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; An SZ, 1997, FEBS LETT, V417, P279, DOI 10.1016/S0014-5793(97)01301-X; An SZ, 1997, BIOCHEM BIOPH RES CO, V231, P619, DOI 10.1006/bbrc.1997.6150; Anand-Apte B, 1997, J BIOL CHEM, V272, P30688, DOI 10.1074/jbc.272.49.30688; Bornfeldt KE, 1996, TRENDS CARDIOVAS MED, V6, P143, DOI 10.1016/1050-1738(96)00038-2; Bretscher MS, 1996, CELL, V85, P465, DOI 10.1016/S0092-8674(00)81246-5; BRETSCHER MS, 1989, EMBO J, V8, P1341, DOI 10.1002/j.1460-2075.1989.tb03514.x; CHECOVICH WJ, 1993, ARTERIOSCLER THROMB, V13, P1662, DOI 10.1161/01.ATV.13.11.1662; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; FASSLER R, 1995, J CELL BIOL, V128, P979, DOI 10.1083/jcb.128.5.979; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HLA T, 1990, J BIOL CHEM, V265, P9308; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Imamura F, 1996, INT J CANCER, V65, P627, DOI 10.1002/(SICI)1097-0215(19960301)65:5<627::AID-IJC12>3.0.CO;2-4; IMAMURA F, 1993, BIOCHEM BIOPH RES CO, V193, P497, DOI 10.1006/bbrc.1993.1651; KUNDRA V, 1995, J CELL BIOL, V130, P725, DOI 10.1083/jcb.130.3.725; LaFlamme SE, 1997, MATRIX BIOL, V16, P153, DOI 10.1016/S0945-053X(97)90003-2; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Panetti TS, 1997, J LAB CLIN MED, V129, P208, DOI 10.1016/S0022-2143(97)90141-4; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SAKAI T, 1995, INT J CANCER, V63, P720, DOI 10.1002/ijc.2910630519; Sakai T, 1998, J CELL BIOL, V141, P527, DOI 10.1083/jcb.141.2.527; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; STOKES CL, 1991, J THEOR BIOL, V152, P377, DOI 10.1016/S0022-5193(05)80201-2; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; Wennerberg K, 1996, J CELL BIOL, V132, P227, DOI 10.1083/jcb.132.1.227; WILKINSON PC, 1988, METHOD ENZYMOL, V162, P3; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Yamaguchi F, 1996, BIOCHEM BIOPH RES CO, V227, P608, DOI 10.1006/bbrc.1996.1553; ZETTER BR, 1990, NEW ENGL J MED, V322, P605; Zhang QH, 1997, MOL BIOL CELL, V8, P1415, DOI 10.1091/mbc.8.8.1415; ZHANG QH, 1994, J CELL BIOL, V127, P1447, DOI 10.1083/jcb.127.5.1447	43	49	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19378	19382		10.1074/jbc.273.31.19378	http://dx.doi.org/10.1074/jbc.273.31.19378			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677354	hybrid			2022-12-25	WOS:000075125200006
J	Zhang, XN; Spudich, JL				Zhang, XN; Spudich, JL			HtrI is a dimer whose interface is sensitive to receptor photoactivation and His-166 replacements in sensory rhodopsin I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE CROSS-LINKING; SINGLE CYTOPLASMIC DOMAIN; METHYL-ACCEPTING PROTEIN; COILED-COIL INTERACTIONS; COLI ASPARTATE RECEPTOR; ESCHERICHIA-COLI; BACTERIAL CHEMOTAXIS; HALOBACTERIUM-HALOBIUM; TRANSDUCER; CHEMORECEPTOR	Single cysteine substitutions were introduced into three positions of otherwise cysteineless HtrI, a phototaxis transducer found in Halobacterium salinarum that transmits signals from the photoreceptor sensory rhodopsin I (SRI) to a cytoplasmic pathway controlling the cell's motility. Oxidative cross-linking of the monocysteine HtrI mutants in membrane suspensions resulted in dimer forms evident in SDS-polyacrylamide gels. The rate of cross-linking of I64C on the cytoplasmic side of HtrI was accelerated by SRI binding in the dark and further increased by SRI photoactivation. Several residue replacements of His-166 in SRI accelerated the cross-linking rate of I64C in the dark and His-166 mutants that exhibit "inverted signaling" (mediating repellent instead of the normally attractant response to orange light) inverted the light effect on the cross-linking rate of I64C, Secondary structure prediction of HtrI indicates a coiled coil structure in the cytoplasmic region following TM2, a dimerization domain found in a diverse group of proteins. We conclude that 1) HtrI exists as a dimer both in the absence of SRI and in the SRI-HtrI complex, 2) binding of SRI in the dark increases reactivity of the two cysteines at position I64C in the dimer by increasing their proximity or mobility, 3) light activation of wild-type SRI further increases their reactivity, 4) His-166 replacements in the SRI receptor have conformational effects on the structure of HtrI at position 64, and 5) inverted signaling by His-166 mutants likely results from an inverted conformational change at this region induced by SRI photoactivation.	Univ Texas, Sch Med, Dept Microbiol & Mol Genet, Houston, TX 77030 USA	University of Texas System	Spudich, JL (corresponding author), Univ Texas, Sch Med, Dept Microbiol & Mol Genet, Houston, TX 77030 USA.				NIGMS NIH HHS [R01-GM27750] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027750] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; CHEN BW, 1994, BIOTECHNIQUES, V17, P657; Chen XM, 1997, BIOCHEMISTRY-US, V36, P11858, DOI 10.1021/bi970911u; CHERVITZ SA, 1995, J BIOL CHEM, V270, P24043, DOI 10.1074/jbc.270.41.24043; CHERVITZ SA, 1995, BIOCHEMISTRY-US, V34, P9722, DOI 10.1021/bi00030a010; Chervitz SA, 1996, P NATL ACAD SCI USA, V93, P2545, DOI 10.1073/pnas.93.6.2545; CLINE SW, 1987, J BACTERIOL, V169, P1341, DOI 10.1128/jb.169.3.1341-1344.1987; Cochran AG, 1996, SCIENCE, V271, P1113, DOI 10.1126/science.271.5252.1113; Falke JJ, 1997, ANNU REV CELL DEV BI, V13, P457, DOI 10.1146/annurev.cellbio.13.1.457; Gardina PJ, 1996, SCIENCE, V274, P425, DOI 10.1126/science.274.5286.425; Hodges RS, 1996, BIOCHEM CELL BIOL, V74, P133, DOI 10.1139/o96-015; HODGES RS, 1981, J BIOL CHEM, V256, P1214; Hoff WD, 1997, ANNU REV BIOPH BIOM, V26, P223, DOI 10.1146/annurev.biophys.26.1.223; Hughson AG, 1996, P NATL ACAD SCI USA, V93, P11546, DOI 10.1073/pnas.93.21.11546; Jung KH, 1996, P NATL ACAD SCI USA, V93, P6557, DOI 10.1073/pnas.93.13.6557; Jung KH, 1998, J BACTERIOL, V180, P2033, DOI 10.1128/JB.180.8.2033-2042.1998; KIM SH, 1992, COLD SPRING HARB SYM, V57, P17, DOI 10.1101/SQB.1992.057.01.004; KRAH M, 1994, EMBO J, V13, P2150, DOI 10.1002/j.1460-2075.1994.tb06491.x; KREBS MP, 1993, P NATL ACAD SCI USA, V90, P3486, DOI 10.1073/pnas.90.8.3486; LEE GF, 1995, P NATL ACAD SCI USA, V92, P3391, DOI 10.1073/pnas.92.8.3391; LEE GF, 1994, J BIOL CHEM, V269, P29920; LeMoual H, 1996, J MOL BIOL, V261, P568, DOI 10.1006/jmbi.1996.0483; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; LYNCH BA, 1991, P NATL ACAD SCI USA, V88, P10402, DOI 10.1073/pnas.88.23.10402; MARUYAMA IN, 1995, J MOL BIOL, V253, P530, DOI 10.1006/jmbi.1995.0571; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; MILLIGAN DL, 1991, SCIENCE, V254, P1651, DOI 10.1126/science.1661030; OLSON KD, 1993, BIOPHYS J, V65, P2578, DOI 10.1016/S0006-3495(93)81295-5; OLSON KD, 1995, P NATL ACAD SCI USA, V92, P3185, DOI 10.1073/pnas.92.8.3185; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PAKULA AA, 1992, P NATL ACAD SCI USA, V89, P4144, DOI 10.1073/pnas.89.9.4144; Perazzona B, 1996, J BACTERIOL, V178, P6475, DOI 10.1128/jb.178.22.6475-6478.1996; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SARKAR G, 1990, NUCLEIC ACIDS RES, V18, P7465, DOI 10.1093/nar/18.24.7465; SEIDEL R, 1995, P NATL ACAD SCI USA, V92, P3036, DOI 10.1073/pnas.92.7.3036; SPUDICH EN, 1993, J BIOL CHEM, V268, P16095; STOCK JB, 1996, ESCHERICHIA COLI SAL, P123; STODDARD BL, 1992, BIOCHEMISTRY-US, V31, P11978, DOI 10.1021/bi00163a004; STODDARD BL, 1992, COLD SPRING HARB SYM, V57, P1; Surette MG, 1996, J BIOL CHEM, V271, P17966, DOI 10.1074/jbc.271.30.17966; TALBOT JA, 1982, ACCOUNTS CHEM RES, V15, P224, DOI 10.1021/ar00079a006; Tatsuno I, 1996, SCIENCE, V274, P423, DOI 10.1126/science.274.5286.423; YAO VJ, 1992, P NATL ACAD SCI USA, V89, P11915, DOI 10.1073/pnas.89.24.11915; Yeh JI, 1996, J MOL BIOL, V262, P186, DOI 10.1006/jmbi.1996.0507; Zhang WS, 1996, P NATL ACAD SCI USA, V93, P8230, DOI 10.1073/pnas.93.16.8230; Zhang WS, 1996, P NATL ACAD SCI USA, V93, P4649, DOI 10.1073/pnas.93.10.4649; Zhang XN, 1997, BIOPHYS J, V73, P1516, DOI 10.1016/S0006-3495(97)78183-9	50	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19722	19728		10.1074/jbc.273.31.19722	http://dx.doi.org/10.1074/jbc.273.31.19722			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677402	hybrid			2022-12-25	WOS:000075125200054
J	Beninga, J; Rock, KL; Goldberg, AL				Beninga, J; Rock, KL; Goldberg, AL			Interferon-gamma can stimulate post-proteasomal trimming of the N terminus of an antigenic peptide by inducing leucine aminopeptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-I MOLECULES; ENDOPLASMIC-RETICULUM; LYMPHOCYTES-T; MHC; DEGRADATION; PROTEIN; IDENTIFICATION; PURIFICATION; EXPRESSION	Most antigenic peptides presented on major histocompatibility complex class I molecules are generated during protein breakdown by proteasomes, whose specificity is altered by interferon-gamma (IFN-gamma). When extended versions of the ovalbumin-derived epitope SIINFEKL are expressed in vivo, the correct C terminus is generated by proteasomal cleavage, but distinct cytosolic protease(s) generate its N terminus. To identify the other protease(s) involved in antigen processing, we incubated soluble extracts of HeLa cells with the 11-mer QLESIINFEKL, which in vivo is processed to the antigenic 8-mer (SIINFEKL) by a proteasome-independent pathway. This 11-mer was converted to the 9-mer by sequential removal of the N-terminal residues, but surprisingly the extract showed little or no endopeptidase or carboxypeptidase activity against this precursor. After treatment of cells with IFN-gamma, this N-terminal trimming was severalfold faster and proceeded to the antigenic 8-mer. The IFN-treated cells also showed greater aminopeptidase activity against many model fluorogenic substrates. Upon extract fractionation, three bestatin-sensitive aminopeptidase peaks were detected, One was induced by IFN-gamma and was identified immunologically as leucine aminopeptidase (LAP). Purified LAP, like the extracts of IFN-gamma-treated cells, processed the 11-mer peptide to SIINFEKL. Thus, IFN-gamma not only promotes proteasomal cleavages that determine the C termini of antigenic peptides, but also can stimulate formation of their N termini by inducing LAP. This enzyme appears to catalyze the trimming of the N terminus of this and presumably other proteasome-derived precursors. Thus, susceptibility to LAP may be an important influence on the generation on immunodominant epitopes.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Univ Massachusetts, Med Ctr, Dept Pathol, Worcester, MA 01655 USA	Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester	Goldberg, AL (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.	agoldber@bcmp.med.harvard.edu						AKI M, 1994, J BIOCHEM, V115, P257, DOI 10.1093/oxfordjournals.jbchem.a124327; ANON LC, 1997, J IMMUNOL, V158, P2535; Bacik I, 1997, J EXP MED, V186, P479, DOI 10.1084/jem.186.4.479; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; BOTBOL V, 1983, J BIOL CHEM, V258, P1942; Cerundolo V, 1997, EUR J IMMUNOL, V27, P336, DOI 10.1002/eji.1830270148; COUX O, 1996, ANNU REV BIOCHEM, V65, P1; Craiu A, 1997, P NATL ACAD SCI USA, V94, P10850, DOI 10.1073/pnas.94.20.10850; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; DICK LR, 1994, J IMMUNOL, V152, P3884; DICK TP, 1996, NATURE, V365, P262; DRISCOLL J, 1993, NATURE, V365, P262, DOI 10.1038/365262a0; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; EISENLOHR LC, 1992, CELL, V71, P963, DOI 10.1016/0092-8674(92)90392-P; ELLIOTT T, 1995, J EXP MED, V181, P1481, DOI 10.1084/jem.181.4.1481; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FEHLING HJ, 1994, SCIENCE, V265, P1234, DOI 10.1126/science.8066463; GACZYNSKA M, 1994, P NATL ACAD SCI USA, V91, P9213, DOI 10.1073/pnas.91.20.9213; GACZYNSKA M, 1993, NATURE, V365, P264, DOI 10.1038/365264a0; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; GRANT EP, 1995, J IMMUNOL, V155, P3750; Groettrup M, 1996, NATURE, V381, P166, DOI 10.1038/381166a0; HARDING CV, 1995, J IMMUNOL, V155, P1767; HARRIS CA, 1992, J BIOL CHEM, V267, P6865; Kisselev AF, 1998, J BIOL CHEM, V273, P1982, DOI 10.1074/jbc.273.4.1982; Lee DH, 1996, J BIOL CHEM, V271, P27280, DOI 10.1074/jbc.271.44.27280; Lehner PJ, 1996, CURR OPIN IMMUNOL, V8, P59, DOI 10.1016/S0952-7915(96)80106-3; MA CP, 1992, J BIOL CHEM, V267, P10515; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MCDONALD JK, 1986, MAMMALIAN PROTEASES, V2; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; MOMBURG F, 1994, J EXP MED, V179, P1613, DOI 10.1084/jem.179.5.1613; Mosse CA, 1998, J EXP MED, V187, P37, DOI 10.1084/jem.187.1.37; Niedermann G, 1996, P NATL ACAD SCI USA, V93, P8572, DOI 10.1073/pnas.93.16.8572; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROELSE J, 1994, J EXP MED, V180, P1591, DOI 10.1084/jem.180.5.1591; SNYDER HL, 1994, J EXP MED, V180, P2389, DOI 10.1084/jem.180.6.2389; SRIVASTAVA PK, 1994, IMMUNOGENETICS, V39, P93; TAYLOR A, 1993, TRENDS BIOCHEM SCI, V18, P167; TAYLOR A, 1993, FASEB J, V7, P290, DOI 10.1096/fasebj.7.2.8440407; TISLJAR U, 1993, BIOL CHEM H-S, V374, P91; UDAKA K, 1992, CELL, V69, P989, DOI 10.1016/0092-8674(92)90617-L; UDAKA K, 1993, P NATL ACAD SCI USA, V90, P11272, DOI 10.1073/pnas.90.23.11272; UENAKA A, 1994, J EXP MED, V180, P1599, DOI 10.1084/jem.180.5.1599; VANENDERT PM, 1995, J EXP MED, V182, P1883, DOI 10.1084/jem.182.6.1883; VANKAER L, 1994, IMMUNITY, V1, P533, DOI 10.1016/1074-7613(94)90043-4; WENZEL T, 1994, FEBS LETT, V349, P205, DOI 10.1016/0014-5793(94)00665-2; York IA, 1996, ANNU REV IMMUNOL, V14, P369, DOI 10.1146/annurev.immunol.14.1.369	50	236	239	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18734	18742		10.1074/jbc.273.30.18734	http://dx.doi.org/10.1074/jbc.273.30.18734			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668046	hybrid			2022-12-25	WOS:000074974700013
J	Pepio, AM; Fan, XT; Sossin, WS				Pepio, AM; Fan, XT; Sossin, WS			The role of C2 domains in Ca2+-activated and Ca2+ independent protein kinase Cs in Aplysia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER BINDING; TRANSFERASE FUSION PROTEINS; PHOSPHATIDYL-L-SERINE; SENSORY NEURONS; PRESYNAPTIC FACILITATION; TRANSMITTER RELEASE; REGULATORY DOMAIN; MIXED MICELLES; LIPID-BINDING; ACTIVATION	In the nervous system of the marine mollusk Aplysia there are two protein kinase C (PKC) isoforms, the Ca2+-activated PKC Apl I and the Ca2+-independent PKC Apl II. PKC Apl I, but not PKC Apl II is activated by a shortterm application of the neurotransmitter serotonin, This may be explained by the fact that purified PKC Apl II requires a higher mole percentage of phosphatidylserine to stimulate enzyme activity than does PKC Apl I. In order to understand the molecular basis for this difference, we have compared the ability of lipids to interact with the purified kinases and with regulatory domain fusion proteins derived from the kinases using a variety of assays including kinase activity, phorbol dibutyrate binding, and Liposome binding. We found that a C2 domain fusion protein derived from PKC Apl I binds to lipids constitutively, while a C2 domain fusion protein derived from PKC Apl II does not. In contrast, fusion proteins containing the C1 domains of PRC Apl I and PKC Apl II showed only small differences in lipid interactions. Thus, while the presence of a C2 domain assists lipid-mediated activation of PKC Apl I, it inhibits activation of PKC Apl II.	McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada	McGill University	Sossin, WS (corresponding author), McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, 3801 Univ Ave, Montreal, PQ H3A 2B4, Canada.	mdws@musica.mcgill.ca						BRAHA O, 1990, P NATL ACAD SCI USA, V87, P2040, DOI 10.1073/pnas.87.5.2040; Csukai M, 1997, J BIOL CHEM, V272, P29200, DOI 10.1074/jbc.272.46.29200; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; DEKKER LV, 1993, J BIOL CHEM, V268, P19498; Edwards AS, 1997, BIOCHEMISTRY-US, V36, P15615, DOI 10.1021/bi9718752; Edwards AS, 1997, J BIOL CHEM, V272, P18382, DOI 10.1074/jbc.272.29.18382; ELIOT LS, 1993, NATURE, V361, P634, DOI 10.1038/361634a0; GHIRARDI M, 1992, NEURON, V9, P479, DOI 10.1016/0896-6273(92)90185-G; Grobler JA, 1996, NAT STRUCT BIOL, V3, P788, DOI 10.1038/nsb0996-788; HANNUN YA, 1987, METHOD ENZYMOL, V141, P287; HANNUN YA, 1986, J BIOL CHEM, V261, P7184; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P21852, DOI 10.1074/jbc.270.37.21852; LEE MH, 1989, J BIOL CHEM, V264, P14797; LEE MH, 1992, BIOCHEMISTRY-US, V31, P5176, DOI 10.1021/bi00137a013; MALENKA RC, 1987, BRAIN RES, V403, P198, DOI 10.1016/0006-8993(87)90145-4; Mosior M, 1996, P NATL ACAD SCI USA, V93, P1907, DOI 10.1073/pnas.93.5.1907; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; NEWTON AC, 1994, BIOCHEMISTRY-US, V33, P6651, DOI 10.1021/bi00187a035; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; NEWTON AC, 1989, J BIOL CHEM, V264, P14909; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1991, PROGR BRAIN RES, V89, P125; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4667, DOI 10.1021/bi00134a019; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4661, DOI 10.1021/bi00134a018; PALMER RH, 1995, J BIOL CHEM, V270, P22412, DOI 10.1074/jbc.270.38.22412; PARFITT KD, 1993, J PHYSIOL-LONDON, V471, P245, DOI 10.1113/jphysiol.1993.sp019900; Pepio AM, 1998, BIOCHEMISTRY-US, V37, P1256, DOI 10.1021/bi971841u; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; PIOMELLI D, 1987, J NEUROSCI, V7, P3675; QUEST AFG, 1994, J BIOL CHEM, V269, P2953; QUEST AFG, 1994, J BIOL CHEM, V269, P20000; QUEST AFG, 1995, METHOD ENZYMOL, V252, P153; RON D, 1994, J BIOL CHEM, V269, P21395; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; Sossin W S, 1994, Learn Mem, V1, P189; SOSSIN WS, 1992, J NEUROSCI, V12, P1160; Sossin WS, 1996, J NEUROCHEM, V67, P220; Sossin WS, 1996, J NEUROSCI, V16, P10; SUGITA S, 1992, J NEUROPHYSIOL, V68, P643, DOI 10.1152/jn.1992.68.2.643	43	26	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19040	19048		10.1074/jbc.273.30.19040	http://dx.doi.org/10.1074/jbc.273.30.19040			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668085	hybrid			2022-12-25	WOS:000074974700052
J	Chaudhry, AZ; Vitullo, AD; Gronostajski, RM				Chaudhry, AZ; Vitullo, AD; Gronostajski, RM			Nuclear factor I (NFI) isoforms differentially activate simple versus complex NFI-responsive promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-TUMOR VIRUS; HUMAN PAPILLOMAVIRUS TYPE-16; ADENOVIRUS DNA-REPLICATION; STEROID-HORMONE RECEPTORS; RNA-POLYMERASE-II; TRANSCRIPTIONAL ACTIVATION; BINDING PROTEINS; MMTV PROMOTER; SYNERGISTIC INTERACTION; MAMMALIAN-CELLS	Promoter-specific differences in the function of transcription factors play a central role in the regulation of gene expression. We have measured the maximal transcriptional activation potentials of nuclear factor I (NFI) proteins encoded by each of the four identified NFI genes (NFI-A, -B, -C, and -X) by transient transfection in JEG-3 cells using two model NFI-dependent promoters: 1) a simple chimeric promoter containing a single NFI-binding site upstream of the adenovirus major late promoter (NFI-Ad), and 2) the more complex mouse mammary tumor virus long terminal repeat promoter. The relative activation potentials for the NFI isoforms differed between the two promoters, with NFI-X being the strongest activator of NFI-Ad and NFI-B being the strongest activator of the MMTV promoter. To determine if these promoter-specific differences in activation potential were due to the presence of glucocorticoid response elements (GREs), we added GREs upstream of the NFI-binding site in NFI-Ad. NFI-X remains the strongest activator of the GRE containing simple promoter, indicating that differences in relative activation potential are not due solely to the presence of GREs. Since NFI proteins bind to DNA as dimers, we assessed the activation potentials of NFI heterodimers. Here, we show that NFI heterodimers have intermediate activation potentials compared with homodimers, demonstrating one potential mechanism by which different NFI proteins can regulate gene expression.	Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol NN1 14, Cleveland, OH 44195 USA; Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Case Western Reserve University	Gronostajski, RM (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol NN1 14, 9500 Euclid Ave, Cleveland, OH 44195 USA.		Vitullo, Alfredo/F-9744-2015	Vitullo, Alfredo/0000-0002-4833-5147; Gronostajski, Richard/0000-0003-4264-208X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD034908] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048796] Funding Source: NIH RePORTER; NICHD NIH HHS [HD34908] Funding Source: Medline; NIDDK NIH HHS [DK48796] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTMANN H, 1994, P NATL ACAD SCI USA, V91, P3901, DOI 10.1073/pnas.91.9.3901; AMEMIYA K, 1992, J BIOL CHEM, V267, P14204; AOYAMA A, 1990, BIOCHEM BIOPH RES CO, V167, P648, DOI 10.1016/0006-291X(90)92074-A; APT D, 1994, NUCLEIC ACIDS RES, V22, P3825, DOI 10.1093/nar/22.19.3825; APT D, 1993, J VIROL, V67, P4455, DOI 10.1128/JVI.67.8.4455-4463.1993; ATTARDI LD, 1993, GENE DEV, V7, P1341, DOI 10.1101/gad.7.7b.1341; BANDYOPADHYAY S, 1994, J BIOL CHEM, V269, P29949; BRUGGEMEIER U, 1990, EMBO J, V9, P2233, DOI 10.1002/j.1460-2075.1990.tb07393.x; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; Chaudhry AZ, 1997, DEV DYNAM, V208, P313; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; DARVILLE MI, 1992, NUCLEIC ACIDS RES, V20, P3575, DOI 10.1093/nar/20.14.3575; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; Gorman C., 1985, DNA CLONING, V2; GOUNARI F, 1990, EMBO J, V9, P559, DOI 10.1002/j.1460-2075.1990.tb08143.x; GOYAL N, 1990, MOL CELL BIOL, V10, P1041, DOI 10.1128/MCB.10.3.1041; GRAVES RA, 1991, GENE DEV, V5, P428, DOI 10.1101/gad.5.3.428; GRONOSTAJSKI RM, 1987, NUCLEIC ACIDS RES, V15, P5545, DOI 10.1093/nar/15.14.5545; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; KIM TK, 1994, P NATL ACAD SCI USA, V91, P4170, DOI 10.1073/pnas.91.10.4170; KNOX JJ, 1991, MOL CELL BIOL, V11, P2946, DOI 10.1128/MCB.11.6.2946; Krebs CJ, 1996, J NEUROCHEM, V66, P1354; KRUSE U, 1994, FEBS LETT, V348, P46, DOI 10.1016/0014-5793(94)00585-0; KRUSE U, 1994, J MOL BIOL, V238, P860, DOI 10.1006/jmbi.1994.1343; Kunzler M, 1996, FEMS MICROBIOL REV, V19, P117; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; Liu YC, 1997, J BIOL CHEM, V272, P10739; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MEISTERERNST M, 1989, BIOCHEMISTRY-US, V28, P8191, DOI 10.1021/bi00446a034; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MIKSICEK R, 1987, EMBO J, V6, P1355, DOI 10.1002/j.1460-2075.1987.tb02375.x; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NAGATA K, 1982, P NATL ACAD SCI-BIOL, V79, P6438, DOI 10.1073/pnas.79.21.6438; NEBL G, 1995, CELL MOL BIOL RES, V41, P85; OCONNOR M, 1995, VIROLOGY, V207, P77, DOI 10.1006/viro.1995.1053; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; RUPP RAW, 1990, NUCLEIC ACIDS RES, V18, P2607, DOI 10.1093/nar/18.9.2607; RUPP RAW, 1987, NUCLEIC ACIDS RES, V15, P9707, DOI 10.1093/nar/15.23.9707; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TANSEY WP, 1994, GENE DEV, V8, P2756, DOI 10.1101/gad.8.22.2756; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TOOHEY MG, 1990, J VIROL, V64, P4477, DOI 10.1128/JVI.64.9.4477-4488.1990; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; WENDLER W, 1994, NUCLEIC ACIDS RES, V22, P2601, DOI 10.1093/nar/22.13.2601; Wenzelides S, 1996, NUCLEIC ACIDS RES, V24, P2416, DOI 10.1093/nar/24.12.2416; XIAO H, 1994, NUCLEIC ACIDS RES, V22, P1966, DOI 10.1093/nar/22.11.1966	58	53	53	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18538	18546		10.1074/jbc.273.29.18538	http://dx.doi.org/10.1074/jbc.273.29.18538			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660824	hybrid			2022-12-25	WOS:000074828500079
J	Kawaguchi, S; Kuramitsu, S				Kawaguchi, S; Kuramitsu, S			Thermodynamics and molecular simulation analysis of hydrophobic substrate recognition by aminotransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI ASPARTATE; AMINO-ACID AMINOTRANSFERASE; ALPHA-CHYMOTRYPSIN CATALYSIS; TYROSINE AMINOTRANSFERASE; ACTIVE-SITE; NUCLEOTIDE-SEQUENCE; CRYSTAL-STRUCTURES; LIGAND-BINDING; LYTIC PROTEASE; CLOSED-FORM	Aromatic amino acid aminotransferase (AroAT) and aspartate aminotransferase (AspAT) are known as dual-substrate enzymes, which can bind acidic and hydro phobic substrates in the same pocket (Kawaguchi, S,, Nobe, Y., Yasuoka, J., Wakamiya, T,, Kusumoto, S,, and Kuramitsu, S, (1997) J, Biochem, (Tokyo) 122, 55-63), In order to elucidate the mechanism of hydrophobic substrate recognition, kinetic and thermodynamic analyses using substrates with different hydrophobicities were performed. They revealed that 1) amino acid substrate specificity (k(max)/K(d)) depended on the affinity for the substrate (1/K(d)) and 2) binding of the hydrophobic side chain was enthalpy-driven, suggesting that van der Waals interactions between the substrate-binding pocket and hydrophobic substrate predominated, Three-dimensional structures of AspAT and AroAT bound to alpha-aminoheptanoic acid were built using the homology modeling method, A molecular dynamic simulation study suggested that the outward-facing position of the Arg(292) Side chain was the preferred state to a greater extent in AroAT than AspAT, which would make the hydrophobic substrate bound state of the former more stable. Furthermore, AroAT appeared to have a more flexible conformation than AspAT. Such flexibility would be expected to reduce the energetic cost of conformational rearrangement induced by substrate binding. These two mechanisms (positional preference of Arg and flexible conformation) may account for the high activity of AroAT toward hydrophobic substrates.	Osaka Univ, Grad Sch Sci, Dept Biol, Osaka 5600043, Japan	Osaka University	Kawaguchi, S (corresponding author), Osaka Univ, Grad Sch Sci, Dept Biol, Osaka 5600043, Japan.	kuramitu@bio.sci.osaka-u.ac.jp						Akasako A, 1997, J BIOL CHEM, V272, P18686, DOI 10.1074/jbc.272.30.18686; BIGLER TL, 1993, PROTEIN SCI, V2, P786, DOI 10.1002/pro.5560020509; CREIGHTON TE, 1993, DPROTEINS, P217; DOROVSKA VN, 1972, FEBS LETT, V23, P122, DOI 10.1016/0014-5793(72)80299-0; DOROVSKATARAN V, 1982, BIOCHIM BIOPHYS ACTA, V702, P37, DOI 10.1016/0167-4838(82)90025-5; DUNKER AK, 1998, PAC S BIOCOMPUT, V3, P471; ERIKSSON AE, 1993, J MOL BIOL, V229, P747, DOI 10.1006/jmbi.1993.1077; Faergeman NJ, 1996, BIOCHEMISTRY-US, V35, P14118, DOI 10.1021/bi960545z; FERSHT A, 1985, ENZYME STRUCTURE MEC, P311; FERSHT A, 1985, ENZYME STRUCTURE MEC, P389; Gillmor SA, 1997, PROTEIN SCI, V6, P1603, DOI 10.1002/pro.5560060801; HANSCH C, 1970, J PHARM SCI, V59, P731, DOI 10.1002/jps.2600590602; HAYASHI H, 1993, BIOCHEMISTRY-US, V32, P12229, DOI 10.1021/bi00096a036; HAYASHI H, 1995, J BIOCHEM-TOKYO, V118, P463, DOI 10.1093/oxfordjournals.jbchem.a124931; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; Helms V, 1996, BIOCHEMISTRY-US, V35, P1485, DOI 10.1021/bi951817l; HUANG K, 1995, PROTEIN SCI, V4, P1985, DOI 10.1002/pro.5560041004; INOUE Y, 1989, J BIOL CHEM, V264, P9673; IWASAKI M, 1994, J BIOCHEM-TOKYO, V115, P156, DOI 10.1093/oxfordjournals.jbchem.a124293; JACKSON SE, 1993, BIOCHEMISTRY-US, V32, P11259, DOI 10.1021/bi00093a001; JAGER J, 1992, FEBS LETT, V306, P234, DOI 10.1016/0014-5793(92)81007-9; JENKINS WT, 1966, J BIOL CHEM, V241, P5667; JENKINS WT, 1985, TRANSAMINASES, P216; Jensen RA, 1996, J BACTERIOL, V178, P2161, DOI 10.1128/jb.178.8.2161-2171.1996; JOHN RA, 1995, BBA-PROTEIN STRUCT M, V1248, P81, DOI 10.1016/0167-4838(95)00025-P; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KARPLUS M, 1983, ANNU REV BIOCHEM, V52, P263, DOI 10.1146/annurev.bi.52.070183.001403; Kasper P, 1996, EUR J BIOCHEM, V240, P751, DOI 10.1111/j.1432-1033.1996.0751h.x; Kawaguchi S, 1997, J BIOCHEM-TOKYO, V122, P55; KIICK DM, 1983, BIOCHEMISTRY-US, V22, P375, DOI 10.1021/bi00271a022; Klyosov AA, 1996, BIOCHEMISTRY-US, V35, P4457, DOI 10.1021/bi9521102; KURAMITSU S, 1990, BIOCHEMISTRY-US, V29, P5469, DOI 10.1021/bi00475a010; KURAMITSU S, 1985, J BIOCHEM, V97, P1259, DOI 10.1093/oxfordjournals.jbchem.a135173; KURAMITSU S, 1985, BIOCHEM BIOPH RES CO, V133, P134, DOI 10.1016/0006-291X(85)91851-0; Lu WY, 1997, J MOL BIOL, V266, P441, DOI 10.1006/jmbi.1996.0781; MACE JE, 1995, J MOL BIOL, V251, P116, DOI 10.1006/jmbi.1995.0420; MACE JE, 1995, J MOL BIOL, V254, P720, DOI 10.1006/jmbi.1995.0650; MALASHKEVICH VN, 1995, J MOL BIOL, V247, P111, DOI 10.1006/jmbi.1994.0126; MALASHKEVICH VN, 1995, NAT STRUCT BIOL, V2, P548, DOI 10.1038/nsb0795-548; MCPHALEN CA, 1992, J MOL BIOL, V227, P197, DOI 10.1016/0022-2836(92)90691-C; MCPHALEN CA, 1992, J MOL BIOL, V225, P495, DOI 10.1016/0022-2836(92)90935-D; MEHTA PK, 1993, EUR J BIOCHEM, V214, P549, DOI 10.1111/j.1432-1033.1993.tb17953.x; MEHTA PK, 1989, EUR J BIOCHEM, V186, P249, DOI 10.1111/j.1432-1033.1989.tb15202.x; MESSING J, 1981, NUCLEIC ACIDS RES, V9, P309, DOI 10.1093/nar/9.2.309; MIYAHARA I, 1994, J BIOCHEM, V116, P1001, DOI 10.1093/oxfordjournals.jbchem.a124620; MIYAZAWA K, 1994, J BIOCHEM, V115, P568, DOI 10.1093/oxfordjournals.jbchem.a124377; MORTON A, 1995, BIOCHEMISTRY-US, V34, P8564, DOI 10.1021/bi00027a006; MURPHY KP, 1992, ADV PROTEIN CHEM, V43, P313, DOI 10.1016/S0065-3233(08)60556-2; NISHIKAWA K, 1972, J PHYS SOC JPN, V32, P1331, DOI 10.1143/JPSJ.32.1331; OKAMOTO A, 1994, J BIOCHEM, V116, P95, DOI 10.1093/oxfordjournals.jbchem.a124509; ONUFFER JJ, 1995, PROTEIN SCI, V4, P1750, DOI 10.1002/pro.5560040910; ONUFFER JJ, 1995, PROTEIN SCI, V4, P1743, DOI 10.1002/pro.5560040909; Oue S, 1997, J BIOCHEM-TOKYO, V121, P161; PERONA JJ, 1995, BIOCHEMISTRY-US, V34, P1489, DOI 10.1021/bi00005a004; PFISTER K, 1985, J BIOL CHEM, V260, P1414; PFISTER K, 1978, P NATL ACAD SCI USA, V75, P145, DOI 10.1073/pnas.75.1.145; Rader SD, 1997, PROTEIN SCI, V6, P1375, DOI 10.1002/pro.5560060701; Rhee S, 1997, J BIOL CHEM, V272, P17293, DOI 10.1074/jbc.272.28.17293; SANDBERG WS, 1991, P NATL ACAD SCI USA, V88, P1706, DOI 10.1073/pnas.88.5.1706; SERRANO L, 1992, J MOL BIOL, V224, P783, DOI 10.1016/0022-2836(92)90562-X; SEVILLE M, 1988, BIOCHEMISTRY-US, V27, P8344, DOI 10.1021/bi00422a009; SHORTLE D, 1990, BIOCHEMISTRY-US, V29, P8033, DOI 10.1021/bi00487a007; SMITH DL, 1989, BIOCHEMISTRY-US, V28, P8161, DOI 10.1021/bi00446a030; SUGINOHARA K, 1991, INT UNION B, V199, P195; Tanford C., 1980, HYDROPHOBIC EFFECT F, V2; Vacca RA, 1997, J BIOL CHEM, V272, P21932, DOI 10.1074/jbc.272.35.21932; WANGIKAR PP, 1995, BIOCHEMISTRY-US, V34, P12302, DOI 10.1021/bi00038a026; WINTER NS, 1993, J MOL BIOL, V230, P1247, DOI 10.1006/jmbi.1993.1239; Wynn R, 1997, PROTEIN SCI, V6, P1621; YANO T, 1991, J BIOL CHEM, V266, P6079; YUTANI K, 1987, P NATL ACAD SCI USA, V84, P4441, DOI 10.1073/pnas.84.13.4441	71	10	10	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18353	18364		10.1074/jbc.273.29.18353	http://dx.doi.org/10.1074/jbc.273.29.18353			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660802	hybrid			2022-12-25	WOS:000074828500057
J	Messageot, F; Carlier, D; Rossignol, JM				Messageot, F; Carlier, D; Rossignol, JM			The C terminus of the hepatitis B virus antigen precursor is required for a tunicamycin-sensitive step that promotes efficient secretion of the antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; PRECORE PROTEIN; VIRAL REPLICATION; CORE PROTEIN; INTRACELLULAR-TRANSPORT; BINDING-SPECIFICITY; SELECTIVE PROTEINS; BETA-GALACTOSIDASE; ESCHERICHIA-COLI; SIGNAL SEQUENCE	The Hepatitis B virus encodes the secreted e antigen (HBe) whose function in the viral life cycle is unknown. HBe derives from a 25-kDa precursor that is directed to the secretory pathway. After cleavage of the signal sequence, the resulting 22-kDa protein (P22) is processed in a post-endoplasmic reticulum compartment to mature HBe by removal of the 34-amino acid C-terminal domain. The efficiency of HBe secretion is specifically decreased in cells grown in the presence of tunicamycin, an inhibitor of N-glycosylation, Inasmuch as HBe precursor is not N-glycosylated, our data suggest that a cellular tunicamycin-sensitive protein increases the intracellular transport through the HBe secretory pathway. The study of the secretion of HBe derived hom C-terminal-truncated precursors demonstrates that the tunicamycin sensitive secretion absolutely requires a part of the C-terminal region that is removed to form mature HBe, indicating that the cellular tunicamycin-sensitive protein increases the efficiency of the intracellular transport of P22. We have also shown that the Escherichia coli beta-galactosidase can be secreted when fused to the HBe precursor signal sequence and that the P22 C-terminal domain renders the secretion of this reporter protein also tunicamycin-sensitive.	CNRS, UPR 9053, Lab Genet Virus, F-98118 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Rossignol, JM (corresponding author), CNRS, UPR 9053, Lab Genet Virus, Ave Terrasse, F-98118 Gif Sur Yvette, France.							Aridor M, 1996, TRENDS CELL BIOL, V6, P315, DOI 10.1016/0962-8924(96)10027-1; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; Buckwold VE, 1996, J VIROL, V70, P5845, DOI 10.1128/JVI.70.9.5845-5851.1996; CARLIER D, 1994, J GEN VIROL, V75, P171, DOI 10.1099/0022-1317-75-1-171; CARLIER D, 1995, J GEN VIROL, V76, P1041, DOI 10.1099/0022-1317-76-4-1041; CHANG C, 1987, J VIROL, V61, P3322, DOI 10.1128/JVI.61.10.3322-3325.1987; CHEN HS, 1992, J VIROL, V66, P5682, DOI 10.1128/JVI.66.9.5682-5684.1992; DORNER AJ, 1994, BIOLOGICALS, V22, P103, DOI 10.1006/biol.1994.1016; DORNER AJ, 1992, EMBO J, V11, P1563, DOI 10.1002/j.1460-2075.1992.tb05201.x; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GANEM D, 1996, VIROLOGY, P2703; GARCIA PD, 1988, J CELL BIOL, V106, P1093, DOI 10.1083/jcb.106.4.1093; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Guidotti LG, 1996, J VIROL, V70, P7056, DOI 10.1128/JVI.70.10.7056-7061.1996; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HARRISON T, 1977, VIROLOGY, V77, P319, DOI 10.1016/0042-6822(77)90428-7; Herbert Daniel N., 1995, Cell, V81, P425; HERMAN GE, 1986, NUCLEIC ACIDS RES, V14, P7130, DOI 10.1093/nar/14.17.7130; HOLLINGER FB, 1996, VIROLOGY, P2738; JACOBSON RH, 1994, NATURE, V369, P761, DOI 10.1038/369761a0; JEANJEAN O, 1989, VIROLOGY, V170, P99, DOI 10.1016/0042-6822(89)90356-5; JUNKER M, 1987, NUCLEIC ACIDS RES, V15, P10117, DOI 10.1093/nar/15.24.10117; Klappa P, 1997, EUR J BIOCHEM, V248, P37, DOI 10.1111/j.1432-1033.1997.t01-1-00037.x; LAMBERTS C, 1993, J VIROL, V67, P3756, DOI 10.1128/JVI.67.7.3756-3762.1993; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; Muresan Z, 1998, MOL ENDOCRINOL, V12, P458, DOI 10.1210/me.12.3.458; PELHAM HRB, 1995, CURR OPIN CELL BIOL, V7, P530, DOI 10.1016/0955-0674(95)80010-7; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Scaglioni PP, 1997, J VIROL, V71, P345, DOI 10.1128/JVI.71.1.345-353.1997; SCHLICHT HJ, 1987, J VIROL, V61, P3701, DOI 10.1128/JVI.61.12.3701-3709.1987; SCHLICHT HJ, 1991, J VIROL, V65, P3489, DOI 10.1128/JVI.65.7.3489-3495.1991; SCHLICHT HJ, 1991, J VIROL, V65, P6817, DOI 10.1128/JVI.65.12.6817-6825.1991; SCHODEL F, 1993, J BIOL CHEM, V268, P1332; TONG S, 1991, VIROLOGY, V181, P733, DOI 10.1016/0042-6822(91)90908-T; WANG J, 1991, J VIROL, V65, P5080, DOI 10.1128/JVI.65.9.5080-5083.1991; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; WASENAUER G, 1992, J VIROL, V66, P5338, DOI 10.1128/JVI.66.9.5338-5346.1992	43	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18594	18598		10.1074/jbc.273.29.18594	http://dx.doi.org/10.1074/jbc.273.29.18594			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660831	hybrid			2022-12-25	WOS:000074828500086
J	Adamski, FM; Zhu, MY; Bahiraei, F; Shieh, BH				Adamski, FM; Zhu, MY; Bahiraei, F; Shieh, BH			Interaction of eye protein kinase C and INAD in Drosophila - Localization of binding domains and electrophysiological characterization of a loss of association in transgenic flies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INVERTEBRATE PHOTORECEPTORS; TRANSDUCTION; GENE; MECHANISMS; RECOVERY; TRP	Drosophila eye-specific protein kinase C (eye-PKC) is involved in light adaptation and deactivation. eye-PKC, NORPA (phospholipase CP), and transient-receptor-potential (TRP) (calcium channel) are integral components of a signal transduction complex organized by INAD, a protein containing five PDZ domains. We previously demonstrated the direct association between the third PDZ domain of INAD with TRP in addition to the carboxyl-terminal half of INAD with the last three residues of NORPA. In this work, the molecular interaction between eye-PKC and INAD is defined via the yeast two-hybrid and ligand overlay assays, We show that the second PDZ domain of INAD interacts with the last three residues in the carboxyl-terminal tail of eye-PKC, Thr-Ile-Ile. The association between eye PKC and INAD is disrupted by an amino acid substitution (Ile-700 to Asp) at the final residue of eye-PKC. In flies lacking endogenous eye-PKC (inaC(p215)), normal visual physiology is restored upon expression of wild-type eye-PKC, whereas the eye-PKCI700D mutant is completely inactive. Flies homozygous for inaC(p209) and InaD(p215), a mutation that causes a loss of the INAD-TRP association, were generated. These double mutants display a more severe response inactivation than either of the single mutants. Based on these findings, we conclude that the in vivo activity of eye-PKC depends on its association with INAD and that the sensitivity of photoreceptors is cooperatively regulated by the presence of both eye-PKC and TRP in the signaling complex.	Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Ctr Mol Neurosci, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Shieh, BH (corresponding author), Vanderbilt Univ, Dept Pharmacol, 402 Med Res Bldg 1, Nashville, TN 37232 USA.	shiehb@ctrvax.vanderbilt.edu			NATIONAL EYE INSTITUTE [R01EY009743] Funding Source: NIH RePORTER; NEI NIH HHS [EY09743] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Acharya JK, 1997, NEURON, V18, P881, DOI 10.1016/S0896-6273(00)80328-1; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; COSENS D, 1972, J INSECT PHYSIOL, V18, P627, DOI 10.1016/0022-1910(72)90190-4; DEER JLR, 1995, J BIOL CHEM, V270, P12623, DOI 10.1074/jbc.270.21.12623; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GOLEMIS EA, 1996, CURRENT PROTOCOLS MO, V33; Hardie RC, 1996, J NEUROSCI, V16, P2924; HARDIE RC, 1993, TRENDS NEUROSCI, V16, P371, DOI 10.1016/0166-2236(93)90095-4; HILLMAN P, 1983, PHYSIOL REV, V63, P668, DOI 10.1152/physrev.1983.63.2.668; Huber A, 1996, J BIOL CHEM, V271, P11710, DOI 10.1074/jbc.271.20.11710; Niemeyer BA, 1996, CELL, V85, P651, DOI 10.1016/S0092-8674(00)81232-5; RANGANATHAN R, 1995, ANNU REV NEUROSCI, V18, P283; RANGANATHAN R, 1994, NEURON, V13, P837, DOI 10.1016/0896-6273(94)90250-X; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SELINGER Z, 1993, BIOCHIM BIOPHYS ACTA, V1179, P283, DOI 10.1016/0167-4889(93)90084-3; SHIEH BH, 1995, NEURON, V14, P201, DOI 10.1016/0896-6273(95)90255-4; Shieh BH, 1997, P NATL ACAD SCI USA, V94, P12682, DOI 10.1073/pnas.94.23.12682; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; SMITH DP, 1991, SCIENCE, V254, P1478, DOI 10.1126/science.1962207; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Thummel CS, 1992, DROS INF SERV, V71, P150; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; YARFITZ S, 1994, J BIOL CHEM, V269, P14329	31	53	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17713	17719		10.1074/jbc.273.28.17713	http://dx.doi.org/10.1074/jbc.273.28.17713			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651370	Green Submitted, hybrid			2022-12-25	WOS:000074816100063
J	Baxter, BK; Smerdon, MJ				Baxter, BK; Smerdon, MJ			Nucleosome unfolding during DNA repair in normal and xeroderma pigmentosum (Group C) human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENTATION GROUP-C; TRANSCRIPTIONALLY ACTIVE CHROMATIN; EXCISION-REPAIR; HUMAN-FIBROBLASTS; AFFINITY-CHROMATOGRAPHY; REARRANGEMENT INVITRO; STRUCTURAL-CHANGES; PYRIMIDINE DIMERS; YEAST; PROTEIN	The fate of nucleosomes during nucleotide excision repair is unclear. We have used organomercurial chromatography to capture accessible thiol groups of proteins at (or near) nascent repair sites in normal and xeroderma pigmentosum (group C) human cells. The reactive groups include cysteine 110 of histone H3, which is exposed in unfolded nucleosomes. Immediately after UV irradiation and a short pulse labeling of repair patches, intact nuclei were digested with restriction enzymes to release similar to 18% of the chromatin into soluble fragments, which are enriched (similar to 4-fold) in a constitutively transcribed gene. Upon organomercurial affinity fractionation, similar to 1.8% of the soluble chromatin remains bound in high salt (0.5 M NaCl) and is released with dithiothreitol. In normal cell chromatin, this fraction is enriched in nascent repair patches (1.5-1.8 fold) over the unbound fraction. This enrichment decreases following short chase periods with a time course similar to the loss of enhanced nuclease sensitivity of these regions (t 1/2 approximate to 30 min). Much less enrichment of nascent repair patches is observed in the thiol-reactive fraction from XPC cells, which repair primarily the transcribed strand of active genes. These results suggest that transient nucleosome unfolding occurs during nucleotide excision repair in normal human cells, and this unfolding may require the XPC protein.	Washington State Univ, Dept Biochem & Biophys, Pullman, WA 99164 USA	Washington State University	Smerdon, MJ (corresponding author), Washington State Univ, Dept Biochem & Biophys, POB 644660, Pullman, WA 99164 USA.	smerdon@mail.wsu.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES002614, R01ES002614, F32ES005699] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES02614, ES05699] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; ALLFREY VG, 1991, METHOD CELL BIOL, V35, P315; BASSETJONES DP, 1996, NUCLEIC ACIDS RES, V24, P321; BOFFA LC, 1992, MOL CARCINOGEN, V5, P174, DOI 10.1002/mc.2940050303; CHEN TA, 1991, J BIOL CHEM, V266, P6489; CHEN TA, 1987, P NATL ACAD SCI USA, V84, P5252, DOI 10.1073/pnas.84.15.5252; CHENCLELAND TA, 1993, J BIOL CHEM, V268, P1118; CHENCLELAND TA, 1993, J BIOL CHEM, V268, P23409; Cleaver JE, 1989, METABOLIC BASIS INHE, V6th, P2949; ELGIN SCR, 1995, CHROMATIN STRUCTURE; Evans E, 1997, EMBO J, V16, P6559, DOI 10.1093/emboj/16.21.6559; Friedberg EC, 1996, ANNU REV BIOCHEM, V65, P15; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENSI; Fritz LK, 1996, J BIOL CHEM, V271, P12972, DOI 10.1074/jbc.271.22.12972; FRITZ LK, 1994, THESIS WASHINGTON ST; Gaillard PHL, 1996, CELL, V86, P887, DOI 10.1016/S0092-8674(00)80164-6; GALE JM, 1988, BIOCHEMISTRY-US, V27, P949; HARLESS J, 1987, MUTAT RES, V183, P177, DOI 10.1016/0167-8817(87)90060-5; HUIJZER JC, 1992, BIOCHEMISTRY-US, V31, P5077, DOI 10.1021/bi00136a021; HUNTING DJ, 1985, BIOCHEMISTRY-US, V24, P3219, DOI 10.1021/bi00334a022; JENSEN KA, 1990, BIOCHEMISTRY-US, V29, P4773, DOI 10.1021/bi00472a005; KANTOR GJ, 1990, MUTAT RES, V235, P171, DOI 10.1016/0921-8777(90)90071-C; LEWIS B, 1997, GENES, V6, P650; LEYS EJ, 1981, MOL CELL BIOL, V1, P961, DOI 10.1128/MCB.1.11.961; LIEBERMAN MW, 1979, ENV CARCINOGENESIS, P345; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; Mu D, 1997, J BIOL CHEM, V272, P7570, DOI 10.1074/jbc.272.12.7570; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; MULLENDERS LHF, 1988, NUCLEIC ACIDS RES, V16, P10607, DOI 10.1093/nar/16.22.10607; NISSEN KA, 1986, J BIOL CHEM, V261, P8585; PARRISH DD, 1992, MUTAT RES, V273, P157, DOI 10.1016/0921-8777(92)90077-G; PARRISH DD, 1990, MUTAT RES, V235, P65, DOI 10.1016/0921-8777(90)90059-E; PARRISH DD, 1992, BIOCHEM BIOPH RES CO, V189, P782, DOI 10.1016/0006-291X(92)92270-8; RAMANATHAN B, 1989, J BIOL CHEM, V264, P11026; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SHIVJI MKK, 1994, J BIOL CHEM, V269, P22749; SMERDON MJ, 1989, NATO ADV SCI I A-LIF, V182, P271; SMERDON MJ, 1979, BIOCHEMISTRY-US, V18, P3732, DOI 10.1021/bi00584a014; SMERDON MJ, 1986, J BIOL CHEM, V261, P244; SMERDON MJ, 1978, P NATL ACAD SCI USA, V75, P4238, DOI 10.1073/pnas.75.9.4238; SMERDON MJ, 1982, J BIOL CHEM, V257, P13441; SMERDON MJ, 1982, BIOCHEMISTRY-US, V21, P3879, DOI 10.1021/bi00259a024; SMERDON MJ, 1998, IN PRESS DNA DAMAGE; SMERDON MJ, 1998, IN PRESS PROGR NUCL; SOGO JM, 1995, CHROMATIN STRUCTURE, P49; Studitsky VM, 1997, SCIENCE, V278, P1960, DOI 10.1126/science.278.5345.1960; Sugasawa K, 1996, MOL CELL BIOL, V16, P4852; SUQUET C, 1995, J BIOL CHEM, V270, P16507, DOI 10.1074/jbc.270.28.16507; THOMA F, 1991, TRENDS GENET, V7, P175, DOI 10.1016/0168-9525(91)90429-T; van Holde KE., 1989, SPRINGER SERIES MOL; vanHolde K, 1996, P NATL ACAD SCI USA, V93, P10548, DOI 10.1073/pnas.93.20.10548; VANHOLDE KE, 1992, J BIOL CHEM, V267, P2837; VENEMA J, 1990, NUCLEIC ACIDS RES, V18, P443, DOI 10.1093/nar/18.3.443; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; WALKER J, 1990, J BIOL CHEM, V265, P5736; WANG YC, 1993, MOL CELL BIOL, V13, P4276, DOI 10.1128/MCB.13.7.4276; WATKINS JF, 1985, BIOCHEMISTRY-US, V24, P7279, DOI 10.1021/bi00346a039; WATKINS JF, 1985, BIOCHEMISTRY-US, V24, P7288, DOI 10.1021/bi00346a040; Wolffe A., 1995, CHROMATIN STRUCTURE	59	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17517	17524		10.1074/jbc.273.28.17517	http://dx.doi.org/10.1074/jbc.273.28.17517			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651343	hybrid			2022-12-25	WOS:000074816100036
J	Leppanen, A; Zhu, Y; Maaheimo, H; Helin, J; Lehtonen, E; Renkonen, O				Leppanen, A; Zhu, Y; Maaheimo, H; Helin, J; Lehtonen, E; Renkonen, O			Biosynthesis of branched polylactosaminoglycans - Embryonal carcinoma cells express midchain beta 1,6-N-acetylglucosaminyltransferase activity that generates branches to preformed linear backbones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-GROUP-I; WHEAT-GERM-AGGLUTININ; HUMAN-SERUM; N-ACETYLLACTOSAMINOGLYCANS; GASTRIC-MUCOSA; LACTOSAMINOGLYCAN; IDENTIFICATION; ANTIGENS; PA1	Two types of beta 1,6-GlcNAc transferases (IGnT6) are involved in in vitro branching of polylactosamines: dIGnT6 (distally acting), transferring to the penultimate galactose residue in accepters like GlcNAc beta 1-3Gal beta 1-4GlcNAc beta 1- R, and cIGnT6 (centrally acting), transferring to the midchain galactoses in accepters of the type (GlcNAc beta 1-3)Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4GlcNAc beta 1-R. The roles of the two transferases in the biosynthesis of branched polylactosamine backbones have not been clearly elucidated. We report here that cIGnT6 activity is expressed in human (PA1) and murine (PC13) embryonal carcinoma (EC) cells, both of which contain branched polylactosamines in large amounts. In the presence of exogenous UDP-GlcNAc, lysates from both EC cells catalyzed the formation of the branched pentasaccharide Gal beta 1-4GlcNAc beta 1-3(GlcNAc beta 1-6)Gal beta 1-4GlcNAc from the linear tetrasaccharide Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4GlcNAc. The PA1 cell lysates were shown to also catalyze the formation of the branched heptasaccharides Gal beta 1-4G1cNAc beta 1-3Gal beta 1-4GlcNAc beta 1-3(GlcNAc beta 1-6)Gal beta 1-4GlcNAc and Gal beta 1-4GlcNAc-beta 1-3(GlcNAc beta 1-6) Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4GlcNAc from the linear hexasaccharide Galpl-LiGlcNAcpl3Galpl-4GlcNAcpl3GalP1-4GlcNAc in reactions characteristic to cIGnT6, By contrast, dIGnT6 activity was not detected in the lysates of the two EC cells that were incubated with UDP-GlcNAc and the acceptor trisaccharide GlcNAc beta 1-3Gal beta 1-4GlcNAc. Hence, it appears likely that cIGnT6, rather than dIGnT6 is responsible for the synthesis of the branched polylactosamine chains in these cells.	Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland; Univ Helsinki, Dept Biosci, FIN-00014 Helsinki, Finland; Univ Helsinki, Haartman Inst, Div Pathol, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki; University of Helsinki	Renkonen, O (corresponding author), Univ Helsinki, Inst Biotechnol, POB 56, FIN-00014 Helsinki, Finland.		Lehtonen, Eero/AGJ-4027-2022	Lehtonen, Eero/0000-0002-8218-635X				BERNSTINE EG, 1973, P NATL ACAD SCI USA, V70, P3893; BIERHUIZEN MFA, 1993, GENE DEV, V7, P468, DOI 10.1101/gad.7.3.468; BIERHUIZEN MFA, 1994, TRENDS GLYCOSCI GLYC, V6, P17; BROCKHAUSEN I, 1986, EUR J BIOCHEM, V157, P463, DOI 10.1111/j.1432-1033.1986.tb09690.x; FUKUDA M, 1984, J BIOL CHEM, V259, P8260; FUKUDA M, 1979, J BIOL CHEM, V254, P3700; FUKUDA MN, 1985, J BIOL CHEM, V260, P6623; GU J, 1992, J BIOL CHEM, V267, P2994; Helin J, 1997, FEBS LETT, V412, P637, DOI 10.1016/S0014-5793(97)00818-1; KINLOCH RA, 1991, J CELL BIOL, V115, P655, DOI 10.1083/jcb.115.3.655; KOENDERMAN AHL, 1987, EUR J BIOCHEM, V166, P199, DOI 10.1111/j.1432-1033.1987.tb13502.x; LEHTONEN E, 1983, EXP CELL RES, V144, P191, DOI 10.1016/0014-4827(83)90453-6; Leppanen A, 1997, BIOCHEMISTRY-US, V36, P7026, DOI 10.1021/bi9627673; LEPPANEN A, 1991, BIOCHEMISTRY-US, V30, P9287, DOI 10.1021/bi00102a022; Maaheimo H, 1997, CARBOHYD RES, V297, P145, DOI 10.1016/S0008-6215(96)00259-5; Naven TJP, 1996, RAPID COMMUN MASS SP, V10, P1361, DOI 10.1002/(SICI)1097-0231(199608)10:11<1361::AID-RCM642>3.0.CO;2-A; Niemela R, 1995, CARBOHYD RES, V279, P331, DOI 10.1016/0008-6215(95)00299-5; PILLER F, 1984, J BIOL CHEM, V259, P3385; RASILO ML, 1982, EUR J BIOCHEM, V123, P397, DOI 10.1111/j.1432-1033.1982.tb19782.x; RENKONEN O, 1983, BIOCHEM SOC T, V11, P265, DOI 10.1042/bst0110265; RENKONEN O, 1991, GLYCOCONJUGATE J, V8, P361, DOI 10.1007/BF00731349; Renkonen O, 1997, GLYCOBIOLOGY, V7, P453, DOI 10.1093/glycob/7.4.453-c; ROPP PA, 1991, J BIOL CHEM, V266, P23863; SABESAN S, 1992, J AM CHEM SOC, V114, P8363, DOI 10.1021/ja00048a004; SCUDDER P, 1984, J BIOL CHEM, V259, P6586; SEPPO A, 1995, BIOCHEMISTRY-US, V34, P4655, DOI 10.1021/bi00014a019; SEPPO A, 1990, BIOCHEM CELL BIOL, V68, P44, DOI 10.1139/o90-006; VILKMAN A, 1992, CARBOHYD RES, V226, P155, DOI 10.1016/0008-6215(92)84061-V; WATANABE K, 1979, J BIOL CHEM, V254, P3221; YATES AD, 1983, CARBOHYD RES, V120, P251, DOI 10.1016/0008-6215(83)88020-3; ZEUTHEN J, 1980, INT J CANCER, V25, P19, DOI 10.1002/ijc.2910250104	31	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17399	17405		10.1074/jbc.273.28.17399	http://dx.doi.org/10.1074/jbc.273.28.17399			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651325	hybrid			2022-12-25	WOS:000074816100018
J	Scotet, E; Houssaint, E				Scotet, E; Houssaint, E			Exon III splicing switch of fibroblast growth factor (FGF) receptor-2 and -3 can be induced by FGF-1 or FGF-2	ONCOGENE			English	Article						fibroblast growth factor receptor; fibroblast growth factor; splicing switch; epithelio-mesenchymal conversion	LIGAND-BINDING; SIGNAL TRANSDUCTION; MESSENGER-RNA; CELLS; GENE; ACTIVATION; PROTEINS; FAMILY; TRANSLOCATION; TRANSCRIPTION	An essential feature of fibroblast growth factor receptors (FGFRs) is the existence of multiple possibilities of alternative splicing. One of these concerns sequences of the mRNA coding for the C-terminal half of Ig domain 3 which corresponds to a part of the ligand-binding site: two alternative exons, IIIb and IIIc, encode the C-terminal half of Ig domain 3. The IIIb/lIIc choice in the FGFR-2 and FGFR-3 is strictly tissue-specific, the IIIb exon being expressed exclusively in epithelial cells. We describe here a reversible switch from IIIb to IIIc for FGFR-2 and FGFR-3 under the influence of exogenous and endogenous FGF-1 or FGF-2. We observed that EGF-induced FGF receptor exon switching (i) occurred as early as Ih after exposure to FGF (ii) was receptor-mediated (iii) was dependent on cell confluency and showed a link with the cell cycle (iv) was correlated with a reversible loss of epithelial properties. These results support a role for FGF in the regulation of expression of alternatively spliced FGFR mRNA.	Inst Biol, INSERM, U463, F-44035 Nantes 01, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Houssaint, E (corresponding author), Inst Biol, INSERM, U463, 9 Quai Moncousu, F-44035 Nantes 01, France.		SCOTET, Emmanuel/L-2576-2015; SCOTET, Emmanuel/AAC-9971-2019	SCOTET, Emmanuel/0000-0001-8010-9556; SCOTET, Emmanuel/0000-0001-8010-9556				BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P979; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COWIN P, 1985, J CELL BIOL, V101, P1442, DOI 10.1083/jcb.101.4.1442; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; HALLEY C, 1988, NUCLEIC ACIDS RES, V16, P10913, DOI 10.1093/nar/16.22.10913; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; HOUSSAINT E, 1990, P NATL ACAD SCI USA, V87, P8180, DOI 10.1073/pnas.87.20.8180; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOUANNEAU J, 1991, P NATL ACAD SCI USA, V88, P2893, DOI 10.1073/pnas.88.7.2893; KIEFER P, 1995, MOL CELL BIOL, V15, P4364; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MIGDAL M, 1995, J CELL PHYSIOL, V162, P266, DOI 10.1002/jcp.1041620212; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; NAKANISHI Y, 1992, P NATL ACAD SCI USA, V89, P5216, DOI 10.1073/pnas.89.12.5216; Oliver L, 1992, GROWTH FACTORS, V7, P97, DOI 10.3109/08977199209046399; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; Prudovsky IA, 1996, J BIOL CHEM, V271, P14198, DOI 10.1074/jbc.271.24.14198; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; SAVAGNER P, 1994, MOL BIOL CELL, V5, P851, DOI 10.1091/mbc.5.8.851; SCOTET E, 1995, ONCOL REP, V2, P203; VAINIKKA S, 1992, EMBO J, V11, P4273, DOI 10.1002/j.1460-2075.1992.tb05526.x; VALLES AM, 1990, P NATL ACAD SCI USA, V87, P1124, DOI 10.1073/pnas.87.3.1124; Wennstrom S, 1991, GROWTH FACTORS, V4, DOI 10.3109/08977199109104816; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x; ZHAN X, 1992, BIOCHEM BIOPH RES CO, V188, P982, DOI 10.1016/0006-291X(92)91328-N	39	25	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 9	1998	17	1					67	76		10.1038/sj.onc.1201908	http://dx.doi.org/10.1038/sj.onc.1201908			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZY936	9671315				2022-12-25	WOS:000074677800008
J	Johnstone, RW; Kerry, JA; Trapani, JA				Johnstone, RW; Kerry, JA; Trapani, JA			The human interferon-inducible protein, IFI 16, is a repressor of transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR DIFFERENTIATION ANTIGEN; TUMOR-SUPPRESSOR PROTEIN; RETINOBLASTOMA PROTEIN; GENE; ACTIVATION; P202; LOCALIZATION; INHIBITION; BINDING; CLUSTER	IFI 16 is a member of a family of interferon-inducible proteins, including the human MNDA (myeloid nuclear differentiation antigen), the recently identified AIM-S (absent in melanoma), and the homologous murine molecules, p202, p204, and D3. IFI 16 contains a domain at the amino terminus capable of binding double-stranded DNA and a bipartite nuclear localization signal. No molecular or biological function has been assigned to any of the human family members, although a role in transcription regulation has been proposed. In the present study, we show IFI 16 fused to the GAL4 DNA binding domain can function as a transcriptional repressor. IFI 16-mediated repression is not dependent on the position or distance of IFI 16 binding, relative to the site of transcription initiation, and it can significantly repress when only one GAL4 DNA element is present in the promoter. We mapped the transcriptional repression domains to the 200 amino acid repeat regions common to all human and mouse family members. We also demonstrate that wild type IFI 16 can repress transcription of a reporter gene containing the minimal promoter region of the human cytomegalovirus UL54 gene. Thus, IFI 16 is a transcriptional repressor, with a modular structure typical of many known transcription regulators.	Austin Hosp, Austin Res Inst, Heidelberg, Vic 3084, Australia; Eastern Virginia Med Sch, Dept Microbiol & Immunol, Norfolk, VA 23501 USA	Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Eastern Virginia Medical School	Johnstone, RW (corresponding author), Austin Hosp, Austin Res Inst, Studley Rd, Heidelberg, Vic 3084, Australia.	r.johnstone@ari.unimelb.edu.au	Johnstone, Ricky w/H-3748-2014	Johnstone, Ricky w/0000-0001-7053-9237; Trapani, Joseph/0000-0003-0983-1532				AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BURRUS GR, 1992, J CELL BIOCHEM, V48, P190, DOI 10.1002/jcb.240480210; CHOUBEY D, 1992, J CELL BIOL, V116, P1333, DOI 10.1083/jcb.116.6.1333; Choubey D, 1996, EMBO J, V15, P5668, DOI 10.1002/j.1460-2075.1996.tb00951.x; CHOUBEY D, 1989, J BIOL CHEM, V264, P17182; CHOUBEY D, 1993, J INTERFERON RES, V13, P43, DOI 10.1089/jir.1993.13.43; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; Datta B, 1996, J BIOL CHEM, V271, P27544, DOI 10.1074/jbc.271.44.27544; DAWSON MJ, 1995, BIOCHEM BIOPH RES CO, V214, P152, DOI 10.1006/bbrc.1995.2269; DAWSON MJ, 1995, IMMUNOGENETICS, V41, P40, DOI 10.1007/BF00188431; Dawson MJ, 1996, J LEUKOCYTE BIOL, V60, P310, DOI 10.1002/jlb.60.3.310; DeYoung KL, 1997, ONCOGENE, V15, P453, DOI 10.1038/sj.onc.1201206; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUHL DM, 1989, J CELL PHYSIOL, V141, P148, DOI 10.1002/jcp.1041410122; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KERRY JA, 1994, J VIROL, V68, P4167, DOI 10.1128/JVI.68.7.4167-4176.1994; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; Luu P, 1997, J VIROL, V71, P6683, DOI 10.1128/JVI.71.9.6683-6691.1997; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; MADDEN SL, 1993, ONCOGENE, V8, P1713; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Min W, 1996, MOL CELL BIOL, V16, P359; NESS SA, 1994, CURR OPIN GENET DEV, V4, P718, DOI 10.1016/0959-437X(94)90139-T; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0	33	66	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17172	17177		10.1074/jbc.273.27.17172	http://dx.doi.org/10.1074/jbc.273.27.17172			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642285	hybrid			2022-12-25	WOS:000074545200075
J	Trink, B; Pai, SI; Spunt, SL; Raman, V; Cairns, P; Jen, J; Gabrielson, E; Sukumar, S; Sidransky, D				Trink, B; Pai, SI; Spunt, SL; Raman, V; Cairns, P; Jen, J; Gabrielson, E; Sukumar, S; Sidransky, D			Absence of TSG101 transcript abnormalities in human cancers	ONCOGENE			English	Article						breast cancer; Wilms' tumor; TSG101; RT-PCR	FHIT GENE; EXPRESSION; 3P14.2	The human TSG101 gene was cloned and mapped to chromosome 11p15, a site suspected to contain a tumor suppressor gene involved in a variety of human cancers. Subsequent investigation described the presence of abnormally spliced transcripts and point mutations of TSG101 in breast cancer, Thus, we performed RT-PCR amplification of the entire open reading frame of TSG101 to test for aberrant transcripts in various human tumor cell lines derived from breast, bladder, head and neck, and lung cancer. In addition, we performed RT-PCR on cDNA from primary human breast and Wilms' tumor tissue. We found a single band of the expected size in 10 of 11 breast cancers and 6 of 6 Wilms' tumor samples after the first round of PCR, The remaining breast cancer sample displayed a barely visible smaller band. However, aberrant bands appeared in most cases after performing nested PCR casting doubt on the physiologic relevance of these spliced variants, We then searched for small intragenic mutations by complete sequence analysis of TSG101 in breast cancer cell lines and tumors, as well as in Wilms' tumors and normal fetal and adult kidney, No point mutations were found in any of the samples, including four breast tumors with chormosomal loss at 11p15, We found no consistent evidence of aberrant splicing or point mutations in breast cancer or Wilms' tumor suggesting that TSG101 is not a primary target of inactivation in human cancer.	Johns Hopkins Univ, Dept Otolaryngol Head & Neck Surg, Div Head & Neck Canc Res, Baltimore, MD 21205 USA; Johns Hopkins Univ, Ctr Oncol, Breast Canc Program, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Sidransky, D (corresponding author), Johns Hopkins Univ, Dept Otolaryngol Head & Neck Surg, Div Head & Neck Canc Res, Baltimore, MD 21205 USA.			Spunt, Sheri/0000-0002-1669-2676; Pai, Sara/0000-0002-6341-9971				BRATTSAND G, 1993, LEUKEMIA, V7, P569; Feinberg AP, 1996, MED PEDIATR ONCOL, V27, P484; Haber D, 1997, NAT GENET, V16, P320, DOI 10.1038/ng0897-320; HANASH SM, 1988, J BIOL CHEM, V263, P12813; Lee MP, 1997, CANCER RES, V57, P3131; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Li LM, 1997, CELL, V88, P143, DOI 10.1016/S0092-8674(00)81866-8; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; MAUCUER A, 1995, P NATL ACAD SCI USA, V92, P3100, DOI 10.1073/pnas.92.8.3100; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; ROOS G, 1993, LEUKEMIA, V7, P1538; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Steiner P, 1997, NAT GENET, V16, P332, DOI 10.1038/ng0897-332; Thiagalingam S, 1996, CANCER RES, V56, P2936; Todd S, 1997, CANCER RES, V57, P1344; WINQVIST R, 1995, CANCER RES, V55, P2660	16	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	1998	16	21					2815	2818		10.1038/sj.onc.1201795	http://dx.doi.org/10.1038/sj.onc.1201795			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ013	9652749				2022-12-25	WOS:000073812200014
J	Yang, WP; Levesque, PC; Little, WA; Conder, ML; Ramakrishnan, P; Neubauer, MG; Blanar, MA				Yang, WP; Levesque, PC; Little, WA; Conder, ML; Ramakrishnan, P; Neubauer, MG; Blanar, MA			Functional expression of two KvLQT1-related potassium channels responsible for an inherited idiopathic epilepsy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHARYBDOTOXIN; INHIBITOR; K(V)LQT1; PROTEINS; FORM	Benign familial neonatal convulsions (BFNC), a class of idiopathic generalized epilepsy, is an autosomal dominantly inherited disorder of newborns. BFNC has been linked to mutations in two putative K+ channel genes, KCNQ2 and KCNQ3, Amino acid sequence comparison reveals that both genes share strong homology to KvLQT1, the potassium channel encoded by KCHQ1, which is responsible for over 50% of inherited long QT syndrome. Here we describe the cloning, functional expression, and characterization of K+ channels encoded by KCNQ2 and KCNQ3 cDNAs, Individually, expression of KCNQ2 or KCNQ3 in Xenopus oocytes elicits voltage-gated, rapidly activating K+-selective currents similar to KCNQ1, However, unlike KCNQ1, KCNQ2 and KCNQ3 currents are not augmented by coexpression with the KCNQ1 beta subunit, KCNE1 (minK, IsK). Northern blot analyses reveal that KCNQ2 and KCNQ3 exhibit similar expression patterns in different regions within the brain. Interestingly, coexpression of KCNQ2 and KCNQ3 results in a substantial synergistic increase in current amplitude. Coexpression of KCNE1 with the two channels strongly suppressed current amplitude and slowed kinetics of activation. The pharmacological and biophysical properties of the K+ currents observed in the coinjected oocytes differ somewhat from those observed after injecting either KCNQ2 or KCNQ3 by itself. The functional interaction between KCNQ2 and KCNQ3 provides a framework for understanding how mutations in either channel can cause a form of idiopathic generalized epilepsy.	Bristol Myers Squibb Pharmaceut Res Inst, Dept Cardiovasc Drug Discovery, Princeton, NJ 08543 USA; Bristol Myers Squibb Pharmaceut Res Inst, Dept Appl Genom, Princeton, NJ 08543 USA	Bristol-Myers Squibb; Bristol-Myers Squibb	Blanar, MA (corresponding author), Bristol Myers Squibb Pharmaceut Res Inst, Dept Cardiovasc Drug Discovery, Mail Code F12-01,Route 206 & Provinceline Rd, Princeton, NJ 08543 USA.							Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Biervert C, 1998, SCIENCE, V279, P403, DOI 10.1126/science.279.5349.403; Charlier C, 1998, NAT GENET, V18, P53, DOI 10.1038/ng0198-53; Chouabe C, 1997, EMBO J, V16, P5472, DOI 10.1093/emboj/16.17.5472; Deal KK, 1996, PHYSIOL REV, V76, P49, DOI 10.1152/physrev.1996.76.1.49; MILLER C, 1985, NATURE, V313, P316, DOI 10.1038/313316a0; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; Shalaby FY, 1997, CIRCULATION, V96, P1733, DOI 10.1161/01.CIR.96.6.1733; Singh NA, 1998, NAT GENET, V18, P25, DOI 10.1038/ng0198-25; Snyder AP, 1996, FIELD ANAL CHEM TECH, V1, P49; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; SUGG EE, 1990, J BIOL CHEM, V265, P18745; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; Yang WP, 1997, P NATL ACAD SCI USA, V94, P4017, DOI 10.1073/pnas.94.8.4017	14	161	170	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19419	19423		10.1074/jbc.273.31.19419	http://dx.doi.org/10.1074/jbc.273.31.19419			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677360	hybrid			2022-12-25	WOS:000075125200012
J	Asker, N; Axelsson, MAB; Olofsson, SO; Hansson, GC				Asker, N; Axelsson, MAB; Olofsson, SO; Hansson, GC			Dimerization of the human MUC2 mucin in the endoplasmic reticulum is followed by a N-glycosylation-dependent transfer of the mono- and dimers to the Golgi apparatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR; INTESTINAL MUCIN; O-GLYCOSYLATION; CELLS; BIOSYNTHESIS; RAT; LIPOPROTEINS; OLIGOMERIZATION; IDENTIFICATION; SECRETION	Pulse-chase experiments in the colon cell line LS 174T combined with subcellular fractionation by sucrose density gradient centrifugation showed that the initial dimerization of the MUC2 apomucin started directly after translocation of the apomucin into the rough endoplasmic reticulum as detected by calnexin reactivity. As the mono- and dimers were chased, O-glycosylated MUC2 mono- and dimers were precipitated using an O-glycosylation-insensitive antiserum against the N-terminal domain of the MUC2 mucin. These O-glycosylated species were precipitated from the fractions that comigrated with the galactosyltransferase activity during the subcellular fractionation, indicating that not only MUC2 dimers but also a significant amount of monomers are transferred into the Golgi apparatus. Inhibition of N-glycosylation with tunicamycin treatment slowed down the rate of dimerization and introduced further oligomerization of the MUC2 apomucin in the endoplasmic reticulum, Results of two-dimensional gel electrophoresis demonstrated that these oligomers (putative tri- and tetramers) were stabilized by disulfide bonds. The non-N-glycosylated species of the MUC2 mucin were retained in the endoplasmic reticulum because no O-glycosylated species were precipitated after inhibition by tunicamycin. This suggests that N-glycans of MUC2 are necessary for the correct folding and dimerization of the MUC2 mucin.	Gothenburg Univ, Dept Med Biochem, S-41390 Gothenburg, Sweden	University of Gothenburg	Hansson, GC (corresponding author), Gothenburg Univ, Dept Med Biochem, Med Gatan 9A, S-41390 Gothenburg, Sweden.		Hansson, Gunnar C./AAF-7324-2019; Hansson, Gunnar C/A-1236-2009	Hansson, Gunnar C./0000-0002-1900-1869; Hansson, Gunnar C/0000-0002-1900-1869				ASKER N, 1995, BIOCHEM J, V308, P873, DOI 10.1042/bj3080873; Axelsson MAB, 1998, J BIOL CHEM, V273, P18864, DOI 10.1074/jbc.273.30.18864; BOREN J, 1990, J BIOL CHEM, V265, P10556; BOREN J, 1994, J BIOL CHEM, V269, P25879; BOSTROM K, 1986, J BIOL CHEM, V261, P3800; DEKKER J, 1989, J BIOL CHEM, V264, P10431; DEKKER J, 1990, J BIOL CHEM, V265, P18116; Forstner Janet F., 1994, P1255; GUM JR, 1992, J BIOL CHEM, V267, P21375; GUM JR, 1994, J BIOL CHEM, V269, P2440; KLOMP LWJ, 1994, BIOCHEM J, V304, P737, DOI 10.1042/bj3040737; KLOMP LWJ, 1994, BIOCHEM J, V304, P693, DOI 10.1042/bj3040693; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCCOOL DJ, 1994, BIOCHEM J, V302, P111, DOI 10.1042/bj3020111; MCEWEN CR, 1967, ANAL BIOCHEM, V20, P114, DOI 10.1016/0003-2697(67)90271-0; OHARA S, 1994, BIOCHEM J, V297, P509, DOI 10.1042/bj2970509; PerezVilar J, 1996, J BIOL CHEM, V271, P9845, DOI 10.1074/jbc.271.16.9845; RUGGERI ZM, 1993, FASEB J, V7, P308, DOI 10.1096/fasebj.7.2.8440408; STROUS GJ, 1992, CRIT REV BIOCHEM MOL, V27, P57, DOI 10.3109/10409239209082559; WAGNER DD, 1986, J CELL BIOL, V102, P1320, DOI 10.1083/jcb.102.4.1320; WAGNER DD, 1984, J CELL BIOL, V99, P2123, DOI 10.1083/jcb.99.6.2123; YAO ZM, 1991, J BIOL CHEM, V266, P3300	22	105	106	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18857	18863		10.1074/jbc.273.30.18857	http://dx.doi.org/10.1074/jbc.273.30.18857			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668061	hybrid			2022-12-25	WOS:000074974700028
J	Murga, C; Laguinge, L; Wetzker, R; Cuadrado, A; Gutkind, JS				Murga, C; Laguinge, L; Wetzker, R; Cuadrado, A; Gutkind, JS			Activation of Akt/protein kinase B by G protein-coupled receptors - A role for alpha and beta gamma subunits of heterotrimeric G proteins acting through phosphatidylinositol-3-OH kinase gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT ACTIVATION; PATHWAY; CELLS; INHIBITION; APOPTOSIS; SIGNALS; AKT; RAS	The serine/threonine protein kinase Akt has recently been shown to be implicated in the pathway leading to cell survival in response to serum and growth factors in a variety of cellular systems. However, the existence of a biochemical route connecting this kinase to the large family of receptors that signal through heterotrimeric G proteins is yet to be explored. in this study, we set out to investigate whether GTP-binding protein (G protein)coupled receptors (GPCRs) can stimulate Akt activity and survival pathways and, if so, to define the mechanism(s) whereby this class of cell surface receptors could regulate Akt function. Using ectopic expression of GPCRs in COS-7 cells as a model, we have observed that both mi and m2 muscarinic acetylcholine receptors, representative of those GPCRs coupled to G, and Gi proteins, respectively, can readily activate an epitope-tagged form of Akt kinase and prevent W-induced apoptosis. We have also found that the pathway connecting G proteins to Akt implicates signals emanating from G alpha(q), G alpha(i) and beta gamma dimers, but not from G alpha(s) Or G alpha(12), in each case acting through a pathway that involves a phosphatidylinositol-3-OH kinase activity. Moreover, our findings suggest a role for a novel py-sensitive complex, p101.phosphatidylinositol-3-OH kinase-gamma, in the transduction of signals leading to Akt stimulation and cell survival by GPCRs and open new avenues for research on the function of the large family of G protein-linked receptors in the regulation of anti-apoptotic pathways.	NIDR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; Univ Jena, Fac Med, Max Planck Res Unit Mol Cell Biol, D-07747 Jena, Germany	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Friedrich Schiller University of Jena; Max Planck Society	Gutkind, JS (corresponding author), NIDR, Oral & Pharyngeal Canc Branch, NIH, 9000 Rockville Pike,Bldg 30,Rm 211, Bethesda, MD 20892 USA.		Murga, Cristina/E-1965-2014; Gutkind, J. Silvio/A-1053-2009; Wetzker, Reinhard/AAD-8713-2019; Gutkind, J. Silvio/J-1201-2016	Murga, Cristina/0000-0002-8964-4077; Gutkind, J. Silvio/0000-0002-5150-4482; Cuadrado, Antonio/0000-0002-4039-7140; Cuadrado, Antonio/0000-0002-3444-9012				BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Boudewijn MT, 1995, NATURE, V376, P599; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Coso OA, 1996, J BIOL CHEM, V271, P3963; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; Gudermann T, 1997, ANNU REV NEUROSCI, V20, P399, DOI 10.1146/annurev.neuro.20.1.399; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Kurosu H, 1997, J BIOL CHEM, V272, P24252, DOI 10.1074/jbc.272.39.24252; LEVIS MJ, 1992, J CELL BIOL, V119, P1297, DOI 10.1083/jcb.119.5.1297; LINDENBOIM L, 1995, J NEUROCHEM, V64, P2491; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PINKASKRAMARSKI R, 1990, NEUROSCI LETT, V108, P335, DOI 10.1016/0304-3940(90)90663-T; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; YAN GM, 1995, MOL PHARMACOL, V47, P248	32	291	294	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19080	19085		10.1074/jbc.273.30.19080	http://dx.doi.org/10.1074/jbc.273.30.19080			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668091	hybrid			2022-12-25	WOS:000074974700058
J	Tsai, TY; Lee, YHW				Tsai, TY; Lee, YHW			Roles of copper ligands in the activation and secretion of Streptomyces tyrosinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLAUCESCENS TYROSINASE; TRANSACTIVATOR MELC1; NEUROSPORA-CRASSA; GENE; PROTEIN; EXPRESSION; APOTYROSINASE; ANTIBIOTICUS; SEQUENCE; BINDING	The expression of the melanin operon (melC) of Streptomyces antibioticus requires the chaperone-like protein MelC1 for the incorporation of two copper ions (designated as Cu-A and Cu-B) and the secretion of the apotyrosinase (MelC2) via a transient binary complex formation between these two proteins. To: investigate whether the copper ligand of tyrosinase is involved in this MelC1 MelC2 binary complex function, six single substitution mutations were introduced into the Cu-A and CUB sites. These mutations led to differential effects on the stability, copper content, and export function of binary complexes but a complete abolishment of tyrosinase activity. The defects in the tyrosinase activity in mutants were not because of the impairment of the formation of MelC1 MelC2 complex but rather the failure of MelC2 to be discharged from the copper-activated binary complex. Moreover, the impairments on the discharge of the mutant MelC2 from all the mutant binary complexes appeared to result from the structural changes in their apoforms or copper-activated forms of the complexes, as evidenced by the fluorescence emission and circular dichroism spectral analysis. Therefore, each of six copper ligands in Streptomyces tyrosinase binuclear copper sites plays a pivotal role in the final maturation and the discharge of tyrosinase from the binary complex but has a less significant role in its secretion.	Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan	National Yang Ming Chiao Tung University	Lee, YHW (corresponding author), Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan.			Lee Wu, Yan-Hwa/0000-0001-7299-7354				BELTRAMINI M, 1982, BIOCHEM J, V205, P173, DOI 10.1042/bj2050173; BELTRAMINI M, 1982, FEBS LETT, V142, P219, DOI 10.1016/0014-5793(82)80138-5; BERNAN V, 1985, GENE, V37, P101, DOI 10.1016/0378-1119(85)90262-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN LY, 1992, J BIOL CHEM, V267, P20100; CHEN LY, 1993, J BIOL CHEM, V268, P18710; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FRY DC, 1983, BIOCHEMISTRY-US, V22, P4949, DOI 10.1021/bi00290a011; GIEBEL LB, 1991, GENOMICS, V9, P435, DOI 10.1016/0888-7543(91)90409-8; HARTL FU, 1995, CURR OPIN STRUC BIOL, V5, P92; HINTERMANN G, 1985, MOL GEN GENET, V200, P422, DOI 10.1007/BF00425726; Hopwood D. A., 1985, GENETIC MANIPULATION; HOPWOOD DA, 1983, J GEN MICROBIOL, V129, P2257; Huber M., 1986, P265; HUBER M, 1988, BIOCHEMISTRY-US, V27, P5610, DOI 10.1021/bi00415a032; HUBER M, 1985, BIOCHEMISTRY-US, V24, P6038, DOI 10.1021/bi00343a003; JACKMAN MP, 1991, BIOCHEM J, V274, P707, DOI 10.1042/bj2740707; KATZ E, 1983, J GEN MICROBIOL, V129, P2703; KERTESZ D, 1972, BIOCHEM BIOPH RES CO, V49, P1208, DOI 10.1016/0006-291X(72)90597-9; KUPPER U, 1989, J BIOL CHEM, V264, P17250; KWON BS, 1988, BIOCHEM BIOPH RES CO, V153, P1301, DOI 10.1016/S0006-291X(88)81370-6; KWON BS, 1987, P NATL ACAD SCI USA, V84, P7473, DOI 10.1073/pnas.84.21.7473; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE YHW, 1988, GENE, V65, P71, DOI 10.1016/0378-1119(88)90418-0; Lee YHW, 1996, ADV INORG BIOCHEM, P223; LERCH K, 1981, MET IONS BIOL SYST, V13, P143; LERCH K, 1980, NATURE, V284, P368, DOI 10.1038/284368a0; LEU WM, 1989, GENE, V84, P267; LEU WM, 1992, J BIOL CHEM, V267, P20108; LIAW LL, 1995, BIOCHEM BIOPH RES CO, V214, P447, DOI 10.1006/bbrc.1995.2307; LINZEN B, 1985, SCIENCE, V229, P519, DOI 10.1126/science.4023698; MASON HS, 1965, ANNU REV BIOCHEM, V34, P595, DOI 10.1146/annurev.bi.34.070165.003115; MULLER G, 1988, EMBO J, V7, P2723, DOI 10.1002/j.1460-2075.1988.tb03126.x; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schmid F., 1990, PROTEIN STRUCTURE PR, P251; TAKASE M, 1992, GENE, V121, P359; WOODY RW, 1995, METHOD ENZYMOL, V246, P34; YONG G, 1990, BIOCHEMISTRY-US, V29, P9684, DOI 10.1021/bi00493a025	39	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19243	19250		10.1074/jbc.273.30.19243	http://dx.doi.org/10.1074/jbc.273.30.19243			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668113	hybrid			2022-12-25	WOS:000074974700080
J	Salvador, JM; Inesi, G; Rigaud, JL; Mata, AM				Salvador, JM; Inesi, G; Rigaud, JL; Mata, AM			Ca2+ transport by reconstituted synaptosomal ATPase is associated with H+ countertransport and net charge displacement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; CALCIUM-TRANSPORT; MEMBRANE-VESICLES; CA-2+ PUMP; PIG BRAIN; PROTEOLIPOSOMES; LIPOSOMES; BACTERIORHODOPSIN; ELECTROGENICITY; CA2+-ATPASE	The synaptosomal plasma membrane Ca2+-ATPase (PMCA) purified from pig brain was reconstituted with liposomes prepared by reverse phase evaporation at a lipid to protein ratio of 150/1 (w/w), ATP-dependent Ca2+ uptake and H+ ejection by the reconstituted proteoliposomes were demonstrated by following light absorption and fluorescence changes undergone by arsenate III and 8-hydroxy-1,3,6-pyrene trisulfonate, respectively. Ca2+ uptake was increased up to 2-3-fold by the Hf ionophore carbonyl cyanide p-trifluoromethoxyphenylhydrazone, consistent with relief of an inhibitory transmembrane pH gradient (Le. lumenal alkalinization) generated by Hf countertransport. The stoichiometric ratio of Ca2+/H+ countertransport was 1.0/0.6, and the ATP/Ca2+ coupling stoichiometry was yl at 25 degrees C. The electrogenic character of the Ca2+/H+ countertransport was demonstrated by measuring light absorption changes undergone by oxonol VI. It was shown that a 20 mV steady state potential (positive on the lumenal side) was formed as a consequence of net charge transfer associated with the 1/1 Ca2+/H+ countertransport, Calmodulin stimulated ATPase activity, Ca2+ uptake, and H+ ejection, demonstrating that these parameters are linked by the same mechanism of PMCA regulation.	Univ Extremadura, Fac Ciencias, Dept Bioquim & Biol Mol & Genet, E-06071 Badajoz, Spain; Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; Inst Curie, Sect Rech, CNRS, UMR 168, F-75231 Paris, France; CEA, LRC, F-75231 Paris, France	Universidad de Extremadura; University System of Maryland; University of Maryland Baltimore; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; PSL Research University Paris; Sorbonne Universite; UNICANCER; Institut Curie; CEA	Mata, AM (corresponding author), Univ Extremadura, Fac Ciencias, Dept Bioquim & Biol Mol & Genet, E-06071 Badajoz, Spain.		Mata, Ana M./J-8460-2014	Mata, Ana M./0000-0002-2887-7854; Salvador, Jesus Maria/0000-0002-1087-9675	NHLBI NIH HHS [P01-HL-27867] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL027867] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carafoli E, 1997, CALCIUM AND CELLULAR METABOLISM, P73; CHIESI M, 1980, BIOCHEMISTRY-US, V19, P2912, DOI 10.1021/bi00554a015; GASSNER B, 1988, CELL CALCIUM, V2, P95; GILL DL, 1981, J BIOL CHEM, V256, P184; HAO LN, 1994, J BIOL CHEM, V269, P14268; INESI G, 1992, J BIOENERG BIOMEMBR, V24, P271; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY D, 1990, J BIOL CHEM, V265, P19524; LEVY D, 1992, BIOCHIM BIOPHYS ACTA, V1107, P283, DOI 10.1016/0005-2736(92)90415-I; MICHAELIS ML, 1994, ANN NY ACAD SCI, V747, P407; NIGGLI V, 1982, J BIOL CHEM, V257, P2350; Pitard B, 1996, EUR J BIOCHEM, V235, P769, DOI 10.1111/j.1432-1033.1996.00769.x; RAEYMAEKERS L, 1993, J MUSCLE RES CELL M, V14, P141, DOI 10.1007/BF00115449; REGA AF, 1986, CA2PLUS PUMP PLASMA, P45; RIGAUD JL, 1995, BBA-BIOENERGETICS, V1231, P223, DOI 10.1016/0005-2728(95)00091-V; RIGAUD JL, 1988, BIOCHEMISTRY-US, V27, P2677, DOI 10.1021/bi00408a007; RIGAUD JL, 1983, BIOCHEM BIOPH RES CO, V111, P373, DOI 10.1016/0006-291X(83)90316-9; Salvador JM, 1998, ARCH BIOCHEM BIOPHYS, V351, P272, DOI 10.1006/abbi.1997.0562; Salvador JM, 1996, BIOCHEM J, V315, P183, DOI 10.1042/bj3150183; Scarpa A, 1979, Methods Enzymol, V56, P301; SORENSEN RG, 1981, J NEUROCHEM, V37, P1407, DOI 10.1111/j.1471-4159.1981.tb06309.x; WAISMAN DM, 1981, J BIOL CHEM, V256, P415; YU X, 1993, BIOPHYS J, V64, P1232, DOI 10.1016/S0006-3495(93)81489-9; YU X, 1994, J BIOL CHEM, V269, P16656; YU X, 1993, FEBS LETT, V328, P301, DOI 10.1016/0014-5793(93)80948-T	26	64	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18230	18234		10.1074/jbc.273.29.18230	http://dx.doi.org/10.1074/jbc.273.29.18230			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660785	hybrid			2022-12-25	WOS:000074828500040
J	Gopal-Srivastava, R; Cvekl, A; Piatigorsky, J				Gopal-Srivastava, R; Cvekl, A; Piatigorsky, J			Involvement of retinoic acid retinoid receptors in the regulation of murine alpha B-crystallin small heat shock protein gene expression in the lens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMEOBOX-CONTAINING GENE; RESPONSE ELEMENT; TRANSCRIPTIONAL REGULATION; ARGININOSUCCINATE LYASE; MOUSE EMBRYOGENESIS; DELTA-CRYSTALLIN; TRANSGENIC MICE; PAIRED DOMAIN; EYELESS GENE; MUTANT MICE	Crystallins are a diverse group of abundant soluble proteins that are responsible for the refractive properties of the transparent eye lens. me showed previously that Pax-6 can activate the alpha B-crystallin/small heat shock protein promoter via the lens specific regulatory regions LSR1 (-147/-118) and LSR2 (-78/-46). Here we demonstrate that retinoic acid can induce the accumulation of alpha B-crystallin in N/N1003A lens cells and that retinoic acid receptor heterodimers (retinoic acid receptor/retinoid X receptor; RAR/RXR) can transactivate LSR1 and LSR2 in cotransfection experiments. DNase I footprinting experiments demonstrated that purified RAR/RXR heterodimers will OCCUPY sequences resembling retinoic acid response elements within LSR1 and LSR2. Electrophoretic mobility shift assays using antibodies indicated that LSR1 and LSR2 can interact with endogenous RAR/RXR complexes in extracts of cultured lens cells. Pax-6 and RAR/RXR together had an additive effect on the activation of alpha B-promoter in the transfected lens cells. Thus, the alpha B-crystallin gene is activated by Pax-6 and retinoic acid receptors, making these transcription factors examples of proteins that have critical roles in early development as well as in the expression of proteins characterizing terminal differentiation.	NEI, Mol & Dev Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Piatigorsky, J (corresponding author), NEI, Mol & Dev Biol Lab, NIH, Bldg 6,Rm 201, Bethesda, MD 20892 USA.	joram@helix.nih.gov	Cvekl, Ales/B-2427-2013					BALKAN W, 1992, P NATL ACAD SCI USA, V89, P3347, DOI 10.1073/pnas.89.8.3347; BALKAN W, 1992, DEV BIOL, V151, P622, DOI 10.1016/0012-1606(92)90200-Z; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; BLOEMENDAL H, 1991, PROG NUCLEIC ACID RE, V41, P259; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CVEKL A, 1994, MOL CELL BIOL, V14, P7363, DOI 10.1128/MCB.14.11.7363; CVEKL A, 1995, MOL CELL BIOL, V15, P653; Cvekl A, 1996, BIOESSAYS, V18, P621, DOI 10.1002/bies.950180805; CVEKL A, 1995, P NATL ACAD SCI USA, V92, P4681, DOI 10.1073/pnas.92.10.4681; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; DEJONG WW, 1989, TRENDS BIOCHEM SCI, V14, P365, DOI 10.1016/0968-0004(89)90009-1; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DUBIN RA, 1991, MOL CELL BIOL, V11, P4340, DOI 10.1128/MCB.11.9.4340; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; DUNCAN M, 1992, DEV BIOL, V154, P1, DOI 10.1016/0012-1606(92)90042-F; Eichele G, 1997, TRENDS GENET, V13, P343, DOI 10.1016/S0168-9525(97)01218-3; EPSTEIN JA, 1994, GENE DEV, V8, P2022, DOI 10.1101/gad.8.17.2022; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; GLASER T, 1994, NAT GENET, V7, P463, DOI 10.1038/ng0894-463; GLASER T, 1992, NAT GENET, V8, P463; GopalSrivastava R, 1996, J BIOL CHEM, V271, P23029, DOI 10.1074/jbc.271.38.23029; GOPALSRIVASTAVA R, 1994, NUCLEIC ACIDS RES, V22, P1281, DOI 10.1093/nar/22.7.1281; GOPALSRIVASTAVA R, 1993, MOL CELL BIOL, V13, P7144, DOI 10.1128/MCB.13.11.7144; GOPALSRIVASTAVA R, 1995, MOL CELL BIOL, V15, P7081; GOTO K, 1988, CELL DIFFER DEV, V24, P139, DOI 10.1016/0045-6039(88)90065-6; Grondona JM, 1996, DEVELOPMENT, V122, P2173; HALDER G, 1995, CURR OPIN GENET DEV, V5, P602, DOI 10.1016/0959-437X(95)80029-8; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; Haynes JI, 1996, DEV DYNAM, V207, P75, DOI 10.1002/(SICI)1097-0177(199609)207:1<75::AID-AJA8>3.3.CO;2-O; Haynes JI, 1997, BIOCHEM BIOPH RES CO, V241, P407, DOI 10.1006/bbrc.1997.7833; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; Hyatt GA, 1996, DEVELOPMENT, V122, P195; Hyatt GA, 1997, INVEST OPHTH VIS SCI, V38, P1471; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; KASTNER P, 1994, CELL, V78, P987, DOI 10.1016/0092-8674(94)90274-7; KLEMENZ R, 1991, MOL CELL BIOL, V11, P803, DOI 10.1128/MCB.11.2.803; KONDOH H, 1991, GENE, V99, P267, DOI 10.1016/0378-1119(91)90137-Z; Krezel W, 1996, P NATL ACAD SCI USA, V93, P9010, DOI 10.1073/pnas.93.17.9010; Li X, 1997, DEV GENET, V20, P258; LOHNES D, 1994, DEVELOPMENT, V120, P2723; MARTHA A, 1994, AM J HUM GENET, V54, P801; MEANS AL, 1902, ANNU REV BIOCHEM, V201, P95; Minucci S, 1998, MOL ENDOCRINOL, V12, P315, DOI 10.1210/me.12.3.315; MINUCCI S, 1994, MOL CELL BIOL, V14, P360, DOI 10.1128/MCB.14.1.360; MORRISSKAY G, 1993, BIOESSAYS, V15, P9, DOI 10.1002/bies.950150103; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; PATEK CE, 1990, EXP EYE RES, V50, P345, DOI 10.1016/0014-4835(90)90135-H; PEREZCASTRO AV, 1993, DEVELOPMENT, V119, P363; PIATIGORSKY J, 1993, DEV DYNAM, V196, P267, DOI 10.1002/aja.1001960408; PIATIGORSKY J, 1988, P NATL ACAD SCI USA, V85, P3479, DOI 10.1073/pnas.85.10.3479; PIATIGORSKY J, 1989, CELL, V57, P197, DOI 10.1016/0092-8674(89)90956-2; PIATIGORSKY J, 1992, J BIOL CHEM, V267, P4277; PIATIGORSKY J, 1993, J BIOL CHEM, V268, P11894; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; REDDAN JR, 1986, DIFFERENTIATION, V33, P168, DOI 10.1111/j.1432-0436.1986.tb00422.x; RICHARDSON J, 1995, P NATL ACAD SCI USA, V92, P4676, DOI 10.1073/pnas.92.10.4676; ROCHETTEEGLY C, 1994, BIOCHEM BIOPH RES CO, V204, P525, DOI 10.1006/bbrc.1994.2491; ROSSANT J, 1991, GENE DEV, V5, P1333, DOI 10.1101/gad.5.8.1333; RUBERTE E, 1992, DEVELOPMENT, V115, P973; Sax C M, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P155; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TINI M, 1995, J BIOL CHEM, V270, P20156, DOI 10.1074/jbc.270.34.20156; TINI M, 1993, GENE DEV, V7, P295, DOI 10.1101/gad.7.2.295; TINI M, 1994, MOL ENDOCRINOL, V8, P1494, DOI 10.1210/me.8.11.1494; Tomarev SI, 1996, EUR J BIOCHEM, V235, P449, DOI 10.1111/j.1432-1033.1996.00449.x; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; TYNDALL C, 1981, NUCLEIC ACIDS RES, V9, P6231, DOI 10.1093/nar/9.23.6231; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; YAMADA T, 1990, CURR EYE RES, V9, P31, DOI 10.3109/02713689009000052	71	50	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17954	17961		10.1074/jbc.273.28.17954	http://dx.doi.org/10.1074/jbc.273.28.17954			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651402	hybrid			2022-12-25	WOS:000074816100095
J	Tournois, C; Mutel, V; Manivet, P; Launay, JM; Kellermann, O				Tournois, C; Mutel, V; Manivet, P; Launay, JM; Kellermann, O			Cross-talk between 5-hydroxytryptamine receptors in a serotonergic cell line - Involvement of arachidonic acid metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; DOPAMINE RELEASE; ACTIVATION; MIGRAINE; PHOSPHOLIPASE-A2; AGONIST; TERATOCARCINOMA; DIFFERENTIATION; PHARMACOLOGY; HYDROLYSIS	The study of signaling cascades and of functional interactions between 5-hydroxytryptamine (5-HT) receptor pathways with heterogenous brain cell populations remains an arduous task. We took advantage of a serotonergic cell Line to elucidate cross-talks between 5-HT receptors and to demonstrate the involvement of two 5-HT2 receptor subtypes in the regulation of 5-HT1B/1D function. The inducible 1C11 cell line has the unique property of acquiring within 4 days a complete serotonergic phenotype (1C11* cells), including three 5-HT receptors. 5-HT1B/1D and 5-HT2B receptors are expressed since day 2 of the serotonergic differentiation while 5-HT2A receptors are induced at day 4. We first established that 5-HT2B receptors are coupled with the phospholipase A2 (PLA2)-mediated release of arachidonic acid (AA) and that the activation of 5-HT2B receptors in 1C11*d2 cells inhibits the 5-HT1B/1D receptor function via a cyclooxygenase dependent AA metabolite. At day 4, this 5-HT2B-mediated inhibition of the 5-HT1B/1D function can be blocked upon concomitant 5-HT2A activation although a 5-HT2A/PLA2 positive coupling was evidenced. This suggests the existence in 1C11*d4 cells of pathway(s) for 5-HT2A receptors, distinct from PLC and PLA2. Finally, this study reveals the antagonistic roles of 5-HT2A and 5-HT2B receptors in regulating the function of 5-HT1B/1D, a receptor involved in neuropsychiatric disorders and migraine pathogenesis.	Inst Pasteur, CNRS, URA 1960, F-75724 Paris 15, France; Hoffmann La Roche Ag, Pharma Res Dept, CH-4002 Basel, Switzerland; Hop Lariboisiere, Serv Biochim, IFR 6, CR C Bernard, F-75010 Paris, France; Univ Paris 05, Fac Pharm, Biol Cellulaire Lab, F-75006 Paris, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Roche Holding; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Kellermann, O (corresponding author), Inst Pasteur, CNRS, URA 1960, 28 Rue Dr Roux, F-75724 Paris 15, France.	okellerm@pasteur.fr	Manivet, Philippe/AAA-1884-2021					Audia JE, 1996, J MED CHEM, V39, P2773, DOI 10.1021/jm960062t; AXELROD J, 1988, TRENDS NEUROSCI, V11, P117, DOI 10.1016/0166-2236(88)90157-9; Bazan N G, 1986, Adv Neurol, V44, P879; BERG KA, 1994, MOL PHARMACOL, V46, P477; Berg KA, 1996, MOL PHARMACOL, V50, P1017; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BERTHOU L, 1992, EUR J CELL BIOL, V58, P377; BONVENTRE JV, 1992, J AM SOC NEPHROL, V3, P128; Branchek T, 1997, ANNU REP MED CHEM, V32, P1, DOI 10.1016/S0065-7743(08)61459-1; BREWERTON TD, 1988, CLIN PHARMACOL THER, V43, P605, DOI 10.1038/clpt.1988.83; BUCCARON MH, 1990, P NATL ACAD SCI USA, V87, P1922, DOI 10.1073/pnas.87.5.1922; Choi DS, 1996, FEBS LETT, V391, P45, DOI 10.1016/0014-5793(96)00695-3; CLARK MA, 1987, J BIOL CHEM, V262, P4402; COHEN ML, 1987, J CARDIOVASC PHARM, V10, P176, DOI 10.1097/00005344-198708000-00007; DOENICKE A, 1988, LANCET, V1, P1309; Duxon MS, 1997, NEUROSCIENCE, V76, P323, DOI 10.1016/S0306-4522(96)00480-0; ELLIS ES, 1995, BRIT J PHARMACOL, V114, P400, DOI 10.1111/j.1476-5381.1995.tb13240.x; FELDER CC, 1990, P NATL ACAD SCI USA, V87, P2187, DOI 10.1073/pnas.87.6.2187; FOZARD JR, 1989, TRENDS PHARMACOL SCI, V10, P307, DOI 10.1016/0165-6147(89)90061-8; FOZARD JR, 1992, CURR OPIN NEUROL NEU, V5, P496; GALLOWAY MP, 1993, SYNAPSE, V15, P90, DOI 10.1002/syn.890150109; GLENNON RA, 1993, DRUG NEWS PERSPECT, V6, P390; HOYER D, 1988, EUR J PHARMACOL, V147, P145, DOI 10.1016/0014-2999(88)90645-0; HOYER D, 1994, PHARMACOL REV, V46, P157; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; Iyer RN, 1996, J PHARMACOL EXP THER, V277, P40; KAUFMAN MJ, 1995, J NEUROCHEM, V64, P199; Kaufmann WE, 1997, PROSTAG OTH LIPID M, V54, P601, DOI 10.1016/S0090-6980(97)00128-7; KELLERMANN O, 1986, DIFFERENTIATION, V32, P74, DOI 10.1111/j.1432-0436.1986.tb00558.x; Kellermann O, 1996, BRIT J PHARMACOL, V118, P1161, DOI 10.1111/j.1476-5381.1996.tb15519.x; Launay JM, 1996, J BIOL CHEM, V271, P3141, DOI 10.1074/jbc.271.6.3141; LORIC S, 1995, MOL PHARMACOL, V47, P458; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PALACIOS JM, 1990, ANN NY ACAD SCI, V600, P36, DOI 10.1111/j.1749-6632.1990.tb16871.x; PAZOS A, 1985, BRAIN RES, V346, P231, DOI 10.1016/0006-8993(85)90857-1; Piomelli D, 1993, CURR OPIN CELL BIOL, V5, P274, DOI 10.1016/0955-0674(93)90116-8; RAITERI M, 1986, J PHARMACOL EXP THER, V237, P644; SANDERSBUSH E, 1988, SERONTONIN RECEPTORS; Schmuck K, 1996, EUR J NEUROSCI, V8, P959, DOI 10.1111/j.1460-9568.1996.tb01583.x; SHIMIZU T, 1990, J NEUROCHEM, V55, P1, DOI 10.1111/j.1471-4159.1990.tb08813.x	41	68	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17498	17503		10.1074/jbc.273.28.17498	http://dx.doi.org/10.1074/jbc.273.28.17498			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651340	hybrid			2022-12-25	WOS:000074816100033
J	Amendt, C; Schirmacher, P; Weber, H; Blessing, M				Amendt, C; Schirmacher, P; Weber, H; Blessing, M			Expression of a dominant negative type II TGF-beta receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development	ONCOGENE			English	Article						TGF-beta; receptor; skin; carcinogenesis; growth control	GROWTH-FACTOR-BETA; TRANSGENIC MICE; TRANSFORMING GROWTH-FACTOR-BETA-1; MALIGNANT CONVERSION; KERATIN-5 GENE; HIGH-RISK; RAS GENE; HA-RAS; CELLS; CARCINOGENESIS	The role of Transforming growth factor beta (TGF-beta) in carcinogenesis is complex. There are reports on both tumor inhibition and tumor promotion by TGF-beta. To elucidate the complex role of TGF-beta in epithelial carcinogenesis, we generated transgenic mice overexpressing a dominant negative type II TGF-beta receptor in the basal cell compartment and in follicular cells of the skin, Despite the reduced responsiveness of transgenic keratinocytes to TGF-beta, both proliferation and differentiation were normal in non-irritated epidermis of these transgenic mice, Thus, interruption of signaling of all three isoforms of TGF-beta in basal and follicular cells does not disturb tissue homeostasis. However, during tumor promotion transgenic mice showed an elevated level of proliferation in the epidermis. This hyperproliferation correlated with a very early onset of carcinoma development and a malignant conversion frequency of 30% from benign papillomas to carcinomas. By comparison, the conversion frequency in wild-type mice of this strain has previously been reported as 5.5%, Even without induction of hyperproliferation by tumor promoters, transgenic mice developed far more carcinomas as controls when treated with a carcinogen. This result indicates that there is a synergistic effect between loss of TGF-beta responsiveness and mutations caused by initiation with a carcinogen leading to an endogeneous tumor promotion in initiated cells only.	Johannes Gutenberg Univ Mainz, Dept Med 1, Boehringer Ingelheim Res Grp, D-55131 Mainz, Germany; Johannes Gutenberg Univ Mainz, Inst Pathol, D-55101 Mainz, Germany	Boehringer Ingelheim; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz	Blessing, M (corresponding author), Johannes Gutenberg Univ Mainz, Dept Med 1, Boehringer Ingelheim Res Grp, SFB-311,Obere Zahlbacher Str 63, D-55131 Mainz, Germany.							AKHURST RJ, 1988, NATURE, V331, P363, DOI 10.1038/331363a0; ARRICK BA, 1992, J CELL BIOL, V118, P715, DOI 10.1083/jcb.118.3.715; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BAILLEUL B, 1990, CELL, V62, P697, DOI 10.1016/0092-8674(90)90115-U; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; BLESSING M, 1993, GENE DEV, V7, P204, DOI 10.1101/gad.7.2.204; Bottinger EP, 1997, CANCER RES, V57, P5564; BRAND T, 1993, J BIOL CHEM, V268, P11500; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; CASATORRES J, 1994, J BIOL CHEM, V269, P20489; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CHOI Y, 1990, CELL REGUL, V1, P791, DOI 10.1091/mbc.1.11.791; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COFFEY RJ, 1988, CANCER RES, V48, P1596; CUI W, 1995, GENE DEV, V9, P945, DOI 10.1101/gad.9.8.945; CUI W, 1994, CANCER RES, V54, P5831; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; DIGIOVANNI J, 1991, PROG EXP TUMOR RES, V33, P192; DROZDOFF V, 1993, J CELL BIOL, V123, P909, DOI 10.1083/jcb.123.4.909; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; ESHERICK JS, 1993, CANCER RES, V53, P5517; FAFEUR V, 1993, MOL BIOL CELL, V4, P135, DOI 10.1091/mbc.4.2.135; Fowlis DJ, 1996, CELL GROWTH DIFFER, V7, P679; FURSTENBERGER G, 1989, INT J CANCER, V43, P915; GITELMAN SE, 1997, CALCIFIED TISSUE INT, V60, P283; GLICK AB, 1994, GENE DEV, V8, P2429, DOI 10.1101/gad.8.20.2429; GLICK AB, 1993, P NATL ACAD SCI USA, V90, P6076, DOI 10.1073/pnas.90.13.6076; HADDOW S, 1991, ONCOGENE, V6, P1465; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; HENNINGS H, 1993, CARCINOGENESIS, V14, P2353, DOI 10.1093/carcin/14.11.2353; HOGAN B, 1986, MANIPULATING MOUSE E; JORCANO JL, 1984, J MOL BIOL, V179, P257, DOI 10.1016/0022-2836(84)90468-6; JORCANO JL, 1984, DIFFERENTIATION, V28, P155, DOI 10.1111/j.1432-0436.1984.tb00278.x; KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KITANO Y, 1983, BRIT J DERMATOL, V108, P555, DOI 10.1111/j.1365-2133.1983.tb01056.x; Knaus PI, 1996, MOL CELL BIOL, V16, P3480; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MANSBRIDGE JN, 1988, J INVEST DERMATOL, V90, P336, DOI 10.1111/1523-1747.ep12456286; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MILLER SJ, 1993, J INVEST DERMATOL, V101, P591, DOI 10.1111/1523-1747.ep12366045; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P9613, DOI 10.1073/pnas.88.21.9613; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oshima M, 1996, DEV BIOL, V179, P297, DOI 10.1006/dbio.1996.0259; PELTON RW, 1991, J CELL BIOL, V115, P1091, DOI 10.1083/jcb.115.4.1091; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; RAMIREZ A, 1994, DIFFERENTIATION, V58, P53, DOI 10.1007/s002580050065; Roberts A.B., 1990, HDB EXPT PHARM PEPTI, V95, P419; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; SANKAR S, 1995, J BIOL CHEM, V270, P13567, DOI 10.1074/jbc.270.22.13567; SELLHEYER K, 1993, P NATL ACAD SCI USA, V90, P5237, DOI 10.1073/pnas.90.11.5237; TORREAMIONE G, 1990, P NATL ACAD SCI USA, V87, P1486, DOI 10.1073/pnas.87.4.1486; Wang XJ, 1997, P NATL ACAD SCI USA, V94, P2386, DOI 10.1073/pnas.94.6.2386; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Zhao Y, 1996, J BIOL CHEM, V271, P2369, DOI 10.1074/jbc.271.5.2369	64	97	101	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 9	1998	17	1					25	34		10.1038/sj.onc.1202161	http://dx.doi.org/10.1038/sj.onc.1202161			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZY936	9671311				2022-12-25	WOS:000074677800004
J	Brown, CL; Meise, KS; Plowman, GD; Coffey, RJ; Dempsey, PJ				Brown, CL; Meise, KS; Plowman, GD; Coffey, RJ; Dempsey, PJ			Cell surface ectodomain cleavage of human amphiregulin precursor is sensitive to a metalloprotease inhibitor - Release of a predominant N-glycosylated 43-kDa soluble form	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; FACTOR-ALPHA; EPITHELIAL-CELLS; FACTOR RECEPTOR; PHORBOL-ESTER; COLORECTAL TUMORS; OVARIAN-CARCINOMA; MEMBRANE-PROTEINS; EGF PRECURSOR; TGF-ALPHA	Biosynthesis and processing of amphiregulin (AR) have been investigated in human colorectal (HCA-7, Caco-2) and mammary (MCF-7) cancer cell lines, as well as in Madin-Darby canine kidney cells stably expressing various human AR precursor (pro-AR) forms. Both cells expressing endogenous and transfected AR produce multiple cellular and soluble forms of AR with an N-glycosylated 50-kDa pro-AR form being predominant. Our results demonstrate that sequential proteolytic cleavage within the ectodomain of the 50-kDa pro-AR form leads to release of a predominant N-glycosylated 43-kDa soluble AR, as well as the appearance of other cellular and soluble AR forms. Cell surface biotinylation studies using a C-terminal epitope-tagged pro-AR indicate that all cell surface forms are membrane-anchored and support that AR is released by ectodomain cleavage of pro-AR at the plasma membrane. We also show that pro-AR ectodomain cleavage is a regulated process, which can be stimulated by phorbol 12-myristate 13-acetate and inhibited by the metalloprotease inhibitor, batimastat. In addition, we provide evidence that high molecular mass AR forms may retain the full-length N-terminal pro-region, which may influence the biological activities of these forms.	Vanderbilt Univ, Med Ctr, Dept Med, GI Div,Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA; Vet Affairs Med Ctr, Nashville, TN 37232 USA; Sugen Inc, Redwood City, CA 94063 USA	Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Coffey, RJ (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, GI Div,Sch Med, CC2218 Med Ctr N, Nashville, TN 37232 USA.		PLOWMAN, Greg D/E-2012-2011		NCI NIH HHS [CA46413] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046413] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAM R, 1995, BBA-MOL CELL RES, V1266, P83, DOI 10.1016/0167-4889(94)00224-3; Adam RM, 1996, GROWTH FACTORS, V13, P193, DOI 10.3109/08977199609003221; ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; BOSENBERG MW, 1993, J CELL BIOL, V122, P95, DOI 10.1083/jcb.122.1.95; CIARDIELLO F, 1991, P NATL ACAD SCI USA, V88, P7792, DOI 10.1073/pnas.88.17.7792; COOK PW, 1991, MOL CELL BIOL, V11, P2547, DOI 10.1128/MCB.11.5.2547; COOK PW, 1992, CANCER RES, V52, P3224; Cook PW, 1997, J CLIN INVEST, V100, P2286, DOI 10.1172/JCI119766; Culouscou JM, 1992, GROWTH FACTORS, V7, DOI 10.3109/08977199209046924; DAVIES B, 1993, CANCER RES, V53, P2087; DeBoer WI, 1997, INT J CANCER, V71, P284, DOI 10.1002/(SICI)1097-0215(19970410)71:2<284::AID-IJC25>3.0.CO;2-G; DeLuca A, 1997, INT J CANCER, V73, P277, DOI 10.1002/(SICI)1097-0215(19971009)73:2<277::AID-IJC19>3.3.CO;2-J; DEMPSEY P, 1997, J CELL BIOL, V138, P1; DEMPSEY PJ, 1994, J BIOL CHEM, V269, P16878; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DERYNCK R, 1992, ADV CANCER RES, V58, P27, DOI 10.1016/S0065-230X(08)60289-4; DUDGEON TJ, 1990, FEBS LETT, V261, P392, DOI 10.1016/0014-5793(90)80600-N; Ehlers MRW, 1996, BIOCHEMISTRY-US, V35, P9549, DOI 10.1021/bi9602425; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; ESKO J, 1985, P NATL ACAD SCI USA, V82, P3179; ESKO JD, 1992, ADV EXP MED BIOL, V313, P97; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; GREGORY H, 1988, REGUL PEPTIDES, V22, P217, DOI 10.1016/0167-0115(88)90034-1; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HUTTNER WB, 1988, ANNU REV PHYSIOL, V50, P363, DOI 10.1146/annurev.ph.50.030188.002051; Inui S, 1997, J CELL PHYSIOL, V171, P291, DOI 10.1002/(SICI)1097-4652(199706)171:3<291::AID-JCP7>3.0.CO;2-J; JOHNSON G, 1992, J CELL BIOL, V113, P741; JOHNSON GR, 1991, BIOCHEM BIOPH RES CO, V180, P481, DOI 10.1016/S0006-291X(05)81090-3; JOHNSON GR, 1993, J BIOL CHEM, V268, P18835; JOHNSON GR, 1994, J BIOL CHEM, V269, P27149; JOHNSON GR, 1993, J BIOL CHEM, V268, P2924; KIMURA H, 1993, P NATL ACAD SCI USA, V90, P2165, DOI 10.1073/pnas.90.6.2165; KIMURA H, 1990, NATURE, V348, P257, DOI 10.1038/348257a0; Kondapaka SB, 1997, INT J CANCER, V70, P722, DOI 10.1002/(SICI)1097-0215(19970317)70:6<722::AID-IJC15>3.3.CO;2-5; LANZREIN M, 1995, BIOCHEM J, V310, P285, DOI 10.1042/bj3100285; LEE DC, 1995, PHARMACOL REV, V47, P51; LI SW, 1992, J CELL PHYSIOL, V153, P103, DOI 10.1002/jcp.1041530114; MartinezLacaci I, 1996, J CELL PHYSIOL, V169, P497, DOI 10.1002/(SICI)1097-4652(199612)169:3<497::AID-JCP10>3.0.CO;2-3; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MATSUNAMI RK, 1991, J CELL BIOCHEM, V46, P242, DOI 10.1002/jcb.240460307; Modrell B, 1992, GROWTH FACTORS, V7, P305, DOI 10.3109/08977199209046413; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; NORMANNO N, 1995, INT J CANCER, V62, P762, DOI 10.1002/ijc.2910620619; PANDIELLA A, 1991, J BIOL CHEM, V266, P5769; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; PARRIES G, 1995, J BIOL CHEM, V270, P27954, DOI 10.1074/jbc.270.46.27954; PIEPKORN M, 1994, J CELL PHYSIOL, V159, P114, DOI 10.1002/jcp.1041590115; PIEPKORN M, 1995, J INVEST DERMATOL, V105, P802, DOI 10.1111/1523-1747.ep12326567; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; RAAB G, 1994, BIOCHEM BIOPH RES CO, V204, P592, DOI 10.1006/bbrc.1994.2500; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; SAEKI T, 1992, CANCER RES, V52, P3467; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SHOYAB M, 1988, P NATL ACAD SCI USA, V85, P6528, DOI 10.1073/pnas.85.17.6528; TEIXIDO J, 1990, J BIOL CHEM, V265, P6410; THOMPSON SA, 1994, J BIOL CHEM, V269, P2541; Thompson SA, 1996, J BIOL CHEM, V271, P17927, DOI 10.1074/jbc.271.30.17927; THORNE BA, 1994, MOL CELL BIOL, V14, P1635, DOI 10.1128/MCB.14.3.1635; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; Zushi S, 1997, INT J CANCER, V73, P917, DOI 10.1002/(SICI)1097-0215(19971210)73:6<917::AID-IJC26>3.0.CO;2-#	65	101	101	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17258	17268		10.1074/jbc.273.27.17258	http://dx.doi.org/10.1074/jbc.273.27.17258			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642297	hybrid			2022-12-25	WOS:000074545200087
J	D'Sa-Eipper, C; Chinnadurai, G				D'Sa-Eipper, C; Chinnadurai, G			Functional dissection of Bfl-1, a Bcl-2 homolog: anti-apoptosis, oncogene-cooperation and cell proliferation activities	ONCOGENE			English	Article						BCL-2 family; mutational analysis; conserved domains; apoptosis; p53; cell transformation; cell proliferation; gain-of-function	NECROSIS-FACTOR-ALPHA; DNA-DAMAGING AGENTS; ADENOVIRUS E1B 19K; CONSERVED DOMAINS; BHRF1 PROTEIN; VIRAL HOMOLOG; FAMILY MEMBER; B-CELLS; C-MYC; DEATH	The human Bfl-1 gene codes for a 175-amino acid BCL-2 family protein that has an anti-apoptosis activity and is overexpressed in certain human epithelial and hematopoietic malignancies. Bfl-1 efficiently suppresses apoptosis induced by the p53 tumor suppressor protein and cooperates with a dominant nuclear oncogene. EIA, in transformation of primary epithelial cells in vitro. Unlike other BCL-2 family proteins, expression of BFL-1 permits limited cell proliferation over an extended period of time when cells are induced to undergo apoptosis. We have carried out mutational analysis to dissect the various activities encoded by Bfl-1 and to determine the sequence requirements for these activities. BFL-1 shares four conserved domains, BH1, BH2, BH3 and BH4 with other BCL-2 family proteins. Mutations within BH1, BH2 and BH4 domains abolish or greatly attenuate the anti-apoptotic, oncogene cooperation and proliferation facilitating activities of BFL-1. In contrast, a mutation within the BH3 domain (which is essential for the activity of pro-apoptotic members of the BCL-2 family) does not significantly affect the BFL-1 functions. Although BFL-1 does not contain a well-defined C-terminal transmembrane domain, deletion of the C-terminal 24 amino acid region (corresponding to the transmembrane domain of other BCL-2 family proteins) partially reduces the various activities of BFL-1. All the mutants defective in the anti-apoptosis activity are also defective in the oncogene cooperation activity suggesting that these two activities may be linked. A unique feature of BFL-1 is the presence of a Gin-rich N-terminal region that overlaps with the BH4 domain. The GIn residues appear to be essential for the proliferation permitting activity of BFL-1. Since mutations of the GIn residues located within the BH4 domain appear to confer an extended cell survival activity in the absence of cell proliferation, our results suggest that BFL-1 communicates with both cell proliferation and apoptosis machineries and suggest a link between these two activities.	St Louis Univ, Hlth Sci Ctr, Inst Mol Virol, St Louis, MO 63110 USA	Saint Louis University	Chinnadurai, G (corresponding author), St Louis Univ, Hlth Sci Ctr, Inst Mol Virol, St Louis, MO 63110 USA.				NCI NIH HHS [CA-33616, R01 CA033616] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033616] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; BOYD JM, 1995, ONCOGENE, V11, P1921; Chen DF, 1997, NATURE, V385, P434, DOI 10.1038/385434a0; Cheng EHY, 1997, P NATL ACAD SCI USA, V94, P690, DOI 10.1073/pnas.94.2.690; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; CHOI SS, 1995, ONCOGENE, V11, P1693; DAWSON CW, 1995, ONCOGENE, V9, P69; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DSaEipper C, 1996, CANCER RES, V56, P3879; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; Han J, 1996, MOL CELL BIOL, V16, P5857; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; Karsan A, 1996, BLOOD, V87, P3089, DOI 10.1182/blood.V87.8.3089.bloodjournal8783089; Kenny JJ, 1997, ONCOGENE, V14, P997, DOI 10.1038/sj.onc.1200898; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KORSMEYER SJ, 1992, BLOOD, V80, P879; Lin EY, 1996, BLOOD, V87, P983, DOI 10.1182/blood.V87.3.983.bloodjournal873983; Mangeney M, 1996, ONCOGENE, V13, P1441; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nava VE, 1997, J VIROL, V71, P4118, DOI 10.1128/JVI.71.5.4118-4122.1997; NEVINS JR, 1992, SCIENCE, V258, P424; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; REYNOLDS JE, 1994, CANCER RES, V54, P6348; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; SMITH CA, 1995, TRENDS CELL BIOL, V5, P344, DOI 10.1016/S0962-8924(00)89061-3; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Subramanian T, 1995, ONCOGENE, V11, P2403; SUBRAMANIAN T, 1993, GENE, V124, P173, DOI 10.1016/0378-1119(93)90391-F; TAKAYAMA S, 1994, DNA CELL BIOL, V13, P679, DOI 10.1089/dna.1994.13.679; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; TARODI B, 1994, VIROLOGY, V201, P404, DOI 10.1006/viro.1994.1309; TARODI B, 1993, INT J ONCOL, V3, P467; Theodorakis P, 1996, ONCOGENE, V12, P1707; Uhlmann EJ, 1996, CANCER RES, V56, P2506; Vairo G, 1996, ONCOGENE, V13, P1511; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	57	58	60	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 18	1998	16	24					3105	3114		10.1038/sj.onc.1201851	http://dx.doi.org/10.1038/sj.onc.1201851			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671389				2022-12-25	WOS:000074261300003
J	Almeida, A; Zhu, XX; Vogt, N; Tyagi, R; Muleris, M; Dutrillaux, AM; Dutrillaux, B; Ross, D; Malfoy, B; Hanash, S				Almeida, A; Zhu, XX; Vogt, N; Tyagi, R; Muleris, M; Dutrillaux, AM; Dutrillaux, B; Ross, D; Malfoy, B; Hanash, S			GAC1, a new member of the leucine-rich repeat superfamily on chromosome band 1q32.1, is amplified and overexpressed in malignant gliomas	ONCOGENE			English	Article						glioma; amplification; overexpression; leucine-rich repeat; chromosome 1	MOUSE NERVOUS-SYSTEM; 2-DIMENSIONAL SEPARATIONS; ADHESION MOLECULE; GENOMIC DNA; GENE; SEQUENCE; PROTEIN; CDNA; CLONING; AMPLIFICATION	We have used two-dimensional electrophoresis of enzyme-digested genomic DNA to identify a novel gene GAC1, which maps at 1q32.1 and which is overexpressed in malignant gliomas in which it is amplified. GAC1 encodes a protein which belongs to the leucine-rich repeat superfamily. Amplification and overexpression of GAC1 was demonstrated in two of eight tumors where amplifications were previously evidenced by comparative genomic hybridization (one glioblastoma multiforme and one anaplastic astrocytoma), and in one of eight unselected glioblastomas multiforme. GAC1 exhibits sequence homology with other proteins which function as cell-adhesion molecules or as signal transduction receptor and is a likely candidate for the target gene in the 1q32.1 amplicon in malignant gliomas.	CNRS UMR 147, Inst Curie, F-75248 Paris 05, France; Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of Michigan System; University of Michigan	Malfoy, B (corresponding author), CNRS UMR 147, Inst Curie, 26 Rue Ulm, F-75248 Paris 05, France.			Zhu, Charles/0000-0003-2922-0042				ADAMS MD, 1993, NAT GENET, V4, P373, DOI 10.1038/ng0893-373; ALMEIDA A, 1994, GENE CHROMOSOME CANC, V11, P63, DOI 10.1002/gcc.2870110110; ASAKAWA J, 1994, P NATL ACAD SCI USA, V91, P9052, DOI 10.1073/pnas.91.19.9052; BUCHANAN SGS, 1996, PROG BIOPHYS MOL BIO, V25, P1; CHANG Z, 1993, DEV BIOL, V160, P315, DOI 10.1006/dbio.1993.1310; COLLINS VP, 1995, GLIA, V15, P289, DOI 10.1002/glia.440150309; Costello JF, 1997, CANCER RES, V57, P1250; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; Forozan F, 1997, TRENDS GENET, V13, P405, DOI 10.1016/S0168-9525(97)01244-4; Grover J, 1996, GENOMICS, V38, P109, DOI 10.1006/geno.1996.0605; IMAI T, 1983, P NATL ACAD SCI-BIOL, V80, P7405, DOI 10.1073/pnas.80.24.7405; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Kim D, 1996, BBA-GENE STRUCT EXPR, V1309, P183, DOI 10.1016/S0167-4781(96)00158-3; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRANTZ DE, 1990, EMBO J, V9, P1969, DOI 10.1002/j.1460-2075.1990.tb08325.x; Kuick R, 1996, GENETICS, V144, P307; KUICK R, 1995, GENOMICS, V25, P345, DOI 10.1016/0888-7543(95)80032-H; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; LEONG SR, 1992, MOL ENDOCRINOL, V6, P870, DOI 10.1210/me.6.6.870; LINDSAY S, 1987, NATURE, V327, P336, DOI 10.1038/327336a0; LOUIS DN, 1995, TRENDS GENET, V11, P412, DOI 10.1016/S0168-9525(00)89125-8; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MIKOL DD, 1990, J CELL BIOL, V110, P471, DOI 10.1083/jcb.110.2.471; MULERIS M, 1994, ONCOGENE, V9, P2717; NOSE A, 1992, CELL, V70, P553, DOI 10.1016/0092-8674(92)90426-D; QIN H, 1993, HUM HERED, V43, P261, DOI 10.1159/000154142; REIFENBERGER J, 1994, AM J PATHOL, V145, P1175; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; SCHROCK E, 1994, AM J PATHOL, V144, P1203; Suzuki Y, 1996, J BIOL CHEM, V271, P22522, DOI 10.1074/jbc.271.37.22522; SZTROLOVICS R, 1994, GENOMICS, V23, P715, DOI 10.1006/geno.1994.1567; Taguchi A, 1996, MOL BRAIN RES, V35, P31, DOI 10.1016/0169-328X(95)00178-U; Taniguchi H, 1996, MOL BRAIN RES, V36, P45, DOI 10.1016/0169-328X(95)00243-L; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Wimmer K, 1997, BIOCHEM SOC T, V25, P262, DOI 10.1042/bst0250262	36	61	67	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 11	1998	16	23					2997	3002		10.1038/sj.onc.1201828	http://dx.doi.org/10.1038/sj.onc.1201828			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZT782	9662332				2022-12-25	WOS:000074125300006
J	Bafico, A; Gazit, A; Wu-Morgan, SS; Yaniv, A; Aaronson, SA				Bafico, A; Gazit, A; Wu-Morgan, SS; Yaniv, A; Aaronson, SA			Characterization of Wnt-1 and Wnt-2 induced growth alterations and signaling pathways in NIH3T3 fibroblasts	ONCOGENE			English	Article						Wnt; oncogene; NIH3T3; cell adhesion; beta-catenin; MAPK	MAMMARY EPITHELIAL-CELLS; GLYCOGEN-SYNTHASE KINASE-3; TRANSCRIPTION FACTOR LEF-1; CADHERIN-CATENIN COMPLEX; BETA-CATENIN; TYROSINE PHOSPHORYLATION; MAP KINASE; PROTEIN; TRANSFORMATION; EXPRESSION	Members of the Wnt family induce mouse mammary tumors and partially transform mammary epithelial cells in culture. However, their mechanism of transformation remains to be elucidated. In NIH3T3 mouse embryo fibroblasts, a standard transformation model, Wnt-1 and Wnt-2 were shown to induce altered properties including increased saturation density and growth in soft agar, Such cells also exhibited increased cell-cell adhesiveness. However, unlike oncogenes such as PDGFB or ras, Wnt-1 and -2 failed to induce detectable transformed foci following transfection, and stable NIH3T3 transfectants lacked tumor forming capacity. Wnt-1 and -2 transfectants exhibited increased uncomplexed, cytosolic beta-catenin, which was not observed with PDGFB, ras or erbB2 transfectants. In transient transfection, Wnt-1 and -2 induced a rapid increase in cytosolic beta-catenin but no detectable increase in the phosphorylated activated forms of MAP kinase, In contrast, ras was a potent activator of MAP kinase but had no effect on free beta-catenin levels. These findings establish that both Wnt signaling and pattern of growth alterations differ from those of oncogenes which activate proliferative signaling pathways in NIH3T3 cells.	CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; Tel Aviv Univ, Sackler Sch Med, Dept Human Microbiol, IL-69978 Tel Aviv, Israel	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Tel Aviv University; Sackler Faculty of Medicine	Aaronson, SA (corresponding author), CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA.				NATIONAL CANCER INSTITUTE [R01CA071672, R01CA066654] Funding Source: NIH RePORTER; NCI NIH HHS [1-R01-CA71672, 1-R01-CA66654] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BLASBAND A, 1992, ONCOGENE, V7, P153; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BRADBURY JM, 1994, ONCOGENE, V9, P2597; BRADLEY RS, 1995, MOL CELL BIOL, V15, P4616; BRADLEY RS, 1993, J CELL BIOL, V123, P1857, DOI 10.1083/jcb.123.6.1857; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; BURRUS LW, 1995, EXP CELL RES, V220, P363, DOI 10.1006/excr.1995.1327; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; Christiansen JH, 1996, ONCOGENE, V12, P2705; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; ECHELARD Y, 1994, DEVELOPMENT, V120, P2213; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; FALCO JP, 1988, ONCOGENE, V2, P573; GUMBINER BM, 1995, CURR OPIN CELL BIOL, V7, P634, DOI 10.1016/0955-0674(95)80104-9; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; JUE SF, 1992, MOL CELL BIOL, V12, P321, DOI 10.1128/MCB.12.1.321; LAROCHELLE WJ, 1995, J CELL BIOL, V129, P357, DOI 10.1083/jcb.129.2.357; LIN TP, 1992, CANCER RES, V52, P4413; MASON JO, 1992, MOL BIOL CELL, V3, P521, DOI 10.1091/mbc.3.5.521; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; MIKI T, 1995, METHOD ENZYMOL, V254, P196; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; OLSON DJ, 1994, CELL GROWTH DIFFER, V5, P197; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; PARKIN NT, 1993, GENE DEV, V7, P2181, DOI 10.1101/gad.7.11.2181; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Perrimon N, 1996, CELL, V86, P513, DOI 10.1016/S0092-8674(00)80124-5; RIJSEWIJK F, 1987, EMBO J, V6, P127, DOI 10.1002/j.1460-2075.1987.tb04729.x; ROELINK H, 1992, ONCOGENE, V7, P487; ROTHBACHER U, 1995, DEV BIOL, V170, P717, DOI 10.1006/dbio.1995.1249; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; SOKOL SY, 1995, DEVELOPMENT, V121, P1637; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278	46	70	74	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	1998	16	21					2819	2825		10.1038/sj.onc.1201797	http://dx.doi.org/10.1038/sj.onc.1201797			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ013	9652750				2022-12-25	WOS:000073812200015
J	Clottes, E; Burchell, A				Clottes, E; Burchell, A			Three thiol groups are important for the activity of the liver microsomal glucose-6-phosphatase system - Unusual behavior of one thiol located in the glucose-6-phosphate translocase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-STORAGE-DISEASE; GLUCOSE 6-PHOSPHATASE; PHOSPHOHYDROLASE COMPONENT; MEMBRANE INTEGRITY; RAPID KINETICS; TRANSPORT; PERMEABILITY; IDENTIFICATION; ACTIVATION; EXPRESSION	Liver microsomal glucose-6-phosphatase (Glc-6-Pase) is a multicomponent system involving both substrate and product carriers and a catalytic subunit, We have investigated the inhibitory effect of N-ethylmaleimide (NEM), a rather specific sulfhydryl reagent, on rat liver Glc-6-Pase activity. Three thiol groups are important for Glc-6-Pase system activity. Two of them are located in the glucose-g-phosphate (Glc-6-P) translocase, and one is located in the catalytic subunit, The other transporters (phosphate and glucose) are not affected by NEM treatment. The NEM alkylation of the catalytic subunit sulfhydryl residue is prevented by preincubating the disrupted microsomes with saturating concentrations of substrate or product. This suggests either that the modified cysteine is located in the protein active site or that substrate binding hides the thiol group via a conformational change in the enzyme structure. Two other thiols important for the Glc-6-Pase system activity are located in the Glc-6-P translocase and are more reactive than the one located in the catalytic subunit. The study of the NEM inhibition of the translocase has provided evidence of the existence of two distinct areas in the protein that can behave independently, with conformational changes occurring during Glc-6-P binding to the transporter. The recent cloning of a human putative Glc-6-P carrier exhibiting homologies with bacterial phosphoester transporters, such as Escherichia coli UhpT (a Glc-6-P translocase), is compatible with the fact that two cysteine residues are important for the bacterial Glc-6-P transport.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Obstet & Gynaecol, Dundee DD1 9SY, Scotland	University of Dundee	Burchell, A (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Obstet & Gynaecol, Dundee DD1 9SY, Scotland.	aburchell@ninewells.dundee.ac.uk	Clottes, Eric/C-6088-2011; Burchell, Ann/B-7475-2008					Arion W J, 1976, J Biol Chem, V251, P4891; Arion WJ, 1998, J BIOL CHEM, V273, P6223, DOI 10.1074/jbc.273.11.6223; ARION WJ, 1980, J BIOL CHEM, V255, P396; ARION WJ, 1983, J BIOL CHEM, V258, P2661; ARION WJ, 1984, BIOCHEM J, V220, P835, DOI 10.1042/bj2200835; ARION WJ, 1975, MOL CELL BIOCHEM, V6, P75, DOI 10.1007/BF01732001; ARION WJ, 1976, J BIOL CHEM, V251, P4901; ARION WJ, 1980, J BIOL CHEM, V255, P387; ARION WJ, 1972, J BIOL CHEM, V247, P2551; BERTELOOT A, 1991, J BIOL CHEM, V266, P5497; BERTELOOT A, 1995, J BIOL CHEM, V270, P21098, DOI 10.1074/jbc.270.36.21098; BLAIR JNR, 1988, BIOCHIM BIOPHYS ACTA, V964, P161, DOI 10.1016/0304-4165(88)90162-6; BREWER CF, 1967, ANAL BIOCHEM, V18, P248, DOI 10.1016/0003-2697(67)90007-3; BURCHELL A, 1988, FEBS LETT, V242, P153, DOI 10.1016/0014-5793(88)81005-6; BURCHELL A, 1988, CLIN CHIM ACTA, V173, P183, DOI 10.1016/0009-8981(88)90256-2; BURCHELL A, 1992, BIOESSAYS, V14, P395, DOI 10.1002/bies.950140609; COLILLA W, 1973, BIOCHIM BIOPHYS ACTA, V309, P328, DOI 10.1016/0005-2744(73)90031-4; COUNTAWAY JL, 1988, J BIOL CHEM, V263, P2673; FOSTER JD, 1991, BIOCHIM BIOPHYS ACTA, V1118, P91, DOI 10.1016/0167-4838(91)90445-6; FULCERI R, 1992, BIOCHEM J, V286, P813, DOI 10.1042/bj2860813; GARLAND RC, 1976, MOL CELL BIOCHEM, V12, P23, DOI 10.1007/BF01731900; Gerin I, 1997, FEBS LETT, V419, P235, DOI 10.1016/S0014-5793(97)01463-4; HEMRICKA W, 1997, FEBS LETT, V409, P17; Hill BC, 1998, ARCH BIOCHEM BIOPHYS, V350, P273, DOI 10.1006/abbi.1997.0528; Kimura T, 1997, J BIOL CHEM, V272, P580; Kishnani PS, 1997, BIOCHEM MOL MED, V61, P168, DOI 10.1006/bmme.1997.2600; KNIGHT P, 1978, BIOCHEM J, V175, P1023, DOI 10.1042/bj1751023; LANGE AJ, 1994, BIOCHEM BIOPH RES CO, V201, P302, DOI 10.1006/bbrc.1994.1702; LANGE AJ, 1980, J BIOL CHEM, V255, P8381; LEI KJ, 1993, SCIENCE, V262, P580, DOI 10.1126/science.8211187; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marcolongo P, 1996, BIOCHEM BIOPH RES CO, V219, P916, DOI 10.1006/bbrc.1996.0333; MEISSNER G, 1988, METHOD ENZYMOL, V157, P417; Nordlie R C, 1974, Curr Top Cell Regul, V8, P33; NORDLIE RC, 1985, ENZYMES BIOL MEMBR, V2, P349; NORDLIE RC, 1976, GLUCONEOGENESIS ITS, P93; Pan CJ, 1998, J BIOL CHEM, V273, P6144, DOI 10.1074/jbc.273.11.6144; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Petrov VV, 1997, J BIOL CHEM, V272, P1688, DOI 10.1074/jbc.272.3.1688; SHULZE HU, 1986, J BIOL CHEM, V261, P16571; SINGH J, 1981, BIOCHIM BIOPHYS ACTA, V678, P477, DOI 10.1016/0304-4165(81)90129-X; STDENIS JF, 1994, J CLIN ENDOCR METAB, V79, P955, DOI 10.1210/jc.79.4.955; STETTEN MR, 1967, BIOCHIM BIOPHYS ACTA, V139, P138, DOI 10.1016/0005-2744(67)90120-9; VALKILI B, 1981, BIOCHEM J, V194, P319; WADA N, 1993, J BIOL CHEM, V268, P14003; WALLIN BK, 1972, BIOCHEM BIOPH RES CO, V48, P694, DOI 10.1016/0006-291X(72)90404-4; Woltjer RL, 1997, BIOCHEMISTRY-US, V36, P9911, DOI 10.1021/bi963007v; YAN RT, 1993, CELL, V75, P37, DOI 10.1016/S0092-8674(05)80082-0; YAN RT, 1995, P NATL ACAD SCI USA, V92, P5973, DOI 10.1073/pnas.92.13.5973; ZAKIM D, 1990, J BIOL CHEM, V265, P201	50	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19391	19397		10.1074/jbc.273.31.19391	http://dx.doi.org/10.1074/jbc.273.31.19391			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677356	hybrid			2022-12-25	WOS:000075125200008
J	Hobba, GD; Lothgren, A; Holmberg, E; Forbes, BE; Francis, GL; Wallace, JC				Hobba, GD; Lothgren, A; Holmberg, E; Forbes, BE; Francis, GL; Wallace, JC			Alanine screening mutagenesis establishes tyrosine 60 of bovine insulin-like growth factor binding protein-2 as a determinant of insulin-like growth factor binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR IGF BINDING; FACTOR (IGF)-BINDING PROTEINS; FACTOR-I; FACTOR BINDING-PROTEIN-4; CHEMICAL MODIFICATION; ANALOGS; SITES; AFFINITY; SEQUENCE; RECEPTOR	The determinants of insulin-like growth factor (IGF) binding to its binding proteins (IGFBPs) are poorly characterized in terms of important residues in the IGFBP molecule. We have previously used tyrosine iodination to implicate Tyr-60 in the IGF-binding site of bovine IGFBP-2 (Hobba, G. D., Forbes, B. E., Parkinson, E. J., Francis, G;. L., and Wallace, J. C, (1996) J. Biol. Chem. 271, 30529-30536). In this report, we show that the mutagenic replacement of Tyr-60 with either Ala or Phe reduced the affinity of bIGFBP-2 for IGF-I (4.0- and 8.4-fold, respectively) and for IGF-II (3.5- and 4.0-fold, respectively). Although adjacent residues Val-59, Thr-61, Pro-62, and Arg-63 are well conserved in IGFBP family members, Ala substitution for these residues did not reduce the IGF affinity of bIGFBP-2. Kinetic analysis of the bIGFBP-2 mutants on IGF biosensor chips in the BIAcore instrument revealed that Tyr-60 --> Phe bIG-FBP-2 bound to the IGF-I surface 3.0-fold more slowly than bIGFBP-2 and was released 2.6-fold more rapidly than bIGFBP-2. We therefore propose that the hydroxyl group of Tyr-60 participates in a hydrogen bond that is important for the initial complex formation with IGF-I and the stabilization of this complex. In contrast, Tyr-60 --> Ala bIGFBP-2 associated with the IGF-I surface 5.0-fold more rapidly than bIGFBP-2 but exhibited an 18.4-fold more rapid release from this surface compared with bIGFBP-2. Thus both the aromatic nature and the hydrogen bonding potential of the tyrosyl side chain of Tyr-60 are important structural determinants of the IGF-binding site of bIGFBP-2.	Univ Adelaide, Dept Biochem, Adelaide, SA 5005, Australia; Cooperat Res Ctr Tissue Growth & Repair, Adelaide, SA 5005, Australia; CSIRO, Div Human Nutr, Adelaide, SA 5000, Australia; Pharmacia & Upjohn AB, Metab Dis Res, S-11287 Stockholm, Sweden	University of Adelaide; Commonwealth Scientific & Industrial Research Organisation (CSIRO); Pfizer; Pharmacia Corporation	Wallace, JC (corresponding author), Univ Adelaide, Dept Biochem, Adelaide, SA 5005, Australia.	jwallace@biochem.adelaide.edu.au	, John/AAP-5150-2020; Forbes, Briony/R-1838-2019	Forbes, Briony/0000-0003-4360-9927				ANDRESS DL, 1993, BIOCHEM BIOPH RES CO, V195, P25, DOI 10.1006/bbrc.1993.2004; Arai T, 1996, J BIOL CHEM, V271, P6099, DOI 10.1074/jbc.271.11.6099; BACH LA, 1993, J BIOL CHEM, V268, P9246; BAGLEY CJ, 1989, BIOCHEM J, V259, P665, DOI 10.1042/bj2590665; BALLARD FJ, 1994, INT CONGR SER, V1056, P131; BAXTER RC, 1994, HORM RES, V42, P140, DOI 10.1159/000184186; BINOUX M, 1991, MODERN CONCEPTS INSU, P329; BOURNER MJ, 1992, J CELL BIOCHEM, V48, P215; Bowles MR, 1997, ANAL BIOCHEM, V244, P133, DOI 10.1006/abio.1996.9888; CASCIERI MA, 1994, HORM RES, V41, P80, DOI 10.1159/000183965; CHERNAUSEK SD, 1995, J BIOL CHEM, V270, P11377, DOI 10.1074/jbc.270.19.11377; CLEMMONS DR, 1992, ENDOCRINOLOGY, V131, P890, DOI 10.1210/en.131.2.890; CONOVER CA, 1995, J BIOL CHEM, V270, P4395, DOI 10.1074/jbc.270.9.4395; EDWARDS PR, 1995, ANAL BIOCHEM, V231, P210, DOI 10.1006/abio.1995.1522; Forbes BE, 1998, J BIOL CHEM, V273, P4647, DOI 10.1074/jbc.273.8.4647; FRANCIS GL, 1993, BIOCHEM J, V293, P713, DOI 10.1042/bj2930713; FRANCIS GL, 1988, BIOCHEM J, V251, P95, DOI 10.1042/bj2510095; Godel H., 1992, LC GC INT, V5, P44; GYLLENSTEN UB, 1989, BIOTECHNIQUES, V7, P700; Heding A, 1996, J BIOL CHEM, V271, P13948, DOI 10.1074/jbc.271.24.13948; Ho PJ, 1997, ENDOCRINOLOGY, V138, P3811, DOI 10.1210/en.138.9.3811; Hobba GD, 1996, J BIOL CHEM, V271, P30529, DOI 10.1074/jbc.271.48.30529; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; HUHTALA ML, 1986, BIOCHEM BIOPH RES CO, V141, P263, DOI 10.1016/S0006-291X(86)80363-1; JONES JI, 1993, J BIOL CHEM, V268, P1125; JONES JI, 1993, P NATL ACAD SCI USA, V90, P10553, DOI 10.1073/pnas.90.22.10553; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landale EC, 1995, GROWTH FACTORS, V12, P245, DOI 10.3109/08977199509028963; LeRoith D, 1997, NEW ENGL J MED, V336, P633, DOI 10.1056/NEJM199702273360907; LOFAS S, 1990, J CHEM SOC CHEM COMM, P1526, DOI 10.1039/c39900001526; MALY P, 1988, J BIOL CHEM, V263, P7068; Manes S, 1997, ENDOCRINOLOGY, V138, P905, DOI 10.1210/en.138.3.905; MCCUSKER RH, 1991, ENDOCRINOLOGY, V129, P939, DOI 10.1210/endo-129-2-939; MOSS JA, 1991, J BIOL CHEM, V266, P909; OH Y, 1993, ENDOCRINOLOGY, V132, P1337, DOI 10.1210/en.132.3.1337; OH Y, 1997, J BIOL CHEM, V271, P30322; Parker A, 1996, J BIOL CHEM, V271, P13523, DOI 10.1074/jbc.271.23.13523; Rechler MM, 1997, ENDOCRINOLOGY, V138, P2645, DOI 10.1210/en.138.7.2645; RECHLER MM, 1993, VITAM HORM, V47, P1, DOI 10.1016/S0083-6729(08)60444-6; ROGHANI M, 1991, J CLIN ENDOCR METAB, V73, P658, DOI 10.1210/jcem-73-3-658; SATO A, 1993, INT J PEPT PROT RES, V41, P433; SOMMER A, 1991, MODERN CONCEPTS INSU, P329; SZABO L, 1988, BIOCHEM BIOPH RES CO, V151, P207, DOI 10.1016/0006-291X(88)90580-3; TORRES AM, 1995, J MOL BIOL, V248, P385, DOI 10.1006/jmbi.1995.0229; TUNON P, 1984, J BIOCHEM BIOPH METH, V9, P171, DOI 10.1016/0165-022X(84)90008-3; WANG JF, 1988, BIOCHEM BIOPH RES CO, V157, P718, DOI 10.1016/S0006-291X(88)80309-7	48	34	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19691	19698		10.1074/jbc.273.31.19691	http://dx.doi.org/10.1074/jbc.273.31.19691			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677398	hybrid			2022-12-25	WOS:000075125200050
J	Lee, H; Kim, HT; Yun, Y				Lee, H; Kim, HT; Yun, Y			Liver-specific enhancer II is the target for the p53-mediated inhibition of hepatitis B viral gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS HBX PROTEIN; RNA POLYMERASE-II; BINDING-PROTEIN; TRANSCRIPTION INITIATION; DNA-BINDING; WILD-TYPE; X-GENE; CORE PROMOTER; 2ND ENHANCER; P53	Here, we established the inhibitory mechanism of p53 on hepatitis B viral gene expression using HepG2 cells. Our results are as follows, First, p53 down-regulated the activities of all four promoters of hepatitis B virus (HBV), suggestive of the presence of a common element mediating the p53-dependent transcriptional repression. Second, employing the 5'-deletion constructs of the pregenomic/core promoter, the liver-specific enhancer II region was localized as a target for the p53-mediated transcriptional repression. Third, in a detailed analysis of the enhancer II region, the 5'-proximal 31-base pair region was defined as a p53-repressible element. Throughout the study, p53-mediated repression was rescued upon coexpression of the X-gene product, HBx. Finally, in an electrophoretic mobility shift assay, the defined p53-repressible element did not bind purified p53 directly, but shifted three bands in HepG2 nuclear extract, two of which was supershifted upon addition of p53 monoclonal antibody. These results display a novel mechanism of p53 dependent transcriptional repression in which p53 negatively regulates the viral-specific DNA enhancer through protein to protein interaction with an enhancer-binding protein. At the same time, the results indicate that p53 plays a defensive role against HBV by transcriptionally repressing the HBV core promoter through liver-specific enhancer II and HBx is required to counteract this inhibitory function of p53.	Mogam Biotechnol Res Inst, Signal Transduct Lab, Kyunggido 449910, South Korea		Yun, Y (corresponding author), Mogam Biotechnol Res Inst, Signal Transduct Lab, 341 Pojungri, Kyunggido 449910, South Korea.							AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; CATTANEO R, 1983, NATURE, V305, P336, DOI 10.1038/305336a0; CHEN IH, 1995, J VIROL, V69, P3647, DOI 10.1128/JVI.69.6.3647-3657.1995; CHIRILLO P, 1997, P NATL ACAD SCI USA, V92, P11215; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FEITELSON MA, 1993, ONCOGENE, V8, P1109; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; JAMEEL S, 1986, MOL CELL BIOL, V6, P710, DOI 10.1128/MCB.6.2.710; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lee H, 1995, J BIOL CHEM, V270, P31405, DOI 10.1074/jbc.270.52.31405; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LOPEZCABRERA M, 1990, P NATL ACAD SCI USA, V87, P5069, DOI 10.1073/pnas.87.13.5069; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MALPIECE Y, 1983, NUCLEIC ACIDS RES, V11, P4645, DOI 10.1093/nar/11.13.4645; Ori A, 1998, EMBO J, V17, P544, DOI 10.1093/emboj/17.2.544; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RALL LB, 1983, MOL CELL BIOL, V3, P1766, DOI 10.1128/MCB.3.10.1766; RANEY AK, 1990, J VIROL, V64, P2360, DOI 10.1128/JVI.64.5.2360-2368.1990; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAUL Y, 1985, EMBO J, V4, P427, DOI 10.1002/j.1460-2075.1985.tb03646.x; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; SU H, 1992, P NATL ACAD SCI USA, V89, P2708, DOI 10.1073/pnas.89.7.2708; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WANG Y, 1990, J VIROL, V64, P3977, DOI 10.1128/JVI.64.8.3977-3981.1990; YAGINUMA K, 1993, J VIROL, V67, P2559, DOI 10.1128/JVI.67.5.2559-2565.1993; YEE JK, 1989, SCIENCE, V246, P658, DOI 10.1126/science.2554495; YUH CH, 1993, J VIROL, V67, P142, DOI 10.1128/JVI.67.1.142-149.1993; YUH CH, 1992, J VIROL, V66, P4073, DOI 10.1128/JVI.66.7.4073-4084.1992; YUH CH, 1990, J VIROL, V64, P4281, DOI 10.1128/JVI.64.9.4281-4287.1990	42	25	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19786	19791		10.1074/jbc.273.31.19786	http://dx.doi.org/10.1074/jbc.273.31.19786			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677410	hybrid			2022-12-25	WOS:000075125200062
J	Nagiec, MM; Skrzypek, M; Nagiec, EE; Lester, RL; Dickson, RC				Nagiec, MM; Skrzypek, M; Nagiec, EE; Lester, RL; Dickson, RC			The LCB4 (YOR171c) and LCB5 (YLR260w) genes of Saccharomyces encode sphingoid long chain base kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREVISIAE; SPHINGOSINE-1-PHOSPHATE; RECEPTOR; SPHINGOLIPIDS; STRAINS; YEAST	Sphingolipid long chain bases (LCBs) and phosphorylated derivatives, particularly sphingosine l-phosphate, are putative signaling molecules. To help elucidate the physiological roles of LCB phosphates, we identified two Saccharomyces cerevisiae genes, LCB4 (YOR171c) and LCB5 (YLR260w), which encode LCB kinase activity. This conclusion is based upon the synthesis of LCB kinase activity in Escherichia coli expressing either LCB gene. LCB4 encodes most (97%) Saccharomyces LCB kinase activity, with the remainder requiring LCB5. Log phase Icb4-deleted yeast cells make no LCB phosphates, showing that the Lcb4 kinase synthesizes all detectable LCB phosphates under these growth conditions. The Lcb4 and Lcb5 proteins are paralogs with 53% amino acid identity but are not related to any known protein, thus revealing a new class of lipid kinase, Two-thirds of the Lcb4 and one-third of the Lcb5 kinase activity are in the membrane fraction of yeast cells, a puzzling finding in that neither protein contains a membrane-localization signal. Both enzymes can use phytosphingosine, dihydrosphingosine, or sphingosine as substrate. LCB4 and LCBB should be useful for probing the functions of LCB phosphates in S. cerevisiae, Potential mammalian cDNA homologs of the LCB kinase genes may prove useful in helping to understand the function of sphingosine l-phosphate in mammals.	Univ Kentucky, Med Ctr, Dept Biochem, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Dickson, RC (corresponding author), Univ Kentucky, Med Ctr, Dept Biochem, 800 Rose St, Lexington, KY 40536 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041302] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41302] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BUEDE R, 1991, J BACTERIOL, V173, P4325, DOI 10.1128/JB.173.14.4325-4332.1991; BUEHRER BM, 1993, ADV LIPID RES, V26, P59; Bunemann M, 1996, EMBO J, V15, P5527, DOI 10.1002/j.1460-2075.1996.tb00937.x; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; BURNS N, 1998, MICROBIAL GENOME MET, P61; Choi OH, 1996, NATURE, V380, P634; Cross FR, 1997, YEAST, V13, P647, DOI 10.1002/(SICI)1097-0061(19970615)13:7<647::AID-YEA115>3.0.CO;2-#; Crowther GJ, 1997, ARCH BIOCHEM BIOPHYS, V337, P284, DOI 10.1006/abbi.1996.9799; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Dickson RC, 1997, J BIOL CHEM, V272, P30196, DOI 10.1074/jbc.272.48.30196; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; HEITMAN J, 1991, P NATL ACAD SCI USA, V88, P1948, DOI 10.1073/pnas.88.5.1948; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; LESTER RL, 1993, ADV LIPID RES, V26, P253; LOUIE DD, 1976, J BIOL CHEM, V251, P4557; Nagiec MM, 1997, J BIOL CHEM, V272, P9809, DOI 10.1074/jbc.272.15.9809; Olivera A, 1998, J BIOL CHEM, V273, P12576, DOI 10.1074/jbc.273.20.12576; PATTON JL, 1992, J BACTERIOL, V174, P7180, DOI 10.1128/jb.174.22.7180-7184.1992; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Postma FR, 1996, EMBO J, V15, P2388, DOI 10.1002/j.1460-2075.1996.tb00595.x; Rius RA, 1997, FEBS LETT, V417, P173, DOI 10.1016/S0014-5793(97)01277-5; SABA DJ, 1997, J BIOL CHEM, V272, P26087; SIKORSKI RS, 1989, GENETICS, V122, P19; Skrzypek M, 1997, J BACTERIOL, V179, P1513, DOI 10.1128/jb.179.5.1513-1520.1997; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; Wells GB, 1998, J BIOL CHEM, V273, P7235, DOI 10.1074/jbc.273.13.7235; WOLFE HW, 1997, NATURE, V387, P708; YATOMI Y, 1995, BLOOD, V86, P193, DOI 10.1182/blood.V86.1.193.bloodjournal861193; ZUHERINGDORF DM, 1997, FEBS LETT, V410, P34	33	138	148	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19437	19442		10.1074/jbc.273.31.19437	http://dx.doi.org/10.1074/jbc.273.31.19437			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677363	hybrid			2022-12-25	WOS:000075125200015
J	Raman, C; Kuo, A; Deshane, J; Litchfield, DW; Kimberly, RP				Raman, C; Kuo, A; Deshane, J; Litchfield, DW; Kimberly, RP			Regulation of casein kinase 2 by direct interaction with cell surface receptor CD5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE LYMPHOCYTES-T; ANTIGEN RECEPTOR; B-CELL; SIGNAL-TRANSDUCTION; MEMBRANE GLYCOPROTEIN; NEGATIVE REGULATION; COMPLEX; SUBSTRATE; ACTIVATION; TYROSINE	The transmembrane protein CD5, expressed on all T cells and the B1 subset of B cells, modulates antigen receptor-mediated activation. We used the yeast two-hybrid system to identify proteins that interact with its cytoplasmic domain and play a role in CD5 proximal signaling events. We found that the beta subunit of the serine/threonine kinase casein kinase 2 (CK2) interacts specifically with the cytoplasmic domain of CD5. Coimmunoprecipitation experiments showed activation-independent association of CK2 with CD5 in human and murine B and T cell lines and murine splenocytes. The interaction of CK2 holoenzyme with CD5 is mediated by the amino terminus of the regulatory subunit beta. CK2 binds and phosphorylates CD5 at the CK2 motifs flanked by Ser(459) and Ser(461). Cross-linking of CD5 bads to the activation of CD5-associated CK2 in a murine B-lymphoma cell line and a human T-leukemia cell line and is independent of net recruitment of CK2 to CD5. In contrast, CK2 is not activated following cross-linking of the B cell receptor complex or the T cell receptor complex. This direct regulation of CK2 by a cell surface receptor provides a novel pathway for control of cell activation that could play a significant role in regulation of CD5-dependent antigen receptor activation in T and B cells.	Univ Alabama Birmingham, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA; Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	University of Alabama System; University of Alabama Birmingham; Western University (University of Western Ontario)	Raman, C (corresponding author), Univ Alabama Birmingham, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA.	craman@uab.edu	Litchfield, David/E-4636-2015	Litchfield, David/0000-0002-2425-6620; Kimberly, Robert/0000-0002-5330-3086	PHS HHS [P60-38520-08] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALBEROLAILA J, 1993, J IMMUNOL, V151, P4423; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Appleyard GD, 1998, CLIN EXP IMMUNOL, V111, P225; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; BEYERS AD, 1992, P NATL ACAD SCI USA, V89, P2945, DOI 10.1073/pnas.89.7.2945; Biancone L, 1996, J EXP MED, V184, P811, DOI 10.1084/jem.184.3.811; Bikah G, 1996, SCIENCE, V274, P1906, DOI 10.1126/science.274.5294.1906; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; BOUSSET K, 1994, CELL MOL BIOL RES, V40, P501; BURGESS KE, 1992, P NATL ACAD SCI USA, V89, P9311, DOI 10.1073/pnas.89.19.9311; CAMBIER JC, 1994, ANNU REV IMMUNOL, V12, P457, DOI 10.1146/annurev.immunol.12.1.457; CEUPPENS JL, 1986, J IMMUNOL, V137, P1816; Chen MZ, 1997, MOL CELL BIOL, V17, P1904, DOI 10.1128/MCB.17.4.1904; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DAVIES AA, 1992, P NATL ACAD SCI USA, V89, P6368, DOI 10.1073/pnas.89.14.6368; FABB SA, 1993, IMMUNOGENETICS, V38, P241, DOI 10.1007/BF00211525; FILHOL O, 1992, J BIOL CHEM, V267, P20577; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GaryGouy H, 1997, J IMMUNOL, V159, P3739; GIETZ RD, 1995, J BIOL CHEM, V270, P13017, DOI 10.1074/jbc.270.22.13017; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; HARDY RR, 1989, CURR OPIN IMMUNOL, V2, P189, DOI 10.1016/0952-7915(89)90187-8; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; HUANG HJS, 1987, P NATL ACAD SCI USA, V84, P204, DOI 10.1073/pnas.84.1.204; IMBODEN JB, 1990, J CLIN INVEST, V85, P130, DOI 10.1172/JCI114402; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; JONES NH, 1986, NATURE, V323, P346, DOI 10.1038/323346a0; JUNE CH, 1987, J IMMUNOL, V138, P2782; KANTOR A, IMMUNOL TODAY, V12, P388; KIPPS TJ, 1989, ADV IMMUNOL, V47, P117, DOI 10.1016/S0065-2776(08)60663-X; KROESEN BJ, 1995, CANCER RES, V55, P4409; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; LANKESTER AC, 1994, EUR J IMMUNOL, V24, P812, DOI 10.1002/eji.1830240406; LEDBETTER JA, 1985, J IMMUNOL, V135, P2331; Li DX, 1997, J BIOL CHEM, V272, P3773, DOI 10.1074/jbc.272.6.3773; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; Lin RT, 1996, MOL CELL BIOL, V16, P1401; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; Litchfield DW, 1996, BIOCHEM CELL BIOL, V74, P541, DOI 10.1139/o96-458; LUO W, 1992, J IMMUNOL, V148, P1630; LUSCHER B, 1994, EUR J BIOCHEM, V220, P521, DOI 10.1111/j.1432-1033.1994.tb18651.x; MEGGIO F, 1994, CELL MOL BIOL RES, V40, P401; OSMAN N, 1993, EUR J IMMUNOL, V23, P1173, DOI 10.1002/eji.1830230530; OSMAN N, 1992, EUR J IMMUNOL, V22, P2995, DOI 10.1002/eji.1830221135; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; Pospisil R, 1996, J EXP MED, V184, P1279, DOI 10.1084/jem.184.4.1279; RAAB M, 1994, MOL CELL BIOL, V14, P2862, DOI 10.1128/MCB.14.5.2862; RAMAN C, 1992, J IMMUNOL, V149, P3858; RESNICK D, 1994, TRENDS BIOCHEM SCI, V19, P5, DOI 10.1016/0968-0004(94)90165-1; RETH M, 1995, IMMUNOL TODAY, V16, P310; SARNO S, 1995, BIOCHEM BIOPH RES CO, V206, P171, DOI 10.1006/bbrc.1995.1024; SEN J, 1990, J IMMUNOL, V144, P2925; Simarro M, 1997, J IMMUNOL, V159, P4307; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; STAUDINGER J, 1993, J BIOL CHEM, V268, P4608; Suzuki H, 1997, J EXP MED, V186, P17, DOI 10.1084/jem.186.1.17; TARAKHOVSKY A, 1995, SCIENCE, V269, P535, DOI 10.1126/science.7542801; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; VAN DE VELDE H, 1991, NATURE, V351, P662; VANDENBERGHE P, 1993, IMMUNOLOGY, V78, P210; VERMEER LA, 1994, EUR J IMMUNOL, V24, P585, DOI 10.1002/eji.1830240314; VERWILGHEN J, 1993, J IMMUNOL, V150, P835; YU Q, 1990, NUCLEIC ACIDS RES, V18, P5296, DOI 10.1093/nar/18.17.5296	64	77	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19183	19189		10.1074/jbc.273.30.19183	http://dx.doi.org/10.1074/jbc.273.30.19183			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668105	hybrid			2022-12-25	WOS:000074974700072
J	Rodriguez-Fernandez, JL; Rozengurt, E				Rodriguez-Fernandez, JL; Rozengurt, E			Bombesin, vasopressin, lysophosphatidic acid, and sphingosylphosphorylcholine induce focal adhesion kinase activation in intact Swiss 3T3 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; SIGNAL-TRANSDUCTION PATHWAYS; STRESS FIBER FORMATION; GROWTH-FACTOR; RAPIDLY STIMULATE; ACTIN CYTOSKELETON; DNA-SYNTHESIS; MAP KINASE; CROSS-TALK; PHOSPHORYLATION	Treatment of quiescent Swiss 3T3 cells with bombesin rapidly increased focal adhesion kinase (FAR)-associated tyrosine kinase activity in immune complexes. The effect was rapid (maximum at 2.5 min) and dose dependent (half-maximum response at 0.05 nM). Addition of vasopressin, lysophosphatidic acid, and sphingosylphosphorylcholine also elicited a rapid increase in FAT-associated tyrosine kinase activity. Addition of the selective Src inhibitor pyrazolopyrimidine directly to the in vitro kinase assay potently inhibited Src kinase activity induced by bombesin but did not :effect the kinase activity of FATE measured by autophosphorylation or by synthetic substrate phosphorylation in paralell assays. In addition, Src activity was not detected in FATE immunoprecipitates using an optimal Src peptide substrate. Thus, agonist-induced tyrosine kinase activity measured in FATE immunoprecipitates is mediated by FATE activation rather than by co-immunoprecipitating Src. Bombesin-induced FATE activation is not dependent either on protein kinase C or Ca2+ mobilization but was completely blocked by treatment with cytochalasin D or by placing the cells in suspension. These findings indicate that FATE activation requires an intact actin cytoskeleton. Our results demonstrate that agonists that act via 7-transmembrane domain receptors stimulate FATE kinase activation.Treatment of quiescent Swiss 3T3 cells with bombesin rapidly increased focal adhesion kinase (FAR)-associated tyrosine kinase activity in immune complexes. The effect was rapid (maximum at 2.5 min) and dose dependent (half-maximum response at 0.05 nM). Addition of vasopressin, lysophosphatidic acid, and sphingosylphosphorylcholine also elicited a rapid increase in FAT-associated tyrosine kinase activity. Addition of the selective Src inhibitor pyrazolopyrimidine directly to the in vitro kinase assay potently inhibited Src kinase activity induced by bombesin but did not :effect the kinase activity of FATE measured by autophosphorylation or by synthetic substrate phosphorylation in paralell assays. In addition, Src activity was not detected in FATE immunoprecipitates using an optimal Src peptide substrate. Thus, agonist-induced tyrosine kinase activity measured in FATE immunoprecipitates is mediated by FATE activation rather than by co-immunoprecipitating Src. Bombesin-induced FATE activation is not dependent either on protein kinase C or Ca2+ mobilization but was completely blocked by treatment with cytochalasin D or by placing the cells in suspension. These findings indicate that FATE activation requires an intact actin cytoskeleton. Our results demonstrate that agonists that act via 7-transmembrane domain receptors stimulate FATE kinase activation.	Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90095 USA; Imperial Canc Res Fund, London WC2A 3PX, England; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cancer Research UK; University of California System; University of California Los Angeles	Rozengurt, E (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, 900 Vet Ave,Warren Hall,Rm 11-124, Los Angeles, CA 90095 USA.		Rodriguez-Fernandez, Jose Luis/Q-5021-2019	Rodriguez-Fernandez, Jose Luis/0000-0001-8874-1425				ALBERT DA, 1992, P NATL ACAD SCI USA, V89, P1597, DOI 10.1073/pnas.89.5.1597; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cary LA, 1996, J CELL SCI, V109, P1787; Charlesworth A, 1996, ONCOGENE, V12, P1337; CHARLESWORTH A, 1994, J BIOL CHEM, V269, P32528; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; ERUSALIMSKY JD, 1988, J BIOL CHEM, V263, P19188; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Hellmich MR, 1997, P NATL ACAD SCI USA, V94, P751, DOI 10.1073/pnas.94.2.751; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Ilic D, 1997, J CELL SCI, V110, P401; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; Lacerda HM, 1997, J BIOL CHEM, V272, P9587; Lacerda HM, 1996, J BIOL CHEM, V271, P439, DOI 10.1074/jbc.271.1.439; LACH EB, 1995, CELL GROWTH DIFFER, V6, P1427; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li X, 1997, J BIOL CHEM, V272, P14341, DOI 10.1074/jbc.272.22.14341; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; Mann DJ, 1997, ONCOGENE, V14, P1759, DOI 10.1038/sj.onc.1201134; MITCHELL FM, 1995, J BIOL CHEM, V270, P8623, DOI 10.1074/jbc.270.15.8623; NANBERG E, 1988, EMBO J, V7, P2741, DOI 10.1002/j.1460-2075.1988.tb03128.x; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; RANKIN S, 1994, J BIOL CHEM, V269, P704; Rankin S, 1996, J BIOL CHEM, V271, P7829, DOI 10.1074/jbc.271.13.7829; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RodriguezFernandez JL, 1996, J BIOL CHEM, V271, P27895, DOI 10.1074/jbc.271.44.27895; ROZENGURT E, 1988, PROG NUCLEIC ACID RE, V35, P261, DOI 10.1016/S0079-6603(08)60616-9; ROZENGURT E, 1991, EUR J CLIN INVEST, V21, P123, DOI 10.1111/j.1365-2362.1991.tb01801.x; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1995, CANCER SURV, V24, P81; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SCHLAEPFER DD, 1994, NATURE, V372, P786; Seckl MJ, 1996, J BIOL CHEM, V271, P29453, DOI 10.1074/jbc.271.46.29453; SECKL MJ, 1995, J BIOL CHEM, V270, P6984, DOI 10.1074/jbc.270.12.6984; SEUFFERLEIN T, 1995, CELL GROWTH DIFFER, V6, P383; Seufferlein T, 1996, MOL BIOL CELL, V7, P1865, DOI 10.1091/mbc.7.12.1865; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P27610; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24343, DOI 10.1074/jbc.270.41.24343; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; Seufferlein T, 1996, J BIOL CHEM, V271, P21471, DOI 10.1074/jbc.271.35.21471; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24334, DOI 10.1074/jbc.270.41.24334; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Withers DJ, 1997, J BIOL CHEM, V272, P2509; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1991, J BIOL CHEM, V266, P24126; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZACHARY I, 1987, J BIOL CHEM, V262, P3947; Zhou Songyang, 1995, Nature (London), V373, P536	71	73	75	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19321	19328		10.1074/jbc.273.30.19321	http://dx.doi.org/10.1074/jbc.273.30.19321			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668122	hybrid			2022-12-25	WOS:000074974700089
J	Teng-umnuay, P; Morris, HR; Dell, A; Panico, M; Paxton, T; West, CM				Teng-umnuay, P; Morris, HR; Dell, A; Panico, M; Paxton, T; West, CM			The cytoplasmic F-box binding protein SKP1 contains a novel pentasaccharide linked to hydroxyproline in Dictyostelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL-ANALYSIS; MASS-SPECTROMETRY; GLYCOPROTEIN; DISCOIDEUM; EXPRESSION; LECTIN; CDNA; FP21	SKP1 is involved in the ubiquitination of certain cell cycle and nutritional regulatory proteins for rapid turnover. SKP1 from Dictyostelium has been known to be modified by an oligosaccharide containing Fuc and Gal, which is unusual for a cytoplasmic or nuclear protein. To establish how it is glycosylated, SKP1 labeled with [H-3]FUC was purified to homogeneity and digested with endo-Lys-C. A single radioactive peptide was found after two-dimensional high performance Liquid chromatography, Analysis in a quadrupole time-of-flight mass spectrometer revealed a predominant ion with a novel mass. Tandem mass spectrometry analysis yielded a set of daughter ions which identified the peptide and showed that it was modified at Pro-143, A second series of daughter ions showed that Pro-143 was hydroxylated and derivatized with a potentially Linear pentasaccharide, Hex-->Hex-->Fuc-->Hex-->HexNAc-->(HyPro). The attachment site was confirmed by Edman degradation. Gas chromatography-mass spectrometry analysis of trimethylsilyl-derivatives of overexpressed SKP1 after methanolysis showed the HexNAc to be GlcNAc. Exoglycosidase digestions of the glycopeptide from normal SKP1 and from a fucosylation mutant, followed by matrix-assisted laser desorption time-of-flight mass spectrometry analysis, showed that the sugar chain consisted of D-Galp alpha 1-->6-D-Galp alpha 1-->L-FUCp alpha 1-->2-D-Galp beta 1-->3GlcNAc. Matrix-assisted laser-desorption time-of-flight mass spectrometry analysis of all SKP1 peptides resolved by reversed phase-high performance liquid chromatography showed that SKP1 was only partially hydroxylated at Pro-143 and that all hydroxylated SKP1 was completely glycosylated, Thus SKP1 is variably modified by an unusual linear pentasaccharide, suggesting the localization of a novel glycosylation pathway in the cytoplasm.	Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AY, England	State University System of Florida; University of Florida; Imperial College London	West, CM (corresponding author), Univ Florida, Coll Med, Dept Anat & Cell Biol, 1600 SW Archer Rd, Gainesville, FL 32610 USA.	westcm@college.med.ufl.edu			Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLEN AK, 1978, BIOCHEM J, V171, P665, DOI 10.1042/bj1710665; ALONSO MD, 1995, FASEB J, V9, P1126, DOI 10.1096/fasebj.9.12.7672505; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; CHEN H, 1995, GENOMICS, V27, P389, DOI 10.1006/geno.1995.1068; DELL A, 1987, ADV CARBOHYD CHEM BI, V45, P19, DOI 10.1016/S0065-2318(08)60136-5; Demetrick DJ, 1996, CYTOGENET CELL GENET, V73, P104, DOI 10.1159/000134318; ELWOOD PC, 1988, ANAL BIOCHEM, V175, P202, DOI 10.1016/0003-2697(88)90379-X; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; FERGUSON TA, 1994, DEV GROWTH DIFFER, V36, P597; FINCHER GB, 1974, BIOCHEM J, V139, P535, DOI 10.1042/bj1390535; FREEZE HH, 1997, NEW COMPREHENSIVE BI, V29, P91; GONZALEZYANES B, 1992, J BIOL CHEM, V267, P9595; Greenwell P, 1997, GLYCOCONJUGATE J, V14, P159, DOI 10.1023/A:1018581503164; HARRIS RJ, 1993, BIOCHEMISTRY-US, V32, P6539, DOI 10.1021/bi00077a007; Hart GW, 1997, ANNU REV BIOCHEM, V66, P315, DOI 10.1146/annurev.biochem.66.1.315; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; Ingram GC, 1997, EMBO J, V16, P6521, DOI 10.1093/emboj/16.21.6521; JACOB GS, 1994, METHOD ENZYMOL, V230, P280; Jung E, 1996, EMBO J, V15, P1238, DOI 10.1002/j.1460-2075.1996.tb00465.x; Kaplan KB, 1997, CELL, V91, P491, DOI 10.1016/S0092-8674(00)80435-3; Kasai K, 1996, J BIOCHEM-TOKYO, V119, P1; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KOZAROV E, 1995, J BIOL CHEM, V270, P3022, DOI 10.1074/jbc.270.7.3022; Li FN, 1997, EMBO J, V16, P5629, DOI 10.1093/emboj/16.18.5629; Liang Y, 1997, GENE, V184, P163, DOI 10.1016/S0378-1119(96)00590-2; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; MARCHASE RB, 1993, J BIOL CHEM, V268, P8341; Medina L, 1998, GLYCOBIOLOGY, V8, P191, DOI 10.1093/glycob/8.2.191; Morris HR, 1996, RAPID COMMUN MASS SP, V10, P889, DOI 10.1002/(SICI)1097-0231(19960610)10:8<889::AID-RCM615>3.0.CO;2-F; Morris HR, 1997, J PROTEIN CHEM, V16, P469, DOI 10.1023/A:1026309410737; MORRIS HR, 1981, BIOCHEM BIOPH RES CO, V101, P623, DOI 10.1016/0006-291X(81)91304-8; REBSTEIN PJ, 1993, DEV GENET, V14, P347, DOI 10.1002/dvg.1020140504; Selzer J, 1996, J BIOL CHEM, V271, P25173, DOI 10.1074/jbc.271.41.25173; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; SOWDEN J, 1995, GENOMICS, V29, P145, DOI 10.1006/geno.1995.1225; Trinchera M, 1996, FEBS LETT, V395, P68, DOI 10.1016/0014-5793(96)01003-4; UroCoste E, 1997, NEUROREPORT, V8, P1675, DOI 10.1097/00001756-199705060-00023; West CM, 1996, J BIOL CHEM, V271, P12024, DOI 10.1074/jbc.271.20.12024; West CM, 1997, GENE, V200, P1, DOI 10.1016/S0378-1119(97)00194-7; WEST CM, 1986, MOL CELL BIOCHEM, V72, P121; Yoho ER, 1997, HEARING RES, V104, P47, DOI 10.1016/S0378-5955(96)00183-9; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; Zhang Y, 1997, GLYCOBIOLOGY, V7, P1153, DOI 10.1093/glycob/7.8.1153	44	65	71	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18242	18249		10.1074/jbc.273.29.18242	http://dx.doi.org/10.1074/jbc.273.29.18242			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660787	hybrid			2022-12-25	WOS:000074828500042
J	Chen, YR; Tan, TH				Chen, YR; Tan, TH			Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin	ONCOGENE			English	Article						curcumin; JNK; c-Jun; AP-1; NF-kappa B; cell signaling	ACTIVATED PROTEIN-KINASE; NECROSIS-FACTOR-ALPHA; KAPPA-B-ALPHA; TRANSDUCTION PATHWAYS; TRANSCRIPTION FACTORS; COLON CARCINOGENESIS; DIETARY CURCUMIN; GAMMA-RADIATION; TUMOR PROMOTION; STRESS	Curcumin, a dietary pigment in curry, suppresses tumor initiation and tumor promotion. Curcumin is also a potent inhibitor for AP-1 and NF-kappa B activation. In this report, we show that curcumin inhibits JNK activation by various agonists including PMA plus ionomycin, anisomycin, UV-C, gamma radiation, TNF-alpha, and sodium orthovanadate. Although both JNK and ERK activation by phorbol 12-myristate 13-acetate (PMA) plus ionomycin were suppressed by curcumin, the JNK pathway was more sensitive. The IC50 (50% inhibition concentration) of curcumin was between 5-10 mu M for JNK activation and was 20 mu M for ERK activation. Tn transfection assays, curcumin moderately suppressed MEKK1-induced JNK activation; however, it effectively blocked JNK activation caused by co-transfection of TAK1, CCK, or HPK1. Curcumin did not directly inhibit JNK, SEK1, MEKK1 or HPK1 activity. Although cnrcumin suppressed TAK1 and GCK activities at high concentrations, this inhibition cannot fully account for the JNK inhibition by curcumin in vivo. Our data suggest that curcumin may affect the JNK pathway by interfering with the signaling molecule(s) at the same level or proximally upstream of the MAPKKK level. Taken together, the inhibition of the MEKK1-JNK pathway reveals a possible mechanism of suppression of AP-1 and NF-kappa B signaling by curcumin, and may explain the potent anti-inflammatory and anti-carcinogenic effects of this chemical.	Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA	Baylor College of Medicine	Tan, TH (corresponding author), Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA.		Tan, Tse-Hua/E-3983-2010; Chen, Yi-Rong/E-3991-2010; Chen, Yi-Rong/CAF-2186-2022; Chen, Yi-Rong/CAH-7991-2022; Tan, Tse-Hua/ABD-7080-2021	Tan, Tse-Hua/0000-0003-4969-3170; Chen, Yi-Rong/0000-0002-4307-3002; Chen, Yi-Rong/0000-0002-4307-3002; Chen, Yi-Rong/0000-0002-4307-3002; Tan, Tse-Hua/0000-0003-4969-3170	NIAID NIH HHS [R01-AI38649] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038649] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HANAZAWA S, 1993, J BIOL CHEM, V268, P9526; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; HUANG MT, 1994, CANCER RES, V54, P5841; HUANG MT, 1988, CANCER RES, V48, P5941; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Janknecht R, 1997, J BIOL CHEM, V272, P4219, DOI 10.1074/jbc.272.7.4219; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KELLY K, 1995, CURR OPIN IMMUNOL, V7, P327, DOI 10.1016/0952-7915(95)80106-5; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Meyer CF, 1996, J BIOL CHEM, V271, P8971, DOI 10.1074/jbc.271.15.8971; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; RAO CV, 1995, CANCER RES, V55, P259; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; RUBY AJ, 1995, CANCER LETT, V94, P79, DOI 10.1016/0304-3835(95)03827-J; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; Wang XHS, 1996, J BIOL CHEM, V271, P31607; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAN MH, 1994, NATURE, V372, P798; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378	52	352	366	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 16	1998	17	2					173	178		10.1038/sj.onc.1201941	http://dx.doi.org/10.1038/sj.onc.1201941			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZZ211	9674701				2022-12-25	WOS:000074706700005
J	Dutra, MB; Ambesi, A; Slayman, CW				Dutra, MB; Ambesi, A; Slayman, CW			Structure-function relationships in membrane segment 5 of the yeast Pma1 H+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; P-TYPE ATPASES; SARCOPLASMIC-RETICULUM; PLASMA-MEMBRANE; TRANSMEMBRANE DOMAIN; AMINO-ACIDS; SCANNING MUTAGENESIS; NEUROSPORA-CRASSA; ALPHA-SUBUNIT; CONSEQUENCES	Membrane segment 5 (M5) is thought to play a direct role in cation transport by the sarcoplasmic reticulum Ca2+-ATPase and the Na+,K+-ATPase of animal cells. In this study, we have examined M5 of the yeast plasma membrane H+-ATPase by alanine-scanning mutagenesis. Mutant enzymes were expressed behind an inducible heat-shock promoter in yeast secretory vesicles as described previously (Nakamoto, R, K,, Rao, R,, and Slayman, C, W, (1991) J, Biol, Chem, 266, 7940-7949), Three substitutions (R695A, H701A, and L706A) led to misfolding of the H+-ATPase as evidenced by extreme sensitivity to trypsin; the altered proteins were arrested in biogenesis, and the mutations behaved genetically as dominant lethals. The remaining mutants reached the secretory vesicles in sufficient amounts to be characterized in detail, One of them (Y691A) had no detectable ATPase activity and appeared, based on trypsinolysis in the presence and absence of ligands, to be blocked in the E-1-to-E-2 step of the reaction cycle. Alanine substitution at an adjacent position (V692A) had substantial ATPase activity (54%), but was likewise affected in the E-1-to-E-2 step, as evidenced by shifts in its apparent affinity for ATP, H+, and orthovanadate, Among the mutants that were sufficiently active to be assayed for ATP-dependent H+ transport by acridine orange fluorescence quenching, none showed an appreciable defect in the coupling of transport to ATP hydrolysis, The only residue for which the data pointed to a possible role in cation liganding was Ser-699, where removal of the hydroxyl group (S699A and S699C) led to a modest acid shift in the pH dependence of the ATPase, This change was substantially smaller than the 13-30-fold decrease in K+ affinity seen in corresponding mutants of the Na+,K+-ATPase (Arguello, J, M,, and Lingrel, J, B (1995) J, Biol, Chem, 270, 22764-22771), Taken together, the results do not give firm evidence for a transport site in M5 of the yeast H+-ATPase, but indicate a critical role for this membrane segment in protein folding and in the conformational changes that accompany the reaction cycle. It is therefore worth noting that the mutationally sensitive residues lie along one face of a putative alpha-helix.	Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA	Yale University; Yale University	Ambesi, A (corresponding author), Yale Univ, Sch Med, Dept Genet, 333 Cedar St, New Haven, CT 06510 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM015761, R01GM015761] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM15761] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambesi A, 1997, ANAL BIOCHEM, V251, P127, DOI 10.1006/abio.1997.2257; Ambesi A, 1996, J BIOL CHEM, V271, P22999, DOI 10.1074/jbc.271.38.22999; ANDERSEN JP, 1995, J BIOL CHEM, V270, P908, DOI 10.1074/jbc.270.2.908; ANDERSEN JP, 1994, FEBS LETT, V354, P93, DOI 10.1016/0014-5793(94)01100-1; Andersen JP, 1996, BBA-BIOENERGETICS, V1275, P118, DOI 10.1016/0005-2728(96)00060-6; ANDERSEN JP, 1992, J BIOL CHEM, V267, P2767; ARGUELLO JM, 1994, J BIOL CHEM, V269, P6892; ARGUELLO JM, 1995, J BIOL CHEM, V270, P22764, DOI 10.1074/jbc.270.39.22764; Arguello JM, 1996, J BIOL CHEM, V271, P24610, DOI 10.1074/jbc.271.40.24610; Blostein R, 1997, J BIOL CHEM, V272, P24987, DOI 10.1074/jbc.272.40.24987; CID A, 1987, CURR GENET, V12, P105, DOI 10.1007/BF00434664; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; Counillon L, 1997, BIOCHEMISTRY-US, V36, P2951, DOI 10.1021/bi9615405; CYRKLAFF M, 1995, EMBO J, V14, P1854, DOI 10.1002/j.1460-2075.1995.tb07177.x; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FAGAN MJ, 1994, J MOL EVOL, V38, P57; FENG JN, 1994, BIOCHEMISTRY-US, V33, P4218, DOI 10.1021/bi00180a015; FENG JN, 1995, CELL MOL BIOL RES, V41, P29; Fiske CH, 1925, J BIOL CHEM, V66, P375; GEITZ RD, 1988, GENE, V74, P527; HARRIS SL, 1994, P NATL ACAD SCI USA, V91, P10531, DOI 10.1073/pnas.91.22.10531; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; Koster JC, 1996, J BIOL CHEM, V271, P2413, DOI 10.1074/jbc.271.5.2413; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Nakamoto RK, 1998, J BIOL CHEM, V273, P7338, DOI 10.1074/jbc.273.13.7338; NAKAMOTO RK, 1991, J BIOL CHEM, V266, P7940; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; Ohta H, 1997, BBA-BIOENERGETICS, V1319, P9, DOI 10.1016/S0005-2728(97)00007-8; PERLIN DS, 1986, ARCH BIOCHEM BIOPHYS, V248, P53, DOI 10.1016/0003-9861(86)90400-5; Portillo F, 1997, FEBS LETT, V402, P136, DOI 10.1016/S0014-5793(96)01515-3; RAO R, 1992, ANN NY ACAD SCI, V671, P195, DOI 10.1111/j.1749-6632.1992.tb43796.x; RAO R, 1996, MYCOTA, V3, P29; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; VILSEN B, 1992, J BIOL CHEM, V267, P25739; VILSEN B, 1995, BIOCHEMISTRY-US, V34, P1455, DOI 10.1021/bi00004a041; Wach A, 1996, BIOCHEMISTRY-US, V35, P883, DOI 10.1021/bi951998r	40	25	28	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17411	17417		10.1074/jbc.273.28.17411	http://dx.doi.org/10.1074/jbc.273.28.17411			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651327	hybrid			2022-12-25	WOS:000074816100020
J	Kostenis, E; Zeng, FY; Wess, J				Kostenis, E; Zeng, FY; Wess, J			Functional characterization of a series of mutant G protein alpha(q) subunits displaying promiscuous receptor coupling properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-BINDING; HETEROTRIMERIC G-PROTEINS; G-BETA-GAMMA; PHOSPHOLIPASE-C; AMINO-TERMINUS; MUSCARINIC RECEPTOR; SYNTHETIC PEPTIDES; PALMITOYLATION; IDENTIFICATION; MYRISTOYLATION	The N termini of two G protein alpha subunits, alpha(q) and alpha(11), differ from those of other alpha subunits in that they display a unique, highly conserved six-amino acid extension (MTLESI(M)). We recently showed that an alpha(q) deletion mutant lacking these six amino acids (in contrast to wild type alpha(q)) was able to couple to several different G(s)- and G(L/o)-coupled receptors, apparently due to promiscuous receptor/G protein coupling (Kostenis, E., Degtyarev, M. Y., Conklin, B. R., and Wess, J. (1997) J. Biol. Chem. 272, 19107-19110). To study which specific amino acids within the N-terminal segment of alpha(q/11) are critical for constraining the receptor coupling selectivity of these subunits, this region of alpha(q) was subjected to systematic deletion and alanine scanning mutagenesis. All mutant alpha(q) constructs (or wild type alpha(q) as a control) were coexpressed (in COS-7 cells) with the m2 muscarinic or the D2 dopamine receptors, two prototypical G(L/o)-coupled receptors, and Ligand-induced increases in inositol phosphate production were determined as a measure of G protein activation. Surprisingly, all 14 mutant G proteins studied (but not wild type alpha(q)) gained the ability to productively interact with the two G(L/o)-linked receptors, Similar results were obtained when we examined the ability of selected mutant alpha(q) subunits to couple to the G(s)-coupled beta 2-adrenergic receptor, Additional experiments indicated that the functional promiscuity displayed by all investigated mutant alpha(q) constructs was not due to overexpression (as compared with wild type alpha(q)), lack of palmitoylation, or initiation of translation at a downstream ATG codon (codon seven). These data are consistent with the notion that the six-amino acid extension characteristic for alpha(q/11) subunits forms a tightly folded protein subdomain that is critical for regulating the receptor coupling selectivity of these subunits.	NIDDK, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Wess, J (corresponding author), NIDDK, Bioorgan Chem Lab, NIH, Bldg 8A,Rm B1A-05, Bethesda, MD 20892 USA.							AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; Chen BW, 1996, BBA-BIOMEMBRANES, V1281, P125, DOI 10.1016/0005-2736(96)00039-9; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Conklin BR, 1996, MOL PHARMACOL, V50, P885; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; CULLEN BR, 1987, METHOD ENZYMOL, V152, P688; DEGTYAREV MY, 1994, J BIOL CHEM, V269, P30898; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; EDGERTON MD, 1994, FEBS LETT, V354, P195, DOI 10.1016/0014-5793(94)01101-X; GARCIA PD, 1995, EMBO J, V14, P4460, DOI 10.1002/j.1460-2075.1995.tb00125.x; GOCAYNE J, 1987, P NATL ACAD SCI USA, V84, P8296, DOI 10.1073/pnas.84.23.8296; GRANDY DK, 1989, P NATL ACAD SCI USA, V86, P9762, DOI 10.1073/pnas.86.24.9762; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; Hepler JR, 1996, J BIOL CHEM, V271, P496, DOI 10.1074/jbc.271.1.496; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P12655; JIANG MS, 1991, P NATL ACAD SCI USA, V88, P3907, DOI 10.1073/pnas.88.9.3907; JUSTICE JM, 1995, J BIOL CHEM, V270, P6436, DOI 10.1074/jbc.270.12.6436; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; Kostenis E, 1997, J BIOL CHEM, V272, P23675, DOI 10.1074/jbc.272.38.23675; Kostenis E, 1997, J BIOL CHEM, V272, P19107, DOI 10.1074/jbc.272.31.19107; Kostenis E, 1997, BIOCHEMISTRY-US, V36, P1487, DOI 10.1021/bi962554d; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; Martin EL, 1996, J BIOL CHEM, V271, P361, DOI 10.1074/jbc.271.1.361; MCCALLUM JF, 1995, BIOCHEM J, V310, P1021, DOI 10.1042/bj3101021; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; NAKAMURA F, 1991, J BIOL CHEM, V266, P12676; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; OFFERMANNS S, 1994, MOL PHARMACOL, V45, P890; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; Onrust R, 1997, SCIENCE, V275, P381, DOI 10.1126/science.275.5298.381; Osawa S, 1995, J BIOL CHEM, V270, P31052, DOI 10.1074/jbc.270.52.31052; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; RASENICK MM, 1994, J BIOL CHEM, V269, P21519; RENSDOMIANO S, 1995, FASEB J, V9, P1059, DOI 10.1096/fasebj.9.11.7649405; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5467; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SHAPIRA H, 1994, FEBS LETT, V348, P89, DOI 10.1016/0014-5793(94)00570-2; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; TAYLOR JM, 1994, J BIOL CHEM, V269, P27618; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WATSON S, 1994, G PROTEIN LINKED REC, P1; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; WILSON PT, 1995, J BIOL CHEM, V270, P9667, DOI 10.1074/jbc.270.16.9667; Zhu X, 1996, P NATL ACAD SCI USA, V93, P2827, DOI 10.1073/pnas.93.7.2827	60	52	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17886	17892		10.1074/jbc.273.28.17886	http://dx.doi.org/10.1074/jbc.273.28.17886			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651394	hybrid			2022-12-25	WOS:000074816100087
J	Mikita, T; Daniel, C; Wu, PG; Schindler, U				Mikita, T; Daniel, C; Wu, PG; Schindler, U			Mutational analysis of the STAT6 SH2 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; CYTOKINE RECEPTORS; SIGNAL TRANSDUCERS; DNA-BINDING; SPECIFICITY; INTERFERON; PROTEIN; PEPTIDE; ACTIVATORS; MOTIFS	The SH2 domain of the STAT family of transcription factors is essential for STAT binding to phosphorylated cytoplasmic domains of activated cytokine receptors, Furthermore, the same domain mediates dimerization of activated STAT monomers, a prerequisite for DNA binding by this family of proteins. To identify amino acid residues within the STAT protein that mediate these various interactions, we have carried out an extensive mutational analysis of the Stat6 SH2 domain. Recombinant proteins carrying C-terminal deletions or double alanine substitutions were expressed in mammalian and insect cells and assayed for DNA binding, transcription activation, tyrosine phosphorylation, and the ability to interact with a tyrosine-phosphorylated peptide derived from the interleukin-4 receptor signaling chain. From these studies, we have identified amino acids that are required for both DNA binding and interleukin-4 receptor interaction, as well as residues that when mutated impair only one of the two functions. Our results suggest that the structural homology between the SH2 domain of Stat6 and that of the distantly related Src protein may be higher than predicted on the basis of primary amino acid sequence comparisons. However, the two types of SH2 domains may differ at their C-terminal ends.	Tularik Inc, San Francisco, CA 94080 USA		Schindler, U (corresponding author), Tularik Inc, 2 Corp Dr, San Francisco, CA 94080 USA.	uli@tularik.com						BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; Gupta S, 1996, EMBO J, V15, P1075, DOI 10.1002/j.1460-2075.1996.tb00445.x; HELM MH, 1995, SCIENCE, V267, P1347; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Inoue M, 1997, J BIOL CHEM, V272, P9550; IVASHKIV LB, 1995, IMMUNITY, V3, P1, DOI 10.1016/1074-7613(95)90152-3; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; Kohlhuber F, 1997, MOL CELL BIOL, V17, P695, DOI 10.1128/MCB.17.2.695; Li XX, 1996, J BIOL CHEM, V271, P5790, DOI 10.1074/jbc.271.10.5790; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; Mikita T, 1996, MOL CELL BIOL, V16, P5811; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; Qureshi SA, 1996, MOL CELL BIOL, V16, P288; Sasse J, 1997, MOL CELL BIOL, V17, P4677, DOI 10.1128/MCB.17.8.4677; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SONGYANG Z, 1995, J BIOL CHEM, V270, P26029, DOI 10.1074/jbc.270.44.26029; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; Yan H, 1996, EMBO J, V15, P1064, DOI 10.1002/j.1460-2075.1996.tb00444.x; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	35	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17634	17642		10.1074/jbc.273.28.17634	http://dx.doi.org/10.1074/jbc.273.28.17634			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651359	hybrid			2022-12-25	WOS:000074816100052
J	Pardee, TS; Bangur, CS; Ponticelli, AS				Pardee, TS; Bangur, CS; Ponticelli, AS			The N-terminal region of yeast TFIIB contains two adjacent functional domains involved in stable RNA polymerase II binding and transcription start site selection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ACTIVATION DOMAINS; PROTEIN; SUBUNIT; MUTATIONS; INTERACTS; TATA; INITIATION; PROMOTERS; COMPLEX	The general transcription factor IIB (TFIIB) is required for accurate and efficient transcription of protein-coding genes by RNA polymerase II (RNAPII). To define functional domains in the highly conserved N-terminal region of TFIIB, we have analyzed 14 site-directed substitution mutants of yeast TFIIB for their ability to support cell viability, transcription in vitro, accurate start site selection in vitro and in vivo, and to form stable complexes with purified RNAPII in vitro. Mutations impairing the formation of stable TFIIB RNAPII complexes mapped to the zinc ribbon fold, whereas mutations conferring downstream shifts in transcription start site selection were identified at multiple positions within a highly conserved homology block adjacent and C-terminal to the zinc ribbon. These results demonstrate that the N-terminal region of yeast TFIIB contains two separable and adjacent functional domains involved in stable RNAPII binding and transcription start site selection, suggesting that downstream shifts in transcription start site selection do not result from impairment of stable TFIIB RNAPII binding. We discuss models for yeast start site selection in which TFIIB may affect the ability of preinitiation complexes to interact with downstream DNA or to affect start site recognition by a scanning polymerase.	SUNY Buffalo, Sch Med & Biomed Sci, Dept Biochem, Buffalo, NY 14214 USA; SUNY Buffalo, Sch Med & Biomed Sci, Ctr Adv Mol Biol & Immunol, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Ponticelli, AS (corresponding author), SUNY Buffalo, Sch Med & Biomed Sci, Dept Biochem, Buffalo, NY 14214 USA.			Pardee, Timothy/0000-0002-1186-6948	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051124, R29GM051124] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51124] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGBY S, 1995, CELL, V82, P857, DOI 10.1016/0092-8674(95)90483-2; Bangur CS, 1997, MOL CELL BIOL, V17, P6784, DOI 10.1128/MCB.17.12.6784; BERROTERAN RW, 1994, MOL CELL BIOL, V14, P226, DOI 10.1128/MCB.14.1.226; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; Bushnell DA, 1996, J BIOL CHEM, V271, P20170, DOI 10.1074/jbc.271.33.20170; Chiang YC, 1996, J BIOL CHEM, V271, P32359, DOI 10.1074/jbc.271.50.32359; COLGAN J, 1995, P NATL ACAD SCI USA, V92, P1955, DOI 10.1073/pnas.92.6.1955; Fang SM, 1996, J BIOL CHEM, V271, P11703, DOI 10.1074/jbc.271.20.11703; FRANKLIN CC, 1995, BIOCHEM J, V305, P967, DOI 10.1042/bj3050967; FURTERGRAVES EM, 1994, NUCLEIC ACIDS RES, V22, P4932, DOI 10.1093/nar/22.23.4932; GIARDINA C, 1993, SCIENCE, V261, P759, DOI 10.1126/science.8342041; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GUARENTE L, 1987, ANNU REV GENET, V21, P425, DOI 10.1146/annurev.genet.21.1.425; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HADZIC E, 1995, MOL CELL BIOL, V15, P4507; HULL MW, 1995, GENE DEV, V9, P481, DOI 10.1101/gad.9.4.481; Knaus R, 1996, EMBO J, V15, P1933, DOI 10.1002/j.1460-2075.1996.tb00544.x; Lagrange T, 1998, GENE DEV, V12, P34, DOI 10.1101/gad.12.1.34; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; MACDONALD PN, 1995, J BIOL CHEM, V270, P4748, DOI 10.1074/jbc.270.9.4748; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; PINTO I, 1994, J BIOL CHEM, V269, P30569; PONTICELLI AS, 1995, MOL CELL BIOL, V15, P983; PONTICELLI AS, 1990, MOL CELL BIOL, V10, P2832, DOI 10.1128/MCB.10.6.2832; SAUER F, 1995, NATURE, V375, P162, DOI 10.1038/375162a0; STRUHL K, 1987, CELL, V49, P295, DOI 10.1016/0092-8674(87)90277-7; Sun ZW, 1996, NUCLEIC ACIDS RES, V24, P2560, DOI 10.1093/nar/24.13.2560; XING LP, 1995, J BIOL CHEM, V270, P17488, DOI 10.1074/jbc.270.29.17488; Zhu WL, 1996, NAT STRUCT BIOL, V3, P122, DOI 10.1038/nsb0296-122	32	74	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17859	17864		10.1074/jbc.273.28.17859	http://dx.doi.org/10.1074/jbc.273.28.17859			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651390	hybrid			2022-12-25	WOS:000074816100083
J	Vaughan, M				Vaughan, M			G protein-coupled receptors minireview series	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Editorial Material									NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Vaughan, M (corresponding author), NHLBI, Pulm Crit Care Med Branch, NIH, Bldg 10, Bethesda, MD 20892 USA.								0	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17297	17297		10.1074/jbc.273.28.17297	http://dx.doi.org/10.1074/jbc.273.28.17297			1	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651308	hybrid			2022-12-25	WOS:000074816100001
J	Jones, PC; Jiang, WP; Fillingame, RH				Jones, PC; Jiang, WP; Fillingame, RH			Arrangement of the multicopy H+-translocating subunit c in the membrane sector of the Escherichia coli F1F0 ATP synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLAR LOOP REGION; DIRECTED MUTAGENESIS; GENE DUPLICATION; F-0; PROTEINS; COMPLEX; F1-ATPASE; ROTATION; EPSILON; BINDING	The multicopy subunit c of the H+-transporting F1F0 ATP synthase of Escherichia coli is thought to fold across the membrane as a hairpin of two hydrophobic cu-helices. The conserved Asp(61), centered in the second transmembrane helix, is essential for H+ transport. In this study, we have made sequential Cys substitutions across both transmembrane helices and used disulfide cross-link formation to determine the oligomeric arrangement of the c subunits. Cross link formation between single Cys substitutions in helix 1 provided initial limitations on how the subunits could be arranged. Double Cys substitutions at positions 14/16, 16/18, and 21/23 in helix 1 and 70/72 in helix 2 led to the formation of cross-linked multimers upon oxidation. Double Cys substitutions in helix 1 and helix 2, at residues 14/72, 21/65, and 20/66, respectively, also formed cross-linked multimers. These results indicate that at least 10 and probably 12 subunits c interact in a front-to-back fashion to form a ring-like arrangement in F-0. Helix 1 packs at the interior and helix 2 at the periphery of the ring. The model indicates that the Asp(61) carboxylate is centered between the helical faces of adjacent subunit c at the center of a four-helix bundle.	Univ Wisconsin, Dept Biomol Chem, Sch Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Fillingame, RH (corresponding author), Univ Wisconsin, Dept Biomol Chem, Sch Med, 587 Med Sci Bldg, Madison, WI 53706 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023105, R01GM023105] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23105] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BIRKENHAGER R, 1995, EUR J BIOCHEM, V230, P58, DOI 10.1111/j.1432-1033.1995.tb20534.x; Blair A, 1996, MICROBIOL-SGM, V142, P17, DOI 10.1099/13500872-142-1-17; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Capaldi RA, 1996, J BIOENERG BIOMEMBR, V28, P397, DOI 10.1007/BF02113980; COX GB, 1984, BIOCHIM BIOPHYS ACTA, V768, P201, DOI 10.1016/0304-4173(84)90016-8; CROSS RL, 1990, FEBS LETT, V259, P227, DOI 10.1016/0014-5793(90)80014-A; Dimroth P, 1997, BBA-BIOENERGETICS, V1318, P11, DOI 10.1016/S0005-2728(96)00127-2; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; Engelbrecht S, 1997, FEBS LETT, V414, P485, DOI 10.1016/S0014-5793(97)00997-6; Fillingame RH, 1995, BIOCHEM SOC T, V23, P760, DOI 10.1042/bst0230760; Fillingame RH, 1997, J EXP BIOL, V200, P217; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FINBOW ME, 1992, PROTEIN ENG, V5, P7, DOI 10.1093/protein/5.1.7; FOSTER DL, 1982, J BIOL CHEM, V257, P2009; FRAGA D, 1989, J BIOL CHEM, V264, P6797; FRIEDL P, 1979, EUR J BIOCHEM, V100, P175, DOI 10.1111/j.1432-1033.1979.tb02046.x; GIRVIN ME, 1995, BIOCHEMISTRY-US, V34, P1635, DOI 10.1021/bi00005a020; GIRVIN ME, 1989, BIOCHEMISTRY-US, V28, P4340, DOI 10.1021/bi00436a032; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; Harvey WR, 1997, J EXP BIOL, V200, P203; HERMOLIN J, 1995, J BIOL CHEM, V270, P2815, DOI 10.1074/jbc.270.6.2815; HOLZENBURG A, 1993, EUR J BIOCHEM, V213, P21, DOI 10.1111/j.1432-1033.1993.tb17730.x; HOPPE J, 1984, BIOCHEMISTRY-US, V23, P5610, DOI 10.1021/bi00318a035; Howitt SM, 1996, J BIOENERG BIOMEMBR, V28, P415, DOI 10.1007/BF02113983; Jones PC, 1995, BIOCHEM J, V312, P739, DOI 10.1042/bj3120739; Kaim G, 1997, BIOCHEMISTRY-US, V36, P9185, DOI 10.1021/bi970831q; KAKINUMA Y, 1993, BIOCHEM BIOPH RES CO, V195, P1063, DOI 10.1006/bbrc.1993.2152; KLUGE C, 1993, BIOCHEMISTRY-US, V32, P10378, DOI 10.1021/bi00090a013; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; Lill H, 1996, J BIOL CHEM, V271, P32737, DOI 10.1074/jbc.271.51.32737; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MCDERMOTT G, 1995, NATURE, V374, P517, DOI 10.1038/374517a0; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MILLER MJ, 1990, P NATL ACAD SCI USA, V87, P4900, DOI 10.1073/pnas.87.13.4900; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; Rahlfs S, 1997, FEBS LETT, V404, P269, DOI 10.1016/S0014-5793(97)00088-4; REES DC, 1989, ANNU REV BIOCHEM, V58, P607; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; Singh S, 1996, FEBS LETT, V397, P30, DOI 10.1016/S0014-5793(96)01127-1; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Takeyasu K, 1996, FEBS LETT, V392, P110, DOI 10.1016/0014-5793(96)00796-X; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIK SB, 1994, J BIOL CHEM, V269, P30364; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; Watts SD, 1996, J BIOL CHEM, V271, P28341, DOI 10.1074/jbc.271.45.28341; ZHANG Y, 1995, J BIOL CHEM, V270, P87, DOI 10.1074/jbc.270.1.87; ZHANG Y, 1995, J BIOL CHEM, V270, P24609, DOI 10.1074/jbc.270.41.24609	52	95	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17178	17185		10.1074/jbc.273.27.17178	http://dx.doi.org/10.1074/jbc.273.27.17178			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642286	hybrid			2022-12-25	WOS:000074545200076
J	Hammami-Hauasli, N; Schumann, H; Raghunath, M; Kilgus, O; Luthi, U; Luger, T; Bruckner-Tuderman, L				Hammami-Hauasli, N; Schumann, H; Raghunath, M; Kilgus, O; Luthi, U; Luger, T; Bruckner-Tuderman, L			Some, but not all, glycine substitution mutations in COL7A1 result in intracellular accumulation of collagen VII, loss of anchoring fibrils, and skin blistering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIC EPIDERMOLYSIS-BULLOSA; GENE COL7A1; EPIDERMAL JUNCTION; MUTANT COLLAGEN; HELIX FORMATION; NC-2 DOMAIN; CONFORMATION; ORGANIZATION; PROCOLLAGEN; EXPRESSION	COL7A1 gene mutations cause dystrophic epidermolysis bullosa, a skin blistering disorder. The phenotypes result from defects of collagen VII, the major component of the anchoring fibrils at the dermo-epidermal junction; however, the molecular mechanisms underlying the phenotypes remain elusive. We investigated naturally occurring COL7A1 mutations and showed that some, but not all, glycine substitutions in collagen VII interfered with biosynthesis of the protein in a dominant-negative manner. Three point mutations in exon 73 caused glycine substitutions G2006D, G2034R, and G2015E in the triple helical domain of collagen VII and interfered with its folding and secretion. Confocal laser scanning studies and semiquantitative immunoblotting determined that dystrophic epidermolysis bullosa keratinocytes retained up to 2.5-fold more procollagen VII within the rough endoplasmic reticulum than controls. Limited proteolytic digestions of mutant procollagen VII produced aberrant fragments and revealed reduced stability of the triple helix. In contrast, the glycine substitution G1519D in another segment of the triple helix affected neither procollagen VII secretion nor anchoring fibril function and remained phenotypically silent. These data demonstrate that collagen VII presents a remarkable exception among collagens in that not all glycine substitutions within the triple helix exert dominant-negative interference and that the biological consequences of the substitutions probably depend on their position within the triple helix.	Univ Munster, Dept Dermatol, D-48149 Munster, Germany; Univ Hamburg, Dept Dermatol, D-22587 Hamburg, Germany; Univ Zurich, Cent Lab Electron Microscopy, CH-8091 Zurich, Switzerland	University of Munster; University of Hamburg; University of Zurich	Bruckner-Tuderman, L (corresponding author), Univ Munster, Dept Dermatol, Von Esmarch Str 56, D-48149 Munster, Germany.		Raghunath, Michael/E-6483-2010; Raghunath, Michael/M-2727-2019	Raghunath, Michael/0000-0002-2138-6614; 				BRUCKNER P, 1981, ANAL BIOCHEM, V110, P360, DOI 10.1016/0003-2697(81)90204-9; BRUCKNERTUDERMAN L, 1988, DERMATOLOGICA, V176, P57, DOI 10.1159/000248673; BRUCKNERTUDERMAN L, 1987, EUR J BIOCHEM, V165, P607, DOI 10.1111/j.1432-1033.1987.tb11483.x; BRUCKNERTUDERMAN L, 1995, J CELL BIOL, V131, P551, DOI 10.1083/jcb.131.2.551; BrucknerTuderman L, 1996, BIOCHEM CELL BIOL, V74, P729, DOI 10.1139/o96-079; BURGESON RE, 1993, J INVEST DERMATOL, V101, P252, DOI 10.1111/1523-1747.ep12365129; BYRS P, 1993, CONNECTIVE TISSUE IT, P317; Christiano A M, 1996, Exp Dermatol, V5, P1, DOI 10.1111/j.1600-0625.1996.tb00086.x; Christiano AM, 1996, AM J HUM GENET, V58, P671; CHRISTIANO AM, 1994, GENOMICS, V21, P160, DOI 10.1006/geno.1994.1238; Dunnill MGS, 1996, J INVEST DERMATOL, V107, P171, DOI 10.1111/1523-1747.ep12329570; GANGULY A, 1993, P NATL ACAD SCI USA, V90, P10325, DOI 10.1073/pnas.90.21.10325; Gardella R, 1996, AM J HUM GENET, V59, P292; GEDDEDAHL T, 1996, PRINCIPLES PRACTICE, V1, P1225; GREENSPAN DS, 1993, HUM MOL GENET, V2, P273, DOI 10.1093/hmg/2.3.273; HammamiHauasli N, 1997, J INVEST DERMATOL, V109, P384, DOI 10.1111/1523-1747.ep12336264; HILAL L, 1993, NAT GENET, V5, P287, DOI 10.1038/ng1193-287; HINTNER H, 1981, J INVEST DERMATOL, V76, P113, DOI 10.1111/1523-1747.ep12525447; HOVNANIAN A, 1994, AM J HUM GENET, V55, P289; HOVNANIAN S, 1997, AM J HUM GENET, V61, P599; Kivirikko S, 1996, J INVEST DERMATOL, V106, P1300, DOI 10.1111/1523-1747.ep12349019; Kon A, 1997, J INVEST DERMATOL, V108, P224, DOI 10.1111/1523-1747.ep12335324; Kon A, 1997, J INVEST DERMATOL, V109, P684, DOI 10.1111/1523-1747.ep12338093; KONIG A, 1994, J INVEST DERMATOL, V102, P105, DOI 10.1111/1523-1747.ep12371741; KONIG A, 1992, J CELL BIOL, V117, P679, DOI 10.1083/jcb.117.3.679; Lee JYY, 1997, J INVEST DERMATOL, V108, P947; LEIGH IM, 1987, EPITHELIA, V1, P17; MCGRATH JA, 1993, J INVEST DERMATOL, V100, P366, DOI 10.1111/1523-1747.ep12471830; OLSEN BR, 1995, CURR OPIN CELL BIOL, V7, P720, DOI 10.1016/0955-0674(95)80115-4; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Raghunath M, 1996, J CLIN INVEST, V98, P1174, DOI 10.1172/JCI118901; RAGHUNATH M, 1994, J MOL BIOL, V236, P940, DOI 10.1006/jmbi.1994.1199; Rousselle P, 1997, J CELL BIOL, V138, P719, DOI 10.1083/jcb.138.3.719; Schumann H, 1997, AM J HUM GENET, V60, P1344, DOI 10.1086/515463; Shimizu H, 1996, J INVEST DERMATOL, V106, P119, DOI 10.1111/1523-1747.ep12329600; SONNENBERG A, 1991, EXP CELL RES, V197, P234, DOI 10.1016/0014-4827(91)90428-W; STEINMANN B, 1995, SCIENCE, V267, P258, DOI 10.1126/science.7809634; Steinmann Beat, 1993, P351; Terracina M, 1997, J INVEST DERMATOL, V109, P405; TIDMAN MJ, 1985, J INVEST DERMAOTL, V88, P448; VIKKULA M, 1995, CELL, V80, P431, DOI 10.1016/0092-8674(95)90493-X; Winberg JO, 1997, HUM MOL GENET, V6, P1125, DOI 10.1093/hmg/6.7.1125	42	62	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19228	19234		10.1074/jbc.273.30.19228	http://dx.doi.org/10.1074/jbc.273.30.19228			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668111	hybrid			2022-12-25	WOS:000074974700078
J	Hata, Y; Duh, E; Zhang, K; Robinson, GS; Aiello, LP				Hata, Y; Duh, E; Zhang, K; Robinson, GS; Aiello, LP			Transcription factors Sp1 and Sp3 alter vascular endothelial growth factor receptor expression through a novel recognition sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE ENHANCER ELEMENTS; BOVINE RETINAL PERICYTES; PERMEABILITY FACTOR; IN-VIVO; FACTOR VEGF; GENE-EXPRESSION; TYROSINE KINASE; DEVELOPMENTAL EXPRESSION; DIABETIC-RETINOPATHY; SIGNAL-TRANSDUCTION	Kinase domain receptor (KDR) is a high affinity, endothelial cell-specific, autophosphorylating tyrosine kinase receptor for vascular endothelial growth factor, This transcriptionally regulated receptor is a critical mediator of endothelial cell (EC) growth and vascular development. In this study, we identify a DNA element modulating KDR promoter activity and evaluate the nuclear binding proteins accounting for a portion of the cell-type specificity of the region. KDR promoter luciferase activity was retained within -85/+296 and was 10-30-fold higher in EC than non-EC, Electrophoretic mobility shift assays demonstrated specific nuclear protein binding to -85/-64, and single point mutations suggested important binding nucleotides between -79/-68 with five critical bases between -74/-70 (5'-CTCCT-3'). DNA-protein complexes were displaced by Spl consensus sequence oligodeoxynucleotides and supershifted by Sp1- and Sp3-specific antibodies. Spl and Sp3 protein in EC nuclear extracts bound the -79/-68 region even when all surrounding classic Spl recognition sites were removed. Spl protein in nuclear extracts was 4-24-fold higher in EC than non-EC, whereas Sp3 was 3-7-fold higher. Sp1/Sp3 ratios in EC were 2-10-fold higher. Overexpression of Spl protein increased KDR promoter activity 3-fold in both EC and non-EC, whereas simultaneous co-expression of Sp3 attenuated this response. An Spl consensus sequence cis element "decoy" reduced EC KDR promoter activity and mRNA expression by 85 and 69%, respectively. An antisense phosphorothioate oligodeoxynucleotide to Spl inhibited Spl and KDR protein expression by 66 and 68%, respectively, without changing Sp3 protein expression. These data illustrate that Spl and Sp3 modulate KDR promoter activity through a novel recognition binding sequence. However, since Spl-mediated promoter activation is attenuated by Sp3, endothelial selective KDR promoter activity may be partially regulated by variations in the Sp1/Sp3 ratio.	Joslin Diabet Ctr, Beetham Eye Inst, Boston, MA 02215 USA; Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02215 USA; Hybridon Inc, Cambridge, MA 02139 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	Aiello, LP (corresponding author), Joslin Diabet Ctr, Beetham Eye Inst, 1 Joslin Pl, Boston, MA 02215 USA.	aiello@joslab.harvard.edu	Zhang, Kang/Y-2740-2019	Zhang, Kang/0000-0002-4549-1697	NATIONAL EYE INSTITUTE [R29EY010827] Funding Source: NIH RePORTER; NEI NIH HHS [EY-10827] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0; Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010; Aiello LP, 1997, DIABETES, V46, P1473, DOI 10.2337/diabetes.46.9.1473; AIELLO LP, 1994, P NATL ACAD SCI USA, V91, P6231, DOI 10.1073/pnas.91.13.6231; AIELLO LP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1538, DOI 10.1001/archopht.1995.01100120068012; AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Baker DL, 1996, J BIOL CHEM, V271, P5921, DOI 10.1074/jbc.271.10.5921; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; BIELINSKA A, 1990, SCIENCE, V250, P997, DOI 10.1126/science.2237444; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; DAngelo DD, 1996, J BIOL CHEM, V271, P19696, DOI 10.1074/jbc.271.33.19696; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DVORAK HF, 1991, J EXP MED, V174, P1275, DOI 10.1084/jem.174.5.1275; FAVARD C, 1991, BIOL CELL, V73, P1, DOI 10.1016/0248-4900(91)90002-5; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; Frank RN, 1997, OPHTHALMIC RES, V29, P341, DOI 10.1159/000268032; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; KRADY JK, 1995, MOL CELL BIOL, V15, P524, DOI 10.1128/MCB.15.1.524; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Lin JX, 1997, MOL CELL BIOL, V17, P3714, DOI 10.1128/MCB.17.7.3714; Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855; Lutty GA, 1996, ARCH OPHTHALMOL-CHIC, V114, P971, DOI 10.1001/archopht.1996.01100140179011; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MILLER JW, 1994, AM J PATHOL, V145, P574; Morishita R, 1997, NAT MED, V3, P894, DOI 10.1038/nm0897-894; MORISHITA R, 1995, P NATL ACAD SCI USA, V92, P5855, DOI 10.1073/pnas.92.13.5855; MURATA T, 1995, OPHTHALMIC RES, V27, P48, DOI 10.1159/000267567; NOMURA M, 1995, J BIOL CHEM, V270, P28316; Noti JD, 1996, MOL CELL BIOL, V16, P2940; PATTERSON C, 1995, J BIOL CHEM, V270, P23111, DOI 10.1074/jbc.270.39.23111; Patterson C, 1997, J BIOL CHEM, V272, P8410, DOI 10.1074/jbc.272.13.8410; Patterson C, 1996, J CLIN INVEST, V98, P490, DOI 10.1172/JCI118816; Persengiev SP, 1996, ENDOCRINOLOGY, V137, P638, DOI 10.1210/en.137.2.638; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; PIERCE JC, 1992, METHOD ENZYMOL, V216, P549; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Robinson GS, 1996, P NATL ACAD SCI USA, V93, P4851, DOI 10.1073/pnas.93.10.4851; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SAFFER JD, 1990, GENE DEV, V4, P659, DOI 10.1101/gad.4.4.659; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SCHAUFELE F, 1990, J BIOL CHEM, V265, P17189; SEETHARAM L, 1995, ONCOGENE, V10, P135; SENGER DR, 1986, CANCER RES, V46, P5629; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566; Strawn LM, 1996, CANCER RES, V56, P3540; Takagi H, 1996, DIABETES, V45, P1016, DOI 10.2337/diabetes.45.8.1016; Takagi H, 1996, INVEST OPHTH VIS SCI, V37, P1311; TAKAHASHI T, 1995, BIOCHEM BIOPH RES CO, V209, P218, DOI 10.1006/bbrc.1995.1492; TAKESHITA S, 1994, J CLIN INVEST, V93, P662, DOI 10.1172/JCI117018; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; THIEME H, 1995, DIABETES, V44, P98, DOI 10.2337/diabetes.44.1.98; Tilton RG, 1997, J CLIN INVEST, V99, P2192, DOI 10.1172/JCI119392; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; VINORES SA, 1995, AM J PATHOL, V147, P1289; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wells JA, 1996, BRIT J OPHTHALMOL, V80, P363, DOI 10.1136/bjo.80.4.363; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006; YAMADA T, 1995, J CLIN INVEST, V96, P1230, DOI 10.1172/JCI118156; YU CY, 1990, MOL CELL BIOL, V10, P282, DOI 10.1128/MCB.10.1.282	76	118	120	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19294	19303		10.1074/jbc.273.30.19294	http://dx.doi.org/10.1074/jbc.273.30.19294			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668119	hybrid, Green Published			2022-12-25	WOS:000074974700086
J	Obaishi, H; Nakanishi, H; Mandai, K; Satoh, K; Satoh, A; Takahashi, K; Miyahara, M; Nishioka, H; Takaishi, K; Takai, Y				Obaishi, H; Nakanishi, H; Mandai, K; Satoh, K; Satoh, A; Takahashi, K; Miyahara, M; Nishioka, H; Takaishi, K; Takai, Y			Frabin, a novel FGD1-related actin filament-binding protein capable of changing cell shape and activating c-Jun N-terminal kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-FAMILY; CDC42HS; CASCADE; RAC1	We purified from rat brain a novel F-actin-binding protein with a M-r of about 105,000 (p105), which was estimated by SDS-polyacrylamide gel electrophoresis. We cloned its cDNA from a rat brain cDNA library and characterized it, p105 was a protein of 766 amino acids and showed a calculated M-r of 86,449. p105 consisted of one F-actin-binding domain at the N-terminal region, one Dbl homology domain and one pleckstrin homology domain at the middle region, and one cysteine-rich domain at the C-terminal region. This domain organization of p105 was similar to that of FGD1, which has been determined to be the genetic locus responsible for facio-genital dysplasia or Aarskog-Scott syndrome. We therefore named p105 frabin (FGD1-related F-actin-binding protein). Frabin bound along the sides of F-actin and showed F-actin-cross-linking activity. Overexpression of frabin in Swiss 3T3 cells and COS7 cells induced cell shape change and c-Jun N-terminal kinase activation, respectively, as described for FGD1. Because FGD1 has been shown to serve as a GDP/GTP exchange protein for Cdc42 small G protein, it is likely that frabin is a direct linker between Cdc42 and the actin cytoskeleton.	Osaka Univ, Sch Med, Dept Biochem & Mol Biol, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, Takai Biotimer Project, ERATO, JCR Pharmaceut Co Ltd,Nishi Ku, Kobe, Hyogo 6512241, Japan	Osaka University; Japan Science & Technology Agency (JST)	Takai, Y (corresponding author), Osaka Univ, Sch Med, Dept Biochem & Mol Biol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.			Mandai, Kenji/0000-0002-0115-6635; Nakanishi, Hiroyuki/0000-0002-9765-0266				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; FRASER AB, 1975, BIOCHEMISTRY-US, V14, P2207, DOI 10.1021/bi00681a025; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hartwig JH, 1991, CURR OPIN CELL BIOL, V3, P87, DOI 10.1016/0955-0674(91)90170-4; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Komuro R, 1996, GENES CELLS, V1, P943, DOI 10.1046/j.1365-2443.1996.760276.x; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; MATSUDAIRA P, 1991, TRENDS BIOCHEM SCI, V16, P87, DOI 10.1016/0968-0004(91)90039-X; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Nakanishi H, 1997, J CELL BIOL, V139, P951, DOI 10.1083/jcb.139.4.951; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PASTERIS NG, 1994, CELL, V79, P669; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; Satoh A, 1998, J BIOL CHEM, V273, P3470, DOI 10.1074/jbc.273.6.3470; SCHRODER RR, 1993, NATURE, V364, P171, DOI 10.1038/364171a0; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; YAKU H, 1994, BIOCHEM BIOPH RES CO, V198, P811, DOI 10.1006/bbrc.1994.1116; Zheng Y, 1996, J BIOL CHEM, V271, P33169, DOI 10.1074/jbc.271.52.33169	24	68	70	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18697	18700		10.1074/jbc.273.30.18697	http://dx.doi.org/10.1074/jbc.273.30.18697			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668039	hybrid			2022-12-25	WOS:000074974700006
J	Pajor, AM; Hirayama, BA; Loo, DDF				Pajor, AM; Hirayama, BA; Loo, DDF			Sodium and lithium interactions with the Na+/dicarboxylate cotransporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANES; SUCCINATE TRANSPORT; XENOPUS OOCYTES; KINETICS	The two-electrode voltage clamp was used to study the currents associated with transport of succinate by the cloned Na+/dicarboxylate cotransporter, NaDC-1, expressed in Xenopus oocytes, The presence of succinate induced inward currents which were dependent on the concentrations of succinate and sodium,;md on the membrane potential. At -50 mV, the K-0.5(succinate) was 180 mu M and the K-0.5(Na+) was 19 mM. The Hill coefficient was 2.3, which is consistent with a transport stoichiometry of 3 Na+:1 divalent anion substrate. Currents wt:re induced in NaDC-1 by a range of di- and tricarboxylates, including citrate, methylsuccinate, fumarate, and tricarbally-late. Although Na+ is the preferred cation, Li+ was also able to support transport. The K-0.5(succinate) was approximately 10-fold higher in Li+ compared with Na+. In the presence of Na+, however, Li+ was a potent inhibitor of transport. Millimolar concentrations of Li+ resulted in decreases in apparent succinate affinity and in the I-max(succinate). Furthermore, lithium inhibition under saturating sodium concentrations showed hyperbolic kinetics, suggesting that one of the three cation binding sites in NaDC-1 has a higher affinity for Li+ than Na+. We conclude that NaDC-1 is an electrogenic anion transporter that accepts either Na+ or Li+ as coupling cations. However, NaDC-1 contains a single high affinity binding site for Li+ that, when occupied,. results in transport inhibition, which may account for its potent inhibitory effects on renal dicarboxylate transport.	Univ Arizona, Coll Med, Dept Physiol, Tucson, AZ 85724 USA; Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA	University of Arizona; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Pajor, AM (corresponding author), Univ Arizona, Coll Med, Dept Physiol, Tucson, AZ 85724 USA.	Pajor@biosci.arizona.edu			NIDDK NIH HHS [DK46269, DK02429] Funding Source: Medline; NIGMS NIH HHS [GM52094] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K02DK002429, R01DK046269] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM052094] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bai LQ, 1997, AM J PHYSIOL-GASTR L, V273, pG267, DOI 10.1152/ajpgi.1997.273.2.G267; BOND PA, 1974, BRIT J PHARMACOL, V50, P283, DOI 10.1111/j.1476-5381.1974.tb08574.x; BOND PA, 1972, BRIT J PHARMACOL, V46, P116, DOI 10.1111/j.1476-5381.1972.tb06854.x; Cao YW, 1997, J NEUROSCI, V17, P2257; Eskandari S, 1997, J BIOL CHEM, V272, P27230, DOI 10.1074/jbc.272.43.27230; Forster IC, 1997, J MEMBRANE BIOL, V160, P9, DOI 10.1007/s002329900291; FUKUHARA Y, 1983, AM J PHYSIOL, V245, pF374, DOI 10.1152/ajprenal.1983.245.3.F374; HAGER K, 1995, J MEMBRANE BIOL, V143, P103; HAMM LL, 1990, KIDNEY INT, V38, P728, DOI 10.1038/ki.1990.265; Hazama A, 1997, J MEMBRANE BIOL, V155, P175, DOI 10.1007/s002329900169; HIRAYAMA B, 1986, PFLUGERS ARCH, V407, P174; Hirayama BA, 1997, J BIOL CHEM, V272, P2110; KANAI Y, 1994, J BIOL CHEM, V269, P20599; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; MARKOVICH D, 1993, P NATL ACAD SCI USA, V90, P8073, DOI 10.1073/pnas.90.17.8073; Murer H, 1992, HDB PHYSL, V2, P2165, DOI DOI 10.1002/CPHY.CP080247); Pajor AM, 1998, BBA-BIOMEMBRANES, V1370, P98, DOI 10.1016/S0005-2736(97)00249-6; Pajor AM, 1996, AM J PHYSIOL-RENAL, V271, pF1093, DOI 10.1152/ajprenal.1996.271.5.F1093; Pajor AM, 1996, AM J PHYSIOL-RENAL, V270, pF642, DOI 10.1152/ajprenal.1996.270.4.F642; Pajor AM, 1996, AM J PHYSIOL-CELL PH, V271, pC1808, DOI 10.1152/ajpcell.1996.271.6.C1808; PAJOR AM, 1995, J BIOL CHEM, V270, P5779, DOI 10.1074/jbc.270.11.5779; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; SCHELL RE, 1985, J PHYSIOL-LONDON, V360, P95, DOI 10.1113/jphysiol.1985.sp015605; Segel I.H., 1975, ENZYME KINETICS; WRIGHT EM, 1982, P NATL ACAD SCI-BIOL, V79, P7514, DOI 10.1073/pnas.79.23.7514; WRIGHT SH, 1983, J BIOL CHEM, V258, P5456; WRIGHT SH, 1982, BIOCHIM BIOPHYS ACTA, V684, P287, DOI 10.1016/0005-2736(82)90019-0	28	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18923	18929		10.1074/jbc.273.30.18923	http://dx.doi.org/10.1074/jbc.273.30.18923			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668069	hybrid			2022-12-25	WOS:000074974700036
J	Shirra, MK; Hansen, U				Shirra, MK; Hansen, U			LSF and NTF-1 share a conserved DNA recognition motif yet require different oligomerization states to form a stable protein-DNA complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR CP2; CRYSTAL-STRUCTURE; VIRUS TYPE-1; OPERATOR COMPLEX; BINDING-PROTEINS; B/HLH/Z DOMAIN; ACTIVATION; REGION; DIMER; RESOLUTION	The mammalian transcription factor LSF (also known as CP2 and LBP-1c) binds as a homo-oligomer to directly repeated elements in viral and cellular promoters. LSF and the Drosophila transcription factor NTF-1 (also known as Elf-1 and Grainyhead) share a similar DNA binding region, which is unlike any established DNA binding motifs. However, we demonstrate that dimeric NTF-1 can bind an LSF half-site, whereas LSF cannot. To characterize further the DNA binding and oligomerization characteristics of LSF, truncation mutants were used to demonstrate that between 234 and 320 amino acids of LSF are required for high affinity DNA binding. Mixing of a truncation mutant with full-length LSF in a DNA binding assay established that the form of LSF that binds DNA is larger than a dimer. Unexpectedly, one C-terminal deletion derivative, partially defective in oligomerization properties, could occupy odd numbers of adjacent, tandem LSF half-sites, unlike full-length LSF. The numbers of DNA-protein complexes formed on multiple half-sites with this mutant indicated that LSF binds DNA as a tetramer, although cross-linking experiments confirmed a previous report concluding that LSF is primarily dimeric in solution. The DNA binding and oligomerization properties of LSF support models depicting novel mechanisms to prevent continual, adjacent binding by a protein that recognizes directly repeated DNA sequences.	Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA; Dana Farber Canc Inst, Div Mol Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute	Hansen, U (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.			Hansen, Ulla/0000-0001-9803-4185	NCI NIH HHS [CA38038, T32 CA09361] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009361, R01CA038038] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATTARDI LD, 1993, GENE DEV, V7, P1341, DOI 10.1101/gad.7.7b.1341; Ausubel FM., 2006, ENZYMATIC MANIPULATI; Bellorini M, 1996, MOL CELL BIOL, V16, P503; BRAY SJ, 1989, GENE DEV, V3, P1130, DOI 10.1101/gad.3.8.1130; BRENNAN RG, 1990, P NATL ACAD SCI USA, V87, P8165, DOI 10.1073/pnas.87.20.8165; BURGERING MJM, 1994, BIOCHEMISTRY-US, V33, P15036, DOI 10.1021/bi00254a012; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DYNLACHT BD, 1989, GENE DEV, V3, P1677, DOI 10.1101/gad.3.11.1677; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; FRIEDMAN AM, 1995, SCIENCE, V268, P1721, DOI 10.1126/science.7792597; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; HUANG HC, 1990, GENE DEV, V4, P287, DOI 10.1101/gad.4.2.287; JANE SM, 1995, EMBO J, V14, P97, DOI 10.1002/j.1460-2075.1995.tb06979.x; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; JONES KA, 1988, GENE DEV, V2, P1101, DOI 10.1101/gad.2.9.1101; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; Lenouvel F, 1997, J BIOL CHEM, V272, P15521, DOI 10.1074/jbc.272.24.15521; LIM LC, 1993, J BIOL CHEM, V268, P18008; LIM LC, 1992, MOL CELL BIOL, V12, P828, DOI 10.1128/MCB.12.2.828; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; MALIM MH, 1989, J VIROL, V63, P3213, DOI 10.1128/JVI.63.8.3213-3219.1989; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; NELSON HCM, 1995, CURR OPIN GENET DEV, V5, P180, DOI 10.1016/0959-437X(95)80006-9; PELLEGRINI L, 1995, NATURE, V376, P490, DOI 10.1038/376490a0; PETERANDERL R, 1992, BIOCHEMISTRY-US, V31, P12272, DOI 10.1021/bi00163a042; RAUMANN BE, 1994, NATURE, V367, P754, DOI 10.1038/367754a0; Romerio F, 1997, J VIROL, V71, P9375, DOI 10.1128/JVI.71.12.9375-9382.1997; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SHIRRA MK, 1994, MOL CELL BIOL, V14, P5076, DOI 10.1128/MCB.14.8.5076; SHIRRA MK, 1995, THESIS HARVARD U; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; SUEYOSHI T, 1995, MOL CELL BIOL, V15, P4158; SUZUKI M, 1993, EMBO J, V12, P3221, DOI 10.1002/j.1460-2075.1993.tb05991.x; UV AE, 1994, MOL CELL BIOL, V14, P4020, DOI 10.1128/MCB.14.6.4020; Volker JL, 1997, GENE DEV, V11, P1435, DOI 10.1101/gad.11.11.1435; WALKER J, 1993, MOL BIOCHEM PARASIT, V61, P255, DOI 10.1016/0166-6851(93)90071-5; WU FK, 1988, EMBO J, V7, P2117, DOI 10.1002/j.1460-2075.1988.tb03051.x; YOON JB, 1994, MOL CELL BIOL, V14, P1776, DOI 10.1128/MCB.14.3.1776; ZHONG FM, 1994, J BIOL CHEM, V269, P21269	47	46	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19260	19268		10.1074/jbc.273.30.19260	http://dx.doi.org/10.1074/jbc.273.30.19260			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668115	hybrid			2022-12-25	WOS:000074974700082
J	Siddhanta, U; Presta, A; Fan, BC; Wolan, D; Rousseau, DL; Stuehr, DJ				Siddhanta, U; Presta, A; Fan, BC; Wolan, D; Rousseau, DL; Stuehr, DJ			Domain swapping in inducible nitric-oxide synthase - Electron transfer occurs between flavin and heme groups located on adjacent subunits in the dimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE NO SYNTHASE; SPECTRAL CHARACTERIZATION; CATALYTIC ACTIVITY; IRON REDUCTION; L-ARGININE; BINDING; ENZYME; CALMODULIN; SUBSTRATE; BRAIN	Cytokine-inducible nitric-oxide (NO) synthase (iNOS) contains an oxygenase domain that binds heme, tetrahydrobiopterin, and L-arginine, and a reductase domain that binds FAD, FMN, calmodulin, and NADPH, Dimerization of two oxygenase domains allows electrons to transfer from the flavins to the heme irons, which enables O-2 binding and NO synthesis from L-arginine. In an iNOS heterodimer comprised of one full-length subunit and an oxygenase domain partner, the single reductase domain transfers electrons to only one of two hemes (Siddhanta, U., Wu, C., Abu-Soud, H. M., Zhang, J., Ghosh, D. K., and Stuehr, D. J. (1996) J. Biol. Chem. 271, 7309-7312). Here, we characterize a pair of heterodimers that contain an L-Arg binding mutation (E371A) in either the full-length or oxygenase domain subunit to identify which heme iron becomes reduced. The E371A mutation prevented L-Arg binding to one oxygenase domain in each heterodimer but did not affect the L-Arg affinity of its oxygenase domain partner and did not prevent heme iron reduction in any case. The mutation prevented NO synthesis when it was located in the oxygenase domain of the adjacent subunit but had no effect when in the oxygenase domain in the same subunit as the reductase domain. Resonance Raman characterization of the heme-L-Arg interaction confirmed that E371A only prevents L-Arg binding in the mutated oxygenase domain. Thus, flavin-to-heme electron transfer proceeds exclusively between adjacent subunits in the heterodimer. This implies that domain swapping occurs in an iNOS dimer to properly align reductase and oxygenase domains for NO synthesis.	Cleveland Clin Fdn, Dept Immunol, Lerner Res Inst, Cleveland, OH 44195 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA	Cleveland Clinic Foundation; Yeshiva University; Albert Einstein College of Medicine	Stuehr, DJ (corresponding author), Cleveland Clin Fdn, Dept Immunol, Lerner Res Inst, NN-1,9500 Euclid Ave, Cleveland, OH 44195 USA.			Wolan, Dennis/0000-0001-9879-8353	NATIONAL CANCER INSTITUTE [R01CA053914, R29CA053914] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054806] Funding Source: NIH RePORTER; NCI NIH HHS [CA53914] Funding Source: Medline; NIGMS NIH HHS [GM54806] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; ABUSOUD HM, 1995, BIOCHEMISTRY-US, V34, P11167, DOI 10.1021/bi00035a023; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32318; ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; Albakri QA, 1996, J BIOL CHEM, V271, P5414, DOI 10.1074/jbc.271.10.5414; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; Chen PF, 1997, J BIOL CHEM, V272, P6114, DOI 10.1074/jbc.272.10.6114; Chen PF, 1996, J BIOL CHEM, V271, P14631, DOI 10.1074/jbc.271.24.14631; CHEN PF, 1994, J BIOL CHEM, V269, P25062; CHEN VJ, 1989, J BIOL CHEM, V264, P21677; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; Crane BR, 1997, SCIENCE, V278, P425, DOI 10.1126/science.278.5337.425; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Gachhui R, 1997, BIOCHEMISTRY-US, V36, P5097, DOI 10.1021/bi970331x; Gachhui R, 1998, J BIOL CHEM, V273, P5451, DOI 10.1074/jbc.273.10.5451; Gachhui R, 1996, J BIOL CHEM, V271, P20594, DOI 10.1074/jbc.271.34.20594; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; Ghosh DK, 1996, BIOCHEMISTRY-US, V35, P1444, DOI 10.1021/bi9521295; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P11316, DOI 10.1021/bi00036a003; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; GOSH DK, 1995, BIOCHEMISTRY-US, V34, P11316; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; Harrison DG, 1997, J CLIN INVEST, V100, P2153, DOI 10.1172/JCI119751; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; Klatt P, 1996, J BIOL CHEM, V271, P7336, DOI 10.1074/jbc.271.13.7336; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; Masters BSS, 1996, FASEB J, V10, P552, DOI 10.1096/fasebj.10.5.8621055; Mayer B, 1997, NITRIC OXIDE-BIOL CH, V1, P50, DOI 10.1006/niox.1996.0102; Mayer B, 1997, BIOCHEMISTRY-US, V36, P8422, DOI 10.1021/bi970144z; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; Morita H, 1997, J BACTERIOL, V179, P7812, DOI 10.1128/jb.179.24.7812-7815.1997; Presta A, 1998, BIOCHEMISTRY-US, V37, P298, DOI 10.1021/bi971944c; Presta A, 1997, NITRIC OXIDE-BIOL CH, V1, P74, DOI 10.1006/niox.1996.0110; PRESTA A, 1998, IN PRESS J AM CHEM S; RICHARDS MK, 1994, BIOCHEMISTRY-US, V33, P14723, DOI 10.1021/bi00253a010; Salerno JC, 1996, BIOCHEMISTRY-US, V35, P7626, DOI 10.1021/bi960607l; Siddhanta U, 1996, J BIOL CHEM, V271, P7309, DOI 10.1074/jbc.271.13.7309; SONO M, 1995, J BIOL CHEM, V270, P19943, DOI 10.1074/jbc.270.34.19943; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; SU ZZ, 1995, J BIOL CHEM, V270, P29117, DOI 10.1074/jbc.270.49.29117; VERMILION JL, 1978, J BIOL CHEM, V253, P2694; Wang J., 1996, METHODS NITRIC OXIDE, P427; WANG JL, 1995, BIOCHEMISTRY-US, V34, P7080, DOI 10.1021/bi00021a020; Wang JL, 1997, BIOCHEMISTRY-US, V36, P4595, DOI 10.1021/bi962309u; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; WOLGEL SA, 1990, METHOD ENZYMOL, V188, P95; Wu CQ, 1996, BIOCHEM BIOPH RES CO, V222, P439, DOI 10.1006/bbrc.1996.0763; Xie QW, 1996, P NATL ACAD SCI USA, V93, P4891, DOI 10.1073/pnas.93.10.4891; XIE QW, 1994, J BIOL CHEM, V269, P28500	56	170	171	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18950	18958		10.1074/jbc.273.30.18950	http://dx.doi.org/10.1074/jbc.273.30.18950			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668073	hybrid			2022-12-25	WOS:000074974700040
J	Young, JC; Obermann, WMJ; Hartl, FU				Young, JC; Obermann, WMJ; Hartl, FU			Specific binding of tetratricopeptide repeat proteins to the C-terminal 12-kDa domain of hsp90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; RECEPTOR COMPLEXES; IMMUNOPHILIN; COMPONENT; FKBP52; CYCLE; HSP70; HIP	The molecular chaperone hsp90 in the eukaryotic cytosol interacts with a variety of protein cofactors, Several of these cofactors have protein domains containing tetratricopeptide repeat (TPR) motifs, which mediate binding to hsp90. Using a yeast two-hybrid screen, the 12-kDa C-terminal domain of human hspg90 alpha (C90) was found to mediate the interaction of hsp90 with TPR-containing sequences from the hsp90 cofactors FKBP51/54 and FKBP52. In addition, the mitochondrial outer membrane protein hTOM34p was identified as a TPR-containing putative partner protein of hsp90, In experiments with purified proteins, the TPR-containing cofactor p60 (Hop) was shown to form stable complexes with hsp90. A deletion mutant of hsp90 lacking the C90 domain was unable to bind p60, whereas deletion of the similar to 25-kDa N-terminal domain of hsp90 did not affect complex formation. Both p60 and FKBP52 bound specifically to the C90 domain fused to glutathione S-transferase and competed with each other for binding. In reticulocyte lysate, the C90 fusion protein recognized the TPR proteins p60, FKBP52, and Cyp40. Thus, our results identify the C90 domain as the specific binding site for a set of hsp90 cofactors having TPR domains.	Max Planck Inst Biochem, Dept Cellular Biochem, D-82152 Martinsried, Germany	Max Planck Society	Hartl, FU (corresponding author), Max Planck Inst Biochem, Dept Cellular Biochem, Klopferspitz 18A, D-82152 Martinsried, Germany.		Obermann, Wolfgang/AAN-3896-2020; Hartl, F. Ulrich/Y-8206-2019					ALIGUE R, 1994, EMBO J, V13, P6099, DOI 10.1002/j.1460-2075.1994.tb06956.x; Bartel P. L., 1993, CELLULAR INTERACTION, P153; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; Frydman J, 1997, TRENDS BIOCHEM SCI, V22, P87, DOI 10.1016/S0968-0004(97)01005-0; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; HOHFELD J, 1995, CELL, V83, P589; Irmer H, 1997, J BIOL CHEM, V272, P2230; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; Johnson JL, 1997, CELL, V90, P201, DOI 10.1016/S0092-8674(00)80327-X; KOYASU S, 1986, P NATL ACAD SCI USA, V83, P8054, DOI 10.1073/pnas.83.21.8054; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; Nair SC, 1997, MOL CELL BIOL, V17, P594, DOI 10.1128/MCB.17.2.594; Nathan DF, 1997, P NATL ACAD SCI USA, V94, P12949, DOI 10.1073/pnas.94.24.12949; NEMOTO T, 1995, EUR J BIOCHEM, V233, P1, DOI 10.1111/j.1432-1033.1995.001_1.x; OwensGrillo JK, 1996, J BIOL CHEM, V271, P13468, DOI 10.1074/jbc.271.23.13468; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; Prapapanich V, 1996, MOL CELL BIOL, V16, P6200; Prapapanich V, 1996, MOL ENDOCRINOL, V10, P420, DOI 10.1210/me.10.4.420; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Pratt WB, 1997, ANNU REV PHARMACOL, V37, P297, DOI 10.1146/annurev.pharmtox.37.1.297; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; RADANYI C, 1994, P NATL ACAD SCI USA, V91, P11197, DOI 10.1073/pnas.91.23.11197; Ratajczak T, 1996, J BIOL CHEM, V271, P2961, DOI 10.1074/jbc.271.6.2961; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Wearsch PA, 1996, BIOCHEMISTRY-US, V35, P16760, DOI 10.1021/bi962068q; Wearsch PA, 1997, J BIOL CHEM, V272, P5152, DOI 10.1074/jbc.272.8.5152; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; Young JC, 1997, FEBS LETT, V418, P139, DOI 10.1016/S0014-5793(97)01363-X	33	207	214	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18007	18010		10.1074/jbc.273.29.18007	http://dx.doi.org/10.1074/jbc.273.29.18007			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660753	hybrid			2022-12-25	WOS:000074828500008
J	Shistik, E; Ivanina, T; Blumenstein, Y; Dascal, N				Shistik, E; Ivanina, T; Blumenstein, Y; Dascal, N			Crucial role of N terminus in function of cardiac L-type Ca2+ channel and its modulation by protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; SENSITIVE CALCIUM-CHANNEL; PHORBOL ESTER INCREASES; GATING CHARGE MOVEMENTS; BETA-SUBUNIT; XENOPUS-OOCYTES; SKELETAL-MUSCLE; VENTRICULAR MYOCYTES; AUXILIARY SUBUNITS; CARBOXYL-TERMINUS	The role of the cytosolic N terminus of the main subunit (alpha(1C)) of cardiac L-type voltage-dependent Ca2+ channel was studied in Xenopus oocyte expression system. Deletion of the initial 46 or 139 amino acids (a.a.) of rabbit heart alpha(1C) caused a 5-10-fold increase in the whole cell Ca2+ channel current carried by Ba2+ (I-Ba), as reported previously (Wei, X., Neely, A., Olcese, R., Lang, W., Stefani, E., and Birnbaumer, L. (1996) Recept. Channels 4, 205-215), The plasma membrane content of alpha(1C) protein, measured immunochemically, was not altered by the 46-a.a. deletion. Patch clamp recordings in the presence of a dihydropyridine agonist showed that this deletion causes a 5-10-fold increase in single channel open probability without changing channel density. Thus, the initial segment of the N terminus affects channel gating rather than expression. The increase in I-Ba caused by coexpression of the auxiliary beta(2A) subunit was substantially stronger in channels with full-length alpha(1C) than in 46- or 139-a.a. truncated mutants, suggesting an interaction between beta(2A) and N terminus. However, only the I-II domain linker of alpha(1C), but not to N or C termini, bound beta(2A) in vitro, The well documented increase of I-Ba caused by activation of protein kinase C (PKC) was fully eliminated by the 46-a.a. deletion. Thus, the N terminus of alpha(1C) plays a crucial role in channel gating and PKC modulation, We propose that PKC and beta subunit enhance the activity of the channel in part by relieving an inhibitory control exerted by the N terminus. Since PKC up-regulation of L-type Ca2+ channels has been reported in many species, we predict that isoforms of alpha(1C) subunits containing the initial N-terminal 46 a.a. similar to those of the rabbit heart alpha(1C) are widespread in cardiac and smooth muscle cells.	Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL-69978 Ramat Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine	Dascal, N (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL-69978 Ramat Aviv, Israel.	dascaln@post.tau.ac.il	Dascal, Nathan/O-3915-2015; Tuluc, Petronel/C-2527-2011	Dascal, Nathan/0000-0002-5397-4146; 				ASAI T, 1996, AM JPHYSL, V39, pH620; Bangalore R, 1996, AM J PHYSIOL-HEART C, V270, pH1521, DOI 10.1152/ajpheart.1996.270.5.H1521; Bendahhou S, 1997, AM J PHYSIOL-CELL PH, V272, pC592, DOI 10.1152/ajpcell.1997.272.2.C592; BIEL M, 1990, FEBS LETT, V269, P409, DOI 10.1016/0014-5793(90)81205-3; BOURINET E, 1992, PFLUG ARCH EUR J PHY, V421, P247, DOI 10.1007/BF00374834; Bouron A, 1995, FEBS LETT, V377, P159, DOI 10.1016/0014-5793(95)01327-X; CATTERALL WA, 1993, TRENDS NEUROSCI, V16, P500, DOI 10.1016/0166-2236(93)90193-P; CHIEN AJ, 1995, J BIOL CHEM, V270, P30036; Chik CL, 1996, FASEB J, V10, P1310, DOI 10.1096/fasebj.10.11.8836045; Dascal N., 1992, METHODS MOL BIOL VOL, VVolume 13, P205; DeJongh KS, 1996, BIOCHEMISTRY-US, V35, P10392, DOI 10.1021/bi953023c; DEWAARD M, 1995, J BIOL CHEM, V270, P12056, DOI 10.1074/jbc.270.20.12056; DOSEMECI A, 1988, CIRC RES, V62, P347, DOI 10.1161/01.RES.62.2.347; FISH RD, 1988, CIRC RES, V62, P1049, DOI 10.1161/01.RES.62.5.1049; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; GROSSMANN H, 1990, REV PHYSL BIOCH PHAR, V114, P1; Gurnett CA, 1996, J BIOL CHEM, V271, P27975, DOI 10.1074/jbc.271.45.27975; HADLEY RW, 1992, AM J PHYSIOL, V262, pH472, DOI 10.1152/ajpheart.1992.262.2.H472; Hille B., 1992, IONIC CHANNELS EXCIT; Hirano Y, 1996, RECEPTOR CHANNEL, V4, P93; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.neuro.17.1.399; Hosey MM, 1996, TRENDS CARDIOVAS MED, V6, P265, DOI 10.1016/S1050-1738(96)00109-0; Hughes AD, 1995, J VASC RES, V32, P353, DOI 10.1159/000159111; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; IVANINA T, 1994, BIOCHEMISTRY-US, V33, P8786, DOI 10.1021/bi00195a021; JOSEPHSON IR, 1994, PFLUG ARCH EUR J PHY, V428, P485, DOI 10.1007/BF00374569; Josephson IR, 1996, BIOPHYS J, V70, P1285, DOI 10.1016/S0006-3495(96)79685-6; KATO H, 1992, BIOCHEM BIOPH RES CO, V188, P934, DOI 10.1016/0006-291X(92)91145-G; KLOCKNER U, 1995, J BIOL CHEM, V270, P17306, DOI 10.1074/jbc.270.29.17306; KOCH WJ, 1990, J BIOL CHEM, V265, P17786; LACERDA AE, 1988, NATURE, V335, P249, DOI 10.1038/335249a0; Levin G, 1996, J BIOL CHEM, V271, P29321, DOI 10.1074/jbc.271.46.29321; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; LIU QY, 1993, BIOCHEM BIOPH RES CO, V191, P796, DOI 10.1006/bbrc.1993.1287; MARINISSEN MJ, 1994, CELL SIGNAL, V6, P531, DOI 10.1016/0898-6568(94)90007-8; McHugh D, 1997, J PHYSIOL-LONDON, V500, P311, DOI 10.1113/jphysiol.1997.sp022022; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; Mitterdorfer J, 1996, BIOCHEMISTRY-US, V35, P9400, DOI 10.1021/bi960683o; NEELY A, 1993, SCIENCE, V262, P575, DOI 10.1126/science.8211185; Olcese R, 1996, J PHYSIOL-LONDON, V497, P675, DOI 10.1113/jphysiol.1996.sp021799; Perets T, 1996, FEBS LETT, V384, P189, DOI 10.1016/0014-5793(96)00303-1; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Puri TS, 1997, BIOCHEMISTRY-US, V36, P9605, DOI 10.1021/bi970500d; Qin N, 1997, P NATL ACAD SCI USA, V94, P8866, DOI 10.1073/pnas.94.16.8866; REUTER H, 1983, NATURE, V301, P569, DOI 10.1038/301569a0; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; SADLER SE, 1981, J BIOL CHEM, V256, P6368; SATOH H, 1992, GEN PHARMACOL, V23, P1097, DOI 10.1016/0306-3623(92)90293-S; SCHUHMANN K, 1994, FEBS LETT, V341, P208, DOI 10.1016/0014-5793(94)80458-3; SHEETS MF, 1995, J GEN PHYSIOL, V106, P617, DOI 10.1085/jgp.106.4.617; SHISTIK E, 1995, J PHYSIOL-LONDON, V489, P55, DOI 10.1113/jphysiol.1995.sp021029; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; SINGERLAHAT D, 1992, FEBS LETT, V306, P113, DOI 10.1016/0014-5793(92)80980-U; SINGERLAHAT D, 1994, RECEPTOR CHANNEL, V2, P215; SLISH DF, 1989, FEBS LETT, V250, P509, DOI 10.1016/0014-5793(89)80786-0; Snutch T P, 1992, Curr Opin Neurobiol, V2, P247, DOI 10.1016/0959-4388(92)90111-W; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; SOLDATOV NM, 1994, GENOMICS, V22, P77, DOI 10.1006/geno.1994.1347; Soldatov NM, 1997, J BIOL CHEM, V272, P3560, DOI 10.1074/jbc.272.6.3560; STEA A, 1995, NEURON, V15, P929, DOI 10.1016/0896-6273(95)90183-3; Tareilus E, 1997, P NATL ACAD SCI USA, V94, P1703, DOI 10.1073/pnas.94.5.1703; TRAUTWEIN W, 1990, ANNU REV PHYSIOL, V52, P257, DOI 10.1146/annurev.ph.52.030190.001353; TSENG GN, 1991, AM J PHYSIOL, V261, pH364, DOI 10.1152/ajpheart.1991.261.2.H364; VARADI G, 1991, NATURE, V352, P159, DOI 10.1038/352159a0; WAKAMORI M, 1993, BIOCHEM BIOPH RES CO, V196, P1170, DOI 10.1006/bbrc.1993.2374; Wei X, 1996, RECEPTOR CHANNEL, V4, P205; WEI XY, 1994, J BIOL CHEM, V269, P1635; WEI XY, 1991, J BIOL CHEM, V266, P21943; WICKMAN K, 1995, PHYSIOL REV, V75, P865, DOI 10.1152/physrev.1995.75.4.865; XIONG ZL, 1995, J MOL CELL CARDIOL, V27, P75, DOI 10.1016/S0022-2828(08)80009-0; YANG J, 1993, NEURON, V10, P127, DOI 10.1016/0896-6273(93)90305-B; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0; ZHANG ST, 1995, CIRC RES, V76, P592, DOI 10.1161/01.RES.76.4.592; Zhou JM, 1997, P NATL ACAD SCI USA, V94, P2301, DOI 10.1073/pnas.94.6.2301	75	92	97	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17901	17909		10.1074/jbc.273.28.17901	http://dx.doi.org/10.1074/jbc.273.28.17901			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651396	hybrid			2022-12-25	WOS:000074816100089
J	Sato, S; Tunashima, K; Mafune, Y; Ohtsuka, H; Koide, N; Endo, Y; Saito, Y; Asakura, H; Kominami, R				Sato, S; Tunashima, K; Mafune, Y; Ohtsuka, H; Koide, N; Endo, Y; Saito, Y; Asakura, H; Kominami, R			Allele-specific inactivation of the alpha 4 integrin gene expression in fibrosarcoma cell lines and relevance for spontaneous metastasis	ONCOGENE			English	Article						allele-specific inactivation; alpha 4 integrin; metastasis	TUMOR-SUPPRESSOR GENE; E-CADHERIN; DNA METHYLATION; CPG METHYLATION; HUMAN CANCERS; HUMAN COLON; CARCINOMAS; MOUSE; ADHESION; RECEPTORS	Deregulated expression of genes is found in cancer cells, which may affect malignant properties, but it is unclear whether such modulation occurs allele-specifically. This study shows that the gene coding alpha 4 integrin, a cell adhesion molecule, underwent allelic inactivation in a series of heterozygous murine fibrosarcoma cell lines (MST lines) with different metastatic potentials. P4 cells expressed the alpha 4 integrin gene from one allele at a level comparable to that of the primary MST1 tumor, whereas the descendent lines of P4 exhibited decreased expression of both alleles, No allelic loss of DNA was observed in these cells, Other four clones derived from P4 and five clones from a different tumor also showed such two-step inactivation, Intriguingly, the loss of expression was correlated with the acquisition of spontaneous, but not artificial, metastatic ability, This is consistent with the previous result of inverse relation between the expression of alpha 4/beta 1 integrin and the invasive potential of B14 melanoma cells. Analysis of DNA methylation and chromatin state of the alpha 4 integrin gene failed to provide a clue to difference between the two alleles in the cell lines, These results suggest that the allelic inactivation is a process giving loss of function to one allele, although the mechanism is unclear.	Niigata Univ, Sch Med, Dept Biochem 1, Niigata 951, Japan; Niigata Univ, Sch Med, Dept Internal Med 3, Niigata 951, Japan	Niigata University; Niigata University	Kominami, R (corresponding author), Niigata Univ, Sch Med, Dept Biochem 1, Asahimachi 1-757, Niigata 951, Japan.							ADAMS RLP, 1982, CRC CR REV BIOCH MOL, V13, P349, DOI 10.3109/10409238209108714; Akama TO, 1997, CANCER RES, V57, P3294; ANTEQUERA F, 1993, DNA METHYLATION MOL, P169; BONHOMME F, 1989, GENETIC VARIANTS STR, P649; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; Cost GJ, 1997, CANCER RES, V57, P926; DAMJANOVICH L, 1992, AM J RESP CELL MOL, V6, P197, DOI 10.1165/ajrcmb/6.2.197; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; Gao AC, 1997, CANCER RES, V57, P846; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; HAN KA, 1992, CANCER RES, V52, P749; HERMAN JG, 1995, CANCER RES, V55, P4525; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KNUDSON AG, 1985, CANCER RES, V45, P1437; KORETZ K, 1991, AM J PATHOL, V138, P741; LAIRD PW, 1994, HUM MOL GENET, V3, P1487, DOI 10.1093/hmg/3.suppl_1.1487; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MAFUNE Y, 1994, ONCOGENE, V9, P2191; MAKOS M, 1993, CANCER RES, V53, P2715; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MORTON RA, 1993, CANCER RES, V53, P3585; NEUHAUS H, 1991, J CELL BIOL, V115, P1149, DOI 10.1083/jcb.115.4.1149; NIGAM AK, 1993, BRIT J CANCER, V68, P507, DOI 10.1038/bjc.1993.377; OCHIAI A, 1994, JPN J CANCER RES, V85, P266, DOI 10.1111/j.1349-7006.1994.tb02092.x; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; OHTSUKA H, 1994, JPN J CANCER RES, V85, P1015, DOI 10.1111/j.1349-7006.1994.tb02899.x; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PAAVONEN T, 1994, INT J CANCER, V58, P298, DOI 10.1002/ijc.2910580225; PELTONEN J, 1989, J CLIN INVEST, V84, P1916, DOI 10.1172/JCI114379; PIGNATELLI M, 1990, BRIT J CANCER, V61, P636, DOI 10.1038/bjc.1990.141; QIAN F, 1994, CELL, V77, P335, DOI 10.1016/0092-8674(94)90149-X; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; RODRIGUEZALFAGEME C, 1992, P NATL ACAD SCI USA, V89, P1482, DOI 10.1073/pnas.89.4.1482; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAKAI T, 1991, AM J HUM GENET, V48, P880; SASAKI H, 1992, GENE DEV, V6, P1843, DOI 10.1101/gad.6.10.1843; SHIMOYAMA Y, 1991, CANCER RES, V51, P2185; Suda T, 1994, DNA Res, V1, P169, DOI 10.1093/dnares/1.4.169; SUZUKI S, 1993, JPN J CANCER RES, V84, P168, DOI 10.1111/j.1349-7006.1993.tb02851.x; TAKADA T, 1992, JPN J CANCER RES, V83, P165, DOI 10.1111/j.1349-7006.1992.tb00082.x; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; Ushijima T, 1997, P NATL ACAD SCI USA, V94, P2284, DOI 10.1073/pnas.94.6.2284; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	52	7	7	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 9	1998	17	1					105	113		10.1038/sj.onc.1201913	http://dx.doi.org/10.1038/sj.onc.1201913			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZY936	9671319				2022-12-25	WOS:000074677800012
J	Crowley, KS; Payne, RM				Crowley, KS; Payne, RM			Ribosome binding to mitochondria is regulated by GTP and the transit peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOUND CYTOPLASMIC POLYSOMES; SIGNAL-RECOGNITION PARTICLE; PROTEIN IMPORT; YEAST MITOCHONDRIA; ENDOPLASMIC-RETICULUM; MALATE-DEHYDROGENASE; OUTER-MEMBRANE; TRANSLOCATION; IDENTIFICATION; PURIFICATION	The association between ribosomes and the pore proteins at the endoplasmic reticulum membrane is important to co-translational translocation. To determine if a similar association occurs between the ribosome and mitochondrial membrane protein(s) during protein import in higher eukaryotes, we examined ribosome-mitochondria binding. By using spectral measurements, analysis of mitochondrial associated RNA, and electron microscopy, we demonstrated that ribosomes stably bind to purified rat liver mitochondria in vitro. Binding of ribosomes to mitochondria was markedly reduced by GTP and nearly abolished by the non-hydrolyzable GTP analogue, guanosine-5'-[thio]-triphosphate (GTP gamma S), but was only modestly reduced by GDP or ATP and unaffected by CTP. The initial rate of GTP hydrolysis by mitochondria was increased by ribosomes, whereas the rate of ATP hydrolysis by mitochondria was not affected. Ribosomes programmed with mRNA for 92 amino acids of the N terminus of mitochondrial malate dehydrogenase bound to mitochondria, but unlike unprogrammed rat liver ribosomes, neither GTP nor GDP disrupted binding; however, GTP gamma S did. These data show that receptors specific for ribosomes are present on the mitochondrial membrane, and a GTP-dependent process mediates this binding. The presence of a nascent chain alters these binding characteristics. These findings support the hypothesis that a co-translational translocation pathway exists for import of proteins into mitochondria.	Wake Forest Univ, Sch Med, Dept Pediat, Winston Salem, NC 27157 USA	Wake Forest University	Payne, RM (corresponding author), Wake Forest Univ, Sch Med, Dept Pediat, Med Ctr Blvd, Winston Salem, NC 27157 USA.	mpayne@bgsm.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM016826] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R03AG014223] Funding Source: NIH RePORTER; NIA NIH HHS [R03 AG14223] Funding Source: Medline; NIGMS NIH HHS [1F32 GM16826-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADES IZ, 1980, J BIOL CHEM, V255, P9918; Bacher G, 1996, NATURE, V381, P248, DOI 10.1038/381248a0; BERKOVITCHYELLIN Z, 1992, CRIT REV BIOCHEM MOL, V27, P403, DOI 10.3109/10409239209082568; Bitte L, 1974, Methods Enzymol, V30, P563; Bloemendal H, 1974, Methods Enzymol, V30, P313; CASCARANO J, 1995, HEPATOLOGY, V22, P837, DOI 10.1016/0270-9139(95)90306-2; CHU TW, 1987, J BIOL CHEM, V262, P12806; Corsi AK, 1996, J BIOL CHEM, V271, P30299, DOI 10.1074/jbc.271.48.30299; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; FUJIKI M, 1991, J BIOL CHEM, V266, P6841; FUJIKI M, 1993, J BIOL CHEM, V268, P1914; GRANT PM, 1986, NUCLEIC ACIDS RES, V14, P6053, DOI 10.1093/nar/14.15.6053; HACHIYA N, 1994, EMBO J, V13, P5146, DOI 10.1002/j.1460-2075.1994.tb06844.x; HACHIYA N, 1995, NATURE, V376, P705, DOI 10.1038/376705a0; Hovland R, 1996, INT J BIOCHEM CELL B, V28, P1089, DOI 10.1016/1357-2725(96)00059-3; KELLEMS RE, 1972, J BIOL CHEM, V247, P8043; KELLEMS RE, 1975, J CELL BIOL, V65, P1, DOI 10.1083/jcb.65.1.1; KELLEMS RE, 1974, J BIOL CHEM, V249, P3304; KESSLER F, 1994, SCIENCE, V266, P1035, DOI 10.1126/science.7973656; KIEBLER M, 1993, J MEMBRANE BIOL, V135, P191; Kjeldgaard M, 1996, FASEB J, V10, P1347, DOI 10.1096/fasebj.10.12.8903506; Komiya T, 1996, J BIOL CHEM, V271, P22105, DOI 10.1074/jbc.271.36.22105; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; LAURING B, 1995, P NATL ACAD SCI USA, V92, P9435, DOI 10.1073/pnas.92.21.9435; LITHGOW T, 1991, BIOCHEM BIOPH RES CO, V180, P1453, DOI 10.1016/S0006-291X(05)81359-2; MAYER A, 1995, CELL, V80, P127, DOI 10.1016/0092-8674(95)90457-3; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; Neuhof A, 1998, MOL BIOL CELL, V9, P103, DOI 10.1091/mbc.9.1.103; ONO H, 1990, ARCH BIOCHEM BIOPHYS, V280, P299, DOI 10.1016/0003-9861(90)90333-T; ROISE D, 1988, J BIOL CHEM, V263, P4509; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Sepuri NBV, 1998, J BIOL CHEM, V273, P1420, DOI 10.1074/jbc.273.3.1420; SHEPHARD EH, 1969, BIOCHEM J, V113, P429, DOI 10.1042/bj1130429; SPURR AR, 1969, J ULTRA MOL STRUCT R, V26, P31, DOI 10.1016/S0022-5320(69)90033-1; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; SUISSA M, 1982, J BIOL CHEM, V257, P3048; TAKEDA S, 1993, J BIOCHEM-TOKYO, V114, P684, DOI 10.1093/oxfordjournals.jbchem.a124237; THOMSON M, 1995, BIOCHIM BIOPHYS ACTA, V1248, P158; VERNER K, 1993, TRENDS BIOCHEM SCI, V18, P366, DOI 10.1016/0968-0004(93)90090-A; WALTER P, 1983, METHOD ENZYMOL, V96, P84; Weibel E R, 1969, Int Rev Cytol, V26, P235, DOI 10.1016/S0074-7696(08)61637-X	41	45	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17278	17285		10.1074/jbc.273.27.17278	http://dx.doi.org/10.1074/jbc.273.27.17278			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642299	hybrid			2022-12-25	WOS:000074545200089
J	Hashimoto, Y; Katayama, H; Kiyokawa, E; Ota, S; Kurata, T; Gotoh, N; Otsuka, N; Shibata, M; Matsuda, M				Hashimoto, Y; Katayama, H; Kiyokawa, E; Ota, S; Kurata, T; Gotoh, N; Otsuka, N; Shibata, M; Matsuda, M			Phosphorylation of CrkII adaptor protein at tyrosine 221 by epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-CONTAINING PROTEINS; PROLINE-RICH SEQUENCES; CELL ANTIGEN RECEPTOR; COMPLEXES IN-VIVO; SH3 DOMAIN; C-CRK; SIGNALING PATHWAYS; DEPENDENT MANNER; GRB2-SOS COMPLEX; ENDOGENOUS CRK	CrkII adaptor protein becomes tyrosine-phosphorylated upon various types of stimulation. We examined whether tyrosine 221, which has been shown to be phosphorylated by c-Abl, was phosphorylated also by other tyrosine kinases, such as epidermal growth factor (EGF) receptor. For this purpose, we developed an antibody that specifically recognizes Tyr(221)-phosphorylated CrkII, and we demonstrated that CrkII was phosphorylated on Tyr(221) upon EGF stimulation. When NRK cells were stimulated with EGF, the tyrosine-phosphorylated CrkII was detected at the periphery of the cells, where ruffling is prominent, suggesting that signaling to CrkII may be involved in EGF-dependent cytoskeletal reorganization. The EGF-dependent phosphorylation of CrkII was also detected in a c-Abl-deficient cell line. Moreover, recombinant CrkII protein was phosphorylated in vitro by EGF receptor. These results strongly suggest that EGF receptor directly phosphorylates CrkII. Mutational analysis revealed that the src homology 2 domain was essential for the phosphorylation of CrkII by EGF receptor but not by c-Abl, arguing that these kinases phosphorylate CrkII by different phosphorylation mechanisms. Finally, we found that the CrkII protein phosphorylated upon EGF stimulation did not bind to the phosphotyrosine-containing peptide and that CrkII initiated dissociation from EGF receptor within 3 min even with the sustained tyrosine phosphorylation of EGF receptor. This result implicated phosphorylation of Tyr(221) in the negative regulation of the src homology a-mediated binding of CrkII to EGF receptor.	Natl Inst Infect Dis, Dept Pathol, Shinjuku Ku, Tokyo 162, Japan; Univ Tokyo, Inst Med Sci, Dept Genet, Minato Ku, Tokyo 182, Japan; Med & Biol Labs, Nagano 396, Japan; Int Med Ctr Japan, Res Inst, Dept Pathol, Shinjuku Ku, Tokyo 1628655, Japan	National Institute of Infectious Diseases (NIID); University of Tokyo; National Center for Global Health & Medicine - Japan	Matsuda, M (corresponding author), Natl Inst Infect Dis, Dept Pathol, Shinjuku Ku, Tokyo 162, Japan.			Matsuda, Michiyuki/0000-0002-5876-9969				Anafi M, 1996, J BIOL CHEM, V271, P21365, DOI 10.1074/jbc.271.35.21365; Barber DL, 1997, BLOOD, V89, P3166, DOI 10.1182/blood.V89.9.3166; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; Blakesley VA, 1997, J BIOL CHEM, V272, P16211, DOI 10.1074/jbc.272.26.16211; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; Chen D, 1996, J BIOL CHEM, V271, P6328, DOI 10.1074/jbc.271.11.6328; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FELLER SM, 1995, ONCOGENE, V10, P1465; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HARLOW E, 1988, ANTIBODIES LAB MANUA, P535; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; Holt KH, 1996, J BIOL CHEM, V271, P8300, DOI 10.1074/jbc.271.14.8300; Ingham RJ, 1996, J BIOL CHEM, V271, P32306, DOI 10.1074/jbc.271.50.32306; Khwaja A, 1996, ONCOGENE, V12, P2491; KizakaKondoh S, 1996, P NATL ACAD SCI USA, V93, P12177, DOI 10.1073/pnas.93.22.12177; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; MATSUDA M, 1990, J BIOL CHEM, V265, P12000; MATSUDA M, 1993, J BIOL CHEM, V268, P4441; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; Matsuda M, 1996, CELL SIGNAL, V8, P335, DOI 10.1016/0898-6568(96)00067-8; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Ota S, 1998, CELL SIGNAL, V10, P283, DOI 10.1016/S0898-6568(97)00130-7; RANI CSS, 1997, J BIOL CHEM, V272, P1077; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; Ribon V, 1996, MOL CELL BIOL, V16, P45; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; Sawasdikosol S, 1996, J IMMUNOL, V157, P110; Smit L, 1996, ONCOGENE, V13, P381; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Torres M, 1996, ONCOGENE, V12, P77; Wang BL, 1996, ONCOGENE, V13, P1379	40	51	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17186	17191		10.1074/jbc.273.27.17186	http://dx.doi.org/10.1074/jbc.273.27.17186			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642287	hybrid			2022-12-25	WOS:000074545200077
J	Cairns, P; Evron, E; Okami, K; Halachmi, N; Esteller, M; Herman, JG; Bose, S; Wang, SI; Parsons, R; Sidransky, D				Cairns, P; Evron, E; Okami, K; Halachmi, N; Esteller, M; Herman, JG; Bose, S; Wang, SI; Parsons, R; Sidransky, D			Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers	ONCOGENE			English	Article						PTEN/MMAC1; bladder cancer; renal cell cancer; chromosome 10q; homozygous deletion	RENAL-CELL CARCINOMA; TUMOR-SUPPRESSOR GENE; COWDEN SYNDROME; IDENTIFICATION; DISEASE; INACTIVATION; METHYLATION; ALLELOTYPE	A new tumor suppressor gene PTEN/MMAC1 was recently isolated at chromosome 10q23 and found to be inactivated by point mutation or homozygous deletion in glioma, prostate and breast cancer. PTEN/MMAC1 was also identified as the gene predisposing to Cowden disease, an autosomal dominant cancer predisposition syndrome associated with an increased risk of breast, skin and thyroid tumors and occasional cases of other cancers including bladder and renal cell carcinoma. We screened 345 urinary tract cancers by microsatellite analysis and found chromosome 10q to be deleted in 65 of 285 (23%) bladder and 15 of 60 (25%) renal cell cancers, We then screened the entire PTEN/MMAC1 coding region for mutation in 25 bladder and 15 renal cell primary tumors with deletion of chromosome 10q, Two somatic point mutations, a frameshift and a splicing variant, were found in the panel of bladder tumors while no mutation was observed in the renal cell carcinomas. To screen for homozygous deletion, we isolated two polymorphic microsatellite repeats from genomic BAC clones containing the PTEN/MMAC1 gene. Using these new informative markers, we identified apparent retention at the gene locus indicative of homozygous deletion of PTEN/MMAC1 in four of 65 bladder and 0 of 15 renal cell tumors with LOH through chromosome 10q, Identification of the second inactivation event in six bladder tumors with LOH of 10q implies that the PTEN/MMAC1 gene is occasionally involved in bladder tumorigenesis. However, the low frequency of biallelic inactivation suggests that either PTEN/MMAC1 is inactivated by other mechanisms or it is not the only target of chromosome 10q deletion in primary bladder and renal cell cancer.	Johns Hopkins Univ, Sch Med, Dept Otolaryngol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21205 USA; Columbia Univ Coll Phys & Surg, Dept Pathol & Med, New York, NY 10032 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Columbia University	Sidransky, D (corresponding author), Johns Hopkins Univ, Sch Med, Dept Otolaryngol, Baltimore, MD 21205 USA.		Esteller, Manel/L-5956-2014	Esteller, Manel/0000-0003-4490-6093; Evron, Ella/0000-0002-1003-5042; Parsons, Ramon/0000-0002-6656-3514				CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CAIRNS P, 1991, ONCOGENE, V6, P2305; Cairns P, 1997, CANCER RES, V57, P4997; ENG C, 1994, J MED GENET, V31, P458, DOI 10.1136/jmg.31.6.458; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; HABUCHI T, 1993, INT J CANCER, V53, P579, DOI 10.1002/ijc.2910530409; HAIBACH H, 1992, AM J CLIN PATHOL, V97, P705, DOI 10.1093/ajcp/97.5.705; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; ISHIKAWA J, 1991, CANCER RES, V51, P5736; KNOWLES MA, 1994, CANCER RES, V54, P531; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MORITA R, 1991, CANCER RES, V51, P5817; MORITA R, 1991, CANCER RES, V51, P820; REITER RE, 1993, CANCER RES, V53, P3092; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANDBERG AA, 1994, J UROLOGY, V151, P545, DOI 10.1016/S0022-5347(17)35014-0; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; STARINK TM, 1986, CLIN GENET, V29, P222; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; VANDERRIET P, 1994, CANCER RES, V54, P25; Wang SI, 1997, CANCER RES, V57, P4183	26	153	159	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 18	1998	16	24					3215	3218		10.1038/sj.onc.1201855	http://dx.doi.org/10.1038/sj.onc.1201855			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671402				2022-12-25	WOS:000074261300016
J	Frizelle, SP; Grim, J; Zhou, J; Gupta, P; Curiel, DT; Geradts, J; Kratzke, RA				Frizelle, SP; Grim, J; Zhou, J; Gupta, P; Curiel, DT; Geradts, J; Kratzke, RA			Re-expression of p16(INK4a) in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression	ONCOGENE			English	Article						p16(INK4a); mesothelioma; tumor suppressor	RETINOBLASTOMA-SUSCEPTIBILITY GENE; LUNG-CANCER; MALIGNANT MESOTHELIOMA; FAMILIAL MELANOMA; WILD-TYPE; RB; MUTATIONS; PRODUCT; PROTEIN; LINES	Absence of expression of the p16(INK4a) gene product is commonly observed in mesothelioma tumors and cell lines, while wild-type pRB expression is maintained. We have examined the biologic and potential therapeutic role of re-expressing p16(INK4a) gene product in mesothelioma cells and tumors. Following transduction with a p16(INK4a) expressing adenovirus (Adp16), over-expression of p16(INK4a) in mesothelioma cells resulted in cell cycle arrest, inhibition of pRB phosphorylation, diminished cell growth, and eventual death of the transduced cells. Expression of p16(INK4a) protein was accompanied by decreased expression of pRB as detected by immunoblot and immunohistochemistry. Experiments in mesothelioma xenografts demonstrated inhibition of tumor formation, tumor growth arrest and diminished tumor size and spread. p16(INK4a) gene product expression was also demonstrated in intraperitoneal xenografts of human mesothelioma cells, These results demonstrate that p16(INK4a) gene transfer may play a therapeutic role in the treatment of mesothelioma.	Vet Affairs Med Ctr, Dept Med, Hematol Oncol Sect, Minneapolis, MN 55417 USA; Univ Minnesota, Sch Med, Minneapolis, MN 55417 USA; Univ Alabama Birmingham, Gene Therapy Program, Birmingham, AL 35294 USA; Univ N Carolina, Sch Med, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities; University of Alabama System; University of Alabama Birmingham; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Kratzke, RA (corresponding author), Vet Affairs Med Ctr, Dept Med, Hematol Oncol Sect, Minneapolis, MN 55417 USA.				NATIONAL CANCER INSTITUTE [R01CA068245] Funding Source: NIH RePORTER; NCI NIH HHS [1 R01 CA 68245-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antman KH, 1989, CANCER PRINCIPLES PR, P1399; BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; BODNER SM, 1992, ONCOGENE, V7, P743; CARBONE M, 1994, ONCOGENE, V9, P1781; Carbone M, 1997, NAT MED, V3, P908, DOI 10.1038/nm0897-908; Chen WD, 1997, ONCOGENE, V14, P1243, DOI 10.1038/sj.onc.1201096; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DeLuca A, 1997, NAT MED, V3, P913, DOI 10.1038/nm0897-913; FUJIWARA T, 1994, J NATL CANCER I, V86, P1458, DOI 10.1093/jnci/86.19.1458; Geradts J, 1996, MODERN PATHOL, V9, P339; GERADTS J, 1995, CANCER RES, V55, P6006; GRIM J, 1997, IN PRESS CLIN CANC R; KRATZKE RA, 1995, J NATL CANCER I, V87, P1870, DOI 10.1093/jnci/87.24.1870; Kratzke RA, 1996, CANCER RES, V56, P3415; METCALF RA, 1992, CANCER RES, V52, P2610; OTTERSON GA, 1994, ONCOGENE, V9, P3375; Parry D, 1996, MOL CELL BIOL, V16, P3844; PASS HI, 1995, ANN THORAC SURG, V59, P835, DOI 10.1016/0003-4975(95)00045-M; Pass HI, 1996, J CELL BIOCHEM, P142; Sakaguchi M, 1996, INT J CANCER, V65, P442, DOI 10.1002/(SICI)1097-0215(19960208)65:4<442::AID-IJC8>3.0.CO;2-X; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; SEKIDO Y, 1995, CANCER RES, V55, P1227; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P505; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SMYTHE WR, 1994, ANN THORAC SURG, V57, P1395, DOI 10.1016/0003-4975(94)90090-6; Treat J, 1996, HUM GENE THER, V7, P2047, DOI 10.1089/hum.1996.7.16-2047; Ueki K, 1996, CANCER RES, V56, P150; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	31	98	101	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 18	1998	16	24					3087	3095		10.1038/sj.onc.1201870	http://dx.doi.org/10.1038/sj.onc.1201870			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671387				2022-12-25	WOS:000074261300001
J	Chevillard, S; Radicella, JP; Levalois, C; Lebeau, J; Poupon, MF; Oudard, S; Dutrillaux, B; Boiteux, S				Chevillard, S; Radicella, JP; Levalois, C; Lebeau, J; Poupon, MF; Oudard, S; Dutrillaux, B; Boiteux, S			Mutations in OGG1, a gene involved in the repair of oxidative DNA damage, are found in human lung and kidney tumours	ONCOGENE			English	Article						oxidative DNA damage; DNA repair; missense mutations of OGG1 gene; human lung and kidney cancer; tumour suppressor gene	GENERATES G.C->T.A TRANSVERSIONS; NONPOLYPOSIS COLON-CANCER; ESCHERICHIA-COLI; MUTATOR LOCUS; BREAST-CANCER; MUTY GENE; GLYCOSYLASE; CLONING; HOMOLOG; 7,8-DIHYDRO-8-OXOGUANINE	The human OGG1 gene encodes a DNA glycosylase activity catalysing the excision of the mutagenic lesion 7,8-dihydro-8-oxoguanine from oxidatively damaged DNA, The OGG1 gene was localized to chromosome 3p25, a region showing frequent loss of heterozygosity (LOH) in lung and kidney tumours. In this study, we have analysed by RT-PCR the expression of OGG1 in 25 small cell lung cancers, in 15 kidney carcinomas and the 15 normal kidney counterparts. The results show that OGG1 messenger RNA can be detected in all tumours tested and that no significant difference was observed in the level of expression between normal and tumoral kidney tissues. Denaturing gradient gel electrophoresis (DGGE) was used to screen this series of human tumours for alterations in the OGG1 cDNA. The study revealed homozygous mutations in three tumours, two from lung and one from kidney, Sequencing analysis of the mutants identified a single base substitution in each of the three cases: two tranversions (GC to TA and TA to AT) and one transition (GC to AT), All three substitutions cause an amino acid change in the hOgg1 protein. For the mutant kidney tumour, the normal tissue counterpart shows a wild-type profile, These results suggest a role for OGG1 mutations in the course of the multistage process of carcinogenesis in lung or kidney.	CNRS CEA Radiobiol Mol & Cellulaire UMR217, Dept Radiobiol & Radiopathol, Lab Radiobiol DNA, F-92265 Fontenay Aux Roses, France; CNRS CEA Radiobiol Mol & Cellulaire UMR217, Dept Radiobiol & Radiopathol, Lab Cancerogenese Expt, F-92265 Fontenay Aux Roses, France; CNRS UMR147, Inst Curie, F-75005 Paris, France; Hotel Dieu, Med Oncol Serv, F-75004 Paris, France; CEA, Dept Radiobiol & Radiopathol, F-92265 Fontenay Aux Roses, France	CEA; UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; CEA	Boiteux, S (corresponding author), CNRS CEA Radiobiol Mol & Cellulaire UMR217, Dept Radiobiol & Radiopathol, Lab Radiobiol DNA, F-92265 Fontenay Aux Roses, France.		Radicella, J. Pablo/AAU-3178-2020	Radicella, J. Pablo/0000-0002-8807-7226; Chevillard, Sylvie/0000-0001-5889-4041; OUDARD, Stephane/0000-0003-0893-285X				Aburatani H, 1997, CANCER RES, V57, P2151; Arai K, 1997, ONCOGENE, V14, P2857, DOI 10.1038/sj.onc.1201139; AU KG, 1989, P NATL ACAD SCI USA, V86, P8877, DOI 10.1073/pnas.86.22.8877; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; Bjoras M, 1997, EMBO J, V16, P6314, DOI 10.1093/emboj/16.20.6314; BOITEUX S, 1987, EMBO J, V6, P3177, DOI 10.1002/j.1460-2075.1987.tb02629.x; BOITEUX S, 1998, IN PRESS DNA DAMAGE; Boiteux S., 1997, BASE EXCISION REPAIR, P31; BREIMER LH, 1990, MOL CARCINOGEN, V3, P188, DOI 10.1002/mc.2940030405; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CABRERA M, 1988, J BACTERIOL, V170, P5405, DOI 10.1128/jb.170.11.5405-5407.1988; Cadet J, 1997, Rev Physiol Biochem Pharmacol, V131, P1; Chevillard S, 1997, CLIN CANCER RES, V3, P2471; Chevillard S, 1996, CANCER, V77, P292, DOI 10.1002/(SICI)1097-0142(19960115)77:2<292::AID-CNCR11>3.0.CO;2-X; Chevillard S, 1996, BREAST CANCER RES TR, V41, P81, DOI 10.1007/BF01807039; DIZDAROGLU M, 1991, FREE RADICAL BIO MED, V10, P225, DOI 10.1016/0891-5849(91)90080-M; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; Fearon ER, 1997, SCIENCE, V278, P1043, DOI 10.1126/science.278.5340.1043; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Girard PM, 1997, NUCLEIC ACIDS RES, V25, P3204, DOI 10.1093/nar/25.16.3204; GROLLMAN AP, 1993, TRENDS GENET, V9, P246, DOI 10.1016/0168-9525(93)90089-Z; HIBI K, 1992, ONCOGENE, V7, P445; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; JIRICNY J, 1994, TRENDS GENET, V10, P164, DOI 10.1016/0168-9525(94)90093-0; Karahalil B, 1998, NUCLEIC ACIDS RES, V26, P1228, DOI 10.1093/nar/26.5.1228; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LOEB LA, 1991, CANCER RES, V51, P3075; Loeb LA, 1997, SCIENCE, V277, P1449, DOI 10.1126/science.277.5331.1449; Lu RZ, 1997, CURR BIOL, V7, P397, DOI 10.1016/S0960-9822(06)00187-4; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; NGHIEM Y, 1988, P NATL ACAD SCI USA, V85, P2709, DOI 10.1073/pnas.85.8.2709; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; RADICELLA JP, 1988, P NATL ACAD SCI USA, V85, P9674, DOI 10.1073/pnas.85.24.9674; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; Richards B, 1997, SCIENCE, V277, P1523, DOI 10.1126/science.277.5331.1523; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Thomas D, 1997, MOL GEN GENET, V254, P171, DOI 10.1007/s004380050405; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252	43	197	202	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 11	1998	16	23					3083	3086		10.1038/sj.onc.1202096	http://dx.doi.org/10.1038/sj.onc.1202096			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZT782	9662341				2022-12-25	WOS:000074125300015
J	Oliveira, MLS; Roberts, TM; Druker, BJ; Armelin, MCS				Oliveira, MLS; Roberts, TM; Druker, BJ; Armelin, MCS			Mapping of polyomavirus middle T domain that is responsible for AP-1 activation	ONCOGENE			English	Article						polyomavirus; middle T antigen; cell transformation; AP-1 activation; phosphatidylinositol-3 kinase	PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; SIZED TUMOR-ANTIGEN; RECOMBINANT RETROVIRUSES; CELL-TRANSFORMATION; PROTEIN-KINASES; INTACT-CELLS; WILD-TYPE; C-FOS; JUN; EXPRESSION	Cell transformation by Polyomavirus middle T (MT) oncoprotein involves binding and activation of several cytoplasmic proteins that participate in growth factors-induced mitogenic signal transduction to the nucleus. We have previously reported that the AP-I transcriptional complex is a target for MT during cell transformation. To analyse the interactions between MT and cellular proteins that are required for constitutive AP-1 activation, we compared wild type and transformation-defective MT mutant cell lines. High AP-1 activity, assessed by gel mobility shift assays, displayed by MT-overexpressing cells, is dependent on MT binding to phosphatidylinositol-3 kinase (PI3K). Treatment with wortmannin (a specific PI3K inhibitor) leads to decreased AP-I activity. Supershift and Western blot analysis with specific antisera, indicate that JunB and cJun, but not cFos or FosB are present in the AP-1 complex. The results confirm the AP-1 complex as a downstream MT target and indicate that AP-1 activation may not be sufficient for cell transformation, since two transformation-defective MT mutants (250phe and MT322) display high AP-1 activity.	Univ Sao Paulo, Inst Quim, BR-05599970 Sao Paulo, SP, Brazil; Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Cellular & Mol Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Oregon Hlth & Sci Univ, Portland, OR 97201 USA	Universidade de Sao Paulo; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Oregon Health & Science University	Armelin, MCS (corresponding author), Univ Sao Paulo, Inst Quim, CP 26077, BR-05599970 Sao Paulo, SP, Brazil.		Oliveira, Maria Leonor S/F-4988-2012	Oliveira, Maria Leonor/0000-0003-4849-3062; Druker, Brian/0000-0001-8331-8206				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Armelin MCS, 1996, BRAZ J MED BIOL RES, V29, P1133; ARMELIN MCS, 1985, COLD SPRING HARBOR C, V3, P195; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOLENJB, 1994, CELL, V38, P767; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CAMPBELL KS, 1995, J VIROL, V69, P3721, DOI 10.1128/JVI.69.6.3721-3728.1995; CARMICHAEL G, 1984, P NATL ACAD SCI-BIOL, V81, P679, DOI 10.1073/pnas.81.3.679; CHERINGTON V, 1986, P NATL ACAD SCI USA, V83, P4307, DOI 10.1073/pnas.83.12.4307; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COHEN B, 1990, MOL CELL BIOL, V10, P2909, DOI 10.1128/MCB.10.6.2909; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; Dahl J, 1996, MOL CELL BIOL, V16, P2728; DEGROOT RP, 1992, ONCOGENE, V7, P841; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; DRUKER BJ, 1990, J VIROL, V64, P4454, DOI 10.1128/JVI.64.9.4454-4461.1990; DRUKER BJ, 1992, J VIROL, V66, P5770, DOI 10.1128/JVI.66.10.5770-5776.1992; DRUKER BJ, 1992, NUCLEIC ACIDS RES, V19, P6855; Dunant NM, 1996, J VIROL, V70, P1323, DOI 10.1128/JVI.70.3.1323-1330.1996; GLENN GM, 1993, J VIROL, V67, P1945, DOI 10.1128/JVI.67.4.1945-1952.1993; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LING LE, 1992, J VIROL, V66, P1702, DOI 10.1128/JVI.66.3.1702-1708.1992; MARKLAND W, 1987, BIOCHIM BIOPHYS ACTA, V907, P299, DOI 10.1016/0304-419X(87)90011-4; MARRA F, 1995, FEBS LETT, V376, P141, DOI 10.1016/0014-5793(95)01261-0; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MORGAN WC, 1988, J VIROL, V62, P3407, DOI 10.1128/JVI.62.9.3407-3414.1988; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; PALLAS DC, 1988, J VIROL, V62, P3934, DOI 10.1128/JVI.62.11.3934-3940.1988; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; POWIS G, 1994, CANCER RES, V54, P2419; RAMEH LE, 1991, ONCOGENE, V6, P1049; RAMEH LE, 1992, MOL CELL BIOL, V12, P4612, DOI 10.1128/MCB.12.10.4612; RAPTIS L, 1985, MOL CELL BIOL, V5, P2476, DOI 10.1128/MCB.5.9.2476; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SCHLEGEL R, 1978, CELL, V14, P587, DOI 10.1016/0092-8674(78)90244-1; SCHONTHAL A, 1992, P NATL ACAD SCI USA, V89, P4972, DOI 10.1073/pnas.89.11.4972; SERUNIAN LA, 1990, J VIROL, V64, P4718, DOI 10.1128/JVI.64.10.4718-4725.1990; SRINIVAS S, 1994, P NATL ACAD SCI USA, V91, P10064, DOI 10.1073/pnas.91.21.10064; SU W, 1995, J BIOL CHEM, V270, P12331, DOI 10.1074/jbc.270.21.12331; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; THOMAS JE, 1993, ONCOGENE, V8, P2521; ULUG ET, 1990, J VIROL, V64, P3895, DOI 10.1128/JVI.64.8.3895-3904.1990; URICH M, 1995, J BIOL CHEM, V270, P29286, DOI 10.1074/jbc.270.49.29286; Urich M, 1997, ONCOGENE, V14, P1235, DOI 10.1038/sj.onc.1200982; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0	51	5	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 11	1998	16	23					2975	2982		10.1038/sj.onc.1201841	http://dx.doi.org/10.1038/sj.onc.1201841			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZT782	9662329				2022-12-25	WOS:000074125300003
J	Zhang, HT; O'Rourke, DM; Zhao, HZ; Murali, R; Mikami, Y; Davis, JG; Greene, MI; Qian, XL				Zhang, HT; O'Rourke, DM; Zhao, HZ; Murali, R; Mikami, Y; Davis, JG; Greene, MI; Qian, XL			Absence of autophosphorylation site Y882 in the p185(neu) oncogene product correlates with a reduction of transforming potential	ONCOGENE			English	Article						p185(neu); tyrosine kinase; Y882; transformation	EPIDERMAL GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; FACTOR-I RECEPTOR; NEU-ONCOGENE; SIGNAL-TRANSDUCTION; INTERMOLECULAR ASSOCIATION; CELL-TRANSFORMATION; RET PROTOONCOGENE; PROTEIN-KINASE; POINT MUTATION	Autophosphorylation of type I receptor tyrosine kinases (RTKs) comprises one step in the signaling events mediated by erbB receptors such as p185(neu) and EGFR. Previous analysis of p185(neu) has indicated that there are at least five tyrosine autophosphorylation sites, Y882, Y1028, E1143, Y1226/7 and Y1253, of which Y882 might be important because of its location in the kinase activity domain. We have specifically analysed the effect of a Y882F (phenylalanine substituted for tyrosine at position 882) mutation in the enzymatic active domain. We also deleted the carboxyl terminal 122 amino acids which contained three other autophosphorylation sites (TAPstop) and combined mutants of that deletion with Y882F (Y882F/APstop). Both in vitro and in vivo transformation assays showed that substitution of tyrosine(882) by phenylalanine significantly decreased the transforming potential of activated, oncogenic p185(neu), although no significant difference in the total phosphotyrosine levels of the mutant proteins were observed. To analyse mitogenic signaling in response to ligand, the intracellular domains of p185(neu) and Y882F were fused with the extracellular domain of the EGF receptor. The proliferation of cells expressing these chimeric receptors was EGF-dependent, and cells expressing EGFR/Y882F chimeric receptors were less responsive to EGF stimulation than those expressing EGFR/neu receptors. In vitro kinase assays demonstrated that abolishing the autophosphorylation site Y882 diminished the enzymatic tyrosine kinase activity of p185(neu). These studies, taken together with the phenotypic inhibition observed with cells expressing Y882F, suggest that the tyrosine(882). residue may be important for p185(neu)-mediated transformation by affecting the enzymatic kinase function of the p185(neu) receptor.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; NCI, Cellular Oncol Lab, Bethesda, MD 20892 USA	University of Pennsylvania; University of Pennsylvania; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Greene, MI (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, 36th & Hamilton Walk, Philadelphia, PA 19104 USA.		O'Rourke, Donald/AAC-3376-2021	Murali, Ramachandran/0000-0002-8384-2793; O'Rourke, Donald/0000-0002-8479-7314				CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CARTER TH, 1994, CRIT REV ONCOGENESIS, V5, P389, DOI 10.1615/CritRevOncog.v5.i4.40; CHANTRY A, 1995, J BIOL CHEM, V270, P3068; COLA C, 1989, BIOCHIM BIOPHYS ACTA, V1012, P191, DOI 10.1016/0167-4889(89)90095-5; DECKER SJ, 1993, J BIOL CHEM, V268, P9176; DOUGALL WC, 1994, ONCOGENE, V9, P2109; DREBIN JA, 1984, NATURE, V312, P545, DOI 10.1038/312545a0; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FANTL WJ, 1989, MOL CELL BIOL, V9, P4473, DOI 10.1128/MCB.9.10.4473; GOTOH N, 1992, BIOCHEM BIOPH RES CO, V186, P768, DOI 10.1016/0006-291X(92)90812-Y; Groenen LC, 1997, BIOCHEMISTRY-US, V36, P3826, DOI 10.1021/bi9614141; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; KIYOKAWA N, 1995, P NATL ACAD SCI USA, V92, P1092, DOI 10.1073/pnas.92.4.1092; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LI NX, 1994, ONCOGENE, V9, P3457; MIKAMI Y, 1992, P NATL ACAD SCI USA, V89, P7335, DOI 10.1073/pnas.89.16.7335; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; Murali R, 1996, P NATL ACAD SCI USA, V93, P6252, DOI 10.1073/pnas.93.13.6252; MYERS JN, 1992, RECEPTOR, V2, P1; ORourke DM, 1997, P NATL ACAD SCI USA, V94, P3250, DOI 10.1073/pnas.94.7.3250; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; QIAN XL, 1995, ONCOGENE, V10, P211; Qian XL, 1996, ONCOGENE, V13, P2149; QIAN XL, 1994, ONCOGENE, V9, P1507; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; SAMANTA A, 1994, P NATL ACAD SCI USA, V91, P1711, DOI 10.1073/pnas.91.5.1711; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SATO KI, 1995, BIOCHEM BIOPH RES CO, V215, P1078, DOI 10.1006/bbrc.1995.2574; TIMMS JF, 1995, BIOCHEM J, V308, P219, DOI 10.1042/bj3080219; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1991, MOL CELL BIOL, V11, P4698, DOI 10.1128/MCB.11.9.4698; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WEINMASTER G, 1984, CELL, V37, P559, DOI 10.1016/0092-8674(84)90386-6	42	15	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 4	1998	16	22					2835	2842		10.1038/sj.onc.1201820	http://dx.doi.org/10.1038/sj.onc.1201820			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZR544	9671404				2022-12-25	WOS:000073988200002
J	Boss, V; Abbott, KL; Wang, XF; Pavlath, GK; Murphy, TJ				Boss, V; Abbott, KL; Wang, XF; Pavlath, GK; Murphy, TJ			The cyclosporin A-sensitive nuclear factor of activated T cells (NFAT) proteins are expressed in vascular smooth muscle cells - Differential localization of NFAT isoforms and induction of NFAT-mediated transcription by phospholipase c-coupled cell surface receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; GENE; CALCINEURIN; FOS; DEPHOSPHORYLATION; TRANSDUCTION; MECHANISM; COMPLEX; KINASE; FAMILY	Expression of the antigen-regulated, cyclosporin A-sensitive nuclear factor of activated T cells (NFAT) is not restricted to lymphoid cells, as thought initially, but the physiological inducers of NFAT-mediated transcription in non-lymphoid cells are unknown. Here, cultured vascular smooth muscle cells (VSMC) are shown to express two isoforms of the NFAT family endogenously, which are localized differentially in cells under resting conditions. Using a retroviral NFAT-specific luciferase reporter, we show that VSMC support previously unrecognized complexities in NEAT-mediated transcription, including evidence for negative regulation by Ca2+ signaling and positive regulation through co-activation of adenylyl cyclase and Ca2+ mobilization, The VSMC mitogen platelet derived growth factor-BE (PDGF-EB) induces NFAT-mediated transcription in VSMC, Thrombin and angiotensin II, which activate G alpha(q)-coupled receptors, are significantly weaker inducers of NFAT-mediated luciferase expression than is PDGF-BB, However, co-stimulation studies show that G alpha(q) receptor agonists augment the NEAT-mediated transcriptional response to PDGF-BB, This synergy can be explained in part by augmented intracellular Ca2+ transients elicited by multiple agonist challenges. These data indicate that agonists for phospholipase C-coupled receptors stimulate NFAT-mediated transcription in VSMC differentially, and that NEAT can function to integrate co-activating signals in the extracellular environment.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Emory Univ, Grad Div Biol & Biomed Sci, Grad Program Mol Therapeut & Toxicol, Atlanta, GA 30322 USA	Emory University; Emory University	Murphy, TJ (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, Rm 5031,OW Rollins Res Bldg, Atlanta, GA 30322 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR043410, P30AR042687] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52801] Funding Source: Medline; NIAMS NIH HHS [AR43410, AR42687] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABEDI H, 1995, CARDIOVASC RES, V30, P544, DOI 10.1016/0008-6363(95)00092-5; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; BRAISER AR, 1989, BIOTECHNIQUES, V7, P1116; CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1, DOI 10.1152/physrev.1979.59.1.1; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COCKERILL GW, 1995, BLOOD, V86, P2689; Condie R, 1996, J BIOL CHEM, V271, P13175, DOI 10.1074/jbc.271.22.13175; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; FIRST MR, 1994, J AM SOC NEPHROL, V4, P30; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; HO AM, 1994, J BIOL CHEM, V269, P28181; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; JACKSON CL, 1992, HYPERTENSION, V20, P713, DOI 10.1161/01.HYP.20.6.713; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JAIN JN, 1993, J IMMUNOL, V151, P837; KOTANI H, 1994, HUM GENE THER, V5, P19, DOI 10.1089/hum.1994.5.1-19; KRAISS LW, 1993, J CLIN INVEST, V92, P338, DOI 10.1172/JCI116572; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; MAJESKY MW, 1990, J CELL BIOL, V111, P2149, DOI 10.1083/jcb.111.5.2149; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MILLER AD, 1993, METHOD ENZYMOL, V217, P581; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; Nickenig G, 1996, MOL PHARMACOL, V50, P743; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; PAVLATH GK, 1989, SOMAT CELL MOLEC GEN, V15, P191, DOI 10.1007/BF01534870; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; RUFF VA, 1995, J BIOL CHEM, V270, P22602, DOI 10.1074/jbc.270.38.22602; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; TAKEUCHI K, 1993, CIRC RES, V73, P612, DOI 10.1161/01.RES.73.4.612; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; Tsai EY, 1996, MOL CELL BIOL, V16, P459; Weiss DL, 1996, MOL CELL BIOL, V16, P228; WILCOX JN, 1988, J CLIN INVEST, V82, P1134, DOI 10.1172/JCI113671; WILCOX JN, 1994, HAEMOSTASIS THROMBOS, P1139; WU J, 1995, MOL CELL BIOL, V15, P4337	43	96	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19664	19671		10.1074/jbc.273.31.19664	http://dx.doi.org/10.1074/jbc.273.31.19664			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677394	hybrid			2022-12-25	WOS:000075125200046
J	Phelan, SA; Loeken, MR				Phelan, SA; Loeken, MR			Identification of a new binding motif for the paired domain of Pax-3 and unusual characteristics of spacing of bipartite recognition elements on binding and transcription activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR ALVEOLAR RHABDOMYOSARCOMA; DNA-BINDING; WAARDENBURG SYNDROME; BOX GENE; PROTEIN; SEQUENCES; DROSOPHILA; FUSION; EXPRESSION; MUTATIONS	Pax-3, a transcription factor that is required for development of the embryonic neural tube, neural crest, and semitic derivatives, contains two DNA-binding domains, a paired domain, and a paired-type homeodomain. Although Pax-3 binds to sequences related to the e5 element of the Drosophila even-skipped gene, the sequence requirements of an optimal Pax-3 response element have not been well characterized. Using both DNA-binding domains and a pool of random oligonucleotides, we identified a new paired box consensus motif, "GT-TAT," which was located 1, 4, 5, 8, or 13 base pairs downstream of the homeobox binding motif, "ATTA." Binding analysis of these sequences demonstrated that the distance between recognition elements for the homeodomain and the paired domain affects affinity. Specifically, spacing elements 1 or 13 base pairs apart from each other conferred low affinity Pax-3 binding, whereas intermediate spacing (5 or 8 bass pairs) conferred high affinity binding. Contrary to previous reports, oligonucleotides deleted for either the ATTA or the GTTAT could also be bound by Pax-5, although both sites were necessary for maximal affinity. Finally, transient transfections demonstrated that Pax-3 trans-activation correlated with binding affinity. Because the Pax-3-responsive genes identified to date contain almost exclusively low affinity binding sequences, our analysis indicates that they may be responsive to Pax-3 only when cellular levels are high.	Joslin Diabet Ctr, Mol Biol Sect, Boston, MA 02215 USA; Harvard Univ, Sch Med, Div Med Sci, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Loeken, MR (corresponding author), Joslin Diabet Ctr, Mol Biol Sect, 1 Joslin Pl, Boston, MA 02215 USA.		Loeken, Mary R./AAC-2450-2022	Loeken, Mary R./0000-0002-8056-9816	NCI NIH HHS [CA50599] Funding Source: Medline; NIDDK NIH HHS [T32 DK07260, DK36836] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007260, P30DK036836] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUERBACH R, 1954, J EXP ZOOL, V127, P305, DOI 10.1002/jez.1401270206; Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; BALDWIN CT, 1992, NATURE, V355, P637, DOI 10.1038/355637a0; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BAUMGARTNER S, 1987, GENE DEV, V1, P1247, DOI 10.1101/gad.1.10.1247; Bennicelli JL, 1996, P NATL ACAD SCI USA, V93, P5455, DOI 10.1073/pnas.93.11.5455; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P12745, DOI 10.1073/pnas.91.26.12745; CHALEPAKIS G, 1994, NUCLEIC ACIDS RES, V22, P3131, DOI 10.1093/nar/22.15.3131; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P3685, DOI 10.1073/pnas.91.9.3685; CHALEPAKIS G, 1995, GENE, V162, P267, DOI 10.1016/0378-1119(95)00345-7; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; EPSTEIN DJ, 1993, P NATL ACAD SCI USA, V90, P532, DOI 10.1073/pnas.90.2.532; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; FAINSOD A, 1991, NUCLEIC ACIDS RES, V19, P4005, DOI 10.1093/nar/19.14.4005; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GAMBAROTTA G, 1994, J BIOL CHEM, V269, P12852; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GOULDING MD, 1993, DEVELOPMENT, V117, P1001; HOCHSCHILD A, 1986, CELL, V44, P681, DOI 10.1016/0092-8674(86)90833-0; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; Jun S, 1996, DEVELOPMENT, V122, P2639; KIOUSSI C, 1995, NEURON, V15, P553, DOI 10.1016/0896-6273(95)90144-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI P, 1993, GENE DEV, V7, P2483, DOI 10.1101/gad.7.12b.2483; LOEKEN MR, 1989, J BIOL CHEM, V264, P6572; Maroto M, 1997, CELL, V89, P139, DOI 10.1016/S0092-8674(00)80190-7; MAULBECKER CC, 1993, EMBO J, V12, P2361, DOI 10.1002/j.1460-2075.1993.tb05890.x; MIURA M, 1989, GENE, V75, P31; NORBY PL, 1992, NUCLEIC ACIDS RES, V20, P6317, DOI 10.1093/nar/20.23.6317; PERKINS AS, 1991, MOL CELL BIOL, V11, P2665, DOI 10.1128/MCB.11.5.2665; Phelan SA, 1997, DIABETES, V46, P1189, DOI 10.2337/diabetes.46.7.1189; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPIRO DN, 1993, CANCER RES, V53, P5108; Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092-8674(00)80189-0; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; TASSABEHJI M, 1993, NAT GENET, V3, P26, DOI 10.1038/ng0193-26; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; TREISMAN J, 1989, CELL, V59, P594; WU C, 1984, NATURE, V311, P81, DOI 10.1038/311081a0	44	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19153	19159		10.1074/jbc.273.30.19153	http://dx.doi.org/10.1074/jbc.273.30.19153			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668101	hybrid, Green Published			2022-12-25	WOS:000074974700068
J	Rossi, R; Barra, D; Bellelli, A; Boumis, G; Canofeni, S; Di Simplicio, P; Lusini, L; Pascarella, S; Amiconi, G				Rossi, R; Barra, D; Bellelli, A; Boumis, G; Canofeni, S; Di Simplicio, P; Lusini, L; Pascarella, S; Amiconi, G			Fast-reacting thiols in rat hemoglobins can intercept damaging species in erythrocytes more efficiently than glutathione	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN MIXED DISULFIDES; BLOOD; OXIDATION; STABILITY; REAGENTS; EXCHANGE; BINDING; CHAINS; CELLS; GSH	The S-conjugation rates of the free-reacting thiols present on each component of rat hemoglobin with 5,5-dithio-bis(2,2-nitrobenzoic acid) (DTNB) have been studied under a variety of conditions. On the basis of their reactivity with DTNB (0.5 mn), three classes of thiols have been defined as follows: fast reacting (fHbSH), with t(1/2) <100 ms; slow reacting (sHbSH), with t(1/2) 30-50 s; and very slow reacting (vsHbSH), with t(1/2) 180-270 s, Under paraphysiological conditions, fHbSH (identified with Cys-125 beta(H3)) conjugates with DTNB 100 times faster than glutathione and similar to 4000 times more rapidly than (v)sHbSH (Cys-13 alpha(All) and Cys-93 beta(F9)). Such characteristics of fHbSH reactivity that are independent of the quaternary state of hemoglobin are mainly due to the following: (i) its low pK (similar to 6.9, the cysteinyl anion being stabilized by a hydrogen bond with Ser-123 beta(H1)) and (ii) the large exposure to the solvent (as measured by analysis of a model of the molecular surface) and make these thiols the kinetically preferred groups in rat erythrocytes for S-conjugation. In addition, because of the high cellular concentration (8 mM, i.e. four times that of glutathione), fHbSHs are expected to intercept damaging species in erythrocytes more efficiently than glutathione, thus adding a new physiopathological role (direct involvement in cellular strategies of antioxidant defense) to cysteinyl residues in proteins.	Univ Roma La Sapienza, Dipartimento Sci Biochim A Rossi Fanelli, I-00185 Rome, Italy; Univ Siena, Ist Clin Malattie Nervose & Mentali, Sez Farmacol, I-53100 Siena, Italy; CNR, Ctr Biol Mol, I-00185 Rome, Italy	Sapienza University Rome; University of Siena; Consiglio Nazionale delle Ricerche (CNR)	Amiconi, G (corresponding author), Univ Roma La Sapienza, Dipartimento Sci Biochim A Rossi Fanelli, Piazzale Aldo Moro 5, I-00185 Rome, Italy.	amigino@axrma.uniromal.it	Bellelli, Andrea/D-2785-2009; Rossi, Ranieri/C-8743-2011; Barra, Donatella/D-1236-2011	Rossi, Ranieri/0000-0002-0187-4530; BOUMIS, Giovanna/0000-0001-5323-7288				AMICONI G, 1989, J BIOL CHEM, V264, P17745; BERGMEYER HU, 1983, METHOD ENZYMAT AN, V2, P202; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BEUTLER E, 1975, RED CELL METABOLISM, P105; BIRCHMEIER W, 1973, BIOCHEMISTRY-US, V12, P3667, DOI 10.1021/bi00743a015; BRIGELIUS R, 1983, BIOCHEM PHARMACOL, V32, P2529, DOI 10.1016/0006-2952(83)90014-X; CHIANCONE E, 1970, J BIOL CHEM, V245, P4105; Chivers PT, 1997, BIOCHEMISTRY-US, V36, P4061, DOI 10.1021/bi9628580; CHUA CG, 1975, BIOCHEM J, V149, P259, DOI 10.1042/bj1490259; CONDO SG, 1981, EUR J BIOCHEM, V116, P243, DOI 10.1111/j.1432-1033.1981.tb05325.x; CREIGHTON TE, 1984, METHOD ENZYMOL, V107, P305; DATTA MC, 1981, HEMOGLOBIN, V5, P701, DOI 10.3109/03630268108991838; DISIMPLICIO P, 1994, BBA-GEN SUBJECTS, V1199, P245; DISIMPLICIO P, 1998, NITRIC OXIDE CELL PR; DISIMPLICIO P, 1988, CLIN CHEM ENZYMOL CO, V1, P71; DISIMPLICIO P, 1996, BIOCHIM BIOPHYS ACTA, V1289, P257; FERRANTI P, 1993, INT J BIOCHEM, V25, P1943, DOI 10.1016/0020-711X(88)90329-1; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; GAREL MC, 1982, EUR J BIOCHEM, V123, P513; GAREL MC, 1986, J BIOL CHEM, V261, P4704; GARRICK LM, 1975, BIOCHEM J, V149, P245, DOI 10.1042/bj1490245; GARRICK LM, 1978, BIOCHEM J, V173, P321, DOI 10.1042/bj1730321; Giardina B, 1981, Methods Enzymol, V76, P417; GIBSON QH, 1973, J BIOL CHEM, V248, P1281; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GILBERT HF, 1995, METHOD ENZYMOL, V251, P8, DOI 10.1016/0076-6879(95)51107-5; GRAUSCHOPF U, 1995, CELL, V83, P947, DOI 10.1016/0092-8674(95)90210-4; GROSSMAN SJ, 1988, J PHARMACOL EXP THER, V244, P118; GUIDOTTI G, 1965, J BIOL CHEM, V240, P3924; HALLAWAY BE, 1980, ARCH BIOCHEM BIOPHYS, V203, P332, DOI 10.1016/0003-9861(80)90184-8; HALLIWELL B, 1989, FREE RADICAL BIO MED, P9; HUBBARD SJ, 1993, NACCESS RELEASE 2 1; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KOSOWER NS, 1977, EUR J BIOCHEM, V77, P529, DOI 10.1111/j.1432-1033.1977.tb11695.x; KOSOWER NS, 1995, METHOD ENZYMOL, V251, P123, DOI 10.1016/0076-6879(95)51116-4; KOSOWER NS, 1989, COENZYMES COFACTOR B, V3, P319; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LUZZATTO L, 1987, CELL BIOCHEM FUNCT, V5, P101, DOI 10.1002/cbf.290050204; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; NIKETIC V, 1992, INT J BIOCHEM, V24, P503, DOI 10.1016/0020-711X(92)90046-4; OKONJO KO, 1993, J PROTEIN CHEM, V12, P33, DOI 10.1007/BF01024911; PACKER L, 1995, METHOD ENZYMOL, V252, pR13; REED DJ, 1990, ANNU REV PHARMACOL, V30, P603, DOI 10.1146/annurev.pa.30.040190.003131; ROSSI R, 1995, BBA-GEN SUBJECTS, V1243, P230, DOI 10.1016/0304-4165(94)00133-I; SIES H, 1993, EUR J BIOCHEM, V215, P213, DOI 10.1111/j.1432-1033.1993.tb18025.x; Sies H., 1982, METABOLIC COMPARTMEN, P205; Starke DW, 1997, FREE RADICAL BIO MED, V23, P373, DOI 10.1016/S0891-5849(97)00009-9; STEIN S, 1971, J BIOL CHEM, V246, P5287; TAYLOR JF, 1966, J BIOL CHEM, V241, P241; TERADA T, 1993, BIOCHEM MOL BIOL INT, V29, P1009; TONDO CV, 1971, AN ACAD BRAS CIENC, V43, P651; TORCHINSKY YM, 1981, SULPHUR PROTEINS; Waring R.H., 1996, BIOL INTERACTIONS SU, P145; YANG AS, 1993, J MOL BIOL, V231, P459, DOI 10.1006/jmbi.1993.1294	58	62	62	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19198	19206		10.1074/jbc.273.30.19198	http://dx.doi.org/10.1074/jbc.273.30.19198			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668107	hybrid, Green Published			2022-12-25	WOS:000074974700074
J	Tomita, S; Kirino, Y; Suzuki, T				Tomita, S; Kirino, Y; Suzuki, T			A basic amino acid in the cytoplasmic domain of Alzheimer's beta-amyloid precursor protein (APP) is essential for cleavage of APP at the alpha-site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; DISEASE; PHOSPHORYLATION; MUTATION; OCCURS; CELLS; GENE; CDNA; COMPARTMENT; DERIVATIVES	In Alzheimer's disease (AD), the beta-amyloid peptide (A alpha) is thought to be produced as a result of the aberrant metabolism of beta-amyloid precursor protein (APP). We report that the APP cytoplasmic domain contains a novel and important signal for APP metabolism. A single amino acid mutation that changed arginine at amino acid 747 of APP770 (corresponding to position 672 of APP695) to a non-basic amino acid greatly increased the production of intracellular APP carboxyl-terminal fragment(s) cleaved at beta-site(s) (CTF beta), but did not result in increased secretion of A beta 40 and A beta 42. This was not due to a simple intracellular accumulation of CTF beta resulting from a lack of gamma-secretase. CTF beta derived from this mutant APP was generated and degraded as efficiently as CTF beta derived from wild-type APP. This result indicates that the increase in the quantity of CTF beta does not always give rise to more A beta production, as was previously suggested by studies of a familial AD mutation of APP, These findings suggest that APP carrying the substitution mutation at this basic amino acid may be metabolized by another protein secretory pathway. Although these results have not completely elucidated why CTF beta derived from the mutant APP escapes from subsequent cleavage by gamma-secretase, analysis of the processing pathway of this mutant APP should provide insights into the pathogenesis of the sporadic type of AD.	Univ Tokyo, Sch Pharmaceut Sci, Lab Neurobiophys, Bunkyo Ku, Tokyo 113, Japan	University of Tokyo	Suzuki, T (corresponding author), Univ Tokyo, Sch Pharmaceut Sci, Lab Neurobiophys, Bunkyo Ku, 7-3-1 Hong, Tokyo 113, Japan.		Suzuki, Toshiharu/B-5342-2013					BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; Chyung ASC, 1997, J CELL BIOL, V138, P671, DOI 10.1083/jcb.138.3.671; CITRON M, 1994, P NATL ACAD SCI USA, V91, P11993, DOI 10.1073/pnas.91.25.11993; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CORDELL B, 1994, ANNU REV PHARMACOL, V34, P69; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DESAUVAGE F, 1989, SCIENCE, V245, P651, DOI 10.1126/science.2569763; DESTROOPER B, 1993, J CELL BIOL, V121, P295, DOI 10.1083/jcb.121.2.295; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1994, J BIOL CHEM, V269, P17741; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KUENTZEL SL, 1993, BIOCHEM J, V295, P367, DOI 10.1042/bj2950367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI A, 1995, J BIOL CHEM, V270, P3565, DOI 10.1074/jbc.270.8.3565; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; Nalbantoglu J, 1997, NATURE, V387, P500, DOI 10.1038/387500a0; NORSTEDT C, 1993, J BIOL CHEM, V268, P608; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; Perez RG, 1996, J BIOL CHEM, V271, P9100, DOI 10.1074/jbc.271.15.9100; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; SELKOE DJ, 1994, J NEUROPATH EXP NEUR, V53, P438, DOI 10.1097/00005072-199409000-00003; SILVA OABDE, 1993, NEUROSCIENCE, V57, P873, DOI 10.1016/0306-4522(93)90031-A; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; SUZUKI T, 1994, EMBO J, V13, P1114, DOI 10.1002/j.1460-2075.1994.tb06360.x; SUZUKI T, 1992, NEUROSCIENCE, V48, P755, DOI 10.1016/0306-4522(92)90264-3; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; Tomita S, 1998, J BIOL CHEM, V273, P6277, DOI 10.1074/jbc.273.11.6277; YAMAMOTO K, 1992, J BIOCHEM-TOKYO, V111, P87, DOI 10.1093/oxfordjournals.jbchem.a123724	42	41	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19304	19310		10.1074/jbc.273.30.19304	http://dx.doi.org/10.1074/jbc.273.30.19304			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668120	hybrid			2022-12-25	WOS:000074974700087
J	Kolupaeva, VG; Pestova, TV; Hellen, CUT; Shatsky, IN				Kolupaeva, VG; Pestova, TV; Hellen, CUT; Shatsky, IN			Translation eukaryotic initiation factor 4G recognizes a specific structural element within the internal ribosome entry site of encephalomyocarditis virus RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRACT-BINDING-PROTEIN; MOUTH-DISEASE VIRUS; SECONDARY STRUCTURE; MUTATIONAL ANALYSIS; COMPLEX-FORMATION; FACTOR EIF-4A; REGION; DOMAIN; SEQUENCE; SUFFICIENT	A complex of eukaryotic initiation factors (eIFs) 4A, 4E, and 4G (collectively termed eIF4F) plays a key role in recruiting mRNAs to ribosomes during translation initiation. The site of ribosomal entry onto most mRNAs is determined by interaction of the 5'-terminal cap with eIF4E; eIFs 4A and 4G may facilitate ribosomal entry by modifying mRNA structure near the cap and by interacting with ribosome-associated factors. eIF4G recruits uncapped encephalomyocarditis virus (EMCV) mRNA to ribosomes without the involvement of eIF4E by binding directly to the similar to 450-nucleotide long EMCV internal ribosome entry site (IRES). We have used chemical and enzymatic probing to map the eIF4G binding site to a structural element within the J-K domain of the EMCV IRES that consists of an oligo(A) loop at the junction of three helices. The oligo(A) loop itself is not sufficient to form stable complexes with eIF4G since alteration of its structural context abolished its interaction with eIF4G. Addition of wild type or trans-dominant mutant forms of eIF4A to binary IRES.eIF4G complexes did not further alter the pattern of chemical/enzymatic modification of the IRES.	Moscow MV Lomonosov State Univ, AN Belozersky Inst Physiochem Biol, Moscow 119899, Russia; SUNY Hlth Sci Ctr, Dept Microbiol & Immunol, Morse Inst Mol Genet, Brooklyn, NY 11203 USA	Lomonosov Moscow State University; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Shatsky, IN (corresponding author), Moscow MV Lomonosov State Univ, AN Belozersky Inst Physiochem Biol, Moscow 119899, Russia.	shatsky@ins.genebee.msu.su	Shatsky, Ivan N/A-5331-2012		NIAID NIH HHS [R01 AI051340] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allain FHT, 1996, NATURE, V380, P646, DOI 10.1038/380646a0; BOROVJAGIN A, 1994, FEBS LETT, V351, P299, DOI 10.1016/0014-5793(94)00848-5; BOROVJAGIN AV, 1991, NUCLEIC ACIDS RES, V19, P4999, DOI 10.1093/nar/19.18.4999; BROWN EA, 1991, J VIROL, V65, P5828, DOI 10.1128/JVI.65.11.5828-5838.1991; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; deQuinto SL, 1997, J VIROL, V71, P4171; EVSTAFIEVA AG, 1991, NUCLEIC ACIDS RES, V19, P665, DOI 10.1093/nar/19.3.665; GORLACH M, 1992, EMBO J, V11, P3289, DOI 10.1002/j.1460-2075.1992.tb05407.x; GOYER C, 1993, MOL CELL BIOL, V13, P4860, DOI 10.1128/MCB.13.8.4860; Haghighat A, 1997, J BIOL CHEM, V272, P21677, DOI 10.1074/jbc.272.35.21677; Hellen CUT, 1995, CURR TOP MICROBIOL, V203, P31; Hoffman MA, 1996, J VIROL, V70, P6425, DOI 10.1128/JVI.70.9.6425-6430.1996; HOFFMAN MA, 1995, J VIROL, V69, P4399, DOI 10.1128/JVI.69.7.4399-4406.1995; HYYPIA T, 1992, P NATL ACAD SCI USA, V89, P8847, DOI 10.1073/pnas.89.18.8847; Imataka H, 1997, MOL CELL BIOL, V17, P6940, DOI 10.1128/MCB.17.12.6940; Jackson RJ, 1995, RNA, V1, P985; KAMINSKI A, 1990, EMBO J, V9, P3753, DOI 10.1002/j.1460-2075.1990.tb07588.x; Kaminski A, 1998, RNA, V4, P626, DOI 10.1017/S1355838298971898; Kolupaeva VG, 1996, RNA, V2, P1199; KUHN R, 1990, J VIROL, V64, P4625; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; MADER S, 1995, MOL CELL BIOL, V15, P4990; MartinezSalas E, 1996, J VIROL, V70, P992; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MEYER K, 1995, J VIROL, V69, P2819, DOI 10.1128/JVI.69.5.2819-2824.1995; Ohlmann T, 1996, EMBO J, V15, P1371, DOI 10.1002/j.1460-2075.1996.tb00479.x; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PAUSE A, 1994, EMBO J, V13, P1205, DOI 10.1002/j.1460-2075.1994.tb06370.x; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; Pestova TV, 1996, MOL CELL BIOL, V16, P6870; Pestova TV, 1996, MOL CELL BIOL, V16, P6859, DOI 10.1128/mcb.16.12.6859; PILIPENKO EV, 1989, NUCLEIC ACIDS RES, V17, P5701, DOI 10.1093/nar/17.14.5701; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SCHEPER GC, 1992, J BIOL CHEM, V267, P7269; VANDERVELDEN A, 1995, VIROLOGY, V214, P82, DOI 10.1006/viro.1995.9952; Witherell GW, 1995, VIROLOGY, V214, P660, DOI 10.1006/viro.1995.0081; Wutz G, 1996, J GEN VIROL, V77, P1719, DOI 10.1099/0022-1317-77-8-1719; YAN RQ, 1992, J BIOL CHEM, V267, P23226; YODERHILL J, 1993, J BIOL CHEM, V268, P5566	40	155	162	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18599	18604		10.1074/jbc.273.29.18599	http://dx.doi.org/10.1074/jbc.273.29.18599			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660832	hybrid			2022-12-25	WOS:000074828500087
J	Tolias, KF; Rameh, LE; Ishihara, H; Shibasaki, Y; Chen, J; Prestwich, GD; Cantley, LC; Carpenter, CL				Tolias, KF; Rameh, LE; Ishihara, H; Shibasaki, Y; Chen, J; Prestwich, GD; Cantley, LC; Carpenter, CL			Type I phosphatidylinositol-4-phosphate 5-kinases synthesize the novel lipids phosphatidylinositol 3,5-bisphosphate and phosphatidylinositol 5-phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAINS; PHOSPHOINOSITIDE KINASES; INOSITOL PHOSPHOLIPIDS; 4-PHOSPHATE 5-KINASE; HUMAN PLATELETS; PATHWAY; CELLS; PHOSPHORYLATION; POLYPHOSPHOINOSITIDES; 3,4-BISPHOSPHATE	Inositol phospholipids regulate a variety of cellular processes including proliferation, survival, vesicular trafficking, and cytoskeletal organization. Recently, two novel phosphoinositides, phosphatidylinositol-3,5-bisphosphate (PtdIns-3,5-P-2) and phosphatidylinositol-5-phosphate (PtdIns-5-P), have been shown to exist in cells. PtdIns-3,5-P-2, which is regulated by osmotic stress, appears to be synthesized by phosphorylation of PtdIns-3-P at the D-5 position. No evidence yet exists for how PtdIns-5-P is produced in cells. Understanding the regulation of synthesis of these molecules will be important for identifying their function in cellular signaling. To determine the pathway by which Ptdins-3,5-P-2 and PtdIns-5-P might be synthesized, we tested the ability of the recently cloned type I PtdIns-4-P 5-kinases (PIP5Ks) alpha and beta to phosphorylate PtdIns-3-P and PtdIns at the D-5 position of the inositol ring.We found that the type I PIP5Ks phosphorylate PtdIns-3-P to form Ptdins-3,B-P-2. The identity of the PtdIns-3,B-P-2 product was determined by anion exchange high performance liquid chromatography analysis and periodate treatment. PtdIns-3,4-P-2 and PtdIns-3,4,5-P-3 were also produced from PtdIns-3-P phosphorylation by both isoforms. When expressed in mammalian cells, PIP5K I alpha and PIP5K I beta differed in their ability to synthesize PtdIns-3,5-P-2 relative to PtdIns-3,4-P-2. me also found that the type I PIP5Ks phosphorylate PtdIns to produce PtdIns-5-P and phosphorylate PtdIns-3,4-P-2 to produce PtdIns-3,4,5-P-3. Our findings suggest that type I PIP5Ks synthesize the novel phospholipids PtdIns-3,B-P-2 and PtdIns-5-P. The ability of PIP5Ks to produce multiple signaling molecules indicates that they may participate in a variety of cellular processes.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA USA; Univ Tokyo, Dept Internal Med 3, Bunkyo Ku, Tokyo 113, Japan; Univ Utah, Dept Med Chem, Salt Lake City, UT 84112 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; University of Tokyo; Utah System of Higher Education; University of Utah	Tolias, KF (corresponding author), Harvard Inst Med, Div Signal Transduct, 330 Brookline Ave, Boston, MA 02115 USA.	ktolias@bidmc.harvard.edu	Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653; Tolias, Kimberley/0000-0002-2092-920X	NIGMS NIH HHS [GM36624, R01 GM041890, GM54389] Funding Source: Medline; NINDS NIH HHS [NS 29632] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890, R01GM036624] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029632] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CUNNINGHAM TW, 1990, J BIOL CHEM, V265, P21676; Dove SK, 1997, NATURE, V390, P187, DOI 10.1038/36613; EBERHARD DA, 1990, BIOCHEM J, V268, P15, DOI 10.1042/bj2680015; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; FRUMAN DA, 1998, IN PRESS ANN REV BIO, V67; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; ISHIHARA H, 1996, J BIOL CHEM, V271, P2361; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; Loijens JC, 1996, ADV ENZYME REGUL, V36, P115, DOI 10.1016/0065-2571(95)00005-4; Loijens JC, 1996, J BIOL CHEM, V271, P32937, DOI 10.1074/jbc.271.51.32937; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Ren XD, 1996, MOL BIOL CELL, V7, P435, DOI 10.1091/mbc.7.3.435; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; STEPHENS L, 1988, BIOCHEM J, V249, P271, DOI 10.1042/bj2490271; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Thum O, 1996, TETRAHEDRON LETT, V37, P9017, DOI 10.1016/S0040-4039(96)02117-X; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Tolias KF, 1998, MOL CELL BIOL, V18, P762, DOI 10.1128/MCB.18.2.762; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Whiteford CC, 1997, BIOCHEM J, V323, P597, DOI 10.1042/bj3230597; YAMAMOTO K, 1990, J BIOL CHEM, V265, P22086; Zhang XL, 1997, J BIOL CHEM, V272, P17756, DOI 10.1074/jbc.272.28.17756	36	114	118	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18040	18046		10.1074/jbc.273.29.18040	http://dx.doi.org/10.1074/jbc.273.29.18040			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660759	hybrid			2022-12-25	WOS:000074828500014
J	Vanden Hoek, TL; Becker, LB; Shao, ZH; Li, CQ; Schumacker, PT				Vanden Hoek, TL; Becker, LB; Shao, ZH; Li, CQ; Schumacker, PT			Reactive oxygen species released from mitochondria during brief hypoxia induce preconditioning in cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; NITRIC-OXIDE; SUPEROXIDE-DISMUTASE; FREE-RADICALS; HEART-MITOCHONDRIA; HYDROGEN-PEROXIDE; ISCHEMIA; ANION; CELLS; REPERFUSION	Reactive oxygen species (ROS) have been proposed to participate in the induction of cardiac preconditioning. However, their source and mechanism of induction are unclear. We tested whether brief hypoxia induces preconditioning by augmenting mitochondrial generation of ROS in chick cardiomyocytes. Cells were preconditioned with 10 min of hypoxia, followed by 1 h of simulated ischemia and 3 h of reperfusion. Preconditioning decreased cell death from 47 +/- 3% to 14 +/- 29. Return of contraction was observed in 3/3 preconditioned versus 0/6 non-preconditioned experiments. During induction, ROS oxidation of the probe dichlorofluorescin (sensitive to H2O2) increased similar to 2.5-fold. As a substitute for hypoxia, the addition of H2O2 (15 mu mol/liter) during normoxia also induced preconditioning-like protection. Conversely, the ROS signal during hypoxia mas attenuated with the thiol reductant 2-mercaptopropionyl glycine, the cytosolic Cu,Zn-superoxide dismutase inhibitor diethyldithiocarbamic acid, and the anion channel inhibitor 4,4'-diisothiocyanato-stilbene-2,2'-disulfonate, all of which also abrogated protection. ROS generation during hypoxia was attenuated by myxothiazol, but not by diphenyleneiodonium or the nitric-oxide synthase inhibitor L-nitroarginine. We conclude that hypoxia increases mitochondrial superoxide generation which initiates preconditioning protection. Furthermore, mitochondrial anion channels and cytosolic dismutation to H2O2 may be important steps for oxidant induction of hypoxic preconditioning.	Univ Chicago, Dept Med, Chicago, IL 60637 USA	University of Chicago	Schumacker, PT (corresponding author), Univ Chicago, Dept Med, MC 6026,5841 S Maryland Ave, Chicago, IL 60637 USA.			Schumacker, Paul T/0000-0001-9591-2034	NHLBI NIH HHS [HL32646, HL03779, HL35440] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035440, R55HL032646, R01HL032646] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMBROSIO G, 1993, J BIOL CHEM, V268, P18532; Baines CP, 1997, J MOL CELL CARDIOL, V29, P207, DOI 10.1006/jmcc.1996.0265; Beavis AD, 1996, J BIOENERG BIOMEMBR, V28, P207, DOI 10.1007/BF02110652; BOND JM, 1991, RES COMMUN CHEM PATH, V71, P195; CARTER WO, 1994, J LEUKOCYTE BIOL, V55, P253; DAWSON TL, 1993, AM J PHYSIOL, V264, pC961, DOI 10.1152/ajpcell.1993.264.4.C961; Downey JM, 1996, ISCHAEMIA PRECONDITI, P21; DURANTEAU J, 1998, INPRESS J BIOL CHEM, V273; FERRARI R, 1993, EUR HEART J, V14, P25; FERRARI R, 1991, AM J CLIN NUTR, V53, pS215, DOI 10.1093/ajcn/53.1.215S; FISHER JR, 1967, DEV BIOL, V15, P289, DOI 10.1016/0012-1606(67)90028-0; GOPALAKRISHNA R, 1989, P NATL ACAD SCI USA, V86, P6758, DOI 10.1073/pnas.86.17.6758; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; HESS ML, 1984, J MOL CELL CARDIOL, V16, P969, DOI 10.1016/S0022-2828(84)80011-5; Kelly RA, 1996, CIRC RES, V79, P363, DOI 10.1161/01.RES.79.3.363; KITAKAZE M, 1995, J MOL CELL CARDIOL, V27, P2149, DOI 10.1016/S0022-2828(95)91335-1; LARSSON R, 1989, CANCER RES, V49, P5627; Liang BT, 1996, AM J PHYSIOL-HEART C, V271, pH1769, DOI 10.1152/ajpheart.1996.271.5.H1769; Lo LW, 1996, ANAL BIOCHEM, V236, P153, DOI 10.1006/abio.1996.0144; MISRA HP, 1979, J BIOL CHEM, V254, P1623; MOHAZZAB HK, 1997, CIRCULATION, V96, P614; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; MURRY CE, 1988, CIRCULATION S2, V78, P77; NATARAJAN V, 1993, J BIOL CHEM, V268, P930; OSADA M, 1994, JPN CIRC J, V58, P259, DOI 10.1253/jcj.58.259; PAKY A, 1993, J APPL PHYSIOL, V74, P2868, DOI 10.1152/jappl.1993.74.6.2868; PATHAK SK, 1995, CIRCULATION S1, V92, P717; PRUTZ WA, 1984, RADIAT ENVIRON BIOPH, V23, P1, DOI 10.1007/BF01326731; RICHARD V, 1993, CARDIOVASC RES, V27, P2016, DOI 10.1093/cvr/27.11.2016; Sampson MJ, 1997, J BIOL CHEM, V272, P18966, DOI 10.1074/jbc.272.30.18966; Strickler J, 1996, J CLIN INVEST, V98, P1773, DOI 10.1172/JCI118976; TAKAHASHI MA, 1983, ARCH BIOCHEM BIOPHYS, V226, P558, DOI 10.1016/0003-9861(83)90325-9; TANAKA M, 1994, CARDIOVASC RES, V28, P980, DOI 10.1093/cvr/28.7.980; Thannickal VJ, 1995, J BIOL CHEM, V270, P30334, DOI 10.1074/jbc.270.51.30334; THIERBACH G, 1981, BIOCHIM BIOPHYS ACTA, V638, P282, DOI 10.1016/0005-2728(81)90238-3; Tritto I, 1997, CIRC RES, V80, P743, DOI 10.1161/01.RES.80.5.743; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Vanden Hoek Terry L., 1997, Journal of Molecular and Cellular Cardiology, V29, P2441, DOI 10.1006/jmcc.1997.0481; VandenHoek TL, 1996, AM J PHYSIOL-HEART C, V270, pH1334, DOI 10.1152/ajpheart.1996.270.4.H1334; VandenHoek TL, 1997, J MOL CELL CARDIOL, V29, P2571, DOI 10.1006/jmcc.1997.0497; Wever RMF, 1997, BIOCHEM BIOPH RES CO, V237, P340, DOI 10.1006/bbrc.1997.7069; Xia Y, 1996, P NATL ACAD SCI USA, V93, P6770, DOI 10.1073/pnas.93.13.6770; ZHOU X, 1997, CIRCULATION, V93, P1177; ZWEIER JL, 1995, NAT MED, V1, P804, DOI 10.1038/nm0895-804	45	586	601	0	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18092	18098		10.1074/jbc.273.29.18092	http://dx.doi.org/10.1074/jbc.273.29.18092			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660766	hybrid			2022-12-25	WOS:000074828500021
J	Zhang, D; Paley, AJ; Childs, G				Zhang, D; Paley, AJ; Childs, G			The transcriptional repressor ZFM1 interacts with and modulates the ability of EWS to activate transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EWS/FLI-1 FUSION GENE; RNA-BINDING PROTEIN; SPLICING FACTOR SF1; POLYMERASE-II; DOMAIN; IDENTIFICATION; PURIFICATION; HOMOLOGY; CONTAINS; TLS/FUS	The ZFM1 protein is both a transcriptional repressor and identical to the splicing factor SF1, ZFM1 was shown to interact with and repress transcription from the glycine, glutamine, serine, and threonine-rich transcription activation domain of the sea urchin transcription factor, stage-specific activator protein (SSAP), EWS, a human protein involved in cellular transformation in Ewing's sarcoma tumors, contains an NH2-terminal transcriptional activation domain (NTD) which resembles that of SSAP in both amino acid composition and the ability to drive transcription to levels higher than VP16 in most cell types. Here we report that ZFM1 also interacts with EWS in both two-hybrid assays and glutathione S-transferase pub-down experiments. The region on EWS which interacts with ZFM1 maps to 37 amino acids within its NTD. Overexpression of ZFM1 in HepG2 cells represses the transactivation of reporter gene expression driven by Gal4-EWS-NTD fusion protein and this repression correlates with ZFM1 binding to EWS, Furthermore, two proteins, TLS and hTAF(II)68, which hare extensive homology to EWS, also interact with ZFM1, Recently, it was discovered that EWS/TLS/hTAF(II)68 are each present in distinct TFIID populations and EWS and hTAF(II)68 were also found to be associated with the RNA polymerase II holoenzyme, The association of ZFM1 with these proteins implies that one normal cellular function for ZFM1 may be to negatively modulate transcription of target genes coordinated by these cofactors.	Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Childs, G (corresponding author), Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030333] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30333] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abovich N, 1997, CELL, V89, P403, DOI 10.1016/S0092-8674(00)80221-4; Amson RB, 1996, P NATL ACAD SCI USA, V93, P3953, DOI 10.1073/pnas.93.9.3953; Arning S, 1996, RNA, V2, P794; Berglund JA, 1997, CELL, V89, P781, DOI 10.1016/S0092-8674(00)80261-5; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; CALVIO C, 1995, RNA, V1, P724; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DEANGELO DJ, 1995, MOL CELL BIOL, V15, P1254; DEANGELO DJ, 1993, MOL CELL BIOL, V13, P1746, DOI 10.1128/MCB.13.3.1746; DeFalco J, 1996, P NATL ACAD SCI USA, V93, P5802, DOI 10.1073/pnas.93.12.5802; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; KRAMER A, 1992, MOL CELL BIOL, V12, P4545; LESSNICK SL, 1995, ONCOGENE, V10, P423; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; May WA, 1997, CURR TOP MICROBIOL, V220, P143; OHNO T, 1994, ONCOGENE, V9, P3087; Powers CA, 1998, MOL ENDOCRINOL, V12, P4, DOI 10.1210/mend.12.1.0043; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Thompson AD, 1996, ONCOGENE, V13, P2649; TODA T, 1994, HUM MOL GENET, V3, P465, DOI 10.1093/hmg/3.3.465; Zhang D, 1998, J BIOL CHEM, V273, P6868, DOI 10.1074/jbc.273.12.6868; Zinszner H, 1997, J CELL SCI, V110, P1741	28	79	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18086	18091		10.1074/jbc.273.29.18086	http://dx.doi.org/10.1074/jbc.273.29.18086			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660765	hybrid			2022-12-25	WOS:000074828500020
J	Huang, YD; Liu, XQ; Rall, SC; Mahley, RW				Huang, YD; Liu, XQ; Rall, SC; Mahley, RW			Apolipoprotein E2 reduces the low density lipoprotein level in transgenic mice by impairing lipoprotein lipase-mediated lipolysis of triglyceride-rich lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; CORONARY-ARTERY DISEASE; III HYPERLIPOPROTEINEMIA; E POLYMORPHISM; APOPROTEIN-E; MYOCARDIAL-INFARCTION; PLASMA; PARTICLES; HYPERTRIGLYCERIDEMIA; HYPERCHOLESTEROLEMIA	Apolipoprotein (apo) E2 is often associated with low levels of low density lipoprotein (LDL) cholesterol and high levels of plasma triglycerides in humans. Mice expressing apoE2 also have low LDL levels. To evaluate the possible role of the LDL receptor in the cholesterol-lowering effect of apoE2, we bred transgenic mice expressing low levels of apoE2 with LDL receptor-null mice (hE(2+/0),LDLR-/-). Even in the absence of the LDL receptor, plasma total and LDL cholesterol levels decreased progressively with increasing levels of plasma apoE2, At plasma apoE2 levels >20 mg/dl, LDL cholesterol was similar to 45% lower than in LDLR-/- mice. Thus, the LDL cholesterol-lowering effect of apoE2 is independent of the LDL receptor. In contrast, plasma triglyceride levels increased (mostly in very low density lipoproteins (VLDL) and intermediate density Lipoproteins (IDL)) progressively as apoE2 levels increased. At plasma apoE2 levels >20 mg/dl, triglycerides were similar to 150% higher than in LDLR-/- mice. Furthermore, in apoE-null mice (hE2(+/0), mE(-/-)), apoE2 levels also correlated positively with plasma triglyceride levels, suggesting impaired lipolysis in both hE2(+/0),LDLR-/- and hE2(+/0),mE(-/-) mice. Incubating VLDL or IDL from the hE2(+/0),LDLR-/- or the hE2(+/0),mE(-/-) mice with mouse postheparin plasma inhibited lipoprotein lipase-mediated lipolysis of apoE2-containing VLDL and IDL by similar to 80 and similar to 70%, respectively, versus normal VLDL and IDL, This observation was confirmed by studies with triglyceride-rich emulsion particles, apoE2, and purified lipoprotein lipase, Furthermore, apoE2-containing VLDL had much less apoC-II than normal VLDL. Adding apoC-II to the incubation partially corrected the apoE2-impaired lipolysis in apoE2-containing VLDL or IDL and corrected it completely in apoE2-containing emulsion particles. Thus, apoE2 lowers LDL cholesterol by impairing lipoprotein lipase mediated lipolysis of triglyceride rich lipoproteins (mostly by displacing or masking apoC-II), Furthermore, the effects of apoE2 on both plasma cholesterol and triglyceride levels are dose dependent and act via different mechanisms. The increase in plasma cholesterol caused by apoE2 is due mostly to impaired clearance, whereas the increase in plasma triglycerides is caused mainly by apoE2-impaired Lipolysis of triglyceride-rich Lipoproteins.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Inst Cardiovasc Res, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Mahley, RW (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.				NHLBI NIH HHS [HL47660] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047660] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AALTOSETALA K, 1992, J CLIN INVEST, V90, P1889, DOI 10.1172/JCI116066; BELLOSTA S, 1995, J BIOL CHEM, V270, P27063, DOI 10.1074/jbc.270.45.27063; Brunzell JD, 1995, METABOLIC BASIS INHE, P1913; CHAIT A, 1978, METABOLISM, V27, P1055, DOI 10.1016/0026-0495(78)90151-8; CHAIT A, 1977, LANCET, V1, P1176; CHUNG BH, 1983, J LIPID RES, V24, P1148; CONNELLY PW, 1994, J BIOL CHEM, V269, P20554; CUMMING AM, 1984, CLIN GENET, V25, P310; DALLONGEVILLE J, 1992, J LIPID RES, V33, P447; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; DESILVA HV, 1994, J LIPID RES, V35, P1297; DESILVA HV, 1994, J BIOL CHEM, V269, P2324; Dong LM, 1996, J BIOL CHEM, V271, P19053, DOI 10.1074/jbc.271.32.19053; EHNHOLM C, 1984, P NATL ACAD SCI-BIOL, V81, P5566, DOI 10.1073/pnas.81.17.5566; EICHNER JE, 1993, AM J CARDIOL, V71, P160, DOI 10.1016/0002-9149(93)90732-R; EISENBERG S, 1984, J LIPID RES, V25, P1017; FAZIO S, 1992, J BIOL CHEM, V267, P6941; FAZIO S, 1993, J CLIN INVEST, V92, P1497, DOI 10.1172/JCI116728; GOLDBERG IJ, 1988, J CLIN INVEST, V81, P561, DOI 10.1172/JCI113354; GOMEZCORONADO D, 1993, BIOCHIM BIOPHYS ACTA, V1167, P70, DOI 10.1016/0005-2760(93)90219-Y; HAVEL RJ, 1980, J CLIN INVEST, V66, P1351, DOI 10.1172/JCI109988; HIXSON JE, 1991, ARTERIOSCLER THROMB, V11, P1237, DOI 10.1161/01.ATV.11.5.1237; HORIE Y, 1992, J BIOL CHEM, V267, P1962; HOSPATTANKAR AV, 1984, J BIOL CHEM, V259, P318; Huang Y, 1997, ARTERIOSCL THROM VAS, V17, P2817, DOI 10.1161/01.ATV.17.11.2817; Huang YD, 1996, J BIOL CHEM, V271, P29146, DOI 10.1074/jbc.271.46.29146; Huang YD, 1997, J BIOL CHEM, V272, P22685, DOI 10.1074/jbc.272.36.22685; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; IVERIUS PH, 1972, J BIOL CHEM, V247, P6610; JI ZS, 1994, J BIOL CHEM, V269, P13421; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KUUSI T, 1989, ARTERIOSCLEROSIS, V9, P237, DOI 10.1161/01.ATV.9.2.237; LUC G, 1994, ARTERIOSCLER THROMB, V14, P1412, DOI 10.1161/01.ATV.14.9.1412; Mahley RW, 1996, ISRAEL J MED SCI, V32, P414; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1995, METABOLIC MOL BASES, P1953; Olivecrona T, 1990, CURR OPIN LIPIDOL, V1, P222; PATSCH JR, 1987, J CLIN INVEST, V80, P341, DOI 10.1172/JCI113078; PITTMAN RC, 1987, J BIOL CHEM, V262, P2435; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; Rensen PCN, 1996, J BIOL CHEM, V271, P14791, DOI 10.1074/jbc.271.25.14791; SHACHTER NS, 1994, J CLIN INVEST, V93, P1683, DOI 10.1172/JCI117151; SPOONER PJR, 1988, J BIOL CHEM, V263, P1444; Stengard JH, 1996, HUM GENET, V97, P677; UTERMANN G, 1984, HUM GENET, V65, P232, DOI 10.1007/BF00286508; UTERMANN G, 1980, AM J HUM GENET, V32, P339; UTERMANN G, 1979, CLIN GENET, V15, P63; WEISGRABER KH, 1990, J BIOL CHEM, V265, P22453; Woollett LA, 1995, P NATL ACAD SCI USA, V92, P12500, DOI 10.1073/pnas.92.26.12500; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	50	68	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17483	17490		10.1074/jbc.273.28.17483	http://dx.doi.org/10.1074/jbc.273.28.17483			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651338	hybrid			2022-12-25	WOS:000074816100031
J	Li, QL; Blau, CA; Clegg, CH; Rohde, A; Stamatoyannopoulos, G				Li, QL; Blau, CA; Clegg, CH; Rohde, A; Stamatoyannopoulos, G			Multiple epsilon-promoter elements participate in the developmental control of epsilon-globin genes in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT CONTROL REGION; LOCUS-CONTROL REGION; HIGH-LEVEL EXPRESSION; HUMAN GAMMA-GLOBIN; CHROMATIN STRUCTURE; ACTIVATION REGION; FACTOR-BINDING; SILENCER; SITE; TRANSCRIPTION	To delineate the regulation of the human epsilon-globin gene, we investigated epsilon-gene expression during the development of transgenic mice carrying constructs with epsilon-promoter truncations linked to a micro-locus control region (mu LCR). Expression levels were compared with those of mu LCR epsilon mice carrying a 2 kilobase epsilon-promoter and beta YAC controls. epsilon mRNA in the embryonic cells of mu LCR (-179)epsilon mice were as high as in mu LCR epsilon mice suggesting that the proximal epsilon-promoter contains most elements required for epsilon-gene activation. epsilon mRNA in adult alpha LCR (-179) epsilon mice was significantly lower than in the embryonic cells indicating that elements involved in epsilon-gene silencing are contained in the proximal epsilon promoter. Extension of the promoter sequence to -463 epsilon decreased epsilon-gene expression in the definitive erythroid cells, supporting previous evidence that the -179 to -463 epsilon region contains an epsilon-gene silencer. However, the epsilon-gene of the mu LCR(-463) epsilon mice was not silenced in the definitive cells of fetal and adult erythropoiesis indicating that additional silencing elements are located upstream of position -463 epsilon. These results provide in vivo evidence that multiple elements of the distal as well as the proximal promoter contribute to epsilon-gene silencing.	Univ Washington, Div Med Genet, Seattle, WA 98195 USA; Univ Washington, Div Hematol, Seattle, WA 98195 USA; Bristol Myers Squibb Pharmaceut Res Inst, Seattle, WA 98121 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Bristol-Myers Squibb	Stamatoyannopoulos, G (corresponding author), Univ Washington, Div Med Genet, Box 357720, Seattle, WA 98195 USA.				NHLBI NIH HHS [HL53750, HL20899] Funding Source: Medline; NIDDK NIH HHS [DK45365] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL020899, R01HL020899, P01HL053750] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK045365, R01DK045365, R37DK045365] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEHRINGER RR, 1990, GENE DEV, V4, P380, DOI 10.1101/gad.4.3.380; CAO SX, 1989, P NATL ACAD SCI USA, V86, P5306, DOI 10.1073/pnas.86.14.5306; CATERINA JJ, 1991, P NATL ACAD SCI USA, V88, P1626, DOI 10.1073/pnas.88.5.1626; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLIS P, 1990, EMBO J, V9, P233, DOI 10.1002/j.1460-2075.1990.tb08100.x; Dyer MA, 1996, MOL CELL BIOL, V16, P829; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; FORRESTER WC, 1989, P NATL ACAD SCI USA, V86, P5439, DOI 10.1073/pnas.86.14.5439; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; FURUKAWA T, 1995, BLOOD CELL MOL DIS, V21, P168, DOI 10.1006/bcmd.1995.0019; GALE RE, 1979, NATURE, V280, P162, DOI 10.1038/280162a0; GONG QH, 1991, MOL CELL BIOL, V11, P2558, DOI 10.1128/MCB.11.5.2558; GONG QH, 1993, MOL CELL BIOL, V13, P911, DOI 10.1128/MCB.13.2.911; Gong QH, 1996, MOL CELL BIOL, V16, P6055; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GUMUCIO DL, 1993, P NATL ACAD SCI USA, V90, P6018, DOI 10.1073/pnas.90.13.6018; GUTMAN PD, 1992, GENE, V110, P197, DOI 10.1016/0378-1119(92)90648-9; HECHT F, 1966, SCIENCE, V152, P91, DOI 10.1126/science.152.3718.91; HUEHNS ER, 1964, NATURE, V201, P1095, DOI 10.1038/2011095a0; LI QL, 1994, MOL CELL BIOL, V14, P6087, DOI 10.1128/MCB.14.9.6087; Li QL, 1997, P NATL ACAD SCI USA, V94, P2444, DOI 10.1073/pnas.94.6.2444; LIU DP, 1992, P NATL ACAD SCI USA, V89, P3899, DOI 10.1073/pnas.89.9.3899; Liu QH, 1997, P NATL ACAD SCI USA, V94, P169, DOI 10.1073/pnas.94.1.169; NAVAS PA, 1998, IN PRESS MOL CELL BI; PESCHLE C, 1985, NATURE, V313, P235, DOI 10.1038/313235a0; PETERS B, 1993, J BIOL CHEM, V268, P3430; PETERSON KR, 1995, P NATL ACAD SCI USA, V92, P5655, DOI 10.1073/pnas.92.12.5655; Peterson KR, 1996, P NATL ACAD SCI USA, V93, P6605, DOI 10.1073/pnas.93.13.6605; PETERSON KR, 1993, P NATL ACAD SCI USA, V90, P7593, DOI 10.1073/pnas.90.16.7593; Peterson KR, 1997, TRENDS GENET, V13, P61, DOI 10.1016/S0168-9525(97)01003-2; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; RAICH N, 1990, SCIENCE, V250, P1147, DOI 10.1126/science.2251502; RAICH N, 1992, BLOOD, V79, P861; RAICH N, 1995, EMBO J, V14, P801, DOI 10.1002/j.1460-2075.1995.tb07058.x; SHIH DM, 1993, J BIOL CHEM, V268, P3066; SHIH DM, 1990, NUCLEIC ACIDS RES, V18, P5465, DOI 10.1093/nar/18.18.5465; STAMATOYANNOPOU.G, 1994, MOL BASIS BLOOD DIS, V2, P107; STAMATOYANNOPOULOS G, 1993, MOL CELL BIOL, V13, P7636, DOI 10.1128/MCB.13.12.7636; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TALBOT D, 1989, NATURE, V338, P352, DOI 10.1038/338352a0; TREPICCHIO WL, 1994, MOL CELL BIOL, V14, P3763, DOI 10.1128/MCB.14.6.3763; TREPICCHIO WL, 1993, MOL CELL BIOL, V13, P7457, DOI 10.1128/MCB.13.12.7457; VANASSENDELFT GB, 1989, CELL, V56, P969, DOI 10.1016/0092-8674(89)90630-2; WADAKIYAMA Y, 1992, J BIOL CHEM, V267, P11532	45	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17361	17367		10.1074/jbc.273.28.17361	http://dx.doi.org/10.1074/jbc.273.28.17361			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651319	hybrid			2022-12-25	WOS:000074816100012
J	Wang, WQ; Merriam, DL; Moses, AS; Francis, GA				Wang, WQ; Merriam, DL; Moses, AS; Francis, GA			Enhanced cholesterol efflux by tyrosyl radical-oxidized high density lipoprotein is mediated by apolipoprotein AI-AII heterodimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	70th Scientific Session of the American-Heart-Association Meeting	NOV 09-13, 1997	ORLANDO, FLORIDA	Amer Heart Assoc			CULTURED FIBROBLASTS; OXIDATIVE TYROSYLATION; POLYACRYLAMIDE GELS; PLASMA-LIPOPROTEINS; HDL; MACROPHAGES; ACYLTRANSFERASE; CELLS; MYELOPEROXIDASE; CHROMATOGRAPHY	Myeloperoxidase secreted by phagocytes in the artery wall may be a catalyst for lipoprotein oxidation, High density lipoprotein (HDL) oxidized by peroxidase-generated tyrosyl radical has a markedly enhanced ability to deplete cultured cells of cholesterol, We have investigated the structural modifications in tyrosylated HDL responsible for this effect. Spherical reconstituted HDL (rHDL) containing the whole apolipoprotein (apo) fraction of tyrosylated HDL reproduced the ability of intact tyrosylated HDL to enhance cholesterol efflux from cholesterol-loaded human fibroblasts when reconstituted with the whole lipid fraction of either HDL or tyrosylated HDL, Free apoAI or apoAII showed no increased capacity to induce cholesterol efflux from cholesterol-loaded fibroblasts following oxidation by tyrosyl radical, either in their lipid-free forms or in rHDL, The product of oxidation of a mixture of apoAI and apoAII (1:1 molar ratio) by tyrosyl radical, however, reproduced the enhanced ability of tyrosylated HDL to induce cholesterol efflux when reconstituted with the whole lipid fraction of HDL, HDL containing only apoAI or apoAII showed no enhanced ability to promote cholesterol efflux following oxidation by tyrosyl radical, whereas HDL containing both apoAI and apoAII did. rHDL containing apoAI-apoAII(monomer) and apoAI-(apoAII)(2) heterodimers showed a markedly increased ability to prevent the accumulation of LDL-derived cholesterol mass by sterol-depleted fibroblasts compared with other apolipoprotein species of tyrosylated HDL, These results indicate a novel product of HDL oxidation, apoAI-apoAII heterodimers, with a markedly enhanced capacity to deplete cells of the regulatory pool of free cholesterol and total cholesterol mass. The recent observation of tyrosyl radical-oxidized LDL in vivo suggests that a similar modification of HDL would significantly enhance its ability to deplete peripheral cells of cholesterol in the first step of reverse cholesterol transport.	Univ Alberta, Lipid & Lipoprot Res Grp, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Med, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta	Francis, GA (corresponding author), Univ Alberta, Lipid & Lipoprot Res Grp, 328 HMRC, Edmonton, AB T6G 2S2, Canada.		应, 宁宁/G-9472-2011	Moses, Audric/0000-0002-2788-1739				ANDERSEN P, 1993, J IMMUNOL METHODS, V161, P29, DOI 10.1016/0022-1759(93)90195-D; BABIY AV, 1990, ATHEROSCLEROSIS, V81, P175, DOI 10.1016/0021-9150(90)90064-P; Banka CL, 1996, CURR OPIN LIPIDOL, V7, P139, DOI 10.1097/00041433-199606000-00005; Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRINTON EA, 1986, J BIOL CHEM, V261, P495; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Cheung M C, 1986, Methods Enzymol, V129, P130; CHEUNG MC, 1986, J LIPID RES, V27, P1135; CHEUNG MC, 1987, J LIPID RES, V28, P913; CHUNG BH, 1980, J LIPID RES, V21, P284; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; FIELDING CJ, 1995, J LIPID RES, V36, P211; FOLCH J, 1957, J BIOL CHEM, V226, P497; FORTE TM, 1986, METHOD ENZYMOL, V128, P442; Francis GA, 1997, ATHEROSCLEROSIS, V134, P366, DOI 10.1016/S0021-9150(97)89863-2; FRANCIS GA, 1993, P NATL ACAD SCI USA, V90, P6631, DOI 10.1073/pnas.90.14.6631; Francis GA, 1996, BIOCHEMISTRY-US, V35, P15188, DOI 10.1021/bi9618169; HARA A, 1978, ANAL BIOCHEM, V90, P420, DOI 10.1016/0003-2697(78)90046-5; HAYASHI K, 1975, ANAL BIOCHEM, V67, P503, DOI 10.1016/0003-2697(75)90324-3; HEIDER JG, 1978, J LIPID RES, V19, P514; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; Hofer G, 1996, CLIN BIOCHEM, V29, P445, DOI 10.1016/0009-9120(96)00061-6; Hurtado I, 1996, ATHEROSCLEROSIS, V125, P39, DOI 10.1016/0021-9150(96)05840-6; JONAS A, 1990, J BIOL CHEM, V265, P22123; JONAS A, 1986, METHOD ENZYMOL, V128, P553; KAPP OH, 1978, ANAL BIOCHEM, V91, P230, DOI 10.1016/0003-2697(78)90835-7; Klebanoff S.J., 1978, NEUTROPHIL FUNCTION; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P1433, DOI 10.1074/jbc.272.3.1433; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARCEL YL, 1989, J BIOL CHEM, V264, P19942; MATZ CE, 1982, J BIOL CHEM, V257, P4541; MCCALL M, 1995, ARTERIOSCL THROM VAS, V15, P1599, DOI 10.1161/01.ATV.15.10.1599; MCCALL MR, 1994, ARTERIOSCLER THROMB, V14, P248, DOI 10.1161/01.ATV.14.2.248; Mitchell G, 1995, METABOLIC MOL BASES, P1077; ORAM JF, 1991, ARTERIOSCLER THROMB, V11, P403, DOI 10.1161/01.ATV.11.2.403; Oram JF, 1996, J LIPID RES, V37, P2473; SALMON S, 1992, BIOCHIM BIOPHYS ACTA, V1125, P230, DOI 10.1016/0005-2760(92)90050-6; Scanu AM, 1979, BIOCH ATHEROSCLEROSI; SCHULTZ JR, 1993, NATURE, V365, P762, DOI 10.1038/365762a0; SKARLATOS SI, 1995, BBA-MOL BASIS DIS, V1270, P19, DOI 10.1016/0925-4439(94)00067-Z; STEINBRECHER UP, 1992, ARTERIOSCLER THROMB, V12, P608, DOI 10.1161/01.ATV.12.5.608; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VADIVELOO PK, 1990, BIOCHIM BIOPHYS ACTA, V1045, P135, DOI 10.1016/0005-2760(90)90142-K; Viani P, 1996, BBA-MOL BASIS DIS, V1315, P78, DOI 10.1016/0925-4439(95)00094-1; Warnick G R, 1986, Methods Enzymol, V129, P101; WEISGRABER KH, 1980, J LIPID RES, V21, P316; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; YLAHERTTUALA S, 1990, EUR HEART J, V11, P88, DOI 10.1093/eurheartj/11.suppl_E.88; YOKOYAMA S, 1982, J BIOCHEM, V91, P1267, DOI 10.1093/oxfordjournals.jbchem.a133811	53	57	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17391	17398		10.1074/jbc.273.28.17391	http://dx.doi.org/10.1074/jbc.273.28.17391			8	Biochemistry & Molecular Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651324	hybrid			2022-12-25	WOS:000074816100017
J	Brown, LA; Amores, A; Schilling, TF; Jowett, T; Baert, JL; de Launoit, Y; Sharrocks, AD				Brown, LA; Amores, A; Schilling, TF; Jowett, T; Baert, JL; de Launoit, Y; Sharrocks, AD			Molecular characterization of the zebrafish PEA3 ETS-domain transcription factor	ONCOGENE			English	Article						ETS-domain; PEA3; transcription factors; zebrafish	DNA-BINDING SPECIFICITIES; PROTEIN-PROTEIN; ONCOGENE FAMILY; FACTORS ELK-1; FACTOR ER81; MAP KINASE; MEMBER; ERM; CASCADES; DISTINCT	The PEA3 subfamily of ETS-domain proteins play important roles in regulating transcriptional activation and have been implicated in several tumorigenic processes. Here we describe the identification of a further member of this family from zebrafish which most likely represents a homologue of PEA3, A high degree of sequence conservation is observed in the ETS DNA-binding domain and acidic transcriptional activation domain. The DNA binding specificity of zebrafish PEA3 is virtually identical to that exhibited by mammalian family members and is autoregulated by cisacting inhibitory domains. Transcriptional activation by zebrafish PEA3 is potentiated by the ERK MAP kinase and protein kinase A pathways. During embryogenesis, PEA3 is expressed in complex spatial and temporal patterns in both mesodermal somites and ectodermal tissues including the brain, dorsal spinal chord and neural crest. Our characterisation of zebrafish PEA3 furthers our understanding of its molecular function and its expression profile suggests a novel role in cell patterning in the early vertebrate embryo.	Univ Newcastle Upon Tyne, Sch Med, Dept Biochem & Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Imperial Canc Res Fund, London WC2A 3PX, England; Inst Pasteur, Inst Biol, CNRS, UMR 319, F-59021 Lille, France	Newcastle University - UK; Cancer Research UK; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Sharrocks, AD (corresponding author), Zeneca Pharmaceut, Alderley Pk, Macclesfield SK10 4TG, Cheshire, England.			Amores, Angel/0000-0002-9307-3609	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAERT JL, 1996, IN PRESS INT J CANC; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; BOSSELUT R, 1993, NUCLEIC ACIDS RES, V21, P5184, DOI 10.1093/nar/21.22.5184; BROWN AL, 1997, UNPUB DEV BIOL; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; ChotteauLelievre A, 1997, ONCOGENE, V15, P937, DOI 10.1038/sj.onc.1201261; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; DEGNAN BM, 1993, NUCLEIC ACIDS RES, V21, P3479, DOI 10.1093/nar/21.15.3479; DELAUNOIT Y, 1997, IN PRESS BIOCH MOL M; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; FRIEDMAN LS, 1995, GENOMICS, V25, P256, DOI 10.1016/0888-7543(95)80133-7; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HIGASHINO F, 1995, ONCOGENE, V10, P1461; HIGASHINO F, 1993, NUCLEIC ACIDS RES, V21, P547, DOI 10.1093/nar/21.3.547; Janknecht R, 1996, ONCOGENE, V13, P1745; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; Kaya M, 1996, ONCOGENE, V12, P221; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KRAUSS S, 1991, EMBO J, V10, P3609, DOI 10.1002/j.1460-2075.1991.tb04927.x; Laget MP, 1996, ONCOGENE, V12, P1325; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MONTE D, 1995, ONCOGENE, V11, P771; MONTE D, 1994, ONCOGENE, V9, P1397; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; NAKAE K, 1995, J BIOL CHEM, V270, P23795, DOI 10.1074/jbc.270.40.23795; OHagan RC, 1996, ONCOGENE, V13, P1323; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; Samakovlis C, 1996, DEVELOPMENT, V122, P1395; Schneikert J, 1996, J BIOL CHEM, V271, P23907, DOI 10.1074/jbc.271.39.23907; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHARROCKS AD, 1993, NUCLEIC ACIDS RES, V21, P215, DOI 10.1093/nar/21.2.215; SHARROCKS AD, 1993, MOL CELL BIOL, V13, P123, DOI 10.1128/MCB.13.1.123; Shore P, 1996, MOL CELL BIOL, V16, P3338; SHORE P, 1995, J BIOL CHEM, V270, P5805, DOI 10.1074/jbc.270.11.5805; SHORE P, 1994, MOL CELL BIOL, V14, P3283, DOI 10.1128/MCB.14.5.3283; SHORE P, 1995, NUCLEIC ACIDS RES, V23, P4698, DOI 10.1093/nar/23.22.4698; Skalicky JJ, 1996, PROTEIN SCI, V5, P296; Taylor JM, 1997, MOL CELL BIOL, V17, P5550, DOI 10.1128/MCB.17.9.5550; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Weinberg ES, 1996, DEVELOPMENT, V122, P271; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	48	52	53	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 9	1998	17	1					93	104		10.1038/sj.onc.1201911	http://dx.doi.org/10.1038/sj.onc.1201911			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZY936	9671318				2022-12-25	WOS:000074677800011
J	Givol, I; Givol, D; Hughes, SH				Givol, I; Givol, D; Hughes, SH			Overexpression of p21(waf1/cip1) arrests the growth of chicken embryo fibroblasts that overexpress E2F1	ONCOGENE			English	Article						retrovirus; growth suppressor; cell cycle; E2F; waf1/cip1	RETINOBLASTOMA SUSCEPTIBILITY GENE; CYCLIN-DEPENDENT KINASES; S-PHASE ENTRY; TRANSCRIPTION FACTOR; CELL-CYCLE; TRANS-ACTIVATION; BINDING PROTEIN; DNA-SYNTHESIS; EXPRESSION; APOPTOSIS	P21(waf1/cip1) is a potent inhibitor of cell cycle progression and can inhibit the growth of both normal cells and cells transformed by a number of oncogenes. However, the ability of p21(waf1/cip1) to inhibit the growth of cells that overexpress the transcriptional transactivator E2F1 is controversial: it has been reported both that E2F1 can and cannot overcome the block in the cell cycle induced by p21(waf1/cip1). To avoid the complications that arise when such experiments are done with permanent cell lines, we tested the effects of overexpressing p21(waf1/cip1) and E2F1 in primary chicken embryo fibroblasts. In this system very high levels of E2F1 overexpression cause considerable apoptosis; however, the surviving cells still overexpress E2F1. These cells are transformed and their growth is blocked by overexpression of p21(waf1/cip1).	NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Frederick, MD 21702 USA; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Weizmann Institute of Science	Hughes, SH (corresponding author), NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Frederick, MD 21702 USA.							Asano M, 1996, GENE DEV, V10, P1422, DOI 10.1101/gad.10.11.1422; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; Givol I, 1995, ONCOGENE, V11, P2609; GIVOL I, 1994, CELL GROWTH DIFFER, V5, P419; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; Hollingsworth RE, 1993, CURR OPIN CELL BIOL, V5, P194, DOI 10.1016/0955-0674(93)90102-V; HUGHES S, 1984, VIROLOGY, V136, P89, DOI 10.1016/0042-6822(84)90250-2; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4923; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Mann DJ, 1996, CURR BIOL, V6, P474, DOI 10.1016/S0960-9822(02)00515-8; Michieli P, 1996, ONCOGENE, V12, P775; Morgan DO, 1996, CURR OPIN CELL BIOL, V8, P767, DOI 10.1016/S0955-0674(96)80076-7; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PETROPOULOS CJ, 1991, J VIROL, V65, P3728, DOI 10.1128/JVI.65.7.3728-3737.1991; Petropoulos CJ, 1996, ONCOGENE, V12, P2611; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YMASAKI L, 1996, CELL, V85, P537; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	53	11	11	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 18	1998	16	24					3115	3122		10.1038/sj.onc.1201849	http://dx.doi.org/10.1038/sj.onc.1201849			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671390				2022-12-25	WOS:000074261300004
J	Takeda, H; Matozaki, T; Fujioka, Y; Takada, T; Noguchi, T; Yamao, T; Tsuda, M; Ochi, F; Fukunaga, K; Narumiya, S; Yamamoto, T; Kasuga, M				Takeda, H; Matozaki, T; Fujioka, Y; Takada, T; Noguchi, T; Yamao, T; Tsuda, M; Ochi, F; Fukunaga, K; Narumiya, S; Yamamoto, T; Kasuga, M			Lysophosphatidic acid-induced association of SHP-2 with SHPS-1: roles of RHO, FAK, and a SRC family kinase	ONCOGENE			English	Article						SHPS-1; SHP-2; LPA; SRC; FAK; tyrosine phosphorylation	PROTEIN-TYROSINE-PHOSPHATASE; FOCAL ADHESION KINASE; SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; BOTULINUM C3 EXOENZYME; ACTIN STRESS FIBERS; SIGNAL-TRANSDUCTION; HOMOLOGY-2 DOMAINS; MAP KINASE; CELL-PROLIFERATION; COUPLED RECEPTORS	SHPS-1 is an similar to 120kDa glycosylated receptor like protein that contains three immunoglobulin-like domains in its extracellular region as well as four potential tyrosine phosphorylation and SRC homology 2 (SH2) domain binding sites in its cytoplasmic region. Lysophosphatidic acid (LPA) stimulated the rapid tyrosine phosphorylation of SHPS-1 and its subsequent association with SHP-2, a protein tyrosine phosphatase containing SH2 domains in Rat-1 fibroblasts. LAP-induced tyrosine phosphorylation of SHPS-1 was inhibited by Clostridium botulinum C3 exoenzyme (which inactivates RHO) but not by pertussis toxin, The protein kinase C activator phorbol ester, 12-O-tetradecanoylphorbol 13-acetate (TPA) also stimulated tyrosine phosphorylation of SHPS-1; however, down-regulation of protein kinase C by prolonged exposure of cells to TPA did not affect LAP-induced tyrosine phosphorylation of SHPS-1. LPA-induced tyrosine phosphorylation of SHPS-1 was markedly reduced in either focal adhesion kinase (FAK)-deficient mouse cells or CHO cells overexpressing the tyrosine kinase CSK. Overexpression of a catalytically inactivate SHP-2 markedly inhibited MAP kinase activation in response to low concentrations of LPA in CHO cells, whereas overexpression of a wild-type SHPS-1 did enhance this effect of LPA, Furthermore, MAP kinase activation in response to a low concentration of LPA was inhibited by botulinum C3 exoenzyme, These results indicate that LPA-induced tyrosine phosphorylation of SHPS-1 and its association with SHP-2 may be mediated by a RHO-dependent pathway that includes FAK and a SRC family kinase, Thus, in addition to its role in receptor tyrosine kinase-mediated MAP kinase activation, the formation of a complex between SHPS-1 and SHP-2 may, in part, play an important role in the activation of MAP kinase in response to low concentrations of LPA.	Kobe Univ, Sch Med, Dept Internal Med 2, Chuo Ku, Kobe, Hyogo 650, Japan; Kyoto Univ, Fac Med, Dept Pharmacol, Sakyo Ku, Kyoto 606, Japan; Univ Tokyo, Inst Med Sci, Dept Oncol, Minato Ku, Tokyo 108, Japan	Kobe University; Kyoto University; University of Tokyo	Matozaki, T (corresponding author), Kobe Univ, Sch Med, Dept Internal Med 2, Chuo Ku, Kusunoki Cho, Kobe, Hyogo 650, Japan.							Adachi M, 1996, CELL, V85, P15; Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; ILLC D, 1995, NATURE, V377, P539; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Kranenburg O, 1997, EMBO J, V16, P3097, DOI 10.1093/emboj/16.11.3097; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; KUMAGAI N, 1995, FEBS LETT, V366, P11, DOI 10.1016/0014-5793(95)00478-R; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MATOZAKI T, 1989, J BIOL CHEM, V264, P14729; Matozaki T, 1996, CELL SIGNAL, V8, P13, DOI 10.1016/0898-6568(95)02015-2; MATOZAKI T, 1994, BIOCHEM BIOPH RES CO, V204, P874, DOI 10.1006/bbrc.1994.2541; MATOZAKI T, 1995, ADV PROTEIN PHOSPHAT, V9, P319; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; Moolenaar Wouter H., 1994, Trends in Cell Biology, V4, P213, DOI 10.1016/0962-8924(94)90144-9; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NARUMIYA S, 1993, CELL SIGNAL, V5, P9, DOI 10.1016/0898-6568(93)90003-5; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Noguchi T, 1996, J BIOL CHEM, V271, P27652, DOI 10.1074/jbc.271.44.27652; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; Ohnishi H, 1996, J BIOL CHEM, V271, P25569, DOI 10.1074/jbc.271.41.25569; OKADA M, 1991, J BIOL CHEM, V266, P24249; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; Schaller Michael D., 1993, Trends in Cell Biology, V3, P258, DOI 10.1016/0962-8924(93)90053-4; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; SCHLAEPFER DD, 1994, NATURE, V372, P786; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; XIAO S, 1994, J BIOL CHEM, V269, P21244; Yamao T, 1997, BIOCHEM BIOPH RES CO, V231, P61, DOI 10.1006/bbrc.1996.6047; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; YANO H, 1993, J BIOL CHEM, V268, P25846; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	54	26	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 11	1998	16	23					3019	3027		10.1038/sj.onc.1201839	http://dx.doi.org/10.1038/sj.onc.1201839			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZT782	9662335				2022-12-25	WOS:000074125300009
J	Zhang, LS; Lau, YK; Xi, L; Hong, RL; Kim, DS; Chen, CF; Hortobagyi, GN; Chang, CJ; Hung, MC				Zhang, LS; Lau, YK; Xi, L; Hong, RL; Kim, DS; Chen, CF; Hortobagyi, GN; Chang, CJ; Hung, MC			Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties	ONCOGENE			English	Article						emodin; anthraquinone; HER-2/neu; tyrosine kinase; experimental metastasis	GROWTH-FACTOR-RECEPTOR; BREAST-CANCER CELLS; NEU ONCOGENE; LUNG-CANCER; PROGNOSTIC-SIGNIFICANCE; POINT MUTATION; TUMOR-CELL; EXPRESSION; GENE; C-ERBB-2	We have previously shown that emodin suppresses tyrosine kinase activity of HER-2/neu-encoded p185(neu) receptor tyrosine kinase. In this study, we examine the relationship between the chemical structure and the activity of emodin and nine derivatives, and identified that one methyl, one hydroxy, and one carbonyl functional groups are critical for the biological activities of emodin. We also found that one of the derivatives 10-(4-acetamidobenzylidene)-9-anthrone (DK-V-47) is more effective than emodin in repressing the tyrosine phosphorylation of p185(neu) and in inhibiting the proliferation and transformation of HER-2/neu-overexpressing human breast cancer cells. Using mutation-activated HER-2/neu transformed 3T3 cells, we also investigated whether emodin and DK-V-47 can inhibit malignant transformation induced solely by the HER-2/neu oncogene. We found that DK-V-47 is more potent than emodin in suppressing transformation phenotypes of activated HER-2/neu transformed 3T3 cells including anchorage-dependent and -independent growth, metastasis-associated properties. These results clearly indicate that the inhibition of p185(neu) tyrosine kinase by both emodin and DK-V-47 is capable of suppressing the HER-2/neu associated transformed phenotypes including the ability to induce metastatic potential. Our results also support the chemotherapeutic implications of the use of either emodin or DK-V-47 to target HER-2/neu-overexpressing cancer cells.	Univ Texas, MD Anderson Cancer Ctr, Dept Tumor Biol, Houston, TX 77030 USA; Natl Taiwan Univ, Dept Oncol, Taipei 10764, Taiwan; Purdue Univ, Dept Med Chem & Pharmacognosy, W Lafayette, IN 47907 USA; Natl Res Inst Chinese Med, Taipei 11211, Taiwan; Natl Yang Ming Med Coll, Taipei 11211, Taiwan; Univ Texas, MD Anderson Cancer Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; National Taiwan University; Purdue University System; Purdue University; Purdue University West Lafayette Campus; National Research Institute of Chinese Medicine; National Yang Ming Chiao Tung University; University of Texas System; UTMD Anderson Cancer Center	Hung, MC (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Tumor Biol, Box 79, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Hong, Ruey-Long/0000-0001-8100-7914	NCI NIH HHS [CA 60856, CA 50743, CA 58880] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060856, R01CA058880, U01CA050743] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BERCHUCK A, 1990, CANCER RES, V50, P4087; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; HOU L, 1992, CANCER LETT, V65, P215, DOI 10.1016/0304-3835(92)90234-M; HUNG MC, 1989, P NATL ACAD SCI USA, V86, P2545, DOI 10.1073/pnas.86.8.2545; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; JAYASURIYA H, 1992, J NAT PROD, V55, P696, DOI 10.1021/np50083a026; KIM DSH, IN PRESS NATL PROD L; Kiyokawa N, 1997, J BIOL CHEM, V272, P18656, DOI 10.1074/jbc.272.30.18656; LACROIX H, 1989, ONCOGENE, V4, P145; LIOTTA LA, 1986, CANCER RES, V46, P1; MCCANN AH, 1991, CANCER RES, V51, P3186; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MYERS RB, 1994, J NATL CANCER I, V86, P1140, DOI 10.1093/jnci/86.15.1140; Nicolson GL, 1989, CURR OPIN CELL BIOL, V1, P1009, DOI 10.1016/0955-0674(89)90073-2; NICOLSON G L, 1991, Current Opinion in Oncology, V3, P75, DOI 10.1097/00001622-199102000-00012; NICOLSON GL, 1988, BIOCHIM BIOPHYS ACTA, V948, P175, DOI 10.1016/0304-419X(88)90010-8; RUBINSTEIN LV, 1990, J NATL CANCER I, V82, P1113, DOI 10.1093/jnci/82.13.1113; SADASIVAN R, 1993, J UROLOGY, V150, P126, DOI 10.1016/S0022-5347(17)35413-7; SCHNEIDER PM, 1989, CANCER RES, V49, P4968; SCHOLAR EM, 1994, CANCER LETT, V87, P159, DOI 10.1016/0304-3835(94)90217-8; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; TAUCHI K, 1989, VIRCHOWS ARCH A, V416, P65, DOI 10.1007/BF01606471; TOIKKANEN S, 1992, J CLIN ONCOL, V10, P1044, DOI 10.1200/JCO.1992.10.7.1044; TSAI CM, 1995, J NATL CANCER I, V87, P682, DOI 10.1093/jnci/87.9.682; TSAI CM, 1993, J NATL CANCER I, V85, P897, DOI 10.1093/jnci/85.11.897; VELTRI RW, 1994, J CELL BIOCHEM, P249; VIJVER M, 1987, MOL CELL BIOL, V7, P2019; WEINER DB, 1990, CANCER RES, V50, P421; Xia WY, 1997, CLIN CANCER RES, V3, P3; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YOKOTA J, 1988, ONCOGENE, V2, P283; YOSHIDA K, 1989, VIRCHOWS ARCH B, V57, P285, DOI 10.1007/BF02899093; YU DH, 1991, ONCOGENE, V6, P1991; Yu DH, 1996, ONCOGENE, V13, P1359; YU DH, 1994, CANCER RES, V54, P3150; YUSA K, 1990, J NATL CANCER I, V82, P1633, DOI 10.1093/jnci/82.20.1633; ZHAN HE, 1990, MOL CARCINOGEN, V3, P254; ZHANG LS, 1995, CANCER RES, V55, P3890; Zhang LS, 1996, ONCOGENE, V12, P571; ZHANG X, 1989, ONCOGENE, V4, P985	46	101	110	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 4	1998	16	22					2855	2863		10.1038/sj.onc.1201813	http://dx.doi.org/10.1038/sj.onc.1201813			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZR544	9671406	Bronze			2022-12-25	WOS:000073988200004
J	Hamazaki, Y; Kojima, H; Mano, H; Nagata, Y; Todokoro, K; Abe, T; Nagasawa, T				Hamazaki, Y; Kojima, H; Mano, H; Nagata, Y; Todokoro, K; Abe, T; Nagasawa, T			Tec is involved in G protein-coupled receptor- and integrin-mediated signalings in human blood platelets	ONCOGENE			English	Article						Tec; platelet; thrombin; integrin	BETA-GAMMA-SUBUNITS; TYROSINE KINASE GENE; THROMBIN-STIMULATED PLATELETS; X-LINKED AGAMMAGLOBULINEMIA; HETEROTRIMERIC G-PROTEINS; HEMATOPOIETIC-CELLS; RABBIT PLATELETS; ACTIVATION; PHOSPHORYLATION; FAMILY	Tec is a non-receptor type tyrosine kinase which is tyrosine phosphorylated and activated upon stimulation of hematopoietic cells with various cytokines. The role of Tec in G protein-coupled receptor-and integrin-mediated signalings has not been elucidated. We therefore investigated the regulation of Tec in human blood platelets. Tec was rapidly tyrosine phosphorylated in response to platelet agonists which activate G protein-coupled receptors such as thromboxane A, analog (U46619), thrombin, and thrombin receptor activating peptide (TRAP). TRAP-induced phosphorylation in Tec was significantly reduced under the conditions which abrogate fibrinogen binding to GP IIb-IIIa and subsequent platelet aggregation. However, TRAP induced significant levels of the phosphorylation even under these conditions and also in thrombasthenic platelets which lack functional GP IIb-IIIa molecules, suggesting that activation of G-protein-coupled receptor causes the phosphorylation. To clarify whether integrin engagement by itself causes the phosphorylation in Tee, we examined the state of the phosphorylation in platelets activated by integrin engagement. Platelet adhesion to immobilized fibrinogen or collagen induced significant levels of the phosphorylation. Furthermore, Tec was translocated to cytoskeleton in response to TRAP in a manner dependent on platelet aggregation, suggesting that Tec can be a component of integrin-mediated signalings. These results collectively indicate that Tec is involved in G protein-coupled receptor-and integrin-mediated signalings in human blood platelets.	Univ Tsukuba, Inst Clin Med, Div Hematol, Tsukuba, Ibaraki 305, Japan; Jichi Med Sch, Dept Biol Mol, Minami Kawachi, Tochigi 32904, Japan; RIKEN, Inst Phys & Chem Res, Tsukuba Life Sci Ctr, Tsukuba, Ibaraki 305, Japan	University of Tsukuba; Jichi Medical University; RIKEN	Kojima, H (corresponding author), Univ Tsukuba, Inst Clin Med, Div Hematol, Tsukuba, Ibaraki 305, Japan.		Hamazaki, Y*/Q-3076-2019	Hamazaki, Y*/0000-0001-5866-7340				AUGUST A, 1994, P NATL ACAD SCI USA, V91, P9347, DOI 10.1073/pnas.91.20.9347; Cichowski K, 1996, J BIOL CHEM, V271, P7544, DOI 10.1074/jbc.271.13.7544; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARK EA, 1994, TRENDS BIOCHEM SCI, V19, P464, DOI 10.1016/0968-0004(94)90131-7; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; CLARK EA, 1994, J BIOL CHEM, V269, P28859; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DHAR A, 1990, MOL PHARMACOL, V37, P519; FAURE M, 1994, J BIOL CHEM, V269, P7851; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; HAIRE RN, 1994, HUM MOL GENET, V3, P897, DOI 10.1093/hmg/3.6.897; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; HEYECK SD, 1993, P NATL ACAD SCI USA, V90, P669, DOI 10.1073/pnas.90.2.669; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Kojima H, 1995, THROMB HAEMOSTASIS, V74, P1541; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LANGHANSRAJASEKARAN SA, 1995, P NATL ACAD SCI USA, V92, P8601, DOI 10.1073/pnas.92.19.8601; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MACHIDE M, 1995, ONCOGENE, V11, P619; MANO H, 1990, ONCOGENE, V5, P1781; MANO H, 1995, BLOOD, V85, P343; MANO H, 1993, ONCOGENE, V8, P417; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; Miyazato A, 1996, CELL GROWTH DIFFER, V7, P1135; ODA A, 1992, J BIOL CHEM, V267, P20075; RASMUSSEN UB, 1993, J BIOL CHEM, V268, P14322; SALARI H, 1990, FEBS LETT, V263, P104, DOI 10.1016/0014-5793(90)80715-U; SCHOENWAELDER SM, 1994, J BIOL CHEM, V269, P32479; SHATTIL SJ, 1992, J BIOL CHEM, V267, P18424; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; TakahashiTezuka M, 1997, ONCOGENE, V14, P2273, DOI 10.1038/sj.onc.1201071; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; TANG B, 1994, MOL CELL BIOL, V14, P8432, DOI 10.1128/MCB.14.12.8432; TOHYAMA Y, 1994, J BIOL CHEM, V269, P32796; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; YAMADA N, 1993, BIOCHEM BIOPH RES CO, V192, P231, DOI 10.1006/bbrc.1993.1404; Yamashita Y, 1997, EXP HEMATOL, V25, P211	45	33	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	1998	16	21					2773	2779		10.1038/sj.onc.1201799	http://dx.doi.org/10.1038/sj.onc.1201799			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ013	9652744				2022-12-25	WOS:000073812200009
J	Mitoma, J; Kasama, T; Furuya, S; Hirabayashi, Y				Mitoma, J; Kasama, T; Furuya, S; Hirabayashi, Y			Occurrence of an unusual phospholipid, phosphatidyl-L-threonine, in cultured hippocampal neurons - Exogenous L-serine is required for the synthesis of neuronal phosphatidyl-L-serine and sphingolipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIN-LAYER CHROMATOGRAMS; HAMSTER OVARY CELLS; CEREBROSPINAL-FLUID; BIOSYNTHESIS; GROWTH; METABOLISM; REAGENT; ENZYME; BRAIN	We have recently reported that L-serine released hom astroglial cells supports the survival and neuritogenesis of hippocampal neurons under a serum- and glia-free culture condition (Mitoma, J., Furuya, S., and Hiraba-yashi, Y. (1998) Neurosci. Res. 30, 195-199). In this study, we show that exogenous L-serine is required for the synthesis of phosphatidyl-L-serine (PS) and sphingolipids in hippocampal neurons. When hippocampal neurons were maintained under an astroglial cell-fi ee condition, the levels of sphingolipids and phosphatidyl-L serine in the neurons were greatly reduced in the absence of external L-serine or glycine, Instead, a novel phospholipid appeared just ahead of PS on TLC. This novel lipid was determined to be phosphatidyl-L-threonine by TLC blotting/negative secondary ion mass spectrometry and amino acid analysis. Biochemical studies on rat brain microsomes have indicated that phosphatidyl-L-threonine is synthesized by the base exchange enzyme that is involved in PS synthesis with much lower affinity, that is, approximately 1/150 of L-serine. Addition of L-serine or glycine to the culture medium restored the synthesis of PS and sphingolipids in the neurons. These observations show that hippocampal neurons require exogenous L-serine for the synthesis of PS and sphingolipids in the absence of astroglial cells and suggested that astroglial cells contribute to neuronal lipid synthesis through the supply of L-serine.	RIKEN, Inst Phys & Chem Res, Lab Cellular Glycobiol, Frontier Res Program, Wako, Saitama 3510198, Japan; RIKEN, Inst Phys & Chem Res, Special Postdoctoral Researchers Program, Wako, Saitama 3510198, Japan; Tokyo Med & Dent Univ, Instrumental Anal Res Ctr Life Sci, Bunkyo Ku, Tokyo 1138510, Japan	RIKEN; RIKEN; Tokyo Medical & Dental University (TMDU)	Hirabayashi, Y (corresponding author), RIKEN, Inst Phys & Chem Res, Lab Cellular Glycobiol, Frontier Res Program, Wako, Saitama 3510198, Japan.	hirabaya@postman.riken.go.jp		Furuya, Shigeki/0000-0001-9020-3597; Hirabayashi, Yoshio/0000-0002-5774-7354				BELL RM, 1991, J BIOL CHEM, V266, P4661; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Furuya S, 1998, J NEUROCHEM, V71, P366; FURUYA S, 1995, J NEUROCHEM, V65, P1551; HANADA K, 1992, J BIOL CHEM, V267, P23527; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HIDARI KIPJ, 1993, BIOCHEM J, V296, P259, DOI 10.1042/bj2960259; HIRABAYASHI Y, 1986, BIOCHIM BIOPHYS ACTA, V876, P178; IGARASHI H, 1958, NATURE, V181, P1282, DOI 10.1038/1811282a0; Irie F., 1997, Society for Neuroscience Abstracts, V23, P1156; KANFER JN, 1992, METHOD ENZYMOL, V209, P341; KUGE O, 1986, J BIOL CHEM, V261, P5795; LEHNINGER AL, 1982, PRINCIPLES BIOCH, P620; MARKMALCHOFF D, 1977, BIOCHEM BIOPH RES CO, V75, P589, DOI 10.1016/0006-291X(77)91513-3; MARKMALCHOFF D, 1978, BIOCHEMISTRY-US, V17, P2684, DOI 10.1021/bi00606a035; Mitoma J, 1998, J NEUROSCI RES, V51, P712, DOI 10.1002/(SICI)1097-4547(19980315)51:6<712::AID-JNR5>3.3.CO;2-Q; Mitoma J, 1998, NEUROSCI RES, V30, P195, DOI 10.1016/S0168-0102(97)00113-2; NORES GA, 1988, CARBOHYD RES, V179, P393, DOI 10.1016/0008-6215(88)84135-1; PINTO WJ, 1992, J BACTERIOL, V174, P2565, DOI 10.1128/jb.174.8.2565-2574.1992; RYU EK, 1979, J LIPID RES, V20, P561; SASTRY PS, 1985, PROG LIPID RES, V24, P69, DOI 10.1016/0163-7827(85)90011-6; SHIMADA N, 1993, J NEUROCHEM, V60, P66, DOI 10.1111/j.1471-4159.1993.tb05823.x; Skipski V.P., 1969, METHOD ENZYMOL, V14, P530; SNELL ME, 1986, J ASSOC PERS SEVERE, V11, P1; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; TAKI T, 1994, ANAL BIOCHEM, V223, P232, DOI 10.1006/abio.1994.1579; TIJBURG LBM, 1989, BIOCHIM BIOPHYS ACTA, V1004, P1, DOI 10.1016/0005-2760(89)90206-3; WRIGHT RS, 1971, J CHROMATOGR, V59, P220, DOI 10.1016/S0021-9673(01)80033-9	28	46	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19363	19366		10.1074/jbc.273.31.19363	http://dx.doi.org/10.1074/jbc.273.31.19363			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677350	hybrid			2022-12-25	WOS:000075125200002
J	Simpson, RU; O'Connell, TD; Pan, QT; Newhouse, J; Somerman, MJ				Simpson, RU; O'Connell, TD; Pan, QT; Newhouse, J; Somerman, MJ			Antisense oligonucleotides targeted against protein kinase CP and C beta II block 1,25-(OH)(2)D-3-induced differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HL-60 LEUKEMIA-CELLS; RAT OSTEOCALCIN GENE; D ENDOCRINE SYSTEM; TRANSCRIPTIONAL REGULATION; MYC PROTOONCOGENE; BINDING PROTEINS; EXPRESSION; 1,25-DIHYDROXYVITAMIN-D3; RECEPTORS; VITAMIN-D3	It is now recognized that protein kinase C (PKC) plays a critical role in 1,25-dihydroxyvitamin D-3 (1,25-(OH)(2)D-3) promotion of HL-60 cell differentiation. In this study, the effects of phosphorothioate antisense oligonucleotides directed against PRC alpha, PKC beta, PKC beta I, and PKC beta II on HL-60 promyelocyte cell differentiation and proliferation were examined. Cellular differentiation was determined by nonspecific esterase activity, nitro blue tetrazolium reduction, and CD14 surface antigen expression. Differentiation promoted by 1,25-(OH)(2)D-3 (20 nM for 48 h) was inhibited similarly in cells treated with PKC beta antisense (30 mu M) 24 h prior to or at the same time as hormone treatment (86 +/- 9% inhibition; n = 4 versus 82 +/- 8% inhibition; n = 4 (mean +/- S.E.), respectively). In contrast, cells treated with PKC beta antisense 24 h after 1,25-(OH)(2)D-3 were unaffected and fully differentiated. PKC alpha antisense did not block 1,25-(OH)(2)D-3 promotion of HL-60 cell differentiation. Next, the ability of PKC beta I- and PKC beta II-specific antisense oligonucleotides to block 1,25-(OH)(2)D-3 promotion of cell differentiation was examined. PKC beta II antisense (30 mu M) completely blocked CD14 expression induced by 1,25-(OH)(2)D-3, whereas PRC beta I antisense had little effect. Interestingly, PKC beta II antisense blocked differentiation by 87 +/- 7% (n = 2, mean +/- S.D.) but had no effect on 1,25-(OH)(2)D-3 inhibition of cellular proliferation. These results indicate that the effects of 1,25-(OH)(2)D-3 on HL-60 cell differentiation and proliferation can be dissociated by blocking PKC beta II expression.	Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Periodont Prevent Geriatr, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Simpson, RU (corresponding author), Univ Michigan, Dept Pharmacol, 2301D MSRB III, Ann Arbor, MI 48109 USA.		O'Connell, Timothy/D-5048-2013; Pan, Quintin/E-3808-2011		NIDCR NIH HHS [DE 10337] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010337] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BELLIDO T, 1991, VITAMIN D, P409; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BORTELL R, 1992, P NATL ACAD SCI USA, V89, P6119, DOI 10.1073/pnas.89.13.6119; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRELVI ZS, 1986, LAB INVEST, V55, P269; Darwish HM, 1996, PROG NUCLEIC ACID RE, V53, P321, DOI 10.1016/S0079-6603(08)60149-X; DESAI RK, 1995, ENDOCRINOLOGY, V136, P5685, DOI 10.1210/en.136.12.5685; DEVALIA V, 1992, BLOOD, V80, P68; GAMARD CJ, 1994, CELL GROWTH DIFFER, V5, P405; HAUSSLER MR, 1995, BONE, V17, pS33, DOI 10.1016/8756-3282(95)00205-R; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; HOFFMANN J, 1997, FASEB J, V11, P649; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; MACDONALD PN, 1993, MOL CELL BIOL, V13, P5907, DOI 10.1128/MCB.13.9.5907; MANGELSDORF DJ, 1984, J CELL BIOL, V98, P391, DOI 10.1083/jcb.98.2.391; MARTELL RE, 1992, J BIOL CHEM, V267, P7511; MARTELL RE, 1987, J BIOL CHEM, V262, P5570; MARTELL RE, 1988, BIOCHEM PHARMACOL, V37, P635, DOI 10.1016/0006-2952(88)90136-0; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NORMAN AW, 1982, ENDOCR REV, V3, P331, DOI 10.1210/edrv-3-4-331; OBEID LM, 1990, J BIOL CHEM, V265, P2370; OCONNELL TD, ENDOCRINOLOGY, V136, P482; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; Pan Q, 1997, BIOCHEM PHARMACOL, V54, P909, DOI 10.1016/S0006-2952(97)00286-4; REITSMA PH, 1983, NATURE, V306, P492, DOI 10.1038/306492a0; SIMPSON RU, 1985, J BIOL CHEM, V260, P8882; SIMPSON RU, 1989, J BIOL CHEM, V264, P19710; SIMPSON RU, 1987, J BIOL CHEM, V262, P4104; SOLOMON DH, 1991, CELL GROWTH DIFFER, V2, P187; TONETTI DA, 1994, J BIOL CHEM, V269, P23230; TONETTI DA, 1992, CELL GROWTH DIFFER, V3, P739; VANLEEUWEN JPTM, 1992, J BIOL CHEM, V267, P12562; WALI RK, 1990, J CLIN INVEST, V85, P1296, DOI 10.1172/JCI114567; WALTERS MR, 1992, ENDOCR REV, V13, P719, DOI 10.1210/er.13.4.719; WEAVER VM, 1992, CELL SIGNAL, V4, P293, DOI 10.1016/0898-6568(92)90069-K; YONEDA T, 1991, ENDOCRINOLOGY, V129, P683, DOI 10.1210/endo-129-2-683	36	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19587	19591		10.1074/jbc.273.31.19587	http://dx.doi.org/10.1074/jbc.273.31.19587			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677384	hybrid			2022-12-25	WOS:000075125200036
J	Baharians, Z; Schonthal, AH				Baharians, Z; Schonthal, AH			Autoregulation of protein phosphatase type 2A expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTER OKADAIC ACID; ELONGATION FACTOR-II; CATALYTIC SUBUNIT; CELL-CYCLE; GENE EXPRESSIONS; PHOSPHORYLATION; INITIATION; PROLIFERATION; SEQUENCE; ANTIGEN	Protein phosphatases are involved in many cellular processes. One of the most abundant of these enzymes, the serine/threonine-specific protein phosphatase type 2A (PP2A), is present in most eukaryotic cells and serves a variety of functions. However, the detailed study of its regulation and function has been hampered by the difficulty of manipulating its expression level in cell culture. By using a new mammalian expression vector to forcibly overexpress PP2A in the mouse fibroblast cell line NIH3T3, we now show that the catalytic subunit of PP2A is subject to a potent autoregulatory mechanism that adjusts PP2A protein to constant levels. This control is exerted at the translational level and does not involve regulation of transcription or RNA processing. Thus, our results demonstrate tight control of PP2A expression, and provide an explanation for the difficulty of increasing PP2A expression experimentally.	Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA	University of Southern California	Schonthal, AH (corresponding author), Univ So Calif, Dept Microbiol, HMR-405,2011 Zonal Ave, Los Angeles, CA 90033 USA.		Schonthal, Axel/ABH-3846-2020	Schonthal, Axel/0000-0003-0662-5653	NCI NIH HHS [R29CA74278-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA074278] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTS AS, 1993, MOL CELL BIOL, V13, P2104, DOI 10.1128/MCB.13.4.2104; Andjelkovic N, 1996, EMBO J, V15, P7156, DOI 10.1002/j.1460-2075.1996.tb01107.x; ARINO J, 1988, P NATL ACAD SCI USA, V85, P4252, DOI 10.1073/pnas.85.12.4252; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BRAUTIGAN DL, 1995, SEMIN CANCER BIOL, V6, P211, DOI 10.1006/scbi.1995.0028; BUSS WC, 1994, BIOCHEM PHARMACOL, V48, P1459, DOI 10.1016/0006-2952(94)90571-1; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; FERNANDEZ A, 1990, J CELL BIOL, V111, P103, DOI 10.1083/jcb.111.1.103; GUO H, 1993, P NATL ACAD SCI USA, V90, P2500, DOI 10.1073/pnas.90.6.2500; Harlow E., 1988, ANTIBODIES LAB MANUA; HARPOLD MM, 1979, CELL, V17, P1025, DOI 10.1016/0092-8674(79)90341-6; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; JaramilloBabb VL, 1996, J BIOL CHEM, V271, P5988, DOI 10.1074/jbc.271.11.5988; KAKINOKI Y, 1992, BIOCHEM BIOPH RES CO, V185, P291, DOI 10.1016/S0006-291X(05)80989-1; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; KHEWGOODALL Y, 1991, BIOCHEMISTRY-US, V30, P89, DOI 10.1021/bi00215a014; Kikuchi K, 1997, CANCER DETECT PREV, V21, P36; KINOSHITA N, 1990, CELL, V63, P405, DOI 10.1016/0092-8674(90)90173-C; Kremmer E, 1997, MOL CELL BIOL, V17, P1692, DOI 10.1128/MCB.17.3.1692; LEE J, 1993, J BIOL CHEM, V268, P19192; LEE TH, 1995, SEMIN CANCER BIOL, V6, P203, DOI 10.1006/scbi.1995.0027; Li H, 1997, J BIOL CHEM, V272, P16729, DOI 10.1074/jbc.272.27.16729; LI M, 1995, BIOCHEMISTRY-US, V34, P1988, DOI 10.1021/bi00006a020; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; NAKAMURA K, 1992, BIOCHEM BIOPH RES CO, V187, P507, DOI 10.1016/S0006-291X(05)81523-2; REDPATH NT, 1990, BIOCHEM J, V272, P175, DOI 10.1042/bj2720175; REDPATH NT, 1989, BIOCHEM J, V262, P69, DOI 10.1042/bj2620069; RONNE H, 1991, MOL CELL BIOL, V11, P4876, DOI 10.1128/MCB.11.10.4876; Ruediger R, 1997, VIROLOGY, V238, P432, DOI 10.1006/viro.1997.8873; RUEDIGER R, 1991, MOL CELL BIOL, V11, P4282, DOI 10.1128/MCB.11.8.4282; SCHONTHAL A, 1993, ONCOGENE, V8, P433; SCHONTHAL A, 1991, ONCOGENE, V6, P423; SCHONTHAL A, 1992, NEW BIOL, V4, P16; SCHONTHAL AH, 1995, SEMIN CANCER BIOL, V6, P239, DOI 10.1006/scbi.1995.0031; SHEAY W, 1993, BIOTECHNIQUES, V15, P856; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; THOMAS G, 1977, EXP CELL RES, V108, P253, DOI 10.1016/S0014-4827(77)80032-3; TUROWSKI P, 1995, J CELL BIOL, V129, P397, DOI 10.1083/jcb.129.2.397; VIRSHUP DM, 1989, EMBO J, V8, P3891, DOI 10.1002/j.1460-2075.1989.tb08568.x; WADZINSKI BE, 1992, J BIOL CHEM, V267, P16883; WELSH GI, 1994, BIOCHEM BIOPH RES CO, V201, P1279, DOI 10.1006/bbrc.1994.1843; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; XIE HY, 1994, J BIOL CHEM, V269, P1981; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988	47	119	128	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19019	19024		10.1074/jbc.273.30.19019	http://dx.doi.org/10.1074/jbc.273.30.19019			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668082	hybrid			2022-12-25	WOS:000074974700049
J	Spillmann, AA; Bandtlow, CE; Lottspeich, F; Keller, F; Schwab, ME				Spillmann, AA; Bandtlow, CE; Lottspeich, F; Keller, F; Schwab, ME			Identification and characterization of a bovine neurite growth inhibitor (bNI-220)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; MYELIN-ASSOCIATED GLYCOPROTEIN; CHONDROITIN SULFATE PROTEOGLYCAN; RAT SPINAL-CORD; CELL-ADHESION MOLECULES; CNS WHITE MATTER; OPTIC-NERVE; AXONAL REGENERATION; NEURONAL PLASTICITY; CORTICOSPINAL TRACT	The poor axonal regeneration that follows lesions of the central nervous system (CNS) is crucially influenced by the local CNS tissue environment through which neurites have to grow. In addition to an inhibitory role of the glial scar, inhibitory substrate effects of CNS myelin and oligodendrocytes have been demonstrated. Several proteins including NI-35/250, myelin-associated glycoprotein, tenascin-R, and NG-2 have been described to have neurite outgrowth inhibitory or repulsive properties in vitro. Antibodies raised against NI-35/250 (monoclonal antibody IN-1) were shown to partially neutralize the growth inhibitory effect of CNS myelin and oligodendrocytes, and to result in long distance! fiber regeneration in the lesioned adult mammalian CNS in vivo, We report here the purification of a myelin protein to apparent homogeneity from bovine spinal; cord which exerts a potent neurite outgrowth inhibitory effect on PC12 cells and chick dorsal root ganglion cells, induces collapse of growth cones of chick dorsal root ganglion cells, and also inhibits the spreading of 3T3 fibroblasts, These activities could be neutralized by the monoclonal antibody IN-1, The purification procedure includes detergent solubilization, anion exchange chromatography, gel filtration, and elution from high resolution SDS-polyacrylamide gel electrophoresis. The active protein has a molecular mass of 220 kDa and an isoelectric point between 5.9 and 6.2, Its inhibitory activity is sensitive to protease treatment and resists harsh treatments like 9 M urea or short heating, Glycosylation is, if present at all, not detectable. Microsequencing resulted ill six peptides and strongly suggests that this proteins is novel.	Univ Zurich, Brain Res Inst, CH-8029 Zurich, Switzerland; Swiss Fed Inst Technol, CH-8029 Zurich, Switzerland; Genzentrum Martinsried, D-82152 Martinsried, Germany	University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich	Bandtlow, CE (corresponding author), Univ Zurich, Brain Res Inst, August Forelstr 1, CH-8029 Zurich, Switzerland.		Schwab, Martin E/B-6818-2016	Keller, Flavio/0000-0002-6449-6960				AMBERGER VR, 1994, CANCER RES, V54, P4017; AVELDANO MI, 1991, J NEUROCHEM, V57, P250, DOI 10.1111/j.1471-4159.1991.tb02122.x; Baka ID, 1996, MOL CELL NEUROSCI, V7, P289, DOI 10.1006/mcne.1996.0022; BANDTLOW C, 1990, J NEUROSCI, V10, P3837, DOI 10.1523/JNEUROSCI.10-12-03837.1990; Bandtlow C, 1996, EUR J BIOCHEM, V241, P468, DOI 10.1111/j.1432-1033.1996.00468.x; BANDTLOW CE, 1993, SCIENCE, V259, P80, DOI 10.1126/science.8418499; BARTSCH U, 1995, NEURON, V15, P1376; BASTMEYER M, 1991, J NEUROSCI, V11, P626; BENEDETTI M, 1993, P NATL ACAD SCI USA, V90, P7859, DOI 10.1073/pnas.90.16.7859; BOXBERG YV, 1988, ANAL BIOCHEM, V169, P372, DOI 10.1016/0003-2697(88)90298-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; CADELLI D, 1991, EUR J NEUROSCI, V3, P825, DOI 10.1111/j.1460-9568.1991.tb00093.x; CARBONETTO S, 1987, J NEUROSCI, V7, P610; CARONI P, 1988, NEURON, V1, P85, DOI 10.1016/0896-6273(88)90212-7; CARONI P, 1988, J CELL BIOL, V106, P1281, DOI 10.1083/jcb.106.4.1281; Chen M. S., 1997, Society for Neuroscience Abstracts, V23, P1723; Clarke GA, 1997, EUR J NEUROSCI, V9, P334, DOI 10.1111/j.1460-9568.1997.tb01403.x; CLARKE GA, 1994, J CELL SCI, V107, P3393; COLMAN DR, 1982, J CELL BIOL, V95, P598, DOI 10.1083/jcb.95.2.598; CONN P, 1990, CELL CULTURE METHODS; CRUTCHER KA, 1989, ANN NEUROL, V26, P580, DOI 10.1002/ana.410260414; CRUTCHER KA, 1989, EXP NEUROL, V104, P39, DOI 10.1016/0014-4886(89)90007-1; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; DAVID S, 1995, J NEUROSCI RES, V42, P594, DOI 10.1002/jnr.490420417; DOU CL, 1994, J NEUROSCI, V14, P7616; FAWCETT JW, 1989, J CELL SCI, V92, P93; FRIEDLANDER DR, 1994, J CELL BIOL, V125, P669, DOI 10.1083/jcb.125.3.669; GRUMET M, 1994, J BIOL CHEM, V269, P12142; HASAN SJ, 1991, RESTOR NEUROL NEUROS, V2, P137, DOI 10.3233/RNN-1991-2303; JOHNSON PW, 1989, NEURON, V3, P377, DOI 10.1016/0896-6273(89)90262-6; KAPFHAMMER JP, 1994, J COMP NEUROL, V340, P194, DOI 10.1002/cne.903400206; KAPFHAMMER JP, 1994, EUR J NEUROSCI, V6, P403, DOI 10.1111/j.1460-9568.1994.tb00283.x; KEIRSTEAD HS, 1992, P NATL ACAD SCI USA, V89, P11664, DOI 10.1073/pnas.89.24.11664; KOBAYASHI H, 1995, DEV BIOL, V168, P383, DOI 10.1006/dbio.1995.1088; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG DM, 1995, J NEUROSCI, V15, P99; Li M, 1996, J NEUROSCI RES, V46, P404, DOI 10.1002/(SICI)1097-4547(19961115)46:4<404::AID-JNR2>3.3.CO;2-W; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; MEIRI KF, 1988, J NEUROSCI, V8, P2571; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MILEV P, 1994, J CELL BIOL, V127, P1703, DOI 10.1083/jcb.127.6.1703; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; Ng WP, 1996, BRAIN RES, V720, P17, DOI 10.1016/0006-8993(96)00062-5; OSHANNESSY DJ, 1987, ANAL BIOCHEM, V163, P204, DOI 10.1016/0003-2697(87)90114-X; PAGANETTI PA, 1988, J CELL BIOL, V107, P2281, DOI 10.1083/jcb.107.6.2281; PERSSON H, 1990, ELECTROPHORESIS, V11, P642, DOI 10.1002/elps.1150110812; PESHEVA P, 1989, J CELL BIOL, V109, P1765, DOI 10.1083/jcb.109.4.1765; RICHARDSON PM, 1980, NATURE, V284, P264, DOI 10.1038/284264a0; ROEBROEK AJM, 1993, J BIOL CHEM, V268, P13439; RUBIN BP, 1994, J NEUROCYTOL, V23, P209, DOI 10.1007/BF01275525; Rubin BP, 1995, EUR J NEUROSCI, V7, P2524, DOI 10.1111/j.1460-9568.1995.tb01052.x; SAGA Y, 1992, GENE DEV, V6, P1821, DOI 10.1101/gad.6.10.1821; SAVIO T, 1990, P NATL ACAD SCI USA, V87, P4130, DOI 10.1073/pnas.87.11.4130; SAVIO T, 1989, J NEUROSCI, V9, P1126; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; SCHNELL L, 1994, NATURE, V367, P170, DOI 10.1038/367170a0; Schwab ME, 1996, NEUROCHEM RES, V21, P755, DOI 10.1007/BF02532297; SCHWAB ME, 1988, J NEUROSCI, V8, P2381; SCHWAB ME, 1985, J NEUROSCI, V5, P2415; Schwab ME, 1996, PHYSIOL REV, V76, P319, DOI 10.1152/physrev.1996.76.2.319; SCHWEGLER G, 1995, J NEUROSCI, V15, P2756; Settles DL, 1997, J NEUROSCI RES, V47, P109; Small DH, 1996, J NEUROCHEM, V67, P889; SOMMER I, 1981, DEV BIOL, V83, P311, DOI 10.1016/0012-1606(81)90477-2; Spillmann AA, 1997, EUR J NEUROSCI, V9, P549, DOI 10.1111/j.1460-9568.1997.tb01631.x; TAYLOR J, 1993, J NEUROSCI RES, V35, P347, DOI 10.1002/jnr.490350402; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Thallmair M, 1998, NAT NEUROSCI, V1, P124, DOI 10.1038/373; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; Towbin H, 1979, 10 1073 PNAS 76 9 43, V76, P4350, DOI [10.1073/pnas.76.9.4350, DOI 10.1073/PNAS.76.9.4350]; TUTTLE R, 1991, J NEUROSCI METH, V39, P193, DOI 10.1016/0165-0270(91)90085-E; VARGA ZM, 1995, P NATL ACAD SCI USA, V92, P10959, DOI 10.1073/pnas.92.24.10959; WATANABE E, 1995, EUR J NEUROSCI, V7, P547, DOI 10.1111/j.1460-9568.1995.tb00659.x; WEHRLEHALLER B, 1993, J CELL SCI, V106, P597; WEIBEL D, 1994, BRAIN RES, V642, P259, DOI 10.1016/0006-8993(94)90930-X; Wilson DJA, 1996, J CELL SCI, V109, P3129; WINTERGERST ES, 1993, EUR J NEUROSCI, V5, P299, DOI 10.1111/j.1460-9568.1993.tb00497.x; Z'Graggen WJ, 1998, J NEUROSCI, V18, P4744	80	122	136	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19283	19293		10.1074/jbc.273.30.19283	http://dx.doi.org/10.1074/jbc.273.30.19283			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668118	hybrid			2022-12-25	WOS:000074974700085
J	Seto-Young, D; Bandell, M; Hall, M; Perlin, DS				Seto-Young, D; Bandell, M; Hall, M; Perlin, DS			Differential exposure of surface epitopes in the beta-strand region of LOOP1 of the yeast H+-ATPase during catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA-2+-ATPASE; PLASMA-MEMBRANE ATPASE; SACCHAROMYCES-CEREVISIAE; CONFORMATIONAL-CHANGES; FUNCTIONAL CONSEQUENCES; MUTATIONS; CLEAVAGE; BINDING; DOMAINS; STATES	The plasma membrane H+-ATPase of yeast assumes distinct conformational states during its catalytic cycle. To better understand structural changes in the LOOP1 domain, a catalytically important cytoplasmic loop segment Linking transmembrane segments 2 and 3, surface epitopes were examined at different stages of catalysis. A polyclonal rabbit antibody was prepared to a fusion protein consisting of LOOP1 and the maltose binding protein. This antibody was affinity-purified to produce a LOOP1-specific fraction that could be used in competition enzyme-linked immunosorbent assays to assess surface exposure of the LOOP1 epitopes. It was found that in an E-1 conformation stabilized with either adenosine 5'-(beta,gamma-imino)triphosphate (AMP-PNP) or ADP, less than 10% of the LOOP1 epitopes were accessible on native enzyme. However, when the enzyme was stabilized in an E-w-state with ATP plus vanadate, approximately 40% of the surface epitopes on LOOP1 became accessible to antibody. The remaining 60% of the LOOP1 epitopes were fully occluded in the native enzyme and never showed surface exposure. Enzyme-linked immunosorbent assays utilizing fusion proteins consisting of LOOP1 subdomains demonstrated that all of the available epitopes were contained in the beta-strand region (Glu-195-Val-267) of LOOP1, The epitopes that were differentially exposed during catalysis were included in regions upstream and downstream of the highly conserved TOES sequence. Our results suggest that during catalysis either the beta-strand region of LOOP1 or an interacting domain undergoes substantial structural rearrangement that facilitates epitope exposure.	Publ Hlth Res Inst City New York Inc, New York, NY 10016 USA		Perlin, DS (corresponding author), Publ Hlth Res Inst City New York Inc, 455 1St Ave, New York, NY 10016 USA.		Perlin, David S/K-4013-2015		NIGMS NIH HHS [GM 38225] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038225] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADDISON R, 1982, J BIOL CHEM, V257, P421; ANDERSEN JP, 1985, J MEMBRANE BIOL, V88, P187, DOI 10.1007/BF01868432; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; Bandell M, 1996, BBA-BIOMEMBRANES, V1280, P81, DOI 10.1016/0005-2736(95)00280-4; CAPIEAUX E, 1993, J BIOL CHEM, V268, P21895; CLARKE DM, 1990, J BIOL CHEM, V265, P14088; COLYER J, 1989, BIOCHEM J, V262, P439, DOI 10.1042/bj2620439; CYRKLAFF M, 1995, EMBO J, V14, P1854, DOI 10.1002/j.1460-2075.1995.tb07177.x; GHISLAIN M, 1987, J BIOL CHEM, V262, P17549; GOFFEAU A, 1990, J BIOL CHEM, V265, P15503; Goldshleger R, 1997, P NATL ACAD SCI USA, V94, P9596, DOI 10.1073/pnas.94.18.9596; GOORMAGHTIGH E, 1994, J BIOL CHEM, V269, P27409; HARRIS SL, 1991, J BIOL CHEM, V266, P24439; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; LEMAIRE M, 1990, J BIOL CHEM, V265, P1111; LUTSENKO S, 1994, J BIOL CHEM, V269, P4555; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MANDALA SM, 1988, J BIOL CHEM, V263, P15122; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCCUSKER JH, 1987, MOL CELL BIOL, V7, P4082, DOI 10.1128/MCB.7.11.4082; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; PERLIN DS, 1989, J BIOL CHEM, V264, P21857; PORTILLO F, 1988, EMBO J, V7, P1793, DOI 10.1002/j.1460-2075.1988.tb03010.x; SERRANO R, 1993, EUR J BIOCHEM, V212, P737, DOI 10.1111/j.1432-1033.1993.tb17712.x; SETOYOUNG D, 1994, J BIOL CHEM, V269, P23988; STOKES DL, 1994, FEBS LETT, V346, P32, DOI 10.1016/0014-5793(94)00297-5; TOROK K, 1988, EUR J BIOCHEM, V173, P361, DOI 10.1111/j.1432-1033.1988.tb14006.x; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; TUNWELL REA, 1991, BIOCHEM J, V279, P203, DOI 10.1042/bj2790203; WACH A, 1992, J BIOENERG BIOMEMBR, V24, P309; Wach A, 1996, BIOCHEMISTRY-US, V35, P883, DOI 10.1021/bi951998r; Wang GF, 1996, J BIOL CHEM, V271, P25438, DOI 10.1074/jbc.271.41.25438; Wang GF, 1997, ARCH BIOCHEM BIOPHYS, V344, P309, DOI 10.1006/abbi.1997.0213; Yonekura K, 1997, BIOPHYS J, V72, P997, DOI 10.1016/S0006-3495(97)78752-6	35	2	2	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18282	18287		10.1074/jbc.273.29.18282	http://dx.doi.org/10.1074/jbc.273.29.18282			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660792	hybrid			2022-12-25	WOS:000074828500047
J	Watson, RH; Neville, PJ; Roy, WJ; Hitchcock, A; Campbell, IG				Watson, RH; Neville, PJ; Roy, WJ; Hitchcock, A; Campbell, IG			Loss of heterozygosity on chromosomes 7p, 7q, 9p and 11q is an early event in ovarian tumorigenesis	ONCOGENE			English	Article						loss of heterozygosity; tumour suppressor gene; ovarian cancer	LOW-GRADE; CANCER; CARCINOMAS; MUTATION; TUMORS; DELETION; FREQUENT; PROTEIN; REGIONS; BENIGN	Forty early stage malignant and seven borderline ovarian tumours mere analysed for loss of heterozygosity (LOH) on chromosomes 6, 7, 9, 11 and 7, LOH involving at least one locus was observed in 32 (80%) early stage and six (86%) borderline tumours, Frequent LOH in the early stage tumours was detected on chromosome arms 7p (31%), 7q (50%), 9p (42%) and 11q (34%) suggesting that these chromosomes harbour tumour suppressor genes which are inactivated early in tumorigenesis, Borderline tumours exhibited a similar pattern of LOH to that observed in the early stage malignant tumours, indicating that the development of both malignant and borderline forms may involve inactivation of the same set of tumour suppressor genes. Together with our previous investigation of benign ovarian tumours this data supports the theory that malignant ovarian tumours may arise from benign and borderline precursors.	Princess Anne Hosp, Southampton SO16 5YA, Hants, England; Southampton Gen Hosp, Dept Histopathol, Southampton SO16 6YD, Hants, England	University of Southampton	Watson, RH (corresponding author), Princess Anne Hosp, Level F,Coxford Rd, Southampton SO16 5YA, Hants, England.		campbell, Ian G/F-6006-2011	Campbell, Ian/0000-0002-7773-4155				CAMPBELL IG, 1994, HUM MOL GENET, V3, P589, DOI 10.1093/hmg/3.4.589; CAMPBELL IG, 1995, INT J CANCER, V63, P222, DOI 10.1002/ijc.2910630213; CHAMPENE MH, 1995, GENE CHROMOSOME CANC, V4, P304; CHENEVIXTRENCH G, 1994, AM J HUM GENET, V55, P143; CLIBY W, 1993, CANCER RES, V53, P2393; Davis M, 1996, CANCER RES, V56, P741; Devlin J, 1996, BRIT J CANCER, V73, P420, DOI 10.1038/bjc.1996.75; DODSON MK, 1993, CANCER RES, V53, P4456; Edelson MI, 1997, ONCOGENE, V14, P2979, DOI 10.1038/sj.onc.1201271; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FOULKES WD, 1995, BRIT J CANCER, V72, P883, DOI 10.1038/bjc.1995.428; FOULKES WD, 1993, BRIT J CANCER, V67, P551, DOI 10.1038/bjc.1993.101; GALLION HH, 1992, GYNECOL ONCOL, V47, P137, DOI 10.1016/0090-8258(92)90096-2; ISHWAD CS, 1995, GENE CHROMOSOME CANC, V14, P51, DOI 10.1002/gcc.2870140109; Kerr J, 1996, ONCOGENE, V13, P1815; Koike M, 1997, GENE CHROMOSOME CANC, V19, P1, DOI 10.1002/(SICI)1098-2264(199705)19:1<1::AID-GCC1>3.0.CO;2-3; Lane RP, 1996, GENOMICS, V35, P456, DOI 10.1006/geno.1996.0385; Latil A, 1995, CLIN CANCER RES, V1, P1385; Li DW, 1996, CARCINOGENESIS, V17, P1751, DOI 10.1093/carcin/17.8.1751; MILNER BJ, 1993, CANCER RES, V53, P2128; MULLENBACH R, 1989, TRENDS GENET, V5, P391; ORPHANOS V, 1995, BRIT J CANCER, V71, P666, DOI 10.1038/bjc.1995.132; OSBORNE RJ, 1994, BRIT J CANCER, V69, P429, DOI 10.1038/bjc.1994.79; Roy WJ, 1997, ONCOGENE, V15, P2031, DOI 10.1038/sj.onc.1201372; SAITO S, 1992, CANCER RES, V52, P5815; SHELLING AN, 1995, BRIT J CANCER, V72, P521, DOI 10.1038/bjc.1995.367; Skomedal H, 1997, J PATHOL, V181, P158; TIBLETTI MG, 1996, CANCER RES, V56, P4493; Turkmen B, 1997, ELECTROPHORESIS, V18, P686, DOI 10.1002/elps.1150180505; Werness BA, 1997, HUM PATHOL, V28, P626, DOI 10.1016/S0046-8177(97)90087-3; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZHENG JP, 1995, J NATL CANCER I, V87, P1146, DOI 10.1093/jnci/87.15.1146; ZHENG JP, 1993, CANCER RES, V53, P4138	33	38	38	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 16	1998	17	2					207	212		10.1038/sj.onc.1201945	http://dx.doi.org/10.1038/sj.onc.1201945			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZZ211	9674705				2022-12-25	WOS:000074706700009
J	New, DR; Maggirwar, SB; Epstein, LG; Dewhurst, S; Gelbard, HA				New, DR; Maggirwar, SB; Epstein, LG; Dewhurst, S; Gelbard, HA			HIV-1 Tat induces neuronal death via tumor necrosis factor-alpha and activation of non-N-methyl-D-aspartate receptors by a NF kappa B-independent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEIN; CELLS; APOPTOSIS; EXPRESSION; NEUROTOXICITY; DISSOCIATION; MACROPHAGES; MORPHOLOGY; CULTURE	Human immunodeficiency virus type 1 (HIV-1) infection of the central nervous system may result in neuronal apoptosis in vulnerable brain regions, including cerebral cortex and basal ganglia. The mechanisms for neuronal loss are Likely to be multifactorial and indi rect, since HIV-1 productively infects brain-resident macrophages and microglia but does not cause cytolytic infection of neurons in the central nervous system. HIV-1 infection of macrophages and microglia leads to production and release of diffusible factors that result in neuronal cell death, including the HIV-1 regulatory protein Tat, We demonstrate in this report that recombinant Tat(1-86) and Tat peptides containing the basic region induce neuronal apoptosis in approximately 50% of vulnerable neurons in both rat and human neuronal cultures, and this apoptotic cell death is mediated by release of the pro-inflammatory cytokine tumor necrosis factor alpha, and by activation of glutamate receptors of the non-N-methyl-D-aspartate subtype, Finally, we show that Tat-induced apoptosis of human neuronal cell cultures occurs in the absence of activation of the transcription factor NF kappa B. These findings further define cellular pathways activated by Tat, that dysregulate production of tumor necrosis factor alpha, and lead to activation of glutamate receptors and neuronal death during HIV-1 infection of the central nervous system.	Univ Rochester, Med Ctr, Dept Neurol, Child Neurol Div, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Neurobiol & Anat, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Dent Res, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Pediat, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Microbiol & Immunol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Physiol & Pharmacol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Ctr Canc, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester; University of Rochester; University of Rochester; University of Rochester	Gelbard, HA (corresponding author), Univ Rochester, Med Ctr, Dept Neurol, Child Neurol Div, Rochester, NY 14642 USA.		Gelbard, Harris/M-9260-2019	Gelbard, Harris/0000-0001-5095-7976; Epstein, Leon/0000-0003-4264-3867; Dewhurst, Stephen/0000-0001-7729-7920	NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH057556] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS010307] Funding Source: NIH RePORTER; NIMH NIH HHS [P01 MH57556] Funding Source: Medline; NINDS NIH HHS [F32-NS10307] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BIEDLER JL, 1973, CANCER RES, V33, P2643; Chen PQ, 1997, J BIOL CHEM, V272, P22385, DOI 10.1074/jbc.272.36.22385; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; EPSTEIN LG, 1993, ANN NEUROL, V33, P429, DOI 10.1002/ana.410330502; EVERALL IP, 1995, NAT MED, V1, P1174, DOI 10.1038/nm1195-1174; FLORES SC, 1993, P NATL ACAD SCI USA, V90, P7632, DOI 10.1073/pnas.90.16.7632; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; GELBARD HA, 1993, DEV NEUROSCI-BASEL, V15, P417, DOI 10.1159/000111367; GELBARD HA, 1994, J VIROL, V68, P4628, DOI 10.1128/JVI.68.7.4628-4635.1994; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; HATTEN ME, 1985, J CELL BIOL, V100, P384, DOI 10.1083/jcb.100.2.384; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; KAWAMOTO JC, 1986, BRAIN RES, V384, P84, DOI 10.1016/0006-8993(86)91222-9; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; LIPTON SA, 1992, NEUROREPORT, V3, P913, DOI 10.1097/00001756-199210000-00023; Ma MH, 1997, J VIROL, V71, P2495, DOI 10.1128/JVI.71.3.2495-2499.1997; Maggirwar SB, 1997, MOL CELL BIOL, V17, P2605, DOI 10.1128/MCB.17.5.2605; MAGNUSON DSK, 1995, ANN NEUROL, V37, P373, DOI 10.1002/ana.410370314; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MUNOZ E, 1994, J VIROL, V68, P8035; Nath A, 1996, J VIROL, V70, P1475, DOI 10.1128/JVI.70.3.1475-1480.1996; New DR, 1997, J NEUROVIROL, V3, P168, DOI 10.3109/13550289709015806; Perry SW, 1997, BIOTECHNIQUES, V22, P1102, DOI 10.2144/97226st01; Perry SW, 1997, BIOTECHNIQUES, V22, P1020, DOI 10.2144/97226bm01; PHILIPPON V, 1994, VIROLOGY, V205, P519, DOI 10.1006/viro.1994.1673; PURVIS SF, 1995, AIDS RES HUM RETROV, V11, P443, DOI 10.1089/aid.1995.11.443; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; TALLEY AK, 1995, MOL CELL BIOL, V15, P2359; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; WESTENDORP MO, 1995, EMBO J, V14, P546, DOI 10.1002/j.1460-2075.1995.tb07030.x; WHITE LA, 1994, J NEUROSCI, V14, P6744; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; ZAULI G, 1993, CANCER RES, V53, P4481	43	152	155	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17852	17858		10.1074/jbc.273.28.17852	http://dx.doi.org/10.1074/jbc.273.28.17852			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651389	hybrid			2022-12-25	WOS:000074816100082
J	Shim, H; Hong, SB; Raushel, FM				Shim, H; Hong, SB; Raushel, FM			Hydrolysis of phosphodiesters through transformation of the bacterial phosphotriesterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; PHOSPHATE DIESTER HYDROLYSIS; BINUCLEAR METAL CENTER; PSEUDOMONAS-DIMINUTA; 3-DIMENSIONAL STRUCTURE; ASPARTATE-AMINOTRANSFERASE; HISTIDINE; INACTIVATION; SPECIFICITY; MECHANISM	The phosphotriesterase from Pseudomonas diminuta catalyzes the hydrolysis of a wide array of phosphotriesters and related phosphonates, including organophosphate pesticides and military nerve agents. It has now been shown that this enzyme can also catalyze the hy drolysis of phosphodiesters, albeit at a greatly reduced rate. However, the enzymatic hydrolysis of ethyl-4-nitrophenyl phosphate (compound I) by the wild-type enzyme was >10(8) times faster than the uncatalyzed reaction (k(cat) = 0.06 s(-1) and K-m = 38 mM). Upon the addition of various alkylamines to the reaction mixture, the k(cat)/K-m for the phosphodiester (compound I) increased up to 200-fold. Four mutant enzymes of the phosphotriesterase were constructed in a preliminary attempt to improve phosphodiester hydrolysis activity of the native enzyme. Met-317, which is thought to reside in close proximity to the pro S-ethoxy arm of the paraoxon substrate, was mutated to arginine, alanine, histidine, and lysine, These mutant enzymes showed slight improvements in the catalytic hydrolysis of organophosphate diesters, The M317K mutant enzyme displayed the most improvement in catalytic activity (k(cat) = 0.34 s(-1) and K-m = 30 mM), The M317A mutant enzyme catalyzed the hydrolysis of the phosphodiester (compound I) in the presence of alkylamines up to 200 times faster than the wildtype enzyme in the absence of added amines, The neutralization of the negative charge on the oxygen atom of the phosphodiester by the ammonium cation within the active site is thought to be responsible for the rate enhancement by these amines in the hydrolytic reaction. These results demonstrate that an active site optimized for the hydrolysis of organophosphate triesters can be made to catalyze the hydrolysis of organophosphate diesters.	Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station	Raushel, FM (corresponding author), Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA.		Raushel, Frank/B-7125-2015	Raushel, Frank/0000-0002-5918-3089	NIGMS NIH HHS [GM 33894] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033894] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER M, 1961, J BIOL CHEM, V236, P3014; BANZON JA, 1995, BIOCHEMISTRY-US, V34, P743, DOI 10.1021/bi00003a006; BANZON JA, 1995, BIOCHEMISTRY-US, V34, P750, DOI 10.1021/bi00003a007; BENNING MM, 1995, BIOCHEMISTRY-US, V34, P7973, DOI 10.1021/bi00025a002; BENNING MM, 1994, BIOCHEMISTRY-US, V33, P15001, DOI 10.1021/bi00254a008; Birikh KR, 1997, EUR J BIOCHEM, V245, P1, DOI 10.1111/j.1432-1033.1997.t01-3-00001.x; BUNTON CA, 1975, J ORG CHEM, V40, P2313, DOI 10.1021/jo00904a011; CALDWELL SR, 1991, BIOCHEMISTRY-US, V30, P7444, DOI 10.1021/bi00244a011; CALDWELL SR, 1991, BIOCHEMISTRY-US, V30, P7438, DOI 10.1021/bi00244a010; CHAE MY, 1993, J AM CHEM SOC, V115, P12173, DOI 10.1021/ja00078a069; CRONIN CN, 1987, J AM CHEM SOC, V109, P2222, DOI 10.1021/ja00241a072; Deal KA, 1996, INORG CHEM, V35, P2792, DOI 10.1021/ic951488l; Deal KA, 1996, J AM CHEM SOC, V118, P1713, DOI 10.1021/ja952306p; DELCARDAYRE SB, 1994, BIOCHEMISTRY-US, V33, P6031, DOI 10.1021/bi00186a001; DONARSKI WJ, 1989, BIOCHEMISTRY-US, V28, P4650, DOI 10.1021/bi00437a021; DUMAS DP, 1989, J BIOL CHEM, V264, P19659; DUMAS DP, 1990, J BIOL CHEM, V265, P21498; HAN MJ, 1997, J CHEM SOC CHEM COMM, P163; HENDRY P, 1989, J AM CHEM SOC, V111, P2521, DOI 10.1021/ja00189a025; Hettich R, 1997, J AM CHEM SOC, V119, P5638, DOI 10.1021/ja964319o; Hong SB, 1996, BIOCHEMISTRY-US, V35, P10904, DOI 10.1021/bi960663m; Kuo JM, 1997, BIOCHEMISTRY-US, V36, P1982, DOI 10.1021/bi962099l; KUO JM, 1994, BIOCHEMISTRY-US, V33, P4265, DOI 10.1021/bi00180a022; Kurpiewski MR, 1996, BIOCHEMISTRY-US, V35, P8846, DOI 10.1021/bi960261e; LEWIS VE, 1988, BIOCHEMISTRY-US, V27, P1591, DOI 10.1021/bi00405a030; MORROW JR, 1988, INORG CHEM, V27, P3387, DOI 10.1021/ic00292a025; OMBURO GA, 1992, J BIOL CHEM, V267, P13278; OMBURO GA, 1993, BIOCHEMISTRY-US, V32, P9148, DOI 10.1021/bi00086a021; ONUFFER JJ, 1995, PROTEIN SCI, V4, P1750, DOI 10.1002/pro.5560040910; TAKAGASHI K, 1982, ENZYMES, V15, P458; Vanhooke JL, 1996, BIOCHEMISTRY-US, V35, P6020, DOI 10.1021/bi960325l; WTKINS LM, 1997, PROTEIN-STRUCT FUNCT, V29, P553	32	44	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17445	17450		10.1074/jbc.273.28.17445	http://dx.doi.org/10.1074/jbc.273.28.17445			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651332	hybrid			2022-12-25	WOS:000074816100025
J	Takafuta, T; Wu, GX; Murphy, GF; Shapiro, SS				Takafuta, T; Wu, GX; Murphy, GF; Shapiro, SS			Human beta-filamin is a new protein that interacts with the cytoplasmic tail of glycoprotein Ib alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	39th Annual Meeting of the American-Society-of-Hematology	DEC 05-09, 1997	SAN DIEGO, CALIFORNIA	Amer Soc Hematol			ACTIN-BINDING-PROTEIN; NON-MUSCLE CELLS; SMOOTH-MUSCLE; IX COMPLEX; HUMAN-PLATELETS; DOMAIN; ABP-280; IDENTIFICATION; PURIFICATION; DYSTROPHIN	We have cloned and sequenced a 9.4-kilobase cDNA specifying a new 280-kDa protein interacting with the cytoplasmic tail of glycoprotein (Gp) Ib alpha and showing considerable homology to actin-binding protein 280 (ABP-280) and chicken retinal filamin. We term this protein human beta-filamin. The gene for beta-filamin localizes to chromosome 3p14.3-p21.1. beta-Filamin mRNA expression was observed in many tissues and in cultured human umbilical vein endothelial cells (HUVECs); only minimal expression was detected in platelets and the megakaryocytic cell line CHRF-288. Like ABP-280, beta-filamin contains an NH2-terminal actin-binding domain, a backbone of 24 tandem repeats, and two "hinge" regions. A polyclonal antibody to the unique beta-filamin first hinge sequence identifies a strong 280-kDa band in HUVECs but only a weak band in platelets, and stains normal human endothelial cells in culture and in situ. We have confirmed the interaction of beta-filamin and GpIb alpha in platelet and HUVEC lysates. In addition, using two-hybrid analysis with deletion mutants, we have localized the binding domain for GpIb alpha in beta-filamin to residues 1862-2148, an area homologous to the GpIb alpha binding domain in ABP-280. beta-Filamin is a new member of the filamin family that may have significance for GpIb alpha function in endothelial cells and platelets.	Thomas Jefferson Univ, Jefferson Med Coll, Cardeza Fdn Hematol Res, Dept Med, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Shapiro, SS (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Cardeza Fdn Hematol Res, Dept Med, 1015 Walnut St, Philadelphia, PA 19107 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL009163, R37HL009163] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL09163] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREWS RK, 1991, J BIOL CHEM, V266, P7144; ANDREWS RK, 1992, J BIOL CHEM, V267, P18605; BARRY CP, 1993, J BIOL CHEM, V268, P25577; BOXER LA, 1976, J CLIN INVEST, V57, P964, DOI 10.1172/JCI108373; Clemetson KJ, 1997, THROMB HAEMOSTASIS, V78, P266; COX D, 1995, J CELL BIOL, V128, P819, DOI 10.1083/jcb.128.5.819; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; Cunningham JG, 1996, J BIOL CHEM, V271, P11581, DOI 10.1074/jbc.271.19.11581; DAVIES PJA, 1978, J BIOL CHEM, V253, P4036; EZZELL RM, 1988, J BIOL CHEM, V263, P13303; FOX JEB, 1985, J BIOL CHEM, V260, P1970; Fucini P, 1997, NAT STRUCT BIOL, V4, P223, DOI 10.1038/nsb0397-223; GOMER RH, 1981, CELL, V23, P524, DOI 10.1016/0092-8674(81)90148-3; GOMER RH, 1983, J CELL BIOL, V96, P321, DOI 10.1083/jcb.96.2.321; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; GORLIN JB, 1993, GENOMICS, V17, P496, DOI 10.1006/geno.1993.1354; HANDA M, 1986, J BIOL CHEM, V261, P2579; HARTWIG JH, 1980, J CELL BIOL, V87, P841, DOI 10.1083/jcb.87.3.841; HARTWIG JH, 1981, J MOL BIOL, V145, P563, DOI 10.1016/0022-2836(81)90545-3; HARTWIG JH, 1975, J BIOL CHEM, V250, P5696; HOCK RS, 1990, BIOCHEMISTRY-US, V29, P9441, DOI 10.1021/bi00492a019; HU RJ, 1992, J BIOL CHEM, V267, P18715; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEEDMAN PJ, 1993, P NATL ACAD SCI USA, V90, P5994, DOI 10.1073/pnas.90.13.5994; Liu GP, 1997, J CELL BIOL, V139, P1719, DOI 10.1083/jcb.139.7.1719; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5616; MAESTRINI E, 1993, HUM MOL GENET, V2, P761, DOI 10.1093/hmg/2.6.761; MANGEAT PH, 1983, CELL MOTIL CYTOSKEL, V3, P657, DOI 10.1002/cm.970030530; Marti A, 1997, J BIOL CHEM, V272, P2620, DOI 10.1074/jbc.272.5.2620; Meyer SC, 1998, J BIOL CHEM, V273, P3013, DOI 10.1074/jbc.273.5.3013; Meyer SC, 1997, J BIOL CHEM, V272, P2914, DOI 10.1074/jbc.272.5.2914; MILLAKE DB, 1989, NUCLEIC ACIDS RES, V17, P6725, DOI 10.1093/nar/17.16.6725; NOEGEL AA, 1989, J CELL BIOL, V109, P607, DOI 10.1083/jcb.109.2.607; OHTA Y, 1991, CELL, V67, P275, DOI 10.1016/0092-8674(91)90179-3; Ott I, 1998, J CELL BIOL, V140, P1241, DOI 10.1083/jcb.140.5.1241; ROSENBERG S, 1981, J CELL BIOL, V91, P201, DOI 10.1083/jcb.91.1.201; SHARMA CP, 1995, J IMMUNOL, V154, P3461; Tachikawa M, 1997, J BIOCHEM-TOKYO, V122, P314; TERASAKI AG, 1995, J CELL SCI, P857; WANG K, 1977, P NATL ACAD SCI USA, V74, P2021, DOI 10.1073/pnas.74.5.2021; WANG K, 1975, P NATL ACAD SCI USA, V72, P4483, DOI 10.1073/pnas.72.11.4483; WANG K, 1977, BIOCHEMISTRY-US, V16, P1857, DOI 10.1021/bi00628a015; WEIHING RR, 1983, BIOCHEMISTRY-US, V22, P1839, DOI 10.1021/bi00277a015; WEIHING RR, 1985, CAN J BIOCHEM CELL B, V63, P397, DOI 10.1139/o85-059; Wu GX, 1997, BLOOD, V90, P2660, DOI 10.1182/blood.V90.7.2660.2660_2660_2669; Wu GX, 1996, BLOOD, V87, P2782, DOI 10.1182/blood.V87.7.2782.bloodjournal8772782; Zhang WJ, 1998, J NEUROSCI, V18, P914	48	96	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17531	17538		10.1074/jbc.273.28.17531	http://dx.doi.org/10.1074/jbc.273.28.17531			8	Biochemistry & Molecular Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651345	hybrid			2022-12-25	WOS:000074816100038
J	Jansch, L; Kruft, V; Schmitz, UK; Braun, HP				Jansch, L; Kruft, V; Schmitz, UK; Braun, HP			Unique composition of the preprotein translocase of the outer mitochondrial membrane from plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE NATIVE ELECTROPHORESIS; PROTEIN IMPORT RECEPTOR; PROCESSING PEPTIDASE; POTATO MITOCHONDRIA; PRECURSOR PROTEINS; RESPIRATORY-CHAIN; COMPLEX; IDENTIFICATION; INSERTION; MACHINERY	Transport of most nuclear encoded mitochondrial proteins into mitochondria is mediated by heteropolymeric translocases in the membranes of the organelles. The translocase of the outer mitochondrial membrane (TOM) was characterized in fungi, and it was shown that TOM from yeast comprises nine different subunits, This publication is the first report on the preparation of the TOM complex from plant mitochondria. The protein complex from potato was purified by (a) blue native polyacrylamide gel electrophoresis and (b) by immunoaffinity chromatography, On blue native gels, the potato TOM complex runs close to cytochrome c oxidase at 230 kDa and hence only comprises about half of the size of fungal TOM complexes. Analysis of the TOM complex from potato by SDS-polyacrylamide gel electrophoresis allows separation of seven different subunits of 70, 36, 23, 9, 8, 7, and 6 kDa The 23-kDa protein is identical to the previously characterized potato TOM20 receptor, as shown by in vitro assembly of this protein into the 230-kDa complex, by immunoblotting and by direct protein sequencing Partial amino acid sequence data of the other subunits allowed us to identify sequence similarity between the 36-kDa protein and fungal TOM40, Sequence analysis of cDNAs encoding the 7-kDa protein revealed significant sequence homology of this protein to TOM7 from yeast. However, potato TOM7 has a N-terminal extension, which is very rich in basic amino acids. Counterparts to the TOM22 and TOM37 proteins from yeast seem to be absent in the potato TOM complex, whereas an additional low molecular mass subunit occurs. Functional implications of these findings are discussed.	Univ Hannover, Inst Angew Genet, D-30419 Hannover, Germany; Appl Biosyst, D-63225 Langen, Germany	Leibniz University Hannover; Thermo Fisher Scientific; Applied Biosystems	Braun, HP (corresponding author), Univ Hannover, Inst Angew Genet, Herrenhauser Str 2, D-30419 Hannover, Germany.		Braun, Hans-Peter/E-7149-2011	Braun, Hans-Peter/0000-0002-4459-9727				ALCONADA A, 1995, MOL CELL BIOL, V15, P6196; BAKER KP, 1990, NATURE, V348, P305; BRAUN HP, 1995, PLANTA, V195, P396, DOI 10.1007/BF00202597; BRAUN HP, 1992, MOL GEN GENET, V231, P217, DOI 10.1007/BF00279794; BRAUN HP, 1992, EMBO J, V11, P3219, DOI 10.1002/j.1460-2075.1992.tb05399.x; Brumme S, 1998, J BIOL CHEM, V273, P13143, DOI 10.1074/jbc.273.21.13143; BURT WJE, 1994, FEBS LETT, V339, P139, DOI 10.1016/0014-5793(94)80401-X; Dekker PJT, 1996, BIOL CHEM, V377, P535; Dietmeier K, 1997, NATURE, V388, P195, DOI 10.1038/40663; ERIKSSON AC, 1994, BBA-BIOENERGETICS, V1186, P221, DOI 10.1016/0005-2728(94)90181-3; GRATZER S, 1995, J CELL BIOL, V129, P25, DOI 10.1083/jcb.129.1.25; Haucke V, 1996, EMBO J, V15, P1231, DOI 10.1002/j.1460-2075.1996.tb00464.x; HAUKE V, 1997, TRENDS CELL BIOL, V7, P103; HEINS L, 1994, J BIOL CHEM, V269, P26402; Heins L, 1996, PLANT J, V9, P829, DOI 10.1046/j.1365-313X.1996.9060829.x; Honlinger A, 1996, EMBO J, V15, P2125, DOI 10.1002/j.1460-2075.1996.tb00566.x; Jansch L, 1996, PLANT J, V9, P357, DOI 10.1046/j.1365-313X.1996.09030357.x; KASSENBROCK CK, 1993, EMBO J, V12, P3023, DOI 10.1002/j.1460-2075.1993.tb05971.x; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; Kugler M, 1997, PHOTOSYNTH RES, V53, P35, DOI 10.1023/A:1005882406718; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITHGOW T, 1995, TRENDS BIOCHEM SCI, V20, P98, DOI 10.1016/S0968-0004(00)88972-0; MOCZKO M, 1992, FEBS LETT, V310, P265, DOI 10.1016/0014-5793(92)81345-M; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; PERRYMAN RA, 1995, ARCH BIOCHEM BIOPHYS, V316, P659, DOI 10.1006/abbi.1995.1088; Pfanner N, 1997, CURR BIOL, V7, pR100, DOI 10.1016/S0960-9822(06)00048-0; Pfanner N, 1996, TRENDS BIOCHEM SCI, V21, P51, DOI 10.1016/0968-0004(96)80864-4; PRASAD TK, 1992, PLANT MOL BIOL, V18, P873, DOI 10.1007/BF00019202; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; Szigyarto C, 1998, PLANT MOL BIOL, V36, P171, DOI 10.1023/A:1005977716814; WATTS FZ, 1992, PLANT MOL BIOL, V18, P23, DOI 10.1007/BF00018453	34	70	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17251	17257		10.1074/jbc.273.27.17251	http://dx.doi.org/10.1074/jbc.273.27.17251			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642296	hybrid			2022-12-25	WOS:000074545200086
J	Hermann, M; Lindstedt, KA; Foisner, R; Morwald, S; Mahon, MG; Wandl, R; Schneider, WJ; Nimpf, J				Hermann, M; Lindstedt, KA; Foisner, R; Morwald, S; Mahon, MG; Wandl, R; Schneider, WJ; Nimpf, J			Apolipoprotein A-I production by chicken granulosa cells	FASEB JOURNAL			English	Article						follicle; vitellogenesis; oocyte	DENSITY-LIPOPROTEIN RECEPTOR; GALLUS-DOMESTICUS; OOCYTE RECEPTOR; PROTEIN; VITELLOGENIN; BIOSYNTHESIS; CHOLESTEROL; DEPOSITION; METABOLISM; SECRETION	In avian species such as the chicken, development of the oocyte is associated with massive deposition of yolk in this cell. Oocytes grow within the follicle, a compartment consisting of a very specialized set of cells and acellular structures. The oocyte is surrounded by the perivitelline layer and granulosa cells, which are separated from the thecae by a pronounced basement membrane. In addition to the production of yolk precursors in the liver, we have long implied that cells within the follicle make a direct contribution to the growth of the oocyte. Here we show that chicken granulosa cells express and actively secrete apolipoprotein A-I (apoA-I) as a part of particles with very high density. The ganulosa cell-derived, apoA-I-containing material is different from the small portion of yolk high density lipoprotein that arises via transfer from the peripheral circulation. We propose that the ApoA-I-containing particles secreted by granulosa cells 1) support the growth of the rapidly growing germ cell, possibly by direct lipid transfer to the plasma membrane of the oocyte, and/or 2) deliver cholesteryl eaters to the steroid-producing cells of the theca layer. These findings are discussed with respect to the proposed functions of apoE (an apolipoprotein not found in chicken) within the mammalian follicle.-Hermann, M., Lindstedt, K. A., Foisner, R., Morwald, S., Mahon, M. G., Wandl, R., Schneider, W. J., Nimpf, J. Apolipoprotein A-I production by chicken granulosa cells.	Bioctr, Dept Mol Genet, A-1030 Vienna, Austria; Univ Vienna, Vienna, Austria; Bioctr, Dept Biochem & Mol Cell Biol, A-1030 Vienna, Austria; Univ Vienna, A-1030 Vienna, Austria	University of Vienna; University of Vienna	Nimpf, J (corresponding author), Bioctr, Dept Mol Genet, Dr Bohrgasse 9-2, A-1030 Vienna, Austria.	JNIMPF@mol.univie.ac.at	Foisner, Roland/AAD-1833-2019	Hermann, Marcela/0000-0003-2298-4269; Foisner, Roland/0000-0003-4734-4647; Nimpf, Johannes/0000-0002-9273-3492				Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ASEM EK, 1993, POULTRY SCI, V72, P1961, DOI 10.3382/ps.0721961; BAIN JM, 1969, AUST J BIOL SCI, V22, P653; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; Bu GJ, 1996, J BIOL CHEM, V271, P22218, DOI 10.1074/jbc.271.36.22218; BUJO H, 1995, J BIOL CHEM, V270, P23546, DOI 10.1074/jbc.270.40.23546; BUJO H, 1994, EMBO J, V13, P5165, DOI 10.1002/j.1460-2075.1994.tb06847.x; DAWSON PA, 1986, J BIOL CHEM, V261, P5681; DYER CA, 1988, J BIOL CHEM, V263, P10965; ETCHES RJ, 1990, J EXP ZOOL, P112, DOI 10.1002/jez.1402560419; GILBERT AB, 1977, J REPROD FERTIL, V50, P179, DOI 10.1530/jrf.0.0500179; GORDON DA, 1989, J INVEST DERMATOL, V92, P96, DOI 10.1111/1523-1747.ep13071302; GWYNNE JT, 1982, ENDOCR REV, V3, P299, DOI 10.1210/edrv-3-3-299; HAYASHI K, 1989, J BIOL CHEM, V264, P3131; HERMIER D, 1985, BIOCHIM BIOPHYS ACTA, V836, P105, DOI 10.1016/0005-2760(85)90226-7; JACOBSEN L, 1995, J BIOL CHEM, V270, P6468, DOI 10.1074/jbc.270.12.6468; JOKINEN EV, 1994, J BIOL CHEM, V269, P26411; KELLEY JL, 1986, METHOD ENZYMOL, V128, P170; Lindstedt KA, 1997, J BIOL CHEM, V272, P30221, DOI 10.1074/jbc.272.48.30221; Lindstedt KA, 1997, DNA CELL BIOL, V16, P35, DOI 10.1089/dna.1997.16.35; MACLACHLAN I, 1994, J BIOL CHEM, V269, P24127; NIMPF J, 1988, J LIPID RES, V29, P657; NIMPF J, 1994, J BIOL CHEM, V269, P212; RAJAVASHISTH TB, 1987, J BIOL CHEM, V262, P7058; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Sambrook J., 1989, MOL CLONING LAB MANU, V1; Schneider Wolfgang J., 1995, Current Opinion in Lipidology, V6, P92, DOI 10.1097/00041433-199504000-00006; SCHULER LA, 1979, J BIOL CHEM, V254, P8662; SHEN XY, 1993, CELL TISSUE RES, V272, P459, DOI 10.1007/BF00318552; SMITH LC, 1978, ANNU REV BIOCHEM, V47, P751, DOI 10.1146/annurev.bi.47.070178.003535; STIFANI S, 1990, P NATL ACAD SCI USA, V87, P1955, DOI 10.1073/pnas.87.5.1955; TARUGI P, 1991, J BIOL CHEM, V266, P7714; VIEIRA PM, 1995, J LIPID RES, V36, P601; WILLIAMS DL, 1985, J BIOL CHEM, V260, P2444; WYNE KL, 1989, J BIOL CHEM, V264, P981	35	23	24	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1998	12	10					897	903		10.1096/fasebj.12.10.897	http://dx.doi.org/10.1096/fasebj.12.10.897			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZY035	9657529				2022-12-25	WOS:000074580100014
J	Fagioli, M; Alcalay, M; Tomassoni, L; Ferrucci, PF; Mencarelli, A; Riganelli, D; Grignani, F; Pozzan, T; Nicoletti, I; Grignani, F; Pelicci, PG				Fagioli, M; Alcalay, M; Tomassoni, L; Ferrucci, PF; Mencarelli, A; Riganelli, D; Grignani, F; Pozzan, T; Nicoletti, I; Grignani, F; Pelicci, PG			Cooperation between the RING+B1-B2 and coiled-coil domains of PML is necessary for its effects on cell survival	ONCOGENE			English	Article						PML; Ring; B-boxes; coiled-coil; apoptotic cell death	ACUTE PROMYELOCYTIC LEUKEMIA; GREEN FLUORESCENT PROTEIN; RAR-ALPHA; T(15-17) TRANSLOCATION; NUCLEAR MATRIX; ZINC FINGER; GENE; FUSION; EXPRESSION; BINDING	PML/RAR alpha is the abnormal protein product of the Acute Promyelocytic Leukemia-specific 15;17 translocation, Both the PML and RAR alpha components are required for the PML/RAR alpha biological activities, namely its capacity to block differentiation and to increase survival of haematopoietic precursors. The physiological role of PML and its contribution to the function of the fusion protein are unknown. PML; localizes to the cytoplasm and within specific nuclear bodies (NBs), In vitro, overexpression of PML correlates with suppression of cell transformation. The PML aminoterminal portion retained within the PML/RAR alpha protein contains the RING finger, two newly defined cystein/histidine-rich motifs called B-boxes (B1 and B2) and a coiled-coil region, We report here that PML has a growth suppressive activity in all the cell lines tested, regardless of their transformed phenotype, and that the cellular basis for the PML growth suppression is induction of apoptotic cell death. Analysis of various nuclear and cytoplasmic PML isoforms showed that the PML growth suppressive activity correlates with its nuclear localization. Analysis of the localization and growth suppressive activity demonstrated that: (i) the Ring + B1-B2 and coiled-coil regions are both indispensable and sufficient to target PML to the NBs; (ii) individual deletions of the various PML domains have no effect on its growth suppressor activity; (iii) the Ring + B1-B2 region exerts a partial growth suppressor activity but its fusion with the coiled-coil region is sufficient to recapitulate the suppressive function of wild type PML, These results indicate that PML is involved in cell survival regulation and that the PML component of the fusion protein (Ring+B1-B2 and coiled-coil regions) retains intact biological activity, thereby suggesting that the effects of PML/RAR alpha on survival derive from the activation of the incorporated PML sequence.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Univ Perugia, Monteluce Policlin, Ist Med Interna & Sci Oncol, I-06100 Perugia, Italy; Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy; Univ Padua, CNR, Ctr Study Mitochrondial Physiol, I-35121 Padua, Italy	IRCCS European Institute of Oncology (IEO); University of Perugia; University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua	Pelicci, PG (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Ripamonti 435, I-20141 Milan, Italy.		Pelicci, Pier Giuseppe/AAL-6572-2020; Alcalay, Myriam/AAB-4300-2019; Ferrucci, Pier Francesco/AAQ-9002-2020; Alcalay, Myriam/B-3182-2016; Grignani, Francesco/AAC-2565-2022	Alcalay, Myriam/0000-0002-5558-4272; Alcalay, Myriam/0000-0002-5558-4272; Ferrucci, Pier Francesco/0000-0001-6255-5851				ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; ALCALAY M, 1998, IN PRESS MOL CELL BI; Altabef M, 1996, EMBO J, V15, P2707, DOI 10.1002/j.1460-2075.1996.tb00631.x; ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; Boddy MN, 1996, ONCOGENE, V13, P971; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; Doucas V, 1996, GENE DEV, V10, P196, DOI 10.1101/gad.10.2.196; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EPSTEIN AL, 1984, J VIROL, V50, P372, DOI 10.1128/JVI.50.2.372-379.1984; EVERETT RD, 1994, EMBO J, V13, P5062, DOI 10.1002/j.1460-2075.1994.tb06835.x; FAGIOLI M, 1992, ONCOGENE, V7, P1083; Ferrucci PF, 1997, P NATL ACAD SCI USA, V94, P10901, DOI 10.1073/pnas.94.20.10901; FLENGHI L, 1995, BLOOD, V85, P1871, DOI 10.1182/blood.V85.7.1871.bloodjournal8571871; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Gambacorta M, 1996, AM J PATHOL, V149, P2023; GANDINI D, 1994, BLOOD, V84, pA439; Gorczyca W., 1993, CANCER RES, V53, P945; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Grignani F, 1996, EMBO J, V15, P4949, DOI 10.1002/j.1460-2075.1996.tb00875.x; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; KORIOTH F, 1995, J CELL BIOL, V130, P1, DOI 10.1083/jcb.130.1.1; LAVAU C, 1995, ONCOGENE, V11, P871; Le XF, 1996, J BIOL CHEM, V271, P130, DOI 10.1074/jbc.271.1.130; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; PAGLIACCI MC, 1993, LYMPHOKINE CYTOK RES, V12, P439; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PUVIONDUTILLEUL F, 1995, EXP CELL RES, V218, P9, DOI 10.1006/excr.1995.1125; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; RIZZUTO R, 1995, CURR BIOL, V5, P635, DOI 10.1016/S0960-9822(95)00128-X; ROGAIA D, 1995, LEUKEMIA, V9, P1467; Stadler M, 1995, ONCOGENE, V11, P2565; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; TKAHASHI M, 1988, MOL CELL BIOL, V8, P1853; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430	51	59	60	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 4	1998	16	22					2905	2913		10.1038/sj.onc.1201811	http://dx.doi.org/10.1038/sj.onc.1201811			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZR544	9671411				2022-12-25	WOS:000073988200009
J	Chen, CC; Wang, JK; Chen, WC; Lin, SB				Chen, CC; Wang, JK; Chen, WC; Lin, SB			Protein kinase C eta mediates lipopolysaccharide-induced nitric-oxide synthase expression in primary astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; GLIAL-CELLS; BINDING-PROTEIN; PHORBOL ESTERS; SUBTYPE-ALPHA; SOLUBLE CD14; INDUCTION; MECHANISMS; HEPATOCYTES; STIMULATION	The signaling pathway involved in protein kinase C (PRC) activation and role of PKC isoforms in lipopolysaccharide (LPS)-induced nitric oxide (NO) release were studied in primary cerebellar astrocytes. LPS caused a dose- and time-dependent increase in NO release and inducible NO synthase (iNOS) expression. The tyrosine kinase inhibitor, genestein, the phosphatidylcholine-phospholipase C inhibitor, D609, and the phosphatidate phosphodrolase inhibitor, propranolol, attenuated the LPS effects, whereas the PI-PLC inhibitor, U73122, had no effect. The PKC inhibitors (staurosporine, Po 31-8220, Go 6976, and calphostin C) also inhibited LPS-induced NO release and iNOS expression. However, long term (24 h) pretreatment of cells with 12-O-tetradecanoyl phorbol-13-acetate (TPA) did not affect the LPS response. Previous results have shown that TPA-induced translocation, but not down-regulation, of PKC eta occurs in astrocytes (Chen, C. C., and Chen, W. C. (1996) Glia 17, 63-71), suggesting possible involvement of PKC eta in LPS-mediated effects. Treatment with antisense oligonucleotides for PKC eta or delta, another isoform abundantly expressed in astrocytes, demonstrated the involvement of PKC eta, but not delta, in LPS-mediated effects. Stimulation of cells for 1 h with LPS caused activation of nuclear factor (NF)-kB in the nuclei as detected by the formation of a NF-kB-specific DNA-protein complex; this effect was inhibited by genestein, D609, propranolol, or Po 31-8220 or by PKC eta antisense oligonucleotides, but not by long term TPA treatment. These data suggest that in astrocytes, LPS might activate phosphatidylcholine-phospholipase C and phosphatidylcholine-phospholipase D through an upstream protein tyrosine kinase to induce PKC activation. Of the PKC isoforms present in these cells, only activation of PKC eta by LPS resulted in the stimulation of NF-kB-specific DNA-protein binding and then initiated the iNOS expression and NO release. This is further evidence demonstrating that different members of the PKC family within a single cell are involved in specific physiological responses.	Natl Taiwan Univ, Coll Med, Inst Pharmacol, Taipei 10018, Taiwan; Natl Taiwan Univ, Coll Med, Inst Med Technol, Taipei 10018, Taiwan	National Taiwan University; National Taiwan University	Chen, CC (corresponding author), Natl Taiwan Univ, Coll Med, Inst Pharmacol, 1 Jen Ai Rd,1st Sect, Taipei 10018, Taiwan.			CHEN, CHING-CHOW/0000-0002-7810-0939				BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Bagasra O, 1995, P NATL ACAD SCI USA, V92, P12041, DOI 10.1073/pnas.92.26.12041; BAZIL V, 1986, EUR J IMMUNOL, V16, P1583, DOI 10.1002/eji.1830161218; BEATY CD, 1994, EUR J IMMUNOL, V24, P1278, DOI 10.1002/eji.1830240606; CHEN CC, 1995, MOL PHARMACOL, V48, P39; Chen CC, 1997, FEBS LETT, V412, P30, DOI 10.1016/S0014-5793(97)00697-2; Chen CC, 1996, GLIA, V17, P63; CHEN CC, 1998, IN PRESS J IMMUNOL; DiazGuerra MJM, 1996, J BIOL CHEM, V271, P32028, DOI 10.1074/jbc.271.50.32028; DiazGuerra MJM, 1996, J BIOL CHEM, V271, P30114, DOI 10.1074/jbc.271.47.30114; DUBYAK GR, 1993, BIOCHEM J, V292, P121, DOI 10.1042/bj2920121; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; Feinstein DL, 1996, J BIOL CHEM, V271, P17724, DOI 10.1074/jbc.271.30.17724; FEINSTEIN DL, 1994, J NEUROCHEM, V62, P315; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; Galea E, 1996, J NEUROIMMUNOL, V64, P19, DOI 10.1016/0165-5728(95)00143-3; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GROSS AH, 1994, J CLIN INVEST, V93, P2684; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; HAZIOT A, 1988, J IMMUNOL, V141, P547; HORTELANO S, 1993, FEBS LETT, V320, P135, DOI 10.1016/0014-5793(93)80078-9; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Jaffrey SR, 1995, ANNU REV CELL DEV BI, V11, P417; Johnson DR, 1996, J BIOL CHEM, V271, P16317, DOI 10.1074/jbc.271.27.16317; Kong LY, 1996, BRAIN RES, V729, P102, DOI 10.1016/0006-8993(96)00417-9; LIN RF, 1993, J EXP MED, V178, P643, DOI 10.1084/jem.178.2.643; LIN SB, 1995, J BIOCHEM-TOKYO, V117, P1100, DOI 10.1093/oxfordjournals.jbchem.a124813; LIN SB, 1993, BIOTECHNIQUES, V14, P795; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; LYONS GR, 1992, J BIOL CHEM, V267, P6370; MERRILL JE, 1993, J IMMUNOL, V151, P2132; MITROVIC B, 1994, NEUROSCIENCE, V61, P575, DOI 10.1016/0306-4522(94)90435-9; MONCADA S, 1991, PHARMACOL REV, V43, P109; MURPHY S, 1993, TRENDS NEUROSCI, V16, P323, DOI 10.1016/0166-2236(93)90109-Y; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NUNOKAWA Y, 1993, BIOCHEM BIOPH RES CO, V191, P89, DOI 10.1006/bbrc.1993.1188; PAUL A, 1995, BRIT J PHARMACOL, V114, P482, DOI 10.1111/j.1476-5381.1995.tb13252.x; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SEVERN A, 1992, BIOCHEM BIOPH RES CO, V199, P461; SIMMONS ML, 1994, GLIA, V11, P227, DOI 10.1002/glia.440110303; STEFANOVA I, 1993, J BIOL CHEM, V268, P20725; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; XIE QW, 1994, J BIOL CHEM, V269, P4705	46	98	99	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19424	19430		10.1074/jbc.273.31.19424	http://dx.doi.org/10.1074/jbc.273.31.19424			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677361	hybrid			2022-12-25	WOS:000075125200013
J	Krishnan, K; Singh, B; Krolewski, JJ				Krishnan, K; Singh, B; Krolewski, JJ			Identification of amino acid residues critical for the Src-homology 2 domain-dependent docking of stat2 to the interferon alpha receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY PHOSPHOTYROSYL PEPTIDE; GAMMA SIGNAL-TRANSDUCTION; PROTEIN-TYROSINE KINASE; TRANSCRIPTION FACTOR; CRYSTAL-STRUCTURES; REGULATORY REGION; BETA RECEPTOR; SH2 DOMAIN; IFN-ALPHA; SUBUNIT	The interaction between Src-homology 2 domains (SH2) domains and phosphorylated tyrosine residues serves a critical role in intracellular signaling. In addition to the phosphotyrosine, adjacent residues are critical mediators of the specificity of this interaction, Upon treatment of cells with interferon alpha (IFN alpha), the IFNaR1 subunit of the IFN alpha receptor becomes tyrosine phosphorylated at position 466, The region surrounding phosphorylated tyrosine 466 subsequently acts as a docking site for the SH2 domain of Stat2, facilitating phosphorylation of the latter and, thus, the transduction of the IFNa signal, In this report site-specific mutagenesis was employed to analyze the nature of the interaction between the SH2 domain of Stat2 and the region surrounding tyrosine 466 on IFNaR1. Mutation of the valine at the +1 position carboxyl-terminal to tyrosine 466 or of the serine at the +5 position inhibits the association of Stat2 with phosphorylated IFNaR1, Moreover, receptors mutated at either of these two positions act in a dominant manner to decrease IFN alpha signaling, as assayed by both Stat2 phosphorylation and expression of an IFN alpha-responsive reporter. The demonstration that these two residues are critical in mediating the interaction between Stat2 and IFNaR1 suggests that STAT proteins might utilize a structurally distinct subset of SH2 domains to mediate signal transduction from the cell surface to the nucleus.	Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Irving Canc Ctr, New York, NY 10032 USA	Columbia University; Columbia University	Krolewski, JJ (corresponding author), Univ Calif Irvine, Dept Pathol, Med Sci D-440, Irvine, CA 92717 USA.	jkrolews@uci.edu			NATIONAL CANCER INSTITUTE [R01CA056862] Funding Source: NIH RePORTER; NCI NIH HHS [CA56862] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMOVICH C, 1994, EMBO J, V13, P5871, DOI 10.1002/j.1460-2075.1994.tb06932.x; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DEEN KC, 1988, NATURE, V331, P82, DOI 10.1038/331082a0; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; Domanski P, 1997, J BIOL CHEM, V272, P26388, DOI 10.1074/jbc.272.42.26388; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; Gibbs VC, 1996, J BIOL CHEM, V271, P28710, DOI 10.1074/jbc.271.45.28710; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; Gupta S, 1996, EMBO J, V15, P1075, DOI 10.1002/j.1460-2075.1996.tb00445.x; HELM MH, 1995, SCIENCE, V267, P1347; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; Improta T, 1997, CYTOKINE, V9, P383, DOI 10.1006/cyto.1996.0180; Krishnan K, 1996, ONCOGENE, V13, P125; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LUTFALLA G, 1995, EMBO J, V14, P5100, DOI 10.1002/j.1460-2075.1995.tb00192.x; MARENGERE LEM, 1994, J CELL SCI, P97; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; Pestka S, 1997, SEMIN ONCOL, V24, P918; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PLATANIAS LC, 1992, J BIOL CHEM, V267, P24053; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SOH JM, 1994, J BIOL CHEM, V269, P18102; SONG Y, 1994, PHYS PLASMAS, V1, P2777, DOI 10.1063/1.870513; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; Yan H, 1996, EMBO J, V15, P1064, DOI 10.1002/j.1460-2075.1996.tb00444.x; Yan H, 1996, MOL CELL BIOL, V16, P2074; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	44	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19495	19501		10.1074/jbc.273.31.19495	http://dx.doi.org/10.1074/jbc.273.31.19495			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677371	hybrid			2022-12-25	WOS:000075125200023
J	Okumura, K; Ohkura, N; Inoue, S; Ikeda, K; Hayashi, K				Okumura, K; Ohkura, N; Inoue, S; Ikeda, K; Hayashi, K			A novel phospholipase A(2) inhibitor with leucine-rich repeats from the blood plasma of Agkistrodon blomhoffii siniticus - Sequence homologies with human leucine-rich alpha(2)-glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE RIBONUCLEASE INHIBITOR; CROTALUS-DURISSUS-TERRIFICUS; THAILAND COBRA; 2 SUBUNITS; PROTEINS; RECEPTOR; MECHANISM; CLONING; SERUM	The phospholipase A(2) (PLA(2)) inhibitor FLIP, purified from the blood plasma of Chinese mamushi snake (Agkistrodon blomhoffii siniticus), is a 160-kDa trimer with three 50-kDa subunits; and it inhibits specifically the enzymatic activity of the basic PLA, from its own venom (Ohkura, N., Okuhara, H., Inoue, S., Ikeda, a, and Hayashi, K. (1997) Biochem. J. 325, 527-531), In the present study, the 50-kDa subunit was found to be glycosylated with N-linked carbohydrate, and enzymatic deglycosylation decreased the molecular mass of the 50-kDa subunit to 39-kDa, One 160-kDa trimer of FLIP was found to form a stable complex with three basic PLA, molecules, indicating that one basic PLA, molecule would bind stoichiometrically to one subunit of FLIP. A cDNA encoding FLIP was isolated from a Chinese mamushi liver cDNA library by use of a probe prepared by a polymerase chain reaction on the basis of the partially determined amino acid sequence of the subunit. The cDNA contained an open reading frame encoding a 23-residue signal sequence followed by a 308-residue protein, which contained the sequences of all the peptides derived by lysyl endopeptidase digestion of the subunit. The molecular mass of the mature protein was calculated to be 34,594 Da, and the deduced amino acid sequence contained four potential N-glycosylation sites. The sequence of FLIP showed no significant homology with that of the known PLA, inhibitors. But, interestingly, it exhibited 33% identity with that of human leucine-rich alpha(2)-glycoprotein, a serum protein of unknown function. The most striking feature of the sequence is that it contained nine leucine-rich repeats (LRRs), each of 24 amino acid residues and thus encompassing over two-thirds of the molecule. LRRs in FLIP might be responsible for the specific binding to basic PLA(2), since LRRs are considered as the motifs involved in protein-protein interactions.	Osaka Univ Pharmaceut Sci, Dept Biochem, Takatsuki, Osaka 5691094, Japan	Osaka University of Pharmaceutical Sciences	Inoue, S (corresponding author), Osaka Univ Pharmaceut Sci, Dept Biochem, Takatsuki, Osaka 5691094, Japan.	inoue@oysun01.oups.ac.jp	Inoue, Seiji/E-5128-2010	Inoue, Seiji/0000-0003-0760-1047				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BENSON DA, 1994, NUCLEIC ACIDS RES, V22, P3441, DOI 10.1093/nar/22.17.3441; CAVINS JF, 1970, ANAL BIOCHEM, V35, P489, DOI 10.1016/0003-2697(70)90211-3; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; EMMERT DB, 1994, NUCLEIC ACIDS RES, V22, P3445, DOI 10.1093/nar/22.17.3445; FORTESDIAS CL, 1994, J BIOL CHEM, V269, P15646; INOUE ES, 1997, BIOCHEM MOL BIOL INT, V41, P529; INOUE S, 1991, J BIOL CHEM, V266, P1001; ISHIZAKI J, 1994, J BIOL CHEM, V269, P5897; KINI RM, 1989, TOXICON, V27, P613, DOI 10.1016/0041-0101(89)90013-5; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KOBE B, 1995, CURR OPIN STRUC BIOL, V5, P409, DOI 10.1016/0959-440X(95)80105-7; KOGAKI H, 1989, J BIOCHEM-TOKYO, V106, P966, DOI 10.1093/oxfordjournals.jbchem.a122983; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; LEE FS, 1988, BIOCHEMISTRY-US, V27, P8545, DOI 10.1021/bi00423a007; OHKURA N, 1993, J BIOCHEM-TOKYO, V113, P413, DOI 10.1093/oxfordjournals.jbchem.a124060; OHKURA N, 1994, BIOCHEM BIOPH RES CO, V200, P784, DOI 10.1006/bbrc.1994.1519; Ohkura N, 1997, BIOCHEM J, V325, P527, DOI 10.1042/bj3250527; OHKURA N, 1994, BIOCHEM BIOPH RES CO, V204, P1212, DOI 10.1006/bbrc.1994.2592; PERALES J, 1995, EUR J BIOCHEM, V227, P19, DOI 10.1111/j.1432-1033.1995.tb20355.x; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; Sambrook KJ, 1989, MOL CLONING LAB MANU; TAKAHASHI N, 1985, P NATL ACAD SCI USA, V82, P1906, DOI 10.1073/pnas.82.7.1906; VICENTINI AM, 1990, BIOCHEMISTRY-US, V29, P8827, DOI 10.1021/bi00489a046; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5	28	44	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19469	19475		10.1074/jbc.273.31.19469	http://dx.doi.org/10.1074/jbc.273.31.19469			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677367	hybrid			2022-12-25	WOS:000075125200019
J	Chang, SH; Oh, CD; Yang, MS; Kang, SS; Lee, YS; Sonn, JK; Chun, JS				Chang, SH; Oh, CD; Yang, MS; Kang, SS; Lee, YS; Sonn, JK; Chun, JS			Protein kinase C regulates chondrogenesis of mesenchymes via mitogen-activated protein kinase signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIMB BUD MESENCHYME; CARTILAGE DIFFERENTIATION; N-CADHERIN; IN-VITRO; PATTERN-FORMATION; GENE-EXPRESSION; MAP KINASE; CELL-SHAPE; CHONDROCYTES; REQUIREMENT	A possible regulatory mechanism of protein kinase C (PKC) in the chondrogenesis of chick limb bud mesenchymes has been investigated. Inhibition or down-regulation of PRC resulted in the activation of a mitogen-activated protein kinase subtype Erk-1 and the inhibition of chondrogenesis, On the other hand, inhibition of Erk-1 with PD98059 enhanced chondrogenesis and relieved PKC-induced blockage of chondrogenesis, Erk-1 inhibition, however, did not affect expression and subcellular distribution of PKC isoforms expressed in mesenchymes nor cell proliferation The results suggest that PHC regulates chondrogenesis by modulating Erk-1 activity. Inhibition or depletion of PKC inhibited proliferation of chondrogenic competent cells, and Erk-1 inhibition did not affect PKC modulation of cell proliferation. However, PKC-induced modulation of expression of cell adhesion molecules involved in precartilage condensation was reversed by the inhibition of Erk-1, Expression of N-cadherin was detected at the early period of chondrogenesis, Inhibition or depletion of PKC induced sustained expression of N-cadherin, and Erk-1 inhibition blocked the effects of PKC modulation, The expression of integrin alpha 5 beta 1 and fibronectin was found to be increased transiently during chondrogenesis, Depletion or inhibition of PKC caused a continuous increase of the expression of these molecules throughout the culture period, and Erk-1 inhibition abolished the modulating effects of PKC, Because reduction of the examined cell adhesion molecule expression is a prerequisite for the progression of chondrogenesis after cell condensation, our results indicate that PKC regulates chondrogenesis by modulating expression of these molecules via Erk-1 signaling.	Kyungpook Natl Univ, Coll Nat Sci, Dept Biol, Pook Gu, Taegu 702701, South Korea; Kyungpook Natl Univ, Coll Nat Sci, Dept Biochem, Taegu 702701, South Korea; Kyungpook Natl Univ, Coll Teachers, Taegu 702701, South Korea	Kyungpook National University; Kyungpook National University; Kyungpook National University	Chun, JS (corresponding author), Kyungpook Natl Univ, Coll Nat Sci, Dept Biol, Pook Gu, Taegu 702701, South Korea.	jschun@bh.kyungpook.ac.kr		Oh, Chundo/0000-0002-5419-8011				ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; BOUAKKA M, 1988, BIOCHEM BIOPH RES CO, V153, P690, DOI 10.1016/S0006-291X(88)81150-1; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; CHOI B, 1995, BIOCHEM BIOPH RES CO, V216, P1034, DOI 10.1006/bbrc.1995.2724; Chun JS, 1996, J BIOL CHEM, V271, P13008, DOI 10.1074/jbc.271.22.13008; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DOWNIE SA, 1994, DEV BIOL, V162, P195, DOI 10.1006/dbio.1994.1078; Duprez DM, 1996, DEV BIOL, V174, P448, DOI 10.1006/dbio.1996.0087; FRENZ DA, 1989, DEV BIOL, V136, P97, DOI 10.1016/0012-1606(89)90133-4; GERSTENFELD LC, 1985, MOL CELL BIOL, V5, P1425, DOI 10.1128/MCB.5.6.1425; GOODNIGHT J, 1994, ADV CANCER RES, V64, P159, DOI 10.1016/S0065-230X(08)60838-6; GREGG BC, 1989, DEVELOPMENT, V105, P769; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Kim SJ, 1997, BIOCHEM BIOPH RES CO, V237, P336, DOI 10.1006/bbrc.1997.7061; Kulyk WM, 1996, EXP CELL RES, V223, P290, DOI 10.1006/excr.1996.0084; KULYK WM, 1991, DEV BIOL, V146, P38, DOI 10.1016/0012-1606(91)90444-8; MACKIE EJ, 1987, J CELL BIOL, V105, P2569, DOI 10.1083/jcb.105.6.2569; MAINI PK, 1991, INT REV CYTOL, V129, P91; Maleski MP, 1996, EXP CELL RES, V225, P55, DOI 10.1006/excr.1996.0156; MAMAJIWALLA SN, 1995, ONCOGENE, V11, P377; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OBERLENDER SA, 1994, DEVELOPMENT, V120, P177; RANSCHT B, 1994, CURR OPIN CELL BIOL, V6, P740, DOI 10.1016/0955-0674(94)90102-3; ROARK EF, 1994, DEV DYNAM, V200, P103, DOI 10.1002/aja.1002000203; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; SAVAGE MP, 1993, DEV DYNAM, V198, P159, DOI 10.1002/aja.1001980302; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Solursh M, 1989, CURR OPIN CELL BIOL, V1, P989, DOI 10.1016/0955-0674(89)90070-7; SONN JK, 1993, DIFFERENTIATION, V53, P155, DOI 10.1111/j.1432-0436.1993.tb00704.x; TAKIGAWA M, 1983, CELL DIFFER DEV, V13, P283, DOI 10.1016/0045-6039(83)90038-6; Tavella S, 1997, J CELL SCI, V110, P2261; TAVELLA S, 1994, EXP CELL RES, V215, P354, DOI 10.1006/excr.1994.1352; TSONIS PA, 1994, EXP CELL RES, V213, P433, DOI 10.1006/excr.1994.1220; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; ZANETTI NC, 1986, DEV BIOL, V113, P110, DOI 10.1016/0012-1606(86)90113-2	40	83	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19213	19219		10.1074/jbc.273.30.19213	http://dx.doi.org/10.1074/jbc.273.30.19213			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668109	hybrid			2022-12-25	WOS:000074974700076
J	Karlsson, K; Carlsson, SR				Karlsson, K; Carlsson, SR			Sorting of lysosomal membrane glycoproteins lamp-1 and lamp-2 into vesicles distinct from mannose 6-phosphate receptor/gamma-adaptin vesicles at the trans-Golgi network	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY INTERACTION; ADP-RIBOSYLATION FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; CYTOPLASMIC DOMAIN; ASSEMBLY PROTEINS; TARGETING SIGNAL; CELLS; BIOSYNTHESIS; LOCALIZATION; WORTMANNIN	Newly synthesized lysosomal membrane glycoproteins lamp-1 and lamp-2 are primarily sorted at the trans-Golgi network (TGN) by recognition of a tyrosine-based signal sequence in their cytoplasmic tails. It is presently unclear how this signal is recognized and what type of vesicle transports lamp-1 and lamp-2. Here, we describe a method to generate transport vesicles containing lamp proteins from the TGN in vitro. The method is based on incorporation of radioactive sialic acid in glycoproteins at the TGN by incubation of membranes with tritiated CMP-sialic acid. The generation of vesicles from labeled membranes required ATP and cytosol, and was temperature-dependent and brefeldin A-sensitive. Analysis on Nycodenz gradients revealed that lamp-vesicles were distinct from vesicles containing gamma-adaptin and mannose B-phosphate receptor (MPR), Moreover, both these types of vesicles migrated differently than vesicles containing proteins destined for the plasma membrane. The conclusion that lamps and MPRs are sorted into different vesicles was further strengthened by the finding that whereas wortmannin both in vitro and in vivo inhibited the production of gamma-adaptin/MPR-containing vesicles, this drug had no effect on the generation of lamp-vesicles and on the sorting of lamps. The results indicate that membrane proteins containing tyrosine-based motifs for sorting at the TGN are segregated from clathrin-coated vesicles containing MPRs.	Umea Univ, Dept Med Biochem & Biophys, S-90187 Umea, Sweden	Umea University	Carlsson, SR (corresponding author), Umea Univ, Dept Med Biochem & Biophys, S-90187 Umea, Sweden.	sven.carlsson@medkem.umu.se		Carlsson, Sven R/0000-0001-5123-135X				Abeijon C, 1997, TRENDS BIOCHEM SCI, V22, P203, DOI 10.1016/S0968-0004(97)01053-0; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; Borregaard N, 1997, BLOOD, V89, P3503, DOI 10.1182/blood.V89.10.3503.3503_3503_3521; Brodsky FM, 1997, TRENDS CELL BIOL, V7, P175, DOI 10.1016/S0962-8924(97)01038-6; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; CARLSSON SR, 1986, J BIOL CHEM, V261, P2779; CARLSSON SR, 1988, J BIOL CHEM, V263, P18911; CARLSSON SR, 1992, ARCH BIOCHEM BIOPHYS, V296, P630, DOI 10.1016/0003-9861(92)90619-8; Chen HJ, 1997, J BIOL CHEM, V272, P7003, DOI 10.1074/jbc.272.11.7003; Cieutat AM, 1998, BLOOD, V91, P1044, DOI 10.1182/blood.V91.3.1044.1044_1044_1058; COLLINS SJ, 1987, BLOOD, V70, P1233; Cowles CR, 1997, EMBO J, V16, P2769, DOI 10.1093/emboj/16.10.2769; DAHLGREN C, 1995, BIOCHEM J, V311, P667, DOI 10.1042/bj3110667; DAVIDSON HW, 1995, J CELL BIOL, V130, P797, DOI 10.1083/jcb.130.4.797; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; DSOUZA MP, 1986, ARCH BIOCHEM BIOPHYS, V249, P522, DOI 10.1016/0003-9861(86)90030-5; FUKUDA M, 1988, J BIOL CHEM, V263, P18920; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; Gaffet P, 1997, J BIOL CHEM, V272, P24170, DOI 10.1074/jbc.272.39.24170; GIESELMANN V, 1983, J CELL BIOL, V97, P1, DOI 10.1083/jcb.97.1.1; GRAHAM JM, 1988, BIOCHEM J, V252, P437, DOI 10.1042/bj2520437; GREEN SA, 1987, J CELL BIOL, V105, P1227, DOI 10.1083/jcb.105.3.1227; GUARNIERI FG, 1993, J BIOL CHEM, V268, P1941; HONING S, 1995, J CELL BIOL, V128, P321, DOI 10.1083/jcb.128.3.321; Honing S, 1996, EMBO J, V15, P5230, DOI 10.1002/j.1460-2075.1996.tb00908.x; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; Keller P, 1997, J CELL SCI, V110, P3001; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; KOEFFLER HP, 1980, BLOOD, V56, P344; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; Kundra A, 1998, J BIOL CHEM, V273, P3848, DOI 10.1074/jbc.273.7.3848; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LeBorgne R, 1996, J BIOL CHEM, V271, P2162; LeBorgne R, 1997, J CELL BIOL, V137, P335; LeCabec V, 1997, BLOOD, V89, P2113, DOI 10.1182/blood.V89.6.2113; LEYTE A, 1992, EMBO J, V11, P4795, DOI 10.1002/j.1460-2075.1992.tb05585.x; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; MARSH M, 1987, J CELL BIOL, V104, P875, DOI 10.1083/jcb.104.4.875; Martys JL, 1996, J BIOL CHEM, V271, P10953, DOI 10.1074/jbc.271.18.10953; MATHEWS PM, 1992, J CELL BIOL, V118, P1027, DOI 10.1083/jcb.118.5.1027; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; NABI IR, 1991, J CELL BIOL, V115, P1573, DOI 10.1083/jcb.115.6.1573; Nakajima Y, 1997, MOL BIOL CELL, V8, P577, DOI 10.1091/mbc.8.4.577; NICKEL W, 1994, J CELL BIOL, V125, P721, DOI 10.1083/jcb.125.4.721; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; Reaves BJ, 1996, J CELL SCI, V109, P749; ROTH J, 1986, J BIOL CHEM, V261, P14307; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; Roth MG, 1997, CURR OPIN CELL BIOL, V9, P519, DOI 10.1016/S0955-0674(97)80028-2; SCHACHTER H, 1983, METHOD ENZYMOL, V98, P98; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Shepherd PR, 1996, TRENDS CELL BIOL, V6, P92, DOI 10.1016/0962-8924(96)80998-6; Traub LM, 1997, CURR OPIN CELL BIOL, V9, P527, DOI 10.1016/S0955-0674(97)80029-4; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; WILSON AP, 1992, J IMMUNOL, V148, P1777; WimerMackin S, 1996, BIOCHEM BIOPH RES CO, V229, P472, DOI 10.1006/bbrc.1996.1828	62	70	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18966	18973		10.1074/jbc.273.30.18966	http://dx.doi.org/10.1074/jbc.273.30.18966			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668075	hybrid			2022-12-25	WOS:000074974700042
J	Rezzonico, R; Burger, D; Dayer, JM				Rezzonico, R; Burger, D; Dayer, JM			Direct contact between T lymphocytes and human dermal fibroblasts or synoviocytes down-regulates types I and III collagen production via cell-associated cytokines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FIBRONECTIN GENE-EXPRESSION; PROCOLLAGEN MESSENGER-RNAS; GROWTH-FACTOR-BETA; INTERFERON-GAMMA; FACTOR-ALPHA; PRO-ALPHA-1(I) COLLAGEN; SYNOVIAL FIBROBLASTS; ADHESION MOLECULES; ENDOTHELIAL-CELLS	In many inflammatory diseases where tissue remodeling occurs, T cells are in close contact with mesenchymal cells. We investigated the effect of direct cell-cell contact between peripheral blood T lymphocytes or HUT-78 lymphoma cells and dermal fibroblasts or synoviocytes on the deposition of the major extracellular matrix components: types I and III collagen. Incubation of dermal fibroblasts and synoviocytes with plasma membrane preparations from resting T cells slightly increased the production of collagen I but did not significantly affect that of collagen III. Conversely, direct contact with either plasma membranes or fixed phytohemagglutinin/phorbol myristate acetate activated T cells markedly inhibited the synthesis of types I and III collagen by 60-70% in untreated dermal fibroblasts and synoviocytes and by 85% in transforming growth factor beta-stimulated fibroblasts. This decrease of collagen synthesis was abrogated when fixed T cells were separated physically hom fibroblasts, demonstrating that direct contact between the two cell types was necessary. This inhibition was associated with a marked decrease in steady-state levels of pro-alpha 1(I) and pro-alpha 1(III) collagen mRNAs. T cell contact decreased the transcription rate but did not significantly alter the stability of the alpha 1(I) and alpha 1(III) transcripts. Finally, using neutralizing antibodies or cytokine inhibitors we provide evidence that this inhibition of extracellular matrix production mediated by T cell contact was partially due to additive effects of T cell membrane-associated interferon gamma, tumor necrosis factor alpha, and interleukin-1 alpha.	Univ Geneva, Hop Cantonal, Unite Immunol Clin,Dept Internal Med, Div Immunol & Allergy,Hans Wilsdorf Lab, CH-1211 Geneva 14, Switzerland	University of Geneva	Rezzonico, R (corresponding author), Univ Geneva, Hop Cantonal, Unite Immunol Clin,Dept Internal Med, Div Immunol & Allergy,Hans Wilsdorf Lab, CH-1211 Geneva 14, Switzerland.		REZZONICO, Roger/N-9626-2016; Burger, Danielle/A-1996-2008	REZZONICO, Roger/0000-0002-8460-1641; 				ABRAHAM D, 1991, ARTHRITIS RHEUM, V34, P1164, DOI 10.1002/art.1780340913; Assenmacher M, 1996, EUR J IMMUNOL, V26, P263, DOI 10.1002/eji.1830260141; AVERSA G, 1993, J EXP MED, V177, P1575, DOI 10.1084/jem.177.6.1575; BERNARD MP, 1983, BIOCHEMISTRY-US, V22, P1139, DOI 10.1021/bi00274a023; BOMBARA MP, 1993, J LEUKOCYTE BIOL, V54, P399, DOI 10.1002/jlb.54.5.399; BURGER D, 1998, IN PRESS ARTHRITIS R; CHIZZOLINI C, 1988, IN PRESS ARTHRITIS R; CHU ML, 1982, NUCLEIC ACIDS RES, V10, P5925, DOI 10.1093/nar/10.19.5925; CHU ML, 1985, J BIOL CHEM, V260, P4357; COLIGE AC, 1992, BIOCHEM J, V285, P215, DOI 10.1042/bj2850215; CZAJA MJ, 1987, J BIOL CHEM, V262, P13348; DAYER JM, 1976, P NATL ACAD SCI USA, V73, P945, DOI 10.1073/pnas.73.3.945; DHAWAN J, 1991, J BIOL CHEM, V266, P8470; Diaz A, 1997, INT J BIOCHEM CELL B, V29, P251, DOI 10.1016/S1357-2725(96)00112-4; DIAZ A, 1993, J BIOL CHEM, V268, P10364; Eckes B, 1996, BIOCHEM J, V315, P549, DOI 10.1042/bj3150549; ELIAS JA, 1990, ANN NY ACAD SCI, V580, P233, DOI 10.1111/j.1749-6632.1990.tb17932.x; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GAZDAR AF, 1980, BLOOD, V55, P409; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GOLDRING S R, 1981, Arthritis and Rheumatism, V24, pS106; GONZALEZAMARO R, 1988, CLIN IMMUNOL IMMUNOP, V46, P412, DOI 10.1016/0090-1229(88)90060-8; GRANSTEIN RD, 1990, J INVEST DERMATOL, V95, pS75, DOI 10.1111/1523-1747.ep12874789; HAYNES BF, 1988, ARTHRITIS RHEUM, V31, P947, DOI 10.1002/art.1780310802; HIBBS MS, 1983, J EXP MED, V157, P47, DOI 10.1084/jem.157.1.47; Ichiki Y, 1997, J RHEUMATOL, V24, P90; KAHARI VM, 1990, J CLIN INVEST, V86, P1489, DOI 10.1172/JCI114866; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; Korn J., 1997, TXB RHEUMATOLOGY, P199; KOVACS EJ, 1994, FASEB J, V8, P854, DOI 10.1096/fasebj.8.11.7520879; KRANE SM, 1984, EXTRACELLULAR MATRIX, P413; KRZESICKI RF, 1991, ARTHRITIS RHEUM-US, V34, P1245, DOI 10.1002/art.1780341007; KURTJONES EA, 1987, J IMMUNOL, V139, P2317; LAFEBER FPJG, 1992, AM J PATHOL, V140, P1421; Langholz O, 1995, J CELL BIOL, V131, P1903, DOI 10.1083/jcb.131.6.1903; Lou J, 1996, EUR J IMMUNOL, V26, P3107, DOI 10.1002/eji.1830261242; MAJORS AK, 1992, EXP CELL RES, V200, P168, DOI 10.1016/S0014-4827(05)80085-0; MAUVIEL A, 1991, J CELL BIOL, V113, P1455, DOI 10.1083/jcb.113.6.1455; MAUVIEL A, 1994, J BIOL CHEM, V269, P25; MCCACHREN SS, 1991, ARTHRITIS RHEUM-US, V34, P1085; MILTENBURG AMM, 1995, J IMMUNOL, V154, P2655; Nakatsuka K, 1997, J RHEUMATOL, V24, P458; PANAYI GS, 1992, ARTHRITIS RHEUM-US, V35, P729, DOI 10.1002/art.1780350702; Parry SL, 1997, J IMMUNOL, V158, P3673; PENTTINEN RP, 1988, P NATL ACAD SCI USA, V85, P1105, DOI 10.1073/pnas.85.4.1105; POSTLETHWAITE AE, 1988, J CELL BIOL, V106, P311, DOI 10.1083/jcb.106.2.311; POSTLETHWAITE AE, 1993, DERMAL IMMUNE SYSTEM, P163; PROCKOP DJ, 1984, NEW ENGL J MED, V311, P376, DOI 10.1056/NEJM198408093110606; REZZONICO R, 1995, J BIOL CHEM, V270, P1261, DOI 10.1074/jbc.270.3.1261; ROUX M, 1995, ARCH DERMATOL, V287, P401; Sebbag M, 1997, EUR J IMMUNOL, V27, P624, DOI 10.1002/eji.1830270308; Sporri B, 1996, CYTOKINE, V8, P631, DOI 10.1006/cyto.1996.0084; Tak PP, 1997, ARTHRITIS RHEUM, V40, P217, DOI 10.1002/art.1780400206; Unemori EN, 1996, J CLIN INVEST, V98, P2739, DOI 10.1172/JCI119099; VANDELOO FAJ, 1995, ARTHRITIS RHEUM, V38, P164; VARGA J, 1990, EUR J CLIN INVEST, V20, P487, DOI 10.1111/j.1365-2362.1990.tb01915.x; VARGA J, 1987, BIOCHEM BIOPH RES CO, V147, P1282, DOI 10.1016/S0006-291X(87)80209-7; VEY E, 1992, J IMMUNOL, V149, P2040	58	61	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18720	18728		10.1074/jbc.273.30.18720	http://dx.doi.org/10.1074/jbc.273.30.18720			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668044	hybrid			2022-12-25	WOS:000074974700011
J	Thompson, SJ; Kim, SJ; Robinson, C				Thompson, SJ; Kim, SJ; Robinson, C			Sec-independent insertion of thylakoid membrane proteins - Analysis of insertion forces and identification of a loop intermediate involving the signal peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; INNER MEMBRANE; PROCESSING PEPTIDASE; PROCOAT PROTEIN; TRANSIT PEPTIDE; PHOTOSYSTEM-II; TRANSPORT; TRANSLOCATION; INTEGRATION; BACTERIOPHAGE-M13	A group of membrane proteins are synthesized with cleavable signal sequences but inserted into the thylakoid membrane by an unusual Sec/SRP-independent mechanism. In this report we describe a key intermediate in the insertion of one such protein, photosystem II subunit W (PSII-W). A single mutation in the terminal cleavage site partially blocks processing mid leads to the formation of an intermediate-size protein in the thylakoid membrane during chloroplast import assays. This protein is in the form of a loop structure: the N and C termini are exposed on the stromal face, whereas the cleavage site has been translocated into the lumen. In this respect the insertion of this protein resembles that of M13 procoat, which also adopts a loop structure during insertion, and we present preliminary evidence that a similar mechanism is used by another thylakoid protein, PSII-X. However, whereas the negative ly charged region of procoat is translocated by an apparently electrophoretic mechanism using the Delta mu H+, the corresponding region of PSII-W is equally acidic but insertion is Delta mu H+ independent, We furthermore show th.at neutralization of this region has no apparent effect on the insertion process. We propose that a central element in this insertion mechanism is a loop structure whose formation is driven by hydrophobic interactions.	Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England	University of Warwick	Robinson, C (corresponding author), Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England.			Thompson, Simon/0000-0003-0769-8555				ANDERSSON H, 1993, EMBO J, V12, P683, DOI 10.1002/j.1460-2075.1993.tb05702.x; BRASSILANA M, 1996, EMBO J, V15, P5202; CAO GQ, 1995, EMBO J, V14, P866, DOI 10.1002/j.1460-2075.1995.tb07068.x; CHADDOCK AM, 1995, EMBO J, V14, P2715, DOI 10.1002/j.1460-2075.1995.tb07272.x; Cline K, 1996, ANNU REV CELL DEV BI, V12, P1, DOI 10.1146/annurev.cellbio.12.1.1; DATE T, 1980, P NATL ACAD SCI-BIOL, V77, P4669, DOI 10.1073/pnas.77.8.4669; DeGier JWL, 1997, FEBS LETT, V408, P1, DOI 10.1016/S0014-5793(97)00402-X; Fincher V, 1998, FEBS LETT, V423, P66, DOI 10.1016/S0014-5793(98)00066-0; GALLUSSER A, 1990, EMBO J, V9, P2723, DOI 10.1002/j.1460-2075.1990.tb07459.x; GEBERT JF, 1988, J BIOL CHEM, V263, P16652; GOUNARIS K, 1983, BIOCHIM BIOPHYS ACTA, V728, P129, DOI 10.1016/0005-2736(83)90445-5; HENRY R, 1994, J BIOL CHEM, V269, P10189; HERRMANN RG, 1993, FEBS LETT, V326, P192, DOI 10.1016/0014-5793(93)81789-3; High S, 1997, J BIOL CHEM, V272, P11622; Kiefer D, 1997, EMBO J, V16, P2197, DOI 10.1093/emboj/16.9.2197; Kim SJ, 1998, FEBS LETT, V424, P105, DOI 10.1016/S0014-5793(98)00148-3; Kim SJ, 1996, FEBS LETT, V390, P175, DOI 10.1016/0014-5793(96)00658-8; KIRWIN PM, 1988, J BIOL CHEM, V263, P18128; KUHN A, 1994, EUR J BIOCHEM, V226, P891, DOI 10.1111/j.1432-1033.1994.00891.x; KUHN A, 1990, EMBO J, V9, P2385, DOI 10.1002/j.1460-2075.1990.tb07413.x; KUHN A, 1995, FEMS MICROBIOL REV, V17, P185; LAMPPA GK, 1988, J BIOL CHEM, V263, P14996; LI XX, 1995, P NATL ACAD SCI USA, V92, P3789, DOI 10.1073/pnas.92.9.3789; LORKOVIC ZJ, 1995, P NATL ACAD SCI USA, V92, P8930, DOI 10.1073/pnas.92.19.8930; Robinson C, 1997, TRENDS PLANT SCI, V2, P431, DOI 10.1016/S1360-1385(97)90027-3; ROBINSON C, 1994, EMBO J, V13, P279, DOI 10.1002/j.1460-2075.1994.tb06260.x; Robinson D, 1996, PLANT J, V10, P149, DOI 10.1046/j.1365-313X.1996.10010149.x; SAAF A, 1995, MOL MEMBR BIOL, V12, P209, DOI 10.3109/09687689509027509; SHACKLETON JB, 1991, J BIOL CHEM, V266, P12152; Traxler B, 1996, J BIOL CHEM, V271, P12394, DOI 10.1074/jbc.271.21.12394; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; VIITANEN PV, 1988, J BIOL CHEM, V263, P15000; VONHEIJNE G, 1994, ANNU REV BIOPH BIOM, V23, P167; WOLFE PB, 1985, J BIOL CHEM, V260, P1836	34	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18979	18983		10.1074/jbc.273.30.18979	http://dx.doi.org/10.1074/jbc.273.30.18979			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668077	hybrid			2022-12-25	WOS:000074974700044
J	Yamaguchi, H; Hara, M; Strobeck, M; Fukasawa, K; Schwartz, A; Varadi, G				Yamaguchi, H; Hara, M; Strobeck, M; Fukasawa, K; Schwartz, A; Varadi, G			Multiple modulation pathways of calcium channel activity by a beta subunit - Direct evidence of beta subunit participation in membrane trafficking of the alpha(1c) subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ CHANNELS; XENOPUS OOCYTES; CHARGE MOVEMENT; IONIC CURRENT; HUMAN HEART; CELLS; INACTIVATION; EXPRESSION; CLONING; ALPHA(1)-SUBUNIT	In order to study the precise mechanisms of alpha(1) subunit modulation by an auxiliary beta subunit of voltage-dependent calcium channels, a recombinant beta(3) subunit fusion protein was produced and introduced into oocytes that express the human alpha(1C) subunit. Injection of the beta 3 subunit protein rapidly modulated the current kinetics and voltage dependence of activation, whereas massive augmentation of peak current amplitude occurred over a longer time scale. Consistent with the latter, a severalfold increase in the amount of the alpha(1C) subunit in the plasma membrane was detected by quantitative confocal laser-scanning microscopy after beta(3) subunit injection, Pretreatment of oocytes with bafilomycin A(1), a vacuolar type H+-ATPase inhibitor, abolished the increase of the alpha(1C) subunit in the plasma membrane, attenuated current increase, but did not affect the modulation of current kinetics and voltage dependence by the beta(3) subunit. These results provide clear evidence that the beta subunit modifies the calcium channel complex in a binary fashion; one is an allosteric modulation of the alpha(1) subunit function and the other is a chaperoning of the alpha(1) subunit to the plasma membrane.	Univ Cincinnati, Inst Mol Pharmacol & Biophys, Coll Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Varadi, G (corresponding author), Univ Cincinnati, Inst Mol Pharmacol & Biophys, Coll Med, 231 Bethesda Ave,POB 670828, Cincinnati, OH 45267 USA.	varadig@email.uc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022619] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL22619-19] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; Brice NL, 1997, EUR J NEUROSCI, V9, P749, DOI 10.1111/j.1460-9568.1997.tb01423.x; CASTELLANO A, 1993, J BIOL CHEM, V268, P3450; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; CHIEN AJ, 1995, J BIOL CHEM, V270, P30036; DEWAARD M, 1995, J PHYSIOL-LONDON, V485, P619, DOI 10.1113/jphysiol.1995.sp020757; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; DEWAARD M, 1995, J BIOL CHEM, V270, P12056, DOI 10.1074/jbc.270.20.12056; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; Gurnett CA, 1996, J BIOL CHEM, V271, P27975, DOI 10.1074/jbc.271.45.27975; Hosey MM, 1996, TRENDS CARDIOVAS MED, V6, P265, DOI 10.1016/S1050-1738(96)00109-0; Josephson IR, 1996, BIOPHYS J, V70, P1285, DOI 10.1016/S0006-3495(96)79685-6; Kamp TJ, 1996, J PHYSIOL-LONDON, V492, P89, DOI 10.1113/jphysiol.1996.sp021291; KLOCKNER U, 1995, J BIOL CHEM, V270, P17306, DOI 10.1074/jbc.270.29.17306; LORY P, 1993, FEBS LETT, V315, P167, DOI 10.1016/0014-5793(93)81156-T; MORI Y, 1991, NATURE, V350, P159; NEELY A, 1995, AM J PHYSIOL-CELL PH, V268, pC732, DOI 10.1152/ajpcell.1995.268.3.C732; NEELY A, 1993, SCIENCE, V262, P575, DOI 10.1126/science.8211185; NISHIMURA S, 1993, FEBS LETT, V324, P283, DOI 10.1016/0014-5793(93)80135-H; OLCESE R, 1994, NEURON, V13, P1433, DOI 10.1016/0896-6273(94)90428-6; PEREZGARCIA MT, 1995, J GEN PHYSIOL, V105, P289, DOI 10.1085/jgp.105.2.289; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; SCHULTZ D, 1993, P NATL ACAD SCI USA, V90, P6228, DOI 10.1073/pnas.90.13.6228; SHISTIK E, 1995, J PHYSIOL-LONDON, V489, P55, DOI 10.1113/jphysiol.1995.sp021029; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; TANG SQ, 1993, NEURON, V11, P1013, DOI 10.1016/0896-6273(93)90215-D; Tareilus E, 1997, P NATL ACAD SCI USA, V94, P1703, DOI 10.1073/pnas.94.5.1703; UMATA T, 1990, J BIOL CHEM, V265, P21940; VARADI G, 1995, TRENDS PHARMACOL SCI, V16, P43, DOI 10.1016/S0165-6147(00)88977-4; VARADI G, 1991, NATURE, V352, P159, DOI 10.1038/352159a0; WAKAMORI M, 1993, BIOCHEM BIOPH RES CO, V196, P1170, DOI 10.1006/bbrc.1993.2374; Walker D, 1998, J BIOL CHEM, V273, P2361, DOI 10.1074/jbc.273.4.2361; WELLING A, 1993, CIRC RES, V73, P974, DOI 10.1161/01.RES.73.5.974; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4	35	78	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19348	19356		10.1074/jbc.273.30.19348	http://dx.doi.org/10.1074/jbc.273.30.19348			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668125	hybrid			2022-12-25	WOS:000074974700092
J	Hehner, SP; Hofmann, TG; Ratter, F; Dumont, A; Droge, W; Schmitz, ML				Hehner, SP; Hofmann, TG; Ratter, F; Dumont, A; Droge, W; Schmitz, ML			Tumor necrosis factor-alpha-induced cell killing and activation of transcription factor NF-kappa B are uncoupled in L929 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED APOPTOSIS; DEATH; IMMUNOSUPPRESSION; GLUCOCORTICOIDS; INHIBITION; RECEPTOR	The induction of transcription factor NF-kappa B has been shown to counteract tumor necrosis factor (TNF)-alpha-induced cell death in various cell types. In this study, we investigated the role of NF-kappa B for TNF-alpha-triggered cell death in the widely used mouse cell line L929 by various approaches. Inhibition of the mitochondrial permeability transition by bongkrekic acid impaired TNF-alpha-induced cell death without affecting the activity of NF-kappa B. The reduction of NF-kappa B-mediated gene expression by the synthetic steroid dexamethasone was associated with a decrease in TNF-alpha-mediated cell killing, suggesting that NF-KB does not protect L929 cells from TNF-alpha-induced cell death. This concept was reinforced by experiments employing L929 cell lines stably overexpressing a transdominant negative form of I kappa B-alpha. These cell lines were unable to activate NF-kappa B and to inducibly express the IL-6 gene, but they showed the same susceptibility toward TNF-alpha-mediated cell death as L929 wild-type cells.	German Canc Res Ctr, Dept Immunochem, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Schmitz, ML (corresponding author), German Canc Res Ctr, Dept Immunochem, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Schmitz, M. Lienhard/D-9328-2017	Schmitz, M. Lienhard/0000-0002-6984-7192				ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BAICHWAL WR, 1997, CURR BIOL, V7, pR94; Baker SJ, 1996, ONCOGENE, V12, P1; Barkett M, 1997, J BIOL CHEM, V272, P29419, DOI 10.1074/jbc.272.47.29419; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Cai ZZ, 1997, J BIOL CHEM, V272, P96; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; DeBosscher K, 1997, P NATL ACAD SCI USA, V94, P13504, DOI 10.1073/pnas.94.25.13504; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; Hehner SP, 1998, J BIOL CHEM, V273, P1288, DOI 10.1074/jbc.273.3.1288; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Schmitz ML, 1996, MOL CELL BIOL, V16, P4052; Sha WC, 1998, J EXP MED, V187, P143, DOI 10.1084/jem.187.2.143; Siebenlist U., 1997, BIOCHIMICA BIOPHYSIC, V1332, P7; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Vandevoorde V, 1997, J CELL BIOL, V137, P1627, DOI 10.1083/jcb.137.7.1627; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Wallach D, 1997, FEBS LETT, V410, P96, DOI 10.1016/S0014-5793(97)00553-X; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	29	41	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18117	18121		10.1074/jbc.273.29.18117	http://dx.doi.org/10.1074/jbc.273.29.18117			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660769	hybrid			2022-12-25	WOS:000074828500024
J	Xu, H; Lee, KW; Goldfarb, M				Xu, H; Lee, KW; Goldfarb, M			Novel recognition motif on fibroblast growth factor receptor mediates direct association and activation of SNT adapter proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRS-1 PTB DOMAIN; INSULIN-RECEPTOR; BETA-RECEPTOR; SH2 DOMAINS; PC12 CELLS; BINDING; RAS; SUBSTRATE-1; DIFFERENTIATION; STIMULATION	Fibroblast growth factors (FGFs) stimulate tyrosine phosphorylation of a membrane-anchored adapter protein, FRS2/SNT-1, promoting its association with Shp-2 tyrosine phosphatase and upstream activators of Ras, Using the yeast two-hybrid protein-protein interaction assay, we show that FRS2/SNT-1 and a newly isolated SNT-2 protein directly bind to FGF receptor-1 (FGFR-1). A juxtamembrane segment of FGFR-1 and the phosphotyrosine-binding domain of SNTs are both necessary and sufficient for interaction in yeast and in vitro, and FGFR-mediated SNT tyrosine phosphorylation in vivo requires these segments of receptor and SNT. Our findings establish SNTs as direct protein links between FGFR-1 and multiple downstream pathways. The SNT binding motif of FGFR-1 is distinct from previously described phosphotyrosine-binding domain recognition motifs, lacking both tyrosine and asparagine residues.	CUNY Mt Sinai Sch Med, Brookdale Ctr Dev & Mol Biol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Grad Program Mol Cellular Biochem & Dev Sci, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Goldfarb, M (corresponding author), CUNY Mt Sinai Sch Med, Brookdale Ctr Dev & Mol Biol, Box 1126,1 Gustave Levy Pl, New York, NY 10029 USA.		Lee, Kyung/AAD-5009-2021	Lee, Kyung/0000-0002-9756-1765	NIGMS NIH HHS [R21-GM55666, T32-GM08553] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008553, R21GM055666] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; Borg JP, 1996, MOL CELL BIOL, V16, P6229; CASE RD, 1994, J BIOL CHEM, V269, P10467; CASTAGNINO P, 1995, ONCOGENE, V10, P723; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; Li SC, 1997, P NATL ACAD SCI USA, V94, P7204, DOI 10.1073/pnas.94.14.7204; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; MARGOLIS B, 1994, J AM SOC NEPHROL, V5, P1288; Margolis B, 1996, J LAB CLIN MED, V128, P235, DOI 10.1016/S0022-2143(96)90022-0; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; Ong SH, 1997, BIOCHEM BIOPH RES CO, V238, P261, DOI 10.1006/bbrc.1997.7272; PAWSON T, 1994, ADV CANCER RES, V64, P87, DOI 10.1016/S0065-230X(08)60835-0; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TAKABE Y, 1988, MOL CELL BIOL, V8, P466; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; VOLIOVITCH H, 1995, J BIOL CHEM, V270, P18083, DOI 10.1074/jbc.270.30.18083; Wang JK, 1996, ONCOGENE, V13, P721; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; White MF, 1998, CURR TOP MICROBIOL, V228, P179; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; Zhou MM, 1996, NAT STRUCT BIOL, V3, P388, DOI 10.1038/nsb0496-388; ZHOU S, 1995, J BIOL CHEM, V270, P14863	31	141	149	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					17987	17990		10.1074/jbc.273.29.17987	http://dx.doi.org/10.1074/jbc.273.29.17987			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660748	hybrid			2022-12-25	WOS:000074828500003
J	Felberg, J; Johnson, P				Felberg, J; Johnson, P			Characterization of recombinant CD45 cytoplasmic domain proteins - Evidence for intramolecular and intermolecular interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE-ACTIVITY; PHOSPHOTYROSINE PHOSPHATASE; CATALYTIC DOMAINS; KINASE PP56LCK; SH2 DOMAINS; RECEPTOR; ACTIVATION; PHOSPHORYLATION; EXPRESSION; PURIFICATION	CD45 is a transmembrane two-domain tyrosine phosphatase required for efficient signal transduction initiated by lymphocyte antigen receptors. As with most transmembrane two-domain phosphatases, the role of the second phosphatase domain is unclear. In this study, recombinant CD45 cytoplasmic domain proteins purified from bacteria were used to evaluate the function of the individual phosphatase domains, A recombinant protein expressing the membrane-proximal region, first phosphatase domain, and spacer region of CD45 (rD1) was catalytically active and found to exist primarily as a dimer, In contrast to this, a recombinant protein expressing the spacer region, the second phosphatase do main and the carboxy tail of CD45 (rD2) existed as a monomer and had no catalytic activity against any of the substrates tested, Comparison of rD1 with the recombinant protein expressing the entire cytoplasmic domain of CD45 (rD1/D2) indicated that rD1/D2 was 2-3-fold more catalytically active, was more thermostable, and existed primarily as a monomer, Limited trypsin digestion of rD1/D2 provided evidence for a noncovalent association between an N-terminal 27-kDa fragment and a C-terminal 53-kDa fragment, suggesting an intramolecular interaction. Furthermore, rD1 was found to specifically associate with rD2 in an in vitro binding assay. Taken together, these data provide evidence for an intramolecular interaction occurring in the cytoplasmic domain of CD45. In the absence of the C-terminal region containing the second phosphatase domain, intermolecular interactions occur, resulting in dimer formation.	Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Johnson, P (corresponding author), Univ British Columbia, Dept Microbiol & Immunol, 300-6174 Univ Blvd, Vancouver, BC V6T 1Z3, Canada.		Johnson, Pauline/G-9659-2019	Johnson, Pauline/0000-0001-7367-4653				AUTERO M, 1994, MOL CELL BIOL, V14, P1308, DOI 10.1128/MCB.14.2.1308; BARFORD D, 1995, NAT STRUCT BIOL, V2, P1043, DOI 10.1038/nsb1295-1043; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; DECHERT U, 1994, J BIOL CHEM, V269, P5602; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; DESAI DM, 1994, EMBO J, V13, P4002, DOI 10.1002/j.1460-2075.1994.tb06716.x; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; GEBBINK MFBG, 1993, BIOCHEMISTRY-US, V32, P13516, DOI 10.1021/bi00212a017; Hao LN, 1997, J BIOL CHEM, V272, P29322, DOI 10.1074/jbc.272.46.29322; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Hoffmann KMV, 1997, J BIOL CHEM, V272, P27505, DOI 10.1074/jbc.272.44.27505; IIDA N, 1994, J BIOL CHEM, V269, P28576; ITOH M, 1992, J BIOL CHEM, V267, P12356; JOHNSON P, 1992, J BIOL CHEM, V267, P8035; JOHNSON P, 1997, WEIRS HDB EXPT IMMUN, V2; KORETZKY GA, 1993, J BIOL CHEM, V268, P8958; Lorenzo HK, 1997, FEBS LETT, V411, P231, DOI 10.1016/S0014-5793(97)00703-5; Majeti R, 1998, SCIENCE, V279, P88, DOI 10.1126/science.279.5347.88; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1992, EUR J IMMUNOL, V22, P1173, DOI 10.1002/eji.1830220510; MUSTELIN T, 1990, ONCOGENE, V5, P809; NG DHW, 1995, J IMMUNOL METHODS, V179, P177, DOI 10.1016/0022-1759(94)00281-Z; NG DHW, 1995, BIOCHEM BIOPH RES CO, V206, P302, DOI 10.1006/bbrc.1995.1042; Ng DHW, 1997, BIOCHEM J, V327, P867; Ng DHW, 1996, J BIOL CHEM, V271, P1295, DOI 10.1074/jbc.271.3.1295; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; SCHRAVEN B, 1991, EUR J IMMUNOL, V21, P2469, DOI 10.1002/eji.1830211025; SHIROO M, 1992, EMBO J, V11, P4887, DOI 10.1002/j.1460-2075.1992.tb05595.x; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; STOVER DR, 1994, MOL CELL BIOL, V14, P5523, DOI 10.1128/MCB.14.8.5523; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAKEDA A, 1992, J BIOL CHEM, V267, P16651; TAN XH, 1993, J BIOL CHEM, V268, P6835; THOMAS ML, 1987, P NATL ACAD SCI USA, V84, P5360, DOI 10.1073/pnas.84.15.5360; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; WANG Y, 1991, EMBO J, V10, P3231, DOI 10.1002/j.1460-2075.1991.tb04886.x; Wu L, 1997, J BIOL CHEM, V272, P6994, DOI 10.1074/jbc.272.11.6994; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; YASUKAWA T, 1995, J BIOL CHEM, V270, P25328, DOI 10.1074/jbc.270.43.25328	44	74	76	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17839	17845		10.1074/jbc.273.28.17839	http://dx.doi.org/10.1074/jbc.273.28.17839			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651387	hybrid			2022-12-25	WOS:000074816100080
J	Fortune, JM; Osheroff, N				Fortune, JM; Osheroff, N			Merbarone inhibits the catalytic activity of human topoisomerase II alpha by blocking DNA cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DRUG-INTERACTION DOMAINS; EXPLOITING MECHANISTIC DIFFERENCES; CELL LUNG-CANCER; PHASE-II; ONCOLOGY-GROUP; BIS(2,6-DIOXOPIPERAZINE) DERIVATIVES; SACCHAROMYCES-CEREVISIAE; DROSOPHILA-MELANOGASTER; ANTICANCER DRUGS; ANTITUMOR AGENT	Merbarone is a catalytic inhibitor of topoisomerase II that is in clinical trials as an anticancer agent. Despite the potential therapeutic value of this drug, the mechanism by which it blocks topoisomerase II activity has not been delineated. Therefore, to determine the mechanistic basis for the inhibitory action of merbarone, the effects of this drug on individual steps of the catalytic cycle of human topoisomerase II alpha were assessed. Concentrations of merbarone that inhibited catalytic activity greater than or equal to 80% had no effect on either enzyme DNA binding or ATP hydrolysis. In contrast, the drug was a potent inhibitor of enzyme-mediated DNA scission (in the absence or presence of ATP), and the inhibitory profiles of merbarone for DNA cleavage and relaxation were similar. These data indicate that merbarone acts primarily by blocking topoisomerase II-mediated DNA cleavage. Merbarone inhibited DNA scission in a global (rather than site-specific) fashion but did not appear to intercalate into DNA or bind in the minor groove. Since the drug competed with etoposide (a cleavage-enhancing agent that binds directly to topoisomerase II), it is proposed that merbarone exerts its inhibitory effects through interactions with the enzyme and that the drug shares an interaction domain on topoisomerase II with cleavage-enhancing agents.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med Oncol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Osheroff, N (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 654 Med Res Bldg 1, Nashville, TN 37232 USA.	osheron@ctrvax.vanderbilt.edu			NCI NIH HHS [5 T32 CA09582] Funding Source: Medline; NIGMS NIH HHS [GM33944] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033944] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AJANI JA, 1994, CANCER INVEST, V12, P488, DOI 10.3109/07357909409021408; Anderson H, 1996, CELL GROWTH DIFFER, V7, P83; BAGULEY BC, 1978, NUCLEIC ACIDS RES, V5, P161, DOI 10.1093/nar/5.1.161; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; BORITZKI TJ, 1988, BIOCHEM PHARMACOL, V37, P4063, DOI 10.1016/0006-2952(88)90096-2; BREWER AD, 1985, BIOCHEM PHARMACOL, V34, P2047, DOI 10.1016/0006-2952(85)90335-1; Burden DA, 1996, J BIOL CHEM, V271, P29238, DOI 10.1074/jbc.271.46.29238; CAIN BF, 1978, J MED CHEM, V21, P658, DOI 10.1021/jm00205a013; Capranico G, 1997, TRENDS PHARMACOL SCI, V18, P323; Capranico G, 1994, Cancer Chemother Biol Response Modif, V15, P67; CHANG AY, 1993, J NATL CANCER I, V85, P388, DOI 10.1093/jnci/85.5.388; CHEN M, 1993, CANCER RES, V53, P5946; CHEN M, 1995, CANCER RES, V55, P1509; COONEY DA, 1985, BIOCHEM PHARMACOL, V34, P3395, DOI 10.1016/0006-2952(85)90368-5; CORBETT AH, 1992, J BIOL CHEM, V267, P683; CORBETT AH, 1993, J BIOL CHEM, V268, P14394; CORBETT AH, 1993, CHEM RES TOXICOL, V6, P585, DOI 10.1021/tx00035a001; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DRAKE FH, 1989, BIOCHEMISTRY-US, V28, P8154, DOI 10.1021/bi00446a029; DRAKE FH, 1989, CANCER RES, V49, P2578; ELSEA SH, 1995, J BIOL CHEM, V270, P1913, DOI 10.1074/jbc.270.4.1913; FERGUSON LR, 1994, ENVIRON MOL MUTAGEN, V24, P245, DOI 10.1002/em.2850240402; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P4474, DOI 10.1073/pnas.73.12.4474; HAMNMONDS TR, 1997, J BIOL CHEM, V272, P32696; Hasinoff BB, 1997, MOL PHARMACOL, V52, P839, DOI 10.1124/mol.52.5.839; ISHIDA R, 1995, CANCER RES, V55, P2299; ISHIDA R, 1994, J CELL BIOL, V126, P1341, DOI 10.1083/jcb.126.6.1341; ISHIDA R, 1991, CANCER RES, V51, P4909; JENSEN PB, 1990, CANCER RES, V50, P3311; Kallio M, 1997, ENVIRON MOL MUTAGEN, V29, P16, DOI 10.1002/(SICI)1098-2280(1997)29:1<16::AID-EM3>3.0.CO;2-B; Kingma PS, 1997, BIOCHEMISTRY-US, V36, P5934, DOI 10.1021/bi970507v; Kingma PS, 1997, J BIOL CHEM, V272, P1148, DOI 10.1074/jbc.272.2.1148; KRAUT EH, 1992, INVEST NEW DRUG, V10, P347, DOI 10.1007/BF00944194; KREUZER KN, 1979, J BACTERIOL, V140, P424, DOI 10.1128/JB.140.2.424-435.1979; Lassota P, 1996, J BIOL CHEM, V271, P26418, DOI 10.1074/jbc.271.42.26418; Lewis RJ, 1996, BIOESSAYS, V18, P661, DOI 10.1002/bies.950180810; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; LIU LF, 1983, J BIOL CHEM, V258, P5365; LIU LF, 1994, ADV PHARM, V29; Look KY, 1996, AM J CLIN ONCOL-CANC, V19, P7, DOI 10.1097/00000421-199602000-00002; Maxwell A, 1997, TRENDS MICROBIOL, V5, P102, DOI 10.1016/S0966-842X(96)10085-8; MAXWELL A, 1993, MOL MICROBIOL, V9, P681, DOI 10.1111/j.1365-2958.1993.tb01728.x; Meczes EL, 1997, CANCER CHEMOTH PHARM, V39, P367, DOI 10.1007/s002800050585; MIZUUCHI K, 1978, P NATL ACAD SCI USA, V75, P5960, DOI 10.1073/pnas.75.12.5960; Nitiss JL, 1996, ANN NY ACAD SCI, V803, P32, DOI 10.1111/j.1749-6632.1996.tb26374.x; Nitiss JL, 1996, EUR J CANCER, V32A, P958, DOI 10.1016/0959-8049(96)00056-1; OSHEROFF N, 1994, CANCER CHEMOTH PHARM, V34, pS19, DOI 10.1007/BF00684859; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P4303, DOI 10.1021/bi00388a018; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; POMMIER Y, 1985, BIOCHEMISTRY-US, V24, P6410, DOI 10.1021/bi00344a015; POMMIER Y, 1997, CANC THERAPEUTICS EX, V1, P153; Pommier Y., 1996, CANC CHEMOTHERAPY BI, P435; ROBINSON MJ, 1993, BIOCHEMISTRY-US, V32, P3638, DOI 10.1021/bi00065a016; ROBINSON MJ, 1991, J BIOL CHEM, V266, P14585; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781, DOI 10.1073/pnas.91.5.1781; Sambrook J., 1989, MOL CLONING LAB MANU, V1; SANDER M, 1985, NUCLEIC ACIDS RES, V13, P1057, DOI 10.1093/nar/13.4.1057; SANDER M, 1983, J BIOL CHEM, V258, P8421; Sato M, 1997, BIOCHEM BIOPH RES CO, V235, P571, DOI 10.1006/bbrc.1997.6851; SHELTON ER, 1983, J BIOL CHEM, V258, P9530; SORENSEN BS, 1992, J MOL BIOL, V228, P778, DOI 10.1016/0022-2836(92)90863-F; SPADARI S, 1986, ANTICANCER RES, V6, P935; STORL K, 1993, FEBS LETT, V317, P157, DOI 10.1016/0014-5793(93)81513-Y; SUGINO A, 1978, P NATL ACAD SCI USA, V75, P4838, DOI 10.1073/pnas.75.10.4838; SUTCLIFFE JG, 1979, COLD SPRING HARB SYM, V43, P77, DOI 10.1101/SQB.1979.043.01.013; TANABE K, 1991, CANCER RES, V51, P4903; THOMSEN B, 1990, J MOL BIOL, V215, P237, DOI 10.1016/S0022-2836(05)80342-0; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; Wang HK, 1997, MED RES REV, V17, P367, DOI 10.1002/(SICI)1098-1128(199707)17:4<367::AID-MED3>3.0.CO;2-U; WASSERMAN RA, 1993, CANCER RES, V53, P3591; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; WOYNAROWSKI JM, 1989, MOL PHARMACOL, V35, P177; ZECHIEDRICH EL, 1990, EMBO J, V9, P4555, DOI 10.1002/j.1460-2075.1990.tb07908.x	78	227	232	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17643	17650		10.1074/jbc.273.28.17643	http://dx.doi.org/10.1074/jbc.273.28.17643			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651360	hybrid			2022-12-25	WOS:000074816100053
J	Juin, P; Pelletier, M; Oliver, L; Tremblais, K; Gregoire, P; Meflah, K; Vallette, FM				Juin, P; Pelletier, M; Oliver, L; Tremblais, K; Gregoire, P; Meflah, K; Vallette, FM			Induction of a caspase-3-like activity by calcium in normal cytosolic extracts triggers nuclear apoptosis in a cell-free system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA FRAGMENTATION; CHROMATIN CONDENSATION; ICE/CED-3 PROTEASE; BCL-2; DEATH; INHIBITOR; CA2+	Calcium is involved in several steps of the apoptotic process. In nuclei, endonucleases are presumed to be the main targets of calcium; however, little is known about its role during the cytosolic phase of apoptosis. We used a cell-free system to address this question. Our results show that CaCl2 triggered nuclear apoptosis (i.e. typical morphological change and DNA fragmentation) at concentrations of 5 mM. This concentration was lowered 10-fold by the co-incubation with cytosolic extracts from nonapoptotic cells. Apoptotic changes induced by the incubation of nuclei with CaCl2 in the presence of these cytosols were strongly reduced in the presence of an inhibitor of caspase-3 and to a lesser extent by an inhibitor of caspase-1. We also show that calcium-induced apoptosis is affected by protease inhibitors such as N-tosyl-L-phenylalanine chloromethyl ketone, but not by calpain or several lysosomal protease inhibitors. The addition of CaCl2 to the cell-free system increased a caspase-3 activity in nonapoptotic cytosols as shown by specific antibodies and an enzymatic assay. No activation of a caspase-3-like activity by the addition of cytochrome c was observed in these extracts under similar conditions. The enhanced caspase-3 activity induced by calcium was inhibited by protease inhibitors affecting morphological nuclear apoptosis except for those responsible for the degradation of lamin A. These results suggest that CaCl2 could trigger, in normal cells, an apoptotic cascade through the activation of cytosolic caspase-3 activity.	Inst Biol, INSERM, U 419, F-44035 Nantes 01, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Vallette, FM (corresponding author), Inst Biol, INSERM, U 419, 9 Quai Moncousu, F-44035 Nantes 01, France.		JUIN, Philippe P/H-3636-2014; Vallette, Francois M/K-9047-2015; Vallette, Francois/N-2361-2018; Oliver, Lisa J/L-3070-2015; JUIN, Philippe/Q-1338-2019	JUIN, Philippe P/0000-0002-4997-3888; Vallette, Francois M/0000-0002-3296-8572; Oliver, Lisa J/0000-0002-5588-7564; JUIN, Philippe/0000-0002-4997-3888; Vallette, Francois/0000-0003-0802-0519				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BAFFY G, 1993, J BIOL CHEM, V268, P6511; CHATEL JM, 1993, P NATL ACAD SCI USA, V90, P2476, DOI 10.1073/pnas.90.6.2476; Cotter T.G., 1996, TECHNIQUES APOPTOSIS; Du YS, 1997, P NATL ACAD SCI USA, V94, P11657, DOI 10.1073/pnas.94.21.11657; EARNSHAW WC, 1995, TRENDS CELL BIOL, V5, P217, DOI 10.1016/S0962-8924(00)89006-6; Han ZY, 1997, J BIOL CHEM, V272, P13432, DOI 10.1074/jbc.272.20.13432; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Marin MC, 1996, ONCOGENE, V12, P2259; McConkey DJ, 1997, BIOCHEM BIOPH RES CO, V239, P357, DOI 10.1006/bbrc.1997.7409; McConkey DJ, 1996, J BIOL CHEM, V271, P22398, DOI 10.1074/jbc.271.37.22398; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NEWMEYER DD, 1991, METHOD CELL BIOL, V36, P607; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sukharev SA, 1997, CELL DEATH DIFFER, V4, P457, DOI 10.1038/sj.cdd.4400263; SUN DY, 1994, J EXP MED, V179, P559, DOI 10.1084/jem.179.2.559; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; TOUNEKTI O, 1995, EXP CELL RES, V217, P506, DOI 10.1006/excr.1995.1116; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	36	102	106	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17559	17564		10.1074/jbc.273.28.17559	http://dx.doi.org/10.1074/jbc.273.28.17559			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651349	hybrid			2022-12-25	WOS:000074816100042
J	Kawabata, S; Kohara, A; Tsutsumi, R; Itahana, H; Hayashibe, S; Yamaguchi, T; Okada, M				Kawabata, S; Kohara, A; Tsutsumi, R; Itahana, H; Hayashibe, S; Yamaguchi, T; Okada, M			Diversity of calcium signaling by metabotropic glutamate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; TRANSDUCTION; OSCILLATIONS; ACTIVATION; ENTRY	During prolonged application of glutamate (20 min), patterns of increase in intracellular Ca2+ concentration ([Ca2+](i)) were studied in HEK-293 cells expressing metabotropic glutamate receptor, mGluR1 alpha or mGluR5a, Stimulation of mGluR1 alpha induced an increase in [Ca2+](i), that consisted of an initial transient peak with a subsequent steady plateau or an oscillatory increase in [Ca2+](i). The transient phase was largely attributed to Ca2+ mobilization from the intracellular Ca2+ stores, but the sustained phase was solely due to Ca2+ influx through the mGluR1 alpha receptor-operated Ca2+ channel. Prolonged stimulation of mGluR5a continuously induced [Ca2+](i) oscillations through mobilization of Ca2+ from the intracellular Ca2+ stores, Studies on mutant receptors of mGluR1 alpha and mGluR5a revealed that the coupling mechanism in the sustained phase of Ca2+ response is determined by oscillatory/non-oscillatory patterns of the initial Ca2+ response but not by the receptor identity. In mGluR1 alpha-expressing cells, activation of protein kinase C selectively desensitized the pathway for intracellular Ca2+ mobilization, but the mGluR1 alpha-operated Ca2+ channel remained active. In mGluR5a-expressing cells, phosphorylation of mGluR5a by protein kinase C, which accounts for the mechanism of mGluR5a controlled [Ca2+](i) oscillations, might prevent desensitization and result in constant oscillatory mobilization of Ca2+ from intracellular Ca2+ stores. Our results provide a novel concept in which oscillatory/non-oscillatory mobilizations of Ca2+ induce different coupling mechanisms during prolonged stimulation of mGluRs.	Yamanouchi Pharmaceut Co Ltd, Inst Drug Discovery Res, Neurosci Res Lab, Tsukuba, Ibaraki 305, Japan; Yamanouchi Pharmaceut Co Ltd, Inst Drug Discovery Res, Mol Med Lab, Tsukuba, Ibaraki 305, Japan; Yamanouchi Pharmaceut Co Ltd, Inst Drug Discovery Res, Chem Lab, Tsukuba, Ibaraki 305, Japan	Astellas Pharmaceuticals; Astellas Pharmaceuticals; Astellas Pharmaceuticals	Okada, M (corresponding author), Yamanouchi Pharmaceut Co Ltd, Inst Drug Discovery Res, Neurosci Res Lab, 21 Miyukigaoka, Tsukuba, Ibaraki 305, Japan.							ABE T, 1992, J BIOL CHEM, V267, P13361; Annoura H, 1996, BIOORG MED CHEM LETT, V6, P763, DOI 10.1016/0960-894X(96)00104-7; ARAMORI I, 1992, NEURON, V8, P757, DOI 10.1016/0896-6273(92)90096-V; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; Berridge MJ, 1997, NATURE, V386, P759, DOI 10.1038/386759a0; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; Chen JG, 1997, J NEUROSCI, V17, P7278; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; GU XN, 1995, NATURE, V375, P784, DOI 10.1038/375784a0; HALLAM TJ, 1989, TRENDS PHARMACOL SCI, V10, P8, DOI 10.1016/0165-6147(89)90092-8; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; JENSEN AM, 1990, J NEUROSCI, V10, P1165; Kawabata S, 1996, NATURE, V383, P89, DOI 10.1038/383089a0; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; MEYER T, 1988, P NATL ACAD SCI USA, V85, P5051, DOI 10.1073/pnas.85.14.5051; Nakahara K, 1997, J NEUROCHEM, V69, P1467; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; Towart R, 1979, BRIT J PHARMACOL, V67, p409P	23	61	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17381	17385		10.1074/jbc.273.28.17381	http://dx.doi.org/10.1074/jbc.273.28.17381			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651322	hybrid			2022-12-25	WOS:000074816100015
J	Heriche, JK; Chambaz, EM				Heriche, JK; Chambaz, EM			Protein kinase CK2 alpha is a target for the Abl and Bcr-Abl tyrosine kinases	ONCOGENE			English	Article						CK2; Abl; Bcr-Abl; signal transduction	GLYCOGEN-SYNTHASE KINASE-3; CASEIN KINASE; GROWTH-FACTOR; BETA-SUBUNIT; PHOSPHORYLATION; CELLS; ACTIVATION	Protein kinase CK2 is a ubiquitous serine-threonine kinase in which a catalytic alpha subunit often associates with a beta subunit, CK2 alpha is required for cell survival in yeast and has been proposed to be involved in cell growth control; however, its regulation in cells remains unclear. Here we present evidence that CK2 alpha may be an associated substrate for the normal and oncogenic forms of the Abl tyrosine kinase. By probing CK2 alpha with antiphosphotyrosine antibodies, we found that CK2 alpha can be phosphorylated on tyrosine in quiescent cells. In vitro phosphorylation of CK2 alpha-containing immunoprecipitates showed that CK2 alpha is substrate of an associated tyrosine kinase activity. Immunoprecipitation experiments revealed that CK2 alpha is associated with normal c-Abl in mouse NIH3T3 fibroblasts and with the Bcr-Abl fusion protein in K562 human myeloid leukemia cells. Coexpression of Bcr-Abl and CK2 alpha in NIH3T3 cells also leads to the formation of a Bcr-Abl/CK2 alpha complex and to the inhibition of CK2 alpha activity, Bcr-Abl-induced inhibition of CK2 alpha could be reverted by incubating CK2 alpha with a tyrosine phosphatase. These observations clearly support the idea that a signal transduction pathway contributes to CK2 regulation and point to CK2 alpha as a possible mediator of Bcr-Abl effects.	INSERM, U244, F-38054 Grenoble, France; CEA Grenoble, Dept Biol Mol & Struct, Lab Biochim Regulat Cellulaires Endocrines, F-38054 Grenoble, France	Institut National de la Sante et de la Recherche Medicale (Inserm); CEA	Heriche, JK (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.			Heriche, Jean-Karim/0000-0001-6867-9425				ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; COOPER JA, 1981, MOL CELL BIOL, V1, P165, DOI 10.1128/MCB.1.2.165; DEPAOLIROACH AA, 1984, J BIOL CHEM, V259, P2144; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; GLOVER CVC, 1983, J BIOL CHEM, V258, P3258; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; LITCHFIELD DW, 1994, CELL MOL BIOL RES, V40, P373; MEGGIO F, 1992, EUR J BIOCHEM, V204, P293, DOI 10.1111/j.1432-1033.1992.tb16636.x; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; PICTON C, 1982, FEBS LETT, V150, P191, DOI 10.1016/0014-5793(82)81332-X; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; SCHMIDTSPANIOL I, 1993, CELL MOL BIOL RES, V39, P761; STIGARE J, 1993, MOL CELL BIOCHEM, V129, P77, DOI 10.1007/BF00926578; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4	21	41	41	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 9	1998	17	1					13	18		10.1038/sj.onc.1201900	http://dx.doi.org/10.1038/sj.onc.1201900			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZY936	9671309				2022-12-25	WOS:000074677800002
J	Droin, N; Dubrez, L; Eymin, B; Renvoize, C; Breard, J; Dimanche-Boitrel, MT; Solary, E				Droin, N; Dubrez, L; Eymin, B; Renvoize, C; Breard, J; Dimanche-Boitrel, MT; Solary, E			Upregulation of CASP genes in human tumor cells undergoing etoposide-induced apoptosis	ONCOGENE			English	Article						apoptosis; caspases; etoposide; human tumor cells	INTERLEUKIN-1-BETA CONVERTING-ENZYME; TOPOISOMERASE-II INHIBITORS; CAENORHABDITIS-ELEGANS; POLY(ADP-RIBOSE) POLYMERASE; IL-1-BETA-CONVERTING ENZYME; ICE/CED-3 PROTEASE; CYSTEINE PROTEASES; MESSENGER-RNA; HL-60 CELLS; DEATH	Caspases are aspartate-specific cysteine proteases that play a pivotal role in drug-induced cell death. We designed RT-PCR assays to analyse the expression of CASP-3, CASP-4, CASP-6 and the long and short isoforms of CASP-2 genes in human cells. These genes heterogeneously coexpress in leukemic cell lines and bone marrow samples from patients with de nova acute myelogenous leukemia at diagnosis. Treatment of U937 and HL60 leukemic cells and HT29 colon carcinoma cells with the topoisomerase IT inhibitor etoposide upregulates CASP-2 and CASP-3 genes in these cells before inducing their apoptosis. This effect of etoposide is not observed in K562 cells and bcl-2-transfected U937 cells which are less sensitive to drug-induced apoptosis. Nuclear run-on experiments demonstrate that etoposide increases GASP gene transcription in U937 cells, an effect that is prevented by Bcl-2 overexpression. Upregulation of GASP genes is associated with an enhanced synthesis of related procaspases that precedes the appearance of apoptosis markers including caspase-3 activation, poly(ADP-ribose) polymerase cleavage and internucleosomal DNA fragmentation. These results suggest that the ability of tumor cells to upregulate CASP-2 and CASP-3 genes in response to cytotoxic drugs could be predictive of their sensitivity to drug-induced apoptosis.	UFR Med, Biol & Therapy Canc Grp, INSERM, CJF 94 08, F-21000 Dijon, France; UFR Pharm, INSERM, U461, Chatenay Malabry, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm)	Solary, E (corresponding author), UFR Med, Biol & Therapy Canc Grp, INSERM, CJF 94 08, 7 Blvd Jeanne dArc, F-21000 Dijon, France.		Eymin, Beatrice/M-1962-2013; Dubrez, Laurence/I-4971-2016; Dimanche-Boitrel, Marie-Therese M/I-4642-2015; Laurence, Dubrez/P-9472-2019; Droin, Nathalie M/Y-5506-2018; eymin, beatrice/U-4670-2019	Eymin, Beatrice/0000-0002-7311-3810; Dubrez, Laurence/0000-0002-7030-2181; Laurence, Dubrez/0000-0002-7030-2181; Droin, Nathalie M/0000-0002-6099-5324; eymin, beatrice/0000-0002-7311-3810; Solary, Eric/0000-0002-8629-1341; Dimanche-Boitrel, Marie-Therese/0000-0002-8038-7780				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; ALNEMRI ES, 1995, J BIOL CHEM, V270, P4312, DOI 10.1074/jbc.270.9.4312; Amson RB, 1996, P NATL ACAD SCI USA, V93, P3953, DOI 10.1073/pnas.93.9.3953; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; CHAPMAN RS, 1994, CANCER RES, V54, P5131; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; DUBREZ J, 1996, EMBO J, V15, P504; DUBREZ L, 1995, LEUKEMIA, V9, P1013; Erhardt P, 1996, J BIOL CHEM, V271, P17601, DOI 10.1074/jbc.271.30.17601; Eymin B, 1997, CANCER RES, V57, P686; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMR.T, 1996, P NATL ACAD SCI USA, V93, P7404; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Gately DP, 1996, BRIT J CANCER, V73, P18, DOI 10.1038/bjc.1996.4; Greidinger EL, 1996, FEBS LETT, V390, P299, DOI 10.1016/0014-5793(96)00678-3; GU Y, 1995, EMBO J, V14, P1923, DOI 10.1002/j.1460-2075.1995.tb07184.x; GU Y, 1995, J BIOL CHEM, V270, P18715, DOI 10.1074/jbc.270.32.18715; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; HENTGARTNER MO, 1994, CELL, V76, P665; Inaba T, 1996, NATURE, V382, P541, DOI 10.1038/382541a0; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KAMESAKI S, 1993, CANCER RES, V53, P4251; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KIMOSHITA M, 1997, J CER BLOOD FLOW MET, V17, P507; KOOS RD, 1989, BIOCHEM BIOPH RES CO, V165, P82, DOI 10.1016/0006-291X(89)91036-X; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUIDA K, 1995, SCIENCE, V267, P200; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Martins LM, 1997, J BIOL CHEM, V272, P7421, DOI 10.1074/jbc.272.11.7421; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; Meisenholder GW, 1996, J BIOL CHEM, V271, P16260, DOI 10.1074/jbc.271.27.16260; Metzstein MM, 1996, NATURE, V382, P545, DOI 10.1038/382545a0; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Monney L, 1996, BIOCHEM BIOPH RES CO, V221, P340, DOI 10.1006/bbrc.1996.0597; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; POMMIER Y, 1994, CANCER INVEST, V12, P530, DOI 10.3109/07357909409021413; Pommier Yves, 1997, P153; RENVOIZE C, 1997, IN PRESS J IMMUNOL; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Shaham S, 1996, CELL, V86, P201, DOI 10.1016/S0092-8674(00)80092-6; Slee EA, 1996, BIOCHEM J, V315, P21, DOI 10.1042/bj3150021; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOLARY E, 1994, LEUKEMIA LYMPHOMA, V15, P21, DOI 10.3109/10428199409051674; SOLARY E, 1993, BLOOD, V81, P1359; SRIVASTAVA KK, 1993, BIOTECHNIQUES, V15, P226; Takahashi A, 1996, CURR OPIN GENET DEV, V6, P50, DOI 10.1016/S0959-437X(96)90010-6; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	58	73	78	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 4	1998	16	22					2885	2894		10.1038/sj.onc.1201821	http://dx.doi.org/10.1038/sj.onc.1201821			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZR544	9671409				2022-12-25	WOS:000073988200007
J	Bashour, AM; Bloom, GS				Bashour, AM; Bloom, GS			58K, a microtubule-binding golgi protein, is a formiminotransferase cyclodeaminase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAST AXONAL-TRANSPORT; ALPHA-TUBULIN; MONOCLONAL-ANTIBODIES; KINESIN HEAVY; BREFELDIN-A; RAT-LIVER; APPARATUS; CELLS; IDENTIFICATION; SYSTEM	58K was previously identified as a rat liver protein that binds microtubules in vitro and is associated with the cytoplasmic surface of the Golgi apparatus in vivo (Bloom, G. S., and Brashear, T. A. (1989) J. Biol. Chem. 264, 16083-16092). We now report that 58K is a formiminotransferase cyclodeaminase (FTCD), a bifunctional enzyme that catalyzes two consecutive steps in the modification of tetrahydrofolate to 5,10-methenyl tetrahydrofolate. Comparative immunoblotting using several monoclonal antibodies made against 58K and a polyclonal antibody made against a chicken liver protein (p60) with similar properties (Hennig, D., Scales, S. J., Moreau, A., Murley, L. L., De Mey, J., and Kreis, T. E. (1998) J. Biol. Chem. 273, 19602-19611) demonstrated precise co purification of protein recognized by all antibodies through multiple fractionation steps, including gel filtration and ion exchange chromatography, and sucrose gradient ultracentrifugation. Eight peptides derived from 58K showed high sequence identity to amino acid sequences predicted by full length cDNA for p60 and porcine liver FTCD. Furthermore, purified 58K was associated with formiminotransferase and cyclodeaminase activities. Based on these collective results, 58K was concluded to be a rat liver version of FTCD. Microtubules assembled from brain tubulin, but not from liver tubulin, were able to bind rat liver FTCD. Binding to brain microtubules is suspected to occur via polyglutamates that are added post-translationally to tubulin in brain, which was shown to contain very low levels of FTCD, but not to tubulin in liver, which was determined to be the richest tissue source, by far, of FTCD. The physiologial significance of the microtubule binding activity of FTCD is thus called into question, but an association of FTCD with the Golgi apparatus has now been established.	Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Bloom, GS (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.							ABERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970; ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; ANDREWS PC, 1987, ANAL BIOCHEM, V161, P524, DOI 10.1016/0003-2697(87)90484-2; Bashour AM, 1997, J CELL BIOL, V137, P1555, DOI 10.1083/jcb.137.7.1555; BEAUDET R, 1976, BIOCHIM BIOPHYS ACTA, V453, P151, DOI 10.1016/0005-2795(76)90259-2; BLOOM GS, 1984, J CELL BIOL, V98, P320, DOI 10.1083/jcb.98.1.320; BLOOM GS, 1985, BIOCHEMISTRY-US, V24, P4185, DOI 10.1021/bi00336a055; BLOOM GS, 1988, BIOCHEMISTRY-US, V27, P3409, DOI 10.1021/bi00409a043; BLOOM GS, 1989, J BIOL CHEM, V264, P16083; BLOOM GS, 1985, P NATL ACAD SCI USA, V82, P5405; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; BULINSKI JC, 1979, P NATL ACAD SCI USA, V76, P293, DOI 10.1073/pnas.76.1.293; COLLINS CA, 1989, CELL MOTIL CYTOSKEL, V14, P491, DOI 10.1002/cm.970140407; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DRURY EJ, 1975, ARCH BIOCHEM BIOPHYS, V169, P662, DOI 10.1016/0003-9861(75)90210-6; EDDE B, 1990, SCIENCE, V247, P83, DOI 10.1126/science.1967194; ELLURU RG, 1995, MOL BIOL CELL, V6, P21, DOI 10.1091/mbc.6.1.21; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; Hennig D, 1998, J BIOL CHEM, V273, P19602, DOI 10.1074/jbc.273.31.19602; HIROKAWA N, 1991, J CELL BIOL, V114, P295, DOI 10.1083/jcb.114.2.295; HOLLENBECK PJ, 1989, J CELL BIOL, V108, P2335, DOI 10.1083/jcb.108.6.2335; IHRKE G, 1993, J CELL BIOL, V123, P1761, DOI 10.1083/jcb.123.6.1761; KOTANI S, 1988, J BIOL CHEM, V263, P5385; KOTANI S, 1986, EUR J BIOCHEM, V156, P23, DOI 10.1111/j.1432-1033.1986.tb09543.x; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; MOSKALEWSKI S, 1975, EXP CELL RES, V95, P440, DOI 10.1016/0014-4827(75)90569-8; MURLEY LL, 1993, J BIOL CHEM, V268, P22820; OLMSTED JB, 1981, J BIOL CHEM, V256, P3507; PAQUIN J, 1985, J BIOL CHEM, V260, P4925; PASCHAL BM, 1987, J CELL BIOL, V105, P1273, DOI 10.1083/jcb.105.3.1273; PFISTER KK, 1989, J CELL BIOL, V108, P1453, DOI 10.1083/jcb.108.4.1453; RAMBOURG A, 1974, AM J ANAT, V140, P27, DOI 10.1002/aja.1001400103; ROGALSKI AA, 1984, J CELL BIOL, V99, P1092, DOI 10.1083/jcb.99.3.1092; SCHOLEY JM, 1984, J BIOL CHEM, V259, P6516; SLOBODA RD, 1975, P NATL ACAD SCI USA, V72, P177, DOI 10.1073/pnas.72.1.177; TABOR H, 1959, J BIOL CHEM, V234, P1830; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALLEE RB, 1983, P NATL ACAD SCI-BIOL, V80, P6259, DOI 10.1073/pnas.80.20.6259; VOET D, 1990, BIOCHEMISTRY-US, P691; WEHLAND J, 1983, P NATL ACAD SCI-BIOL, V80, P4286, DOI 10.1073/pnas.80.14.4286; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WEITMAN S, 1994, VITAMIN RECPETORS VI, P259; WOLFF A, 1992, EUR J CELL BIOL, V59, P425; ZAMIEROWSKI M, 1974, BIOCHEM BIOPH RES CO, P81	47	60	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19612	19617		10.1074/jbc.273.31.19612	http://dx.doi.org/10.1074/jbc.273.31.19612			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677387	hybrid			2022-12-25	WOS:000075125200039
J	Wells, RD; Parniewski, P; Pluciennik, A; Bacolla, A; Gellibolian, R; Jaworski, A				Wells, RD; Parniewski, P; Pluciennik, A; Bacolla, A; Gellibolian, R; Jaworski, A			Small slipped register genetic instabilities in Escherichia coli in triplet repeat sequences associated with hereditary neurological diseases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRAGILE-X LOCI; MISMATCH REPAIR; MYOTONIC-DYSTROPHY; CELL-LINES; SACCHAROMYCES-CEREVISIAE; MOLECULAR-BASIS; DUPLEX DNA; REPLICATION; MUTATIONS; DELETION	Genetic instability investigations on three triplet repeat sequences (TRS) involved in human hereditary neurological diseases (CTG.CAG, CGG.CCG, and GAA.TTC) revealed a high frequency of small expansions or deletions in 3-base pair registers in Escherichia coli. The presence of G to A polymorphisms in the CTG.CAG sequences served as reporters for the size and location of these instabilities. For the other two repeat sequences, length determinations confirmed the conclusions found for CTG.CAG. These studies were conducted in strains deficient in methyl-directed mismatch repair or nucleotide excision repair in order to investigate the involvement of these postreplicative processes in the genetic instabilities of these TRS. The observation that small and large instabilities for (CTG.CAG)(175) fall into distinct size classes (1-8 repeats and approximate multiples of 41 repeats, respectively) leads to the conclusion that more than one DNA instability process is involved. The slippage of the complementary strands of the TRS is probably responsible for the small deletions and expansions in methyl-directed mismatch repair-deficient and nucleotide excision repair deficient cells. A model is proposed to explain the observed instabilities via strand misalignment, incision, or excision, followed by DNA synthesis and ligation. This slippage-repair mechanism may be responsible for the small expansions in type 1 hereditary neurological diseases involving polyglutamine expansions. Furthermore, these observations may relate to the high frequency of small deletions versus a lower frequency of large instabilities observed in lymphoblastoid cells from myotonic dystrophy patients.	Texas A&M Univ, Med Ctr, Dept Biochem & Biophys, Ctr Genome Res,Inst Biosci & Technol, Houston, TX 77030 USA; Polish Acad Sci, Ctr Microbiol & Virol, PL-93232 Lodz, Poland	Texas A&M University System; Polish Academy of Sciences	Wells, RD (corresponding author), Texas A&M Univ, Med Ctr, Dept Biochem & Biophys, Ctr Genome Res,Inst Biosci & Technol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	rwells@ibt.tamu.edu	Bacolla, Albino/N-3877-2013; Bacolla, Albino/AAP-1727-2020	Bacolla, Albino/0000-0003-0206-8423; Bacolla, Albino/0000-0003-0206-8423	NIGMS NIH HHS [GM52982] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM052982] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn BC, 1996, J BIOL CHEM, V271, P21462, DOI 10.1074/jbc.271.35.21462; Ashizawa T, 1996, GENOMICS, V36, P47, DOI 10.1006/geno.1996.0424; Bacolla A, 1997, J BIOL CHEM, V272, P16783, DOI 10.1074/jbc.272.27.16783; Bowater RP, 1996, J MOL BIOL, V264, P82, DOI 10.1006/jmbi.1996.0625; Bowater RP, 1997, NUCLEIC ACIDS RES, V25, P2861, DOI 10.1093/nar/25.14.2861; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; DELORENZO V, 1990, J BACTERIOL, V172, P6568, DOI 10.1128/jb.172.11.6568-6572.1990; EICHLER EE, 1994, NAT GENET, V8, P88, DOI 10.1038/ng0994-88; FISHEL R, 1995, CURR OPIN GENET DEV, V5, P382, DOI 10.1016/0959-437X(95)80055-7; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Freudenreich CH, 1997, MOL CELL BIOL, V17, P2090, DOI 10.1128/MCB.17.4.2090; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Gellibolian R, 1997, J BIOL CHEM, V272, P16793, DOI 10.1074/jbc.272.27.16793; Gordenin DA, 1997, NAT GENET, V16, P116, DOI 10.1038/ng0697-116; Harvey SC, 1997, BIOCHEMISTRY-US, V36, P3047, DOI 10.1021/bi962771e; JAWORSKI A, 1995, P NATL ACAD SCI USA, V92, P11019, DOI 10.1073/pnas.92.24.11019; Kang S, 1996, J MOL BIOL, V258, P543, DOI 10.1006/jmbi.1996.0266; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; Kirkpatrick DT, 1997, NATURE, V387, P929, DOI 10.1038/43225; KORNBERG A, 1964, P NATL ACAD SCI USA, V51, P315, DOI 10.1073/pnas.51.2.315; Kramer PR, 1996, HUM GENET, V98, P151, DOI 10.1007/s004390050179; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; KUNKEL TA, 1993, NATURE, V365, P207, DOI 10.1038/365207a0; LECHNER RL, 1983, J BIOL CHEM, V258, P1174; Leeflang EP, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P543; LEVINSON G, 1987, MOL BIOL EVOL, V4, P203; Lovett ST, 1996, P NATL ACAD SCI USA, V93, P7120, DOI 10.1073/pnas.93.14.7120; MADSEN CS, 1993, P NATL ACAD SCI USA, V90, P7671, DOI 10.1073/pnas.90.16.7671; Mangiarini L, 1997, NAT GENET, V15, P197, DOI 10.1038/ng0297-197; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; Maurer DJ, 1996, MOL CELL BIOL, V16, P6617; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Monckton DG, 1997, NAT GENET, V15, P193, DOI 10.1038/ng0297-193; Mortlock DP, 1996, NAT GENET, V13, P284, DOI 10.1038/ng0796-284; Muragaki Y, 1996, SCIENCE, V272, P548, DOI 10.1126/science.272.5261.548; Ohshima K, 1998, J BIOL CHEM, V273, P14588, DOI 10.1074/jbc.273.23.14588; Ohshima K, 1996, J BIOL CHEM, V271, P16773, DOI 10.1074/jbc.271.28.16773; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; Paulson HL, 1996, ANNU REV NEUROSCI, V19, P79; Pearson CE, 1996, BIOCHEMISTRY-US, V35, P5041, DOI 10.1021/bi9601013; RICHARDS RI, 1994, NAT GENET, V6, P114, DOI 10.1038/ng0294-114; RIPLEY LS, 1990, ANNU REV GENET, V24, P189, DOI 10.1146/annurev.ge.24.120190.001201; Rosche WA, 1996, J BACTERIOL, V178, P5042, DOI 10.1128/jb.178.16.5042-5044.1996; Samadashwily GM, 1997, NAT GENET, V17, P298, DOI 10.1038/ng1197-298; Sambrook J., 2002, MOL CLONING LAB MANU; Schweitzer JK, 1997, HUM MOL GENET, V6, P349, DOI 10.1093/hmg/6.3.349; Schweitzer JK, 1998, HUM MOL GENET, V7, P69, DOI 10.1093/hmg/7.1.69; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; Shimizu M, 1996, J MOL BIOL, V258, P614, DOI 10.1006/jmbi.1996.0273; Sia EA, 1997, MOL CELL BIOL, V17, P2851, DOI 10.1128/MCB.17.5.2851; Steinbach P, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P509; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; Strauss BS, 1997, NUCLEIC ACIDS RES, V25, P806, DOI 10.1093/nar/25.4.806; TAUTZ D, 1994, CURR OPIN GENET DEV, V4, P832, DOI 10.1016/0959-437X(94)90067-1; Trottier Y, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P447; UMAR A, 1994, J BIOL CHEM, V269, P14367; UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wells R.D., 1998, GENETIC INSTABILITIE; WELLS RD, 1965, J MOL BIOL, V14, P221, DOI 10.1016/S0022-2836(65)80242-X; Wells RD, 1996, J BIOL CHEM, V271, P2875, DOI 10.1074/jbc.271.6.2875; WELLS RD, 1993, GENOME ANAL, V7, P107; Yao M, 1996, J BIOL CHEM, V271, P30672, DOI 10.1074/jbc.271.48.30672; Zou Y, 1997, J BIOL CHEM, V272, P4820, DOI 10.1074/jbc.272.8.4820	71	55	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19532	19541		10.1074/jbc.273.31.19532	http://dx.doi.org/10.1074/jbc.273.31.19532			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677376	hybrid			2022-12-25	WOS:000075125200028
J	Li, SH; Hosseini, SH; Gutekunst, CA; Hersch, SM; Ferrante, RJ; Li, XJ				Li, SH; Hosseini, SH; Gutekunst, CA; Hersch, SM; Ferrante, RJ; Li, XJ			A human HAP1 homologue - Cloning, expression, and interaction with huntingtin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPANDED CAG REPEAT; DISEASE GENE; BRAIN; TRINUCLEOTIDE; EXPANSION; PROTEINS; LENGTH; IDENTIFICATION; INACTIVATION; PATHOGENESIS	Huntington's disease (HD) is caused by the expansion of a glutamine repeat in the protein huntingtin. The expanded glutamine repeat is thought to mediate a gain of function by causing huntingtin to abnormally interact with other proteins. We previously identified a rat huntingtin-associated protein (HAP1) that binds to huntingtin; HAP1 binds more tightly to huntingtin with an expanded glutamine repeat than to wild type huntingtin. Identification of the human homologue of HAP1 is necessary for investigation of the potential role of HAP1 in HD pathology. Here, we report the cloning of a human HAP1 homologue (hHAP) that shares 62% identity with rat HAP1 over its entire sequence and 82% amino acid identity in the putative huntingtin-binding region. The hHAP gene encodes a 4.1-kilobase transcript and a 75-kDa protein which are specifically expressed in human brain tissues. Its expression in Huntington's disease brains is reduced in parallel with a decreased expression of huntingtin. While two isoforms of rat HAP1 are expressed at similar levels in rat brain, only a single major form of hHAP is found in primate brains. In vitro binding, immunoprecipitation, and coexpression studies confirm the interaction of hHAP with huntingtin. The in vitro binding of hHAP to huntingtin is enhanced by lengthening the glutamine repeat. Despite similar binding properties of rat HAP1 and hHAP, differences in the sequences and expression of hHAP may contribute to a specific role for its interaction with huntingtin in humans.	Emory Univ, Sch Med, Dept Genet, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Ctr Mol Med, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; Boston Univ, Sch Med, Dept Neurol & Pathol, Bedford Vet Adm Med Ctr,Geriatr Res Educ & Clin C, Boston, MA 02115 USA	Emory University; Emory University; Emory University; Boston University; Geriatric Research Education & Clinical Center	Li, XJ (corresponding author), Emory Univ, Sch Med, Dept Genet, 1462 Clifton Rd NE, Atlanta, GA 30322 USA.	xiaoli@genetics.emory.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS016375, R01NS036232, P50NS016375] Funding Source: NIH RePORTER; NINDS NIH HHS [NS36232, NS 16375] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBIN RL, 1995, TRENDS NEUROSCI, V18, P11, DOI 10.1016/0166-2236(95)93943-R; AMBROSE CM, 1994, SOMAT CELL MOLEC GEN, V20, P27, DOI 10.1007/BF02257483; ANDREW SE, 1993, NAT GENET, V4, P398, DOI 10.1038/ng0893-398; Bao J, 1996, P NATL ACAD SCI USA, V93, P5037, DOI 10.1073/pnas.93.10.5037; BlockGalarza J, 1997, NEUROREPORT, V8, P2247, DOI 10.1097/00001756-199707070-00031; Burke JR, 1996, NAT MED, V2, P347, DOI 10.1038/nm0396-347; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DUYAO MP, 1995, SCIENCE, V269, P407, DOI 10.1126/science.7618107; DUYAO MP, 1993, HUM MOL GENET, V2, P673, DOI 10.1093/hmg/2.6.673; Engelender S, 1997, HUM MOL GENET, V6, P2205, DOI 10.1093/hmg/6.13.2205; Ferrante RJ, 1997, J NEUROSCI, V17, P3052; FERRANTE RJ, 1985, SCIENCE, V230, P561, DOI 10.1126/science.2931802; GUTEKUNST CA, 1995, P NATL ACAD SCI USA, V92, P8710, DOI 10.1073/pnas.92.19.8710; Gutekunst Claire-Anne, 1997, Society for Neuroscience Abstracts, V23, P1911; Kalchman MA, 1997, NAT GENET, V16, P44, DOI 10.1038/ng0597-44; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; LI SH, 1993, GENOMICS, V16, P572, DOI 10.1006/geno.1993.1232; Li SH, 1998, J NEUROSCI, V18, P1261, DOI 10.1523/jneurosci.18-04-01261.1998; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; Li XJ, 1996, P NATL ACAD SCI USA, V93, P4839, DOI 10.1073/pnas.93.10.4839; MacDonald ME, 1996, CURR OPIN NEUROBIOL, V6, P638, DOI 10.1016/S0959-4388(96)80097-3; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Martin E. J., 1997, Society for Neuroscience Abstracts, V23, P1910; MARTIN JB, 1986, NEW ENGL J MED, V315, P1267; NAGAFUCHI S, 1994, NAT GENET, V6, P14, DOI 10.1038/ng0194-14; NASIR J, 1995, CELL, V81, P811, DOI 10.1016/0092-8674(95)90542-1; ROSS CA, 1995, NEURON, V15, P493, DOI 10.1016/0896-6273(95)90138-8; STINE OC, 1993, HUM MOL GENET, V2, P1547, DOI 10.1093/hmg/2.10.1547; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; WANKER EE, 1997, HUM MOL GENET, V6, P47; White JK, 1997, NAT GENET, V17, P404, DOI 10.1038/ng1297-404	33	56	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19220	19227		10.1074/jbc.273.30.19220	http://dx.doi.org/10.1074/jbc.273.30.19220			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668110	hybrid			2022-12-25	WOS:000074974700077
J	Ling, YH; Tornos, C; Perez-Soler, R				Ling, YH; Tornos, C; Perez-Soler, R			Phosphorylation of Bcl-2 is a marker of M phase events and not a determinant of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; SIGNAL-TRANSDUCTION; PROTEIN; TAXOL; KINASE; RAF-1; ASSOCIATION; MECHANISM; REQUIRES; C-RAF-1	Phosphorylation of Bcl-2 protein is a post-translational modification of unclear functional consequences. We studied the correlation between Bcl-2 phosphorylation, mitotic arrest, and apoptosis induced by the antitubulin agent paclitaxel, Continuous exposure of human cervical carcinoma HeLa cells to 50 ng/ml paclitaxel resulted in mitotic arrest with a symmetrical bell-shaped curve over time. The number of mitotic cells was highest at 24 h (82%), then declined as arrested cells progressed into apoptosis, and barely no mitotic cells were present at 48-60 h. The time curves of paclitaxel-induced cyclin B1 accumulation and stimulation of Cdc2/cyclin B1 kinase activity were identical and superimposable to that of M phase arrest. In contrast, apoptosis was first detected at 12 h and steadily increased thereafter until the termination of the experiments at 48-60 h, when about 80-96% of cells were apoptotic. Bcl-2 phosphorylation was closely associated in time with M phase arrest, accumulation of cyclin B1, and activation of Cdc2/cyclin B1 kinase, but not with apoptosis. At 24 h, when about 82% of the cells were in mitosis, almost all Bcl-2 protein was phosphorylated, whereas at 48 h, when 70-90% of the cells were apoptotic, all Bcl-2 protein was unphosphorylated, Similar results were obtained with SKOV3 cells, indicating that the association of paclitaxel-induced M phase arrest and Bcl-2 phosphorylation is not restricted to HeLa cells, We used short exposure to nocodazole and double thymidine to synchronize HeLa cells and investigate the association of Bcl-2 phosphorylation with mitosis, These studies demonstrated that Bcl-2 phosphorylation occurs in tight association with the number of mitotic cells in experimental conditions that do not lead to apoptosis. However, a continuous exposure to nocodazole resulted in a pattern of Bcl-2 phosphorylation, M phase arrest, and apoptosis similar to that observed with paclitaxel, The phosphatase inhibitor okadaic acid was found to inhibit the dephosphorylation of phosphorylated Bcl-2 and to delay the progression of nocodazole M phase-arrested cells into interphase, In contrast, the serine/threonine kinase inhibitor staurosporine, but not the tyrosine kinase inhibitor genistein, led to rapid dephosphorylation of phosphorylated Bcl-2 and accelerated the progression of nocodazole M phase-arrested cells into interphase, Immune complex kinase assays in cell-free systems demonstrated that Bcl-2 protein can be a substrate of Cdc2/cyclin B1 kinase isolated from paclitaxel-treated cells arrested in M phase. Taken together, these studies suggest that Bcl-2 phosphorylation is tightly associated with mitotic arrest and fail to demonstrate that it is a determinant of progression into apoptosis after mitotic arrest induced by anti-tubulin agents.	Univ Texas, MD Anderson Cancer Ctr, Dept Thorac Head & Neck Med Oncol, Sect Expt Therapy, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Perez-Soler, R (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Thorac Head & Neck Med Oncol, Sect Expt Therapy, Box 080,1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA50270] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050270] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALNEMRI ES, 1992, P NATL ACAD SCI USA, V89, P7295, DOI 10.1073/pnas.89.16.7295; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; Blagosklonny MV, 1997, CANCER RES, V57, P130; Blagosklonny MV, 1996, CANCER RES, V56, P1851; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Haldar S, 1997, CANCER RES, V57, P229; Hunter JJ, 1996, J BIOL CHEM, V271, P8521, DOI 10.1074/jbc.271.15.8521; Ibrado AM, 1997, CANCER RES, V57, P1109; Jordan MA, 1996, CANCER RES, V56, P816; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Ling YH, 1998, INT J CANCER, V75, P925, DOI 10.1002/(SICI)1097-0215(19980316)75:6<925::AID-IJC16>3.0.CO;2-1; LING YH, 1993, CANCER RES, V53, P1845; Ling YH, 1996, MOL PHARMACOL, V49, P832; LU QL, 1994, J CELL SCI, V107, P363; MANFREDI JJ, 1984, PHARMACOL THERAPEUT, V25, P83, DOI 10.1016/0163-7258(84)90025-1; MAY WS, 1994, J BIOL CHEM, V269, P26865; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Pathan NI, 1996, J BIOL CHEM, V271, P30315, DOI 10.1074/jbc.271.48.30315; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; ROWINSKY EK, 1990, JNCI-J NATL CANCER I, V82, P1247, DOI 10.1093/jnci/82.15.1247; WANG HG, 1994, ONCOGENE, V9, P2751; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	27	218	225	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18984	18991		10.1074/jbc.273.30.18984	http://dx.doi.org/10.1074/jbc.273.30.18984			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668078	hybrid			2022-12-25	WOS:000074974700045
J	Zhao, R; Assaraf, YG; Goldman, ID				Zhao, R; Assaraf, YG; Goldman, ID			A mutated murine reduced folate carrier (RFC1) with increased affinity for folic acid, decreased affinity for methotrexate, and an obligatory anion requirement for transport function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE VESICLES; L1210 LEUKEMIA-CELLS; DIHYDROFOLATE-REDUCTASE; MEDIATED TRANSPORT; SYSTEM; CDNA; SENSITIVITY; DEFICIENT; EXTENT; LINE	In an ongoing study of structure-function relationships of the murine reduced folate carrier 1 (RFC1), a glutamate to lysine mutation at amino acid 45 was identified in a methotrexate (MTX)-resistant L1210 clonal variant in which MTX and 5-formyltetrahydrofolate (5-CHO-THF) influx was markedly decreased. The characteristics of the mutated carrier, RFC1-E45K, were studied by cDNA transfection into the murine MTX(r)A line in which endogenous carrier is not functional. Folic acid influx doubled in the transfectant MTX(r)A-E45K as compared with L1210 or MTX(r)A cells; in contrast, MTX and 5-CHO-THF influx was only 14 and 27% that of L1210 cells, respectively. 5-CHO-THF influx in MTX(r)A-E45K cells was characterized by a 12- and 3.6-fold decrease in influx V-max and K-t respectively, relative to L1210 cells. The folic acid influx K-i in L1210 cells was more than 50-fold greater than that of MTX based upon inhibition of 5-CHO-THF influx. In comparison, the mutated carrier had comparable affinities for folic acid and MTX in MTX(r)A-E45K cells due to a 7-fold decrease in the folic acid influx K-i and 7-fold increase in the MTX influx K-i. Transport via native RFC1 is inhibited by a variety of anions in L1210 cells associated with an increase in influx K-i. However, influx of 5-CHO-THF in MTX(r)A-E45K cells in a HEPES buffer (9 mM chloride) was decreased by 70% due to a 3-fold fall in the V-max.In the complete absence of chloride (K+-HEPES-sucrose buffer) 5-CHO-THF influx was only 10% that in HBS buffer. 5-CHO-THF influx was restored by addition of chloride, fluoride, or nitrate but not by sulfate, phosphate, or ATP which were all inhibitory over a broad range of concentrations. The data suggest that substitution of a positive for a negative amino acid at position 45 results in the loss of RFC1 mobility in the absence of small inorganic anions that bind to, and neutralize the positive charge on, the lysine residue. Inhibition by higher charged anions may be due to interactions at another carrier site present in both the mutated and wild type carrier. This and other studies suggest that amino acids in the first predicted transmembrane domain play an important role in determining the spectrum of affinities for, and mobility of, RFC1 and is a cluster region for mutations; when cells are placed under selective pressure with antifolates that utilize RFC1 as the major route of entry into mammalian cells.	Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Comprehens Canc Ctr, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Goldman, ID (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Comprehens Canc Ctr, Chanin 2,1300 Morris Pk Ave, Bronx, NY 10461 USA.				NATIONAL CANCER INSTITUTE [R35CA039807] Funding Source: NIH RePORTER; NCI NIH HHS [CA-39807] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Assaraf YG, 1998, J BIOL CHEM, V273, P8106, DOI 10.1074/jbc.273.14.8106; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; BRIGLE KE, 1995, J BIOL CHEM, V270, P22974, DOI 10.1074/jbc.270.39.22974; BUTTERWORTH CE, 1993, HLTH DIS, P165; DALY LE, 1995, JAMA-J AM MED ASSOC, V274, P1698, DOI 10.1001/jama.274.21.1698; DIXON KH, 1994, J BIOL CHEM, V269, P17; FRY DW, 1982, J BIOL CHEM, V257, P1890; GOLDMAN ID, 1971, BIOCHIM BIOPHYS ACTA, V233, P624, DOI 10.1016/0005-2736(71)90162-3; GOLDMAN ID, 1968, J BIOL CHEM, V243, P5007; GOLDMAN ID, 1971, ANN NY ACAD SCI, V186, P400; GOLDMAN ID, 1986, MEMBRANE TRANSPORT A, P283; Gorlick R, 1997, BLOOD, V89, P1013, DOI 10.1182/blood.V89.3.1013; HENDERSON GB, 1990, ANNU REV NUTR, V10, P319, DOI [10.1146/annurev.nutr.10.1.319, 10.1146/annurev.nu.10.070190.001535]; HENDERSON GB, 1990, CANCER RES, V50, P1709; HENDERSON GB, 1983, BIOCHEM INT, V6, P507; HENDERSON GB, 1980, ARCH BIOCHEM BIOPHYS, V200, P149, DOI 10.1016/0003-9861(80)90341-0; HENDERSON GB, 1983, ARCH BIOCHEM BIOPHYS, V221, P438, DOI 10.1016/0003-9861(83)90162-5; LEE GSF, 1992, J MOL BIOL, V223, P617, DOI 10.1016/0022-2836(92)90978-S; MATHERLY LH, 1995, BLOOD, V85, P500; MOSCOW JA, 1995, CANCER RES, V55, P3790; MULLERBERGER S, 1995, BIOCHEMISTRY-US, V34, P9325; PRASAD PD, 1995, BIOCHEM BIOPH RES CO, V206, P681, DOI 10.1006/bbrc.1995.1096; Rimm EB, 1998, JAMA-J AM MED ASSOC, V279, P359, DOI 10.1001/jama.279.5.359; Roy K, 1998, J BIOL CHEM, V273, P2526, DOI 10.1074/jbc.273.5.2526; SCHUETZ JD, 1988, J BIOL CHEM, V263, P9840; SIROTNAK FM, 1985, CANCER RES, V45, P4732; SIROTNAK FM, 1986, MEMBRANE TRANSPORT A, P241; SIROTNAK FM, 1987, NCI MONOGRAPHS, V5, P27; SPINELLA MJ, 1995, J BIOL CHEM, V270, P7842, DOI 10.1074/jbc.270.14.7842; Tse A., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P162; WILLIAMS FMR, 1994, J BIOL CHEM, V269, P5810; WILLIAMS FMR, 1995, J BIOL CHEM, V270, P2987, DOI 10.1074/jbc.270.7.2987; WONG SC, 1995, J BIOL CHEM, V270, P17468, DOI 10.1074/jbc.270.29.17468; YANG CH, 1983, J MEMBRANE BIOL, V75, P11, DOI 10.1007/BF01870795; YANG CH, 1984, J MEMBRANE BIOL, V79, P285, DOI 10.1007/BF01871067; Zhao RB, 1998, J BIOL CHEM, V273, P7873, DOI 10.1074/jbc.273.14.7873; Zhao RB, 1997, J BIOL CHEM, V272, P21207, DOI 10.1074/jbc.272.34.21207	37	64	64	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19065	19071		10.1074/jbc.273.30.19065	http://dx.doi.org/10.1074/jbc.273.30.19065			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668089	hybrid			2022-12-25	WOS:000074974700056
J	Dammeier, J; Beer, HD; Brauchle, M; Werner, S				Dammeier, J; Beer, HD; Brauchle, M; Werner, S			Dexamethasone is a novel potent inducer of connective tissue growth factor expression - Implications for glucocorticoid therapy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR GENE-EXPRESSION; INDUCIBLE GENE; WOUND REPAIR; FACTOR-BETA; IDENTIFICATION	Due to its potent effect on fibroblast proliferation and extracellular matrix deposition, connective tissue growth factor (CTGF) seems to play an important role in the pathogenesis of fibrotic disease. Since glucocorticoids are frequently used for the therapy of these disorders, we determined a potential effect of these steroids on CTGF expression. In cultured fibroblasts, a striking induction of CTGF expression was observed after dexamethasone treatment and occurred in a time- and dose-dependent manner, This effect was obviously not mediated by the CTGF inducer transforming growth factor-beta 1, since expression of this factor was down-regulated by the glucocorticoid. Most importantly, CTGF expression levels also increased substantially in various tissues and organs by systemic glucocorticoid treatment of mice, After cutaneous injury, a strong induction of CTGF expression was seen in the wounds of nontreated mice, However, no further increase in the levels of CTGF mRNA occurred in wounded skin compared with unwounded skin of glucocorticoid-treated animals, suggesting the presence of other factors in the wound that might compensate for the effect of the steroids. Tumor necrosis factor-alpha was identified as a possible mediator of this effect because this factor suppressed CTGF expression in cultured fibroblasts and also blocked the glucocorticoid-induced CTGF production by these cells. These findings indicate that glucocorticoids stimulate CTGF expression in normal tissues and organs but not in highly inflamed areas.	Max Planck Inst Biochem, D-82152 Martinsried, Germany	Max Planck Society	Werner, S (corresponding author), Max Planck Inst Biochem, Klopferspitz 18A, D-82152 Martinsried, Germany.	werner@biochem.mpg.de		Beer, Hans-Dietmar/0000-0002-8085-713X; Dammeier, Johanna/0000-0002-6040-2779; Werner, Sabine/0000-0001-7397-8710				ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; Bemelmans MHA, 1996, CRIT REV IMMUNOL, V16, P1; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EHRLICH HP, 1968, ANN SURG, V167, P324, DOI 10.1097/00000658-196803000-00004; Franklin TJ, 1997, INT J BIOCHEM CELL B, V29, P79, DOI 10.1016/S1357-2725(96)00121-5; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Frazier KS, 1997, INT J BIOCHEM CELL B, V29, P153, DOI 10.1016/S1357-2725(96)00127-6; Grotendorst G R, 1997, Expert Opin Investig Drugs, V6, P777, DOI 10.1517/13543784.6.6.777; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; Hubner G, 1996, CYTOKINE, V8, P548, DOI 10.1006/cyto.1996.0074; Igarashi A, 1996, J INVEST DERMATOL, V106, P729, DOI 10.1111/1523-1747.ep12345771; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Kireeva ML, 1997, EXP CELL RES, V233, P63, DOI 10.1006/excr.1997.3548; Kothapalli D, 1997, CELL GROWTH DIFFER, V8, P61; LEIBOVICH SJ, 1975, AM J PATHOL, V78, P71; LOMBES M, 1995, CIRCULATION, V92, P175, DOI 10.1161/01.CIR.92.2.175; OBRIAN TP, 1990, MOL CELL BIOL, V4, P637; Oemar BS, 1997, CIRCULATION, V95, P831; REED BR, 1985, J AM ACAD DERMATOL, V13, P919, DOI 10.1016/S0190-9622(85)70242-3; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; SHULL S, 1995, LUNG, V173, P71, DOI 10.1007/BF02981467; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; Stoecklin E, 1997, MOL CELL BIOL, V17, P6708, DOI 10.1128/MCB.17.11.6708; Wahl S, 1989, ANTIINFLAMMATORY STE, P280; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896	28	121	129	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18185	18190		10.1074/jbc.273.29.18185	http://dx.doi.org/10.1074/jbc.273.29.18185			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660779	hybrid			2022-12-25	WOS:000074828500034
J	Dron, M; Dandoy-Dron, F; Guillot, F; Benboudjema, L; Hauw, JJ; Lebon, P; Dormont, D; Tovey, MG				Dron, M; Dandoy-Dron, F; Guillot, F; Benboudjema, L; Hauw, JJ; Lebon, P; Dormont, D; Tovey, MG			Characterization of the human analogue of a Scrapie-responsive gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; EXPRESSION; PROTEIN; BRAIN	We have recently described a novel mRNA denominated ScRG-1, the level of which is increased in the brains of Scrapie-infected mice (Dandoy-Dron, F., Guillo, F., Benboudjema, L., Deslys, J.-P., Lasmezas, C., Dormont, D., Tovey, M. G., and Dron, M. (1998) J. Biol. Chem, 273, 7691-7697), The increase in ScRG-1 mRNA in the brain follows the accumulation of PrPSc, the proteinase K-resistant form of the prion protein (PrP), and precedes the widespread neuronal death that occurs in late stage disease. In the present study, we have isolated a cDNA encoding the human counterpart of ScRG-1, Comparison of the human and mouse transcripts firmly established that both sequences encode a highly conserved protein of 98 amino acids that contains a signal peptide, suggesting that the protein may be secreted. Examination of the distribution of human ScRG-1 mRNA in adult and fetal tissues revealed that the gene was expressed primarily in the central nervous system as a 0.7-kilobase message and was under strict developmental control.	Lab Viral Oncol, CNRS, UPR 9045, IFC1, F-94801 Villejuif, France; Grp Hosp Pitie Salpetriere, INSERM, U360,Assoc Claude Bernard, Lab Neuropathol Raymond Escourolle, F-75651 Paris 13, France; Hop St Vincent de Paul, Virol Lab, F-75674 Paris 14, France; CEA, Lab Neurovirol, F-92265 Fontenay Aux Roses, France	Centre National de la Recherche Scientifique (CNRS); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; CEA	Tovey, MG (corresponding author), Lab Viral Oncol, CNRS, UPR 9045, IFC1, 7 Rue Guy Moquet,BP8, F-94801 Villejuif, France.		DRON, Michel/M-7093-2017	Tovey, Michael/0000-0002-3058-0494				Brown DR, 1996, NATURE, V380, P345, DOI 10.1038/380345a0; CAMPBELL IL, 1994, J VIROL, V68, P2383, DOI 10.1128/JVI.68.4.2383-2387.1994; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5291; Dandoy-Dron F, 1998, J BIOL CHEM, V273, P7691, DOI 10.1074/jbc.273.13.7691; DIEDRICH JF, 1991, J VIROL, V65, P4759, DOI 10.1128/JVI.65.9.4759-4768.1991; DUGUID J, 1993, P NATL ACAD SCI USA, V90, P114, DOI 10.1073/pnas.90.1.114; GOMI H, 1995, NEURON, V14, P29, DOI 10.1016/0896-6273(95)90238-4; LEMERE CA, 1995, AM J PATHOL, V146, P848; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; Raeber AJ, 1997, EMBO J, V16, P6057, DOI 10.1093/emboj/16.20.6057; RIGIER R, 1997, NAT MED, V3, P1383; Williams A, 1997, BRAIN RES, V754, P171, DOI 10.1016/S0006-8993(97)00067-X	12	26	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18015	18018		10.1074/jbc.273.29.18015	http://dx.doi.org/10.1074/jbc.273.29.18015			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660755	hybrid			2022-12-25	WOS:000074828500010
J	Knight, SAB; Sepuri, NBV; Pain, D; Dancis, A				Knight, SAB; Sepuri, NBV; Pain, D; Dancis, A			Mt-Hsp70 homolog, Ssc2p, required for maturation of yeast frataxin and mitochondrial iron homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN-70; SACCHAROMYCES-CEREVISIAE; MEMBRANE; COMPLEX; TRANSLOCATION; TRANSPORT	Here we show that the yeast mitochondrial chaperone Ssc2p, a homolog of mt-Hsp70, plays a critical role in mitochondrial iron homeostasis. Yeast with ssc2-1 mutations were identified by a screen for altered iron-dependent gene regulation and mitochondrial dysfunction. These mutants exhibit increased cellular iron uptake, and the iron accumulates exclusively within mitochondria. Yfh1p is homologous to frataxin, the human protein implicated in the neurodegenerative disease, Friedreich's ataxia, Like mutants of yfh1, ssc2-1 mutants accumulate vast quantities of iron in mitochondria, Furthermore, using import studies with isolated mitochondria, we demonstrate a specific role for Ssc2p in the maturation of Yfh1p within this organelle. This function for a mitochondrial Hsp70 chaperone is likely to be conserved, implying that a human homolog of Ssc2p may be involved in iron homeostasis and in neurodegenerative disease.	Univ Penn, Dept Med, Div Hematol Oncol, Stellar Chance Labs 1009, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Dancis, A (corresponding author), Univ Penn, Dept Med, Div Hematol Oncol, Stellar Chance Labs 1009, 422 Curie Blvd, Philadelphia, PA 19104 USA.		Sepuri, Naresh/AAF-2704-2020	Knight, Simon/0000-0001-7407-3390				BACOCK M, 1997, SCIENCE, V276, P1709; BYERS B, 1991, P602; Cammack R, 1990, IRON TRANSPORT STORA, P17; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; Finke K, 1996, EMBO J, V15, P1482, DOI 10.1002/j.1460-2075.1996.tb00492.x; Foury F, 1997, FEBS LETT, V411, P373, DOI 10.1016/S0014-5793(97)00734-5; GAMBILL BD, 1993, J CELL BIOL, V123, P109, DOI 10.1083/jcb.123.1.109; Goldstein J., 1981, SCANNING ELECT MICRO; GRAHAM LA, 1993, J BIOENERG BIOMEMBR, V25, P245, DOI 10.1007/BF00762586; Horst M, 1997, EMBO J, V16, P1842, DOI 10.1093/emboj/16.8.1842; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; Koutnikova H, 1997, NAT GENET, V16, P345, DOI 10.1038/ng0897-345; Langer T, 1996, EXPERIENTIA, V52, P1069, DOI 10.1007/BF01952104; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; Rep M, 1996, SCIENCE, V274, P103, DOI 10.1126/science.274.5284.103; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; Rotig A, 1997, NAT GENET, V17, P215, DOI 10.1038/ng1097-215; Schilke B, 1996, J CELL BIOL, V134, P603, DOI 10.1083/jcb.134.3.603; SCRIVER CR, 1995, METABOLIC MOL BASES, P2427; SCRIVER CR, 1995, METABOLIC MOL BASIS, P1860; SHERMAN F, 1991, P3; Wilson RB, 1997, NAT GENET, V16, P352, DOI 10.1038/ng0897-352; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x	26	145	148	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18389	18393		10.1074/jbc.273.29.18389	http://dx.doi.org/10.1074/jbc.273.29.18389			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660806	hybrid			2022-12-25	WOS:000074828500061
J	Palmer, CNA; Axen, E; Hughes, V; Wolf, CR				Palmer, CNA; Axen, E; Hughes, V; Wolf, CR			The repressor protein, Bm3R1, mediates an adaptive response to toxic fatty acids in Bacillus megaterium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-BINDING PROTEIN; ESCHERICHIA-COLI; ACTIVATED RECEPTOR; TRANSCRIPTIONAL REGULATOR; PEROXISOME PROLIFERATORS; OMEGA-HYDROXYLATION; SOLUBLE SYSTEM; BETA-OXIDATION; GENE; CYTOCHROME-P-450	Bm3R1 is a helix-turn-helix transcriptional repressor from Bacillus megaterium whose binding to DNA is inhibited by fatty acids and a wide range of compounds that modulate lipid metabolism. The inactivation of Bm3R1/DNA binding activity results in the activation of transcription of the operon encoding a fatty acid hydroxylase, cytochrome P450 102, The metabolic role of this operon is unknown. It is possible that it is involved in the synthesis of modified fatty acids as part of normal cellular metabolism or may represent a protective mechanism by which B, megaterium detoxifies harmful foreign lipids. In this report we demonstrate that poly unsaturated fatty acids (PUFA) activate the transcription of the CYP102 operon, These PUFA are the most potent activators of the CYP102 operon observed to date, and we show that their effects are due to binding directly to Bm3R1, In addition, cultures that have been treated with the CYP102 inducer, nafenopin, are protected against PUFA toxicity. Resistance to PUFA toxicity is also seen in a Bm3R1-deficient strain that constitutively expresses CYP102, The resistant phenotype of this Bm3R1 mutant strain is reversed by specific chemical inactivation of CYP102, These data demonstrate that Bm3R1 can act as a direct sensor of toxic fatty acids and, in addition, provide the first direct evidence of fatty acids binding to a prokaryotic transcription factor.	Univ Dundee, Ninewells Hosp & Med Sch, ICRF, Mol Pharmacol Unit, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee	Wolf, CR (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, ICRF, Mol Pharmacol Unit, Dundee DD1 9SY, Scotland.		Palmer, Colin NA/C-7053-2008	Palmer, Colin NA/0000-0002-6415-6560				BELL DR, 1992, EUR J BIOCHEM, V206, P979, DOI 10.1111/j.1432-1033.1992.tb17009.x; BUCHANAN JF, 1978, BIOCHEM BIOPH RES CO, V85, P1254, DOI 10.1016/0006-291X(78)91138-5; Burr GO, 1930, J BIOL CHEM, V86, P0587; Capdevila JH, 1996, J BIOL CHEM, V271, P22663, DOI 10.1074/jbc.271.37.22663; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; DIRUSSO CC, 1988, NUCLEIC ACIDS RES, V16, P7995, DOI 10.1093/nar/16.16.7995; DIRUSSO CC, 1992, J BIOL CHEM, V267, P8685; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; ENGLISH N, 1994, J BIOL CHEM, V269, P26836; English N, 1996, BIOCHEM J, V316, P279, DOI 10.1042/bj3160279; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FULCO AJ, 1967, BIOCHIM BIOPHYS ACTA, V144, P701, DOI 10.1016/0005-2760(67)90065-3; GEBREMEDHIN D, 1993, J VASC RES, V30, P53, DOI 10.1159/000158975; GIBSON G, 1993, PEROXISOMES BIOL IMP; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; HENRY MF, 1992, CELL, V70, P671, DOI 10.1016/0092-8674(92)90435-F; KANEDA T, 1977, BACTERIOL REV, V41, P391, DOI 10.1128/MMBR.41.2.391-418.1977; Karpichev IV, 1997, MOL CELL BIOL, V17, P69, DOI 10.1128/MCB.17.1.69; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KLIEWER SA, 1997, P NATL ACAD SCI USA, V94, P4312; LEE SST, 1995, MOL CELL BIOL, V15, P3012; MCPHAIL LC, 1984, SCIENCE, V224, P622, DOI 10.1126/science.6231726; MIURA Y, 1974, J BIOL CHEM, V249, P1880; PALMER CNA, 1993, BIOCHIM BIOPHYS ACTA, V1172, P161, DOI 10.1016/0167-4781(93)90285-L; PALMER CNA, 1994, J BIOL CHEM, V269, P18083; ROMAN LJ, 1993, ARCH BIOCHEM BIOPHYS, V307, P57, DOI 10.1006/abbi.1993.1560; Rottensteiner H, 1996, EMBO J, V15, P2924, DOI 10.1002/j.1460-2075.1996.tb00655.x; RUETTINGER RT, 1989, J BIOL CHEM, V264, P10987; SAGAR PS, 1995, PROSTAG LEUKOTR ESS, V53, P287, DOI 10.1016/0952-3278(95)90129-9; SHA RS, 1993, J BIOL CHEM, V268, P7885; SHAW GC, 1992, J BIOL CHEM, V267, P5515; Shaw GC, 1995, BIOCHEM MOL BIOL INT, V37, P1197; Shaw GC, 1996, CURR MICROBIOL, V32, P124, DOI 10.1007/s002849900022; SHAW GC, 1993, J BIOL CHEM, V268, P2997; SHIRANE N, 1993, BIOCHEMISTRY-US, V32, P13732, DOI 10.1021/bi00212a044; STRAUCH MA, 1992, MOL MICROBIOL, V6, P2909, DOI 10.1111/j.1365-2958.1992.tb01750.x; VONEULER VS, 1936, J PHYSIOL-LONDON, V88, P208; WEISSBART D, 1992, BIOCHIM BIOPHYS ACTA, V1124, P135, DOI 10.1016/0005-2760(92)90089-E; WEN LP, 1987, J BIOL CHEM, V262, P6676; XU ZH, 1993, J BIOL CHEM, V268, P7874; YOU SY, 1989, J BIOL CHEM, V264, P16489	41	31	34	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18109	18116		10.1074/jbc.273.29.18109	http://dx.doi.org/10.1074/jbc.273.29.18109			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660768	hybrid			2022-12-25	WOS:000074828500023
J	Park, YC; Bedouelle, H				Park, YC; Bedouelle, H			Dimeric tyrosyl-tRNA synthetase from Bacillus stearothermophilus unfolds through a monomeric intermediate - A quantitative analysis under equilibrium conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; SITE-DIRECTED MUTAGENESIS; SUBUNIT INTERFACE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; MOLTEN GLOBULE; FOLDED STATE; PROTEIN; STABILITY; ENZYME	Tyrosyl-tRNA synthetase from Bacillus stearother-mophilus comprises an N-terminal domain (residues 1-319), which is dimeric and forms tyrosyladenylate, and a C-terminal domain (residues 320-419), which binds the anticodon arm of tRNA(Tyr). The N-terminal domain has the characteristic fold of the class I amino-acyl-tRNA synthetases. The unfolding of the N-terminal domain by urea at 25 degrees C under equilibrium conditions was monitored by its intensities of Light emission at 330 and 350 nm, the ratio of these intensities, its ellipticity at 229 nm, and its partition coefficient, in spectrofluorometry, circular dichroism, and size-exclusion chromatography experiments, respectively. These experiments showed the existence of an equilibrium between the native dimeric state of the N-terminal domain, a monomeric intermediate state, and the unfolded state. The intermediate was compact and had secondary structure, and its tryptophan residues were partially buried. These properties of the intermediate and its inability to bind 1-anilino-8-naphthalenesulfonate showed that it was not in a molten globular state. The variation of free energy Delta G(H2O) and its coefficient m of dependence on the concentration of urea were, respectively, 13.8 +/- 0.2 kcal mol-l and 0.9 +/- 0.1 kcal.mol(-1).M-1 for the dissociation of the native dimer and 13.9 +/- 0.6 kcal.mol(-1) and 2.5 +/- 0.1 kcal.mol(-1).M-1 for the unfolding of the monomeric intermediate.	Inst Pasteur, Unite Biochim Cellulaire, CNRS, URA 1129,Grp Ingn Prot, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Bedouelle, H (corresponding author), Inst Pasteur, Unite Biochim Cellulaire, CNRS, URA 1129,Grp Ingn Prot, 28 Rue Docteur Roux, F-75724 Paris 15, France.							Ackers G K, 1970, Adv Protein Chem, V24, P343, DOI 10.1016/S0065-3233(08)60245-4; Arnez JG, 1997, TRENDS BIOCHEM SCI, V22, P211, DOI 10.1016/S0968-0004(97)01052-9; AVIS JM, 1993, BIOCHEMISTRY-US, V32, P5312, DOI 10.1021/bi00071a005; BEDOUELLE H, 1986, NATURE, V320, P371, DOI 10.1038/320371a0; Blondel A, 1996, PROTEIN ENG, V9, P231, DOI 10.1093/protein/9.2.231; BRAND L, 1972, ANNU REV BIOCHEM, V41, P843, DOI 10.1146/annurev.bi.41.070172.004211; BRICK P, 1989, J MOL BIOL, V208, P83, DOI 10.1016/0022-2836(89)90090-9; BRICK P, 1987, J MOL BIOL, V194, P287, DOI 10.1016/0022-2836(87)90376-7; CALENDAR R, 1966, BIOCHEMISTRY-US, V5, P1681, DOI 10.1021/bi00869a033; CHENG XD, 1993, BIOCHEMISTRY-US, V32, P8130, DOI 10.1021/bi00083a011; CLARK AC, 1993, J BIOL CHEM, V268, P10773; CORBETT RJT, 1984, BIOCHEMISTRY-US, V23, P1888, DOI 10.1021/bi00303a047; CUSACK S, 1995, NAT STRUCT BIOL, V2, P824, DOI 10.1038/nsb1095-824; DOUBLIE S, 1995, STRUCTURE, V3, P17, DOI 10.1016/S0969-2126(01)00132-0; EFTINK MR, 1994, BIOCHEMISTRY-US, V33, P10220, DOI 10.1021/bi00200a002; FERSHT AR, 1987, BIOCHEMISTRY-US, V26, P8031, DOI 10.1021/bi00399a001; GRISLEY JK, 1997, BIOCHEMISTRY-US, V36, P14366; GuezIvanier V, 1996, J MOL BIOL, V255, P110, DOI 10.1006/jmbi.1996.0010; HAUGLAND RP, 1991, HDB FLUORESCENT PROB; HIBBARD LS, 1978, BIOCHEMISTRY-US, V17, P5460, DOI 10.1021/bi00618a021; JAKUBOWSKI H, 1984, J BACTERIOL, V158, P769, DOI 10.1128/JB.158.3.769-776.1984; JONES DH, 1985, BIOCHEMISTRY-US, V24, P5852, DOI 10.1021/bi00342a024; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; NATH U, 1995, BIOCHEMISTRY-US, V34, P1702, DOI 10.1021/bi00005a027; NEET KE, 1994, PROTEIN SCI, V3, P2167, DOI 10.1002/pro.5560031202; Pace C N, 1986, Methods Enzymol, V131, P266; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; UVERSKY VN, 1993, BIOCHEMISTRY-US, V32, P13288, DOI 10.1021/bi00211a042; UVERSKY VN, 1994, BIOCHEMISTRY-US, V33, P2782, DOI 10.1021/bi00176a006; VIDALCROS A, 1992, J MOL BIOL, V223, P801, DOI 10.1016/0022-2836(92)90991-R; WARD WHJ, 1988, BIOCHEMISTRY-US, V27, P1041, DOI 10.1021/bi00403a029; WARD WHJ, 1987, BIOCHEMISTRY-US, V26, P4131, DOI 10.1021/bi00387a058; WAYE MMY, 1983, EMBO J, V2, P1827, DOI 10.1002/j.1460-2075.1983.tb01665.x; WILKINSON AJ, 1983, BIOCHEMISTRY-US, V22, P3581, DOI 10.1021/bi00284a007	35	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18052	18059		10.1074/jbc.273.29.18052	http://dx.doi.org/10.1074/jbc.273.29.18052			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660761	hybrid			2022-12-25	WOS:000074828500016
J	Pikuleva, IA; Babiker, A; Waterman, MR; Bjorkhem, I				Pikuleva, IA; Babiker, A; Waterman, MR; Bjorkhem, I			Activities of recombinant human cytochrome P450c27 (CYP27) which produce intermediates of alternative bile acid biosynthetic pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTEROL 7-ALPHA-HYDROXYLASE GENE; RABBIT LIVER-MITOCHONDRIA; SMOOTH-MUSCLE CELLS; STEROL 27-HYDROXYLASE; CEREBROTENDINOUS XANTHOMATOSIS; SIDE-CHAIN; CHENODEOXYCHOLIC ACIDS; 26-HYDROXYCHOLESTEROL; 27-HYDROXYCHOLESTEROL; 26-HYDROXYLATION	The primary physiological significance of cytochrome P450c27 (CYP27) has been associated with its role in the degradation of the side chain of C-27 steroids in the hepatic bile acid biosynthesis pathway, which begins with 7 alpha-hydroxylation of cholesterol in liver. However, recognition that in humans P450c27 is a widely or ubiquitously expressed mitochondrial P450, and that there are alternative pathways of bile acid synthesis which begin with 27-hydroxylation of cholesterol catalyzed by P450c27, suggests the need to reevaluate the role of this enzyme and its catalytic properties. 27-Hydroxycholesterol was thought to be the only product formed upon reaction of P450c27 with cholesterol. However, the present study demonstrates that recombinant human P450c27 is also able to further oxidize 27-hydroxycholesterol giving first an aldehyde and then 3 beta-hydroxy-5-cholestenoic acid. Kinetic data indicate that in a reconstituted system, after 27-hydroxycholesterol is formed from cholesterol, it is released from the P450 and then competes with cholesterol for reentry the enzyme active site for further oxidation, Under subsaturating substrate concentrations, the efficiencies of oxidation of 27-hydroxycholesterol and 3 beta-hydroxy-5-cholestenal to the acid by human P450c27 are greater than the efficiency of hydroxylation of cholesterol to 27-hydroxycholesterol indicating that the first hydroxylation step in the overall conversion of cholesterol into 3 beta-hydroxy-5-cholestenoic acid is rate-limiting. Interestingly, 3 beta-hydroxy-5-cholestenoic acid was found to be further metabolized by the recombinant human P450c27, giving two monohydroxylated products with the hydroxyl group introduced at different positions on the steroid nucleus.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Huddinge Hosp, Karolinska Inst, Dept Clin Chem, S-14188 Huddinge, Sweden	Vanderbilt University; Karolinska Institutet	Pikuleva, IA (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 221 Kirkland Hall, Nashville, TN 37232 USA.			Pikuleva, Irina/0000-0001-9742-6232; Bjorkhem, Ingemar/0000-0002-0575-9425; Bjorkhem, Ingemar/0000-0001-6087-9190	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037942, R37GM037942] Funding Source: NIH RePORTER; NIEHS NIH HHS [P30 ES00267] Funding Source: Medline; NIGMS NIH HHS [GM37942] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON KE, 1972, J CLIN INVEST, V51, P112, DOI 10.1172/JCI106780; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARINGER L, 1971, STEROIDS, V18, P381, DOI 10.1016/0039-128X(71)90052-3; AXELSON M, 1990, J STEROID BIOCHEM, V36, P631, DOI 10.1016/0022-4731(90)90182-R; AXELSON M, 1988, J LIPID RES, V29, P629; AXEN E, 1994, P NATL ACAD SCI USA, V91, P10014, DOI 10.1073/pnas.91.21.10014; Babiker A, 1997, J BIOL CHEM, V272, P26253, DOI 10.1074/jbc.272.42.26253; BARANOWSKI A, 1982, ATHEROSCLEROSIS, V41, P255, DOI 10.1016/0021-9150(82)90190-3; BJORKHEM I, 1973, EUR J BIOCHEM, V36, P201, DOI 10.1111/j.1432-1033.1973.tb02902.x; BJORKHEM I, 1992, BIOCHIM BIOPHYS ACTA, V1128, P73, DOI 10.1016/0005-2760(92)90259-X; BJORKHEM I, 1994, P NATL ACAD SCI USA, V91, P8592, DOI 10.1073/pnas.91.18.8592; CALI JJ, 1991, J BIOL CHEM, V266, P7774; Crisby M, 1997, BBA-LIPID LIPID MET, V1344, P278, DOI 10.1016/S0005-2760(96)00152-X; DAHLBACK H, 1988, BIOCHEM BIOPH RES CO, V153, P267, DOI 10.1016/S0006-291X(88)81217-8; Diczfalusy U, 1996, SCAND J CLIN LAB INV, V56, P9; GUSTAFSSON J, 1978, J BIOL CHEM, V253, P199; HABERLAND ME, 1973, P NATL ACAD SCI USA, V70, P2313, DOI 10.1073/pnas.70.8.2313; HARIKKHAN R, 1990, J STEROID BIOCHEM, V36, P351, DOI 10.1016/0022-4731(90)90228-K; HOLMBERGBETSHOL.I, 1995, J STEROID BIOCHEM, V55, P115; HOLMBERGBETSHOLTZ I, 1993, J BIOL CHEM, V268, P11079; Ishibashi S, 1996, J BIOL CHEM, V271, P18017, DOI 10.1074/jbc.271.30.18017; JAVITT NB, 1990, J LIPID RES, V31, P1527; JAVITT NB, 1982, J LIPID RES, V23, P627; Kimura T, 1978, Methods Enzymol, V52, P132; Lee C, 1996, J LIPID RES, V37, P1356; Lund E, 1996, ARTERIOSCL THROM VAS, V16, P208, DOI 10.1161/01.ATV.16.2.208; LUND E, 1993, BIOCHIM BIOPHYS ACTA, V1166, P177, DOI 10.1016/0005-2760(93)90094-P; LUND E, 1992, J BIOL CHEM, V267, P25092; LUND E, 1995, ACCOUNTS CHEM RES, V28, P241, DOI 10.1021/ar00054a001; MARTIN KO, 1993, J LIPID RES, V34, P581; Martin KO, 1997, J LIPID RES, V38, P1053; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; OFTEBRO H, 1980, J CLIN INVEST, V65, P1418, DOI 10.1172/JCI109806; PAL S, 1983, J LIPID RES, V24, P1281; PENG SK, 1985, ATHEROSCLEROSIS, V54, P121, DOI 10.1016/0021-9150(85)90172-8; PENG SK, 1978, ARCH PATHOL LAB MED, V102, P57; PETRACK B, 1993, J LIPID RES, V34, P643; Pikuleva IA, 1996, ARCH BIOCHEM BIOPHYS, V334, P183, DOI 10.1006/abbi.1996.0445; PILULEVA IA, 1997, ARCH BIOCHEM BIOPHYS, V343, P123; PRINCEN HMG, 1991, BIOCHEM J, V275, P501, DOI 10.1042/bj2750501; Reiss AB, 1997, J LIPID RES, V38, P1254; Schwarz M, 1996, J BIOL CHEM, V271, P18024, DOI 10.1074/jbc.271.30.18017; Schwarz M, 1997, J BIOL CHEM, V272, P23995, DOI 10.1074/jbc.272.38.23995; SEGEL IH, 1993, ENZYME KINETICS, P47; Selley ML, 1996, THROMB RES, V83, P449, DOI 10.1016/0049-3848(96)00154-5; SHODA J, 1993, HEPATOLOGY, V17, P395; SKREDE S, 1986, J CLIN INVEST, V78, P729, DOI 10.1172/JCI112633; STAPLETON G, 1995, J BIOL CHEM, V270, P29739, DOI 10.1074/jbc.270.50.29739; SU P, 1990, DNA CELL BIOL, V9, P657, DOI 10.1089/dna.1990.9.657; SWELL L, 1980, J LIPID RES, V21, P455; TUCKEY RC, 1993, EUR J BIOCHEM, V217, P209, DOI 10.1111/j.1432-1033.1993.tb18235.x; Vlahcevic ZR, 1997, GASTROENTEROLOGY, V113, P1949, DOI 10.1016/S0016-5085(97)70015-5; VOET D, 1990, BIOCHEMISTRY-US, P338; WIKVALL K, 1984, J BIOL CHEM, V259, P3800; ZHOU Q, 1993, P SOC EXP BIOL MED, V202, P75	55	87	88	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18153	18160		10.1074/jbc.273.29.18153	http://dx.doi.org/10.1074/jbc.273.29.18153			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660774	hybrid			2022-12-25	WOS:000074828500029
J	Saha, P; Thome, KC; Yamaguchi, R; Hou, ZH; Weremowicz, S; Dutta, A				Saha, P; Thome, KC; Yamaguchi, R; Hou, ZH; Weremowicz, S; Dutta, A			The human homolog of Saccharomyces cerevisiae CDC45	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; S-PHASE; BUDDING YEAST; FISSION YEAST; CELL-CYCLE; INITIATION; GENE; COMPLEX; PROTEIN; CLONING	In budding yeast Saccharomyces cerevisiae CDC45 is an essential gene required for initiation of DNA replication. A structurally related protein Tsd2 is necessary for DNA replication in Ustilago maydis. We have identified and cloned the gene for a human protein homologous to the fungal proteins. The human gene CDC45L is 30 kilobases long and contains 15 introns, The 16 exons encode a protein of 566 amino acids. The human protein is 52 and 49.5% similar to CDC45p and Tsd2p, respectively. The level of CDC45L mRNA peaks at G(1)-S transition, but total protein amount remains constant throughout the cell cycle. Consistent with a role of CDC45L protein in the initiation of DNA replication it co-immunoprecipitates from cell extracts with a putative replication initiator protein, human ORC2L, In addition, subcellular fractionation indicates that the association of the protein with the nuclear fraction becomes labile as S phase progresses. The CDC45L gene is located to chromosome 22q11.2 region by cytogenetics and by fluorescence in situ hybridization, This region, known as DiGeorge syndrome critical region, is a minimal area of 2 megabases, which is consistently deleted in DiGeorge syndrome and related disorders. The syndrome is marked by parathyroid hypoplasia, thymic aplasia, or hypoplasia and congenital cardiac abnormalities, CDC45L is the first gene mapped to the DiGeorge syndrome critical region interval whose loss may negatively affect cell proliferation.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Dutta, A (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.		Dutta, Anindya/P-3203-2016	Dutta, Anindya/0000-0002-4319-0073; Yamaguchi, Ryuji/0000-0002-1706-7063; Saha, Partha/0000-0002-4514-6391	NATIONAL CANCER INSTITUTE [R01CA060499] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA060499, R01 CA060499-05, CA60499] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1995, CELL, V83, P563, DOI 10.1016/0092-8674(95)90096-9; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; DALTON S, 1995, P NATL ACAD SCI USA, V92, P2514, DOI 10.1073/pnas.92.7.2514; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; Gong WK, 1996, HUM MOL GENET, V5, P789, DOI 10.1093/hmg/5.6.789; HADY C, 1997, GENE AMST, V187, P239; HENNESSY KM, 1990, GENE DEV, V4, P2252, DOI 10.1101/gad.4.12b.2252; Hopwood B, 1996, P NATL ACAD SCI USA, V93, P12309, DOI 10.1073/pnas.93.22.12309; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LISZIEWICZ J, 1988, NUCLEIC ACIDS RES, V16, P11507, DOI 10.1093/nar/16.24.11507; MORROW B, 1995, AM J HUM GENET, V56, P1391; MuziFalconi M, 1996, P NATL ACAD SCI USA, V93, P1566, DOI 10.1073/pnas.93.4.1566; NEY PA, 1993, MOL CELL BIOL, V13, P5604, DOI 10.1128/MCB.13.9.5604; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; Onel K, 1997, MOL GEN GENET, V253, P463, DOI 10.1007/s004380050344; Owens JC, 1997, P NATL ACAD SCI USA, V94, P12521, DOI 10.1073/pnas.94.23.12521; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; Quintana DG, 1997, J BIOL CHEM, V272, P28247, DOI 10.1074/jbc.272.45.28247; Saha P, 1997, MOL CELL BIOL, V17, P4338, DOI 10.1128/MCB.17.8.4338; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; Sirotkin H, 1997, GENOMICS, V42, P245, DOI 10.1006/geno.1997.4734; Williams RS, 1997, P NATL ACAD SCI USA, V94, P142, DOI 10.1073/pnas.94.1.142; ZHOU C, 1989, J BIOL CHEM, V264, P9022; Zou L, 1998, SCIENCE, V280, P593, DOI 10.1126/science.280.5363.593; Zou L, 1997, MOL CELL BIOL, V17, P553, DOI 10.1128/MCB.17.2.553; ZWERSCHKE W, 1994, J BIOL CHEM, V269, P23351	31	49	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18205	18209		10.1074/jbc.273.29.18205	http://dx.doi.org/10.1074/jbc.273.29.18205			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660782	hybrid			2022-12-25	WOS:000074828500037
J	Raats, CJI; Bakker, MAH; Hoch, W; Tamboer, WPM; Groffen, AJA; van den Heuvel, LPWJ; Berden, JHM; van den Born, J				Raats, CJI; Bakker, MAH; Hoch, W; Tamboer, WPM; Groffen, AJA; van den Heuvel, LPWJ; Berden, JHM; van den Born, J			Differential expression of agrin in renal basement membranes as revealed by domain-specific antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; DENSITY-LIPOPROTEIN-RECEPTOR; CELL-ADHESION MOLECULES; EPIDERMAL GROWTH-FACTOR; TORPEDO ELECTRIC ORGAN; EXTRACELLULAR-MATRIX; ALPHA-DYSTROGLYCAN; ACETYLCHOLINE-RECEPTORS; NEUROMUSCULAR-JUNCTION; MONOCLONAL-ANTIBODY	We determined the specificity of two hamster monoclonal antibodies and a sheep polyclonal antiserum against heparan sulfate proteoglycan isolated from rat glomerular basement membrane. The antibodies were characterized by enzyme-linked immunosorbent assay on various basement membrane components and immunoprecipitation with heparan sulfate proteoglycan with or without heparitinase pre-treatment. These experiments showed that the antibodies specifically recognize approximately 150-, 105-, and 70-kDa core proteins of rat glomerular basement membrane heparan sulfate proteoglycan. Recently, we showed that agrin is a major heparan sulfate proteoglycan in the glomerular basement membrane (Groffen, A. J. A., Ruegg, M. A., Dijkman, H. B. P. M., Van der Velden, T. J., Buskens, C. A., van den Born, J., Assmann, It. J. M., Monnens, L. A. H., Veerkamp, J. H., and van den Heuvel, L. P. W. J. (1998) J. Histochem. Cytochem. 46, 19-27). Therefore, we tested whether our antibodies recognize agrin. To this end, we evaluated staining of Chinese hamster ovary cells transfected with constructs encoding full-length or the C-terminal half of rat agrin by analysis on a fluorescence-activated cell sorter. Both hamster monoclonals and the sheep antiserum clearly stained cells transfected with the construct encoding full-length agrin, whereas wild type cells and cells transfected with the construct encoding the C-terminal part of agrin were not recognized. A panel of previously characterized monoclonals, directed against C-terminal agrin, clearly stained cells transfected with either of the constructs but not wild type cells. This indicates that both hamster monoclonals and the sheep antiserum recognize epitopes on the N-terminal half of agrin. By immunohistochemistry on rat renal tissue, we compared distribution of N-terminal agrin with that of C-terminal agrin. The monoclonal antibodies against C-terminal agrin stained almost exclusively the glomerular basement membrane, whereas the anti-N-terminal agrin antibodies recognized all renal basement membranes, including tubular basement membranes. Based on these results, we hypothesize that full-length agrin is predominantly expressed in the glomerular basement membrane, whereas in most other renal basement membranes a truncated isoform of agrin is predominantly found that misses (part of) the C terminus, which might be due to alternative splicing and/or posttranslational processing. The possible significance of this finding is discussed.	Univ Nijmegen St Radboud Hosp, Div Nephrol 545, NL-6500 HB Nijmegen, Netherlands; Univ Nijmegen St Radboud Hosp, Dept Pediat, NL-6500 HB Nijmegen, Netherlands; Max Planck Inst Entwicklungsbiol, Dept Biochem, D-72076 Tubingen, Germany	Radboud University Nijmegen; Radboud University Nijmegen; Max Planck Society	Raats, CJI (corresponding author), Univ Nijmegen St Radboud Hosp, Div Nephrol 545, POB 9101, NL-6500 HB Nijmegen, Netherlands.		van den Heuvel, Lambertus/AAM-1772-2021; Groffen, A.J.A./C-1118-2009; Berden, J.H.M./H-8009-2014; van den Heuvel, L.P.W.J./H-8044-2014	van den Heuvel, Lambertus/0000-0003-3917-6727; Groffen, A.J.A./0000-0003-0046-4027; van den Heuvel, L.P.W.J./0000-0003-3917-6727				BOWE MA, 1995, ANNU REV NEUROSCI, V18, P443; CAMPANELLI JT, 1991, CELL, V67, P909, DOI 10.1016/0092-8674(91)90364-5; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; DeChiara TM, 1996, CELL, V85, P501, DOI 10.1016/S0092-8674(00)81251-9; Denzer AJ, 1997, J CELL BIOL, V137, P671, DOI 10.1083/jcb.137.3.671; DENZER AJ, 1995, J CELL BIOL, V131, P1547, DOI 10.1083/jcb.131.6.1547; DURBEEJ M, 1995, J CELL BIOL, V130, P79, DOI 10.1083/jcb.130.1.79; FARQUHAR MG, 1985, NEPHROLOGY, P580; FERNS M, 1992, NEURON, V8, P1079, DOI 10.1016/0896-6273(92)90129-2; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; Gallagher JT, 1989, CURR OPIN CELL BIOL, V1, P1201, DOI 10.1016/S0955-0674(89)80072-9; Gesemann M, 1998, J BIOL CHEM, V273, P600, DOI 10.1074/jbc.273.1.600; Gesemann M, 1996, NEURON, V16, P755, DOI 10.1016/S0896-6273(00)80096-3; Glass DJ, 1996, CELL, V85, P513, DOI 10.1016/S0092-8674(00)81252-0; GODFREY EW, 1991, EXP CELL RES, V195, P99, DOI 10.1016/0014-4827(91)90504-N; GODFREY EW, 1988, J CELL BIOL, V106, P1263, DOI 10.1083/jcb.106.4.1263; GODFREY EW, 1984, J CELL BIOL, V99, P615, DOI 10.1083/jcb.99.2.615; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; Groffen AJ, 1998, J HISTOCHEM CYTOCHEM, V46, P19, DOI 10.1177/002215549804600104; Groffen AJA, 1997, EUR J BIOCHEM, V247, P175, DOI 10.1111/j.1432-1033.1997.00175.x; HAGEN SG, 1993, J BIOL CHEM, V268, P7261; HIRANO Y, 1989, J NEUROSCI, V9, P1555; HOCH W, 1994, EMBO J, V13, P2814, DOI 10.1002/j.1460-2075.1994.tb06575.x; HOCH W, 1993, NEURON, V11, P479, DOI 10.1016/0896-6273(93)90152-H; Hopf C, 1996, J BIOL CHEM, V271, P5231; Hopf C, 1997, EUR J NEUROSCI, V9, P1170, DOI 10.1111/j.1460-9568.1997.tb01471.x; Joseph SJ, 1996, DEVELOPMENT, V122, P3443; KALLUNKI P, 1992, J CELL BIOL, V116, P559, DOI 10.1083/jcb.116.2.559; KANWAR YS, 1991, SEMIN NEPHROL, V11, P390; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; NITKIN RM, 1987, J CELL BIOL, V105, P2471, DOI 10.1083/jcb.105.6.2471; NOONAN DM, 1993, KIDNEY INT, V43, P53, DOI 10.1038/ki.1993.10; NOONAN DM, 1991, J BIOL CHEM, V266, P22939; OToole JJ, 1996, P NATL ACAD SCI USA, V93, P7369, DOI 10.1073/pnas.93.14.7369; Raats CJI, 1997, J BIOL CHEM, V272, P26734, DOI 10.1074/jbc.272.42.26734; Ruegg MA, 1998, TRENDS NEUROSCI, V21, P22, DOI 10.1016/S0166-2236(97)01154-5; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; SHIMOMURA H, 1987, DIABETES, V36, P374, DOI 10.2337/diabetes.36.3.374; TSEN G, 1995, J BIOL CHEM, V270, P3392, DOI 10.1074/jbc.270.7.3392; TSEN GS, 1995, J BIOL CHEM, V270, P15934, DOI 10.1074/jbc.270.27.15934; VALENZUELA DM, 1995, NEURON, V15, P573, DOI 10.1016/0896-6273(95)90146-9; vandenBorn J, 1995, J BIOL CHEM, V270, P31303, DOI 10.1074/jbc.270.52.31303; VANDENBORN J, 1992, KIDNEY INT, V41, P115, DOI 10.1038/ki.1992.15; VANDENBORN J, 1993, KIDNEY INT, V43, P454, DOI 10.1038/ki.1993.67; VANDENBORN J, 1994, J HISTOCHEM CYTOCHEM, V42, P89, DOI 10.1177/42.1.8263327; VANDENHEUVEL LPWJ, 1989, BIOCHEM J, V264, P457, DOI 10.1042/bj2640457; WALLACE BG, 1990, J NEUROSCI, V10, P3576	50	69	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17832	17838		10.1074/jbc.273.28.17832	http://dx.doi.org/10.1074/jbc.273.28.17832			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651386	hybrid, Green Published			2022-12-25	WOS:000074816100079
J	Wang, QM; Luo, X; Kheir, A; Coffman, FD; Studzinski, GP				Wang, QM; Luo, X; Kheir, A; Coffman, FD; Studzinski, GP			Retinoblastoma protein-overexpressing HL60 cells resistant to 1,25-dihydroxyvitamin D-3 display increased CDK2 and CDK6 activity and shortened G1 phase	ONCOGENE			English	Article						retinoblastoma; vitamin D; human leukemia; cell cycle; cyclins	ACUTE PROMYELOCYTIC LEUKEMIA; TRANS-RETINOIC ACID; HL-60 CELLS; CYCLE PROGRESSION; RESTRICTION POINT; GENE-EXPRESSION; SP1-MEDIATED TRANSCRIPTION; MONOCYTIC DIFFERENTIATION; MACROPHAGE PROLIFERATION; LINE HL-60	Drug resistance that occurs during cancer chemotherapy has been a major problem in controlling neoplastic progression. To study the cellular mechanisms of acquired drug resistance we developed 1,25-dihydroxy-vitamin D-3 (1,25D(3))-resistant sublines of promyelocytic leukemia HL60 cells which have increased proliferation rates (Exp, Cell Xes., 224, 312, 1996; Cancer Res., 50, 5513, 1996), We report here that the resistant sublines display varying degrees of shortening of the G1 phase as compared to the parental HL60-G cells. Protein levels of cyclins E, D1, D2 and D3 are elevated in these resistant cell lines, and cyclin D1 is especially high in 40AF cells, which has the shortest G1 length. The protein levels of cyclin-dependent kinase (Cdk)2, Cdk4 and Cdk6 are not altered in the resistant sublines. Both Cdk2 and Cdk6-associated kinase activites are increased in the resistant sublines, but not Cdk4 kinase activity. Protein levels of p27(Kip1) are not consistently altered in the resistant sublines as compared to the parental HL60-G cells, but are reduced relative to HL60-G cells arrested by 96 h treatment with 1,25D(3). Interestingly, the resistant cell lines constitutively express high levels of retinoblastoma protein (pRb), and pRb is highly phosphorylated, indicating that the G1 cyclin/Cdk complexes in the resistant cells are physiologically active. The results suggest that the increased activity of cyclin D/Cdk6, and perhaps cyclin E/Cdk2, lead to rapid hyperphosphorylation of pRb and consequently a shorter early G1 phase, and that in the resistant cells the increased ratio of cyclin E to p27(Kip1) results in activation of Cdk2 and contributes to the abrogation of the 1,25D(3)-induced block to the S phase entry. Additionally, it is apparent that constitutively increased levels of pRb are compatible with increased rates of cell proliferation.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pathol & Lab Med, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Studzinski, GP (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pathol & Lab Med, 185 S Orange Ave, Newark, NJ 07103 USA.				PHS HHS [R01-44722] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bergh G, 1997, BLOOD, V89, P2938, DOI 10.1182/blood.V89.8.2938; BRELVI ZS, 1986, J CELL BIOL, V102, P2234, DOI 10.1083/jcb.102.6.2234; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DOU QP, 1993, CANCER RES, V53, P1493; GALLAGHER R, 1979, BLOOD, V54, P713; GODYN JJ, 1994, CELL PROLIFERAT, V27, P37, DOI 10.1111/j.1365-2184.1994.tb01404.x; GONG J, 1995, LEUKEMIA, V9, P893; HAUSSLER MR, 1969, P NATL ACAD SCI USA, V62, P155, DOI 10.1073/pnas.62.1.155; HOLICK MF, 1971, BIOCHEMISTRY-US, V10, P2799; HUME DA, 1982, ADV EXP MED BIOL, V155, P261; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG W, 1993, ONCOGENE, V8, P3447; Juan G, 1996, CELL PROLIFERAT, V29, P259, DOI 10.1046/j.1365-2184.1996.01000.x; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; Kolla Sarah S, 1994, Molecular and Cellular Differentiation, V2, P169; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KURIBAYASHI T, 1983, ENDOCRINOLOGY, V113, P1992, DOI 10.1210/endo-113-6-1992; LASKY SR, 1994, BLOOD, V84, P4238; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; MULLER R, 1985, NATURE, V314, P546, DOI 10.1038/314546a0; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; REITSMA PH, 1983, NATURE, V306, P492, DOI 10.1038/306492a0; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; Sanchez I, 1996, CURR OPIN CELL BIOL, V8, P318, DOI 10.1016/S0955-0674(96)80004-4; SAWYER RT, 1986, J LEUKOCYTE BIOL, V39, P77, DOI 10.1002/jlb.39.1.77; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; SLADEK TL, 1992, J VIROL, V66, P1059, DOI 10.1128/JVI.66.2.1059-1065.1992; Studzinski George P., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P279; Studzinski GP, 1997, EXP CELL RES, V232, P376, DOI 10.1006/excr.1997.3484; Tallman MS, 1997, NEW ENGL J MED, V337, P1021, DOI 10.1056/NEJM199710093371501; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; Wajchman HJ, 1996, EXP CELL RES, V224, P312, DOI 10.1006/excr.1996.0141; Wang QM, 1997, CANCER RES, V57, P2851; Wang QM, 1996, CANCER RES, V56, P264; Wang XN, 1997, J NATL CANCER I, V89, P1199, DOI 10.1093/jnci/89.16.1199; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Yang Xiao-He, 1995, Gene Expression, V4, P195; ZHANG F, 1994, CELL PROLIFERAT, V27, P643, DOI 10.1111/j.1365-2184.1994.tb01379.x	53	18	19	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	1998	16	21					2729	2737		10.1038/sj.onc.1201803	http://dx.doi.org/10.1038/sj.onc.1201803			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ013	9652739				2022-12-25	WOS:000073812200004
J	Chang, S; Hu, T; Hsieh, TS				Chang, S; Hu, T; Hsieh, TS			Analysis of a core domain in Drosophila DNA topoisomerase II - Targeting of an antitumor agent ICRF-159	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; CLEAVAGE SITES; SACCHAROMYCES-CEREVISIAE; 2-GATE MECHANISM; PROTEIN CLAMP; ENZYME; YEAST; INHIBITION; DERIVATIVES; TRANSPORT	To investigate the biochemical properties of individual domains of eukaryotic topoisomerase (topo) II, two truncation mutants of Drosophila topo II were generated, ND406 and core domain. Both mutants lack the ATPase domain, corresponding to the N-terminal 406 amino acid residues in Drosophila protein. The core domain also lacks 240 amino acid residues of the hydrophilic C-terminal region. The mutant proteins have lost DNA strand passage activity while retaining the ability to cleave the DNA and the sequence preference in protein/DNA interaction, The cleavage experiments carried out in the presence of several topo II poisons suggest that the core domain is the key target for these drugs. We have used glass-fiber filter binding assay and CsCl density gradient ultracentrifugation to monitor the formation of a salt-stable, protein-clamp complex. Both truncation mutant proteins can form a clamp complex in the presence of an antitumor agent, ICRF-159, suggesting that the drug targets the core domain of the enzyme and promotes the intradimeric closure at the N-terminal interface of the core domain. Furthermore, the salt stability of the closed protein clamp induced by ICRF-159 depends on the presence and closure of the N-terminal ATPase domain.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Hsieh, TS (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Box 3711 DUMC, Durham, NC 27710 USA.		Hsieh, Tao-shih/G-9305-2012; Wu, Wan-lin/G-8937-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029006] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM29006] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi N, 1997, NUCLEIC ACIDS RES, V25, P3135, DOI 10.1093/nar/25.15.3135; Berger JM, 1996, CURR OPIN STRUC BIOL, V6, P84, DOI 10.1016/S0959-440X(96)80099-6; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; BORITZKI TJ, 1988, BIOCHEM PHARMACOL, V37, P4063, DOI 10.1016/0006-2952(88)90096-2; BOROS I, 1984, GENE, V30, P257, DOI 10.1016/0378-1119(84)90130-6; BROWN PO, 1979, P NATL ACAD SCI USA, V76, P6110, DOI 10.1073/pnas.76.12.6110; Caron P R, 1994, Adv Pharmacol, V29B, P271; CARON PR, 1994, MOL CELL BIOL, V14, P3197, DOI 10.1128/MCB.14.5.3197; CHEN GL, 1984, J BIOL CHEM, V259, P3560; CORBETT AH, 1993, J BIOL CHEM, V268, P14394; COZZARELLI NR, 1980, CELL, V22, P327, DOI 10.1016/0092-8674(80)90341-4; CRENSHAW DG, 1993, J BIOL CHEM, V268, P21328; DEPEW RE, 1978, J BIOL CHEM, V253, P511; DRAKE FH, 1989, CANCER RES, V49, P2578; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; GELLERT M, 1979, P NATL ACAD SCI USA, V83, P7152; HSIANG YH, 1989, MOL PHARMACOL, V36, P371; HSIEH T-S, 1992, Current Opinion in Cell Biology, V4, P396, DOI 10.1016/0955-0674(92)90004-V; HSIEH TS, 1983, METHOD ENZYMOL, V100, P161; Hu T, 1998, J BIOL CHEM, V273, P9586, DOI 10.1074/jbc.273.16.9586; Ishida R, 1996, ANTICANCER RES, V16, P2735; ISHIDA R, 1995, CANCER RES, V55, P2299; ISHIDA R, 1994, J CELL BIOL, V126, P1341, DOI 10.1083/jcb.126.6.1341; JENSEN PB, 1990, CANCER RES, V50, P3311; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MP, 1989, J BIOL CHEM, V264, P21779; LEE MP, 1992, NUCLEIC ACIDS RES, V20, P5027, DOI 10.1093/nar/20.19.5027; LEE MP, 1994, J MOL BIOL, V235, P436, DOI 10.1006/jmbi.1994.1004; Li W, 1997, J BIOL CHEM, V272, P31190, DOI 10.1074/jbc.272.49.31190; LINDSLEY JE, 1993, NATURE, V361, P749, DOI 10.1038/361749a0; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; RIOU JF, 1986, BIOCHEM BIOPH RES CO, V137, P154, DOI 10.1016/0006-291X(86)91189-7; Roca J, 1996, P NATL ACAD SCI USA, V93, P4057, DOI 10.1073/pnas.93.9.4057; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781, DOI 10.1073/pnas.91.5.1781; SHIOZAKI K, 1992, J CELL BIOL, V119, P1023, DOI 10.1083/jcb.119.5.1023; SHIOZAKI K, 1991, MOL CELL BIOL, V11, P6093, DOI 10.1128/MCB.11.12.6093; TANABE K, 1991, CANCER RES, V51, P4903; THOMAS CA, 1979, ANAL BIOCHEM, V93, P158, DOI 10.1016/S0003-2697(79)80130-X; UDVARDY A, 1985, CELL, V40, P933, DOI 10.1016/0092-8674(85)90353-8; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WIGLEY DB, 1995, ANNU REV BIOPH BIOM, V24, P185, DOI 10.1146/annurev.bb.24.060195.001153; WYCKOFF E, 1988, P NATL ACAD SCI USA, V85, P6272, DOI 10.1073/pnas.85.17.6272; YANG L, 1985, CELL, V41, P127, DOI 10.1016/0092-8674(85)90067-4	50	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19822	19828		10.1074/jbc.273.31.19822	http://dx.doi.org/10.1074/jbc.273.31.19822			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677416	hybrid			2022-12-25	WOS:000075125200068
J	Hennig, D; Scales, SJ; Moreau, A; Murley, LL; De Mey, J; Kreis, TE				Hennig, D; Scales, SJ; Moreau, A; Murley, LL; De Mey, J; Kreis, TE			A formiminotransferase cyclodeaminase isoform is localized to the Golgi complex and can mediate interaction of trans-Golgi network-derived vesicles with microtubules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MDCK CELLS; PLASMA-MEMBRANE; KIDNEY-CELLS; HEAVY-CHAINS; PROTEIN; SEQUENCE; BINDING; IDENTIFICATION; PURIFICATION; ANTIBODIES	A protein of 60 kDa (p60) has been identified using a quantitative in vitro vesicle-microtubule binding assay. Purified p60 induces co-sedimentation with microtubules of trans-Golgi network-derived vesicles isolated from polarized, perforated Madin-Darby canine kidney cells. Sequencing of the cDNA coding for this protein revealed that it is the chicken homologue of formiminotransferase cyclodeaminase (FTCD), a liver specific enzyme involved in the histidine degradation pathway. Purified p60 from chicken liver has formiminotransferase activity, confirming that it is FTCD or an isoform of this enzyme. Isoforms of FTCD were identified in chicken hepatoma and HeLa cells, and immunolocalize to the region of the Golgi complex and vesicular structures in its vicinity. Furthermore, 58K, a previously identified microtubule-binding Golgi protein from rat liver (Bloom, G. S., and Brashear, T. A. (1989) J. Biol. Chem. 264, 16083-16092), is identical to FTCD. Both proteins co-purify with microtubules and co-localize with membranes of the Golgi complex. The capacity of FTCD to bind both to microtubules and Golgi-derived membranes may suggest that this protein, or one of its isoforms, might have in addition to its enzymatic activity, a second physiological function in mediating interaction of Golgi-derived membranes with microtubules.	Univ Geneva, Dept Cell Biol, CH-1211 Geneva 4, Switzerland; Inst Jacques Monod, Dept Supramol & Cell Biol, F-75251 Paris, France; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	University of Geneva; UDICE-French Research Universities; Universite Paris Cite; McGill University	Kreis, TE (corresponding author), Univ Geneva, Dept Cell Biol, 30 Quai Ernest Ansermet, CH-1211 Geneva 4, Switzerland.		Scales, Suzie J./H-4507-2019	Scales, Suzie J./0000-0003-2544-0283				AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; Allan V, 1996, CURR BIOL, V6, P630, DOI 10.1016/S0960-9822(09)00434-5; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BACALLAO R, 1989, J CELL BIOL, V109, P2817, DOI 10.1083/jcb.109.6.2817; BAIROCH A, 1989, EMBL BIOCOMPUTING TE; Bashour AM, 1998, J BIOL CHEM, V273, P19612, DOI 10.1074/jbc.273.31.19612; BEAUDET R, 1976, BIOCHIM BIOPHYS ACTA, V453, P151, DOI 10.1016/0005-2795(76)90259-2; BENNETT MK, 1988, EMBO J, V7, P4075, DOI 10.1002/j.1460-2075.1988.tb03301.x; BLOOM GS, 1989, J BIOL CHEM, V264, P16083; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHISTOSERDOVA LV, 1994, J BACTERIOL, V176, P7398, DOI 10.1128/JB.176.23.7398-7404.1994; DANEELS G, 1986, J IMMUNOL METHODS, V89, P89, DOI 10.1016/0022-1759(86)90035-9; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRURY EJ, 1975, ARCH BIOCHEM BIOPHYS, V169, P662, DOI 10.1016/0003-9861(75)90210-6; EDDE B, 1990, SCIENCE, V247, P83, DOI 10.1126/science.1967194; FINDLAY WA, 1989, BIOCHIM BIOPHYS ACTA, V999, P52, DOI 10.1016/0167-4838(89)90029-0; FINDLAY WA, 1987, BIOCHEMISTRY-US, V26, P1948, DOI 10.1021/bi00381a024; FINDLAY WA, 1988, BIOCHEMISTRY-US, V27, P3404, DOI 10.1021/bi00409a042; GAUSEPOHL H, 1986, ADV METHODS PROTEIN, P149; GIBBONS IR, 1987, J BIOL CHEM, V262, P2780; Goodson HV, 1997, CURR OPIN CELL BIOL, V9, P18, DOI 10.1016/S0955-0674(97)80147-0; INGOLD AL, 1988, J CELL BIOL, V107, P2657, DOI 10.1083/jcb.107.6.2657; JACKSON RC, 1979, DEV BIOCHEM, V4, P665; Keller P, 1997, J CELL SCI, V110, P3001; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFONT F, 1994, NATURE, V372, P801; LANGLOIS AJ, 1974, CANCER RES, V34, P1457; MacKenzie R E, 1980, Methods Enzymol, V66, P626; MACKENZIE RE, 1980, BIOCHIM BIOPHYS ACTA, V611, P187, DOI 10.1016/0005-2744(80)90054-6; MACKENZIE RE, 1979, DEV BIOCHEM, V4, P443; MCCLAIN LD, 1975, J NEUROCHEM, V24, P719, DOI 10.1111/j.1471-4159.1975.tb03854.x; MURLEY LL, 1995, BIOCHEMISTRY-US, V34, P10358, DOI 10.1021/bi00033a006; MURLEY LL, 1993, J BIOL CHEM, V268, P22820; NEVINS JR, 1983, ANNU REV BIOCHEM, V52, P441, DOI 10.1146/annurev.bi.52.070183.002301; PAQUIN J, 1985, J BIOL CHEM, V260, P4925; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; RECHID R, 1989, COMPUT APPL BIOSCI, V5, P107; RICKARD JE, 1991, J BIOL CHEM, V266, P17597; RICKARD JE, 1990, J CELL BIOL, V110, P1623, DOI 10.1083/jcb.110.5.1623; Rickard JE, 1996, TRENDS CELL BIOL, V6, P178, DOI 10.1016/0962-8924(96)10017-9; Sambrook J., 2002, MOL CLONING LAB MANU; SCHEEL J, 1991, J BIOL CHEM, V266, P18141; Schroer TA, 1996, SEMIN CELL DEV BIOL, V7, P321, DOI 10.1006/scdb.1996.0041; SHANE B, 1984, FOLATES PTERINS, V1, P433; Sheetz MP, 1996, SEMIN CELL DEV BIOL, V7, P329, DOI 10.1006/scdb.1996.0042; SHESTAKOVA E, 1998, IN PRESS EUR J CELL; SIBBALD PR, 1990, COMPUT APPL BIOSCI, V6, P279; TABOR H, 1959, J BIOL CHEM, V234, P1830; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; VANDERSLUIJS P, 1990, J CELL SCI, V95, P545; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987	56	39	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19602	19611		10.1074/jbc.273.31.19602	http://dx.doi.org/10.1074/jbc.273.31.19602			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677386	hybrid			2022-12-25	WOS:000075125200038
J	Mark, BL; Wasney, GA; Salo, TJS; Khan, AR; Cao, ZM; Robbins, PW; James, MNG; Triggs-Raine, BL				Mark, BL; Wasney, GA; Salo, TJS; Khan, AR; Cao, ZM; Robbins, PW; James, MNG; Triggs-Raine, BL			Structural and functional characterization of Streptomyces plicatus beta-N-acetylhexosaminidase by comparative molecular modeling and site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAY-SACHS-DISEASE; AMINO-ACID-SEQUENCE; GLYCOSYL HYDROLASES; ALPHA-SUBUNIT; HEXOSAMINIDASE-A; ESCHERICHIA-COLI; HUMAN ENZYME; CLONING; CDNA; GENE	We have sequenced the Streptomyces plicatus beta-N-acetylhexosaminidase (SpHex) gene and identified the encoded protein as a member of family 20 glycosyl hydrolases, This family includes human beta-N-acetylhexosaminidases whose deficiency results in various forms of G(M2) gangliosidosis, Based upon the x-ray structure of Serratia marcescens chitobiase (SmChb), we generated a three-dimensional model of SpHex by comparative molecular modeling. The overall structure of the enzyme is very similar to homology modeling-derived structures of human beta-N-acetylhexosaminidases, with differences being confined mainly to loop regions. From previous studies of the human enzymes, sequence alignments of family 20 enzymes, and analysis of the SmChb x-ray structure, we selected and mutated putative SpHex active site residues. Arg(162) --> His mutation increased K-m 40-fold and reduced V-max 5-fold, providing the first biochemical evidence for this conserved Arg residue (Arg(178) in human beta-N-acetylhexosaminidase A (HexA) and Arg(349) in SmChb) as a substrate-binding residue in a family 20 enzyme, a finding consistent with our three-dimensional model of SpHex, Glu(314) --> Gln reduced V-max 296-fold, reduced K-m 7-fold, and altered the pH profile, consistent with it being the catalytic acid residue as suggested by our model and other studies. Asp(246) --> Asn reduced V-max 2-fold and increased K-m only 1.2-fold, suggesting that Asp(246) may play a lesser role in the catalytic mechanism of this enzyme. Taken together with the xray structure of SmChb, these studies suggest a common catalytic mechanism for family 20 glycosyl hydrolases.	Univ Manitoba, Dept Biochem & Mol Biol, Winnipeg, MB R3E 0W3, Canada; Univ Manitoba, Dept Human Genet, Winnipeg, MB R3E 0W3, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; MIT, Ctr Canc Res, Cambridge, MA 02139 USA	University of Manitoba; University of Manitoba; University of Alberta; Massachusetts Institute of Technology (MIT)	Triggs-Raine, BL (corresponding author), Univ Manitoba, Dept Biochem & Mol Biol, Winnipeg, MB R3E 0W3, Canada.		Triggs-Raine, Barbara/AAF-6209-2021	Triggs-Raine, Barbara/0000-0003-4719-6779; Mark, Brian/0000-0002-7344-1355; Robbins, Phillips/0000-0002-5121-1524; Khan, Amir/0000-0003-1176-6952				BAPAT B, 1988, FEBS LETT, V237, P191, DOI 10.1016/0014-5793(88)80199-6; BAYLERAN J, 1987, AM J HUM GENET, V41, P532; BEANAN MJ, 1995, J EUKARYOT MICROBIOL, V42, P632, DOI 10.1111/j.1550-7408.1995.tb05919.x; BEBENEK K, 1989, NUCLEIC ACIDS RES, V17, P5408, DOI 10.1093/nar/17.13.5408; BECCARI T, 1992, BIOCHEM J, V285, P593, DOI 10.1042/bj2850593; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN CA, 1991, J BIOL CHEM, V266, P15855; BROWN CA, 1989, J BIOL CHEM, V264, P21705; BROWN CA, 1993, AM J HUM GENET, V53, P497; BRUNGER AT, 1993, XPLOR SYSTEM XRAY CR, P125; CANNON RD, 1994, J BACTERIOL, V176, P2640, DOI 10.1128/JB.176.9.2640-2647.1994; Cao ZM, 1997, J BIOL CHEM, V272, P14975, DOI 10.1074/jbc.272.23.14975; CARTER P, 1991, DIRECTED MUTAGENESIS, P1; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; Fernandes Maria, 1992, Human Molecular Genetics, V1, P759, DOI 10.1093/hmg/1.9.759; Fernandes MJG, 1997, J BIOL CHEM, V272, P814, DOI 10.1074/jbc.272.2.814; GRAHAM TR, 1988, J BIOL CHEM, V263, P16823; Gravel R. A., 1995, METABOLIC BASIS INHE, P1807; Henderson Peter J.F., 1993, P277; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LOVATT A, 1994, MICROBIOL-UK, V140, P3399, DOI 10.1099/13500872-140-12-3399; MOSIMANN S, 1995, PROTEINS, V23, P301, DOI 10.1002/prot.340230305; MULDOON LL, 1994, AM J PATHOL, V144, P1109; MYEROWITZ R, 1985, P NATL ACAD SCI USA, V82, P7830, DOI 10.1073/pnas.82.23.7830; NAGAMATSU Y, 1995, BIOSCI BIOTECH BIOCH, V59, P219, DOI 10.1271/bbb.59.219; NISEN P, 1979, P NATL ACAD SCI USA, V76, P6240, DOI 10.1073/pnas.76.12.6240; ODOWD BF, 1985, P NATL ACAD SCI USA, V82, P7830; Pennybacker M, 1997, J BIOL CHEM, V272, P8002, DOI 10.1074/jbc.272.12.8002; POWELL MJD, 1977, MATH PROGRAM, V12, P241, DOI 10.1007/BF01593790; ROBBINS PW, 1988, J BIOL CHEM, V263, P443; ROBBINS PW, 1992, GENE, V111, P69, DOI 10.1016/0378-1119(92)90604-N; Sambrook J., 1989, MOL CLONING LAB MANU, V1; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; SOMERVILLE CC, 1993, P NATL ACAD SCI USA, V90, P6751, DOI 10.1073/pnas.90.14.6751; SOTOGIL RW, 1989, J BIOL CHEM, V264, P14778; Tews I, 1996, NAT STRUCT BIOL, V3, P638, DOI 10.1038/nsb0796-638; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUJIBO H, 1995, APPL ENVIRON MICROB, V61, P804, DOI 10.1128/AEM.61.2.804-806.1995	47	59	59	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19618	19624		10.1074/jbc.273.31.19618	http://dx.doi.org/10.1074/jbc.273.31.19618			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677388	hybrid			2022-12-25	WOS:000075125200040
J	Meredith, J; Mu, ZM; Saido, T; Du, XP				Meredith, J; Mu, ZM; Saido, T; Du, XP			Cleavage of the cytoplasmic domain of the integrin beta(3) subunit during endothelial cell apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; OUT SIGNAL-TRANSDUCTION; FOCAL ADHESION KINASE; PROTEASE INHIBITORS; NPXY MOTIF; CALPAIN; ACTIVATION; IDENTIFICATION; PP125(FAK); MUTATION	In this study, we report that the cytoplasmic domain of the integrin beta(3) subunit is a target for limited proteolysis during apoptosis of human umbilical vein endothelial cells, Calpain inhibitors inhibited the cleavage of the beta(3) cytoplasmic domain, indicating that calpain is required. Calpain-mediated proteolysis of fodrin was also detected, indicating that calpain is activated during endothelial cell apoptosis. A phosphatase inhibitor, sodium orthovanadate, inhibited endothelial cell apoptosis and cleavage beta(3), suggesting that protein dephosphorylation preceded integrin cleavage in the apoptosis signaling pathway. beta(3) cleavage was observed in cells that were viable, suggesting that it is an early event and not the consequence of post-death proteolysis. The extent of beta(3) cleavage correlated with a loss in the capacity of cells to reattach to matrix proteins. Loss of reattachment capacity during apoptosis was significantly retarded by a calpain inhibitor. As the beta(3) cytoplasmic domain is required for integrin signaling and interaction with the cytoskeleton, our results suggest that cleavage in the beta(3) cytoplasmic domain by calpain or a calpain-like protease negatively regulates integrin-mediated adhesion, signaling, and cytoskeleton association.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA; RIKEN, Brain Sci Inst, Lab Proteolyt Neurosci, Wako, Saitama 3510198, Japan	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Scripps Research Institute; RIKEN	Du, XP (corresponding author), Univ Illinois, Dept Pharmacol M C868, 835 S Wolcott Ave, Chicago, IL 60612 USA.		Sado, Takaomi/AAN-2759-2021; Saido, Takaomi C/N-5472-2015	Sado, Takaomi/0000-0003-1970-6903; Saido, Takaomi C/0000-0003-1970-6903	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL052547] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52547] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIYAMA SK, 1994, J BIOL CHEM, V269, P15961; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; CHEN YP, 1994, BLOOD, V84, P1857; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10169, DOI 10.1073/pnas.89.21.10169; CHEN YP, 1994, J BIOL CHEM, V269, P18307; Cooray P, 1996, BIOCHEM J, V318, P41, DOI 10.1042/bj3180041; DU XP, 1995, J BIOL CHEM, V270, P26146, DOI 10.1074/jbc.270.44.26146; FATH KR, 1989, J CELL SCI, V92, P67; FILARDO EJ, 1995, J CELL BIOL, V130, P441, DOI 10.1083/jcb.130.2.441; FOX JEB, 1985, J BIOL CHEM, V260, P1060; FOX JEB, 1994, ANN NY ACAD SCI, V714, P75, DOI 10.1111/j.1749-6632.1994.tb12032.x; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GEORGE JN, 1990, BLOOD, V75, P1383; Gressner AM, 1997, BIOCHEM BIOPH RES CO, V231, P457, DOI 10.1006/bbrc.1996.5777; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Knezevic I, 1996, J BIOL CHEM, V271, P16416, DOI 10.1074/jbc.271.27.16416; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; LEONG L, 1995, J CELL SCI, V108, P3817; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; Lu Q, 1996, ARCH BIOCHEM BIOPHYS, V334, P175, DOI 10.1006/abbi.1996.0443; Maeda S, 1996, BIOCHEM MOL BIOL INT, V39, P447; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Mellgren RL, 1996, J BIOL CHEM, V271, P15568, DOI 10.1074/jbc.271.26.15568; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; ODA A, 1993, J BIOL CHEM, V268, P12603; OTOOLE TE, 1995, J BIOL CHEM, V270, P8553, DOI 10.1074/jbc.270.15.8553; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; SARIN A, 1994, J IMMUNOL, V153, P862; SARIN A, 1993, J EXP MED, V178, P1693, DOI 10.1084/jem.178.5.1693; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Shinohara K, 1996, BIOCHEM J, V317, P385, DOI 10.1042/bj3170385; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Tahiliani PD, 1997, J BIOL CHEM, V272, P7892, DOI 10.1074/jbc.272.12.7892; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Yang CL, 1996, CELL GROWTH DIFFER, V7, P161; YLANNE J, 1995, J BIOL CHEM, V270, P9550; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223; ZHU W, 1995, BIOCHEM BIOPH RES CO, V214, P1130, DOI 10.1006/bbrc.1995.2403; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	53	48	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19525	19531		10.1074/jbc.273.31.19525	http://dx.doi.org/10.1074/jbc.273.31.19525			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677375	hybrid			2022-12-25	WOS:000075125200027
J	Blanchard, CZ; Waldrop, GL				Blanchard, CZ; Waldrop, GL			Overexpression and kinetic characterization of the carboxyltransferase component of acetyl-CoA carboxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BIOTIN CARBOXYLASE; PYRUVATE-CARBOXYLASE; SUBUNIT; GENES	Acetyl-CoA carboxylase catalyzes the first committed step in the biosynthesis of fatty acids. The Escherichia coli form of the enzyme consists of a biotin carboxylase protein, a biotin carboxyl carrier protein, and a carboxyltransferase protein. In this report the overexpression of the genes for the carboxyltransferase component is described. The steady-state kinetics of the recombinant carboxyltransferase are characterized in the reverse direction, in which malonyl-CoA reacts with biocytin to form acetyl-CoA and carboxybiocytin. The initial velocity patterns indicated that the kinetic mechanism is equilibrium-ordered with malonyl-CoA binding before biocytin and the binding of malonyl-CoA to carboxyltransferase at equilibrium. The biotin analogs, desthiobiotin and 2-imidazolidone, inhibited carboxyltransferase. Both analogs exhibited parabolic noncompetitive inhibition, which means that two molecules of inhibitor bind to the enzyme. The pH dependence for both the maximum velocity (V) and the (V/K)(biocytin) parameters decreased at low pH. A single ionizing group on the enzyme with a pK of 6.2 or lower in the (V/K)biocytin profile and 7.5 in the V profile must be unprotonated for catalysis. Carboxyltransferase was inactivated by N-ethylmaleimide, whereas malonyl-CoA protected against inactivation. This suggests that a thiol in or near the active site is needed for catalysis. The rate of inactivation of carboxyltransferase by N-ethylmaleimide decreased with decreasing pH and indicated that the pK of the sulfhydryl group had a pK value of 7.3. It is proposed that the thiolate ion of a cysteine acts as a catalytic base to remove the N1' proton of biocytin.	Louisiana State Univ, Dept Biochem, Baton Rouge, LA 70803 USA	Louisiana State University System; Louisiana State University	Waldrop, GL (corresponding author), Louisiana State Univ, Dept Biochem, Rm 322 Choppin Hall, Baton Rouge, LA 70803 USA.				NIGMS NIH HHS [GM51261] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051261] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATTWOOD PV, 1986, BIOCHEMISTRY-US, V25, P8197, DOI 10.1021/bi00373a012; BOGNAR AL, 1987, J BIOL CHEM, V262, P12337; Boyer P. D., 1970, ENZYMES, V2; Cleland W W, 1979, Methods Enzymol, V63, P103; CLELAND WW, 1967, ADV ENZYMOL RAMB, V29, P1; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; GRONWALD JW, 1994, BIOCHEM SOC T, V22, P616, DOI 10.1042/bst0220616; Guchhait R B, 1975, Methods Enzymol, V35, P32, DOI 10.1016/0076-6879(75)35135-5; GUCHHAIT RB, 1974, J BIOL CHEM, V249, P6633; LAZZARINI RA, 1971, J BIOL CHEM, V246, P4381; LI SJ, 1992, J BIOL CHEM, V267, P855; LI SJ, 1992, J BIOL CHEM, V267, P16841; MARAGOUDAKIS ME, 1971, J BIOL CHEM, V246, P348; Miles E W, 1977, Methods Enzymol, V47, P431; NONET ML, 1987, J BIOL CHEM, V262, P12209; POLAKIS SE, 1973, J BIOL CHEM, V248, P7957; POLAKIS SE, 1974, J BIOL CHEM, V249, P6657; TIPTON PA, 1988, BIOCHEMISTRY-US, V27, P4317, DOI 10.1021/bi00412a019; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WALDROP GL, 1994, BIOCHEMISTRY-US, V33, P10249, DOI 10.1021/bi00200a004; WERNEBURG BG, 1993, ARCH BIOCHEM BIOPHYS, V303, P214, DOI 10.1006/abbi.1993.1275; YANG YR, 1993, PROTEIN SCI, V2, P1013, DOI 10.1002/pro.5560020614	22	45	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19140	19145		10.1074/jbc.273.30.19140	http://dx.doi.org/10.1074/jbc.273.30.19140			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668099	hybrid			2022-12-25	WOS:000074974700066
J	Fujisawa, K; Madaule, P; Ishizaki, T; Watanabe, G; Bito, H; Saito, Y; Hall, A; Narumiya, S				Fujisawa, K; Madaule, P; Ishizaki, T; Watanabe, G; Bito, H; Saito, Y; Hall, A; Narumiya, S			Different regions of Rho determine Rho-selective binding of different classes of Rho target molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H-RAS P21; ADP-RIBOSYLATION; PROTEIN-RHO; SERINE/THREONINE KINASE; GENE-PRODUCT; EFFECTOR REGION; COILED-COIL; DOMAIN; GTPASE; ACTIVATION	Based on their Rho binding motifs several Rho target molecules can be classified into three groups; class I includes the protein kinase PKN, rhophilin, and rhotekin, class II includes the protein kinases, Rho-associated coiled-coil containing protein kinases, ROCK-I and ROCK-II, and class III includes citron, Taking advantage of the selectivity in recognition by these targets between Rho and Rac, we examined the regions in Rho required for selective binding of each class of Rho target molecules, Yeast two-hybrid assays were performed using Rho/Rac chimeras and either rhophilin, ROCK-I, or citron, This study showed the existence of act least two distinct regions in Rho (amino acids 23-40 and 75-92) that are critical for the selective binding of these targets. The former was required for binding: to citron, whereas the latter was necessary for binding to rhophilin, On the other hand, either region showed affinity to ROCK-I. This was further confirmed by ligand overlay assay using both recombinant ROCK-I and ROCK-II proteins. Consistently, Rho/Rac chimeras containing either region can induce stress fibers in transfected HeLa cells, and this induction is suppressed by treatment with Y-27632, a specific inhibitor of ROCK kinases. These results suggest that the selective binding of different classes of Rho targets to Rho is determined by interaction between distinct Rho-binding motifs of the targets and different regions of Rho.	Univ London Univ Coll, MRC, Mol Cell Biol Lab, CRC Oncogene & Signal Transduct Grp, London WC1E 6BT, England; Univ London Univ Coll, Dept Biochem, London WC1E 6BT, England; Kyoto Univ, Fac Med, Dept Pharmacol, Sakyo Ku, Kyoto 606, Japan	University of London; University College London; University of London; University College London; Kyoto University	Narumiya, S (corresponding author), Kyoto Univ, Fac Med, Dept Pharmacol, Sakyo Ku, Kyoto 6068315, Japan.	snaru@mfour.med.kyoto-u.ac.jp	Bito, Haruhiko/A-8635-2008	Bito, Haruhiko/0000-0001-6315-9594				ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; Flynn P, 1998, J BIOL CHEM, V273, P2698, DOI 10.1074/jbc.273.5.2698; Freeman JL, 1996, J BIOL CHEM, V271, P19794, DOI 10.1074/jbc.271.33.19794; Fujisawa K, 1996, J BIOL CHEM, V271, P23022, DOI 10.1074/jbc.271.38.23022; FUJITAYOSHIGAKI J, 1995, J BIOL CHEM, V270, P4661, DOI 10.1074/jbc.270.9.4661; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HIRATA K, 1992, J BIOL CHEM, V267, P8719; Hotta K, 1996, BIOCHEM BIOPH RES CO, V225, P69, DOI 10.1006/bbrc.1996.1132; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; Madaule P, 1995, FEBS LETT, V377, P243, DOI 10.1016/0014-5793(95)01351-2; MATSUI T, EMBO J, V15, P2208; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORII N, 1993, J BIOL CHEM, V268, P27160; MORII N, 1992, J BIOL CHEM, V267, P20921; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; NEMOTO Y, 1991, J BIOL CHEM, V266, P19312; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Pal E.F., 1989, NATURE, V341, P209; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	45	102	109	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18943	18949		10.1074/jbc.273.30.18943	http://dx.doi.org/10.1074/jbc.273.30.18943			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668072	hybrid			2022-12-25	WOS:000074974700039
J	Tateno, H; Saneyoshi, A; Ogawa, T; Muramoto, K; Kamiya, H; Saneyoshi, M				Tateno, H; Saneyoshi, A; Ogawa, T; Muramoto, K; Kamiya, H; Saneyoshi, M			Isolation and characterization of rhamnose-binding lectins from eggs of steelhead trout (Oncorhynchus mykiss) homologous to low density lipoprotein receptor superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ANTHOCIDARIS-CRASSISPINA EGGS; RAINBOW-TROUT; MOLECULAR CHARACTERIZATION; VITELLOGENIN RECEPTORS; CHICKEN OOCYTE; ANIMAL LECTINS; LIGAND-BINDING; YOLK PROTEINS; FAMILY	Two L-rhamnose-binding lectins named STL1 and STL2 were isolated from eggs of steelhead trout (Oncorhynchus mykiss) by affinity chromatography and ion exchange chromatography. The apparent molecular masses of purified STL1 and STL2 were estimated to be 84 and 68 kDa, respectively, by gel filtration chromatography. Sodium dodecyl sulfate polyacrylamide gel electrophoresis and matrix-assisted laser desorption ionization time of flight mass spectrometry of these lectins revealed that STL1 was composed of noncovalently linked trimer of 31.4-kDa subunits, and STL2 was noncovalently linked trimer of 21.5-kDa subunits. The minimum concentrations of STL1, a major component, and STL2, a minor component, needed to agglutinate rabbit erythrocytes were 9 and 0.2 mu g/ml, respectively. The most effective saccharide in the hemagglutination inhibition assay for both STL1 and STL2 was L-rhamnose. Saccharides possessing the same configuration of hydroxyl groups at C2 and C4 as that in L-rhamnose, such as L-arabinose and D-galactose, also inhibited. The amino acid sequence of STL2 was determined by analysis of peptides generated by digestion of the S-carboxamidomethylated protein with Achromobacter protease I or Staphylococcus aureus VS protease. The STL2 subunit of 195 amino acid residues proved to have a unique polypeptide architecture; that is, it was composed of two tandemly repeated homologous domains (STL2-N and STL2-C) with 52% internal homology. These two domains showed a sequence homology to the subunit (105 amino acid residues) of D-galactoside-specific sea urchin (Anthocidaris crassispina) egg lectin (37% for STL2-N and 46% for STL2-C, respectively). The N terminus of the STL1 subunit was blocked with an acetyl group. However, a partial amino acid sequence of the subunit showed a sequence similarity to STL2. Moreover, STL2 also showed a sequence homology to the ligand binding domain of the vitellogenin receptor. We have also employed surface plasmon resonance biosensor methodology to investigate the interactions between STL2 and major egg yolk proteins from steelhead trout, lipo-vitellin, and beta'-component, which are known as vitellogenin digests. Interestingly, STL2 showed distinct interactions with both egg yolk proteins. The estimated values for the affinity constant (K-alpha) of STL2 to lipo-vitellin and beta' component were 3.44 x 10(6) and 4.99 x 10(6), respectively. These results suggest that the fish egg lectins belong to a new family of animal lectin structurally related to the low density lipoprotein receptor superfamily.	Tohoku Univ, Grad Sch Agr, Dept Biol Resource Sci, Sendai, Miyagi 9818555, Japan; Kitasato Univ, Sch Fisheries Sci, Sanriku, Iwate 0220101, Japan; Teikyo Univ Sci & Technol, Dept Biol Sci, Yamanashi 4090193, Japan	Tohoku University; Kitasato University	Muramoto, K (corresponding author), Tohoku Univ, Grad Sch Agr, Dept Biol Resource Sci, Sendai, Miyagi 9818555, Japan.	muramoto@biochem.tohoku.ac.jp		Ogawa, Tomohisa/0000-0001-8700-6330				ANSTEE DJ, 1973, VOX SANG, V25, P347, DOI 10.1111/j.1423-0410.1973.tb04383.x; BARBER DL, 1991, J BIOL CHEM, V266, P18761; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUJO H, 1994, EMBO J, V13, P5165, DOI 10.1002/j.1460-2075.1994.tb06847.x; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; FUJITA Y, 1975, BIOCHEMISTRY-US, V14, P4465, DOI 10.1021/bi00691a019; Gabius HJ, 1997, EUR J BIOCHEM, V243, P543, DOI 10.1111/j.1432-1033.1997.t01-1-00543.x; Gheorghe MT, 1997, ANAL BIOCHEM, V254, P119, DOI 10.1006/abio.1997.2380; GINSBURG AS, 1961, J EMBRYOL EXP MORPH, V9, P173; GITT MA, 1992, J BIOL CHEM, V267, P10601; HADARI YR, 1995, J BIOL CHEM, V270, P3447, DOI 10.1074/jbc.270.7.3447; HAKON L, 1997, GLYCOTECH, V9, P9; HARA A, 1978, COMP BIOCHEM PHYS B, V59, P339, DOI 10.1016/0305-0491(78)90011-1; HIRABAYASHI J, 1992, J BIOL CHEM, V267, P15485; Hiramatsu N, 1996, COMP BIOCHEM PHYS A, V115, P243, DOI 10.1016/0300-9629(96)00055-2; HOSONO M, 1992, BIOMED RES-TOKYO, V13, P443, DOI 10.2220/biomedres.13.443; HOSONO M, 1993, BIOL PHARM BULL, V16, P239; HOSONO M, 1993, TOHOKU YAKKA DAIGAKU, V40, P21; Iwasaki M., 1985, GLYCOCONJUGATE J, V2, P209, DOI [10.1007/BF01049269, DOI 10.1007/BF01049269]; KAMIYA H, 1990, NIPPON SUISAN GAKK, V56, P1139; KNECHT R, 1986, ANAL CHEM, V58, P2375, DOI 10.1021/ac00125a006; KRAJHANZL A, 1978, BIOCHIM BIOPHYS ACTA, V532, P215, DOI 10.1016/0005-2795(78)90575-5; Krajhanzl A, 1985, LECTINS BIOL BIOCH C, V4, P397; KRAJHANZL A, 1990, ADV LECTIN RES, V3, P83; KUBO T, 1993, DEV BIOL, V156, P381, DOI 10.1006/dbio.1993.1085; KUDO S, 1986, ZOOL SCI, V3, P323; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MURAMOTO K, 1990, ANAL BIOCHEM, V189, P223, DOI 10.1016/0003-2697(90)90112-M; NOSEK J, 1983, HISTOCHEMISTRY, V79, P131, DOI 10.1007/BF00494350; ODA Y, 1993, J BIOL CHEM, V268, P5929; OZAKI H, 1983, DEV COMP IMMUNOL, V7, P77, DOI 10.1016/0145-305X(83)90057-5; OZEKI Y, 1991, BIOCHEMISTRY-US, V30, P2391, DOI 10.1021/bi00223a014; OZEKI Y, 1995, EXP CELL RES, V216, P318, DOI 10.1006/excr.1995.1040; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POWELL LD, 1995, J BIOL CHEM, V270, P14243, DOI 10.1074/jbc.270.24.14243; Rodriguez JN, 1996, J EXP ZOOL, V274, P163, DOI 10.1002/(SICI)1097-010X(19960215)274:3&lt;163::AID-JEZ3&gt;3.0.CO;2-M; SAHIN U, 1995, P NATL ACAD SCI USA, V92, P11810, DOI 10.1073/pnas.92.25.11810; Sappington TW, 1996, P NATL ACAD SCI USA, V93, P8934, DOI 10.1073/pnas.93.17.8934; Schneider WJ, 1996, INT REV CYTOL, V166, P103, DOI 10.1016/S0074-7696(08)62507-3; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; Tyler CR, 1996, J COMP PHYSIOL B, V166, P11, DOI 10.1007/BF00264634; UHLENBRUCK G, 1967, VOX SANG, V12, P465, DOI 10.1111/j.1423-0410.1967.tb03376.x; VOSS EW, 1978, ARCH BIOCHEM BIOPHYS, V186, P25, DOI 10.1016/0003-9861(78)90459-9; YAMAZAKI M, 1984, J LEUKOCYTE BIOL, V35, P241; YOUSIF AN, 1994, DIS AQUAT ORGAN, V20, P127, DOI 10.3354/dao020127	49	102	111	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19190	19197		10.1074/jbc.273.30.19190	http://dx.doi.org/10.1074/jbc.273.30.19190			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668106	hybrid			2022-12-25	WOS:000074974700073
J	Lai, MM; Burnett, PE; Wolosker, H; Blackshaw, S; Snyder, SH				Lai, MM; Burnett, PE; Wolosker, H; Blackshaw, S; Snyder, SH			Cain, a novel physiologic protein inhibitor of calcineurin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; FK506 BINDING-PROTEIN; LONG-TERM POTENTIATION; NITRIC-OXIDE SYNTHASE; CYCLOSPORINE-A; RYANODINE RECEPTOR; T-CELLS; PHOSPHATASE; BRAIN; IDENTIFICATION	Calcineurin is a widely distributed protein phosphatase regulated by calcium and calmodulin. It mediates the immunosuppressive actions of drugs such as cyclosporin and FK506, and has been implicated in a number of calcium-sensitive pathways in the nervous system, including regulation of neurotransmitter release and modulation of long-term changes in synaptic plasticity. Calcineurin associates physiologically with other proteins, including calmodulin, FKBP12 (FK506-binding protein), the ryanodine receptor, and the inositol 1,4,5-trisphosphate receptor. We now report the identification, molecular cloning, and functional characterization of a novel protein, cain (ca lcineurin inhibitor), that interacts with and inhibits calcineurin. The full-length cain cDNA predicts a 240-kDa protein with no significant homology to any known protein. Cain associates with calcineurin both in vitro and in vivo, leading to a non-competitive inhibition of calcineurin activity. The putative calcineurin-binding domain of cain, a 38-amino acid region defined by mutational analysis, is highly basic. Like calcineurin, cain has a prominent neuronal expression and a wide tissue distribution. Cain's expression pattern in the brain closely resembles that of calcineurin, indicating a physiologic association between the two proteins.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Snyder, SH (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA.			Wolosker, Herman/0000-0001-5508-9194	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH018501, R37MH018501] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-00074] Funding Source: Medline; NIGMS NIH HHS [GM-07309] Funding Source: Medline; NIMH NIH HHS [MH-18501] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABEL T, 1997, CELL, V88, P1; Blackshaw S, 1997, J NEUROSCI, V17, P8074; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; CAMERON AM, 1995, P NATL ACAD SCI USA, V92, P1784, DOI 10.1073/pnas.92.5.1784; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; CARDENAS ME, 1994, EMBO J, V13, P5944, DOI 10.1002/j.1460-2075.1994.tb06940.x; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHOI DW, 1992, SCIENCE, V258, P241, DOI 10.1126/science.1357748; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; DAWSON TM, 1994, NEUROSCIENCE, V62, P569, DOI 10.1016/0306-4522(94)90389-1; DECAMILLI P, 1996, NEURON, V16, P2479; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; Huang YY, 1996, LEARN MEMORY, V3, P74, DOI 10.1101/lm.3.2-3.74; HUBBARD MJ, 1991, MOL NEUROBIOL, P135; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; LIEBERMAN DN, 1994, NATURE, V369, P235, DOI 10.1038/369235a0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU JP, 1994, SCIENCE, V265, P970, DOI 10.1126/science.8052858; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; Lu YF, 1996, NEUROSCI LETT, V205, P103, DOI 10.1016/0304-3940(96)12384-3; Luo C, 1996, MOL CELL BIOL, V16, P3955; Mansuy IM, 1998, CELL, V92, P39, DOI 10.1016/S0092-8674(00)80897-1; Mayford M, 1997, CURR BIOL, V7, pR580, DOI 10.1016/S0960-9822(06)00287-9; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; NICHOLS RA, 1994, J BIOL CHEM, V269, P23817; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Roberson ED, 1996, LEARN MEMORY, V3, P1, DOI 10.1101/lm.3.1.1; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHARP AH, 1993, J NEUROSCI, V13, P3051; SIHRA TS, 1995, BIOCHEM BIOPH RES CO, V212, P609, DOI 10.1006/bbrc.1995.2013; STEWART AA, 1982, FEBS LETT, V137, P80, DOI 10.1016/0014-5793(82)80319-0; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; TONG G, 1995, SCIENCE, V267, P1510, DOI 10.1126/science.7878472; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; Wang JH, 1997, J NEUROSCI, V17, P4600; Wang XT, 1996, NATURE, V383, P434, DOI 10.1038/383434a0; Wesselborg S, 1996, J BIOL CHEM, V271, P1274, DOI 10.1074/jbc.271.3.1274; Winder DG, 1998, CELL, V92, P25, DOI 10.1016/S0092-8674(00)80896-X; Yakel JL, 1997, TRENDS PHARMACOL SCI, V18, P124, DOI 10.1016/S0165-6147(97)01046-8	54	203	214	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18325	18331		10.1074/jbc.273.29.18325	http://dx.doi.org/10.1074/jbc.273.29.18325			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660798	hybrid			2022-12-25	WOS:000074828500053
J	Ericsson, J; Edwards, PA				Ericsson, J; Edwards, PA			CBP is required for sterol-regulated and sterol regulatory element-binding protein regulated transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FARNESYL DIPHOSPHATE SYNTHASE; MUTANT HAMSTER-CELLS; NF-Y; COACTIVATOR; PROMOTER; GENES; CREB; CHOLESTEROL	Cells were transfected with luciferase reporter genes, under the control of promoters derived from either the farnesyl diphosphate (FPP) synthase, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) synthase, HMG-CoA reductase, or low density lipoprotein receptor genes. The increase in luciferase activity that occurred when cells were either incubated in sterol-depleted medium or cotransfected with a cDNA encoding sterol regulatory element-binding protein (SREBP)-1a was prevented by coexpression of wild type E1A or a Gal4-CBP (1-451) fusion protein. The inhibitory effect of E1A was overcome by coexpression of CBP. The increase in reporter gene activity noted above was not affected when the cells were cotransfected with cDNAs that encoded either a mutant E1A that is unable to interact with the transcriptional activator CBP or Gal4-CBP fusion proteins encoding separate fragments of CBP, which span the remainder of the CBP molecule, A preformed SREBP-1a:[P-32]DNA complex bound specifically to membrane-immobilized GST-CBP fusion proteins that contained amino terminal portions of CBP, In order to investigate the role of CBP in the regulation of endogenous genes, we isolated stable transformants that express Ga14-CBP(1-451) in response to added doxycycline. Induction of endogenous FPP synthase and HMG-CoA synthase mRNAs, in response to cellular cholesterol depletion, was prevented when cells expressed Ga14-CBP(1-451), We conclude that when cells are incubated in the absence of sterols, the transcriptional activation of the HMG-CoA synthase, HMG-CoA reductase, FPP synthase, and low density lipoprotein receptor genes is dependent on a specific interaction between SREBP, which is bound to the promoter DNA, and the amino terminal domain (amino acids 1-451) of CBP.	Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Edwards, PA (corresponding author), Univ Calif Los Angeles, Dept Biol Chem, CHS 33-257, Los Angeles, CA 90095 USA.	pedwards@medicine.medsch.UCLA.edu	Ericsson, Johan/AAA-6664-2020	Ericsson, Johan/0000-0003-1186-6574	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 30568] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Athanikar JN, 1997, MOL CELL BIOL, V17, P5193, DOI 10.1128/MCB.17.9.5193; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Eckner R, 1996, BIOL CHEM, V377, P685; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; Ericsson J, 1996, J BIOL CHEM, V271, P24359, DOI 10.1074/jbc.271.40.24359; EVANS MJ, 1993, MOL CELL BIOL, V13, P5175, DOI 10.1128/MCB.13.9.5175; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Guan GM, 1997, J BIOL CHEM, V272, P10295; JACKSON SM, 1995, J BIOL CHEM, V270, P21445, DOI 10.1074/jbc.270.37.21445; Jackson SM, 1996, J LIPID RES, V37, P1712; JCKSON SM, 1998, J LIPID RES, V39, P767; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; Sato R, 1996, J BIOL CHEM, V271, P26461, DOI 10.1074/jbc.271.43.26461; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; WANG XD, 1993, J BIOL CHEM, V268, P14497; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	34	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17865	17870		10.1074/jbc.273.28.17865	http://dx.doi.org/10.1074/jbc.273.28.17865			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651391	hybrid			2022-12-25	WOS:000074816100084
J	Ishikawa, K; Ishida, H; Koyama, Y; Kawarabayasi, Y; Kawahara, J; Matsui, E; Matsui I				Ishikawa, K; Ishida, H; Koyama, Y; Kawarabayasi, Y; Kawahara, J; Matsui, E; Matsui, I			Acylamino acid-releasing enzyme from the thermophilic archaeon Pyrococcus horikoshii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-PEPTIDE HYDROLASE; RAT-LIVER; ACYLPEPTIDE HYDROLASE; PROLYL OLIGOPEPTIDASE; AMINO-ACIDS; PROTEIN; PURIFICATION; SEQUENCE; RESIDUE; FAMILY	When the genome of the thermophilic archaeon Pyrococcus horikoshii was sequenced, a gene homologous to the mammalian gene for an acylamino acid-releasing enzyme (EC 3.4.19.1) was found in which the enzyme's proposed active residues were conserved. The P. horikoshii gene comprised an open reading frame of 1,896 base pairs with an ATG initiation codon and a TAG termination codon, encoding a 72,390-Da protein of 632 amino acid residues. This gene was overexpressed in Escherichia coli with the pET vector system, and the resulting enzyme showed the anticipated amino-terminal sequence and high hydrolytic activity for acylpeptides. This enzyme was concluded to be the first acylamino acid-releasing enzyme from an organism other than a eukaryotic cell. The existence of the enzyme in archaea suggests that the mechanisms of protein degradation or initiation of protein synthesis or both in archaea may be similar to those in eukaryotes. The enzyme was stable at 90 degrees C, with its Optimum temperature over 90 degrees C. The specific activity of the enzyme increased 7-14-fold with heat treatment, suggesting the modification of the enzyme's structure for optimal hydrolytic activity by heating. This enzyme is expected to be useful for the removal of N(alpha)-acylated residues in short peptide sequence analysis at high temperatures.	Natl Inst Biosci & Human Technol, Tsukuba, Ibaraki 305, Japan; Natl Inst Mat & Chem Res, Tsukuba, Ibaraki 305, Japan; Natl Inst Technol & Evaluat, Tokyo 151, Japan	National Institute of Advanced Industrial Science & Technology (AIST); National Institute of Advanced Industrial Science & Technology (AIST)	Ishikawa, K (corresponding author), Natl Inst Biosci & Human Technol, 1-1 Higashi, Tsukuba, Ibaraki 305, Japan.	ishikawa@nibh.go.jp						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BOYEN A, 1996, THERMOPHILES 1996, P178; BROWN JL, 1976, J BIOL CHEM, V251, P1009; DOI E, 1981, ANAL BIOCHEM, V118, P173, DOI 10.1016/0003-2697(81)90175-5; GADE W, 1978, J BIOL CHEM, V253, P5012; HERSHKO A, 1984, P NATL ACAD SCI-BIOL, V81, P7021, DOI 10.1073/pnas.81.22.7021; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; ISHIKAWA K, 1997, NATURE BIOTECH SHORT, V8, P63; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; JONES WM, 1991, P NATL ACAD SCI USA, V88, P2194, DOI 10.1073/pnas.88.6.2194; KAMATA T, 1973, J COLLOID INTERF SCI, V43, P89, DOI 10.1016/0021-9797(73)90351-2; Kaneko T, 1995, DNA Res, V2, P153, DOI 10.1093/dnares/2.4.153; KOBAYASHI K, 1987, J BIOL CHEM, V262, P11435; KOBAYASHI K, 1989, J BIOL CHEM, V264, P8892; LEVITT M, 1976, J MOL BIOL, V104, P59, DOI 10.1016/0022-2836(76)90004-8; LIEW CC, 1970, NATURE, V226, P414, DOI 10.1038/226414a0; MARKS N, 1983, J NEUROCHEM, V41, P201, DOI 10.1111/j.1471-4159.1983.tb13670.x; MATSUI E, 1997, NATURE BIOTECH SHORT, V8, P65; MITA M, 1989, J BIOCH, V106, P548; MIYAGI M, 1995, J BIOCHEM-TOKYO, V118, P771, DOI 10.1093/oxfordjournals.jbchem.a124979; NARITA K, 1969, BIOCHEM BIOPH RES CO, V37, P327, DOI 10.1016/0006-291X(69)90738-4; PALMER JR, 1995, J BACTERIOL, V177, P1844, DOI 10.1128/jb.177.7.1844-1849.1995; PALMITER RD, 1978, P NATL ACAD SCI USA, V75, P94, DOI 10.1073/pnas.75.1.94; PIKE ER, 1975, J CHEM PHYS, V62, P3188, DOI 10.1063/1.430867; POLGAR L, 1992, FEBS LETT, V311, P281, DOI 10.1016/0014-5793(92)81120-B; RAWLINGS ND, 1991, BIOCHEM J, V279, P907, DOI 10.1042/bj2790907; RUBENSTEIN PA, 1983, J BIOL CHEM, V258, P1354; SWINBANKS D, 1995, NATURE, V374, P583; TSUNASAWA S, 1984, METHOD ENZYMOL, V106, P165; TSUNASAWA S, 1975, J BIOCHEM, V77, P89; TSUNASAWA S, 1983, J BIOCHEM-TOKYO, V93, P1217, DOI 10.1093/oxfordjournals.jbchem.a134248; YOSHIDA A, 1970, P NATL ACAD SCI USA, V67, P1600, DOI 10.1073/pnas.67.3.1600	33	49	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17726	17731		10.1074/jbc.273.28.17726	http://dx.doi.org/10.1074/jbc.273.28.17726			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651372	hybrid			2022-12-25	WOS:000074816100065
J	Roth, M; Helm-Kruse, S; Friedrich, T; Jeltsch, A				Roth, M; Helm-Kruse, S; Friedrich, T; Jeltsch, A			Functional roles of conserved amino acid residues in DNA methyltransferases investigated by site-directed mutagenesis of the EcoRV adenine-N-6-methyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MODIFICATION METHYLASE; SEQUENCE MOTIFS; HHAI METHYLTRANSFERASE; RECOGNITION SEQUENCE; CATALYTIC MECHANISM; CRYSTAL-STRUCTURE; COFACTOR ANALOGS; NUCLEIC-ACID; BINDING; ADENINE	All DNA methyltransferases (MTases) have similar catalytic domains containing nine blocks of conserved amino acid residues. We have investigated by site directed mutagenesis the function of 17 conserved residues in the EcoRV alpha-adenine-N(6-)DNA methyltransferase, The structure of this class of MTases has been predicted recently. The variants were characterized with respect to their catalytic activities and their abilities to bind to DNA and the S-adenosylmethionine (AdoMet) cofactor. Amino acids located in motifs X, I, and II are shown to be involved in AdoMet binding (Lys(16), Glu(37), Phe(39), and Asp(58)). Some of the mutants defective in AdoMet binding are also impaired in DNA binding, suggesting allosteric interactions between the AdoMet and DNA binding site. Asp(78) (motif III), which was supposed to form a hydrogen bond to the AdoMet on the basis of the structure predictions, turned out not to be important for AdoMet binding, suggesting that motif III has not been identified correctly. R128A and N130A having mutations in the putative DNA binding domain, are unable to bind to DNA, Residues located in motifs TV, V, VI, and VIII are involved in catalysis (Asp(193), Tyr(196), Asp(211), Ser(229), Trp(231), and Tyr(258)), some of them presumably in binding the flipped target base, because mutations at these residues fail to significantly interfere with DNA and AdoMet binding but strongly reduce catalysis. Our results are in substantial agreement with the structure prediction for EcoRV alpha-adenine-N-6-methyltransferase and x-ray structures of other MTases.	Justus Liebig Univ, Fachbereich Biol, Inst Biochem, D-35392 Giessen, Germany	Justus Liebig University Giessen	Jeltsch, A (corresponding author), Justus Liebig Univ, Fachbereich Biol, Inst Biochem, Heinrich Buff Ring 58, D-35392 Giessen, Germany.		Jeltsch, Albert/O-7404-2014	Jeltsch, Albert/0000-0001-6113-9290				ADAMS RLP, 1995, BIOESSAYS, V17, P139, DOI 10.1002/bies.950170209; Ahmad I, 1996, CRIT REV BIOCHEM MOL, V31, P361, DOI 10.3109/10409239609108722; Ahmad I, 1996, J MOL BIOL, V259, P229, DOI 10.1006/jmbi.1996.0315; Allan BW, 1996, BIOCHEMISTRY-US, V35, P14757, DOI 10.1021/bi9615708; Bokar JA, 1997, RNA, V3, P1233; Cal S, 1997, J BIOL CHEM, V272, P490; Cal S, 1996, J BIOL CHEM, V271, P1008, DOI 10.1074/jbc.271.2.1008; CHEN L, 1993, J AM CHEM SOC, V115, P5318, DOI 10.1021/ja00065a063; CHENG XD, 1995, ANNU REV BIOPH BIOM, V24, P293, DOI 10.1146/annurev.bb.24.060195.001453; CHENG XD, 1993, CELL, V74, P299, DOI 10.1016/0092-8674(93)90421-L; COUNTS JL, 1995, CELL, V83, P13, DOI 10.1016/0092-8674(95)90228-7; Djordjevic S, 1997, STRUCTURE, V5, P545, DOI 10.1016/S0969-2126(97)00210-4; DUBEY AK, 1992, NUCLEIC ACIDS RES, V20, P3167, DOI 10.1093/nar/20.12.3167; Friedrich T, 1998, BIOL CHEM, V379, P475, DOI 10.1515/bchm.1998.379.4-5.475; Gong WM, 1997, NUCLEIC ACIDS RES, V25, P2702, DOI 10.1093/nar/25.14.2702; GUYOT JB, 1993, NUCLEIC ACIDS RES, V21, P3183, DOI 10.1093/nar/21.14.3183; Hodel AE, 1996, CELL, V85, P247, DOI 10.1016/S0092-8674(00)81101-0; Hornby D P, 1993, Methods Mol Biol, V16, P201, DOI 10.1385/0-89603-234-5:201; Hough RF, 1997, RNA, V3, P356; ITO W, 1991, GENE, V102, P67, DOI 10.1016/0378-1119(91)90539-N; Jeltsch A, 1998, J MOL BIOL, V275, P747, DOI 10.1006/jmbi.1997.1492; Jeltsch A, 1996, PROTEIN ENG, V9, P413, DOI 10.1093/protein/9.5.413; KLIMASAUSKAS S, 1989, NUCLEIC ACIDS RES, V17, P9823, DOI 10.1093/nar/17.23.9823; Kong HM, 1997, NUCLEIC ACIDS RES, V25, P3687, DOI 10.1093/nar/25.18.3687; KUMAR S, 1994, NUCLEIC ACIDS RES, V22, P1, DOI 10.1093/nar/22.1.1; LABAHN J, 1994, P NATL ACAD SCI USA, V91, P10957, DOI 10.1073/pnas.91.23.10957; MALONE T, 1995, J MOL BIOL, V253, P618, DOI 10.1006/jmbi.1995.0577; NEWMAN PC, 1990, BIOCHEMISTRY-US, V29, P9891, DOI 10.1021/bi00494a020; NOYERWEIDNER M, 1993, DNA METHYLATION MOL, P40; NWOSU VU, 1988, NUCLEIC ACIDS RES, V16, P3705, DOI 10.1093/nar/16.9.3705; OGara M, 1996, J MOL BIOL, V263, P597, DOI 10.1006/jmbi.1996.0601; OGara M, 1996, J MOL BIOL, V261, P634, DOI 10.1006/jmbi.1996.0489; REICH NO, 1990, J BIOL CHEM, V265, P8966; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; SCHLUCKEBIER G, 1995, GENE, V157, P131, DOI 10.1016/0378-1119(94)00690-T; Schluckebier G, 1997, J MOL BIOL, V265, P56, DOI 10.1006/jmbi.1996.0711; SCHLUCKEBIER G, 1995, J MOL BIOL, V247, P16, DOI 10.1006/jmbi.1994.0117; SMITH HO, 1990, P NATL ACAD SCI USA, V87, P826, DOI 10.1073/pnas.87.2.826; SZCZELKUN MD, 1995, BIOCHEMISTRY-US, V34, P10734, DOI 10.1021/bi00034a005; SZCZELKUN MD, 1995, BIOCHEMISTRY-US, V34, P10724, DOI 10.1021/bi00034a004; VIDGREN J, 1994, NATURE, V368, P354, DOI 10.1038/368354a0; WILLCOCK DF, 1994, EMBO J, V13, P3902, DOI 10.1002/j.1460-2075.1994.tb06701.x; WILSON GG, 1992, METHOD ENZYMOL, V216, P259; WU JC, 1987, J BIOL CHEM, V262, P4778; Yoder JA, 1996, BIOL CHEM, V377, P605	45	58	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17333	17342		10.1074/jbc.273.28.17333	http://dx.doi.org/10.1074/jbc.273.28.17333			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651316	hybrid			2022-12-25	WOS:000074816100009
J	Suy, S; Mitchell, JB; Ehleiter, D; Haimovitz-Friedman, A; Kasid, U				Suy, S; Mitchell, JB; Ehleiter, D; Haimovitz-Friedman, A; Kasid, U			Nitroxides tempol and tempo induce divergent signal transduction pathways in MDA-MB 231 breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; FLOW CYTOMETRIC DETECTION; TUMOR-NECROSIS-FACTOR; C-JUN; MAP KINASE; PHOSPHATIDYLSERINE EXPRESSION; SPHINGOMYELIN PATHWAY; INDUCED APOPTOSIS; TERMINAL KINASES; OXIDATIVE DAMAGE	Tempol and tempo are stable free radical nitroxides that possess antioxidant properties. In this study, we examined the effects of these compounds on components of the mitogen-activated protein kinase signal transduction cascade. Tempo treatment (15 min), of MDA-MB 231 human breast cancer cells resulted in significant levels of tyrosine phosphorylation of several as yet unidentified proteins compared with equimolar concentration of tempol (10 mM). Both compounds caused tyrosine phosphorylation and activation of Raf-l protein kinase (30 min, 2-3-fold). Interestingly, however, only tempol caused increased extracellular signal-regulated kinase 1 activity (2 h, similar to 3-fold). On the other hand, tempo, but not tempol, potently activated stress-activated protein kinase (2 h, >3-fold). Consistent with these data, tempol was found to be noncytotoxic, whereas tempo induced apoptotic cell death (2 h, >50%). Tempo treatment also resulted in significant elevation of ceramide levels at 30 min (54% over control) and 1 h (71% over control) posttreatment, preceding stress-activated protein kinase activation and apoptosis. These data suggest that in the absence of an environmental oxidative stress, tempol and tempo elicit distinct cellular signaling pathways. The recognition of the molecular mechanisms of nitroxide action may have important implications for biological effectiveness of these compounds.	Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Dept Radiat Med, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA; NCI, Div Radiat Biol, NIH, Bethesda, MD 20892 USA; Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA	Georgetown University; Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Memorial Sloan Kettering Cancer Center	Kasid, U (corresponding author), Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Dept Radiat Med, E208,Res Bldg,3970 Reservoir Rd NW, Washington, DC 20007 USA.				NCI NIH HHS [CA58984, CA74175, CA68322/OD68322] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058984, P01CA074175, R55CA068322] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BENNETT HF, 1987, MAGNET RESON MED, V4, P93, DOI 10.1002/mrm.1910040202; BENNETT HF, 1987, INVEST RADIOL, V22, P502, DOI 10.1097/00004424-198706000-00011; BERLINER LJ, 1979, SPIN LABELLING, V2; BERLINGER LJ, 1976, SPIN LABELING THEORY; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Bogoyevitch MA, 1996, CIRC RES, V79, P162, DOI 10.1161/01.RES.79.2.162; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DEGRAFF WG, 1992, ENVIRON MOL MUTAGEN, V19, P21, DOI 10.1002/em.2850190105; DEGRAFF WG, 1992, FREE RADICAL BIO MED, V13, P479, DOI 10.1016/0891-5849(92)90142-4; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; FADOK VA, 1992, J IMMUNOL, V148, P2207; FIALKOW L, 1993, J BIOL CHEM, V268, P17131; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; GELVAN D, 1991, P NATL ACAD SCI USA, V88, P4680, DOI 10.1073/pnas.88.11.4680; GOFFMAN T, 1992, INT J RADIAT ONCOL, V22, P803, DOI 10.1016/0360-3016(92)90528-P; HAHN SM, 1995, CAN J PHYSIOL PHARM, V73, P399, DOI 10.1139/y95-051; HAHN SM, 1992, RADIAT RES, V132, P87, DOI 10.2307/3578338; HAHN SM, 1992, CANCER RES, V52, P1750; HAHN SM, 1994, CANCER RES, V54, pS2006; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HALLIWELL B, 1989, FREE RADICAL BIO MED, V7, P645, DOI 10.1016/0891-5849(89)90145-7; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HEO DS, 1989, CANCER RES, V49, P5167; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; KADIS U, 1996, NATURE, V382, P813; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kocherginsky N., 1995, NITROXIDE SPIN LABEL, P15; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Kolesnick Richard, 1992, Trends in Cell Biology, V2, P232, DOI 10.1016/0962-8924(92)90310-J; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Krishna MC, 1996, J BIOL CHEM, V271, P26018, DOI 10.1074/jbc.271.42.26018; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Mendelson KG, 1996, P NATL ACAD SCI USA, V93, P12908, DOI 10.1073/pnas.93.23.12908; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MITCHELL JB, 1990, BIOCHEMISTRY-US, V29, P2802, DOI 10.1021/bi00463a024; MITCHELL JB, 1991, ARCH BIOCHEM BIOPHYS, V289, P62, DOI 10.1016/0003-9861(91)90442-L; MYERS ML, 1985, CIRCULATION, V72, P915, DOI 10.1161/01.CIR.72.4.915; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; POMBO CM, 1994, J BIOL CHEM, V269, P26546; PUSHKAREVA M, 1995, IMMUNOL TODAY, V16, P294, DOI 10.1016/0167-5699(95)80184-7; QUINTANILHA AT, 1977, P NATL ACAD SCI USA, V74, P570, DOI 10.1073/pnas.74.2.570; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SAMUNI A, 1991, BIOCHEMISTRY-US, V30, P555, DOI 10.1021/bi00216a033; SAMUNI A, 1988, J BIOL CHEM, V263, P17921; SAMUNI A, 1990, FREE RADICAL RES COM, V9, P241, DOI 10.3109/10715769009145682; SAMUNI A, 1991, J CLIN INVEST, V87, P1526, DOI 10.1172/JCI115163; SAMUNI A, 1990, ADV EXP MED BIOL, V264, P85; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; STRZALKA K, 1990, ARCH BIOCHEM BIOPHYS, V281, P312, DOI 10.1016/0003-9861(90)90449-9; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Suy S, 1997, ONCOGENE, V15, P53, DOI 10.1038/sj.onc.1201165; UCKUN FM, 1992, P NATL ACAD SCI USA, V89, P9005, DOI 10.1073/pnas.89.19.9005; VANASBECK BS, 1985, SCIENCE, V227, P756, DOI 10.1126/science.2982213; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Watts JD, 1997, P NATL ACAD SCI USA, V94, P7292, DOI 10.1073/pnas.94.14.7292; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WU J, 1994, INSULIN ACTION EFFEC, P151; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	80	49	57	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17871	17878		10.1074/jbc.273.28.17871	http://dx.doi.org/10.1074/jbc.273.28.17871			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651392	hybrid			2022-12-25	WOS:000074816100085
J	Crookes, WJ; Olsen, LJ				Crookes, WJ; Olsen, LJ			The effects of chaperones and the influence of protein assembly on peroxisomal protein import	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; TARGETING SIGNAL; IN-VIVO; 3-KETOACYL-COA THIOLASE; MOLECULAR CHAPERONES; PLANT PEROXISOMES; CARBOXY TERMINUS; ISOCITRATE LYASE; BIOGENESIS; RECEPTOR	Peroxisomal proteins are synthesized in the cytoplasm and post-translationally translocated into the organelle. The role of chaperones and protein folding in peroxisomal protein transport is still unclear. Translocation of proteins into mitochondria requires that precursor proteins assume an extended conformation; cytosolic chaperones are thought to help maintain this conformation. In contrast, peroxisomal protein import does not require unfolding of the targeted protein. However, the molecular chaperones Hsp70 and Hsp40 may be important for translocation. We present several lines of evidence that show that plant peroxisomal protein import is enhanced by chaperones. First, peroxisomes isolated from heat-shocked pumpkin seedling tissues exhibited increased protein import relative to control peroxisomes. Second, antibodies raised against wheat germ cytosolic Hsp70 and Escherichia coli Hsp40 inhibited import of the peroxisomal protein isocitrate lyase. To our knowledge, this is the first time that Hsp90 has been directly implicated in a protein transport event. Third, peroxisomal proteins were immunoprecipitated by wheat germ Hsp70 antibodies. We also present results that suggest that the efficiency of peroxisomal protein import is influenced by the structure of the targeted protein; monomeric isocitrate lyase was imported more efficiently than oligomeric isocitrate lyase. Taken together, these data demonstrate that the assembly state of peroxisomal proteins and the chaperones that may mediate those states are both important for efficient peroxisomal protein import.	Univ Michigan, Dept Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Olsen, LJ (corresponding author), Univ Michigan, Dept Biol, Ann Arbor, MI 48109 USA.			Goodson, Wendy/0000-0001-5147-9291				ALLEN LAH, 1989, P NATL ACAD SCI USA, V86, P7012, DOI 10.1073/pnas.86.18.7012; BEHARI R, 1993, J BIOL CHEM, V268, P7315; Boston RS, 1996, PLANT MOL BIOL, V32, P191, DOI 10.1007/BF00039383; Brickner DG, 1997, PLANT PHYSIOL, V113, P1213, DOI 10.1104/pp.113.4.1213; Brickner DG, 1998, PLANT PHYSIOL, V116, P309, DOI 10.1104/pp.116.1.309; Corpas FJ, 1997, EUR J CELL BIOL, V73, P49; Dittmar KD, 1997, J BIOL CHEM, V272, P13047, DOI 10.1074/jbc.272.20.13047; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; ETTINGER WF, 1990, ARCH BIOCHEM BIOPHYS, V281, P139, DOI 10.1016/0003-9861(90)90423-V; FRANSEN M, 1995, J BIOL CHEM, V270, P7731, DOI 10.1074/jbc.270.13.7731; Freedman Robert B., 1992, P455; Gietl C, 1996, PHYSIOL PLANTARUM, V97, P599, DOI 10.1111/j.1399-3054.1996.tb00521.x; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; GLOVER JR, 1994, P NATL ACAD SCI USA, V91, P10541, DOI 10.1073/pnas.91.22.10541; GLOVER JR, 1994, J BIOL CHEM, V269, P7558; Goodfriend Joyce D., 1992, MEMBRANE BIOGENESIS, P221; GOODMAN JM, 1984, J BIOL CHEM, V259, P8485; GOULD SJ, 1988, J CELL BIOL, V107, P897, DOI 10.1083/jcb.107.3.897; GOULD SJ, 1987, J CELL BIOL, V105, P2923, DOI 10.1083/jcb.105.6.2923; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; GOULD SJ, 1990, EMBO J, V9, P85, DOI 10.1002/j.1460-2075.1990.tb08083.x; GRAY JC, 1995, TRENDS CELL BIOL, V5, P243, DOI 10.1016/S0962-8924(00)89018-2; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HAUCKE V, 1997, TRENDS CELL BIOL, V7, P13; Hausler T, 1996, J CELL BIOL, V132, P311, DOI 10.1083/jcb.132.3.311; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; KINDL H, 1992, CELL BIOCHEM FUNCT, V10, P153, DOI 10.1002/cbf.290100304; LANGER T, 1994, BIOL HEAT SHOCK PROT, P53; LAZAROW PB, 1982, ANN NY ACAD SCI, V386, P285, DOI 10.1111/j.1749-6632.1982.tb21423.x; LAZAROW PB, 1973, J CELL BIOL, V59, P507, DOI 10.1083/jcb.59.2.507; Lee MS, 1997, PLANT CELL, V9, P185, DOI 10.1105/tpc.9.2.185; MARZIOCH M, 1994, EMBO J, V13, P4908, DOI 10.1002/j.1460-2075.1994.tb06818.x; MCKAY DB, 1994, BIOL HEAT SHOCK PROT, P153; MCNEW JA, 1994, J CELL BIOL, V127, P1245, DOI 10.1083/jcb.127.5.1245; McNew JA, 1996, TRENDS BIOCHEM SCI, V21, P54, DOI 10.1016/S0968-0004(96)80181-2; Miernyk JA, 1997, TRENDS PLANT SCI, V2, P180; Nielsen E, 1997, EMBO J, V16, P935, DOI 10.1093/emboj/16.5.935; OLSEN LJ, 1993, PLANT CELL, V5, P941, DOI 10.1105/tpc.5.8.941; OLSEN LJ, 1995, ANNU REV PLANT PHYS, V46, P123, DOI 10.1146/annurev.pp.46.060195.001011; OLSEN LJ, 1998, IN PRESS PLANT MOL B, V377; PRATT WB, 1993, J BIOL CHEM, V268, P21455; PREISIGMULLER R, 1994, EUR J BIOCHEM, V219, P57, DOI 10.1111/j.1432-1033.1994.tb19914.x; Sambrook J., 2002, MOL CLONING LAB MANU; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Subramani S, 1996, CURR OPIN CELL BIOL, V8, P513, DOI 10.1016/S0955-0674(96)80029-9; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; TISSIERES A, 1974, J MOL BIOL, V84, P389, DOI 10.1016/0022-2836(74)90447-1; VANDERKLEI IJ, 1995, J BIOL CHEM, V270, P17229, DOI 10.1074/jbc.270.29.17229; WALTON PA, 1994, J CELL BIOL, V125, P1037, DOI 10.1083/jcb.125.5.1037; WALTON PA, 1995, MOL BIOL CELL, V6, P675, DOI 10.1091/mbc.6.6.675; WENDLAND M, 1993, J CELL BIOL, V120, P675, DOI 10.1083/jcb.120.3.675; WIEMER EAC, 1995, J CELL BIOL, V130, P51, DOI 10.1083/jcb.130.1.51; Wimmer B, 1997, P NATL ACAD SCI USA, V94, P13624, DOI 10.1073/pnas.94.25.13624; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; ZHANG JW, 1995, J CELL BIOL, V129, P65, DOI 10.1083/jcb.129.1.65	55	55	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17236	17242		10.1074/jbc.273.27.17236	http://dx.doi.org/10.1074/jbc.273.27.17236			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642294	hybrid			2022-12-25	WOS:000074545200084
J	Heyes, MP; Saito, K; Lackner, A; Wiley, CA; Achim, CL; Markey, SP				Heyes, MP; Saito, K; Lackner, A; Wiley, CA; Achim, CL; Markey, SP			Sources of the neurotoxin quinolinic acid in the brain of HIV-1-infected patients and retrovirus-infected macaques	FASEB JOURNAL			English	Article						macrophages; astrocytes; indoleamine-2,3-dioxygenase; kynurenine-3-hydroxylase; kynureninase; kynurenine aminotransferase; L-tryptophan; L-kynurenine; kynurenic acid; retrovirus; blood-brain barrier; cytokines; nonhuman primates	HUMAN-IMMUNODEFICIENCY-VIRUS; KYNURENINE PATHWAY METABOLITES; COMPLEX PARTIAL SEIZURES; CENTRAL-NERVOUS-SYSTEM; CONVERT L-TRYPTOPHAN; CEREBROSPINAL-FLUID; NEUROLOGICAL DISEASE; IMMUNE ACTIVATION; NEUROACTIVE KYNURENINES; CEREBRAL-ISCHEMIA	This: study investigated the sources of quinolinic acid, a neurotoxic tryptophan-kynurenine pathway metabolite, in the brain and blood of HIV-infected patients and retrovirus-infected macaques.In brain, quinolinic acid concentrations in HIV-infected patients were elevated by >300-fold to concentrations that exceeded cerebrospinal fluid (CSF) by 8.9-fold. There were no significant correlations between elevated serum quinolinic acid levels with those in CSF and brain parenchyma. Because nonretrovirus-induced encephalitis confounds the interpretation of human postmortem data, rhesus macaques infected with retrovirus were used to examine the mechanisms of increased quinolinic acid accumulations and determine the relationships of quinolinic acid to encephalitits and systemic responses. The largest kynurenine pathway responses in brain were associated with encephalitis and were independent of systemic responses. CSF quinolinic acid levels were also elevated in all infected macaques, but particularly those with retrovirus-induced encephalitis. In contrast to the brain changes, there was no difference in any systemic measure between macaques with encephalitis: vs. those without. Direct measures of the amount of quinolinic acid in brain derived from blood in a macaque with encephalitis showed that almost all quinolinic acid (>98%) was synthesized locally within the brain. These results demonstrate a role for induction of indoleamine-2,3-dioxygenase in accelerating the local formation of quinolinic acid within the brain tissue, particularly in areas of encephalitis, rather than entry of quinolinic acid into the brain from the meninges or blood. Strategies to reduce QUIN production, targeted at intracerebral sites, are potential approaches to therapy.-Heyes, M. P., Saito, K., Lackner, A., Wiley, C. A., Achim, C. L., Markey, S. P. Sources of the neurotoxin quinolinic acid in the brain of HIV-l-infected patients and retrovirus-infected macaques.	NIMH, Lab Neurotoxicol, Bethesda, MD 20892 USA; Harvard Univ, Sch Med, New England Reg Primate Res Ctr, Southborough, MA 01772 USA; Presbyterian Univ Hosp, Div Neuropathol, Pittsburgh, PA 15213 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Harvard University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; UPMC Presbyterian	Heyes, MP (corresponding author), NIMH, Lab Neurotoxicol, Bldg 10,Room 3D40,9000 Rockville Pike, Bethesda, MD 20892 USA.				NCRR NIH HHS [RR00169, RR00168] Funding Source: Medline; NINDS NIH HHS [NS30769] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000168, P51RR000169] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030769] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACHIM CL, 1993, J CLIN INVEST, V91, P2769, DOI 10.1172/JCI116518; Adamson DC, 1996, SCIENCE, V274, P1917, DOI 10.1126/science.274.5294.1917; BASILE AS, 1995, GASTROENTEROLOGY, V108, P818, DOI 10.1016/0016-5085(95)90456-5; Beagles KE, 1998, J NEUROCHEM, V70, P281; BENDER DA, 1982, MOL ASPECTS MED, V6, P101; BLIGHT AR, 1995, BRAIN, V118, P735, DOI 10.1093/brain/118.3.735; BONI RL, 1989, 6 INT STUD GROUP TRY, P481; BRENNEMAN DE, 1988, NATURE, V335, P639, DOI 10.1038/335639a0; BREW BJ, 1995, J NEUROVIROL, V1, P328; BROUWERS P, 1993, J INFECT DIS, V168, P1380, DOI 10.1093/infdis/168.6.1380; BUKRINSKY MI, 1995, J EXP MED, V181, P735, DOI 10.1084/jem.181.2.735; DEMITRACK MA, 1995, BIOL PSYCHIAT, V37, P512, DOI 10.1016/0006-3223(94)00173-Z; DREYER EB, 1990, SCIENCE, V248, P364, DOI 10.1126/science.2326646; Espey MG, 1997, NEUROREPORT, V8, P431, DOI 10.1097/00001756-199701200-00011; GENIS P, 1992, J EXP MED, V176, P1703, DOI 10.1084/jem.176.6.1703; Giulian D, 1996, J NEUROSCI, V16, P3139; GIULIAN D, 1990, SCIENCE, V250, P1593, DOI 10.1126/science.2148832; HAYES MP, 1997, BIOCHEM J, V326, P351; HAYMAN M, 1993, NEUROSCIENCE, V53, P1, DOI 10.1016/0306-4522(93)90278-N; HEYES MP, 1994, EPILEPSIA, V35, P251, DOI 10.1111/j.1528-1157.1994.tb02428.x; HEYES MP, 1992, J NEUROIMMUNOL, V40, P71, DOI 10.1016/0165-5728(92)90214-6; HEYES MP, 1990, J CHROMATOGR-BIOMED, V530, P108, DOI 10.1016/S0378-4347(00)82308-7; HEYES MP, 1991, ANN NEUROL, V29, P202, DOI 10.1002/ana.410290215; Heyes MP, 1996, BIOCHEM J, V320, P595, DOI 10.1042/bj3200595; HEYES MP, 1992, BRAIN, V115, P1249, DOI 10.1093/brain/115.5.1249; HEYES MP, 1992, BRAIN RES, V570, P237, DOI 10.1016/0006-8993(92)90587-Y; Heyes MP, 1997, J NEUROCHEM, V68, P280; HEYES MP, 1988, ANAL BIOCHEM, V174, P349, DOI 10.1016/0003-2697(88)90556-8; HEYES MP, 1992, FASEB J, V6, P2977, DOI 10.1096/fasebj.6.11.1322853; Heyes MP, 1997, J NEUROCHEM, V69, P1519; HEYES MP, 1991, NEUROSCI LETT, V122, P265, DOI 10.1016/0304-3940(91)90874-S; HEYES MP, 1992, BIOCHEM J, V283, P633, DOI 10.1042/bj2830633; HEYES MP, 1989, ANN NEUROL, V26, P275; HEYES MP, 1993, BRAIN, V116, P1425, DOI 10.1093/brain/116.6.1425; HEYES MP, 1988, BIOMED ENVIRON MASS, V15, P291, DOI 10.1002/bms.1200150509; HEYES MP, 1990, EPILEPSIA, V31, P172, DOI 10.1111/j.1528-1167.1990.tb06302.x; HEYES MP, 1990, J NEUROCHEM, V55, P338, DOI 10.1111/j.1471-4159.1990.tb08857.x; Kerr SJ, 1997, NEUROLOGY, V49, P1671, DOI 10.1212/WNL.49.6.1671; KOKA P, 1995, J EXP MED, V182, P941, DOI 10.1084/jem.182.4.941; KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751; Lane JH, 1996, J NEUROVIROL, V2, P423, DOI 10.3109/13550289609146909; MARTIN A, 1992, J NEUROPSYCH CLIN N, V4, P270; Martin A., 1993, NEUROPSYCHOLOGY, V7, P149, DOI DOI 10.1037/0894-4105.7.2.149; MILSTIEN S, 1994, J NEUROCHEM, V63, P1178; MOURDIAN MM, 1989, NEUROSCI LETT, V105, P233, DOI 10.1016/0304-3940(89)90043-8; Namboodiri AMA, 1996, J NEUROVIROL, V2, P433, DOI 10.3109/13550289609146910; NARITSIN DB, 1995, J NEUROCHEM, V65, P2217; Nottet HSLM, 1996, J NEUROVIROL, V2, P111, DOI 10.3109/13550289609146544; PETITO CK, 1992, ANN NEUROL, V32, P658, DOI 10.1002/ana.410320509; PULLIAM L, 1991, J CLIN INVEST, V87, P503, DOI 10.1172/JCI115024; RAUSCH DM, 1994, J NEUROPATH EXP NEUR, V53, P165, DOI 10.1097/00005072-199403000-00008; Reinhard J F Jr, 1994, Adv Pharmacol, V30, P85, DOI 10.1016/S1054-3589(08)60173-8; SAITO K, 1993, BIOCHEM J, V291, P11, DOI 10.1042/bj2910011; SAITO K, 1992, NEUROSCIENCE, V51, P25, DOI 10.1016/0306-4522(92)90467-G; SAITO K, 1993, J NEUROCHEM, V60, P180, DOI 10.1111/j.1471-4159.1993.tb05836.x; SAITO K, 1993, J BIOL CHEM, V268, P15496; SAITO K, 1993, J NEUROCHEM, V61, P2061, DOI 10.1111/j.1471-4159.1993.tb07443.x; SAITO K, 1991, BRAIN RES, V546, P151, DOI 10.1016/0006-8993(91)91171-V; SAITO K, 1993, ARCH BIOCHEM BIOPHYS, V307, P104, DOI 10.1006/abbi.1993.1567; SEI S, 1995, J INFECT DIS, V172, P638, DOI 10.1093/infdis/172.3.638; Sei Y, 1996, J NEUROCHEM, V66, P296; SMITH MO, 1995, LAB INVEST, V72, P547; SPENCER DC, 1992, ANNU REV MICROBIOL, V46, P655; STONE TW, 1993, PHARMACOL REV, V45, P309; TARDIEU M, 1992, ANN NEUROL, V32, P11, DOI 10.1002/ana.410320104; TAYLOR MW, 1991, FASEB J, V5, P2516, DOI 10.1096/fasebj.5.11.1907934; TYOR WR, 1992, ANN NEUROL, V31, P349, DOI 10.1002/ana.410310402; Vogelgesang SA, 1996, J RHEUMATOL, V23, P850; WHETSELL WO, 1989, NEUROSCI LETT, V97, P271, DOI 10.1016/0304-3940(89)90609-5; WILEY CA, 1994, ANN NEUROL, V36, P673, DOI 10.1002/ana.410360422; Yates J. R., 1997, Society for Neuroscience Abstracts, V23, P1384	71	119	126	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	1998	12	10					881	896		10.1096/fasebj.12.10.881	http://dx.doi.org/10.1096/fasebj.12.10.881			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZY035	9657528				2022-12-25	WOS:000074580100013
J	Liang, SH; Hong, D; Clarke, MF				Liang, SH; Hong, D; Clarke, MF			Cooperation of a single lysine mutation and a C-terminal domain in the cytoplasmic sequestration of the p53 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; GREEN FLUORESCENT PROTEIN; TUMOR-SUPPRESSOR PROTEIN; DNA-BINDING FUNCTION; CELL-CYCLE; BREAST-CANCER; NUCLEAR ACCUMULATION; GROWTH SUPPRESSION; GENE; OLIGOMERIZATION	Cytoplasmic sequestration of the p53 tumor suppresser protein has been proposed as a mechanism involved in abolishing p53 function. However, the mechanisms regulating p53 subcellular localization remain unclear. In this report, we analyzed the possible existence of cis-acting sequences involved in intracellular trafficking of the p53 protein. To study p53 trafficking, the jellyfish green fluorescent protein (GFP:) was fused to the wild-type or mutated p53 proteins for fast and sensitive analysis of protein localization in human MCF-7 breast cancer, RHO colon cancer, and SAOS-2 sarcoma cells. The wild-type p53/GFP fusion protein was localized in the cytoplasm, the nucleus, or both compartments in a subset of the cells. Mutagenesis analysis demonstrated that a single amino acid mutation of Lys-305 (mt p53) caused cytoplasmic sequestration of the p53 protein in the MCF-7 and RKO cells, whereas the fusion protein was distributed in both the cytoplasm and the nucleus of SAOS-2 cells, In SAOS-2 cells, the :mutant p53 was a less efficient inducer of p21/CIP1/WAF1 expression. Cytoplasmic sequestration of the mt p53 was dependent upon the C-terminal region (residues 326-355) of the protein. These results indicated the involvement of cis-acting sequences in the regulation of p53 subcellular localization. Lys-305 is needed for nuclear import of p53 protein, and amino acid residues 326-355 can sequester mt p53 in the cytoplasm.	Univ Michigan, Ctr Med, Dept Internal Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Clarke, MF (corresponding author), Univ Michigan, Ctr Med, Dept Internal Med, Ann Arbor, MI 48109 USA.				NCI NIH HHS [CA67140] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA067140, R01CA067140] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BOSARI S, 1995, AM J PATHOL, V147, P790; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Carey KL, 1996, J CELL BIOL, V133, P985, DOI 10.1083/jcb.133.5.985; CASEY G, 1991, ONCOGENE, V6, P1791; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; DANG CV, 1989, J BIOL CHEM, V264, P18019; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAN SJ, 1995, CANCER RES, V55, P1649; FRITSCHE M, 1993, ONCOGENE, V8, P307; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Koepp DM, 1996, CELL, V87, P1, DOI 10.1016/S0092-8674(00)81315-X; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Liner D.I., 1979, CELL, V17, P43; MARTINEZ E, 1991, EMBO J, V10, P263, DOI 10.1002/j.1460-2075.1991.tb07946.x; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MIYASHITA T, 1995, CELL, V80, P293; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Nunez Gabriel, 1994, Trends in Cell Biology, V4, P399, DOI 10.1016/0962-8924(94)90053-1; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; ROBERTS BL, 1987, CELL, V50, P465, DOI 10.1016/0092-8674(87)90500-9; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SMITH ML, 1995, ONCOGENE, V10, P1053; SOUSSI T, 1990, ONCOGENE, V5, P945; STURZBECHER HW, 1990, ONCOGENE, V5, P795; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZERRAHN J, 1992, ONCOGENE, V7, P1371	49	51	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19817	19821		10.1074/jbc.273.31.19817	http://dx.doi.org/10.1074/jbc.273.31.19817			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677415	hybrid			2022-12-25	WOS:000075125200067
J	Shapira, H; Amit, I; Revach, M; Oron, Y; Battey, JF				Shapira, H; Amit, I; Revach, M; Oron, Y; Battey, JF			G alpha(14) and G alpha(q) mediate the response to trypsin in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-ALPHA-SUBUNITS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE HYDROLYSIS; THYROTROPIN-RELEASING-HORMONE; PHOSPHOLIPASE-C; LAEVIS OOCYTES; HUMAN PLATELETS; CELL-LINES; GQ FAMILY; RECEPTOR; EXPRESSION	Xenopus oocytes respond to trypsin with a characteristic chloride current, virtually indistinguishable from responses mediated by a large number of native and expressed G protein-coupled receptors. We studied the involvement of G proteins of the G alpha(q) family as possible mediators of this and other G protein-coupled receptor-mediated responses in Xenopus oocytes. We have cloned the third member of the G alpha(q) family, Xenopus G alpha(14), in addition to the previously cloned Xenopus G alpha(q) and Ga,, (Shapira, H., Way, J., Lipinsky, D., Oron, Y., and Battey, J. F. (1994) FEES Lett. 348, 89-92). Amphibian G alpha(14) is 354 amino acids long and is 93% identical to its mammalian counterpart. Based on the G alpha(14) cDNA sequence, we designed a specific antisense DNA oligonucleotide (antiG alpha(14)) that, together with antiG alpha(q) and antiG alpha(11), was used in antisense depletion experiments. 24 h after injection into oocytes, either antiG alpha(q) or antiG alpha(14) reduced the response to 1 mu g/ml trypsin by 70%, whereas antiG alpha(11) had no effect. A mixture of antiG alpha(q) and antiG alpha(14) virtually abolished the response. These data strongly suggest that G alpha(q) and G alpha(14) are the exclusive mediators of the trypsin-evoked response in Xenopus oocytes. Similar experiments with the expressed gastrin-releasing peptide receptor and muscarinic mi receptor revealed the coupling of G alpha(q) and G alpha(11) but not G alpha(14) to these receptors in oocytes. These results confirm the hypothesis that endogenous members of the Gag family discriminate among different native receptors in vivo.	Tel Aviv Univ, Sackler Fac Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel; Natl Inst Deafness & Other Commun Disorders, NIH, Rockville, MD 20850 USA	Tel Aviv University; Sackler Faculty of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD)	Shapira, H (corresponding author), Tel Aviv Univ, Sackler Fac Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel.	hshapira@post.tau.ac.il						AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; ARAGAY AM, 1992, J BIOL CHEM, V267, P24983; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; CARROLL DJ, 1995, DEV BIOL, V170, P690, DOI 10.1006/dbio.1995.1247; DAVIS LG, 1986, BASIC METHODS MOL BI, P1; Dippel E, 1996, P NATL ACAD SCI USA, V93, P1391, DOI 10.1073/pnas.93.4.1391; DURIEUX ME, 1994, FEBS LETT, V337, P235, DOI 10.1016/0014-5793(94)80198-3; Gallo CJ, 1996, DEV BIOL, V177, P300, DOI 10.1006/dbio.1996.0164; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HSEI KP, 1992, MOL ENDOCRINOL, V6, P1673; Kai H, 1996, MOL PHARMACOL, V49, P96; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; Kuhn B, 1996, MOL ENDOCRINOL, V10, P1697, DOI 10.1210/me.10.12.1697; LIPINSKY D, 1992, FEBS LETT, V307, P237, DOI 10.1016/0014-5793(92)80775-C; MAREZLEPRETRE N, 1996, J BIOL CHEM, V272, P5261; MILLIGAN G, 1993, J NEUROCHEM, V61, P845, DOI 10.1111/j.1471-4159.1993.tb03595.x; MILLIGAN G, 1993, TRENDS PHARMACOL SCI, V14, P413, DOI 10.1016/0165-6147(93)90064-Q; Milligan G, 1996, TRENDS PHARMACOL SCI, V17, P235, DOI 10.1016/0165-6147(96)10026-2; MILLIGAN G, 1993, BIOCHIM BIOPHYS ACTA, V1179, P208, DOI 10.1016/0167-4889(93)90143-D; MITCHELL FM, 1993, BIOCHEM J, V293, P495, DOI 10.1042/bj2930495; MORIARTY TM, 1990, NATURE, V343, P79, DOI 10.1038/343079a0; OFFERMANNS S, 1994, FEBS LETT, V349, P201, DOI 10.1016/0014-5793(94)00667-9; Offermanns S, 1996, MOL ENDOCRINOL, V10, P566, DOI 10.1210/me.10.5.566; OLATE J, 1989, FEBS LETT, V244, P188, DOI 10.1016/0014-5793(89)81190-1; PADRELL E, 1991, J BIOL CHEM, V266, P9771; PANG IH, 1990, J BIOL CHEM, V265, P18707; QUICK MW, 1994, J BIOL CHEM, V269, P30164; SAWAKI K, 1993, ARCH BIOCHEM BIOPHYS, V305, P546, DOI 10.1006/abbi.1993.1459; SHAH BH, 1995, P NATL ACAD SCI USA, V92, P1886, DOI 10.1073/pnas.92.6.1886; SHAPIRA H, 1994, FEBS LETT, V348, P89, DOI 10.1016/0014-5793(94)00570-2; SHAPIRA H, 1993, METHODS NEUROSCI, V13, P220; SHENKER A, 1991, J BIOL CHEM, V266, P9309; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; WESTERLO E, 1995, BIOCHEM J, V310, P559; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; WU DQ, 1995, J BIOL CHEM, V270, P9828, DOI 10.1074/jbc.270.17.9828; WU DQ, 1992, J BIOL CHEM, V267, P25798	38	18	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19431	19436		10.1074/jbc.273.31.19431	http://dx.doi.org/10.1074/jbc.273.31.19431			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677362	hybrid			2022-12-25	WOS:000075125200014
J	Axelsson, MAB; Asker, N; Hansson, GC				Axelsson, MAB; Asker, N; Hansson, GC			O-glycosylated MUC2 monomer and dimer from LS 174T cells are water-soluble, whereas larger MUC2 species formed early during biosynthesis are insoluble and contain nonreducible intermolecular bonds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SMALL-INTESTINE; VONWILLEBRAND-FACTOR; MOLECULAR-CLONING; GLYCOPROTEINS; APOPROTEIN; COMPLEX; MUCINS; REGION; CDNA	The MUC2 mucin is the major gel-forming mucin in the small and large intestine. Due to its sequence similarities with the von Willebrand factor, it has been suggested to dimerize in the endoplasmic reticulum and polymerize in the trans-Golgi network. Using an O-glycosylation-sensitive MUGS antiserum, a dimerization has been shown to occur in the endoplasmic reticulum of LS 174T cells (Asker, N., Axelsson, M. A. B., Olofsson, S.-O., and Hansson, G. C. (1998) J. Biol. Chem. 278, 18857-18863). Using an antiserum immunoprecipitating O-glycosylated MUGS mucin, monomers and dimers mere shown to occur in soluble form in the lysate of LS 174T cells. The amount of O-glycosylated dimer was small, and no larger species were found even after long chase periods. However, most of the labeled MUGS mucin was found in pelleted debris of the cell lysate. This insoluble MUC2 mucin was recovered by immunoprecipitation after reduction of disulfide bonds. Analysis by agarose gel electrophoresis revealed two bands, of which the smaller migrated as the O-glycosylated monomer and the larger migrated as the O-glycosylated dimer of the cell lysis supernatant. Mucins insoluble in 6 M guanidinium chloride could also be obtained from LS 174T cells. Such mucins have earlier been found in the small intestine (Carlstedt, I., Herrmann, A., Karlsson, H., Sheehan, J., Fransson, L.-A., and Hansson, G. C. (1993) J. Biol. Chem. 268, 18771-18781). Reduction of the mucins followed by purification by isopycnic density gradient ultracentrifugation and analysis by agarose gel electrophoresis revealed two bands reacting with an anti-MUC2 tandem repeat antibody after deglycosylation. These bands migrated identically to the bands shown by metabolic labeling, and they could also be separated by rate zonal ultracentrifugation. These results suggest that the MUC2 mucin is forming nonreducible intermolecular bonds early in biosynthesis, but after initial O-glycosylation.	Gothenburg Univ, Dept Med Biochem, S-41390 Gothenburg, Sweden	University of Gothenburg	Hansson, GC (corresponding author), Gothenburg Univ, Dept Med Biochem, Med Gatan 9, S-41390 Gothenburg, Sweden.	gunnar.hansson@medkem.gu.se	Hansson, Gunnar C/A-1236-2009; Hansson, Gunnar C./AAF-7324-2019	Hansson, Gunnar C/0000-0002-1900-1869; Hansson, Gunnar C./0000-0002-1900-1869				Asker N, 1998, J BIOL CHEM, V273, P18857, DOI 10.1074/jbc.273.30.18857; ASKER N, 1995, BIOCHEM J, V308, P873, DOI 10.1042/bj3080873; AUDIE JP, 1993, J HISTOCHEM CYTOCHEM, V41, P1479, DOI 10.1177/41.10.8245407; AXELSSON MAB, 1998, IN PRESS GLYCOCONJ J; BAECKSTROM D, 1994, J BIOL CHEM, V269, P14430; CARLSTEDT I, 1985, ESSAYS BIOCHEM, V20, P40; CARLSTEDT I, 1993, J BIOL CHEM, V268, P18771; CARLSTEDT I, 1983, BIOCHEM J, V213, P427, DOI 10.1042/bj2130427; CARLSTEDT I, 1983, BIOCHEM J, V211, P13, DOI 10.1042/bj2110013; CARLSTEDT I, 1982, ADV EXP MED BIOL, V144, P155; CARLSTEDT I, 1996, 4 INT WORKSH CARC AS; CHANG SK, 1994, GASTROENTEROLOGY, V107, P28, DOI 10.1016/0016-5085(94)90057-4; Forstner Janet F., 1994, P1255; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P604; Gipson IK, 1997, BIOL REPROD, V56, P999, DOI 10.1095/biolreprod56.4.999; GUM JR, 1992, J BIOL CHEM, V267, P21375; GUM JR, 1994, J BIOL CHEM, V269, P2440; HANSSON GC, 1994, BIOCHEM BIOPH RES CO, V198, P181, DOI 10.1006/bbrc.1994.1026; Li JD, 1997, P NATL ACAD SCI USA, V94, P967, DOI 10.1073/pnas.94.3.967; MCEWEN CR, 1967, ANAL BIOCHEM, V20, P114, DOI 10.1016/0003-2697(67)90271-0; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; ROBERTON AM, 1989, BIOCHEM J, V261, P637, DOI 10.1042/bj2610637; SHEEHAN JK, 1984, BIOCHEM J, V217, P93, DOI 10.1042/bj2170093; WAGNER DD, 1986, J CELL BIOL, V102, P1320, DOI 10.1083/jcb.102.4.1320; WAGNER DD, 1990, ANNU REV CELL BIOL, V6, P217, DOI 10.1146/annurev.cellbio.6.1.217; Xu GQ, 1996, GLYCOCONJUGATE J, V13, P81, DOI 10.1007/BF01049683; XU GQ, 1992, J BIOL CHEM, V267, P5401	27	78	80	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18864	18870		10.1074/jbc.273.30.18864	http://dx.doi.org/10.1074/jbc.273.30.18864			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668062	hybrid			2022-12-25	WOS:000074974700029
J	Burlacu-Miron, S; Perrier, V; Gilles, AM; Pistotnik, E; Craescu, CT				Burlacu-Miron, S; Perrier, V; Gilles, AM; Pistotnik, E; Craescu, CT			Structural and energetic factors of the increased thermal stability in a genetically engineered Escherichia coli adenylate kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-BINDING; H-1-NMR SPECTRA; PROTEIN; SPECTROSCOPY; ASSIGNMENT; RESOLUTION; COMPLEX; DOMAIN	Several variants of Escherichia coli adenylate kinase, designed to bind a Zn2+ ion, were produced by site-directed mutagenesis. The metal binding and enzymatic properties of the engineered variants have been described (Perrier, V., Burlacu-Miron, S,, Bourgeois, S., Surewicz, W. K., and Gilles, A.-M. (1998) J. Biol, Chem. 273, 19097-19101), Here we report the structural properties and stability changes in a 4-Cys variant which binds a Zn2+ ion and has an increased thermal stability. CD studies indicate a very similar secondary structure content in the wild type and the engineered variant. NMR analysis revealed that the topology of the parallel P-sheet, belonging to the protein core, and of the peripheral antiparallel P-sheet are also conserved. The small local changes observed in the neighborhood of the substitution sites reflect a more compact state of the metal-binding domain. The Zn2+-bound quadruple mutant shows an increased thermal stability, reflected in a 9 degrees C increase of the mid-temperature of the first cooperative unfolding step. finding of a bisubstrate analog P-1,P-5-di(adenosine-5')-pentaphosphate increases, by about 7 degrees C, the midpoint of this transition in both wild type and modified variant. The NMR data suggest that the peripheral domains involved in substrate binding unfold during the first denaturation step. Urea denaturation experiments indicate an increased resistance against chemical unfolding of the Zn2+-binding variant. In contrast, the Gibbs free energy of unfolding (at physiologically relevant conditions) of the quadruple mutant is lower than that of the wild type.	Inst Curie Rech, INSERM, U350, Ctr Univ, F-91405 Orsay, France; Inst Pasteur, URA D1129, Lab Chim Struct Macromol, F-7524 Paris 15, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Craescu, CT (corresponding author), Inst Curie Rech, INSERM, U350, Ctr Univ, Bat 110-112, F-91405 Orsay, France.	craescu@curie.u-psud.fr	Miron, Simona/M-9223-2018; Perrier, Veronique/AAK-3594-2020	perrier, veronique/0000-0002-6570-7504				BERRY MB, 1994, PROTEINS, V19, P183, DOI 10.1002/prot.340190304; Bilderback T, 1996, BIOCHEMISTRY-US, V35, P6100, DOI 10.1021/bi951833i; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; GERSTEIN M, 1993, J MOL BIOL, V229, P494, DOI 10.1006/jmbi.1993.1048; GLASER P, 1992, BIOCHEMISTRY-US, V31, P3038, DOI 10.1021/bi00127a002; JOHNSON CW, 1990, PROTEIN-STRUCT FUNCT, V7, P205; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; MacedoRibeiro S, 1996, STRUCTURE, V4, P1291, DOI 10.1016/S0969-2126(96)00137-2; MIYOSHI K, 1990, J BIOCHEM-TOKYO, V108, P267, DOI 10.1093/oxfordjournals.jbchem.a123192; MONNOT M, 1987, J BIOL CHEM, V262, P2502; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; Muller CW, 1996, STRUCTURE, V4, P147, DOI 10.1016/S0969-2126(96)00018-4; Pace C N, 1986, Methods Enzymol, V131, P266; Perrier V, 1998, J BIOL CHEM, V273, P19097, DOI 10.1074/jbc.273.30.19097; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; REINSTEIN J, 1990, BIOCHEMISTRY-US, V29, P7440, DOI 10.1021/bi00484a013; SCHULZ GE, 1990, J MOL BIOL, V213, P627, DOI 10.1016/S0022-2836(05)80250-5; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; VONRHEIN C, 1995, STRUCTURE, V3, P483, DOI 10.1016/S0969-2126(01)00181-2; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Wuthrich K, 1986, NMR PROTEINS NUCL AC	22	22	22	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19102	19107		10.1074/jbc.273.30.19102	http://dx.doi.org/10.1074/jbc.273.30.19102			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668095	hybrid			2022-12-25	WOS:000074974700062
J	Harris, VK; Liaudet-Coopman, EDE; Boyle, BJ; Wellstein, A; Riegel, AT				Harris, VK; Liaudet-Coopman, EDE; Boyle, BJ; Wellstein, A; Riegel, AT			Phorbol ester-induced transcription of a fibroblast growth factor-binding protein is modulated by a complex interplay of positive and negative regulatory promoter elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C; COLLAGENASE GENE; C/EBP FAMILY; ACTIVATION; NF-IL6; AP-1; FOS; EXPRESSION; DNA; INDUCTION	Earlier studies from our laboratory showed that a secreted binding protein for fibroblast growth factors (FGF-BP) is expressed at high levels in squamous cell carcinoma (SCC) cell lines. Overexpression studies or conversely reduced expression of FGF-BP by ribozyme targeting have elucidated a direct role of this protein in angiogenesis during tumor development. We have also observed a significant up-regulation of FGF-BP during TPA (12-O-tetradecanoylphorbol-13-acetate) promotion of skin cancer. Here we investigate the mechanism of TPA induction of FGF-BP gene expression in the human ME-180 SCC cell line. We found that TPA increased FGF-BP mRNA levels in a time- and dose-dependent manner mediated via the protein kinase C signal transduction pathway. Results from actinomycin D and cycloheximide experiments as well as nuclear transcription assays revealed that TPA up-regulated the steady-state levels of FGF-BP mRNA by increasing its rate of gene transcription independently of de novo protein synthesis. We isolated the human FGF-BP promoter and determined by deletion analysis that TPA regulatory elements were all contained in the first 118 base pairs upstream of the transcription start site. Further mutational analysis revealed that full TPA induction required interplay between several regulatory elements with homology to Ets, AP-1, and CAATT/enhancer binding protein C/EBP sites, In addition, deletion or mutation of a 10-base pair region juxtaposed to the AP-1 site dramatically increased TPA induced FGF-BP gene expression. This region represses the extent of the FGF-BP promoter response to TPA and contained sequences recognized by the family of E box helix-loop-helix transcription factors. Gel shift analysis showed specific and TPA-inducible protein binding to the Ets, AP-1, and C/EBP sites. Furthermore, distinct, specific, and TPA-inducible binding to the imperfect E box repressor element was also apparent. Overall, our data indicate that TPA effects on FGF-BP gene transcription are tightly controlled by a complex interplay of positive elements and a novel negative regulatory element.	Georgetown Univ, Dept Pharmacol, Washington, DC 20007 USA; Georgetown Univ, Vincent T Lombardi Canc Ctr, Washington, DC 20007 USA	Georgetown University; Georgetown University	Wellstein, A (corresponding author), Georgetown Univ, Dept Pharmacol, Res Bldg,E307,3970 Reservoir Rd NW, Washington, DC 20007 USA.		Liaudet-Coopman, Emmanuelle/N-4744-2017	Liaudet-Coopman, Emmanuelle/0000-0001-9313-9690; Wellstein, Anton/0000-0002-0570-4950	NATIONAL CANCER INSTITUTE [R01CA071508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K04DK002141] Funding Source: NIH RePORTER; NCI NIH HHS [CA71508] Funding Source: Medline; NIDDK NIH HHS [DK02141] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BERGHARD A, 1993, MOL CELL BIOL, V13, P677, DOI 10.1128/MCB.13.1.677; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; Combates NJ, 1997, CELL GROWTH DIFFER, V8, P213; Czubayko F, 1997, NAT MED, V3, P1137, DOI 10.1038/nm1097-1137; CZUBAYKO F, 1994, J BIOL CHEM, V269, P28243; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Goppelt A, 1996, EMBO J, V15, P3105, DOI 10.1002/j.1460-2075.1996.tb00673.x; GRANT PA, 1995, EMBO J, V14, P4501, DOI 10.1002/j.1460-2075.1995.tb00129.x; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HARVAT BL, 1995, CELL GROWTH DIFFER, V6, P955; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; Jenkins TD, 1997, J BIOL CHEM, V272, P24433, DOI 10.1074/jbc.272.39.24433; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; KLAMPFER L, 1994, MOL CELL BIOL, V14, P6561, DOI 10.1128/MCB.14.10.6561; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; Kurtz A, 1997, ONCOGENE, V14, P2671, DOI 10.1038/sj.onc.1201117; KUSHNER PJ, 1994, MOL ENDOCRINOL, V8, P405, DOI 10.1210/me.8.4.405; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LiaudetCoopman EDE, 1996, BIOCHEM BIOPH RES CO, V229, P930, DOI 10.1006/bbrc.1996.1904; LiaudetCoopman EDE, 1997, CLIN CANCER RES, V3, P179; LiaudetCoopman EDE, 1996, J BIOL CHEM, V271, P21303, DOI 10.1074/jbc.271.35.21303; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; Newberry EP, 1997, MOL ENDOCRINOL, V11, P1129, DOI 10.1210/me.11.8.1129; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PATERSON JM, 1995, NEUROSCI LETT, V191, P185, DOI 10.1016/0304-3940(95)11588-N; Rak J, 1997, NAT MED, V3, P1083, DOI 10.1038/nm1097-1083; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; RIEGEL AT, 1991, MOL ENDOCRINOL, V5, P1973, DOI 10.1210/mend-5-12-1973; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; TRAUTWEIN C, 1994, J CLIN INVEST, V93, P2554, DOI 10.1172/JCI117266; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WEDEL A, 1995, IMMUNOBIOLOGY, V193, P171, DOI 10.1016/S0171-2985(11)80541-3; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; WU DQ, 1991, J BIOL CHEM, V266, P16778; Zhang M, 1997, CELL GROWTH DIFFER, V8, P179	52	28	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19130	19139		10.1074/jbc.273.30.19130	http://dx.doi.org/10.1074/jbc.273.30.19130			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668098	hybrid			2022-12-25	WOS:000074974700065
J	Blakesley, VA; Koval, AP; Stannard, BS; Scrimgeour, A; LeRoith, D				Blakesley, VA; Koval, AP; Stannard, BS; Scrimgeour, A; LeRoith, D			Replacement of tyrosine 1251 in the carboxyl terminus of the insulin-like growth factor-I receptor disrupts the actin cytoskeleton and inhibits proliferation and anchorage-independent growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAPID COLORIMETRIC ASSAY; FOCAL ADHESION FORMATION; YEAST 2-HYBRID SYSTEM; MAP KINASE KINASE; IGF-I; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; RAT GLIOBLASTOMA; P85 SUBUNIT; PROTEIN	Insulin-like growth factor (IGF)-I signaling through the IGF-I receptor modulates cellular adhesion and proliferation and the transforming ability of cells overexpressing the IGF-I receptor. Tyrosine phosphorylation of intracellular proteins is essential for this transduction of the IGF-I-induced mitogenic and tumorigenic signals. IGF-I induces specific cytoskeletal structure and the phosphorylation of proteins in the associated focal adhesion complexes. The determination of the exact pathways emanating from the IGF-I receptor that are involved in mediating these signals will contribute greatly to the understanding of IGF-I action. We have previously shown that replacement of tyrosine residues 1250 and 1251 in the carboxyl terminus of the IGF-I receptor abrogates IGF-I-induced cellular proliferation and tumor formation in nude mice. In this study, replacement of either tyrosine 1250 or 1251 similarly re duces the cells ability to grow in an anchorage-independent manner. The actin cytoskeleton and cellular localization of vinculin are disrupted by replacement of tyrosine 1251, Tyrosine residues 1250 and 1251 are not essential for tyrosine phosphorylation of two known substrates; insulin receptor substrate-1 and SHC, nor association of known downstream adaptor proteins to these substrates. In addition, these mutant IGF-I receptors do not affect IGF-I-stimulated p42/p44 mitogen-activated protein kinase activation or phosphatidylinositol (PI) 3'-kinase activity. Thus, it appears that in fibroblasts expressing tyrosine 1250 and 1251 mutant IGF-I receptors, the signal transduction pathways impacting on mitogenesis and tumorigenesis do not occur exclusively through the PI 3'-kinase or mitogen-activated protein kinase pathways.	NIDDK, Diabet Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	LeRoith, D (corresponding author), NIDDK, Diabet Branch, NIH, Bldg 10 Rm 8S235A,10 Ctr Dr MSC 1770, Bethesda, MD 20892 USA.	derek@helix.nih.gov	Scrimgeour, Angus/D-6794-2013					ALTSCHULER D, 1994, MOL ENDOCRINOL, V8, P1139, DOI 10.1210/me.8.9.1139; ARTEAGA CL, 1989, CANCER RES, V49, P6237; BACKER JM, 1992, J BIOL CHEM, V267, P1367; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; Balaram SK, 1997, J VASC SURG, V25, P866, DOI 10.1016/S0741-5214(97)70216-7; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; Berfield AK, 1997, J HISTOCHEM CYTOCHEM, V45, P583, DOI 10.1177/002215549704500410; BLAKESLEY VA, 1995, J BIOL CHEM, V270, P2764, DOI 10.1074/jbc.270.6.2764; Blakesley VA, 1996, ENDOCRINOLOGY, V137, P410, DOI 10.1210/en.137.2.410; Blakesley Vicky A., 1996, P824; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CASE RD, 1994, J BIOL CHEM, V269, P10467; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COLL JL, 1995, P NATL ACAD SCI USA, V92, P9161, DOI 10.1073/pnas.92.20.9161; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; DEVRIESSMITS AMM, 1995, ONCOGENE, V10, P919; Ezzell RM, 1997, EXP CELL RES, V231, P14, DOI 10.1006/excr.1996.3451; Feldman EL, 1997, NEUROBIOL DIS, V4, P201, DOI 10.1006/nbdi.1997.0156; FERNANDEZ JLR, 1993, J CELL BIOL, V122, P1285, DOI 10.1083/jcb.122.6.1285; GANSLER T, 1989, AM J PATHOL, V135, P961; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; Guvakova MA, 1997, EXP CELL RES, V231, P149, DOI 10.1006/excr.1996.3457; Harder BA, 1996, J MOL CELL CARDIOL, V28, P19, DOI 10.1006/jmcc.1996.0003; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Ito T, 1996, MOL CELL BIOL, V16, P943; JHUN BH, 1994, J BIOL CHEM, V269, P5699; JOCKUSCH BM, 1981, P NATL ACAD SCI-BIOL, V78, P3005, DOI 10.1073/pnas.78.5.3005; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; KALEBIC T, 1994, CANCER RES, V54, P5531; KATO H, 1994, MOL ENDOCRINOL, V8, P40, DOI 10.1210/me.8.1.40; KATO H, 1993, J BIOL CHEM, V268, P2655; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LAMOTHE B, 1995, FEBS LETT, V373, P51, DOI 10.1016/0014-5793(95)01011-3; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Leventhal PS, 1997, J BIOL CHEM, V272, P5214, DOI 10.1074/jbc.272.8.5214; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; Loeser RF, 1997, ARTHRITIS RHEUM, V40, P270, DOI 10.1002/art.1780400211; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MIURA M, 1995, J BIOL CHEM, V270, P22639, DOI 10.1074/jbc.270.38.22639; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; Neuenschwander S, 1996, J CLIN INVEST, V97, P2225, DOI 10.1172/JCI118663; Nissley P, 1991, Growth Factors, V5, P29, DOI 10.3109/08977199109000269; Nolan MK, 1997, INT J CANCER, V72, P828, DOI 10.1002/(SICI)1097-0215(19970904)72:5<828::AID-IJC20>3.0.CO;2-3; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; PRONK GJ, 1993, ONCOGENE, V8, P2773; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; RESNICOFF M, 1994, CANCER RES, V54, P2218; RESNICOFF M, 1994, CANCER RES, V54, P4848; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAMUELSSON SJ, 1993, J CELL BIOL, V122, P485, DOI 10.1083/jcb.122.2.485; SANCHEZMARGALET V, 1995, MOL ENDOCRINOL, V9, P435, DOI 10.1210/me.9.4.435; Sasaoka T, 1996, ENDOCRINOLOGY, V137, P4427, DOI 10.1210/en.137.10.4427; SEGER R, 1992, J BIOL CHEM, V267, P14373; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SHAPIRO DN, 1994, J CLIN INVEST, V94, P1235, DOI 10.1172/JCI117441; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; Sydor AM, 1996, J CELL BIOL, V134, P1197, DOI 10.1083/jcb.134.5.1197; TARTAREDECKERT S, 1995, J BIOL CHEM, V270, P23456, DOI 10.1074/jbc.270.40.23456; TartareDeckert S, 1996, ENDOCRINOLOGY, V137, P1019, DOI 10.1210/en.137.3.1019; TOBE K, 1991, J BIOL CHEM, V266, P24793; TROJAN J, 1993, SCIENCE, V259, P94, DOI 10.1126/science.8418502; TROJAN J, 1992, P NATL ACAD SCI USA, V89, P4874, DOI 10.1073/pnas.89.11.4874; VARNUMFINNEY B, 1994, J CELL BIOL, V127, P1071, DOI 10.1083/jcb.127.4.1071; VOLBERG T, 1995, J CELL SCI, V108, P2253; WESTMEYER A, 1990, EMBO J, V9, P2071, DOI 10.1002/j.1460-2075.1990.tb07374.x; WOODS A, 1992, J CELL SCI, V101, P277	80	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18411	18422		10.1074/jbc.273.29.18411	http://dx.doi.org/10.1074/jbc.273.29.18411			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660809	hybrid			2022-12-25	WOS:000074828500064
J	Jung, K; Altendorf, K				Jung, K; Altendorf, K			Truncation of amino acids 12-128 causes deregulation of the phosphatase activity of the sensor kinase KdpD of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 REGULATORY COMPONENTS; POTASSIUM-TRANSPORT; CONTROL EXPRESSION; OPERON EXPRESSION; TURGOR PRESSURE; KDPABC OPERON; PROTEIN; BINDING; SIGNAL; SYSTEM	The kdpFABC operon, which encodes the structural genes for the high affinity K+ transport complex KdpFABC, is regulated by the sensor kinase KdpD and the response regulator KdpE. KdpD is a bifunctional enzyme catalyzing the autophosphorylation by ATP and the dephosphorylation of the corresponding response regulator KdpE. Here, we demonstrate that the phosphatase activity of KdpD is dependent on ATP, whereas GTP, ITP, CTP, ADP, and GDP have no effect. The phosphatase activity requires only ATP binding, because nonhydrolyzable analogs (adenosine-5'-[gamma-thio]triphos phate and adenosine-5'-[beta,gamma-imido]triphosphate) work as well. However, KdpD proteins missing amino acids 12-128 are characterized by a phosphatase activity that is independent of ATP. These proteins are still able to respond to K+ starvation, but an increase in osmolarity is no longer sensed. Comparison of different KdpD sequences reveals a conserved motif in this amino acid region that is very similar to a classical ATP-binding site (Walker A motif), Replacement of the conserved Gly(37), Lys(38) and Thr(39) residues in the consensus ATP-binding sequence results in a KdpD protein that causes a kdp-FABC expression pattern comparable with that seen with KdpD proteins missing amino acids 12-128. However, in vitro phosphatase activity is comparable with that of wild-type KdpD. These results suggest that amino acids 12-128 of KdpD are important for its activity and that an additional ATP-binding site in the N-terminal region seems to be involved in modulation of the phosphatase activity.	Univ Osnabruck, Fachbereich Biol Chem, Abt Mikrobiol, D-49069 Osnabruck, Germany	University Osnabruck	Jung, K (corresponding author), Univ Osnabruck, Fachbereich Biol Chem, Abt Mikrobiol, D-49069 Osnabruck, Germany.							AIBA H, 1989, J BIOL CHEM, V264, P14090; AIBA H, 1989, J BIOL CHEM, V264, P8563; ALTENDORF K, 1994, RES MICROBIOL, V145, P374, DOI 10.1016/0923-2508(94)90084-1; ALTENDORF K, 1996, BIOMEMBR, V5, P403; ASHA H, 1993, J BACTERIOL, V175, P4528, DOI 10.1128/JB.175.14.4528-4537.1993; Beier D, 1996, MOL GEN GENET, V252, P169, DOI 10.1007/BF02173217; BLAT Y, 1994, BIOCHEMISTRY-US, V33, P902, DOI 10.1021/bi00170a008; CHARLES TC, 1993, J BACTERIOL, V175, P6614, DOI 10.1128/jb.175.20.6614-6625.1993; CSONKA LN, 1991, ANNU REV MICROBIOL, V45, P569, DOI 10.1146/annurev.mi.45.100191.003033; EPSTEIN W, 1986, FEMS MICROBIOL LETT, V39, P73; EPSTEIN W, 1992, ACTA PHYSIOL SCAND, V146, P193; Epstein W, 1970, J BACTERIOL, V101, P836, DOI 10.1128/JB.101.3.836-843.1970; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HESSE JE, 1984, P NATL ACAD SCI-BIOL, V81, P4746, DOI 10.1073/pnas.81.15.4746; HUANG WJ, 1994, STRUCTURE, V2, P407, DOI 10.1016/S0969-2126(00)00042-3; IGO MM, 1989, GENE DEV, V3, P1725, DOI 10.1101/gad.3.11.1725; Jung K, 1997, J BIOL CHEM, V272, P10847; JUNG K, 1998, IN PRESS BIOCH BIOPH; KAMBEROV ES, 1994, J BIOL CHEM, V269, P28294; KEENER J, 1988, P NATL ACAD SCI USA, V85, P4976, DOI 10.1073/pnas.85.14.4976; KOLLMANN R, 1993, BIOCHIM BIOPHYS ACTA, V1143, P62, DOI 10.1016/0005-2728(93)90216-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIMINS LA, 1981, P NATL ACAD SCI-BIOL, V78, P464, DOI 10.1073/pnas.78.1.464; Miller JH., 1992, SHORT COURSE BACTERI, P72; NAKASHIMA K, 1993, MOL MICROBIOL, V7, P109, DOI 10.1111/j.1365-2958.1993.tb01102.x; NINFA AJ, 1986, P NATL ACAD SCI USA, V83, P5909, DOI 10.1073/pnas.83.16.5909; OHWADA T, 1987, ARCH BIOCHEM BIOPHYS, V259, P157, DOI 10.1016/0003-9861(87)90481-4; PEREGO M, 1994, CELL, V79, P1047, DOI 10.1016/0092-8674(94)90035-3; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; POLAREK JW, 1992, J BACTERIOL, V174, P2145, DOI 10.1128/JB.174.7.2145-2151.1992; Puppe W, 1996, J BIOL CHEM, V271, P25027, DOI 10.1074/jbc.271.40.25027; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5467; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SIEBERS A, 1992, ALKALI CATION TRANSP, P225; Stock J.B., 1995, 2 COMPONENT SIGNAL T, P25; SUGIURA A, 1994, MOL MICROBIOL, V14, P929, DOI 10.1111/j.1365-2958.1994.tb01328.x; TRAUT TW, 1994, EUR J BIOCHEM, V222, P9, DOI 10.1111/j.1432-1033.1994.tb18835.x; VOELKNER P, 1993, EUR J BIOCHEM, V217, P1019, DOI 10.1111/j.1432-1033.1993.tb18333.x; WALDERHAUG MO, 1992, J BACTERIOL, V174, P2152, DOI 10.1128/JB.174.7.2152-2159.1992; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZIMMANN P, 1995, J BIOL CHEM, V270, P28282	43	42	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17406	17410		10.1074/jbc.273.28.17406	http://dx.doi.org/10.1074/jbc.273.28.17406			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651326	hybrid			2022-12-25	WOS:000074816100019
J	Medkova, M; Cho, WW				Medkova, M; Cho, WW			Mutagenesis of the C2 domain of protein kinase C-alpha - Differential roles of Ca2+ ligands and membrane binding residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC PHOSPHOLIPASE A(2); LIPID-BINDING; HIGH-AFFINITY; ANNEXIN-V; MONOLAYERS; PHOSPHATIDYLSERINE; SYNAPTOTAGMIN; CALCIUM; BOVINE; DIACYLGLYCEROL	The C2 domains of conventional protein kinase C (PKC) have been implicated in their Ca2+-dependent membrane binding. The C2 domain of PKC-alpha contains several Ca2+ ligands that bind multiple Ca2+ ions and other putative membrane binding residues. To understand the roles of individual Ca2+ ligands and protein-bound Ca2+ ions in the membrane binding and activation of PKC-alpha, we mutated five putative Ca2+ Ligands (D187N, D193N, D246N, D248N, and D254N) and measured the effects of mutations on vesicle binding, enzyme activity and monolayer penetration of PKC-alpha. Altered properties of these mutants indicate that individual Ca2+ ions and their ligands have different roles in the membrane binding and activation of PKC-alpha. The binding of Ca2+ to Asp(187), Asp(193), and Asp(246) of PKC-alpha is important for the initial binding of protein to membrane surfaces, On the other hand, the binding of another Ca2+ to Asp(187), Asp(246), Asp(248) and Asp(254) induces the conformational change of PKC-alpha, which in turn triggers its membrane penetration and activation. Among these Ca2+ ligands, Asp(246) was shown to be most essential for both membrane binding and activation of PKC-alpha, presumably due to its coordination to multiple Ca2+ ions. Furthermore, to identify the residues in the C2 domain that are involved in membrane binding of PKC-alpha, we mutated four putative membrane binding residues (Trp(245), Trp(247), Arg(249) and Arg(252)). Membrane binding and enzymatic properties of two double site mutants (W245A/W247A and R249A/R252A) indicate that Arg(249) and Arg(252) are involved in electrostatic interactions of PRC-alpha with anionic membranes, whereas Trp(245) and Trp247 participate in its penetration into membranes and resulting hydrophobic interactions. Taken together, these studies provide the first experimental evidence for the role of C2 domain of conventional PKC as a membrane docking unit as web as a module that triggers conformational changes to activate the protein.	Univ Illinois, Dept Chem, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Cho, WW (corresponding author), Univ Illinois, Dept Chem, M-C 111,845 W Taylor St, Chicago, IL 60607 USA.	wcho@uic.edu			NIGMS NIH HHS [GM53987, GM52598] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053987, R01GM052598] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAZZI MD, 1990, BIOCHEMISTRY-US, V29, P7624, DOI 10.1021/bi00485a012; BAZZI MD, 1991, BIOCHEMISTRY-US, V30, P971, DOI 10.1021/bi00218a013; BELL RM, 1991, J BIOL CHEM, V266, P4661; BERS DM, 1982, AM J PHYSIOL, V242, pC404, DOI 10.1152/ajpcell.1982.242.5.C404; BLUME A, 1979, BIOCHIM BIOPHYS ACTA, V557, P32, DOI 10.1016/0005-2736(79)90087-7; CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; DEMEL RA, 1975, BIOCHIM BIOPHYS ACTA, V406, P97, DOI 10.1016/0005-2736(75)90045-0; DUA R, 1995, J BIOL CHEM, V270, P263, DOI 10.1074/jbc.270.1.263; Edwards AS, 1997, BIOCHEMISTRY-US, V36, P15615, DOI 10.1021/bi9718752; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; GAINES JGL, 1966, INSOLUBLE MONOLAYERS, P208; Grobler JA, 1996, NAT STRUCT BIOL, V3, P788, DOI 10.1038/nsb0996-788; Han SK, 1997, J BIOL CHEM, V272, P3573, DOI 10.1074/jbc.272.26.16152; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HU W, 1993, BIOCHEMISTRY-US, V32, P7035, DOI 10.1021/bi00078a032; JACOBS RE, 1989, BIOCHEMISTRY-US, V28, P3421, DOI 10.1021/bi00434a042; Johnson JE, 1997, J BIOL CHEM, V272, P30787, DOI 10.1074/jbc.272.49.30787; KATES M, 1986, TECHNIQUES LIPIDOLOG, P113; Kim Y, 1997, ANAL BIOCHEM, V250, P109, DOI 10.1006/abio.1997.2200; LANDS WEM, 1960, J BIOL CHEM, V235, P2233; Lee BI, 1996, BIOCHEMISTRY-US, V35, P4231, DOI 10.1021/bi9524777; Medkova M, 1998, BIOCHEMISTRY-US, V37, P4892, DOI 10.1021/bi972495j; MOREAU H, 1988, BIOCHEMISTRY-US, V27, P2319, DOI 10.1021/bi00407a012; Mosior M, 1996, P NATL ACAD SCI USA, V93, P1907, DOI 10.1073/pnas.93.5.1907; MOSIOR M, 1993, BIOCHEMISTRY-US, V32, P65, DOI 10.1021/bi00052a010; Mukhopadhyay S, 1996, BBA-BIOMEMBRANES, V1279, P58, DOI 10.1016/0005-2736(95)00201-4; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; Nalefski EA, 1997, BIOCHEMISTRY-US, V36, P12011, DOI 10.1021/bi9717340; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ORR JW, 1992, J BIOL CHEM, V267, P15263; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4667, DOI 10.1021/bi00134a019; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4661, DOI 10.1021/bi00134a018; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; SAIDO TC, 1992, BIOCHEMISTRY-US, V31, P482, DOI 10.1021/bi00117a026; SEELIG A, 1987, BIOCHIM BIOPHYS ACTA, V899, P196, DOI 10.1016/0005-2736(87)90400-7; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; SHEN Z, 1994, BIOCHEMISTRY-US, V33, P11598, DOI 10.1021/bi00204a022; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; SWAIRJO MA, 1995, NAT STRUCT BIOL, V2, P968, DOI 10.1038/nsb1195-968; VERGER R, 1982, CHEM PHYS LIPIDS, V30, P189, DOI 10.1016/0009-3084(82)90052-4; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	48	104	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17544	17552		10.1074/jbc.273.28.17544	http://dx.doi.org/10.1074/jbc.273.28.17544			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651347	hybrid			2022-12-25	WOS:000074816100040
J	Zhang, WQ; Shields, JM; Sogawa, K; Fujii-Kuriyama, Y; Yang, VW				Zhang, WQ; Shields, JM; Sogawa, K; Fujii-Kuriyama, Y; Yang, VW			The gut-enriched Kruppel-like factor suppresses the activity of the CYP1A1 promoter in an Sp1-dependent fashion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; INDUCIBLE EXPRESSION; NUCLEAR PROTEINS; GENE STRUCTURE; CACCC ELEMENT; ZINC FINGERS; SP1; BINDING; FAMILY; IDENTIFICATION	The gut-enriched Kruppel-like factor (GKLF) is a newly identified zinc finger-containing transcription factor. Recent studies indicate that GKLF binds to a core DNA sequence of 5'-(G/A) (G/A)GG(C/T)G(C/T)-3', which is found in an endogenous cis element, the basic transcription element (BTE) of the cytochrome P-450LA1 (CYP1A1) promoter. The present study characterizes the ability of GKLF to regulate CYP1A1 expression. By electrophoretic mobility gel shift assay (EMSA) and methylation interference assay, GKLF was found to bind BTE in a manner similar to several other transcription factors known to interact with BTE including Spl and BTEB. Cotransfection studies in Chinese hamster ovary cells showed that GKLF inhibited the CYP1A1 promoter in a dose and BTE dependent manner. The same exper iments also revealed that BTE was responsible for a significant portion of the CYP1A1 promoter activity. EMSA of nuclear extracts from Chinese hamster ovary cells showed that Spl and Sp3 were two major proteins that interacted with BTE. Additional cotransfection studies showed that GKLF inhibited Spl mediated activation of the CYP1A1 promoter. In contrast, GKLF enhanced Sp3-dependent suppression of the same promoter. Moreover, the ability of GKLF to inhibit Sp1-dependent transactivation was in part due to physical interaction of the two proteins. These findings indicate that GKLF is a negative regulator of the CYP1A1 promoter in a BTE-dependent fashion and that this inhibitory effect is in part mediated by physical interaction with Sp1.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Tohoku Univ, Dept Chem, Sendai, Miyagi 980, Japan	Johns Hopkins University; Johns Hopkins University; Tohoku University	Yang, VW (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Ross 918,720 Rutland Ave, Baltimore, MD 21205 USA.	vyang@welchlink.welch.jhu.edu			NCI NIH HHS [R01 CA084197, R01 CA084197-01] Funding Source: Medline; NIDDK NIH HHS [R01 DK052230-04, DK44484, R01 DK052230, DK09345, DK52230] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009345, R01DK052230, P01DK044484] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; Austen M, 1997, J BIOL CHEM, V272, P1709, DOI 10.1074/jbc.272.3.1709; BEALE EG, 1992, BIOTECHNIQUES, V12, P320; BERG JM, 1990, J BIOL CHEM, V265, P6513; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; BIEKER JJ, 1995, MOL CELL BIOL, V15, P852; Bigger CB, 1997, J BIOL CHEM, V272, P25976, DOI 10.1074/jbc.272.41.25976; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CHUNG I, 1995, MOL PHARMACOL, V47, P677; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FUJIIKURIYAMA Y, 1992, FASEB J, V6, P706, DOI 10.1096/fasebj.6.2.1537460; Galvin KM, 1997, MOL CELL BIOL, V17, P3723, DOI 10.1128/MCB.17.7.3723; GARGIABLANCO MA, 1989, GENE DEV, V3, P739, DOI 10.1101/gad.3.6.739; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HARRINGTON MA, 1988, P NATL ACAD SCI USA, V85, P2066, DOI 10.1073/pnas.85.7.2066; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; HASHIMOTO H, 1993, EUR J BIOCHEM, V218, P585, DOI 10.1111/j.1432-1033.1993.tb18412.x; HENDRICKSON W, 1985, P NATL ACAD SCI USA, V82, P3129, DOI 10.1073/pnas.82.10.3129; HOOVERS JMN, 1992, GENOMICS, V12, P254, DOI 10.1016/0888-7543(92)90372-Y; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; Itoh S, 1997, BBA-GENE STRUCT EXPR, V1350, P155, DOI 10.1016/S0167-4781(96)00215-1; Jenkins TD, 1998, J BIOL CHEM, V273, P10747, DOI 10.1074/jbc.273.17.10747; JOUNAIDI Y, 1994, BIOCHEM BIOPH RES CO, V205, P1741, DOI 10.1006/bbrc.1994.2870; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAMINE J, 1992, J VIROL, V66, P3932, DOI 10.1128/JVI.66.6.3932-3936.1992; KLUG A, 1987, COLD SPRING HARB SYM, V52, P473, DOI 10.1101/SQB.1987.052.01.054; Kobayashi A, 1996, J BIOL CHEM, V271, P12310, DOI 10.1074/jbc.271.21.12310; Kuo CT, 1997, GENE DEV, V11, P2996, DOI 10.1101/gad.11.22.2996; Kuo CT, 1997, SCIENCE, V277, P1986, DOI 10.1126/science.277.5334.1986; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; Lee YH, 1997, MOL CELL BIOL, V17, P2038, DOI 10.1128/MCB.17.4.2038; LETOVSKY J, 1989, NUCLEIC ACIDS RES, V17, P2639, DOI 10.1093/nar/17.7.2639; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; Ohlsson C, 1998, ENDOCRINOLOGY, V139, P1101, DOI 10.1210/en.139.3.1101; PELHAM HRB, 1980, P NATL ACAD SCI-BIOL, V77, P4170, DOI 10.1073/pnas.77.7.4170; PERKINS AC, 1995, NATURE, V375, P318; QUATTROCHI LC, 1989, MOL PHARMACOL, V36, P66; SCHUH R, 1986, CELL, V47, P1025, DOI 10.1016/0092-8674(86)90817-2; Shi Y, 1997, BBA-REV CANCER, V1332, pF49, DOI 10.1016/S0304-419X(96)00044-3; Shields JM, 1998, NUCLEIC ACIDS RES, V26, P796, DOI 10.1093/nar/26.3.796; Shields JM, 1997, J BIOL CHEM, V272, P18504, DOI 10.1074/jbc.272.29.18504; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; SOGAWA K, 1993, J BIOCHEM, V114, P605, DOI 10.1093/oxfordjournals.jbchem.a124224; SOGAWA K, 1993, NUCLEIC ACIDS RES, V21, P1527, DOI 10.1093/nar/21.7.1527; Strom AC, 1996, NUCLEIC ACIDS RES, V24, P1981, DOI 10.1093/nar/24.11.1981; SUWA Y, 1985, J BIOL CHEM, V260, P7980; SWICK AG, 1992, P NATL ACAD SCI USA, V89, P1812, DOI 10.1073/pnas.89.5.1812; TRABER PG, 1992, BIOCHIM BIOPHYS ACTA, V1171, P167, DOI 10.1016/0167-4781(92)90117-I; TRABER PG, 1992, AM J PHYSIOL, V263, pG215, DOI 10.1152/ajpgi.1992.263.2.G215; TRABER PG, 1988, J BIOL CHEM, V263, P9449; Trejo SR, 1997, J BIOL CHEM, V272, P27411, DOI 10.1074/jbc.272.43.27411; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; VENEPALLY P, 1995, J BIOL CHEM, V270, P25402, DOI 10.1074/jbc.270.43.25402; YANAGIDA A, 1990, MOL CELL BIOL, V10, P1470, DOI 10.1128/MCB.10.4.1470; Yet SF, 1998, J BIOL CHEM, V273, P1026, DOI 10.1074/jbc.273.2.1026	68	113	116	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17917	17925		10.1074/jbc.273.28.17917	http://dx.doi.org/10.1074/jbc.273.28.17917			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651398	Green Accepted, hybrid			2022-12-25	WOS:000074816100091
J	Klok, EJ; van Genesen, ST; Civil, A; Schoenmakers, JGG; Lubsen, NH				Klok, EJ; van Genesen, ST; Civil, A; Schoenmakers, JGG; Lubsen, NH			Regulation of expression within a gene family - The case of the rat gamma b- and gamma d-crystallin promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; LENS EPITHELIAL EXPLANTS; MAF NUCLEAR ONCOPROTEIN; DNA METHYLATION; CHLORAMPHENICOL ACETYLTRANSFERASE; FIBER DIFFERENTIATION; CELL-DIFFERENTIATION; TRANSCRIPTION FACTOR; MAMMALIAN-CELLS; BINDING-PROTEIN	The six closely related and clustered rat gamma-crystallin genes, the gamma A- to gamma F-crystallin genes, are simultaneously activated in the embryonic lens but differentially shut down during postnatal development with the gamma B-crystallin gene, the last one to be active. We show here that developmental silencing of the gamma D-crystallin promoter correlates with delayed demethylation during lens fiber cell differentiation. Methylation silencing of the gamma D-crystallin promoter is a general effect and does not require the methylation of a specific CpG, nor does methylation interfere with factor binding to the proximal activator. In later development, the gamma D-crystallin promoter is also shut down earlier by a repressor that footprints to the -91/-78 region. A factor with identical properties is present in brain. Hence, a ubiquitous factor has been recruited as a developmental regulator by the lens. All gamma-crystallin promoters tested contain upstream silencers, but at least the gamma B-crystallin silencer is distinct from the gamma D-crystallin silencer. The gamma-crystallin promoters were found to share a proximal activator (the gamma-box; around -50), which behaves as a MARE. The gamma B-box is recognized with much lower avidity than the gamma D-box. By swapping elements between the gamma B- and the gamma D-crystallin promoter, we show that activation by the gamma B-box requires a directly adjacent -46/-38 AP-1 consensus site. These experiments also uncovered another positive element in the gamma D-crystallin promoter, around -10. In the context of the gamma D-crystallin promoter, this element is redundant; in the context of the gamma B-crystallin promoter, it can replace the -46/-38 element.	Catholic Univ Nijmegen, Dept Mol Biol, NL-6525 ED Nijmegen, Netherlands	Radboud University Nijmegen	Lubsen, NH (corresponding author), Catholic Univ Nijmegen, Dept Mol Biol, Toernooiveld 1, NL-6525 ED Nijmegen, Netherlands.	nhl@sci.kun.nl	Lubsen, Nicolette H./B-8426-2011					AMMENDOLA R, 1990, MOL CELL BIOL, V10, P387, DOI 10.1128/MCB.10.1.387; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BENHATTAR J, 1988, GENE, V65, P219, DOI 10.1016/0378-1119(88)90458-1; Blank V, 1997, TRENDS BIOCHEM SCI, V22, P437, DOI 10.1016/S0968-0004(97)01105-5; BRAKENHOFF RH, 1991, NUCLEIC ACIDS RES, V19, P1279, DOI 10.1093/nar/19.6.1279; Chamberlain CG, 1997, PROG RETIN EYE RES, V16, P443, DOI 10.1016/S1350-9462(96)00034-1; Chamberlain CG, 1989, GROWTH FACTORS, V1, P125, DOI 10.3109/08977198909029122; Collignon J, 1996, DEVELOPMENT, V122, P509; DENDUNNEN JT, 1986, J MOL BIOL, V189, P37, DOI 10.1016/0022-2836(86)90379-7; DENNY P, 1992, EMBO J, V11, P3705, DOI 10.1002/j.1460-2075.1992.tb05455.x; Dirks RPH, 1996, DEV BIOL, V173, P14, DOI 10.1006/dbio.1996.0003; GORING DR, 1993, DEV DYNAM, V196, P143, DOI 10.1002/aja.1001960208; GORING DR, 1992, EXP EYE RES, V54, P785, DOI 10.1016/0014-4835(92)90034-P; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; IGARASHI K, 1995, P NATL ACAD SCI USA, V92, P7445, DOI 10.1073/pnas.92.16.7445; JAIN VK, 1991, ANAL BIOCHEM, V199, P119, DOI 10.1016/0003-2697(91)90278-2; KAMACHI Y, 1995, EMBO J, V14, P3510, DOI 10.1002/j.1460-2075.1995.tb07357.x; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; Kataoka K, 1996, ONCOGENE, V12, P53; KERPPOLA TK, 1994, ONCOGENE, V9, P675; KESHET I, 1985, P NATL ACAD SCI USA, V82, P2560, DOI 10.1073/pnas.82.9.2560; KRUCZEK I, 1983, P NATL ACAD SCI-BIOL, V80, P7586, DOI 10.1073/pnas.80.24.7586; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LIU QR, 1991, MOL CELL BIOL, V11, P1531, DOI 10.1128/MCB.11.3.1531; LOK S, 1985, MOL CELL BIOL, V5, P2221, DOI 10.1128/MCB.5.9.2221; LOVICU FJ, 1989, EXP EYE RES, V49, P479, DOI 10.1016/0014-4835(89)90056-0; LOVICU FJ, 1992, INVEST OPHTH VIS SCI, V33, P2269; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MCAVOY JW, 1986, CURR EYE RES, V5, P711, DOI 10.3109/02713688609015139; MCAVOY JW, 1989, DEVELOPMENT, V107, P221; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; MURERORLANDO M, 1987, DEV BIOL, V119, P260, DOI 10.1016/0012-1606(87)90227-2; OGINO H, 1996, EXP EYE RES, V62, P226; ORCHARD K, 1993, NUCLEIC ACIDS RES, V21, P3335, DOI 10.1093/nar/21.14.3335; ORKIN SH, 1995, EUR J BIOCHEM, V231, P271, DOI 10.1111/j.1432-1033.1995.tb20697.x; PEEK R, 1992, DEV BIOL, V152, P152, DOI 10.1016/0012-1606(92)90165-D; PEEK R, 1990, NUCLEIC ACIDS RES, V18, P1189, DOI 10.1093/nar/18.5.1189; PEEK R, 1992, NUCLEIC ACIDS RES, V20, P4865, DOI 10.1093/nar/20.18.4865; PEEK R, 1991, NUCLEIC ACIDS RES, V19, P77, DOI 10.1093/nar/19.1.77; RICHARDSON NA, 1990, EXP EYE RES, V50, P203, DOI 10.1016/0014-4835(90)90232-J; Sakai M, 1997, ONCOGENE, V14, P745, DOI 10.1038/sj.onc.1200869; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; TULLIUS TD, 1989, ANNU REV BIOPHYS BIO, V18, P213, DOI 10.1146/annurev.bb.18.060189.001241; VANLEEN RW, 1987, DEV BIOL, V120, P457, DOI 10.1016/0012-1606(87)90249-1; VOORTER CEM, 1990, EXP EYE RES, V50, P429, DOI 10.1016/0014-4835(90)90144-J; YISRAELI J, 1988, P NATL ACAD SCI USA, V85, P4638, DOI 10.1073/pnas.85.13.4638; Yoshida K, 1997, INVEST OPHTH VIS SCI, V38, P2679; YU CCK, 1990, DEVELOPMENT, V110, P131	52	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17206	17215		10.1074/jbc.273.27.17206	http://dx.doi.org/10.1074/jbc.273.27.17206			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642290	hybrid			2022-12-25	WOS:000074545200080
J	Ojaniemi, M; Langdon, WY; Vuori, K				Ojaniemi, M; Langdon, WY; Vuori, K			Oncogenic forms of Cbl abrogate the anchorage requirement but not the growth factor requirement for proliferation	ONCOGENE			English	Article						anchorage-independent growth; integrin signaling; oncogene	MEDIATED CELL-ADHESION; PRODUCT C-CBL; TYROSINE PHOSPHORYLATION; PROTOONCOGENE PRODUCT; PROTEIN PRODUCT; PHOSPHATIDYLINOSITOL 3-KINASE; ANTIGEN RECEPTOR; EGF STIMULATION; SH3 DOMAIN; EXTRACELLULAR-MATRIX	Recent studies have demonstrated that Chi, the 120 kDa protein product of the c-cbl proto-oncogene, becomes tyrosine phosphorylated in response to stimulation of growth factor receptors and upon integrin-mediated cell adhesion. As a result, Cbl forms complexes with SH2 and SH3 domain-containing proteins, pointing to its role in signal transduction. The cellular form of CM can be rendered into transforming by naturally occurring or engineered mutations to its amino acid sequence. To gain insight into the mechanisms how oncogenic forms of Cbl render cells tumorigenic and what the function of the cellular CM might be, we have undertaken an analysis of NIH3T3 cells transfected with mild-type and oncogenic forms of Chi. We demonstrate that unlike cellular Cbl, the mutant forms of Cbl are tyrosine phosphorylated in an adhesion-independent manner and interact with and activate SH2-containing signaling molecules in both suspended and adherent cells. Our data further show that oncogenic forms of Cbl induce anchorage-independent but serum-dependent growth. These results support the view that transformation by oncogenic forms of Cbl results from constitutive activation of integrin-dependent, rather than growth factor-dependent signaling events and, as a corollary, suggest that cellular Chi might be a functionally important mediator of integrin signaling.	Burnham Inst, La Jolla Canc Res Ctr, La Jolla, CA 92037 USA; Univ Western Australia, Dept Pathol, Nedlands, WA 6009, Australia	Sanford Burnham Prebys Medical Discovery Institute; University of Western Australia	Vuori, K (corresponding author), Burnham Inst, La Jolla Canc Res Ctr, La Jolla, CA 92037 USA.				NCI NIH HHS [CA72560, CA76037] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA072560, R01CA076037] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; Barber DL, 1997, BLOOD, V89, P3166, DOI 10.1182/blood.V89.9.3166; BLAKE TJ, 1992, ONCOGENE, V7, P757; BLAKE TJ, 1991, ONCOGENE, V6, P653; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; JONGEWARD GD, 1995, GENETICS, V139, P1553; KIM TJ, 1995, J BIOL CHEM, V270, P27504, DOI 10.1074/jbc.270.46.27504; Kontani K, 1996, J BIOL CHEM, V271, P1534; Langdon WY, 1995, AUST NZ J MED, V25, P859, DOI 10.1111/j.1445-5994.1995.tb02892.x; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Ojaniemi M, 1997, J BIOL CHEM, V272, P3780, DOI 10.1074/jbc.272.6.3780; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; SASAKI K, 1995, BIOCHEM BIOPH RES CO, V216, P338, DOI 10.1006/bbrc.1995.2629; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Schwartz MA, 1996, EMBO J, V15, P6525, DOI 10.1002/j.1460-2075.1996.tb01043.x; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; Thien CBF, 1997, ONCOGENE, V14, P2239, DOI 10.1038/sj.onc.1201193; TUCKER R W, 1981, Journal of Supramolecular Structure and Cellular Biochemistry, V15, P29, DOI 10.1002/jsscb.1981.380150104; Verfaillie CM, 1997, ACTA HAEMATOL-BASEL, V97, P40; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0	45	17	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 18	1998	16	24					3159	3167		10.1038/sj.onc.1201859	http://dx.doi.org/10.1038/sj.onc.1201859			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671395				2022-12-25	WOS:000074261300009
J	Sekido, Y; Ahmadian, M; Wistuba, II; Latif, F; Bader, S; Wei, MH; Duh, FM; Gazdar, AF; Lerman, MI; Minna, JD				Sekido, Y; Ahmadian, M; Wistuba, II; Latif, F; Bader, S; Wei, MH; Duh, FM; Gazdar, AF; Lerman, MI; Minna, JD			Cloning of a breast cancer homozygous deletion junction narrows the region of search for a 3p21.3 tumor suppressor gene	ONCOGENE			English	Article						breast cancer; chromosome 3; homozygous deletion; somatic mutation; breakpoint cloning; lung cancer	CELL LUNG-CANCER; CHROMOSOME 3P; HUMAN SEMAPHORIN; LINE U2020; FHIT GENE; CARCINOMAS; HETEROZYGOSITY; IDENTIFICATION; 3P14.2	Chromosome 3p abnormalities and allele loss are frequent in lung and breast cancers, and several lung cancer cell lines exhibit homozygous deletions of 3p indicating potential sites of tumor suppressor genes at regions 3p21.3, 3p14.2 and 3p12. We have identified and characterized a nem 3p21.3 homozygous deletion in a breast cancer cell line and the primary tumor that overlaps those previously described in small cell lung cancer (SCLC), This homozygous deletion is approximately 220 kb in length and represents a somatically acquired change in the primary breast cancer. Cloning and sequencing of the breakpoint demonstrated that this resulted from an interstitial deletion and precisely pinpoints this deletion within the three SCLC homozygous deletions previously reported. This deletion significantly narrows the minimum common deleted region to 120 kb and is distinct from the previously reported region that suppresses tumor formation of the murine A9 fibrosarcoma cells, These findings suggest that a common homozygous deletion region on 3p21.3 is important in both lung and breast cancers. It is likely that this very well characterized region either contains one tumor suppressor gene common to both tumor types or two closely linked tumor suppressor genes specific for each tumor.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; NCI, Frederick Canc Res & Dev Ctr, Immunobiol Lab, SAIC Frederick, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, Biol Carcinogenesis & Dev Program, SAIC Frederick, Frederick, MD 21702 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Minna, JD (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.		Sekido, Yoshitaka/P-9756-2015	Sekido, Yoshitaka/0000-0002-2428-3848	NATIONAL CANCER INSTITUTE [R01CA071618] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA71618] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmadian M, 1997, CANCER RES, V57, P3664; Boldog F, 1997, HUM MOL GENET, V6, P193, DOI 10.1093/hmg/6.2.193; BUCHHAGEN DL, 1994, INT J CANCER, V57, P473, DOI 10.1002/ijc.2910570406; CHEN LC, 1994, CANCER RES, V54, P3021; DALY MC, 1993, ONCOGENE, V8, P1721; Deng GR, 1996, SCIENCE, V274, P2057, DOI 10.1126/science.274.5295.2057; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; DRABKIN HA, 1992, GENE CHROMOSOME CANC, V5, P67, DOI 10.1002/gcc.2870050110; Fong KM, 1997, CANCER RES, V57, P2256; Hayashi S, 1997, CANCER RES, V57, P1981; HIBI K, 1992, ONCOGENE, V7, P445; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P558, DOI 10.1001/jama.273.7.558; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOK K, 1994, CANCER RES, V54, P4183; LATIF F, 1992, GENE CHROMOSOME CANC, V5, P119, DOI 10.1002/gcc.2870050205; Latif F, 1997, HUM GENET, V99, P334, DOI 10.1007/s004390050368; MURATA Y, 1994, HUM MOL GENET, V3, P1341, DOI 10.1093/hmg/3.8.1341; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; Negrini M, 1996, CANCER RES, V56, P3173; Ong ST, 1997, GENE CHROMOSOME CANC, V20, P16, DOI 10.1002/(SICI)1098-2264(199709)20:1<16::AID-GCC3>3.0.CO;2-C; PANDIS N, 1995, GENE CHROMOSOME CANC, V12, P173, DOI 10.1002/gcc.2870120304; PANDIS N, 1993, GENE CHROMOSOME CANC, V6, P151, DOI 10.1002/gcc.2870060304; Roche J, 1996, ONCOGENE, V12, P1289; Sambrook J., 2002, MOL CLONING LAB MANU; SATO T, 1991, CANCER RES, V51, P5794; SEKIDO Y, 1994, ONCOGENE, V9, P1599; Sekido Y, 1996, P NATL ACAD SCI USA, V93, P4120, DOI 10.1073/pnas.93.9.4120; Sithanandam G, 1996, MOL CELL BIOL, V16, P868; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Todd MC, 1996, ONCOGENE, V13, P2387; Todd S, 1997, CANCER RES, V57, P1344; Wei MH, 1996, CANCER RES, V56, P1487; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; Xiang RH, 1996, GENOMICS, V32, P39, DOI 10.1006/geno.1996.0074; YAMAKAWA K, 1993, ONCOGENE, V8, P327	35	123	137	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 18	1998	16	24					3151	3157		10.1038/sj.onc.1201858	http://dx.doi.org/10.1038/sj.onc.1201858			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671394				2022-12-25	WOS:000074261300008
J	Zurovec, M; Petrenko, O; Roll, R; Enrietto, PJ				Zurovec, M; Petrenko, O; Roll, R; Enrietto, PJ			A chicken c-Rel-estrogen receptor chimeric protein shows conditional nuclear localization, DNA binding, transformation and transcriptional activation	ONCOGENE			English	Article						c-Rel; NF-kappa B; transformation; apoptosis	NF-KAPPA-B; V-REL; EXHIBIT DEFECTS; FUSION PROTEIN; IN-VITRO; EXPRESSION; CELLS; ALPHA; INHIBITOR; VIRUS	In this report, we characterize the biological and biochemical properties of a conditional protein containing chicken c-Rel fused to the hormone-binding domain of the human estrogen receptor. This chimeric c-RelER protein causes estrogen-dependent, but otherwise c-Rel-specific, transformation of avian fibroblasts in vitro. Our results demonstrate that c-RelER heterodimerizes with wild-type c-Rel and forms specific complexes with I kappa B-alpha. Estrogen causes translocation of c-RelER to the nucleus and stabilizes its binding to DNA. Hormone-activated c-RelER induces transcription of at least four cellular genes that are constitutively active in wild-type c-Rel-transformed fibroblasts. Two distinct cell populations were examined that differed with respect to their growth phenotypes. The growth of fibroblasts with moderate expression levels of c-RelER was stimulated by estrogen. In contrast, the addition of estrogen to cells with high c-RelER expression levels resulted in inhibition of cytokinesis and the arrest of growth. The carboxy terminal transactivation domain of c-Rel was required for the induction of these effects since neither v-Rel nor c-Rel deletion mutants were able to induce similar changes. Taken together, our results demonstrate that high levels of c-Rel expression can affect cell cycle control and/or cytokinesis. Furthermore, they also indicate that the biological properties of c-Rel in cell growth and differentiation will potentially differ depending on the level of expression.	SUNY Stony Brook, Dept Microbiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Zurovec, M (corresponding author), Univ S Bohemia, Fac Biol, Branisovska 31, Ceske Budejovice 37005, Czech Republic.		Zurovec, Michal/AAE-8185-2021; Zurovec, Michal/H-2562-2014	Zurovec, Michal/0000-0002-0913-166X; Zurovec, Michal/0000-0002-0913-166X	FOGARTY INTERNATIONAL CENTER [F05TW004933] Funding Source: NIH RePORTER; FIC NIH HHS [1FO TW04933-01] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CAPOBIANCO AJ, 1993, VIROLOGY, V193, P160, DOI 10.1006/viro.1993.1112; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Gerondakis S, 1996, P NATL ACAD SCI USA, V93, P3405, DOI 10.1073/pnas.93.8.3405; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; Gilmore TD, 1996, ONCOGENE, V13, P1367; GREEN S, 1991, OESTROGEN RECEPTOR P, P15; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HRDLICKOVA R, 1995, J VIROL, V69, P403; HRDLICKOVA R, 1994, J VIROL, V68, P2371; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KABRUN N, 1991, P NATL ACAD SCI USA, V88, P1783, DOI 10.1073/pnas.88.5.1783; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; KRALOVA J, 1994, J VIROL, V68, P2073, DOI 10.1128/JVI.68.4.2073-2083.1994; KUMAR V, 1986, EMBO J, V5, P2331; METZ T, 1991, EMBO J, V10, P837, DOI 10.1002/j.1460-2075.1991.tb08016.x; MORRISON LE, 1991, ONCOGENE, V6, P1657; MORRISON LE, 1989, ONCOGENE, V4, P667; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; NEHYBA J, 1994, J VIROL, V68, P2039, DOI 10.1128/JVI.68.4.2039-2050.1994; PETRENKO O, 1995, GENE, V160, P305, DOI 10.1016/0378-1119(95)00210-W; Petrenko O, 1997, ONCOGENE, V15, P1671, DOI 10.1038/sj.onc.1201334; SCHATZLE JD, 1995, J VIROL, V69, P5383, DOI 10.1128/JVI.69.9.5383-5390.1995; SCHWARTZ RC, 1988, VIROLOGY, V165, P182, DOI 10.1016/0042-6822(88)90671-X; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; TUNG HYL, 1988, P NATL ACAD SCI USA, V85, P2479, DOI 10.1073/pnas.85.8.2479; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Vogt PK, 1969, FUNDAMENTAL TECHNIQU, P198; WAKELING AE, 1988, J STEROID BIOCHEM, V31, P645, DOI 10.1016/0022-4731(88)90014-3; Zhang GQ, 1996, ONCOGENE, V12, P1153; ZHANG GQ, 1995, MOL CELL BIOL, V15, P1806	44	9	9	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 18	1998	16	24					3133	3142		10.1038/sj.onc.1201860	http://dx.doi.org/10.1038/sj.onc.1201860			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671392				2022-12-25	WOS:000074261300006
J	Konig, J; Prenen, J; Nilius, B; Gerke, V				Konig, J; Prenen, J; Nilius, B; Gerke, V			The annexin II-p11 complex is involved in regulated exocytosis in bovine pulmonary artery endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PANCREATIC BETA-CELLS; DEPENDENT EXOCYTOSIS; INSULIN-SECRETION; CHROMAFFIN CELLS; CALPACTIN-I; CALCIUM; P36; PHOSPHORYLATION; SUBSTRATE	Annexin II is a member of a multigene family of Ca2+-regulated, membrane-binding proteins implicated through biochemical and perforated cell experiments in Ca2+-triggered secretion. Within most cells annexin II resides in a tight heterotetrameric complex with a cellular protein ligand, pll, and complex formation is mediated via the N-terminal 14 residues of annexin II including the N-terminal acetyl group. To analyze at the single cell level whether the annexin II-pll complex is involved in regulated secretion, we used membrane capacitance measurements to follow exocytotic fusion events in bovine aortic endothelial cells manipulated with respect to their annexin II-pll complex formation. Upon guanosine 5'-O-(thiotriphosphate) (GTP gamma S) stimulation, the endothelial cells show a significant increase in membrane capacitance which is generally preceded by a transient rise in intracellular Ca2+ and thus indicative of the occurrence of Ca2+-regulated secretion. The GTP gamma S-induced capacitance increase is markedly reduced in cells loaded with a synthetic peptide, Acl-14, which corresponds in sequence to the N-terminal 14 residues of annexin II in their correctly acetylated form and which is capable of disrupting preformed annexin II-pll complexes. The effect of the peptide is highly specific as the nonacetylated variant, N1-14, which is incapable of disrupting annexin II-pll, does not interfere with the GTP gamma S-induced increase in membrane capacitance, These data show that intact annexin II-p11 complexes are indispensable for regulated exocytosis to occur in an efficient manner in endothelial cells.	Univ Munster, Inst Med Biochem, D-48149 Munster, Germany; Catholic Univ Louvain, Physiol Lab, B-3000 Louvain, Belgium	University of Munster; Universite Catholique Louvain	Gerke, V (corresponding author), Univ Munster, Inst Med Biochem, Von Esmarch Str 56, D-48149 Munster, Germany.							ALI SM, 1989, NATURE, V340, P313, DOI 10.1038/340313a0; BECKER T, 1990, EMBO J, V9, P4207, DOI 10.1002/j.1460-2075.1990.tb07868.x; Celio MR, 1996, GUIDEBOOK CALCIUM BI; ChasserotGolaz S, 1996, J CELL BIOL, V133, P1217, DOI 10.1083/jcb.133.6.1217; Coorssen JR, 1996, EMBO J, V15, P3787, DOI 10.1002/j.1460-2075.1996.tb00752.x; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; Delouche B, 1997, J NEUROCHEM, V68, P1720; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; EMANS N, 1993, J CELL BIOL, V120, P1357, DOI 10.1083/jcb.120.6.1357; Emeis JJ, 1997, J CELL BIOL, V139, P245, DOI 10.1083/jcb.139.1.245; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; Gerke V, 1997, BBA-MOL CELL RES, V1357, P129, DOI 10.1016/S0167-4889(97)00038-4; GLENNEY JR, 1985, P NATL ACAD SCI USA, V82, P7884, DOI 10.1073/pnas.82.23.7884; Graham ME, 1997, MOL BIOL CELL, V8, P431, DOI 10.1091/mbc.8.3.431; HARDER T, 1993, J CELL BIOL, V123, P1119, DOI 10.1083/jcb.123.5.1119; HARRISON VJ, 1995, P NATL ACAD SCI USA, V92, P6344, DOI 10.1073/pnas.92.14.6344; JOHNSSON N, 1988, EMBO J, V7, P2435, DOI 10.1002/j.1460-2075.1988.tb03089.x; JOHNSSON N, 1986, EMBO J, V5, P3455, DOI 10.1002/j.1460-2075.1986.tb04669.x; JOHNSSON N, 1986, FEBS LETT, V198, P361, DOI 10.1016/0014-5793(86)80437-9; JOHNSTONE SA, 1992, J BIOL CHEM, V267, P25976; Jost M, 1997, J CELL SCI, V110, P221; Jost M, 1996, BBA-MOL CELL RES, V1313, P283, DOI 10.1016/0167-4889(96)00101-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambert O, 1997, J MOL BIOL, V272, P42, DOI 10.1006/jmbi.1997.1183; MILLER SG, 1991, J CELL BIOL, V112, P39, DOI 10.1083/jcb.112.1.39; NAKATA T, 1990, J CELL BIOL, V110, P13, DOI 10.1083/jcb.110.1.13; NEHER E, 1988, J PHYSIOL-LONDON, V395, P193, DOI 10.1113/jphysiol.1988.sp016914; Nilius B, 1996, J BIOL CHEM, V271, P30631, DOI 10.1074/jbc.271.48.30631; Oberhauser AF, 1996, BIOPHYS J, V71, P1131, DOI 10.1016/S0006-3495(96)79315-3; OSBORN M, 1988, EXP CELL RES, V175, P81, DOI 10.1016/0014-4827(88)90257-1; Proks P, 1996, J PHYSIOL-LONDON, V496, P255, DOI 10.1113/jphysiol.1996.sp021682; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; REGAZZI R, 1995, EMBO J, V14, P2723, DOI 10.1002/j.1460-2075.1995.tb07273.x; REGNOUF F, 1995, J BIOL CHEM, V270, P27143, DOI 10.1074/jbc.270.45.27143; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SARAFIAN T, 1991, J CELL BIOL, V114, P1135, DOI 10.1083/jcb.114.6.1135; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Seemann J, 1996, BIOCHEM J, V319, P123, DOI 10.1042/bj3190123; THIEL C, 1992, J CELL SCI, V103, P733; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALLAR L, 1987, J BIOL CHEM, V262, P5049; WAGNER DD, 1993, THROMB HAEMOSTASIS, V70, P105; WOLLHEIM CB, 1987, BIOSCIENCE REP, V7, P443, DOI 10.1007/BF01362507	43	71	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19679	19684		10.1074/jbc.273.31.19679	http://dx.doi.org/10.1074/jbc.273.31.19679			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677396	hybrid			2022-12-25	WOS:000075125200048
J	Frye, EB; Degenhardt, TP; Thorpe, SR; Baynes, JW				Frye, EB; Degenhardt, TP; Thorpe, SR; Baynes, JW			Role of the Maillard reaction in aging of tissue proteins - Advanced glycation end product-dependent increase in imidazolium cross-links in human lens proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NON-ENZYMATIC GLYCOSYLATION; DIABETIC COMPLICATIONS; AMINO-ACIDS; NONENZYMATIC GLYCOSYLATION; SKIN COLLAGEN; GLYOXALASE SYSTEM; ALBUMIN INVIVO; SERUM-ALBUMIN; METHYLGLYOXAL; IDENTIFICATION	Dicarbonyl compounds such as glyoxal and methylglyoxal are reactive dicarbonyl intermediates in the nonenzymatic browning and cross-linking of proteins during the Maillard reaction. We describe here the quantification of glyoxal and methylglyoxal-derived imidazolium cross-links in tissue proteins. The imidazolium salt cross links, glyoxal-lysine dimer (GOLD) and methylglyoxal-lysine dimer (MOLD), were measured by liquid chromatography/mass spectrometry and were present in lens protein at concentrations of 0.02-0.2 and 0.1-0.8 mmol/mol of lysine, respectively. The lens concentrations of GOLD and MOLD correlated significantly with one another and also increased with lens age. GOLD and MOLD were present at significantly higher concentrations than the fluorescent cross-links pentosidine and dityrosine, identifying them as major Maillard reaction cross-links in lens proteins. Like the N-carboxy-alkyllysines N-epsilon-(carboxymethyl)lysine and N-epsilon-(carboxyethyl)lysine, these cross-links were also detected at lower concentrations in human skin collagen and increased with age in collagen. The presence of GOLD and MOLD in tissue proteins implicates methylglyoxal and glyoxal, either free or protein-bound, as important precursors of protein cross-links formed during Maillard reactions in vivo during aging and in disease.	Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA; Univ S Carolina, Dept Ophthalmol, Columbia, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Baynes, JW (corresponding author), Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA.	baynes@psc.sc.edu			NIDDK NIH HHS [DK-19971] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019971, R37DK019971] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmed MU, 1997, BIOCHEM J, V324, P565, DOI 10.1042/bj3240565; AHMED MU, 1986, J BIOL CHEM, V261, P4889; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BRINKMANN E, 1995, J CHEM SOC P1, V1, P2817; BUCKINGHAM B, 1990, J CLIN INVEST, V86, P1046, DOI 10.1172/JCI114807; DUNN JA, 1991, BIOCHEMISTRY-US, V30, P1205, DOI 10.1021/bi00219a007; DUNN JA, 1989, BIOCHEMISTRY-US, V28, P9454; DYER DG, 1991, J BIOL CHEM, V266, P11654; DYER DG, 1993, J CLIN INVEST, V91, P2463, DOI 10.1172/JCI116481; Fu MX, 1996, J BIOL CHEM, V271, P9982, DOI 10.1074/jbc.271.17.9982; GARLICK RL, 1983, J BIOL CHEM, V258, P6142; GLOMB MA, 1995, J BIOL CHEM, V270, P10017, DOI 10.1074/jbc.270.17.10017; HAYASHI T, 1986, AGR BIOL CHEM TOKYO, V50, P1965, DOI 10.1080/00021369.1986.10867692; HAYASHI T, 1986, AGR BIOL CHEM TOKYO, V50, P1959, DOI 10.1080/00021369.1986.10867691; Heath MM, 1996, BBA-MOL BASIS DIS, V1315, P176, DOI 10.1016/0925-4439(95)00120-4; HENLE T, 1994, Z LEBENSM UNTERS FOR, V199, P55, DOI 10.1007/BF01192954; HODGE JE, 1953, J AGR FOOD CHEM, V1, P928, DOI 10.1021/jf60015a004; HOFMANN K, 1960, J AM CHEM SOC, V82, P3727, DOI 10.1021/ja01499a064; IBERG N, 1986, J BIOL CHEM, V261, P3542; KONOSHI Y, 1994, BIOSCI BIOTECH BIOCH, V58, P1953; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDL F, 1990, ANGEW CHEM INT EDIT, V29, P565, DOI 10.1002/anie.199005653; LO TWC, 1994, J BIOL CHEM, V269, P32299; LOIDLSTAHLHOFEN A, 1995, CHEM PHYS LIPIDS, V77, P113, DOI 10.1016/0009-3084(95)02459-V; MCLAUGHLIN JA, 1980, P NATL ACAD SCI-BIOL, V77, P949, DOI 10.1073/pnas.77.2.949; MCLELLAN AC, 1994, CLIN SCI, V87, P21, DOI 10.1042/cs0870021; MITCHEL REJ, 1977, ANAL BIOCHEM, V81, P47, DOI 10.1016/0003-2697(77)90597-8; Nagaraj RH, 1996, J BIOL CHEM, V271, P19338, DOI 10.1074/jbc.271.32.19338; PATRICK JS, 1990, J GERONTOL, V45, pB18, DOI 10.1093/geronj/45.1.B18; RAY M, 1987, J BIOL CHEM, V262, P5974; REICHARD GA, 1986, DIABETES, V35, P668, DOI 10.2337/diabetes.35.6.668; RICHARD JP, 1991, BIOCHEMISTRY-US, V30, P4581, DOI 10.1021/bi00232a031; SHAPIRO R, 1980, J BIOL CHEM, V255, P3120; SKOVSTED IC, 1997, P 6 INT MAILL S LOND, pA165; THORNALLEY PJ, 1993, MOL ASPECTS MED, V14, P287, DOI 10.1016/0098-2997(93)90002-U; Thornalley PJ, 1996, CLIN SCI, V91, P575, DOI 10.1042/cs0910575; THORNALLEY PJ, 1994, AMINO ACIDS, V6, P15, DOI 10.1007/BF00808119; THORNALLEY PJ, 1989, DIABETES RES CLIN PR, V7, P115, DOI 10.1016/0168-8227(89)90101-0; Thorpe SR, 1996, DRUG AGING, V9, P69, DOI 10.2165/00002512-199609020-00001; VANDERJAGT DL, 1992, J BIOL CHEM, V267, P4364; VLASSARA H, 1994, J LAB CLIN MED, V124, P19; WATKINS NG, 1985, J BIOL CHEM, V260, P629; WATKINS NG, 1987, J BIOL CHEM, V262, P7207; WELLSKNECHT KJ, 1995, BIOCHEMISTRY-US, V34, P3702, DOI 10.1021/bi00011a027; WELLSKNECHT KJ, 1995, J ORG CHEM, V60, P6246, DOI 10.1021/jo00125a001; WELLSKNECHT MC, 1993, J BIOL CHEM, V268, P12348; YIM HS, 1995, J BIOL CHEM, V270, P28228	47	273	289	2	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18714	18719		10.1074/jbc.273.30.18714	http://dx.doi.org/10.1074/jbc.273.30.18714			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668043	hybrid			2022-12-25	WOS:000074974700010
J	Huse, M; Eck, MJ; Harrison, SC				Huse, M; Eck, MJ; Harrison, SC			A Zn2+ ion links the cytoplasmic tail of CD4 and the N-terminal region of Lck	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PROTEIN-KINASE; CELL ANTIGEN RECEPTOR; MICE LACKING P56(LCK); SIGNAL-TRANSDUCTION; T-CELLS; P56LCK; ASSOCIATION; COMPLEX; REQUIREMENT; ACTIVATION	Lck is a lymphoid-specific, Src family protein-tyrosine kinase that is known to interact with the T-cell coreceptors, CD4 and CD8. This interaction, which is critical for proper T-cell function, is mediated by the N-terminal unique region of Lck and the C-terminal cytoplasmic tail of the coreceptors. A pair of cysteines on each molecule is essential for association, suggesting that CD4 or CD8 may interact with Lck by jointly coordinating a metal ion. We describe here experiments in which a maltose-binding protein fusion protein bearing the CD4 tail has been coexpressed in Escherichia coli with an N-terminal fragment of Lck. The proteins associate in the expressing cells, forming a complex that can be affinity-purified. Formation of this complex, like the in vivo interaction, depends upon the two pairs of cysteines. Biochemical and biophysical experiments show that the complex dissociates in the presence of EDTA and that it contains a single Zn2+ ion. These results are consistent with the proposal that Lck and CD4 associate by thiol-mediated co-coordination of zinc.	Harvard Univ, Childrens Hosp, Mol Med Lab, Boston, MA 02115 USA; Harvard Univ, Dept Cellular & Mol Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Harrison, SC (corresponding author), Harvard Univ, Childrens Hosp, Mol Med Lab, Boston, MA 02115 USA.	harrison@crystal.harvard.edu						ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ADAM D, 1993, J BIOL CHEM, V268, P19882; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; BURGESS KE, 1991, EUR J IMMUNOL, V21, P1663, DOI 10.1002/eji.1830210712; Campbell KS, 1995, ANN NY ACAD SCI, V766, P89, DOI 10.1111/j.1749-6632.1995.tb26652.x; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; COLLINS TL, 1992, J IMMUNOL, V148, P2159; FRANKEL AD, 1988, SCIENCE, V240, P70, DOI 10.1126/science.2832944; GASSMANN M, 1993, J RECEPTOR RES, V13, P711, DOI 10.3109/10799899309073688; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; KIM YJ, 1993, J IMMUNOL, V151, P1255; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; Lim GEK, 1998, EUR J IMMUNOL, V28, P745, DOI 10.1002/(SICI)1521-4141(199802)28:02<745::AID-IMMU745>3.0.CO;2-6; LUO KX, 1992, MOL CELL BIOL, V12, P4724, DOI 10.1128/MCB.12.10.4724; MOLINA TJ, 1993, J IMMUNOL, V151, P699; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; PENNINGER J, 1993, SCIENCE, V260, P358, DOI 10.1126/science.8469988; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; RUDD CE, 1989, IMMUNOL REV, V111, P223; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; vanOers NSC, 1996, J EXP MED, V183, P1053, DOI 10.1084/jem.183.3.1053; VEGA MA, 1990, EUR J IMMUNOL, V20, P453, DOI 10.1002/eji.1830200235; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; XU H, 1993, CELL, V74, P633, DOI 10.1016/0092-8674(93)90511-N	30	71	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18729	18733		10.1074/jbc.273.30.18729	http://dx.doi.org/10.1074/jbc.273.30.18729			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668045	hybrid			2022-12-25	WOS:000074974700012
J	Meyers, MB; Puri, TS; Chien, AJ; Gao, TY; Hsu, PH; Hosey, MM; Fishman, GI				Meyers, MB; Puri, TS; Chien, AJ; Gao, TY; Hsu, PH; Hosey, MM; Fishman, GI			Sorcin associates with the pore-forming subunit of voltage-dependent L-type Ca2+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE RYANODINE-RECEPTOR; CALCIUM-RELEASE CHANNEL; SKELETAL-MUSCLE; SARCOPLASMIC-RETICULUM; CARDIAC-MUSCLE; RABBIT SKELETAL; ALPHA-1 SUBUNIT; PROTEIN-KINASE; CELL LINES; CONTRACTION	Intracellular Ca2+ release in muscle is governed by functional communication between the voltage-dependent L-type Ca2+ channel and the intracellular Ca2+ release channel by processes that are incompletely understood, We previously showed that sorcin binds to cardiac Ca2+ release channel/ryanodine receptors and decreases channel open probability in planar lipid bilayers. In addition, we showed that sorcin antibody immunoprecipitates ryanodine receptors from metabolically labeled cardiac myocytes along with a second protein having a molecular weight similar to that of the alpha(1) subunit of cardiac L-type Ca2+ channels. We now demonstrate that sorcin biochemically associates with cardiac and skeletal muscle L-type Ca2+ channels specifically within the cytoplasmically oriented C-terminal region of the alpha(1) subunits, providing evidence that the second protein recovered by sorcin antibody from cardiac myocytes was the 240-kDa L-type Ca2+ channel alpha(1) subunit, Anti-sorcin antibody immunoprecipitated full-length alpha(1) subunits from cardiac myocytes, C2C12 myotubes, and transfected non-muscle cells expressing alpha(1) subunits, In contrast, the anti-sorcin antibody did not immunoprecipitate C-terminal truncated forms of alpha(1) subunits that were detected in myotubes. Recombinant sorcin bound to cardiac and skeletal HIS6-tagged alpha(1) C termini immobilized on Ni2+ resin, Additionally, anti-sorcin antibody immunoprecipitated C-terminal fragments of the cardiac alpha(1) subunit exogenously expressed in mammalian cells. The results identified a putative sorcin binding domain within the C terminus of the alpha(1) subunit, These observations, along with the demonstration that sorcin accumulated substantially during physiological maturation of the excitation-contraction coupling apparatus in developing postnatal rat heart and differentiating C2C12 muscle cells, suggest that sorcin may mediate interchannel communication during excitation-contraction coupling in heart and skeletal muscle.	CUNY Mt Sinai Sch Med, Dept Med, Cardiovasc Inst, New York, NY 10029 USA; Northwestern Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Chicago, IL 60611 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Northwestern University	Meyers, MB (corresponding author), CUNY Mt Sinai Sch Med, Dept Med, Cardiovasc Inst, Box 1030,1 Gustave L Levy Pl, New York, NY 10029 USA.	marian_meyers@smtplink.mssm.edu		Fishman, Glenn/0000-0002-2366-8527	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL023306, R37HL023306] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [F30MH010770] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL23306] Funding Source: Medline; NIMH NIH HHS [1 F30-MH10770] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AIREY JA, 1991, DEV BIOL, V148, P365, DOI 10.1016/0012-1606(91)90344-3; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; ARAI M, 1992, AM J PHYSIOL, V262, P614; BASSANI JWM, 1994, CIRC RES, V74, P991, DOI 10.1161/01.RES.74.5.991; BEAM KG, 1992, NATURE, V360, P169, DOI 10.1038/360169a0; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; Bers D.M., 1993, EXCITATION CONTRACTI; BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092-8674(95)90179-5; BRAWLEY RM, 1992, J BIOL CHEM, V267, P18218; BRILLANTES AMB, 1994, CIRC RES, V75, P503, DOI 10.1161/01.RES.75.3.503; Brownawell AM, 1997, J BIOL CHEM, V272, P22182, DOI 10.1074/jbc.272.35.22182; Cannell MB, 1997, BIOPHYS J, V73, P112, DOI 10.1016/S0006-3495(97)78052-4; CANNELL MB, 1995, SCIENCE, V268, P1045, DOI 10.1126/science.7754384; Chavis P, 1996, NATURE, V382, P719, DOI 10.1038/382719a0; CHEN SRW, 1993, BIOCHEMISTRY-US, V32, P3743, DOI 10.1021/bi00065a029; CHIEN AJ, 1995, J BIOL CHEM, V270, P30036; COHEN MM, 1998, J PHYSL, V406, P115; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; DeJongh KS, 1996, BIOCHEMISTRY-US, V35, P10392, DOI 10.1021/bi953023c; DEJONGH KS, 1991, P NATL ACAD SCI USA, V88, P10778, DOI 10.1073/pnas.88.23.10778; DIESSEROTH K, 1996, NEURON, V16, P89; Flucher BE, 1996, P NATL ACAD SCI USA, V93, P8101, DOI 10.1073/pnas.93.15.8101; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; FUENTES O, 1994, CELL CALCIUM, V15, P305, DOI 10.1016/0143-4160(94)90070-1; Gao TY, 1997, J BIOL CHEM, V272, P19401, DOI 10.1074/jbc.272.31.19401; Gomez AM, 1997, SCIENCE, V276, P800, DOI 10.1126/science.276.5313.800; GYORKE S, 1993, SCIENCE, V260, P807, DOI 10.1126/science.8387229; Hosey MM, 1996, TRENDS CARDIOVAS MED, V6, P265, DOI 10.1016/S1050-1738(96)00109-0; Kaftan E, 1996, CIRC RES, V78, P990, DOI 10.1161/01.RES.78.6.990; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1992, AM J PHYSIOL, V263, pC365, DOI 10.1152/ajpcell.1992.263.2.C365; LIGERONA JL, 1997, J MUSCLE RES CELL M, V18, P587; LIPP P, 1994, CIRC RES, V74, P979, DOI 10.1161/01.RES.74.5.979; LIU L, 1995, CIRCULATION, V92, P372; Lokuta AJ, 1997, J BIOL CHEM, V272, P25333, DOI 10.1074/jbc.272.40.25333; LOPEZLOPEZ JR, 1995, SCIENCE, V268, P1042, DOI 10.1126/science.7754383; Lovry O.H., 1951, J BIOL CHEM, V193, P265; MAYRLEITNER M, 1994, CELL CALCIUM, V15, P99, DOI 10.1016/0143-4160(94)90048-5; MCPHERSON PS, 1991, NEURON, V7, P17, DOI 10.1016/0896-6273(91)90070-G; Meyers M B, 1989, Cancer Commun, V1, P233; Meyers M. B., 1991, NOVEL CALCIUM BINDIN, P385, DOI 10.1007/978-3-642-76150-8_22; MEYERS MB, 1995, J BIOL CHEM, V270, P26411, DOI 10.1074/jbc.270.44.26411; MEYERS MB, 1995, FEBS LETT, V357, P230, DOI 10.1016/0014-5793(94)01338-2; MEYERS MB, 1990, STIMULUS RESPONSE CO, P159; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MILLER JB, 1990, J CELL BIOL, V111, P1149, DOI 10.1083/jcb.111.3.1149; MORAD M, 1995, ADV EXP MED BIOL, V382, P89; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; Pickel VM, 1997, J COMP NEUROL, V386, P625, DOI 10.1002/(SICI)1096-9861(19971006)386:4<625::AID-CNE8>3.0.CO;2-4; Puri TS, 1997, BIOCHEMISTRY-US, V36, P9605, DOI 10.1021/bi970500d; Santana LF, 1996, CIRC RES, V78, P166, DOI 10.1161/01.RES.78.1.166; SELBERT S, 1995, J CELL SCI, V108, P85; SIPIDO KR, 1995, CIRC RES, V76, P102, DOI 10.1161/01.RES.76.1.102; TAKEKURA H, 1995, J MUSCLE RES CELL M, V16, P465, DOI 10.1007/BF00126431; TAKESHIMA H, 1994, NATURE, V369, P556, DOI 10.1038/369556a0; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TSUGORKA A, 1995, SCIENCE, V269, P1723, DOI 10.1126/science.7569901; VANDERBLIEK AM, 1986, EMBO J, V5, P3201, DOI 10.1002/j.1460-2075.1986.tb04630.x; Wagenknecht T, 1997, J BIOL CHEM, V272, P32463, DOI 10.1074/jbc.272.51.32463; Wier WG, 1997, CIRC RES, V81, P462, DOI 10.1161/01.RES.81.4.462; Xiao RP, 1997, J PHYSIOL-LONDON, V500, P343, DOI 10.1113/jphysiol.1997.sp022025; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; Zamparelli C, 1997, FEBS LETT, V409, P1, DOI 10.1016/S0014-5793(97)00464-X; Zhou JM, 1997, P NATL ACAD SCI USA, V94, P2301, DOI 10.1073/pnas.94.6.2301	64	95	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18930	18935		10.1074/jbc.273.30.18930	http://dx.doi.org/10.1074/jbc.273.30.18930			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668070	hybrid			2022-12-25	WOS:000074974700037
J	Pepe, JC; Lory, S				Pepe, JC; Lory, S			Amino acid substitutions in PilD, a bifunctional enzyme of Pseudomonas aeruginosa - Effect on leader peptidase and N-methyltransferase activities in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREPILIN PEPTIDASE; PROTEIN SECRETION; MEMBRANE-PROTEIN; SIGNAL PEPTIDASE; GENE; CLEAVAGE; METHYLATION; ADHERENCE; SEQUENCE; MUTAGENESIS	Subunits of type IV pill and a subset of proteins of the type II extracellular protein secretion apparatus undergo two consecutive post-translational modifications: leader peptide cleavage, followed by methylation of the newly created N-terminal amino acid. These two reactions are carried out by a single bifunctional enzyme encoded in Pseudomonas aeruginosa by the pilD gene. Properties of PilD mutants at positions Gly(95) and/or Lys(96) which were differentially affected in leader peptidase and N-methyltransferase function were characterized. None of the single amino acid substitutions showed a significant alteration in their ability to cleave the prepilin leader peptide; however, two double mutants did exhibit a modest reduction in the efficiency of cleavage. In contrast, a significant decrease of N-methyltransferase activity was detected in PilD having substitutions at Gly(95). Mutants with substitutions at position Lys(96) showed a variable effect on N-methyltransferase activity with an apparent requirement for any charged amino acid at this position. Absence of N-methyltransferase activity did not appear to interfere with the ability of P. aeruginosa to assemble functional pill. Moreover, pilin monomers isolated from P. aeruginosa expressing PilD with Gly(95) substitutions were not methylated. Although complete methylation does not appear to be absolutely required for pilus assembly in P. aeruginosa, this modification may be important for pilus function in its natural habitat.	Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Lory, S (corresponding author), Univ Washington, Sch Med, Dept Microbiol, Box 357242, Seattle, WA 98195 USA.	guidos@u.washington.edu			NIAID NIH HHS [R0I AI 21451] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021451] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALLY M, 1992, MOL MICROBIOL, V6, P1121, DOI 10.1111/j.1365-2958.1992.tb01550.x; BALLY M, 1991, J BACTERIOL, V173, P479, DOI 10.1128/jb.173.2.479-486.1991; BERKA RM, 1981, INFECT IMMUN, V34, P1071, DOI 10.1128/IAI.34.3.1071-1074.1981; BLAKE MS, 1989, J EXP MED, V170, P1727, DOI 10.1084/jem.170.5.1727; BLISS CI, 1970, STAT BIOL, P17; BODEY GP, 1983, REV INFECT DIS, V5, P279; CHATTERJEE S, 1995, J MOL BIOL, V245, P311, DOI 10.1006/jmbi.1994.0025; DALBEY RE, 1988, J BIOL CHEM, V263, P404; DEV IK, 1985, J BIOL CHEM, V260, P5891; DONNENBERG MS, 1992, MOL MICROBIOL, V6, P3427, DOI 10.1111/j.1365-2958.1992.tb02210.x; EISENTHAL R, 1974, BIOCHEM J, V139, P715, DOI 10.1042/bj1390715; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; GILBERT DG, 1989, ENZYME KINETICS; GREENE PJ, 1981, J BIOL CHEM, V256, P2143; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU PV, 1966, J INFECT DIS, V116, P112, DOI 10.1093/infdis/116.1.112; NUNN D, 1990, J BACTERIOL, V172, P2911, DOI 10.1128/jb.172.6.2911-2919.1990; NUNN DN, 1991, P NATL ACAD SCI USA, V88, P3281, DOI 10.1073/pnas.88.8.3281; NUNN DN, 1993, J BACTERIOL, V175, P4375, DOI 10.1128/JB.175.14.4375-4382.1993; NUNN DN, 1992, P NATL ACAD SCI USA, V89, P47, DOI 10.1073/pnas.89.1.47; PEPE JC, 1990, J BACTERIOL, V172, P3780, DOI 10.1128/jb.172.7.3780-3789.1990; Sambrook J, 1989, MOL CLONING LAB MANU, V1 and 3; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; SIMPSON DA, 1992, INFECT IMMUN, V60, P3771, DOI 10.1128/IAI.60.9.3771-3779.1992; SOM S, 1987, NUCLEIC ACIDS RES, V15, P313, DOI 10.1093/nar/15.1.313; STROM MS, 1992, J BACTERIOL, V174, P7345, DOI 10.1128/jb.174.22.7345-7351.1992; STROM MS, 1991, J BIOL CHEM, V266, P1656; STROM MS, 1991, J BACTERIOL, V173, P1175, DOI 10.1128/jb.173.3.1175-1180.1991; STROM MS, 1993, J BIOL CHEM, V268, P15788; STROM MS, 1993, P NATL ACAD SCI USA, V90, P2404, DOI 10.1073/pnas.90.6.2404; WOODS DE, 1980, INFECT IMMUN, V30, P694	32	42	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19120	19129		10.1074/jbc.273.30.19120	http://dx.doi.org/10.1074/jbc.273.30.19120			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668097	hybrid			2022-12-25	WOS:000074974700064
J	Chu, BY; Zhong, R; Soncin, F; Stevenson, MA; Calderwood, SK				Chu, BY; Zhong, R; Soncin, F; Stevenson, MA; Calderwood, SK			Transcriptional activity of heat shock factor 1 at 37 degrees C is repressed through phosphorylation on two distinct serine residues by glycogen synthase kinase 3 alpha and protein kinases C alpha, and C zeta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; GENE-EXPRESSION; MAP KINASE; BETA-CATENIN; HSP70 GENE; FACTOR-I; ACTIVATION; CELLS; STRESS; YEAST	Heat shock factor 1 (HSF1) is the key transcriptional regulator of the heat shock genes that protect cells from environmental stress. However, because heat shock gene expression is deleterious to growth and development, we have examined mechanisms for HSF1 repression at growth temperatures, focusing on the role of phosphorylation. Mitogen-activated protein kinases (MAPKs) of the ERR family phosphorylate HSF1 and represses transcriptional function. The mechanism of repression involves initial phosphorylation by MAP kinase on serine 307, which primes HSF1 for secondary phosphorylation by glycogen synthase kinase 3 on a key residue in repression (serine 303). In vivo expression of glycogen synthase kinase 3 (alpha or beta) thus represses HSF1 through phosphorylation of serine 303. HSF1 is also phosphorylated by MAPK in vitro on a second residue (serine 363) adjacent to activation domain 1, and this residue is additionally phosphorylated by protein kinase C. In vivo, HSF1 is repressed through phosphorylation of this residue by protein kinase C alpha or -zeta but not MAPK. Regulation at 37 degrees C, therefore, involves the action of three protein kinase cascades that repress HSF1 through phosphorylation of serine residues 303, 307, and 363 and may promote growth by suppressing the heat shock response.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Joint Ctr Radiat Therapy, Dept Adult Oncol, Boston, MA 02115 USA; Inst Pasteur, CNRS, EP 560, F-59021 Lille, France	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Calderwood, SK (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.	stuart_calderwood@dfci.harvard.edu	SONCIN, Fabrice/A-1475-2009	SONCIN, Fabrice/0000-0001-6312-0673	NATIONAL CANCER INSTITUTE [R01CA050642, P01CA031303] Funding Source: NIH RePORTER; NCI NIH HHS [CA31303, CA4707, CA50642] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRUCE JL, 1993, CANCER RES, V53, P12; Cahill CM, 1996, J BIOL CHEM, V271, P24874; Chen CM, 1997, J BIOL CHEM, V272, P26803, DOI 10.1074/jbc.272.43.26803; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; Cotto JJ, 1996, J BIOL CHEM, V271, P3355; Didichenko SA, 1996, CURR BIOL, V6, P1271, DOI 10.1016/S0960-9822(02)70713-6; Ding XZ, 1996, J INVEST MED, V44, P144; ENGELBERG D, 1994, MOL CELL BIOL, V14, P4929, DOI 10.1128/MCB.14.7.4929; FEDER JH, 1992, GENE DEV, V6, P1402, DOI 10.1101/gad.6.8.1402; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; GREEN M, 1995, MOL CELL BIOL, V15, P3354; HENSOLD JO, 1990, MOL CELL BIOL, V10, P1600, DOI 10.1128/MCB.10.4.1600; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HOLBROOK NJ, 1992, MOL CELL BIOL, V12, P1528, DOI 10.1128/MCB.12.4.1528; Holmberg CI, 1997, J BIOL CHEM, V272, P6792, DOI 10.1074/jbc.272.10.6792; KEMP BE, 1991, METHOD ENZYMOL, V200, P121; Kline MP, 1997, MOL CELL BIOL, V17, P2107, DOI 10.1128/MCB.17.4.2107; Knauf U, 1996, GENE DEV, V10, P2782, DOI 10.1101/gad.10.21.2782; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; Krebs RA, 1997, CELL STRESS CHAPERON, V2, P60, DOI 10.1379/1466-1268(1997)002<0060:DCOHOI>2.3.CO;2; LANE HA, 1991, METHOD ENZYMOL, V200, P268; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARUI N, 1991, BIOCHEM BIOPH RES CO, V179, P1662, DOI 10.1016/0006-291X(91)91766-6; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; MIVECHI NF, 1995, CANCER RES, V55, P5512; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; Newton EM, 1996, MOL CELL BIOL, V16, P839; NIKILOKAKI E, 1993, ONCOEGNE, V8, P833; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OLIVIER AR, 1992, BIOCHEM SOC T, V20, P603, DOI 10.1042/bst0200603; PARKER PJ, 1994, PROTEIN KINASES, P68; PRICE BD, 1991, MOL CELL BIOL, V11, P3365, DOI 10.1128/MCB.11.6.3365; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SCHILLER P, 1988, J MOL BIOL, V203, P97, DOI 10.1016/0022-2836(88)90094-0; Soncin F, 1997, PROTEIN EXPRES PURIF, V9, P27, DOI 10.1006/prep.1996.0672; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; STEVENSON MA, 1994, CANCER RES, V54, P12; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; Voellmy Richard, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P357; WESTWOOD JT, 1993, MOL CELL BIOL, V13, P3481, DOI 10.1128/MCB.13.6.3481; Woodgett JR, 1991, METHOD ENZYMOL, V200, P564; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Xia WL, 1997, J BIOL CHEM, V272, P4094, DOI 10.1074/jbc.272.7.4094	51	144	156	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18640	18646		10.1074/jbc.273.29.18640	http://dx.doi.org/10.1074/jbc.273.29.18640			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660838	hybrid			2022-12-25	WOS:000074828500093
J	Conrad, J; Sun, DH; Englund, N; Ofengand, J				Conrad, J; Sun, DH; Englund, N; Ofengand, J			The rluC gene of Escherichia coli codes for a pseudouridine synthase that is solely responsible for synthesis of pseudouridine at positions 955, 2504, and 2580 in 23 S ribosomal RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYLTRANSFERASE CENTER; 16S RNA; PURIFICATION; SUBUNIT; CLONING; RESIDUES; ENZYMES; BASE; LOOP; IV	Escherichia coli ribosomal RNA contains 10 pseudouridines, one in the 16 S RNA and nine in the 23 S RNA. Previously, the gene for the synthase responsible for the 16 S RNA pseudouridine was identified and cloned, as was a gene for a synthase that makes a single pseudouridine in 23 S RNA. The yceC open reading frame of E. coli is one of a set of genes homologous to these previously identified ribosomal RNA pseudouridine synthases. In this work, the gene was cloned, overexpressed, and shown to code for a pseudouridine synthase able to react with in vitro transcripts of 23 S ribosomal RNA. Deletion of the gene and analysis of the 23 S RNA from the deletion strain for the presence of pseudouridine at its nine known sites revealed that this synthase is solely responsible in Dice for the synthesis of three of the nine pseudouridine residues, at positions 955, 2504, and 2580, Therefore, this gene has been renamed rluC. Despite the absence of one-third of the normal complement of pseudouridines, there was no change in the exponential growth rate in either LB or M-9 medium at temperatures ranging from 24 to 42 degrees C. From this work and our previous studies, we have now identified three synthases that account for 50% of the pseudouridines in the E, coli ribosome.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA	University of Miami	Ofengand, J (corresponding author), Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA.	jofengan@mednet.med.miami.edu						BAKIN A, 1994, NUCLEIC ACIDS RES, V22, P3681, DOI 10.1093/nar/22.18.3681; BAKIN A, 1994, BIOCHEMISTRY-US, V33, P13475, DOI 10.1021/bi00249a036; BAKIN A, 1993, BIOCHEMISTRY-US, V32, P9754, DOI 10.1021/bi00088a030; BAKIN A, 1998, METHODS MOL BIOL PRO, pCH22; Becker HF, 1997, NUCLEIC ACIDS RES, V25, P4493, DOI 10.1093/nar/25.22.4493; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bocchetta M, 1998, P NATL ACAD SCI USA, V95, P3525, DOI 10.1073/pnas.95.7.3525; CUNNINGHAM PR, 1993, BIOCHEMISTRY-US, V32, P7172, DOI 10.1021/bi00079a014; CUNNINGHAM PR, 1992, BIOCHEMISTRY-US, V31, P12012, DOI 10.1021/bi00163a008; Dokudovskaya S, 1996, RNA, V2, P146; Grosjean H, 1997, BIOCHIMIE, V79, P293, DOI 10.1016/S0300-9084(97)83517-1; Gu J, 1998, NUCLEIC ACIDS RES, V26, P160, DOI 10.1093/nar/26.1.160; Gustafsson C, 1996, NUCLEIC ACIDS RES, V24, P3756, DOI 10.1093/nar/24.19.3756; GUTELL RR, 1993, NUCLEIC ACIDS RES, V21, P3055, DOI 10.1093/nar/21.13.3055; Hall BG, 1998, J BACTERIOL, V180, P2862, DOI 10.1128/JB.180.11.2862-2865.1998; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; JAEGER JA, 1990, METHOD ENZYMOL, V183, P281; KAMMEN HO, 1988, J BIOL CHEM, V263, P2255; Koonin EV, 1996, NUCLEIC ACIDS RES, V24, P2411, DOI 10.1093/nar/24.12.2411; Kowalak JA, 1996, NUCLEIC ACIDS RES, V24, P688, DOI 10.1093/nar/24.4.688; Lecointe F, 1998, J BIOL CHEM, V273, P1316, DOI 10.1074/jbc.273.3.1316; Maden B E, 1990, Prog Nucleic Acid Res Mol Biol, V39, P241, DOI 10.1016/S0079-6603(08)60629-7; Massenet S., 1998, MODIFICATION EDITING, P201; Miller J. H., 1992, SHORT COURSE BACTERI, P357; NURSE K, 1995, RNA, V1, P102; Ofengand J, 1997, J MOL BIOL, V266, P246, DOI 10.1006/jmbi.1996.0737; Ofengand J., 1998, MODIFICATION EDITING, P229, DOI DOI 10.1128/9781555818296.CH12; SANTER M, 1993, BIOCHEMISTRY-US, V32, P5539, DOI 10.1021/bi00072a007; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; STOKER NG, 1982, GENE, V18, P3353; SUPEKOVA L, 1995, J BIOL CHEM, V270, P13726; WEITZMANN CJ, 1990, NUCLEIC ACIDS RES, V18, P3515, DOI 10.1093/nar/18.12.3515; WRZESINSKI J, 1995, BIOCHEMISTRY-US, V34, P8904, DOI 10.1021/bi00027a043; WRZESINSKI J, 1995, RNA, V1, P437; ZYSKIND JW, 1992, RECOMBINANT DNA LAB, P187	35	69	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18562	18566		10.1074/jbc.273.29.18562	http://dx.doi.org/10.1074/jbc.273.29.18562			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660827	hybrid			2022-12-25	WOS:000074828500082
J	Crouse, JA; Elliott, GE; Burgess, TL; Chiu, L; Bennett, L; Moore, J; Nicolson, M; Pacifici, RE				Crouse, JA; Elliott, GE; Burgess, TL; Chiu, L; Bennett, L; Moore, J; Nicolson, M; Pacifici, RE			Altered cell surface expression and signaling of leptin receptors containing the fatty mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OBESE GENE; OB-R; MISSENSE MUTATION; DIABETIC MICE; RAT FATTY; FA/FA RAT; CLONING; IDENTIFICATION; PROTEIN; SUBSTITUTION	Leptin and the leptin receptor are key players in the regulation of body weight. In an attempt to dissect the molecular mechanism of the Zucker fatty rat leptin receptor mutation (Gln(269) --> Pro) we analyzed the effects of this mutation on leptin receptor signaling and expression in three different expression systems: 1) 32D cells expressing leptin/erythropoietin receptor chimeras, 2) COS-7 cells expressing a leptin receptor short form, and 3) 293 cells expressing soluble receptor forms. To determine if the Gln(269) --> Pro mutation is critical for the observed phenotype, we made a similar Gln --> Pro mutation at a vicinal residue two amino acids upstream of the fatty mutation to see if it would have similar effects. Incorporation of either of the Gln --> Pro mutations into wild type receptor forms did not interfere with leptin binding, but it resulted in a signaling-incompetent receptor. In addition, the majority of the mutant receptor protein was localized intracellularly. Our results suggest that the obese phenotype resulting from the Gln(269) --> Pro mutation in the leptin receptor of the Zucker fatty rat may be due not only to a reduced cell surface expression of this form of the leptin receptor, but also to a post-leptin binding malfunction of the receptor that interferes with subsequent signal transduction.	Amgen Inc, Dept Computat Biol, Thousand Oaks, CA 91320 USA; Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; Amgen Inc, Dept Cell Biol, Thousand Oaks, CA 91320 USA; Amgen Inc, Dept Mammalian Cell Mol Biol, Thousand Oaks, CA 91320 USA; Amgen Inc, Dept Mol Genom, Thousand Oaks, CA 91320 USA; Amgen Inc, Dept Neurosci, Thousand Oaks, CA 91320 USA	Amgen; University of Southern California; Amgen; Amgen; Amgen; Amgen	Pacifici, RE (corresponding author), Amgen Inc, Dept Computat Biol, 1 Amgen Ctr Dr 14-1-D, Thousand Oaks, CA 91320 USA.							Banks WA, 1996, PEPTIDES, V17, P305, DOI 10.1016/0196-9781(96)00025-3; Bjorbaek C, 1997, J BIOL CHEM, V272, P32686, DOI 10.1074/jbc.272.51.32686; BRIZZI MF, 1991, INT J CELL CLONING, V9, P274, DOI 10.1002/stem.5530090404; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; Chua SC, 1996, DIABETES, V45, P1141, DOI 10.2337/diabetes.45.8.1141; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; Devos R, 1997, J BIOL CHEM, V272, P18304, DOI 10.1074/jbc.272.29.18304; Devos R, 1996, P NATL ACAD SCI USA, V93, P5668, DOI 10.1073/pnas.93.11.5668; DUQUESNOY P, 1994, EMBO J, V13, P1386, DOI 10.1002/j.1460-2075.1994.tb06392.x; DUQUESNOY P, 1991, P NATL ACAD SCI USA, V88, P10272, DOI 10.1073/pnas.88.22.10272; Fei H, 1997, P NATL ACAD SCI USA, V94, P7001, DOI 10.1073/pnas.94.13.7001; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HIGUCHI R, 1989, PCR PROTOCOLS GUIDE, P177; Hoggard N, 1997, BIOCHEM BIOPH RES CO, V232, P383, DOI 10.1006/bbrc.1997.6245; IHLE JN, 1981, J IMMUNOL, V126, P2184; Iida M, 1996, BIOCHEM BIOPH RES CO, V222, P19, DOI 10.1006/bbrc.1996.0691; Iida M, 1996, BIOCHEM BIOPH RES CO, V224, P597, DOI 10.1006/bbrc.1996.1070; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; LUCH SM, 1997, J MOL ENDOCRINOL, V18, P77; PACIFICI RE, 1994, J BIOL CHEM, V269, P1571; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Phillips MS, 1996, NAT GENET, V13, P18, DOI 10.1038/ng0596-18; Rosenblum CI, 1996, ENDOCRINOLOGY, V137, P5178, DOI 10.1210/en.137.11.5178; Takaya K, 1996, BIOCHEM BIOPH RES CO, V225, P75, DOI 10.1006/bbrc.1996.1133; Takaya K, 1996, NAT GENET, V14, P130, DOI 10.1038/ng1096-130; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; White DW, 1997, P NATL ACAD SCI USA, V94, P10657, DOI 10.1073/pnas.94.20.10657; WuPeng XS, 1997, DIABETES, V46, P513, DOI 10.2337/diabetes.46.3.513; Yamashita T, 1997, DIABETES, V46, P1077, DOI 10.2337/diabetes.46.6.1077; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; ZUCKER LM, 1961, J HERED, V52, P275, DOI 10.1093/oxfordjournals.jhered.a107093; ZUCKER TF, 1963, J NUTR, V80, P6, DOI 10.1093/jn/80.1.6; ZUCKER TF, 1962, P SOC EXP BIOL MED, V110, P165, DOI 10.3181/00379727-110-27455	42	24	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18365	18373		10.1074/jbc.273.29.18365	http://dx.doi.org/10.1074/jbc.273.29.18365			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660803	hybrid			2022-12-25	WOS:000074828500058
J	Reczek, D; Bretscher, A				Reczek, D; Bretscher, A			The carboxyl-terminal region of EBP50 binds to a site in the amino-terminal domain of ezrin that is masked in the dormant molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-H+ EXCHANGER; PROTEIN; MOESIN; FAMILY; PHOSPHORYLATION; CYTOSKELETON; LOCALIZATION; INVOLVEMENT; ASSOCIATION; MECHANISM	EBP50 ((e) under bar zrin-radixin-moesin-(b) under bar inding (p) under bar hosphoprotein <(50)under bar>) was recently identified by affinity chromatography on the immobilized NH2-terminal domain of ezrin. Here we map and characterize the regions in EBP50 and ezrin necessary for this association. Using blot overlays and in solution binding assays, the COOH-terminal 30 residues of EBP50 were found to be sufficient for an association with residues 1-286 of ezrin. EBP50 did not bind to full-length (1-585) ezrin, indicating that the EBP50 binding site is masked in the full-length molecule. Ezrin contains two complementary self-association domains known as N- and C-ERMADs ((e) under bar zrin-(r) under bar adixin-(m) under bar oesin-(a) under bar ssociation (d) under bar omains), encompassing residues 1-296 and 479-585, respectively. An ezrin 1-583 construct lacking the two terminal residues necessary for this association was found to have an unmasked EBP50 binding site. Moreover, binding of EBP50 and the C-ERMAD to ezrin residues 1-296 was found to be mutually exclusive, with the C-ERMAD having a higher affinity. These results suggest that in full-length ezrin, the binding site for EBP50 is masked through an intramolecular N/C-ERMAD association, Based on these and additional results, we propose a model whereby dormant ezrin can be activated to bind EBP50 on its NH2-terminal end and F-actin on its COOH-terminal end. Since EBP50 is proposed to bind membrane proteins through its PDZ domains, this provides a molecular description of the regulated linkage of microfilaments to membranes in cell surface microvilli.	Cornell Univ, Biochem Mol & Cell Biol Sect, Ithaca, NY 14853 USA	Cornell University	Bretscher, A (corresponding author), Cornell Univ, Biochem Mol & Cell Biol Sect, Biotechnol Bldg, Ithaca, NY 14853 USA.				NIGMS NIH HHS [GM 36652] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036652] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERRYMAN M, 1995, J CELL BIOL, V131, P1231, DOI 10.1083/jcb.131.5.1231; BRETSCHER A, 1983, J CELL BIOL, V97, P425, DOI 10.1083/jcb.97.2.425; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; Bretscher A, 1997, J CELL SCI, V110, P3011; Crepaldi T, 1997, J CELL BIOL, V138, P423, DOI 10.1083/jcb.138.2.423; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; GARY R, 1993, P NATL ACAD SCI USA, V90, P10846, DOI 10.1073/pnas.90.22.10846; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; GOULD KL, 1989, EMBO J, V8, P4133, DOI 10.1002/j.1460-2075.1989.tb08598.x; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANKES WT, 1991, P NATL ACAD SCI USA, V88, P8297, DOI 10.1073/pnas.88.19.8297; Lue RA, 1996, J CELL BIOL, V135, P1125, DOI 10.1083/jcb.135.4.1125; Marfatia SM, 1996, J CELL BIOL, V135, P753, DOI 10.1083/jcb.135.3.753; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Nakamura F, 1995, J BIOL CHEM, V270, P31377, DOI 10.1074/jbc.270.52.31377; PESTONJAMASP K, 1995, MOL BIOL CELL, V6, P247, DOI 10.1091/mbc.6.3.247; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Roy C, 1997, J BIOL CHEM, V272, P20088, DOI 10.1074/jbc.272.32.20088; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8; TURUNEN O, 1989, J BIOL CHEM, V264, P16727; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; Vaheri A, 1997, CURR OPIN CELL BIOL, V9, P659, DOI 10.1016/S0955-0674(97)80119-6; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; WEINMAN EJ, 1993, J CLIN INVEST, V92, P1781, DOI 10.1172/JCI116767; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010	30	173	174	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18452	18458		10.1074/jbc.273.29.18452	http://dx.doi.org/10.1074/jbc.273.29.18452			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660814	hybrid			2022-12-25	WOS:000074828500069
J	Watkins, PA; Lu, JF; Steinberg, SJ; Gould, SJ; Smith, KD; Braiterman, LT				Watkins, PA; Lu, JF; Steinberg, SJ; Gould, SJ; Smith, KD; Braiterman, LT			Disruption of the Saccharomyces cerevisiae FAT1 gene decreases very long-chain fatty acyl-CoA synthetase activity and elevates intracellular very long-chain fatty acid concentrations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED ADRENOLEUKODYSTROPHY; PEROXISOMAL MEMBRANE-PROTEIN; PICHIA-PASTORIS; PTS1 RECEPTOR; RAT; EXPRESSION; YEAST; ACTIVATION; OXIDATION; CLONING	Activation of fatty acids to their coenzyme A derivatives is necessary for subsequent metabolism, Very long-chain fatty acids, which accumulate in tissues of patients with X-Linked adrenoleukodystrophy, are activated by very long-chain acyl-CoA synthetase (VLCS) normally found in peroxisomes and microsomes, We identified a candidate yeast VLCS gene (FAT1), previously identified as encoding a fatty acid transport protein, by its homology to rat liver peroxisomal VLCS, Disruption of this gene decreased, but did not abolish, cellular VLCS activity. Fractionation studies showed that VLCS activity, but not long-chain acyl-CoA synthetase activity, was reduced to about 40% of wild-type level in both 27,000 x g supernatant and pellet fractions. Separation of organelles in the pellet fraction by density gradient centrifugation revealed that VLCS activity was associated with peroxisomes and microsomes but not mitochondria, FAT1 deletion strains exhibited decreased growth on medium containing dextrose, oleic acid, and cerulenin, an inhibitor of fatty acid synthesis. FAT1 deletion strains grown on either dextrose or oleic acid medium accumulated very long-chain fatty acids. Compared wth wild-type yeast, C22:0, C24:0, and C26:0 levels were increased approximately 20-, 18-, and 3-fold in deletion strains grown on dextrose, and 2-, 7-, and B-fold in deletion strains grow on oleate. Long-chain fatty acid levels in wild-type and deletion strains were not significantly different.All biochemical defects in FAT1 deletion strains were restored to normal after functional complementation with the FAT1 gene. The level of VLCS activity measured in both wild-type and deletion yeast strains transformed with FAT1 cDNA paralleled the level of expression of the transgene. The extent of both the decrease in peroxisomal VLCS activity and the very long-chain fatty acid accumulation in the yeast FAT1 deletion model resembles that observed in cells from X-linked adrenoleukodystrophy patients. These studies suggest that the FAT1 gene product has VLCS activity that is essential for normal cellular very long-chain fatty acid homeostasis.	Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University; Kennedy Krieger Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Watkins, PA (corresponding author), Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, 707 N Broadway, Baltimore, MD 21205 USA.			Watkins, Paul A./0000-0002-3246-1405	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024061] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD010981] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS010533] Funding Source: NIH RePORTER; NICHD NIH HHS [HD24061, HD10981] Funding Source: Medline; NINDS NIH HHS [NS10533] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABE T, 1992, J BIOCHEM-TOKYO, V111, P123, DOI 10.1093/oxfordjournals.jbchem.a123707; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Black PN, 1997, J BIOL CHEM, V272, P4896, DOI 10.1074/jbc.272.8.4896; Brachmann CB, 1998, YEAST, V14, P115; Braiterman LT, 1998, HUM MOL GENET, V7, P239, DOI 10.1093/hmg/7.2.239; Braverman N, 1997, NAT GENET, V15, P369, DOI 10.1038/ng0497-369; CARTIER N, 1995, P NATL ACAD SCI USA, V92, P1674, DOI 10.1073/pnas.92.5.1674; Chang CC, 1997, NAT GENET, V15, P385, DOI 10.1038/ng0497-385; CRANE DI, 1994, J BIOL CHEM, V269, P21835; DIECKMANN R, 1995, FEBS LETT, V357, P212, DOI 10.1016/0014-5793(94)01342-X; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; DOLE VP, 1956, J CLIN INVEST, V35, P150, DOI 10.1172/JCI103259; EINERHAND AWC, 1993, EUR J BIOCHEM, V214, P323, DOI 10.1111/j.1432-1033.1993.tb17927.x; Elgersma Y, 1996, J BIOL CHEM, V271, P26375, DOI 10.1074/jbc.271.42.26375; ERDMANN R, 1995, J CELL BIOL, V128, P509, DOI 10.1083/jcb.128.4.509; Faergeman NJ, 1997, J BIOL CHEM, V272, P8531, DOI 10.1074/jbc.272.13.8531; Folch J, 1957, J BIOL CHEM, V226, P457; Fujino T, 1996, J BIOL CHEM, V271, P16748, DOI 10.1074/jbc.271.28.16748; FUJINO T, 1992, J BIOCHEM-TOKYO, V111, P197, DOI 10.1093/oxfordjournals.jbchem.a123737; GOULD SJ, 1990, EMBO J, V9, P85, DOI 10.1002/j.1460-2075.1990.tb08083.x; Hettema EH, 1996, EMBO J, V15, P3813, DOI 10.1002/j.1460-2075.1996.tb00755.x; HO JK, 1995, J CLIN INVEST, V96, P1455, DOI 10.1172/JCI118182; JOHNSON DR, 1994, J CELL BIOL, V127, P751, DOI 10.1083/jcb.127.3.751; KALISH JE, 1995, BIOCHEM BIOPH RES CO, V206, P335, DOI 10.1006/bbrc.1995.1046; KAMIJO K, 1990, J BIOL CHEM, V265, P4534; KNAZEK RA, 1983, J CLIN INVEST, V72, P245, DOI 10.1172/JCI110963; KNOLL LJ, 1995, J BIOL CHEM, V270, P10861, DOI 10.1074/jbc.270.18.10861; KNOLL LJ, 1994, J BIOL CHEM, V269, P16348; KOK F, 1995, HUM MUTAT, V6, P104, DOI 10.1002/humu.1380060203; LAZO O, 1988, P NATL ACAD SCI USA, V85, P7647, DOI 10.1073/pnas.85.20.7647; LombardPlatet G, 1996, P NATL ACAD SCI USA, V93, P1265, DOI 10.1073/pnas.93.3.1265; LORENZ MC, 1995, GENE, V158, P113, DOI 10.1016/0378-1119(95)00144-U; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILLER GL, 1959, ANAL CHEM, V31, P964, DOI 10.1021/ac60149a611; Moser HW, 1991, TECHNIQUES DIAGNOSTI, P177; Moser HW, 1995, METABOLIC MOL BASES, V7h, P2325; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; Reuber B. E., 1997, American Journal of Human Genetics, V61, pA54; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; Shani N, 1996, P NATL ACAD SCI USA, V93, P11901, DOI 10.1073/pnas.93.21.11901; Shani N., 1996, Molecular Biology of the Cell, V7, p433A; Shani N., 1994, American Journal of Human Genetics, V55, pA138; Sherman F, 1979, METHODS YEAST GENETI; SHIMOZAWA N, 1992, SCIENCE, V255, P1132, DOI 10.1126/science.1546315; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGH H, 1988, ARCH BIOCHEM BIOPHYS, V266, P486, DOI 10.1016/0003-9861(88)90281-0; SINGH I, 1993, J BIOL CHEM, V268, P9972; Steinberg SJ, 1997, AM J HUM GENET, V61, pA262; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; Uchida Y, 1996, J BIOCHEM, V119, P565; Uchiyama A, 1996, J BIOL CHEM, V271, P30360, DOI 10.1074/jbc.271.48.30360; WANDERS RJA, 1988, BIOCHEM BIOPH RES CO, V153, P618, DOI 10.1016/S0006-291X(88)81140-9; WANG TW, 1994, J BIOL CHEM, V269, P24480; WATKINS PA, 1991, ARCH BIOCHEM BIOPHYS, V289, P329, DOI 10.1016/0003-9861(91)90419-J; Watkins PA, 1997, PROG LIPID RES, V36, P55, DOI 10.1016/S0163-7827(97)00004-0; WATKINS PA, 1995, ANN NEUROL, V38, P472, DOI 10.1002/ana.410380322; WHITCOMB RW, 1988, J CLIN INVEST, V81, P185, DOI 10.1172/JCI113292; Yahraus T, 1996, EMBO J, V15, P2914, DOI 10.1002/j.1460-2075.1996.tb00654.x	58	129	133	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18210	18219		10.1074/jbc.273.29.18210	http://dx.doi.org/10.1074/jbc.273.29.18210			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660783	hybrid			2022-12-25	WOS:000074828500038
J	Witzenbichler, B; Maisonpierre, PC; Jones, P; Yancopoulos, GD; Isner, JM				Witzenbichler, B; Maisonpierre, PC; Jones, P; Yancopoulos, GD; Isner, JM			Chemotactic properties of angiopoietin-1 and -2, ligands for the endothelial-specific receptor tyrosine kinase Tie2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; GROWTH-FACTOR; VASCULAR ENDOTHELIUM; ENHANCED EXPRESSION; TUMOR ANGIOGENESIS; GENE; TEK; NEOVASCULARIZATION; VASCULOGENESIS; PROLIFERATION	Angiopoietin-1 and its putative natural antagonist, angiopoietin-2, were recently isolated, and the critical role of angiopoietin-1 in embryogenic angiogenesis was demonstrated by targeted gene disruption. Specific biological effects of angiopoietin-1, however, have yet to be defined. in this study we demonstrate that angiopoietin-1, but not angiopoietin-2, is chemotactic for endothelial cells. In contrast, angiopoietin-1 as well as angiopoietin-2 exhibit no proliferative effect on endothelial cells. Excess soluble Tie2, but not Tiel receptor, abolish the chemotactic response of endothelial cells toward angiopoietin-1. Angiopoietin-2 dose-dependently blocks directed migration toward angiopoietin-1, consistent with the role of angiopoietin-2 as a naturally occurring inhibitor of angiopoietin-1. Fibroblasts stably transfected with Tie2 receptor exhibit chemotactic responses for both angiopoietin-1 and angiopoietin-2. Fibroblasts stably expressing a transfected chimeric receptor consisting of the ectodomain of TrkC fused to the cytoplasmic domain of Tie2 also exhibit a chemotactic response to neurotrophin 3 (NT-3), a specific Ligand for TrkC, Endothelial cells are shown to express angiopoietin-2 mRNA and protein, indicating the potential for autocrine activation of angiopoietin/Tie2, Finally, the demonstration that Tie2 as well as angiopoietin-1 are expressed in normal human arteries and veins suggests that the role of angiopoietin/Tie2 may extend beyond embryonic angiogenesis to maintaining integrity of the adult vasculature.	Tufts Univ, Sch Med, St Elizabeths Med Ctr Boston, Dept Cardiovasc Res, Boston, MA 02135 USA; Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA	St. Elizabeth's Medical Center; Tufts University; Regeneron	Isner, JM (corresponding author), Tufts Univ, Sch Med, St Elizabeths Med Ctr Boston, Dept Cardiovasc Res, 736 Cambridge St, Boston, MA 02135 USA.		Witzenbichler, Bernhard/ABC-2525-2021		NHLBI NIH HHS [HL 57516, HL 53354, HL 40518] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057516, R01HL040518, R37HL053354, R01HL053354] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BUTTKE TM, 1993, J IMMUNOL METHODS, V157, P233, DOI 10.1016/0022-1759(93)90092-L; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Couffinhal T, 1997, AM J PATHOL, V150, P1673; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DUMONT DJ, 1992, ONCOGENE, V7, P1471; DUMONT DJ, 1995, DEV DYNAM, V203, P80, DOI 10.1002/aja.1002030109; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Enholm B, 1997, ONCOGENE, V14, P2475, DOI 10.1038/sj.onc.1201090; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; GROTENDORST GR, 1982, J CELL PHYSIOL, V113, P261, DOI 10.1002/jcp.1041130213; HAIMOVITZFRIEDM.I, 1994, CANCER RES, V115, P245; Isner JM, 1996, LANCET, V348, P370, DOI 10.1016/S0140-6736(96)03361-2; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Joukov V, 1996, EMBO J, V15, P290; KAIPAINEN A, 1994, CANCER RES, V54, P6571; KORHONEN J, 1992, BLOOD, V80, P2548; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; MADER SL, 1992, J GERONTOL, V47, pB32, DOI 10.1093/geronj/47.2.B32; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; MAISONPIERRE PC, 1993, ONCOGENE, V8, P1631; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; PICKERING JG, 1992, J AM COLL CARDIOL, V20, P1430, DOI 10.1016/0735-1097(92)90259-P; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLATE KH, 1993, CANCER RES, V53, P5822; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; RISAU W, 1995, FASEB J, V9, P926, DOI 10.1096/fasebj.9.10.7615161; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAMBROOK J, 1989, MOL CLONING LAB MANU, P204; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHNURCH H, 1993, DEVELOPMENT, V119, P957; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHOLLEY MM, 1984, LAB INVEST, V51, P624; Spyridopoulos I, 1997, J MOL CELL CARDIOL, V29, P1321, DOI 10.1006/jmcc.1996.0365; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; TAKESHITA S, 1994, J CLIN INVEST, V93, P662, DOI 10.1172/JCI117018; Tsurumi Y, 1997, NAT MED, V3, P879, DOI 10.1038/nm0897-879; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Vikkula M, 1996, CELL, V87, P1181, DOI 10.1016/S0092-8674(00)81814-0; ZIEGLER SF, 1993, ONCOGENE, V8, P663	47	368	393	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18514	18521		10.1074/jbc.273.29.18514	http://dx.doi.org/10.1074/jbc.273.29.18514			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660821	hybrid			2022-12-25	WOS:000074828500076
J	Mukhopadhyay, T; Roth, JA				Mukhopadhyay, T; Roth, JA			Superinduction of wild-type p53 protein after 2-methoxyestradiol treatment of Ad5p53-transduced cells induces tumor cell apoptosis	ONCOGENE			English	Article						p53; lung cancer; apoptosis; methoxyestradiol; gene expression	LUNG-CANCER CELLS; IN-VIVO; GENE; ADENOVIRUS; INDUCTION	Because 2-methoxyestradiol (2-MeOE2) induces and stabilizes wild-type p53 protein (wt p53) in human lung cancer cell lines posttranscriptionally, we sought to study its effects on Ad5p53-transduced lung cancer cell lines at a low multiplicity of infection (1 MOI). Treating these cells with 2-MeOE2 resulted in superinduction of wt p53 protein expression followed by apoptosis, as shown by terminal deoxynucleotidyl transferase (TdT) staining, and upregulation of wt p53 expression, as shown by Western blot analysis. When transduced with Ad5p53 alone at 1 MOI, the cell lines grew rapidly. Moreover, adenoviral-vector-mediated p53 gene transfer followed by 2-MeOE2 treatment caused 80% growth inhibition in the cell lines regardless of their p53 status, Thus, p53 superinduction and apoptosis after 2-MeOE2 treatment in Ad5p53-transduced cells appears to be a unique strategy with significant implications for cancer gene therapy.	Univ Texas, MD Anderson Cancer Ctr, Dept Thorac Surg, Sect Thorac Mol Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Cardiovasc Surg, Sect Thorac Mol Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Mukhopadhyay, T (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Thorac Surg, Sect Thorac Mol Oncol, Box 109,1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [P50CA070907, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [P50-CA70907, CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attalla H, 1996, BIOCHEM BIOPH RES CO, V228, P467, DOI 10.1006/bbrc.1996.1683; CAI DW, 1993, HUM GENE THER, V4, P617, DOI 10.1089/hum.1993.4.5-617; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; FOTIS T, 1994, NATURE, V368, P237; FUJIWARA T, 1994, CANCER RES, V54, P2287; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Maxwell SA, 1996, ELECTROPHORESIS, V17, P1772, DOI 10.1002/elps.1150171115; MUKHOPADHYAY T, 1993, CANCER RES, V53, P4362; Mukhopadhyay T, 1997, ONCOGENE, V14, P379, DOI 10.1038/sj.onc.1200835; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Seegers JC, 1997, J STEROID BIOCHEM, V62, P253, DOI 10.1016/S0960-0760(97)00043-5; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TISHLER RB, 1995, CANCER RES, V55, P6021; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1996, ONCOGENE, V12, P2197; ZHANG WW, 1995, HUM GENE THER, V6, P155, DOI 10.1089/hum.1995.6.2-155; ZHANG WW, 1993, BIOTECHNIQUES, V15, P868	20	59	59	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 16	1998	17	2					241	246		10.1038/sj.onc.1201909	http://dx.doi.org/10.1038/sj.onc.1201909			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZZ211	9674709				2022-12-25	WOS:000074706700013
J	Graddis, TJ; Brasel, K; Friend, D; Srinivasan, S; Wee, SF; Lyman, SD; March, CJ; McGrew, JT				Graddis, TJ; Brasel, K; Friend, D; Srinivasan, S; Wee, SF; Lyman, SD; March, CJ; McGrew, JT			Structure-function analysis of FLT3 ligand-FLT3 receptor interactions using a rapid functional screen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; HEMATOPOIETIC-CELLS; PROGENITOR CELLS; HUMAN HOMOLOG; GROWTH-FACTOR; STEM-CELLS; YEAST; EXPRESSION; CLONING; VARIANTS	FLT3 ligand (FLT3L) stimulates primitive hematopoietic cells by binding to and activating the FLT3 receptor (FLT3R), We carried out a structure-activity study of human FLT3L in order to define the residues involved in receptor binding. We developed a rapid method to screen randomly mutagenized FLT3L using a FLT3R-Fc fusion protein to probe the relative binding activities of mutated ligand, Approximately 60,000 potential mutants were screened, and the DNA from 59 clones was sequenced. Thirty-one single amino acid substitutions at 24 positions of FLT3L either enhanced or reduced activity in receptor binding and cell proliferation assays. Eleven representative proteins were purified and analyzed for receptor affinity, specific activity, and physical properties. Receptor affinity and bioactivity were highly correlated. FLT3L affinity for receptor improved when four individual mutations that enhance FLT3L receptor affinity were combined in a single molecule. A model of FLT3L three-dimensional structure was generated based on sequence alignment and x-ray structure of macrophage colony-stimulating factor. Most residues implicated in receptor binding are widely dispersed in the primary structure of FLT3L, yet they localize to a surface patch in the tertiary model. A mutation that maps to and is predicted to disrupt the proposed dimerization interface between FLT3L monomers exhibits a Stokes radius that is concentration-dependent, suggesting that this mutation disrupts the FLT3L dimer.	Immunex Res & Dev Corp, Dept Cell Sci, Seattle, WA 98101 USA; Immunex Res & Dev Corp, Dept Prot Chem, Seattle, WA 98101 USA; Immunex Res & Dev Corp, Dept Immunobiol, Seattle, WA 98101 USA; Immunex Res & Dev Corp, Dept Biochem, Seattle, WA 98101 USA; Immunex Res & Dev Corp, Dept Analyt Chem, Seattle, WA 98101 USA; Immunex Res & Dev Corp, Dept Mol Biol, Seattle, WA 98101 USA		McGrew, JT (corresponding author), Immunex Res & Dev Corp, Dept Cell Sci, 51 Univ St, Seattle, WA 98101 USA.							BRASEL K, 1995, LEUKEMIA, V9, P1212; Escobar S, 1995, BLOOD, V86, P74; HANNUM C, 1994, NATURE, V368, P643, DOI 10.1038/368643a0; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HOLM C, 1986, GENE, V42, P169, DOI 10.1016/0378-1119(86)90293-3; Hsu YR, 1997, J BIOL CHEM, V272, P6406, DOI 10.1074/jbc.272.10.6406; JACOBSEN SEW, 1995, J EXP MED, V181, P1357, DOI 10.1084/jem.181.4.1357; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; Lemmon MA, 1997, J BIOL CHEM, V272, P6311, DOI 10.1074/jbc.272.10.6311; Leung DW, 1989, TECHNIQUE, V1, P11; LYMAN SD, 1995, ONCOGENE, V10, P149; LYMAN SD, 1995, INT J HEMATOL, V62, P63; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; LYMAN SD, 1994, BLOOD, V83, P2795, DOI 10.1182/blood.V83.10.2795.2795; LYMAN SD, 1995, BLOOD, V86, P4091, DOI 10.1182/blood.V86.11.4091.bloodjournal86114091; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; PANDIT J, 1992, SCIENCE, V258, P1358, DOI 10.1126/science.1455231; PARK LS, 1986, J BIOL CHEM, V261, P4177; PRICE V, 1987, GENE, V55, P287, DOI 10.1016/0378-1119(87)90288-5; Reddy CC, 1996, NAT BIOTECHNOL, V14, P1696, DOI 10.1038/nbt1296-1696; ROSNET O, 1993, BLOOD, V82, P1110, DOI 10.1182/blood.V82.4.1110.bloodjournal8241110; ROZWARSKI DA, 1994, STRUCTURE, V2, P159, DOI 10.1016/S0969-2126(00)00018-6; SAGGIO I, 1995, EMBO J, V14, P3045, DOI 10.1002/j.1460-2075.1995.tb07307.x; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SMALL D, 1994, P NATL ACAD SCI USA, V91, P459, DOI 10.1073/pnas.91.2.459; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; SRINIVASAN S, 1993, PROTEIN SCI, V2, P277; TAYLOR EW, 1994, J BIOL CHEM, V269, P31171; Toniatti C, 1996, EMBO J, V15, P2726, DOI 10.1002/j.1460-2075.1996.tb00633.x	29	23	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17626	17633		10.1074/jbc.273.28.17626	http://dx.doi.org/10.1074/jbc.273.28.17626			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651358	hybrid			2022-12-25	WOS:000074816100051
J	Kurbanov, FT; Choe, JY; Honzatko, RB; Fromm, HJ				Kurbanov, FT; Choe, JY; Honzatko, RB; Fromm, HJ			Directed mutations in the poorly defined region of porcine liver fructose 1,6-bispbosphatase significantly affect catalysis and the mechanism of AMP inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG-KIDNEY FRUCTOSE-1,6-BISPHOSPHATASE; ALLOSTERIC INHIBITION; CRYSTAL-STRUCTURE; 2,6-BISPHOSPHATE; 1,6-BISPHOSPHATASE; BISPHOSPHATASE; COOPERATIVITY; PROTEIN; BINDING; SITE	Asn(64), Asp(68), Lys(71), Lys(72), and Asp(74) of porcine liver fructose-1,6-bisphosphatase (FBPase) are conserved residues and part of a loop for which no electron density has been observed in crystal structures. Yet mutations of the above dramatically affect catalytic rates and/or AMP inhibition. The Asp(74) --> Ala and Asp(74) --> Asn mutant enzymes exhibited 50,000- and 2,000-fold reductions, respectively, in k(cat) relative to wild-type FBPase. The pH optimum for the catalytic activity of the Asp(74), Glu, Asp(68) --> Glu, Asn(64) --> Gln, and Asn(64) --> Ala mutant enzymes shifted from pH 7.0 (wild-type enzyme) to pH 8.5, whereas the Lys(71) --> Ala mutant and Lys(71,72) --> Met double mutant had optimum activity at pH 7.5. Mg2+ cooperativity, K-m for fructose 1,6-bisphosphate, and K-i for fructose 2,6-bisphosphate were comparable for the mutant and wild-type enzymes. Nevertheless, for the Asp(74) --> Glu, Asp(68) --> Glu, Asn(64) --> Gln, and Asn(64) --> Ala mutants, the binding affinity for Mg2+ decreased by 40-125-fold relative to the wild type enzyme. In addition, the Asp(74) --> Glu and Asn(64) --> Ala mutants exhibited no AMP cooperativity, and the kinetic mechanism of AMP inhibition with respect to Mg2+ was changed from competitive to noncompetitive. The double mutation Lys(71,72) --> Met increased K-i for AMP by 175-fold and increased Mg2+ affinity by 2-fold relative to wild-type FBPase. The results reported here strongly suggest that loop 51-72 is important for catalytic activity and the mechanism of allosteric inhibition of FBPase by AMP.	Iowa State Univ Sci & Technol, Dept Biochem & Biophys, Ames, IA 50011 USA	Iowa State University	Fromm, HJ (corresponding author), Iowa State Univ Sci & Technol, Dept Biochem & Biophys, 1210 Mol Biol Bldg, Ames, IA 50011 USA.	hjfromm@iastate.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS010546, R56NS010546] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 10546] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENCOVIC ST, 1982, ADV ENZYMOL RELAT AR, V53, P45; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURTON VA, 1993, BIOCHEM BIOPH RES CO, V192, P511, DOI 10.1006/bbrc.1993.1445; CHATTERJEE T, 1985, J BIOL CHEM, V260, P3553; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; HORECKER BL, 1975, ADV ENZYMOL RAMB, V42, P193; KE H, 1989, J MOL BIOL, V212, P513; KE HM, 1990, P NATL ACAD SCI USA, V87, P5243, DOI 10.1073/pnas.87.14.5243; Kelley N, 1996, BIOCHEM BIOPH RES CO, V219, P848, DOI 10.1006/bbrc.1996.0321; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEATHERBARROW RJ, 1987, NONLINEAR REGRESSION, P13; LIANG JY, 1992, P NATL ACAD SCI USA, V89, P2404, DOI 10.1073/pnas.89.6.2404; LIU F, 1988, J BIOL CHEM, V263, P9122; LIU F, 1990, J BIOL CHEM, V265, P7401; LU G, 1997, J BIOL CHEM, V270, P5076; Lu GQ, 1996, PROTEIN SCI, V5, P2333, DOI 10.1002/pro.5560051120; MACGREGOR JS, 1982, ARCH BIOCHEM BIOPHYS, V217, P652, DOI 10.1016/0003-9861(82)90547-1; MARCUS F, 1987, BIOCHEMISTRY-US, V26, P7029, DOI 10.1021/bi00396a026; MARCUS F, 1982, P NATL ACAD SCI-BIOL, V79, P7161, DOI 10.1073/pnas.79.23.7161; NIMMO HG, 1975, EUR J BIOCHEM, V58, P575, DOI 10.1111/j.1432-1033.1975.tb02408.x; PILKIS SJ, 1981, J BIOL CHEM, V256, P3619; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; PONTREMOLI S, 1982, ARCH BIOCHEM BIOPHYS, V218, P609, DOI 10.1016/0003-9861(82)90386-1; SCHEFFLER JE, 1986, BIOCHEMISTRY-US, V25, P6659, DOI 10.1021/bi00369a050; Shyur LF, 1996, J BIOL CHEM, V271, P33301, DOI 10.1074/jbc.271.52.33301; Shyur LF, 1997, J BIOL CHEM, V272, P26295, DOI 10.1074/jbc.272.42.26295; SIANO DB, 1975, ARCH BIOCHEM BIOPHYS, V170, P587, DOI 10.1016/0003-9861(75)90154-X; STONE SR, 1980, BIOCHEMISTRY-US, V19, P620, DOI 10.1021/bi00545a003; TAKETA K, 1965, J BIOL CHEM, V240, P651; TEJWANI GA, 1983, ADV ENZYMOL RAMB, V54, P121; Ulm E H, 1975, Methods Enzymol, V42, P369; VANSCHAFTINGEN E, 1981, P NATL ACAD SCI-BIOL, V78, P2861; VILLERET V, 1995, BIOCHEMISTRY-US, V34, P4307, DOI 10.1021/bi00013a020; ZHANG RL, 1995, BIOCHEMISTRY-US, V34, P8190, DOI 10.1021/bi00025a026; ZHANG YP, 1994, J MOL BIOL, V244, P609, DOI 10.1006/jmbi.1994.1755; ZHANG YP, 1993, BIOCHEMISTRY-US, V32, P1844, DOI 10.1021/bi00058a019	36	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17511	17516		10.1074/jbc.273.28.17511	http://dx.doi.org/10.1074/jbc.273.28.17511			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651342	hybrid			2022-12-25	WOS:000074816100035
J	Rother, KI; Imai, Y; Caruso, M; Beguinot, F; Formisano, P; Accili, D				Rother, KI; Imai, Y; Caruso, M; Beguinot, F; Formisano, P; Accili, D			Evidence that IRS-2 phosphorylation is required for insulin action in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; SELECTIVE INHIBITOR WORTMANNIN; RECEPTOR SUBSTRATE-1 IRS1; PROTEIN-KINASE-B; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; GLUCOSE-TRANSPORT; TARGETED DISRUPTION; HEMATOPOIETIC-CELLS; GLYCOGEN-SYNTHASE	Insulin receptor substrates (IRSs) are tyrosine-phosphorylated following stimulation with insulin, insulinlike growth factors (IGFs), and interleukins. A key questionis whether different IRSs play different roles to mediate insulin's metabolic and growth-promoting effects. In a novel system of insulin receptor-deficient hepatocytes, insulin fails to (i) stimulate glucose phosphorylation, (ii) enhance glycogen synthesis, (iii) suppress glucose production, and (iv) promote mitogenesis, However, insulin's ability to induce IRS-1 and gab-1 phosphorylation and binding to phosphatidylinositol (PI) 3-kinase is unaffected, by virtue of the compensatory actions of IGF-1 receptors, In contrast, phosphorylation of IRS-2 and generation of IRS-2/PI 3-kinase complexes are markedly reduced. Thus, absence of insulin receptors selectively reduces IRS-2, but not IRS-1 phosphorylation, and the impairment of IRS-S activation is associated with lack of insulin effects. To address whether phosphorylation of additional IRSs is also affected, we analyzed phosphotyrosine-containing proteins in PI 3-kinase immunoprecipitates from insulin-treated cells, However, these experiments indicate that IRS-1 and IRS-2 are the main PI 3-kinase bound proteins in hepatocytes, These data identify IRS-2 as the main effector of both the metabolic and growth-promoting actions of insulin through PI 3-kinase in hepatocytes, and IRS-1 as the main substrate mediating the mitogenic actions of IGF-1 receptors.	NICHD, Dev Endocrinol Branch, NIH, Bethesda, MD 20892 USA; Univ N Carolina, Sch Med, Div Endocrinol, Chapel Hill, NC 27514 USA; Univ Naples, Sch Med, Dipartimento Biol & Patol Cellulare, Naples, Italy; Univ Naples, Sch Med, CNR, Ctr Endocrinol & Oncol Sperimentale, Naples, Italy	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II	Accili, D (corresponding author), NICHD, Dev Endocrinol Branch, NIH, Bldg 10,Rm 10D 18, Bethesda, MD 20892 USA.		Formisano, Pietro/J-4237-2018	Formisano, Pietro/0000-0001-7020-6870; Imai, Yumi/0000-0001-5046-4223				Accili D, 1996, NAT GENET, V12, P106, DOI 10.1038/ng0196-106; ACCILI D, 1986, ENDOCRINOLOGY, V119, P1274, DOI 10.1210/endo-119-3-1274; Accili D, 1997, TRENDS ENDOCRIN MET, V8, P101, DOI 10.1016/S1043-2760(97)00031-3; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; BERGER J, 1994, BIOCHEM BIOPH RES CO, V205, P570, DOI 10.1006/bbrc.1994.2703; Bruning JC, 1997, MOL CELL BIOL, V17, P1513; Bruning JC, 1997, CELL, V88, P561, DOI 10.1016/S0092-8674(00)81896-6; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Caruso M, 1997, J BIOL CHEM, V272, P7290, DOI 10.1074/jbc.272.11.7290; CHOU JY, 1985, METHOD ENZYMOL, V109, P385; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DiCola G, 1997, J CLIN INVEST, V99, P2538, DOI 10.1172/JCI119438; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; EFSTRATIADIS A, 1996, EXP CLIN ENDOCR S2, V104, P4; Ferre T, 1996, P NATL ACAD SCI USA, V93, P7225, DOI 10.1073/pnas.93.14.7225; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; IYNEDJIAN PB, 1995, J CLIN INVEST, V95, P1966, DOI 10.1172/JCI117880; Joshi RL, 1996, EMBO J, V15, P1542, DOI 10.1002/j.1460-2075.1996.tb00498.x; KABURAGI Y, 1993, J BIOL CHEM, V268, P16610; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; Louvi A, 1997, DEV BIOL, V189, P33, DOI 10.1006/dbio.1997.8666; Morrione A, 1997, P NATL ACAD SCI USA, V94, P3777, DOI 10.1073/pnas.94.8.3777; MOSES AC, 1995, DIABETES RES CLIN PR, V28, pS185, DOI 10.1016/0168-8227(95)01084-Q; MOSES AC, 1991, INSULIN LIKE GROWTH, P245; MYERS MG, 1994, J BIOL CHEM, V269, P28783; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NIKOLICRORDORF T, 1995, J BIOL CHEM, V270, P3662; OKADA T, 1994, J BIOL CHEM, V269, P3568; OUWENS DM, 1994, J BIOL CHEM, V269, P33116; RAHN T, 1994, FEBS LETT, V350, P314, DOI 10.1016/0014-5793(94)00797-7; SAKAUE H, 1995, J BIOL CHEM, V270, P11304, DOI 10.1074/jbc.270.19.11304; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; SawkaVerhelle D, 1997, J BIOL CHEM, V272, P16414, DOI 10.1074/jbc.272.26.16414; Sciacchitano S, 1997, ENDOCRINOLOGY, V138, P4931, DOI 10.1210/en.138.11.4931; Shepherd PR, 1997, DIABETOLOGIA, V40, P1172, DOI 10.1007/s001250050803; SHIMIZU Y, 1994, BIOCHEM BIOPH RES CO, V202, P660, DOI 10.1006/bbrc.1994.1981; SmithHall J, 1997, BIOCHEMISTRY-US, V36, P8304, DOI 10.1021/bi9630974; Su TZ, 1998, J BIOL CHEM, V273, P3173, DOI 10.1074/jbc.273.6.3173; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TOMIYAMA K, 1995, BIOCHEM BIOPH RES CO, V212, P263, DOI 10.1006/bbrc.1995.1965; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; Welsh GI, 1997, FEBS LETT, V410, P418, DOI 10.1016/S0014-5793(97)00579-6; WHITE MF, 1994, J BIOL CHEM, V269, P1; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; YAMAUCHI K, 1994, J BIOL CHEM, V269, P31107; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634	63	135	141	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17491	17497		10.1074/jbc.273.28.17491	http://dx.doi.org/10.1074/jbc.273.28.17491			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651339	hybrid, Green Published			2022-12-25	WOS:000074816100032
J	Yue, JB; Buard, A; Mulder, KM				Yue, JB; Buard, A; Mulder, KM			Blockade of TGF beta(3) up-regulation of p27(Kip1) and p21(Cip1) by expression of RasN17 in epithelial cells	ONCOGENE			English	Article						TGF beta; p21(Cip1); P27(Kip1); Ras, cell cycle; intestinal epithelial cells	GROWTH-FACTOR-BETA; CYCLIN-DEPENDENT KINASES; TGF-BETA; CDK; INHIBITOR; ARREST; ACTIVATION; PROTEIN; P21; SENSITIVITY	Our previous data demonstrated that Ras activation is necessary and sufficient for transforming growth factor beta (TGF beta)-mediated Erk1 activation, and is partially required for the inhibition of cyclin-dependent kinase 2 (Cdk2) activity, cyclin A expression and DNA synthesis by TGF beta (KM Mulder and SL Morris, J. Biol. Chem., 267: 5029-5031, 1992; MT Hartsough and KM Mulder, J. Biol. Chem., 270: 7117-7124, 1995; and MT Hartsough et nl., J. Biol. Chem., 271: 22368-22375, 1996). Here, we examined the kinetics and role of Ras in TGF beta(3)-mediated effects on specific G(1) cell cycle components in TGF beta-sensitive (4-1) and TGF beta-resistant (4-6) intestinal epithelial cells (IEC's). Our results indicate that inactivation of Ras by stable, inducible expression of a dominant-negative mutant of Ras (RasN17) completely abrogated the ability of TGF beta(3) to up-regulate both CKI's. In contrast, the ability of TGF beta(3) to up-regulate p27(Kip1) and p21(Cip1) was maintained in ZnCl2-treated control cells. Inactivation of Ras also completely blocked the rapid TGF beta-mediated increase in new synthesis of p27(Kip1) protein. Moreover, up-regulation of p21(Cip1) protein levels and new synthesis of p27(Kip1), as well as the association of these CKI's with Cdk2, preceded the decrease in Cdk2 activity by TGF beta. Collectively, our results suggest that p21(Cip1) and p27(Kip1) are upstream effecters of the TGF beta-mediated inhibition of Cdk2 activity in IEC 4-1 cells, and demonstrate that Ras activation is obligatory for TGF beta-mediated upregulation of these CKIs in untransformed epithelial cells.	Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Pharmacol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Mulder, KM (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Pharmacol, Hershey, PA 17033 USA.		Yue, Jianbo/AAC-4588-2019; Yue, Jianbo/C-4463-2009; Yue, Jianbo/K-8002-2015	Yue, Jianbo/0000-0001-6384-5447	NCI NIH HHS [K04 CA59552, CA54816, CA51452] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA051452, R01CA051452, K04CA059552, R01CA054816] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHEN RH, 1995, NATURE, V377, P548, DOI 10.1038/377548a0; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Derynck R, 1996, CURR BIOL, V6, P1226, DOI 10.1016/S0960-9822(96)00702-6; DERYNCK R, 1994, TIBS, V19, P539; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; Feng XH, 1996, J BIOL CHEM, V271, P13123, DOI 10.1074/jbc.271.22.13123; Florenes VA, 1996, ONCOGENE, V13, P2447; Frey RS, 1997, CANCER LETT, V117, P41, DOI 10.1016/S0304-3835(97)00211-5; Frey RS, 1997, CANCER RES, V57, P628; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; HARPER JW, 1993, CELL, V75, P805; Hartsough MT, 1996, J BIOL CHEM, V271, P22368, DOI 10.1074/jbc.271.37.22368; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Hartsough MT, 1997, PHARMACOL THERAPEUT, V75, P21, DOI 10.1016/S0163-7258(97)00020-X; Iavarone A, 1997, NATURE, V387, P417; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; Malliri A, 1996, CELL GROWTH DIFFER, V7, P1291; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MULDER KM, 1993, J CELL PHYSIOL, V154, P162, DOI 10.1002/jcp.1041540120; MULDER KM, 1992, J BIOL CHEM, V267, P5029; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Sgambato A, 1997, CELL GROWTH DIFFER, V8, P393; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Wang TW, 1996, SCIENCE, V271, P1120, DOI 10.1126/science.271.5252.1120; Wang TW, 1996, CELL, V86, P435, DOI 10.1016/S0092-8674(00)80116-6; Wrana JL, 1996, TRENDS GENET, V12, P493, DOI 10.1016/S0168-9525(96)30109-1	36	35	36	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 9	1998	17	1					47	55		10.1038/sj.onc.1201903	http://dx.doi.org/10.1038/sj.onc.1201903			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZY936	9671313				2022-12-25	WOS:000074677800006
J	Wang, CC; Lu, SC; Chen, HL; Liao, TH				Wang, CC; Lu, SC; Chen, HL; Liao, TH			Porcine spleen deoxyribonuclease II - Covalent structure, cDNA sequence, molecular cloning, and gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC DEOXYRIBONUCLEASE; LYSOSOMAL-ENZYMES; DNASE-II; PURIFICATION	Porcine spleen DNase II, a lysosomal acid hydrolase, is a noncovalently linked alpha.beta heterodimer (Liao, T.-H, (1985) J, Biol, Chem, 260, 10708-10713), The cu subunit, after disulfide cleavage, yields two chains, alpha 1 and alpha 2. The complete amino acid sequences of the alpha 1, beta, and alpha 2 chains were elucidated by protein sequencing, and the pairings of one interchain disulfide between alpha 1 and alpha 2 and of three intrachain disulfides in a2 were assigned. Six carbohydrate attachment sites, two in beta and four in alpha 2, were detected by sugar analyses. The cDNA of DNase II was amplified using primers synthesized on the basis of the amino acid sequences determined. The amplified fragments shown to be a cDNA sequence of 1,292 bases. This cDNA sequence has an open reading frame encoding a 364-amino acid polypeptide containing a putative transmembrane peptide at the NH2-end, two small connecting peptides in the middle, and a peptide at the COOH terminus, These are evidently removed to form mature DNase II. Thus, all three chains in the sequence alpha 1, beta, and alpha 2 are coded by the same cDNA, When Chinese hamster ovary cells were transfected with a cloned plasmid with an inserted cDNA fragment encoding the entire reading frame, the expressed protein was released into the growth medium as an active form of DNase II.	Natl Taiwan Univ, Coll Med, Inst Biochem, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, Hepatitis Res Ctr, Taipei, Taiwan	National Taiwan University; National Taiwan University	Liao, TH (corresponding author), Natl Taiwan Univ, Coll Med, Inst Biochem, 1,Sect 1,JenAi Rd, Taipei, Taiwan.			Chen, Hui-Ling/0000-0002-2572-0595				BARRY MA, 1993, ARCH BIOCHEM BIOPHYS, V300, P440, DOI 10.1006/abbi.1993.1060; Bernardi G., 1971, HYDROLYSIS, P271; Beyer BM, 1996, J BIOL CHEM, V271, P15590, DOI 10.1074/jbc.271.26.15590; BOYER MJ, 1993, ADV CANCER RES, V60, P269; CHANG HC, 1990, ARCH BIOCHEM BIOPHYS, V280, P320, DOI 10.1016/0003-9861(90)90336-W; CHANG YM, 1994, BIOTECHNOL APPL BIOC, V19, P129; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEDUVE C, 1983, EUR J BIOCHEM, V137, P391, DOI 10.1111/j.1432-1033.1983.tb07841.x; FLORINCHRISTENSEN M, 1989, EUR J CELL BIOL, V48, P1; Guimaraes MJ, 1996, J BIOL CHEM, V271, P13697, DOI 10.1074/jbc.271.23.13697; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; KOIZUMI T, 1995, EXP ANIM TOKYO, V44, P169, DOI 10.1538/expanim.44.169; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KUKURUZINSKA MA, 1987, ANN REV BIOCH, V56, P15; LIAO TH, 1989, BIOCHIM BIOPHYS ACTA, V1007, P15, DOI 10.1016/0167-4781(89)90124-3; LIAO TH, 1985, J BIOL CHEM, V260, P708; Liao TH, 1997, J FORMOS MED ASSOC, V96, P481; Liao YF, 1996, J BIOL CHEM, V271, P28348, DOI 10.1074/jbc.271.45.28348; MANIATIS T, 1982, MOL CLONING LAB MANU, P11; MORDIER SB, 1995, EUR J BIOCHEM, V229, P35, DOI 10.1111/j.1432-1033.1995.0035l.x; NAKAMURA Y, 1989, MECH AGEING DEV, V50, P215, DOI 10.1016/0047-6374(89)90101-2; NEUFELD EF, 1991, ANNU REV BIOCHEM, V60, P257, DOI 10.1146/annurev.biochem.60.1.257; Ord T, 1997, ARCH BIOCHEM BIOPHYS, V339, P64, DOI 10.1006/abbi.1996.9870; OSHIMA RG, 1973, J BIOL CHEM, V248, P7522; PAUDEL HK, 1986, J BIOL CHEM, V261, P6006; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Shen Pei-Ming, 1993, Journal of the Chinese Biochemical Society, V22, P99; SUZUKI Y, 1995, JPN J CLIN MED, V53, P2887; TORRIGLIA A, 1995, J BIOL CHEM, V270, P28579, DOI 10.1074/jbc.270.48.28579; Yasuda T, 1998, J BIOL CHEM, V273, P2610, DOI 10.1074/jbc.273.5.2610	30	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17192	17198		10.1074/jbc.273.27.17192	http://dx.doi.org/10.1074/jbc.273.27.17192			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642288	hybrid			2022-12-25	WOS:000074545200078
J	Wong, HN; Ward, MA; Bell, AW; Chevet, E; Bains, S; Blackstock, WP; Solari, R; Thomas, DY; Bergeron, JJM				Wong, HN; Ward, MA; Bell, AW; Chevet, E; Bains, S; Blackstock, WP; Solari, R; Thomas, DY; Bergeron, JJM			Conserved in vivo phosphorylation of calnexin at casein kinase II sites as well as a protein kinase C proline-directed kinase site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; MOLECULAR CHAPERONE; MASS-SPECTROMETRY; MEMBRANE-PROTEIN; QUALITY-CONTROL; CALRETICULIN; ASSOCIATION; BINDING; GLYCOPROTEINS; PEPTIDES	Calnexin is a lectin-like chaperone of the endoplasmic reticulum (ER) that couples temporally and spatially N-linked oligosaccharide modifications with the productive folding of newly synthesized glycoproteins. Calnexin was originally identified as a major type I integral membrane protein substrate of kinase(s) associated with the ER, Casein kinase II (CK2) was subsequently identified as an ER-associated kinase responsible for the in vitro phosphorylation of calnexin in microsomes (Ou, W-J,, Thomas, D. Y., Bell, A. W., and Bergeron, J, J, M, (1992) J. Biol. Chem. 267, 23789-23796). We now report on the in vivo sites of calnexin phosphorylation, After (PO4)-P-32 labeling of HepG2 and Madin-Darby canine kidney cells, immunoprecipitated calnexin was phosphorylated exclusively on serine residues. Using nonradiolabeled cells, we subjected calnexin immunoprecipitates to in gel tryptic digestion followed by nanoelectrospray mass spectrometry employing selective scans specific for detection of phosphorylated fragments. Mass analyses identified three phosphorylated sites in calnexin from either HepG2 or Madin-Darby canine kidney cells. The three sites were localized to the more carboxyl-terminal half of the cytosolic domain: S(534)DAE (CK2 motif), S(544)QEE (CK2 motif), and (SPR)-P-563. We conclude that CK2 is a kinase that phosphorylates calnexin in vivo as well as in microsomes in vitro, Another yet to be identified kinase (protein kinase C and/or proline-directed kinase) is directed toward the most COOH-terminaI serine residue. Elucidation of the signaling cascade responsible for calnexin phosphorylation at these sites in vivo may define a novel regulatory function for calnexin in cargo folding and transport to the ER exit sites.	McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada; McGill Univ, Dept Biol, Montreal, PQ H3A 2B2, Canada; Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada; Glaxo Wellcome Res & Dev Ltd, Stevenage SG1 2NY, Herts, England	McGill University; McGill University; National Research Council Canada; GlaxoSmithKline	Bergeron, JJM (corresponding author), McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada.	eh14@musica.mcgill.ca	chevet, eric/E-4992-2016; Bergeron, John/AAW-1893-2021; Thomas, David/M-7661-2017	chevet, eric/0000-0001-5855-4522; Thomas, David/0000-0002-8854-762X				ALLEN G, 1989, SEQUENCING PROTEINS; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; Betts JC, 1997, J BIOL CHEM, V272, P12922, DOI 10.1074/jbc.272.20.12922; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CALA SE, 1993, J BIOL CHEM, V268, P2969; CAPPS GG, 1994, J BIOL CHEM, V269, P11634; Carr SA, 1996, ANAL BIOCHEM, V239, P180, DOI 10.1006/abio.1996.0313; COVEY T, 1991, ADV LIF SCI, P249; Covey T R, 1988, Rapid Commun Mass Spectrom, V2, P249, DOI 10.1002/rcm.1290021111; DAVID V, 1993, J BIOL CHEM, V268, P9585; FERAMISCO JR, 1980, J BIOL CHEM, V255, P4240; GLASS DB, 1986, J BIOL CHEM, V261, P2987; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; Helenius A, 1997, TRENDS CELL BIOL, V7, P193; Ikawa M, 1997, NATURE, V387, P607, DOI 10.1038/42484; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; LE AQ, 1994, J BIOL CHEM, V269, P7514; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; OPAS M, 1991, J CELL PHYSIOL, V149, P160, DOI 10.1002/jcp.1041490120; OU WJ, 1995, J BIOL CHEM, V270, P18051, DOI 10.1074/jbc.270.30.18051; OU WJ, 1992, J BIOL CHEM, V267, P23789; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PARLATI F, 1995, J BIOL CHEM, V270, P244, DOI 10.1074/jbc.270.1.244; PARLATI F, 1995, EMBO J, V14, P3064, DOI 10.1002/j.1460-2075.1995.tb07309.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rodan AR, 1996, EMBO J, V15, P6921, DOI 10.1002/j.1460-2075.1996.tb01084.x; Schaller J, 1997, RAPID COMMUN MASS SP, V11, P418, DOI 10.1002/(SICI)1097-0231(19970228)11:4<418::AID-RCM795>3.0.CO;2-R; SCHUE V, 1994, BIOCHEM BIOPH RES CO, V203, P22, DOI 10.1006/bbrc.1994.2143; SONNICHSEN B, 1994, J CELL SCI, V107, P2705; Tanaka H, 1997, GENE, V204, P159, DOI 10.1016/S0378-1119(97)00537-4; TECTOR M, 1994, J BIOL CHEM, V269, P25816; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TJOELKER LW, 1994, BIOCHEMISTRY-US, V33, P3229, DOI 10.1021/bi00177a013; WADA I, 1991, J BIOL CHEM, V266, P19599; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; WATANABE D, 1994, J BIOL CHEM, V269, P7744; Wilm M, 1996, ANAL CHEM, V68, P527, DOI 10.1021/ac950875+; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; WILM MS, 1994, INT J MASS SPECTROM, V136, P167, DOI 10.1016/0168-1176(94)04024-9; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; Zapun A, 1997, CELL, V88, P29, DOI 10.1016/S0092-8674(00)81855-3; Zapun A, 1998, J BIOL CHEM, V273, P6009, DOI 10.1074/jbc.273.11.6009	52	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17227	17235		10.1074/jbc.273.27.17227	http://dx.doi.org/10.1074/jbc.273.27.17227			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642293	hybrid			2022-12-25	WOS:000074545200083
J	Muralikrishnan, D; Mohanakumar, KP				Muralikrishnan, D; Mohanakumar, KP			Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice	FASEB JOURNAL			English	Article						MPTP; hydroxyl radicals; dopamine neurotoxicity; neuroprotection; GSH; free radical scavenger; antioxidant enzymes	OXYGEN RADICAL FORMATION; HYDROXYL FREE-RADICALS; MPTP-TREATED MICE; LIPID-PEROXIDATION; PARKINSONS-DISEASE; MONOAMINE-OXIDASE; SUBSTANTIA-NIGRA; RECEPTOR AGONISTS; MPP(+) TOXICITY; MOUSE-BRAIN	Mice were treated with l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP; 30 mg/kg i.p. twice, 16 h apart), This resulted in changes in motor performance and toxic insult of nigral neurons as evidenced by dopamine depletion in nucleus caudatus putamen, In vitro and in vivo treatment of MPTP caused the generation of hydroxyl radicals ( OH) as measured by a sensitive salicylate hydroxylation procedure, A dopamine agonist, bromocriptine (10 mu M and 10 mg/kg i,p.), blocked OH formation caused by MPTP in vitro (20 mu M) and in vivo (30 mg/kg i,p,), An MPTP-induced increase in the activity of catalase and superoxide dismutase in substantia nigra on the seventh day was reduced by bromocriptine pretreatment, Bromocriptine blocked MPTP-induced behavioral dysfunction as well as glutathione and dopamine depletion, indicating its potent neuroprotective action, This study suggests that bromocriptine stimulates antioxidant mechanisms in the brain and acts as a free radical scavenger in addition to its action at dopamine receptors, thus indicating its strength as a valuable neuroprotectant, -Muralikrishnan, D., Mohanakumar, K. P. Neuroprotection by bromocriptine against 1-methyl-4-phhenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice.	Indian Inst Chem Biol, Div Pharmacol & Expt Therapeut, Neurochem Lab, Kolkata 700032, W Bengal, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)	Muralikrishnan, D (corresponding author), Indian Inst Chem Biol, Div Pharmacol & Expt Therapeut, Neurochem Lab, 4 Raja SC Mullick Rd, Kolkata 700032, W Bengal, India.		Mohanakumar, Kochupurackal P/ABE-8492-2020	Mohanakumar, Kochupurackal P/0000-0002-4985-1100				ACUNACASTROVIEJ.D, 1997, LIFE SCI, V60, P23; ADAMS JD, 1993, FREE RADICAL BIO MED, V15, P181, DOI 10.1016/0891-5849(93)90057-2; AEBI H, 1984, METHOD ENZYMOL, V105, P121; AMBANI LM, 1975, ARCH NEUROL-CHICAGO, V32, P114, DOI 10.1001/archneur.1975.00490440064010; ARAI N, 1995, J NEURAL TRANSM-PARK, V10, P55, DOI 10.1007/BF02256629; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; BURKI HR, 1978, J PHARM PHARMACOL, V30, P261; BURNS RS, 1983, P NATL ACAD SCI-BIOL, V80, P4546, DOI 10.1073/pnas.80.14.4546; CALNE DB, 1974, BMJ-BRIT MED J, V4, P442, DOI 10.1136/bmj.4.5942.442; CHIBA K, 1984, BIOCHEM BIOPH RES CO, V120, P574, DOI 10.1016/0006-291X(84)91293-2; CHIUEH CC, 1994, ANN NY ACAD SCI, V738, P25; CLEMENS JA, 1994, ANN NY ACAD SCI, V738, P250; COHEN G, 1974, J BIOL CHEM, V249, P2447; COHN VH, 1966, ANAL BIOCHEM, V14, P434, DOI 10.1016/0003-2697(66)90286-7; DESOLE MS, 1993, NEUROSCI LETT, V161, P121, DOI 10.1016/0304-3940(93)90274-O; DEXTER D, 1986, LANCET, V2, P639; DEXTER DT, 1987, LANCET, V2, P1219; FELTEN DL, 1992, NEUROBIOL AGING, V13, P339, DOI 10.1016/0197-4580(92)90048-3; FREDRIKSSON A, 1994, PHARMACOL TOXICOL, V75, P36, DOI 10.1111/j.1600-0773.1994.tb00321.x; GAGNON C, 1990, EUR J PHARMACOL, V178, P115, DOI 10.1016/0014-2999(90)94802-5; HALLIWELL B, 1991, FREE RADICAL BIO MED, V10, P439, DOI 10.1016/0891-5849(91)90052-5; HEIKKILA RE, 1984, SCIENCE, V224, P1451, DOI 10.1126/science.6610213; JACKSON DM, 1988, PSYCHOPHARMACOLOGY, V95, P433; JAVITCH JA, 1985, P NATL ACAD SCI USA, V82, P2173, DOI 10.1073/pnas.82.7.2173; KISH SJ, 1985, NEUROSCI LETT, V58, P343, DOI 10.1016/0304-3940(85)90078-3; KONDO T, 1994, ANN NY ACAD SCI, V738, P222; MARKLUND S, 1974, EUR J BIOCHEM, V47, P469; MARZATICO F, 1993, NEUROCHEM RES, V18, P1101, DOI 10.1007/BF00966691; MITRA N, 1992, BRAIN RES BULL, V28, P355, DOI 10.1016/0361-9230(92)90035-V; MITRA N, 1994, J NEUROCHEM, V62, P1906; MIZUNO Y, 1988, NEUROSCI LETT, V91, P349, DOI 10.1016/0304-3940(88)90705-7; MOCHIZUKI H, 1994, NEUROSCI LETT, V168, P251, DOI 10.1016/0304-3940(94)90462-6; Mohanakumar K.P., 1994, NEW TRENDS CLIN NEUR, V8, P50, DOI [10.1111/j.1749-6632.1994.tb21828.x, DOI 10.1111/J.1749-6632.1994.TB21828.X]; MOHANAKUMAR KP, 1994, ANN NY ACAD SCI, V738, P392; MOHANAKUMAR KP, 1990, NEUROSCI LETT, V120, P91, DOI 10.1016/0304-3940(90)90175-9; NAKAMURA H, 1989, ACTA NEUROPATHOL, V77, P489, DOI 10.1007/BF00687250; OBATA T, 1992, J NEURAL TRANSM-GEN, V89, P139, DOI 10.1007/BF01245361; OGAWA N, 1994, BRAIN RES, V657, P207, DOI 10.1016/0006-8993(94)90969-5; OISHI T, 1993, J NEURAL TRANSM-PARK, V6, P45, DOI 10.1007/BF02252622; PERRY TL, 1982, NEUROSCI LETT, V33, P305, DOI 10.1016/0304-3940(82)90390-1; PRZEDBORSKI S, 1995, MOVEMENT DISORD, V10, P312, DOI 10.1002/mds.870100314; SZIRAKI I, 1998, IN PRESS NEUROSCIENC; TEMLETT JA, 1994, J NEUROCHEM, V62, P134; THIFFAULT C, 1995, J NEUROCHEM, V65, P2725; TIPTON KF, 1993, J NEUROCHEM, V61, P1191, DOI 10.1111/j.1471-4159.1993.tb13610.x; WEIHMULLER FB, 1988, NEUROSCI LETT, V85, P137, DOI 10.1016/0304-3940(88)90443-0; WU RM, 1994, ANN NY ACAD SCI, V738, P214; Wullner U, 1996, NEUROREPORT, V7, P921; YOSHIKAWA T, 1994, J NEUROCHEM, V62, P1034; ZANG LY, 1993, J BIOL CHEM, V268, P16504	51	198	203	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1998	12	10					905	912		10.1096/fasebj.12.10.905	http://dx.doi.org/10.1096/fasebj.12.10.905			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZY035	9657530				2022-12-25	WOS:000074580100015
J	Busch, C; Hofmann, F; Selzer, J; Munro, S; Jeckel, D; Aktories, K				Busch, C; Hofmann, F; Selzer, J; Munro, S; Jeckel, D; Aktories, K			A common motif of eukaryotic glycosyltransferases is essential for the enzyme activity of large clostridial cytotoxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SORDELLII LETHAL TOXIN; NOVYI ALPHA-TOXIN; RHO-PROTEINS; DIFFICILE; GLUCOSYLATION; TRANSFERASE; RAS	A fragment of the N-terminal 546 amino acid residues of Clostridium sordellii lethal toxin possesses full enzyme activity and glucosylates Rho and Ras GTPases in vitro. Here we identified several amino acid residues in C. sordellii lethal toxin that are essential for the enzyme activity of the active toxin fragment. Exchange of aspartic acid at position 286 or 288 with alanine or asparagine decreased glucosyltransferase activity by about 5000-fold and completely blocked glucohydrolase activity. No enzyme activity was detected with the double mutant D286A/D288A. Whereas the wild-type fragment of C. sordellii lethal toxin was labeled by azido-UDP-glucose after UV irradiation, mutation of the DXD motif prevented radiolabeling. At high concentrations (10 mM) of manganese ions, the transferase activities of the D286A and D288A mutants but not that of wild-type fragment were increased by about 20-fold. The exchange of Asp(270) and Arg(273) reduced glucosyltransferase activity by about 200-fold and blocked glucohydrolase activity. The data indicate that the DXD motif, which is highly conserved in all large clostridial cytotoxins and also in a large number of glycosyltransferases, is functionally essential for the enzyme activity of the toxins and may participate in coordination of the divalent cation and/or in the binding of UDP-glucose.	Univ Freiburg, Inst Pharmakol & Toxikol, D-79104 Freiburg, Germany; MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Zentrum Biochem, D-69120 Heidelberg, Germany	University of Freiburg; MRC Laboratory Molecular Biology; Ruprecht Karls University Heidelberg	Aktories, K (corresponding author), Univ Freiburg, Inst Pharmakol & Toxikol, Hermann Herder Str 5, D-79104 Freiburg, Germany.	aktories@ruf.uni-freiburg.de	Aktories, Klaus/CAJ-5682-2022	Aktories, Klaus/0000-0002-5397-0436; Munro, Sean/0000-0001-6160-5773				AKTORIES K, 1995, TRENDS CELL BIOL, V5, P441, DOI 10.1016/S0962-8924(00)89107-2; Aktories K, 1997, TRENDS MICROBIOL, V5, P282, DOI 10.1016/S0966-842X(97)01067-6; BARROSO LA, 1994, MICROB PATHOGENESIS, V16, P297, DOI 10.1006/mpat.1994.1030; BETTE P, 1991, TOXICON, V29, P877, DOI 10.1016/0041-0101(91)90224-F; BONGAERTS GPA, 1994, MICROB PATHOGENESIS, V17, P1, DOI 10.1006/mpat.1994.1047; Genth H, 1996, BIOCHEM BIOPH RES CO, V229, P370, DOI 10.1006/bbrc.1996.1812; HATHEWAY CL, 1990, CLIN MICROBIOL REV, V3, P66, DOI 10.1128/CMR.3.1.66-98.1990; HENDRICKSON TL, 1995, BIOCHEMISTRY-US, V34, P9444, DOI 10.1021/bi00029a020; Herrmann C, 1998, J BIOL CHEM, V273, P16134, DOI 10.1074/jbc.273.26.16134; Hofmann F, 1998, INFECT IMMUN, V66, P1076, DOI 10.1128/IAI.66.3.1076-1081.1998; Hofmann F, 1997, J BIOL CHEM, V272, P11074; Just I, 1996, J BIOL CHEM, V271, P10149, DOI 10.1074/jbc.271.17.10149; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; KELLY CP, 1994, NEW ENGL J MED, V330, P257, DOI 10.1056/NEJM199401273300406; Lyerly David M., 1995, P867; MCGREGOR JA, 1989, AM J OBSTET GYNECOL, V161, P987, DOI 10.1016/0002-9378(89)90768-0; PARKER CG, 1995, EMBO J, V14, P1294, DOI 10.1002/j.1460-2075.1995.tb07115.x; Popoff MR, 1996, J BIOL CHEM, V271, P10217, DOI 10.1074/jbc.271.17.10217; Pothoulakis C, 1996, J CLIN INVEST, V98, P641, DOI 10.1172/JCI118835; Sehr P, 1998, BIOCHEMISTRY-US, V37, P5296, DOI 10.1021/bi972592c; Selzer J, 1996, J BIOL CHEM, V271, P25173, DOI 10.1074/jbc.271.41.25173; TAYLOR NS, 1981, INFECT IMMUN, V34, P1036, DOI 10.1128/IAI.34.3.1036-1043.1981; TSOPANAKIS AD, 1978, EUR J BIOCHEM, V83, P179, DOI 10.1111/j.1432-1033.1978.tb12082.x; vonEichelStreiber C, 1996, TRENDS MICROBIOL, V4, P375, DOI 10.1016/0966-842X(96)10061-5; WIGGINS CAR, 1998, IN PRESS P NATL ACAD	26	189	200	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19566	19572		10.1074/jbc.273.31.19566	http://dx.doi.org/10.1074/jbc.273.31.19566			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677381	hybrid			2022-12-25	WOS:000075125200033
J	Kemper, C; Zipfel, PF; Gigli, I				Kemper, C; Zipfel, PF; Gigli, I			The complement cofactor protein (SBP1) from the barred sand bass (Paralabrax nebulifer) mediates overlapping regulatory activities of both human C4b binding protein and factor H	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPONENT C4B-BINDING PROTEIN; HUMAN C4-BINDING PROTEIN; PATHWAY C-3 CONVERTASE; CLASSICAL PATHWAY; C3B INACTIVATOR; MOLECULAR-CLONING; SYSTEM; PURIFICATION; PHYLOGENY; PROTEOLYSIS	We have previously shown that serum of the teleost fish barred sand bass (Paralabrax nebulifer) cleaves the alpha'-chain of human C4b and C3b, The proteins that participate in these reactions were purified, and a specific protease and a single cofactor protein were identified. Functional characterization of the recombinantly expressed sand bass cofactor protein (SBP1) and truncated forms containing short consensus repeats (SCRs) 1-2, 1-3, 1-4, 1-5, and 12-17 revealed that SBP1 and SCRs 1-4 mediate the functional activities of the human plasma regulatory protein C4bp and factor Il, They form a complex with C4b, inhibit the formation, and accelerate the decay of the classical pathway C3 convertase and display cofactor activity for the cleavage of C4b, In contrast, the interaction of SBP1 and SCRs 1-4 with human C3b in all these activities was limited. This difference is due to species-specific incompatibilities between the cofactor protein and human C3b, SBP1 and SCRs 1-5 displayed full binding and cofactor activity for methylamine-treated C3 from trout, a species closely related to the sand bass. The presence of only one cofactor in the fish plasma that combines the functional activities of C4bp and factor Il demonstrates that the sand bass cofactor protein is the ancestral precursor to the two complement regulatory proteins in human plasma.	Univ Texas, Inst Mol Med Prevent Human Dis, Houston, TX 77030 USA; Bernhard Nocht Inst Trop Med, Dept Mol Parasitol, D-20359 Hamburg, Germany; Univ Hamburg, Dept Biol, Hamburg, Germany	University of Texas System; Bernhard Nocht Institut fur Tropenmedizin; University of Hamburg	Gigli, I (corresponding author), Univ Texas, Inst Mol Med Prevent Human Dis, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	igigli@imm2.imm.uth.tmc.edu	Kemper, Claudia/A-3673-2008; Kemper, Claudia/B-1502-2015	Kemper, Claudia/0000-0003-4196-1417	PHS HHS [A120067] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Accardo P, 1996, J IMMUNOL, V157, P4935; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHUNG LP, 1985, BIOCHEM J, V230, P133, DOI 10.1042/bj2300133; DAHLBACK B, 1983, BIOCHEM J, V209, P837, DOI 10.1042/bj2090837; DAHLBACK B, 1983, BIOCHEM J, V209, P847, DOI 10.1042/bj2090847; DAHLBACK B, 1983, P NATL ACAD SCI-BIOL, V80, P3461, DOI 10.1073/pnas.80.11.3461; DAHMEN A, 1994, BIOCHEM J, V301, P391, DOI 10.1042/bj3010391; DAY NKB, 1970, J EXP MED, V132, P941, DOI 10.1084/jem.132.5.941; FARRIES TC, 1991, IMMUNOL TODAY, V12, P295, DOI 10.1016/0167-5699(91)90002-B; FEARON DT, 1973, J EXP MED, V138, P1305, DOI 10.1084/jem.138.6.1305; FUJITA T, 1979, J EXP MED, V150, P267, DOI 10.1084/jem.150.2.267; FUJITA T, 1978, J EXP MED, V148, P1044, DOI 10.1084/jem.148.4.1044; GIGLI I, 1971, ANNU REV MICROBIOL, V25, P309, DOI 10.1146/annurev.mi.25.100171.001521; GIGLI I, 1979, P NATL ACAD SCI USA, V76, P6596, DOI 10.1073/pnas.76.12.6596; GIGLI I, 1981, J EXP MED, V154, P1, DOI 10.1084/jem.154.1.1; GORDON DL, 1995, J IMMUNOL, V155, P348; Hardig Y, 1997, BIOCHEM J, V323, P469; HAWKES R, 1982, ANAL BIOCHEM, V119, P142, DOI 10.1016/0003-2697(82)90677-7; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; HILLARP A, 1990, P NATL ACAD SCI USA, V87, P1183, DOI 10.1073/pnas.87.3.1183; Innis MA, 1990, PCR PROTOCOLS GUIDE; JANATOVA J, 1989, BIOCHEMISTRY-US, V28, P4754, DOI 10.1021/bi00437a036; KAI S, 1980, J IMMUNOL, V125, P2409; KAIDOH T, 1987, J IMMUNOL, V139, P194; KAIDOH T, 1989, J IMMUNOL, V142, P1605; KHYSEANDERSON J, 1984, J BIOCHEM BIOPH METH, V10, P203; KRISTENSEN T, 1987, FASEB J, V46, P2463; KRUSHKAL J, 1998, IN PRESS J MOL EVOL; KUHN S, 1995, GENE, V162, P225, DOI 10.1016/0378-1119(95)00360-I; Kuhn S, 1996, EUR J IMMUNOL, V26, P2383, DOI 10.1002/eji.1830261017; KUHN S, 1995, J IMMUNOL, V155, P5663; Kuroda N, 1996, IMMUNOGENETICS, V44, P459, DOI 10.1007/BF02602808; LAMBRIS JD, 1994, ANN NY ACAD SCI, V712, P354, DOI 10.1111/j.1749-6632.1994.tb33593.x; LAW S K, 1979, Journal of Immunology, V122, P759; LEE HH, 1978, J VIROL, V27, P754, DOI 10.1128/JVI.27.3.754-767.1978; MUELLEREBERHARD HJ, 1972, J EXP MED, V135, P1003; NAGASAWA S, 1977, IMMUNOCHEMISTRY, V14, P749, DOI 10.1016/0019-2791(77)90345-7; NAGASAWA S, 1980, J IMMUNOL, V125, P578; NAKAO M, 1988, FISH PATHOL, V23, P243, DOI 10.3147/jsfp.23.243; NONAKA M, 1984, J IMMUNOL, V133, P3242; OGATA RT, 1993, J IMMUNOL, V150, P2273; PANGBURN MK, 1984, SPRINGER SEMIN IMMUN, V7, P163, DOI 10.1007/BF01893019; POLLEY MJ, 1968, J EXP MED, V128, P533, DOI 10.1084/jem.128.3.533; REID KMB, 1989, IMMUNOL TODAY, V7, P230; RIPOCHE J, 1988, BIOCHEM J, V249, P593, DOI 10.1042/bj2490593; Sambrook J, 1988, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHARFSTEIN J, 1978, J EXP MED, V148, P207, DOI 10.1084/jem.148.1.207; Seeger A, 1996, MOL IMMUNOL, V33, P511, DOI 10.1016/0161-5890(96)00002-8; Sharma AK, 1996, P NATL ACAD SCI USA, V93, P10996, DOI 10.1073/pnas.93.20.10996; SIM RB, 1982, BIOCHEM J, V205, P285, DOI 10.1042/bj2050285; SITOMER G, 1966, IMMUNOCHEMISTRY, V3, P57, DOI 10.1016/0019-2791(66)90282-5; Smith LC, 1996, J IMMUNOL, V156, P593; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; Sunyer JO, 1997, BIOCHEM J, V326, P877, DOI 10.1042/bj3260877; Sunyer JO, 1996, P NATL ACAD SCI USA, V93, P8546, DOI 10.1073/pnas.93.16.8546; ZICCARDI RJ, 1983, J BIOL CHEM, V258, P6187	57	30	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19398	19404		10.1074/jbc.273.31.19398	http://dx.doi.org/10.1074/jbc.273.31.19398			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677357	hybrid			2022-12-25	WOS:000075125200009
J	Oguro, A; Kakeshita, H; Nakamura, K; Yamane, K; Wang, W; Bechhofer, DH				Oguro, A; Kakeshita, H; Nakamura, K; Yamane, K; Wang, W; Bechhofer, DH			Bacillus subtilis RNase III cleaves both 5 '- and 3 '-sites of the small cytoplasmic RNA precursor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-RECOGNITION PARTICLE; ESCHERICHIA-COLI RIBONUCLEOPROTEIN; T7 EARLY RNAS; PROTEIN TRANSLOCATION; SEQUENCE RECOGNITION; RIBONUCLEASE-III; MESSENGER-RNA; 4.5S RNA; IN-VIVO; HOMOLOG	Bacillus subtilis small cytoplasmic RNA (scRNA) is a member of the signal recognition particle RNA family. It is transcribed as a 354-nucleotide primary transcript and processed to a 271-nucleotide mature scRNA, In the precursor, the 5'- and 3'-flanking regions form a stable double-stranded structure based on their complementary sequence. This structure is similar to those of substrates for the double-stranded RNA processing enzyme, RNase III. The B. subtilis enzyme that has similar activity to Escherichia coli RNase III has been purified and is designated Bs-RNase III. Recently, B, subtilis rncS has been shown to encode Bs-RNase III (Wang, W., and Bechhofer, D. H. (1997) J. Bacteriol. 179, 7379-7385). We show here that Bs-RNase III and the purified His-tagged product of rncS cleave pre-scRNA at both 5'- and 3'-sites to produce an intermediate scRNA (scRNA-275), although processing at the 3'-site is less efficient. The 5'-end of scRNA-275 was identical to that of the mature scRNA, whereas it contains four excess nucleotides at the 3'-end. Bs-RNase III cleavage yields a two-base S'-overhang, which is consistent with the manner in which E. coli RNase III cleaves, We also show that truncation of the rncS gene affected processing, and significant amounts of an intermediate scRNA (scRNA-275) were found to accumulate in the rncS-truncated mutant. It is concluded that Bs-RNase III is an enzyme that processes pre-scRNA.	Univ Tsukuba, Inst Biol Sci, Tsukuba, Ibaraki 305, Japan; Univ Tsukuba, Gene Expt Ctr, Tsukuba, Ibaraki 305, Japan; CUNY Mt Sinai Sch Med, Dept Biochem, New York, NY 10029 USA	University of Tsukuba; University of Tsukuba; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Yamane, K (corresponding author), Univ Tsukuba, Inst Biol Sci, Tsukuba, Ibaraki 305, Japan.	kyamane@sakura.cc.tsukuba.ac.jp						AbouElela S, 1996, CELL, V85, P115, DOI 10.1016/S0092-8674(00)81087-9; AMBULOS NP, 1987, GENE, V51, P281, DOI 10.1016/0378-1119(87)90317-9; BARRY G, 1980, P NATL ACAD SCI-BIOL, V77, P3331, DOI 10.1073/pnas.77.6.3331; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; Bunai K, 1996, BIOCHEM BIOPH RES CO, V227, P762, DOI 10.1006/bbrc.1996.1582; COURT D, 1993, CONTROL MRNA STABILI, P70; DUNN JJ, 1973, P NATL ACAD SCI USA, V70, P1559, DOI 10.1073/pnas.70.5.1559; DUNN JJ, 1973, P NATL ACAD SCI USA, V70, P3296, DOI 10.1073/pnas.70.12.3296; HENNER DJ, 1990, METHOD ENZYMOL, V185, P223; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LOZERON HA, 1977, J MOL BIOL, V109, P359, DOI 10.1016/S0022-2836(77)80039-9; LUIRINK J, 1992, NATURE, V359, P741, DOI 10.1038/359741a0; LUIRINK J, 1994, EMBO J, V13, P2289, DOI 10.1002/j.1460-2075.1994.tb06511.x; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; MITRA S, 1994, J BIOL CHEM, V269, P31450; NAKAMURA K, 1994, BIOCHEM BIOPH RES CO, V199, P1394, DOI 10.1006/bbrc.1994.1385; Oguro A, 1995, DNA Res, V2, P95, DOI 10.1093/dnares/2.2.95; Oguro A, 1996, GENE, V172, P17, DOI 10.1016/0378-1119(96)00181-3; PANGANIBAN AT, 1983, CELL, V33, P907, DOI 10.1016/0092-8674(83)90033-8; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; Rotondo G, 1996, NUCLEIC ACIDS RES, V24, P2377, DOI 10.1093/nar/24.12.2377; Shibata T, 1996, J BIOL CHEM, V271, P13162, DOI 10.1074/jbc.271.22.13162; SIEGEL V, 1988, P NATL ACAD SCI USA, V85, P1801, DOI 10.1073/pnas.85.6.1801; STRUCK JCR, 1989, MOL GEN GENET, V215, P478, DOI 10.1007/BF00427046; STRUCK JCR, 1988, NUCLEIC ACIDS RES, V16, P2719, DOI 10.1093/nar/16.6.2719; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0; Wang W, 1997, J BACTERIOL, V179, P7379, DOI 10.1128/jb.179.23.7379-7385.1997; YOUNG RA, 1978, P NATL ACAD SCI USA, V75, P3593, DOI 10.1073/pnas.75.8.3593	29	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19542	19547		10.1074/jbc.273.31.19542	http://dx.doi.org/10.1074/jbc.273.31.19542			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677377	hybrid			2022-12-25	WOS:000075125200029
J	Teter, K; Chandy, G; Quinones, B; Pereyra, K; Machen, T; Moore, HPH				Teter, K; Chandy, G; Quinones, B; Pereyra, K; Machen, T; Moore, HPH			Cellubrevin-targeted fluorescence uncovers heterogeneity in the recycling endosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETANUS-TOXIN; TRANSFERRIN RECEPTORS; ENDOCYTIC PATHWAY; LIVING CELLS; PH; ACIDIFICATION; TRANSPORT; CLEAVAGE; VESICLE; NA+,K+-ATPASE	The pH and trafficking of recycling endosomes have previously been studied using transferrin. We have used another approach, one in which the vesicle transport protein cellubrevin was appended with a luminal IgG epitope to allow targeting of fluorescein-5'-isothiocyanate (FITC)-labeled anti-IgG F(ab) antibodies to the recycling endosomes in living cells, FITC-F(ab) was specifically internalized by COS cells transfected with cellubrevin-Ig, which at steady state accumulated in a pericentriolar region similar to rhodamine-transferrin. Confocal microscopic analysis showed that endosome labeling by these two markers was heterogeneous. This differential distribution was not induced by the IgG tag, since endogenous Cb and Tf were also partitioned into separate endosomal populations. We used fluorescence ratio imaging of internalized FITC-F(ab) to measure the pH of cellubrevin-enriched recycling endosomes (pH(Cb)) and FITC-transferrin to measure the pH of transferrin-enriched recycling endosomes (pH(Tf)). In COS cells, cellubrevin endosomes (mean pH(Cb) 6.1 +/- 0.05; range, 5.2-6.6) were more acidic than transferrin endosomes (mean pH(Tf) 6.5 +/- 0.05; range, 5.6-7.2). Similar results were obtained in Chinese hamster ovary cells. Treatment with the vacuolar H+-ATPase inhibitor bafilomycin A(1) caused pH(Tf) to increase (Delta pH(Tf) = 1.2 pH units) to a greater extent than pH(Cb) (Delta pH(Cb) = 0.5 pH units). Furthermore, inhibition of the Na+/K+-ATPase by ouabain or acetylstrophanthidin caused pH(Tf) to decrease by 0.6 pH units but had no effect on pH(Cb). Based on the combination of these morphological and functional data, we suggest that the recycling endosomes are heterogeneous in their biochemical compositions, ion transport properties, and PEI values.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Moore, HPH (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 142 Life Sci Addit 3200, Berkeley, CA 94720 USA.			Quinones, Beatriz/0000-0001-5010-9889; Teter, Ken/0000-0003-4176-9361	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035239] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK95006] Funding Source: Medline; NIGMS NIH HHS [GM35239] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT MK, 1995, CURR OPIN CELL BIOL, V7, P581, DOI 10.1016/0955-0674(95)80016-6; CAIN CC, 1989, P NATL ACAD SCI USA, V86, P544, DOI 10.1073/pnas.86.2.544; CHILCOTE TJ, 1995, J CELL BIOL, V129, P219, DOI 10.1083/jcb.129.1.219; COLE NB, 1995, CURR OPIN CELL BIOL, V7, P55, DOI 10.1016/0955-0674(95)80045-X; D'Souza S, 1998, J BIOL CHEM, V273, P2035, DOI 10.1074/jbc.273.4.2035; Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; Demaurex N, 1998, J BIOL CHEM, V273, P2044, DOI 10.1074/jbc.273.4.2044; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; FUCHS R, 1989, J BIOL CHEM, V264, P2212; FUCHS R, 1989, P NATL ACAD SCI USA, V86, P539, DOI 10.1073/pnas.86.2.539; GALLI T, 1994, J CELL BIOL, V125, P1015, DOI 10.1083/jcb.125.5.1015; GRIFFITHS G, 1989, J CELL BIOL, V109, P2703, DOI 10.1083/jcb.109.6.2703; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; HOPKINS CR, 1983, CELL, V35, P321, DOI 10.1016/0092-8674(83)90235-0; Johnson AO, 1996, J CELL BIOL, V135, P1749, DOI 10.1083/jcb.135.6.1749; JOHNSON LS, 1993, MOL BIOL CELL, V4, P1251, DOI 10.1091/mbc.4.12.1251; KELLY RB, 1990, CELL, V61, P5, DOI 10.1016/0092-8674(90)90206-T; Kim JH, 1996, J CELL BIOL, V134, P1387, DOI 10.1083/jcb.134.6.1387; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; LINK E, 1993, J BIOL CHEM, V268, P18423; LUKACS GL, 1991, J BIOL CHEM, V266, P24540; MARSH EW, 1995, J CELL BIOL, V129, P1509, DOI 10.1083/jcb.129.6.1509; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Nunez MT, 1997, J BIOL CHEM, V272, P19425, DOI 10.1074/jbc.272.31.19425; ORCI L, 1994, J CELL BIOL, V126, P1149, DOI 10.1083/jcb.126.5.1149; Presley JF, 1997, J BIOL CHEM, V272, P13929, DOI 10.1074/jbc.272.21.13929; Rybak SL, 1997, BIOPHYS J, V73, P674, DOI 10.1016/S0006-3495(97)78102-5; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SIPE DM, 1987, P NATL ACAD SCI USA, V84, P7119, DOI 10.1073/pnas.84.20.7119; STOORVOGEL W, 1991, CELL, V65, P417, DOI 10.1016/0092-8674(91)90459-C; TOOZE J, 1991, J CELL BIOL, V115, P635, DOI 10.1083/jcb.115.3.635; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; VANWEERT AWM, 1995, J CELL BIOL, V130, P821, DOI 10.1083/jcb.130.4.821; Wei ML, 1998, J CELL BIOL, V140, P565, DOI 10.1083/jcb.140.3.565; Wilson JM, 1997, J CELL BIOL, V136, P319, DOI 10.1083/jcb.136.2.319; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; ZEN K, 1992, J CELL BIOL, V119, P99, DOI 10.1083/jcb.119.1.99	40	60	60	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19625	19633		10.1074/jbc.273.31.19625	http://dx.doi.org/10.1074/jbc.273.31.19625			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677389	hybrid			2022-12-25	WOS:000075125200041
J	Agati, JM; Yeagley, D; Quinn, PG				Agati, JM; Yeagley, D; Quinn, PG			Assessment of the roles of mitogen-activated protein kinase, phosphatidylinositol 3-kinase, protein kinase B, and protein kinase C in insulin inhibition of cAMP-induced phosphoenolpyruvate carboxykinase gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; BINDING PROTEIN; CYCLIC-AMP; MULTIHORMONAL REGULATION; RECEPTOR SUBSTRATE-1; RAT ADIPOCYTES; INTACT RAT; MAP KINASE; PEPCK GENE; EXPRESSION	Transcription of the phosphoenolpyruvate carboxykinase (PEPCK) gene is induced by glucagon, acting through cAMP and protein kinase A, and this induction is inhibited by insulin. Conflicting reports have suggested that insulin inhibits induction by cAMP by activating the Ras/mitogen-activated protein kinase (MAPK) pathway or by activating the phosphatidylinositol 3-kinase (PI3-kinase), but not MAPK, pathway. Insulin activated PI3-kinase phosphorylates Lipids that activate protein kinase B (PKB) and Ca2+/diacylglycerol-insensitive forms of protein kinase C (PKC). We have assessed the roles of these pathways in insulin inhibition of cAMP/PKA-induced transcription of PEPCK by using dominant negative and dominant active forms of regulatory enzymes in the Ras/MAPK and PKB pathways and chemical inhibitors of PKC isoforms. Three independently acting inhibitory enzymes of the Ras/MAPK pathway, blocking SOS, Ras, and MAPK had no effect upon insulin inhibition. However, dominant active Ras prevented induction of PEPCK and also stimulated transcription mediated by Elk, a MAPK target. Insulin did not stimulate Elk-mediated transcription, indicating that insulin did not functionally activate the Ras/MAPK pathway. Inhibitors of PI3-kinase, LY294002 and wortmannin, abolished insulin inhibition of PEPCK gene transcription. However, inhibitors of PKC and mutated forms of PKB, both of which are known downstream targets of PI3-binase, had no effect upon insulin inhibition. Dominant negative forms of PKB did not interfere with insulin inhibition and a dominant active form of PKB did not prevent induction by PKA. Phorbol eater-mediated inhibition of PEPCK transcription was blocked by bisindole maleimide and by staurosporine, but insulin-mediated inhibition was unaffected. Thus, insulin inhibition of PKA-induced PEPCK expression does not require MAPK activation but does require activation of PI3-binase, although this signal. is not transmitted through the PKB or PKC pathways.	Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Quinn, PG (corresponding author), Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, 500 Univ Dr, Hershey, PA 17033 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049600] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49600] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BELLACOSA A, 1993, ONCOGENE, V8, P745; BOS JL, 1995, TRENDS BIOCHEM SCI, V20, P441, DOI 10.1016/S0968-0004(00)89097-0; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU DTW, 1987, MOL ENDOCRINOL, V1, P53, DOI 10.1210/mend-1-1-53; CHU DTW, 1986, J BIOL CHEM, V261, P6848; Cohen P, 1997, FEBS LETT, V410, P3, DOI 10.1016/S0014-5793(97)00490-0; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; CORBIN JD, 1998, MESSENGER PHOSPHOPRO, V21, P75; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FILLAT C, 1993, FEBS LETT, V318, P287, DOI 10.1016/0014-5793(93)80530-8; FOLLI F, 1992, J BIOL CHEM, V267, P22171; Franke TF, 1997, NATURE, V390, P116, DOI 10.1038/36442; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Gabbay RA, 1996, J BIOL CHEM, V271, P1890, DOI 10.1074/jbc.271.4.1890; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GRANNER D, 1990, J BIOL CHEM, V265, P10173; HADARI YR, 1992, J BIOL CHEM, V267, P17483; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOWARD P, 1991, J BIOL CHEM, V266, P10189; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; MAGNUSON MA, 1987, J BIOL CHEM, V262, P14917; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mendez R, 1997, MOL CELL BIOL, V17, P5184, DOI 10.1128/MCB.17.9.5184; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; OKADA T, 1994, J BIOL CHEM, V269, P3568; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; QUINN PG, 1994, J BIOL CHEM, V269, P14375; QUINN PG, 1990, MOL CELL BIOL, V10, P3357, DOI 10.1128/MCB.10.7.3357; QUINN PG, 1993, J BIOL CHEM, V268, P16999; ROBERSON MS, 1995, MOL CELL BIOL, V15, P3531; ROESLER WJ, 1995, J BIOL CHEM, V270, P8225, DOI 10.1074/jbc.270.14.8225; ROESLER WJ, 1993, J BIOL CHEM, V268, P3791; Roesler WJ, 1996, J BIOL CHEM, V271, P8068, DOI 10.1074/jbc.271.14.8068; RUTTER GA, 1995, CURR BIOL, V5, P890, DOI 10.1016/S0960-9822(95)00179-5; SASAKI K, 1984, J BIOL CHEM, V259, P5242; STANDAERT ML, 1995, BIOCHEM BIOPH RES CO, V209, P1082, DOI 10.1006/bbrc.1995.1608; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Sutherland C, 1997, DIABETES, V46, P17, DOI 10.2337/diabetes.46.1.17; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; Sutherland C, 1998, J BIOL CHEM, V273, P3198, DOI 10.1074/jbc.273.6.3198; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TOKER A, 1994, J BIOL CHEM, V269, P32358; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WHITE MF, 1994, J BIOL CHEM, V269, P1; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; XING LP, 1993, MOL ENDOCRINOL, V7, P1484, DOI 10.1210/me.7.11.1484; Yeagley D, 1998, J BIOL CHEM, V273, P18743, DOI 10.1074/jbc.273.30.18743	65	71	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18751	18759		10.1074/jbc.273.30.18751	http://dx.doi.org/10.1074/jbc.273.30.18751			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668048	hybrid			2022-12-25	WOS:000074974700015
J	Iwamoto, Y; Chin, YE; Peng, XB; Fu, XY				Iwamoto, Y; Chin, YE; Peng, XB; Fu, XY			Identification of a membrane-associated inhibitor(s) of epidermal growth factor-induced signal transducer and activator of transcription activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; DNA-BINDING ACTIVITY; INTERFERON-ALPHA; CYTOKINE RECEPTORS; SH3 DOMAINS; PHOSPHORYLATION; PATHWAY; PROMOTER; FAMILY; STAT3	Many growth factors, including epidermal growth factor (EGF), can activate the signal transducer and activator of transcription (STAT) signaling pathway. Here, we demonstrate that STAT activation by EGF treatment is conditional. EGF activates STAT1 and STAT3 in A431 but not in HeLa and PC12 cells. Using a reconstituted in vitro STAT activation system, we have identified and partially purified a potential inhibitor (s) that is membrane-associated and can block STAT activation induced by EGF in vitro. However, this inhibitor has no effect on STAT complexes after they are formed. We have further shown that this inhibitor(s) also exists in many other cancer cell lines, suggesting that blocking the STAT activation during growth factor signal transduction may play a significant role in the development of many kinds of cancers.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA	Yale University	Fu, XY (corresponding author), Yale Univ, Sch Med, Dept Pathol, 310 Cedar St, New Haven, CT 06520 USA.				NIAID NIH HHS [R01AI34522] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034522] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Chen J, 1997, P NATL ACAD SCI USA, V94, P2295, DOI 10.1073/pnas.94.6.2295; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1992, SCIENCE, V257, P813, DOI 10.1126/science.1496402; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FU XY, 1995, J LEUKOCYTE BIOL, V57, P529, DOI 10.1002/jlb.57.4.529; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Park OK, 1996, P NATL ACAD SCI USA, V93, P13704, DOI 10.1073/pnas.93.24.13704; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WILKS AF, 1994, BIOESSAYS, V16, P313, DOI 10.1002/bies.950160505; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	41	10	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18198	18204		10.1074/jbc.273.29.18198	http://dx.doi.org/10.1074/jbc.273.29.18198			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660781	hybrid			2022-12-25	WOS:000074828500036
J	Lazari, RDM; Bertrand, JE; Nakamura, K; Liu, XB; Krupnick, JG; Benovic, JL; Ascoli, M				Lazari, RDM; Bertrand, JE; Nakamura, K; Liu, XB; Krupnick, JG; Benovic, JL; Ascoli, M			Mutation of individual serine residues in the C-terminal tail of the lutropin/choriogonadotropin receptor reveal distinct structural requirements for agonist-induced uncoupling and agonist-induced internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; LUTROPIN-CHORIOGONADOTROPIN RECEPTOR; LEYDIG TUMOR-CELLS; MEDIATED ENDOCYTOSIS; LUTEINIZING-HORMONE; BETA-ARRESTIN; INDUCED PHOSPHORYLATION; CYTOPLASMIC TAIL; PROTEIN; DESENSITIZATION	We have previously mapped the agonist-induced phosphorylation of the rat lutropin/choriogonadotropin receptor (rLHR) to a locus of four serines (Ser(635), Ser(639), Ser(649), and Ser(652)) located in the C-terminal tail. The removal or mutation of this locus delays the time course of agonist-induced uncoupling of the rLHR from its effector system without affecting the overall magnitude of uncoupling, and it retards the endocytosis of the agonist-receptor complex. We have now prepared and analyzed four new rLHR mutants in which each of these serines were individually mutated to alanines, The data presented show that each mutation reduces agonist-promoted rLHR phosphorylation by 20-40%. Mutation of Ser(635) or Ser(639) delayed the time course of agonist-induced uncoupling to about the same extent as the simultaneous mutation of all four serines. Mutation of Ser(635) or Ser(639) also retarded agonist-induced internalization, but the magnitude of this decrease was less than that induced by the simultaneous mutation of all four serines, Mutation of Ser(649) had no effect on agonist-induced uncoupling but retarded agonist-induced internalization to the same extent as the simultaneous mutation of all four serines. R Mutation of Ser(652) has little or no effect on either of these two parameters. Co-transfection studies with dominant-negative arrestins and dominant-negative dynamin reveal that, despite differences in their rates of internalization, rLHR-wild-type, rLHR-S639A, and rLHR-S649A are internalized by an arrestin- and dynamin-dependent pathway. These data show that the structural requirements needed for the agonist-induced uncoupling and internalization of the rLHR are distinct.	Univ Iowa, Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	University of Iowa; Jefferson University	Ascoli, M (corresponding author), Univ Iowa, Coll Med, Dept Pharmacol, 2-512 BSB, Iowa City, IA 52242 USA.				NATIONAL CANCER INSTITUTE [R01CA040629] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM047417, R01GM047417] Funding Source: NIH RePORTER; NCI NIH HHS [CA-40629] Funding Source: Medline; NIDDK NIH HHS [DK-25295] Funding Source: Medline; NIGMS NIH HHS [GM-47417] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASCOLI M, 1984, J CELL BIOL, V99, P1242, DOI 10.1083/jcb.99.4.1242; ASCOLI M, 1982, J BIOL CHEM, V257, P13306; ASCOLI M, 1987, ENDOCRINOLOGY, V120, P1161, DOI 10.1210/endo-120-3-1161; ASCOLI M, 1978, P NATL ACAD SCI USA, V75, P99, DOI 10.1073/pnas.75.1.99; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Dhanwada KR, 1996, MOL ENDOCRINOL, V10, P544, DOI 10.1210/me.10.5.544; DONOSO LA, 1990, CURR EYE RES, V9, P343, DOI 10.3109/02713689008999622; Fabritz J, 1998, BIOCHEMISTRY-US, V37, P664, DOI 10.1021/bi972355+; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; GHINEA N, 1992, J CELL BIOL, V118, P1347, DOI 10.1083/jcb.118.6.1347; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HIPKIN RW, 1993, MOL ENDOCRINOL, V7, P823, DOI 10.1210/me.7.7.823; HIPKIN RW, 1995, MOL ENDOCRINOL, V9, P151, DOI 10.1210/me.9.2.151; HOELSCHER SR, 1991, ENDOCRINOLOGY, V128, P2837, DOI 10.1210/endo-128-6-2837; Krupnick JG, 1997, J BIOL CHEM, V272, P18125, DOI 10.1074/jbc.272.29.18125; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P14152, DOI 10.1074/jbc.272.22.14152; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; PITCHER J, 1992, BIOCHEMISTRY-US, V31, P3193, DOI 10.1021/bi00127a021; Premont RT, 1996, J BIOL CHEM, V271, P6403, DOI 10.1074/jbc.271.11.6403; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; RODRIGUEZ MC, 1990, ENDOCRINOLOGY, V127, P674, DOI 10.1210/endo-127-2-674; ROSEMBLIT N, 1988, ENDOCRINOLOGY, V123, P2284, DOI 10.1210/endo-123-5-2284; Schlador ML, 1997, J BIOL CHEM, V272, P18882, DOI 10.1074/jbc.272.30.18882; STERNEMARR R, 1993, J BIOL CHEM, V268, P15640; STRICKLAND TW, 1981, ENDOCRINOLOGY, V109, P1933, DOI 10.1210/endo-109-6-1933; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; WANG H, 1991, J BIOL CHEM, V266, P780; Wang Z, 1997, MOL ENDOCRINOL, V11, P183, DOI 10.1210/me.11.2.183; Wang Z, 1996, MOL ENDOCRINOL, V10, P748, DOI 10.1210/me.10.6.748; Warnock Dale E., 1996, Bioessays, V18, P885, DOI 10.1002/bies.950181107; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; Xu J, 1997, NATURE, V389, P505, DOI 10.1038/39068; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	42	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18316	18324		10.1074/jbc.273.29.18316	http://dx.doi.org/10.1074/jbc.273.29.18316			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660797	hybrid			2022-12-25	WOS:000074828500052
J	Rudolph, MG; Bayer, P; Abo, A; Kuhlmann, J; Vetter, IR; Wittinghofer, A				Rudolph, MG; Bayer, P; Abo, A; Kuhlmann, J; Vetter, IR; Wittinghofer, A			The Cdc42/Rac interactive binding region motif of the Wiskott Aldrich syndrome protein (WASP) is necessary but not sufficient for tight binding to Cdc42 and structure formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMR-SPECTROSCOPY; MOLECULAR-CLONING; HUMAN RAF-1; KINASE; RAS; GTPASE; FAMILY; IDENTIFICATION; EFFECTOR; DOMAIN	Wiskott Aldrich syndrome is a rare hereditary disease that affects cell morphology and signal transduction in hematopoietic cells, Different size fragments of the Wiskott Aldrich syndrome protein, W4, W7 and W13, were expressed in Escherichia coli or obtained from proteolysis, ALI contain the GTPase binding domain (GBD), also called Cdc42/Rac interactive binding region (CRIB), found in many putative downstream effecters of Rac and Cdc42. We have developed assays to measure the binding interaction between these fragments and Cdc42 employing fluorescent N-methylanthraniloyl-guanine nucleotide analogues. The fragments bind with submicromolar affinities in a GTP-dependent manner, with the largest fragment having the highest affinity, showing that the GBD/CRIB motif is necessary but not sufficient for tight binding. Rate constants for the interaction with W13 have been determined via surface plasmon resonance, and the equilibrium dissociation constant obtained from their ratio agrees with the value obtained by fluorescence measurements. Far UV circular dichroism spectra show significant secondary structure only for W13, supported by fluorescence studies using intrinsic protein fluorescence and quenching by acrylamide, Proton and N-15 NMR measurements show that the GBD/CRIB motif has no apparent secondary structure and that the region C-terminal to the GBD/ CRIB region is cu-helical, The binding of Cdc42 induces a structural rearrangement of residues in the GBD/CRIB motif, or alternatively, the Wiskott Aldrich syndrome protein fragments have an ensemble of conformations, one of which is stabilized by Cdc42 binding. Thus, in contrast to Ras effecters, which have no conserved sequence elements but a defined domain structure with ubiquitin topology, Rac/Cdc42 effecters have a highly conserved binding region but no defined domain structure in the absence of the GTP-binding protein. Deviating from common belief GBD/CRIB is neither a structural domain nor sufficient for tight binding as regions outside this motif are necessary for structure formation and tight interaction with Rho/Rac proteins.	Max Planck Inst Mol Physiol, Abt Sturkturelle Biol & Phys Biochem, D-44139 Dortmund, Germany; Onyx Pharmaceut, Richmond, CA 94608 USA	Max Planck Society	Wittinghofer, A (corresponding author), Max Planck Inst Mol Physiol, Abt Sturkturelle Biol & Phys Biochem, Rheinlanddamm 201, D-44139 Dortmund, Germany.		Bayer, Peter/B-8803-2009	Bayer, Peter/0000-0003-0435-7202; Rudolph, Markus/0000-0003-0447-1101				Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BIRKS JB, 1970, PHOTOPHYSICS AROMATI, P443; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; EMERSON SD, 1994, BIOCHEMISTRY-US, V33, P7745, DOI 10.1021/bi00191a001; Geyer M, 1997, NAT STRUCT BIOL, V4, P694, DOI 10.1038/nsb0997-694; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Gorman C, 1996, J BIOL CHEM, V271, P6713, DOI 10.1074/jbc.271.12.6713; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; HOLZWARTH G, 1965, J AM CHEM SOC, V87, P218, DOI 10.1021/ja01080a015; Huang L, 1997, NAT STRUCT BIOL, V4, P609, DOI 10.1038/nsb0897-609; JOHN J, 1988, J BIOL CHEM, V263, P11792; Kuhlmann J, 1997, BIOCHEMISTRY-US, V36, P12027, DOI 10.1021/bi970524k; LEONARD DA, 1994, BIOCHEMISTRY-US, V33, P12323, DOI 10.1021/bi00206a040; Leonard DA, 1997, BIOCHEMISTRY-US, V36, P1173, DOI 10.1021/bi9622837; LOUNSBURY KM, 1994, J BIOL CHEM, V269, P11285; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; OSHANNESSY DJ, 1992, ANAL BIOCHEM, V205, P132, DOI 10.1016/0003-2697(92)90589-Y; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; SCHEFFLER JE, 1994, J BIOL CHEM, V269, P22340; Schmid FX., 1989, SPECTRAL METHODS CHA, P251; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; TEO M, 1995, J BIOL CHEM, V270, P26690, DOI 10.1074/jbc.270.44.26690; Tu H, 1997, MOL CELL BIOL, V17, P5876, DOI 10.1128/MCB.17.10.5876; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; VILLA A, 1995, NAT GENET, V9, P414, DOI 10.1038/ng0495-414; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WITTINGHOFER A, 1995, FEBS LETT, V369, P52, DOI 10.1016/0014-5793(95)00667-X; Woody R. W., 1994, CIRCULAR DICHROISM P, P473; Wuthrich K, 1986, NMR PROTEINS NUCL AC, P117; YANG JT, 1986, CALCULATION PROTEIN, P208; Zhang BL, 1997, J BIOL CHEM, V272, P21999, DOI 10.1074/jbc.272.35.21999	46	112	114	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18067	18076		10.1074/jbc.273.29.18067	http://dx.doi.org/10.1074/jbc.273.29.18067			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660763	hybrid			2022-12-25	WOS:000074828500018
J	Brenner, AJ; Stampfer, MR; Aldaz, CM				Brenner, AJ; Stampfer, MR; Aldaz, CM			Increased p16 expression with first senescence arrest in human mammary epithelial cells and extended growth capacity with p16 inactivation	ONCOGENE			English	Article						p16(INK4a); p21(WAF1); immortal; extended life; breast	HUMAN PAPILLOMAVIRUS TYPE-16; HUMAN FIBROBLASTS; BREAST-CANCER; IMMORTALIZATION; CULTURE; METHYLATION; GENE; P16(INK4A); CODELETION; P16/CDKN2	Aberrations affecting the tumor suppressor gene p16(INK4a) have been described for a variety of tumors. In breast cancer, approximately 50% of tumors show low or lack p16 expression. While evidence provided by some studies has implicated a possible role for p16 in normal replicative senescence, other studies have suggested that the Rb, pathway through which p16 functions, may not be involved in senescence control. Previously we observed that all immortal lines derived from normal mammary epithelium which were analysed for p16 displayed inactivation of this gene through distinct mechanisms, supporting p16 inactivation as a possible necessary event in escape from senescence. To further clarify this issue, we have analysed p16 expression in a panel of normal finite lifespan human mammary epithelial cells (HMEC) from initial propagation through growth arrest, using media which confer different replicative capacity. Approximately 10-25-fold increase in pld expression was observed for all normal HMEC with initial onset of a senescence phenotype following 15-25 population doublings in culture. These cells also displayed expression of the senescence associated beta-galactosidase, Interestingly, HMEC with additional long term replicative capacity (approximately 80 population doublings) arose from these growth arrested cultures, showing lack of pld expression. This extended growth capacity appears to be associated with a methylation phenomenon since treatment of these cells with the methylation inhibitor 5-aza-2-deoxycytidine resulted in growth arrest concurrent with reacquisition of p16 expression and senescence associated beta-galactosidase. Analysis of p21waf1 expression revealed no change in expression during growth in vitro. These results support p16(INK4a) as the 9p senescence gene and suggest a role for p16 loss in the escape from initial onset of senescence and in acquisition of an extended life span of human mammary epithelial cells.	Univ Texas, Md Anderson Canc Ctr, Dept Carcinogenesis, Div Res, Smithville, TX 78957 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA	University of Texas System; UTMD Anderson Cancer Center; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Aldaz, CM (corresponding author), Univ Texas, Md Anderson Canc Ctr, Dept Carcinogenesis, Div Res, Smithville, TX 78957 USA.		Aldaz, C. Marcelo/E-7868-2011	Aldaz, C. Marcelo/0000-0002-2453-2939	NCI NIH HHS [CA-24844] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA024844, R01CA024844] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; BARRETT JC, 1994, COLD SPRING HARB SYM, V59, P411, DOI 10.1101/SQB.1994.059.01.046; BRENNER AJ, 1995, CANCER RES, V55, P2892; Brenner AJ, 1996, CLIN CANCER RES, V2, P1993; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DREYLING MH, 1995, CANCER RES, V55, P984; Foster SA, 1996, ONCOGENE, V12, P1773; GERADTS J, 1995, CANCER RES, V55, P6006; Gollahon LS, 1996, ONCOGENE, V12, P715; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435; HERMAN JG, 1995, CANCER RES, V55, P4525; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAY JW, 1995, MOL CELL BIOL, V15, P425, DOI 10.1128/MCB.15.1.425; SHAY JW, 1993, ONCOGENE, V8, P1407; SHAY JW, 1993, BREAST CANCER RES TR, V25, P83, DOI 10.1007/BF00662404; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; STAMPFER M, 1980, IN VITRO CELL DEV B, V16, P415; STAMPFER M, 1994, CANC SURVEYS, V18, P7; Stampfer M, 1985, J TISSUE CULTURE MET, V9, P107; STAMPFER MR, 1982, IN VITRO CELL DEV B, V18, P531; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; XIAO S, 1995, ONCOGENE, V11, P511; XIAO S, 1995, CANCER RES, V55, P2968; YANG LQ, 1995, EXP CELL RES, V221, P126, DOI 10.1006/excr.1995.1359	30	218	224	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 16	1998	17	2					199	205		10.1038/sj.onc.1201919	http://dx.doi.org/10.1038/sj.onc.1201919			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZZ211	9674704				2022-12-25	WOS:000074706700008
J	Chen, ME; Lin, SH; Chung, LWK; Sikes, RA				Chen, ME; Lin, SH; Chung, LWK; Sikes, RA			Isolation and characterization of PAGE-1 and GAGE-7 - New genes expressed in the LNCaP prostate cancer progression model that share homology with melanoma-associated antigens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOLYTIC T-LYMPHOCYTES; SYNTHETIC PEPTIDE; MESSENGER-RNA; TUMOR-CELLS; MAGE GENES; DIFFERENTIAL DISPLAY; EPITHELIAL-CELLS; BONE FIBROBLASTS; GROWTH-INVIVO; FAMILY	The LNCaP progression model of human prostate cancer consists of lineage-related sublines that differ in their androgen sensitivity and metastatic potential. A differential display polymerase chain reaction was employed to evaluate mRNA expression differences between the LNCaP sublines in order to define the differences in gene expression between the androgen-sensitive, nontumorigenic LNCaP cell line and the androgen-insensitive, metastatic LNCaP sublines, C4-2 and C4-2B. An amplicon, BG16.21, was isolated that showed increased expression in the androgen-independent and metastatic LNCaP sublines, C4-2 and C4-2B. Hybridization screening of a lambda gt11 expression library with BG16.21 revealed two transcripts, both homologous to BG16.21 at the 3' end, A GenBank(TM) data base search using the GCG Wisconsin software package revealed the shorter similar to 600-bp transcript (designated GAGE-7) to be a new member of the GAGE family, The second similar to 700-bp transcript was a novel gene (designated PAGE-1, "prostate associated gene") with only 45% homology to GAGE gene family members. RNA blot analysis demonstrated that GAGE-7 mRNA was expressed at equal levels in all lineage related prostate cancer cell sublines, while PAGE-1 mRNA levels were elevated 5-fold in C4-2 and C4-2B as compared with LNCaP cells, Neither GAGE-7 nor PAGE-1 demonstrated any regulation by androgens in the prostate cancer cell lines used in this study. PAGE-1 and GAGE-7 expression was found to be restricted to testes (high) and placenta (low) on human multiple tissue Northern blots. As GAGE/MAGE antigens were reported preciously to be targets for tumor-specific cytotoxic lymphocytes in melanoma, these results suggest that PAGE-1 and GAGE-7 may be related to prostate cancer progression and may serve as potential targets for novel therapies.	Univ Virginia, Hlth Sci Ctr, Dept Urol, Mol Urol & Therapeut Program, Charlottesville, VA 22908 USA; Univ Texas, MD Anderson Cancer Ctr, Houston, TX 77030 USA	University of Virginia; University of Texas System; UTMD Anderson Cancer Center	Sikes, RA (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Urol, Mol Urol & Therapeut Program, Box 422, Charlottesville, VA 22908 USA.				NCI NIH HHS [CA64863, CA-16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064863, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMARCOSTESEC A, 1994, BIOCHEM BIOPH RES CO, V204, P710, DOI 10.1006/bbrc.1994.2517; AUSUBEL FM, 1994, PREPARING DNA SMALL, V1; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BAUER D, 1993, NUCLEIC ACIDS RES, V21, P4272, DOI 10.1093/nar/21.18.4272; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; BRASSEUR F, 1992, INT J CANCER, V52, P839, DOI 10.1002/ijc.2910520528; CELIS E, 1994, P NATL ACAD SCI USA, V91, P2105, DOI 10.1073/pnas.91.6.2105; CHANG SM, 1989, ENDOCRINOLOGY, V125, P2719, DOI 10.1210/endo-125-5-2719; CHEN Q, 1994, CANC IMMUNOL IMMUNOL, V34, P385; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG LWK, 1989, INT J CANCER, V43, P1179, DOI 10.1002/ijc.2910430636; DEPLAEN E, 1994, IMMUNOGENETICS, V40, P360, DOI 10.1007/BF01246677; DePlaen E, 1997, GENOMICS, V40, P305, DOI 10.1006/geno.1996.4566; DeSmet C, 1996, P NATL ACAD SCI USA, V93, P7149, DOI 10.1073/pnas.93.14.7149; DING M, 1994, BIOCHEM BIOPH RES CO, V202, P549, DOI 10.1006/bbrc.1994.1963; GAUGLER B, 1994, J EXP MED, V179, P921, DOI 10.1084/jem.179.3.921; GLEAVE M, 1991, CANCER RES, V51, P3753; GLEAVE ME, 1992, J UROLOGY, V147, P1151, DOI 10.1016/S0022-5347(17)37506-7; Harlow E., 1988, ANTIBODIES LAB MANUA; HOON DSB, 1995, J IMMUNOL, V154, P730; Huggins C, 1941, CANCER RES, V1, P293; HUGGINS C, 1946, JAMA-J AM MED ASSOC, V131, P576, DOI 10.1001/jama.1946.02870240008003; INOUE H, 1995, INT J CANCER, V64, P76, DOI 10.1002/ijc.2910640115; KOCHER T, 1995, CANCER RES, V55, P2236; KURPISZ M, 1988, J IMMUNOL METHODS, V115, P195, DOI 10.1016/0022-1759(88)90288-8; Li J, 1996, CLIN CANCER RES, V2, P1619; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; MAHANA W, 1993, J IMMUNOL METHODS, V161, P187, DOI 10.1016/0022-1759(93)90294-H; MUSCATELLI F, 1995, P NATL ACAD SCI USA, V92, P4987, DOI 10.1073/pnas.92.11.4987; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; PATARD JJ, 1995, INT J CANCER, V64, P60, DOI 10.1002/ijc.2910640112; RIMOLDI D, 1993, INT J CANCER, V54, P527, DOI 10.1002/ijc.2910540329; RUSSO V, 1995, INT J CANCER, V64, P216, DOI 10.1002/ijc.2910640313; SALGALLER ML, 1994, CANCER IMMUNOL IMMUN, V39, P105, DOI 10.1007/s002620050101; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schook LB, 1987, MONOCLONAL ANTIBODY; Serrano A, 1996, INT J CANCER, V68, P464, DOI 10.1002/(SICI)1097-0215(19961115)68:4<464::AID-IJC11>3.0.CO;2-5; SHICHIO S, 1995, INT J CANCER, V64, P158, DOI 10.1002/ijc.2910640303; SIKES RA, 1992, CANCER RES, V52, P3174; TAKAHASHI K, 1995, CANCER RES, V55, P3478; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; THALMANN GN, 1994, CANCER RES, V54, P2577; VALABHJI A, 1996, FUTURE ONCOLOGY, V2, P282; VANDENEYNDE B, 1995, J EXP MED, V182, P689, DOI 10.1084/jem.182.3.689; VANDERBRUGGEN P, 1994, EUR J IMMUNOL, V24, P3038, DOI 10.1002/eji.1830241218; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; WEBER J, 1994, CANCER RES, V54, P1766; WEYNANTS P, 1994, INT J CANCER, V56, P826, DOI 10.1002/ijc.2910560612; WU HC, 1994, INT J CANCER, V57, P406, DOI 10.1002/ijc.2910570319; YAMASAKI S, 1995, CANCER IMMUNOL IMMUN, V40, P268; ZAKUT R, 1993, CANCER RES, V53, P5	52	69	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17618	17625		10.1074/jbc.273.28.17618	http://dx.doi.org/10.1074/jbc.273.28.17618			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651357	hybrid			2022-12-25	WOS:000074816100050
J	Fisher, M; Zamir, A; Pick, U				Fisher, M; Zamir, A; Pick, U			Iron uptake by the halotolerant alga Dunaliella is mediated by a plasma membrane transferrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHYTOPLANKTON; BINDING; MECHANISM; RELEASE; SALINA; SITES; SALT	A 150-kDa transferrin-like protein (Ttf) is associated with the plasma membrane of the halotolerant unicellular alga Dunaliella salina (Fisher, M., Gokhman, I., pick, U., and Zamir, A. (1997) J. Biol. Chem. 272, 1565-1570), The Ttf level rises with medium salinity or upon iron depletion. Evidence that Ttf is involved in iron uptake by Dunaliella is presented here. Algal iron uptake exhibits characteristics resembling those of animal transferrins: high specificity and affinity for Fe3+ ions, strict dependence on carbonate/bicarbonate ions, and very low activity in acidic pH. Reducing the level of Ttf by mild proteolysis of whole cells is accompanied by lowered uptake activity. Conversely, accumulation of high levels of Ttf is correlated with an enhancement of iron uptake. Kinetically, iron uptake consists of two steps: an energy-independent binding of iron to the cell surface and an energy-dependent internalization. Salinities as high as 3.5 M NaCl do not inhibit iron uptake or decrease the apparent affinity for Fe3+ ions, implying that Ttf activity is not affected by high salt, These results indicate that transferrins, hitherto identified only in animals, are present and function in iron transport also in plant systems.	Weizmann Inst Sci, Dept Biol Chem, IL-71600 Rehovot, Israel	Weizmann Institute of Science	Pick, U (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-71600 Rehovot, Israel.							AZARI P, 1970, ARCH BIOCHEM BIOPHYS, V138, P32, DOI 10.1016/0003-9861(70)90280-8; CHASTEEN ND, 1981, BIOCHEM J, V193, P717, DOI 10.1042/bj1930717; CHASTEEN ND, 1983, ADV INORG BIOCHEM, V5, P210; EGAN TJ, 1992, INORG CHEM, V31, P1994, DOI 10.1021/ic00037a005; Fisher M, 1996, J BIOL CHEM, V271, P17718, DOI 10.1074/jbc.271.30.17718; Fisher M, 1997, J BIOL CHEM, V272, P1565, DOI 10.1074/jbc.272.3.1565; HUDSON RJM, 1990, LIMNOL OCEANOGR, V35, P1002, DOI 10.4319/lo.1990.35.5.1002; KENNARD ML, 1995, EMBO J, V14, P4178, DOI 10.1002/j.1460-2075.1995.tb00091.x; KOLBER ZS, 1994, NATURE, V371, P145, DOI 10.1038/371145a0; MARTIN JH, 1988, NATURE, V331, P341, DOI 10.1038/331341a0; MARTIN RB, 1986, J INORG BIOCHEM, V28, P181, DOI 10.1016/0162-0134(86)80081-2; SADKA A, 1991, PLANT PHYSIOL, V95, P822, DOI 10.1104/pp.95.3.822; SCHLABACH MR, 1975, J BIOL CHEM, V250, P2182; WELCH S, 1992, TRANSFERRIN IRON CAR; ZAK O, 1995, BIOCHEMISTRY-US, V34, P14428, DOI 10.1021/bi00044a020	15	64	72	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17553	17558		10.1074/jbc.273.28.17553	http://dx.doi.org/10.1074/jbc.273.28.17553			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651348	hybrid			2022-12-25	WOS:000074816100041
J	Wu, JJ; Eyre, DR				Wu, JJ; Eyre, DR			Matrilin-3 forms disulfide-linked oligomers with matrilin-1 in bovine epiphyseal cartilage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX PROTEIN; CROSS-LINKING; COILED COILS; COLLAGEN; EXPRESSION; MATURATION; SITES; GENE	A comparison of noncollagenous matrix proteins from different types of bovine cartilage by SDS polyacrylamide gel electrophoresis showed a prominent 240-kDa component in extracts of epiphyseal but not tracheal tissue. On amino-terminal sequence analysis, it gave two sequences. One matched the NH2 terminus of cartilage matrix protein (CMP) as reported for tracheal cartilage. The other did not match any known protein sequence. Further analysis of the 240-kDa protein after reduction of disulfides resolved two bands on SDS-polyacrylamide gel electrophoresis, Isolation and sequence analysis of tryptic peptides confirmed that one was bovine GRIP and the other a CMP homolog. A data base search identified the latter as matrilin-3, a molecule recently predicted from human and mouse cDNA sequences (Wagener, R,, Kobbe, B., and Paulsson, M. (1997) FEBS Lett. 413, 129-134). Matrilin-3 and GRIP (matrilin-1) were prominent in equimolar amounts in fetal bovine epiphyseal cartilage and absent from adult articular cartilage. Adult tracheal cartilage contained almost exclusively CMP. Although the mechanism of polymeric assembly is unknown, the matrilin-3 chain appears to function in the matrix linked to matrilin-1 in the form of disulfide-bonded heteromeric molecules. The results indicate a molecular stoichiometry of (matrilin-1)(2)(matrilin-3)(2).	Univ Washington, Dept Orthopaed, Orthopaed Res Labs, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Wu, JJ (corresponding author), Univ Washington, Dept Orthopaed, Orthopaed Res Labs, Box 356500, Seattle, WA 98195 USA.	wujj@u.washington.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036794, R37AR037318, R01AR037318, R37AR036794] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR37318, R37 AR037318, R01 AR036794, AR36794] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Beck K, 1996, J MOL BIOL, V256, P909, DOI 10.1006/jmbi.1996.0137; Beck K, 1997, EMBO J, V16, P3767, DOI 10.1093/emboj/16.13.3767; Belluoccio D, 1997, FEBS LETT, V415, P212, DOI 10.1016/S0014-5793(97)01126-5; CHEN Q, 1995, DEV BIOL, V172, P293, DOI 10.1006/dbio.1995.0024; CHEN Q, 1995, MOL BIOL CELL, V6, P1743, DOI 10.1091/mbc.6.12.1743; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; Deak F, 1997, J BIOL CHEM, V272, P9268; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HAUDENSCHILD DR, 1995, J BIOL CHEM, V270, P23150, DOI 10.1074/jbc.270.39.23150; Hauser N, 1996, J BIOL CHEM, V271, P32247, DOI 10.1074/jbc.271.50.32247; Hodges RS, 1996, BIOCHEM CELL BIOL, V74, P133, DOI 10.1139/o96-015; JENKINS RN, 1990, J BIOL CHEM, V265, P19624; KISS I, 1989, J BIOL CHEM, V264, P8126; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATAGNE A, 1991, BIOCHEM J, V280, P553, DOI 10.1042/bj2800553; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MUNDLOS S, 1994, DEV DYNAM, V199, P241, DOI 10.1002/aja.1001990308; NIYIBIZI C, 1987, T ORTHOP RES SOC, V12, P111; PAULSSON M, 1982, BIOCHEM J, V207, P207, DOI 10.1042/bj2070207; PAULSSON M, 1984, BIOCHEM J, V221, P623, DOI 10.1042/bj2210623; PAULSSON M, 1981, BIOCHEM J, V197, P367, DOI 10.1042/bj1970367; ROSENBERG L, 1991, J BIOL CHEM, V266, P7016; TONDRAVI MM, 1993, PROG CLIN BIOL RES, V383, P515; Wagener R, 1997, FEBS LETT, V413, P129, DOI 10.1016/S0014-5793(97)00895-8; WINTERBOTTOM N, 1992, DEV DYNAM, V193, P266, DOI 10.1002/aja.1001930307; WU JJ, 1992, J BIOL CHEM, V267, P23007; WU JJ, 1987, BIOCHEM J, V248, P373, DOI 10.1042/bj2480373; Zeineldin R, 1997, BIOCHEM J, V328, P665, DOI 10.1042/bj3280665	28	55	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17433	17438		10.1074/jbc.273.28.17433	http://dx.doi.org/10.1074/jbc.273.28.17433			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651330	hybrid			2022-12-25	WOS:000074816100023
J	Barbieri, MA; Kohn, AD; Roth, RA; Stahl, PD				Barbieri, MA; Kohn, AD; Roth, RA; Stahl, PD			Protein kinase B/akt and Rab5 mediate ras activation of endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL GTPASE RAB5; PHOSPHATIDYLINOSITOL 3-KINASE; MOLECULAR-CLONING; ENDOSOME FUSION; SER/THR KINASE; AKT; INHIBITION	Transient expression of oncogenic Ha-Ras (Ras:V12) stimulates endocytosis. Using NIH3T3 cells expressing constitutively active protein kinase B/akt (PKB/akt) or kinase-dead PKB/akt, we show that PKB/akt mediates the stimulatory effect of Ras on endocytosis. Fluid phase endocytosis of horseradish peroxidase in cells expressing the constitutively active form of PKB/akt was elevated and insensitive to phosphatidylinositol 3-kinase inhibitors. However, expression of dominant negative Rab5:N34 blocked endocytosis in cells expressing the constitutively active form of PKB/akt. Transient expression of either Rab5:wt or Rab5:L79, a GTPase deficient mutant of Rab5, in cells expressing constitutively activated PKB/akt further increased endocytic rate. However, in cells expressing kinase-dead PKB/akt, endocytic rate was not affected by transient expression of Rab5:wt, Rab5:L79, on the other hand, increased endocytosis in cells expressing kinase-dead PKB/akt. Similar results were obtained using an in vitro endosome fusion reconstitution assay with cytosol prepared from cells expressing the activated PKB/akt or kinase-dead PKB/akt. Both Rab5:wt and Rab5:L79 stimulated endosome fusion when assayed in cytosol containing the activated PKB/akt, whereas only Rab5:L79 activated fusion when the assay utilized cytosol from kinase-dead expressing cells. We conclude that Ras activation of endocytosis requires both PKB/akt and Rab5 and that active kinase is required for activation Rab5.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Stanford Univ, Sch Med, Dept Mol Pharmacol, Palo Alto, CA 94305 USA	Washington University (WUSTL); Stanford University	Stahl, PD (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA.	pstahl@cellbio.wustl.edu	Stahl, Philip/D-6315-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034926, P30DK020579, P60DK020579, R01DK034926] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042259] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK20579, DK34926] Funding Source: Medline; NIGMS NIH HHS [GM42259] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; BARBIERI MA, 1994, J BIOL CHEM, V269, P18720; Barbieri MA, 1996, ARCH BIOCHEM BIOPHYS, V326, P64, DOI 10.1006/abbi.1996.0047; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DATTA K, 1995, MOL CELL BIOL, V15, P2304; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DIAZ R, 1988, J BIOL CHEM, V263, P6093; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Jones AT, 1998, MOL BIOL CELL, V9, P323, DOI 10.1091/mbc.9.2.323; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; LI GP, 1994, J BIOL CHEM, V269, P14631; LI GP, 1993, J BIOL CHEM, V268, P24475; Li GP, 1997, J BIOL CHEM, V272, P10337; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Seabra MC, 1996, J BIOL CHEM, V271, P14398, DOI 10.1074/jbc.271.24.14398; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; TOKER A, 1994, J BIOL CHEM, V269, P32358	31	68	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19367	19370		10.1074/jbc.273.31.19367	http://dx.doi.org/10.1074/jbc.273.31.19367			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677351	hybrid			2022-12-25	WOS:000075125200003
J	Lelievre, V; Pineau, N; Du, J; Wen, CH; Nguyen, T; Janet, T; Muller, JM; Waschek, JA				Lelievre, V; Pineau, N; Du, J; Wen, CH; Nguyen, T; Janet, T; Muller, JM; Waschek, JA			Differential effects of peptide histidine isoleucine (PHI) and related peptides on stimulation and suppression of neuroblastoma cell proliferation - A novel VIP-independent action of PHI via map kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLASE-ACTIVATING POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE; 38-AMINO ACID FORM; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; PACAP RECEPTOR; FUNCTIONAL EXPRESSION; SELECTIVE INHIBITOR; MOLECULAR-CLONING; NEURITE OUTGROWTH	The growth rate of rodent embryonic neuroblasts and human neuroblastoma cell lines is regulated in part by autocrine or paracrine actions of neuropeptides of the family that includes vasoactive intestinal peptide (VIP), peptide histidine isoleucine (PHI), and pituitary adenylate cyclase-activating peptide (PACAP). These peptides act via seven transmembrane G-protein-linked receptors coupled to cAMP elevation, phospholipase C activation, intracellular Ca2+ release, and/or of mitogen-activated protein (MAP) kinase activation. Here we investigated the action of these peptides on the mouse neuroblastoma cell line Neuro2a PHI and VIP inhibited proliferation at concentrations as low as 10(-13) ns and 10(-10) M, respectively. In contrast, PACAP action was biphasic, with stimulation occurring at subnanomolar doses and inhibition at higher doses. Peptide actions were studied further by measuring cAMP and ERK1/2 MAP kinase activity and by assessing H-3-thymidine in corporation in conjunction with a panel of signal transduction pathways inhibitors. The data obtained indicated that the PHI-inhibitory and PACAP-stimulatory activities were mediated by corresponding changes in activity of the MAP kinase pathway and independent of protein kinase A (PRA) or protein kinase C (PKC). In contrast, the inhibitory actions of VIP and PACAP were specifically blocked by antagonists of PKA Northern blot analysis revealed gene expression for only the PACAP-preferring (PAC(1)) receptor. However, binding experiments using I-125-labeled PACAP27, PHI, and VIP, demonstrated the presence of PACAP-preferring sites, bivalent VIP/PACAP sites, and PHI-binding sites that did not interact with VIP. The studies demonstrate potent regulatory actions of PACAP, PHI, and VIP on neuroblastoma cell proliferation which al,pear to be mediated by multiple subsets of receptors which differentially couple to MAP kinase and PKA signaling pathways.	Univ Calif Los Angeles, Inst Neuropsychiat, Mental Retardat Res Ctr, Dept Psychiat, Los Angeles, CA 90024 USA; Univ Poitiers, UFR Sci, Lab Biol Interact Cellulaires, CNRS UMR 6558, F-86022 Poitiers, France	University of California System; University of California Los Angeles; Centre National de la Recherche Scientifique (CNRS); Universite de Poitiers	Waschek, JA (corresponding author), Univ Calif Los Angeles, Inst Neuropsychiat, Mental Retardat Res Ctr, Dept Psychiat, 68-225 NPI,760 Westwood Plaza, Los Angeles, CA 90024 USA.	jwaschek@mednet.ucla.edu		Muller, Jean-Marc/0000-0001-6009-7471; Lelievre, Vincent/0000-0003-4150-8233	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD004612] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD034475, P01HD006576] Funding Source: NIH RePORTER; NICHD NIH HHS [HD06576, HD04612, HD34475] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ALEXANDER LD, 1995, NEUROPEPTIDES, V28, P167, DOI 10.1016/0143-4179(95)90112-4; Barrie AP, 1997, J BIOL CHEM, V272, P19666, DOI 10.1074/jbc.272.32.19666; Chatterjee TK, 1996, J BIOL CHEM, V271, P32226, DOI 10.1074/jbc.271.50.32226; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CHISTOPHE J, 1993, BBRC, V1154, P183; DEUTSCH PJ, 1993, J NEUROSCI RES, V35, P312, DOI 10.1002/jnr.490350311; DEUTSCH PJ, 1992, J BIOL CHEM, V267, P5108; HANNIBAL J, 1995, REGUL PEPTIDES, V55, P133, DOI 10.1016/0167-0115(94)00099-J; HARMAR AJ, 1998, IN PRESS PHARM REV; HOSHINO M, 1993, NEUROSCI LETT, V159, P35, DOI 10.1016/0304-3940(93)90792-J; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; ITOH N, 1983, NATURE, V304, P547, DOI 10.1038/304547a0; Jin JG, 1997, GASTROENTEROLOGY, V112, pA1159; JOURNOT L, 1995, BIOCHEM SOC T, V23, P133, DOI 10.1042/bst0230133; KOH SWM, 1991, BIOCHEM BIOPH RES CO, V174, P452, DOI 10.1016/0006-291X(91)91437-H; Lelievre V, 1996, NEUROPEPTIDES, V30, P313, DOI 10.1016/S0143-4179(96)90019-0; LUTZ EM, 1993, FEBS LETT, V334, P3, DOI 10.1016/0014-5793(93)81668-P; MULLER JM, 1989, J BIOL CHEM, V264, P3647; MULLER JM, 1995, MOL NEUROBIOL, V10, P115, DOI 10.1007/BF02740671; MURTHY KS, 1993, AM J PHYSIOL, V265, pG660, DOI 10.1152/ajpgi.1993.265.4.G660; ODORISIO MS, 1992, REGUL PEPTIDES, V37, P213; OHKUBO S, 1992, DNA CELL BIOL, V11, P21, DOI 10.1089/dna.1992.11.21; Pantaloni C, 1996, J BIOL CHEM, V271, P22146, DOI 10.1074/jbc.271.36.22146; PAUL S, 1987, LIFE SCI, V41, P2373, DOI 10.1016/0024-3205(87)90661-8; PENCE JC, 1993, ARCH SURG-CHICAGO, V128, P591; PISEGNA JR, 1993, P NATL ACAD SCI USA, V90, P6345, DOI 10.1073/pnas.90.13.6345; Prins BA, 1996, J BIOL CHEM, V271, P14156, DOI 10.1074/jbc.271.24.14156; Rawlings SR, 1996, ENDOCR REV, V17, P4, DOI 10.1210/er.17.1.4; SAID SI, 1991, TRENDS ENDOCRIN MET, V2, P107, DOI 10.1016/S1043-2760(05)80006-2; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; Straub SG, 1996, J BIOL CHEM, V271, P1660, DOI 10.1074/jbc.271.3.1660; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Vertongen P, 1996, NEUROPEPTIDES, V30, P491, DOI 10.1016/S0143-4179(96)90015-3; Vertongen P, 1996, J CELL PHYSIOL, V167, P36, DOI 10.1002/(SICI)1097-4652(199604)167:1<36::AID-JCP4>3.0.CO;2-D; Villalba M, 1997, J NEUROSCI, V17, P83, DOI 10.1523/JNEUROSCI.17-01-00083.1997; WASCHEK JA, 1995, CANCER LETT, V92, P143, DOI 10.1016/0304-3835(95)03768-R; Waschek JA, 1997, PEPTIDES, V18, P835, DOI 10.1016/S0196-9781(97)00015-6; WOLLMAN Y, 1993, BRAIN RES, V624, P339, DOI 10.1016/0006-8993(93)90100-2; Wray V, 1995, Biomed Pept Proteins Nucleic Acids, V1, P77; YAMAGUCHI K, 1992, BIOMED RES-TOKYO, V13, P279; YU D, ENDOCRINOLOGY, V131, P1188	42	71	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19685	19690		10.1074/jbc.273.31.19685	http://dx.doi.org/10.1074/jbc.273.31.19685			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677397	hybrid			2022-12-25	WOS:000075125200049
J	Tamori, Y; Kawanishi, M; Niki, T; Shinoda, H; Araki, S; Okazawa, H; Kasuga, M				Tamori, Y; Kawanishi, M; Niki, T; Shinoda, H; Araki, S; Okazawa, H; Kasuga, M			Inhibition of insulin-induced GLUT4 translocation by Munc18c through interaction with syntaxin4 in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE DOCKING; UNC-18 GENE ENCODES; RAT ADIPOSE CELL; GLUCOSE-TRANSPORT; GOLGI TRANSPORT; RECOMBINANT ADENOVIRUS; ENDOPLASMIC-RETICULUM; PLASMA-MEMBRANE; MAMMALIAN-CELLS; BINDING PROTEIN	Insulin induces the translocation of vesicles containing the glucose transporter GLUT4 from an intracellular compartment to the plasma membrane in adipocytes. SNARE proteins have been implicated in the docking and fusion of these vesicles with the cell membrane. The role of Munc18c, previously identified as an n-Sec1/Munc18 homolog in 3T3-L1 adipocytes, in insulin-regulated GLUT4 trafficking has now been investigated in 3T3-L1 adipocytes. In these cells, Munc18c was predominantly associated with syntaxin4, although it bound both syntaxin2 and syntaxin4 to similar extents in vitro. In addition, SNAP-23, an adipocyte homolog of SNAP-25, associated with both syntaxins 2 and 4 in 3T3-L1 adipocytes. Overexpression of Munc18c in 3T3-L1 adipocytes by adenovirus-mediated gene transfer resulted in inhibition of insulin-stimulated glucose transport in a virus dose-dependent manner (maximal effect, similar to 50%) as well as in inhibition of sorbitol-induced glucose transport (by similar to 35%), which is mediated by a pathway different from that used by insulin. In contrast, Munc18b, which is also expressed in adipocytes but which did not bind to syntaxin4, had no effect on glucose transport. Furthermore, overexpression of Munc18c resulted in inhibition of insulin-induced translocation of GLUT4, but not of that of GLUT1, to the plasma membrane. These results suggest that Munc18c is involved in the insulin-dependent trafficking of GLUT4 from the intracellular storage compartment to the plasma membrane in 3T3-L1 adipocytes by modulating the formation of a SNARE complex that includes syntaxin4.	Kobe Univ, Sch Med, Dept Internal Med 2, Chuo Ku, Kobe, Hyogo 650, Japan	Kobe University	Tamori, Y (corresponding author), Kobe Univ, Sch Med, Dept Internal Med 2, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 650, Japan.	gt@med.kobe-u.ac.jp	Okazawa, Hideki/C-3836-2011; Shinoda, Hiroyuki/Q-3230-2019; Okazawa, Hideki/E-3055-2010					AALTO MK, 1991, YEAST, V7, P643, DOI 10.1002/yea.320070613; Araki S, 1997, BIOCHEM BIOPH RES CO, V234, P257, DOI 10.1006/bbrc.1997.6560; CAIN CC, 1992, J BIOL CHEM, V267, P11681; Cheatham B, 1996, P NATL ACAD SCI USA, V93, P15169, DOI 10.1073/pnas.93.26.15169; Chen D, 1997, J BIOL CHEM, V272, P27401, DOI 10.1074/jbc.272.43.27401; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; COWLES CR, 1994, J CELL SCI, V107, P3449; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DASCHER C, 1994, J BIOL CHEM, V269, P29363; FROST SC, 1985, J BIOL CHEM, V260, P2646; Fujita Y, 1996, J BIOL CHEM, V271, P7265, DOI 10.1074/jbc.271.13.7265; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; GENGYOANDO K, 1993, NEURON, V11, P703, DOI 10.1016/0896-6273(93)90080-B; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HASHIRAMOTO M, 1992, J BIOL CHEM, V267, P17502; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; Holman GD, 1997, DIABETOLOGIA, V40, P991, DOI 10.1007/s001250050780; HOSONO R, 1992, J NEUROCHEM, V58, P1517, DOI 10.1111/j.1471-4159.1992.tb11373.x; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; KANEGAE Y, 1994, JPN J MED SCI BIOL, V47, P157, DOI 10.7883/yoken1952.47.157; KATAGIRI H, 1995, J BIOL CHEM, V270, P4963, DOI 10.1074/jbc.270.10.4963; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; Lee W, 1997, J BIOL CHEM, V272, P21427, DOI 10.1074/jbc.272.34.21427; Livingstone C, 1996, BIOCHEM J, V315, P487, DOI 10.1042/bj3150487; Macaulay SL, 1997, BIOCHEM J, V324, P217, DOI 10.1042/bj3240217; Macaulay SL, 1997, BIOCHEM BIOPH RES CO, V237, P388, DOI 10.1006/bbrc.1997.7143; Martin S, 1997, J CELL SCI, V110, P2281; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; Olson AL, 1997, MOL CELL BIOL, V17, P2425, DOI 10.1128/MCB.17.5.2425; ORITA S, 1995, BIOCHEM BIOPH RES CO, V206, P439, DOI 10.1006/bbrc.1995.1062; OSSIG R, 1991, MOL CELL BIOL, V11, P2980, DOI 10.1128/MCB.11.6.2980; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; PIPER RC, 1994, EUR J CELL BIOL, V65, P305; PIPER RC, 1991, AM J PHYSIOL, V260, P570; ROBINSON LJ, 1992, AM J PHYSIOL, V263, P383; Sakaue H, 1997, MOL ENDOCRINOL, V11, P1552, DOI 10.1210/me.11.10.1552; SALZBERG A, 1993, DEVELOPMENT, V117, P1309; SCHULZE KL, 1994, NEURON, V13, P1099, DOI 10.1016/0896-6273(94)90048-5; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Tamori Y, 1996, BIOCHEM BIOPH RES CO, V220, P740, DOI 10.1006/bbrc.1996.0474; Tellam JT, 1997, J BIOL CHEM, V272, P6179, DOI 10.1074/jbc.272.10.6179; TELLAM JT, 1995, J BIOL CHEM, V270, P5857, DOI 10.1074/jbc.270.11.5857; Timmers KI, 1996, BIOCHEM J, V320, P429, DOI 10.1042/bj3200429; Verhage M, 1997, NEURON, V18, P453, DOI 10.1016/S0896-6273(00)81245-3; VOLCHUK A, 1995, J BIOL CHEM, V270, P8233, DOI 10.1074/jbc.270.14.8233; WADA Y, 1990, MOL CELL BIOL, V10, P2214, DOI 10.1128/MCB.10.5.2214; Waters SB, 1997, J BIOL CHEM, V272, P23323, DOI 10.1074/jbc.272.37.23323; WHITE MF, 1994, J BIOL CHEM, V269, P1; Wu MN, 1998, EMBO J, V17, P127, DOI 10.1093/emboj/17.1.127; YANG J, 1993, J BIOL CHEM, V268, P4600	60	128	129	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19740	19746		10.1074/jbc.273.31.19740	http://dx.doi.org/10.1074/jbc.273.31.19740			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677404	hybrid			2022-12-25	WOS:000075125200056
J	Shuba, YM; Iwata, T; Naidenov, VG; Oz, M; Sandberg, K; Kraev, A; Carafoli, E; Morad, M				Shuba, YM; Iwata, T; Naidenov, VG; Oz, M; Sandberg, K; Kraev, A; Carafoli, E; Morad, M			A novel molecular determinant for cAMP-dependent regulation of the frog heart Na+-Ca2+ exchanger	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGER; FUNCTIONAL EXPRESSION; XENOPUS OOCYTES; ATP-BINDING; HELA-CELLS; CLONING; ISOFORMS; CONTRACTION; VENTRICLE; MUSCLE	Na+-Ca2+ exchanger is one of the major sarcolemmal Ca2+ transporters of cardiac myocytes, In frog ventricular myocytes the exchanger is regulated by isoproterenol via a beta-adrenoreceptor/adenylate-cyclase/cAMP-dependent signaling pathway providing a molecular mechanism for the relaxant effect of the hormone. Here, we report on the presence of a novel exon of 27-base pair insertion, which generates a nucleotide binding motif (P-loop) in the frog cardiac Na+-Ca2+ exchanger. To examine the functional role of this motif, we constructed a full-length frog heart Na+-Ca2+ exchanger cDNA (fNCX1a) containing this exon. The functional expression of fNCX1a in oocytes showed characteristic voltage dependence, divalent (Ni2+, Cd2+) inhibition, and sensitivity to cAMP in a manner similar to that of native exchanger in frog myocytes. In oocytes expressing the dog heart NCX1 or the frog mutant (Delta fNCX1a) lacking the 9-amino acid exon, cAMP failed to regulate Na+-dependent Ca2+ uptake. We suggest that this motif is responsible for the observed cAMP-dependent functional differences between the frog and the mammalian hearts.	Georgetown Univ, Med Ctr, Dept Pharmacol, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Med, Washington, DC 20007 USA; ETH Zurich, Biochem Lab, CH-8092 Zurich, Switzerland	Georgetown University; Georgetown University; ETH Zurich	Morad, M (corresponding author), Georgetown Univ, Med Ctr, Dept Pharmacol, 3900 Reservoir Rd NW, Washington, DC 20007 USA.	moradm@gunet.georgetown.edu	Oz, Murat/E-2148-2012; Carafoli, Ernesto/K-5192-2016; Shuba, Yaroslav/AAT-6758-2021	Carafoli, Ernesto/0000-0002-7826-0094; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016152] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL16152-22] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACETO JF, 1992, ARCH BIOCHEM BIOPHYS, V298, P553, DOI 10.1016/0003-9861(92)90449-7; FABIATO A, 1998, METHOD ENZYMOL, V157, P358; Fan J, 1996, P NATL ACAD SCI USA, V93, P5527, DOI 10.1073/pnas.93.11.5527; FISCHMEISTER R, 1986, J PHYSIOL-LONDON, V376, P183, DOI 10.1113/jphysiol.1986.sp016148; Flesch M, 1996, CIRCULATION, V94, P992, DOI 10.1161/01.CIR.94.5.992; FURMAN I, 1993, FEBS LETT, V319, P105, DOI 10.1016/0014-5793(93)80046-W; HATEM SN, 1994, CIRC RES, V74, P253, DOI 10.1161/01.RES.74.2.253; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; Iwata T, 1996, ANN NY ACAD SCI, V779, P37, DOI 10.1111/j.1749-6632.1996.tb44768.x; KOFUJI P, 1993, AM J PHYSIOL, V265, pF598, DOI 10.1152/ajprenal.1993.265.4.F598; KOMURO I, 1992, P NATL ACAD SCI USA, V89, P4769, DOI 10.1073/pnas.89.10.4769; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kraev A, 1996, GENOMICS, V37, P105, DOI 10.1006/geno.1996.0526; Kraev A, 1996, ANN NY ACAD SCI, V779, P103, DOI 10.1111/j.1749-6632.1996.tb44774.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUREBAYASHI N, 1993, FOLIA PHARMACOL JPN, V102, pP46; KUREBAYASHI N, 1998, IN PRESS J MOL CELL; LEVITSKY DO, 1994, J BIOL CHEM, V269, P22847; LI ZP, 1994, J BIOL CHEM, V269, P17434; LONGONI S, 1988, AM J PHYSIOL, V255, pC870, DOI 10.1152/ajpcell.1988.255.6.C870; LOW W, 1993, FEBS LETT, V316, P63, DOI 10.1016/0014-5793(93)81737-K; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; MORAD M, 1971, J PHYSIOL-LONDON, V219, P167, DOI 10.1113/jphysiol.1971.sp009656; Morad M., 1973, Progress Biophys Molec Biol, V27, P257, DOI 10.1016/0079-6107(73)90008-4; MORAD M, 1981, J PHYSL, V311, P168; NABAUER M, 1992, J PHYSIOL-LONDON, V457, P627; NAKASAKI Y, 1993, J BIOCHEM-TOKYO, V114, P528, DOI 10.1093/oxfordjournals.jbchem.a124211; Nicoll DA, 1996, J BIOL CHEM, V271, P24914, DOI 10.1074/jbc.271.40.24914; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; Quednau BD, 1997, AM J PHYSIOL-CELL PH, V272, pC1250, DOI 10.1152/ajpcell.1997.272.4.C1250; SANFORD J, 1991, J BIOL CHEM, V266, P9570; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Shuba YM, 1996, PFLUG ARCH EUR J PHY, V432, P562, DOI 10.1007/s004240050170; SMITH AA, 1987, FASEB J, V1, P380, DOI 10.1096/fasebj.1.5.2824269; VASSORT G, 1972, PFLUG ARCH EUR J PHY, V331, P191, DOI 10.1007/BF00589126; VILSEN B, 1992, FEBS LETT, V306, P213, DOI 10.1016/0014-5793(92)81003-5; WHITE MM, 1990, MOL PHARMACOL, V37, P720	37	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18819	18825		10.1074/jbc.273.30.18819	http://dx.doi.org/10.1074/jbc.273.30.18819			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668056	hybrid			2022-12-25	WOS:000074974700023
J	Ueda, A; Takeshita, F; Yamashiro, S; Yoshimura, T				Ueda, A; Takeshita, F; Yamashiro, S; Yoshimura, T			Positive regulation of the human macrophage stimulating protein gene transcription - Identification of a new hepatocyte nuclear factor-4 (HNF-4) binding element and evidence that indicates direct association between NF-Y and HNF-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-RECEPTOR SUPERFAMILY; TYROSINE KINASE; MOLECULAR-CLONING; SEQUENCE IDENTITY; GROWTH-FACTOR; EXPRESSION; MEMBER; YEAST; PURIFICATION; DOMAIN	We previously reported that the transcription of the human macrophage stimulating protein (MSP) gene was positively regulated by the binding of NF-Y to the CAATT sequence in the promoter region of this gene. Here we confirmed our previous results and further characterized the MSP promoter. Luciferase assay with deletion constructs showed the importance of the region, +32 to +39, for the promoter activity in Hep3B cells. Two nuclear protein-DNA probe (+15 to +40) complexes, C1 and C2, were detected by electrophoretic mobility shift assay. C2 was specific to hepatoma cells and contained hepatocyte nuclear factor-4 (HNF-4). DNase I footprinting with recombinant HNF-4 located another HNF-4-binding site in the distal region, -89 to -54. Mutations in the CAATT or the proximal HNF-4-binding site significantly reduced the promoter activity in Hep3B cells and HNF-4-transfected HeLa cells, whereas mutations in the distal HNF-4-binding site had no effect. The close proximity between the CAATT and the proximal HNF-4-binding site suggested that a direct contact between NF-Y and HNF-4 might be important, Protein-protein interaction between the A-subunit of NF-Y and HNF-4 was detected by a yeast two-hybrid system. The binding of in vitro translated HNF-4 to immobilized NF-YA and in vitro translated NF-YA to immobilized HNF-4 was also detected. These results suggest the binding of HNF-4 to the proximal HNF-4-binding site directs the basal transcription of the MSP gene, and the maximal promoter activity may depend on the direct association between HNF-4 and NF-Y.	NCI, Immunopathol Sect, Immunobiol Lab, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; Yokohama City Univ, Sch Med, Dept Internal Med 1, Yokohama, Kanagawa 236, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Yokohama City University	Yoshimura, T (corresponding author), NCI, Immunopathol Sect, Immunobiol Lab, Frederick Canc Res & Dev Ctr, Bldg 560,Rm 12-71, Frederick, MD 21702 USA.			Yoshimura, Teizo/0000-0002-3853-2075				BAOWEI C, 1994, BIOTECHNIQUES, V17, P657; Bartel P. L., 1993, CELLULAR INTERACTION, P153; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; HARPER JW, 1993, CELL, V75, P805; IWABUCHI K, 1993, ONCOGENE, V8, P1693; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; JIANG GQ, 1995, MOL CELL BIOL, V15, P5131; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; KOLLMAR R, 1993, P SOC EXP BIOL MED, V203, P127; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LAI E, 1991, TRENDS BIOCHEM SCI, V16, P427, DOI 10.1016/0968-0004(91)90169-V; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEFEVRE C, 1987, EMBO J, V6, P971, DOI 10.1002/j.1460-2075.1987.tb04847.x; LEONARD EJ, 1976, EXP CELL RES, V102, P434, DOI 10.1016/0014-4827(76)90065-3; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; MAITY SN, 1990, P NATL ACAD SCI USA, V87, P5378, DOI 10.1073/pnas.87.14.5378; MALIK S, 1991, P NATL ACAD SCI USA, V88, P9553, DOI 10.1073/pnas.88.21.9553; Malik S, 1996, MOL CELL BIOL, V16, P1824; OGAMI K, 1991, J BIOL CHEM, V266, P9640; PINTO I, 1994, J BIOL CHEM, V269, P30569; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; RONSIN C, 1993, ONCOGENE, V8, P1195; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; SKEEL A, 1994, J IMMUNOL, V152, P4618; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; UEDA A, 1994, J IMMUNOL, V153, P2052; Ueda A, 1996, J BIOL CHEM, V271, P20265, DOI 10.1074/jbc.271.34.20265; VUORIO T, 1990, J BIOL CHEM, V265, P22480; Waltz SE, 1996, J BIOL CHEM, V271, P9024, DOI 10.1074/jbc.271.15.9024; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WANG MH, 1995, P NATL ACAD SCI USA, V92, P3933, DOI 10.1073/pnas.92.9.3933; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; YOSHIMURA T, 1993, J BIOL CHEM, V268, P15461	39	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19339	19347		10.1074/jbc.273.30.19339	http://dx.doi.org/10.1074/jbc.273.30.19339			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668124	hybrid			2022-12-25	WOS:000074974700091
J	Abuladze, N; Lee, I; Newman, D; Hwang, J; Boorer, K; Pushkin, A; Kurtz, I				Abuladze, N; Lee, I; Newman, D; Hwang, J; Boorer, K; Pushkin, A; Kurtz, I			Molecular cloning, chromosomal localization, tissue distribution, and functional expression of the human pancreatic sodium bicarbonate cotransporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PH-REGULATORY MECHANISMS; PROXIMAL CONVOLUTED TUBULE; CENTRAL-NERVOUS-SYSTEM; GUINEA-PIG PANCREAS; RETINAL GLIAL-CELLS; INTRACELLULAR PH; BASOLATERAL MEMBRANE; NA-HCO3 COTRANSPORT; EXOCRINE SECRETION; INTERLOBULAR DUCTS	We report the cloning, sequence analysis, tissue distribution, functional expression, and chromosomal localization of the human pancreatic sodium bicarbonate cotransport protein (pancreatic NBC (pNBC)), The transporter was identified by searching the human expressed sequence tag data base. An I.M.A.G.E. clone W39298 was identified, and a polymerase chain reaction probe was generated to screen a human pancreas cDNA library. pNBC encodes a 1079-residue polypeptide that differs at the N terminus from the recently cloned human sodium bicarbonate cotransporter isolated from kidney (kNBC) (Burnham, C. E., Amlal, H., Wang, Z., Shull, G, E,, and Soleimani, M. (1997) J. Biol. Chem. 272, 19111-19114), Northern blot analysis using a probe specific for the N terminus of pNBC revealed an similar to 7.7-kilobase transcript expressed predominantly in pancreas, with less expression in kidney, brain, liver, prostate, colon, stomach, thyroid, and spinal chord. In contrast, a probe to the unique 5' region of kNBC detected an similar to 7.6-kilobase transcript only in the kidney. In situ hybridization studies in pancreas revealed expression in the acini and ductal cells. The gene was mapped to chromosome 4q21 using fluorescent in situ hybridization. Expression of pNBC in Xenopus laevis oocytes induced sodium bicarbonate cotransport, These data demonstrate that pNBC encodes the sodium bicarbonate cotransporter in the mammalian pancreas. pNBC is also expressed at a lower level in several other organs, whereas kNBC is expressed uniquely in kidney.	Univ Calif Los Angeles, Ctr Hlth Sci, Sch Med, Div Nephrol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Kurtz, I (corresponding author), Univ Calif Los Angeles, Ctr Hlth Sci, Sch Med, Div Nephrol, 10833 Le Conte Ave,Rm 7-155 Factor Bldg, Los Angeles, CA 90095 USA.	IKurtz@med1.medsch.ucla.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046976] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46976] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABULADZE N, 1998, AM J PHYSIOL, V43, P628; ALPER SL, 1991, ANNU REV PHYSIOL, V53, P549, DOI 10.1146/annurev.physiol.53.1.549; ALPERN RJ, 1985, J GEN PHYSIOL, V86, P613, DOI 10.1085/jgp.86.5.613; ALPERN RJ, 1987, J GEN PHYSIOL, V89, P581, DOI 10.1085/jgp.89.4.581; ARRUDA JAL, 1992, AM J PHYSIOL, V262, pF560; BORON WF, 1989, KIDNEY INT, V36, P392, DOI 10.1038/ki.1989.208; BORON WF, 1983, J GEN PHYSIOL, V81, P53, DOI 10.1085/jgp.81.1.53; Burnham CE, 1997, J BIOL CHEM, V272, P19111, DOI 10.1074/jbc.272.31.19111; CASE RM, 1989, CURR OPIN GASTROEN, V5, P665, DOI 10.1097/00001574-198910000-00012; CASE RM, 1972, J PHYSIOL-LONDON, V223, P649, DOI 10.1113/jphysiol.1972.sp009867; DART C, 1992, J PHYSIOL-LONDON, V451, P365, DOI 10.1113/jphysiol.1992.sp019169; DEITMER JW, 1987, J PHYSIOL-LONDON, V388, P261, DOI 10.1113/jphysiol.1987.sp016614; DEITMER JW, 1991, J GEN PHYSIOL, V98, P637, DOI 10.1085/jgp.98.3.637; DeOndarza J, 1997, AM J PHYSIOL-GASTR L, V272, pG124, DOI 10.1152/ajpgi.1997.272.1.G124; FITZ JG, 1989, AM J PHYSIOL, V256, pG491, DOI 10.1152/ajpgi.1989.256.3.G491; FREEDMAN SD, 1994, ANN NY ACAD SCI, V713, P199, DOI 10.1111/j.1749-6632.1994.tb44066.x; GLEESON D, 1989, J CLIN INVEST, V84, P312, DOI 10.1172/JCI114156; GRAY MA, 1993, AM J PHYSIOL, V264, pC591, DOI 10.1152/ajpcell.1993.264.3.C591; GUGGINO WB, 1983, J MEMBRANE BIOL, V71, P227, DOI 10.1007/BF01875464; Ishiguro H, 1996, J PHYSIOL-LONDON, V495, P169, DOI 10.1113/jphysiol.1996.sp021582; Ishiguro H, 1996, J PHYSIOL-LONDON, V495, P179, DOI 10.1113/jphysiol.1996.sp021583; JACOBSON HR, 1981, AM J PHYSIOL, V240, pF54, DOI 10.1152/ajprenal.1981.240.1.F54; KURTZ I, 1989, J CLIN INVEST, V83, P616, DOI 10.1172/JCI113925; KURTZ I, 1987, J CLIN INVEST, V80, P928, DOI 10.1172/JCI113184; LAGADICGOSSMANN D, 1992, J PHYSIOL-LONDON, V458, P361, DOI 10.1113/jphysiol.1992.sp019422; LUBMAN RL, 1995, RESP PHYSIOL, V100, P15, DOI 10.1016/0034-5687(94)00114-F; MACHEN TE, 1989, ANN NY ACAD SCI, V574, P447; MUALLEM S, 1990, J BIOL CHEM, V265, P12806; NAKHOUL NL, 1990, AM J PHYSIOL, V258, pF371, DOI 10.1152/ajprenal.1990.258.2.F371; NEWMAN EA, 1991, GLIA, V4, P424, DOI 10.1002/glia.440040411; Newman EA, 1996, J NEUROSCI, V16, P159; NOVAK I, 1993, PFLUG ARCH EUR J PHY, V425, P272, DOI 10.1007/BF00374178; Romero M. F., 1996, Journal of the American Society of Nephrology, V7, P1259; Romero MF, 1997, NATURE, V387, P409, DOI 10.1038/387409a0; SASAKI S, 1988, J CLIN INVEST, V81, P1004, DOI 10.1172/JCI113410; SASAKI S, 1992, BIOCHIM BIOPHYS ACTA, V1137, P45, DOI 10.1016/0167-4889(92)90098-V; SCHWARTZ GJ, 1983, AM J PHYSIOL, V245, pF382, DOI 10.1152/ajprenal.1983.245.3.F382; STUENKEL EL, 1988, AM J PHYSIOL, V254, pG925, DOI 10.1152/ajpgi.1988.254.6.G925; VAZHAIKKURICHI M, 1991, J CLIN INVEST, V88, P1379; VEEL T, 1992, ACTA PHYSIOL SCAND, V144, P239, DOI 10.1111/j.1748-1716.1992.tb09292.x; VILLANGER O, 1995, GASTROENTEROLOGY, V108, P850, DOI 10.1016/0016-5085(95)90460-3; WEINTRAUB WH, 1989, AM J PHYSIOL, V257, pG317, DOI 10.1152/ajpgi.1989.257.3.G317; YOSHITOMI K, 1985, PFLUG ARCH EUR J PHY, V405, P360, DOI 10.1007/BF00595689; ZHAO H, 1994, J GEN PHYSIOL, V104, P57, DOI 10.1085/jgp.104.1.57; ZHAO H, 1994, AM J PHYSIOL, V36, pC385	45	203	213	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17689	17695		10.1074/jbc.273.28.17689	http://dx.doi.org/10.1074/jbc.273.28.17689			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651366	hybrid			2022-12-25	WOS:000074816100059
J	Bugge, TH; Lund, LR; Kombrinck, KK; Nielsen, BS; Holmback, K; Drew, AF; Flick, MJ; Witte, DP; Dano, K; Degen, JL				Bugge, TH; Lund, LR; Kombrinck, KK; Nielsen, BS; Holmback, K; Drew, AF; Flick, MJ; Witte, DP; Dano, K; Degen, JL			Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice	ONCOGENE			English	Article						cancer; gene targeting; mammary carcinoma; metastasis; plasminogen	LEWIS LUNG-CARCINOMA; ASCITES TUMOR-GROWTH; BREAST-CANCER; UROKINASE RECEPTOR; MESSENGER-RNA; ACTIVATOR ACTIVITY; COLORECTAL-CANCER; STROMA FORMATION; MELANOMA-CELLS; INHIBITION	To investigate the role of plasmin(ogen) in mammary tumor development and progression, plasminogen-deficient mice were crossed with transgenic mice expressing Polyoma middle T antigen under the control of the mouse mammary tumor virus long terminal repeat. Virgin females carrying the Polyoma middle T antigen uniformly developed multiple, bilateral mammary tumors, regardless of the presence or absence of circulating plasminogen. Both the age at which these tumors became palpable and subsequent tumor growth were indistinguishable between plasminogen-deficient mice and plasminogen-expressing littermates. Hoowever, plasminogen was found to greatly modify the metastatic potential in this model system; lung metastasis in plasminogen-deficient mice was significantly reduced as compared to littermate controls with respect to frequency of occurrence, total number of metastases, and total metastatic tumor burden. Plasminogen activators, as well as other key factors that govern the conversion of plasminogen to plasmin, were expressed within the mammary tumors, suggesting that the plasminogen/plasmin system may promote metastasis by contributing to tumor-associated extracellular proteolysis. The data provide direct evidence that plasmin(ogen) is a tumor progression factor in PymT-induced mammary cancer, and support the hypothesis that hemostatic factors play an important role in tumor biology.	Childrens Hosp Res Fdn, Div Dev Biol, Cincinnati, OH 45229 USA; Childrens Hosp Res Fdn, Div Pathol, Cincinnati, OH 45229 USA; Finsen Lab, DK-2100 Copenhagen, Denmark	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Degen, JL (corresponding author), Childrens Hosp Res Fdn, Div Dev Biol, IDR NRB Room 2025,3333 Burnet Ave, Cincinnati, OH 45229 USA.				NHLBI NIH HHS [HL47826] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047826] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson IC, 1996, CANCER RES, V56, P715; BELIN D, 1985, EUR J BIOCHEM, V148, P225, DOI 10.1111/j.1432-1033.1985.tb08829.x; BROWN LF, 1988, CANCER RES, V48, P1920; BRUNNER G, 1991, J CELL BIOL, V114, P1275, DOI 10.1083/jcb.114.6.1275; Bugge TH, 1997, BLOOD, V90, P4522; BUGGE TH, 1995, GENE DEV, V9, P794, DOI 10.1101/gad.9.7.794; Bugge TH, 1996, CELL, V87, P709, DOI 10.1016/S0092-8674(00)81390-2; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; Coleman JL, 1997, CELL, V89, P1111, DOI 10.1016/S0092-8674(00)80298-6; COLLEN D, 1994, MOL BASIS BLOOD DIS, P725; Conway JG, 1996, CLIN EXP METASTAS, V14, P115, DOI 10.1007/BF00121208; CRAWFORD HC, 1994, INVAS METAST, V14, P234; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; DANO K, 1994, FIBRINOLYSIS, V8, P189, DOI 10.1016/0268-9499(94)90717-X; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; Drew AF, 1998, BLOOD, V91, P1616, DOI 10.1182/blood.V91.5.1616.1616_1616_1624; DUFFY MJ, 1992, CLIN EXP METASTAS, V10, P145, DOI 10.1007/BF00132746; DUFFY MJ, 1990, CANCER RES, V50, P6827; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; DVORAK HF, 1992, ANN NY ACAD SCI, V667, P101, DOI 10.1111/j.1749-6632.1992.tb51603.x; FOEKENS JA, 1992, CANCER RES, V52, P6101; FRAKI JE, 1983, BRIT J DERMATOL, V108, P39, DOI 10.1111/j.1365-2133.1983.tb04577.x; GANESH S, 1994, CANCER RES, V54, P4065; GRODAHLHANSEN J, 1993, CANCER RES, V53, P2513; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HARRIS NL, 1982, AM J PATHOL, V108, P119; HEARING VJ, 1988, CANCER RES, V48, P1270; HEINERT G, 1988, J UROLOGY, V140, P1466; HEISS MM, 1995, NAT MED, V1, P1035, DOI 10.1038/nm1095-1035; Holmback K, 1996, EMBO J, V15, P5760, DOI 10.1002/j.1460-2075.1996.tb00962.x; JANICKE F, 1989, LANCET, V2, P1049; KOBAYASHI H, 1994, THROMB HAEMOSTASIS, V71, P474; KOBAYASHI H, 1994, INT J CANCER, V57, P727, DOI 10.1002/ijc.2910570520; KOHN EC, 1995, CANCER RES, V55, P1856; KOOK YH, 1994, EMBO J, V13, P3983, DOI 10.1002/j.1460-2075.1994.tb06714.x; KRISTENSEN P, 1991, J HISTOCHEM CYTOCHEM, V39, P341, DOI 10.1177/39.3.1899685; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Martin DC, 1996, ONCOGENE, V13, P569; Min HY, 1996, CANCER RES, V56, P2428; MOCHAN E, 1984, J RHEUMATOL, V11, P123; MUELLER BM, 1995, P NATL ACAD SCI USA, V92, P205, DOI 10.1073/pnas.92.1.205; MULCAHY HE, 1994, LANCET, V344, P583, DOI 10.1016/S0140-6736(94)91968-2; NAGY JA, 1995, CANCER RES, V55, P376; NAGY JA, 1995, CANCER RES, V55, P369; NEKARDA H, 1994, LANCET, V343, P117, DOI 10.1016/S0140-6736(94)90845-1; Nielsen BS, 1996, LAB INVEST, V74, P168; ODEKON LE, 1994, J CELL PHYSIOL, V158, P398, DOI 10.1002/jcp.1041580303; OKA T, 1991, CANCER RES, V51, P3522; OSSOWSKI L, 1991, CANCER RES, V51, P274; OSSOWSKI L, 1988, CELL, V52, P321, DOI 10.1016/S0092-8674(88)80025-4; OSSOWSKI L, 1983, CELL, V35, P611, DOI 10.1016/0092-8674(83)90093-4; PEDERSEN H, 1994, CANCER RES, V54, P4671; PLOPLIS VA, 1995, CIRCULATION, V92, P2585, DOI 10.1161/01.CIR.92.9.2585; PRENDERGAST GC, 1990, MOL CELL BIOL, V10, P1265, DOI 10.1128/MCB.10.3.1265; PYKE C, 1991, CANCER RES, V51, P4067; PYKE C, 1993, CANCER RES, V53, P1911; PYKE C, 1991, AM J PATHOL, V138, P1059; Rabbani SA, 1995, INT J CANCER, V63, P840, DOI 10.1002/ijc.2910630615; Romer J, 1996, NAT MED, V2, P287, DOI 10.1038/nm0396-287; ROMER J, 1991, J INVEST DERMATOL, V97, P803, DOI 10.1111/1523-1747.ep12486833; SAFTIG P, 1995, EMBO J, V14, P3599, DOI 10.1002/j.1460-2075.1995.tb00029.x; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SALONEN EM, 1987, ACTA OPHTHALMOL, V65, P3; SAPPINO AP, 1987, CANCER RES, V47, P4043; Schuster V, 1997, BLOOD, V90, P958, DOI 10.1182/blood.V90.3.958.958_958_966; SCHWARTZ MK, 1995, CLIN CHIM ACTA, V237, P67, DOI 10.1016/0009-8981(95)06065-L; Shapiro RL, 1996, CANCER RES, V56, P3597; Shipley JM, 1996, P NATL ACAD SCI USA, V93, P3942, DOI 10.1073/pnas.93.9.3942; SKRIVER L, 1984, Journal of Cell Biology, V99, P752; SLEDGE GW, 1995, J NATL CANCER I, V87, P1546, DOI 10.1093/jnci/87.20.1546; SOEDA E, 1980, NATURE, V283, P445, DOI 10.1038/283445a0; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; Tsirka SE, 1997, J NEUROSCI, V17, P543; Tsirka SE, 1997, P NATL ACAD SCI USA, V94, P9779, DOI 10.1073/pnas.94.18.9779; Vassalli J D, 1992, Curr Top Microbiol Immunol, V181, P65; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; WERB Z, 1977, NEW ENGL J MED, V296, P1017, DOI 10.1056/NEJM197705052961801; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402; Xiao Q, 1997, P NATL ACAD SCI USA, V94, P10335, DOI 10.1073/pnas.94.19.10335; YU H, 1990, CANCER RES, V50, P7623	80	130	135	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 18	1998	16	24					3097	3104		10.1038/sj.onc.1201869	http://dx.doi.org/10.1038/sj.onc.1201869			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671388				2022-12-25	WOS:000074261300002
J	Cowell, JK; Bia, B				Cowell, JK; Bia, B			A novel missense mutation in patients from a retinoblastoma pedigree showing only mild expression of the tumor phenotype	ONCOGENE			English	Article						retinoblastoma; missense mutation; incomplete penetrance; SSCP	ONCOGENIC POINT MUTATIONS; GERM-LINE MUTATIONS; RB1 GENE; HEREDITARY RETINOBLASTOMA; FAMILIAL RETINOBLASTOMA; INCOMPLETE PENETRANCE; MECHANISMS; SPECTRUM; IDENTIFICATION; SITES	We have used single strand conformation polymorphism analysis to study the 27 exons of the RB1 gene in individuals from a family showing 'mild' expression of the retinoblastoma phenotype. In this family affected individuals developed unilateral tumors and, as a result of linkage analysis, unaffected mutation carriers were also identified within the pedigree. A single band shift using SSCP was identified in exon 21 which resulted in a missense mutation converting a cys-->arg at nucleotide position 28 in the exon. The mutation destroyed an NdeI restriction enzyme site. Analysis of all family members demonstrated that the missense mutation co-segregated with patients with tumors or who, as a result of linkage analysis had been predicted to carry the predisposing mutation. These observations point to another region of the RBI gene where mutations only modify the function of the gene and raise important questions for genetic counseling in families with these distinctive phenotypes.	Cleveland Clin Fdn, Dept Neurosci, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Cowell, JK (corresponding author), Cleveland Clin Fdn, Dept Neurosci, 9500 Euclid Ave, Cleveland, OH 44195 USA.			Cowell, John/0000-0002-2079-5950				BLANQUET V, 1995, HUM MOL GENET, V4, P383, DOI 10.1093/hmg/4.3.383; BLANQUET V, 1993, HUM MOL GENET, V2, P975, DOI 10.1093/hmg/2.7.975; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CAVENEE WK, 1985, SCIENCE, V228, P501, DOI 10.1126/science.3983638; COMINGS DE, 1973, P NATL ACAD SCI USA, V70, P3324, DOI 10.1073/pnas.70.12.3324; CONNOLLY MJ, 1983, HUM GENET, V65, P122, DOI 10.1007/BF00286647; Cowell JK, 1996, ONCOGENE, V12, P431; Cowell JK, 1996, EUR J CANCER, V32A, P1749, DOI 10.1016/0959-8049(96)00201-8; Cowell John K., 1994, European Journal of Human Genetics, V2, P281; DRAPER GJ, 1992, BRIT J CANCER, V66, P211, DOI 10.1038/bjc.1992.244; DRYJA TP, 1993, AM J HUM GENET, V52, P1122; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; DUNN JM, 1989, MOL CELL BIOL, V9, P4596, DOI 10.1128/MCB.9.11.4596; HOGG A, 1992, ONCOGENE, V7, P1445; HOGG A, 1993, P NATL ACAD SCI USA, V90, P7351, DOI 10.1073/pnas.90.15.7351; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KRATZKE RA, 1994, ONCOGENE, V9, P1321; LIU ZX, 1995, GENE CHROMOSOME CANC, V14, P277, DOI 10.1002/gcc.2870140406; Lohmann DR, 1996, AM J HUM GENET, V58, P940; LOHMANN DR, 1994, HUM MOL GENET, V3, P2187, DOI 10.1093/hmg/3.12.2187; MACKLIN MT, 1960, AM J HUM GENET, V12, P1; ONADIM Z, 1992, P NATL ACAD SCI USA, V89, P6177, DOI 10.1073/pnas.89.13.6177; ONADIM Z, 1993, BRIT J CANCER, V68, P958, DOI 10.1038/bjc.1993.461; ONADIM ZO, 1990, ARCH DIS CHILD-FETAL, V65, P651, DOI 10.1136/adc.65.7_Spec_No.651; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SHIMIZU T, 1994, AM J HUM GENET, V54, P793; WIGGS J, 1988, NEW ENGL J MED, V318, P151, DOI 10.1056/NEJM198801213180305; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501	29	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 18	1998	16	24					3211	3213		10.1038/sj.onc.1201833	http://dx.doi.org/10.1038/sj.onc.1201833			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671401				2022-12-25	WOS:000074261300015
J	Lee, HY; Chaudhary, J; Walsh, GL; Hong, WK; Kurie, JM				Lee, HY; Chaudhary, J; Walsh, GL; Hong, WK; Kurie, JM			Suppression of c-Fos gene transcription with malignant transformation of human bronchial epithelial cells	ONCOGENE			English	Article						Jun N-terminal kinase; extra-cellular signal-related kinase	SERUM RESPONSE ELEMENT; SIGNAL-TRANSDUCTION PATHWAYS; MONOCLONAL-ANTIBODY; SEQUENCE ELEMENTS; PROTO-ONCOGENE; ACTIVATION; GROWTH; INDUCTION; BINDING; EXPRESSION	The Activator Protein-1 (AP-1) complex is a dimeric transcription factor composed of fos and jun proteins that regulates cellular growth and differentiation. We previously demonstrated a reduction in basal AP-1 transcriptional activity associated with the malignant transformation of human bronchial epithelial (HBE) cells that was, in part, a consequence of decreased c-fos expression. In this study, we investigated the mechanisms underlying the reduction in c-fos expression associated with the malignant transformation of HBE cells. c-Fos gene transcription was lower in tumorigenic HBE cells than in normal HBE cells, and the reduction in transcription involved c-fos gene promoter elements from -327 to +40. DNasel footprinting and band shift analyses of motifs within this c-fos promoter region, including a cyclic AMP response element (CRE), serum response element (SRE), sis-inducible element (SIE), and a YY1 site, revealed that binding to these motifs was greater in tumorigenic HBE cells than in normal HBE cells. Site-directed mutagenesis of the CRE partially relieved the repression of c-fas promoter activity in tumorigenic HBE cells. Further, the activity of the Jun N-terminal Kinase (JNK)-dependent pathway, which was a positive regulator of the c-fos promoter, was greater in normal HBE cells than in tumorigenic HBE cells. These findings demonstrate a transcriptionally-mediated suppression of c-fos gene expression associated with the malignant transformation of HBE cells. The decreased activity of the c-fos promoter in tumorigenic 1170I cells appeared to involve suppression through a CRE site and reduced activation by JNK-dependent pathways.	Univ Texas, MD Anderson Cancer Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA; Washington State Univ, Dept Genet & Cell Biol, Pullman, WA 99164 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Washington State University	Kurie, JM (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Thorac Head & Neck Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.			Lee, Ho-Young/0000-0001-7556-9312	NCI NIH HHS [R29-CA67353, P50-CA70907] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA070907, R29CA067353] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRAVO R, 1985, EMBO J, V4, P1193, DOI 10.1002/j.1460-2075.1985.tb03759.x; BUSCHER M, 1988, ONCOGENE, V3, P301; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COHEN D R, 1989, Critical Reviews in Oncogenesis, V1, P65; CURRAN T, 1985, CANCER SURV, V4, P655; FAN Z, 1993, CANCER RES, V53, P4637; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; Galvin KM, 1997, MOL CELL BIOL, V17, P3723, DOI 10.1128/MCB.17.7.3723; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GUALBERTO A, 1992, MOL CELL BIOL, V12, P4209, DOI 10.1128/MCB.12.9.4209; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Janknecht R, 1997, J BIOL CHEM, V272, P4219, DOI 10.1074/jbc.272.7.4219; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KIM YH, 1995, CANCER RES, V55, P5603; KLEINSZANTO AJP, 1992, P NATL ACAD SCI USA, V89, P6693, DOI 10.1073/pnas.89.15.6693; Lee HY, 1997, CELL GROWTH DIFFER, V8, P283; Mansour SJ, 1996, CELL GROWTH DIFFER, V7, P243; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; NATESAN S, 1995, MOL CELL BIOL, V15, P5975; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; Putnam E A, 1992, Surg Oncol, V1, P49, DOI 10.1016/0960-7404(92)90056-Q; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; REDDEL RR, 1988, CANCER RES, V48, P1904; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; Rusch V, 1997, CLIN CANCER RES, V3, P515; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SOBOL RE, 1987, J NATL CANCER I, V79, P403; TALMAGE DA, 1994, ONCOGENE, V9, P3557; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WHALEY PD, 1995, ENDOCRINOLOGY, V136, P3046, DOI 10.1210/en.136.7.3046; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	45	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 11	1998	16	23					3039	3046		10.1038/sj.onc.1201843	http://dx.doi.org/10.1038/sj.onc.1201843			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZT782	9662337				2022-12-25	WOS:000074125300011
J	Leonard, AS; Davare, MA; Horne, MC; Garner, CC; Hell, JW				Leonard, AS; Davare, MA; Horne, MC; Garner, CC; Hell, JW			SAP97 is associated with the alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor GluR1 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; CENTRAL NERVOUS-SYSTEM; GLUTAMATE-RECEPTOR; RAT-BRAIN; NMDA; LOCALIZATION; TOPOLOGY; PSD-95; SAP102; LIGHT	Rapid glutamatergic synaptic transmission is mediated by ionotropic glutamate receptors and depends on their precise localization at postsynaptic membranes opposing the presynaptic neurotransmitter release sites. Postsynaptic localization of N-methyl-D-aspartate-type glutamate receptors may be mediated by the synapse-associated proteins (SAPs) SAP90, SAP102, and chapsyn-110, SAPs contain three PDZ domains that can interact with the C termini of proteins such as N-methyl-D-aspartate receptor subunits that carry a serine or threonine at the -2 position and a valine, isoleucine, or leucine at the very C terminus (position 0), We now show that SAP97, a SAP whose function at the synapse has been unclear, is associated with alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA)-type glutamate receptors, AMPA receptors are probably tetramers and are formed by two or more of the four AMPA receptor subunits GluR1-4. GluR1 possesses a C-terminal consensus sequence for interactions with PDZ domains of SAPs, SAP97 was present in AMPA receptor complexes immunoprecipitated from detergent extracts of rat brain. After treatment of rat brain membrane fractions with the cross-linker dithiobis(succinimidylpropionate) and solubilization with sodium dodecylsulfate, SAP97 was associated with GluR1 but not GluR2 or GluR3. In vitro experiments with recombinant proteins indicate that SAP97 specifically associates with the C terminus of GluR1 but not other AMPA receptor subunits, Our findings suggest that SAP97 may be involved in localizing AMPA receptors at postsynaptic sites through its interaction with the GluR1 subunit.	Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA; Univ Alabama Birmingham, Neurobiol Res Ctr, Birmingham, AL 35213 USA	University of Wisconsin System; University of Wisconsin Madison; University of Alabama System; University of Alabama Birmingham	Hell, JW (corresponding author), Univ Wisconsin, Dept Pharmacol, 3770 MSC,1300 Univ Ave, Madison, WI 53706 USA.	jwhell@facstaff.wisc.edu	Hell, Johannes W./P-5085-2019	Davare, Monika/0000-0003-1802-7597; Horne, Mary/0000-0002-2799-3212; Garner, Craig/0000-0003-1970-5417	NIA NIH HHS [AG12978] Funding Source: Medline; NINDS NIH HHS [R01-NS35563] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012978] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; BENNETT JA, 1995, NEURON, V14, P373, DOI 10.1016/0896-6273(95)90293-7; Blahos J, 1996, J BIOL CHEM, V271, P15669, DOI 10.1074/jbc.271.26.15669; Brenman JE, 1996, J NEUROSCI, V16, P7407; Castillo PE, 1997, NATURE, V388, P182, DOI 10.1038/40645; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; FIRESTONE GL, 1990, METHOD ENZYMOL, V182, P688; Garner CC, 1996, TRENDS CELL BIOL, V6, P429, DOI 10.1016/S0962-8924(96)10036-2; HELL JW, 1993, J BIOL CHEM, V268, P19451; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; HUNTLEY GW, 1994, J NEUROSCI, V14, P3603; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KISTNER U, 1993, J BIOL CHEM, V268, P4580; Kornau HC, 1997, CURR OPIN NEUROBIOL, V7, P368, DOI 10.1016/S0959-4388(97)80064-5; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kuhlendahl S, 1998, EUR J BIOCHEM, V252, P305, DOI 10.1046/j.1432-1327.1998.2520305.x; Lau LF, 1996, J BIOL CHEM, V271, P21622, DOI 10.1074/jbc.271.35.21622; Leonard AS, 1997, J BIOL CHEM, V272, P12107, DOI 10.1074/jbc.272.18.12107; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; Malenka RC, 1997, NATURE, V390, P552, DOI 10.1038/37472; Martin KC, 1996, NEURON, V17, P567, DOI 10.1016/S0896-6273(00)80188-9; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; PETRALIA RS, 1992, J COMP NEUROL, V318, P329, DOI 10.1002/cne.903180309; PETRALIA RS, 1994, J NEUROSCI, V14, P6102; PETRALIA RS, 1994, J NEUROSCI, V14, P667; Rosenmund C, 1998, SCIENCE, V280, P1596, DOI 10.1126/science.280.5369.1596; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Thomas U, 1997, NEURON, V19, P787, DOI 10.1016/S0896-6273(00)80961-7; WENTHOLD RJ, 1992, J BIOL CHEM, V267, P501; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0	39	342	349	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19518	19524		10.1074/jbc.273.31.19518	http://dx.doi.org/10.1074/jbc.273.31.19518			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677374	hybrid			2022-12-25	WOS:000075125200026
J	Ushio-Fukai, M; Griendling, KK; Akers, M; Lyons, PR; Alexander, RW				Ushio-Fukai, M; Griendling, KK; Akers, M; Lyons, PR; Alexander, RW			Temporal dispersion of activation of phospholipase C-beta 1 and -gamma isoforms by angiotensin II in vascular smooth muscle cells - Role of alpha(q/11), alpha(12), and beta gamma G protein subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ RELEASE; RECEPTOR; EXPRESSION; KINASE; G(12); ANTIBODIES; C-GAMMA-1; PATHWAY; CLONING; SIGNAL	Activation of phospholipase C (PLC) is one of the earliest events in angiotensin II (Ang II) type 1 (AT(1)) receptor (R)-mediated signal transduction in vascular smooth muscle cells (VSMCs). The coupling mechanisms of AT(1) Rs to PLC, however, are controversial, because both tyrosine phosphorylation of PLC-gamma and G protein-dependent PLC-beta activation pathways have been reported. The expression of PLC-beta 1, furthermore, has not been consistently demonstrated in VSMCs. Here we identified the PLC subtypes and subunits of heterotrimeric Gr proteins involved in AT(1) R-PLC coupling using cultured rat VSMCs. Western analysis revealed the expression of PLC-beta 1, -gamma 1, and -delta 1 in VSMCs. Ang II-stimulated inositol trisphosphate (IP3) formation measured at 15 s, which corresponds to the peak response, was significantly inhibited by electroporation of antibodies against PLC-beta 1, but not by anti-PLC-gamma and -delta antibodies. Electroporation of anti-G alpha(q/11), and -G alpha(12) antibodies also showed significant inhibition of the Ang II-induced IP3 generation at 15 s, while anti-G alpha(i) and G alpha(13) antibodies were ineffective. Furthermore, in VSMCs electroporated with anti-G beta antibody and cells stably transfected with the plasmid encoding the G beta gamma-binding region of the carboxyl terminus of beta-adrenergic receptor kinase1, the peak Ang II-stimulated PLC activity (at 15 s) was significantly inhibited. The tyrosine kinase inhibitor, genistein, had no effect on the peak. response to Ang II stimulation, but significantly inhibited IP3 production after 30 s, a time period which temporally correlated with PLC-gamma tyrosine phosphorylation in response to Ang II. Moreover, electroporation of anti-PLC-gamma antibody markedly inhibited the IP3 production measured at 30 s, indicating that tyrosine phosphorylation of PLC-gamma contributes mainly to the later phase of PLC activation. Thus, these results suggest that: 1) AT(1) receptors sequentially couple to PLC-beta 1 via a heterotrimeric G protein and to PLC-gamma via a downstream tyrosine kinase; 2) the initial AT(1) receptor-PLC-beta 1 coupling is mediated by G alpha(q/11)beta gamma and G alpha(q/11)beta gamma; 3) G beta gamma acts as a signal transducer for activation of PLC in VSMCs. The sequential coupling of AT(1) receptors to PLC-beta 1 and PLC-gamma, as well as dual coupling of AT(1) receptors to distinct Ga proteins, suggests a novel mechanism for a temporally controlled, highly organized and convergent Ang II-signaling network in VSMCs.	Emory Univ, Sch Med, Div Cardiol, Dept Med, Atlanta, GA 30322 USA	Emory University	Ushio-Fukai, M (corresponding author), Emory Univ, Sch Med, Div Cardiol, Dept Med, 1639 Pierce Dr,Rm 319, Atlanta, GA 30322 USA.			Griendling, Kathy/0000-0002-9456-8582	NHLBI NIH HHS [HL47557] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047557] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDER RW, 1985, HYPERTENSION, V7, P447, DOI 10.1161/01.HYP.7.3.447; BAHK YY, 1994, J BIOL CHEM, V269, P8240; Coso OA, 1996, J BIOL CHEM, V271, P3963; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; GRIENDLING KK, 1991, J BIOL CHEM, V266, P15498; GRIENDLING KK, 1989, J CARDIOVASC PHARM, V14, pS27, DOI 10.1097/00005344-198906146-00008; GRIENDLING KK, 1994, TXB HYPERTENSION, P244; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HOMMA Y, 1993, BIOCHEM J, V290, P649, DOI 10.1042/bj2900649; Kai H, 1996, MOL PHARMACOL, V49, P96; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KU CY, 1995, ENDOCRINOLOGY, V136, P1509, DOI 10.1210/en.136.4.1509; Macrez N, 1997, J BIOL CHEM, V272, P23180, DOI 10.1074/jbc.272.37.23180; MacrezLepretre N, 1997, J BIOL CHEM, V272, P10095; MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; OKUDA K, 1996, AM J PHYSIOL, V271, pH595; Post GR, 1996, MOL BIOL CELL, V7, P1679, DOI 10.1091/mbc.7.11.1679; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; Schelling JR, 1997, AM J PHYSIOL-CELL PH, V272, pC1558, DOI 10.1152/ajpcell.1997.272.5.C1558; Schelling JR, 1996, AM J PHYSIOL-RENAL, V270, pF682, DOI 10.1152/ajprenal.1996.270.4.F682; SOCORRO L, 1990, BIOCHEM J, V265, P799, DOI 10.1042/bj2650799; STEHNOBITTEL L, 1995, J BIOL CHEM, V270, P30068; SU XL, 1994, J BIOL CHEM, V269, P12925; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; ZHANG BX, 1992, J BIOL CHEM, V267, P24387	30	97	98	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19772	19777		10.1074/jbc.273.31.19772	http://dx.doi.org/10.1074/jbc.273.31.19772			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677408	hybrid			2022-12-25	WOS:000075125200060
J	Bouvet, P; Diaz, JJ; Kindbeiter, K; Madjar, JJ; Amalric, F				Bouvet, P; Diaz, JJ; Kindbeiter, K; Madjar, JJ; Amalric, F			Nucleolin interacts with several ribosomal proteins through its RGG domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; RNA-BINDING PROTEINS; HAMSTER OVARY CELLS; TARGETING SEQUENCES; POLYACRYLAMIDE-GEL; RAT-LIVER; LOCALIZATION; GLYCINE; RICH; NG,NG-DIMETHYLARGININE	Nucleolin is one of the major nonribosomal proteins of the nucleolus, Through its four RNA-binding domains, nucleolin interacts specifically with pre-rRNA as soon as synthesis begins, but it is not found in mature cyto-plasmic ribosomes, Nucleolin is able to shuttle between the cytoplasm and the nucleus. These data suggest that nucleolin might be involved in the nucleolar import of cytoplasmic components and in the assembly of pre-ribosomal particles. Here we show, using two-dimensional blots in a ligand blotting assay, th at nucleolin interacts with 18 ribosomal proteins from rat (14 and 4 from the large and small subunit, respectively). The C-terminal domain of nucleolin (p50) interacts with 10 of these identified ribosomal proteins, In vitro binding assays show that the glycine-arginine rich, domain of nucleolin (RGG domain) is sufficient for the interaction with one of these proteins. Interestingly, most of the proteins that interact with p50 belong to the core ribosomal proteins, which are resistant to extraction with high salt concentration. These findings suggest that nucleolin might be involved in the nucleolar targeting of some ribosomal proteins and in their assembly within pre-ribosomal particles.	CNRS, Inst Biol Cellulaire & Genet, UPR 9006, Lab Biol Mol Eucaryote, F-31062 Toulouse, France; Fac Med Lyon, RTH Laennec, CNRS, UMR5537, F-69372 Lyon 08, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)	Bouvet, P (corresponding author), CNRS, Inst Biol Cellulaire & Genet, UPR 9006, Lab Biol Mol Eucaryote, 118 Route Narbonne, F-31062 Toulouse, France.		, Bouvet/AAC-8779-2020; DIAZ, Jean-Jacques/H-3018-2014; DIAZ, Jean-Jacques/AAT-3846-2021	DIAZ, Jean-Jacques/0000-0002-7914-4319; DIAZ, Jean-Jacques/0000-0002-7914-4319; Bouvet, Philippe/0000-0003-4524-2233				BELENGUER P, 1990, MOL CELL BIOL, V10, P3607, DOI 10.1128/MCB.10.7.3607; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BOURBON HM, 1983, MOL BIOL REP, V9, P39, DOI 10.1007/BF00777472; Bouvet P, 1997, EMBO J, V16, P5235, DOI 10.1093/emboj/16.17.5235; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CAIZERGUESFERRER M, 1987, BIOCHEMISTRY-US, V26, P7876, DOI 10.1021/bi00398a051; Cartegni L, 1996, J MOL BIOL, V259, P337, DOI 10.1006/jmbi.1996.0324; Chan YL, 1996, BIOCHEM BIOPH RES CO, V225, P952, DOI 10.1006/bbrc.1996.1277; CHOOI WY, 1981, P NATL ACAD SCI-BIOL, V78, P4823, DOI 10.1073/pnas.78.8.4823; COBIANCHI F, 1988, J BIOL CHEM, V263, P1063; CREANCIER L, 1993, MOL BIOL CELL, V4, P1239, DOI 10.1091/mbc.4.12.1239; DANG CV, 1989, J BIOL CHEM, V264, P18019; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; ERARD MS, 1988, EUR J BIOCHEM, V175, P525, DOI 10.1111/j.1432-1033.1988.tb14224.x; GHISOLFI L, 1992, EUR J BIOCHEM, V209, P541, DOI 10.1111/j.1432-1033.1992.tb17318.x; GhisolfiNieto L, 1996, J MOL BIOL, V260, P34, DOI 10.1006/jmbi.1996.0380; Ginisty H, 1998, EMBO J, V17, P1476, DOI 10.1093/emboj/17.5.1476; GIRARD JP, 1994, J BIOL CHEM, V269, P18499; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; Kim S, 1997, BIOCHEMISTRY-US, V36, P5185, DOI 10.1021/bi9625509; KUBOTA S, 1989, BIOCHEM BIOPH RES CO, V162, P963, DOI 10.1016/0006-291X(89)90767-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPEYRE B, 1985, NUCLEIC ACIDS RES, V13, P5805, DOI 10.1093/nar/13.16.5805; LISCHWE MA, 1985, J BIOL CHEM, V260, P14304; LISCHWE MA, 1985, BIOCHEMISTRY-US, V24, P6025, DOI 10.1021/bi00343a001; MADJAR JJ, 1979, MOL GEN GENET, V171, P121, DOI 10.1007/BF00269998; MADJAR JJ, 1980, MOL GEN GENET, V179, P89, DOI 10.1007/BF00268450; MCCONKEY EH, 1979, MOL GEN GENET, V169, P1, DOI 10.1007/BF00267538; Michael WM, 1996, J BIOL CHEM, V271, P11571, DOI 10.1074/jbc.271.19.11571; NADLER SG, 1991, BIOCHEMISTRY-US, V30, P2968, DOI 10.1021/bi00225a034; ORRICK LR, 1973, P NATL ACAD SCI USA, V70, P1316, DOI 10.1073/pnas.70.5.1316; PECULIS BA, 1992, J CELL BIOL, V116, P1, DOI 10.1083/jcb.116.1.1; Quaye IKE, 1996, EUR J CELL BIOL, V69, P151; REBOUD JP, 1974, ACTA BIOL MED GER, V33, P661; Rout MP, 1997, CELL, V89, P715, DOI 10.1016/S0092-8674(00)80254-8; RUSSO G, 1997, J BIOL CHEM, V272, P52229; SCHMIDT C, 1995, MOL BIOL CELL, V6, P1875, DOI 10.1091/mbc.6.12.1875; SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799; Serin G, 1996, BIOCHIMIE, V78, P530, DOI 10.1016/0300-9084(96)84759-6; Serin G, 1997, J BIOL CHEM, V272, P13109, DOI 10.1074/jbc.272.20.13109; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SUZUKI K, 1991, J BIOL CHEM, V266, P20007; WELFLE H, 1976, ACTA BIOL MED GER, V35, P401; Wool I. G., 1996, TRANSLATIONAL CONTRO, P685; YAN C, 1993, J CELL BIOL, V123, P1081, DOI 10.1083/jcb.123.5.1081; Yaseen NR, 1997, P NATL ACAD SCI USA, V94, P4451, DOI 10.1073/pnas.94.9.4451	47	163	165	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19025	19029		10.1074/jbc.273.30.19025	http://dx.doi.org/10.1074/jbc.273.30.19025			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668083	hybrid			2022-12-25	WOS:000074974700050
J	Franz, C; Durussel, I; Cox, JA; Schafer, BW; Heizmann, CW				Franz, C; Durussel, I; Cox, JA; Schafer, BW; Heizmann, CW			Binding of Ca2+ and Zn2+ to human nuclear S100A2 and mutant proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING; ZINC-BINDING; CA2+-BINDING PROTEINS; HIGH-AFFINITY; TROPONIN-C; FAMILY; EXPRESSION; CALCYCLIN; MEMBER; GENES	The Ca2+-binding protein S100A2 is an unusual member of the 5100 family, characterized by its nuclear localization and down-regulated expression in tumorigenic cells. In this study, we investigated the properties of human recombinant S100A2 (wtS100A2) and of two mutants in which the amino-terminal Ca2+-binding site I (N mutant) and in addition the carboxyl-terminal site II (NC mutant) were replaced by the canonical loop (EF-site) of cu-parvalbumin. Size exclusion chromatography and circular dichroism showed that, irrespective of the state of cation binding, wtS100A2 and mutants are dimers and rich in alpha-helical structure. Flow dialysis revealed that wtS100A2 binds four Ca2+ atoms per dimer with pronounced positive cooperativity. Both mutants also bind four Ca2+ atoms but with a higher affinity than wtS100A2 and with negative cooperativity. The binding of the first two Ca2+ ions to the N mutant occurred with 100-fold higher affinity than in wtS100A2 and a a-fold increase for the last two Ca2+ ions. A further 2-3-fold increase of affinity was observed for respective binding steps of the NC mutant. The Hummel-Dryer method demonstrated that the wild type and mutants bind four Zn2+ atoms per dimer with similar affinity. Fluorescence and difference spectrophotometry showed that the binding of Ca2+ and Zn2+ induces considerable conformational changes, mostly attributable to changes in the microenvironment of Tyr(76) located in site II. Fluorescence enhancement of 4,4'-dianilino-1,1'-binaphthyl-5,5'-disulfonic acid clearly indicated that Ca2+ and Zn2+ binding induce a hydrophobic patch at the surface of wtS100A2, which, as in calmodulin, may be instrumental for the regulatory role of S100A2 in the nucleus.	Univ Geneva, Dept Biochem, CH-1211 Geneva 4, Switzerland; Univ Zurich, Dept Pediat, Div Clin Chem & Biochem, CH-8032 Zurich, Switzerland	University of Geneva; University of Zurich	Cox, JA (corresponding author), Univ Geneva, Dept Biochem, CH-1211 Geneva 4, Switzerland.	jos.cox@biochem.unige.ch		Schafer, Beat/0000-0001-5988-2915				Allen BG, 1996, BIOCHEM CELL BIOL, V74, P687, DOI 10.1139/o96-075; BAUDIER J, 1986, J BIOL CHEM, V261, P8192; BAUDIER J, 1995, BIOCHEMISTRY-US, V34, P7834, DOI 10.1021/bi00024a007; COLOWICK SP, 1969, J BIOL CHEM, V244, P774; Cox J.A., 1996, GUIDEBOOK CALCIUM BI, P1; DELLANGELICA EC, 1994, J BIOL CHEM, V269, P28929; DONATO R, 1991, CELL CALCIUM, V12, P713, DOI 10.1016/0143-4160(91)90040-L; Drohat AC, 1996, BIOCHEMISTRY-US, V35, P11577, DOI 10.1021/bi9612226; Drohat AC, 1998, BIOCHEMISTRY-US, V37, P2729, DOI 10.1021/bi972635p; Durussel I, 1997, BBA-PROTEIN STRUCT M, V1343, P139, DOI 10.1016/S0167-4838(97)00106-4; ENGELKAMP D, 1993, P NATL ACAD SCI USA, V90, P6547, DOI 10.1073/pnas.90.14.6547; FALKE JJ, 1994, Q REV BIOPHYS, V27, P219, DOI 10.1017/S0033583500003012; FILIPEK A, 1990, FEBS LETT, V264, P263, DOI 10.1016/0014-5793(90)80263-I; Finkbeiner S, 1997, BIOESSAYS, V19, P657, DOI 10.1002/bies.950190803; FOHR UG, 1995, J BIOL CHEM, V270, P21056, DOI 10.1074/jbc.270.36.21056; FOHR UG, 1993, EUR J BIOCHEM, V215, P719, DOI 10.1111/j.1432-1033.1993.tb18084.x; GAGNE SM, 1994, PROTEIN SCI, V3, P1961, DOI 10.1002/pro.5560031108; GLENNEY JR, 1989, J CELL BIOL, V108, P569, DOI 10.1083/jcb.108.2.569; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; Heierhorst J, 1997, EUR J BIOCHEM, V249, P127, DOI 10.1111/j.1432-1033.1997.00127.x; Heizmann CW, 1996, MOL CELLS, V6, P629; HILT DC, 1991, NOVEL CALCIUM BINDIN, P65; Ilg EC, 1996, INT J CANCER, V68, P325, DOI 10.1002/(SICI)1097-0215(19961104)68:3<325::AID-IJC10>3.0.CO;2-7; JOHANSSON C, 1991, EUR J BIOCHEM, V202, P1283, DOI 10.1111/j.1432-1033.1991.tb16501.x; JOHANSSON C, 1993, BIOCHEMISTRY-US, V32, P8429, DOI 10.1021/bi00084a007; Kilby PM, 1996, STRUCTURE, V4, P1041, DOI 10.1016/S0969-2126(96)00111-6; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; LACKMANN M, 1993, J IMMUNOL, V150, P2981; LEE SW, 1992, P NATL ACAD SCI USA, V89, P2504, DOI 10.1073/pnas.89.6.2504; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; LEUNG IKM, 1987, FEBS LETT, V214, P35, DOI 10.1016/0014-5793(87)80008-X; LINSE S, 1995, ADV SEC MESS PHOSPH, V30, P89; Matsumura H, 1998, STRUCTURE, V6, P233, DOI 10.1016/S0969-2126(98)00024-0; Onions J, 1997, J BIOL CHEM, V272, P23930, DOI 10.1074/jbc.272.38.23930; Pace C.N., 1990, PROTEIN STRUCTURE PR, P311; PACE CN, 1990, TRENDS BIOTECHNOL, V8, P93, DOI 10.1016/0167-7799(90)90146-O; Pan BS, 1996, J BIOL CHEM, V271, P817, DOI 10.1074/jbc.271.2.817; PARKER C, 1994, DNA CELL BIOL, V13, P343, DOI 10.1089/dna.1994.13.343; PAULS TL, 1994, BIOCHEMISTRY-US, V33, P10393, DOI 10.1021/bi00200a021; PEDROCCHI M, 1994, BIOCHEMISTRY-US, V33, P6732, DOI 10.1021/bi00187a045; PEDROCCHI M, 1994, INT J CANCER, V57, P684, DOI 10.1002/ijc.2910570513; PerezTerzic C, 1997, BIOESSAYS, V19, P787, DOI 10.1002/bies.950190908; Potts BCM, 1996, PROTEIN SCI, V5, P2162, DOI 10.1002/pro.5560051103; POTTS BCM, 1995, NAT STRUCT BIOL, V2, P790, DOI 10.1038/nsb0995-790; Precheur B, 1996, FEBS LETT, V395, P89, DOI 10.1016/0014-5793(96)01007-1; Raftery MJ, 1996, BIOCHEM J, V316, P285, DOI 10.1042/bj3160285; Rhyner JA, 1996, BBA-MOL CELL RES, V1313, P179, DOI 10.1016/0167-4889(96)00087-0; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; Sastry M, 1998, STRUCTURE, V6, P223, DOI 10.1016/S0969-2126(98)00023-9; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SCHAFER BW, 1995, GENOMICS, V25, P638, DOI 10.1016/0888-7543(95)80005-7; Smith SP, 1998, STRUCTURE, V6, P211, DOI 10.1016/S0969-2126(98)00022-7; Treves S, 1997, BIOCHEMISTRY-US, V36, P11496, DOI 10.1021/bi970160w; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; Wicki R, 1997, CELL CALCIUM, V22, P243, DOI 10.1016/S0143-4160(97)90063-4; Wicki R, 1996, BIOCHEM BIOPH RES CO, V227, P594, DOI 10.1006/bbrc.1996.1551; Wicki R, 1996, CELL CALCIUM, V20, P459, DOI 10.1016/S0143-4160(96)90087-1	57	44	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18826	18834		10.1074/jbc.273.30.18826	http://dx.doi.org/10.1074/jbc.273.30.18826			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668057	hybrid			2022-12-25	WOS:000074974700024
J	Duguay, SJ; Jin, Y; Stein, J; Duguay, AN; Gardner, P; Steiner, DF				Duguay, SJ; Jin, Y; Stein, J; Duguay, AN; Gardner, P; Steiner, DF			Post-translational processing of the insulin-like growth factor-2 precursor - Analysis of O-glycosylation and endoproteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-II GENE; E-DOMAIN; TUMOR HYPOGLYCEMIA; IGF-II; SERUM; BIOSYNTHESIS; EXPRESSION; PROTEIN; MOUSE; CELLS	Insulin-like growth factor-2 (IGF-2) is expressed in most embryonic tissues and is required for normal development during gestation. After birth IGF-2 expression is extinguished in most tissues, but the gene is often reactivated during tumorigenesis. Tumors secrete high molecular weight forms of IGF-2 that result from aberrant post-translational processing of pro-IGF-2. As a first step toward understanding how high molecular weight IGF-P peptides might contribute to tumor progression, we have characterized the biosynthesis of IGF-P in a human embryonic cell line. We have found that pro-IGF-a can initially form two disulfide isomers that undergo rearrangement to a single conformation in vivo. The addition of N-acetylgalactosamine to Ser(71), Thr(72), Thr(75), and Thr(139) likely occurs in the cis-Golgi apparatus. Sialic acid addition begins in the trans Golgi apparatus, but IGF-2 peptides must reach the trans-Golgi network for oligosaccharide maturation to be completed. Endoproteolysis occurs concomitant to or slightly after oligosaccharide maturation. Cleavage was observed only at Arg(104), resulting in the secretion of IGF-2-(1-104) and free Et-peptide. Proteolysis required basic residues in the P1 (Arg(104)), and P4 (Arg(101)) positions, was completely blocked by a furin inhibitor, and was enhanced by coexpression with furin, PACE4, PC6A, PC6B, and LPC. These data suggest that members of the subtilisin-related proprotein convertase family mediate processing of pro-IGF-2 at Arg(104). We did not detect the IGF-S peptides that are most abundant in normal serum, mature IGF-S, and IGF-2-(1-87), in this expression system, which indicates that novel endoproteases are responsible for generating these products.	Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago; University of Chicago	Duguay, SJ (corresponding author), Transkaryot Therapies Inc, 195 Albany St, Cambridge, MA 02139 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK013914, P30DK020595, P60DK020595, R37DK013914] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK20595, DK13914] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson ED, 1997, EMBO J, V16, P1508, DOI 10.1093/emboj/16.7.1508; CHRISTOFORI G, 1995, NAT GENET, V10, P196, DOI 10.1038/ng0695-196; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; DAUGHADAY WH, 1988, NEW ENGL J MED, V319, P1434, DOI 10.1056/NEJM198812013192202; DAUGHADAY WH, 1993, P NATL ACAD SCI USA, V90, P5823, DOI 10.1073/pnas.90.12.5823; DAUGHADAY WH, 1992, J CLIN ENDOCR METAB, V75, P641, DOI 10.1210/jc.75.2.641; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DUGUAY SJ, 1995, FEBS LETT, V371, P69, DOI 10.1016/0014-5793(95)00879-E; DUGUAY SJ, 1995, J BIOL CHEM, V270, P17566, DOI 10.1074/jbc.270.29.17566; Duguay SJ, 1997, J BIOL CHEM, V272, P6663, DOI 10.1074/jbc.272.10.6663; GOWAN LK, 1987, ENDOCRINOLOGY, V121, P449, DOI 10.1210/endo-121-2-449; GRIFFITHS G, 1983, J CELL BIOL, V96, P835, DOI 10.1083/jcb.96.3.835; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; HOBER S, 1992, BIOCHEMISTRY-US, V31, P1749, DOI 10.1021/bi00121a024; HOBER S, 1994, BIOCHEMISTRY-US, V33, P6758, DOI 10.1021/bi00188a003; HOEFLICH A, 1995, EUR J BIOCHEM, V232, P172, DOI 10.1111/j.1432-1033.1995.tb20796.x; HOLTHUIZEN PE, 1993, REGUL PEPTIDES, V48, P77, DOI 10.1016/0167-0115(93)90337-8; Hounsell EF, 1996, GLYCOCONJUGATE J, V13, P19, DOI 10.1007/BF01049675; HUDGINS WR, 1992, J BIOL CHEM, V267, P8153; HYLKA VW, 1985, J BIOL CHEM, V260, P4417; Jespersen S, 1996, J MASS SPECTROM, V31, P893, DOI 10.1002/(SICI)1096-9888(199608)31:8<893::AID-JMS374>3.0.CO;2-S; LEE AV, 1994, MOL CELL ENDOCRINOL, V99, P211, DOI 10.1016/0303-7207(94)90010-8; MILLER JA, 1993, BIOCHEMISTRY-US, V32, P5203, DOI 10.1021/bi00070a032; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; NIELSEN FC, 1993, MOL CELL ENDOCRINOL, V93, P87, DOI 10.1016/0303-7207(93)90143-8; RINDERKNECHT E, 1978, FEBS LETT, V89, P283, DOI 10.1016/0014-5793(78)80237-3; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; SHAPIRO ET, 1990, J CLIN INVEST, V85, P1672, DOI 10.1172/JCI114619; SHUI RPC, 1988, ENDOCRINOLOGY, V123, P1456; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; STYLIANOPOULOU F, 1988, P NATL ACAD SCI USA, V85, P141, DOI 10.1073/pnas.85.1.141; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; TOOZE SA, 1988, J CELL BIOL, V106, P1475, DOI 10.1083/jcb.106.5.1475; VALENZANO KJ, 1995, J BIOL CHEM, V270, P16441, DOI 10.1074/jbc.270.27.16441; Valenzano KJ, 1997, J BIOL CHEM, V272, P4804, DOI 10.1074/jbc.272.8.4804; VEY M, 1994, J CELL BIOL, V127, P1829, DOI 10.1083/jcb.127.6.1829; Werner H, 1996, ADV CANCER RES, V68, P183, DOI 10.1016/S0065-230X(08)60354-1; Yang CQ, 1996, ENDOCRINOLOGY, V137, P2766, DOI 10.1210/en.137.7.2766; YANG YWH, 1985, J BIOL CHEM, V260, P2570; ZAPF J, 1992, J CLIN INVEST, V90, P2574, DOI 10.1172/JCI116152; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	42	95	108	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18443	18451		10.1074/jbc.273.29.18443	http://dx.doi.org/10.1074/jbc.273.29.18443			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660813	hybrid			2022-12-25	WOS:000074828500068
J	Fuller, SJ; Gillespie-Brown, J; Sugden, PH				Fuller, SJ; Gillespie-Brown, J; Sugden, PH			Oncogenic src, raf, and ras stimulate a hypertrophic pattern of gene expression and increase cell size in neonatal rat ventricular myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MUSCLE-SPECIFIC GENES; CARDIAC MYOCYTES; TYROSINE KINASE; GROWTH-FACTOR; ANGIOTENSIN-II; MYOCARDIAL-CELLS; MOLECULAR CHARACTERIZATION; ADRENERGIC STIMULATION; ENHANCED EXPRESSION	In response to hormones and growth factors, cultured neonatal ventricular myocytes increase in profile, exhibit myofibrillogenesis, and re-express genes whose expression is normally restricted to the fetal stage of ventricular development. These include atrial natriuretic factor (ANF), beta-myosin heavy chain (beta-MHC), and skeletal muscle (SkM)-alpha-actin. By using luciferase reporter plasmids, we examined whether oncogenes that activate the extracellular signal-regulated kinase cascade (src(F527), Ha-ras(V12), and v-raf) increased expression of "fetal" genes. Transfection of myocytes with src(F527) stimulated expression of ANF, SkM-alpha-actin, and beta-MHC by 62-, 6.7-, and 50-fold, respectively, but did not induce DNA synthesis. Stimulation of ANF expression by src(F527) was greater than by Ha-ras(V12), which in turn was greater than by v-raf. General gene expression was also increased but to a lesser extent. The response to src(F527) was inhibited by dominant-negative Ha-ras(N17). Myocyte area was increased by src(F527), Ha-ras(V12), and v-raf, and although it altered myocyte morphology by causing a pseudopodial appearance, src(F527) did not detectably increase myofibrillogenesis either alone or in combination with Ha-ras(V12). A kinase-dead src mutant increased myocyte size to a much lesser extent than src(F527), and also did not inhibit ANF-luciferase expression in response to phenylephrine. We conclude that members of the Src family of tyrosine kinases may be important in mediating the transcriptional changes occurring during cardiac myocyte hypertrophy and that Ras and Raf may be downstream effectors.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst Div, Sect Cardiac Med, London SW3 6LY, England	Imperial College London	Fuller, SJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst Div, Sect Cardiac Med, Dovehouse St, London SW3 6LY, England.	stephen.fuller@ic.ac.uk		Brown, Judith/0000-0003-4092-9685				Abdellatif M, 1997, J BIOL CHEM, V272, P525; ABDELLATIF M, 1994, J BIOL CHEM, V269, P15423; Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BOGOYEVITCH MA, 1993, FEBS LETT, V317, P271, DOI 10.1016/0014-5793(93)81291-7; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; Bogoyevitch MA, 1996, CIRC RES, V79, P162, DOI 10.1161/01.RES.79.2.162; BRAND T, 1993, J BIOL CHEM, V268, P11500; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; CHERRINGTON JM, 1989, J VIROL, V63, P1435, DOI 10.1128/JVI.63.3.1435-1440.1989; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; Clerk A, 1996, BIOCHEM J, V317, P109, DOI 10.1042/bj3170109; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DECOCK JBJ, 1994, FEBS LETT, V356, P275, DOI 10.1016/0014-5793(94)01283-0; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DENT P, 1994, P NATL ACAD SCI USA, V91, P9544, DOI 10.1073/pnas.91.20.9544; DOSTAL DE, 1992, AM J HYPERTENS, V5, P276; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; DUERR RL, 1995, J CLIN INVEST, V95, P619, DOI 10.1172/JCI117706; DUNNMON PM, 1990, J MOL CELL CARDIOL, V22, P901, DOI 10.1016/0022-2828(90)90121-H; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; Foncea R, 1997, J BIOL CHEM, V272, P19115, DOI 10.1074/jbc.272.31.19115; Fuller SJ, 1997, BIOCHEM J, V323, P313, DOI 10.1042/bj3230313; GILLESPIEBROWN J, 1995, J BIOL CHEM, V270, P28092; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HENRICH CJ, 1988, J MOL CELL CARDIOL, V20, P1081, DOI 10.1016/0022-2828(88)90588-3; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; ITO H, 1993, CIRCULATION, V87, P1715, DOI 10.1161/01.CIR.87.5.1715; ITO H, 1991, CIRC RES, V69, P209, DOI 10.1161/01.RES.69.1.209; IWAKI K, 1990, J BIOL CHEM, V265, P13809; KEFALAS P, 1995, INT J BIOCHEM CELL B, V27, P551, DOI 10.1016/1357-2725(95)00024-J; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOMURO I, 1990, J BIOL CHEM, V265, P3595; KOMURO I, 1991, J BIOL CHEM, V266, P1265; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAZOU A, 1994, CIRC RES, V75, P932, DOI 10.1161/01.RES.75.5.932; LEE HR, 1988, J BIOL CHEM, V263, P7352; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; PARKER TG, 1992, J BIOL CHEM, V267, P3343; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; PAWSON T, 1995, NATURE, V373, P477, DOI 10.1038/373477a0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Post GR, 1996, J BIOL CHEM, V271, P8452, DOI 10.1074/jbc.271.14.8452; Ramirez MT, 1997, J BIOL CHEM, V272, P14057, DOI 10.1074/jbc.272.22.14057; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SADOSHIMA J, 1995, CIRC RES, V76, P1; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Sambrook J., 1989, MOL CLONING LABORATO, P33; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; Sugden PH, 1997, CELL SIGNAL, V9, P337, DOI 10.1016/S0898-6568(96)00191-X; SUPERTIFURGA G, 1995, FEBS LETT, V369, P62, DOI 10.1016/0014-5793(95)00636-N; SUPERTIFURGA G, 1995, BIOESSAYS, V17, P321, DOI 10.1002/bies.950170408; THORBURN A, 1993, J BIOL CHEM, V268, P2244; THORBURN J, 1994, BIOCHEM BIOPH RES CO, V202, P1586, DOI 10.1006/bbrc.1994.2113; THORBURN J, 1995, MOL BIOL CELL, V6, P1479, DOI 10.1091/mbc.6.11.1479; THORBURN J, 1994, J BIOL CHEM, V269, P30580; THORBURN J, 1994, J CELL BIOL, V126, P1565, DOI 10.1083/jcb.126.6.1565; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; YAMAZAKI T, 1993, J BIOL CHEM, V268, P12069	80	53	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18146	18152		10.1074/jbc.273.29.18146	http://dx.doi.org/10.1074/jbc.273.29.18146			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660773	hybrid			2022-12-25	WOS:000074828500028
J	Parker, AE; Van de Weyer, I; Laus, MC; Verhasselt, P; Luyten, WHML				Parker, AE; Van de Weyer, I; Laus, MC; Verhasselt, P; Luyten, WHML			Identification of a human homologue of the Schizosaccharomyces pombe rad17(+) checkpoint gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CHECKPOINT; WILD-TYPE P53; DNA POLYMERASE-DELTA; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; INSITU HYBRIDIZATION; ACCESSORY PROTEINS; 2-HYBRID SYSTEM; NUCLEAR ANTIGEN; DAMAGE	In the fission yeast Schizosaccharomyces pombe the rad17(+) gene is required for both the DNA damage-dependent and the DNA replication dependent cell cycle checkpoints, We have identified a human cDNA homologue of the S. pombe rad17(+) checkpoint gene, designated Hrad17. Hrad17 has 49% identity to the S. pombe rad17(+) sequence at the DNA level and 49% identity and 72% similarity at the amino acid level. Northern blot analysis indicates elevated levels of expression in testis and in cancer cell lines. Chromosomal localization by fluorescence in situ hybridization indicates that Hrad17 is located on chromosome 4q13.3-21.2. This region is subject to loss of heterozygosity in several human cancers. To begin to understand the protein-protein interactions of the human checkpoint machinery, Fee have used the yeast two-hybrid system to examine potential interactions between Hrad1, Hrad9, and Hrad17, We demonstrate a physical interaction between Hrad17 and Hrad1 but no interaction with Hrad9.	Janssen Res Fdn, Dept Expt Mol Biol, B-2340 Beerse, Belgium; Janssen Res Fdn, Dept Appl Mol Biol, B-2340 Beerse, Belgium	Johnson & Johnson; Johnson & Johnson	Luyten, WHML (corresponding author), Janssen Res Fdn, Dept Expt Mol Biol, Turnhoutseweg 30, B-2340 Beerse, Belgium.	wluyten@janbe.jnj.com						ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; CARR AM, 1995, TRENDS CELL BIOL, V5, P32, DOI 10.1016/S0962-8924(00)88934-5; CARR AM, 1994, INT J RAD BIOL S, V66, P133; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; GRIFFITHS DJF, 1995, EMBO J, V14, P5812, DOI 10.1002/j.1460-2075.1995.tb00269.x; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Heng H H, 1994, Methods Mol Biol, V33, P35; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; IWABUCHI K, 1993, ONCOGENE, V8, P1693; Kaiser C., 1994, METHODS YEAST GENETI; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KATO R, 1994, NUCLEIC ACIDS RES, V22, P3104, DOI 10.1093/nar/22.15.3104; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE SH, 1991, J BIOL CHEM, V266, P22707; LEE SH, 1990, P NATL ACAD SCI USA, V87, P5672, DOI 10.1073/pnas.87.15.5672; LEE SH, 1991, J BIOL CHEM, V266, P594; Leupold U., 1970, METHODS CELL PHYSL, V4, P169; LI B, 1993, FASEB J, V7, P957, DOI 10.1096/fasebj.7.10.8344494; Lieberman HB, 1996, P NATL ACAD SCI USA, V93, P13890, DOI 10.1073/pnas.93.24.13890; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; Parker AE, 1998, J BIOL CHEM, V273, P18332, DOI 10.1074/jbc.273.29.18332; Parkinson EK, 1997, EUR J CANCER, V33, P727, DOI 10.1016/S0959-8049(97)00063-4; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Petersen I, 1997, BRIT J CANCER, V75, P79, DOI 10.1038/bjc.1997.13; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Schwendel A, 1997, INT J CANCER, V74, P86, DOI 10.1002/(SICI)1097-0215(19970220)74:1<86::AID-IJC15>3.0.CO;2-G; Tirkkonen M, 1997, CANCER RES, V57, P1222; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; VERHAEGH GWCT, 1995, AM J HUM GENET, V57, P1095; WEINERT TA, 1990, MOL CELL BIOL, V10, P6554, DOI 10.1128/MCB.10.12.6554; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	47	69	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18340	18346		10.1074/jbc.273.29.18340	http://dx.doi.org/10.1074/jbc.273.29.18340			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660800	hybrid			2022-12-25	WOS:000074828500055
J	Sharma, PM; Egawa, K; Huang, Y; Martin, JL; Huvar, I; Boss, GR; Olefsky, JM				Sharma, PM; Egawa, K; Huang, Y; Martin, JL; Huvar, I; Boss, GR; Olefsky, JM			Inhibition of phosphatidylinositol 3-kinase activity by adenovirus-mediated gene transfer and its effect on insulin action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE RELEASING-FACTOR; GLYCOGEN-SYNTHASE; 3T3-L1 ADIPOCYTES; GLUCOSE-TRANSPORT; RECEPTOR SUBSTRATE-1; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; DNA-SYNTHESIS; GROWTH-FACTOR; WILD-TYPE	Phosphatidylinositol 3-kinase (PI 3-K) is implicated in cellular events including glucose transport, glycogen synthesis, and protein synthesis. It is activated in insulin-stimulated cells by binding of the Src homology 2 (SH2) domains in its 85-kDa regulatory subunit to insulin receptor substrate-1 (IRS-1), and, others. We have previously she-con that IRS-l-associated PI 3-kinase activity is not essential for insulin-stimulated glucose transport in 3T3-L1 adipocytes, and that alternate pathways exist in these cells. We now show that adenovirus-mediated overexpression of the p85N-SH2 domain in these cells behaves in a dominant-negative manner, interfering with complex formation between endogenous PI 3-K and its SH2 binding targets. This not only inhibited insulin-stimulated IRS-l-associated PI 3-kinase activity, but also completely blocked anti-phosphotyrosine-associated PI 3-kinase activity, which would include the non-IRS-1-associated activity. This resulted in inhibition of insulin-stimulated glucose transport, glycogen synthase activity and DNA synthesis. Further, Ser/Thr phosphorylation of downstream molecules Akt and p70 S6 kinase was inhibited. However, co expression of a membrane-targeted p110(CAAX) With the p85N-SH2 protein rescued glucose transport, supporting our argument that the p85N-SH2 protein specifically blocks insulin-mediated PI 3-kinase activity, and, that the signaling pathways downstream of PI 3-kinase are intact. Unexpectedly, GTP-bound Pas was elevated in the basal state. Since p85 is known to interact with GTPase-activating protein in 3T3-L1 adipocytes, the overexpressed p85N-SH2 peptide could titrate out cellular GTPase-activating protein by direct association, such that it is unavailable to hydrolyze GTP-bound Pas. However, insulin-induced mitogen-activated protein kinase phosphorylation was inhibited. Thus, PI 3-kinase may be required for this action at a step independent of and downstream of Pas. We conclude that, in 3T3-L1 adipocytes, non-IRS-l-associated PI 3-kinase activity is crucial for insulin's metabolic signaling, and that overexpressed p85N-SH2 protein inhibits a variety of insulin's ultimate biological effects.	Univ Calif San Diego, Dept Med 0673, Div Endocrinol & Metab, La Jolla, CA 92093 USA; Univ Calif San Diego, Whittier Inst Diabet & Endocrinol, La Jolla, CA 92093 USA; Vet Adm Res Serv, La Jolla, CA 92161 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Olefsky, JM (corresponding author), Univ Calif San Diego, Dept Med 0673, Div Endocrinol & Metab, 9500 Gilman Dr, La Jolla, CA 92093 USA.			Boss, Gerry/0000-0002-9758-8714	NIDDK NIH HHS [R01 DK 36651] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BALTENSPERGER K, 1994, J BIOL CHEM, V269, P28937; BENJAMIN WB, 1994, BIOCHEM J, V300, P477, DOI 10.1042/bj3000477; BERGER J, 1994, BIOCHEM BIOPH RES CO, V205, P570, DOI 10.1006/bbrc.1994.2703; Braselmann S, 1997, CURR BIOL, V7, pR470, DOI 10.1016/S0960-9822(06)00239-9; Carel K, 1996, J BIOL CHEM, V271, P30625, DOI 10.1074/jbc.271.48.30625; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; Conricode KM, 1995, BIOCHEM MOL BIOL INT, V36, P835; Cross DAE, 1997, FEBS LETT, V406, P211, DOI 10.1016/S0014-5793(97)00240-8; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DePaolo D, 1996, MOL CELL BIOL, V16, P1450; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DRAZNIN B, 1993, J BIOL CHEM, V268, P19998; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; FRY MJ, 1994, BBA-MOL BASIS DIS, V1226, P237, DOI 10.1016/0925-4439(94)90036-1; Gluzman Y., 1982, EUKARYOTIC VIRAL VEC, P187; GUINOVART JJ, 1979, FEBS LETT, V106, P284, DOI 10.1016/0014-5793(79)80515-3; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; JHUN BH, 1994, J BIOL CHEM, V269, P5699; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; Kaburagi Y, 1997, J BIOL CHEM, V272, P25839, DOI 10.1074/jbc.272.41.25839; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KLIP A, 1984, AM J PHYSIOL, V247, pE291, DOI 10.1152/ajpendo.1984.247.3.E291; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Krook A, 1996, J BIOL CHEM, V271, P7134, DOI 10.1074/jbc.271.12.7134; LANGLOIS J, 1995, ENDOCRINE, V3, P475, DOI 10.1007/BF02738820; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; Lawrence JC, 1997, DIABETES, V46, P541, DOI 10.2337/diabetes.46.4.541; LIU H, 1996, DIABETES S2, V45, pA119; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; MARGALETSANCHEZ V, 1994, BIOCHEM BIOPH RES CO, V204, P446; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; MYERS MG, 1995, TRENDS ENDOCRIN MET, V6, P209, DOI 10.1016/1043-2760(95)00092-V; OKADA T, 1994, J BIOL CHEM, V269, P3568; PARKER PJ, 1983, EUR J BIOCHEM, V130, P227; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SCHEELE JS, 1995, P NATL ACAD SCI USA, V92, P1097, DOI 10.1073/pnas.92.4.1097; Sharma PM, 1997, MOL CELL BIOL, V17, P7386, DOI 10.1128/MCB.17.12.7386; SHARMA PM, 1994, P NATL ACAD SCI USA, V91, P9931, DOI 10.1073/pnas.91.21.9931; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; SHULMAN RG, 1995, P NATL ACAD SCI USA, V92, P8535, DOI 10.1073/pnas.92.19.8535; SJOLANDER A, 1991, P NATL ACAD SCI USA, V88, P7908, DOI 10.1073/pnas.88.18.7908; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Suga J, 1997, DIABETES, V46, P735, DOI 10.2337/diabetes.46.5.735; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; TOBE K, 1995, J BIOL CHEM, V270, P5698, DOI 10.1074/jbc.270.11.5698; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Waters SB, 1996, TRENDS CELL BIOL, V6, P1, DOI 10.1016/0962-8924(96)81024-5; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; ZHANG WW, 1995, BIOTECHNIQUES, V18, P444	64	108	109	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18528	18537		10.1074/jbc.273.29.18528	http://dx.doi.org/10.1074/jbc.273.29.18528			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660823	hybrid			2022-12-25	WOS:000074828500078
J	Karnik, P; Chen, P; Paris, M; Yeger, H; Williams, BRG				Karnik, P; Chen, P; Paris, M; Yeger, H; Williams, BRG			Loss of heterozygosity at chromosome 11p15 in Wilms tumors: identification of two independent regions	ONCOGENE			English	Article						Wilms tumor; tumor suppressor genes; chromosome 11p15; loss of heterozygosity	BECKWITH-WIEDEMANN SYNDROME; LOCUS; GENE; LOCALIZATION; DELETION; TRANSCRIPTS; FRAGMENTS; D11S988	Loss of heterozygosity (LOH) on the short arm of chromosome 11 is the most frequent genetic alteration in Wilms tumors, indicating that one or more tumor suppressor genes that map to this chromosomal region are involved in the development of the disease, The WT1 gene located on 11p13 has been characterized but mutations in this gene occur in only about 10% of Wilms tumors, A second locus (WT2) at chromosome 11p15 has also been described in Wilms tumors but thus far efforts to clone the WT2 gene(s) have been frustrated by the large size (similar to 10 Mb) of this region. Using a high-density marker LOH analysis of 11p15.5-15.4, we have refined the location of a Wilms tumor suppressor gene between the markers D11S1318-D11S1288 (similar to 800 kb) within 11p15.5, We have also identified a second, novel region of LOH that spans the markers D11S1338-D11S1323 (similar to 336 kb) at 11p15.5-p15.4. Thus a second distinct locus, in addition to the previously defined WT2, on chromosome 11p15.5, appears to play a role in the development of Wilms tumors.	Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; Hosp Sick Children, Toronto, ON M5G 1X8, Canada	Cleveland Clinic Foundation; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Karnik, P (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.		Williams, Bryan R. G./A-5021-2009	Williams, Bryan R. G./0000-0002-4969-1151				ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; Baffa R, 1996, CANCER RES, V56, P268; BesnardGuerin C, 1996, HUM GENET, V97, P163, DOI 10.1007/BF02265259; BONETTA L, 1990, SCIENCE, V250, P994, DOI 10.1126/science.2173146; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; COPPES MJ, 1992, GENE CHROMOSOME CANC, V5, P326, DOI 10.1002/gcc.2870050408; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GRUNDY P, 1995, HEMATOL ONCOL CLIN N, V9, P1201, DOI 10.1016/S0889-8588(18)30041-8; Hannigan GE, 1997, GENOMICS, V42, P177, DOI 10.1006/geno.1997.4719; Hoovers JMN, 1995, P NATL ACAD SCI USA, V92, P12456, DOI 10.1073/pnas.92.26.12456; HUANG A, 1990, SCIENCE, V250, P991, DOI 10.1126/science.2173145; JAMES MR, 1994, NAT GENET, V8, P70, DOI 10.1038/ng0994-70; KARNIK P, 1995, HUM MOL GENET, V4, P1889, DOI 10.1093/hmg/4.10.1889; KARNIK P, 1998, IN PRESS HUMAN MOL G; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PING AJ, 1989, AM J HUM GENET, V44, P720; Reid LH, 1997, GENOMICS, V43, P366, DOI 10.1006/geno.1997.4826; Reid LH, 1996, HUM MOL GENET, V5, P239, DOI 10.1093/hmg/5.2.239; SAIT SNJ, 1994, GENE CHROMOSOME CANC, V11, P97; Sotelo-Avila C, 1976, Perspect Pediatr Pathol, V3, P255; Tran YK, 1996, CANCER RES, V56, P2916; VARANASI R, 1994, P NATL ACAD SCI USA, V91, P3554, DOI 10.1073/pnas.91.9.3554; VIEL A, 1992, BRIT J CANCER, V66, P1030, DOI 10.1038/bjc.1992.405; WINQVIST R, 1995, CANCER RES, V55, P2660; YOUNG J L JR, 1986, Cancer, V58, P598, DOI 10.1002/1097-0142(19860715)58:2+<598::AID-CNCR2820581332>3.0.CO;2-C	28	35	36	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 16	1998	17	2					237	240		10.1038/sj.onc.1201959	http://dx.doi.org/10.1038/sj.onc.1201959			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZZ211	9674708				2022-12-25	WOS:000074706700012
J	Hugl, SR; White, MF; Rhodes, CJ				Hugl, SR; White, MF; Rhodes, CJ			Insulin-like growth factor I (IGF-I)-stimulated pancreatic beta-cell growth is glucose-dependent - Synergistic activation of insulin receptor substrate-mediated signal transduction pathways by glucose and IGF-I in INS-1 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FETAL-RAT ISLETS; PROTEIN-KINASE; TISSUE-CULTURE; HORMONE; PROLIFERATION; BIOSYNTHESIS; PROLACTIN; REPLICATION; MECHANISMS; SECRETION	Nutrients and certain growth factors stimulate pancreatic beta-cell mitogenesis, however, the appropriate mitogenic signal transduction pathways have not been defined, In the glucose sensitive pancreatic beta-cell line, INS-I, it was found that glucose (6-18 mM) independently increased INS-1 cell proliferation (>20-fold at 15 mM glucose). Insulin-like growth factor I (IGF-I)-induced INS-1 cell proliferation was glucose-dependent only in the physiologically relevant concentration range (6-18 mm glucose), The combination of IGF-I and glucose was synergistic, increasing INS-1 cell-proliferation >20-fold at 15 mM glucose + 10 nM IGF-I, Glucose metabolism and phosphatidylinositol S'-kinase (PI 3'-kinase) activation were necessary for both glucose and IGF-I-stimulated INS-1 cell proliferation, IGF-I and 15 mM glucose increased tyrosine phosphorylation mediated recruitment of Grb2/mSOS and PI 3'-kinase to IRS-2 and pp60, Glucose and IGF-I also induced Shc association with Grb2/ mSOS, Glucose (3-18 mM) and IGF-I, independently of glucose, activated mitogen-activated protein kinase but this did not correlate with IGF-I-induced beta-cell proliferation, In contrast, p70(S6K) was activated with increasing glucose concentration (between 6 and 18 mM), and potentiated by IGF I in the same glucose concentration range which correlated with INS-1 cell proliferation rate. Thus, glucose and IGF-I-induced beta-cell proliferation were mediated via a signaling mechanism that was facilitated by mitogen-activated protein kinase but de pendent on IRS-mediated induction of PI 3'-kinase activity and downstream activation of p70S6K. The glucose dependence of IGF-I mediated INS-1 cell proliferation emphasizes beta-cell signaling mechanisms are rather unique in being tightly linked to glycolytic metabolic flux.	Univ Texas, SW Med Ctr, Dept Internal Med, Gifford Labs Diabet Res, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Gifford Labs Diabet Res, Dallas, TX 75235 USA; Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.	Rhodes, CJ (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, Gifford Labs Diabet Res, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	rhodes02@utsw.swmed.edu			NIDDK NIH HHS [DK 50610] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK050610, R01DK050610] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; ASHCROFT SJH, 1980, DIABETOLOGIA, V18, P5, DOI 10.1007/BF01228295; Benito M, 1996, INT J BIOCHEM CELL B, V28, P499, DOI 10.1016/1357-2725(95)00168-9; BILLESTRUP N, 1991, ENDOCRINOLOGY, V129, P883, DOI 10.1210/endo-129-2-883; BILLESTRUP N, 1990, P NATL ACAD SCI USA, V87, P7210, DOI 10.1073/pnas.87.18.7210; BONNERWEIR S, 1992, DIABETES NUTR MET S1, V5, P1; BRELJE TC, 1991, ENDOCRINOLOGY, V128, P45, DOI 10.1210/endo-128-1-45; BROCKENBROUGH JS, 1988, DIABETES, V37, P232, DOI 10.2337/diabetes.37.2.232; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHICK WL, 1973, DIABETES, V22, P687, DOI 10.2337/diab.22.9.687; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; FRODIN M, 1995, J BIOL CHEM, V270, P7882, DOI 10.1074/jbc.270.14.7882; Hansen LH, 1996, J BIOL CHEM, V271, P12669, DOI 10.1074/jbc.271.21.12669; Harbeck MC, 1996, DIABETES, V45, P711, DOI 10.2337/diabetes.45.6.711; HELLERSTROM C, 1991, DIABETES, V40, P89, DOI 10.2337/diab.40.2.S89; HELLERSTROM C, 1991, ACTA PAEDIATR SCAND, P55; HOFMANN C, 1989, ENDOCRINOLOGY, V124, P257, DOI 10.1210/endo-124-1-257; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Kadowaki Takashi, 1996, Endocrine Journal, V43, pS33, DOI 10.1507/endocrj.43.Suppl_S33; Khoo S, 1997, P NATL ACAD SCI USA, V94, P5599, DOI 10.1073/pnas.94.11.5599; Lavan BE, 1997, J BIOL CHEM, V272, P11439; LEAHY JL, 1992, DIABETES CARE, V15, P442, DOI 10.2337/diacare.15.3.442; Liu JP, 1996, MOL CELL ENDOCRINOL, V116, P1, DOI 10.1016/0303-7207(95)03706-3; Macfarlane WM, 1997, J BIOL CHEM, V272, P20936, DOI 10.1074/jbc.272.33.20936; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; MYERS MG, 1994, J BIOL CHEM, V269, P28783; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; NIELSEN JH, 1989, MOL ENDOCRINOL, V3, P165, DOI 10.1210/mend-3-1-165; NIELSEN JH, 1989, EXP CLIN ENDOCRINOL, V93, P277; OGREID D, 1994, EUR J BIOCHEM, V221, P1089, DOI 10.1111/j.1432-1033.1994.tb18828.x; Prentki M, 1996, EUR J ENDOCRINOL, V134, P272, DOI 10.1530/eje.0.1340272; ROTHENBERG PL, 1995, DIABETES, V44, P802, DOI 10.2337/diabetes.44.7.802; Scharfmann R, 1990, Diabetes Res, V15, P137; SCHUPPIN GT, 1998, IN PRESS DIABETES; Sekine N, 1996, ENDOCRINOLOGY, V137, P1841, DOI 10.1210/en.137.5.1841; Sjoholm A, 1997, DIABETES, V46, P1141, DOI 10.2337/diabetes.46.7.1141; SmithHall J, 1997, BIOCHEMISTRY-US, V36, P8304, DOI 10.1021/bi9630974; SWENNE I, 1980, DIABETES, V29, P686, DOI 10.2337/diab.29.9.686; SWENNE I, 1987, DIABETES, V36, P288, DOI 10.2337/diabetes.36.3.288; SWENNE I, 1992, DIABETOLOGIA, V35, P193, DOI 10.1007/BF00400917; WELSH M, 1988, P NATL ACAD SCI USA, V85, P116, DOI 10.1073/pnas.85.1.116; WELSH M, 1993, DIABETES METAB REV, V9, P25, DOI 10.1002/dmr.5610090104; WENHAM RM, 1994, J BIOL CHEM, V269, P4947; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608	46	207	212	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17771	17779		10.1074/jbc.273.28.17771	http://dx.doi.org/10.1074/jbc.273.28.17771			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651378	hybrid			2022-12-25	WOS:000074816100071
J	Qiu, YC; Benet, LZ; Burlingame, AL				Qiu, YC; Benet, LZ; Burlingame, AL			Identification of the hepatic protein targets of reactive metabolites of acetaminophen in vivo in mice using two-dimensional gel electrophoresis and mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							PARACETAMOL-INDUCED HEPATOTOXICITY; ISOLATED MOUSE HEPATOCYTES; GLUTATHIONE-S-TRANSFERASE; TIME-OF-FLIGHT; COMMON ARYLATING INTERMEDIATE; ACETYL-PARA-BENZOQUINONEIMINE; 56-KDA SELENIUM-BINDING; BOUND LIVER PROTEINS; OXIDATIVE STRESS; COVALENT BINDING	Liver toxicity following an overdose of acetaminophen is frequently considered a model for drug-induced hepatotoxicity. Extensive studies over many years have established that such toxicity is web correlated with liver protein arylation by acetaminophen metabolites. Identification of protein targets for covalent modifications is a challenging but necessary step in understanding how covalent binding could lead to liver toxicity. Previous approaches suffered from technical limitations, and thus over the last 10 years heroic efforts were required to determine the identity of only a few target proteins. We present a new mass spectrometry-based strategy for identification of all target proteins that now provides a comprehensive survey of the suite of Liver proteins modified. After administration of radiolabeled acetaminophen to mice, the proteins in the liver tissue lysate were separated by two-dimensional polyacrylamide gel electrophoresis. In-gel digestion of the radiolabeled gel spots gave a set of tryptic peptides, which were analyzed by matrix-assisted laser desorption ionization mass spectrometry. Interrogation of data bases based on experimentally determined molecular a-eights of peptides and product ion tags from postsource decay mass spectra was employed for the determination of the identities of modified liver proteins. Using this method, more than 20 new drug-labeled proteins have been identified.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Liver, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Burlingame, AL (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, 513 Parnassus Ave, San Francisco, CA 94143 USA.		Benet, Leslie Z/K-8286-2016		NCRR NIH HHS [RR 01614] Funding Source: Medline; NIGMS NIH HHS [GMS 36633] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036633] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ADAMSON GM, 1993, BIOCHEM PHARMACOL, V45, P2289, DOI 10.1016/0006-2952(93)90201-7; ADAMSON GM, 1989, BIOCHEM PHARMACOL, V38, P3323, DOI 10.1016/0006-2952(89)90630-8; Adessi C, 1997, ELECTROPHORESIS, V18, P127, DOI 10.1002/elps.1150180124; Anderson NG, 1996, ELECTROPHORESIS, V17, P443, DOI 10.1002/elps.1150170303; ANDERSSON BS, 1990, CHEM-BIOL INTERACT, V75, P201, DOI 10.1016/0009-2797(90)90118-7; ANIYA Y, 1993, JPN J PHARMACOL, V62, P9, DOI 10.1254/jjp.62.9; ANSHER SS, 1983, HEPATOLOGY, V3, P932; ARNAIZ SL, 1995, FREE RADICAL BIO MED, V19, P303, DOI 10.1016/0891-5849(95)00023-Q; BARTOLONE JB, 1989, TOXICOL APPL PHARM, V99, P240, DOI 10.1016/0041-008X(89)90006-9; BARTOLONE JB, 1987, BIOCHEM PHARMACOL, V36, P1193, DOI 10.1016/0006-2952(87)90069-4; BARTOLONE JB, 1988, BIOCHEM PHARMACOL, V37, P4763, DOI 10.1016/0006-2952(88)90350-4; BARTOLONE JB, 1989, FUND APPL TOXICOL, V13, P859, DOI 10.1016/0272-0590(89)90339-4; BARTOLONE JB, 1992, TOXICOL APPL PHARM, V113, P19, DOI 10.1016/0041-008X(92)90004-C; BIRGE RB, 1990, TOXICOL APPL PHARM, V105, P472, DOI 10.1016/0041-008X(90)90150-S; BOELSTERLI UA, 1993, DRUG METAB REV, V25, P395, DOI 10.3109/03602539308993981; BRUNO MK, 1992, TOXICOL APPL PHARM, V112, P282, DOI 10.1016/0041-008X(92)90198-2; BULERA SJ, 1995, TOXICOL APPL PHARM, V134, P313, DOI 10.1006/taap.1995.1197; BURCHAM PC, 1990, TOXICOL LETT, V50, P37, DOI 10.1016/0378-4274(90)90250-P; BURCHAM PC, 1991, J BIOL CHEM, V266, P5049; BURLINGAME AL, 1996, MASS SPECTROMETRY BI, P546; Chang PWG, 1997, J CELL BIOCHEM, V64, P217, DOI 10.1002/(SICI)1097-4644(199702)64:2<217::AID-JCB5>3.0.CO;2-#; CHIEN CI, 1994, BBA-PROTEIN STRUCT M, V1204, P175, DOI 10.1016/0167-4838(94)90006-X; CLAUSER KR, 1995, P NATL ACAD SCI USA, V92, P5072, DOI 10.1073/pnas.92.11.5072; CLAUSER KR, 1996, P 44 ASMS C MASS SPE, P365; COMPORTI M, 1989, CHEM-BIOL INTERACT, V72, P1, DOI 10.1016/0009-2797(89)90016-1; CORCORAN GB, 1980, MOL PHARMACOL, V18, P536; DAHLIN DC, 1982, J MED CHEM, V25, P885, DOI 10.1021/jm00350a001; DAHLIN DC, 1984, P NATL ACAD SCI-BIOL, V81, P1327, DOI 10.1073/pnas.81.5.1327; DONNELLY PJ, 1994, ARCH TOXICOL, V68, P110, DOI 10.1007/s002040050043; Ellouk-Achard S, 1995, Arch Toxicol Suppl, V17, P209; Epstein LB, 1996, ELECTROPHORESIS, V17, P1655, DOI 10.1002/elps.1150171103; ESTERLINE RL, 1989, BIOCHEM PHARMACOL, V38, P2387, DOI 10.1016/0006-2952(89)90481-4; GERSON RJ, 1985, BIOCHEM BIOPH RES CO, V126, P1129, DOI 10.1016/0006-291X(85)90303-1; Gibson JD, 1996, CHEM RES TOXICOL, V9, P580, DOI 10.1021/tx950153d; Goldin RD, 1996, J PATHOL, V179, P432; GUPTA S, 1995, TOXICOLOGIST, V153; HAENEN GRMM, 1991, ARCH BIOCHEM BIOPHYS, V287, P48, DOI 10.1016/0003-9861(91)90386-W; HALL SC, 1993, P NATL ACAD SCI USA, V90, P1927, DOI 10.1073/pnas.90.5.1927; Halmes NC, 1996, CHEM RES TOXICOL, V9, P541, DOI 10.1021/tx950158a; HARVISON PJ, 1988, CHEM RES TOXICOL, V1, P47, DOI 10.1021/tx00001a009; HAYES JD, 1990, BIOCHEM J, V272, P281, DOI 10.1042/bj2720281; HINSON JA, 1981, LIFE SCI, V29, P107, DOI 10.1016/0024-3205(81)90278-2; HINSON JA, 1994, DRUG METAB REV, V26, P395, DOI 10.3109/03602539409029805; HOLME JA, 1984, BIOCHEM PHARMACOL, V33, P401, DOI 10.1016/0006-2952(84)90232-6; HOLTZMAN JL, 1995, DRUG METAB REV, V27, P277, DOI 10.3109/03602539509029827; HONG M, 1994, TOXICOLOGIST, V427; HORIE T, 1995, J TOXICOL SCI, V20, P13; ISHII T, 1993, J BIOL CHEM, V268, P18633; JOLLOW DJ, 1973, J PHARMACOL EXP THER, V187, P195; KAMIYAMA T, 1993, TOXICOL LETT, V66, P7, DOI 10.1016/0378-4274(93)90073-7; KASTER JK, 1996, TOXICOLOGIST, V30, P280; KATYARE SS, 1989, BRIT J PHARMACOL, V96, P51, DOI 10.1111/j.1476-5381.1989.tb11783.x; KELLER RJ, 1991, DRUG METAB DISPOS, V19, P184; KYLE ME, 1987, BIOCHEM BIOPH RES CO, V149, P889, DOI 10.1016/0006-291X(87)90491-8; Landin JS, 1996, TOXICOL APPL PHARM, V141, P299; LANFEAR J, 1993, CARCINOGENESIS, V14, P335, DOI 10.1093/carcin/14.3.335; LASKEY RA, 1984, RADIOISTOPE DETECTIO, V2; LASKIN DL, 1986, TOXICOL APPL PHARM, V86, P204, DOI 10.1016/0041-008X(86)90051-7; LASKIN DL, 1995, HEPATOLOGY, V21, P1045, DOI 10.1002/hep.1840210424; LASKIN DL, 1986, TOXICOL APPL PHARM, V86, P216, DOI 10.1016/0041-008X(86)90052-9; MANAUTOU JE, 1995, J TOXICOL ENV HEALTH, V46, P263, DOI 10.1080/15287399509532034; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; Matsui NM, 1997, ELECTROPHORESIS, V18, P409, DOI 10.1002/elps.1150180315; Medzihradszky KF, 1997, INT J MASS SPECTROM, V160, P357, DOI 10.1016/S0168-1176(96)04525-9; Medzihradszky KF, 1996, J AM SOC MASS SPECTR, V7, P1, DOI 10.1016/1044-0305(95)00621-4; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; MEYERS LL, 1988, TOXICOL APPL PHARM, V93, P378, DOI 10.1016/0041-008X(88)90040-3; MILLER JA, 1994, CANCER LETT, V83, P9, DOI 10.1016/0304-3835(94)90292-5; MILLER JA, 1994, CANCER RES, V54, pS1879; MINER DJ, 1979, BIOCHEM PHARMACOL, V28, P3285, DOI 10.1016/0006-2952(79)90123-0; MITCHELL AE, 1995, CHEM RES TOXICOL, V8, P1054, DOI 10.1021/tx00050a009; MYERS TG, 1995, CHEM RES TOXICOL, V8, P403, DOI 10.1021/tx00045a012; NAKAE D, 1988, ARCH BIOCHEM BIOPHYS, V267, P651, DOI 10.1016/0003-9861(88)90073-2; NELSON SD, 1995, DRUG METAB REV, V27, P147, DOI 10.3109/03602539509029821; NELSON SD, 1990, SEMIN LIVER DIS, V10, P267, DOI 10.1055/s-2008-1040482; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OZDEMIRLER G, 1994, J APPL TOXICOL, V14, P297, DOI 10.1002/jat.2550140410; PARMAR DV, 1995, EUR J PHARM-ENVIRON, V293, P225, DOI 10.1016/S0922-4106(05)80047-1; POTTER WZ, 1974, PHARMACOLOGY, V12, P129, DOI 10.1159/000136531; Pumford NR, 1997, J PHARMACOL EXP THER, V280, P501; PUMFORD NR, 1990, BIOCHEM PHARMACOL, V40, P573, DOI 10.1016/0006-2952(90)90558-3; PUMFORD NR, 1992, BIOCHEM BIOPH RES CO, V182, P1348, DOI 10.1016/0006-291X(92)91881-P; Rabilloud T, 1997, ELECTROPHORESIS, V18, P307, DOI 10.1002/elps.1150180303; RAMSAY RR, 1989, ARCH BIOCHEM BIOPHYS, V273, P449, DOI 10.1016/0003-9861(89)90504-3; RASHED MS, 1990, DRUG METAB DISPOS, V18, P765; Righetti PG, 1997, ANAL BIOCHEM, V247, P1, DOI 10.1006/abio.1997.2000; ROBERTS DW, 1991, AM J PATHOL, V138, P359; ROBERTS DW, 1987, J PHARMACOL EXP THER, V241, P527; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; ROUSE JC, 1995, J AM SOC MASS SPECTR, V6, P822, DOI 10.1016/1044-0305(95)00325-8; Sanchez JC, 1997, ELECTROPHORESIS, V18, P324, DOI 10.1002/elps.1150180305; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Stimson E, 1997, INT J MASS SPECTROM, V169, P231, DOI 10.1016/S0168-1176(97)00227-9; STRUBELT O, 1992, BIOCHEM PHARMACOL, V44, P163, DOI 10.1016/0006-2952(92)90050-S; TIRMENSTEIN MA, 1990, J BIOL CHEM, V265, P3059; VANDERZEE J, 1988, CHEM-BIOL INTERACT, V65, P15, DOI 10.1016/0009-2797(88)90027-0; VANDESTRAAT R, 1987, BIOCHEM PHARMACOL, V36, P2065, DOI 10.1016/0006-2952(87)90132-8; VERMEULEN NPE, 1992, DRUG METAB REV, V24, P367, DOI 10.3109/03602539208996298; VESTAL ML, 1995, RAPID COMMUN MASS SP, V9, P1044, DOI 10.1002/rcm.1290091115; WU XW, 1989, P NATL ACAD SCI USA, V86, P9412, DOI 10.1073/pnas.86.23.9412; [No title captured]	102	242	254	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17940	17953		10.1074/jbc.273.28.17940	http://dx.doi.org/10.1074/jbc.273.28.17940			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651401	hybrid			2022-12-25	WOS:000074816100094
J	Roesijadi, G; Bogumil, R; Vasak, M; Kagi, JHR				Roesijadi, G; Bogumil, R; Vasak, M; Kagi, JHR			Modulation of DNA binding of a tramtrack zinc finger peptide by the metallothionein-thionein conjugate pair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; METAL-BINDING; TUMOR-CELLS; PROTEIN; DROSOPHILA; CADMIUM; DOMAINS; GENE; SPECIFICITY; EXPRESSION	The ability of metallothionein (MT) to modulate DNA binding by a two-finger peptide of Tramtrack (TTK), a CCHH zinc transcription factor, was investigated using metal bound and metal-deficient forms of rabbit MT-2 and the TTK peptide. Thionein inhibited DNA binding by zinc-bound TTK, and Zn-MT restored DNA-binding by zinc deficient apo-TTK. "Free" zinc at low concentrations was as effective as Zn-MT in restoring DNA binding by apopeptide but was inhibitory at concentrations equal to zinc bound to 2 mol eq and higher of Zn-MT. Substitution of cadmium for zinc reduced the affinity of the peptide for its DNA binding site. This effect was reversed by incubation with Zn-MT. The circular dichroic spectra of the TTK peptide indicated that zinc removal resulted in loss of a-helical structures, which are sites of DNA contact points. Reconstitution with cadmium resulted in stoichiometric substitution of 2 mol of Cd/mol of peptide but not recovery of a-helical structures. Incubation of Cd-TTK with Zn MT restored the secondary structure expected for zinc-bound TTK. The ability of Zn-MT and thionein to restore or inhibit DNA-binding by TTK was associated with effects on the metallation status of the peptide and related alterations in its secondary structure.	Univ Maryland, Chesapeake Biol Lab, Ctr Environm Sci, Solomons, MD 20688 USA; Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland	University System of Maryland; University of Maryland Center for Environmental Science; University of Zurich	Roesijadi, G (corresponding author), Univ Maryland, Chesapeake Biol Lab, Ctr Environm Sci, POB 38, Solomons, MD 20688 USA.	groes@cbl.umces.edu			FIC NIH HHS [1 F06 TW02150-1A1] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F06TW002150] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Abshire MK, 1996, J TOXICOL ENV HEALTH, V48, P359, DOI 10.1080/009841096161258; ATAR D, 1995, J BIOL CHEM, V270, P2473, DOI 10.1074/jbc.270.6.2473; Badenhorst P, 1996, GENES CELLS, V1, P707, DOI 10.1111/j.1365-2443.1996.tb00011.x; BERG JM, 1990, J BIOL CHEM, V265, P6513; Berg JM, 1997, ANNU REV BIOPH BIOM, V26, P357, DOI 10.1146/annurev.biophys.26.1.357; BERG JM, 1989, J AM CHEM SOC, V111, P3759, DOI 10.1021/ja00192a050; BROWN JL, 1991, EMBO J, V10, P665, DOI 10.1002/j.1460-2075.1991.tb07995.x; BURKE CJ, 1992, J BIOL CHEM, V267, P9639; CanoGauci DF, 1996, FEBS LETT, V386, P1, DOI 10.1016/0014-5793(96)00356-0; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CHAN HM, 1993, BIOCHEM CELL BIOL, V71, P133, DOI 10.1139/o93-022; CHERIAN MG, 1994, ENVIRON HEALTH PERSP, V102, P131, DOI 10.2307/3431776; CHERIAN MG, 1993, METALLOTHIONEIN, V3, P87; CHURCHICH JE, 1989, BIOCHIM BIOPHYS ACTA, V996, P181, DOI 10.1016/0167-4838(89)90245-8; Da Silva JJR, 1991, BIOL CHEM ELEMENTS, P299; FAIRALL L, 1992, J MOL BIOL, V226, P349, DOI 10.1016/0022-2836(92)90952-G; FAIRALL L, 1993, NATURE, V366, P483, DOI 10.1038/366483a0; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hanas JS, 1996, NUCLEIC ACIDS RES, V24, P924, DOI 10.1093/nar/24.5.924; HARRISON SD, 1990, EMBO J, V9, P207, DOI 10.1002/j.1460-2075.1990.tb08097.x; HENEHAN CJ, 1993, PROTEIN SCI, V2, P1756, DOI 10.1002/pro.5560021019; HUANG PC, 1993, METALLOTHIONEIN, V3, P407; HUNZIKER PE, 1995, BIOCHEM J, V306, P265, DOI 10.1042/bj3060265; Jacob C, 1998, P NATL ACAD SCI USA, V95, P3489, DOI 10.1073/pnas.95.7.3489; Jiang LJ, 1998, P NATL ACAD SCI USA, V95, P3483, DOI 10.1073/pnas.95.7.3483; KAGI JHR, 1993, ADV LIF SCI, P29; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; KRIZEK BA, 1993, INORG CHEM, V32, P937, DOI 10.1021/ic00058a030; KRIZEK BA, 1993, PROTEIN SCI, V2, P1313, DOI 10.1002/pro.5560020814; KUWAHARA J, 1990, BIOCHEMISTRY-US, V29, P8627, DOI 10.1021/bi00489a019; LAZO JS, 1995, ANNU REV PHARMACOL, V35, P635; Maret W, 1998, P NATL ACAD SCI USA, V95, P3478, DOI 10.1073/pnas.95.7.3478; MARET W, 1994, P NATL ACAD SCI USA, V91, P237, DOI 10.1073/pnas.91.1.237; Maret W, 1997, P NATL ACAD SCI USA, V94, P2233, DOI 10.1073/pnas.94.6.2233; NETTESHEIM DG, 1985, BIOCHEMISTRY-US, V24, P6744, DOI 10.1021/bi00345a003; OTVOS JD, 1993, METALLOTHIONEIN, V3, P57; PATTANAIK A, 1994, J INORG BIOCHEM, V54, P91, DOI 10.1016/0162-0134(94)80023-5; POSEWITZ MC, 1995, CHEM RES TOXICOL, V8, P1020, DOI 10.1021/tx00050a005; Roesijadi G, 1996, COMP BIOCHEM PHYS C, V113, P117, DOI 10.1016/0742-8413(95)02077-2; SATO M, 1993, FREE RADICAL BIO MED, V14, P325, DOI 10.1016/0891-5849(93)90029-T; SIMONS TJB, 1991, J MEMBRANE BIOL, V123, P63, DOI 10.1007/BF01993964; Sunderman FW, 1996, MOL REPROD DEV, V43, P444; THIESEN HJ, 1991, BIOCHEM BIOPH RES CO, V176, P551, DOI 10.1016/S0006-291X(05)80219-0; UDOM AO, 1980, BIOCHEM J, V187, P329, DOI 10.1042/bj1870329; VALLEE BL, 1972, ANNU REV BIOCHEM, V41, P91, DOI 10.1146/annurev.bi.41.070172.000515; VASAK M, 1991, METHOD ENZYMOL, V205, P41; VASAK M, 1991, METHOD ENZYMOL, V205, P452; Vasak M, 1997, NATO ASI 2, V26, P195; VASAK M, 1983, MET IONS BIOL SYST, V15, P213; WILLNER H, 1987, BIOCHEMISTRY-US, V26, P6287, DOI 10.1021/bi00393a049; Woo ES, 1996, EXP CELL RES, V224, P365, DOI 10.1006/excr.1996.0146; YANG JT, 1986, METHOD ENZYMOL, V130, P208; ZENG J, 1991, FEBS LETT, V279, P310, DOI 10.1016/0014-5793(91)80175-3; ZENG J, 1991, P NATL ACAD SCI USA, V88, P9984, DOI 10.1073/pnas.88.22.9984; ZENG J, 1991, THESIS U ZURICH ZURI, P55; ZENG J, 1995, HDB EXPT PHARM, P333	56	82	84	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17425	17432		10.1074/jbc.273.28.17425	http://dx.doi.org/10.1074/jbc.273.28.17425			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651329	hybrid			2022-12-25	WOS:000074816100022
J	Vooijs, M; van der Valk, M; te Riele, H; Berns, A				Vooijs, M; van der Valk, M; te Riele, H; Berns, A			Flp-mediated tissue-specific inactivation of the retinoblastoma tumor suppressor gene in the mouse	ONCOGENE			English	Article						Rb inactivation; tissue-specific; Flp site-specific DNA recombination; pituitary gland tumor; tumor progression; mouse model for sporadic cancer	SITE-SPECIFIC RECOMBINATION; EMBRYONIC STEM-CELLS; LOCUS-CONTROL REGION; TRANSGENIC MICE; DNA RECOMBINATION; SWITCH RECOMBINATION; MAMMALIAN-CELLS; CRE RECOMBINASE; CHIMERIC MICE; IN-VIVO	The yeast-derived Flp-frt site-specific DNA recombination system was used to achieve pituitary-specific inactivation of the retinoblastoma (Rb) tumor suppressor gene. Whereas mice carrying only frt sites in both alleles of Iib remain tumor free, tumorigenesis ensues when the Flp recombinase is expressed. The rate of tumorigenesis in these mice depends both on the expression level of the Flp recombinase and on the presence of frt sites in one or both Rb alleles. This permitted a more accurate definition of the consecutive steps in pituitary tumorigenesis. Our study illustrates the potential of this approach for studying sporadic cancer in a defined mouse model.	Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Berns, A (corresponding author), Netherlands Canc Inst, Div Mol Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.		Vooijs, Marc/K-3522-2019					Akagi K, 1997, NUCLEIC ACIDS RES, V25, P1766, DOI 10.1093/nar/25.9.1766; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; Betz UAK, 1996, CURR BIOL, V6, P1307, DOI 10.1016/S0960-9822(02)70717-3; Brown MA, 1997, TRENDS GENET, V13, P202, DOI 10.1016/S0168-9525(97)01132-3; Buchholz F, 1996, NUCLEIC ACIDS RES, V24, P4256, DOI 10.1093/nar/24.21.4256; CAPECCHI MR, 1989, TRENDS GENET, V5, P70, DOI 10.1016/0168-9525(89)90029-2; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Donehower LA, 1996, SEMIN CANCER BIOL, V7, P269, DOI 10.1006/scbi.1996.0035; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; DONOGHUE MJ, 1991, J CELL BIOL, V115, P423, DOI 10.1083/jcb.115.2.423; Dymecki SM, 1996, P NATL ACAD SCI USA, V93, P6191, DOI 10.1073/pnas.93.12.6191; Feil R, 1996, P NATL ACAD SCI USA, V93, P10887, DOI 10.1073/pnas.93.20.10887; Festenstein R, 1996, SCIENCE, V271, P1123, DOI 10.1126/science.271.5252.1123; FIERING S, 1993, P NATL ACAD SCI USA, V90, P8469, DOI 10.1073/pnas.90.18.8469; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; HAMMER GD, 1990, MOL ENDOCRINOL, V4, P1689, DOI 10.1210/mend-4-11-1689; HARRISON DJ, 1995, ONCOGENE, V10, P1615; HARVEY M, 1995, CANCER RES, V55, P1146; HASTY P, 1991, NATURE, V350, P243, DOI 10.1038/350243a0; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU NP, 1994, ONCOGENE, V9, P1021; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jacks T, 1996, ANNU REV GENET, V30, P603, DOI 10.1146/annurev.genet.30.1.603; JUNG S, 1993, SCIENCE, V259, P984, DOI 10.1126/science.8438159; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; KNUDSON AG, 1993, NAT GENET, V5, P103, DOI 10.1038/ng1093-103; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LAKSO M, 1992, P NATL ACAD SCI USA, V89, P6232, DOI 10.1073/pnas.89.14.6232; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LOW MJ, 1993, J BIOL CHEM, V268, P24967; MAANDAG ECR, 1994, EMBO J, V13, P4260, DOI 10.1002/j.1460-2075.1994.tb06746.x; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; MAGIN TM, 1992, NUCLEIC ACIDS RES, V20, P3795, DOI 10.1093/nar/20.14.3795; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; Nikitin AY, 1996, GENE DEV, V10, P1870, DOI 10.1101/gad.10.15.1870; OGORMAN S, 1991, SCIENCE, V251, P1351, DOI 10.1126/science.1900642; ORBAN PC, 1992, P NATL ACAD SCI USA, V89, P6861, DOI 10.1073/pnas.89.15.6861; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; ROBERTSON G, 1995, P NATL ACAD SCI USA, V92, P5371, DOI 10.1073/pnas.92.12.5371; SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166; SCHLUTER C, 1993, J CELL BIOL, V123, P513, DOI 10.1083/jcb.123.3.513; Shoemaker AR, 1997, BBA-REV CANCER, V1332, pF25, DOI 10.1016/S0304-419X(96)00041-8; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9; VALANCIUS V, 1991, MOL CELL BIOL, V11, P1402, DOI 10.1128/MCB.11.3.1402; VANDERLUGT N, 1991, GENE, V105, P263, DOI 10.1016/0378-1119(91)90161-4; Wang Y, 1996, P NATL ACAD SCI USA, V93, P3932, DOI 10.1073/pnas.93.9.3932; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0	56	104	108	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 9	1998	17	1					1	12		10.1038/sj.onc.1202169	http://dx.doi.org/10.1038/sj.onc.1202169			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZY936	9671308				2022-12-25	WOS:000074677800001
J	Aandahl, EM; Aukrust, P; Skalhegg, BS; Muller, F; Froland, SS; Hansson, V; Tasken, K				Aandahl, EM; Aukrust, P; Skalhegg, BS; Muller, F; Froland, SS; Hansson, V; Tasken, K			Protein kinase A type I antagonist restores immune responses of T cells from HIV-infected patients	FASEB JOURNAL			English	Article						cAMP; PKA; AIDS; Rp-8-Br-cAMPS	LYMPHOCYTE ACTIVATION; SURFACE MOLECULES; RI-ALPHA; CAMP; RESTORATION; PATHWAY; REPLICATION; RECEPTOR; ANALOGS; VITRO	Cyclic AMP-dependent protein kinase A (PKA) type I has been established as an acute inhibitor of T cell activation. For this reason, we investigated the possible role of PKA. type I in HIV-induced T cell dysfunction, T cells from HIV-infected patients have increased levels of cAMP and are more sensitive to inhibition by cAMP analog than are normal T cells. A PKA type I-selective antagonist increases the impaired proliferation of T cells from HIV-infected patients to normal or subnormal levels (up to 2.8-fold). Follow-up of patients after initiation of highly active antiretroviral treatment revealed that a majority of patients have a persistent T cell dysfunction that is normalized by incubation of T cells with Rp-8-Br-cAMPS, These observations imply that increased activation of PKA. type I may contribute to the progressive T cell dysfunction in HIV infection and that PKA. type I may be a potential target for immunomodulating therapy.-Aandahl, E. M., Aukrust, P., Skalhegg, B. S., Muller, F., Froland, S. S., Hansson, V., Tasken, K. Protein kinase A type I antagonist restores immune responses of T cells from HIV-infected patients.	Univ Oslo, Inst Med Biochem, N-0317 Oslo, Norway; Univ Oslo, Internal Med Res Inst, N-0317 Oslo, Norway; Natl Hosp Norway, Dept Med A, Sect Clin Immunol & Infect Dis, N-0027 Oslo, Norway	University of Oslo; University of Oslo; University of Oslo; National Hospital Norway	Tasken, K (corresponding author), Univ Oslo, Inst Med Biochem, POB 1112, N-0317 Oslo, Norway.		Skålhegg, Bjørn Steen/AAZ-2976-2021	Skålhegg, Bjørn Steen/0000-0002-3481-8084; Aandahl, Einar Martin/0000-0002-0115-8382; Tasken, Kjetil/0000-0003-2841-4697				CDC (Centers for Disease Control and Prevention), 1993, MMWR RECOMM REP, V41, P1; CLERICI M, 1993, SCIENCE, V262, P1721, DOI 10.1126/science.7903123; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; Dayal AK, 1996, ARTHRITIS RHEUM-US, V39, P23, DOI 10.1002/art.1780390104; GJERTSEN BT, 1995, J BIOL CHEM, V270, P20599, DOI 10.1074/jbc.270.35.20599; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; HARAGUCHI S, 1995, IMMUNOL TODAY, V16, P595, DOI 10.1016/0167-5699(95)80083-2; HOFMANN B, 1993, AIDS, V7, P659, DOI 10.1097/00002030-199305000-00008; HOFMANN B, 1993, P NATL ACAD SCI USA, V90, P6676, DOI 10.1073/pnas.90.14.6676; KAMMER GM, 1988, P NATL ACAD SCI USA, V85, P792, DOI 10.1073/pnas.85.3.792; KAMMER GM, 1994, J CLIN INVEST, V94, P422, DOI 10.1172/JCI117340; KAMMER GM, 1988, IMMUNOL TODAY, V9, P222, DOI 10.1016/0167-5699(88)91220-0; Landay AL, 1996, J INFECT DIS, V173, P1085, DOI 10.1093/infdis/173.5.1085; LAXMINARAYANA D, 1993, J CLIN INVEST, V92, P2207, DOI 10.1172/JCI116823; Laxminarayana D, 1996, J IMMUNOL, V156, P497; LEDBETTER JA, 1986, J IMMUNOL, V137, P3299; Levy FO, 1996, EUR J IMMUNOL, V26, P1290, DOI 10.1002/eji.1830260617; NOKTA MA, 1992, AIDS RES HUM RETROV, V8, P1255, DOI 10.1089/aid.1992.8.1255; Pantaleo G, 1997, NAT MED, V3, P483, DOI 10.1038/nm0597-483; SKALHEGG BS, 1994, SCIENCE, V263, P84, DOI 10.1126/science.8272870; SKALHEGG BS, 1992, J BIOL CHEM, V267, P15707; TASKEN K, 1993, J BIOL CHEM, V268, P23483; TASKEN K, 1993, J BIOL CHEM, V268, P21276; Torgersen KM, 1997, J BIOL CHEM, V272, P5495, DOI 10.1074/jbc.272.9.5495	25	96	107	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	1998	12	10					855	862		10.1096/fasebj.12.10.855	http://dx.doi.org/10.1096/fasebj.12.10.855			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZY035	9657525				2022-12-25	WOS:000074580100010
J	Kwon, BS; Wang, SA; Udagawa, N; Haridas, V; Lee, ZH; Kim, KK; Oh, KO; Greene, J; Li, YL; Su, J; Gentz, R; Aggarwal, BB; Ni, J				Kwon, BS; Wang, SA; Udagawa, N; Haridas, V; Lee, ZH; Kim, KK; Oh, KO; Greene, J; Li, YL; Su, J; Gentz, R; Aggarwal, BB; Ni, J			TR1, a new member of the tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption	FASEB JOURNAL			English	Article						TNFR; anti-TR1 mAb; osteoclast; immunization; monoclonal antibody	NERVE GROWTH-FACTOR; OSTEOBLASTIC CELLS; RUFFLED BORDERS; DIFFERENTIATION; IDENTIFICATION; EXPRESSION; MECHANISM; PROTEINS; FAMILY; GENES	A newly identified member of the tumor necrosis factor receptor (TNFR) superfamily shows activities associated with osteoclastogenesis inhibition and fibroblast proliferation. This new member, called TR1, was identified from a search of an expressed sequence tag database, and encodes 401 amino acids with a 21-residue signal sequence. Unlike other members of TNFR, TR1 does not contain a transmembrane domain and is secreted as a 62 kDa glycoprotein. TR1 gem maps to chromosome 8q23-24.1 and its mRNA is abundantly expressed on primary osteoblasts, osteogenic sarcoma cell lines, and primary fibroblasts. The receptors for TR1 were detected on a monocytic cell line (THP-1) and in human fibroblasts. Scatchard analyses indicated two classes of high and medium-high affinity receptors with a kD of approximately 45 and 320 pM, respectively. Recombinant TRI induced proliferation of human foreskin fibroblasts and potentiated TNF-induced proliferation in these cells. In a coculture system of osteoblasts and bone marrow cells, recombinant TR1 completely inhibited the differentiation of osteoclast-like multinucleated cell formation in the presence of several bone-resorbing factors. TR1 also strongly inhibited bone-resorbing function on dentine slices by mature osteoclasts and decreased Ca-45 release in fetal long-bone organ cultures. Anti-TR1 monoclonal antibody promoted the formation of osteoclasts in mouse marrow culture assays. These results indicate that TRI has broad biological activities in fibroblast growth and in osteoclast differentiation and its functions.-Kwon, B. S., Wang, S., Udagawa, N., Haridas, V., Lee, Z. H., Rim, K. K., Oh, K.-O., Greene, J., Li, Y., Su, J., Gentz., R., Aggarwal, B. B., Ni, J. TR1, a new member of tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption.	Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46202 USA; Showa Univ, Sch Dent, Dept Biochem, Shinagawa Ku, Tokyo 142, Japan; Univ Texas, MD Anderson Cancer Ctr, Dept Mol Oncol, Cytokine Res Lab, Houston, TX 77030 USA; Chosun Univ, Sch Dent, Dept Microbiol, Kwangju 501759, South Korea; Seoul Natl Univ, Sch Dent, Dept Oral Microbiol, Chongro Ku, Seoul, South Korea; Human Genome Sci Inc, Rockville, MD 20850 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Walther Cancer Institute; Showa University; University of Texas System; UTMD Anderson Cancer Center; Chosun University; Seoul National University (SNU); GlaxoSmithKline; Human Genome Sciences Inc	Kwon, BS (corresponding author), Indiana Univ, Sch Med, Dept Microbiol & Immunol, 635 Barnhill Dr,MS 255, Indianapolis, IN 46202 USA.	kkwon@sunflower.bio.indiana.edu	Kim, Kack-Kyun/C-5031-2012; Aggarwal, Bharat B/G-3388-2013	Kim, Kack-Kyun/0000-0002-1279-5387; 	NIAID NIH HHS [AI 28175, AI 42379] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028175, R03AI042379] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; AGGARWAL BB, 1995, FEBS LETT, V364, P5, DOI 10.1016/0014-5793(95)00339-B; AKATSU T, 1991, J BONE MINER RES, V6, P183; AKATSU T, 1992, J BONE MINER RES, V7, P1297; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARMITAGE RJ, 1994, CURR OPIN IMMUNOL, V6, P407, DOI 10.1016/0952-7915(94)90119-8; BANCHEREAU J, 1991, SCIENCE, V251, P70, DOI 10.1126/science.1702555; BAUM PR, 1994, EMBO J, V13, P3992, DOI 10.1002/j.1460-2075.1994.tb06715.x; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; DOWER SK, 1984, J IMMUNOL, V132, P751; DUNSTAN CR, 1997, J BONE MINER RES  S1, V12, pS136; JIMI E, 1995, ENDOCRINOLOGY, V136, P806; KANEHISA J, 1990, BONE, V11, P287, DOI 10.1016/8756-3282(90)90082-A; KRAMMER PH, 1994, CURR OPIN IMMUNOL, V6, P279, DOI 10.1016/0952-7915(94)90102-3; Kwon BS, 1997, J BIOL CHEM, V272, P14272, DOI 10.1074/jbc.272.22.14272; KWON BS, 1989, P NATL ACAD SCI USA, V86, P1963, DOI 10.1073/pnas.86.6.1963; MALLETT S, 1991, IMMUNOL TODAY, V12, P220, DOI 10.1016/0167-5699(91)90033-P; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; MURAKAMI H, 1995, BONE, V17, P137, DOI 10.1016/S8756-3282(95)00150-6; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; POLLOK KE, 1993, J IMMUNOL, V150, P771; SASAKI T, 1989, ANAT REC, V224, P379, DOI 10.1002/ar.1092240307; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHATCHARD G, 1949, ANN NY ACAD SCI, V51, P660; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SMITH GL, 1993, J GEN VIROL, V74, P1725, DOI 10.1099/0022-1317-74-9-1725; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; Suda Tatsuo, 1996, P87; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo-123-5-2600; TAKAHASHI N, 1988, ENDOCRINOLOGY, V122, P1373, DOI 10.1210/endo-122-4-1373; TAMURA T, 1993, J BONE MINER RES, V8, P953; TARTAGLIA LA, 1993, CELL, V74; Torcia M, 1996, CELL, V85, P345, DOI 10.1016/S0092-8674(00)81113-7; Tsuda E, 1997, BIOCHEM BIOPH RES CO, V234, P137, DOI 10.1006/bbrc.1997.6603; UDAGAWA N, 1995, J EXP MED, V182, P1461, DOI 10.1084/jem.182.5.1461	38	139	151	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	1998	12	10					845	854		10.1096/fasebj.12.10.845	http://dx.doi.org/10.1096/fasebj.12.10.845			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZY035	9657524				2022-12-25	WOS:000074580100009
J	Takahama, Y; Ochiya, T; Sasaki, H; Baba-Toriyama, H; Konishi, H; Nakano, H; Terada, M				Takahama, Y; Ochiya, T; Sasaki, H; Baba-Toriyama, H; Konishi, H; Nakano, H; Terada, M			Molecular cloning and functional analysis of cDNA encoding a rat leukemia inhibitory factor: towards generation of pluripotent rat embryonic stem cells	ONCOGENE			English	Article						sequence; gene targeting; gene expression; LIF; ES cell	KREBS ASCITES-CELLS; CONDITIONED MEDIUM; FEEDER CELLS; FACTOR LIF; IN-VITRO; DIFFERENTIATION; PURIFICATION; EXPRESSION; LINES; CARCINOMA	Embryonic stem (ES) cells are pluripotent cell lines established directly from the early embryo. Maintenance of the stem-cell phenotype of ES cells in vitro requires the presence of a feeder layer of fibroblasts or of a soluble factor, differentiation inhibitory activity (DIA) such as leukemia inhibitory factor (LIF). Here we report the cloning of complete rat LIF cDNA and its nucleotide sequence so as to facilitate studies of rat ES cell technologies on tumor biology. The nucleotide sequence of the rat LIF cDNA indicated that the rat LIF has 91% amino acid sequence identity with murine LIF. The cloned rat LTP cDNA has a putative biological activity as a differentiation-inducing factor on the murine myeloid leukemia cell line MI cells. Culture supernatant of the rat LIF cDNA-transduced rat fibroblast cell line could maintain the stem-cell phenotype of rat ES cells which shelved alkaline phosphatase activity, and this effect was much stronger than that by murine LIF. The availability of rat LIF which shows DIA will assist the in vitro analysis of rat ES cells, and culture of these cells is a route for the generation of gene targeting in rat.	Natl Canc Ctr, Res Inst, Div Genet, Tokyo 104, Japan; Natl Canc Ctr, Res Inst, Chemotherapy Div, Tokyo 104, Japan; Nara Med Univ, Dept Surg 1, Kashihara, Nara 634, Japan	National Cancer Center - Japan; National Cancer Center - Japan; Nara Medical University	Terada, M (corresponding author), Natl Canc Ctr, Res Inst, Div Genet, Tokyo 104, Japan.		Ochiya, Takahiro/AAH-7585-2019					ABE E, 1986, P NATL ACAD SCI USA, V83, P5958, DOI 10.1073/pnas.83.16.5958; Akiyama N, 1997, CANCER RES, V57, P3548; CAPECCHI MR, 1989, TRENDS GENET, V5, P70, DOI 10.1016/0168-9525(89)90029-2; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; Douglas AM, 1997, ONCOGENE, V14, P661, DOI 10.1038/sj.onc.1200882; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; FIRST NL, 1994, REPROD FERT DEVELOP, V6, P553, DOI 10.1071/RD9940553; GEARING DP, 1987, EMBO J, V6, P3995, DOI 10.1002/j.1460-2075.1987.tb02742.x; GODARD A, 1988, BLOOD, V71, P1618; GOUGH NM, 1989, CANCER CELL-MON REV, V1, P77; GOUGH NM, 1988, P NATL ACAD SCI USA, V85, P2623, DOI 10.1073/pnas.85.8.2623; HILTON DJ, 1988, J BIOL CHEM, V263, P9238; HILTON DJ, 1988, ANAL BIOCHEM, V173, P359, DOI 10.1016/0003-2697(88)90200-X; HOGAN B, 1986, MANIPULATING MOUSE E, P207; IANNACCONE PM, 1994, DEV BIOL, V163, P288, DOI 10.1006/dbio.1994.1146; Ide H, 1997, ONCOGENE, V14, P1377, DOI 10.1038/sj.onc.1200964; Joyner A. L., 1993, GENE TARGETING PRACT, P36; KINOSHITA K, 1994, FEBS LETT, V337, P221, DOI 10.1016/0014-5793(94)80195-9; Kishi T, 1997, BIOCHEM BIOPH RES CO, V232, P5, DOI 10.1006/bbrc.1997.6218; KOOPMAN P, 1984, EXP CELL RES, V154, P233, DOI 10.1016/0014-4827(84)90683-9; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PAGLIA D, 1995, J INTERF CYTOK RES, V15, P455, DOI 10.1089/jir.1995.15.455; Pain B, 1996, DEVELOPMENT, V122, P2339; PEASE S, 1990, DEV BIOL, V141, P344, DOI 10.1016/0012-1606(90)90390-5; Savatier P, 1996, ONCOGENE, V12, P309; SMITH AG, 1987, DEV BIOL, V121, P1, DOI 10.1016/0012-1606(87)90132-1; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; SMITH TA, 1983, EXP CELL RES, V145, P458, DOI 10.1016/0014-4827(83)90025-3; SUKOYAN MA, 1992, MOL REPROD DEV, V33, P418, DOI 10.1002/mrd.1080330408; SUN L, 1995, MOL MAR BIOL BIOTECH, V4, P193; THOMSON JA, 1995, P NATL ACAD SCI USA, V92, P7844, DOI 10.1073/pnas.92.17.7844; TOMIDA M, 1984, J BIOL CHEM, V259, P978; WHEELER MB, 1994, REPROD FERT DEVELOP, V6, P288; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; YAMAMORI T, 1989, SCIENCE, V246, P1412, DOI 10.1126/science.2512641; ZIOMEK CA, 1990, J HISTOCHEM CYTOCHEM, V38, P437, DOI 10.1177/38.3.1689343	37	19	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 18	1998	16	24					3189	3196		10.1038/sj.onc.1201826	http://dx.doi.org/10.1038/sj.onc.1201826			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671398				2022-12-25	WOS:000074261300012
J	Goller, ME; Iacovoni, JS; Vogt, PK; Kruse, U				Goller, ME; Iacovoni, JS; Vogt, PK; Kruse, U			Glutaredoxin is a direct target of oncogenic jun	ONCOGENE			English	Article						jun; target gene; glutaredoxin; cytochrome P450; growth associated protein (GAP)-43; differential expression; subtractive hybridization	MESSENGER-RNAS; LEUCINE ZIPPER; TRANSFORMATION; DNA; FAMILY; FOS; TRANSACTIVATION; FIBROBLASTS; PROTEINS	We have analysed differential gene expression in v-jun-transformed chicken embryo fibroblasts (CEF) compared to normal CEF by using the directional tag PCR subtraction method. From a first generation of putative Jun targets four clones were selected for study; they are upregulated in jun-transformed cells. Three of these clones showed homology to known genes: glutaredoxin, growth associated protein (GAP)-43/neuromodulin, and phenobarbital-induced cytochrome P450. The expression of these genes was analysed in fibroblasts transformed by various oncogenes. Expression of the glutaredoxin mRNA could be induced by a Jun-estrogen receptor chimaera in the absence of de novo protein biosynthesis. Based on this observation we conclude that glutaredoxin is a direct target of v-Jun.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Vogt, PK (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, BCC239,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500	NATIONAL CANCER INSTITUTE [R35CA042564] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42564] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BAIZER L, 1990, MOL BRAIN RES, V7, P61, DOI 10.1016/0169-328X(90)90074-N; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BUSSLINGER M, 1994, FOS JUN FAMILIES TRA, P1833; Hadman M, 1996, ONCOGENE, V12, P135; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HANSEN AJ, 1989, DNA-J MOLEC CELL BIO, V8, P179, DOI 10.1089/dna.1.1989.8.179; HARTL M, 1995, P NATL ACAD SCI USA, V92, P11731, DOI 10.1073/pnas.92.25.11731; HARTL M, 1992, CELL GROWTH DIFFER, V3, P899; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P283; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; Kruse U, 1997, P NATL ACAD SCI USA, V94, P12396, DOI 10.1073/pnas.94.23.12396; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LI J, 1993, P NATL ACAD SCI USA, V90, P4490, DOI 10.1073/pnas.90.10.4490; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MORGAN IM, 1992, ONCOGENE, V7, P1119; Picard Didier, 1993, Trends in Cell Biology, V3, P278, DOI 10.1016/0962-8924(93)90057-8; Sambrook J., 2002, MOL CLONING LAB MANU; USUI H, 1994, J NEUROSCI, V14, P4915	20	23	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 4	1998	16	22					2945	2948		10.1038/sj.onc.1201819	http://dx.doi.org/10.1038/sj.onc.1201819			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZR544	9671415				2022-12-25	WOS:000073988200013
J	Kato-Yamada, Y; Noji, H; Yasuda, R; Kinosita, K; Yoshida, M				Kato-Yamada, Y; Noji, H; Yasuda, R; Kinosita, K; Yoshida, M			Direct observation of the rotation of epsilon subunit in F-1-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI F1 ATPASE; ESCHERICHIA-COLI; GAMMA-SUBUNIT; ADENOSINE-TRIPHOSPHATASE; F1-ATPASE; BINDING; SYNTHASE; COMPLEX; SITE	Rotation of the epsilon subunit in F-1-ATPase from thermophilic Bacillus strain PS3 (TF1) was observed under a fluorescence microscope by the method used for observation of the gamma subunit rotation (Noji, H., Yasuda, R., Yoshida, M., and Kinosita, K., Jr. (1997) Nature 386, 299-302). The alpha(3)beta(3)gamma epsilon complex of TF, was fixed to a solid surface, and fluorescently labeled actin filament was attached to the epsilon subunit through biotin-streptavidin. In the presence of ATP, the filament attached to epsilon subunit rotated in a unidirection. The direction of the rotation was the same as that observed for the gamma subunit. The rotational velocity was slightly slower than the filament attached to the gamma subunit, probably due to the experimental setup used. Thus, as suggested from biochemical studies (Aggeler, R., Ogilvie, I., and Capaldi, R. A. (1997) J. Biol. Chem. 272, 19621-19624), the epsilon subunit rotates with the gamma subunit in F-1-ATPase during catalysis.	Tokyo Inst Technol, Resources Utilizat Res Lab, Yokohama, Kanagawa 2268503, Japan; Keio Univ, Fac Sci & Technol, Dept Phys, Yokohama, Kanagawa 2238522, Japan; Teikyo Univ, Biotechnol Res Ctr 3F, Genet Programming Team 13, CREST, Kawasaki, Kanagawa 2160001, Japan	Tokyo Institute of Technology; Keio University; Japan Science & Technology Agency (JST); Teikyo University	Yoshida, M (corresponding author), Tokyo Inst Technol, Resources Utilizat Res Lab, R-1,4259 Nagatsuta, Yokohama, Kanagawa 2268503, Japan.	myoshida@res.titech.ac.jp	Yasuda, Ryohei/E-7726-2011	Yasuda, Ryohei/0000-0001-6263-9297				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Aggeler R, 1997, J BIOL CHEM, V272, P19621, DOI 10.1074/jbc.272.31.19621; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; AGGELER R, 1995, BBA-BIOENERGETICS, V1230, P62, DOI 10.1016/0005-2728(95)00040-P; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Dunn SD, 1997, BBA-BIOENERGETICS, V1319, P177, DOI 10.1016/S0005-2728(96)00159-4; DUNN SD, 1982, J BIOL CHEM, V257, P7354; Hisabori T, 1997, EUR J BIOCHEM, V247, P1158, DOI 10.1111/j.1432-1033.1997.01158.x; HUNT AJ, 1994, BIOPHYS J, V67, P766, DOI 10.1016/S0006-3495(94)80537-5; Kaibara C, 1996, J BIOL CHEM, V271, P2433, DOI 10.1074/jbc.271.5.2433; Kato Y, 1997, J BIOL CHEM, V272, P24906, DOI 10.1074/jbc.272.40.24906; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGET PP, 1979, ARCH BIOCHEM BIOPHYS, V197, P83, DOI 10.1016/0003-9861(79)90222-4; MATSUI T, 1995, BBA-BIOENERGETICS, V1231, P139, DOI 10.1016/0005-2728(95)00070-Y; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schulenberg B, 1997, EUR J BIOCHEM, V249, P134, DOI 10.1111/j.1432-1033.1997.t01-1-00134.x; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SMITH JB, 1977, BIOCHEMISTRY-US, V16, P306, DOI 10.1021/bi00621a023; Tang CL, 1996, J BIOL CHEM, V271, P3018, DOI 10.1074/jbc.271.6.3018; Uhlin U, 1997, STRUCTURE, V5, P1219, DOI 10.1016/S0969-2126(97)00272-4; Watts SD, 1996, J BIOL CHEM, V271, P28341, DOI 10.1074/jbc.271.45.28341; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7; YOKOYAMA K, 1989, J BIOL CHEM, V264, P21837; YOSHIDA M, 1977, J BIOL CHEM, V252, P3480; Zhou YT, 1996, BBA-BIOENERGETICS, V1275, P96, DOI 10.1016/0005-2728(96)00056-4	32	161	165	5	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19375	19377		10.1074/jbc.273.31.19375	http://dx.doi.org/10.1074/jbc.273.31.19375			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677353	hybrid			2022-12-25	WOS:000075125200005
J	Tetaud, E; Manai, F; Barrett, MP; Nadeau, K; Walsh, CT; Fairlamb, AH				Tetaud, E; Manai, F; Barrett, MP; Nadeau, K; Walsh, CT; Fairlamb, AH			Cloning and characterization of the two enzymes responsible for trypanothione biosynthesis in Crithidia fasciculata	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GLUTATHIONYLSPERMIDINE METABOLISM; GLUTATHIONE-REDUCTASE; HYDROGEN-PEROXIDE; TRYPANOSOMA-CRUZI; PURIFICATION; POLYAMINES; DNA; SYNTHETASE; INHIBITORS	Protozoa of the order Kinetoplastida differ from other organisms in their ability to conjugate glutathione (gamma-Glu-Cys-Gly) and spermidine to form trypanothione (N-1,N-8-bis(glutathionyl)spermidine), which is involved in maintaining intracellular thiol redox and in defense against oxidants, In this study, the genes from Crithidia fasciculata, Cf-GSS and Cf-TRS, which encode, respectively, glutathionylspermidine synthetase (EC 6.3.1.8) and trypanothione synthetase (EC 6.3.1.9) have been cloned and expressed. The deduced amino acid sequence of both Cf-GSS and Cf-TRS share 50% sequence similarity with the Escherichia coli glutathionylspermidine synthetase/amidase. Both genes are present as single copies in the C. fasciculata genome. When expressed in E. coli and Saccharomyces cerevisiae, neither protein was present in an active soluble form. However, thiol analysis of S. cerevisiae demonstrated that cells transformed with the Cf-GSS gene contained substantial amounts of glutathionylspermidine, whereas cells expressing both the Cf-GSS and Cf-TRS genes contained glutathionylspermidine and trypanothione, confirming that these genes encode the functional glutathionylspermidine and trypanothione synthetases from C. fasciculata. The translation products of Cf-GSS and Cf-TRS show significant homology to the amidase domain present in E. coli glutathionylspermidine synthetase, which can catalyze both synthesis and degradation of glutathionylspermidine. Glutathionylspermidine synthetase isolated from C, fasciculata was found to possess a similar amidase activity.	Univ Dundee, Dept Biochem, Dundee DD1 4HN, Scotland; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	University of Dundee; Harvard University; Harvard Medical School	Fairlamb, AH (corresponding author), Univ Dundee, Dept Biochem, Wellcome Trust Bldg, Dundee DD1 4HN, Scotland.		Fairlamb, Alan/A-5272-2009	Fairlamb, Alan/0000-0001-5134-0329; Barrett, Mike/0000-0001-9447-3519	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AWAD S, 1992, INT J RADIAT BIOL, V62, P401, DOI 10.1080/09553009214552281; BERNARDS A, 1981, CELL, V27, P497, DOI 10.1016/0092-8674(81)90391-3; Bey P., 1987, INHIBITION POLYAMINE, P1; BOLLINGER JM, 1995, J BIOL CHEM, V270, P14031, DOI 10.1074/jbc.270.23.14031; BOVERIS A, 1980, BIOCHEM J, V188, P643, DOI 10.1042/bj1880643; BOVERIS A, 1977, EXPERIENTIA, V33, P1306, DOI 10.1007/BF01920148; BURLAND V, 1995, NUCLEIC ACIDS RES, V23, P2105, DOI 10.1093/nar/23.12.2105; Chen SJ, 1997, BIOORG MED CHEM LETT, V7, P505; Chen SJ, 1997, J MED CHEM, V40, P3842, DOI 10.1021/jm970414b; DUBIN DT, 1959, BIOCHEM BIOPH RES CO, V1, P26; DUNCAN K, 1988, BIOCHEMISTRY-US, V27, P3709, DOI 10.1021/bi00410a028; ELSKENS MT, 1991, J GEN MICROBIOL, V137, P637, DOI 10.1099/00221287-137-3-637; FAIRLAMB AH, 1987, MOL BIOCHEM PARASIT, V24, P185, DOI 10.1016/0166-6851(87)90105-8; FAIRLAMB AH, 1985, MOL BIOCHEM PARASIT, V14, P187, DOI 10.1016/0166-6851(85)90037-4; FAIRLAMB AH, 1992, ANNU REV MICROBIOL, V46, P695, DOI 10.1146/annurev.micro.46.1.695; FAIRLAMB AH, 1985, SCIENCE, V227, P1485, DOI 10.1126/science.3883489; FAIRLAMB AH, 1986, MOL BIOCHEM PARASIT, V21, P247, DOI 10.1016/0166-6851(86)90130-1; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; HENDERSON GB, 1990, BIOCHEMISTRY-US, V29, P3924, DOI 10.1021/bi00468a019; Koenig K, 1997, J BIOL CHEM, V272, P11908, DOI 10.1074/jbc.272.18.11908; Kwon DS, 1997, J BIOL CHEM, V272, P2429; Lin CH, 1997, CHEM BIOL, V4, P859, DOI 10.1016/S1074-5521(97)90118-6; LIN VH, 1997, BIOCHEMISTRY-US, V36, P14930; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; MCCANN PP, 1992, PHARMACOL THERAPEUT, V54, P195, DOI 10.1016/0163-7258(92)90032-U; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MEISTER A, 1974, ENZYMES, V10, P699; Meister A., 1974, ENZYMES, V10, P671; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PENKETH PG, 1987, FEBS LETT, V221, P427, DOI 10.1016/0014-5793(87)80968-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAMES SL, 1986, BIOCHEMISTRY-US, V25, P3519, DOI 10.1021/bi00360a007; SHIM H, 1988, J GEN MICROBIOL, V134, P807; SMITH K, 1992, PROTEIN SCI, V1, P874, DOI 10.1002/pro.5560010705; SMITH K, 1995, BIOCHEM J, V312, P465, DOI 10.1042/bj3120465; Stadtman E.R., 1974, ENZYMES, V10, P755; STONE KL, 1993, PRACTICAL GUIDE PROT, P45; STRAHERN JN, 1982, MOL BIOL YEAST SACCH; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TABOR H, 1975, J BIOL CHEM, V250, P2648; Verbruggen C, 1996, BIOORG MED CHEM LETT, V6, P253, DOI 10.1016/0960-894X(96)00001-7; WANG CC, 1995, ANNU REV PHARMACOL, V35, P93, DOI 10.1146/annurev.pa.35.040195.000521; YANG TP, 1992, BIOCHIM BIOPHYS ACTA, V1130, P227, DOI 10.1016/0167-4781(92)90535-8; YASUKAWA T, 1995, J BIOL CHEM, V270, P25328, DOI 10.1074/jbc.270.43.25328	44	41	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19383	19390		10.1074/jbc.273.31.19383	http://dx.doi.org/10.1074/jbc.273.31.19383			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677355	hybrid			2022-12-25	WOS:000075125200007
J	He, B; Kukarin, A; Temiakov, D; Chin-Bow, ST; Lyakhov, DL; Rong, MQ; Durbin, RK; McAllister, WT				He, B; Kukarin, A; Temiakov, D; Chin-Bow, ST; Lyakhov, DL; Rong, MQ; Durbin, RK; McAllister, WT			Characterization of an unusual, sequence-specific termination signal for T7 RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION TERMINATION; DNA; BACTERIOPHAGE-T7; INITIATION; ELONGATION; PROMOTER; INVITRO; OPERON; VIRUS; SITE	We have characterized an unusual type of termination signal for T7 RNA polymerase that requires a conserved 7-base pair sequence in the DNA (ATCTGTT in the nontemplate strand). Each of the nucleotides within this sequence is critical for function, as any substitutions abolish termination. The primary site of termination occurs 7 nucleotides downstream from this sequence but is context-independent (that is, the sequence around the site of termination, and in particular the nucleotide at the site of termination, need not be conserved). Termination requires the presence of the conserved sequence and its complement in duplex DNA and is abolished or diminished if the signal is placed downstream of regions in which the non-template strand is missing or mismatched. Under the latter conditions, much of the RNA product remains associated with the template. The latter results suggest that proper resolution of the transcription bubble at its trailing edge and/or displacement of the RNA product are required for termination at this class of signal.	SUNY Hlth Sci Ctr, Morse Inst Mol Genet, Dept Immunol & Microbiol, Brooklyn, NY 11203 USA; Russian Acad Sci, Inst Mol Genet, Lab Mol Genet Microorganisms, Moscow 123182, Russia; Russian Acad Sci, VA Engelhardt Mol Biol Inst, Moscow 117984, Russia	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Russian Academy of Sciences; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS	McAllister, WT (corresponding author), SUNY Hlth Sci Ctr, Morse Inst Mol Genet, Dept Immunol & Microbiol, 450 Clarkson Ave,POB 44, Brooklyn, NY 11203 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038147] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38147, R01 GM038147-14, R01 GM038147] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chan CL, 1997, J MOL BIOL, V268, P54, DOI 10.1006/jmbi.1997.0935; CHAN CL, 1994, TRANSCRIPTION MECHAN, P297; CHRISTIANSEN J, 1988, NUCLEIC ACIDS RES, V16, P7457, DOI 10.1093/nar/16.15.7457; DAUBE SS, 1994, BIOCHEMISTRY-US, V33, P340, DOI 10.1021/bi00167a044; FODOR E, 1995, J VIROL, V69, P4012, DOI 10.1128/JVI.69.7.4012-4019.1995; Hartvig L, 1996, EMBO J, V15, P4767, DOI 10.1002/j.1460-2075.1996.tb00854.x; He B, 1997, PROTEIN EXPRES PURIF, V9, P142, DOI 10.1006/prep.1996.0663; IKEDA RA, 1987, J BIOL CHEM, V262, P3790; IKEDA RA, 1986, P NATL ACAD SCI USA, V83, P3614, DOI 10.1073/pnas.83.11.3614; JENG ST, 1990, J BIOL CHEM, V265, P3823; JENG ST, 1992, J BIOL CHEM, V267, P19306; Landick R, 1997, CELL, V88, P741, DOI 10.1016/S0092-8674(00)81919-4; Lyakhov DL, 1997, J MOL BIOL, V269, P28, DOI 10.1006/jmbi.1997.1015; LYAKHOV DL, 1998, IN PRESS J MOL BIOL; MACDONALD LE, 1993, J MOL BIOL, V232, P1030, DOI 10.1006/jmbi.1993.1458; MACDONALD LE, 1994, J MOL BIOL, V238, P145, DOI 10.1006/jmbi.1994.1277; MASLAK M, 1993, BIOCHEMISTRY-US, V32, P4281, DOI 10.1021/bi00067a017; MASLAK M, 1994, BIOCHEMISTRY-US, V33, P6918, DOI 10.1021/bi00188a022; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MULLER DK, 1988, BIOCHEMISTRY-US, V27, P5763, DOI 10.1021/bi00415a055; PLATT T, 1996, RNA STRUCTURE FUNCTI, P541; RING BZ, 1994, CELL, V78, P317, DOI 10.1016/0092-8674(94)90300-X; Sambrook J., 2002, MOL CLONING LAB MANU; SHI YB, 1988, J BIOL CHEM, V263, P527; STEEN R, 1986, EMBO J, V5, P1099, DOI 10.1002/j.1460-2075.1986.tb04328.x; TSAO YP, 1989, CELL, V56, P111, DOI 10.1016/0092-8674(89)90989-6; TYAGARAJAN K, 1991, BIOCHEMISTRY-US, V30, P10920, DOI 10.1021/bi00109a016; Ujvari A, 1997, J MOL BIOL, V273, P775, DOI 10.1006/jmbi.1997.1350; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; Villemain J, 1997, J MOL BIOL, V273, P958, DOI 10.1006/jmbi.1997.1358; Weston BF, 1997, J MOL BIOL, V272, P21, DOI 10.1006/jmbi.1997.1199; WHELAN SPJ, 1995, P NATL ACAD SCI USA, V92, P8388, DOI 10.1073/pnas.92.18.8388; YOUNG RA, 1979, J BIOL CHEM, V254, P2725; ZHANG X, 1995, J MOL BIOL, V250, P156, DOI 10.1006/jmbi.1995.0367; Zhang X, 1997, J MOL BIOL, V269, P10, DOI 10.1006/jmbi.1997.1016	36	39	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18802	18811		10.1074/jbc.273.30.18802	http://dx.doi.org/10.1074/jbc.273.30.18802			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668054	hybrid			2022-12-25	WOS:000074974700021
J	Kozel, PJ; Friedman, RA; Erway, LC; Yamoah, EN; Liu, LH; Riddle, T; Duffy, JJ; Doetschman, T; Miller, ML; Cardell, EL; Shull, GE				Kozel, PJ; Friedman, RA; Erway, LC; Yamoah, EN; Liu, LH; Riddle, T; Duffy, JJ; Doetschman, T; Miller, ML; Cardell, EL; Shull, GE			Balance and hearing deficits in mice with a null mutation in the gene encoding plasma membrane Ca2+-ATPase isoform 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-PUMP ISOFORMS; MOLECULAR-CLONING; MESSENGER-RNAS; CA-2+-TRANSPORTING ATPASE; CA2+ PUMP; RAT-BRAIN; EXPRESSION; DOMAINS	Plasma membrane Ca2+-ATPase isoform 2 (PMCA2) exhibits a highly restricted tissue distribution, suggesting that it serves more specialized physiological functions than some of the other isoforms, A unique role in hearing is indicated by the high levels of PMCA2 expression in cochlear outer hair cells and spiral ganglion cells. To analyze the physiological role of PMCA2 we used gene targeting to produce PMCA2-deficient mice, Breeding of heterozygous mice yielded live homozygous mutant offspring. PMCA2-null mice grow more slowly than heterozygous and wild-type mice and exhibit an unsteady gait and difficulties in maintaining balance. Histological analysis of the cerebellum and inner ear of mutant and wild-type mice revealed that null mutants had slightly increased numbers of Purkinje neurons tin which PMCA2 is highly expressed), a decreased thickness of the molecular layer, an absence of otoconia in the vestibular system, and a range of abnormalities of the organ of Corti. Analysis of auditory evoked brainstem responses revealed that homozygous mutants were deaf and that heterozygous mice had a significant hearing loss. These data demonstrate that PMCA2 is required for both balance and hearing and suggest that it may be a major source of the calcium used in the formation and maintenance of otoconia.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Cell Biol & Anat, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USA; Univ Cincinnati, Dept Biol Sci, Cincinnati, OH 45221 USA; House Ear Inst, Los Angeles, CA 90057 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; House Research Institute	Shull, GE (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Bethesda Ave,ML 524, Cincinnati, OH 45267 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041496] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050594, R37DK050594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [K08DC000119] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41496] Funding Source: Medline; NIDCD NIH HHS [K08 DC000119-06] Funding Source: Medline; NIDDK NIH HHS [DK50594] Funding Source: Medline; NIEHS NIH HHS [ES06096] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADAMO HP, 1992, BIOCHEM J, V283, P355, DOI 10.1042/bj2830355; Apicella S, 1997, NEUROSCIENCE, V79, P1145, DOI 10.1016/S0306-4522(97)00035-3; BRANDT P, 1992, J BIOL CHEM, V267, P4376; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; Crouch JJ, 1995, HEARING RES, V92, P112, DOI 10.1016/0378-5955(95)00201-4; Elwess NL, 1997, J BIOL CHEM, V272, P17981, DOI 10.1074/jbc.272.29.17981; ERWAY LC, 1993, HEARING RES, V65, P125, DOI 10.1016/0378-5955(93)90207-H; Faddis BT, 1998, HEARING RES, V115, P6, DOI 10.1016/S0378-5955(97)00172-X; FURATA H, 1998, IN PRESS HEARING RES; GREEB J, 1989, J BIOL CHEM, V264, P18569; HEIM R, 1992, EUR J BIOCHEM, V205, P333, DOI 10.1111/j.1432-1033.1992.tb16784.x; HILFIKER H, 1994, J BIOL CHEM, V269, P26178; HUDSPETH AJ, 1994, NEURON, V12, P1, DOI 10.1016/0896-6273(94)90147-3; HUDSPETH AJ, 1989, NATURE, V341, P397, DOI 10.1038/341397a0; KAWAMATA S, 1995, ANAT RECORD, V242, P259, DOI 10.1002/ar.1092420216; KEETON TP, 1995, BIOCHEM J, V306, P779, DOI 10.1042/bj3060779; KEETON TP, 1993, J BIOL CHEM, V268, P2740; Liu LH, 1997, J BIOL CHEM, V272, P30538, DOI 10.1074/jbc.272.48.30538; MULLEN RJ, 1976, P NATL ACAD SCI USA, V73, P208, DOI 10.1073/pnas.73.1.208; SHULL GE, 1988, J BIOL CHEM, V263, P8646; STAHL WL, 1992, MOL BRAIN RES, V16, P223, DOI 10.1016/0169-328X(92)90229-5; STREHLER EE, 1990, J BIOL CHEM, V265, P2835; STREHLER EE, 1989, P NATL ACAD SCI USA, V86, P6908, DOI 10.1073/pnas.86.18.6908; VERMA AK, 1988, J BIOL CHEM, V263, P14152; Wang K K, 1992, Trends Cell Biol, V2, P46, DOI 10.1016/0962-8924(92)90162-G; Yamoah EN, 1998, J NEUROSCI, V18, P610	26	244	254	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18693	18696		10.1074/jbc.273.30.18693	http://dx.doi.org/10.1074/jbc.273.30.18693			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668038	hybrid			2022-12-25	WOS:000074974700005
J	Li, SS; Wang, GQ; Lin, HN; Huang, CH				Li, SS; Wang, GQ; Lin, HN; Huang, CH			Calorimetric studies of phosphatidylethanolamines with saturated sn-1 and dienoic sn-2 acyl chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHASE; DILAUROYLPHOSPHATIDYLETHANOLAMINE	We have semi-synthesized 18 species of mixed chain phosphatidylethanolamines (PE) in which the sn-l acyl chain is derived from stearic, arachidic, and behenic acids, and the sn-2 acyl chain is originated from cis,cis-octadecadienoic and cis,cis-eicosadienoic acids with the two methylene-interrupted double bonds loca.ted at various positions, These PEs constituting the bilayers in the aqueous dispersion were subjected to differential scanning calorimetric experiments. The T-m values associated with the gel-to-liquid crystalline phase transitions for these PEs are found to be significantly smaller than those of the saturated counterparts. Moreover, the magnitude of the T-m-lowering effect of acyl chain diun-saturation depends critically on the positions of the two methylene-interrupted cis double bonds in the sn-2 acyl chain. Specifically, if the sn-2 acyl chain is derived from cis,cis-octadecadienoic acid, the T-m-lowering effect has the following decreasing order: Delta(9,12) > Delta(6,9) > Delta(12,15). For cis,cis-eicosadienoyl acyl chain, the T-m-lowering effect is stronger in the order of Delta(10,13) > Delta(11,14) > Delta(8,11) > Delta(5,8) > Delta(14,17). Finally, a refined molecular model is presented that can adequately explain the T-m-lowering effect of sn-2 acyl chain diunsaturation, Moreover, this same refined molecular model can also be invoked, to better interpret the T-m-lowering effect observed for sn-l saturated/sn-2 monoenoic PE.	Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia	Huang, CH (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Biochem, Box 440, Charlottesville, VA 22908 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM017452] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-17452] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BATTA AK, 1984, J CHROMATOGR, V284, P257, DOI 10.1016/S0021-9673(01)87825-0; CHANG H, 1983, BIOCHIM BIOPHYS ACTA, V728, P319, DOI 10.1016/0005-2736(83)90501-1; Christie W.W., 1967, CHEM PHYS LIPIDS, V1, P407; HITCHCOCK PB, 1974, P NATL ACAD SCI USA, V71, P3036, DOI 10.1073/pnas.71.8.3036; HUANG C, 1994, BBA-BIOMEMBRANES, V1189, P7, DOI 10.1016/0005-2736(94)90273-9; HUANG C, 1998, CELL PHYSL SOURCE BO, P39; Huang CH, 1997, J BIOL CHEM, V272, P21917, DOI 10.1074/jbc.272.35.21917; Huang CH, 1996, ARCH BIOCHEM BIOPHYS, V334, P135, DOI 10.1006/abbi.1996.0438; KEOUGH KMW, 1990, BIOCHEM SOC T, V18, P835, DOI 10.1042/bst0180835; MANTSCH HH, 1983, BIOCHIM BIOPHYS ACTA, V728, P325, DOI 10.1016/0005-2736(83)90502-3; Mason JT, 1996, HDB NONMEDICAL APPL, V1, P195; SEDDON JM, 1983, J BIOL CHEM, V258, P3850; TAYLOR WR, 1950, J AM CHEM SOC, V72, P4623; Wang GQ, 1997, BIOPHYS J, V73, P283, DOI 10.1016/S0006-3495(97)78069-X; WANG ZQ, 1994, J BIOL CHEM, V269, P23491	15	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19009	19018		10.1074/jbc.273.30.19009	http://dx.doi.org/10.1074/jbc.273.30.19009			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668081	hybrid			2022-12-25	WOS:000074974700048
J	Ostrander, DB; O'Brien, DJ; Gorman, JA; Carman, GM				Ostrander, DB; O'Brien, DJ; Gorman, JA; Carman, GM			Effect of CTP synthetase regulation by CTP on phospholipid synthesis in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDP-CHOLINE PATHWAY; HAMSTER OVARY CELLS; PHOSPHATIDYLETHANOLAMINE METHYLATION PATHWAY; CYTIDINE 5'-TRIPHOSPHATE SYNTHETASE; TRANSFER PROTEIN; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; FUNCTIONAL COMPLEMENTATION; INOSITOL SYNTHESIS; GENE DISRUPTION; URA7 GENE	CTP synthetase (EC 6.3.4.2, UTP:ammonia ligase (ADP-forming)) activity in Saccharomyces cerevisiae is allosterically regulated by CTP product inhibition. Amino acid residue Glu(161) in the URA7-encoded and URA8-encoded CTP synthetases was identified as being involved in the regulation of these enzymes by CTP product inhibition. The specific activities of the URA7-encoded and URA8-encoded enzymes with a Glu(161) --> Lys (E161K) mutation were S-fold greater when compared with the wild-type enzymes. The E161K mutant URA7-encoded and URA8-encoded CTP synthetases were less sensitive to CTP product inhibition with inhibitor constants for CTP of 8.4- and 5-fold greater, respectively, than those of their wild-type counterparts. Cells expressing the E161K mutant enzymes on a multicopy plasmid exhibited an increase in resistance to the pyrimidine poison and cancer therapeutic drug cyclopentenylcytosine and accumulated elevated (6-15-fold) levels of CTP when compared with cells expressing the wild-type enzymes. Cells expressing the E161K mutation in the URA7 encoded CTP synthetase exhibited an increase (1.5-fold) in the utilization of the Kennedy pathway for phosphatidylcholine synthesis when compared with control cells. Cells bearing the mutation also exhibited an increase in the synthesis of phosphatidylcholine (1.5-fold), phosphatidylethanolamine (1.3-fold), and phosphatidate (2-fold) and a decrease in the synthesis of phosphatidylserine (1.7-fold). These alterations were accompanied by an inositol excretion phenotype due to the misregulation of the INO1 gene. Moreover, cells bearing the E161K mutation exhibited an increase (1.6-fold) in the ratio of total neutral lipids to phospholipids, an increase in triacylglycerol (1.4-fold), free fatty acids (1.7-fold), and ergosterol ester (1.8-fold), and a decrease in diacylglycerol (1.3-fold) when compared with control cells. These data indicated that the regulation of CTP synthetase activity by CTP plays an important role in the regulation of phospholipid synthesis.	Rutgers State Univ, Cook Coll, New Jersey Agr Expt Stn, Dept Food Sci, New Brunswick, NJ 08901 USA; Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Microbial Mol Biol, Princeton, NJ 08543 USA	Rutgers State University New Brunswick; Bristol-Myers Squibb	Carman, GM (corresponding author), Rutgers State Univ, Cook Coll, New Jersey Agr Expt Stn, Dept Food Sci, 65 Dudley Rd, New Brunswick, NJ 08901 USA.	carman@aesop.rutgers.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050679] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-50679] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ARONOW B, 1984, J BIOL CHEM, V259, P9035; ARONOW B, 1987, J BIOL CHEM, V262, P5106; ATKINSON K, 1980, J BIOL CHEM, V255, P6653; ATKINSON KD, 1980, J BACTERIOL, V141, P558, DOI 10.1128/JB.141.2.558-564.1980; BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; BECKER DM, 1991, P NATL ACAD SCI USA, V88, P1968, DOI 10.1073/pnas.88.5.1968; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; Carman GM, 1996, J BIOL CHEM, V271, P13293, DOI 10.1074/jbc.271.23.13293; CARMAN GM, 1989, PHOSPHATIDYLCHOLINE, P165; CARTER JR, 1966, J LIPID RES, V7, P678; CHU EHY, 1984, BIOCHEM GENET, V22, P701, DOI 10.1007/BF00485854; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; CULBERTSON MR, 1975, GENETICS, V80, P23; DESAINTVINCENT BR, 1980, BIOCHIM BIOPHYS ACTA, V610, P352; ESKO JD, 1980, J BIOL CHEM, V255, P4474; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Greenberg ML, 1996, MICROBIOL REV, V60, P1; GREENBERG ML, 1982, GENETICS, V100, P19; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HAID A, 1983, METHOD ENZYMOL, V96, P192; Henderson RJ, 1992, LIPID ANAL PRACTICAL, P65; Henry S. A., 1982, MOL BIOL YEAST SACCH, P101; Henry SA, 1998, PROG NUCLEIC ACID RE, V61, P133, DOI 10.1016/S0079-6603(08)60826-0; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; HOMANN MJ, 1987, J BACTERIOL, V169, P533, DOI 10.1128/jb.169.2.533-539.1987; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KANG GJ, 1989, J BIOL CHEM, V264, P713; KAUFMAN ER, 1986, MUTAT RES, V161, P19, DOI 10.1016/0027-5107(86)90096-5; Kearns BG, 1997, NATURE, V387, P101, DOI 10.1038/387101a0; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; KIZAKI H, 1980, CANCER RES, V40, P3921; KODAKI T, 1987, J BIOL CHEM, V262, P15428; KODAKI T, 1989, EUR J BIOCHEM, V185, P243, DOI 10.1111/j.1432-1033.1989.tb15109.x; LIBERMAN I, 1956, J BIOL CHEM, V222, P765; LONG CW, 1967, J BIOL CHEM, V242, P4715; LOPES JM, 1991, NUCLEIC ACIDS RES, V19, P1687, DOI 10.1093/nar/19.7.1687; MCDONOUGH VM, 1995, J BIOL CHEM, V270, P18774, DOI 10.1074/jbc.270.32.18774; MCGEE TP, 1994, J BACTERIOL, V176, P6861, DOI 10.1128/JB.176.22.6861-6868.1994; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; MCGRAW P, 1989, GENETICS, V122, P317; MCMASTER CR, 1994, J BIOL CHEM, V269, P14776; MCMASTER CR, 1994, J BIOL CHEM, V269, P28010; MEUTH M, 1979, P NATL ACAD SCI USA, V76, P6505, DOI 10.1073/pnas.76.12.6505; MEUTH M, 1982, SOMAT CELL GENET, V8, P423, DOI 10.1007/BF01538705; MORLOCK KR, 1988, J BACTERIOL, V170, P3561, DOI 10.1128/jb.170.8.3561-3566.1988; NADKARNI AK, 1995, J BIOL CHEM, V270, P24982, DOI 10.1074/jbc.270.42.24982; OZIERKALOGEROPOULOS O, 1991, MOL GEN GENET, V231, P7, DOI 10.1007/BF00293815; OZIERKALOGEROPOULOS O, 1994, MOL GEN GENET, V242, P431, DOI 10.1007/BF00281793; PALTAUF F, 1992, MOL CELLULAR BIOL YE, P415; PattonVogt JL, 1997, J BIOL CHEM, V272, P20873, DOI 10.1074/jbc.272.33.20873; ROSENBERG M, 1990, MICROBIAL CELL SURFA, P1; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCLAFANI RA, 1984, P NATL ACAD SCI-BIOL, V81, P5821, DOI 10.1073/pnas.81.18.5821; Sha BD, 1998, NATURE, V391, P506, DOI 10.1038/35179; Shen H, 1996, J BIOL CHEM, V271, P29043, DOI 10.1074/jbc.271.46.29043; Shen HF, 1997, J BIOL CHEM, V272, P11215; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; SKINNER HB, 1995, P NATL ACAD SCI USA, V92, P112, DOI 10.1073/pnas.92.1.112; Sreenivas A, 1998, J BIOL CHEM, V273, P16635, DOI 10.1074/jbc.273.27.16635; SUMMERS EF, 1988, GENETICS, V120, P909; TAYLOR FR, 1978, J BACTERIOL, V136, P531, DOI 10.1128/JB.136.2.531-537.1978; TAYLOR FR, 1979, BIOCHIM BIOPHYS ACTA, V575, P204, DOI 10.1016/0005-2760(79)90022-5; TEEGARDEN D, 1990, J BIOL CHEM, V265, P6042; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TIPPLES G, 1995, J BIOL CHEM, V270, P7908, DOI 10.1074/jbc.270.14.7908; TRACH K, 1988, J BACTERIOL, V170, P4194, DOI 10.1128/jb.170.9.4194-4208.1988; TROTTER PJ, 1995, J BIOL CHEM, V270, P6071, DOI 10.1074/jbc.270.11.6071; TROTTER PJ, 1995, J BIOL CHEM, V270, P6062, DOI 10.1074/jbc.270.11.6062; VANCE DE, 1996, BIOCH LIPIDS LIPOPRO, P153; VANCE DE, 1991, BIOCH LIPIDS LIPOPRO, P205; VANDENBERG AA, 1993, EUR J BIOCHEM, V216, P161; WEBER G, 1980, LIFE SCI, V27, P793, DOI 10.1016/0024-3205(80)90333-1; WEBER G, 1979, ADV ENZYME REGUL, V17, P1; WENG M, 1986, J BIOL CHEM, V261, P5568; WHELAN J, 1993, NAT GENET, V3, P317, DOI 10.1038/ng0493-317; YAMAUCHI M, 1990, EMBO J, V9, P2095, DOI 10.1002/j.1460-2075.1990.tb07377.x; YANG WL, 1994, BIOCHEMISTRY-US, V33, P10785, DOI 10.1021/bi00201a028; ZHANG H, 1993, CANCER RES, V53, P5714; [No title captured]	85	97	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18992	19001		10.1074/jbc.273.30.18992	http://dx.doi.org/10.1074/jbc.273.30.18992			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668079	hybrid			2022-12-25	WOS:000074974700046
J	Pikas, DS; Li, JP; Vlodavsky, I; Lindahl, U				Pikas, DS; Li, JP; Vlodavsky, I; Lindahl, U			Substrate specificity of heparanases from human hepatoma and platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; ESCHERICHIA-COLI K5; SUBENDOTHELIAL EXTRACELLULAR-MATRIX; CAPSULAR POLYSACCHARIDE; SULFATE PROTEOGLYCANS; MOUSE MASTOCYTOMA; MELANOMA-CELLS; CORE PROTEIN; HEPARIN; BIOSYNTHESIS	Heparan sulfate proteoglycans, attached to cell surfaces or in the extracellular matrix, interact with a multitude of proteins via their heparan sulfate side chains. Degradation of these chains by limited (endoglycosidic) heparanase cleavage is believed 60 affect a variety of biological processes. Although the occurrence of heparanase activity in mammalian tissues has been recognized for many years, the molecular characteristics and substrate recognition properties of the enzyme(s) have remained elusive. In the present study, the substrate specificity and cleavage site of heparanase from human hepatoma and platelets were investigated. Both enzyme preparations were found to cleave the single beta-D-glucuronidic Linkage of a heparin octasaccharide. A capsular polysaccharide from Escherichia coli K5, with the same (-GlcUA beta 1, 4-GlcNAc alpha 1,4-)(n) structure as the unmodified backbone of heparan sulfate, resisted heparanase degradation in its native state as well as after chemical N-deaeetylation/N-sulfation or partial enzymatic C-5 epimerization of beta-DGlcUA to alpha-L-IdceA By contrast, a chemically O-sulfated (but still N-acetylated) K5 derivative was susceptible to heparanase cleavage. O-Sulfate groups, but not N-sulfate or IdceA residues, thus are essential for substrate recognition by the heparanase(s). In particular, selective O-desulfation of the heparin octasaccharide implicated a 2-O-sulfate group on a hexuronic acid residue located two monosaccharide units from the cleavage site, toward the reducing end.	Univ Uppsala, Dept Med Biochem & Microbiol, Ctr Biomed, S-75123 Uppsala, Sweden; Hadassah Univ Hosp, Dept Oncol, IL-91120 Jerusalem, Israel	Uppsala University; Hebrew University of Jerusalem	Pikas, DS (corresponding author), Univ Uppsala, Dept Med Biochem & Microbiol, Ctr Biomed, Box 575, S-75123 Uppsala, Sweden.	Dagmar.Pikas@medkem.uu.se						Bai XM, 1997, J BIOL CHEM, V272, P23172, DOI 10.1074/jbc.272.37.23172; Bame KJ, 1997, J BIOL CHEM, V272, P2245; BAME KJ, 1993, J BIOL CHEM, V268, P19956; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; CAMPBELL P, 1994, J BIOL CHEM, V269, P26953; CASU B, 1994, CARBOHYD RES, V263, P271, DOI 10.1016/0008-6215(94)00172-3; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; Feyzi E, 1997, J BIOL CHEM, V272, P5518, DOI 10.1074/jbc.272.9.5518; Goshen R, 1996, MOL HUM REPROD, V2, P679, DOI 10.1093/molehr/2.9.679; Graham LD, 1996, BIOCHEM MOL BIOL INT, V39, P563; GUO Y, 1989, ANAL BIOCHEM, V176, P96, DOI 10.1016/0003-2697(89)90278-9; HOOGEWERF AJ, 1995, J BIOL CHEM, V270, P3268, DOI 10.1074/jbc.270.7.3268; HOOK M, 1982, ANAL BIOCHEM, V119, P236, DOI 10.1016/0003-2697(82)90580-2; IRIMURA T, 1986, BIOCHEMISTRY-US, V25, P5322, DOI 10.1021/bi00366a050; ISHAIMICHAELI R, 1990, CELL REGUL, V1, P833, DOI 10.1091/mbc.1.11.833; JASEJA M, 1989, CAN J CHEM, V67, P1449, DOI 10.1139/v89-221; KJELLEN L, 1985, J BIOL CHEM, V260, P8416; KLEIN U, 1976, BIOCHEM BIOPH RES CO, V73, P569, DOI 10.1016/0006-291X(76)90848-2; KLEIN U, 1979, H-S Z PHYSIOL CHEM, V360, P1465, DOI 10.1515/bchm2.1979.360.2.1465; KLEIN U, 1976, BIOCHEM BIOPH RES CO, V69, P158, DOI 10.1016/S0006-291X(76)80286-0; KUSCHE M, 1988, J BIOL CHEM, V263, P15474; KUSCHE M, 1991, BIOCHEM J, V275, P151, DOI 10.1042/bj2750151; KUSCHE M, 1990, J BIOL CHEM, V265, P7292; Lapierre F, 1996, GLYCOBIOLOGY, V6, P355, DOI 10.1093/glycob/6.3.355; LEVY L, 1962, P SOC EXP BIOL MED, V109, P901; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; NAGASAWA K, 1977, CARBOHYD RES, V58, P47, DOI 10.1016/S0008-6215(00)83402-3; NAKAJIMA M, 1983, SCIENCE, V220, P611, DOI 10.1126/science.6220468; NAKAJIMA M, 1984, J BIOL CHEM, V259, P2283; NAKAJIMA M, 1988, J CELL BIOCHEM, V36, P157, DOI 10.1002/jcb.240360207; NAKAJIMA M, 1986, ANAL BIOCHEM, V157, P162, DOI 10.1016/0003-2697(86)90209-5; OGREN S, 1975, J BIOL CHEM, V250, P2690; OLDBERG A, 1980, BIOCHEMISTRY-US, V19, P5755, DOI 10.1021/bi00566a014; OOSTA GM, 1982, J BIOL CHEM, V257, P1249; Pillarisetti S, 1997, J BIOL CHEM, V272, P15753, DOI 10.1074/jbc.272.25.15753; RAZI N, 1995, BIOCHEM J, V309, P465, DOI 10.1042/bj3090465; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; Santini F, 1997, CARBOHYD RES, V302, P103, DOI 10.1016/S0008-6215(97)00111-0; SCHMIDTCHEN A, 1994, EUR J BIOCHEM, V223, P211, DOI 10.1111/j.1432-1033.1994.tb18985.x; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3935; SIVARAM P, 1995, J BIOL CHEM, V270, P29760; Stringer SE, 1997, INT J BIOCHEM CELL B, V29, P709, DOI 10.1016/S1357-2725(96)00170-7; THUNBERG L, 1982, J BIOL CHEM, V257, P278; THUNBERG L, 1982, CARBOHYD RES, V100, P393, DOI 10.1016/S0008-6215(00)81050-2; VANN WF, 1981, EUR J BIOCHEM, V116, P359, DOI 10.1111/j.1432-1033.1981.tb05343.x; VLODAVSKY I, 1994, INVAS METAST, V14, P290; VLODAVSKY I, 1983, CANCER RES, V43, P2704; VLODAVSKY I, 1992, INVAS METAST, V12, P112; VLODAVSKY I, 1991, TRENDS BIOCHEM SCI, V16, P268, DOI 10.1016/0968-0004(91)90102-2; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9505	51	209	228	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18770	18777		10.1074/jbc.273.30.18770	http://dx.doi.org/10.1074/jbc.273.30.18770			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668050	hybrid			2022-12-25	WOS:000074974700017
J	Rea, S; Martin, LB; McIntosh, S; Macaulay, SL; Ramsdale, T; Baldini, G; James, DE				Rea, S; Martin, LB; McIntosh, S; Macaulay, SL; Ramsdale, T; Baldini, G; James, DE			Syndet, an adipocyte target SNARE involved in the insulin-induced translocation of GLUT4 to the cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADIPOSE-CELLS; GLUCOSE-TRANSPORTER; 3T3-L1 ADIPOCYTES; PROTEIN; VESICLES; LOCALIZATION; SPECIFICITY; TRAFFICKING; STIMULATION; CELLUBREVIN	In adipocytes, insulin stimulates the translocation of the glucose transporter, GLUT4, from an intracellular storage compartment to the cell surface. Substantial evidence exists to suggest that in the basal state GLUT4 resides in discrete storage vesicles. A direct interaction of GLUT I storage vesicles with the plasma membrane has been implicated because the v-SNARE, vesicle-associated membrane protein-2 (VAMP2), appears to be a specific component of these vesicles. In the present study we sought to identify the cognate target SNAREs for VAMPS in mouse 3T3-L1 adipocytes. Membrane fractions were isolated from adipocytes and probed by far Western blotting with the cytosolic portion of VAMPS fused to glutathione S-transferase. Two plasma membrane-enriched proteins, p25 and p35, were specifically labeled with this probe. By using a combination of immunoblotting, detergent extraction, and anion exchange chromatography, we identified p35 as Syntaxin- 4 and p25 as the recently identified murine SNAP-25 homologue, Syndet (mSNAP-23). By using surface plasmon resonance we show that VAMP2, Syntaxin-4, and Syndet form a ternary SDS-resistant SNARE complex. Microinjection of anti-Syndet antibodies into 3T3-L1 adipocytes, or incubation of permeabilized adipocytes with a synthetic peptide comprising the C-terminal 24 amino acids of Syndet, inhibited insulin-stimulated GLUT4 translocation to the cell surface by similar to 40%. GLUT1 trafficking remained unaffected by the presence of the peptide. Our data suggest that Syntaxin 4 and Syndet are important cell-surface target SNAREs within adipocytes that regulate docking and fusion of GLUT-4-containing vesicles with the plasma membrane in response to insulin.	Univ Queensland, Ctr Cellular & Mol Biol, St Lucia, Qld 4072, Australia; Univ Queensland, Dept Physiol & Pharmacol, St Lucia, Qld 4072, Australia; Univ Queensland, Ctr Drug Design & Dev, St Lucia, Qld 4072, Australia; CSIRO, Div Mol Sci, Parkville, Vic 3052, Australia; Columbia Univ Coll Phys & Surg, Dept Anat & Cell Biol, New York, NY 10032 USA	University of Queensland; University of Queensland; University of Queensland; Commonwealth Scientific & Industrial Research Organisation (CSIRO); Columbia University	James, DE (corresponding author), Univ Queensland, Ctr Cellular & Mol Biol, St Lucia, Qld 4072, Australia.	D.James@cmcb.uq.edu.au	Martin, Laura/N-1789-2013; mcintosh, shane/AAL-4279-2021; Macaulay, Stuart Lance/A-6086-2008; Rea, Shane/F-4073-2014	Martin, Laura/0000-0002-4431-4381; Macaulay, Stuart Lance/0000-0001-5069-9516; James, David/0000-0001-5946-5257; mcintosh, shane/0000-0003-2835-7936				Banerjee A, 1996, J BIOL CHEM, V271, P20227, DOI 10.1074/jbc.271.34.20227; Bock JB, 1997, NATURE, V387, P133, DOI 10.1038/387133a0; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; GOODYEAR LJ, 1990, AM J PHYSIOL, V258, pE667, DOI 10.1152/ajpendo.1990.258.4.E667; Holman GD, 1996, SEMIN CELL DEV BIOL, V7, P259, DOI 10.1006/scdb.1996.0034; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; James David E., 1994, Trends in Cell Biology, V4, P120, DOI 10.1016/0962-8924(94)90066-3; JAMES DE, 1993, J CELL SCI, V104, P607; Martin LB, 1998, J BIOL CHEM, V273, P1444, DOI 10.1074/jbc.273.3.1444; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; MCMAHON HT, 1995, J BIOL CHEM, V270, P2213, DOI 10.1074/jbc.270.5.2213; Niemann Heiner, 1994, Trends in Cell Biology, V4, P179, DOI 10.1016/0962-8924(94)90203-8; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; PLOUG T, 1987, AM J PHYSIOL, V253, pE12, DOI 10.1152/ajpendo.1987.253.1.E12; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; RAY P, 1993, J BIOL CHEM, V268, P11057; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; Ross SA, 1996, J BIOL CHEM, V271, P3328, DOI 10.1074/jbc.271.6.3328; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Tamori Y, 1996, BIOCHEM BIOPH RES CO, V220, P740, DOI 10.1006/bbrc.1996.0474; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Veit M, 1996, FEBS LETT, V385, P119, DOI 10.1016/0014-5793(96)00362-6; VOLCHUK A, 1995, J BIOL CHEM, V270, P8233, DOI 10.1074/jbc.270.14.8233; Wang GY, 1997, J CELL SCI, V110, P505	32	92	96	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18784	18792		10.1074/jbc.273.30.18784	http://dx.doi.org/10.1074/jbc.273.30.18784			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668052	hybrid			2022-12-25	WOS:000074974700019
J	Takagi, H; Shi, DS; Ha, Y; Allewell, NM; Theil, EC				Takagi, H; Shi, DS; Ha, Y; Allewell, NM; Theil, EC			Localized unfolding at the junction of three ferritin subunits - A mechanism for iron release?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; H-CHAIN FERRITIN; MAMMALIAN FERRITIN; CORE FORMATION; APOFERRITIN; OXIDATION; PROTEINS; CRYSTALLIZATION; RESOLUTION; KINETICS	How and where iron exits from ferritin for cellular use is unknown. Twenty-four protein subunits create a cavity in ferritin where iron is concentrated >10(11)-fold as a mineral. Proline substitution for conserved leucine 134 (L134P) allowed normal assembly but increased iron exit rates. X-ray crystallography of H-L134P ferritin revealed localized unfolding at the S-fold axis, also iron entry sites, consistent with shared use sites for iron exit and entry. The junction of three ferritin subunits appears to be a dynamic aperture with a "shutter" that cytoplasmic factors might open or close to regulate iron release in vivo.	N Carolina State Univ, Dept Biochem, Raleigh, NC 27695 USA; Univ Minnesota, Dept Biochem, St Paul, MN 55108 USA	University of North Carolina; North Carolina State University; University of Minnesota System; University of Minnesota Twin Cities	Theil, EC (corresponding author), Childrens Hosp, Oakland Res Inst, 747 52nd St, Oakland, CA 94609 USA.			Shi, Dashuang/0000-0002-5491-1104	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020251, R01DK050727, R56DK020251, R37DK020251] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK20251, DK50727] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANYARD SH, 1978, NATURE, V271, P282, DOI 10.1038/271282a0; BAUMINGER ER, 1993, BIOCHEM J, V296, P709, DOI 10.1042/bj2960709; Beard JL, 1996, J NUTR, V126, P154, DOI 10.1093/jn/126.1.154; BRUNGER AT, 1992, X PLOR MANUAL VERSIO; DILL KA, 1991, ANNU REV BIOCHEM, V60, P795, DOI 10.1146/annurev.bi.60.070191.004051; Fetter J, 1997, J BIOL INORG CHEM, V2, P652, DOI 10.1007/s007750050180; Ha Y, 1997, ACTA CRYSTALLOGR D, V53, P513, DOI 10.1107/S0907444997003983; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; Hempstead PD, 1997, J MOL BIOL, V268, P424, DOI 10.1006/jmbi.1997.0970; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES T, 1978, BIOCHEMISTRY-US, V17, P4011, DOI 10.1021/bi00612a021; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAWSON DM, 1991, NATURE, V349, P541, DOI 10.1038/349541a0; MERTZ JR, 1983, J BIOL CHEM, V258, P1719; Pereira AS, 1997, BIOCHEMISTRY-US, V36, P7917, DOI 10.1021/bi970348f; Proudhon D, 1996, J MOL EVOL, V42, P325, DOI 10.1007/BF02337543; Rouault TA, 1996, J BIOL INORG CHEM, V1, P494, DOI 10.1007/s007750050083; Santambrogio P, 1997, BIOCHEM J, V322, P461, DOI 10.1042/bj3220461; SAUER UH, 1992, J BIOL CHEM, V267, P2393; STEFANINI S, 1989, BIOCHEMISTRY-US, V28, P378, DOI 10.1021/bi00427a052; SUN SJ, 1993, BIOCHEMISTRY-US, V32, P9362, DOI 10.1021/bi00087a015; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; THEIL EC, 1994, BIOCHEM J, V304, P1; TREFFRY A, 1993, BIOCHEM J, V296, P721, DOI 10.1042/bj2960721; TREFFRY A, 1995, BIOCHEMISTRY-US, V34, P15204, DOI 10.1021/bi00046a028; TRIKHA J, 1995, J MOL BIOL, V248, P949, DOI 10.1006/jmbi.1995.0274; TRIKHA J, 1994, PROTEINS, V18, P107, DOI 10.1002/prot.340180204; Waldo G. S., 1996, COMPREHENSIVE SUPRAM, V5, P65; WALDO GS, 1993, SCIENCE, V259, P796, DOI 10.1126/science.8430332; WALDO GS, 1993, BIOCHEMISTRY-US, V32, P13262, DOI 10.1021/bi00211a039; WATT GD, 1988, P NATL ACAD SCI USA, V85, P7457, DOI 10.1073/pnas.85.20.7457; WATT GD, 1985, P NATL ACAD SCI USA, V82, P3640, DOI 10.1073/pnas.82.11.3640; WAUTERS M, 1978, FEBS LETT, V91, P276, DOI 10.1016/0014-5793(78)81191-0; YABLONSKI MJ, 1992, BIOCHEMISTRY-US, V31, P9680, DOI 10.1021/bi00155a022	37	113	117	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18685	18688		10.1074/jbc.273.30.18685	http://dx.doi.org/10.1074/jbc.273.30.18685			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668036	hybrid			2022-12-25	WOS:000074974700003
J	Gallardo-Madueno, R; Leal, JFM; Dorado, G; Holmgren, A; Lopez-Barea, J; Pueyo, C				Gallardo-Madueno, R; Leal, JFM; Dorado, G; Holmgren, A; Lopez-Barea, J; Pueyo, C			In vivo transcription of nrdAB operon and of grxA and fpg genes is triggered in Escherichia coli lacking both thioredoxin and glutaredoxin 1 or thioredoxin and glutathione, respectively	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; NEGATIVE MUTANTS; HYDROGEN DONOR; RNA; EXPRESSION; DNA; BIOSYNTHESIS; CONSTRUCTION; K12; FIS	We have previously described (1) that Escherichia coli maintains a balanced supply of deoxyribonucleotides by a regulatory, mechanism that up-regulates the levels of ribonucleotide reductase with the lack of its main hydrogen donors thioredoxin, glutaredoxin 1, and glutathione (GSH). By using a semi-quantitative reverse transcription/multiplex polymerase chain reaction fluorescent procedure that enables simultaneous analysis of up to seven mRNA species, we now demonstrate that regulation operates at the transcriptional level. Double mutant cells lacking both thioredoxin and glutaredoxin 1 had increased transcription of the nrdAB operon, as compared with the corresponding wild type parent (maximal induction of 10- and 9-fold for mRNA of nrdA and nrdB genes, respectively). Likewise, a dramatic increase of 36-fold in grxA mRNA was observed in bacteria simultaneously deficient in thioredoxin and GSH (the physiological reductant of all glutaredoxins). The increased expression of the grxA gene in trxA gshA double mutant bacteria was mimicked in trxA single mutant cells by depletion of GSH with diethylmaleate (DEM). This induction of grxA transcription was rapid since maximal increase was detected upon 10 min of DEM exposure. Like grxA expression, the basal level of fpg mRNA, encoding formamidopyrimidine-DNA glycosylase, was increased (about 4-fold) in a trxA gshA double mutant strain; this expression was also induced upon exposure to DEM (11-fold maximal induction). These results suggest that transcription of grxA might share common redox regulatory mechanism(s) with that of the fpg gene, involved in the repair of 8-oxoguanine in DNA.	Univ Cordoba, Dept Bioquim & Biol Mol, E-14071 Cordoba, Spain; Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, S-17177 Stockholm, Sweden	Universidad de Cordoba; Karolinska Institutet	Pueyo, C (corresponding author), Univ Cordoba, Dept Bioquim & Biol Mol, Avda Medina Azahara S-N, E-14071 Cordoba, Spain.	bblpucuc@uco.es	Leal, Juan F Martinez/N-6328-2013; Pueyo, Carmen/B-4509-2016; Lopez-Barea, Juan/K-7258-2014	Leal, Juan F Martinez/0000-0002-7538-0875; Pueyo, Carmen/0000-0002-2624-2011; Lopez-Barea, Juan/0000-0002-2280-3379				APONTOWEIL P, 1975, MOL GEN GENET, V141, P91, DOI 10.1007/BF00267676; ASLUND F, 1994, P NATL ACAD SCI USA, V91, P9813, DOI 10.1073/pnas.91.21.9813; AUGUSTIN LB, 1994, J BACTERIOL, V176, P378, DOI 10.1128/JB.176.2.378-387.1994; BALL CA, 1992, J BACTERIOL, V174, P8043, DOI 10.1128/JB.174.24.8043-8056.1992; CHARPENTIER B, 1994, J BACTERIOL, V176, P830, DOI 10.1128/jb.176.3.830-839.1994; DAVIS NK, 1982, J GEN MICROBIOL, V128, P1631; DellaSeta F, 1997, J BACTERIOL, V179, P5218, DOI 10.1128/jb.179.16.5218-5221.1997; Ding HE, 1996, P NATL ACAD SCI USA, V93, P9449, DOI 10.1073/pnas.93.18.9449; EMORY SA, 1990, J BACTERIOL, V172, P4472, DOI 10.1128/jb.172.8.4472-4481.1990; GARDNER PR, 1987, J BIOL CHEM, V262, P17591; GILBERT I, 1990, Molecular and General Genetics, V220, P400; HANKE PD, 1983, J BACTERIOL, V156, P1192, DOI 10.1128/JB.156.3.1192-1197.1983; HANKE PD, 1983, J BACTERIOL, V154, P1040, DOI 10.1128/JB.154.3.1040-1045.1983; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Jamieson D. J., 1997, OXIDATIVE STRESS MOL, P91; Jordan A, 1996, MOL MICROBIOL, V19, P777, DOI 10.1046/j.1365-2958.1996.424950.x; Jordan A, 1997, J BIOL CHEM, V272, P18044, DOI 10.1074/jbc.272.29.18044; Kim HS, 1996, MUTAT RES-DNA REPAIR, V363, P115, DOI 10.1016/0921-8777(96)00006-7; Kranendonk M, 1997, MUTAGENESIS, V12, P245, DOI 10.1093/mutage/12.4.245; MATA AM, 1984, Z NATURFORSCH C, V39, P908; MEISTER A, 1985, METHOD ENZYMOL, V113, P571; MirandaVizuete A, 1996, J BIOL CHEM, V271, P19099, DOI 10.1074/jbc.271.32.19099; MIRANDAVIZUETE A, 1994, J BIOL CHEM, V269, P16631; MULDER GJ, 1988, GLUTATHIONE CONJUGAT, P357; PROVENCE DL, 1994, METHODS GEN MOL BACT, P343; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; Reichard P, 1997, TRENDS BIOCHEM SCI, V22, P81, DOI 10.1016/S0968-0004(97)01003-7; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; RUSSEL M, 1988, P NATL ACAD SCI USA, V85, P990, DOI 10.1073/pnas.85.4.990; RUSSEL M, 1986, J BIOL CHEM, V261, P4997; RYCHLIK W, 1993, METHODS MOL BIOL PCR, P31; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SUN L, 1994, J BACTERIOL, V176, P4617, DOI 10.1128/JB.176.15.4617-4626.1994; SUN L, 1992, MOL BIOL CELL, V3, P1095, DOI 10.1091/mbc.3.10.1095; SUN L, 1994, J BACTERIOL, V176, P2415, DOI 10.1128/JB.176.8.2415-2426.1994; Tao K, 1997, J BACTERIOL, V179, P5967, DOI 10.1128/jb.179.18.5967-5970.1997; WALLACE SS, 1997, OXIDATIVE STRESS MOL, P49; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718	39	30	32	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18382	18388		10.1074/jbc.273.29.18382	http://dx.doi.org/10.1074/jbc.273.29.18382			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660805	hybrid			2022-12-25	WOS:000074828500060
J	Graner, MW; Bunch, TA; Baumgartner, S; Kerschen, A; Brower, DL				Graner, MW; Bunch, TA; Baumgartner, S; Kerschen, A; Brower, DL			Splice variants of the Drosophila PS2 integrins differentially interact with RGD-containing fragments of the extracellular proteins tiggrin, ten-m, and D-laminin alpha 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIR-RULE GENE; FIBRONECTIN-RECEPTOR; SECONDARY STRUCTURE; LIGAND-BINDING; SUBUNIT; SPECIFICITY; MORPHOGENESIS; REQUIREMENTS; MELANOGASTER; ATTACHMENTS	Two new potential ligands of the Drosophila PS2 integrins have been characterized by functional interaction in cell culture. These potential ligands are a new Drosophila laminin alpha 2 chain encoded by the wing blister locus and Ten-m, an extracellular protein known to be involved in embryonic pattern formation. As with previously identified PS2 ligands, both contain RGD sequences, and RGD-containing fragments of these two proteins (DLAM-RGD and TENM-RGD) can support PS2 integrin-mediated cell spreading. In all cases, this spreading is inhibited specifically by short RGD-containing peptides. As previously found for the PS2 ligand tiggrin (and the tiggrin fragment TIG-RGD), TENM-RGD induces maximal spreading of cells expressing integrin containing the alpha(PS2C) splice variant. This is in contrast to DLAM-RGD, which is the first Drosophila polypeptide shown to interact preferentially with cells expressing the alpha(PS2m8) splice variant. The beta(PS) integrin subunit also varies in the presumed ligand binding region as a result of alternative splicing. For TIG-RGD and TENM-RGD, the beta splice variant has little effect, but for DLAM-RGD, maximal cell spreading is supported only by the beta(PS4A) form of the protein. Thus, the diversity in PS2 integrins due to splicing variations, in combination with diversity of matrix ligands, can greatly enhance the functional complexity of PS2-ligand interactions in the developing animal. The data also suggest that the splice variants may alter regions of the subunits that are directly involved in ligand interactions, and this is discussed with respect to models of integrin structure.	Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA; Univ Arizona, Dept Biochem, Tucson, AZ 85721 USA; Friedrich Miescher Inst, CH-4002 Basel, Switzerland; Lund Univ, Dept Cell & Mol Biol, S-22100 Lund, Sweden	University of Arizona; University of Arizona; Friedrich Miescher Institute for Biomedical Research; Lund University	Brower, DL (corresponding author), Univ Arizona, Dept Mol & Cellular Biol, Life Sci S Bldg, Tucson, AZ 85721 USA.	dbrower@u.arizona.edu	Baumgartner, Stefan/A-5879-2011	Baumgartner, Stefan/0000-0001-5320-8321	NCI NIH HHS [T32 CA09213] Funding Source: Medline; NIGMS NIH HHS [R01 GM42474] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009213] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042474] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUMGARTNER S, 1994, EMBO J, V13, P3728, DOI 10.1002/j.1460-2075.1994.tb06682.x; BOGAERT T, 1987, CELL, V51, P929, DOI 10.1016/0092-8674(87)90580-0; BRABANT MC, 1993, DEV BIOL, V157, P49, DOI 10.1006/dbio.1993.1111; BROWER DL, 1995, DEVELOPMENT, V121, P1311; BROWER DL, 1984, P NATL ACAD SCI-BIOL, V81, P7485, DOI 10.1073/pnas.81.23.7485; BROWER DL, 1989, NATURE, V342, P285, DOI 10.1038/342285a0; BROWN NH, 1993, BIOESSAYS, V15, P383, DOI 10.1002/bies.950150604; BROWN NH, 1989, CELL, V59, P185, DOI 10.1016/0092-8674(89)90880-5; BUNCH TA, 1992, DEVELOPMENT, V116, P239; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; Bunch TA, 1998, DEVELOPMENT, V125, P1679; Coller BS, 1997, J CLIN INVEST, V99, P1467, DOI 10.1172/JCI119307; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; Erickson HP, 1993, CURR OPIN CELL BIOL, V5, P869, DOI 10.1016/0955-0674(93)90037-Q; FOGERTY FJ, 1994, DEVELOPMENT, V120, P1747; GOTWALS PJ, 1994, P NATL ACAD SCI USA, V91, P11447, DOI 10.1073/pnas.91.24.11447; GOTWALS PJ, 1994, CURR OPIN CELL BIOL, V6, P734, DOI 10.1016/0955-0674(94)90101-5; HENCHCLIFFE C, 1993, DEVELOPMENT, V118, P325; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; Irie A, 1997, P NATL ACAD SCI USA, V94, P7198, DOI 10.1073/pnas.94.14.7198; IRIE A, 1995, EMBO J, V14, P5550, DOI 10.1002/j.1460-2075.1995.tb00242.x; Kamata T, 1996, J BIOL CHEM, V271, P18610, DOI 10.1074/jbc.271.31.18610; KUSCHEGULLBERG M, 1992, EMBO J, V11, P4519, DOI 10.1002/j.1460-2075.1992.tb05553.x; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; LEPTIN M, 1987, EMBO J, V6, P1037, DOI 10.1002/j.1460-2075.1987.tb04856.x; LEPTIN M, 1989, CELL, V56, P401, DOI 10.1016/0092-8674(89)90243-2; LEVINE A, 1994, CELL, V77, P587, DOI 10.1016/0092-8674(94)90220-8; Lin ECK, 1997, J BIOL CHEM, V272, P14236, DOI 10.1074/jbc.272.22.14236; MACKRELL AJ, 1988, P NATL ACAD SCI USA, V85, P2633, DOI 10.1073/pnas.85.8.2633; MERCURIO AM, 1995, TRENDS CELL BIOL, V5, P419, DOI 10.1016/S0962-8924(00)89100-X; MINER JH, 1995, J BIOL CHEM, V270, P28523, DOI 10.1074/jbc.270.48.28523; Oh ES, 1997, J BIOL CHEM, V272, P8133, DOI 10.1074/jbc.272.13.8133; Roote CE, 1996, DEVELOPMENT, V122, P1985; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SPRING J, 1994, P NATL ACAD SCI USA, V91, P3334, DOI 10.1073/pnas.91.8.3334; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; Stark KA, 1997, DEVELOPMENT, V124, P4583; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; Takagi J, 1997, J BIOL CHEM, V272, P19794, DOI 10.1074/jbc.272.32.19794; Takagi Y, 1996, J BIOL CHEM, V271, P18074, DOI 10.1074/jbc.271.30.18074; Tozer EC, 1996, J BIOL CHEM, V271, P21978, DOI 10.1074/jbc.271.36.21978; Tuckwell DS, 1997, FEBS LETT, V400, P297, DOI 10.1016/S0014-5793(96)01368-3; Varner JA, 1996, CURR OPIN CELL BIOL, V8, P724, DOI 10.1016/S0955-0674(96)80115-3; WERHLI M, 1993, MECH DEVELOP, V43, P21; WILCOX M, 1981, CELL, V25, P159, DOI 10.1016/0092-8674(81)90240-3; WOODRUFF RC, 1979, GENETICS, V92, P133; WRIGHT TRF, 1960, J EXP ZOOL, V143, P77, DOI 10.1002/jez.1401430107; YEE G, 1993, THESIS MIT; ZAVORTINK M, 1993, CELL ADHES COMMUN, V1, P251, DOI 10.3109/15419069309097258; Ziober BL, 1997, MOL BIOL CELL, V8, P1723, DOI 10.1091/mbc.8.9.1723; ZUSMAN S, 1993, DEVELOPMENT, V118, P737	53	57	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18235	18241		10.1074/jbc.273.29.18235	http://dx.doi.org/10.1074/jbc.273.29.18235			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660786	hybrid			2022-12-25	WOS:000074828500041
J	Icatlo, FC; Kuroki, M; Kobayashi, C; Yokoyama, H; Ikemori, Y; Hashi, T; Kodama, Y				Icatlo, FC; Kuroki, M; Kobayashi, C; Yokoyama, H; Ikemori, Y; Hashi, T; Kodama, Y			Affinity purification of Helicobacter pylori urease - Relevance to gastric mucin adherence by urease protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE MODEL; CELLS; INFECTION; ADHESION; BINDING; PH; COLONIZATION; IMMUNIZATION; SULFATIDES; ANTIBODIES	A simple, reproducible and high yield method of Helicobacter pylori urease enzyme purification was developed using a heparinoid (Cellufine sulfate) affinity gel. The purification method involved two sequential steps using the same gel that takes advantage of the differential affinity of urease to the heparinoid at two levels of hydrogen ion concentration, SDS-polyacrylamide gel electrophoresis analysis of affinity-purified urease revealed two major protein bands with about 62- and 30-kDa molecular mass. When whole cell lysates of clinical and laboratory strains of H. pylori were probed by Western blot, anti-urease hyperimmune serum produced by affinity-purified urease in rabbit recognized only the two bands corresponding to the urease A and B subunits. To probe the molecular relevance of affinity gel adherence to mucin adherence, the purified urease was derivatized with N-hydroxysuccinimidobiotin and used in adherence assays. Competitive inhibition tests revealed commonality of urease receptors among gastric mucin, heparin, and heparinoid, Composite data on adherence kinetics modulated by pH, salt, incubation time, and concentration of urease or mucin were indicative of conformation-dependent ligand-receptor interaction.	Ghen Corp, Immunol Res Inst, Gifu 50111, Japan		Icatlo, FC (corresponding author), Ghen Corp, Immunol Res Inst, 839-1 Sano, Gifu 50111, Japan.							ASCENCIO F, 1993, J MED MICROBIOL, V38, P240, DOI 10.1099/00222615-38-4-240; CLYNE M, 1995, INFECT IMMUN, V63, P1669, DOI 10.1128/IAI.63.5.1669-1673.1995; Clyne M, 1996, INFECT IMMUN, V64, P2817, DOI 10.1128/IAI.64.7.2817-2820.1996; CorthesyTheulaz I, 1996, INFECT IMMUN, V64, P3827; DAVIES J, 1995, INFECT IMMUN, V63, P2485, DOI 10.1128/IAI.63.7.2485-2492.1995; DUNN BE, 1990, J BIOL CHEM, V265, P9464; Dunn BE, 1997, INFECT IMMUN, V65, P1181, DOI 10.1128/IAI.65.4.1181-1188.1997; EATON KA, 1994, INFECT IMMUN, V62, P3604, DOI 10.1128/IAI.62.9.3604-3607.1994; EATON KA, 1995, SCAND J GASTROENTERO, V30, P434, DOI 10.3109/00365529509093303; EVANS DJ, 1991, MICROB PATHOGENESIS, V10, P15, DOI 10.1016/0882-4010(91)90062-F; FERRERO RL, 1994, INFECT IMMUN, V62, P4981, DOI 10.1128/IAI.62.11.4981-4989.1994; Haas R, 1997, BIOLOGICALS, V25, P175, DOI 10.1006/biol.1997.0080; Harris PR, 1996, GASTROENTEROLOGY, V111, P419, DOI 10.1053/gast.1996.v111.pm8690207; HEMALATHA SG, 1991, J MED MICROBIOL, V35, P197, DOI 10.1099/00222615-35-4-197; HU LT, 1990, INFECT IMMUN, V58, P992, DOI 10.1128/IAI.58.4.992-998.1990; Huesca M, 1996, INFECT IMMUN, V64, P2643, DOI 10.1128/IAI.64.7.2643-2648.1996; Kabir AMA, 1997, GUT, V41, P49, DOI 10.1136/gut.41.1.49; Kamisago S, 1996, INFECT IMMUN, V64, P624, DOI 10.1128/IAI.64.2.624-628.1996; Kawasaki H, 1996, GLYCOCONJUGATE J, V13, P873, DOI 10.1007/BF00702352; LABIGNE A, 1991, J BACTERIOL, V173, P1920, DOI 10.1128/jb.173.6.1920-1931.1991; Labigne A, 1996, INFECT AGENT DIS, V5, P191; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CK, 1995, J INFECT DIS, V172, P161, DOI 10.1093/infdis/172.1.161; MARCHETTI M, 1995, SCIENCE, V267, P1655, DOI 10.1126/science.7886456; MICHETTI P, 1994, GASTROENTEROLOGY, V107, P1002, DOI 10.1016/0016-5085(94)90224-0; NAGATA K, 1992, INFECT IMMUN, V60, P4826, DOI 10.1128/IAI.60.11.4826-4831.1992; NATOMI H, 1990, J CLIN GASTROENTEROL, V12, pS52, DOI 10.1097/00004836-199001001-00010; NATOMI H, 1993, LIPIDS, V28, P737, DOI 10.1007/BF02535996; NMAVAR F, 1998, INFECT IMMUN, V66, P444; OFEK I, 1986, J CLIN MICROBIOL, V24, P512, DOI 10.1128/JCM.24.4.512-516.1986; Phadnis SH, 1996, INFECT IMMUN, V64, P905, DOI 10.1128/IAI.64.3.905-912.1996; PIOTROWSKI J, 1991, BIOCHEM INT, V24, P749; Rostand KS, 1997, INFECT IMMUN, V65, P1; SAITOH T, 1992, EUR J GASTROEN HEPAT, V4, pS49; SCHADE C, 1994, GASTROENTEROLOGY, V107, P180, DOI 10.1016/0016-5085(94)90075-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUDA M, 1994, INFECT IMMUN, V62, P3586, DOI 10.1128/IAI.62.8.3586-3589.1994; TURBETT GR, 1992, INFECT IMMUN, V60, P5259, DOI 10.1128/IAI.60.12.5259-5266.1992; TZOUVELEKIS LS, 1991, INFECT IMMUN, V59, P4252, DOI 10.1128/IAI.59.11.4252-4254.1991; Utt M, 1997, J MED MICROBIOL, V46, P541, DOI 10.1099/00222615-46-7-541; Vanet A, 1998, INFECT IMMUN, V66, P1023, DOI 10.1128/IAI.66.3.1023-1027.1998; Williams CL, 1996, FEMS IMMUNOL MED MIC, V13, P87, DOI 10.1111/j.1574-695X.1996.tb00220.x; WYATT JI, 1987, J CLIN PATHOL, V40, P841, DOI 10.1136/jcp.40.8.841	43	31	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18130	18138		10.1074/jbc.273.29.18130	http://dx.doi.org/10.1074/jbc.273.29.18130			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660771	hybrid, Green Submitted			2022-12-25	WOS:000074828500026
J	Joneson, T; Bar-Sagi, D				Joneson, T; Bar-Sagi, D			A Rac1 effector site controlling mitogenesis through superoxide production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NADPH OXIDASE; ACTIN POLYMERIZATION; CELL PROLIFERATION; JUN KINASE; PATHWAY; GTPASES; CDC42; FIBROBLASTS; DISTINCT	The Rac GTP-binding protein controls signal transduction pathways that are critical for mitogenesis and oncogenesis (1, 2). The biochemical nature of these signaling pathways is presently unknown. Here we report that a region in Rad (residues 124-135), previously defined as the insert region (3), is essential for its mitogenic activity. Deletion of this region does not interfere with the ability of Rad to induce cytoskeletal changes or to activate the Jun kinase mitogen-activated protein kinase cascade but abrogates Rad-induced stimulation of DNA synthesis and Rad-mediated superoxide production in quiescent fibroblasts. Treatment of cells with agents that abolish superoxide generation inhibits specifically the mitogenic effect of Rad. Our results identify an effector site in Rad that is necessary for mitogenic signaling and implicate superoxide generation as a candidate effector pathway of Rac1 dependent cell growth.	SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Bar-Sagi, D (corresponding author), SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.			Bar-Sagi, Dafna/0000-0003-2597-8948	NCI NIH HHS [CA55360] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R56CA055360, R37CA055360, R01CA055360] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; BURDON RH, 1993, FREE RADICAL RES COM, V19, P203, DOI 10.3109/10715769309111603; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; Freeman JL, 1996, J BIOL CHEM, V271, P19794, DOI 10.1074/jbc.271.33.19794; GILI J, 1995, J BIOL CHEM, V270, P29079; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; KWONG CH, 1995, J BIOL CHEM, V270, P19868, DOI 10.1074/jbc.270.34.19868; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; MALY FE, 1989, J IMMUNOL, V142, P1260; MEIER B, 1991, BIOCHEM J, V275, P241, DOI 10.1042/bj2750241; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Nisimoto Y, 1997, J BIOL CHEM, V272, P18834, DOI 10.1074/jbc.272.30.18834; OBERLEY TD, 1995, FREE RADICAL BIO MED, V19, P53, DOI 10.1016/0891-5849(95)00012-M; OLSON M, 1995, SCIENCE, V268, P1270; QUI RG, 1995, NATURE, V374, P457; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	27	157	160	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					17991	17994		10.1074/jbc.273.29.17991	http://dx.doi.org/10.1074/jbc.273.29.17991			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660749	hybrid			2022-12-25	WOS:000074828500004
J	Manya, H; Aoki, J; Watanabe, M; Adachi, T; Asou, H; Inoue, Y; Arai, H; Inoue, K				Manya, H; Aoki, J; Watanabe, M; Adachi, T; Asou, H; Inoue, Y; Arai, H; Inoue, K			Switching of platelet-activating factor acetylhydrolase catalytic subunits in developing rat brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPERGILLUS-NIDULANS; NEURONAL MIGRATION; NUCLEAR MIGRATION; LIS-1 GENE; EXPRESSION; MESSENGER; CLONING; PURIFICATION; PRODUCT	In a previous study, we demonstrated that Platelet-activating Factor (PAF) acetylhydrolase purified from bovine brain cortical cytosol consists of two mutually homologous catalytic subunits (alpha 1 and alpha 2) and one putative regulatory beta subunit, The latter is a product of the LIS1 gene, which is defective in the Miller-Dieker syndrome, a form of lissencephaly. In this study, we examined the expression patterns of these three subunits in the developing rat brain. All three subunits were expressed in embryonic brain, whereas only alpha 2 and beta subunit were detected in the adult brain by Western blotting, Biochemical analyses revealed that the alpha 1/alpha 2 heterodimer and alpha 2/alpha 2 homodimer are major catalytic units of embryonic and adult brain PAF acetylhydrolases, respectively. The alpha 1 transcript and protein were detected predominantly in embryonic and postnatal neural tissues, such as the brain and spinal cord. Furthermore, we found using primary cultured cells isolated from neonatal rat brain that alpha 1 protein were expressed only in neurons but not in glial cells and fibroblasts. In contrast, alpha 2 and beta transcripts and proteins were detected both in neural and non-neural tissues, and their expression level was almost constant from fetal stages through adulthood, These results indicate that alpha 1 expression is restricted to actively migrating neurons in rats and that switching of catalytic subunits from the alpha 1/alpha 2 heterodimer to the alpha 2/alpha 2 homodimer occurred in these cells during brain development, suggesting that PAF acetylhydrolase plays a role(s) in neuronal migration.	Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Hlth Chem, Bunkyo Ku, Tokyo 113, Japan; Hokkaido Univ, Grad Sch Med, Div Brain Sci, Lab Mol Neuroanat, Sapporo, Hokkaido 060, Japan; Tokyo Metropolitan Inst Gerontol, Dept Cell Biol, Itabashi Ku, Tokyo 173, Japan	University of Tokyo; Hokkaido University; Tokyo Metropolitan Institute of Gerontology	Arai, H (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Hlth Chem, Bunkyo Ku, 7-3-1 Hongo, Tokyo 113, Japan.		Watanabe, Masahiko/S-3614-2019; WATANABE, Masahiko/A-4055-2012	Watanabe, Masahiko/0000-0001-5037-7138; WATANABE, Masahiko/0000-0001-5037-7138; Manya, Hiroshi/0000-0003-1573-9177; Aoki, Junken/0000-0001-9435-1896				ADACHI H, 1995, BIOCHEM BIOPH RES CO, V214, P180, DOI 10.1006/bbrc.1995.2272; Adachi H, 1997, BIOCHEM BIOPH RES CO, V233, P10, DOI 10.1006/bbrc.1997.6383; Albrecht U, 1996, DEV BIOL, V180, P579, DOI 10.1006/dbio.1996.0330; AXTELL SM, 1995, MOL ENDOCRINOL, V9, P312, DOI 10.1210/me.9.3.312; BAZAN NG, 1995, NEUROCHEM INT, V26, P435, DOI 10.1016/0197-0186(94)00138-K; BOOK KJ, 1990, J COMP NEUROL, V297, P55, DOI 10.1002/cne.902970105; Gibbons IR, 1996, CELL STRUCT FUNCT, V21, P331, DOI 10.1247/csf.21.331; HATTORI K, 1995, J BIOL CHEM, V270, P22308, DOI 10.1074/jbc.270.38.22308; Hattori K, 1996, J BIOL CHEM, V271, P33032, DOI 10.1074/jbc.271.51.33032; Hattori M, 1995, J BIOL CHEM, V270, P31345, DOI 10.1074/jbc.270.52.31345; HATTORI M, 1993, J BIOL CHEM, V268, P18748; HATTORI M, 1994, J BIOL CHEM, V269, P23150; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; Ho YS, 1997, NATURE, V385, P89, DOI 10.1038/385089a0; KATO K, 1994, NATURE, V367, P175, DOI 10.1038/367175a0; Morris SM, 1997, MOL ENDOCRINOL, V11, P229, DOI 10.1210/me.11.2.229; OSMANI AH, 1990, J CELL BIOL, V111, P543, DOI 10.1083/jcb.111.2.543; RAKIC P, 1971, J COMP NEUROL, V141, P283, DOI 10.1002/cne.901410303; REINER O, 1995, J NEUROSCI, V15, P3730; Sapir T, 1997, EMBO J, V16, P6977, DOI 10.1093/emboj/16.23.6977; Stafforini DM, 1996, BBA-LIPID LIPID MET, V1301, P161, DOI 10.1016/0005-2760(96)00040-9; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; WANG DS, 1995, BIOCHEM BIOPH RES CO, V209, P622, DOI 10.1006/bbrc.1995.1545; WATANABE M, 1997, BIOCHIM BIOPHYS ACTA, V1409, P73; Willins DA, 1997, MOL GEN GENET, V255, P194, DOI 10.1007/s004380050489; XIANG X, 1995, MOL BIOL CELL, V6, P297, DOI 10.1091/mbc.6.3.297; XIANG X, 1994, P NATL ACAD SCI USA, V91, P2100, DOI 10.1073/pnas.91.6.2100; YANOSHITA R, 1988, J BIOCHEM-TOKYO, V103, P815, DOI 10.1093/oxfordjournals.jbchem.a122352	28	62	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18567	18572		10.1074/jbc.273.29.18567	http://dx.doi.org/10.1074/jbc.273.29.18567			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660828	hybrid			2022-12-25	WOS:000074828500083
J	Milanini, J; Vinals, F; Pouyssegur, J; Pages, G				Milanini, J; Vinals, F; Pouyssegur, J; Pages, G			p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; PROTEIN-KINASE; FACTOR EXPRESSION; MAMMALIAN-CELLS; 3T3 CELLS; ACTIVATION; HYPOXIA; MITOGEN; ANGIOGENESIS; FAMILY	Vascular Endothelial Growth Factor (VEGF) is a potent mitogen for vascular endothelial cells that has been implicated in tumor neovascularization. We show that, in hamster fibroblasts (CCL39 cells), VEGF mRNAs are expressed at low levels in serum-deprived or exponentially growing cells, whereas it is rapidly induced after stimulation of quiescent cells with serum. CCL39 derivatives, transformed with Polyoma virus or with active members of the p42/p44 mitogen-activated protein (MAP) kinase pathway, Gly/Val point mutant of Ras at position 12 (Ras-Val(12)), MKK1 in which Ser(218) and Ser(222) were mutated to Asp (MKK1-SS/DD)), express very high levels of VEGF mRNA, To analyze the contribution of the p42/p44MAP kinase in this induction, we used the CCL39 derived cell line (Raf-1:ER) expressing an estradiol-activable Raf-l. We show a time and an estradiol dose-dependent up-regulation of VEGF mRNA clearly detectable after 2 h of stimulation. The induction of VEGF mRNA in response to conditioned activation of Raf-l is reverted by an inhibitor of MKK1, PD 098059, highlighting a specific role for the p42/p44 MAP kinase pathway in VEGF expression. Interestingly, hypoxia has an additive effect on VEGF induction in CCL39 cells stimulated by serum or in Raf-l:ER cells stimulated by estradiol, In contrast to VEGF, the isoforms VEGF-B and VEGF-C are poorly regulated by growth and oncogenic factors. We have identified a GC-rich region of the VEGF promoter between -88 and -66 base pairs which contains all the elements responsible of its up-regulation by constitutive active Ras or MKK1-SS/DD. By mutation of the putative binding sites and electrophoretic mobility supershift experiments, we showed that the GC-rich region constitutively binds Spl and AP-2 transcription factors. Furthermore, following activation of the p42/p44 MAP kinase module, the binding of Spl and AP-2 is increased in the complexes formed in this region of the promoter. Altogether, these data suggest that hypoxia and p42/p44 MAP kinase independently play a key role in the regulation of the VEGF expression.	Univ Nice, Ctr Biochim, CNRS, UMR 6543, F-06108 Nice, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Pages, G (corresponding author), Univ Nice, Ctr Biochim, CNRS, UMR 6543, Parc Valrose, F-06108 Nice, France.	gpages@unice.fr	Pages, Gilles/N-7135-2017; Viñals, Francesc/F-5928-2016; Vinals, Francesc/P-6278-2019	Viñals, Francesc/0000-0002-9918-6751; Milanini, Julie/0000-0002-5861-2830				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; Breier G, 1996, TRENDS CELL BIOL, V6, P454, DOI 10.1016/0962-8924(96)84935-X; BROGI E, 1994, CIRCULATION, V90, P649, DOI 10.1161/01.CIR.90.2.649; BRUNET A, 1994, ONCOGENE, V9, P3379; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; COZZOLINO F, 1993, J CLIN INVEST, V91, P2504, DOI 10.1172/JCI116486; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Enholm B, 1997, ONCOGENE, V14, P2475, DOI 10.1038/sj.onc.1201090; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FINKENZELLER G, 1995, BIOCHEM BIOPH RES CO, V208, P432, DOI 10.1006/bbrc.1995.1356; FOLKMAN J, 1971, J EXP MED, V133, P275, DOI 10.1084/jem.133.2.275; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; Gille J, 1997, EMBO J, V16, P750, DOI 10.1093/emboj/16.4.750; GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; Joukov V, 1996, EMBO J, V15, P290; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; Lenormand P, 1996, J BIOL CHEM, V271, P15762, DOI 10.1074/jbc.271.26.15762; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Pedram A, 1997, J BIOL CHEM, V272, P17097, DOI 10.1074/jbc.272.27.17097; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SAMUELS ML, 1994, MOL CELL BIOL, V14, P7855, DOI 10.1128/MCB.14.12.7855; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SEUWEN K, 1988, EMBO J, V7, P161, DOI 10.1002/j.1460-2075.1988.tb02796.x; Shima DT, 1996, J BIOL CHEM, V271, P3877, DOI 10.1074/jbc.271.7.3877; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; TISCHER E, 1991, J BIOL CHEM, V266, P11947; TOI M, 1991, BIOCHEM BIOPH RES CO, V174, P1287, DOI 10.1016/0006-291X(91)91561-P; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Yoshida S, 1997, MOL CELL BIOL, V17, P4015, DOI 10.1128/MCB.17.7.4015	55	287	302	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18165	18172		10.1074/jbc.273.29.18165	http://dx.doi.org/10.1074/jbc.273.29.18165			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660776	hybrid, Green Published			2022-12-25	WOS:000074828500031
J	Schissel, SL; Keesler, GA; Schuchman, EH; Williams, KJ; Tabas, I				Schissel, SL; Keesler, GA; Schuchman, EH; Williams, KJ; Tabas, I			The cellular trafficking and zinc dependence of secretory and lysosomal sphingomyelinase, two products of the acid sphingomyelinase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; NIEMANN-PICK DISEASE; PROTEIN RECOGNITION DETERMINANTS; PHOSPHOLIPASE-C; PROCATHEPSIN-D; CHOLESTEROL ESTERIFICATION; ATHEROGENIC LIPOPROTEINS; ATHEROSCLEROTIC LESIONS; ENZYME PHOSPHORYLATION; MACROPHAGE UPTAKE	The acid sphingomyelinase (ASM) gene, which has been implicated in ceramide-mediated cell signaling and atherogenesis, gives rise to both lysosomal SMase (L-SMase), which is reportedly cation-independent, and secretory SMase (S-SMase), which is fully or partially dependent on Zn2+ for enzymatic activity. Herein we present evidence for a model to explain how a single mRNA gives rise to two forms of SMase with different cellular trafficking and apparent differences in Zn2+ dependence. First, we show that both S-SMase and SMase, which contain several highly conserved zinc-binding motifs, are directly activated by zinc. In addition, SMase assayed from a lysosome-rich fraction of Chinese hamster ovary cells was found to be partially zinc-dependent, suggesting that intact lysosomes from these cells contain subsaturating levels of Zn2+. Analysis of Asn-linked oligosaccharides and of N-terminal amino acid sequence indicated that S-SMase arises by trafficking through the Golgi secretory pathway, not by cellular release of L-SMase during trafficking to lysosomes or after delivery to lysosomes. Most importantly, when Zn2+-dependent S-SMase was incubated with SMase-negative cells, the enzyme was internalized, trafficked to lysosomes, and became zinc-independent. We conclude that L-SMase is exposed to cellular Zn2+ during trafficking to lysosomes, in lysosomes, and/or during cell homogenization. In contrast, the pathway targeting S-SMase to secretion appears to be relatively sequestered from cellular pools of Zn2+; thus S-SMase requires exogeneous Zn2+ for full activity. This model provides important information for understanding the enzymology and regulation of L- and S-SMase and for exploring possible roles of ASM gene products in cell signaling and atherogenesis.	Columbia Univ, Dept Med, New York, NY 10032 USA; Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA; Amgen, Boulder, CO 80301 USA; CUNY Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; Thomas Jefferson Univ, Div Endocrinol Diabet & Metab Dis, Dorrance H Hamilton Res Labs, Philadelphia, PA 19107 USA	Columbia University; Columbia University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Jefferson University	Tabas, I (corresponding author), Columbia Univ, Dept Med, 630 W 168th St, New York, NY 10032 USA.			Williams, Kevin Jon/0000-0002-0000-2159	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD028607] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028607] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039703, P50HL021006] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL39703, HL 21006] Funding Source: Medline; NICHD NIH HHS [HD28607] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AHMAD TY, 1985, J LIPID RES, V26, P1160; ALOIA RC, 1988, P NATL ACAD SCI USA, V85, P900, DOI 10.1073/pnas.85.3.900; BARANSKI TJ, 1992, J BIOL CHEM, V267, P23342; BAUER J, 1994, J NEUROSCI RES, V38, P365, DOI 10.1002/jnr.490380402; BETTGER WJ, 1981, LIFE SCI, V28, P1425, DOI 10.1016/0024-3205(81)90374-X; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOWSER PA, 1978, J INVEST DERMATOL, V70, P331, DOI 10.1111/1523-1747.ep12543516; Brady R. O., 1983, METABOLIC BASIS INHE, P831; Brand IA, 1996, J BIOL CHEM, V271, P1941, DOI 10.1074/jbc.271.4.1941; CALLAHAN JW, 1978, CAN J BIOCHEM CELL B, V56, P885, DOI 10.1139/o78-137; CALLAHAN JW, 1983, J NEUROSCI RES, V10, P151, DOI 10.1002/jnr.490100205; CANTOR AB, 1992, J BIOL CHEM, V267, P23349; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; CSERMELY P, 1987, CARCINOGENESIS, V8, P1663, DOI 10.1093/carcin/8.11.1663; DANSCHER G, 1985, HISTOCHEMISTRY, V83, P419, DOI 10.1007/BF00509203; DUSTIN ML, 1995, J BIOL CHEM, V270, P170, DOI 10.1074/jbc.270.1.170; FAUST PL, 1987, J CELL BIOL, V105, P1937, DOI 10.1083/jcb.105.5.1937; FRANCIS SH, 1994, J BIOL CHEM, V269, P22477; Guyton JR, 1996, ARTERIOSCL THROM VAS, V16, P4, DOI 10.1161/01.ATV.16.1.4; HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HARTUNG HP, 1992, J NEUROIMMUNOL, V40, P197, DOI 10.1016/0165-5728(92)90134-7; HASILIK A, 1992, EXPERIENTIA, V48, P130, DOI 10.1007/BF01923507; HOFF HF, 1985, ANN NY ACAD SCI, V454, P183, DOI 10.1111/j.1749-6632.1985.tb11857.x; HOFF HF, 1990, EUR HEART J, V11, P105, DOI 10.1093/eurheartj/11.suppl_E.105; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; HORTIN GL, 1989, PREP BIOCHEM, V19, P49, DOI 10.1080/10826068908544896; HOUGH E, 1989, NATURE, V338, P357, DOI 10.1038/338357a0; Hung CH, 1997, J BIOL CHEM, V272, P13772, DOI 10.1074/jbc.272.21.13772; HURWITZ R, 1994, J BIOL CHEM, V269, P5440; IOANNOU YA, 1992, J CELL BIOL, V119, P1137, DOI 10.1083/jcb.119.5.1137; Jiang LJ, 1998, P NATL ACAD SCI USA, V95, P3483, DOI 10.1073/pnas.95.7.3483; KHOO JC, 1988, ARTERIOSCLEROSIS, V8, P348, DOI 10.1161/01.ATV.8.4.348; KHOO JC, 1989, BIOCHIM BIOPHYS ACTA, V1012, P215, DOI 10.1016/0167-4889(89)90099-2; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; LEVADE T, 1986, J CLIN CHEM CLIN BIO, V24, P205; LEVRAN O, 1991, P NATL ACAD SCI USA, V88, P3748, DOI 10.1073/pnas.88.9.3748; Lin XH, 1998, J BIOL CHEM, V273, P14374, DOI 10.1074/jbc.273.23.14374; LITTLE C, 1975, BIOCHIM BIOPHYS ACTA, V391, P326, DOI 10.1016/0005-2744(75)90256-9; LUDWIG T, 1991, J CELL BIOL, V115, P1561, DOI 10.1083/jcb.115.6.1561; Marathe S, 1998, J BIOL CHEM, V273, P4081, DOI 10.1074/jbc.273.7.4081; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Nagase H, 1996, ADV EXP MED BIOL, V389, P23; Neufeld E F, 1980, Birth Defects Orig Artic Ser, V16, P77; Newrzella D, 1996, J BIOL CHEM, V271, P32089, DOI 10.1074/jbc.271.50.32089; NIEVELSTEIN PFEM, 1991, ARTERIOSCLER THROMB, V11, P1795, DOI 10.1161/01.ATV.11.6.1795; Nishikawa A, 1997, J BIOL CHEM, V272, P19408, DOI 10.1074/jbc.272.31.19408; OKWU AK, 1994, J LIPID RES, V35, P644; OTTERBACH B, 1995, CELL, V77, P759; Panchenko MV, 1996, J BIOL CHEM, V271, P7113, DOI 10.1074/jbc.271.12.7113; PORN MI, 1995, BIOCHEM J, V308, P269; PRACK MM, 1994, BIOCHEMISTRY-US, V33, P5049, DOI 10.1021/bi00183a007; RAO BG, 1976, J LIPID RES, V17, P506; Reynolds J J, 1996, Oral Dis, V2, P70; RUNQUIST EA, 1991, J BIOL CHEM, V266, P22557; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Schissel SL, 1996, J CLIN INVEST, V98, P1455, DOI 10.1172/JCI118934; Schissel SL, 1998, J BIOL CHEM, V273, P2738, DOI 10.1074/jbc.273.5.2738; Schissel SL, 1996, J BIOL CHEM, V271, P18431, DOI 10.1074/jbc.271.31.18431; SCHNEIDER PB, 1967, J LIPID RES, V8, P202; SCHUCHMAN EH, 1991, J BIOL CHEM, V266, P8531; Skiba PJ, 1996, J BIOL CHEM, V271, P13392, DOI 10.1074/jbc.271.23.13392; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; SPENCE MW, 1993, ADV LIPID RES, V26, P3; SPENCE MW, 1989, J BIOL CHEM, V264, P5358; SRIPADA PK, 1987, J LIPID RES, V28, P710; SUITS AG, 1989, P NATL ACAD SCI USA, V86, P2713, DOI 10.1073/pnas.86.8.2713; SVENSSON M, 1993, BRAIN RES BULL, V30, P499, DOI 10.1016/0361-9230(93)90284-I; TABAS I, 1993, J BIOL CHEM, V268, P20419; Tomiuk S, 1998, P NATL ACAD SCI USA, V95, P3638, DOI 10.1073/pnas.95.7.3638; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VAN GENDEREN IL, 1994, VIROLOGY, V200, P831, DOI 10.1006/viro.1994.1252; VARKI A, 1983, J BIOL CHEM, V258, P2808; WATANABE K, 1983, J LIPID RES, V24, P596; WATERMAN MR, 1995, SCIENCE, V267, P1780, DOI 10.1126/science.7892600; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551; XU XX, 1991, J BIOL CHEM, V266, P24849; YAMAGUCHI S, 1977, J BIOL CHEM, V252, P3805; YAMAMOTO K, 1994, J BIOCHEM, V116, P229, DOI 10.1093/oxfordjournals.jbchem.a124510; Zha XH, 1998, J CELL BIOL, V140, P39, DOI 10.1083/jcb.140.1.39	84	194	199	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18250	18259		10.1074/jbc.273.29.18250	http://dx.doi.org/10.1074/jbc.273.29.18250			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660788	hybrid			2022-12-25	WOS:000074828500043
J	Gotoh, Y; Cooper, JA				Gotoh, Y; Cooper, JA			Reactive oxygen species- and dimerization-induced activation of apoptosis signal-regulating kinase 1 in tumor necrosis factor-alpha signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANGANOUS SUPEROXIDE-DISMUTASE; PROTEIN-KINASE; IONIZING-RADIATION; N-ACETYLCYSTEINE; MAP KINASE; CELLS; STRESS; CYTOTOXICITY; INVOLVEMENT; CERAMIDE	Reactive oxygen species (ROS) have been implicated in the induction of apoptosis by tumor necrosis factor-alpha (TNF alpha) and other cytotoxic insults, although the molecule(s) regulated by ROS in TNF alpha signaling have not been identified. Apoptosis signal regulating kinase 1 (ASK1) is a member of the mitogen activated protein kinase kinase kinase (MAPKKK) superfamily that has been shown to be activated during TNF alpha-induced apoptosis. ASK1 increases apoptosis when overexpressed, but the mechanism of ASK1 activation and the mechanisms of ASK1-induced apoptosis are unclear. We now report that hydrogen peroxide induces the activation of ASK1 in 293 cells. TNF alpha induced activation of ASK1 was inhibited by antioxidants. Hydrogen peroxide-induced apoptosis was markedly enhanced by the expression of ASK1. These results suggest that TNF alpha-induced activation of ASK1 is mediated by ROS. We also examined how ASK1 activity is regulated by ROS. We found that ASK1 formed dimers or higher order oligomers in 293 cells. TNF alpha or hydrogen peroxide treatment increased the dimeric form of ASK1, and pretreatment with N-acetylcysteine decreased it. Furthermore, synthetic dimerization of an ASK1-gyrase B fusion protein by coumermycin resulted in substantial activation of ASK1, suggesting that dimerization of ASK1 is sufficient for its activation. These results taken together suggest that TNF alpha causes ASK1 activation via ROS-mediated dimerization of ASK1.	Childrens Hosp, Div Neurosci, Boston, MA 02115 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Fred Hutchinson Cancer Center; Harvard University; Harvard Medical School	Gotoh, Y (corresponding author), Childrens Hosp, Div Neurosci, 300 Longwood Ave,Enders 260, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA054786] Funding Source: NIH RePORTER; NCI NIH HHS [CA54786] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMSON GM, 1992, ARCH BIOCHEM BIOPHYS, V294, P223, DOI 10.1016/0003-9861(92)90161-O; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; BASS DA, 1983, J IMMUNOL, V130, P1910; CHANG DJ, 1992, BIOCHEM BIOPH RES CO, V188, P538, DOI 10.1016/0006-291X(92)91089-9; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DROGE W, 1992, IMMUNOL TODAY, V13, P211, DOI 10.1016/0167-5699(92)90156-2; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527, DOI 10.1073/pnas.92.10.4527; HECHT D, 1992, BIOCHEM BIOPH RES CO, V188, P773, DOI 10.1016/0006-291X(92)91123-8; HIROSE K, 1993, FASEB J, V7, P361, DOI 10.1096/fasebj.7.2.8440412; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Inouye C, 1997, SCIENCE, V278, P103, DOI 10.1126/science.278.5335.103; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MATSUDA M, 1991, J IMMUNOL, V147, P3837; MATTHEWS N, 1987, IMMUNOLOGY, V62, P153; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; TALLEY AK, 1995, MOL CELL BIOL, V15, P2359; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; Wallach D, 1997, TRENDS BIOCHEM SCI, V22, P107, DOI 10.1016/S0968-0004(97)01015-3; Wang XHS, 1996, J BIOL CHEM, V271, P31607; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1991, P NATL ACAD SCI USA, V88, P4372, DOI 10.1073/pnas.88.10.4372; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; ZIMMERMAN RJ, 1989, J IMMUNOL, V142, P1405; ZIMMERMAN RJ, 1989, CANCER RES, V49, P1644; ZOR U, 1993, BIOCHEM J, V295, P879, DOI 10.1042/bj2950879	56	312	323	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17477	17482		10.1074/jbc.273.28.17477	http://dx.doi.org/10.1074/jbc.273.28.17477			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651337	hybrid			2022-12-25	WOS:000074816100030
J	Hayes, CS; Setlow, P				Hayes, CS; Setlow, P			Identification of protein-protein contacts between alpha/beta-type small, acid-soluble spore proteins of Bacillus species bound to DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBTILIS SPORES; GENE-EXPRESSION; SIGMA-FACTOR; BINDING; SPORULATION; CLONING	Small, acid-soluble spore proteins (SASP) of the alpha/beta-type from several Bacillus species were cross-linked into homodimers, heterodimers and homooligomers with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) in the presence of linear plasmid DNA. Significant protein cross-linking was not detected in the absence of DNA. In all four alpha/beta-type SASP examined, the amino donor in the EDC induced amide cross-links was the cu-amino group of the protein. However, the carboxylate containing amino acid residues involved in cross linking varied. In SASP-A and SASP-C of Bacillus megateriun two conserved glutamate residues, which form part of the germination protease recognition sequence, were involved in cross-link formation. In SscP-A from Bacillus subtilis and Bcel from Bacillus cereus the acidic residues involved in cross-link formation were not in the protease recognition sequence, but at a site closer to the N terminus of the proteins. These data indicate that, although there are likely to be subtle structural differences between different alpha/beta-type SASP, the N-terminal regions of these proteins are involved in protein-protein interactions while in the DNA bound state.	Univ Connecticut, Ctr Hlth, Dept Biochem, Farmington, CT 06030 USA	University of Connecticut	Setlow, P (corresponding author), Univ Connecticut, Ctr Hlth, Dept Biochem, Farmington, CT 06030 USA.	setlow@sun.uchc.edu	Hayes, Christopher/A-5505-2009		NIGMS NIH HHS [GM19698] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019698, R01GM019698] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CARRILLOMARTINEZ Y, 1994, J BACTERIOL, V176, P5357, DOI 10.1128/JB.176.17.5357-5363.1994; GRIFFITH J, 1994, P NATL ACAD SCI USA, V91, P8224, DOI 10.1073/pnas.91.17.8224; Hayes CS, 1997, J BACTERIOL, V179, P6020, DOI 10.1128/jb.179.19.6020-6027.1997; LOSHON CA, 1986, J BACTERIOL, V167, P168, DOI 10.1128/jb.167.1.168-173.1986; MASON JM, 1986, J BACTERIOL, V167, P174, DOI 10.1128/jb.167.1.174-178.1986; MASON JM, 1988, J BACTERIOL, V170, P239, DOI 10.1128/jb.170.1.239-244.1988; NICHOLSON WL, 1990, J BACTERIOL, V172, P6900, DOI 10.1128/jb.172.12.6900-6906.1990; RAO H, 1992, FEBS LETT, V305, P115, DOI 10.1016/0014-5793(92)80876-I; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SETLOW B, 1991, J BACTERIOL, V173, P1642, DOI 10.1128/jb.173.5.1642-1653.1991; SETLOW B, 1995, J BACTERIOL, V177, P4149, DOI 10.1128/jb.177.14.4149-4151.1995; SETLOW B, 1992, J BACTERIOL, V174, P2312, DOI 10.1128/JB.174.7.2312-2322.1992; SETLOW P, 1975, J BIOL CHEM, V250, P8168; SETLOW P, 1969, J BACTERIOL, V100, P1155, DOI 10.1128/JB.100.3.1155-1160.1969; SETLOW P, 1995, ANNU REV MICROBIOL, V49, P29, DOI 10.1146/annurev.mi.49.100195.000333; SETLOW P, 1988, ANNU REV MICROBIOL, V42, P319, DOI 10.1146/annurev.mi.42.100188.001535; STRAGIER P, 1988, CELL, V52, P697, DOI 10.1016/0092-8674(88)90407-2; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUN DX, 1989, GENE DEV, V3, P141, DOI 10.1101/gad.3.2.141; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	20	8	8	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17326	17332		10.1074/jbc.273.28.17326	http://dx.doi.org/10.1074/jbc.273.28.17326			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651315	hybrid			2022-12-25	WOS:000074816100008
J	Mate, Z; Sass, L; Szekeres, M; Vass, I; Nagy, F				Mate, Z; Sass, L; Szekeres, M; Vass, I; Nagy, F			UV-B-induced differential transcription of psbA genes encoding the D1 protein of photosystem II in the cyanobacterium Synechocystis 6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SP STRAIN PCC-7942; ELECTRON-TRANSPORT; NUCLEOTIDE-SEQUENCE; PISUM-SATIVUM; RADIATION; PHOTOSYNTHESIS; LIGHT; EXPRESSION; DEGRADATION; INHIBITION	UV-B irradiation of intact Synechocystis sp, PCC 6803 cells results in the loss of photosystem II activity, which can be repaired via de novo synthesis of the D1 land D2) reaction center subunits, In this study, we investigated the effect of UV-B irradiation on the transcription of the psbA2 and psbA3 genes encoding identical D1 proteins. We show that UV-B irradiation increases the level of psbA2 mRNA 2-3-fold and, more dramatically, it induces a 20-30-fold increase in the accumulation of the psbA3 mRNA even at levels of irradiation too low to produce losses of either photosystem II activity or D1 protein. The induction of psbA3 transcript accumulation is specific for UV-B light (290-330 nm). Low intensity UV-A emission (330-390 nm) and white light induce only a small, at most, 2-3-fold enhancement, whereas no effect of blue light was observed, Expression patterns of chimeric genes containing the promoter regions of the psbA2, psbA3 genes fused to the firefly luciferase (luc) reporter gene indicate that (i) transcription of psbA2/luc and psbA3/luc transgenes was elevated, similarly to that of the endogenous psbA genes, by UV-B irradiation, and that (ii) a short, 80-base pair psbA3 promoter fragment is sufficient to maintain UV-B-induced transcription of the luc reporter gene. Furthermore, our findings indicate that UV-B induced expression of the psbA2 and psbA3 genes is a defense response against UV-B stress, which is regulated, at least, partially at the level of transcription and does not require active electron transport.	Hungarian Acad Sci, Biol Res Ctr, Inst Plant Biol, H-6701 Szeged, Hungary	Hungarian Academy of Sciences; Hungarian Biological Research Center	Vass, I (corresponding author), Hungarian Acad Sci, Biol Res Ctr, Inst Plant Biol, POB 521, H-6701 Szeged, Hungary.	imre@everx.szbk.u-szeged.hu	Nagy, Ferenc/D-3532-2015; Vass, Imre/AAS-6171-2021	Nagy, Ferenc/0000-0002-6157-9269; Vass, Imre/0000-0003-4987-7842; Szekeres, Miklos/0000-0002-6354-1790				ALLEN JF, 1995, CURR BIOL, V5, P869, DOI 10.1016/S0960-9822(95)00176-X; Andersson B., 1991, CURRENT TOPICS BIOEN, V16, P1; BASIOUNY FM, 1978, PHYSIOL PLANTARUM, V42, P29, DOI 10.1111/j.1399-3054.1978.tb01533.x; BORNMAN JF, 1989, J PHOTOCH PHOTOBIO B, V4, P145, DOI 10.1016/1011-1344(89)80001-6; BORNMAN JF, 1984, PHOTOBIOCH PHOTOBIOP, V8, P305; BRANDLE JR, 1977, PLANT PHYSIOL, V60, P165, DOI 10.1104/pp.60.1.165; BUSTOS SA, 1992, MOL GEN GENET, V232, P221, DOI 10.1007/BF00280000; Campbell D, 1998, P NATL ACAD SCI USA, V95, P364, DOI 10.1073/pnas.95.1.364; CATENHOLZ RW, 1998, ECOLOGY CYANOBACTERI; FEJES E, 1990, PLANT MOL BIOL, V15, P921, DOI 10.1007/BF00039431; FISCUS EL, 1995, PHOTOSYNTH RES, V43, P81, DOI 10.1007/BF00042965; FRISO G, 1994, BBA-BIOENERGETICS, V1184, P78, DOI 10.1016/0005-2728(94)90156-2; GOLDEN SS, 1986, EMBO J, V5, P2789, DOI 10.1002/j.1460-2075.1986.tb04569.x; GREENBERG BM, 1989, P NATL ACAD SCI USA, V86, P6617, DOI 10.1073/pnas.86.17.6617; JANSSON C, 1987, PLANT PHYSIOL, V85, P1021, DOI 10.1104/pp.85.4.1021; JONES LW, 1966, PLANT PHYSIOL, V41, P1037, DOI 10.1104/pp.41.6.1037; KASTING JF, 1993, SCIENCE, V259, P920, DOI 10.1126/science.11536547; KREPS S, 1990, MOL GEN GENET, V221, P129, DOI 10.1007/BF00280378; KULANDAIVELU G, 1983, PHYSIOL PLANTARUM, V58, P389, DOI 10.1111/j.1399-3054.1983.tb04199.x; Lao KQ, 1996, P NATL ACAD SCI USA, V93, P5258, DOI 10.1073/pnas.93.11.5258; MELIS A, 1992, BIOCHIM BIOPHYS ACTA, V1100, P312, DOI 10.1016/0167-4838(92)90487-X; METZ J, 1990, NUCLEIC ACIDS RES, V18, P6715, DOI 10.1093/nar/18.22.6715; MOHAMED A, 1989, PLANT MOL BIOL, V13, P693, DOI 10.1007/BF00016024; MOHAMED A, 1993, MOL GEN GENET, V238, P161, DOI 10.1007/BF00279543; NAGY F, 1998, PLANT MOL BIOL MANUA, P1; NOGUES S, 1995, PLANT CELL ENVIRON, V18, P781, DOI 10.1111/j.1365-3040.1995.tb00581.x; RAVNIKAR PD, 1989, NUCLEIC ACIDS RES, V17, P3991, DOI 10.1093/nar/17.10.3991; RONTO G, 1989, J PHOTOCH PHOTOBIO B, V3, P497, DOI 10.1016/1011-1344(89)80075-2; Salih GF, 1997, PLANT CELL, V9, P869, DOI 10.1105/tpc.9.6.869; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; Sass L, 1997, PHOTOSYNTH RES, V54, P55, DOI 10.1023/A:1005895924892; SMITH RC, 1992, SCIENCE, V255, P952, DOI 10.1126/science.1546292; STRID A, 1990, BIOCHIM BIOPHYS ACTA, V1020, P260, DOI 10.1016/0005-2728(90)90156-X; SVENSSON B, 1991, Z NATURFORSCH C, V46, P765; TREBST A, 1990, Z NATURFORSCH C, V45, P765; TSINOREMAS NF, 1994, J BIOL CHEM, V269, P16143; Vass I, 1996, BIOCHEMISTRY-US, V35, P8964, DOI 10.1021/bi9530595; VASS I, 1996, HDB PHOTOSYNTHESIS, P931; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; ZHANG JW, 1994, BBA-BIOENERGETICS, V1185, P295, DOI 10.1016/0005-2728(94)90244-5	40	77	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17439	17444		10.1074/jbc.273.28.17439	http://dx.doi.org/10.1074/jbc.273.28.17439			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651331	hybrid			2022-12-25	WOS:000074816100024
J	Ramocki, MB; White, MA; Konieczny, SF; Taparowsky, EJ				Ramocki, MB; White, MA; Konieczny, SF; Taparowsky, EJ			A role for RalGDS and a novel Ras effector in the Ras-mediated inhibition of skeletal myogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; CELL-TRANSFORMATION; ONCOGENIC RAS; PROTEIN; KINASE; DIFFERENTIATION; SUFFICIENT; BINDING; RHOA; RAC1	Oncogenic Ras inhibits the differentiation of skeletal muscle cells through the activation of multiple downstream signaling pathways, including a Raf-dependent, mitogen-activated or extracellular signal-regulated kinase kinase/mitogen-activated protein kinase (MEK/MAPK)-independent pathway. Here we report that a non-Raf binding Ras effector-loop variant (H-Ras G12V,E37G), which retains interaction with the Ral guanine nucleotide dissociation stimulator (RalGDS), inhibits the conversion of MyoD-expressing C3H10T1/2 mouse fibroblasts to skeletal muscle. We show that H-Ras G12V,E37G, RalGDS, and the membrane-localized RalGDS CAAX protein inhibit the activity of alpha-actin-Luc, a muscle-specific reporter gene containing a necessary E-box and serum response factor (SRF) binding site, while a RalGDS protein defective for Ras interaction has no effect on alpha-actin-Luc transcription. H-Ras G12V,E37G does not activate endogenous MAPK, but does increase SRI-dependent transcription. Interestingly, RalGDS, RalGDS CAAX, and RalA G23V inhibit H-Ras G12V,E37G-induced expression of an SRF-regulated reporter gene, demonstrating that signaling through RalGDS does not duplicate the action of H-Ras G12V,E37G in this system. As additional evidence for this, we show that H-Ras G12V,E37G inhibits the expression of troponin I-Luc, an SRF-independent muscle-specific reporter gene, whereas RalGDS and RalGDS CAAX do not. Although our studies show that signaling through RalGDS can interfere with the expression of reporter genes dependent on SRF activity (including alpha-actin-Luc), our studies also provide strong evidence that an additional signaling molecule(s) activated by H-Ras G12V,E37G is required to achieve the complete inhibition of the myogenic differentiation program.	Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, Dallas, TX 75235 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Taparowsky, EJ (corresponding author), Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA.				NCI NIH HHS [T32 CA09634, CA71443] Funding Source: Medline; NIAMS NIH HHS [AR41115] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009634, R01CA071443] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041115] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Johnson SE, 1996, MOL CELL BIOL, V16, P1604; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KONG YF, 1995, MOL CELL BIOL, V15, P5205; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; Okazaki M, 1997, ONCOGENE, V14, P515, DOI 10.1038/sj.onc.1200860; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; PINSET C, 1997, DEV REP BIOL, V320, P367; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Ramocki MB, 1997, MOL CELL BIOL, V17, P3547, DOI 10.1128/MCB.17.7.3547; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Weyman CM, 1997, ONCOGENE, V14, P697, DOI 10.1038/sj.onc.1200874; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Wolthuis RMF, 1996, ONCOGENE, V13, P353	22	43	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17696	17701		10.1074/jbc.273.28.17696	http://dx.doi.org/10.1074/jbc.273.28.17696			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651367	hybrid			2022-12-25	WOS:000074816100060
J	Snow, BE; Hall, RA; Krumins, AM; Brothers, GM; Bouchard, D; Brothers, CA; Chung, S; Mangion, J; Gilman, AG; Lefkowitz, RJ; Siderovski, DP				Snow, BE; Hall, RA; Krumins, AM; Brothers, GM; Bouchard, D; Brothers, CA; Chung, S; Mangion, J; Gilman, AG; Lefkowitz, RJ; Siderovski, DP			GTPase activating specificity of RGS12 and binding specificity of an alternatively spliced PDZ (PSD-95/Dlg/ZO-1) domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA-SUBUNITS; PHOSPHOLIPASE C-BETA-1; PHOSPHATASE; RECEPTOR; KINASE; FAMILY; SYSTEM	Regulator of G-protein signaling (RGS) proteins increase the intrinsic guanosine triphosphatase (GTPase) activity of G-protein cu subunits in vitro, but how specific G-protein-coupled receptor systems are targeted for down-regulation by RGS proteins remains uncharacterized. Here, we describe the GTPase specificity of RGS12 and identify four alternatively spliced forms of human RGS12 mRNA, Two RGS12 isoforms of 6.3 and 5.7 kilobases (kb), encoding both an N-terminal PDZ ((P) under bar SD-95/ (D) under bar lg/(Z) under bar O-1) domain and the RGS domain, are expressed in most tissues, with highest levels observed in testis, ovary, spleen, cerebellum, and caudate nucleus. The 5,7-kb isoform has an alternative 3' end encoding a putative C-terminal PDZ domain docking site. Two smaller isoforms, of 3.1 and 3.7 kb, which lack the PDZ domain and encode the RGS domain with and without the alternative 3' end, respectively, are most abundantly expressed in brain, kidney, thymus, and prostate. In vitro biochemical assays indicate that RGS12 is a GTPase-activating protein for Gi class a subunits, Biochemical and interaction trap experiments suggest that the RGS12 N terminus acts as a classical PDZ domain, binding selectively to C-terminal (A/S)-T-X-(L/V) motifs as found within both the interleukin-8 receptor B (CXCR2) and the alternative 3' exon form of RGS12. The presence of an alternatively spliced PDZ domain within RGS12 suggests a mechanism by which RGS proteins may target specific G-protein-coupled receptor systems for desensitization.	Amgen Inst, Quantitat Biol lab, Toronto, ON M5G 2C1, Canada; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Biochem, Durham, NC 27710 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Siderovski, DP (corresponding author), Amgen Inst, Quantitat Biol lab, 620 Univ Ave, Toronto, ON M5G 2C1, Canada.		Lefkowitz, Robert/AAW-2649-2021; Siderovski, David Peter/AAA-9603-2019	Siderovski, David Peter/0000-0002-0688-8210; Hall, Randy/0000-0002-8318-8728	NHLBI NIH HHS [HL16037] Funding Source: Medline; NIGMS NIH HHS [GM34497] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R37GM034497] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gold SJ, 1997, J NEUROSCI, V17, P8024; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; James P, 1996, GENETICS, V144, P1425; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; LEE E, 1994, METHOD ENZYMOL, V237, P146; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P245, DOI 10.1016/S0968-0004(96)30027-3; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; Siderovski DP, 1996, CURR BIOL, V6, P211, DOI 10.1016/S0960-9822(02)00454-2; SIDEROVSKI DP, 1994, DNA CELL BIOL, V13, P125, DOI 10.1089/dna.1994.13.125; Snow BE, 1998, GENE, V206, P247, DOI 10.1016/S0378-1119(97)00593-3; Snow BE, 1997, BIOCHEM BIOPH RES CO, V233, P770, DOI 10.1006/bbrc.1997.6537; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; SUPERTIFURGA G, 1995, FEBS LETT, V369, P62, DOI 10.1016/0014-5793(95)00636-N; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805	27	184	187	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17749	17755		10.1074/jbc.273.28.17749	http://dx.doi.org/10.1074/jbc.273.28.17749			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651375	hybrid			2022-12-25	WOS:000074816100068
J	Telo, P; Breviario, F; Huber, P; Panzeri, C; Dejana, E				Telo, P; Breviario, F; Huber, P; Panzeri, C; Dejana, E			Identification of a novel cadherin (vascular endothelial cadherin-2) located at intercellular junctions in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION MOLECULE; CYTOPLASMIC REGION; CATENIN COMPLEX; NERVOUS-SYSTEM; VE-CADHERIN; N-CADHERIN; PROTEIN; CLONING; FAMILY; EXPRESSION	Endothelial cells express two major cadherins, VE and N-cadherins, but only the former consistently participates in adherens junction organization. In heart microvascular endothelial cells, we identified a new member of the cadherin superfamily using polymerase chain reaction. The entire putative coding sequence was determined. Similarly to protocadherins, while the extracellular domain presented homology with other members of the cadherin superfamily, the intracellular region was unrelated either to cadherins or to any other known protein. We propose for this new protein the name of vascular endothelial cadherin-2. By Northern blot analysis, the mRNA was present only in cultured endothelial cell lines but not in other cell types such as NIH 3T3, Chinese hamster ovary, or L cells. In addition, mRNA was particularly abundant in highly vascularized organs such as lung or kidney. In endothelial cells and transfectants, this cadherin was unable to bind catenins and presented a weak association with the cytoskeleton. This new molecule shares some functional properties with VE-cadherin and other members of the cadherin family. In Chinese hamster ovary transfectants it promoted homotypic Ca2+ dependent aggregation and adhesion and clustered at intercellular junctions. However, in contrast to VE-cadherin, it did not modify paracellular permeability, cell migration, and density-dependent cell growth. These observations suggest that different cadherins may promote homophilic cell-to cell adhesion but that the functional consequences of this interaction depend on their binding to specific intracellular signaling/cytoskeletal proteins.	Mario Negri Inst Pharmacol Res, I-20157 Milan, Italy; Commiss Energie Atom, Lab Transgenese & Differenciat Cellulaire, Dept Biol Mol & Struct, F-38054 Grenoble, France; Univ Milan, Fac Farmacol, I-20129 Milan, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; CEA; University of Milan	Telo, P (corresponding author), Mario Negri Inst Pharmacol Res, Via Eritrea 62, I-20157 Milan, Italy.	telo@irfmn.mnegri.it	Huber, Philippe/C-7971-2019; Carla, Panzeri Maria/AAN-5327-2020	Huber, Philippe/0000-0002-4153-7694; Carla, Panzeri Maria/0000-0002-3019-0314; DEJANA, ELISABETTA/0000-0002-0007-0426				Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; ALEXANDER JS, 1993, J CELL PHYSIOL, V156, P610, DOI 10.1002/jcp.1041560321; AYALON O, 1994, J CELL BIOL, V126, P247, DOI 10.1083/jcb.126.1.247; Bardin N, 1996, BIOCHEM BIOPH RES CO, V218, P210, DOI 10.1006/bbrc.1996.0037; BERNDORFF D, 1994, J CELL BIOL, V125, P1353, DOI 10.1083/jcb.125.6.1353; BREVIARIO F, 1992, J BIOL CHEM, V267, P22190; BREVIARIO F, 1995, ARTERIOSCL THROM VAS, V15, P1229, DOI 10.1161/01.ATV.15.8.1229; Caveda L, 1996, J CLIN INVEST, V98, P886, DOI 10.1172/JCI118870; DEJANA E, 1997, J CLIN INVEST S, V100, P7; DELISSER HM, 1994, IMMUNOL TODAY, V15, P490, DOI 10.1016/0167-5699(94)90195-3; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FRACHET P, 1990, MOL BIOL REP, V14, P27, DOI 10.1007/BF00422712; FUSENIG NE, 1982, CANCER FORUM, V6, P209; GARLANDA C, 1994, P NATL ACAD SCI USA, V91, P7291, DOI 10.1073/pnas.91.15.7291; HATTA K, 1988, J CELL BIOL, V106, P873, DOI 10.1083/jcb.106.3.873; HIRANO S, 1987, J CELL BIOL, V105, P2501, DOI 10.1083/jcb.105.6.2501; KOCH PJ, 1994, CURR OPIN CELL BIOL, V6, P682, DOI 10.1016/0955-0674(94)90094-9; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Kreft B, 1997, J CELL BIOL, V136, P1109, DOI 10.1083/jcb.136.5.1109; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lampugnani MG, 1997, CURR OPIN CELL BIOL, V9, P674, DOI 10.1016/S0955-0674(97)80121-4; LAMPUGNANI MG, 1995, J CELL BIOL, V129, P203, DOI 10.1083/jcb.129.1.203; LEACH L, 1993, J CELL SCI, V104, P1073; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; Navarro P, 1998, J CELL BIOL, V140, P1475, DOI 10.1083/jcb.140.6.1475; Navarro P, 1995, J BIOL CHEM, V270, P30965, DOI 10.1074/jbc.270.52.30965; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PEIFER M, 1995, TRENDS CELL BIOL, V5, P224, DOI 10.1016/S0962-8924(00)89015-7; RANSCHT B, 1991, NEURON, V7, P391, DOI 10.1016/0896-6273(91)90291-7; RINGWALD M, 1987, EMBO J, V6, P3647, DOI 10.1002/j.1460-2075.1987.tb02697.x; Rubin Lee L., 1992, Current Opinion in Cell Biology, V4, P830, DOI 10.1016/0955-0674(92)90107-N; SAGO H, 1995, GENOMICS, V29, P631, DOI 10.1006/geno.1995.9956; SALOMON D, 1992, J CELL SCI, V102, P7; SANO K, 1993, EMBO J, V12, P2249, DOI 10.1002/j.1460-2075.1993.tb05878.x; SCHNURCH H, 1993, DEVELOPMENT, V119, P957; Shibata T, 1997, J BIOL CHEM, V272, P5236, DOI 10.1074/jbc.272.8.5236; SUZUKI S, 1991, CELL REGUL, V2, P261, DOI 10.1091/mbc.2.4.261; Suzuki ST, 1996, J CELL SCI, V109, P2609; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TANIHARA H, 1994, CELL ADHES COMMUN, V2, P15, DOI 10.3109/15419069409014199; VECCHI A, 1994, EUR J CELL BIOL, V63, P247; VOLBERG T, 1986, J CELL BIOL, V102, P1832, DOI 10.1083/jcb.102.5.1832; WILLIAMS RL, 1989, CELL, V57, P1053, DOI 10.1016/0092-8674(89)90343-7	45	60	64	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17565	17572		10.1074/jbc.273.28.17565	http://dx.doi.org/10.1074/jbc.273.28.17565			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651350	hybrid			2022-12-25	WOS:000074816100043
J	Nicolas, E; Beggs, JM; Haltiwanger, BM; Taraschi, TF				Nicolas, E; Beggs, JM; Haltiwanger, BM; Taraschi, TF			A new class of DNA glycosylase apurinic/apyrimidinic lyases that act on specific adenines in single-stranded DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOME-INACTIVATING PROTEINS; T4 ENDONUCLEASE-V; CATALYTIC MECHANISM; DAMAGED DNA; GLYCOSIDASE; EXCISION; REPAIR; RNA; RECOGNITION; RESISTANCE	Although the biological function of DNA glycosylases is to protect the genome by removal of potentially cytotoxic or mutagenic bases, this investigation describes the existence of natural DNA glycosylases with activity on undamaged, nonmispaired bases. Gelonin, pokeweed antiviral protein, and ricin, previously described as ribosome-inactivating proteins, are shown to damage single-stranded DNA by removal of a protein-specific set of adenines and cleavage at the resulting abasic sites. Using an oligonucleotide as the substrate reveals that the reaction proceeds via the enzyme-DNA imino intermediate characteristic of DNA glycosylase/AP lyases. The adenine glycosylase activity on single-stranded DNA reported here challenges the concept that a normal base has to be in a mismatch to be specifically removed. By contrast to other glycosylases, these enzymes are expected to damage DNA rather than participate in repair processes. The significance of this DNase activity to the biological function of these plant proteins and to their toxicity to animal cells remains to be determined.	Jefferson Med Coll, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Jefferson University	Taraschi, TF (corresponding author), Jefferson Med Coll, Dept Pathol Anat & Cell Biol, 1020 Locust St,Rm 229, Philadelphia, PA 19107 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI027247, R01AI027247, R01AI041761] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-27247, AI-41761] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barbieri L, 1996, BIOCHEM J, V319, P507, DOI 10.1042/bj3190507; BARBIERI L, 1994, NATURE, V372, P624, DOI 10.1038/372624a0; BARBIERI L, 1993, BIOCHIM BIOPHYS ACTA, V1154, P237, DOI 10.1016/0304-4157(93)90002-6; BARBIERI L, 1997, NUCLEIC ACIDS RES, V25, P58; Cunningham RP, 1997, MUTAT RES-DNA REPAIR, V383, P189, DOI 10.1016/S0921-8777(97)00008-6; DeMott MS, 1996, J BIOL CHEM, V271, P30068, DOI 10.1074/jbc.271.47.30068; DODSON ML, 1994, J BIOL CHEM, V269, P32709; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; ENDO Y, 1987, J BIOL CHEM, V262, P5908; FRANKEL AE, 1995, SEMIN CANCER BIOL, V6, P307, DOI 10.1006/scbi.1995.0039; Girard PM, 1997, NUCLEIC ACIDS RES, V25, P3204, DOI 10.1093/nar/25.16.3204; Girbes T, 1996, NATURE, V379, P777, DOI 10.1038/379777b0; GO TTM, 1992, LIFE SCI, V51, P1347, DOI 10.1016/0024-3205(92)90634-2; Hilbert TP, 1996, BIOCHEMISTRY-US, V35, P2505, DOI 10.1021/bi952516e; IWAI S, 1995, BIOCHEMISTRY-US, V34, P4601, DOI 10.1021/bi00014a013; KAHN JO, 1994, ANTIMICROB AGENTS CH, V38, P260, DOI 10.1128/AAC.38.2.260; Kavli B, 1996, EMBO J, V15, P3442, DOI 10.1002/j.1460-2075.1996.tb00710.x; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Krokan HE, 1997, BIOCHEM J, V325, P1; LI MX, 1991, NUCLEIC ACIDS RES, V19, P6309, DOI 10.1093/nar/19.22.6309; LING J, 1994, BIOORG CHEM, V22, P395, DOI 10.1006/bioo.1994.1033; LING J, 1995, BIOL CHEM H-S, V376, P637, DOI 10.1515/bchm3.1995.376.11.637; LING J, 1994, FEBS LETT, V345, P143, DOI 10.1016/0014-5793(94)00421-8; MANUEL RC, 1995, J BIOL CHEM, V270, P2652, DOI 10.1074/jbc.270.6.2652; Manuel RC, 1997, BIOCHEMISTRY-US, V36, P11140, DOI 10.1021/bi9709708; Maxam A M, 1980, Methods Enzymol, V65, P499; MCGRATH MS, 1989, P NATL ACAD SCI USA, V86, P2844, DOI 10.1073/pnas.86.8.2844; NAKABEPPU Y, 1981, P NATL ACAD SCI-BIOL, V78, P2742, DOI 10.1073/pnas.78.5.2742; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Nicolas E, 1997, FEBS LETT, V406, P162, DOI 10.1016/S0014-5793(97)00267-6; Nicolas E, 1997, BIOCHEM J, V327, P413, DOI 10.1042/bj3270413; Olivieri F, 1996, FEBS LETT, V396, P132, DOI 10.1016/0014-5793(96)01089-7; POVIRK LF, 1988, BIOCHEMISTRY-US, V27, P380; RAY T, 1995, ELECTROPHORESIS, V16, P888, DOI 10.1002/elps.11501601149; Roncuzzi L, 1996, FEBS LETT, V392, P16, DOI 10.1016/0014-5793(96)00776-4; SCHARER OD, 1997, P NATL ACAD SCI USA, V78, P2742; SHAH DM, 1995, TRENDS BIOTECHNOL, V13, P362, DOI 10.1016/S0167-7799(00)88982-9; SHICK VV, 1980, J MOL BIOL, V139, P491, DOI 10.1016/0022-2836(80)90143-6; Stirpe F, 1996, FEBS LETT, V382, P309, DOI 10.1016/0014-5793(96)00188-3; SUN B, 1995, J BIOL CHEM, V270, P19501, DOI 10.1074/jbc.270.33.19501; TCHOU J, 1995, J BIOL CHEM, V270, P11671, DOI 10.1074/jbc.270.19.11671; TELTOW GJ, 1983, ANTIMICROB AGENTS CH, V23, P390, DOI 10.1128/AAC.23.3.390; Tumer NE, 1997, P NATL ACAD SCI USA, V94, P3866, DOI 10.1073/pnas.94.8.3866; VASSYLYEV DG, 1995, CELL, V83, P773, DOI 10.1016/0092-8674(95)90190-6; Zharkov DO, 1997, J BIOL CHEM, V272, P5335, DOI 10.1074/jbc.272.8.5335	45	56	59	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17216	17220		10.1074/jbc.273.27.17216	http://dx.doi.org/10.1074/jbc.273.27.17216			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642291	hybrid			2022-12-25	WOS:000074545200081
J	Risse-Hackl, G; Adamkiewicz, J; Wimmel, A; Schuermann, M				Risse-Hackl, G; Adamkiewicz, J; Wimmel, A; Schuermann, M			Transition from SCLC to NSCLC phenotype is accompanied by an increased TRE-binding activity and recruitment of specific AP-1 proteins	ONCOGENE			English	Article						AP-1; Jun; Fos; Fra-1, Ras; lung cancer; transdifferentiation	TRANSCRIPTION FACTOR AP-1; PROGRAMMED CELL-DEATH; FOS-RELATED ANTIGEN; C-FOS; LUNG-CANCER; JUN PROTEINS; TUMOR PROGRESSION; GENE-EXPRESSION; PROMOTER ACTIVITY; GROWTH-FACTORS	Transitions from small cell (SCLC) to non-small cell lung cancer (NSCLC) cells have been documented both in vitro and in vivo and are thought to be an important step during tumor progression of human small cell lung cancer towards a treatment-resistant tumor state. We have screened NSCLC and SCLC cell lines for differences in the composition of nuclear transcription factors using consensus oligonucleotide sequences (SRE, Ets, TRE, CRE, B-motif, GAS, E-box), We found NSCLC cells to exhibit significantly higher AP-1 binding activity than SCLC cells consistent with the increased expression of CD44, an AP-1 target gene. To gain more insight into the molecular mechanisms underlying these differences, we analysed SCLC cell lines (NCI-N592 and NCI-H69) which were phenotypically transformed into NSCLC-type cells by transfection with activated H-l ns and c-myc oncogenes, In these cells, I as-induced transition is accompanied by a strong induction of AP-l-binding activity along with increased expression of CD 44 mRNA and protein. When analysing the composition of the AP-1 complex in more detail and comparing ras-induced versus phorbol ester-induced changes, we found Fra-1 to be the major component induced in ras-transfected but not in phorbol-ester treated or non-treated parental SCLC cells. This finding is paralleled by the observation that among the various members of the Fos and Jun family analysed (c-Fos, FosB, Fra-1, Fra-2, c-Jun, JunD, JunB) fra-1 is the only gene to be exclusively expressed in NSCLC cells but not in cells of SCLC origin. Our data, thus, point to a histiotype-related mechanism of recruitment among AP-1 proteins which may have bearings on the fate of lung cancer development.	Univ Marburg, Hamatol Onkol Abt, Zentrum Innere Med, D-35033 Marburg, Germany; Univ Marburg, Inst Molekularbiol & Tumorforsch, D-35037 Marburg, Germany	Philipps University Marburg; Philipps University Marburg	Schuermann, M (corresponding author), Univ Marburg, Hamatol Onkol Abt, Zentrum Innere Med, Baldingerstr, D-35033 Marburg, Germany.							ADAMKIEWICZ J, 1990, ONCOGENE, V5, P525; ADAMKIEWICZ J, 1993, INT J ONCOL, V2, P503; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARCARI P, 1984, NUCLEIC ACIDS RES, V12, P9179, DOI 10.1093/nar/12.23.9179; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; Barr LF, 1996, CELL GROWTH DIFFER, V7, P1149; BARR LF, 1991, CANCER RES, V51, P5514; BERNARDS R, 1995, CURR BIOL, V5, P859, DOI 10.1016/S0960-9822(95)00173-4; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BRASELMANN S, 1993, P NATL ACAD SCI USA, V90, P1657, DOI 10.1073/pnas.90.5.1657; BURGER C, 1994, MOL CELL DIFFER, V2, P373; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1990, CRIT REV ONCOGEN, V1, P6184; DIXIT VM, 1989, J BIOL CHEM, V264, P16905; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; FALCO JP, 1990, J CLIN INVEST, V85, P1740, DOI 10.1172/JCI114630; Givehchian M, 1996, ONCOGENE, V12, P1137; GOLDSTONE SD, 1994, ONCOGENE, V9, P2305; HANNAN RD, 1993, J MOL CELL CARDIOL, V25, P1137, DOI 10.1006/jmcc.1993.1127; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; HAYNES BF, 1991, CANCER CELL-MON REV, V3, P347; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOFMANN M, 1993, CANCER RES, V53, P1516; JALKANEN S, 1992, J CELL BIOL, V116, P817, DOI 10.1083/jcb.116.3.817; JAMAL HH, 1994, ONCOGENE, V9, P417; Kalemkerian GP, 1993, LUNG CANCER, P57; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; Lengyel E, 1996, J BIOL CHEM, V271, P23176, DOI 10.1074/jbc.271.38.23176; MABRY M, 1988, P NATL ACAD SCI USA, V85, P6523, DOI 10.1073/pnas.85.17.6523; MABRY M, 1991, CANCER CELL-MON REV, V3, P53; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUI M, 1990, ONCOGENE, V5, P249; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; MELAMED D, 1993, CELL GROWTH DIFFER, V4, P689; MIANO JM, 1993, AM J PATHOL, V142, P715; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; NOMURA N, 1990, NUCLEIC ACIDS RES, V18, P3047, DOI 10.1093/nar/18.10.3047; PARK K, 1992, J BIOL CHEM, V267, P10810; PENNO MB, 1994, CANCER RES, V54, P1381; PERSICO AM, 1993, MOL BRAIN RES, V20, P91, DOI 10.1016/0169-328X(93)90113-4; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; ROGGLI VL, 1985, HUM PATHOL, V16, P569, DOI 10.1016/S0046-8177(85)80106-4; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1991, ONCOGENE, V6, P533; SATO H, 1993, ONCOGENE, V8, P395; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; SHERMAN L, 1994, CURR OPIN CELL BIOL, V6, P726, DOI 10.1016/0955-0674(94)90100-7; SIDEROVSKI DP, 1990, DNA CELL BIOL, V9, P579, DOI 10.1089/dna.1990.9.579; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; STEPHENS JM, 1993, MOL CELL BIOCHEM, V123, P63, DOI 10.1007/BF01076476; STJOHN T, 1990, CELL, V60, P45, DOI 10.1016/0092-8674(90)90714-P; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; TROEN BR, 1991, CELL GROWTH DIFFER, V2, P23; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; WANG ZQ, 1993, J BONE MINER RES, V8, P839; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; WIMMEL A, 1997, LUNG CANCER, V16, P239; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	70	47	49	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 11	1998	16	23					3057	3068		10.1038/sj.onc.1201845	http://dx.doi.org/10.1038/sj.onc.1201845			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZT782	9662339				2022-12-25	WOS:000074125300013
J	Maggiora, P; Marchio, S; Stella, MC; Giai, M; Belfiore, A; De Bortoli, M; Di Renzo, MF; Costantino, A; Sismondi, P; Comoglio, PM				Maggiora, P; Marchio, S; Stella, MC; Giai, M; Belfiore, A; De Bortoli, M; Di Renzo, MF; Costantino, A; Sismondi, P; Comoglio, PM			Overexpression of the RON gene in human breast carcinoma	ONCOGENE			English	Article						protein-tyrosine kinase; RON; breast neoblasts	HEPATOCYTE GROWTH-FACTOR; MACROPHAGE-STIMULATING PROTEIN; RECEPTOR TYROSINE KINASE; SCATTER FACTOR-RECEPTOR; MET PROTOONCOGENE; OVARIAN-CANCER; IDENTIFICATION; CELLS; EXPRESSION; TRANSFORMATION	Constitutive activation of the RON gene, known to code for the tyrosine-kinase receptor for Macrophage Stimulating Protein (also known as Scatter Factor 2), has been shown to induce invasive-metastatic phenotype in vitro. As yet, nothing is known about the expression of this novel member of the MET-oncogene family in spontaneously occurring human cancers. Here we report that Ron is expressed at abnormally high levels in about 50% primary breast carcinomas (35/74 patients). Among these, the expression is increased more than 20-fold in 12 cases and the overexpressed protein is constitutively phosphorylated on tyrosine residues. Notably, Ron is only barely detectable in epithelial cells of the mammary gland, and its expression remains unchanged in benign breast lesions (including adenomas and papillomas). Overexpression was observed in different histotypic variants of carcinomas; it is associated with the disease at any stage and correlates with the post-menopausal status. In breast carcinoma cells grown im vitro, activation of the Ron receptor resulted in proliferation, migration and invasion through reconstituted basement membranes. Altogether, these data suggest a role for the RON gene in progression of human breast carcinomas to the invasive-metastatic phenotype.	Univ Turin, Sch Med, Inst Canc Res & Treatment, IRCC, I-10060 Turin, Italy; Univ Turin, Sch Med, Dept Gynecol Oncol, I-10060 Turin, Italy; Univ Turin, Dept Biol, LMCB, I-10123 Turin, Italy; Univ Catania, Sch Med, Dept Endocrinol, I-95123 Catania, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; University of Turin; University of Turin; University of Catania	Comoglio, PM (corresponding author), Univ Turin, Sch Med, Inst Canc Res, Str Prov 142,Km 3-95, I-10060 Turin, Italy.		Marchiò, Serena/G-9054-2017; DI RENZO, Maria Flavia/B-6091-2012; De Bortoli, Michele/B-5418-2013; Belfiore, Antonino/B-4652-2011	Marchiò, Serena/0000-0001-8214-0776; DI RENZO, Maria Flavia/0000-0002-5093-3373; De Bortoli, Michele/0000-0002-6666-9052; Belfiore, Antonino/0000-0002-6181-4193; Comoglio, Paolo/0000-0002-7056-5328; Sismondi, Piero/0000-0002-2505-5716				BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; BYERS S, 1994, BREAST CANCER RES TR, V31, P203, DOI 10.1007/BF00666154; Collesi C, 1996, MOL CELL BIOL, V16, P5518; DELGATTO F, 1995, BBA-GENE STRUCT EXPR, V1263, P93, DOI 10.1016/0167-4781(95)00082-R; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; DIRENZO MF, 1994, INT J CANCER, V58, P658, DOI 10.1002/ijc.2910580507; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; FOX SB, 1994, BREAST CANCER RES TR, V29, P41, DOI 10.1007/BF00666180; Gambarotta G, 1996, ONCOGENE, V13, P1911; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Gaudino G, 1995, ONCOGENE, V11, P2627; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GIORDANO S, 1997, P NATL ACAD SCI USA, V94, P11445; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; Hartmann A, 1997, TRENDS GENET, V13, P27, DOI 10.1016/S0168-9525(96)10043-3; HENNIPMAN A, 1989, CANCER RES, V49, P516; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; KOBAYASHI H, 1992, CANCER RES, V52, P3610; Kovach JS, 1996, P NATL ACAD SCI USA, V93, P1093, DOI 10.1073/pnas.93.3.1093; Kurihara N, 1996, BLOOD, V87, P3704, DOI 10.1182/blood.V87.9.3704.bloodjournal8793704; Lin JC, 1996, ONCOGENE, V13, P2001; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAGY J, 1995, J SURG ONCOL, V60, P95, DOI 10.1002/jso.2930600206; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Rahimi N, 1996, CELL GROWTH DIFFER, V7, P263; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; RONSIN C, 1993, ONCOGENE, V8, P1195; SAINSBURY JRC, 1985, LANCET, V1, P364; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TOI M, 1994, BREAST CANCER RES TR, V29, P51, DOI 10.1007/BF00666181; Tuck AB, 1996, AM J PATHOL, V148, P225; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WERNERT N, 1994, CANCER RES, V54, P5683; YAMASHITA J, 1994, CANCER RES, V54, P1630	42	175	192	0	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 4	1998	16	22					2927	2933		10.1038/sj.onc.1201812	http://dx.doi.org/10.1038/sj.onc.1201812			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZR544	9671413				2022-12-25	WOS:000073988200011
J	Fang, TY; Alechina, O; Aleshin, AE; Fromm, HJ; Honzatko, RB				Fang, TY; Alechina, O; Aleshin, AE; Fromm, HJ; Honzatko, RB			Identification of a phosphate regulatory site and a low affinity binding site for glucose 6-phosphate in the N-terminal half of human brain hexokinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFICATION; HALVES; MUTAGENESIS; RESIDUES; ENZYME; ATP	Crystal structures of human hexokinase I reveal identical binding sites for phosphate and the g-phosphoryl group of glucose B-phosphate in proximity to Gly(87), Ser(88), Thr(232), and Ser(415), a binding site for the pyranose moiety of glucose B-phosphate in proximity to Asp(84), Asp(413), and Ser(449), and a single salt link involving Arg(801) between the N- and C-terminal halves. Purified wildtype and mutant enzymes (Asp(84) --> Ala, Gly(87) --> Tyr, Ser(88) --> Ala, Th-232 --> Ala, Asp(413) --> Ala, Ser(415) --> Ala, Ser(449) --> Ala, and Arg(801) --> Ala) were studied by kinetics and circular dichroism spectroscopy. All eight mutant hexokinases have k(cat) and K-m values for substrates similar to those of wild-type hexokinase I. Inhibition of wild-type enzyme by 1,5-anhydroglucitol B-phosphate is consistent with a high affinity binding site (K-i = 50 mu M) and a second, low affinity binding site (K-ii = 0.7 mM), The mutations of Asp(84), Gly(87), and Thr232 listed above eliminate inhibition because of the low affinity site, but none of the eight mutations influence K-i of the high affinity site. Relief of 1,5-anhydroglucitol B-phosphate inhibition by phosphate for Asp(84) --> Ala, Ser(88) --> Ala, Ser(415) --> Ala, Ser(449) --> Ala and Arg(801) --> Ala mutant enzymes is substantially less than that of wild-type hexokinase and completely absent in the Gly(87) --> Tyr and Thr(232) --> Ala mutants. The results support several conclusions. (i) The phosphate regulatory site is at the N-terminal domain as identified in crystal structures. (ii) The glucose B-phosphate binding site at the N-terminal domain is a low affinity site and not the high affinity site associated with potent product inhibition. (iii) Arg(801) participates in the regulatory mechanism of hexokinase I.	Iowa State Univ Sci & Technol, Dept Biochem & Biophys, Ames, IA 50011 USA	Iowa State University	Honzatko, RB (corresponding author), Iowa State Univ Sci & Technol, Dept Biochem & Biophys, Ames, IA 50011 USA.				NINDS NIH HHS [NS 10546] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS010546, R56NS010546] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aleshin AE, 1998, STRUCTURE, V6, P39, DOI 10.1016/S0969-2126(98)00006-9; ALESHIN AE, 1998, IN PRESS J MOL BIOL; ARORA KK, 1993, J BIOL CHEM, V268, P18259; ARORA KK, 1991, J BIOL CHEM, V266, P5359; BAIJAL M, 1995, ARCH BIOCHEM BIOPHYS, V321, P413, DOI 10.1006/abbi.1995.1412; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; EASTERBY JS, 1973, EUR J BIOCHEM, V38, P201, DOI 10.1111/j.1432-1033.1973.tb03051.x; ELLISON WR, 1975, J BIOL CHEM, V250, P1864; FERRARI RICHARD A., 1959, ARCH BIOCHEM AND BIOPHYS, V80, P372, DOI 10.1016/0003-9861(59)90264-4; FROMM HJ, 1981, REGULATION CARBOHYDR, P45; HOLROYDE MJ, 1976, FEBS LETT, V62, P215, DOI 10.1016/0014-5793(76)80056-7; KATZEN HM, 1965, P NATL ACAD SCI USA, V54, P1218, DOI 10.1073/pnas.54.4.1218; KATZEN HM, 1970, J BIOL CHEM, V245, P4081; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LIU F, 1991, BIOCHEM BIOPH RES CO, V177, P305, DOI 10.1016/0006-291X(91)91983-J; LOWRY OH, 1964, J BIOL CHEM, V239, P31; MAGNANI M, 1992, BIOCHEM J, V285, P193, DOI 10.1042/bj2850193; MANNING TA, 1984, BIOCHEM BIOPH RES CO, V118, P90, DOI 10.1016/0006-291X(84)91071-4; Rapoport S, 1968, Essays Biochem, V4, P69; TSAI HJ, 1995, ARCH BIOCHEM BIOPHYS, V316, P206, DOI 10.1006/abbi.1995.1029; URETA T, 1982, COMP BIOCHEM PHYS B, V71, P549, DOI 10.1016/0305-0491(82)90461-8; URETA T, 1975, ISOZYMES, V3, P575; WHITE TK, 1989, ARCH BIOCHEM BIOPHYS, V274, P375, DOI 10.1016/0003-9861(89)90451-7; WILSON JE, 1995, REV PHYSIOL BIOCH P, V126, P65, DOI 10.1007/BFb0049776; Zeng CB, 1996, BIOCHEMISTRY-US, V35, P13157, DOI 10.1021/bi960750e; ZENG CB, 1995, J BIOL CHEM, V270, P10509, DOI 10.1074/jbc.270.18.10509; Zeng CB, 1998, J BIOL CHEM, V273, P700, DOI 10.1074/jbc.273.2.700	27	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19548	19553		10.1074/jbc.273.31.19548	http://dx.doi.org/10.1074/jbc.273.31.19548			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677378	hybrid			2022-12-25	WOS:000075125200030
J	Tai, AW; Chuang, JZ; Sung, CH				Tai, AW; Chuang, JZ; Sung, CH			Localization of Tctex-1, a cytoplasmic dynein light chain, to the golgi apparatus and evidence for dynein complex heterogeneity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE T-COMPLEX; ENDOPLASMIC-RETICULUM; BREFELDIN-A; INTERMEDIATE CHAINS; SECRETORY PROTEINS; MEMBRANE-PROTEIN; OKADAIC ACID; HEAVY-CHAIN; HELA-CELLS; EXPRESSION	To date, much attention has been focused on the heavy and intermediate chains of the multisubunit cytoplasmic dynein complex; however, little is known about the localization or function of dynein light chains. In this study, we find that Tctex-1, a light chain of cytoplasmic dynein, localizes predominantly to the Golgi apparatus in interphase fibroblasts, Immunofluorescent staining reveals striking juxtanuclear staining characteristic of the Golgi apparatus as well as nuclear envelope and punctate cytoplasmic staining that often decorates microtubules, Tctex-1 colocalization with Golgi compartment markers, its distribution upon treatment with various pharmacological agents, and the cofractionation of Tctex-1-associated membranes with Golgi membranes are all consistent with a Golgi localization. The distribution of Tctex-1 in interphase cells only partially overlaps with the dynein intermediate chain and p150(Glued) upon immunofluorescence, but most of Tctex-1 is redistributed onto mitotic spindles along with other dynein/dynactin subunits, Using sequential immunoprecipitations, we demonstrate that there is a subset of Tctex-1 not associated with the intermediate chain at steady state; the converse also appears to be true, Distinct populations of dynein complexes are likely to exist, and such diversity may occur in part at the level of their light chain compositions.	Cornell Univ, Coll Med, Margaret M Dyson Vis Res Inst, Dept Cell Biol & Anat, New York, NY 10021 USA; Cornell Univ, Coll Med, Margaret M Dyson Vis Res Inst, Dept Ophthalmol, New York, NY 10021 USA	Cornell University; Cornell University	Sung, CH (corresponding author), Cornell Univ, Coll Med, Vis Res Inst, 1300 York Ave, New York, NY 10021 USA.	chsung@mail.med.cornell.edu	Tai, Andrew W./M-8380-2017	Tai, Andrew W./0000-0002-6877-450X	NEI NIH HHS [EY11307, EY07138, R01 EY011307] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011307, T32EY007138] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANIENTO F, 1993, J CELL BIOL, V123, P1373, DOI 10.1083/jcb.123.6.1373; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; Benashski SE, 1997, J BIOL CHEM, V272, P20929, DOI 10.1074/jbc.272.33.20929; BLOOM GS, 1989, J BIOL CHEM, V264, P16083; BLOSE SH, 1984, J CELL BIOL, V98, P847, DOI 10.1083/jcb.98.3.847; BROWN WJ, 1987, P NATL ACAD SCI USA, V84, P9001, DOI 10.1073/pnas.84.24.9001; BURKE B, 1982, EMBO J, V1, P1621, DOI 10.1002/j.1460-2075.1982.tb01364.x; Burkhardt JK, 1997, J CELL BIOL, V139, P469, DOI 10.1083/jcb.139.2.469; BURNS DM, 1982, J BIOL CHEM, V257, P9991; CAUGHEY B, 1983, BIOCHIM BIOPHYS ACTA, V757, P296, DOI 10.1016/0304-4165(83)90054-5; CHUANG JZ, 1995, J CELL BIOL, V128, P1095, DOI 10.1083/jcb.128.6.1095; CORTHESYTHEULAZ I, 1992, J CELL BIOL, V118, P1333, DOI 10.1083/jcb.118.6.1333; DEBRABANDER MJ, 1976, CANCER RES, V36, P905; DILLMAN JF, 1994, J CELL BIOL, V127, P1671, DOI 10.1083/jcb.127.6.1671; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DOOLITTLE MH, 1991, ANAL BIOCHEM, V195, P364, DOI 10.1016/0003-2697(91)90342-Q; DUNPHY WG, 1983, J CELL BIOL, V97, P270, DOI 10.1083/jcb.97.1.270; ESHEL D, 1993, P NATL ACAD SCI USA, V90, P11172, DOI 10.1073/pnas.90.23.11172; FATH KR, 1994, J CELL BIOL, V126, P661, DOI 10.1083/jcb.126.3.661; Fath KR, 1997, J CELL BIOL, V139, P1169, DOI 10.1083/jcb.139.5.1169; FEDDE KN, 1990, AM J HUM GENET, V47, P767; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GILL SR, 1994, MOL BIOL CELL, V5, P645, DOI 10.1091/mbc.5.6.645; GOLDBERG DE, 1983, J BIOL CHEM, V258, P3159; Harrison A, 1998, J CELL BIOL, V140, P1137, DOI 10.1083/jcb.140.5.1137; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; HO WC, 1989, EUR J CELL BIOL, V48, P250; HORN M, 1994, BIOCHEM J, V301, P69, DOI 10.1042/bj3010069; HUW LY, 1995, DEV BIOL, V170, P183, DOI 10.1006/dbio.1995.1206; King SM, 1996, J BIOL CHEM, V271, P19358, DOI 10.1074/jbc.271.32.19358; King SM, 1996, J BIOL CHEM, V271, P32281, DOI 10.1074/jbc.271.50.32281; KOONCE MP, 1990, CELL MOTIL CYTOSKEL, V15, P51, DOI 10.1002/cm.970150108; LADER E, 1989, CELL, V58, P969, DOI 10.1016/0092-8674(89)90948-3; LI YY, 1993, P NATL ACAD SCI USA, V90, P10096, DOI 10.1073/pnas.90.21.10096; LIN SXH, 1994, J CELL BIOL, V127, P1009, DOI 10.1083/jcb.127.4.1009; LIN SXH, 1993, J CELL SCI, V105, P579; LIN SXH, 1992, J CELL SCI, V101, P125; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LUCOCQ JM, 1989, J CELL BIOL, V109, P463, DOI 10.1083/jcb.109.2.463; LUCOCQ JM, 1987, EMBO J, V6, P3239, DOI 10.1002/j.1460-2075.1987.tb02641.x; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; LYON MF, 1986, CELL, V44, P357, DOI 10.1016/0092-8674(86)90770-1; MARTINIUK F, 1981, BIOCHIM BIOPHYS ACTA, V658, P248, DOI 10.1016/0005-2744(81)90295-3; Mazumdar M, 1996, P NATL ACAD SCI USA, V93, P6552, DOI 10.1073/pnas.93.13.6552; Niclas J, 1996, J CELL BIOL, V133, P585, DOI 10.1083/jcb.133.3.585; OLMSTED JB, 1986, METHOD ENZYMOL, V134, P467; PatelKing RS, 1997, J CELL BIOL, V137, P1081, DOI 10.1083/jcb.137.5.1081; PFARR CM, 1990, NATURE, V345, P263, DOI 10.1038/345263a0; Pfister KK, 1996, J BIOL CHEM, V271, P1687, DOI 10.1074/jbc.271.3.1687; PLAMANN M, 1994, J CELL BIOL, V127, P139, DOI 10.1083/jcb.127.1.139; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; Reinsch S, 1997, CURR BIOL, V7, P211, DOI 10.1016/S0960-9822(97)70092-7; ROBINSON MS, 1990, J CELL BIOL, V111, P2319, DOI 10.1083/jcb.111.6.2319; ROGALSKI AA, 1984, J CELL BIOL, V99, P1101, DOI 10.1083/jcb.99.3.1101; RON D, 1992, BIOTECHNIQUES, V13, P866; ROUX AF, 1994, HUM MOL GENET, V3, P257, DOI 10.1093/hmg/3.2.257; SARASTE J, 1986, P NATL ACAD SCI USA, V83, P6425, DOI 10.1073/pnas.83.17.6425; SARASTE J, 1991, J CELL SCI, V100, P415; SAUNDERS WS, 1995, J CELL BIOL, V128, P617, DOI 10.1083/jcb.128.4.617; SCHLIWA M, 1982, J CELL BIOL, V92, P79, DOI 10.1083/jcb.92.1.79; SILVER LM, 1993, TRENDS GENET, V9, P250, DOI 10.1016/0168-9525(93)90090-5; Sodeik B, 1997, J CELL BIOL, V136, P1007, DOI 10.1083/jcb.136.5.1007; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; TURNER JR, 1989, J CELL BIOL, V109, P2081, DOI 10.1083/jcb.109.5.2081; Vaisberg EA, 1996, J CELL BIOL, V133, P831, DOI 10.1083/jcb.133.4.831; VALLEE RB, 1990, ANNU REV BIOCHEM, V59, P909, DOI 10.1146/annurev.biochem.59.1.909; Vallee RB, 1995, COLD SPRING HARB SYM, V60, P803, DOI 10.1101/SQB.1995.060.01.086; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507; VESLASCO A, 1993, J CELL BIOL, V122, P39; Wang ZH, 1995, BIOPHYS J, V69, P2011, DOI 10.1016/S0006-3495(95)80071-8; Watanabe TK, 1996, CYTOGENET CELL GENET, V73, P153, DOI 10.1159/000134329; XIANG X, 1994, P NATL ACAD SCI USA, V91, P2100, DOI 10.1073/pnas.91.6.2100; YOSHIDA T, 1994, J CELL SCI, V107, P625	76	68	71	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19639	19649		10.1074/jbc.273.31.19639	http://dx.doi.org/10.1074/jbc.273.31.19639			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677391	hybrid			2022-12-25	WOS:000075125200043
J	Zakharova, N; Hoffman, PS; Berg, DE; Severinov, K				Zakharova, N; Hoffman, PS; Berg, DE; Severinov, K			The largest subunits of RNA polymerase from gastric Helicobacters are tethered	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SP-NOV; PYLORI; GENOME; TRANSCRIPTION; DIVERSITY; SEQUENCE	The rpoB and rpoC genes of eubacteria and archaea, coding respectively for the beta- and beta'-like subunits of DNA-dependent RNA polymerase, are organized in an operon with rpoB always preceding rpoC. The genome sequence of the gastric pathogen Helicobacter pylori (strain 26695) revealed homologs of two genes in one continuous open reading frame that potentially could encode one 2890-amino acid-long beta-beta' fusion protein. Here, we show that this open reading frame does in fact encode a fused beta-beta' polypeptide. In addition, we establish by DNA sequencing that rpoB and rpoC are also fused in each of four other unrelated strains of H. pylori, as well as in Helicobacter felis, another member of the same genus. In contrast, the rpoB and rpoC genes are separate in two members of the related genus Campylobacter (Campylobacter jejuni and Campylobacter fetus) and encode separate RNA polymerase subunits. The Campylobacter genes are also unusual in overlapping one another rather than being separated by a spacer as in other Gramnegative bacteria. We propose that the unique organization of rpoB and rpoC in H. pylori may contribute to its ability to colonize the human gastric mucosa.	Rutgers State Univ, Waksman Inst, Piscataway, NJ 08854 USA; Dalhousie Univ, Dept Microbiol & Immunol, Halifax, NS B3H 4H7, Canada; Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; Rutgers State Univ, Dept Genet, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Dalhousie University; Washington University (WUSTL); Washington University (WUSTL); Rutgers State University New Brunswick	Severinov, K (corresponding author), Rutgers State Univ, Waksman Inst, POB 759, Piscataway, NJ 08854 USA.		Severinov, Konstantin/C-8545-2016		NHGRI NIH HHS [HG00820] Funding Source: Medline; NIAID NIH HHS [AI38166] Funding Source: Medline; NIDDK NIH HHS [DK48029] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R55HG000820, R01HG000820] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048029] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akopyants NS, 1998, MOL MICROBIOL, V28, P37, DOI 10.1046/j.1365-2958.1998.00770.x; AKOPYANZ N, 1992, NUCLEIC ACIDS RES, V20, P6221, DOI 10.1093/nar/20.23.6221; BORODIN AM, 1988, BIOORG KHIM+, V14, P1179; Buhler J.M., 1987, RNA POLYM REGULATION, P25; BUKANOV NO, 1994, MOL MICROBIOL, V11, P509, DOI 10.1111/j.1365-2958.1994.tb00332.x; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Dykxhoorn DM, 1996, MOL MICROBIOL, V19, P483, DOI 10.1046/j.1365-2958.1996.384913.x; EATON KA, 1993, INT J SYST BACTERIOL, V43, P99, DOI 10.1099/00207713-43-1-99; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Fox J G, 1997, Semin Gastrointest Dis, V8, P124; GARNER JA, 1995, J INFECT DIS, V172, P290, DOI 10.1093/infdis/172.1.290; GOODMAN TG, 1983, J CLIN MICROBIOL, V18, P825, DOI 10.1128/JCM.18.4.825-829.1983; Guruge JL, 1998, P NATL ACAD SCI USA, V95, P3925, DOI 10.1073/pnas.95.7.3925; Lee A, 1997, GASTROENTEROLOGY, V112, P1386, DOI 10.1016/S0016-5085(97)70155-0; MURRAY CL, 1981, J BIOL CHEM, V256, P5153; OVCHINNIKOV YA, 1981, EUR J BIOCHEM, V116, P621, DOI 10.1111/j.1432-1033.1981.tb05381.x; PASTER BJ, 1991, INT J SYST BACTERIOL, V41, P31, DOI 10.1099/00207713-41-1-31; PUHLER G, 1989, P NATL ACAD SCI USA, V86, P4569, DOI 10.1073/pnas.86.12.4569; Severinov K, 1997, J BIOL CHEM, V272, P24137, DOI 10.1074/jbc.272.39.24137; STETTER KO, 1974, EUR J BIOCHEM, V48, P527, DOI 10.1111/j.1432-1033.1974.tb03794.x; SUAREZ DL, 1997, J VET MICROBIOL, V57, P325; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; WHIPPLE FW, 1992, J MOL BIOL, V223, P399, DOI 10.1016/0022-2836(92)90660-C; Xu Q, 1997, J BACTERIOL, V179, P6807, DOI 10.1128/jb.179.21.6807-6815.1997	24	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19371	19374		10.1074/jbc.273.31.19371	http://dx.doi.org/10.1074/jbc.273.31.19371			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677352	hybrid			2022-12-25	WOS:000075125200004
J	Murao, K; Wada, Y; Nakamura, T; Taylor, AH; Mooradian, AD; Wong, NCW				Murao, K; Wada, Y; Nakamura, T; Taylor, AH; Mooradian, AD; Wong, NCW			Effects of glucose and insulin on rat apolipoprotein A-I gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISCHEMIC-HEART-DISEASE; HIGH-DENSITY-LIPOPROTEIN; GROWTH-HORMONE GENE; PYRUVATE-KINASE; DIABETES-MELLITUS; MESSENGER-RNA; GLUCAGON GENE; 5'-FLANKING REGION; RESPONSE ELEMENT; RISK FACTOR	We have examined the regulation of apolipoprotein A-I (apoA-I) gene expression in response to glucose and insulin. In Hep G2 cells, endogenous apoA-I mRNA was suppressed by one-half or induced 2-fold following 48 h of exposure to high concentrations of glucose (22.4 mM) or insulin (100 microunits/ml), respectively, compared with control. Transcriptional activity of the rat apoA-I promoter (-474 to -7) in Hep G2 cells paralleled endogenous mRNA expression, and this activity was dependent on the dose of glucose or insulin. Deletional analysis showed that a 50-base pair fragment spanning -425 to -376 of the promoter mediated the effects of both insulin and glucose. Within this DNA fragment there is a motif (-411 to -404) that is homologous to a previously identified insulin response core element (IRCE). Mutation of this motif abolished not only the induction of the promoter by insulin but also abrogated its suppression by glucose. Electrophoretic mobility shift assay analysis of nuclear extracts from Hep G2 cells revealed IRCE binding activity that formed a duplex with radiolabeled probe. The IRCE binding activity correlated with insulin induction of apoA-I expression. In summary, our data show that glucose decreases and insulin increases apoA-I promoter activity. This effect appears to be mediated by a single cis-acting element.	Univ Calgary, Hlth Sci Ctr, Dept Med, Endocrine Res Grp,Fac Med, Calgary, AB T2N 4N1, Canada; Univ Calgary, Fac Med, Dept Biochem Med, Endocrine Res Grp, Calgary, AB T2N 4N1, Canada; St Louis Univ, Dept Internal Med, Div Endocrinol, St Louis, MO 63104 USA; St Louis Vet Affairs Med Ctr, St Louis, MO 63104 USA	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Calgary; Saint Louis University	Wong, NCW (corresponding author), Univ Calgary, Hlth Sci Ctr, Dept Med, Endocrine Res Grp,Fac Med, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	ncwwong@acs.ucalgary.ca		Taylor, Anthony/0000-0002-5746-9091				ALEXANDER MC, 1988, P NATL ACAD SCI USA, V85, P5092, DOI 10.1073/pnas.85.14.5092; ALEXANDERBRIDGES M, 1992, J CELL BIOCHEM, V48, P129, DOI 10.1002/jcb.240480204; ALEXANDERBRIDGES M, 1992, ADV ENZYME REGUL, V32, P149; BARR DP, 1951, AM J MED, V11, P480, DOI 10.1016/0002-9343(51)90183-0; BarreraHernandez G, 1996, J BIOL CHEM, V271, P9969, DOI 10.1074/jbc.271.17.9969; BARRETTCONNOR E, 1987, AM J PREV MED, V3, P206; Barter PJ, 1996, ATHEROSCLEROSIS, V121, P1, DOI 10.1016/0021-9150(95)05675-0; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; BRESLOW JL, 1982, P NATL ACAD SCI USA, V7922, P6861; CHEN C, 1987, MOL CELL BIOL, V7, P27; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CUIF MH, 1992, MOL CELL BIOL, V12, P4852, DOI 10.1128/MCB.12.11.4852; Despres JP, 1996, NEW ENGL J MED, V334, P952, DOI 10.1056/NEJM199604113341504; DYER RB, 1995, BIOTECHNIQUES, V19, P192; FLORESRIVEROS JR, 1993, BIOCHEM BIOPH RES CO, V194, P1148, DOI 10.1006/bbrc.1993.1942; Forte Trudy M., 1994, Current Opinion in Lipidology, V5, P354, DOI 10.1097/00041433-199410000-00007; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUERRA MJMD, 1993, MOL CELL BIOL, V13, P7725, DOI 10.1128/MCB.13.12.7725; Guyton A.C., 2011, HALL TXB MED PHYSL; HADDAD IA, 1986, J BIOL CHEM, V261, P3268; HATADA EN, 1989, J BIOL CHEM, V264, P6741; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HICKEY DA, 1994, P NATL ACAD SCI USA, V91, P11109, DOI 10.1073/pnas.91.23.11109; HIGUCHI K, 1988, J BIOL CHEM, V263, P18530; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; JACOB KK, 1995, J BIOL CHEM, V270, P27773, DOI 10.1074/jbc.270.46.27773; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; Kaytor EN, 1997, J BIOL CHEM, V272, P7525, DOI 10.1074/jbc.272.11.7525; KELLER SA, 1990, GENE DEV, V4, P450; KNEPEL W, 1990, J BIOL CHEM, V265, P8725; LAAKSO M, 1985, ARTERIOSCLEROSIS, V5, P653, DOI 10.1161/01.ATV.5.6.653; LIU ZR, 1993, J BIOL CHEM, V268, P12787; MAGOULAS C, 1993, GENETICS, V134, P507; MEISLER MH, 1989, ANNU REV PHYSIOL, V51, P701, DOI 10.1146/annurev.physiol.51.1.701; MILLER GJ, 1975, LANCET, V1, P16; MILLER NE, 1985, NATURE, V314, P109, DOI 10.1038/314109a0; NAKABAYASHI H, 1991, MOL CELL BIOL, V11, P5885, DOI 10.1128/MCB.11.12.5885; NASRIN N, 1990, P NATL ACAD SCI USA, V87, P5273, DOI 10.1073/pnas.87.14.5273; NASRIN N, 1991, NATURE, V354, P317, DOI 10.1038/354317a0; NOGUCHI T, 1985, J BIOL CHEM, V260, P4393; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OBRIEN RM, 1993, ADV SEC MESS PHOSPH, V28, P245; PHILIPPE J, 1989, J CLIN INVEST, V84, P672, DOI 10.1172/JCI114214; PHILIPPE J, 1991, P NATL ACAD SCI USA, V88, P7224, DOI 10.1073/pnas.88.16.7224; PRAGER D, 1988, J BIOL CHEM, V263, P16580; PRAGER D, 1990, J CLIN INVEST, V85, P1680, DOI 10.1172/JCI114620; REAVEN GM, 1991, DIABETES CARE, V14, P195, DOI 10.2337/diacare.14.3.195; ROMNEY JS, 1992, MOL ENDOCRINOL, V6, P943, DOI 10.1210/me.6.6.943; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SNIDERMAN A, 1992, J CLIN EPIDEMIOL, V45, P1357, DOI 10.1016/0895-4356(92)90197-U; SOLYMOSS BC, 1995, AM J CARDIOL, V76, P1152, DOI 10.1016/S0002-9149(99)80326-9; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; STANLEY F, 1988, J BIOL CHEM, V263, P13444; Taylor AH, 1996, J LIPID RES, V37, P2232; TOWLE HC, 1995, J BIOL CHEM, V270, P23235, DOI 10.1074/jbc.270.40.23235; WANKE IE, 1991, J BIOL CHEM, V266, P6068; WONG NCW, 1986, J BIOL CHEM, V261, P387; WONG NCW, 1989, J BIOL CHEM, V26, P4466	58	110	113	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18959	18965		10.1074/jbc.273.30.18959	http://dx.doi.org/10.1074/jbc.273.30.18959			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668074	hybrid			2022-12-25	WOS:000074974700041
J	Eggers, A; Siemann, G; Blume, R; Knepel, W				Eggers, A; Siemann, G; Blume, R; Knepel, W			Gene-specific transcriptional activity of the insulin cAMP-responsive element is conferred by NF-Y in combination with cAMP response element-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; PANCREATIC BETA-CELLS; RNA POLYMERASE-II; RAT GLUCAGON GENE; CBF-DNA COMPLEX; REGULATORY ELEMENT; MEMBRANE DEPOLARIZATION; NEGATIVE REGULATION; FUNCTIONAL DOMAINS; NUCLEAR-PROTEIN	Cyclic AMP stimulates insulin gene transcription through a cAMP response element (CRE). In the present study the insulin CRE-binding proteins and their functions were investigated. A mutational analysis of nuclear protein binding in electrophoretic mobility shift assays in combination with specific antisera showed that in the CRE of the rat insulin I gene the imperfect CRE octamer-like sequence TGACGTCC interacts weakly with CREB and overlaps with two sequence motifs (TTGTTGAC and CCAAT) that bind winged helix-like proteins and the transcription factor NF-Y, respectively. Transient transfection of wild-type and mutant insulin CRE-reporter fusion genes and the inactivation of cellular CREB or NF-Y by overexpression of the dominant negative mutants KCREB or NF-YA29, respectively, indicate that cAMP inducibility of the insulin CRE is mediated by CREB or closely related proteins; however, NF-Y binding to the insulin CRE confers constitutive, basal activity and decreases the ability of CREB to mediate cAMP-stimulated transcription and calcium responsiveness. Results from these studies demonstrate that NF-Y binds to the insulin CRE and modulates the function of CREB. Together with the nonpalindromic sequence of the CRE octamer motif, the interaction of NF-Y with CREB may be responsible for the gene-specific transcriptional activity of the insulin CRE and explain why it has considerable basal activity but is less responsive to cAMP stimulation than others.	Univ Gottingen, Dept Mol Pharmacol, D-37070 Gottingen, Germany	University of Gottingen	Knepel, W (corresponding author), Univ Gottingen, Dept Mol Pharmacol, Robert Koch Str 40, D-37070 Gottingen, Germany.							AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; Alonso CR, 1996, J BIOL CHEM, V271, P22271, DOI 10.1074/jbc.271.36.22271; Baler R, 1997, J BIOL CHEM, V272, P6979, DOI 10.1074/jbc.272.11.6979; Bellorini M, 1997, NUCLEIC ACIDS RES, V25, P2174, DOI 10.1093/nar/25.11.2174; BOULARAND S, 1995, J BIOL CHEM, V270, P3757, DOI 10.1074/jbc.270.8.3757; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; Carlone DL, 1997, MOL ENDOCRINOL, V11, P292, DOI 10.1210/me.11.3.292; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CLEVIDENCE DE, 1993, P NATL ACAD SCI USA, V90, P3948, DOI 10.1073/pnas.90.9.3948; COCKELL M, 1995, MOL CELL BIOL, V15, P1933; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; Diedrich T, 1997, BIOL CHEM, V378, P89, DOI 10.1515/bchm.1997.378.2.89; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOCHERTY K, 1994, FASEB J, V8, P20, DOI 10.1096/fasebj.8.1.8299887; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; Ericsson J, 1996, J BIOL CHEM, V271, P24359, DOI 10.1074/jbc.271.40.24359; Furstenau U, 1997, MOL CELL BIOL, V17, P1805; GEDRICH RW, 1995, J VIROL, V69, P2333, DOI 10.1128/JVI.69.4.2333-2340.1995; GERMAN MS, 1994, MOL CELL BIOL, V14, P4067, DOI 10.1128/MCB.14.6.4067; GERMAN MS, 1990, J BIOL CHEM, V265, P22063; Ginty DD, 1997, NEURON, V18, P183, DOI 10.1016/S0896-6273(00)80258-5; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; GUTIERREZHARTMANN A, 1994, MOL ENDOCRINOL, V8, P1447, DOI 10.1210/me.8.11.1447; HOCHHUTH C, 1994, ENDOCRINE, V2, P833; HOEFFLER JP, 1989, MOL ENDOCRINOL, V3, P868, DOI 10.1210/mend-3-5-868; HOLZ GG, 1992, TRENDS BIOCHEM SCI, V17, P388, DOI 10.1016/0968-0004(92)90006-U; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; KENNEDY GC, 1990, J BIOL CHEM, V265, P6279; Kim IS, 1996, MOL CELL BIOL, V16, P4003; KINANE TB, 1993, J BIOL CHEM, V268, P24669; KNEPEL W, 1990, J BIOL CHEM, V265, P8725; KNEPEL W, 1991, MOL ENDOCRINOL, V5, P1457, DOI 10.1210/mend-5-10-1457; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; LI XY, 1992, J BIOL CHEM, V267, P8984; Liu XD, 1996, AM J PHYSIOL-RENAL, V271, pF347, DOI 10.1152/ajprenal.1996.271.2.F347; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; Marziali G, 1997, MOL CELL BIOL, V17, P1387, DOI 10.1128/MCB.17.3.1387; MELLOUL D, 1993, P NATL ACAD SCI USA, V90, P3865, DOI 10.1073/pnas.90.9.3865; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MILLER CP, 1993, MOL CELL BIOL, V13, P7080, DOI 10.1128/MCB.13.11.7080; MILOS PM, 1992, GENE DEV, V6, P991, DOI 10.1101/gad.6.6.991; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; NITSCH D, 1993, P NATL ACAD SCI USA, V90, P5479, DOI 10.1073/pnas.90.12.5479; Nizielski SE, 1996, AM J PHYSIOL-REG I, V270, pR1005, DOI 10.1152/ajpregu.1996.270.5.R1005; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OETJEN E, 1994, J BIOL CHEM, V269, P27036; Osawa H, 1996, J BIOL CHEM, V271, P17296, DOI 10.1074/jbc.271.29.17296; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; PARK EA, 1993, J BIOL CHEM, V268, P613; PATEL YM, 1994, J BIOL CHEM, V269, P5619; PHILIPPE J, 1990, J BIOL CHEM, V265, P1465; PHILIPPE J, 1995, MOL ENDOCRINOL, V9, P368, DOI 10.1210/me.9.3.368; PHILIPPE J, 1994, MOL CELL BIOL, V14, P3514, DOI 10.1128/MCB.14.5.3514; PiseMasison CA, 1997, MOL CELL BIOL, V17, P1236, DOI 10.1128/MCB.17.3.1236; REED GE, 1995, BRAIN RES, V682, P1, DOI 10.1016/0006-8993(95)00284-W; ROESLER WJ, 1995, J BIOL CHEM, V270, P8225, DOI 10.1074/jbc.270.14.8225; Roy B, 1996, J BIOL CHEM, V271, P28995, DOI 10.1074/jbc.271.46.28995; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; Sato R, 1996, J BIOL CHEM, V271, P26461, DOI 10.1074/jbc.271.43.26461; SCHWANINGER M, 1993, J BIOL CHEM, V268, P23111; SCHWANINGER M, 1995, J BIOL CHEM, V270, P8860, DOI 10.1074/jbc.270.15.8860; SCHWANINGER M, 1993, J BIOL CHEM, V268, P5168; SHARMA A, 1994, MOL CELL BIOL, V14, P871, DOI 10.1128/MCB.14.2.871; Sinha S, 1996, MOL CELL BIOL, V16, P328; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VALLEJO M, 1992, J BIOL CHEM, V267, P12876; VALLEJO M, 1994, J NEUROENDOCRINOL, V6, P587, DOI 10.1111/j.1365-2826.1994.tb00623.x; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Wrege Antje, 1995, Gene Expression, V4, P205; WRIGHT KL, 1994, EMBO J, V13, P4042, DOI 10.1002/j.1460-2075.1994.tb06721.x; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Zhang PL, 1996, MOL ENDOCRINOL, V10, P147, DOI 10.1210/me.10.2.147	81	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18499	18508		10.1074/jbc.273.29.18499	http://dx.doi.org/10.1074/jbc.273.29.18499			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660819	hybrid			2022-12-25	WOS:000074828500074
J	Krause, KH; Fivaz, M; Monod, A; van der Goot, FG				Krause, KH; Fivaz, M; Monod, A; van der Goot, FG			Aerolysin induces G-protein activation and Ca2+ release from intracellular stores in human granulocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMING TOXIN AEROLYSIN; STAPHYLOCOCCAL ALPHA-TOXIN; ESCHERICHIA-COLI HEMOLYSIN; PLANAR LIPID BILAYERS; AEROMONAS-HYDROPHILA; HUMAN-NEUTROPHILS; POLYMORPHONUCLEAR LEUKOCYTES; PROTEOLYTIC ACTIVATION; HL-60 CELLS; CHANNEL	Aerolysin is a pore-forming toxin that plays a key role in the pathogenesis of Aeromonas hydrophila infections. In this study, we have analyzed the effect of aerolysin on human granulocytes (HL-60 cells). Proaerolysin could bind to these cells, was processed into active aerolysin, and led to membrane depolarization, indicating that granulocytes are potential targets for this toxin, Fura-a measurements were used to analyze the effect of aerolysin lysin on cytosolic [Ca2+] homeostasis. As expected for a pore-forming toxin, aerolysin addition led to Ca2+ influx across the plasma membrane. In addition, the toxin triggered Ca2+ release from agonist and thapsigargin-sensitive intracellular Ca2+ stores. This Ca2+ release was independent of the aerolysin-induced Ca2+ influx and occurred in two kinetically distinct phases: an initial rapid and transient phase and a second, more sustained, phase. The first, but not the second phase was sensitive to pertussis toxin, Activation of pertussis toxin-sensitive G-proteins appeared to be a consequence of pore formation, rather than receptor activation through aerolysin-binding, as ik (i) was not observed with a binding competent, insertion-incompetent aerolysin mutant, (ii) had a marked lag time, and (iii) was also observed in response to other bacterial pore-forming toxins (staphylococcal alpha-toxin, streptolysin O) which are thought to bind to different receptors, G-protein activation through pore-forming toxins stimulated cellular functions, as evidenced by pertussis toxin-sensitive chemotaxis. Our results demonstrate that granulocytes are potential target cells for aerolysin and that in these cells, Ca2+ signaling in response to a pore-forming toxin involves G-protein-dependent cell activation and Ca2+ release from intracellular stores.	Univ Geneva, Dept Biochem, CH-1211 Geneva 4, Switzerland; Univ Hosp, Div Infect Dis, CH-1211 Geneva, Switzerland	University of Geneva; University of Geneva	van der Goot, FG (corresponding author), Univ Geneva, Dept Biochem, CH-1211 Geneva 4, Switzerland.		van der Goot, Gisou G/B-2279-2012; Krause, Karl-Heinz/E-8030-2011	van der Goot, Gisou G/0000-0002-8522-274X; Krause, Karl-Heinz/0000-0002-9033-6768; Fivaz, Marc/0000-0003-1003-7934				Abrami L, 1998, J CELL BIOL, V140, P525, DOI 10.1083/jcb.140.3.525; Bhakdi S, 1996, ARCH MICROBIOL, V165, P73, DOI 10.1007/s002030050300; BUCKLEY JT, 1990, BIOCHEM CELL BIOL, V68, P221, DOI 10.1139/o90-029; CHAKRABORTY T, 1987, INFECT IMMUN, V55, P2274, DOI 10.1128/IAI.55.9.2274-2280.1987; COWLL S, 1997, MOL MICROBIOL, V25, P343; CYBULSKY AV, 1989, AM J PHYSIOL, V257, pF826, DOI 10.1152/ajprenal.1989.257.5.F826; DAILY OP, 1981, J CLIN MICROBIOL, V13, P769, DOI 10.1128/JCM.13.4.769-777.1981; DEMAUREX N, 1994, BIOCHEM J, V297, P595, DOI 10.1042/bj2970595; DEMAUREX N, 1992, J BIOL CHEM, V267, P2318; Diep DB, 1998, J BIOL CHEM, V273, P2355, DOI 10.1074/jbc.273.4.2355; DONTA ST, 1978, INFECT IMMUN, V21, P989, DOI 10.1128/IAI.21.3.989-993.1978; FINK D, 1989, CELL SIGNAL, V1, P387, DOI 10.1016/0898-6568(89)90057-0; GARLAND WJ, 1988, INFECT IMMUN, V56, P1249, DOI 10.1128/IAI.56.5.1249-1253.1988; GRIMMINGER F, 1991, J CLIN INVEST, V88, P1531, DOI 10.1172/JCI115463; Grimminger F, 1997, J IMMUNOL, V159, P1909; GRUBER HJ, 1994, MOL MICROBIOL, V14, P1093, DOI 10.1111/j.1365-2958.1994.tb01341.x; HOWARD SP, 1985, J BACTERIOL, V163, P336, DOI 10.1128/JB.163.1.336-340.1985; HOWARD SP, 1982, BIOCHEMISTRY-US, V21, P1662, DOI 10.1021/bi00536a029; JANDA JM, 1984, J CLIN MICROBIOL, V17, P588; JIN GF, 1992, FEMS MICROBIOL LETT, V98, P285; KAPER JB, 1981, J APPL BACTERIOL, V50, P359, DOI 10.1111/j.1365-2672.1981.tb00900.x; KASNER SE, 1992, AM J PHYSIOL, V262, pF462, DOI 10.1152/ajprenal.1992.262.3.F462; KRAUSE KH, 1985, J CLIN INVEST, V76, P1348, DOI 10.1172/JCI112109; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Moniatte M, 1996, FEBS LETT, V384, P269, DOI 10.1016/0014-5793(96)00328-6; MORGAN BP, 1985, BIOCHEM J, V231, P205, DOI 10.1042/bj2310205; MOUSLI M, 1990, TRENDS PHARMACOL SCI, V11, P358, DOI 10.1016/0165-6147(90)90179-C; Nelson KL, 1997, J BIOL CHEM, V272, P12170, DOI 10.1074/jbc.272.18.12170; PAPINI E, 1988, EMBO J, V7, P3353, DOI 10.1002/j.1460-2075.1988.tb03207.x; PRENTKI M, 1984, J BIOL CHEM, V259, P3777; SCHLIZ M, 1995, EUR J DERMATOL, V5, P54; STAALI L, 1998, IN PRESS BACTERIAL P; SUTTORP N, 1988, INFECT IMMUN, V56, P2228, DOI 10.1128/IAI.56.9.2228-2234.1988; TschodrichRotter M, 1996, BIOPHYS J, V70, P723, DOI 10.1016/S0006-3495(96)79612-1; VANDERGOOT FG, 1992, BIOCHEMISTRY-US, V31, P8566, DOI 10.1021/bi00151a026; VANDERGOOT FG, 1994, J BIOL CHEM, V269, P30496; VANDERGOOT FG, 1993, J BIOL CHEM, V268, P18272; WILMSEN HU, 1990, J MEMBRANE BIOL, V115, P71, DOI 10.1007/BF01869107; WILMSEN HU, 1992, EMBO J, V11, P2457, DOI 10.1002/j.1460-2075.1992.tb05310.x	39	62	63	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18122	18129		10.1074/jbc.273.29.18122	http://dx.doi.org/10.1074/jbc.273.29.18122			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660770	hybrid			2022-12-25	WOS:000074828500025
J	Noda, Y; Mamiya, T; Nabeshima, T; Nishi, M; Higashioka, M; Takeshima, H				Noda, Y; Mamiya, T; Nabeshima, T; Nishi, M; Higashioka, M; Takeshima, H			Loss of antinociception induced by naloxone benzoylhydrazone in nociceptin receptor-knockout mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPIOID RECEPTORS; ORPHANIN-FQ; NEUROPEPTIDE; AGONIST; OPIATE	Nociceptin and nociceptin receptor, which show structural similarities to opioid peptides and opioid receptors, respectively, have been recently found to constitute a novel neuromodulatory system. In the brain, however, the physiological role of the modulation via the nociceptin receptor is still unclear. Administered nociceptin produces hyperalgesia and hypolocomotion, whereas the nociceptin receptor-knockout mice show no significant abnormalities in nociceptive thresholds and locomotion. To clarify possible involvement of the nociceptin receptor in the regulation of nociception and locomotion, we made use of the knockout mice and naloxone benzoylhydrazone (NalBzoH) identified originally as a ligand for opioid receptors, Experiments on the cultured cells transfected with the nociceptin receptor cDNA showed that NalBzoH competed with [H-3]nociceptin binding and attenuated the nociceptin-induced inhibition of cAMP accumulation. Furthermore, behavioral studies demonstrated that NalBzoH completely inhibited nociceptin-induced hyperalgesia and hypolocomotion. It is therefore likely that NalBzoH can act as a potent antagonist for the nociceptin receptor in vivo. In wild-type mice, NalBzoH induced antinociception but did not affect locomotor activity. In contrast, in the knockout mice, no significant changes in nociception and locomotion were induced by NalBzoH. These results clearly suggest that the nociceptin system takes part in the physiological regulation of nociceptive thresholds but not in the basal modulation of locomotion.	Nagoya Univ, Sch Med, Dept Neuropsychopharmacol & Hosp Pharm, Showa Ku, Nagoya, Aichi 4668560, Japan; Univ Tokyo, Fac Med, Dept Pharmacol, Bunkyo Ku, Tokyo 1138564, Japan	Nagoya University; University of Tokyo	Nabeshima, T (corresponding author), Nagoya Univ, Sch Med, Dept Neuropsychopharmacol & Hosp Pharm, Showa Ku, Nagoya, Aichi 4668560, Japan.			Takeshima, Hiroshi/0000-0003-4525-3725				CLARK JA, 1989, J PHARMACOL EXP THER, V251, P889; Devine DP, 1996, NEUROCHEM RES, V21, P1387, DOI 10.1007/BF02532380; FUKUDA K, 1994, FEBS LETT, V343, P42, DOI 10.1016/0014-5793(94)80603-9; GISTRAK MA, 1989, J PHARMACOL EXP THER, V251, P469; Henderson G, 1997, TRENDS PHARMACOL SCI, V18, P293, DOI 10.1016/S0165-6147(97)90645-3; KNAPP RJ, 1995, FASEB J, V9, P516, DOI 10.1096/fasebj.9.7.7737460; Mamiya T, 1998, BRAIN RES, V783, P236, DOI 10.1016/S0006-8993(97)01406-6; Mathis JP, 1997, BIOCHEM BIOPH RES CO, V230, P462, DOI 10.1006/bbrc.1996.5867; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; Nishi M, 1997, EMBO J, V16, P1858, DOI 10.1093/emboj/16.8.1858; OkudaAshitaka E, 1996, MOL BRAIN RES, V43, P96, DOI 10.1016/S0169-328X(96)00165-9; Pasternak GW, 1996, TRENDS PHARMACOL SCI, V17, P217, DOI 10.1016/0165-6147(96)81602-6; PRICE M, 1989, MOL PHARMACOL, V35, P67; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; Wollemann M, 1996, TRENDS PHARMACOL SCI, V17, P217, DOI 10.1016/0165-6147(96)81601-4; ZUKIN RS, 1988, P NATL ACAD SCI USA, V85, P4061, DOI 10.1073/pnas.85.11.4061	16	81	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18047	18051		10.1074/jbc.273.29.18047	http://dx.doi.org/10.1074/jbc.273.29.18047			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660760	hybrid			2022-12-25	WOS:000074828500015
J	Pan, CQ; Dodge, TH; Baker, DL; Prince, WS; Sinicropi, DV; Lazarus, RA				Pan, CQ; Dodge, TH; Baker, DL; Prince, WS; Sinicropi, DV; Lazarus, RA			Improved potency of hyperactive and actin-resistant human DNase I variants for treatment of cystic fibrosis and systemic lupus erythematosus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE; RESOLUTION; COMPLEX; PCR	The ability of recombinant human DNase I (DNase I) to degrade DNA to lower molecular weight fragments is the basis for its therapeutic use in cystic fibrosis (CF) patients and its potential use as a treatment for systemic lupus erythematosus (SLE), To increase the potency of human DNase I, we have generated and characterized three classes of mutants: (a) hyperactive variants, which have from one to six additional positively charged residues (+1 to +6) and digest DNA much more efficiently relative to wild type, (b) actin-resistant variants, which are no longer inhibited by G-actin, a potent inhibitor of DNase I, and (c) combination variants that are both hyperactive and actin-resistant. For DNA scission in CF sputum where the DNA concentration and length are large, we measured a similar to 20-fold increase in potency relative to wild type for the +3 hyperactive variant Q9R/E13R/N74K or the actin-resistant variant A114F; the hyperactive and actin-resistant combination variant was similar to 100-fold more potent than wild type DNase I. For digesting lower concentrations of DNA complexed to anti-DNA antibodies in human serum, we found a maximal enhancement of similar to 400-fold over wild type for the +2 variant E13R/N74K. The +3 enzymes have similar to 4000-fold enhancement for degrading moderate levels of exogenous DNA spiked into human serum, whereas the +6 enzyme has similar to 30,000-fold increased activity for digesting the extremely low levels of endogenous DNA found in serum. The actin resistance property of the combination mutants further enhances the degree of potency in human serum. Thus, the human DNase I variants we have engineered for improved biochemical and pharmacodynamic properties have greater therapeutic potential for treatment of both CF and SLE.	Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA; Genentech Inc, Dept Bioanalyt Technol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	Lazarus, RA (corresponding author), Genentech Inc, Dept Prot Engn, 1 DNA Way, San Francisco, CA 94080 USA.	lazarus.bob@gene.com						BARON WF, 1998, IN PRESS GENE AMST; Boat T.J., 1989, METABOLIC BASIS INHE, P2649; CAMPBELL VW, 1980, J BIOL CHEM, V255, P3726; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; Deininger PL, 1989, MOBILE DNA, P619; FROST P. G., 1968, CLIN EXP IMMUNOL, V3, P447; FUCHS HJ, 1994, NEW ENGL J MED, V331, P637, DOI 10.1056/NEJM199409083311003; GARDNER WD, 1979, J BIOL CHEM, V254, P5238; Hahn BH, 1997, DUBOIS LUPUS ERYTHEM, P69; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KISSANE JM, 1958, J BIOL CHEM, V233, P184; LIVAK KJ, 1995, PCR METH APPL, V4, P357; Macanovic M, 1996, CLIN EXP IMMUNOL, V106, P243, DOI 10.1046/j.1365-2249.1996.d01-839.x; MCCOUBREYHOYER A, 1984, AM J MED, V77, P23, DOI 10.1016/0002-9343(84)90431-5; MEJEAN C, 1987, J IMMUNOL METHODS, V99, P129; Pan CQ, 1998, J BIOL CHEM, V273, P11701, DOI 10.1074/jbc.273.19.11701; Pan CQ, 1997, BIOCHEMISTRY-US, V36, P6624, DOI 10.1021/bi962960x; Pan CQ, 1998, PROTEIN SCI, V7, P628, DOI 10.1002/pro.5560070312; PRINCE WS, 1998, IN PRESS CLIN EXP IM; PRUSS D, 1995, BIOESSAYS, V17, P161, DOI 10.1002/bies.950170211; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RAMSEY BW, 1993, AM REV RESPIR DIS, V148, P145, DOI 10.1164/ajrccm/148.1.145; Ramsey BW, 1996, NEW ENGL J MED, V335, P179, DOI 10.1056/NEJM199607183350307; Rodriguez AM, 1997, GENOMICS, V42, P507, DOI 10.1006/geno.1997.4748; STEINMAN CR, 1982, METHOD ENZYMOL, V84, P187; Ulmer JS, 1996, P NATL ACAD SCI USA, V93, P8225, DOI 10.1073/pnas.93.16.8225; WESTON SA, 1992, J MOL BIOL, V226, P1237, DOI 10.1016/0022-2836(92)91064-V; WOLF E, 1995, PROTEIN ENG, V8, P79; WOODS VL, 1993, TXB RHEUMATOLOGY, V1, P999; Zeng ZZ, 1997, BIOCHEM BIOPH RES CO, V231, P499, DOI 10.1006/bbrc.1996.5923; [No title captured]	32	30	38	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18374	18381		10.1074/jbc.273.29.18374	http://dx.doi.org/10.1074/jbc.273.29.18374			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660804	hybrid			2022-12-25	WOS:000074828500059
J	Cormier-Regard, S; Nguyen, SV; Claycomb, WC				Cormier-Regard, S; Nguyen, SV; Claycomb, WC			Adrenomedullin gene expression is developmentally regulated and induced by hypoxia in rat ventricular cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR GENE; TRANSCRIPTIONAL REGULATION; INDUCIBLE FACTOR-1; DIFFERENTIAL DISPLAY; HYPOTENSIVE PEPTIDE; HEART-FAILURE; MESSENGER-RNA; PLASMA; HYPERTENSION; ACTIVATION	Adrenomedullin is a recently discovered hypotensive peptide that is expressed in a variety of cell and tissue types. Using the technique of differential display, the adrenomedullin gene was observed to be differentially expressed in developing rat heart. Reverse transcription polymerase chain reaction analysis revealed that the level of adrenomedullin mRNA was significantly higher in adult ventricular cardiac muscle as compared with embryonic day 17 ventricular cardiac muscle. Adrenomedullin receptor mRNA was constitutively expressed throughout development of the ventricular heart. Two potential hypoxia-inducible factor-1 (HLF-1) consensus binding sites were identified in the mouse adrenomedullin promoter at -1095 and -770 nucleotides from the transcription start site. Exposure of cultured adult rat ventricular cardiac myocytes to hypoxia (1% O-2) resulted in a significant, time-dependent increase in adrenomedullin mRNA levels. Transfection studies revealed that the 5'-flanking sequence of adrenomedullin was capable of mediating a hypoxia-inducible increase in transcription. Mutation of the putative HIF-1 consensus binding sites revealed that the major regulatory sequence that mediates the hypoxia-inducible transcriptional response is located at -1095. These data demonstrate that the adrenomedullin gene is developmentally regulated in ventricular cardiomyocytes, that adrenomedullin transcription can be induced by hypoxia, and that this response is primarily mediated by HIF-1 consensus sites in the adrenomedullin promoter.	Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA	Louisiana State University System	Claycomb, WC (corresponding author), Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, 1901 Perdido St, New Orleans, LA 70112 USA.	wclayc@lsumc.edu	Cormier, Stephania A/I-7382-2017	Cormier, Stephania A/0000-0002-6050-6172				Ausubel FM, 1994, CURRENT PROTOCOLS MO; Claycomb WC, 1998, P NATL ACAD SCI USA, V95, P2979, DOI 10.1073/pnas.95.6.2979; CLAYCOMB WC, 1984, IN VITRO CELL DEV B, V20, P647, DOI 10.1007/BF02619615; CLAYCOMB WC, 1980, DEV BIOL, V80, P309; CormierRegard S, 1997, MOL CELL BIOCHEM, V172, P111; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; ISHIMITSU T, 1994, J CLIN INVEST, V94, P2158, DOI 10.1172/JCI117573; ISHIYAMA Y, 1995, CLIN EXP PHARMACOL P, V22, P614, DOI 10.1111/j.1440-1681.1995.tb02075.x; Jougasaki M, 1996, J CLIN INVEST, V97, P2370, DOI 10.1172/JCI118680; KAPAS S, 1995, J BIOL CHEM, V270, P25344, DOI 10.1074/jbc.270.43.25344; Kato J, 1996, J CLIN ENDOCR METAB, V81, P180, DOI 10.1210/jc.81.1.180; KITAMURA K, 1995, DRUGS, V49, P485, DOI 10.2165/00003495-199549040-00001; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; McGary EC, 1997, J BIOL CHEM, V272, P8628, DOI 10.1074/jbc.272.13.8628; Miller MJ, 1996, J BIOL CHEM, V271, P23345; MONTUENGA LM, 1997, ENDOCRINOLOGY, V138, P1; MUFF R, 1995, EUR J ENDOCRINOL, V133, P17, DOI 10.1530/eje.0.1330017; Nishikimi T, 1997, HYPERTENSION, V30, P1369, DOI 10.1161/01.HYP.30.6.1369; Richards AM, 1996, CLIN SCI, V91, P3, DOI 10.1042/cs0910003; SAKATA J, 1994, FEBS LETT, V352, P105, DOI 10.1016/0014-5793(94)00928-7; Seko Y, 1996, BIOCHEM BIOPH RES CO, V226, P530, DOI 10.1006/bbrc.1996.1389; Semenza GL, 1996, TRENDS CARDIOVAS MED, V6, P151, DOI 10.1016/1050-1738(96)00039-4; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SPRINGHORN JP, 1989, BIOCHEM J, V258, P73, DOI 10.1042/bj2580073; WANG X, 1996, MOL BIOL CELL, V7, P468; WANG XK, 1995, P NATL ACAD SCI USA, V92, P11480, DOI 10.1073/pnas.92.25.11480; WASHIMINE H, 1994, BIOCHEM BIOPH RES CO, V202, P1081, DOI 10.1006/bbrc.1994.2039	34	189	194	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17787	17792		10.1074/jbc.273.28.17787	http://dx.doi.org/10.1074/jbc.273.28.17787			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651380	Green Published, hybrid			2022-12-25	WOS:000074816100073
J	Saraswat, LD; Lowey, S				Saraswat, LD; Lowey, S			Subunit interactions within an expressed regulatory domain of chicken skeletal myosin - Location of the NH2 terminus of the regulatory light chain by fluorescence resonance energy transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; PHOSPHORYLATION-DEPENDENT REGULATION; SINGLE CYSTEINE MUTANTS; SCALLOP MYOSIN; TROPONIN-C; RESOLUTION; MOTOR; SEQUENCE; RESIDUES; BINDING	The regulatory domain (RD), or neck region of the myosin head, consists of two classes of light chains that stabilize an alpha-helical segment of the heavy chain. RD from chicken skeletal muscle myosin was prepared in Escherichia coli by coexpression of a 9-kDa heavy chain fragment with the essential light chain. Recombinant regulatory light chain (RLC), wild type or mutant, was added separately to reconstitute the complex. The affinity of RD for divalent cations was determined by measuring the change in fluorescence of a pair of heavy chain tryptophans upon addition of calcium or magnesium. The complex bound divalent cations with high affinity, similar to the association constants determined for native myosin, The intrinsic fluorescence of the tryptophans could be used as a donor to measure the fluorescence resonance energy transfer distance to a single labeled cysteine engineered at position 2 on RLC, Dansylated Cys(2) could also serve as a donor by preparing RLC with a second cysteine at position 79 which was labeled with an acceptor probe. These fluorescence resonance energy transfer distances (24-30 Angstrom), together with a previous measurement between Cys(2) and Cys(155) (Wolff-Long, V. L., Tao, T., and Lowey, S. (1995) J. Biol. Chem. 270, 31111-31118) suggest a location for the NH2 terminus of RLC that appears to preclude a direct interaction between the phosphorylatable serine and specific residues in the COOH-terminal domain.	Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02254 USA	Brandeis University	Lowey, S (corresponding author), Univ Vermont, Dept Mol Physiol & Phys, Burlington, VT 05405 USA.	lowey@salus.med.uvm.edu			NIAMS NIH HHS [AR17350] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR017350, R01AR017350] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; ALEXIS MN, 1978, BIOCHEMISTRY-US, V17, P2319, DOI 10.1021/bi00605a010; BOEY W, 1994, EUR J BIOCHEM, V219, P603, DOI 10.1111/j.1432-1033.1994.tb19976.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN R F, 1967, Analytical Letters, V1, P35; COLLINS JH, 1991, J MUSCLE RES CELL M, V12, P3, DOI 10.1007/BF01781170; COLLINS K, 1990, J CELL BIOL, V110, P1137, DOI 10.1083/jcb.110.4.1137; CREMO CR, 1995, J BIOL CHEM, V270, P2171, DOI 10.1074/jbc.270.5.2171; DALE RE, 1979, BIOPHYS J, V26, P161, DOI 10.1016/S0006-3495(79)85243-1; Diffee G. M., 1997, Biophysical Journal, V72, pA331; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; HOLROYDE MJ, 1979, J BIOL CHEM, V254, P6478; Houdusse A, 1996, STRUCTURE, V4, P21, DOI 10.1016/S0969-2126(96)00006-8; IKEBE M, 1994, P NATL ACAD SCI USA, V91, P9096, DOI 10.1073/pnas.91.19.9096; ITAKURA S, 1993, BIOCHEM BIOPH RES CO, V196, P1504, DOI 10.1006/bbrc.1993.2422; KWON H, 1990, P NATL ACAD SCI USA, V87, P4771, DOI 10.1073/pnas.87.12.4771; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKEY JH, 1991, J MOL BIOL, V218, P639, DOI 10.1016/0022-2836(91)90707-D; LAKOWITZ JR, 1983, PRINCIPLES FLUORESCE; LOWEY S, 1994, MYOLOGY, P485; MOLINA MI, 1987, J BIOL CHEM, V262, P6478; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; NABESHIMA Y, 1982, NUCLEIC ACIDS RES, V10, P6099, DOI 10.1093/nar/10.19.6099; Offer G, 1996, J MOL BIOL, V256, P407, DOI 10.1006/jmbi.1996.0096; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; SARASWAT LD, 1992, J BIOL CHEM, V267, P21112; SARASWAT LD, 1991, J BIOL CHEM, V266, P19777; SCOTT TG, 1970, J AM CHEM SOC, V92, P687, DOI 10.1021/ja00706a043; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; STORER AC, 1976, BIOCHEM J, V159, P1; SWEENEY HL, 1993, AM J PHYSIOL, V264, pC1085, DOI 10.1152/ajpcell.1993.264.5.C1085; SZENTGYORGYI AG, 1994, MYOLOGY, P506; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TRYBUS KM, 1994, J CELL BIOL, V124, P963, DOI 10.1083/jcb.124.6.963; TRYBUS KM, 1993, J BIOL CHEM, V268, P4412; TRYBUS KM, 1984, J BIOL CHEM, V259, P8564; Trybus KM, 1997, P NATL ACAD SCI USA, V94, P48, DOI 10.1073/pnas.94.1.48; WALLER GS, 1995, J BIOL CHEM, V270, P15348, DOI 10.1074/jbc.270.25.15348; WolffLong VL, 1995, J BIOL CHEM, V270, P31111, DOI 10.1074/jbc.270.52.31111; WOLFFLONG VL, 1993, J BIOL CHEM, V268, P23162; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0; YANG ZH, 1995, J BIOL CHEM, V270, P24646, DOI 10.1074/jbc.270.42.24646	44	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17671	17679		10.1074/jbc.273.28.17671	http://dx.doi.org/10.1074/jbc.273.28.17671			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651364	hybrid			2022-12-25	WOS:000074816100057
J	Saura, CK; Mallol, J; Canela, EI; Lluis, C; Franco, R				Saura, CK; Mallol, J; Canela, EI; Lluis, C; Franco, R			Adenosine deaminase and A(1) adenosine receptors internalize together following agonist-induced receptor desensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE CELL-LINE; PROTEIN-KINASE-C; BETA-ARRESTIN; R-PIA; BETA(2)-ADRENERGIC RECEPTOR; HOMOLOGOUS DESENSITIZATION; A(1)-ADENOSINE RECEPTOR; INTRACELLULAR CALCIUM; GUANINE-NUCLEOTIDE; AFFINITY STATES	A(1) adenosine receptors (A(1)Rs) and adenosine deaminase (ADA; EC 3.5.4.4) interact on the cell surface of DDT1MF-2 smooth muscle cells. The interaction facilitates ligand binding and signaling via A(1)R, but it is not known whether it has a role in homologous desensitization of A(1)Rs. Here we show that chronic exposure of DDT1MF-2 cells to the A(1)R agonist, N-6-(R)-(phenylisopropyl)adenosine (R-PIA), caused a rapid aggregation or clustering of A(1) receptor molecules on the cell membrane, which was enhanced by pretreatment with ADA Colocalization between A(1)R and ADA occurred in the R-PLA-induced clusters. Interestingly, colocalization between A(1)R and ADA also occurred in intracellular vesicles after internalization of both protein molecules in response to R-PIA. Agonist-induced aggregation of A(1)Rs was mediated by phosphorylation of A(1)Rs, which was enhanced and accelerated in the presence of ADA Ligand-induced second-messenger desensitization of A(1)Rs was also accelerated in the presence of exogenous ADA, and it correlated well with receptor phosphorylation, However, although phosphorylation of A(1)R returned to its basal state within minutes, desensitization continued for hours. The loss of cell-surface binding sites (sequestration) induced by the agonist was time-dependent (t(1/2) = 10 +/- 1 h) and was accelerated by ADA. All of these results strongly suggest that ADA plays a key role in the regulation of A(1)Rs by accelerating ligand-induced desensitization and internalization and provide evidence that the two cell surface proteins internalize via the same endocytic pathway.	Univ Barcelona, Fac Quim, Dept Bioquim & Biol Mol, E-08028 Barcelona, Catalunya, Spain	University of Barcelona	Franco, R (corresponding author), Univ Barcelona, Fac Quim, Dept Bioquim & Biol Mol, Marti & Franques 1, E-08028 Barcelona, Catalunya, Spain.		Franco, Rafael/C-3694-2015; Canela, Enric I./M-8726-2013; Saura, Carlos A/AFM-9239-2022; Saura, Carlos A/D-2727-2011; Mallol, Josefa/I-4194-2015	Franco, Rafael/0000-0003-2549-4919; Canela, Enric I./0000-0003-4992-7440; Saura, Carlos A/0000-0003-3692-5657; Mallol, Josefa/0000-0002-2479-4162				ARAN JM, 1991, J HISTOCHEM CYTOCHEM, V39, P1001, DOI 10.1177/39.8.1856451; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BELARDINELLI L, 1993, DRUG DEVELOP RES, V28, P263, DOI 10.1002/ddr.430280313; CASADO V, 1990, J NEUROSCI RES, V26, P461, DOI 10.1002/jnr.490260409; CASADO V, 1991, FEBS LETT, V286, P221, DOI 10.1016/0014-5793(91)80978-C; Ciruela F, 1997, MOL PHARMACOL, V52, P788, DOI 10.1124/mol.52.5.788; Ciruela F, 1995, J NEUROSCI RES, V42, P818, DOI 10.1002/jnr.490420610; Ciruela F, 1996, FEBS LETT, V380, P219, DOI 10.1016/0014-5793(96)00023-3; Conlay LA, 1997, NATURE, V389, P136, DOI 10.1038/38160; DENNIS DM, 1995, J PHARMACOL EXP THER, V272, P1024; DICKENSON JM, 1993, BRIT J PHARMACOL, V108, P85, DOI 10.1111/j.1476-5381.1993.tb13444.x; ElHashim A, 1996, BRIT J PHARMACOL, V119, P1262, DOI 10.1111/j.1476-5381.1996.tb16031.x; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; FERNANDEZ M, 1996, LIFE SCI, V9, P769; Figler RA, 1996, MOL PHARMACOL, V50, P1587; Franco R, 1997, PROG NEUROBIOL, V52, P283, DOI 10.1016/S0301-0082(97)00013-0; Franco R, 1996, BIOCHEMISTRY-US, V35, P3007, DOI 10.1021/bi952415g; FREDHOLM BB, 1995, PHARMACOL TOXICOL, V76, P228, DOI 10.1111/j.1600-0773.1995.tb00135.x; Garland AM, 1996, MOL PHARMACOL, V49, P438; GERWINS P, 1990, MOL PHARMACOL, V38, P660; GERWINS P, 1992, J BIOL CHEM, V267, P16081; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GREEN A, 1992, J BIOL CHEM, V267, P3223; GREEN A, 1990, J BIOL CHEM, V265, P5206; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3450; Holtmann MH, 1996, J BIOL CHEM, V271, P23566, DOI 10.1074/jbc.271.38.23566; JOCKERS R, 1994, J BIOL CHEM, V269, P32077; Krueger KM, 1997, J BIOL CHEM, V272, P5; LEE HT, 1993, AM J PHYSIOL, V265, pH1916, DOI 10.1152/ajpheart.1993.265.6.H1916; LOHSE MJ, 1984, MOL PHARMACOL, V26, P1; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LONDOS C, 1980, P NATL ACAD SCI-BIOL, V77, P2551, DOI 10.1073/pnas.77.5.2551; LONGABAUGH JP, 1989, MOL PHARMACOL, V36, P681; MUNSHI R, 1991, J BIOL CHEM, V266, P22285; Nyce JW, 1997, NATURE, V385, P721, DOI 10.1038/385721a0; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; PALMER TM, 1995, NEUROPHARMACOLOGY, V34, P683, DOI 10.1016/0028-3908(95)00044-7; Palmer TM, 1996, J BIOL CHEM, V271, P15272, DOI 10.1074/jbc.271.25.15272; PEI G, 1995, MOL PHARMACOL, V48, P173; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; Post SR, 1996, J BIOL CHEM, V271, P895, DOI 10.1074/jbc.271.2.895; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; RAMKUMAR V, 1991, MOL PHARMACOL, V40, P639; Rao RV, 1997, MOL PHARMACOL, V51, P185, DOI 10.1124/mol.51.2.185; Ruiz A, 1996, BBA-MOL CELL RES, V1310, P168, DOI 10.1016/0167-4889(95)00152-2; Sanders MA, 1996, J NEUROCHEM, V67, P2362; SAURA C, 1996, J NEUROCHEM, V66, P675; SORENSEN K, 1986, EXPERIENTIA, V42, P161, DOI 10.1007/BF01952446; SPIELMAN WS, 1991, HYPERTENSION, V17, P117, DOI 10.1161/01.HYP.17.2.117; Yang EB, 1996, BIOCHEM BIOPH RES CO, V224, P309, DOI 10.1006/bbrc.1996.1026; YU SS, 1993, J BIOL CHEM, V268, P337	52	90	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17610	17617		10.1074/jbc.273.28.17610	http://dx.doi.org/10.1074/jbc.273.28.17610			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651356	Green Published, hybrid			2022-12-25	WOS:000074816100049
J	Schmid, E; El Benna, J; Galter, D; Klein, G; Droge, W				Schmid, E; El Benna, J; Galter, D; Klein, G; Droge, W			Redox priming of the insulin receptor beta-chain associated with altered tyrosine kinase activity and insulin responsiveness in the absence of tyrosine autophosphorylation	FASEB JOURNAL			English	Article						redox regulation; signal transduction; glutathione; CHO-HIR; BCNU	CELL HEXOSE TRANSPORT; RAT ADIPOCYTES; GLUTATHIONE-REDUCTASE; HYDROGEN-PEROXIDE; INTACT-CELLS; PHOSPHORYLATION; VANADATE; AGENTS; THIOL; INVOLVEMENT	Induction of tyrosine kinase activity of the insulin receptor (IR) beta-chain is believed to require its autophosphorylation at Tyr(1162), Tyr(1163), and Tyr(1158). However, the mechanism of the initial phosphorylation is poorly understood. We show that treatment of IR-transfected Chinese hamster ovary cells with antioxidants inhibits insulin responsiveness. Conversely, partial inhibition of glutathione biosynthesis by buthionine sulfoximine (BSO) and glutathione reductase by 1,3-bis- (2-chloroethyl)-l-nitrosourea (BCNU), i.e., procedures that intracellularly induce mildly oxidative conditions, caused a decrease in IR beta-chain sulfhydryl groups and enhanced synergistically the induction of IR tyrosine phosphorylation by insulin. The IR beta-chain from cells treated with BSO/BCNU in the absence of insulin was not detectably tyrosine phosphorylated, but nevertheless was functionally altered, as demonstrated in vitro by a moderate kinase activity at low ATP concentrations (5 nM) and a strong kinase activity at 25 mu M ATP. This activity was found to be specific for tyrosine (not for serine or threonine), and tryptic peptide maps indicated that it is more selective than that induced by insulin. Moreover, the kinase activity from BSO/BCNU-treated cells showed a spontaneous decay that was not prevented by the phosphatase inhibitor vanadate. Together, these results suggest that optimal insulin responsiveness may require a process of 'redox priming' of the IR beta-chain that involves structural and functional changes in the absence of detectable tyrosine phosphorylation of the beta-chain.-Schmid, E., El Benna, J., Gaiter, D., Klein, G., Droge, W. Redox priming of the insulin receptor beta-chain associated with altered tyrosine kinase activity and insulin responsiveness in the absence of tyrosine autophosphorylation.	Deutsch Krebsforschungszentrum, Div Immunochem, D-69120 Heidelberg, Germany; INSERM, U294, F-75018 Paris, France; Lab Immunohemato, F-75018 Paris, France	Helmholtz Association; German Cancer Research Center (DKFZ); Institut National de la Sante et de la Recherche Medicale (Inserm)	Droge, W (corresponding author), Deutsch Krebsforschungszentrum, Div Immunochem, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Galter, Dagmar/C-4826-2011	Galter, Dagmar/0000-0001-6485-6244				BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BERNIER M, 1995, BIOCHEMISTRY-US, V34, P8357, DOI 10.1021/bi00026a017; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CARPENTIER JL, 1992, P NATL ACAD SCI USA, V89, P162, DOI 10.1073/pnas.89.1.162; CLARK S, 1993, BIOCHEM J, V292, P217, DOI 10.1042/bj2920217; CZECH MP, 1974, P NATL ACAD SCI USA, V71, P4173, DOI 10.1073/pnas.71.10.4173; CZECH MP, 1976, J BIOL CHEM, V251, P1164; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1985, P NATL ACAD SCI USA, V82, P8014, DOI 10.1073/pnas.82.23.8014; ECK HP, 1989, BIOL CHEM H-S, V370, P101, DOI 10.1515/bchm3.1989.370.1.101; ElBenna J, 1997, J BIOL CHEM, V272, P17204, DOI 10.1074/jbc.272.27.17204; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; FEENER EP, 1993, J BIOL CHEM, V268, P11256; FRISCHER H, 1977, J LAB CLIN MED, V89, P1080; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; Gross A, 1996, AIDS RES HUM RETROV, V12, P1639, DOI 10.1089/aid.1996.12.1639; HAYES GR, 1987, P NATL ACAD SCI USA, V84, P8115, DOI 10.1073/pnas.84.22.8115; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HOMMES MJT, 1991, METABOLISM, V40, P651, DOI 10.1016/0026-0495(91)90059-6; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; KADOTA S, 1987, J BIOL CHEM, V262, P8252; KARPLUS PA, 1988, EUR J BIOCHEM, V171, P193, DOI 10.1111/j.1432-1033.1988.tb13775.x; KOSHIO O, 1988, BIOCHEM J, V250, P95, DOI 10.1042/bj2500095; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; LUDVIGSEN C, 1982, METABOLISM, V31, P284, DOI 10.1016/0026-0495(82)90066-X; MACAULAY SL, 1995, BIOCHEM J, V306, P811, DOI 10.1042/bj3060811; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; Seres T, 1996, J IMMUNOL, V156, P1973; TAMURA S, 1984, J BIOL CHEM, V259, P6650; TAYLOR SS, 1995, FASEB J, V9, P1255, DOI 10.1096/fasebj.9.13.7557015; WILDEN PA, 1987, BIOCHEM J, V245, P325, DOI 10.1042/bj2450325; Woltjer RL, 1997, BIOCHEMISTRY-US, V36, P9911, DOI 10.1021/bi963007v	35	63	63	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1998	12	10					863	870		10.1096/fasebj.12.10.863	http://dx.doi.org/10.1096/fasebj.12.10.863			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZY035	9657526				2022-12-25	WOS:000074580100011
J	Burchert, A; Attar, EC; McCloskey, P; Fridell, YWC; Liu, ET				Burchert, A; Attar, EC; McCloskey, P; Fridell, YWC; Liu, ET			Determinants for transformation induced by the Axl receptor tyrosine kinase	ONCOGENE			English	Article						receptor tyrosine kinase; retroviruses, mutations; transformations; Axl	GROWTH-FACTOR RECEPTOR; LONG TERMINAL REPEAT; ALTERED AUTOPHOSPHORYLATION SITES; MURINE LEUKEMIA-VIRUS; POINT MUTATION; PROTO-ONCOGENE; SIGNAL TRANSDUCTION; INSULIN-RECEPTOR; CELLS; GENE	The Axl receptor tyrosine kinase is a transforming oncogene in NIH3T3 cells, In order to define structural requirements of the Axl receptor necessary for transformation me passaged recombinant retroviruses carrying the axl cDNA in NIH3T3 cells, generating randomly mutated axl variants. Using this strategy, we have isolated three axl viral strains (1B1, SV8, and FFa4) that show augmented 3T3 cell transforming capacity associated with elevated p140(Axl). Upon sequencing, the 1B1 and SV8 proviruses possessed only silent mutations, making p140(Axl) overexpression the most likely explanation for their increased transformation activity. However, the characterization of FFa4 revealed a deletion of sequences encoding the carboxy-terminal 45 amino acids leading to the generation of a chimeric transcript comprised of a truncated Axl receptor with a segment of the 3' UTR region. Mutational analysis revealed that the transforming activity of FFa4 was specific to the formation of the chimeric receptor rather than to the carboxyl-terminal truncation, Intriguingly, none of the viral strains were able to transform the murine cell lines. NR-6 and 32D despite equivalent expression of surface p140(Axl) protein. Further analysis showed that Axl's transforming potential is dependent on the host cell type, the presence of a putative pp190 as a facilitator for transformation, and the level of p140(Axl) expression, Taken together, these results underscore the complexity of Axl biology which is dependent on receptor stoichiometry and the cellular background.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Liu, ET (corresponding author), NCI, Div Clin Sci, NIH, 31-3A11,31 Ctr Dr,MSC 2440, Bethesda, MD 20892 USA.		Liu, Edison/C-4141-2008; Burchert, Andreas/S-9563-2017	Burchert, Andreas/0000-0002-8411-8844	NATIONAL CANCER INSTITUTE [R01CA049240, P50CA058223] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA49240, CA58223-04] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ALVAREZ CV, 1995, J BIOL CHEM, V270, P16271, DOI 10.1074/jbc.270.27.16271; ANDO A, 1992, J BIOL CHEM, V267, P12788; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BELLOSTA P, 1995, MOL CELL BIOL, V15, P614; BERTICS PJ, 1988, J BIOL CHEM, V263, P3610; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTER TH, 1995, VIROLOGY, V212, P277, DOI 10.1006/viro.1995.1484; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; CRAVEN RJ, 1995, INT J CANCER, V60, P791, DOI 10.1002/ijc.2910600611; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; DOUGHERTY JP, 1988, J VIROL, V62, P2817, DOI 10.1128/JVI.62.8.2817-2822.1988; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FAN H, 1988, VIROLOGY, V166, P58, DOI 10.1016/0042-6822(88)90146-8; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; Fridell YWC, 1996, MOL CELL BIOL, V16, P135; GASIC GP, 1992, P NATL ACAD SCI USA, V89, P2317, DOI 10.1073/pnas.89.6.2317; Goruppi S, 1996, ONCOGENE, V12, P471; GREZ M, 1991, J VIROL, V65, P4691, DOI 10.1128/JVI.65.9.4691-4698.1991; HANECAK R, 1991, J VIROL, V65, P5357, DOI 10.1128/JVI.65.10.5357-5363.1991; HERBST R, 1995, ONCOGENE, V10, P369; HONEGGER A, 1988, EMBO J, V7, P3053, DOI 10.1002/j.1460-2075.1988.tb03170.x; HONEGGER A, 1988, EMBO J, V7, P3045, DOI 10.1002/j.1460-2075.1988.tb03169.x; JIA R, 1992, J VIROL, V66, P5975, DOI 10.1128/JVI.66.10.5975-5987.1992; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; Kornilova E, 1996, J BIOL CHEM, V271, P30340, DOI 10.1074/jbc.271.48.30340; LAI C, 1994, ONCOGENE, V9, P2567; Li RH, 1996, J NEUROSCI, V16, P2012; Lorenzi MV, 1996, P NATL ACAD SCI USA, V93, P8956, DOI 10.1073/pnas.93.17.8956; MCCLOSKEY P, 1994, CELL GROWTH DIFFER, V5, P1105; MCMANUS MJ, 1995, J VIROL, V69, P3631, DOI 10.1128/JVI.69.6.3631-3638.1995; MEDORI R, 1992, BIOTECHNIQUES, V12, P346; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MONK RJ, 1992, J VIROL, V66, P3683, DOI 10.1128/JVI.66.6.3683-3689.1992; NAKANO T, 1995, J BIOL CHEM, V270, P5702, DOI 10.1074/jbc.270.11.5702; OBRYAN JP, 1995, J BIOL CHEM, V270, P551, DOI 10.1074/jbc.270.2.551; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; PULIDO D, 1992, EMBO J, V11, P391, DOI 10.1002/j.1460-2075.1992.tb05067.x; QUONG RYY, 1994, MELANOMA RES, V4, P313, DOI 10.1097/00008390-199410000-00008; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Taylor ICA, 1995, ONCOGENE, V11, P2619; THIES RS, 1989, J BIOL CHEM, V264, P12820; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VELU TJ, 1989, MOL CELL BIOL, V9, P1772, DOI 10.1128/MCB.9.4.1772; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; Zhang QK, 1996, J VIROL, V70, P8089, DOI 10.1128/JVI.70.11.8089-8097.1996	53	46	46	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 18	1998	16	24					3177	3187		10.1038/sj.onc.1201865	http://dx.doi.org/10.1038/sj.onc.1201865			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671397				2022-12-25	WOS:000074261300011
J	Lim, CP; Jain, N; Cao, XM				Lim, CP; Jain, N; Cao, XM			Stress-induced immediate-early gene, egr-1, involves activation of p38/JNK1	ONCOGENE			English	Article						egr-1; stress; MAP kinases; p38/JNK1	SIGNAL-TRANSDUCTION PATHWAYS; SERUM RESPONSE ELEMENT; MAP KINASE KINASE; C-FOS PROMOTER; PROTEIN-KINASE; TERNARY COMPLEX; SODIUM ARSENITE; HUMAN FIBROBLASTS; MAMMALIAN-CELLS; PLASMA-MEMBRANE	The Ras/Raf/MAP kinase (ERK) pathway is a major signaling pathway induced by growth factors in mammalian cells. Two other types of mammalian MAP kinases, JNK (SAPK) and p38 (RK, CSBP), are induced by environmental stress. Although the immediate-early gene, egr-1, is induced by growth factors, cytokines, differentiation signals and DNA damaging agents, less is known about its induction by environmental stress and the mechanism involved. Here we report that in NIH3T3 cells, egr-1 is induced by various stress treatments such as heat shock, sodium arsenite, ultraviolet (U.V.) radiation, and anisomycin. p38 and JNK1, but not ERK2, were activated by these stress treatments. Induction of egr-1 by anisomycin is inhibited by a specific inhibitor of p38, SE 203580. We also show that p38 and JNK1 activated by their upstream kinases induce egr-1 promoter activity through activation of the ternary complex factor, Elk-l. The stress treatments also lead to an increase in Egr-1 protein phosphorylation and its DNA binding activity. Together, our data suggest that induction of egr-1 gene by growth factors and stress are mediated through different subgroups of MAP kinases which may also differentially affect egr-1 function on its target genes.	Natl Univ Singapore, Inst Mol & Cell Biol, Signal Transduct Lab, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Cao, XM (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, Signal Transduct Lab, Singapore 117609, Singapore.							Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CAO XM, 1993, J BIOL CHEM, V268, P16949; CAO XM, 1992, J BIOL CHEM, V267, P1345; CAO XM, 1992, J BIOL CHEM, V267, P12991; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DATTA R, 1992, P NATL ACAD SCI USA, V89, P10149, DOI 10.1073/pnas.89.21.10149; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HER JH, 1991, NUCLEIC ACIDS RES, V19, P3743, DOI 10.1093/nar/19.13.3743; HERSCHMAN HR, 1989, CARCINOGENESIS, V10, P1495, DOI 10.1093/carcin/10.8.1495; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HUANG RN, 1995, ENVIRON MOL MUTAGEN, V25, P188, DOI 10.1002/em.2850250304; HUANG RP, 1995, ONCOGENE, V10, P467; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; JOHNSTON D, 1980, J BIOL CHEM, V255, P6975; KHARBANDA S, 1995, J BIOL CHEM, V270, P18871, DOI 10.1074/jbc.270.32.18871; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KHARBANDA S, 1993, BIOCHEMISTRY-US, V32, P9137, DOI 10.1021/bi00086a019; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LIM RW, 1987, ONCOGENE, V1, P263; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; van Wijk R, 1985, Int J Hyperthermia, V1, P147, DOI 10.3109/02656738509029281; VANWIJK R, 1993, J CELL PHYSIOL, V155, P265, DOI 10.1002/jcp.1041550207; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	61	147	151	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 4	1998	16	22					2915	2926		10.1038/sj.onc.1201834	http://dx.doi.org/10.1038/sj.onc.1201834			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZR544	9671412				2022-12-25	WOS:000073988200010
J	Van Heek, M; Schmitt, D; Toren, P; Cathcart, MK; DiCorleto, PE				Van Heek, M; Schmitt, D; Toren, P; Cathcart, MK; DiCorleto, PE			Cholesteryl hydroperoxyoctadecadienoate from oxidized low density lipoprotein inactivates platelet-derived growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-LIKE MOLECULES; POLAR STEROL ESTERS; FACTOR-LIKE PROTEIN; ENDOTHELIAL-CELLS; HUMAN ATHEROMA; LIPID-PEROXIDATION; 15-LIPOXYGENASE; ATHEROSCLEROSIS; PROLIFERATION; INHIBITION	Both oxidized low density lipoprotein (ox-LDL) and platelet-derived growth factor (PDGF) have been implicated in the genesis of various inflammatory responses, including atherosclerosis. We demonstrate here a novel interaction between specific oxidized lipids derived from ox-LDL and PDGF. The lipid moieties of ox-LDL caused concentration-dependent inactivation of PDGF as measured by loss of its mitogenic activity and its binding to high affinity receptors. Reverse-phase and normal-phase HPLC were used to purify the inactivating component in the lipid mixture. By fast atom bombardment mass spectrometry and infrared spectroscopy, we identified the inactivating lipids as the 9- and 13-hydroperoxy derivatives of cholesteryl linoleate, cholesteryl hydroperoxyoctadecadienoate. When a series of cholesteryl esters were subjected to oxidizing conditions, only those containing two or more double bonds caused inactivation of PDGF; the extent of inactivation increased with increased levels of oxidation. Exposing PDGF to cumene hydroperoxide, t-butyl hydroperoxide, or hydrogen peroxide did not affect the activity of the mitogen. The oxidized lipid had no effect on the mitogenic activity of epidermal growth factor but did abolish the mitogenic activity of basic fibroblast growth factor and the antiproliferative activity of transforming growth factor beta 1. The inactivation of PDGF and other cytokines by lipid hydroperoxides may occur in such processes as vascular disease, inflammation, and wound healing.	Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	DiCorleto, PE (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, 9500 Euclid Ave,NC10, Cleveland, OH 44195 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029582] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00080] Funding Source: Medline; NHLBI NIH HHS [HL-29582] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABELL LL, 1952, J BIOL CHEM, V195, P357; Belkner J, 1992, Agents Actions Suppl, V37, P78; BOWENPOPE DF, 1982, J BIOL CHEM, V257, P5161; BROOKS CJW, 1971, ATHEROSCLEROSIS, V13, P223, DOI 10.1016/0021-9150(71)90025-6; DICORLETO PE, 1985, J CLIN INVEST, V75, P1153, DOI 10.1172/JCI111810; EDELSTEIN C, 1986, BIOCH BIOL PLASMA LI, V11, P495; ENGLEKA KA, 1992, J BIOL CHEM, V267, P11307; FOLCIK VA, 1994, J LIPID RES, V35, P1570; FOLCIK VA, 1995, J CLIN INVEST, V96, P404; FOX PL, 1984, J CELL PHYSIOL, V121, P298, DOI 10.1002/jcp.1041210206; FOX PL, 1987, J BIOL CHEM, V262, P6046; GAN QF, 1995, BIOCHEMISTRY-US, V34, P7069, DOI 10.1021/bi00021a019; GRANT MM, 1992, AM J PHYSIOL, V263, pL370, DOI 10.1152/ajplung.1992.263.3.L370; HARLAN JM, 1986, J CELL BIOL, V103, P1129, DOI 10.1083/jcb.103.3.1129; HARLAND WA, 1973, BIOCHIM BIOPHYS ACTA, V316, P378, DOI 10.1016/0005-2760(73)90076-3; HARLAND WA, 1971, ATHEROSCLEROSIS, V13, P239, DOI 10.1016/0021-9150(71)90026-8; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; KUHN H, 1992, EICOSANOIDS, V5, P17; KUHN H, 1994, J EXP MED, V179, P1903, DOI 10.1084/jem.179.6.1903; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTINET Y, 1986, NATURE, V319, P158, DOI 10.1038/319158a0; MOREL DW, 1984, ARTERIOSCLEROSIS, V4, P357, DOI 10.1161/01.ATV.4.4.357; MOWRI H, 1986, BIOCHEM INT, V12, P347; RAINES EW, HDB EXPT PHARM, V951, P173; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; SCHUH J, 1978, P NATL ACAD SCI USA, V75, P3173, DOI 10.1073/pnas.75.7.3173; SEIFERT RA, 1984, NATURE, V311, P669, DOI 10.1038/311669a0; Shen JH, 1996, J CLIN INVEST, V98, P2201, DOI 10.1172/JCI119029; SHIMOKADO K, 1985, CELL, V43, P277, DOI 10.1016/0092-8674(85)90033-9; STOCKER R, 1991, P NATL ACAD SCI USA, V88, P1646, DOI 10.1073/pnas.88.5.1646; WALKER LN, 1986, P NATL ACAD SCI USA, V83, P7311, DOI 10.1073/pnas.83.19.7311; YAMAMOTO Y, 1989, BIOCHEM BIOPH RES CO, V165, P988, DOI 10.1016/0006-291X(89)92700-9; ZAK B, 1954, ANAL CHEM, V26, P776, DOI 10.1021/ac60088a058	34	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19405	19410		10.1074/jbc.273.31.19405	http://dx.doi.org/10.1074/jbc.273.31.19405			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677358	hybrid			2022-12-25	WOS:000075125200010
J	Yan, D; Swain, PK; Breuer, D; Tucker, RM; Wu, WP; Fujita, R; Rehemtulla, A; Burke, D; Swaroop, A				Yan, D; Swain, PK; Breuer, D; Tucker, RM; Wu, WP; Fujita, R; Rehemtulla, A; Burke, D; Swaroop, A			Biochemical characterization and subcellular localization of the mouse retinitis pigmentosa GTPase regulator (mRpgr)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCHANGE FACTOR; RETINAL DEGENERATION; BREFELDIN-A; PROTEIN; RHODOPSIN; TRANSPORT; GENE; RCC1; CHOROIDEREMIA; DEFICIENCY	The retinitis pigmentosa GTPase regulator (RPGR) gene encodes a protein homologous to the RCC1 guanine nucleotide exchange factor and is mutated in 20% of patients with X-linked retinitis pigmentosa. We have characterized the fall-length and variant cDNAs corresponding to the mouse homolog of the RPGR gene (mRpgr). Comparison with the human cDNA revealed sequence identity primarily in the region of RCC1 homology repeats. As in humans, the mRpgr gene maps within 50 kilobases from the 5'-end of the Otc gene. The mRpgr transcripts are detected as early as E7 during embryonic development and are expressed widely in the adult mice. Variant mRpgr isoforms are generated by alternative splicing and by utilizing two in-frame initiation codons. The products of mRpgr cDNAs migrate aberrantly in SDS-polyacrylamide gels because of a charged domain. In transfected COS cells, the mRpgr protein is isoprenylated and is localized in the Golgi complex. This subcellular distribution is not observed after treatments with brefeldin A or mevastatin and when the conserved isoprenylation sequence (CTIL) at the carboxyl terminus is deleted or mutagenized. These studies suggest a role for the mRpgr protein in Golgi transport and form the basis for investigating the mechanism of photoreceptor degeneration in X-linked retinitis pigmentosa.	Univ Michigan, WK Kellogg Eye Ctr, Dept Ophthalmol, Ann Arbor, MI 48105 USA; Univ Michigan, Dept Human Genet, Ann Arbor, MI 48105 USA; Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48105 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Swaroop, A (corresponding author), Univ Michigan, WK Kellogg Eye Ctr, Dept Ophthalmol, 1000 Wall St, Ann Arbor, MI 48105 USA.	swaroop@umich.edu		Fujita, Ricardo/0000-0002-9617-5109; Burke, David/0000-0002-2564-7949; Swaroop, Anand/0000-0002-1975-1141	NCRR NIH HHS [M01-RR00042] Funding Source: Medline; NEI NIH HHS [R01 EY7961, EY07003] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY007961] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Aldred MA, 1994, MOL GENETICS INHERIT, P259; Andreasson S, 1997, AM J OPHTHALMOL, V124, P95; ARVEILER B, 1991, Technique (Philadelphia), V3, P24; BIRD AC, 1975, BRIT J OPHTHALMOL, V59, P177, DOI 10.1136/bjo.59.4.177; BLAIR HJ, 1994, GENOMICS, V19, P215, DOI 10.1006/geno.1994.1050; Buraczynska M, 1997, AM J HUM GENET, V61, P1287, DOI 10.1086/301646; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; Coligan JE, 1995, CURRENT PROTOCOLS PR; COLLEY NJ, 1995, P NATL ACAD SCI USA, V92, P3070, DOI 10.1073/pnas.92.7.3070; COULSON A, 1991, Technique (Philadelphia), V3, P17; DERETIC D, 1995, PROG RETIN EYE RES, V14, P249, DOI 10.1016/1350-9462(94)00004-3; Farber DB, 1997, CURR OPIN NEUROBIOL, V7, P666, DOI 10.1016/S0959-4388(97)80087-6; Ferreira PA, 1996, NATURE, V383, P637, DOI 10.1038/383637a0; Foster R, 1996, MOL CELL BIOL, V16, P2689; Fujita R, 1996, Mol Vis, V2, P4; Gelb MH, 1997, SCIENCE, V275, P1750, DOI 10.1126/science.275.5307.1750; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; HANSEN JE, 1995, BIOCHEM J, V308, P801, DOI 10.1042/bj3080801; Heckenlively J. R., 1988, RETINITIS PIGMENTOSA; HSIEH CL, 1990, SOMAT CELL MOLEC GEN, V16, P407, DOI 10.1007/BF01232469; HUNTER DG, 1988, ARCH OPHTHALMOL-CHIC, V106, P362; Jacobson SG, 1997, INVEST OPHTH VIS SCI, V38, P1983; Jilkina O, 1996, BBA-MOL CELL RES, V1314, P157, DOI 10.1016/S0167-4889(96)00073-0; Kaufman R. J., 1992, Gene amplification in mammalian cells: a comprehensive guide., P315; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Li TS, 1996, P NATL ACAD SCI USA, V93, P14176, DOI 10.1073/pnas.93.24.14176; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MCCAFFERY JM, 1995, METHOD ENZYMOL, V257, P259; Meindl A, 1996, NAT GENET, V13, P35, DOI 10.1038/ng0596-35; Moore DD, 1995, GLOB MOB SURV; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; ORCI L, 1991, CELL, V64, P1183; Renault L, 1998, NATURE, V392, P97, DOI 10.1038/32204; Roepman R, 1996, HUM MOL GENET, V5, P1035, DOI 10.1093/hmg/5.7.1035; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SEABRA MC, 1993, SCIENCE, V259, P377, DOI 10.1126/science.8380507; SEABRA MC, 1995, J BIOL CHEM, V270, P24420, DOI 10.1074/jbc.270.41.24420; Seki T, 1996, J BIOCHEM, V120, P207; SUNG CH, 1994, J NEUROSCI, V14, P5818; SWAROOP A, 1993, CYTOGENET CELL GENET, V64, P292, DOI 10.1159/000133595; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39	42	68	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19656	19663		10.1074/jbc.273.31.19656	http://dx.doi.org/10.1074/jbc.273.31.19656			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677393	hybrid			2022-12-25	WOS:000075125200045
J	Dooley, CT; Ny, P; Bidlack, JM; Houghten, RA				Dooley, CT; Ny, P; Bidlack, JM; Houghten, RA			Selective ligands for the mu, delta, and Kappa opioid receptors identified from a single mixture based tetrapeptide positional scanning combinatorial library	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLID-PHASE SYNTHESIS; PEPTIDE LIGANDS; AMINO-ACIDS; BINDING; LEVEL; CELLS	A combinatorial library of 6,250,000 tetrapeptides in the mixture based positional scanning format was screened in binding assays for the three opioid receptors, mu, delta, and kappa, Three different binding profiles were found. Individual peptides were synthesized representing all possible combinations of the active amino acids identified from the screening data. New, highly active peptides selective for each of the three receptors were chosen. This study demonstrates the power of mixture-based combinatorial Libraries to identify distinctly different ligands for closely related receptors.	Torrey Pines Inst Mol Studies, San Diego, CA 92121 USA; Univ Rochester, Med Ctr, Dept Physiol & Pharmacol, Rochester, NY 14642 USA	Torrey Pines Institute for Molecular Studies, California; University of Rochester	Houghten, RA (corresponding author), Torrey Pines Inst Mol Studies, 3550 Gen Atom Ct, San Diego, CA 92121 USA.	houghten@tpims.org			NATIONAL INSTITUTE ON DRUG ABUSE [R01DA003742, R01DA009410] Funding Source: NIH RePORTER; NIDA NIH HHS [DA09410, DA03742] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHARPENTIER S, 1991, BIOCHEM BIOPH RES CO, V179, P1161, DOI 10.1016/0006-291X(91)91693-7; CHILDERS SR, 1991, LIFE SCI, V48, P1991, DOI 10.1016/0024-3205(91)90154-4; Dooley C. T., 1995, PEPTIDES 94, P805; DOOLEY CT, 1995, PEPTIDE RES, V8, P124; DOOLEY CT, 1993, P NATL ACAD SCI USA, V90, P10811, DOI 10.1073/pnas.90.22.10811; DOOLEY CT, 1993, LIFE SCI, V52, P1509, DOI 10.1016/0024-3205(93)90113-H; DOOLEY CT, 1994, SCIENCE, V266, P2019, DOI 10.1126/science.7801131; Eichler J, 1996, J PEPT SCI, V2, P240, DOI 10.1002/psc.310020402; Gear RW, 1996, NAT MED, V2, P1248, DOI 10.1038/nm1196-1248; GEYSEN HM, 1986, MOL IMMUNOL, V23, P709, DOI 10.1016/0161-5890(86)90081-7; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; HOUGHTEN RA, 1993, BIOORG MED CHEM LETT, V3, P405, DOI 10.1016/S0960-894X(01)80222-5; HOUGHTEN RA, 1986, INT J PEPT PROT RES, V27, P673; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003-2697(70)90146-6; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LAW PY, 1983, MOL PHARMACOL, V23, P26; LAWERENCE DMP, 1993, J PHARMACOL EXP THER, V266, P1678; LAWRENCE DMP, 1995, BIOCHEM PHARMACOL, V49, P81, DOI 10.1016/0006-2952(94)00440-W; OSTRESH JM, 1994, BIOPOLYMERS, V34, P1681, DOI 10.1002/bip.360341212; PINILLA C, 1992, BIOTECHNIQUES, V13, P901; POKORNY V, 1994, INNOVATION PERSPECTI, P643; SCHILLER PW, 1989, J MED CHEM, V32, P698, DOI 10.1021/jm00123a035; TAM JP, 1983, J AM CHEM SOC, V105, P6442, DOI 10.1021/ja00359a014; TOVEY KC, 1974, CLIN CHIM ACTA, V56, P221, DOI 10.1016/0009-8981(74)90133-8; WALKER JS, 1995, LIFE SCI, V57, P371, DOI 10.1016/0024-3205(95)00296-I; YU VC, 1988, J PHARMACOL EXP THER, V245, P350; Zadina JE, 1997, NATURE, V386, P499, DOI 10.1038/386499a0	29	75	97	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18848	18856		10.1074/jbc.273.30.18848	http://dx.doi.org/10.1074/jbc.273.30.18848			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668060	hybrid			2022-12-25	WOS:000074974700027
J	Lundblad, JR; Kwok, RPS; Laurance, ME; Huang, MS; Richards, JP; Brennan, RG; Goodman, RH				Lundblad, JR; Kwok, RPS; Laurance, ME; Huang, MS; Richards, JP; Brennan, RG; Goodman, RH			The human T-cell leukemia virus-1 transcriptional activator Tax enhances cAMP-responsive element-binding protein (CREB) binding activity through interactions with the DNA minor groove	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; X-RAY STRUCTURE; HTLV-I; LEUCINE-ZIPPER; CYCLIC-AMP; 21-BASE-PAIR REPEATS; TRANSACTIVATOR TAX; COMPLEX-FORMATION; CRYSTAL-STRUCTURE; ENERGY-TRANSFER	Tax-1, the transcriptional activation protein of human T-cell leukemia virus-1, increases transcription hom the human T-cell leukemia virus-1 long terminal repeat and specific cellular promoters through interactions with cellular DNA-binding proteins. The Tax response elements (TxREs) of the long terminal repeat resemble cAMP response elements (CREs), the target of cAMP-responsive element-binding protein (CREB). CREB binds the TxRE with reduced affinity; however, the interaction is specifically enhanced by Tax. Using a fluorescence quenching method, we determined that CREB dimerizes in the absence of DNA, and that Tax does not enhance dimerization. DNA footprinting of the TxRE with 1,10-phenanthroline-copper complex demonstrates that Tax contacts DNA and extends the footprint of CREB to GC-rich sequences Banking the core CRE-like element. The minor groove-binding drug chromomycin A,, but not distamycin A, disrupted Tax-enhanced CREB binding to the TxRE. Substitution of the guanine-rich sequences flanking the core of the TxRE with inosine residues also blocked the Tax effect. Finally, the IC-substituted TxRE binds CREB with increased affinity, suggesting Banking DNA influences the binding of CREB to the core CRE-like element. These data indicate that Tax does not regulate DNA binding of CREB by altering dimerization, but rather enhances DNA binding by additionally interacting with the minor groove of flanking DNA sequences.	Oregon Hlth Sci Univ, Dept Med, Div Mol Med, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Div Hematol Oncol, Dept Pediat, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Lundblad, JR (corresponding author), Oregon Hlth Sci Univ, Dept Med, Div Mol Med, NRC-5, Portland, OR 97201 USA.			Brennan, Richard/0000-0001-7647-485X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK051732] Funding Source: NIH RePORTER; NIDDK NIH HHS [R29 DK51732] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADYA N, 1995, J VIROL, V69, P1834, DOI 10.1128/JVI.69.3.1834-1841.1995; ADYA N, 1994, P NATL ACAD SCI USA, V91, P5642, DOI 10.1073/pnas.91.12.5642; ANDERSON MG, 1994, NUCLEIC ACIDS RES, V22, P3194, DOI 10.1093/nar/22.15.3194; BAILLY C, 1995, EMBO J, V14, P2121, DOI 10.1002/j.1460-2075.1995.tb07204.x; Bantignies F, 1996, MOL CELL BIOL, V16, P2174; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; Barnabas S, 1997, J BIOL CHEM, V272, P20684, DOI 10.1074/jbc.272.33.20684; BRAUWEILER A, 1995, J BIOL CHEM, V270, P12814, DOI 10.1074/jbc.270.21.12814; Chiang SY, 1996, J BIOL CHEM, V271, P23999, DOI 10.1074/jbc.271.39.23999; CHIANG SY, 1994, BIOCHEMISTRY-US, V33, P7033, DOI 10.1021/bi00189a003; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; FUJISAWA J, 1989, J VIROL, V63, P3234, DOI 10.1128/JVI.63.8.3234-3239.1989; FUJISAWA J, 1986, EMBO J, V5, P713, DOI 10.1002/j.1460-2075.1986.tb04272.x; GAO XL, 1989, BIOCHEMISTRY-US, V28, P751, DOI 10.1021/bi00428a051; GIAM CZ, 1989, J BIOL CHEM, V264, P15236; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gitlin Scott D., 1993, P159; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GOREN I, 1995, J VIROL, V69, P5806, DOI 10.1128/JVI.69.9.5806-5811.1995; Heuer KH, 1996, BIOCHEMISTRY-US, V35, P9069, DOI 10.1021/bi952817o; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; KRYLOV D, 1994, EMBO J, V13, P2849, DOI 10.1002/j.1460-2075.1994.tb06579.x; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Laurance ME, 1997, J BIOL CHEM, V272, P2646, DOI 10.1074/jbc.272.5.2646; Lenzmeier BA, 1998, MOL CELL BIOL, V18, P721, DOI 10.1128/MCB.18.2.721; LORIAUX MM, 1993, P NATL ACAD SCI USA, V90, P9046, DOI 10.1073/pnas.90.19.9046; LOW KG, 1994, MOL CELL BIOL, V14, P4958, DOI 10.1128/MCB.14.7.4958; Lundblad JR, 1996, MOL ENDOCRINOL, V10, P607, DOI 10.1210/me.10.6.607; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MARRIOTT SJ, 1990, MOL CELL BIOL, V10, P4192, DOI 10.1128/MCB.10.8.4192; Maxam A M, 1980, Methods Enzymol, V65, P499; Metallo SJ, 1997, NAT STRUCT BIOL, V4, P115, DOI 10.1038/nsb0297-115; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MONTAGNE J, 1990, EMBO J, V9, P957, DOI 10.1002/j.1460-2075.1990.tb08194.x; NYBORG JK, 1988, P NATL ACAD SCI USA, V85, P1457, DOI 10.1073/pnas.85.5.1457; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PACAUCCARALERTKUN S, 1994, MOL CELL BIOL, V14, P456, DOI 10.1128/MCB.14.1.456; PAPAVASSILIOU AG, 1995, BIOCHEM J, V305, P345, DOI 10.1042/bj3050345; Park C, 1996, J AM CHEM SOC, V118, P4235, DOI 10.1021/ja950653t; PATEL LR, 1994, P NATL ACAD SCI USA, V91, P7360, DOI 10.1073/pnas.91.15.7360; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; PERNELLE C, 1993, BIOCHEMISTRY-US, V32, P11682, DOI 10.1021/bi00094a026; Richards JP, 1996, J BIOL CHEM, V271, P13716, DOI 10.1074/jbc.271.23.13716; SANTIAGORIVERA ZI, 1993, PROTEIN SCI, V2, P1461, DOI 10.1002/pro.5560020910; SELLERS JW, 1990, MOL CELL BIOL, V10, P5077, DOI 10.1128/MCB.10.10.5077; SELVIN PR, 1995, METHOD ENZYMOL, V246, P300; SIGMAN DS, 1991, METHOD ENZYMOL, V208, P414; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Starr DB, 1996, GENE DEV, V10, P1271, DOI 10.1101/gad.10.10.1271; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Tie F, 1996, J VIROL, V70, P8368, DOI 10.1128/JVI.70.12.8368-8374.1996; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; WILLIAMS JS, 1995, P NATL ACAD SCI USA, V92, P3819, DOI 10.1073/pnas.92.9.3819; WILLIAMS JS, 1993, DNA CELL BIOL, V12, P183, DOI 10.1089/dna.1993.12.183; Yin MJ, 1996, J BIOL CHEM, V271, P4781, DOI 10.1074/jbc.271.9.4781; YIN MJ, 1995, J VIROL, V69, P3420, DOI 10.1128/JVI.69.6.3420-3432.1995; Yin MJ, 1996, J MOL BIOL, V264, P20, DOI 10.1006/jmbi.1996.0620; Yin MJ, 1996, MOL CELL BIOL, V16, P3156; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	66	62	62	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19251	19259		10.1074/jbc.273.30.19251	http://dx.doi.org/10.1074/jbc.273.30.19251			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668114	hybrid			2022-12-25	WOS:000074974700081
J	Sturm, NR; Fleischmann, J; Campbell, DA				Sturm, NR; Fleischmann, J; Campbell, DA			Efficient trans-splicing of mutated spliced leader exons in Leishmania tarentolae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINI-EXON; TRYPANOSOMA-BRUCEI; IN-VIVO; LEPTOMONAS-COLLOSOMA; MESSENGER-RNAS; GENE; EXPRESSION; ELEMENTS; TRANSCRIPTION; METHYLATIONS	Every kinetoplastid mRNA receives a common, conserved leader sequence via the process of trans-splicing. In Leishmania tarentolae the precursor spliced leader RNA is 96 nucleotides, with a 39-nucleotide exon that is 7meG-capped and methylated on the first 4 nucleotides. trans-Splicing was inferred from the presence of tagged leader in the high molecular weight RNA population and confirmed for accuracy by cDNA cloning. Linker scan substitutions within the exon between positions 10 and 39 did not affect trans-splicing. The trans-splicing efficiency for three of the scan exons was proportional to the tagged:wild type ratio in the spliced leader precursor population. Two scan leader RNAs that were efficiently spliced showed reduced methylation. Longer exons showed reduced splicing, whereas 10- or 20-base pair deletions abolished splicing. These results indicate that size, but not content, of the exon is a constraint on the splicing process. These results, in combination with previous data eliminating a role in transcription initiation, suggest that translation may be the selective pressure on the leader content.	Univ Calif Los Angeles, Sch Med, Dept Immunol & Microbiol, Los Angeles, CA 90095 USA; W Los Angeles Vet Affairs Med Ctr, Dept Med, Los Angeles, CA 90073 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center	Campbell, DA (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Immunol & Microbiol, Los Angeles, CA 90095 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007323, R01AI034536] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34536, 2-T32-AI-07323] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGAMI R, 1994, NUCLEIC ACIDS RES, V22, P1959, DOI 10.1093/nar/22.11.1959; COOK GA, 1987, MOL BIOCHEM PARASIT, V25, P113, DOI 10.1016/0166-6851(87)90024-7; DELAFAILLE MAC, 1992, P NATL ACAD SCI USA, V89, P2703, DOI 10.1073/pnas.89.7.2703; Dungan JM, 1996, EMBO J, V15, P4016, DOI 10.1002/j.1460-2075.1996.tb00775.x; FERNANDES O, 1994, MOL BIOCHEM PARASIT, V66, P261, DOI 10.1016/0166-6851(94)90153-8; FLEISCHMANN J, 1994, GENE, V144, P45, DOI 10.1016/0378-1119(94)90201-1; FREISTADT MS, 1987, NUCLEIC ACIDS RES, V15, P9861, DOI 10.1093/nar/15.23.9861; Gunzl A, 1997, MOL BIOCHEM PARASIT, V85, P67, DOI 10.1016/S0166-6851(96)02816-2; HANNON GJ, 1990, EMBO J, V9, P1915, DOI 10.1002/j.1460-2075.1990.tb08318.x; HARRIS KA, 1995, RNA, V1, P351; KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084; LECUYER KA, 1993, BIOCHEMISTRY-US, V32, P5301, DOI 10.1021/bi00071a004; LENARDO MJ, 1985, MOL CELL BIOL, V5, P2487, DOI 10.1128/MCB.5.9.2487; Lucke S, 1996, EMBO J, V15, P4380, DOI 10.1002/j.1460-2075.1996.tb00811.x; MARONEY PA, 1991, EMBO J, V10, P3869, DOI 10.1002/j.1460-2075.1991.tb04956.x; MASLOV DA, 1993, MOL BIOCHEM PARASIT, V61, P127, DOI 10.1016/0166-6851(93)90165-T; MCNALLY KP, 1992, MOL CELL BIOL, V12, P4844, DOI 10.1128/MCB.12.11.4844; MUHICH ML, 1987, NUCLEIC ACIDS RES, V15, P3141, DOI 10.1093/nar/15.7.3141; PERRY KL, 1987, P NATL ACAD SCI USA, V84, P8190, DOI 10.1073/pnas.84.23.8190; Roberts TG, 1996, MOL BIOCHEM PARASIT, V83, P163, DOI 10.1016/S0166-6851(96)02762-4; SAITO RM, 1994, EMBO J, V13, P5460, DOI 10.1002/j.1460-2075.1994.tb06881.x; STEITZ JA, 1992, SCIENCE, V257, P888, DOI 10.1126/science.1386941; STURM NR, 1995, FEMS MICROBIOL LETT, V130, P177, DOI 10.1111/j.1574-6968.1995.tb07716.x; STURM NR, 1994, MOL CELL BIOL, V14, P6171, DOI 10.1128/MCB.14.9.6171; STURM NR, 1990, CELL, V61, P871, DOI 10.1016/0092-8674(90)90197-M; ULLU E, 1991, P NATL ACAD SCI USA, V88, P10074, DOI 10.1073/pnas.88.22.10074; ULLU E, 1993, J BIOL CHEM, V268, P13068; WATKINS KP, 1994, CELL, V76, P171, DOI 10.1016/0092-8674(94)90181-3; WISE JA, 1993, SCIENCE, V262, P1978, DOI 10.1126/science.8266091	29	29	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18689	18692		10.1074/jbc.273.30.18689	http://dx.doi.org/10.1074/jbc.273.30.18689			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668037	hybrid			2022-12-25	WOS:000074974700004
J	Bogsch, EG; Sargent, F; Stanley, NR; Berks, BC; Robinson, C; Palmer, T				Bogsch, EG; Sargent, F; Stanley, NR; Berks, BC; Robinson, C; Palmer, T			An essential component of a novel bacterial protein export system with homologues in plastids and mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; THYLAKOID MEMBRANE; FORMATE DEHYDROGENASE; NITRATE REDUCTASE; SECA-PROTEIN; TRANSPORT; PEPTIDES; PATHWAY; GENE; IDENTIFICATION	Proteins are transported across the bacterial plasma membrane and the chloroplast thylakoid membrane by means of protein translocases that recognize N-terminal targeting signals in their cognate substrates, Transport of many of these proteins involves the well defined Sec apparatus that operates in both membranes. We describe here the identification of a novel component of a bacterial Sec-independent translocase, The system probably functions in a similar manner to a Sec-independent translocase in the thylakoid membrane, and substrates for both systems bear a characteristic twin-arginine motif in the targeting peptide. The translocase component is encoded in Escherichia coli by an unassigned reading frame, yigU, disruption of which blocks the export of at least five twin-Arg-containing precursor proteins that are predicted to bind redox cofactors, and hence fold, prior to translocation. The Sec pathway remains unaffected in the deletion strain, The gene has been designated tatC (for twin-arginine translocation), and we show that homologous genes are present in a range of bacteria, plastids, and mitochondria. These findings suggest a central role for TatC-type proteins in the translocation of tightly folded proteins across a spectrum of biological membranes.	Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England; John Innes Ctr Plant Sci Res, Nitrogen Fixat Lab, Norwich NR4 7UH, Norfolk, England	University of East Anglia; University of Warwick; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Palmer, T (corresponding author), Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England.			Berks, Ben/0000-0001-9685-4067; Stanley-Wall, Nicola/0000-0002-5936-9721; Sargent, Frank/0000-0002-6841-3624; Palmer, Tracy/0000-0001-9043-2592				ATLUNG T, 1989, J BACTERIOL, V171, P1683, DOI 10.1128/jb.171.3.1683-1691.1989; BALLANTINE SP, 1985, J BACTERIOL, V163, P454, DOI 10.1128/JB.163.2.454-459.1985; Berks BC, 1996, MOL MICROBIOL, V22, P393, DOI 10.1046/j.1365-2958.1996.00114.x; BILOUS PT, 1985, J BACTERIOL, V162, P1151, DOI 10.1128/JB.162.3.1151-1155.1985; CASADABAN MJ, 1979, P NATL ACAD SCI USA, V76, P4530, DOI 10.1073/pnas.76.9.4530; CHADDOCK AM, 1995, EMBO J, V14, P2715, DOI 10.1002/j.1460-2075.1995.tb07272.x; CLINE K, 1992, J BIOL CHEM, V267, P2688; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; COHEN G N, 1956, Ann Inst Pasteur (Paris), V91, P693; CREIGHTON AM, 1995, J BIOL CHEM, V270, P1663, DOI 10.1074/jbc.270.4.1663; ENOCH HG, 1975, J BIOL CHEM, V250, P6693; GRAHAM A, 1980, FEMS MICROBIOL LETT, V7, P145, DOI 10.1111/j.1574-6941.1980.tb01595.x; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HENRY R, 1994, J BIOL CHEM, V269, P10189; IZARD JW, 1994, MOL MICROBIOL, V13, P765, DOI 10.1111/j.1365-2958.1994.tb00469.x; Johnson Kit, 1992, Current Opinion in Biotechnology, V3, P481, DOI 10.1016/0958-1669(92)90075-T; JONES RW, 1977, BIOCHEM J, V164, P199, DOI 10.1042/bj1640199; KALMAN LV, 1989, J BACTERIOL, V171, P3810, DOI 10.1128/jb.171.7.3810-3816.1989; MOULD RM, 1991, J BIOL CHEM, V266, P12189; NAKAI M, 1994, J BIOL CHEM, V269, P31338; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; OSBORN MJ, 1972, J BIOL CHEM, V247, P3973; Robinson C, 1997, TRENDS PLANT SCI, V2, P431, DOI 10.1016/S1360-1385(97)90027-3; ROBINSON C, 1994, EMBO J, V13, P279, DOI 10.1002/j.1460-2075.1994.tb06260.x; Santini CL, 1998, EMBO J, V17, P101, DOI 10.1093/emboj/17.1.101; Sargent F, 1998, EMBO J, V17, P3640, DOI 10.1093/emboj/17.13.3640; SARGENT F, 1998, IN PRESS EUR J BIOCH, V225; SAWERS G, 1994, ANTON LEEUW INT J G, V66, P57, DOI 10.1007/BF00871633; SETTLES MA, 1997, SCIENCE, V278, P1467; SILVESTRO A, 1988, BIOCHIM BIOPHYS ACTA, V954, P1, DOI 10.1016/0167-4838(88)90049-0; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; Weiner JH, 1998, CELL, V93, P93, DOI 10.1016/S0092-8674(00)81149-6; YUAN JG, 1994, SCIENCE, V266, P796, DOI 10.1126/science.7973633	33	329	340	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18003	18006		10.1074/jbc.273.29.18003	http://dx.doi.org/10.1074/jbc.273.29.18003			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660752	hybrid			2022-12-25	WOS:000074828500007
J	Gray, M; Szabo, G; Otero, AS; Gray, L; Hewlett, E				Gray, M; Szabo, G; Otero, AS; Gray, L; Hewlett, E			Distinct mechanisms for K+ efflux, intoxication, and hemolysis by Bordetella pertussis AC toxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE TOXIN; ESCHERICHIA-COLI HEMOLYSIN; GRAM-NEGATIVE BACTERIA; TARGET-CELL MEMBRANES; RED-BLOOD-CELLS; SHEEP ERYTHROCYTES; FATTY-ACYLATION; CALCIUM; PENETRATION; PURIFICATION	Adenylate cyclase (AC) toxin from Bordetella pertussis delivers its catalytic domain to the interior of target cells where it converts host ATP to cAMP in a process referred to as intoxication. This toxin also hemolyzes sheep erythrocytes by a mechanism presumed to include pore formation and osmotic lysis, Intoxication and hemolysis appear at strikingly different toxin concentrations and evolve over different time scales, suggesting that different molecular processes may be involved. The present study was designed to test the hypothesis that intoxication and hemolysis occur by distinct mechanisms. Although the hemolytic activity of AC toxin has a lag of >1 h, intoxication starts immediately. Because of this difference, we sought a surrogate or precursor lesion that leads to hemolysis, and potassium efflux has been observed from erythrocytes treated with Other pore-forming toxins, AC toxin elicits an increase in K+ efflux from sheep erythrocytes and Jurkat cells, a human T-cell leukemia line, that beans within minutes of toxin addition. The toxin concentration dependence along with the analysis of the time course suggest that toxin monomers are sufficient to elicit release of K+ and to deliver the catalytic domain to the cell interior. Hemolysis, on the other hand, is a highly cooperative event that Likely requires a subsequent oligomerization of these individual units. Although induction of Kf efflux shares some structural and environmental requirements with both intoxication and hemolysis, it can occur under conditions in which intoxication is reduced or prevented. The data presented here suggest that the transmembrane pathway by which K+ is released is separate and distinct from the structure required for intoxication but may be related to, or a precursor of, that which is ultimately responsible for hemolysis.	Univ Virginia, Sch Med, Dept Med, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Pathol, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Pharmacol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia; University of Virginia	Hewlett, E (corresponding author), Univ Virginia, Sch Med, Dept Med, Box 419, Charlottesville, VA 22908 USA.			gray, mary/0000-0003-4441-5905	NHLBI NIH HHS [HL37127] Funding Source: Medline; NIAID NIH HHS [AI18000] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037127, R37HL037127] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018000] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AU DC, 1989, BIOCHEMISTRY-US, V28, P2772, DOI 10.1021/bi00433a005; BARRY EM, 1991, J BACTERIOL, V173, P720, DOI 10.1128/jb.173.2.720-726.1991; BAUMANN U, 1993, EMBO J, V12, P3357, DOI 10.1002/j.1460-2075.1993.tb06009.x; BELLALOU J, 1990, INFECT IMMUN, V58, P3242, DOI 10.1128/IAI.58.10.3242-3247.1990; BENZ R, 1994, J BIOL CHEM, V269, P27231; BERKOWITZ SA, 1980, ANN NY ACAD SCI, V1, P356; BHAKDI S, 1989, J EXP MED, V169, P737, DOI 10.1084/jem.169.3.737; BHAKDI S, 1986, INFECT IMMUN, V52, P63, DOI 10.1128/IAI.52.1.63-69.1986; Brooker G, 1979, Adv Cyclic Nucleotide Res, V10, P1; CLINKENBEARD KD, 1991, INFECT IMMUN, V59, P1148, DOI 10.1128/IAI.59.3.1148-1152.1991; CONFER DL, 1982, SCIENCE, V217, P948, DOI 10.1126/science.6287574; COOTE JG, 1992, FEMS MICROBIOL LETT, V88, P137, DOI 10.1016/0378-1097(92)90688-K; EHRMANN IE, 1992, FEBS LETT, V304, P51, DOI 10.1016/0014-5793(92)80587-7; EHRMANN IE, 1991, FEBS LETT, V278, P79, DOI 10.1016/0014-5793(91)80088-K; ENDOH M, 1980, MICROBIOL IMMUNOL, V24, P95, DOI 10.1111/j.1348-0421.1980.tb00567.x; GENTILE F, 1988, EUR J BIOCHEM, V175, P447, DOI 10.1111/j.1432-1033.1988.tb14215.x; GLASER P, 1988, MOL MICROBIOL, V2, P19, DOI 10.1111/j.1365-2958.1988.tb00003.x; GUISO N, 1989, MICROB PATHOGENESIS, V7, P373, DOI 10.1016/0882-4010(89)90040-5; HACKETT M, 1994, SCIENCE, V266, P433, DOI 10.1126/science.7939682; HACKETT M, 1995, J BIOL CHEM, V270, P20250, DOI 10.1074/jbc.270.35.20250; HANSKI E, 1985, J BIOL CHEM, V260, P5526; HEWLETT EL, 1976, P NATL ACAD SCI USA, V73, P1926, DOI 10.1073/pnas.73.6.1926; HEWLETT EL, 1991, J BIOL CHEM, V266, P17503; HEWLETT EL, 1989, J BIOL CHEM, V264, P19379; HEWLETT EL, 1993, J BIOL CHEM, V268, P7842; HEWLETT EL, 1990, BACTERIAL PROTEIN TO, P249; HEWLETT EL, 1992, BACTERIAL PROTEIN TO, P241; JORGENSEN SE, 1983, TOXICON, V21, P717, DOI 10.1016/0041-0101(83)90277-5; KELLERMAYER M, 1994, J CELL PHYSIOL, V159, P197, DOI 10.1002/jcp.1041590202; KIM HR, 1993, LIFE SCI, V53, P571, DOI 10.1016/0024-3205(93)90714-E; MADOFF MA, 1964, J BACTERIOL, V87, P145, DOI 10.1002/path.1700870120; OTERO AS, 1995, J BIOL CHEM, V270, P9695, DOI 10.1074/jbc.270.17.9695; PEARSON RD, 1987, J IMMUNOL, V139, P2749; ROGEL A, 1989, EMBO J, V8, P2755, DOI 10.1002/j.1460-2075.1989.tb08417.x; ROGEL A, 1992, J BIOL CHEM, V267, P22599; ROGEL A, 1991, J BIOL CHEM, V266, P3154; ROSE T, 1995, J BIOL CHEM, V270, P26370, DOI 10.1074/jbc.270.44.26370; SAKAMOTO H, 1992, J BIOL CHEM, V267, P13598; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SEBO P, 1991, GENE, V104, P19, DOI 10.1016/0378-1119(91)90459-O; SHATTUCK RL, 1985, BIOCHEMISTRY-US, V24, P6323, DOI 10.1021/bi00344a001; STANLEY P, 1994, SCIENCE, V266, P1992, DOI 10.1126/science.7801126; SZABO G, 1994, J BIOL CHEM, V269, P22496; VISSERS MCM, 1994, FREE RADICAL BIO MED, V16, P703, DOI 10.1016/0891-5849(94)90185-6; WALEV I, 1993, INFECT IMMUN, V61, P4972, DOI 10.1128/IAI.61.12.4972-4979.1993; WEISS AA, 1983, INFECT IMMUN, V42, P33, DOI 10.1128/IAI.42.1.33-41.1983; WELCH RA, 1991, MOL MICROBIOL, V5, P521, DOI 10.1111/j.1365-2958.1991.tb00723.x; Westrop G, 1997, J BACTERIOL, V179, P871, DOI 10.1128/jb.179.3.871-879.1997	48	76	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18260	18267		10.1074/jbc.273.29.18260	http://dx.doi.org/10.1074/jbc.273.29.18260			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660789	hybrid			2022-12-25	WOS:000074828500044
J	Hermsen, B; Stetzer, E; Thees, R; Heiermann, R; Schrattenholz, A; Ebbinghaus, U; Kretschmer, A; Methfessel, C; Reinhardt, S; Maelicke, A				Hermsen, B; Stetzer, E; Thees, R; Heiermann, R; Schrattenholz, A; Ebbinghaus, U; Kretschmer, A; Methfessel, C; Reinhardt, S; Maelicke, A			Neuronal nicotinic receptors in the locust Locusta migratoria - Cloning and expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; RAT HIPPOCAMPAL-NEURONS; ACETYLCHOLINE-RECEPTOR; MONOCLONAL-ANTIBODIES; ALPHA-BUNGAROTOXIN; BINDING-SITE; PATCH-CLAMP; SUBUNITS; DROSOPHILA; CELLS	We have identified five cDNA clones that encode nicotinic acetylcholine receptor (nAChR) subunits expressed in the nervous system of the locust Locusta migratoria. Four of the subunits are ligand-binding alpha subunits, and the other is a structural beta subunit. The existence of at least one more nAChR gene, probably encoding a beta subunit, is indicated. Based on Northern analysis and in situ hybridization, the five subunit genes are expressed. loc alpha 1, loc alpha 3, and loc beta 1 are the most abundant subunits and are expressed in similar areas of the head ganglia and retina of the adult locust. Because Loc alpha 3 binds alpha-bungarotoxin with high affinity, it may form a homomeric nAChR subtype such as the mammalian alpha 7 nAChR Loc alpha 1 and Loc beta 1 may then form the predominant heteromeric nAChR in the locust brain. loc alpha 4 is mainly expressed in optic lobe ganglionic cells and loc alpha 2 in peripherally located somata of mushroom body neurons. loc alpha 3 mRNA was additionally detected in cells interspersed in the somatogastric epithelium of the locust embryo, suggesting that this isoform may also be involved in functions other than neuronal excitability, Transcription of all nAChR subunit genes begins approximately 3 days before hatching and continues throughout adult life. Electrophysiological recordings from head ganglionic neurons also indicate the existence of more than one functionally distinct nAChR subtype, Our results suggest the existence of several nAChR subtypes, at least some of them heteromeric, in this insect species.	Johannes Gutenberg Univ Mainz, Sch Med, Inst Physiol Chem & Pathobiochem, Mol Neurobiol Lab, D-55099 Mainz, Germany; Bayer AG, Cent Res Unit, D-5090 Leverkusen, Germany	Johannes Gutenberg University of Mainz; Bayer AG	Maelicke, A (corresponding author), Johannes Gutenberg Univ Mainz, Sch Med, Inst Physiol Chem & Pathobiochem, Mol Neurobiol Lab, 6 Duesbergweg, D-55099 Mainz, Germany.	alfred.maelicke@uni-mainz.de						Albuquerque EX, 1997, J RECEPT SIGNAL TR R, V17, P243, DOI 10.3109/10799899709036607; ALKONDON M, 1994, J PHARMACOL EXP THER, V271, P494; ALKONDON M, 1993, J PHARMACOL EXP THER, V265, P1455; Battey, 1986, BASIC METHODS MOL BI; BAUMANN A, 1990, NUCLEIC ACIDS RES, V18, P3640, DOI 10.1093/nar/18.12.3640; BENKE D, 1989, COMP BIOCHEM PHYS C, V94, P71, DOI 10.1016/0742-8413(89)90146-1; BENSON JA, 1993, COMP MOL NEUROBIOLOG, P390; BENSON JA, 1988, NATO ASI SERIES H, V25, P227; BERTRAND D, 1992, NEUROSCI LETT, V146, P87, DOI 10.1016/0304-3940(92)90179-B; BERTRAND D, 1994, EUR J NEUROSCI, V6, P869, DOI 10.1111/j.1460-9568.1994.tb00997.x; BERTRAND D, 1993, P NATL ACAD SCI USA, V90, P6971, DOI 10.1073/pnas.90.15.6971; BOSSY B, 1988, EMBO J, V7, P611, DOI 10.1002/j.1460-2075.1988.tb02854.x; BREER H, 1981, Neurochemistry International, V3, P43, DOI 10.1016/0197-0186(81)90048-6; BREER H, 1985, J NEUROSCI, V5, P3386; BREER H, 1987, J INSECT PHYSIOL, V33, P771, DOI 10.1016/0022-1910(87)90025-4; BULLER AL, 1990, J MEMBRANE BIOL, V115, P179, DOI 10.1007/BF01869456; CONROY WG, 1995, J BIOL CHEM, V270, P4424, DOI 10.1074/jbc.270.9.4424; CONTITRONCONI BM, 1990, BIOCHEMISTRY-US, V29, P6221, DOI 10.1021/bi00478a016; CONTITRONCONI BM, 1991, BIOCHEMISTRY-US, V30, P2575, DOI 10.1021/bi00224a003; COUTURIER S, 1990, J BIOL CHEM, V265, P17560; DENERIS ES, 1991, TRENDS PHARMACOL SCI, V12, P34, DOI 10.1016/0165-6147(91)90486-C; Eastham HM, 1998, EUR J NEUROSCI, V10, P879, DOI 10.1046/j.1460-9568.1998.00095.x; ELGOYHEN AB, 1994, CELL, V79, P705, DOI 10.1016/0092-8674(94)90555-X; FELS G, 1986, J BIOL CHEM, V261, P5746; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P577, DOI 10.1113/jphysiol.1982.sp014393; Forsayeth JR, 1997, J NEUROSCI, V17, P1531; GEHLE VM, 1991, MOL BRAIN RES, V11, P17, DOI 10.1016/0169-328X(91)90016-Q; GERSCHENFELD HM, 1973, PHYSIOL REV, V53, P1, DOI 10.1152/physrev.1973.53.1.1; GERZANICH V, 1994, MOL PHARMACOL, V45, P212; GRANDO SA, 1995, J INVEST DERMATOL, V105, P774, DOI 10.1111/1523-1747.ep12325606; GUNDELFINGER ED, 1992, BIOCHIM BIOPHYS ACTA, V1137, P299, DOI 10.1016/0167-4889(92)90150-A; HANKE W, 1986, NATURE, V321, P171, DOI 10.1038/321171a0; HERMANSBORGMEYER I, 1986, EMBO J, V5, P1503, DOI 10.1002/j.1460-2075.1986.tb04389.x; Lansdell SJ, 1997, J NEUROCHEM, V68, P1812; LEITCH B, 1993, J COMP NEUROL, V334, P47, DOI 10.1002/cne.903340104; LENOVERE N, 1995, J MOL EVOL, V40, P155, DOI 10.1007/BF00167110; Lindstrom J, 1996, Ion Channels, V4, P377; MAELICKE A, 1984, ANGEW CHEM INT EDIT, V23, P195, DOI 10.1002/anie.198401951; MARSHALL J, 1990, EMBO J, V9, P4391, DOI 10.1002/j.1460-2075.1990.tb07889.x; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; RamirezLatorre J, 1996, NATURE, V380, P347, DOI 10.1038/380347a0; SAFRAN A, 1989, NATO ADV STUDY I CB, V32, P373; Sambrook J., 1989, MOL CLONING LAB MANU, V1; SATELLE DB, 1989, P R SOC LONDON B, V237, P501; SATELLE DB, 1980, ADV INSECT PHYSL, V15, P215; SCHRODER B, 1994, J BIOL CHEM, V269, P10407; Stetzer E, 1996, FEBS LETT, V397, P39, DOI 10.1016/S0014-5793(96)01115-5; Usherwood P.N.R., 1980, INSECT NEUROBIOLOGY, P115; Wang F, 1996, J BIOL CHEM, V271, P17656, DOI 10.1074/jbc.271.30.17656; WEBER H, 1938, COMPENDIUM ENTOMOLOG; ZWART R, 1994, PESTIC BIOCHEM PHYS, V48, P202, DOI 10.1006/pest.1994.1021	51	54	60	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18394	18404		10.1074/jbc.273.29.18394	http://dx.doi.org/10.1074/jbc.273.29.18394			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660807	hybrid			2022-12-25	WOS:000074828500062
J	Rieder, C; Strauss, G; Fuchs, G; Arigoni, D; Bacher, A; Eisenreich, W				Rieder, C; Strauss, G; Fuchs, G; Arigoni, D; Bacher, A; Eisenreich, W			Biosynthesis of the diterpene verrucosan-2 beta-ol in the phototrophic Eubacterium Chloroflexus aurantiacus - A retrobiosynthetic NMR study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NON-MEVALONATE PATHWAY; VERRUCOSANE DITERPENOIDS; ISOPRENOID BIOSYNTHESIS; BACTERIA; CHLOROBIUM; FIXATION; ABSENCE	The biosynthesis of verrucosan-2 beta-ol in the green phototrophic eubacterium Chloroflexus aurantiacus was investigated by in vivo incorporation of singly or doubly C-13-labeled acetate, The C-13 labeling of the isolated diterpene was analyzed by one- and two-dimensional NMR spectroscopy. The C-13-labeling patterns of verrucosan-2 beta-ol were compared with the labeling patterns of intermediary metabolites (acetyl-CoA, pyruvate, and glyceraldehyde 3-phosphate) which were deduced from amino acids and nucleosides by retrobiosynthetic analysis. The results show that verrucosan-2 beta-ol is synthesized via mevalonate and not via the deoxyxylulose pathway, which was discovered recently in some eubacteria, algae, and plants. A scheme for the formation of the unusual tetracyclic ring system is offered. The cyclization process is initiated by the solvolysis of pyrophosphate from geranyllinaloyl pyrophosphate and the mechanism involves a Wagner-Meerwein rearrangement, a 1,5-hydride shift, and a cyclopropylcarbinyl to cyclopropylcarbinyl rearrangement.	Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany; Univ Freiburg, Fac Biol, Dept Microbiol, D-79104 Freiburg, Germany; ETH Zurich, Organ Chem Lab, CH-8092 Zurich, Switzerland	Technical University of Munich; University of Freiburg; ETH Zurich	Eisenreich, W (corresponding author), Tech Univ Munich, Inst Organ Chem & Biochem, Lichtenbergstr 4, D-85747 Garching, Germany.		Eisenreich, Wolfgang/A-1258-2013	Eisenreich, Wolfgang/0000-0002-9832-8279				ARIGONI D, 1958, EXPERIENTIA, V14, P153, DOI 10.1007/BF02157135; Arigoni D, 1997, P NATL ACAD SCI USA, V94, P10600, DOI 10.1073/pnas.94.20.10600; ARIGONI D, 1968, Pure and Applied Chemistry, V17, P331, DOI 10.1351/pac196817030331; BIRCH AJ, 1962, J CHEM SOC, P1502, DOI 10.1039/jr9620001502; BLOCH K, 1965, SCIENCE, V150, P19, DOI 10.1126/science.150.3692.19; Broers STJ, 1994, THESIS EIDGENOSSISCH; CANE DE, 1985, ACCOUNTS CHEM RES, V18, P220, DOI 10.1021/ar00115a005; CANONICA L, 1967, TETRAHEDRON LETT, P4657; Cartayrade A., 1994, 2 S EUR NETW PLANT T; DAUBEN WG, 1967, TETRAHEDRON LETT, P1735; EICHINGER D, 1997, THESIS TU MUNCHEN; EISENREICH W, 1993, EUR J BIOCHEM, V215, P619, DOI 10.1111/j.1432-1033.1993.tb18073.x; Eisenreich W, 1997, TETRAHEDRON LETT, V38, P3889, DOI 10.1016/S0040-4039(97)00761-2; Eisenreich W, 1996, P NATL ACAD SCI USA, V93, P6431, DOI 10.1073/pnas.93.13.6431; EISENREICH W, 1991, J BIOL CHEM, V266, P9622; FUKUYAMA Y, 1988, PHYTOCHEMISTRY, V27, P1797, DOI 10.1016/0031-9422(88)80446-1; GIBSON J, 1985, SYST APPL MICROBIOL, V6, P152, DOI 10.1016/S0723-2020(85)80048-5; GODTFREDSEN S, 1977, CHIMIA, V31, P62; Grammes C, 1997, PHYTOCHEMISTRY, V44, P1495, DOI 10.1016/S0031-9422(96)00781-9; HALFEN LN, 1972, ARCH MIKROBIOL, V82, P240, DOI 10.1007/BF00412195; HAYASHI S, 1978, CHEM LETT, P953, DOI 10.1246/cl.1978.953; HEFTER J, 1993, J GEN MICROBIOL, V139, P2757, DOI 10.1099/00221287-139-11-2757; HOLO H, 1989, ARCH MICROBIOL, V151, P252, DOI 10.1007/BF00413138; JURGENS UJ, 1987, ARCH MICROBIOL, V148, P72, DOI 10.1007/BF00429651; KENYON CN, 1974, J BACTERIOL, V120, P131, DOI 10.1128/JB.120.1.131-138.1974; KNUDSEN E, 1982, ARCH MICROBIOL, V132, P149, DOI 10.1007/BF00508721; KUBO I, 1984, J ORG CHEM, V49, P4644, DOI 10.1021/jo00198a013; Lichtenthaler HK, 1997, FEBS LETT, V400, P271, DOI 10.1016/S0014-5793(96)01404-4; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MATSUO A, 1978, J CHEM SOC CHEM COMM, P198, DOI 10.1039/c39780000198; MATSUO A, 1984, Z NATURFORSCH B, V39, P1281, DOI 10.1515/znb-1984-0923; MEISSNER J, 1988, J BACTERIOL, V170, P3213, DOI 10.1128/jb.170.7.3213-3216.1988; NOZAKI H, 1998, J CHEM SOC P2, P763; OYAIZU H, 1987, SYST APPL MICROBIOL, V9, P47, DOI 10.1016/S0723-2020(87)80055-3; Rohmer M, 1996, J AM CHEM SOC, V118, P2564, DOI 10.1021/ja9538344; ROHMER M, 1993, BIOCHEM J, V295, P517, DOI 10.1042/bj2950517; Schwarz M, 1994, THESIS EIDGENOSSISCH; Schwender J, 1996, BIOCHEM J, V316, P73, DOI 10.1042/bj3160073; STONE KJ, 1969, J CHEM SOC CHEM COMM, P530, DOI 10.1039/c29690000530; STRAUSS G, 1992, EUR J BIOCHEM, V205, P853, DOI 10.1111/j.1432-1033.1992.tb16850.x; TAKAOKA D, 1979, J CHEM SOC PERK T 1, P2711, DOI 10.1039/p19790002711; TAKAOKA D, 1983, PHYTOCHEMISTRY, V22, P1653, DOI 10.1016/0031-9422(83)80103-4; Tanaka J, 1997, CHEM LETT, P489, DOI 10.1246/cl.1997.489; WOESE CR, 1987, MICROBIOL REV, V51, P227	44	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18099	18108		10.1074/jbc.273.29.18099	http://dx.doi.org/10.1074/jbc.273.29.18099			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660767	hybrid			2022-12-25	WOS:000074828500022
J	Sells, MA; Barratt, JT; Caviston, J; Ottilie, S; Leberer, E; Chernoff, J				Sells, MA; Barratt, JT; Caviston, J; Ottilie, S; Leberer, E; Chernoff, J			Characterization of Pak2p, a pleckstrin homology domain-containing, p21-activated protein kinase from fission yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; ACTIN POLYMERIZATION; CELL-GROWTH; JUN KINASE; PH DOMAIN; PATHWAY; CDC42; STE20; ACTIVATION	p21-activated kinases (PAKs) bind to and are activated by Rho family GTPases such as Cdc42 and Rac. Since these GTPases play key roles in regulating cell polarity, stress responses, and cell cycle progression, the ability of PAK to affect these processes has been examined, me previously showed that fission yeast pak1(+) encodes an essential protein that affects mating and cell polarity. Here, we characterize a second pak gene (pak2(+)) from Schizosaccharomyces pombe. Like the Saccharomyces cerevisiae proteins Cla4p and Skm1p, fission yeast Pak2p contains an N-terminal pleckstrin homology domain in addition to a pal-binding domain and a protein kinase domain that are common to other members of the PAK family. Unlike pak1(+), pak2+ is not essential for vegetative growth or for mating in S. pombe. Overexpression of the wild-type pak2(+) allele suppresses the lethal growth defect associated with deletion of pak1(+), and this suppression requires both the pleckstrin homology- and the pll-binding domains of Pak2p, as well as kinase activity. A substantial fraction of Pak2p is associated with membranous components, an association mediated both by the pleckstrin homology- and by the pal-binding domains. These results show that S. pombe encodes at least two pak genes with distinct functions and suggest that the membrane localization of Pak2p, directed by its interactions with membrane lipids and Cdc42p, is critical to its biological activity.	Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; Idun Pharmaceut, San Diego, CA 92121 USA; Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada	Fox Chase Cancer Center; National Research Council Canada	Chernoff, J (corresponding author), Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA.	J_Chernoff@fccc.edu	Chernoff, Jonathan/I-7631-2014	Chernoff, Jonathan/0000-0002-4803-7836				AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Benton BK, 1997, MOL CELL BIOL, V17, P5067, DOI 10.1128/MCB.17.9.5067; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; FORSBURG SL, 1993, NUCLEIC ACIDS RES, V21, P2955, DOI 10.1093/nar/21.12.2955; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; GRIMM C, 1988, MOL GEN GENET, V215, P81, DOI 10.1007/BF00331307; Gutz H., 1974, HDB GENETICS, V1, P395; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LEBERER E, 1992, EMBO J, V11, P4805, DOI 10.1002/j.1460-2075.1992.tb05586.x; Leberer E, 1997, EMBO J, V16, P83, DOI 10.1093/emboj/16.1.83; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LEHRACH H, 1990, GENETIC PHYSICAL MAP, V1; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MARCUS S, 1995, P NATL ACAD SCI USA, V92, P6180, DOI 10.1073/pnas.92.13.6180; Martin H, 1997, MOL MICROBIOL, V23, P431, DOI 10.1046/j.1365-2958.1997.d01-1870.x; MILLER PJ, 1994, MOL CELL BIOL, V14, P1075, DOI 10.1128/MCB.14.2.1075; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; OTTILIE S, 1995, EMBO J, V14, P5908, DOI 10.1002/j.1460-2075.1995.tb00278.x; Peter M, 1996, EMBO J, V15, P7046, DOI 10.1002/j.1460-2075.1996.tb01096.x; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; Rose M. D., 1990, METHODS YEAST GENETI, P155; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; SELLS MA, 1995, GENE, V152, P187, DOI 10.1016/0378-1119(94)00685-L; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; VanAelst L, 1996, EMBO J, V15, P3778, DOI 10.1002/j.1460-2075.1996.tb00751.x; WU CL, 1995, J BIOL CHEM, V270, P15984, DOI 10.1074/jbc.270.27.15984; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	38	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18490	18498		10.1074/jbc.273.29.18490	http://dx.doi.org/10.1074/jbc.273.29.18490			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660818	hybrid			2022-12-25	WOS:000074828500073
J	Tanikawa, M; Yamada, K; Tominaga, K; Morisaki, H; Kaneko, Y; Ikeda, K; Suzuki, M; Kiho, T; Tomokiyo, K; Furuta, K; Noyori, R; Nakanishi, M				Tanikawa, M; Yamada, K; Tominaga, K; Morisaki, H; Kaneko, Y; Ikeda, K; Suzuki, M; Kiho, T; Tomokiyo, K; Furuta, K; Noyori, R; Nakanishi, M			Potent prostaglandin A(1) analogs that suppress tumor cell growth through induction of p21 and reduction of cyclin E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITOR; ANTINEOPLASTIC PROSTAGLANDINS; CDK6 INHIBITOR; LEUKEMIA-CELLS; DNA-DAMAGE; DIFFERENTIATION; EXPRESSION; ARREST; CANCER; MECHANISM	Although the cyclopentenone prostaglandin A(1) (PGA(1)) is known to arrest the cell cycle at the G(1) phase in vitro and to suppress tumor growth in vivo, its relatively weak activity limits its usefulness in cancer chemotherapy, In an attempt to develop antitumor drugs of greater potency and conspicuous biological specificity, we synthesized novel analogs based on the structure of PGA(1). Of the newly synthesized analogs, 15-epi Delta(7)-PGA(1), methyl ester (NAG-0092), 12-iso-Delta(7)-PGA(1), methyl ester (NAG-0093), and ent-Delta(7)-PGA(1), methyl ester (NAG-0022) possess a cross conjugated dienone structure around the five-member ring with unnatural configurations at C(12) and/or C(15) and were found to be far more potent than native PGA(1) in inhibiting cell growth and causing G(1) arrest in A172 human glioma cells. These three analogs induced the expression of p21 at both RNA and protein levels in a time- and dose-dependent fashion. Kinase assays with A172 cells treated with these analogs revealed that both cyclin A- and E-dependent kinase activities were markedly reduced, although cyclin D1-dependent kinase activity was unaffected. Immunoprecipitation-Western blot analysis showed that the decrease in cyclin A-dependent kinase activity was due to an increased association of p21 with cyclin A-cyclin-dependent kinase 2 complexes, whereas the decrease in cyclin E-dependent activity was due to a combined mechanism involving reduction in cyclin E protein itself and increased association of p21. Thus, these newly synthesized PGA(1) analogs may prove to be powerful tools in cancer chemotherapy as well as in investigations of the structural basis of the antiproliferative activity of A series prostaglandins.	Natl Inst Longev Sci, Dept Geriatr Res, Aichi 474, Japan; Nagoya City Univ, Sch Med, Dept Neurosurg, Nagoya, Aichi 467, Japan; Gifu Univ, Fac Engn, Dept Biomol Sci, Gifu 50111, Japan; Nagoya Univ, Dept Chem, Chikusa Ku, Nagoya, Aichi 46401, Japan; Nagoya Univ, Mol Chiral Res Unit, Chikusa Ku, Nagoya, Aichi 46401, Japan	Nagoya City University; Gifu University; Nagoya University; Nagoya University	Nakanishi, M (corresponding author), Natl Inst Longev Sci, Dept Geriatr Res, 36-3 Gengo,Morioka Cho, Aichi 474, Japan.	mnakani@nils.go.jp	Tominaga, Kaoru/AAL-4250-2020	Tominaga, Kaoru/0000-0001-8799-528X				Akimaru K, 1997, ADV EXP MED BIOL, V407, P387; BREGMAN MD, 1986, CANCER RES, V46, P2740; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FUKUSHIMA M, 1994, ANN NY ACAD SCI, V744, P161, DOI 10.1111/j.1749-6632.1994.tb52733.x; FUKUSHIMA M, 1990, EICOSANOIDS, V3, P189; Gorospe M, 1996, CANCER RES, V56, P475; Gorospe M, 1996, MOL CELL BIOL, V16, P762; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V74, P1009; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Hitomi M, 1996, J BIOL CHEM, V271, P9376, DOI 10.1074/jbc.271.16.9376; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; ISHIKAWA T, 1993, J BIOL CHEM, V268, P20116; JIANG HP, 1994, ONCOGENE, V9, P3397; KIKUCHI Y, 1992, J CANCER RES CLIN, V118, P453, DOI 10.1007/BF01629429; KIKUCHI Y, 1992, INT J IMMUNOPHARMACO, V14, P105; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MICHIELI P, 1994, CANCER RES, V54, P3391; NAKANISHI M, 1995, P NATL ACAD SCI USA, V92, P4352, DOI 10.1073/pnas.92.10.4352; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NARUMIYA S, 1987, J PHARMACOL EXP THER, V242, P306; NARUMIYA S, 1986, J PHARMACOL EXP THER, V239, P500; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OHNO K, 1986, BIOCHEM BIOPH RES CO, V139, P808, DOI 10.1016/S0006-291X(86)80062-6; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; SANTORO MG, 1986, CANCER RES, V46, P6073; SASAKI H, 1994, ANTI-CANCER DRUG, V5, P131, DOI 10.1097/00001813-199404000-00002; SASAKI H, 1991, GYNECOL ONCOL, V41, P36, DOI 10.1016/0090-8258(91)90251-Y; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Suzuki M, 1997, J AM CHEM SOC, V119, P2376, DOI 10.1021/ja9628359; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975	50	47	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18522	18527		10.1074/jbc.273.29.18522	http://dx.doi.org/10.1074/jbc.273.29.18522			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660822	hybrid			2022-12-25	WOS:000074828500077
J	Wong, P; Burgess, WH				Wong, P; Burgess, WH			FGF2-heparin co-crystal complex-assisted design of mutants FGF1 and FGF7 with predictable heparin affinities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; SITE-DIRECTED MUTAGENESIS; FACTOR FAMILY; FACTOR-I; ENDOTHELIAL-CELLS; FACTOR RECEPTORS; ACIDIC FGF; BINDING; EXPRESSION; INVITRO	The co-crystal structures of FGF2 and heparin derived tetra- and hexasaccharides demonstrated the existence of high and low affinity contact residues that are likely to be involved in heparin binding (Faham, S., Hileman, R, E., Fromm, J. R., Linhardt, R. J., and Rees, D. C. (1996) Science 271, 1116-1120), To study the role of these putative contact residues, me chose three fibroblast growth factor family members with distinct heparin affinities for comparative mutagenesis studies. Only one amino acid significantly differed between FGF1 and FGF2 and was mutated, FGF1-31K. FGF7, also called keratinocyte growth factor, was mutated to mimic either FGF1 or FGF2 at two of the putative high contact points termed FGF7-1 and FGF7-2, respectively, FGF2 has higher apparent heparin affinity than FGF1 or FGF7, and FGF1 has higher heparin affinity than FGF7, All three mutants showed an increase in apparent heparin affinity compared with wild types, FGF7-1 has a lower apparent heparin affinity than FGF7-2, analogous to wild type FGF1 and FGF2, The FGF1-31K mutant showed no change in mitogenic activity, whereas the FGF7 mutants exhibited a decrease in activity, These results indicate that the co-crystal structure of the FGF2-heparin complexes can be used to design a rational approach to the generation of mutants with defined affinities for heparin or heparan sulfate proteoglycans.	Amer Red Cross, Jerome H Holland Lab, Dept Tissue Biol, Rockville, MD 20855 USA; George Washington Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20037 USA; George Washington Univ, Med Ctr, Inst Biomed Sci, Washington, DC 20037 USA	American Red Cross; George Washington University; George Washington University	Burgess, WH (corresponding author), Amer Red Cross, Jerome H Holland Lab, Dept Tissue Biol, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.							AARONSON SA, 1991, ANN NY ACAD SCI, V638, P62, DOI 10.1111/j.1749-6632.1991.tb49018.x; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; BURGESS WH, 1994, MOL REPROD DEV, V39, P56, DOI 10.1002/mrd.1080390110; BURGESS WH, 1991, J CELL BIOCHEM, V45, P131, DOI 10.1002/jcb.240450203; BURGESS WH, 1990, J CELL BIOL, V111, P2129, DOI 10.1083/jcb.111.5.2129; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Fromm JR, 1997, ARCH BIOCHEM BIOPHYS, V346, P252, DOI 10.1006/abbi.1997.0299; FROMM JR, 1995, ARCH BIOCHEM BIOPHYS, V323, P279, DOI 10.1006/abbi.1995.9963; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; HARPER JW, 1988, BIOCHEMISTRY-US, V27, P671, DOI 10.1021/bi00402a027; Herr AB, 1997, J BIOL CHEM, V272, P16382, DOI 10.1074/jbc.272.26.16382; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; KAPLOW JM, 1990, BIOCHEM BIOPH RES CO, V172, P107, DOI 10.1016/S0006-291X(05)80179-2; KIMBALL ES, 1988, CELL IMMUNOL, V113, P341, DOI 10.1016/0008-8749(88)90032-9; Krufka A, 1996, BIOCHEMISTRY-US, V35, P11131, DOI 10.1021/bi960125+; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOBB RR, 1988, BIOCHEMISTRY-US, V27, P2572, DOI 10.1021/bi00407a045; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MUELLER SN, 1989, J CELL PHYSIOL, V140, P439, DOI 10.1002/jcp.1041400306; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; ROGHANI M, 1992, J BIOL CHEM, V267, P22156; RON D, 1993, J BIOL CHEM, V268, P2984; ROSENGART TK, 1988, BIOCHEM BIOPH RES CO, V152, P432, DOI 10.1016/S0006-291X(88)80732-0; RUSNATI M, 1993, J CELL PHYSIOL, V154, P152, DOI 10.1002/jcp.1041540119; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHREIBER AB, 1985, P NATL ACAD SCI USA, V82, P6138, DOI 10.1073/pnas.82.18.6138; STRAIN AJ, 1994, EXP CELL RES, V210, P253, DOI 10.1006/excr.1994.1037; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WONG P, 1995, J BIOL CHEM, V270, P25805, DOI 10.1074/jbc.270.43.25805; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	37	6	8	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18617	18622		10.1074/jbc.273.29.18617	http://dx.doi.org/10.1074/jbc.273.29.18617			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660835	hybrid			2022-12-25	WOS:000074828500090
J	Zhang, JW; Parra, KJ; Liu, JZ; Kane, PM				Zhang, JW; Parra, KJ; Liu, JZ; Kane, PM			Characterization of a temperature-sensitive yeast vacuolar ATPase mutant with defects in actin distribution and bud morphology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; MEMBRANE H+-ATPASE; CELL-CYCLE CONTROL; SACCHAROMYCES-CEREVISIAE; INTRACELLULAR PH; GENE ENCODES; NEUROSPORA-CRASSA; CDC24 GENE; SUBUNIT; CALCIUM	The 27-kDa E subunit, encoded by the VMA4 gene, is a peripheral membrane subunit of the yeast vacuolar H+ - ATPase. We hare randomly mutagenized the VMA4 gene in order to examine the structure and function of the 27-kDa subunit. Cells lacking a functional VMA4 gene are unable to grow at pH > 7 or in elevated concentrations of CaCl2. Plasmid-borne, mutagenized vma4 genes were screened for failure to complement these phenotypes. Mutants producing Vma4 proteins detectable by immunoblot were selected; one (vma4-1(ts)) is temperature conditional, exhibiting the Vma(-) phenotype only at elevated temperature (37 degrees C). Sequencing revealed that a single point mutation, D145G, was responsible for the phenotypes of the vma4-1(ts) allele. The unassembled 27-kDa subunit made in the vma4-1(ts) cells is rapidly degraded, particularly at 37 degrees C, but can be protected from degradation by prior assembly into the V-ATPase complex. In purified vacuolar resides from the mutant cells, the peripheral subunits are localized to the vacuolar membrane at decreased levels and a comparably decreased level of ATPase activity (14% of the activity in wild-type vesicles) is observed. When vma4-1(ts) mutant cells are shifted to pH 7.5 medium at 37 degrees C, the cells become enlarged and exhibit multiple large buds, elongated buds, and other abnormal morphologies, together with delocalization of actin and chitin, within 4 h. These phenotypes suggest connections between the vacuolar ATPase, bud morphology, and cytokinesis that had not been recognized previously.	SUNY Hlth Sci Ctr, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Kane, PM (corresponding author), SUNY Hlth Sci Ctr, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA.	kanepm@hscsyr.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050322] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM50322, R01 GM050322] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; ANRAKU Y, 1991, BIOCHIM BIOPHYS ACTA, V1093, P169, DOI 10.1016/0167-4889(91)90119-I; ANRAKU Y, 1992, J BIOENERG BIOMEMBR, V24, P395, DOI 10.1007/BF00762532; BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; BOWMAN EJ, 1995, BBA-BIOMEMBRANES, V1237, P95, DOI 10.1016/0005-2736(95)00108-F; Bowman EJ, 1997, J BIOL CHEM, V272, P14776, DOI 10.1074/jbc.272.23.14776; BUSA WB, 1984, AM J PHYSIOL, V246, pR409, DOI 10.1152/ajpregu.1984.246.4.R409; Chant J, 1991, CURR OPIN GENET DEV, V1, P342, DOI 10.1016/S0959-437X(05)80298-9; Davies SA, 1996, J BIOL CHEM, V271, P30677, DOI 10.1074/jbc.271.48.30677; DENHOLLANDER JA, 1981, BIOCHEMISTRY-US, V20, P5871, DOI 10.1021/bi00523a034; Dietz KJ, 1996, BBA-BIOMEMBRANES, V1281, P134, DOI 10.1016/0005-2736(96)00044-2; DOHERTY RD, 1993, J BIOL CHEM, V268, P16845; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; DRUBIN DG, 1993, MOL BIOL CELL, V4, P1277, DOI 10.1091/mbc.4.12.1277; EDMONDS BT, 1995, J BIOL CHEM, V270, P15222, DOI 10.1074/jbc.270.25.15222; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; Ferea TL, 1996, GENETICS, V143, P147; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; Forgac M, 1996, SOC GEN PHY, V51, P121; FOURY F, 1990, J BIOL CHEM, V265, P18554; GILLIES RJ, 1981, P NATL ACAD SCI-BIOL, V78, P2125, DOI 10.1073/pnas.78.4.2125; GILLIES RJ, 1990, P NATL ACAD SCI USA, V87, P7414, DOI 10.1073/pnas.87.19.7414; Greener A., 1994, STRATEGIES, V7, P32; GREER C, 1982, MOL CELL BIOL, V2, P1279, DOI 10.1128/MCB.2.10.1279; Guo YQ, 1996, BBA-BIOMEMBRANES, V1283, P4, DOI 10.1016/0005-2736(96)00103-4; HALACHMI D, 1993, FEBS LETT, V316, P73, DOI 10.1016/0014-5793(93)81739-M; HO MN, 1993, J BIOL CHEM, V268, P221; HOLTZMAN DA, 1993, J CELL BIOL, V122, P635, DOI 10.1083/jcb.122.3.635; IIDA H, 1990, J BIOL CHEM, V265, P21216; KANE PM, 1989, J BIOL CHEM, V264, P19236; KANE PM, 1995, J BIOL CHEM, V270, P17025; KANE PM, 1992, J BIOENERG BIOMEMBR, V24, P383, DOI 10.1007/BF00762531; KANEKO R, 1991, ADV INFO STORAGE SYS, V1, P267; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KLIONSKY DJ, 1992, J BIOL CHEM, V267, P3416; LEW DJ, 1995, CURR OPIN GENET DEV, V5, P17, DOI 10.1016/S0959-437X(95)90048-9; Liu JZ, 1996, BIOCHEMISTRY-US, V35, P10938, DOI 10.1021/bi9608065; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4128, DOI 10.1021/bi00313a018; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; MCCUSKER JH, 1987, MOL CELL BIOL, V7, P4082, DOI 10.1128/MCB.7.11.4082; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MIYAMOTO S, 1987, GENE, V54, P125, DOI 10.1016/0378-1119(87)90354-4; MORANO KA, 1994, J CELL SCI, V107, P2813; MUNN AL, 1994, J CELL BIOL, V127, P373, DOI 10.1083/jcb.127.2.373; Murray JW, 1996, J CELL BIOL, V135, P1309, DOI 10.1083/jcb.135.5.1309; NASMYTH KA, 1980, P NATL ACAD SCI-BIOL, V77, P2119, DOI 10.1073/pnas.77.4.2119; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; OHSUMI Y, 1983, J BIOL CHEM, V258, P5614; OHYA Y, 1991, J BIOL CHEM, V266, P13971; Oluwatosin YE, 1998, MOL CELL BIOL, V18, P1534, DOI 10.1128/MCB.18.3.1534; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHERMAN F, 1982, METHODS YEAST GENETI, P177; SIKORSKI RS, 1989, GENETICS, V122, P19; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; STEVENS TH, 1986, J CELL BIOL, V102, P1551, DOI 10.1083/jcb.102.5.1551; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Temesvari LA, 1996, J CELL SCI, V109, P1479; VALLEJO CG, 1989, YEAST, V5, P307, DOI 10.1002/yea.320050411; Vexler ZS, 1996, J BIOL CHEM, V271, P22281, DOI 10.1074/jbc.271.37.22281; White WH, 1997, GENETICS, V147, P43; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737	70	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18470	18480		10.1074/jbc.273.29.18470	http://dx.doi.org/10.1074/jbc.273.29.18470			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660816	hybrid			2022-12-25	WOS:000074828500071
J	Goodman, PA; Niehoff, LB; Uckun, FM				Goodman, PA; Niehoff, LB; Uckun, FM			Role of tyrosine kinases in induction of the c-jun proto-oncogene in irradiated B-lineage lymphoid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR SUBSTRATE-1; MYELOID-LEUKEMIA CELLS; MICE LACKING JAK3; TRANSCRIPTIONAL REGULATION; ACTIVATION DOMAIN; INDUCED APOPTOSIS; PRECURSOR CELLS; RADIATION; PHOSPHORYLATION; SEQUENCE	Exposure of B-lineage lymphoid cells to ionizing radiation induces an elevation of c-jun proto-oncogene mRNA levels. This signal is abrogated by protein-tyrosine kinase (PTK) inhibitors, indicating that activation of an as yet unidentified PTK is mandatory for radiation-induced c-jun expression. Here, we provide experimental evidence that the cytoplasmic tyrosine kinases BTK, SYK, and LYN are not required for this signal. Lymphoma B-cells rendered deficient for LYN, SYK, or both by targeted gene disruption showed increased c-jun expression levels after radiation exposure, but the magnitude of the stimulation was lower than in wild-type cells. Thus, these PTKs may participate in the generation of an optimal signal. Notably, an inhibitor of JAK-3 (Janus family kinase-3) abrogated radiation-induced c-jun activation, prompting the hypothesis that a chicken homologue of JAK-3 may play a key role in initiation of the radiation-induced c-jun signal in B-lineage lymphoid cells.	Wayne Hughes Inst, Dept Mol Oncol, St Paul, MN 55113 USA; Wayne Hughes Inst, Dept Mol Genet, St Paul, MN 55113 USA		Uckun, FM (corresponding author), Wayne Hughes Inst, Dept Mol Oncol, 2665 Long Lake Rd, St Paul, MN 55113 USA.	fatih_uckun@mercury.ih.org		Uckun, Fatih M./0000-0001-9334-183X				ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; AOKI Y, 1994, P NATL ACAD SCI USA, V91, P10606, DOI 10.1073/pnas.91.22.10606; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CHAE HP, 1993, CANCER RES, V53, P447; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLATA F, 1992, J BIOL CHEM, V267, P18278; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; Demoulin JB, 1996, MOL CELL BIOL, V16, P4710; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dibirdik I, 1998, J BIOL CHEM, V273, P4035, DOI 10.1074/jbc.273.7.4035; Dosch J, 1996, ONCOGENE, V13, P1927; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Fusaki N, 1997, J BIOL CHEM, V272, P6214, DOI 10.1074/jbc.272.10.6214; Gurniak CB, 1996, BLOOD, V87, P3151, DOI 10.1182/blood.V87.8.3151.bloodjournal8783151; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Hanissian SH, 1997, IMMUNITY, V6, P379, DOI 10.1016/S1074-7613(00)80281-2; Haque SJ, 1997, P NATL ACAD SCI USA, V94, P8563, DOI 10.1073/pnas.94.16.8563; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hoffman SMG, 1997, GENOMICS, V43, P109, DOI 10.1006/geno.1997.4792; Ihle JN, 1996, PHILOS T R SOC B, V351, P159, DOI 10.1098/rstb.1996.0012; Ihle JN, 1996, BIOESSAYS, V18, P95, DOI 10.1002/bies.950180204; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; Jugloff LS, 1997, J IMMUNOL, V159, P1096; Kaneko S, 1997, CLIN EXP IMMUNOL, V109, P185, DOI 10.1046/j.1365-2249.1997.4191324.x; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KHARBANDA SM, 1990, J CLIN INVEST, V86, P1517, DOI 10.1172/JCI114870; Kumar A, 1996, ONCOGENE, V13, P2009; KUROSAKI T, 1995, J EXP MED, V182, P1815, DOI 10.1084/jem.182.6.1815; Kurosaki T, 1997, CURR OPIN IMMUNOL, V9, P309, DOI 10.1016/S0952-7915(97)80075-1; LARNER AC, 1984, P NATL ACAD SCI-BIOL, V81, P6733, DOI 10.1073/pnas.81.21.6733; LARNER AC, 1986, J BIOL CHEM, V261, P453; LAW DA, 1993, CURR BIOL, V3, P645, DOI 10.1016/0960-9822(93)90062-S; Leonard WJ, 1996, NAT MED, V2, P968, DOI 10.1038/nm0996-968; Levy David E., 1997, Cytokine and Growth Factor Reviews, V8, P81, DOI 10.1016/S1359-6101(96)00054-8; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; MYERS DE, 1995, P NATL ACAD SCI USA, V92, P9575, DOI 10.1073/pnas.92.21.9575; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; NOMOTO Y, 1990, CHEM PHARM BULL, V38, P1591; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; Qin SF, 1997, J BIOL CHEM, V272, P2098; Rathbun RK, 1997, BLOOD, V90, P974, DOI 10.1182/blood.V90.3.974.974_974_985; Riedy MC, 1996, GENOMICS, V37, P57, DOI 10.1006/geno.1996.0520; ROLLING C, 1995, ONCOGENE, V10, P1757; Rolling C, 1996, FEBS LETT, V393, P53, DOI 10.1016/0014-5793(96)00835-6; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; RUBIN E, 1991, MOL PHARMACOL, V39, P697; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; Safford MG, 1997, EXP HEMATOL, V25, P374; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; Sharfe N, 1997, J IMMUNOL, V159, P1107; Sharfe N, 1997, CLIN EXP IMMUNOL, V108, P552, DOI 10.1046/j.1365-2249.1997.4001304.x; TAKATA M, 1995, J EXP MED, V182, P907, DOI 10.1084/jem.182.4.907; Thomas C.L.M., 1970, CATALYTIC PROCESSES; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; TORTOLANI PJ, 1995, J IMMUNOL, V155, P5220; TuelAhlgren L, 1996, LEUKEMIA LYMPHOMA, V20, P417, DOI 10.3109/10428199609052423; UCKUN FM, 1995, SCIENCE, V267, P886, DOI 10.1126/science.7531365; UCKUN FM, 1993, J CLIN INVEST, V91, P1044, DOI 10.1172/JCI116261; Uckun FM, 1996, SCIENCE, V273, P1096, DOI 10.1126/science.273.5278.1096; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WITTHUHN B, 1998, IN PRESS LEUK LYMPHO; YIN TG, 1995, J BIOL CHEM, V270, P20497, DOI 10.1074/jbc.270.35.20497	67	55	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17742	17748		10.1074/jbc.273.28.17742	http://dx.doi.org/10.1074/jbc.273.28.17742			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651374	hybrid			2022-12-25	WOS:000074816100067
J	Ilic, MZ; Robinson, HC; Handley, CJ				Ilic, MZ; Robinson, HC; Handley, CJ			Characterization of aggrecan retained and lost from the extracellular matrix of articular cartilage - Involvement of carboxyl-terminal processing in the catabolism of aggrecan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN CORE; PROTEOGLYCAN; CLEAVAGE; CULTURES; SEQUENCE; FRAGMENTS; DOMAIN; IDENTIFICATION; BIOSYNTHESIS; DEGRADATION	The catabolism of aggrecan in bovine articular cartilage explants is characterized by the release into the culture medium of high molecular weight aggrecan fragments, generated by the proteolytic cleavage of the core protein between residues Glu(373) and Ala(374) within the interglobular domain. In this study, the position of the carboxyl-terminus of these aggrecan fragments, as well as a major proteolytically shortened aggrecan core protein present in cartilage matrix, have been deduced by characterizing the peptides generated by the reaction of aggrecan core protein peptides with cyanogen bromide. It was shown that two out of three such peptide fragments having an amino terminus starting at Ala(374) have their carboxyl terminus located within the chondroitin sulfate 1 domain. The third and largest aggrecan core protein peptide, with an amino terminus starting at Ala(374), has a carboxyl terminus in a region of core protein between the chondroitin sulfate 1 domain and the chondroitin sulfate 2 domain. The carboxyl terminus of this peptide appeared to be the same as that of the proteolytically degraded aggrecan core protein, which is retained within the extracellular matrix of the tissue. Another two aggrecan fragments recovered from the medium of explant cultures with amino-terminal sequences in the chondroitin sulfate 2 domain at Ala(1772) and Leu(1872) were shown to have their carboxyl termini within the G3 globular domain. These results suggest that the catabolism of aggrecan between residues Glu(373) and Ala(374) in the interglobular domain by the putative proteinase, aggrecanase, may be dependent on prior proteolytic processing within the carboxyl-terminal region of the core protein.	La Trobe Univ, Sch Human Biosci, Bundoora, Vic 3083, Australia; Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3168, Australia	La Trobe University; Monash University	Handley, CJ (corresponding author), La Trobe Univ, Sch Human Biosci, Bundoora, Vic 3083, Australia.	C.Handley@latrobe.edu.au						ANTONSSON P, 1989, J BIOL CHEM, V264, P16170; BALDWIN CT, 1989, J BIOL CHEM, V264, P15747; BAYLISS MT, 1990, SEMIN ARTHRITIS RHEU, V20, P12; BONNET F, 1983, BIOCHIM BIOPHYS ACTA, V743, P82, DOI 10.1016/0167-4838(83)90420-X; Buttle DJ, 1997, J CLIN PATHOL-MOL PA, V50, P153, DOI 10.1136/mp.50.3.153; BUTTLE DJ, 1993, ARTHRITIS RHEUM, V36, P1709, DOI 10.1002/art.1780361210; CAMPBELL MA, 1989, BIOCHEM J, V259, P21, DOI 10.1042/bj2590021; CATERSON B, 1985, FED PROC, V44, P386; FLANNERY C, 1992, ARCH BIOCHEM BIOPHYS, V297, P52, DOI 10.1016/0003-9861(92)90640-I; FOSANG AJ, 1991, J BIOL CHEM, V266, P15579; FULOP C, 1993, J BIOL CHEM, V268, P17377; HASCALL VC, 1983, ARCH BIOCHEM BIOPHYS, V224, P206, DOI 10.1016/0003-9861(83)90205-9; Hering TM, 1997, ARCH BIOCHEM BIOPHYS, V345, P259, DOI 10.1006/abbi.1997.0261; HEY NJ, 1990, BIOCHIM BIOPHYS ACTA, V1034, P73, DOI 10.1016/0304-4165(90)90155-P; ILIC MZ, 1995, ARCH BIOCHEM BIOPHYS, V322, P22, DOI 10.1006/abbi.1995.1431; ILIC MZ, 1990, BIOCHEM INT, V21, P977; ILIC MZ, 1992, ARCH BIOCHEM BIOPHYS, V294, P115, DOI 10.1016/0003-9861(92)90144-L; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHMANDER LS, 1993, ARTHRITIS RHEUM, V36, P1214; LOULAKIS P, 1992, BIOCHEM J, V284, P589, DOI 10.1042/bj2840589; MEHMET H, 1986, EUR J BIOCHEM, V157, P385, DOI 10.1111/j.1432-1033.1986.tb09680.x; MOK MT, 1992, ARCH BIOCHEM BIOPHYS, V292, P442, DOI 10.1016/0003-9861(92)90014-N; OEGEMA TR, 1984, J BIOL CHEM, V259, P1720; OIKE Y, 1980, BIOCHEM J, V191, P203, DOI 10.1042/bj1910203; OLDBERG A, 1987, BIOCHEM J, V243, P255, DOI 10.1042/bj2430255; PERIN JP, 1984, FEBS LETT, V176, P37, DOI 10.1016/0014-5793(84)80907-2; PLAAS AHK, 1993, MATRIX, V13, P135, DOI 10.1016/S0934-8832(11)80072-7; SANDY JD, 1991, J BIOL CHEM, V266, P8683	28	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17451	17458		10.1074/jbc.273.28.17451	http://dx.doi.org/10.1074/jbc.273.28.17451			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651333	hybrid			2022-12-25	WOS:000074816100026
J	Alzuherri, HM; White, RJ				Alzuherri, HM; White, RJ			Regulation of a TATA-binding protein-associated factor during cellular differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-III; TRANSCRIPTION FACTOR-TFIIIB; PROXIMAL SEQUENCE ELEMENT; HUMAN U6; GENE; SUBUNIT; COMPLEX; TBP; COMPONENT; ENCODES	RNA polymerase III transcription is down-regulated when F9 embryonal carcinoma cells differentiate into parietal endoderm. This reflects a decrease in the activity of TFIIIB, a multisubunit complex that is required for all class III gene expression. Two essential components of TFIIIB are the TATA-binding protein (TBP) and an associated polypeptide called BRF that is specific to this complex. The abundance of both TBP and BRF decreases during F9 cell differentiation. Whereas the amount of TBP assembled into TFIIIB is down-regulated, this is not the case for all TBP-containing complexes. BRF levels show a more dramatic decline that appears sufficient to account for the overall change in transcriptional activity. Developmental regulation of a specific class of genes may therefore be achieved through changes in the availability of a TBP-associated factor.	Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	White, RJ (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.							BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; KASSAVETIS GA, 1995, P NATL ACAD SCI USA, V92, P9786, DOI 10.1073/pnas.92.21.9786; KHOO B, 1994, GENE DEV, V8, P2879, DOI 10.1101/gad.8.23.2879; KOVELMAN R, 1992, J BIOL CHEM, V267, P24446; Larminie CGC, 1997, EMBO J, V16, P2061, DOI 10.1093/emboj/16.8.2061; Larminie CGC, 1998, DNA SEQUENCE, V9, P49, DOI 10.3109/10425179809050025; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MEISSNER W, 1995, MOL CELL BIOL, V15, P5888; MEYERS RE, 1993, MOL CELL BIOL, V13, P7953, DOI 10.1128/MCB.13.12.7953; Mital R, 1996, MOL CELL BIOL, V16, P7031; MURPHY D, 1983, CELL, V35, P865, DOI 10.1016/0092-8674(83)90119-8; Nothias JY, 1996, EMBO J, V15, P5715, DOI 10.1002/j.1460-2075.1996.tb00955.x; RIGBY PWJ, 1993, CELL, V72, P7, DOI 10.1016/0092-8674(93)90042-O; Roberts S, 1996, J BIOL CHEM, V271, P14903, DOI 10.1074/jbc.271.25.14903; Ruth J, 1996, EMBO J, V15, P1941, DOI 10.1002/j.1460-2075.1996.tb00545.x; Shen YH, 1996, MOL CELL BIOL, V16, P4163; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; TEICHMANN M, 1995, EMBO J, V14, P5974, DOI 10.1002/j.1460-2075.1995.tb00286.x; VASSEUR M, 1985, EMBO J, V4, P1749, DOI 10.1002/j.1460-2075.1985.tb03846.x; WANG ZX, 1995, P NATL ACAD SCI USA, V92, P7026, DOI 10.1073/pnas.92.15.7026; White R. J., 1998, RNA POLYMERASE 3 TRA; WHITE RJ, 1992, CELL, V71, P1041, DOI 10.1016/0092-8674(92)90398-V; WHITE RJ, 1989, CELL, V59, P1081, DOI 10.1016/0092-8674(89)90764-2; WHITE RJ, 1995, MOL CELL BIOL, V15, P6653; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; WHITE RJ, 1995, MOL CELL BIOL, V15, P1983; YOON JB, 1995, MOL CELL BIOL, V15, P2019	34	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17166	17171		10.1074/jbc.273.27.17166	http://dx.doi.org/10.1074/jbc.273.27.17166			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642284	hybrid			2022-12-25	WOS:000074545200074
J	Pesche, S; Latil, A; Muzeau, F; Cussenot, O; Fournier, G; Longy, M; Eng, C; Lidereau, R				Pesche, S; Latil, A; Muzeau, F; Cussenot, O; Fournier, G; Longy, M; Eng, C; Lidereau, R			PTEN/MMAC1/TEP1 involvement in primary prostate cancers	ONCOGENE			English	Article						prostate cancer; chromosome arm 10q; LOH; PTEN	ALLELIC LOSS; MICROSATELLITE INSTABILITY; DISTINCT REGIONS; CHROMOSOME-10; HETEROZYGOSITY; DELETION; LOCI; GENE; PROGRESSION; ADENOCARCINOMA	The PTEN/MMAC1/TEP1 gene, located at 10q23.3, is a tumor suppressor gene responsible for the familial cancer syndromes Cowden disease and Bannayan-Zonana syndrome, and is commonly somatically mutated in several types of cancers. Mutations of the PTEN gene have been found in prostate cancer cell lines and LOH at 10q22-24 in prostate tumors have also been described with a high frequency. To determine the role of this gene in prostate tumorigenesis, we therefore analysed 22 primary tumors for loss of heterozygosity (LOH) within the 10q22-23 region such that tumors hemizygous at those loci may be examined for somatic PTEN mutations. Losses of heterozygosity of at least one locus was found in 12 (55%) of the 22 tumors DNAs. Among these, six tumors exhibited allele loss in the interval between D10S1765 and D10S541 wherein lies the PTEN gene. We searched the entire coding region of PTEN for somatic mutations in these six tumors. One somatic mutation (17%), a 1 bp deletion, was detected in exon 7 of the gene, in ode tumor, indicating that somatic mutations of the PTEN gene may occur in primary prostate tumors.	Ctr Rene Huguenin, Lab Oncogenet, F-92211 St Cloud, France; CHU St Louis, Dept Urol, F-75010 Paris, France; Hop Cavale Blanche, Dept Urol, F-29609 Brest, France; Ctr Reg Lutte Canc, Inst Bergonie, F-33076 Bordeaux, France; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Univ Cambridge, CRC, Human Canc Genet Res Grp, Cambridge CB2 2QQ, England	Rene Huguenin Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Brest; Universite de Bretagne Occidentale; UNICANCER; Institut Bergonie; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Cambridge	Lidereau, R (corresponding author), Ctr Rene Huguenin, Lab Oncogenet, 9 Rue Gaston Latouche, F-92211 St Cloud, France.			Eng, Charis/0000-0002-3693-5145; cussenot, olivier/0000-0002-9912-0533				ALBRECHT S, 1992, CANCER-AM CANCER SOC, V70, P869, DOI 10.1002/1097-0142(19920815)70:4<869::AID-CNCR2820700424>3.0.CO;2-E; BERGERHEIM USR, 1991, GENE CHROMOSOME CANC, V3, P215, DOI 10.1002/gcc.2870030308; BOVA GS, 1993, CANCER RES, V53, P3869; CAIRNS P, 1994, CANCER RES, V54, P1422; Cairns P, 1997, CANCER RES, V57, P4997; Cappellen D, 1997, ONCOGENE, V14, P3059, DOI 10.1038/sj.onc.1201154; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Cooney KA, 1996, CANCER RES, V56, P1142; DAHIA PLM, IN PRESS CANC RES; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249; GAO X, 1995, CANCER RES, V55, P1002; GRAY IC, 1995, CANCER RES, V55, P4800; Guldberg P, 1997, CANCER RES, V57, P3660; HERBST RA, 1994, CANCER RES, V54, P3111; HUDSON TJ, 1992, GENOMICS, V13, P622, DOI 10.1016/0888-7543(92)90133-D; Ittmann M, 1996, CANCER RES, V56, P2143; KARLBOM AE, 1993, HUM GENET, V92, P169; Komiya A, 1996, GENE CHROMOSOME CANC, V17, P245; KUNIMI K, 1991, GENOMICS, V11, P530, DOI 10.1016/0888-7543(91)90059-N; Lacombe L, 1996, INT J CANCER, V69, P110, DOI 10.1002/(SICI)1097-0215(19960422)69:2<110::AID-IJC7>3.0.CO;2-3; LATIL A, 1994, GENE CHROMOSOME CANC, V11, P119, DOI 10.1002/gcc.2870110208; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; MACGROGAN D, 1994, GENE CHROMOSOME CANC, V10, P151, DOI 10.1002/gcc.2870100302; Marsh DJ, 1997, CANCER RES, V57, P500; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; MELLINGER GT, 1967, J UROLOGY, V97, P331, DOI 10.1016/S0022-5347(17)63039-8; MORITA R, 1991, CANCER RES, V51, P5817; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Nelen MR, 1996, NAT GENET, V13, P114, DOI 10.1038/ng0596-114; Nelen MR, 1997, HUM MOL GENET, V6, P1383, DOI 10.1093/hmg/6.8.1383; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; PEIFFER SL, 1995, CANCER RES, V55, P1922; PHILLIPS SMA, 1994, BRIT J UROL, V73, P390, DOI 10.1111/j.1464-410X.1994.tb07602.x; REMPEL SA, 1993, CANCER RES, V53, P2386; Rhei E, 1997, CANCER RES, V57, P3657; SCHRODER FH, 1992, PROSTATE, P129; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki H, 1998, CANCER RES, V58, P204; Tashiro H, 1997, CANCER RES, V57, P3935; Trybus TM, 1996, CANCER RES, V56, P2263; WATANABE M, 1995, BRIT J CANCER, V72, P562, DOI 10.1038/bjc.1995.374; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370	46	114	121	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 4	1998	16	22					2879	2883		10.1038/sj.onc.1202081	http://dx.doi.org/10.1038/sj.onc.1202081			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZR544	9671408				2022-12-25	WOS:000073988200006
J	Gerik, KJ; Li, XY; Pautz, A; Burgers, PMJ				Gerik, KJ; Li, XY; Pautz, A; Burgers, PMJ			Characterization of the two small subunits of Saccharomyces cerevisiae DNA polymerase delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; POLYACRYLAMIDE-GEL ELECTROPHORESIS; C-TERMINAL REGION; REPLICATION FORK; CDC2 GENE; YEAST; PROTEIN; REPAIR; BINDING; SEPARATION	Yeast DNA polymerase delta (Pol delta) has three subunits of 125, 58, and 55 kDa, The gene for the 125-kDa catalytic subunit (POL3) has been known for several years. Here we describe the cloning of the genes for the 58- and 55-kDa subunits using peptide sequence analysis and searching of the yeast genome data base, The 58-kDa subunit, encoded by the POL31 gene, shows 23-28% sequence similarity to the 48-kDa subunit of:human PoL delta and to S. pombe Cdc1. POL31 is allelic to HYS2 and SDP5. The 55-kDa subunit is encoded by the POL32 gene (ORF YJR043c in the yeast data base). Very limited sequence similarity was observed between Pol32p and Schizosaccharomyces pombe Cdc27, the functionally analogous subunit in S. pombe Pol delta. The POL32 gene is not essential, but a deletion mutant shows cold sensitivity for growth and is sensitive to hydroxyurea and DNA damaging agents. in addition, lethality was observed when the POL32 deletion mutation was combined with conditional mutations in either the POL3 or POL31 gene. Pol32 Delta strains are weak antimutators and are defective for damage-induced mutagenesis. The POL32 gene product binds proliferating cell nuclear antigen. A gel filtration analysis showed that Pol32p is a dimer in solution, When POL31 and POL32 were co-expressed in Escherichia coli, a tetrameric (Pol31p.Pol32p)(2) species was detected by gel filtration, indicating that the two subunits form a complex.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Burgers, PMJ (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA.		Burgers, Peter M/AAW-6621-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032431] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32431, R01 GM032431] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGUILERA A, 1988, GENETICS, V119, P779; AYYAGARI R, 1995, MOL CELL BIOL, V15, P4420; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BAUER GA, 1988, P NATL ACAD SCI USA, V85, P7506, DOI 10.1073/pnas.85.20.7506; BAUER GA, 1988, J BIOL CHEM, V263, P917; BLANK A, 1994, P NATL ACAD SCI USA, V91, P9047, DOI 10.1073/pnas.91.19.9047; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BOULET A, 1989, EMBO J, V8, P1849, DOI 10.1002/j.1460-2075.1989.tb03580.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUDD ME, 1995, MOL CELL BIOL, V15, P2173; BURGERS PMJ, 1988, J BIOL CHEM, V263, P925; Burgers PMJ, 1995, METHOD ENZYMOL, V262, P49; Burgers PMJ, 1998, J BIOL CHEM, V273, P19756, DOI 10.1074/jbc.273.31.19756; Cuesta R, 1998, GENETICS, V148, P1007; Eissenberg JC, 1997, MOL CELL BIOL, V17, P6367, DOI 10.1128/MCB.17.11.6367; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gibbs E, 1997, J BIOL CHEM, V272, P2373; GIOT L, 1995, MOL GEN GENET, V246, P212, DOI 10.1007/BF00294684; Giot L, 1997, GENETICS, V146, P1239; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P12; Halas A, 1997, CURR GENET, V31, P292, DOI 10.1007/s002940050208; Harlow E., 1988, ANTIBODIES LAB MANUA; HARTWELL LH, 1976, J MOL BIOL, V104, P803, DOI 10.1016/0022-2836(76)90183-2; Hindges R, 1997, BIOL CHEM, V378, P345; Kaiser C., 1994, METHODS YEAST GENETI; KAWASAKI H, 1990, ANAL BIOCHEM, V191, P332, DOI 10.1016/0003-2697(90)90227-Z; KOBAYASHI M, 1985, ANAL BIOCHEM, V145, P351, DOI 10.1016/0003-2697(85)90373-2; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; MacNeill SA, 1996, EMBO J, V15, P4613, DOI 10.1002/j.1460-2075.1996.tb00839.x; MCINTOSH EM, 1993, CURR GENET, V24, P185, DOI 10.1007/BF00351790; MORRISON A, 1994, MOL GEN GENET, V242, P289, DOI 10.1007/BF00280418; MORRISON A, 1993, EMBO J, V12, P1467, DOI 10.1002/j.1460-2075.1993.tb05790.x; MORRISON A, 1989, J BACTERIOL, V171, P5659, DOI 10.1128/jb.171.10.5659-5667.1989; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; NASMYTH K, 1981, MOL GEN GENET, V182, P119, DOI 10.1007/BF00422777; PERCIVAL KJ, 1989, J BIOL CHEM, V264, P2593; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMON M, 1991, EMBO J, V10, P2165, DOI 10.1002/j.1460-2075.1991.tb07751.x; SITNEY KC, 1989, CELL, V56, P599, DOI 10.1016/0092-8674(89)90582-5; SMITH RF, 1992, PROTEIN ENG, V5, P35, DOI 10.1093/protein/5.1.35; SUGIMOTO K, 1995, NUCLEIC ACIDS RES, V23, P3493, DOI 10.1093/nar/23.17.3493; SUGINO A, 1995, TRENDS BIOCHEM SCI, V20, P319, DOI 10.1016/S0968-0004(00)89059-3; Sun YB, 1997, J BIOL CHEM, V272, P13013, DOI 10.1074/jbc.272.20.13013; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; VONBORSTEL RC, 1993, MUTAT RES, V289, P97, DOI 10.1016/0027-5107(93)90135-3; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; Zhou JQ, 1997, NUCLEIC ACIDS RES, V25, P1094, DOI 10.1093/nar/25.6.1094; Zlotkin T, 1996, EMBO J, V15, P2298, DOI 10.1002/j.1460-2075.1996.tb00583.x; Zuo SJ, 1997, P NATL ACAD SCI USA, V94, P11244, DOI 10.1073/pnas.94.21.11244	55	179	186	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19747	19755		10.1074/jbc.273.31.19747	http://dx.doi.org/10.1074/jbc.273.31.19747			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677405	hybrid			2022-12-25	WOS:000075125200057
J	Lange, Y; Ye, J; Steck, TL				Lange, Y; Ye, J; Steck, TL			Circulation of cholesterol between lysosomes and the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPROTEIN-DERIVED CHOLESTEROL; CULTURED HUMAN-FIBROBLASTS; INTRACELLULAR-TRANSPORT; LDL CHOLESTEROL; CELLS; TRAFFICKING; STORAGE; SUPPRESSION; HOMEOSTASIS; ENDOCYTOSIS	The cholesterol in the lysosomes of cultured human fibroblasts was determined to constitute similar to 6% of the cell total. This pool was enlarged by as much as 10-fold in Niemann-Pick type C cells. Certain amphiphiles (e.g. U18666A, progesterone, and imipramine) caused lysosomal cholesterol to increase to similarly high levels at a rate of similar to 0.8% of cell cholesterol/h. Lysosomal cholesterol accumulated even in the absence of exogenous lipoproteins. Furthermore, nearly all of the lysosomal cholesterol in both of the two perturbed systems was shown to be derived from the plasma membrane. Oxysterols known to alter cholesterol movement and homeostasis blocked lysosomal cholesterol accretion in amphiphile-treated cells, suggesting that this process is regulated physiologically. Treating cells with amphiphiles slightly reduced the efflux of cholesterol from lysosomes and slightly increased the influx from the plasma membrane, causing the lysosomal cholesterol compartment to double in size in similar to 15 h. After more prolonged amphiphile treatments, a population of buoyant lysosomes appeared that exchanged cholesterol with the plasma membrane completely but slowly, Niemann-Pick type C lysosomes were similarly buoyant and sluggish. We conclude that cholesterol circulates bidirectionally between the plasma membrane and lysosomes. The massive accumulation of lysosomal cholesterol in the perturbed cells does not appear to reflect disabled lysosomal transport but rather the formation of lysosomes modified for lipid storage, i.e. lamellar bodies.	Rush Presbyterian St Lukes Med Ctr, Dept Pathol, Chicago, IL 60612 USA; Rush Presbyterian St Lukes Med Ctr, Dept Biochem, Chicago, IL 60612 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	Rush University; Rush University; University of Chicago	Lange, Y (corresponding author), Rush Presbyterian St Lukes Med Ctr, Dept Pathol, 1653 W Congress Pkwy, Chicago, IL 60612 USA.		Lange, Yvonne/A-7794-2009		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R55HL028448, R01HL028448] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL028448] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AXELSON M, 1995, J BIOL CHEM, V270, P15102, DOI 10.1074/jbc.270.25.15102; BRASAEMLE DL, 1990, J LIPID RES, V31, P103; BROWN MS, 1974, J BIOL CHEM, V249, P7306; BUTLER JD, 1992, J BIOL CHEM, V267, P23797; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Crawford JM, 1996, SEMIN LIVER DIS, V16, P169, DOI 10.1055/s-2007-1007230; DEGRELLA RF, 1982, J BIOL CHEM, V257, P4256; DRAYE JP, 1987, EUR J BIOCHEM, V170, P405, DOI 10.1111/j.1432-1033.1987.tb13714.x; DRAYE JP, 1988, J CELL BIOL, V107, P2109, DOI 10.1083/jcb.107.6.2109; ECHEVARRIA F, 1990, J BIOL CHEM, V265, P8484; FREEMAN DA, 1989, ENDOCRINOLOGY, V124, P2527, DOI 10.1210/endo-124-5-2527; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HRUBAN Z, 1984, ENVIRON HEALTH PERSP, V55, P53, DOI 10.2307/3429692; Hunziker W, 1996, BIOESSAYS, V18, P379, DOI 10.1002/bies.950180508; JOHNSON WJ, 1990, J BIOL CHEM, V265, P5546; LANGE Y, 1988, J BIOL CHEM, V263, P9366; Lange Y, 1997, J BIOL CHEM, V272, P17018, DOI 10.1074/jbc.272.27.17018; LANGE Y, 1984, J BIOL CHEM, V259, P4624; LANGE Y, 1985, J BIOL CHEM, V260, P5592; LANGE Y, 1993, J BIOL CHEM, V268, P13838; LANGE Y, 1991, J BIOL CHEM, V266, P21439; Lange Y, 1996, TRENDS CELL BIOL, V6, P205, DOI 10.1016/0962-8924(96)20016-9; Lange Y, 1997, J BIOL CHEM, V272, P13103, DOI 10.1074/jbc.272.20.13103; LANGE Y, 1994, J BIOL CHEM, V269, P29371; LANGE Y, 1989, J BIOL CHEM, V264, P3786; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; LISCUM L, 1989, J BIOL CHEM, V264, P11796; LISCUM L, 1995, J BIOL CHEM, V270, P15443, DOI 10.1074/jbc.270.26.15443; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; PADH H, 1993, J BIOL CHEM, V268, P6742; Pentchev P. G., 1995, METABOLIC MOL BASES, P2625; PENTCHEV PG, 1994, BBA-MOL BASIS DIS, V1225, P235, DOI 10.1016/0925-4439(94)90001-9; PENTCHEV PG, 1987, FASEB J, V1, P40, DOI 10.1096/fasebj.1.1.3609608; REINHART MP, 1990, EXPERIENTIA, V46, P599, DOI 10.1007/BF01939699; Rodriguez A, 1997, J CELL BIOL, V137, P93, DOI 10.1083/jcb.137.1.93; RODRIGUEZLAFRASSE C, 1990, BIOCHIM BIOPHYS ACTA, V1043, P123, DOI 10.1016/0005-2760(90)90284-5; SANDHOFF K, 1994, FEBS LETT, V346, P103, DOI 10.1016/0014-5793(94)00282-7; SCHMITZ G, 1991, J LIPID RES, V32, P1539; SHANG TY, 1997, ANN REV BIOCH, V66, P613; SLOTTE JP, 1987, BIOCHEM J, V248, P237, DOI 10.1042/bj2480237; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; THILO L, 1985, BIOCHIM BIOPHYS ACTA, V822, P243, DOI 10.1016/0304-4157(85)90010-3; TRAGANOS F, 1994, METHOD CELL BIOL, V41, P185; Traub LM, 1996, J CELL BIOL, V135, P1801, DOI 10.1083/jcb.135.6.1801; Underwood KW, 1998, J BIOL CHEM, V273, P4266, DOI 10.1074/jbc.273.7.4266; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247	47	105	106	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18915	18922		10.1074/jbc.273.30.18915	http://dx.doi.org/10.1074/jbc.273.30.18915			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668068	hybrid			2022-12-25	WOS:000074974700035
J	Perrier, V; Burlacu-Miron, S; Bourgeois, S; Surewicz, WK; Gilles, AM				Perrier, V; Burlacu-Miron, S; Bourgeois, S; Surewicz, WK; Gilles, AM			Genetically engineered zinc-chelating adenylate kinase from Escherichia coli with enhanced thermal stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR ANALYSIS; BACILLUS-SUBTILIS; BINDING; PROTEINS; GENE; BACTERIOPHAGE-T4; CATALYSIS; SEQUENCE; CLONING; COMPLEX	In contrast with adenylate kinase from Gram-negative bacteria, the enzyme from Gram-positive organisms harbors a structural Zn2+ bound to 3 or 4 Cys residues in the structural motif Cys-X-2-Cys-X-16-Cys-X-2-Cys/Asp. Site-directed mutagenesis of His(126), Ser(129), Asp(146), and Thr(149) (corresponding to Cys(130), Cys(133), Cys(150), and Cys(153) in adenylate kinase from Bacillus stearothermophilus) in Escherichia coli adenylate kinase was undertaken for determining whether the presence of Cys residues is the only prerequisite to bind zinc or (possible) other cations. A number of variants of adenylate kinase from E. coli, containing 1-4 Cys residues were obtained, purified, and analyzed for metal content, structural integrity, activity, and thermodynamic stability. All mutants bearing 3 or 4 cysteine residues acquired zinc binding properties. Moreover, the quadruple mutant exhibited a remarkably high thermal stability as compared with the wild-type form with preservation of the kinetic parameters of the parent enzyme.	Inst Pasteur, Lab Chim Struct Macromol, F-75724 Paris 15, France; Inst Curie Rech, INSERM, U350, F-91405 Orsay, France; Inst Natl Agron, Ctr Grignon, Lab Sci Sols & Hydrol, F-78850 Thiverval Grignon, France; Univ Missouri, Dept Ophthalmol, Columbia, MO 65212 USA	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; AgroParisTech; University of Missouri System; University of Missouri Columbia	Gilles, AM (corresponding author), Inst Pasteur, Lab Chim Struct Macromol, 28 Rue Dr Roux, F-75724 Paris 15, France.	amgilles@pasteur.fr	Miron, Simona/M-9223-2018; Perrier, Veronique/AAK-3594-2020	perrier, veronique/0000-0002-6570-7504				BARZU O, 1983, FEBS LETT, V153, P280, DOI 10.1016/0014-5793(83)80624-3; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; Boyer P.D, 1973, ENZYMES, P279; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNE M, 1985, NUCLEIC ACIDS RES, V13, P7139, DOI 10.1093/nar/13.19.7139; Burlacu-Miron S, 1998, J BIOL CHEM, V273, P19102, DOI 10.1074/jbc.273.30.19102; Deligiannakis Y, 1997, BIOCHEMISTRY-US, V36, P9446, DOI 10.1021/bi970021e; GIEDROC DP, 1986, P NATL ACAD SCI USA, V83, P8452, DOI 10.1073/pnas.83.22.8452; GILLES AM, 1993, EUR J BIOCHEM, V218, P921, DOI 10.1111/j.1432-1033.1993.tb18448.x; GILLES AM, 1994, J BACTERIOL, V176, P520, DOI 10.1128/JB.176.2.520-523.1994; GLASER P, 1992, BIOCHEMISTRY-US, V31, P3038, DOI 10.1021/bi00127a002; HAASE GHW, 1989, J MOL BIOL, V207, P151, DOI 10.1016/0022-2836(89)90446-4; Himmelreich R, 1996, NUCLEIC ACIDS RES, V24, P4420, DOI 10.1093/nar/24.22.4420; HUNT JB, 1984, J BIOL CHEM, V259, P4793; KLEMBA M, 1995, NAT STRUCT BIOL, V2, P368, DOI 10.1038/nsb0595-368; KOIVULA T, 1991, J GEN MICROBIOL, V137, P2595, DOI 10.1099/00221287-137-11-2595; KONRAD M, 1993, J BIOL CHEM, V268, P11326; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASKELL DJ, 1991, MOL MICROBIOL, V5, P1013, DOI 10.1111/j.1365-2958.1991.tb01874.x; Miller J.H., 1972, EXPT MOL GENETICS; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; Muller CW, 1996, STRUCTURE, V4, P147, DOI 10.1016/S0969-2126(96)00018-4; NAKAMURA K, 1990, J BIOCHEM-TOKYO, V107, P603; PERRIER V, 1994, BIOCHEMISTRY-US, V33, P9960, DOI 10.1021/bi00199a019; RALEIGH EA, 1989, CURRENT PROTOCOLS MO; REGAN L, 1993, ANNU REV BIOPH BIOM, V22, P257, DOI 10.1146/annurev.bb.22.060193.001353; REGAN L, 1990, BIOCHEMISTRY-US, V29, P10878, DOI 10.1021/bi00501a003; REINSTEIN J, 1988, BIOCHEMISTRY-US, V27, P4712, DOI 10.1021/bi00413a020; SAINTGIRONS I, 1987, J BIOL CHEM, V262, P622; Schlauderer GJ, 1996, PROTEIN SCI, V5, P434; SCHULZ GE, 1990, J MOL BIOL, V213, P627, DOI 10.1016/S0022-2836(05)80250-5; SCHULZ GE, 1986, EUR J BIOCHEM, V161, P127, DOI 10.1111/j.1432-1033.1986.tb10132.x; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TOMASSELLI AG, 1986, FEBS LETT, V202, P303, DOI 10.1016/0014-5793(86)80706-2; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VALLEE BL, 1993, P NATL ACAD SCI USA, V90, P2715, DOI 10.1073/pnas.90.7.2715; VALLEE BL, 1993, BIOCHEMISTRY-US, V32, P6493, DOI 10.1021/bi00077a001; VONRHEIN C, 1995, STRUCTURE, V3, P483, DOI 10.1016/S0969-2126(01)00181-2	41	23	26	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19097	19101		10.1074/jbc.273.30.19097	http://dx.doi.org/10.1074/jbc.273.30.19097			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668094	hybrid			2022-12-25	WOS:000074974700061
J	Favata, MF; Horiuchi, KY; Manos, EJ; Daulerio, AJ; Stradley, DA; Feeser, WS; Van Dyk, DE; Pitts, WJ; Earl, RA; Hobbs, F; Copeland, RA; Magolda, RL; Scherle, PA; Trzaskos, JM				Favata, MF; Horiuchi, KY; Manos, EJ; Daulerio, AJ; Stradley, DA; Feeser, WS; Van Dyk, DE; Pitts, WJ; Earl, RA; Hobbs, F; Copeland, RA; Magolda, RL; Scherle, PA; Trzaskos, JM			Identification of a novel inhibitor of mitogen-activated protein kinase kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; GROWTH-FACTOR; IN-VITRO; MECHANISMS; CELLS; PATHWAYS; RECEPTOR; GLUCOCORTICOIDS; PROLIFERATION; TRANSCRIPTION	The compound U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene) was identified as an inhibitor of AP-1 transactivation in a cell-based reporter assay. U0126 was also shown to inhibit endogenous promoters containing AP-1 response elements but did not affect genes lacking an AP-1 response element in their promoters. These effects of U0126 result from direct inhibition of the mitogen-activated protein kinase kinase family members, MEK-1 and MEK-2. Inhibition is selective for MEK-1 and -2, as U0126 shows little, if any, effect on the kinase activities of protein kinase C, Abl, Raf, MEKK, ERK, JNK, MKK-3, MKK-4/SEK, MKK6, Cdk2, or Cdk4. Comparative kinetic analysis of U0126 and the MEK inhibitor PD098059 (Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., and Saltiel, A. R. (1995) Proc. Natl. Acad. Sci U. S. A. 92, 7686-7689) demonstrates that U0126 and PD098059 are noncompetitive inhibitors with respect to both MEK substrates, ATP and ERK. We further demonstrate that the two compounds bind to S218E/S222D MEK in a mutually exclusive fashion, suggesting that they may share a common or overlapping binding site(s). Quantitative evaluation of the steady state kinetics of MEK inhibition by these compounds reveals that U0126 has approximately 100-fold higher affinity for Delta N3-S218E/S222D MEK than does PD098059. We further tested the effects of these compounds on the activity of wild type MEK isolated after activation from stimulated cells. Surprisingly, we observe a significant diminution in affinity of both compounds for wild type MEK as compared with the Delta N3-S218E/S222D mutant enzyme. These results suggest that the affinity of both compounds is mediated by subtle conformational differences between the two activated MEK forms. The MEK affinity of U0126, its selectivity for MEK over other kinases, and its cellular efficacy suggest that this compound will serve as a powerful tool for in vitro and cellular investigations of mitogen-activated protein kinase-mediated signal transduction.	Dupont Merck Res Labs, Inflammatory Dis Res, Wilmington, DE 19880 USA; Dupont Merck Res Labs, Chem Enzymol, Wilmington, DE 19880 USA; Dupont Merck Res Labs, Chem & Phys Sci, Wilmington, DE 19880 USA		Trzaskos, JM (corresponding author), Dupont Merck Res Labs, Inflammatory Dis Res, POB 80400, Wilmington, DE 19880 USA.			Pitts, William/0000-0002-1034-6043				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Azpiazu I, 1996, J BIOL CHEM, V271, P5033; BAXTER JD, 1976, PHARMACOL THER PT B, V2, P605, DOI 10.1016/0306-039X(76)90010-6; BEHRENS TW, 1989, ARTHRITIS ALLIED CON, P604; BELL JE, 1988, PROTEINS ENZYMES, P378; BorschHaubold AG, 1996, BIOCHEM J, V318, P207; Brattsand R, 1996, ALIMENT PHARM THERAP, V10, P81, DOI 10.1046/j.1365-2036.1996.22164025.x; BURT DW, 1989, J BIOL CHEM, V264, P7357; Carlson BA, 1996, CANCER RES, V56, P2973; Cato ACB, 1996, BIOESSAYS, V18, P371, DOI 10.1002/bies.950180507; CATO ACB, 1992, PROG NUCL ACID RES M, V43; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; COOK PW, 1988, MOL CELL BIOL, V8, P1449, DOI 10.1128/MCB.8.4.1449; COPELAND RA, 1996, ENZYMES PRACTICAL IN, P187; DAVIS LG, 1986, BASIC METHODS MOL BI, P143; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7868; Dumont FJ, 1998, J IMMUNOL, V160, P2579; FANGER GR, 1997, GENET DEV, V7, P67; FULLER PJ, 1991, FASEB J, V5, P3902; GEHRING U, 1987, TRENDS BIOCHEM SCI, V12, P399, DOI 10.1016/0968-0004(87)90195-2; Graf K, 1997, HYPERTENSION, V29, P334, DOI 10.1161/01.HYP.29.1.334; Granner D. K., 1970, METHODS ENZYMOL    A, V17, P633; HANDEL ML, 1993, AGENTS ACTIONS, V680, P219; HERRLICH P, 1994, TRENDS ENDOCRIN MET, V5, P341, DOI 10.1016/1043-2760(94)90164-3; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Karin M, 1991, CURR OPIN CELL BIOL, V3, P467, DOI 10.1016/0955-0674(91)90075-A; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; Kuroki M, 1997, BIOCHEM BIOPH RES CO, V232, P474, DOI 10.1006/bbrc.1997.6296; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; MANGELSDORF DJ, 1995, CELL, V83, P385; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MIDDLETON WJ, 1958, J AM CHEM SOC, V80, P2783, DOI 10.1021/ja01544a053; MIDDLETON WJ, 1958, J AM CHEM SOC, V80, P2822, DOI 10.1021/ja01544a058; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; OWAKI H, 1992, BIOCHEM BIOPH RES CO, V182, P1416, DOI 10.1016/0006-291X(92)91891-S; PARRILLO JE, 1979, ANNU REV PHARMACOL, V19, P179, DOI 10.1146/annurev.pa.19.040179.001143; Post GR, 1996, J BIOL CHEM, V271, P8452, DOI 10.1074/jbc.271.14.8452; RINGOLD GM, 1985, ANNU REV PHARMACOL, V25, P529, DOI 10.1146/annurev.pa.25.040185.002525; Schroen DJ, 1996, GENE EXPRESSION, V6, P197; Servant MJ, 1996, J BIOL CHEM, V271, P16047, DOI 10.1074/jbc.271.27.16047; Simon C, 1996, CANCER RES, V56, P5369; Vincenti MP, 1996, CRIT REV EUKAR GENE, V6, P391, DOI 10.1615/CritRevEukarGeneExpr.v6.i4.40; WheelerJones CPD, 1996, FEBS LETT, V388, P180, DOI 10.1016/0014-5793(96)00547-9; ZHANG C, 1993, J BIOL CHEM, V268, P11435	49	2703	2769	2	125	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18623	18632		10.1074/jbc.273.29.18623	http://dx.doi.org/10.1074/jbc.273.29.18623			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660836	hybrid			2022-12-25	WOS:000074828500091
J	Schedlich, LJ; Young, TF; Firth, SM; Baxter, RC				Schedlich, LJ; Young, TF; Firth, SM; Baxter, RC			Insulin-like growth factor-binding protein (IGFBP)-3 and IGFBP-5 share a common nuclear transport pathway in T47D human breast carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR A-CHAIN; CANCER CELLS; IGF-I; ENDOTHELIAL-CELLS; RETINOIC ACID; HUMAN-PLASMA; RECEPTORS; LOCALIZATION; FIBROBLASTS; INHIBITION	Insulin-like growth factor-binding proteins (IGFBPs) play an integral role in modifying insulin-like growth factor actions in a wide variety of cell types. Recent evidence suggests that IGFBP-3 and IGFBP-5 also have effects on cell growth that are insulin-like growth factor-independent. In investigating possible mechanisms for this effect, the intracellular trafficking of IGFBP-3 and IGFBP-5, both of which contain sequences with the potential for nuclear localization, was studied in T47D cells. Nuclear uptake of fluorescently labeled IGFBP-3 and IGFBP-5 was observed in a proportion of T47D cells that appeared to be rapidly dividing. IGFBP-1 and IGFBP-2, which do not possess the putative domain for nuclear translocation, were not transported to the nuclei of T47D cells. When T47D cells were preincubated with excess unlabeled IGFBP-3, nuclear localization of labeled IGFBP-3 or IGFBP-5 was not detected, indicating that their nuclear translocation involves a common pathway, Inhibition of receptor-mediated endocytosis did not affect nuclear uptake of IGFBP-3, suggesting that it uses an alternative non-classical import pathway for transport across the plasma membrane. In addition, a variant form of IGFBP-3 with a mutation in the putative nuclear localization sequence was unable to translocate to the nuclei of T47D cells, suggesting that nuclear translocation of IGFBP-3 was dependent on these carboxyl-terminal basic residues.	Univ Sydney, Royal N Shore Hosp, Kolling Inst Med Res, Sydney, NSW 2065, Australia	Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research	Schedlich, LJ (corresponding author), Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia.		Baxter, Robert C/F-3927-2012	Baxter, Robert C/0000-0001-5061-2142				ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; ANDRESS DL, 1995, J BIOL CHEM, V270, P28289; BAXTER RC, 1987, J CLIN ENDOCR METAB, V65, P423, DOI 10.1210/jcem-65-3-423; BAXTER RC, 1993, TRENDS ENDOCRIN MET, V4, P91, DOI 10.1016/1043-2760(93)90085-S; BAXTER RC, 1986, J CLIN INVEST, V78, P1504, DOI 10.1172/JCI112742; Baxter Robert C., 1995, Progress in Growth Factor Research, V6, P215, DOI 10.1016/0955-2235(95)00004-6; BOOTH BA, 1995, GROWTH REGULAT, V5, P1; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; COHEN P, 1993, MOL ENDOCRINOL, V7, P380, DOI 10.1210/me.7.3.380; COLLINS T, 1987, NATURE, V328, P621, DOI 10.1038/328621a0; CONOVER CA, 1990, ENDOCRINOLOGY, V127, P2795, DOI 10.1210/endo-127-6-2795; DEMELLOW JSM, 1988, BIOCHEM BIOPH RES CO, V156, P199, DOI 10.1016/S0006-291X(88)80824-6; Efthymiadis A, 1997, J BIOL CHEM, V272, P22134, DOI 10.1074/jbc.272.35.22134; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; Firth SM, 1998, J BIOL CHEM, V273, P2631, DOI 10.1074/jbc.273.5.2631; GOLTZ JS, 1992, P NATL ACAD SCI USA, V89, P7026, DOI 10.1073/pnas.89.15.7026; Gucev ZS, 1996, CANCER RES, V56, P1545; GUI GPH, 1995, BRIT J SURG, V82, P1192, DOI 10.1002/bjs.1800820914; GuiochonMantel A, 1996, J STEROID BIOCHEM, V56, P3, DOI 10.1016/0960-0760(95)00268-5; GURWELL JA, 1993, DEV BRAIN RES, V76, P293, DOI 10.1016/0165-3806(93)90222-V; HENDERSON JE, 1995, MOL CELL BIOL, V15, P4064; Ho PJ, 1997, CLIN ENDOCRINOL, V46, P333; IMAMURA T, 1994, EXP CELL RES, V215, P363, DOI 10.1006/excr.1994.1353; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; Jaques G, 1997, ENDOCRINOLOGY, V138, P1767, DOI 10.1210/en.138.4.1767; JIN MJ, 1993, J BIOL CHEM, V268, P18390; JONES JI, 1993, P NATL ACAD SCI USA, V90, P10553, DOI 10.1073/pnas.90.22.10553; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; JOSEPH DR, 1996, ENDOCRINOLOGY, V137, P1318; Li WL, 1997, ENDOCRINOLOGY, V138, P1763, DOI 10.1210/en.138.4.1763; MAHER DW, 1989, MOL CELL BIOL, V9, P2251, DOI 10.1128/MCB.9.5.2251; MARTIN JL, 1986, J BIOL CHEM, V261, P8754; MARTIN JL, 1995, ENDOCRINOLOGY, V136, P1219, DOI 10.1210/en.136.3.1219; MARTIN JL, 1992, ENDOCRINOLOGY, V131, P1703, DOI 10.1210/en.131.4.1703; MASSAGUE J, 1982, J BIOL CHEM, V257, P5038; MILLER DS, 1988, SCIENCE, V240, P506, DOI 10.1126/science.2451860; MOHAN S, 1995, J BIOL CHEM, V270, P20424, DOI 10.1074/jbc.270.35.20424; OH Y, 1993, J BIOL CHEM, V268, P26045; OH Y, 1995, J BIOL CHEM, V270, P13589, DOI 10.1074/jbc.270.23.13589; OH YM, 1993, J BIOL CHEM, V268, P14964; RADULESCU RT, 1994, TRENDS BIOCHEM SCI, V19, P278, DOI 10.1016/0968-0004(94)90004-3; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Russo VC, 1997, ENDOCRINOLOGY, V138, P4858, DOI 10.1210/en.138.11.4858; SOLER AP, 1989, P NATL ACAD SCI USA, V86, P6640, DOI 10.1073/pnas.86.17.6640; SULLIVAN PM, 1993, MOL ENDOCRINOL, V7, P702, DOI 10.1210/me.7.5.702; TUREK JJ, 1993, J CELL SCI, V106, P423; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; Twigg SM, 1998, J BIOL CHEM, V273, P6074, DOI 10.1074/jbc.273.11.6074; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; WRAIGHT CJ, 1997, 4 INT S INS LIK GROW, P139	51	219	223	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18347	18352		10.1074/jbc.273.29.18347	http://dx.doi.org/10.1074/jbc.273.29.18347			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660801	hybrid			2022-12-25	WOS:000074828500056
J	Hock, B; Bohme, B; Karn, T; Feller, S; Rubsamen-Waigmann, H; Strebhardt, K				Hock, B; Bohme, B; Karn, T; Feller, S; Rubsamen-Waigmann, H; Strebhardt, K			Tyrosine-614, the major autophosphorylation site of the receptor tyrosine kinase HEK2, functions as multi-docking site for SH2-domain mediated interactions	ONCOGENE			English	Article						Eph-related kinases; HEK2; SH2-domains; signal transduction	COMMISSURAL AXONS; C-CRK; EPH; BINDING; PROTEIN; FAMILY; ACTIVATION; PROMOTES; GUIDANCE; DOMAIN	HEK2 belongs to the family of EPH-related receptor tyrosine kinases (RTK) which are involved in axonal pathfinding and the formation of the embryonic body plan. The knowledge about intracellular pathways of signal transduction mediated by EPH-related receptors is still limited, Many of the known key players of cellular signalling contain Src homology 2 (SH2) domains, which recognize phosphotyrosine motifs in RTKs, Thus, we examined the interactions of various SH2-containing molecules like PLC-gamma 1, rasGAP, p85 subunit of PI3-kinase, Src, Fyn, Crk, Nck, GrbZ and Shc with HEK2 using in vitro binding assays, immunoprecipitations and yeast Two-Hybrid assays. We found that rasGAP, Crk and Fyn bind in a SH2-dependent manner to autophosphorylated HEK2, rasGAP, which contains two SH2- and one SH3-domain, was shown to associate with its N-terminal SH2-domain to HEK2, Furthermore, we demonstrated that a single amino acid substitution (Y614F) clearly reduces the phosphotyrosine content of HEK2 and abrogates its ability to bind rasGAP, Crk and Fyn indicating that this residue functions as major phosphorylation and multi-docking site. The conservation of this predicted binding site among various EPH-related RTKs provides evidence that Fyn, Crk and rasGAP are key players in signal transduction of at least a subset of these receptors.	Chemotherapeut Forschungsinst, D-60596 Frankfurt, Germany; Med Inst Strahlenkunde & Zellforsch MSZ, Lab Mol Onkol, D-97078 Wurzburg, Germany; Bayer AG, Inst Virol, D-42096 Wuppertal, Germany	Bayer AG	Strebhardt, K (corresponding author), Chemotherapeut Forschungsinst, Georg Speyer Haus,Paul Ehrlich Str 42-44, D-60596 Frankfurt, Germany.		Strebhardt, Klaus/E-8765-2011; karn, t/C-7452-2013; Karn, Thomas/AAE-7723-2019	karn, t/0000-0002-3264-6573; Karn, Thomas/0000-0002-3264-6573; Strebhardt, Klaus/0000-0003-2173-9763				Bohme B, 1996, J BIOL CHEM, V271, P24747, DOI 10.1074/jbc.271.40.24747; BOHME B, 1993, ONCOGENE, V8, P2857; Brambilla R, 1995, MOL CELL NEUROSCI, V6, P487, DOI 10.1006/mcne.1995.0001; Braunger J, 1997, ONCOGENE, V14, P2619, DOI 10.1038/sj.onc.1201123; Ellis C, 1996, ONCOGENE, V12, P1727; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FELLER SM, 1995, ONCOGENE, V10, P1465; FOX GM, 1995, ONCOGENE, V10, P897; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Hu KQ, 1997, EMBO J, V16, P473, DOI 10.1093/emboj/16.3.473; KARN T, 1993, ONCOGENE, V8, P3433; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; Orioli D, 1996, EMBO J, V15, P6035, DOI 10.1002/j.1460-2075.1996.tb00992.x; PANDEY A, 1994, J BIOL CHEM, V269, P30154; PANDEY A, 1995, J BIOL CHEM, V270, P19201, DOI 10.1074/jbc.270.33.19201; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	22	51	52	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 16	1998	17	2					255	260		10.1038/sj.onc.1201907	http://dx.doi.org/10.1038/sj.onc.1201907			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZZ211	9674711				2022-12-25	WOS:000074706700015
J	Furukawa, T; Nukada, T; Mori, Y; Wakamori, M; Fujita, Y; Ishida, H; Fukuda, K; Kato, S; Yoshii, M				Furukawa, T; Nukada, T; Mori, Y; Wakamori, M; Fujita, Y; Ishida, H; Fukuda, K; Kato, S; Yoshii, M			Differential interactions of the C terminus and the cytoplasmic I-II loop of neuronal Ca2+ channels with G-protein alpha and beta gamma subunits - I. Molecular determination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEIN; CALCIUM CHANNELS; FUNCTIONAL EXPRESSION; INHIBITION; MODULATION; RECEPTORS; SUBTYPES; CLONING; OOCYTES; BRAIN	Interactions of G-protein a (G alpha) and beta gamma subunits (G beta gamma) with N- (alpha(1B)) and P/Q-type (alpha(1A)) Ca2+ channels were investigated using the Xenopus oocyte expression system. G(i3)alpha was found to inhibit both N- and P/Q-type channels by receptor agonists, whereas G beta(1)gamma(2) was responsible for prepulse facilitation of N-type channels. L-type channels (alpha(1C)) were not regulated by G alpha or G beta gamma. For N-type, prepulse facilitation mediated via G beta gamma was impaired when the cytoplasmic I-II loop (loop 1) was deleted or replaced with the alpha(1C) loop 1. G alpha-mediated inhibitions were also impaired by substitution of the alpha(1C) loop 1, but only when the C terminus was deleted. For P/Q type, by contrast, deletion of the C terminus alone diminished G alpha-mediated inhibition. Moreover, a chimera of L-type with the alpha(1B) loop 1 gained G beta gamma-dependent ent facilitation, whereas an L type chimera with the Nor P/Q-type C terminus gained G alpha-mediated inhibition. These findings provide evidence that loop 1 of N-type channels is a regulatory site for G beta gamma and the C termini of P/Q- and N-types for G alpha.	Tokyo Inst Psychiat, Dept Neurochem, Setagaya Ku, Tokyo 156, Japan; Tokyo Inst Psychiat, Dept Neurophysiol, Setagaya Ku, Tokyo 156, Japan; Teikyo Univ, Fac Med, Dept Internal Med, Itabashi Ku, Tokyo 173, Japan; Natl Inst Physiol Sci, Dept Informat Physiol, Okazaki, Aichi 444, Japan; Univ Cincinnati, Coll Med, Inst Mol Pharmacol & Biophys, Cincinnati, OH 45267 USA; Kyoto Univ Hosp, Dept Anesthesia, Sakyo Ku, Kyoto 60601, Japan; Kyoto Univ, Fac Med, Dept Mol Genet, Kyoto 60601, Japan	Tokyo Institute of Psychiatry; Tokyo Institute of Psychiatry; Teikyo University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); University System of Ohio; University of Cincinnati; Kyoto University; Kyoto University	Yoshii, M (corresponding author), Tokyo Inst Psychiat, Dept Neurochem, Setagaya Ku, 2-1-8 Kamikitazawa, Tokyo 156, Japan.			Wakamori, Minoru/0000-0001-8574-3310	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022619] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL22619-20] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; Bourinet E, 1996, P NATL ACAD SCI USA, V93, P1486, DOI 10.1073/pnas.93.4.1486; CAMPBELL V, 1995, J PHYSIOL-LONDON, V485, P365, DOI 10.1113/jphysiol.1995.sp020735; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; DeWaard M, 1997, NATURE, V385, P446, DOI 10.1038/385446a0; DIDSBURY JR, 1987, FEBS LETT, V219, P259, DOI 10.1016/0014-5793(87)81228-0; ELLINOR PT, 1994, NATURE, V372, P272, DOI 10.1038/372272a0; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; FUJITA Y, 1993, NEURON, V10, P585, DOI 10.1016/0896-6273(93)90162-K; FUKUDA K, 1993, FEBS LETT, V327, P311, DOI 10.1016/0014-5793(93)81011-N; Furukawa T, 1998, J BIOL CHEM, V273, P17595, DOI 10.1074/jbc.273.28.17595; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; Herlitze S, 1997, P NATL ACAD SCI USA, V94, P1512, DOI 10.1073/pnas.94.4.1512; HESCHELER J, 1987, NATURE, V325, P445, DOI 10.1038/325445a0; HILLE B, 1994, TRENDS NEUROSCI, V17, P531, DOI 10.1016/0166-2236(94)90157-0; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; KASAI H, 1992, J PHYSIOL-LONDON, V448, P189, DOI 10.1113/jphysiol.1992.sp019036; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; MCFADZEAN I, 1989, NEURON, V3, P177, DOI 10.1016/0896-6273(89)90030-5; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NAKAMURA K, 1994, J PHYSIOL-LONDON, V474, P35, DOI 10.1113/jphysiol.1994.sp020000; OLATE J, 1989, FEBS LETT, V244, P188, DOI 10.1016/0014-5793(89)81190-1; Page KM, 1997, J NEUROSCI, V17, P1330; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Qin N, 1997, P NATL ACAD SCI USA, V94, P8866, DOI 10.1073/pnas.94.16.8866; TAKAO K, 1994, NEURON, V13, P747, DOI 10.1016/0896-6273(94)90041-8; TANG SQ, 1993, NEURON, V11, P1013, DOI 10.1016/0896-6273(93)90215-D; Tareilus E, 1997, P NATL ACAD SCI USA, V94, P1703, DOI 10.1073/pnas.94.5.1703; TSUNOO A, 1986, P NATL ACAD SCI USA, V83, P9832, DOI 10.1073/pnas.83.24.9832; WAKAMORI M, 1994, RECEPTOR CHANNEL, V2, P303; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0; Zhang JF, 1996, NEURON, V17, P991, DOI 10.1016/S0896-6273(00)80229-9	34	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17585	17594		10.1074/jbc.273.28.17585	http://dx.doi.org/10.1074/jbc.273.28.17585			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651353	hybrid			2022-12-25	WOS:000074816100046
J	Huang, BL; Gudi, R; Wu, PF; Harris, RA; Hamilton, J; Popov, KM				Huang, BL; Gudi, R; Wu, PF; Harris, RA; Hamilton, J; Popov, KM			Isoenzymes of pyruvate dehydrogenase phosphatase - DNA-derived amino acid sequences, expression, and regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE-TISSUE; FUEL SELECTION; LIPOYL DOMAIN; KINASE; MITOCHONDRIA; MECHANISM; COMPLEX; CALCIUM; IONS; RAT	Pyruvate dehydrogenase phosphatase (PDP) is one of the few mammalian phosphatases residing within the mitochondrial matrix space. It is responsible for dephosphorylation and reactivation of the pyruvate dehydrogenase complex (PDC) and, by this means, is intimately involved in the regulation of utilization of carbohydrate fuels in mammals. PDP is a dimeric enzyme consisting of catalytic and regulatory subunits, The catalytic subunit of PDP is a Mg2+-dependent enzyme homologous to the cytosolic phosphatases of the 2C family. In the present study, we isolated two cDNAs encoding for mitochondrial phosphatases, The first cDNA is highly homologous to the previously identified cDNA encoding for the catalytic subunit of PDP (PDP1). The second cDNA. encodes a previously unknown catalytic subunit of PDP (PDP2), The new phosphatase, expressed as the recombinant protein in Escherichia coli, shows strict substrate specificity toward PDC and does not use phosphorylated branched chain alpha-ketoacid dehydrogenase as substrate. Like PDP1, PDP2 is a Mg2+-dependent enzyme, but its sensitivity to Mg2+ ions is almost 10-fold lower than that of PDP1. In contrast to PDP1, PDP2 is not regulated by Ca2+ ions, Instead, it is sensitive to the biological polyamine spermine, which, in turn, has no effect on the enzymatic activity of PDP1, Western blot analysis of PDP extracted from mitochondria isolated from liver and skeletal muscle revealed that PDP1 is predominantly expressed in mitochondria from skeletal muscle, whereas PDP2 is much more abundant in the liver rather than muscle mitochondria. Both isoenzymes are expressed in mitochondria from 3T3-L1 adipocytes, but the level of expression of PDP2 is considerably higher. These observations are consistent with previous findings on the enzymatic parameters of PDP in adipose tissue. Thus, our results provide the first evidence that there are at least two isoenzymes of PDP in mammals that are different with respect to tissue distribution and kinetic parameters and, therefore, are likely to be different functionally.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Popov, KM (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, 635 Barnhill Dr, Indianapolis, IN 46202 USA.	kpopov@iupui.edu			NIDDK NIH HHS [DK 47844] Funding Source: Medline; NIGMS NIH HHS [GM 51262] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047844] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM051262, R01GM051262] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEHAL RH, 1993, ANNU REV NUTR, V13, P497, DOI 10.1146/annurev.nu.13.070193.002433; Bowker-Kinley MM, 1998, BIOCHEM J, V329, P191, DOI 10.1042/bj3290191; Chen GL, 1996, J BIOL CHEM, V271, P28064, DOI 10.1074/jbc.271.45.28064; CHISHOLM D, 1989, BIOTECHNIQUES, V7, P21; Das AK, 1996, EMBO J, V15, P6798, DOI 10.1002/j.1460-2075.1996.tb01071.x; DEBURGOS NMG, 1994, ARCH BIOCHEM BIOPHYS, V308, P520, DOI 10.1006/abbi.1994.1073; GUDI R, 1995, J BIOL CHEM, V270, P28989, DOI 10.1074/jbc.270.48.28989; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; HUCHO F, 1972, Archives of Biochemistry and Biophysics, V151, P328, DOI 10.1016/0003-9861(72)90504-8; Johnson  D., 1967, METHOD ENZYMOL, V10, P94, DOI DOI 10.1016/0076-6879(67)10018-9; KEDISHVILI NY, 1994, ARCH BIOCHEM BIOPHYS, V315, P317, DOI 10.1006/abbi.1994.1506; KERBEY AL, 1976, BIOCHEM J, V154, P327, DOI 10.1042/bj1540327; KOROTCHKINA LG, 1995, J BIOL CHEM, V270, P14297, DOI 10.1074/jbc.270.24.14297; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JE, 1993, BIOCHEMISTRY-US, V32, P8987, DOI 10.1021/bi00086a002; LINN TC, 1969, P NATL ACAD SCI USA, V62, P234, DOI 10.1073/pnas.62.1.234; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCORMACK JG, 1980, BIOCHEM J, V190, P95, DOI 10.1042/bj1900095; PETTIT FH, 1972, BIOCHEM BIOPH RES CO, V49, P563, DOI 10.1016/0006-291X(72)90448-2; RAHMATULLAH M, 1988, J BIOL CHEM, V263, P8106; RANDLE PJ, 1986, BIOCHEM SOC T, V14, P799, DOI 10.1042/bst0140799; RANDLE PJ, 1995, P NUTR SOC, V54, P317, DOI 10.1079/PNS19950057; Ravindran S, 1996, J BIOL CHEM, V271, P653, DOI 10.1074/jbc.271.2.653; Rowles J, 1996, J BIOL CHEM, V271, P22376, DOI 10.1074/jbc.271.37.22376; RUTTER GA, 1989, ANN NY ACAD SCI, V573, P206, DOI 10.1111/j.1749-6632.1989.tb14998.x; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SEVERSON DL, 1974, BIOCHEM J, V140, P225, DOI 10.1042/bj1400225; SONG H, 1994, J BIOL CHEM, V269, P31573; STEPP LR, 1983, J BIOL CHEM, V258, P9454; SUGDEN MC, 1995, J NUTR, V125, pS1746; SUGDEN PH, 1978, BIOCHEM J, V173, P659, DOI 10.1042/bj1730659; TEAGUE WM, 1982, BIOCHEMISTRY-US, V21, P5585, DOI 10.1021/bi00265a031; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; Wu PF, 1998, BIOCHEM J, V329, P197, DOI 10.1042/bj3290197; Yan JG, 1996, P NATL ACAD SCI USA, V93, P4953, DOI 10.1073/pnas.93.10.4953; YEAMAN SJ, 1978, BIOCHEMISTRY-US, V17, P2364, DOI 10.1021/bi00605a017	38	170	180	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17680	17688		10.1074/jbc.273.28.17680	http://dx.doi.org/10.1074/jbc.273.28.17680			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651365	hybrid			2022-12-25	WOS:000074816100058
J	Cavrois, M; Leclercq, I; Gout, O; Gessain, A; Wain-Hobson, S; Wattel, E				Cavrois, M; Leclercq, I; Gout, O; Gessain, A; Wain-Hobson, S; Wattel, E			Persistent oligoclonal expansion of human T-cell leukemia virus type 1 infected circulating cells in patients with Tropical spastic paraparesis HTLV-1 associated myelopathy	ONCOGENE			English	Article						HTLV-1; ATLL; leukemogenesis; TSP/HAM	BLOOD MONONUCLEAR-CELLS; I PROVIRAL DNA; PERIPHERAL-BLOOD; HTLV-1-ASSOCIATED MYELOPATHY; IMMUNOSUPPRESSIVE TREATMENT; ASYMPTOMATIC CARRIERS; NEUROLOGICAL DISEASE; TRANSACTIVATOR TAX; MESSENGER-RNA; KAPPA-B	The pattern of HTLV-1 replication was assessed through PCR amplification of the 3' proviral integration sites in patients with TSP/HAM at different times. Integration sites mere sequenced and oligonucleotides specific for the flanking sequences were synthesized. Together with HTLV-1 LTR specific primers, clonotypic nested PCR was performed on peripheral blood from two patients. The frequencies of five clones studied ranged from 1/300 to 1/1500 PBMCs while four clones persisted for more than 1-5 years. It would seem that Tax driven expansion of T cells may persist for considerable periods of time in TSP/HAM despite strong cellular immunity. This may provide a background for the accumulation of subsequent mutations leading to malignancy.	Inst Rech Canc Lille, INSERM, U124, Paris, France; Hop La Pitie Salpetriere, Federat Neurol, Paris, France; Inst Pasteur, Unite Epidemiol Virus Oncogenes, Paris, France; Inst Pasteur, Unite Retrovirol Mol, Paris, France; Ctr Oscar Lambret, Unite Oncogenese Virale, F-59020 Lille, France; CHU Lille, Serv Malad Sang, F-59037 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UNICANCER; Centre Oscar Lambret; Universite de Lille - ISITE; CHU Lille	Wattel, E (corresponding author), Inst Rech Canc Lille, INSERM, U124, Paris, France.							BEILKE MA, 1991, J MED VIROL, V33, P64, DOI 10.1002/jmv.1890330113; Cavrois M, 1996, ONCOGENE, V12, P2419; CAVROIS M, 1995, RES VIROLOGY, V146, P179, DOI 10.1016/0923-2516(96)80578-4; Cavrois M, 1996, BLOOD, V88, P4646, DOI 10.1182/blood.V88.12.4646.bloodjournal88124646; CHO IM, 1995, AM J TROP MED HYG, V53, P412, DOI 10.4269/ajtmh.1995.53.412; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DUYAO MP, 1992, AIDS RES HUM RETROV, V8, P752; ELOVAARA I, 1993, J EXP MED, V177, P1567, DOI 10.1084/jem.177.6.1567; FUJII M, 1991, ONCOGENE, V6, P1023; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; FURUKAWA Y, 1995, BLOOD, V85, P1865, DOI 10.1182/blood.V85.7.1865.bloodjournal8571865; FURUKAWA Y, 1992, BLOOD, V80, P1012; GESSAIN A, 1990, BLOOD, V75, P428; GESSAIN A, 1992, J VIROL, V66, P2288, DOI 10.1128/JVI.66.4.2288-2295.1992; GESSAIN A, 1985, LANCET, V2, P407; GESSAIN A, 1991, J VIROL, V65, P1628, DOI 10.1128/JVI.65.3.1628-1633.1991; HIRAI H, 1994, P NATL ACAD SCI USA, V91, P3584, DOI 10.1073/pnas.91.9.3584; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; JACOBSON S, 1990, NATURE, V348, P245, DOI 10.1038/348245a0; JEANG KT, 1988, J VIROL, V62, P4499, DOI 10.1128/JVI.62.12.4499-4509.1988; JENKS PJ, 1995, CLIN INFECT DIS, V21, P992, DOI 10.1093/clinids/21.4.992; KINOSHITA T, 1989, P NATL ACAD SCI USA, V86, P5620, DOI 10.1073/pnas.86.14.5620; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NAKADA K, 1987, INT J CANCER, V40, P145, DOI 10.1002/ijc.2910400203; Newbound GC, 1996, J VIROL, V70, P2101, DOI 10.1128/JVI.70.4.2101-2106.1996; PARKER CE, 1994, J VIROL, V68, P2860, DOI 10.1128/JVI.68.5.2860-2868.1994; Plumelle Y, 1997, AM J CLIN PATHOL, V107, P81; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; RICHARDSON JH, 1990, J VIROL, V64, P5682, DOI 10.1128/JVI.64.11.5682-5687.1990; ROBINSON RD, 1990, J TROP MED HYG, V94, P411; SETOYAMA M, 1994, INT J CANCER, V57, P760, DOI 10.1002/ijc.2910570525; SHINZATO O, 1991, BLOOD, V78, P2082; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; SUZUKI T, 1993, ONCOGENE, V8, P2391; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TACHIBANA N, 1988, INT J CANCER, V42, P829, DOI 10.1002/ijc.2910420605; Tsukasaki K, 1997, BLOOD, V89, P948, DOI 10.1182/blood.V89.3.948; TSURUMI H, 1992, AM J HEMATOL, V41, P292, DOI 10.1002/ajh.2830410414; VARTANIAN JP, 1991, J VIROL, V65, P1779, DOI 10.1128/JVI.65.4.1779-1788.1991; WATTEL E, 1992, J ACQ IMMUN DEF SYND, V5, P943; WATTEL E, 1995, J VIROL, V69, P2863, DOI 10.1128/JVI.69.5.2863-2868.1995; Wattel E, 1996, J ACQUIR IMMUNE D S1, V13, P92; Yin MJ, 1996, J BIOL CHEM, V271, P4781, DOI 10.1074/jbc.271.9.4781; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; ZANKE BW, 1989, TRANSPLANTATION, V48, P695; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	46	89	91	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 9	1998	17	1					77	82		10.1038/sj.onc.1201906	http://dx.doi.org/10.1038/sj.onc.1201906			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZY936	9671316				2022-12-25	WOS:000074677800009
J	Tanimura, S; Chatani, Y; Hoshino, R; Sato, M; Watanabe, S; Kataoka, T; Nakamura, T; Kohno, M				Tanimura, S; Chatani, Y; Hoshino, R; Sato, M; Watanabe, S; Kataoka, T; Nakamura, T; Kohno, M			Activation of the 41/43 kDa mitogen-activated protein kinase signaling pathway is required for hepatocyte growth factor-induced cell scattering	ONCOGENE			English	Article						HGF; cell scattering; MAP kinase signaling pathway; MEK inhibitor	MET PROTOONCOGENE PRODUCT; FACTOR-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; CARCINOMA-CELLS; RAS ACTIVATION; FAMILY; CASCADE; INHIBITION	Hepatocyte growth factor (HGF) markedly induced the spreading, dissociation and scattering of Madin-Darby canine kidney epithelial cells (MDCK) and human stomach adenocarcinoma cells (TMK1). Scattering of MDCK and TMK1 cells was induced by 12-O-tetradecanoyl-phorbol-13-acetate (PMA) and epidermal growth factor (EGF), respectively. In all these agent-stimulated cells, rapid activation of Raf-l, MAP kinase/ERK kinase (MEK), 41/43 kDa MAP kinases and p90(rsk) was commonly observed. In contrast, PMA neither induced the scattering nor activation of all these kinases in TMK1 cells. Pretreatment of MDCK and TMK1 cells with 2-(2-amino-3-methoxyphenyl) choromone (AMPC), a specific inhibitor of MEK, selectively inhibited the HGF-, PMA- and EGF-stimulated activities of MEM, 41/43 kDa MAP kinases and p90(rsk) in a dose dependent manner. AMPC-pretreatment, however, did not affect HGF-, PMA- or EGF-induced activation of Raf-l, nor HGF-induced activation of phosphatidylinositol 3-kinase in these cells. Importantly, HGF-, PMA- and EGF-induced scattering of MDCK and TMK1 cells was inhibited at doses of AMPC similar to those that gave comparable levels of inhibition of the activities of MER, 41/43 kDa MAP kinases and p90(rsk), These results suggest that activation of the 41/43 kDa MAP kinase signaling pathway is required for the motility response of MDCK and TMK1 cells induced by agents such as HGF, PMA and EGF.	Nagasaki Univ, Sch Pharmaceut Sci, Lab Cell Regulat, Nagasaki 8528131, Japan; Gifu Pharmaceut Univ, Gifu 502, Japan; Osaka Univ, Sch Med, Biomed Res Ctr, Suita, Osaka 565, Japan	Nagasaki University; Gifu Pharmaceutical University; Osaka University	Kohno, M (corresponding author), Nagasaki Univ, Sch Pharmaceut Sci, Lab Cell Regulat, 1-14 Bunkyo Machi, Nagasaki 8528131, Japan.		Kohno, Michiaki/R-6532-2019	Kohno, Michiaki/0000-0002-7644-0059				AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P273; BIRCHMEIER C, 1993, ANNU REV CELL BIOL, V9, P511, DOI 10.1146/annurev.cb.09.110193.002455; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUDAY L, 1995, ONCOGENE, V11, P1327; CHATANI Y, 1992, J BIOL CHEM, V267, P9911; Chatani Y, 1995, J BIOL CHEM, V270, P30686, DOI 10.1074/jbc.270.51.30686; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Comoglio PM, 1996, GENES CELLS, V1, P347, DOI 10.1046/j.1365-2443.1996.37037.x; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DOWRICK PG, 1991, CYTOKINE, V3, P299, DOI 10.1016/1043-4666(91)90498-3; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Ferby IM, 1996, J BIOL CHEM, V271, P11684, DOI 10.1074/jbc.271.20.11684; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Klippel A, 1996, MOL CELL BIOL, V16, P4117; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1991, Progress in Growth Factor Research, V3, P67, DOI 10.1016/0955-2235(91)90014-U; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Okada T, 1996, BIOCHEM J, V317, P475, DOI 10.1042/bj3170475; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Porfiri E, 1996, J BIOL CHEM, V271, P5871, DOI 10.1074/jbc.271.10.5871; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Scheid MP, 1996, J BIOL CHEM, V271, P18134, DOI 10.1074/jbc.271.30.18134; Schramek H, 1997, J BIOL CHEM, V272, P11426; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; SMITH DB, 1990, CURRENT PROTOCOLS MO, V2; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883	44	90	95	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 9	1998	17	1					57	65		10.1038/sj.onc.1201905	http://dx.doi.org/10.1038/sj.onc.1201905			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZY936	9671314				2022-12-25	WOS:000074677800007
J	White, A; Lamb, PW; Barrett, JC				White, A; Lamb, PW; Barrett, JC			Frequent downregulation of the KAI1(CD82) metastasis suppressor protein in human cancer cell lines	ONCOGENE			English	Article						KAI1 (CD82); metastasis suppressor gene; prostate cancer; transmembrane four superfamily	LEUKEMIA-VIRUS TYPE-1; ANTIPROLIFERATIVE ANTIBODY; MONOCLONAL-ANTIBODY; SYNCYTIUM FORMATION; PROSTATE-CANCER; C33 ANTIGEN; T-CELLS; EXPRESSION; SURFACE; MOTILITY	KAI1 is a metastasis suppressor gene on human chromosome 11p11.2 that encodes a glycoprotein of the transmembrane four superfamily, Reduced KAI1 expression associates with malignant progression of human prostatic, lung and pancreatic cancers, but the role of KAI1 protein in the malignant progression of other human cancers remains to be elucidated. We analysed KAI1 protein in normal and cancer cells of the prostate, ovary, bladder, endometrium, lung and melanocytes by Western blot to determine if KAI1 may be involved in multiple cancers. We also investigated the relationship of KAI1 expression and two other transmembrane four superfamily proteins, CD81 and CD9, in the cells. We found that KAI1 protein was downregulated in 31/42 of the cancer cell lines analysed. Alternatively, some ovarian, bladder and endometrial cells had distinct, heterogeneous KAI1 protein band patterns in Western blots that were due primarily to N-linked glycosylation. Most of the cancer cells expressed two other transmembrane four superfamily proteins, CD81 and CD9, Downregulation of KAI1 protein may be an indicator of metastatic potential in cancers of urogenital, gynecological, and pulmonary origin and in melanomas, KAI1 may also have post-translational modifications specific to tissue type or malignant progression.	NIEHS, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Barrett, JC (corresponding author), NIEHS, Mol Carcinogenesis Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.							Adachi M, 1996, CANCER RES, V56, P1751; ANGELISOVA P, 1994, IMMUNOGENETICS, V39, P249; ATKINSON B, 1985, HYBRIDOMA, V4, P243, DOI 10.1089/hyb.1985.4.243; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; DEAR TN, 1990, MOL ASPECTS MED, V11, P243, DOI 10.1016/0098-2997(90)90005-M; Dennis J W, 1991, Semin Cancer Biol, V2, P411; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Dong JT, 1996, CANCER RES, V56, P4387; ENGEL P, 1994, LEUKEMIA LYMPHOMA, V13, P61, DOI 10.3109/10428199409052677; FUKUDOME K, 1992, J VIROL, V66, P1394, DOI 10.1128/JVI.66.3.1394-1401.1992; FUSENIG NE, 1991, HUMAN CANC PRIMARY C, P55; GAUGITSCH HW, 1991, EUR J IMMUNOL, V21, P377, DOI 10.1002/eji.1830210219; Guo XZ, 1996, CANCER RES, V56, P4876; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; IMAI T, 1993, J IMMUNOL, V151, P6470; Kakizoe T, 1995, Int J Urol, V2 Suppl 2, P58, DOI 10.1111/j.1442-2042.1995.tb00480.x; KOHN EC, 1993, ANTICANCER RES, V13, P2553; Lagaudriere-Gesbert C, 1997, J IMMUNOL, V158, P2790; LEBELBINAY S, 1994, CELL IMMUNOL, V154, P468, DOI 10.1006/cimm.1994.1092; MIYAKE M, 1995, CANCER RES, V55, P4127; MIYAKE M, 1991, J EXP MED, V174, P1347, DOI 10.1084/jem.174.6.1347; NOJIMA Y, 1993, CELL IMMUNOL, V152, P249, DOI 10.1006/cimm.1993.1285; OREN R, 1990, MOL CELL BIOL, V10, P4007, DOI 10.1128/MCB.10.8.4007; Rubinstein E, 1996, EUR J IMMUNOL, V26, P2657, DOI 10.1002/eji.1830261117; SHARKEY FE, 1979, INT J CANCER, V24, P733, DOI 10.1002/ijc.2910240605; TAKAHASHI S, 1990, J IMMUNOL, V145, P2207; Ueda T, 1996, AM J PATHOL, V149, P1435	27	66	76	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 18	1998	16	24					3143	3149		10.1038/sj.onc.1201852	http://dx.doi.org/10.1038/sj.onc.1201852			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671393	Bronze			2022-12-25	WOS:000074261300007
J	Barker, EL; Perlman, MA; Adkins, EM; Houlihan, WJ; Pristupa, ZB; Niznik, HB; Blakely, RD				Barker, EL; Perlman, MA; Adkins, EM; Houlihan, WJ; Pristupa, ZB; Niznik, HB; Blakely, RD			High affinity recognition of serotonin transporter antagonists defined by species-scanning mutagenesis - An aromatic residue in transmembrane domain I dictates species-selective recognition of citalopram and mazindol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NOREPINEPHRINE TRANSPORTER; SINGLE AMINO-ACID; DOPAMINE TRANSPORTER; RAT-BRAIN; EXPRESSION CLONING; STRUCTURAL DOMAINS; OVERLAP EXTENSION; COCAINE BINDING; RNA-POLYMERASE; SITE	Human and Drosophila melanogaster serotonin (5-HT) transporters (SERTs) exhibit similar 5-HT transport kinetics and can be distinguished pharmacologically by many, but not all, biogenic amine transporter antagonists. By using human and Drosophila SERT chimeras, major determinants of potencies of two transporter antagonists, mazindol and citalopram, were tracked to the amino-terminal domains encompassing transmembrane domains I and II. Species-scanning mutagenesis, whereby amino acid substitutions are made switching residues from one species to another, was employed on the eight amino acids that differ between human and Drosophila SERTs in this region, and antagonist potencies were reassessed in 5-HT uptake assays. A single mutation in transmembrane domain I of human SERT, Y95F, shifted both citalopram and mazindol to Drosophila SERT-Iike potencies, Strikingly, these potency changes were in opposite directions suggesting Tyros contributes both positive and negative determinants of antagonist potency. To gain insight into how the Y95F mutant might influence mazindol potency, we determined how structural variants of mazindol responded to the mutation, Our studies demonstrate the importance of the hydroxyl group on the heterocyclic nucleus of mazindol for maintaining species-selective recognition of mazindol and suggest that transmembrane domain I participates in the formation of antagonist-binding sites for amine transporters.	Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Neurosci, Nashville, TN 37232 USA; Purdue Univ, Sch Pharm, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA; Drew Univ, Charles A Dana Res Inst, Madison, NJ 07940 USA; Clarke Inst Psychiat, Dept Psychiat, Toronto, ON M5T 1RS, Canada; Clarke Inst Psychiat, Mol Neurobiol Lab, Toronto, ON M5T 1RS, Canada	Vanderbilt University; Vanderbilt University; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Drew University; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada	Blakely, RD (corresponding author), Vanderbilt Univ, Sch Med, Dept Pharmacol, 412 MRB 2, Nashville, TN 37232 USA.				NATIONAL INSTITUTE ON DRUG ABUSE [R03DA008516, F32DA005679, R01DA007390] Funding Source: NIH RePORTER; NIDA NIH HHS [R01-DA7390, F32-DA05679, R03-DA8516-02] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		BARCZA S, 1975, J PHARM SCI, V64, P829, DOI 10.1002/jps.2600640522; Barker EL, 1996, MOL PHARMACOL, V50, P957; BARKER EL, 1994, MOL PHARMACOL, V46, P799; BARKER EL, 1998, NEUROTRANSMITTER TRA; Barker Eric L., 1995, P321; Bennett ER, 1997, J BIOL CHEM, V272, P1203, DOI 10.1074/jbc.272.2.1203; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; BRUSS M, 1995, J BIOL CHEM, V270, P9197; Buck KJ, 1995, MOL PHARMACOL, V48, P1030; BUCK KJ, 1994, P NATL ACAD SCI USA, V91, P12584, DOI 10.1073/pnas.91.26.12584; Chang AS, 1996, MOL BRAIN RES, V43, P185, DOI 10.1016/S0169-328X(96)00172-6; Chen JG, 1997, BIOCHEMISTRY-US, V36, P1479, DOI 10.1021/bi962256g; CHEN JX, 1997, NEUR ABSTR, V23; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Clark JA, 1997, J BIOL CHEM, V272, P14695, DOI 10.1074/jbc.272.23.14695; COREY JL, 1994, P NATL ACAD SCI USA, V91, P1188, DOI 10.1073/pnas.91.3.1188; DEMCHYSHYN LL, 1994, P NATL ACAD SCI USA, V91, P5158, DOI 10.1073/pnas.91.11.5158; DUGGER HA, 1976, DRUG METAB DISPOS, V4, P262; FONG TM, 1992, J BIOL CHEM, V267, P25668; FOZARD J, 1989, PERIPHERAL ACTIONS 5; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GAOZZA CH, 1972, J HETEROCYCLIC CHEM, V9, P883, DOI 10.1002/jhet.5570090422; GIROS B, 1994, J BIOL CHEM, V269, P15985; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HALL JM, 1993, TRENDS PHARMACOL SCI, V14, P376, DOI 10.1016/0165-6147(93)90096-3; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; HOULIHAN WJ, 1982, J ORG CHEM, V47, P5177, DOI 10.1021/jo00147a027; Houlihan WJ, 1996, J MED CHEM, V39, P4935, DOI 10.1021/jm960288w; HOULIHAN WJ, 1998, IN PRESS MED CHEM RE; KAO HT, 1992, FEBS LETT, V307, P324, DOI 10.1016/0014-5793(92)80705-L; KILTY JE, 1991, SCIENCE, V254, P578, DOI 10.1126/science.1948035; KITAYAMA S, 1993, SYNAPSE, V15, P58, DOI 10.1002/syn.890150107; KITAYAMA S, 1992, P NATL ACAD SCI USA, V89, P7782, DOI 10.1073/pnas.89.16.7782; KOE BK, 1976, J PHARMACOL EXP THER, V199, P649; MELIKIAN HE, 1994, J BIOL CHEM, V269, P12290; Melikian HE, 1996, MOL PHARMACOL, V50, P266; Meltesics W, 1975, Patent No. [US 3905994 A, 3905994]; MOORE KR, 1994, BIOTECHNIQUES, V17, P130; OKSENBERG D, 1992, NATURE, V360, P161, DOI 10.1038/360161a0; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; Padbury JF, 1997, MOL BRAIN RES, V45, P163, DOI 10.1016/S0169-328X(96)00309-9; Qian Y, 1997, J NEUROSCI, V17, P45, DOI 10.1523/JNEUROSCI.17-01-00045.1997; QIAN Y, 1995, J NEUROSCI, V15, P1261; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; REIZER J, 1994, BBA-REV BIOMEMBRANES, V1197, P133, DOI 10.1016/0304-4157(94)90003-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; TATE CG, 1994, J BIOL CHEM, V269, P26303; VAUGHAN RA, 1995, MOL PHARMACOL, V47, P956; WADZINSKI BE, 1992, J BIOL CHEM, V267, P16883; ZIFA E, 1992, PHARMACOL REV, V44, P401	54	126	128	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19459	19468		10.1074/jbc.273.31.19459	http://dx.doi.org/10.1074/jbc.273.31.19459			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677366	hybrid			2022-12-25	WOS:000075125200018
J	Hii, CST; Huang, ZH; Bilney, A; Costabile, M; Murray, AW; Rathjen, DA; Der, CJ; Ferrante, A				Hii, CST; Huang, ZH; Bilney, A; Costabile, M; Murray, AW; Rathjen, DA; Der, CJ; Ferrante, A			Stimulation of p38 phosphorylation and activity by arachidonic acid in HeLa cells, HL60 promyelocytic leukemic cells, and human neutrophils - Evidence for cell type-specific activation of mitogen-activated protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYUNSATURATED FATTY-ACIDS; GAP-JUNCTIONAL COMMUNICATION; NECROSIS-FACTOR-ALPHA; NADPH-OXIDASE; WB CELLS; SUPEROXIDE PRODUCTION; 2ND MESSENGER; PHORBOL ESTER; MAP KINASE; LONG-CHAIN	Although it is well appreciated that arachidonic acid, a second messenger molecule that is released by ligand-stimulated phospholipase A(2), stimulates a wide range of cell types, the mechanisms that mediate the actions of arachidonic acid are still poorly understood, We now report that arachidonic acid stimulated the appearance of dual-phosphorylated (active) p38 mitogen-activated protein kinase as detected by Western blotting in HeLa cells, HL60 cells, human neutrophils, and human umbilical vein endothelial cells but not Jurkat cells. An increase in p38 kinase activity caused by arachidonic acid was also observed. Further studies with neutrophils show that the stimulation of p38 dual phosphorylation by arachidonic acid was transient, peaking;at 5 min, and was concentration-dependent. The effect of arachidonic acid was not affected by either nordihydroguaiaretic acid, an inhibitor of the 5-, 12-, and 15-lipoxygenases or by indomethacin, an inhibitor of cyclooxygenase, Arachidonic acid also stimulated the phosphorylation and/or activity of the extracellular signal-regulated protein kinase and of c-jun N-terminal. kinase in a cell-type-specific manner. An examination of the mechanisms through which arachidonic acid stimulated the phosphorylation/activity of p38 and extracellular signal-regulated protein kinase in neutrophils revealed an involvement of protein kinase C, Thus, arachidonic acid stimulated the translocation of protein kinase C alpha; beta I, and beta II to a particulate fraction, and the effects of arachidonic acid on mitogen-activated protein kin;ase phosphorylation/activity were partially inhibited by GF109203X, an inhibitor of protein kinase C, This study Is the first to demonstrate that a polyunsaturated fatty acid causes the dual phosphorylation and activation of p38.	Womens & Childrens Hosp, Dept Immunopathol, N Adelaide, SA 5006, Australia; Flinders Univ S Australia, Sch Biol Sci, Bedford Pk, SA 5042, Australia; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA	Flinders University South Australia; University of North Carolina; University of North Carolina Chapel Hill	Hii, CST (corresponding author), Womens & Childrens Hosp, Dept Immunopathol, N Adelaide, SA 5006, Australia.		costabile, maurizio/AEN-4356-2022	costabile, maurizio/0000-0002-2162-6497; Der, Channing/0000-0002-7751-2747				ABRAMSON SB, 1991, J IMMUNOL, V147, P231; Alessi DR, 1997, FEBS LETT, V402, P121, DOI 10.1016/S0014-5793(96)01510-4; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANEL A, 1993, BIOCHEMISTRY-US, V32, P530, DOI 10.1021/bi00053a018; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BAND AM, 1992, J MOL ENDOCRINOL, V8, P95, DOI 10.1677/jme.0.0080095; BATES EJ, 1995, ATHEROSCLEROSIS, V116, P247, DOI 10.1016/0021-9150(95)05553-9; BATES EJ, 1993, J LEUKOCYTE BIOL, V53, P420, DOI 10.1002/jlb.53.4.420; Berk PD, 1996, P SOC EXP BIOL MED, V212, P1; BorschHaubold AG, 1997, EUR J BIOCHEM, V245, P751, DOI 10.1111/j.1432-1033.1997.t01-1-00751.x; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; CLARKE SD, 1993, PROG LIPID RES, V32, P139, DOI 10.1016/0163-7827(93)90013-M; COREY SJ, 1991, J LAB CLIN MED, V118, P343; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; Cui XL, 1997, P NATL ACAD SCI USA, V94, P3771, DOI 10.1073/pnas.94.8.3771; DECOURSEY TE, 1993, BIOPHYS J, V65, P1590, DOI 10.1016/S0006-3495(93)81198-6; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; El-Shemerly MYM, 1997, J BIOL CHEM, V272, P30599, DOI 10.1074/jbc.272.49.30599; ElBenna J, 1996, ARCH BIOCHEM BIOPHYS, V334, P395; FERRANTE A, 1982, J IMMUNOL METHODS, V48, P81, DOI 10.1016/0022-1759(82)90212-5; FINSTAD HS, 1994, BLOOD, V84, P3799, DOI 10.1182/blood.V84.11.3799.bloodjournal84113799; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HARDY SJ, 1995, BIOCHEM J, V311, P689, DOI 10.1042/bj3110689; HENDERSON LM, 1995, J BIOL CHEM, V270, P5909, DOI 10.1074/jbc.270.11.5909; HII CST, 1995, J BIOL CHEM, V270, P4201, DOI 10.1074/jbc.270.9.4201; HII CST, 1995, CARCINOGENESIS, V16, P1505, DOI 10.1093/carcin/16.7.1505; HII CST, 1991, J BIOL CHEM, V266, P20238; HII CST, 1994, BIOCHEM J, V303, P475, DOI 10.1042/bj3030475; Huang ZH, 1997, BIOCHEM J, V325, P553, DOI 10.1042/bj3250553; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LU Y, 1994, J IMMUNOL, V153, P1495; MCPHAIL LC, 1984, SCIENCE, V224, P622, DOI 10.1126/science.6231726; MURAKAMI K, 1985, FEBS LETT, V192, P189, DOI 10.1016/0014-5793(85)80105-8; NICHOLS RC, 1990, J EXP MED, V171, P367, DOI 10.1084/jem.171.2.367; POULOS A, 1991, IMMUNOLOGY, V73, P102; RAO GN, 1994, J BIOL CHEM, V269, P32586; Rizzo MT, 1996, BLOOD, V88, P3792, DOI 10.1182/blood.V88.10.3792.bloodjournal88103792; Robinson BS, 1997, IMMUNOLOGY, V91, P274, DOI 10.1046/j.1365-2567.1997.d01-2227.x; Robinson BS, 1996, J LIPID RES, V37, P1234; ROSE H, 1990, J MOL CELL CARDIOL, V22, P883, DOI 10.1016/0022-2828(90)90119-M; Sakata N, 1995, J BIOL CHEM, V270, P30823, DOI 10.1074/jbc.270.51.30823; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SMALLWOOD JI, 1992, J LEUKOCYTE BIOL, V51, P84, DOI 10.1002/jlb.51.1.84; Smirnov SV, 1996, CIRC RES, V79, P20, DOI 10.1161/01.RES.79.1.20; STEINBECK MJ, 1991, J BIOL CHEM, V266, P16336; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VYSKA K, 1991, CIRC RES, V69, P857, DOI 10.1161/01.RES.69.3.857; Wieland SJ, 1996, J BIOL CHEM, V271, P19037, DOI 10.1074/jbc.271.32.19037; WOLF BA, 1986, J BIOL CHEM, V261, P3501; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	56	95	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19277	19282		10.1074/jbc.273.30.19277	http://dx.doi.org/10.1074/jbc.273.30.19277			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668117	hybrid			2022-12-25	WOS:000074974700084
J	Humpf, HU; Schmelz, EM; Meredith, FI; Vesper, H; Vales, TR; Wang, E; Menaldino, DS; Liotta, DC; Merrill, AH				Humpf, HU; Schmelz, EM; Meredith, FI; Vesper, H; Vales, TR; Wang, E; Menaldino, DS; Liotta, DC; Merrill, AH			Acylation of naturally occurring and synthetic 1-deoxysphinganines by ceramide synthase - Formation of N-palmitoyl-aminopentol produces a toxic metabolite of hydrolyzed fumonisin, AP(1), and a new category of ceramide synthase inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NOVO SPHINGOLIPID BIOSYNTHESIS; FUSARIUM-MONILIFORME; ESOPHAGEAL CANCER; SPHINGOSINE; CYTOTOXICITY; BASES; CELLS; CORN; SPHINGANINE; MYCOTOXINS	Fumonisin B-1 (FB1) is the predominant member of a family of mycotoxins produced by Fusarium moniliforme (Sheldon) and related fungi. Certain foods also contain the aminopentol backbone (AP(1)) that is formed upon base hydrolysis of the ester-linked tricarballylic acids of FB,. Both FB, and, to a lesser extent, AP(1) inhibit ceramide synthase due to structural similarities between fumonisins (as 1-deoxy-analogs of sphinganine) and sphingoid bases. To explore these structure-function relationships further, erythro- and threo-2-amino, 3-hydroxy- (and 3, 5-dihydroxy-) octadecanes were prepared by highly stereoselective syntheses. All of these analogs inhibit the acylation of sphingoid bases by ceramide synthase, and are themselves acylated with V-max/K-m of 40-125 for the erythro-isomers (compared with approximately 250 for D-erythro-sphinganine) and 4-6 for the threo-isomers. Ceramide synthase also acylates AP(1) (but not FB,, under the conditions tested) to N-palmitoyl-AP(1) (PAP(1)) with a V-max/K-m of approximately 1. The toxicity of PAP(1) was evaluated using HT29 cells, a human colonic cell line. PAP(1) was at least 10 times more toxic than FB, or AP(1) and caused sphinganine accumulation as an inhibitor of ceramide synthase. These studies demonstrate that: the 1-hydroxyl group is not required for sphingoid bases to be acylated; both erythro- and threo isomers are acylated with the highest apparent V-max/K-m for the erythro-analogs; and AP(1) is acylated to PAP(1), a new category of ceramide synthase inhibitor as well as a toxic metabolite that may play a role in the diseases caused by fumonisins.	Univ Wurzburg, Lehrstuhl Lebensmittelchem, D-97074 Wurzburg, Germany; Emory Univ, Sch Med, Dept Chem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; USDA ARS, Toxicol & Mycotoxin Res Unit, Athens, GA 30613 USA	University of Wurzburg; Emory University; Emory University; United States Department of Agriculture (USDA)	Humpf, HU (corresponding author), Univ Wurzburg, Lehrstuhl Lebensmittelchem, Hubland, D-97074 Wurzburg, Germany.	amerril@emory.edu	Schmelz, Eva M/E-6579-2012; Humpf, Hans-Ulrich/AAV-4845-2020	Merrill, Alfred/0000-0002-6673-968X; Humpf, Hans-Ulrich/0000-0003-3296-3058	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046368] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 46368] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEZUIDENHOUT SC, 1988, J CHEM SOC CHEM COMM, P743, DOI 10.1039/c39880000743; Bhat RV, 1997, J TOXICOL-CLIN TOXIC, V35, P249, DOI 10.3109/15563659709001208; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; Blackwell BA, 1996, ADV EXP MED BIOL, V392, P75; BRANHAM BE, 1993, J NAT PROD, V56, P1630, DOI 10.1021/np50099a030; CHU FS, 1994, APPL ENVIRON MICROB, V60, P847, DOI 10.1128/AEM.60.3.847-852.1994; Harrison L R, 1990, J Vet Diagn Invest, V2, P217; HENDRICH S, 1993, J AGR FOOD CHEM, V41, P1649, DOI 10.1021/jf00034a025; Jarvis WD, 1996, J BIOL CHEM, V271, P8275, DOI 10.1074/jbc.271.14.8275; KARLSSON KA, 1970, LIPIDS, V5, P878, DOI 10.1007/BF02531119; KELLERMAN TS, 1990, ONDERSTEPOORT J VET, V57, P269; KRAUS GA, 1992, J AGR FOOD CHEM, V40, P2331, DOI 10.1021/jf00024a001; Marasas WFO, 1996, ADV EXP MED BIOL, V392, P1; MERRILL AH, 1993, ADV LIPID RES, V26, P215; Merrill AH, 1996, TRENDS CELL BIOL, V6, P218, DOI 10.1016/0962-8924(96)10021-0; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; MERRILL AH, 1992, METHOD ENZYMOL, V209, P427; Nikolova-Karakashian M. N., 1997, SPHINGOLIPID MEDIATE, P159; OHTA H, 1995, CANCER RES, V55, P691; RHEEDER JP, 1992, PHYTOPATHOLOGY, V82, P353, DOI 10.1094/Phyto-82-353; Riley Ronald T., 1996, Natural Toxins, V4, P3, DOI 10.1002/19960401NT2; RILEY RT, 1993, TOXICOL APPL PHARM, V118, P105, DOI 10.1006/taap.1993.1015; SCHMELZ EM, 1994, J NUTR, V124, P702, DOI 10.1093/jn/124.5.702; Schmelz EM, 1998, TOXICOL APPL PHARM, V148, P252, DOI 10.1006/taap.1997.8356; Shephard Gordon S., 1995, Natural Toxins, V3, P145, DOI 10.1002/nt.2620030305; SHEPHARD GS, 1992, TOXICON, V30, P768, DOI 10.1016/0041-0101(92)90011-S; STEVENS VL, 1990, BIOCHIM BIOPHYS ACTA, V1051, P37, DOI 10.1016/0167-4889(90)90171-9; STOFFEL W, 1973, H-S Z PHYSIOL CHEM, V354, P169, DOI 10.1515/bchm2.1973.354.1.169; Sweeney EA, 1996, INT J CANCER, V66, P358, DOI 10.1002/(SICI)1097-0215(19960503)66:3<358::AID-IJC16>3.0.CO;2-7; SYDENHAM EW, 1990, J AGR FOOD CHEM, V38, P1900, DOI 10.1021/jf00100a004; Voss KA, 1998, ENVIRON TOXICOL PHAR, V5, P101, DOI 10.1016/S1382-6689(97)10009-6; Voss KA, 1996, FOOD CHEM TOXICOL, V34, P623, DOI 10.1016/0278-6915(96)00024-5; WANG E, 1992, J NUTR, V122, P1706, DOI 10.1093/jn/122.8.1706; WANG E, 1991, J BIOL CHEM, V266, P14486; Wilson T M, 1990, J Vet Diagn Invest, V2, P213; YOO HS, 1992, TOXICOL APPL PHARM, V114, P9, DOI 10.1016/0041-008X(92)90090-F; Yoo HS, 1996, TOXICOL APPL PHARM, V138, P211, DOI 10.1006/taap.1996.0119	38	133	139	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19060	19064		10.1074/jbc.273.30.19060	http://dx.doi.org/10.1074/jbc.273.30.19060			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668088	hybrid			2022-12-25	WOS:000074974700055
J	Li, XL; Matsuoka, Y; Bennett, V				Li, XL; Matsuoka, Y; Bennett, V			Adducin preferentially recruits spectrin to the fast growing ends of actin filaments in a complex requiring the MARCKS-related domain and a newly defined oligomerization domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HUMAN-ERYTHROCYTE MEMBRANE; GEL-SOL TRANSFORMATION; REGULATORY PROTEIN; BUNDLING PROTEIN; CROSS-LINKING; ATOMIC MODEL; BARBED ENDS; GELSOLIN; CALMODULIN	Adducin is a protein associated with spectrin and actin in membrane skeletons of erythrocytes sind possibly other cells, Adducin has activities in in vitro assays of association with the sides of actin filaments, capping the fast growing ends of actin filaments, and: recruiting spectrin to actin filaments, This study presents evidence that adducin exhibits a preference for the fast growing ends of actin filaments for recruiting spectrin to actin and for direct association with actin, beta-Adducin-(335-726) promoted recruitment of spectrin to gelsolin-sensitive sites at fast growing ends of actin filaments with half-maximal activity at 15 nM and to gelsolin-insensitive sites with half-maximal activity at 75 nM,. beta-Adducin(335-726) also exhibited a preference for actin filament ends in direct binding assays; the half-maximal concentration for binding of adducin to gelsolin-sensitive sites at filament ends was 60 nM, and the K-d for binding to lateral sites was 1.5 mu M. The concentration of beta-adducin(335-726) of 60 nM required for half-maximal binding to filament ends is in the same range as the concentration of 150 nM required for half-maximal actin capping activity. All interactions of adducin with actin require the myristoylated alanine-rich protein kinase substrate-related domain as well as a newly defined oligomerization site localized in the neck domain of adducin. Surprisingly, the head domain of adducin is not required for spectrin-actin interactions, although it could play a role in forming tetramers, The relative activities of adducin imply that an important role of adducin in cells is to form a complex with the fast growing ends of actin filaments that recruits spectrin and prevents addition or loss of actin subunits.	Duke Univ, Med Ctr, Dept Cell Biol & Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA	Duke University; Duke University; Howard Hughes Medical Institute	Bennett, V (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol & Biochem, Durham, NC 27710 USA.			Li, Xiaolin/0000-0001-9611-2434				BENNETT V, 1988, J BIOL CHEM, V263, P5860; BENNETT V, 1993, ANN REV CELL BIOL, V9, P7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burtnick LD, 1997, CELL, V90, P661, DOI 10.1016/S0092-8674(00)80527-9; BYERS TJ, 1985, P NATL ACAD SCI USA, V82, P6153, DOI 10.1073/pnas.82.18.6153; DAVIS J, 1983, J BIOL CHEM, V258, P7757; DERICK LH, 1992, EUR J CELL BIOL, V57, P317; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FENNER C, 1975, ANAL BIOCHEM, V63, P595, DOI 10.1016/0003-2697(75)90386-3; Fowler VM, 1996, CURR OPIN CELL BIOL, V8, P86, DOI 10.1016/S0955-0674(96)80052-4; FOWLER VM, 1984, J BIOL CHEM, V259, P5978; GARDNER K, 1987, NATURE, V328, P359, DOI 10.1038/328359a0; GARDNER K, 1986, J BIOL CHEM, V261, P1339; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; Holleran EA, 1996, J CELL BIOL, V135, P1815, DOI 10.1083/jcb.135.6.1815; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; HUGHES CA, 1995, J BIOL CHEM, V270, P18990, DOI 10.1074/jbc.270.32.18990; JANMEY PA, 1987, J BIOL CHEM, V262, P12228; JANMEY PA, 1985, BIOCHEMISTRY-US, V24, P3714, DOI 10.1021/bi00335a046; JOSHI R, 1990, J BIOL CHEM, V265, P13130; JOSHI R, 1991, J CELL BIOL, V115, P665, DOI 10.1083/jcb.115.3.665; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KAISER HW, 1989, J CELL BIOL, V109, P557, DOI 10.1083/jcb.109.2.557; Kimura K, 1998, J BIOL CHEM, V273, P5542, DOI 10.1074/jbc.273.10.5542; Kuhlman PA, 1996, J BIOL CHEM, V271, P7986, DOI 10.1074/jbc.271.14.7986; Kuhlman PA, 1997, BIOCHEMISTRY-US, V36, P13461, DOI 10.1021/bi970601b; LAMB JA, 1993, J BIOL CHEM, V268, P8999; Li XL, 1996, J BIOL CHEM, V271, P15695, DOI 10.1074/jbc.271.26.15695; LIN DC, 1979, P NATL ACAD SCI USA, V76, P2345, DOI 10.1073/pnas.76.5.2345; LIN HF, 1994, DEVELOPMENT, V120, P947; LING E, 1986, J BIOL CHEM, V261, P13875; LO SH, 1994, J CELL BIOL, V125, P1067, DOI 10.1083/jcb.125.5.1067; LORENZ M, 1995, J MOL BIOL, V246, P108, DOI 10.1006/jmbi.1994.0070; Matsuoka Y, 1996, J BIOL CHEM, V271, P25157, DOI 10.1074/jbc.271.41.25157; MATSUOKA Y, 1998, IN PRESS J CELL BIOL; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; MISCHE SM, 1987, J CELL BIOL, V105, P2837, DOI 10.1083/jcb.105.6.2837; NEHLS V, 1991, BLOOD, V78, P1692; PARDEE JD, 1982, METHOD CELL BIOL, V24, P217; POLLARD TD, 1983, ANAL BIOCHEM, V134, P406, DOI 10.1016/0003-2697(83)90316-0; Schafer DA, 1996, J CELL BIOL, V135, P169, DOI 10.1083/jcb.135.1.169; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SHEN BW, 1986, J CELL BIOL, V102, P997, DOI 10.1083/jcb.102.3.997; SIEGEL DL, 1985, J CELL BIOL, V100, P775, DOI 10.1083/jcb.100.3.775; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAYLOR KA, 1994, BIOPHYS J, V67, P1976, DOI 10.1016/S0006-3495(94)80680-0; WEBER A, 1987, BIOCHEMISTRY-US, V26, P2528, DOI 10.1021/bi00383a019; WEBER A, 1994, J CELL BIOL, V127, P1672; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0; YIN HL, 1981, J BIOL CHEM, V256, P9693; YIN HL, 1981, J CELL BIOL, V91, P901, DOI 10.1083/jcb.91.3.901; YIN HL, 1987, BIOESSAYS, V7, P176, DOI 10.1002/bies.950070409	54	85	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19329	19338		10.1074/jbc.273.30.19329	http://dx.doi.org/10.1074/jbc.273.30.19329			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668123	hybrid			2022-12-25	WOS:000074974700090
J	Druey, KM; Sullivan, BM; Brown, D; Fischer, ER; Watson, N; Blumer, KJ; Gerfen, CR; Scheschonka, A; Kehrl, JH				Druey, KM; Sullivan, BM; Brown, D; Fischer, ER; Watson, N; Blumer, KJ; Gerfen, CR; Scheschonka, A; Kehrl, JH			Expression of GTPase-deficient G(i alpha 2) results in translocation of cytoplasmic RGS4 to the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-PROTEIN; RECEPTORS; FAMILY; DOMAIN; CELLS; GAIP	The members of a recently identified protein family termed regulators of G-protein signaling (RGS) act as GTPase activating proteins for certain G(alpha) subunits in vitro, but their physiological effects in cells are uncertain in the face of similar biochemical activity and overlapping patterns of tissue expression. Consistent with its activity in in vitro GTPase-activating protein assays, RGS4 interacts efficiently with endogenous proteins of the G(i) and G(q) subclasses of G(alpha) subunits but not with G(12 alpha) or G(s alpha). Unlike other RGS proteins such as RGS9, RGS-GAIP, and Sst2p, which have been reported to be largely membrane-associated, a majority of cellular RGS4 is found as a soluble protein in the cytoplasm, However, the expression of a GTPase-deficient G(i alpha) subunit (G(i alpha 2)-Q204L) resulted in the translocation of both wild type RGS4 and a non-G(1 alpha)-binding mutant (L159F) to the plasma membrane. These data suggest that RGS4 may be recruited to the plasma membrane indirectly by G-protein activation and that multiple RGS proteins within a given cell might be differentially localized to determine a physiologic response to a G-protein-linked stimulus.	NIAID, Immunoregulat Lab, Rocky Mt Labs, NIH, Bethesda, MD 20892 USA; NIAID, Mol Biol Lab, Rocky Mt Labs, NIH, Bethesda, MD 20892 USA; NIMH, Neurophysiol Lab, NIH, Bethesda, MD 20892 USA; Massachusetts Gen Hosp, Renal Unit, Charlestown, MA 02129 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Harvard University; Massachusetts General Hospital; Washington University (WUSTL)	Kehrl, JH (corresponding author), NIAID, Immunoregulat Lab, Rocky Mt Labs, NIH, Bldg 10,Rm 11B-13,10 Ctr Dr,MSC 1876, Bethesda, MD 20892 USA.		Blumer, Kendall J/C-5268-2012; Kehrl, John/AAE-6292-2019	Kehrl, John/0000-0002-6526-159X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038452] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38452] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; CHAKRABARTI R, 1993, J CELL BIOL, V123, P79, DOI 10.1083/jcb.123.1.79; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; Dohlman HG, 1996, MOL CELL BIOL, V16, P5194; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Druey KM, 1997, P NATL ACAD SCI USA, V94, P12851, DOI 10.1073/pnas.94.24.12851; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; Gold SJ, 1997, J NEUROSCI, V17, P8024; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Huang CF, 1997, P NATL ACAD SCI USA, V94, P6159, DOI 10.1073/pnas.94.12.6159; HUNT TW, 1996, NATURE, V383, P174; INOUE A, 1992, J BIOL CHEM, V267, P10613; KLEE WA, 1974, P NATL ACAD SCI USA, V71, P3474, DOI 10.1073/pnas.71.9.3474; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Neill JD, 1997, ENDOCRINOLOGY, V138, P843, DOI 10.1210/en.138.2.843; SATO M, 1995, J BIOL CHEM, V270, P15269, DOI 10.1074/jbc.270.25.15269; Scidmore MA, 1996, J CELL BIOL, V134, P363, DOI 10.1083/jcb.134.2.363; Srinivasa SP, 1998, P NATL ACAD SCI USA, V95, P5584, DOI 10.1073/pnas.95.10.5584; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; VILLARO MT, 1994, BRAIN RES MOL BRAIN, V21, P30; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Yan YB, 1997, J BIOL CHEM, V272, P11924, DOI 10.1074/jbc.272.18.11924	26	72	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18405	18410		10.1074/jbc.273.29.18405	http://dx.doi.org/10.1074/jbc.273.29.18405			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660808	hybrid			2022-12-25	WOS:000074828500063
J	Fu, DX; Maloney, PC				Fu, DX; Maloney, PC			Structure-function relationships in OxlT, the oxalate/formate transporter of Oxalobacter formigenes - Topological features of transmembrane helix 11 as visualized by site-directed fluorescent labeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; ESCHERICHIA-COLI; TRANSLOCATION PATHWAY; FORMATE EXCHANGE; MEMBRANE CARRIER; LACTOSE CARRIER; PROTEIN; PERMEASE; OXALATE; IDENTIFICATION	Analysis of hydropathy suggests that in OxlT, the oxalate/formate antiporter of Oxalobacter formigenes, lysine 355 is within transmembrane helix no. 11. To test this idea, we used single-cysteine, histidine-tagged OxlT variants to study the organization of a 30-residue segment (residues 344-373) containing this region. Topology was examined by probing the A345C and A370C proteins with Oregon Green maleimide carboxylic acid, an impermeant and fluorescent thiol-reactive agent. Examination of purified protein showed that only A370C was fluorescent after treating intact cells with the probe, while both proteins were modified in tests with isolated membrane ghosts, In addition, labeling of A370C,but not A345C, was blocked when external cysteines were protected with the impermeant and nonfluorescent agent, methanethiosulfonate ethyltrimethylammonium. These findings confirm that A345 faces the cytoplasm, while 4370C faces the periplasm, A similar study focused on 13 single-cysteine variants positioned throughout the target segment. That work revealed a striking discontinuity in reactivity toward Oregon Green maleimide; cysteines within a 10-residue central core (residues 351-360) were not labeled when membranes were probed, but were readily modified after protein denaturation. We suggest this core resides within the lipid bilayer, unavailable to an impermeant reporter. Since this region includes position 355, we also suggest that lysine 355 lies within the OxlT hydrophobic sector, where it may facilitate the binding and translocation of the anionic substrates, oxalate and formate.	Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA	Johns Hopkins University	Maloney, PC (corresponding author), Johns Hopkins Univ, Sch Med, Dept Physiol, 725 N Wolfe St, Baltimore, MD 21205 USA.			Fu, Dax/0000-0002-2663-1316				Abe K, 1996, J BIOL CHEM, V271, P6789, DOI 10.1074/jbc.271.12.6789; ANANTHARAM V, 1989, J BIOL CHEM, V264, P7244; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; Clayton RA, 1997, NATURE, V387, P459, DOI 10.1038/387459a0; DEISENHOFER J, 1989, EMBO J, V8, P2149, DOI 10.1002/j.1460-2075.1989.tb08338.x; DUNTEN RL, 1993, BIOCHEMISTRY-US, V32, P3139, DOI 10.1021/bi00063a028; ENGLEMAN DM, 1986, ANN REV BIOPHYS CHEM, V15, P321; Fu DX, 1997, J BIOL CHEM, V272, P2129; GOSWITZ VC, 1995, PROTEIN SCI, V4, P534; GRIFFITH J K, 1992, Current Opinion in Cell Biology, V4, P684, DOI 10.1016/0955-0674(92)90090-Y; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; HAMA H, 1994, J BIOL CHEM, V269, P1063; Harold F. M., 1996, ESCHERICHIA COLI SAL, P283; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Kimura T, 1996, BIOCHEMISTRY-US, V35, P15896, DOI 10.1021/bi961568g; KING SC, 1991, BIOCHIM BIOPHYS ACTA, V1062, P177, DOI 10.1016/0005-2736(91)90390-T; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE JI, 1993, J BIOL CHEM, V268, P20007; MALONEY PC, 1992, J BIOL CHEM, V267, P10531; MALONEY PC, 1994, CURR OPIN CELL BIOL, V6, P571, DOI 10.1016/0955-0674(94)90079-5; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; Matos M, 1996, J BIOL CHEM, V271, P18571, DOI 10.1074/jbc.271.31.18571; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; POURCHER T, 1993, J BIOL CHEM, V268, P3209; RUAN ZS, 1992, J BIOL CHEM, V267, P10537; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Tamai E, 1997, PROTEIN EXPRES PURIF, V10, P275, DOI 10.1006/prep.1997.0754; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; VARADHACHARY A, 1990, MOL MICROBIOL, V4, P1407, DOI 10.1111/j.1365-2958.1990.tb00720.x; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; YAN RT, 1993, CELL, V75, P37, DOI 10.1016/S0092-8674(05)80082-0	34	34	35	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17962	17967		10.1074/jbc.273.28.17962	http://dx.doi.org/10.1074/jbc.273.28.17962			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651403	hybrid			2022-12-25	WOS:000074816100096
J	Johnson, AO; Subtil, A; Petrush, R; Kobylarz, K; Keller, SR; McGraw, TE				Johnson, AO; Subtil, A; Petrush, R; Kobylarz, K; Keller, SR; McGraw, TE			Identification of an insulin-responsive, slow endocytic recycling mechanism in Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUT4 GLUCOSE-TRANSPORTER; SUBCELLULAR TRAFFICKING KINETICS; RECEPTOR CYTOPLASMIC DOMAIN; RAT ADIPOSE-CELLS; TRANSFERRIN RECEPTOR; INTERNALIZATION MOTIF; 3T3-L1 ADIPOCYTES; PLASMA-MEMBRANE; CHO CELLS; SIGNAL	In adipocytes, the insulin-regulated aminopeptidase (IRAP) is trafficked through the same insulin-regulated recycling pathway as the GLUT4 glucose transporter. We find that a chimera, containing the cytoplasmic domain of IRAP fused to transmembrane and extracellular domains of the transferrin receptor, is slowly recycled and rapidly internalized in Chinese hamster ovary cells. Morphological studies indicate that the chimera is slowly trafficked through the general endosomal recycling compartment rather than being sorted to a specialized recycling pathway. A chimera in which a di-leucine sequence within the cytoplasmic domain of IRAP has been mutated to alanines is rapidly internalized and rapidly recycled, indicating that this di-leucine is required for the slow recycling but not for the rapid internalization. Insulin stimulates a 2-3-fold increase in the recycling of the chimera and only a 1.2-fold increase in the recycling of the transferrin receptor. The effect of insulin on the recycling of the chimera is blocked by wortmannin, a phosphatidylinositol S'-kinase inhibitor. GTP gamma S (guanosine 5'-3-O-(thio)triphosphate) increases the recycling of the chimera by 50% but has no effect on the recycling of the transferrin receptor. In these studies, we have identified in Chinese hamster ovary cells a novel, slow endocytic recycling mechanism that is regulated by insulin.	Cornell Univ Med Coll, Dept Biochem, New York, NY 10021 USA; Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA	Cornell University; Dartmouth College	McGraw, TE (corresponding author), Cornell Univ Med Coll, Dept Biochem, 1300 York Ave, New York, NY 10021 USA.	temcgraw@mail.med.cornell.med	Subtil, Agathe/C-7464-2017	Subtil, Agathe/0000-0002-7481-4846	NIDDK NIH HHS [R01-DK52852] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052852] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Araki S, 1996, BIOCHEM J, V315, P153, DOI 10.1042/bj3150153; ASANO T, 1992, J BIOL CHEM, V267, P19636; BALDINI G, 1991, J BIOL CHEM, V266, P4037; Chavez RA, 1996, J CELL BIOL, V133, P1177, DOI 10.1083/jcb.133.6.1177; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; CORVERA S, 1994, J CELL BIOL, V126, P979, DOI 10.1083/jcb.126.4.979; CZECH MP, 1993, J CELL BIOL, V123, P127, DOI 10.1083/jcb.123.1.127; Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; GARIPPA RJ, 1994, J CELL BIOL, V124, P705, DOI 10.1083/jcb.124.5.705; Garippa RJ, 1996, J BIOL CHEM, V271, P20660, DOI 10.1074/jbc.271.34.20660; HANEY PM, 1991, J CELL BIOL, V114, P689, DOI 10.1083/jcb.114.4.689; HANEY PM, 1995, J CELL BIOL, V129, P641, DOI 10.1083/jcb.129.3.641; HUDSON AW, 1992, J CELL BIOL, V116, P785, DOI 10.1083/jcb.116.3.785; JAMES DE, 1994, J CELL BIOL, V126, P1123, DOI 10.1083/jcb.126.5.1123; JHUN BH, 1992, J BIOL CHEM, V267, P17710; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; Johnson AO, 1996, J CELL BIOL, V135, P1749, DOI 10.1083/jcb.135.6.1749; JOHNSON LS, 1994, J CELL PHYSIOL, V158, P29, DOI 10.1002/jcp.1041580105; JOHNSON LS, 1993, MOL BIOL CELL, V4, P1251, DOI 10.1091/mbc.4.12.1251; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; KANAI F, 1993, J BIOL CHEM, V268, P14523; KANDROR KV, 1994, J BIOL CHEM, V269, P3077; KELLER SR, 1995, J BIOL CHEM, V270, P23612, DOI 10.1074/jbc.270.40.23612; KELLER SR, 1998, INPRESS HDB PROTEOLY; KOVAL M, 1989, J CELL BIOL, V108, P2169, DOI 10.1083/jcb.108.6.2169; LUZIO JP, 1993, TRENDS BIOCHEM SCI, V18, P395, DOI 10.1016/0968-0004(93)90097-7; Malide D, 1997, FEBS LETT, V409, P461, DOI 10.1016/S0014-5793(97)00563-2; MARSH BJ, 1995, J CELL BIOL, V130, P1081, DOI 10.1083/jcb.130.5.1081; MARSH EW, 1995, J CELL BIOL, V129, P1509, DOI 10.1083/jcb.129.6.1509; Martin S, 1997, J CELL SCI, V110, P2281; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; MARTYS JL, 1995, J BIOL CHEM, V270, P25976, DOI 10.1074/jbc.270.43.25976; Martys JL, 1996, J BIOL CHEM, V271, P10953, DOI 10.1074/jbc.271.18.10953; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MCGRAW TE, 1993, J CELL PHYSIOL, V155, P579, DOI 10.1002/jcp.1041550316; MCGRAW TE, 1987, J CELL BIOL, V105, P207, DOI 10.1083/jcb.105.1.207; ODORIZZI JF, 1994, J CELL BIOL, V126, P707; PRESLEY JF, 1993, J CELL BIOL, V122, P1231, DOI 10.1083/jcb.122.6.1231; PYTOWSKI B, 1995, J BIOL CHEM, V270, P9067, DOI 10.1074/jbc.270.16.9067; ROBINSON L, 1992, J CELL BIOL, V117, P1118; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; Ross SA, 1996, J BIOL CHEM, V271, P3328, DOI 10.1074/jbc.271.6.3328; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SATOH S, 1993, J BIOL CHEM, V268, P17820; SHIBASAKI Y, 1992, BIOCHEM J, V281, P829, DOI 10.1042/bj2810829; SPIRO DJ, 1996, MOL BIOL CELL, V7, P335; Sumitani S, 1997, ENDOCRINOLOGY, V138, P1029, DOI 10.1210/en.138.3.1029; TANNER LI, 1987, J BIOL CHEM, V262, P8975; Todaka M, 1996, BIOCHEM J, V315, P875, DOI 10.1042/bj3150875; VERHEY KJ, 1995, J CELL BIOL, V130, P1071, DOI 10.1083/jcb.130.5.1071; VERHEY KJ, 1994, J BIOL CHEM, V269, P2353; Waters SB, 1997, J BIOL CHEM, V272, P23323, DOI 10.1074/jbc.272.37.23323; Wei ML, 1998, J CELL BIOL, V140, P565, DOI 10.1083/jcb.140.3.565; YANG J, 1993, J BIOL CHEM, V268, P4600; YEH JI, 1995, BIOCHEMISTRY-US, V34, P15523, DOI 10.1021/bi00047a018; Yoshimori T, 1996, J CELL BIOL, V133, P247, DOI 10.1083/jcb.133.2.247	59	50	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17968	17977		10.1074/jbc.273.28.17968	http://dx.doi.org/10.1074/jbc.273.28.17968			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651404	hybrid			2022-12-25	WOS:000074816100097
J	Noel, J; Turcotte, B				Noel, J; Turcotte, B			Zinc cluster proteins Leu3p and Uga3p recognize highly related but distinct DNA targets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZN(2)CYS(6) BINUCLEAR CLUSTER; SACCHAROMYCES-CEREVISIAE; REGULATORY GENE; BINDING DOMAIN; DAL81 GENE; IN-VIVO; SEQUENCE; GAL4; ACTIVATION; ELEMENTS	Members of the family of fungal zinc cluster DNA-binding proteins possess 6 highly conserved cysteines that bind to two zinc atoms forming a structure (Zn,Cys,) that is required for recognition of specific DNA sequences. Many zinc cluster proteins have been shown to bind as homodimers to a pair of CGG triplets oriented either as direct (CGG NX CGG), inverted (CGG NX CCG), or everted repeats (CCG NX CGG), where N indicates nucleotides. Variation in the spacing between the CGG triplets also contributes to the diversity of sites recognized. For example, Leu3p binds to the everted sequence CCG N4 CGG with a strict requirement for a 4-base pair spacing. Here, we show that another member of the family, Uga3p, recognizes the same DNA motif as Leu3p. However, these transcription factors have distinct DNA targets. We demonstrate that additional specificity of binding is provided by nucleotides located between the two everted CGG triplets. Altering the 4 nucleotides between to the two everted CGG triplets switches the specificity from a Uga3p site to a Leu3p site in both in vitro and in vivo assays. Thus, our results identify a new mechanism that expands the repertoire of DNA targets of the family of zinc cluster proteins. These experiments provide a model for discrimination between targets of zinc cluster proteins.	McGill Univ, Royal Victoria Hosp, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3A 1A1, Canada	McGill University; Royal Victoria Hospital; McGill University	Turcotte, B (corresponding author), McGill Univ, Royal Victoria Hosp, Dept Med, 687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.							ANDRE B, 1990, MOL GEN GENET, V220, P269; BALEJA JD, 1992, NATURE, V356, P450, DOI 10.1038/356450a0; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BRICMONT PA, 1991, MOL CELL BIOL, V11, P1161, DOI 10.1128/MCB.11.2.1161; BRISCO PRG, 1990, J BIOL CHEM, V265, P11667; COORNAERT D, 1991, GENE, V97, P163, DOI 10.1016/0378-1119(91)90048-G; Davis MA, 1996, J BACTERIOL, V178, P3406, DOI 10.1128/jb.178.11.3406-3409.1996; DELAHODDE A, 1995, MOL CELL BIOL, V15, P4043; DELAVEAU T, 1992, YEAST, V8, P761, DOI 10.1002/yea.320080909; DELAVEAU T, 1994, MOL GEN GENET, V244, P501, DOI 10.1007/BF00583901; FORSBURG SL, 1988, MOL CELL BIOL, V8, P647, DOI 10.1128/MCB.8.2.647; FRIDEN P, 1987, MOL CELL BIOL, V7, P2708, DOI 10.1128/MCB.7.8.2708; FRIDEN P, 1988, MOL CELL BIOL, V8, P2690, DOI 10.1128/MCB.8.7.2690; Gray WM, 1996, MOL CELL BIOL, V16, P347; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; Ha N, 1996, NUCLEIC ACIDS RES, V24, P1453, DOI 10.1093/nar/24.8.1453; HALVORSEN YDC, 1991, MOL CELL BIOL, V11, P1777, DOI 10.1128/MCB.11.4.1777; Hellauer K, 1996, MOL CELL BIOL, V16, P6096; Holmberg S, 1996, GENETICS, V144, P467; HU YM, 1995, MOL CELL BIOL, V15, P52, DOI 10.1128/MCB.15.1.52; KALTZMANN DJ, 1994, MOL CELL BIOL, V14, P4653; Karpichev IV, 1997, MOL CELL BIOL, V17, P69, DOI 10.1128/MCB.17.1.69; KIRKPATRICK CR, 1995, MOL CELL BIOL, V15, P4021; KRAULIS PJ, 1992, NATURE, V356, P448, DOI 10.1038/356448a0; Lenouvel F, 1997, J BIOL CHEM, V272, P15521, DOI 10.1074/jbc.272.24.15521; Liang SD, 1996, MOL CELL BIOL, V16, P3773; LOHR D, 1995, FASEB J, V9, P777, DOI 10.1096/fasebj.9.9.7601342; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MARMORSTEIN R, 1994, GENE DEV, V8, P2504, DOI 10.1101/gad.8.20.2504; REECE RJ, 1993, SCIENCE, V261, P909, DOI 10.1126/science.8346441; REMBOUTSIKA E, 1994, MOL CELL BIOL, V14, P5547, DOI 10.1128/MCB.14.8.5547; ROY A, 1990, MOL CELL BIOL, V10, P5257, DOI 10.1128/MCB.10.10.5257; Schjerling P, 1996, NUCLEIC ACIDS RES, V24, P4599, DOI 10.1093/nar/24.23.4599; Schwabe JWR, 1997, NAT STRUCT BIOL, V4, P680, DOI 10.1038/nsb0997-680; SIDDIQUI AH, 1989, MOL CELL BIOL, V9, P4706, DOI 10.1128/MCB.9.11.4706; SIKORSKI RS, 1989, GENETICS, V122, P19; Strauss J, 1998, MOL CELL BIOL, V18, P1339, DOI 10.1128/MCB.18.3.1339; Swaminathan K, 1997, NAT STRUCT BIOL, V4, P751, DOI 10.1038/nsb0997-751; SZE JY, 1992, SCIENCE, V258, P1143, DOI 10.1126/science.1439822; TALIBI D, 1995, NUCLEIC ACIDS RES, V23, P550, DOI 10.1093/nar/23.4.550; Todd RB, 1997, FUNGAL GENET BIOL, V21, P388, DOI 10.1006/fgbi.1997.0993; TU H, 1990, NUCLEIC ACIDS RES, V18, P3923, DOI 10.1093/nar/18.13.3923; VASHEE S, 1993, J BIOL CHEM, V268, P24699; VISSERS S, 1990, EUR J BIOCHEM, V187, P611, DOI 10.1111/j.1432-1033.1990.tb15344.x; Walters KJ, 1997, NAT STRUCT BIOL, V4, P744, DOI 10.1038/nsb0997-744; Zhang L, 1996, EMBO J, V15, P4676, DOI 10.1002/j.1460-2075.1996.tb00844.x; ZHANG L, 1994, GENE DEV, V8, P2110, DOI 10.1101/gad.8.17.2110; [No title captured]	48	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17463	17468		10.1074/jbc.273.28.17463	http://dx.doi.org/10.1074/jbc.273.28.17463			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651335	hybrid, Green Submitted			2022-12-25	WOS:000074816100028
J	Wang, XJ; Greenhalgh, DA; Jiang, AB; He, DC; Zhong, L; Medina, D; Brinkley, BR; Roop, DR				Wang, XJ; Greenhalgh, DA; Jiang, AB; He, DC; Zhong, L; Medina, D; Brinkley, BR; Roop, DR			Expression of a p53 mutant in the epidermis of transgenic mice accelerates chemical carcinogenesis	ONCOGENE			English	Article						p53 mutants; c-ras(Ha); skin, chemical carcinogenesis; centrosome; genomic instability	GROWTH-FACTOR-ALPHA; TUMOR-SUPPRESSOR GENE; WILD-TYPE P53; SKIN-CANCER; CELL-CYCLE; MOUSE SKIN; V-FOS; MUTATIONS; RAS; PROGRESSION	To develop an in vivo model for studying the role of the p53 tumor suppressor in skin carcinogenesis, a murine p53(172H) mutant (equivalent to human p53(175H)) was expressed in the epidermis of transgenic mice, utilizing a targeting vector based on the human keratin 1 gene (HK1.p53(m)), HK1.p53(m) mice developed normally and did not exhibit an obvious epidermal phenotype or develop spontaneous tumors. However, these mice demonstrated an increased susceptibility to a two-stage chemical carcinogenesis protocol, with the rate of formation and number of papillomas being dramatically increased as compared to non-transgenic controls, The majority of papillomas in control mice regressed after termination of 12-O-tetradecanoylphorbol-13-acetate (TPA) treatment, whereas p53(m) papillomas progressed to carcinomas and metastases. In addition, more advanced malignancy, i.e., undifferentiated spindle cell carcinomas, were exclusively observed in p53(m) mice. Increased bromodeoxyuridine (BrdU) labeling, accompanied by decreased expression of p21, was observed in HK1.p53(m) papillomas. In situ examination of centrosomes in HK1.p53(m) papillomas also revealed marked abnormalities, with 75% of the cells containing greater than or equal to 3 centrosomes/cell, whereas centrosome numbers in papillomas from control animals remained normal. These data suggest that the accelerated tumorigenesis observed in chemically-treated p53(m) mice is most likely due to increased genomic instability resulting from an inhibition of G1 arrest and abnormal amplification of centrosomes.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Dermatol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Roop, DR (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R37CA041424, R01CA052607, R01CA041424] Funding Source: NIH RePORTER; NCI NIH HHS [CA41424, CA52607] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOUFFLER SD, 1995, CANCER RES, V55, P3888; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BRINKLEY BR, 1985, ANNU REV CELL BIOL, V1, P145, DOI 10.1146/annurev.cellbio.1.1.145; BROWN CR, 1994, J CELL PHYSIOL, V160, P47, DOI 10.1002/jcp.1041600107; BURNS PA, 1991, ONCOGENE, V6, P2363; CARDER P, 1993, ONCOGENE, V8, P1397; CHEN YM, 1994, MOL CELL BIOL, V14, P6764, DOI 10.1128/MCB.14.10.6764; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; Chung Su Y., 1994, Molecular and Cellular Differentiation, V2, P61; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DErrico M, 1997, CANCER RES, V57, P747; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DOMINEY AM, 1993, CELL GROWTH DIFFER, V4, P1071; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fukasawa K, 1997, MOL CELL BIOL, V17, P506, DOI 10.1128/MCB.17.1.506; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Greenhalgh DA, 1996, CANCER RES, V56, P4413; GREENHALGH DA, 1993, ONCOGENE, V8, P2145; GREENHALGH DA, 1993, MOL CARCINOGEN, V7, P99, DOI 10.1002/mc.2940070208; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Jacks T, 1996, J CANCER RES CLIN, V122, P319, DOI 10.1007/BF01220798; JHAPPAN C, 1994, CELL GROWTH DIFFER, V5, P385; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEE JM, 1994, ONCOGENE, V9, P3731; LI B, 1997, IN PRESS ONCOGENE; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; MOLES JP, 1993, ONCOGENE, V8, P583; NAKAZAWA H, 1994, P NATL ACAD SCI USA, V91, P360, DOI 10.1073/pnas.91.1.360; OConnor PM, 1997, CANCER SURV, V29, P151; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RUGGERI B, 1991, CANCER RES, V51, P6615; SCHAEFER DI, 1993, CANCER RES, V53, P4946; Wahl GM, 1997, CANCER SURV, V29, P183; Weinberg WC, 1997, ONCOGENE, V15, P685, DOI 10.1038/sj.onc.1201230; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAJDEL MEB, 1988, ONCOGENE, V2, P579; ZHANG W, 1993, ONCOGENE, V8, P2555; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	51	60	66	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 9	1998	17	1					35	45		10.1038/sj.onc.1201890	http://dx.doi.org/10.1038/sj.onc.1201890			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZY936	9671312				2022-12-25	WOS:000074677800005
J	Chakravarti, D; Mailander, P; Franzen, J; Higginbotham, S; Cavalieri, EL; Rogan, EG				Chakravarti, D; Mailander, P; Franzen, J; Higginbotham, S; Cavalieri, EL; Rogan, EG			Detection of dibenzo[a,l]pyrene-induced H-ras codon 61 mutant genes in preneoplastic SENCAR mouse skin using a new PCR-RFLP method	ONCOGENE			English	Article						dibenzo[a,l]pyrene; SENCAR mouse; quantitative PCR; gleaning efficiency; in vivo mutation; DNA repair	MUTAGENIC SPECIFICITY; ADDUCTS; IDENTIFICATION; BENZO<A>PYRENE; PAPILLOMAS; MUTATIONS; EPOXIDE; TUMORS; ARISE; SITES	One of the key events in tumor initiation in mouse skin is mutational activation of the H-ras gene. Papillomas induced by the most carcinogenic environmental polycyclic aromatic hydrocarbon (PAH), dibenzo[a,l]pyrene (DB[a,l]P), in SENCAR mouse skin contain a specific H-ras codon 61 (CAA-->CTA) mutation. We describe here detection of these mutations in preneoplastic skin by measuring the frequency of an induced XbaI RFLP, created by the mutation. Development of the PCR-XbaI RFLP method, sensitive enough to detect 1 codon 61 mutant allele among 10 000 wild-type genes, is described. The results indicate that codon 61 mutations are induced 1 day (0.1%) after DB[a,l]P treatment on mouse skin, reach a high value (5%) by day 3, rapidly decline between days 7-9 and increase again during the clonal expansion of pre-papillomas into tumors. The detection of codon 61 mutations 1 day after DB[a,l]P exposure suggests that mutations occurred by pre-replication misrepair.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center	Rogan, EG (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc, 600 S 42Nd St, Omaha, NE 68198 USA.				NCI NIH HHS [F32 CA 68761, CA36727, P01 CA49210] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA068761, P01CA049210, P30CA036727] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDAZ CM, 1985, CANCER RES, V45, P2753; Casale GP, 1997, FUND APPL TOXICOL, V36, P71, DOI 10.1006/faat.1997.2291; CHA RS, 1994, P NATL ACAD SCI USA, V91, P3749, DOI 10.1073/pnas.91.9.3749; CHAKRAVARTI D, 1995, P NATL ACAD SCI USA, V92, P10422, DOI 10.1073/pnas.92.22.10422; Chakravarti D., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P135; CHARY P, 1995, NUCLEIC ACIDS RES, V23, P1398, DOI 10.1093/nar/23.8.1398; DEVANESAN PD, 1993, CHEM RES TOXICOL, V6, P364, DOI 10.1021/tx00033a018; DROUIN EE, 1993, BIOCHEMISTRY-US, V32, P6555, DOI 10.1021/bi00077a009; Finch JS, 1996, CARCINOGENESIS, V17, P2551, DOI 10.1093/carcin/17.12.2551; GILL RD, 1991, ENVIRON MOL MUTAGEN, V18, P200, DOI 10.1002/em.2850180307; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; KEMP CJ, 1994, COLD SPRING HARB SYM, V59, P427, DOI 10.1101/SQB.1994.059.01.048; KOPPSCHNEIDER A, 1992, CARCINOGENESIS, V13, P973, DOI 10.1093/carcin/13.6.973; Lehmann AR, 1996, MUTAT RES-DNA REPAIR, V364, P245, DOI 10.1016/S0921-8777(96)00037-7; Li K.-M., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P127; NAKAJIMA H, 1993, RES COMMUN CHEM PATH, V79, P3; NAKAZAWA H, 1992, ONCOGENE, V7, P2295; NELSON MA, 1993, P NATL ACAD SCI USA, V90, P781; NELSON MA, 1992, P NATL ACAD SCI USA, V89, P6398, DOI 10.1073/pnas.89.14.6398; RODRIGUEZ H, 1993, CARCINOGENESIS, V14, P373, DOI 10.1093/carcin/14.3.373; RUANO G, 1989, NUCLEIC ACIDS RES, V17, P5407, DOI 10.1093/nar/17.13.5407; RYCHLIK W, 1995, BIOTECHNIQUES, V18, P84; SARKAR G, 1990, NUCLEIC ACIDS RES, V18, P7465, DOI 10.1093/nar/18.24.7465; SAWYER TW, 1988, CARCINOGENESIS, V9, P1197, DOI 10.1093/carcin/9.7.1197; SCHAAPER RM, 1987, J MOL BIOL, V198, P187, DOI 10.1016/0022-2836(87)90305-6; SLAGA TJ, 1974, CANCER RES, V34, P771	26	43	45	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 18	1998	16	24					3203	3210		10.1038/sj.onc.1201853	http://dx.doi.org/10.1038/sj.onc.1201853			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671400				2022-12-25	WOS:000074261300014
J	Carter, S; Auer, KL; Reardon, DB; Birrer, M; Fisher, PB; Valerie, K; Schmidt-Ullrich, R; Mikkelsen, R; Dent, P				Carter, S; Auer, KL; Reardon, DB; Birrer, M; Fisher, PB; Valerie, K; Schmidt-Ullrich, R; Mikkelsen, R; Dent, P			Inhibition of the mitogen activated protein (MAP) kinase cascade potentiates cell killing by low dose ionizing radiation in A431 human squamous carcinoma cells	ONCOGENE			English	Article						MAP kinase; p21(Cip-1); ionizing radiation; cell death	CYCLIN-DEPENDENT KINASES; GROWTH-FACTOR RECEPTOR; P53-INDEPENDENT PATHWAY; INDUCED APOPTOSIS; EGF RECEPTOR; DNA-DAMAGE; C-JUN; DIFFERENTIATION; STRESS; P21	The molecular mechanism(s) by which tumor cells survive after exposure to ionizing radiation are not fully understood. Exposure of A431 cells to low doses of radiation (1Gy) caused prolonged activations of the mitogen activated protein (MAP) kinase and stress activated protein (SAP) kinase pathways, and induced p21(Cip-1/WAF1) via a MAP kinase dependent mechanism. In contrast, higher doses of radiation (6 Gy) caused a much weaker activation of the MAP kinase cascade, but a similar degree of SAP kinase cascade activation. In the presence of MAP kinase blockade by the specific MEK1 inhibitor (PD98059) the basal activity of the SAP kinase pathway was enhanced twofold, and the ability of a 1 Gy radiation exposure to activate the SAP kinase pathway was increased similar to sixfold 60 min after irradiation, In the presence of MAP kinase blockade by PD98059 the ability of a single 1Gy exposure to cause double stranded DNA breaks (TUNEL assay) was enhanced at least threefold over the following 24-48h. The increase in DNA damage within 48 h was also mirrored by a similar decrease in A431 cell growth as judged by MTT assays over the next 4-8 days following radiation exposure. This report demonstrates that the MAP kinase cascade is a key cytoprotective pathway in A431 human squamous carcinoma cells which is activated in response to clinically used doses of ionizng radiation, Inhibition of this pathway potentiates the ability of low dose radiation exposure to induce cell death im vitro.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Immunol & Microbiol, Richmond, VA 23298 USA; Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; NIH, Bethesda, MD 20892 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Columbia University; National Institutes of Health (NIH) - USA	Dent, P (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA.		Valerie, Kristoffer/AAL-8299-2021		NCI NIH HHS [CA65896] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065896] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyama T, 1997, CANCER RES, V57, P1495; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Balaban N, 1996, BBA-MOL CELL RES, V1314, P147, DOI 10.1016/S0167-4889(96)00068-7; BERNHARD EJ, 1995, RADIAT ENVIRON BIOPH, V34, P79, DOI 10.1007/BF01275210; BOYLE W, 1990, CELL, V64, P573; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CARMICHAEL J, 1987, CANCER RES, V47, P943; Chmura SJ, 1997, CANCER RES, V57, P1270; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; Freemerman AJ, 1997, LEUKEMIA, V11, P504, DOI 10.1038/sj.leu.2400625; JARVIS DW, 1996, J BIOL CHEM, V271, P8275; JARVIS WD, 1997, IN PRESS MOL PHARM; JARVIS WD, 1997, FEBS LETT, V112, P9; JOHNSON M, 1994, MOL CARCINOGEN, V11, P59, DOI 10.1002/mc.2940110202; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kasid U, 1996, NATURE, V382, P813, DOI 10.1038/382813a0; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Liu Y, 1996, CANCER RES, V56, P31; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MICHIELI P, 1994, CANCER RES, V54, P3391; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; MOTHERSILL C, 1995, RADIAT RES, V142, P181, DOI 10.2307/3579027; Muschel RJ, 1997, VITAM HORM, V53, P1, DOI 10.1016/S0083-6729(08)60702-5; Perkins GR, 1996, BLOOD, V87, P3669, DOI 10.1182/blood.V87.9.3669.bloodjournal8793669; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SchmidtUllrich RK, 1997, ONCOGENE, V15, P1191, DOI 10.1038/sj.onc.1201275; SchmidtUllrich RK, 1996, RADIAT RES, V145, P81, DOI 10.2307/3579199; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Spector MS, 1997, MOL CELL BIOL, V17, P3556, DOI 10.1128/MCB.17.7.3556; TOMBES RM, 1998, IN PRESS BIOCH J; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TSAI LH, 1993, ONCOGENE, V8, P1593; VALERIE K, 1995, MUTAT RES-DNA REPAIR, V336, P91, DOI 10.1016/0921-8777(94)00046-9; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; Wixler V, 1996, FEBS LETT, V385, P131, DOI 10.1016/0014-5793(96)00363-8; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	53	148	149	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	1998	16	21					2787	2796		10.1038/sj.onc.1201802	http://dx.doi.org/10.1038/sj.onc.1201802			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ013	9652746				2022-12-25	WOS:000073812200011
J	Fiddes, RJ; Janes, PW; Sivertsen, SP; Sutherland, RL; Musgrove, EA; Daly, RJ				Fiddes, RJ; Janes, PW; Sivertsen, SP; Sutherland, RL; Musgrove, EA; Daly, RJ			Inhibition of the MAP kinase cascade blocks heregulin-induced cell cycle progression in T-47D human breast cancer cells	ONCOGENE			English	Article						heregulin; MAP kinase; erbB; cell cycle; breast cancer	EPIDERMAL-GROWTH-FACTOR; GTPASE-ACTIVATING PROTEIN; MAMMARY EPITHELIAL-CELLS; SIGNAL-REGULATED KINASE; FACTOR RECEPTOR FAMILY; PHOSPHOLIPASE-C-GAMMA; ERBB3 GENE-PRODUCT; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; DIFFERENTIATION	Members of the erbB family of receptor tyrosine kinases are commonly overexpressed in human breast cancer. However, the relative contribution of particular signalling pathways activated downstream of these receptors to the mitogenic response of transformed breast epithelial cells remains poorly characterized. Administration of heregulin-beta 2 (HRG), a ligand for erbB3 and erbB4, to growth arrested T-47D human breast cancer cells leads to activation of both the PI3-kinase and MAP kinase signalling pathways and potent stimulation of cell cycle progression. Specific inhibitors were used to assess the role of these pathways in HRG-induced mitogenesis and to identify underlying mechanisms in terms of regulation of gene expression. Treatment with the MEK inhibitor PD98059 led to a complete block of HRG-induced entry into S-phase, whilst administration of the PI3-kinase inhibitor wortmannin resulted in only modest inhibition. In addition, administration of PD98059 8 h after HRG was equipotent with simultaneous administration in inhibiting entry into S-phase, However, delaying addition for 14-16 h after HRG, when the cells were entering S-phase, was without effect. HRG stimulation led to sequential induction of c-myc, cyclin D1, cyclin E and cyclin A. gene expression and hyperphosphorylation of the retinoblastoma protein pRB, p21 (WAF1/CIP1/ SDI1) gene expression was rapidly induced by HRG, but significant changes in p27 (KIP1) protein levels were not detected. Preincubation with PD98059 blocked the HRG-dependent induction of cyclin DI mRNA, p21 and c-Myc protein and pRB phosphorylation, These findings demonstrate that MEK activation is critical to HRG-induced S-phase entry in these cells whilst PI3-kinase plays a minor role. Moreover, these data are compatible with HRG-induced activation of MEK being critical for a mid-G1 transition point and implicate c-myc and cyclin D1 as key targets of the MAP kinase pathway involved in this response.	St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia; St Vincents Hosp, Garvan Inst Med Res, CRC Biopharmaceut Res, Sydney, NSW 2010, Australia	Garvan Institute of Medical Research; St Vincents Hospital Sydney; Garvan Institute of Medical Research; St Vincents Hospital Sydney	Daly, RJ (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia.		Sutherland, Robert L/A-8378-2008; Daly, Roger J/C-8179-2009	Janes, Peter/0000-0002-9039-1097; Daly, Roger/0000-0002-5739-8027				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ALEXANDER IE, 1989, MOL ENDOCRINOL, V3, P1377, DOI 10.1210/mend-3-9-1377; Bacus SS, 1996, ONCOGENE, V12, P2535; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CARRAWAY KL, 1997, NATURE, V387, P52; CHAN YL, 1984, J BIOL CHEM, V259, P224; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COBB MH, 1994, CELL MOL BIOL RES, V40, P253; CROSS MJ, 1995, J BIOL CHEM, V270, P25352, DOI 10.1074/jbc.270.43.25352; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; FIDDES RJ, 1995, CELL GROWTH DIFFER, V6, P1567; FILMUS J, 1994, ONCOGENE, V9, P3627; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; IVARAMAN VS, 1997, J CLIN INVEST, V99, P1478; JANES PW, 1994, ONCOGENE, V9, P3601; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KIM HH, 1994, J BIOL CHEM, V269, P24747; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; LIU JJ, 1995, MOL CELL BIOL, V15, P364; Liu Y, 1996, CANCER RES, V56, P31; MARRA F, 1995, FEBS LETT, V376, P141, DOI 10.1016/0014-5793(95)01261-0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTE BM, 1995, MOL ENDOCRINOL, V9, P14, DOI 10.1210/me.9.1.14; MARTE BM, 1995, ONCOGENE, V10, P167; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MUSGROVE EA, 1989, CANCER RES, V49, P2398; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; Musgrove EA, 1997, MOL ENDOCRINOL, V11, P54, DOI 10.1210/me.11.1.54; MUSGROVE EA, 1993, EUR J CANCER, V29, P21273; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; POWIS G, 1994, CANCER RES, V54, P2419; PRALL OWJ, 1998, UNPUB; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; Ram TG, 1996, CELL GROWTH DIFFER, V7, P551; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SAINSBURY JRC, 1987, LANCET, V1, P1398; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; TZAHAR E, 1994, J BIOL CHEM, V269, P26226; VASTRIK I, 1994, CRIT REV ONCOGENESIS, V5, P59, DOI 10.1615/CritRevOncog.v5.i1.30; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Winston JT, 1996, ONCOGENE, V12, P127; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	82	65	75	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	1998	16	21					2803	2813		10.1038/sj.onc.1201815	http://dx.doi.org/10.1038/sj.onc.1201815			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ013	9652748				2022-12-25	WOS:000073812200013
J	McCormack, SJ; Weaver, Z; Deming, S; Natarajan, G; Torri, J; Johnson, MD; Liyanage, M; Ried, T; Dickson, RB				McCormack, SJ; Weaver, Z; Deming, S; Natarajan, G; Torri, J; Johnson, MD; Liyanage, M; Ried, T; Dickson, RB			Myc/p53 interactions in transgenic mouse mammary development, tumorigenesis and chromosomal instability	ONCOGENE			English	Article						c-myc; genomic instability; chromosome 11; mammary development	WILD-TYPE P53; TUMOR-SUPPRESSOR P53; CELL-CYCLE ARREST; C-MYC; GENE AMPLIFICATION; HUMAN-BREAST; EPITHELIAL-CELLS; MICE; APOPTOSIS; CANCER	We have examined defects in mammary development and tumorigenesis in a transgenic model expressing the c-myc gene under the MMTV-LTR promoter, The stochastic tumors which arise from hyperplastic ductal and lobular lesions in this model are characterized by high rates both of apoptosis and of chromosomal instability, Since the p53 gene product is thought to be central in the maintenance of genomic integrity, in part due to its ability to induce apoptosis in cells harboring DNA damage, we examined its expression and possible mutation. Initially, we observed that unmutated p53 is strongly expressed in premalignant mammary glands and in mammary tumors derived from the MMTV-c-myc strain. We then mated the MMTV-myc strain to a p53-deficient strain as a means of examining the effect of this lesion on mammary development and tumorigenesis in the context of c-myc overexpression, A lack of both p53 alleles in the presence of c-myc overexpression resulted in a dramatic hyerplastic alteration in mammary gland development, Specifically, in female bitransgenic MMTV-c-myc/p53 null mice (MMTV-myc/p53(-/-)), lobular hyperplasias were observed at almost every ductal end bud as early as 32 days of age, In contrast, only mild ductal and lobular hyperplasias were seen in MMTV-myc mice that contained both p53 alleles (MMTV-myc/p53(+/+)); an intermediate phenotype occurred in mice with a single intact (MMTV-myc/p53(+/-)) p53 allele, Mammary carcinomas arose with a high frequency in MMTV-myc/p53(+/-) mice; the tumors were comparable in frequency, histology and apoptotic index to the tumors in MMTV-myc/p53(+/+) mice, Also, as previously observed (Elson et al,, 1995), lymphomas arose with extremely short latency in MMTV-myc/ p53(-/-) mice, precluding study of the fate of their hyperplastic mammary lesions in situ, The frequency of p53 mutations in MMTV-myc/p53(+/+) and MMTV-myc/ p53+/- mammary tumors and in cell lines derived from these tumors was examined by direct sequencing. No point mutations or deletions in p53 were observed in mammary tumors or cell lines from either genotype, Finally, a detailed chromosomal analysis using multicolor spectral karyotyping (SKY) revealed that there were multiple chromosomal alterations in the c-myc-overexpressing cells that contained either one or two unmutated p53 alleles, Variable ploidy changes, a common translocation of chromosome 11, and other chromosomal aberrations were observed. Our data thus support an interaction between c-Myc and p53 in mammary development, but suggest that loss of p53 is required neither for c-myc-dependent tumorigenesis nor for c-myc-dependent chromosomal instability.	Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Washington, DC 20007 USA; Natl Human Genome Res Inst, NIH, Bethesda, MD 20892 USA	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Dickson, RB (corresponding author), Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Washington, DC 20007 USA.				NCI NIH HHS [IP5OCA58185] Funding Source: Medline; NIA NIH HHS [R01AG1496-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058185] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMUNDADOTTIR LT, 1995, CELL GROWTH DIFFER, V6, P737; Amundadottir LT, 1996, ONCOGENE, V13, P757; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BLYTH K, 1995, ONCOGENE, V10, P1717; BONILLA M, 1988, J NATL CANCER I, V80, P665, DOI 10.1093/jnci/80.9.665; BUCHBERG AM, 1989, GENETICS, V122, P153; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELSON A, 1995, ONCOGENE, V11, P181; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GUTIERREZ MI, 1992, CANCER RES, V52, P1032; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; HERMEKING H, 1995, ONCOGENE, V11, P1409; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JERRY DJ, 1994, MOL CARCINOGEN, V9, P175, DOI 10.1002/mc.2940090309; Jones JM, 1997, CELL GROWTH DIFFER, V8, P829; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; Li ML, 1996, CELL GROWTH DIFFER, V7, P13; LIU Q, 1995, BIOTECHNIQUES, V18, P470; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Liyanage M, 1996, NAT GENET, V14, P312, DOI 10.1038/ng1196-312; MAI S, 1995, GENOME, V38, P780, DOI 10.1139/g95-099; MAI S, 1994, GENE, V148, P253, DOI 10.1016/0378-1119(94)90696-3; Mai S, 1996, ONCOGENE, V12, P277; MARIANICOSTANTINI R, 1988, CANCER RES, V48, P199; McCullagh P, 1989, GEN LINEAR MODELS, P151; MERLO GR, 1995, J CELL BIOL, V128, P1185, DOI 10.1083/jcb.128.6.1185; MIYASHITA T, 1995, CELL, V80, P293; Nass SJ, 1996, BIOCHEM BIOPH RES CO, V227, P248, DOI 10.1006/bbrc.1996.1497; Plummer SJ, 1997, ONCOGENE, V14, P2339, DOI 10.1038/sj.onc.1201073; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; Ryan KM, 1996, BIOCHEM J, V314, P713, DOI 10.1042/bj3140713; Schrock E, 1996, SCIENCE, V273, P494, DOI 10.1126/science.273.5274.494; Schrock E, 1996, HUM GENET, V97, P256, DOI 10.1007/BF02265277; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; TELENIUS H, 1992, GENE CHROMOSOME CANC, V4, P257, DOI 10.1002/gcc.2870040311; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; VOJTESEK B, 1993, J CELL SCI, V105, P607; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	44	73	77	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	1998	16	21					2755	2766		10.1038/sj.onc.1201804	http://dx.doi.org/10.1038/sj.onc.1201804			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ013	9652742				2022-12-25	WOS:000073812200007
J	Kolatkar, AR; Leung, AK; Isecke, R; Brossmer, R; Drickamer, K; Weis, WI				Kolatkar, AR; Leung, AK; Isecke, R; Brossmer, R; Drickamer, K; Weis, WI			Mechanism of N-acetylgalactosamine binding to a C-type animal lectin carbohydrate-recognition domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; MANNOSE-BINDING; SUGAR LIGANDS; PROTEIN; MACROPHAGES	The mammalian hepatic asialoglycoprotein receptor, a member of the C-type animal lectin family, displays preferential binding to N-acetylgalactosamine compared with galactose. The structural basis for selective binding to N-acetylgalactosamine has been investigated. Regions of the carbohydrate-recognition domain of the receptor believed to be important in preferential binding to N-acetylgalactosamine have been inserted into the homologous carbohydrate-recognition domain of a mannose-binding protein mutant that was previously altered to bind galactose, Introduction of a single histidine residue corresponding to residue 256 of the hepatic asialoglycoprotein receptor was found to cause a 14-fold increase in the relative affinity for N-acetylgalactosamine compared with galactose, The relative ability of various acyl derivatives of galactosamine 60 compete for binding to this modified carbohydrate-recognition domain suggest that it is a good model for the natural N-acetylgalactosamine binding site of the asialoglycoprotein receptor. Crystallographic analysis of this mutant carbohydrate-recognition domain in complex with N-acetylgalactosamine reveals a direct interaction between the inserted histidine residue and the methyl group of the N-acetyl substituent of the sugar. Evidence for the role of the side chain at position 208 of the receptor in positioning this key histidine residue was obtained from structural analysis and mutagenesis experiments. The corresponding serine residue in the modified carbohydrate-recognition domain of mannose-binding protein forms a hydrogen bond to the imidazole side chain. When this serine residue is changed to valine, loss in selectivity for N-acetylgalactosamine is observed, The structure of this mutant reveals that the beta-branched valine side chain interacts directly with the histidine side chain, resulting in an altered imidazole ring orientation.	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA; Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England; Heidelberg Univ, Inst Biochem 2, D-69120 Heidelberg, Germany	Stanford University; University of Oxford; Ruprecht Karls University Heidelberg	Weis, WI (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA.	weis@fucose.stanford.edu	Weis, William I/G-1437-2011	Weis, William I/0000-0002-5583-6150; Leung, Anthony/0000-0001-5569-4036	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050565] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50565] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		BRUNGER AT, 1998, IN PRESS ACTA CRYS D; CONNOLLY DT, 1982, J BIOL CHEM, V257, P939; DAVIDSON EA, 1966, METHOD ENZYMOL, V8, P52; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; HORTON D, 1966, BIOCH PREP, V11, P1; IOBST ST, 1994, J BIOL CHEM, V269, P15512; Iobst ST, 1996, J BIOL CHEM, V271, P6686, DOI 10.1074/jbc.271.12.6686; IOBST ST, 1994, J BIOL CHEM, V269, P15505; ISECKE R, 1993, TETRAHEDRON, V49, P10009, DOI 10.1016/S0040-4020(01)80197-6; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAWASAKI T, 1986, CARBOHYD RES, V151, P197, DOI 10.1016/S0008-6215(00)90340-9; Kolatkar AR, 1996, J BIOL CHEM, V271, P6679, DOI 10.1074/jbc.271.12.6679; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Maniatis T., 1982, MOL CLONING LAB MANU; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Pannu NS, 1996, ACTA CRYSTALLOGR A, V52, P659, DOI 10.1107/S0108767396004370; PERKINS SJ, 1980, BIOCHEMISTRY-US, V19, P245, DOI 10.1021/bi00543a001; SARKAR M, 1979, J BIOL CHEM, V254, P3170; SATO M, 1992, J BIOCHEM-TOKYO, V111, P331, DOI 10.1093/oxfordjournals.jbchem.a123758; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3	24	67	75	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19502	19508		10.1074/jbc.273.31.19502	http://dx.doi.org/10.1074/jbc.273.31.19502			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677372	hybrid			2022-12-25	WOS:000075125200024
J	Quinn, SJ; Kifor, O; Trivedi, S; Diaz, R; Vassilev, P; Brown, E				Quinn, SJ; Kifor, O; Trivedi, S; Diaz, R; Vassilev, P; Brown, E			Sodium and ionic strength sensing by the calcium receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARATHYROID-HORMONE RELEASE; BODY-FLUID HOMEOSTASIS; RAT SUBFORNICAL ORGAN; D-ASPARTATE RECEPTOR; EXTRACELLULAR CALCIUM; LAMINA-TERMINALIS; EXPRESSION; CELLS; CLONING; BOVINE	The calcium-sensing receptor (CaR) is activated by small changes in extracellular calcium [Ca2+](o)) in the physiological range, allowing the parathyroid gland to regulate serum [Ca2+](o); however, the CaR is also distributed in a number of other tissues where it may sense other endogenous agonists and modulators. CaR agonists are polycationic molecules, and charged residues in the extracellular domain of the CaR appear critical for receptor activation through electrostatic interactions, suggesting that ionic strength could modulate CaR activation by polycationic agonists, Changes in the concentration of external NaCl potently altered the activation of the CaR by external Ca2+ and spermine. Ionic strength had an inverse effect on the sensitivity of CaR to its agonists, with lowering of ionic strength rendering the receptor more sensitive to activation by [Ca2+](o) and raising of ionic strength producing the converse effect. Effects of osmolality could not account for the modulation seen with changes in NaCl, Other salts, which differed in the cationic or anionic species, showed shifts in the activation of the CaR by [Ca2+](o) similar to that elicited by NaCl, Parathyroid cells were potently modulated by ionic strength, with addition of 40 mM NaCl shifting the EC50 for [Ca2+](o) inhibition of parathyroid hormone by at least 0.5 mM, Several CaR-expressing tissues, including regions of the brain such as the subfornical organ and hypothalamus, could potentially use the CaR as a sensor for ionic strength and NaCl, The Journal guidelines state that the summary should be no longer than 200 words.	Brigham & Womens Hosp, Div Endocrine Hypertens, Dept Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Quinn, SJ (corresponding author), Brigham & Womens Hosp, Div Endocrine Hypertens, Dept Med, 221 Longwood Ave, Boston, MA 02115 USA.		Vehi, Josep/D-6602-2013	Vehi, Josep/0000-0001-6884-9789	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041415, R01DK044588, R01DK048330] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41415, DK44588, DK48330] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; BATES RG, 1970, ANAL CHEM, V42, P867, DOI 10.1021/ac60290a006; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BROWN EM, 1991, PHYSIOL REV, V71, P371, DOI 10.1152/physrev.1991.71.2.371; BROWN EM, 1995, CELL, V83, P679, DOI 10.1016/0092-8674(95)90180-9; BROWN EM, 1990, ENDOCRINOLOGY, V127, P1064, DOI 10.1210/endo-127-3-1064; BUTLER JN, 1968, BIOPHYS J, V8, P1426, DOI 10.1016/S0006-3495(68)86564-6; Denton DA, 1996, P NATL ACAD SCI USA, V93, P7397, DOI 10.1073/pnas.93.14.7397; Emanuel RL, 1996, MOL ENDOCRINOL, V10, P555, DOI 10.1210/me.10.5.555; Fitzsimons J T, 1989, Acta Physiol Scand Suppl, V583, P15; GARRETT JE, 1995, ENDOCRINOLOGY, V136, P5202, DOI 10.1210/en.136.11.5202; Hebert S C, 1996, Curr Opin Nephrol Hypertens, V5, P45, DOI 10.1097/00041552-199601000-00009; Johnson AK, 1996, CLIN EXP PHARMACOL P, V23, P183, DOI 10.1111/j.1440-1681.1996.tb02594.x; JOHNSON AK, 1993, FASEB J, V7, P678, DOI 10.1096/fasebj.7.8.8500693; LEBOFF MS, 1985, J CLIN INVEST, V75, P49, DOI 10.1172/JCI111696; LENG G, 1982, NEUROENDOCRINOLOGY, V34, P75, DOI 10.1159/000123280; LOBAUGH B, 1980, J NTUR, V111, P298; McKinley MJ, 1996, CLIN EXP PHARMACOL P, V23, P271, DOI 10.1111/j.1440-1681.1996.tb02823.x; OLDFIELD BJ, 1991, BRAIN RES, V561, P151, DOI 10.1016/0006-8993(91)90760-S; OLIET SHR, 1994, TRENDS NEUROSCI, V17, P340, DOI 10.1016/0166-2236(94)90177-5; PULLAN LM, 1992, J NEUROCHEM, V59, P2087; Quinn SJ, 1997, AM J PHYSIOL-CELL PH, V273, pC1315, DOI 10.1152/ajpcell.1997.273.4.C1315; REYNOLDS IJ, 1988, EUR J PHARMACOL, V151, P103, DOI 10.1016/0014-2999(88)90697-8; RICCARDI D, 1995, P NATL ACAD SCI USA, V92, P131, DOI 10.1073/pnas.92.1.131; Richter CP, 1937, ENDOCRINOLOGY, V21, P50, DOI 10.1210/endo-21-1-50; ROCK DM, 1995, ANNU REV PHARMACOL, V35, P463; Rogers KV, 1997, BRAIN RES, V744, P47, DOI 10.1016/S0006-8993(96)01070-0; ROMANO C, 1994, NEUROPHARMACOLOGY PO, P81; RUAT M, 1995, P NATL ACAD SCI USA, V92, P3161, DOI 10.1073/pnas.92.8.3161; SANDS JM, 1997, J CLIN INVEST, V99, P1917; SHAW GG, 1994, NEUROPHARMACOLOGY PO, P61; SIBBALD JR, 1988, BRAIN RES, V461, P205, DOI 10.1016/0006-8993(88)90251-X; SIGGAARDANDERSEN O, 1983, SCAND J CLIN LAB INV, V43, P11; SMITH DW, 1995, BRAIN RES, V698, P232, DOI 10.1016/0006-8993(95)00975-V; TARJAN E, 1984, PHYSL THIRST SODIUM, P473; THORNTON SN, 1984, PHYSL THIRST SODIUM, P103; THRASHER TN, 1980, AM J PHYSIOL, V238, pR333, DOI 10.1152/ajpregu.1980.238.5.R333; Tordoff MG, 1996, NEUROSCI BIOBEHAV R, V20, P89, DOI 10.1016/0149-7634(95)00051-F; TRAYNELIS SF, 1995, SCIENCE, V268, P873, DOI 10.1126/science.7754371; WEISINGER RS, 1984, PHYSL THIRST SODIUM, P485	40	113	119	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19579	19586		10.1074/jbc.273.31.19579	http://dx.doi.org/10.1074/jbc.273.31.19579			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677383	hybrid			2022-12-25	WOS:000075125200035
J	Zimmermann, G; Zhou, DM; Taussig, R				Zimmermann, G; Zhou, DM; Taussig, R			Mutations uncover a role for two magnesium ions in the catalytic mechanism of adenylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING DOMAIN; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; PROTEIN; PURIFICATION; EXPRESSION; ALPHA; SUBUNITS; BETA	The recent determination of the crystal structure of adenylyl cyclase has elucidated many structural features that determine the regulatory properties of the enzyme. In addition, the characterization of adenylyl cyclase by mutagenic techniques and the identification of the binding site for P-site inhibitors have led to modeling studies that describe the ATP-binding site. Despite these advances, the catalytic mechanism of adenylyl cyclase remains uncertain, especially with respect to the role that magnesium ions may play in this process. We have identified four mutant mammalian adenylyl cyclases defective in their metal dependence, allowing us to further characterize the function of metal ions in the catalytic mechanism of this enzyme. The wild-type adenylyl cyclase shows a biphasic Mg2+ dose-response curve in which the high-affinity component displays cooperativity (Hill coefficient of 1.4). Two mutations (C441R and Y442H) reduce the affinity of the adenylyl cyclase for Mg2+ dramatically without affecting the binding of MgATP, suggesting that there is a metal requirement in addition to the ATP-bound Mg2+. The results of this study thus demonstrate multiple metal requirements of adenylyl cyclase and support the existence of a Mg2+ ion essential for catalysis and distinct from the ATP-bound ion. We propose that adenylyl cyclase employs a catalytic mechanism analogous to that of DNA polymerase, in which two key magnesium ions facilitate the nucleophilic attack, of the S'-hydroxyl group and the subsequent elimination of pyrophosphate.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Taussig, R (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, 3301E MSRB III, Ann Arbor, MI 48109 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053645] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53645] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Artymiuk PJ, 1997, NATURE, V388, P33, DOI 10.1038/40310; CASPERSON GF, 1985, P NATL ACAD SCI USA, V82, P5060, DOI 10.1073/pnas.82.15.5060; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; COOPER DMF, 1998, ADV 2 MESSENGERS PHO, V32, P1; COPELAND WC, 1993, J BIOL CHEM, V268, P11028; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Gao TY, 1997, J BIOL CHEM, V272, P19401, DOI 10.1074/jbc.272.31.19401; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; LEE E, 1994, METHOD ENZYMOL, V237, P146; Liu Y, 1997, P NATL ACAD SCI USA, V94, P13414, DOI 10.1073/pnas.94.25.13414; MATSUMOTO K, 1981, MOL CELL BIOL, V1, P83, DOI 10.1128/MCB.1.2.83; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; PIERONI JP, 1995, J BIOL CHEM, V270, P21368, DOI 10.1074/jbc.270.36.21368; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Segel I.H., 1975, ENZYME KINETICS BEHA, Vsecond, P100; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; SOMKUTI SG, 1982, J BIOL CHEM, V257, P6387; Steitz TA, 1998, NATURE, V391, P231, DOI 10.1038/34542; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; TAUSSIG R, 1994, METHOD ENZYMOL, V238, P95; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; Taussig Ronald, 1998, Advances in Second Messenger and Phosphoprotein Research, V32, P81; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; Whisnant RE, 1996, P NATL ACAD SCI USA, V93, P6621, DOI 10.1073/pnas.93.13.6621; WU ZL, 1993, J BIOL CHEM, V268, P23766; Yan SZ, 1996, J BIOL CHEM, V271, P10941, DOI 10.1074/jbc.271.18.10941; Yan SZ, 1997, J BIOL CHEM, V272, P18849, DOI 10.1074/jbc.272.30.18849; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0; Zimmermann G, 1998, J BIOL CHEM, V273, P6968, DOI 10.1074/jbc.273.12.6968	33	50	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19650	19655		10.1074/jbc.273.31.19650	http://dx.doi.org/10.1074/jbc.273.31.19650			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677392	hybrid			2022-12-25	WOS:000075125200044
J	Lee, KK; Murakawa, M; Takahashi, S; Tsubuki, S; Kawashima, S; Sakamaki, K; Yonehara, S				Lee, KK; Murakawa, M; Takahashi, S; Tsubuki, S; Kawashima, S; Sakamaki, K; Yonehara, S			Purification, molecular cloning, and characterization of TRP32, a novel thioredoxin-related mammalian protein of 32 kDa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; NF-KAPPA-B; ESCHERICHIA-COLI; DISULFIDE-ISOMERASE; REDOX REGULATION; REDUCTION; CELL; ANTIOXIDANTS; ACTIVATION; RECEPTOR	We purified a protein of 32 kDa from human thymoma HPB-ALL cells that was co-purified with a catalytic fragment of MST (mammalian STE-20-like), a kinase of the STE20 family, which is proteolytically activated by caspase in apoptosis (Lee, K.-K., Murakawa, M., Nishida, E., Tsubuki, S., Kawashima, S., Sakamaki, K., and Yonehara, S. (1998) Oncogene 16, in press). Molecular cloning of the gene encoding this 32-kDa protein (TRP32) reveals that it is a novel protein of 289 amino acid residues and contains an NH2-terminal thioredoxin domain with a conserved thioredoxin active site. The human and mouse TRP32 proteins have 99% homology, and the thioredoxin domains are completely identical. The thioredoxin domain of TRP32 has thioredoxin-like reducing activity, which can reduce the interchain disulfide bridges of insulin in vitro. However, the thioredoxin domain of TRP32 is more sensitive to oxidation than human thioredoxin. Northern blot analysis showed that TRP32 is expressed in all human tissues. Expression of TRP32 was also confirmed in all mammalian cell lines tested by Western blot analysis using anti-TRP32 monoclonal antibody. Subcellular fractionation and immunostaining analysis showed TRP32 is cytoplasmic protein. These findings suggest that TRP32 is a novel cytoplasmic regulator of the redox state in higher eukaryotes.	Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan; Tokyo Metropolitan Inst Med Sci, Tokyo 1130021, Japan	Kyoto University; Tokyo Metropolitan Institute of Medical Science	Yonehara, S (corresponding author), Kyoto Univ, Inst Virus Res, Sakyo Ku, Kawahara Cho, Kyoto 6068507, Japan.	syonehar@virus.kyoto-u.ac.jp		Sakamaki, Kazuhiro/0000-0002-7072-9628				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; Chivers PT, 1996, EMBO J, V15, P2659, DOI 10.1002/j.1460-2075.1996.tb00626.x; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; FORMANKAY JD, 1991, BIOCHEMISTRY-US, V30, P2685, DOI 10.1021/bi00224a017; FREEDMAN RB, 1988, BIOCHEM SOC T, V16, P96, DOI 10.1042/bst0160096; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; GUEHMANN S, 1992, NUCLEIC ACIDS RES, V20, P2279, DOI 10.1093/nar/20.9.2279; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HOLMGREN A, 1984, METHOD ENZYMOL, V107, P295; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; JENG MF, 1994, STRUCTURE, V2, P853, DOI 10.1016/S0969-2126(94)00086-7; KAWASAKI H, 1990, ANAL BIOCHEM, V191, P332, DOI 10.1016/0003-2697(90)90227-Z; KIVIRIKKO KI, 1989, FASEB J, V3, P1609, DOI 10.1096/fasebj.3.5.2537773; Kurooka H, 1997, GENOMICS, V39, P331, DOI 10.1006/geno.1996.4493; LAURENT TC, 1964, J BIOL CHEM, V239, P3436; LEE KK, 1998, IN PRESS ONCOGENE, V16; LIM CJ, 1985, J BACTERIOL, V161, P799, DOI 10.1128/JB.161.2.799-802.1985; LOFERER H, 1994, TRENDS BIOCHEM SCI, V19, P169, DOI 10.1016/0968-0004(94)90279-8; LUNDSTROM J, 1990, J BIOL CHEM, V265, P9114; Masutani H, 1996, IMMUNOL LETT, V54, P67, DOI 10.1016/S0165-2478(96)02651-X; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MYRSET AH, 1993, EMBO J, V12, P4625, DOI 10.1002/j.1460-2075.1993.tb06151.x; NAKAMURA H, 1994, IMMUNOL LETT, V42, P75, DOI 10.1016/0165-2478(94)90038-8; NEWMAN GW, 1994, J EXP MED, V180, P359, DOI 10.1084/jem.180.1.359; OKAMOTO T, 1992, INT IMMUNOL, V4, P811, DOI 10.1093/intimm/4.7.811; QIN J, 1994, STRUCTURE, V2, P503, DOI 10.1016/S0969-2126(00)00051-4; REN XL, 1993, BIOCHEMISTRY-US, V32, P9701, DOI 10.1021/bi00088a023; RUSSEL M, 1985, P NATL ACAD SCI USA, V82, P29, DOI 10.1073/pnas.82.1.29; SCHALLREUTER KU, 1986, BIOCHEM BIOPH RES CO, V136, P630, DOI 10.1016/0006-291X(86)90487-0; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPECTOR A, 1988, J BIOL CHEM, V263, P4984; Spyrou G, 1997, J BIOL CHEM, V272, P2936, DOI 10.1074/jbc.272.5.2936; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; TSANG MLS, 1976, J BACTERIOL, V125, P923, DOI 10.1128/JB.125.3.923-933.1976; WASYLYK C, 1993, NUCLEIC ACIDS RES, V21, P523, DOI 10.1093/nar/21.3.523; WOLLMAN EE, 1988, J BIOL CHEM, V263, P15506; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	41	78	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19160	19166		10.1074/jbc.273.30.19160	http://dx.doi.org/10.1074/jbc.273.30.19160			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668102	hybrid			2022-12-25	WOS:000074974700069
J	Scheenen, WJJM; Wollheim, CB; Pozzan, T; Fasolato, C				Scheenen, WJJM; Wollheim, CB; Pozzan, T; Fasolato, C			Ca2+ depletion from granules inhibits exocytosis - A study with insulin-secreting cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; CHROMAFFIN CELLS; RECEPTOR SUBTYPE-3; SYNAPTIC VESICLES; B-CELLS; CALCIUM; RELEASE; MITOCHONDRIAL; PHOSPHATE; ISLETS	The secretory compartment is characterized by low luminal pH and high Ca2+ content. Previous studies in several cell types have shown that the size of the acidic Ca2+ pool, of which secretory granules represent a major portion, could be estimated by applying first a Ca2+ ionophore followed by agents that collapse acidic pH gradients. In the present study we have employed this protocol in the insulin-secreting cell line Ins-1 to determine whether the Ca2+ trapped in the secretory granules plays a role in exocytosis. The results demonstrate that a high proportion of ionophore-mobilizable Ca2+ in Ins-1 cells resides in the acidic compartment. The latter pool, however, does not significantly contribute to the [Ca2+](i) changes elicited by thapsigargin and the inositol trisphosphate-producing agonist carbachol. By monitoring membrane capacitance at the single cell level or by measuring insulin release in cell populations, we show that Ca2+ mobilization from nonacidic Ca2+ pools causes a profound and long lasting increase in depolarization-induced secretion, whereas breakdown of granule pH had no significant effect. In contrast, releasing Ca2+ from the acidic pool markedly reduces secretion. It is suggested that a high Ca2+ concentration in the secretory compartment is needed to sustain optimal exocytosis.	Univ Padua, Dept Biomed Sci, Ctr Biomembranes, Consiglio Nazl Ric, I-35100 Padua, Italy; Univ Geneva, Med Ctr, Dept Internal Med, Div Clin Biochem, CH-1211 Geneva 4, Switzerland	Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Geneva	Scheenen, WJJM (corresponding author), Univ Nijmegen, Dept Cellular Anim Physiol, Toernooiveld 1, NL-6525 ED Nijmegen, Netherlands.	scheenen@sci.kun.nl	Scheenen, Wim/E-3674-2012; Fasolato, Cristina/AAE-6024-2019	Fasolato, Cristina/0000-0002-9816-7751				ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; AUGUSTINE GJ, 1992, J PHYSIOL-LONDON, V450, P247, DOI 10.1113/jphysiol.1992.sp019126; Austin CD, 1996, J BIOL CHEM, V271, P1194, DOI 10.1074/jbc.271.2.1194; BASTIANUTTO C, 1995, J CELL BIOL, V130, P847, DOI 10.1083/jcb.130.4.847; BLONDEL O, 1994, P NATL ACAD SCI USA, V91, P7777, DOI 10.1073/pnas.91.16.7777; BOKVIST K, 1995, EMBO J, V14, P50, DOI 10.1002/j.1460-2075.1995.tb06974.x; Calakos N, 1996, PHYSIOL REV, V76, P1; CARNELL L, 1994, J CELL BIOL, V127, P693, DOI 10.1083/jcb.127.3.693; Chilcoat ND, 1996, J CELL BIOL, V135, P1775, DOI 10.1083/jcb.135.6.1775; CHOW RH, 1994, P NATL ACAD SCI USA, V91, P12765, DOI 10.1073/pnas.91.26.12765; DEAN PM, 1973, DIABETOLOGIA, V9, P115, DOI 10.1007/BF01230690; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; Grohovaz F, 1996, P NATL ACAD SCI USA, V93, P4799, DOI 10.1073/pnas.93.10.4799; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; HEINEMANN C, 1994, BIOPHYS J, V67, P2546, DOI 10.1016/S0006-3495(94)80744-1; Helmchen F, 1997, BIOPHYS J, V72, P1458, DOI 10.1016/S0006-3495(97)78792-7; HORRIGAN FT, 1993, BIOPHYS J, V64, P101; HUTTON JC, 1983, BIOCHEM J, V210, P297, DOI 10.1042/bj2100297; Innocenti B, 1996, J BIOL CHEM, V271, P8582, DOI 10.1074/jbc.271.15.8582; Kennedy ED, 1996, J CLIN INVEST, V98, P2524, DOI 10.1172/JCI119071; Lang IM, 1996, J BIOL CHEM, V271, P2754, DOI 10.1074/jbc.271.5.2754; LI GD, 1994, MOL BIOL CELL, V5, P1199, DOI 10.1091/mbc.5.11.1199; LINDAU M, 1988, PFLUG ARCH EUR J PHY, V411, P137, DOI 10.1007/BF00582306; Martin TFJ, 1997, TRENDS CELL BIOL, V7, P271, DOI 10.1016/S0962-8924(97)01060-X; Martinez JR, 1996, BIOCHEM J, V320, P627, DOI 10.1042/bj3200627; NICAISE G, 1992, BIOL CELL, V75, P89, DOI 10.1016/0248-4900(92)90128-N; Petersen OH, 1996, TRENDS NEUROSCI, V19, P411; Pizzo P, 1997, J CELL BIOL, V136, P355, DOI 10.1083/jcb.136.2.355; Ravazzola M, 1996, P NATL ACAD SCI USA, V93, P2745, DOI 10.1073/pnas.93.7.2745; Renstrom E, 1996, J PHYSIOL-LONDON, V494, P41, DOI 10.1113/jphysiol.1996.sp021474; SEKINE N, 1994, J BIOL CHEM, V269, P4895; Sekine N, 1997, DIABETES, V46, P1424, DOI 10.2337/diabetes.46.9.1424; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; Takahashi N, 1997, J CELL BIOL, V138, P55, DOI 10.1083/jcb.138.1.55; THIRION S, 1995, NEUROSCIENCE, V64, P125, DOI 10.1016/0306-4522(94)00414-Z; THOMAS P, 1993, NEURON, V11, P93, DOI 10.1016/0896-6273(93)90274-U; THOMASREETZ AC, 1994, FASEB J, V8, P209, DOI 10.1096/fasebj.8.2.7907072; VONRUDEN L, 1993, SCIENCE, V262, P1061, DOI 10.1126/science.8235626; WOLLHEIM CB, 1996, DIABETES REV, V4, P276; Yule DI, 1997, J BIOL CHEM, V272, P9093	40	52	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19002	19008		10.1074/jbc.273.30.19002	http://dx.doi.org/10.1074/jbc.273.30.19002			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668080	hybrid			2022-12-25	WOS:000074974700047
J	Motta, MC; Landsberger, N; Merli, C; Badaracco, G				Motta, MC; Landsberger, N; Merli, C; Badaracco, G			In vitro reconstitution of Artemia satellite chromatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITION EFFECT VARIEGATION; CELL-FREE SYSTEM; NUCLEOSOME REMODELING FACTOR; LINKER HISTONES; SACCHAROMYCES-CEREVISIAE; SPACED CHROMATIN; W-CHROMOSOME; RAT-LIVER; DNA; SEQUENCE	We report the characterization of an in vitro chromatin assembly system derived from Artemia embryos and its application to the study of AluI-113 satellite DNA organization in nucleosomes. The system efficiently reconstitutes chromatin templates by associating DNA, core histones, and H1. The polynucleosomal complexes show physiological spacing of repeat length 190 +/- 5 base pairs, and the internucleosomal distances are modulated by energy-using activities that contribute to the dynamics of chromatin conformation. The assembly extract was used to reconstitute tandemly repeated AluI-113 sequences. The establishment of preferred histone octamer/satellite DNA interactions was observed, In vitro, AluI-113 elements dictated the same nucleosome translational localizations as found in rico. Specific rotational constraints seem to be the central structural requirement for nucleosome association. Satellite dinucleosomes showed decreased translational mobility compared with mononucleosomes. This could be the consequence of interactions between rotationally positioned nucleosomes separated by Linker DNA of uniform length. AluI-113 DNA led to weak cooperativity of nucleosome association in the proximal flanking regions, which decreased with distance. Moreover, the structural properties of satellite chromatin can spread, thus leading to a specific organization of adjacent nucleosomes.	Univ Milan, Fac Sci 3, Dipartimento Biol Stutterale & Funz, I-21100 Varese, Italy	University of Milan	Badaracco, G (corresponding author), Univ Milan, Fac Sci 3, Dipartimento Biol Stutterale & Funz, Via Ravasi 2, I-21100 Varese, Italy.	hetero@imiucca.csi.unimi.it	Motta, Maria Cristina M/I-3140-2014	Landsberger, Nicoletta/0000-0003-0820-3155				ALLSHIRE RC, 1994, CELL, V76, P157, DOI 10.1016/0092-8674(94)90180-5; ALMOUZNI G, 1993, EXP CELL RES, V205, P1, DOI 10.1006/excr.1993.1051; ALMOUZNI G, 1988, EMBO J, V7, P4355, DOI 10.1002/j.1460-2075.1988.tb03334.x; BADARACCO G, 1992, BIOCHEM J, V282, P249, DOI 10.1042/bj2820249; BANERJEE S, 1990, MOL CELL BIOL, V10, P2863, DOI 10.1128/MCB.10.6.2863; BANERJEE S, 1991, NUCLEIC ACIDS RES, V19, P5999, DOI 10.1093/nar/19.21.5999; BARSACCHIPILONE G, 1986, CHROMOSOMA, V93, P435, DOI 10.1007/BF00285826; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; BENFANTE R, 1989, NUCLEIC ACIDS RES, V17, P8273, DOI 10.1093/nar/17.20.8273; BLANK TA, 1995, J MOL BIOL, V252, P305, DOI 10.1006/jmbi.1995.0498; BOCK H, 1984, J MOL BIOL, V176, P131, DOI 10.1016/0022-2836(84)90385-1; BUTTINELLI M, 1993, P NATL ACAD SCI USA, V90, P9315, DOI 10.1073/pnas.90.20.9315; CARRERA P, 1991, NUCLEIC ACIDS RES, V19, P5639, DOI 10.1093/nar/19.20.5639; COSTANZO G, 1990, J MOL BIOL, V216, P363, DOI 10.1016/S0022-2836(05)80327-4; DIMITROV S, 1995, BBA-GENE STRUCT EXPR, V1260, P1, DOI 10.1016/0167-4781(94)00182-3; DORER DR, 1994, CELL, V77, P993, DOI 10.1016/0092-8674(94)90439-1; DREW HR, 1991, J MOL BIOL, V219, P391, DOI 10.1016/0022-2836(91)90179-A; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; Elgin SCR, 1996, CURR OPIN GENET DEV, V6, P193, DOI 10.1016/S0959-437X(96)80050-5; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FITZGERALD DJ, 1994, J BIOL CHEM, V269, P21303; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; GLIKIN GC, 1984, CELL, V37, P33, DOI 10.1016/0092-8674(84)90298-8; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Heitz E., 1928, JB WEISS BOT, V69, P726; HENIKOFF S, 1994, GENETICS, V138, P1; HOLMQUIST GP, 1987, AM J HUM GENET, V40, P151; HORZ W, 1996, NUCLEIC ACIDS RES, V3, P3213; HSIEH CH, 1988, CELL, V52, P535, DOI 10.1016/0092-8674(88)90466-7; JEONG SW, 1991, J MOL BIOL, V222, P1131, DOI 10.1016/0022-2836(91)90597-Y; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KARPOV VL, 1982, NUCLEIC ACIDS RES, V10, P4321, DOI 10.1093/nar/10.14.4321; KIYOE U, 1995, EMBO J, V14, P3752; KODAMA H, 1987, CHROMOSOMA, V96, P18, DOI 10.1007/BF00285878; LASKEY RA, 1977, CELL, V10, P237, DOI 10.1016/0092-8674(77)90217-3; LASKEY RA, 1980, NATURE, V286, P763, DOI 10.1038/286763a0; LEWIS EB, 1950, ADV GENET, V3, P73, DOI 10.1016/S0065-2660(08)60083-8; LIMADEFARIA A, 1968, NATURE, V217, P138, DOI 10.1038/217138a0; LINXWEILER W, 1985, CELL, V42, P281; Liu K, 1997, J MOL BIOL, V270, P559, DOI 10.1006/jmbi.1997.1136; LOCKE J, 1988, GENETICS, V120, P181; LOHE AR, 1995, CURR OPIN GENET DEV, V5, P746, DOI 10.1016/0959-437X(95)80007-R; LOHR D, 1986, J BIOL CHEM, V261, P9904; LOHR D, 1979, P NATL ACAD SCI USA, V76, P6326, DOI 10.1073/pnas.76.12.6326; LOO S, 1994, SCIENCE, V264, P1768, DOI 10.1126/science.8209257; MARTINEZBALBAS A, 1990, BIOCHEMISTRY-US, V29, P2342, DOI 10.1021/bi00461a019; MEERSSEMAN G, 1992, EMBO J, V11, P2951, DOI 10.1002/j.1460-2075.1992.tb05365.x; MEERSSEMAN G, 1991, J MOL BIOL, V220, P89, DOI 10.1016/0022-2836(91)90383-H; ORLANDO V, 1995, CURR OPIN GENET DEV, V5, P174, DOI 10.1016/0959-437X(95)80005-0; PAGES M, 1988, EUR J BIOCHEM, V174, P391, DOI 10.1111/j.1432-1033.1988.tb14110.x; PARDUE ML, 1994, CURR OPIN GENET DEV, V4, P845, DOI 10.1016/0959-437X(94)90069-8; PENNINGS S, 1994, P NATL ACAD SCI USA, V91, P10275, DOI 10.1073/pnas.91.22.10275; PENNINGS S, 1991, J MOL BIOL, V220, P101, DOI 10.1016/0022-2836(91)90384-I; PENNINGS S, 1989, J MOL BIOL, V207, P183, DOI 10.1016/0022-2836(89)90449-X; PFEIFFER W, 1975, NATURE, V258, P450, DOI 10.1038/258450a0; RADIC MZ, 1987, CELL, V50, P1101, DOI 10.1016/0092-8674(87)90176-0; RODRIGUEZCAMPOS A, 1989, J MOL BIOL, V209, P135, DOI 10.1016/0022-2836(89)90177-0; SAITOH Y, 1991, CHROMOSOMA, V101, P32, DOI 10.1007/BF00360684; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SATCHWELL SC, 1986, J MOL BIOL, V191, P659, DOI 10.1016/0022-2836(86)90452-3; SATCHWELL SC, 1989, EMBO J, V8, P229, DOI 10.1002/j.1460-2075.1989.tb03368.x; SESSA G, 1990, NUCLEIC ACIDS RES, V18, P5449, DOI 10.1093/nar/18.18.5449; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; SIMPSON RT, 1991, PROG NUCLEIC ACID RE, V40, P143; SIMPSON RT, 1978, BIOCHEMISTRY-US, V17, P5524, DOI 10.1021/bi00618a030; SPOFFORD JB, 1976, GENETICS BIOL DROS C, V1, P955; STEIN A, 1989, METHOD ENZYMOL, V170, P585; STRAUSS F, 1983, EMBO J, V2, P51, DOI 10.1002/j.1460-2075.1983.tb01379.x; TRAVERS AA, 1989, ANNU REV BIOCHEM, V58, P427, DOI 10.1146/annurev.biochem.58.1.427; TRIFONOV EN, 1980, P NATL ACAD SCI-BIOL, V77, P3816, DOI 10.1073/pnas.77.7.3816; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; URA K, 1995, EMBO J, V14, P3752, DOI 10.1002/j.1460-2075.1995.tb00045.x; VARGAWEISZ PD, 1995, EMBO J, V14, P2209, DOI 10.1002/j.1460-2075.1995.tb07215.x; WALLRATH LL, 1995, GENE DEV, V9, P1263, DOI 10.1101/gad.9.10.1263; WIDOM J, 1992, P NATL ACAD SCI USA, V89, P1095, DOI 10.1073/pnas.89.3.1095; WOODCOCK CL, 1993, P NATL ACAD SCI USA, V90, P9021, DOI 10.1073/pnas.90.19.9021; YAO J, 1993, P NATL ACAD SCI USA, V90, P9364, DOI 10.1073/pnas.90.20.9364; ZHANG XY, 1983, NUCLEIC ACIDS RES, V11, P4287, DOI 10.1093/nar/11.13.4287; ZHANG XY, 1984, J MOL BIOL, V176, P105, DOI 10.1016/0022-2836(84)90384-X	81	2	2	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18028	18039		10.1074/jbc.273.29.18028	http://dx.doi.org/10.1074/jbc.273.29.18028			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660758	hybrid			2022-12-25	WOS:000074828500013
J	Dong, LQ; Porter, S; Hu, DR; Liu, F				Dong, LQ; Porter, S; Hu, DR; Liu, F			Inhibition of hGrb10 binding to the insulin receptor by functional domain-mediated oligomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; GRB-IR; KINASE; PROTEIN; ASSOCIATION	hGrb10 is a newly identified Src homology 2 (SH2) and pleckstrin homology (PH) domain-containing protein that binds to autophosphorylated receptor tyrosine kinases, including the insulin and insulin-like growth factor receptors. To identify potential downstream proteins that interact with hGrb10, we screened a yeast two-hybrid cDNA library using the full-length hGrb10 gamma as bait. A fragment of hGrb10, which included the IPS (insert between the PH and SH2 domain) and the SH2 domains, was found to bind with high affinity to the full-length protein. The interaction between the IPSI SH2 domain and the full-length hGrb10 was further confirmed by in, vitro glutathione S-transferase fusion protein binding studies. Gel filtration assays showed that hGrb10 underwent tetramerization in mammalian cells. The interaction involved at least two functional domains, the IPS/SH2 region and the PH domain, both of which interacted with the NH2-terminal amino acid sequence of hGrb10 gamma (hGrb10 gamma Delta C, residues 4-414), Competition studies showed that hGrb10 gamma Delta C inhibited the binding of hGrb10 to the tyrosine-phosphorylated insulin receptor, suggesting that this region may play a regulatory role in hGrb10/insulin receptor interaction. We present a model for hGrb10 tetramerization and its potential role in receptor tyrosine kinase signal transduction.	Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio	Liu, F (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pharmacol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052933] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52933] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Cattanach BM, 1996, GENET RES, V68, P35, DOI 10.1017/S0016672300033863; Dong LQ, 1997, MOL ENDOCRINOL, V11, P1757, DOI 10.1210/me.11.12.1757; Dong LQ, 1997, J BIOL CHEM, V272, P29104, DOI 10.1074/jbc.272.46.29104; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; Hansen H, 1996, J BIOL CHEM, V271, P8882, DOI 10.1074/jbc.271.15.8882; He WM, 1998, J BIOL CHEM, V273, P6860, DOI 10.1074/jbc.273.12.6860; Jerome CA, 1997, GENOMICS, V40, P215, DOI 10.1006/geno.1996.4535; KOTZOT D, 1995, HUM MOL GENET, V4, P583, DOI 10.1093/hmg/4.4.583; Laviola L, 1997, J CLIN INVEST, V99, P830, DOI 10.1172/JCI119246; Liu F, 1998, MOL CELL BIOCHEM, V182, P73, DOI 10.1023/A:1006899832614; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; Miyoshi N, 1998, P NATL ACAD SCI USA, V95, P1102, DOI 10.1073/pnas.95.3.1102; Morrione A, 1997, J BIOL CHEM, V272, P26382, DOI 10.1074/jbc.272.42.26382; Morrione A, 1996, CANCER RES, V56, P3165; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; Nantel A, 1998, J BIOL CHEM, V273, P10475, DOI 10.1074/jbc.273.17.10475; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; OOI J, 1995, ONCOGENE, V10, P1610; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; PARSON T, 1997, SCIENCE, V278, P2075; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; TOUHARA K, 1995, J BIOL CHEM, V270, P17000, DOI 10.1074/jbc.270.28.17000; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175	25	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17720	17725		10.1074/jbc.273.28.17720	http://dx.doi.org/10.1074/jbc.273.28.17720			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651371	hybrid			2022-12-25	WOS:000074816100064
J	Haussmann, C; Rohdich, F; Schmidt, E; Bacher, A; Richter, F				Haussmann, C; Rohdich, F; Schmidt, E; Bacher, A; Richter, F			Biosynthesis of pteridines in Escherichia coli - Structural and mechanistic similarity of dihydroneopterin-triphosphate epimerase and dihydroneopterin aldolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP CYCLOHYDROLASE-I; PNEUMOCYSTIS-CARINII; FOLIC-ACID; DIHYDROPTEROATE SYNTHASE; GENE; SULFONAMIDES; SEQUENCE; PLASMID; STRAIN	An open reading frame located at 69.0 kilobases on the Escherichia coli chromosome was shown to code for dihydroneopterin aldolase, catalyzing the conversion of 7,8 dihydroneopterin to 6-hydroxymethyl-7,8-dihydropterin in the biosynthetic pathway of tetrahydrofolate, The gene was subsequently designated folB. The FolB protein shows 30% identity to the paralogous dihydroneopterin-triphosphate epimerase, which is specified by the folX gene located at 2427 kilobases on the E. coli chromosome, The folX and folB gene products were both expressed to high yield in recombinant E. coli strains, and the recombinant proteins were purified to homogeneity. Both enzymes form homo octamers. Aldolase can use L-threo-dihydroneopterin and D-erythro-dihydroneopterin as substrates for the formation of 6-hydroxymethyldihydropterin, but it can also catalyze the epimerization of carbon 2' of dihydroneopterin and dihydromonapterin at appreciable velocity. Epimerase catalyzes the epimerization of carbon 2' in the triphosphates of dihydroneopterin and dihydromonapterin, However, the enzyme can also catalyze the cleavage of the position 6 side chain of several pteridine derivatives at a slow rate. Steady-state kinetic parameters are reported for the various enzyme catalyzed reactions. We propose that the polarization of the 3'-hydroxy group of the substrate could serve as the initial reaction step for the aldolase as web as for the epimerase activity. A deletion mutant obtained by targeting the folX gene of E, coli has normal growth properties on complete medium as well as on minimal medium. Thus, the physiological role of the E. coli epimerase remains unknown. The open reading frame ygiG of Hemophilus influenzae specifies a protein with the catalytic properties of an aldolase. However, the genome of H. influenzae does not specify a dihydroneopterin-triphosphate epimerase.	Tech Univ Munich, Dept Organ Chem & Biochem, D-85747 Garching, Germany	Technical University of Munich	Bacher, A (corresponding author), Tech Univ Munich, Dept Organ Chem & Biochem, Lichtenbergstr 4, D-85747 Garching, Germany.	Bacher@oc3gra.org.chemie.tu-muenchen.de	Richter, Gerald/F-3642-2011					Achari A, 1997, NAT STRUCT BIOL, V4, P490, DOI 10.1038/nsb0697-490; BROEDEL SE, 1990, J BACTERIOL, V172, P4023, DOI 10.1128/jb.172.7.4023-4031.1990; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; Chio LC, 1996, ANTIMICROB AGENTS CH, V40, P727, DOI 10.1128/AAC.40.3.727; Chistoserdova L, 1997, MICROBIOL-UK, V143, P1729, DOI 10.1099/00221287-143-5-1729; DESAIZIEU A, 1995, BIOCHEM J, V306, P371, DOI 10.1042/bj3060371; Fermer C, 1997, J BACTERIOL, V179, P831, DOI 10.1128/jb.179.3.831-837.1997; FIHN SD, 1988, ANN INTERN MED, V108, P350, DOI 10.7326/0003-4819-108-3-350; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GARG SK, 1986, INT J CLIN PHARM TH, V24, P23; GERDING H, 1989, BIOL CHEM H-S, V370, P383; Green J. C., 1996, ESCHERICHIA COLI SAL, P665; GUROFF G, 1969, J BIOL CHEM, V244, P142; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; Haussmann C, 1997, J BACTERIOL, V179, P949, DOI 10.1128/jb.179.3.949-951.1997; HEINE MC, 1975, BIOCHIM BIOPHYS ACTA, V411, P236, DOI 10.1016/0304-4165(75)90304-9; Hughes WT, 1996, ANTIMICROB AGENTS CH, V40, P962, DOI 10.1128/AAC.40.4.962; Kaneko T, 1996, DNA Res, V3, P109; LACKS SA, 1995, J BACTERIOL, V177, P66, DOI 10.1128/jb.177.1.66-74.1995; LANE TM, 1992, ANAL ULTRACENTRIFUGA, P90; Mathis J B, 1980, Methods Enzymol, V66, P556; Nar H, 1995, P NATL ACAD SCI USA, V92, P12120, DOI 10.1073/pnas.92.26.12120; NORRBY SR, 1990, REV INFECT DIS, V12, P458; Philipp WJ, 1996, P NATL ACAD SCI USA, V93, P3132, DOI 10.1073/pnas.93.7.3132; Richter G, 1997, J BACTERIOL, V179, P2022, DOI 10.1128/jb.179.6.2022-2028.1997; RUSSEL M, 1984, J BACTERIOL, V159, P1034, DOI 10.1128/JB.159.3.1034-1039.1984; SLOCK J, 1990, J BACTERIOL, V172, P7211, DOI 10.1128/jb.172.12.7211-7226.1990; SPITZY KH, 1991, INFECTION, V19, pS52, DOI 10.1007/BF01644736; STUBER D, 1990, IMMUNOLOGICAL METHOD, V4, P121; SUZUKI Y, 1974, J BIOL CHEM, V249, P2405; VOLPE F, 1995, GENE, V160, P41, DOI 10.1016/0378-1119(95)00203-I; ZAMENHOF PJ, 1972, J BACTERIOL, V110, P171, DOI 10.1128/JB.110.1.171-178.1972	32	36	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17418	17424		10.1074/jbc.273.28.17418	http://dx.doi.org/10.1074/jbc.273.28.17418			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651328	hybrid			2022-12-25	WOS:000074816100021
J	Miyoshi, H; Iwata, J; Sakamoto, K; Furukawa, H; Takada, M; Iwamura, H; Watanabe, T; Kodama, Y				Miyoshi, H; Iwata, J; Sakamoto, K; Furukawa, H; Takada, M; Iwamura, H; Watanabe, T; Kodama, Y			Specificity of pyridinium inhibitors of the ubiquinone reduction sites in mitochondrial complex I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENINE DINUCLEOTIDE DEHYDROGENASE; BINDING SITE; ELECTRON-TRANSPORT; ESCHERICHIA-COLI; Q OXIDOREDUCTASE; PIERICIDIN-A; NADH; ANALOGS; 1-METHYL-4-PHENYLPYRIDINIUM; ROTENONE	Dual binding sites for pyridinium-type inhibitors in bovine heart mitochondrial complex I have been proposed (Gluck, Ri. R., Krueger, M. J., Ramsay, R. R., Sablin, S. O., Singer, T. P., and Nickles, W. J. (1994) J. Biol. Chem. 269, 3167-3174). The marked biphasic nature of the dose-response curve for inhibition of the enzyme by MP-6(N-methyl-4-[2-(p-tert-butylbenzyl)propyl]-pyridinium) makes this compound the first selective inhibitor of the two sites (Miyoshi, H., Inoue, M., Okamoto, S., Ohshima, M., Sakamoto, K., and Iwamura, H. (1997) J. Biol. Chem. 272, 16176-16183). Modifications of the structure of MP-6 show that a tert-butyl group on the benzene ring, a methyl group attached to the pyridine nitrogen atom, para-substitution pattern in the pyridine ring, and the presence of a branched structure in the spacer moiety are important for the selective inhibition. On the basis of the structural specificity, we synthesized a selective inhibitor, MP-24 (N-methyl-4-[2-methyl-2-(p-tert-butylbenzyl)propyl]pyridinium), which elicits greater selectivity. Characterization of the inhibitory behavior of MP-24 provided further strong evidence for the dual binding sites model.	Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Sakyo Ku, Kyoto 6068502, Japan; Meiji Seika Kaisha Ltd, Pharmaceut Res Ctr, Kohoku Ku, Yokohama, Kanagawa 2228567, Japan	Kyoto University; Meiji Holdings Co., Ltd.	Miyoshi, H (corresponding author), Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Sakyo Ku, Kyoto 6068502, Japan.	miyoshi@kais.kyoto-u.ac.jp	Sakamoto, Kimitoshi/G-4539-2014					ESTORNELL E, 1993, FEBS LETT, V332, P127, DOI 10.1016/0014-5793(93)80498-J; FRIEDRICH T, 1994, EUR J BIOCHEM, V219, P691, DOI 10.1111/j.1432-1033.1994.tb19985.x; GLUCK MR, 1994, J BIOL CHEM, V269, P3167; GUTMAN M, 1970, J BIOL CHEM, V245, P1992; GUTMAN M, 1970, BIOCHEMISTRY-US, V9, P2678, DOI 10.1021/bi00815a016; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.bi.54.070185.005055; HE DY, 1994, BIOCHEMISTRY-US, V33, P880, DOI 10.1021/bi00170a005; KEAN EA, 1971, J BIOL CHEM, V246, P2346; MAJANDER A, 1994, J BIOL CHEM, V269, P21037; MATSUNOYAGI A, 1985, J BIOL CHEM, V260, P4424; Miyoshi H, 1997, J BIOL CHEM, V272, P16176, DOI 10.1074/jbc.272.26.16176; MURPHY MP, 1995, BIOCHEM J, V306, P359, DOI 10.1042/bj3060359; Ohshima M, 1998, BIOCHEMISTRY-US, V37, P6436, DOI 10.1021/bi9800202; RAMSAY RR, 1992, BIOCHEM BIOPH RES CO, V189, P47, DOI 10.1016/0006-291X(92)91523-S; RAMSAY RR, 1987, ARCH BIOCHEM BIOPHYS, V259, P645, DOI 10.1016/0003-9861(87)90531-5; RAMSAY RR, 1991, BIOCHEM J, V273, P481, DOI 10.1042/bj2730481; RYDON HN, 1988, ORG SYNTH, V50-9, P830; Sakamoto K, 1996, EUR J BIOCHEM, V237, P128, DOI 10.1111/j.1432-1033.1996.0128n.x; Sakamoto K, 1996, J BIOL CHEM, V271, P29897, DOI 10.1074/jbc.271.47.29897; SAYRE LM, 1990, ARCH BIOCHEM BIOPHYS, V280, P274, DOI 10.1016/0003-9861(90)90330-2; UENO H, 1994, EUR J BIOCHEM, V225, P411, DOI 10.1111/j.1432-1033.1994.00411.x; vanBelzen R, 1997, BIOCHEMISTRY-US, V36, P886, DOI 10.1021/bi9612982; VINOGRADOV AD, 1995, FEBS LETT, V370, P83, DOI 10.1016/0014-5793(95)00803-H; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; YAGI T, 1990, ARCH BIOCHEM BIOPHYS, V281, P305, DOI 10.1016/0003-9861(90)90448-8	25	16	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17368	17374		10.1074/jbc.273.28.17368	http://dx.doi.org/10.1074/jbc.273.28.17368			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651320	hybrid			2022-12-25	WOS:000074816100013
J	Perry, SW; Hamilton, JA; Tjoelker, LW; Dbaibo, G; Dzenko, KA; Epstein, LG; Hannun, Y; Whittaker, JS; Dewhurst, S; Gelbard, HA				Perry, SW; Hamilton, JA; Tjoelker, LW; Dbaibo, G; Dzenko, KA; Epstein, LG; Hannun, Y; Whittaker, JS; Dewhurst, S; Gelbard, HA			Platelet-activating factor receptor activation - An initiator step in HIV-1 neuropathogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TUMOR-NECROSIS-FACTOR; GLUTAMATE UPTAKE; INDUCED APOPTOSIS; ARACHIDONIC-ACID; 2 DISTINCT; RAT-BRAIN; EXPRESSION; DEMENTIA; CELLS	Human immunodeficiency virus type 1 (HIV-1) infection of the central nervous system results in neuronal apoptosis. Activated HIV-1-infected monocytes secrete high levels of the proinflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) and the phospholipid mediator platelet-activating factor (PAF). TNF-alpha and PAF are elevated in the central nervous system of patients with HIV-1-associated dementia. We now demonstrate that conditioned media from activated HIV-1-infected monocytes induces neuronal apoptosis, which can be prevented by co-incubation with PAF acetylhydrolase, the enzyme that catabolizes PAF in the central nervous system. Preceding apoptosis is a TNF-alpha-induced increase in neuronal ceramide levels. TNF-alpha-mediated neuronal apoptosis can also be blocked by co-incubation with PAF acetylhydrolase, or a PAF receptor antagonist. Blocking pathologic activation of PAF receptors may therefore be a pivotal step in the treatment of HIV-1-associated dementia.	Univ Rochester, Med Ctr, Dept Neurol, Child Neurol Div, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Pediat, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Microbiol & Immunol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Pharmacol & Physiol, Rochester, NY 14642 USA; ICOS Corp, Bothell, WA 98021 USA; Amer Univ Beirut, Dept Pediat, Beirut, Lebanon; Univ Connecticut, Dept Pharmacol, Farmington, CT 06030 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester; Icos Corporation; American University of Beirut; University of Connecticut; Duke University	Gelbard, HA (corresponding author), Univ Rochester, Med Ctr, Dept Neurol, Child Neurol Div, Box 631601 Elmwood Ave, Rochester, NY 14642 USA.	hgelbard@mail.neurology.rochester.edu	Gelbard, Harris/M-9260-2019; Dbaibo, Ghassan S./X-2978-2019	Perry, Seth W/0000-0002-1503-6634; Dewhurst, Stephen/0000-0001-7729-7920; Epstein, Leon/0000-0003-4264-3867; Gelbard, Harris/0000-0001-5095-7976	NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH057556, R01MH056838] Funding Source: NIH RePORTER; NIMH NIH HHS [P01 MH57556, R01 MH56838] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ADLEBIASSETTE H, 1995, NEUROPATH APPL NEURO, V21, P218, DOI 10.1111/j.1365-2990.1995.tb01053.x; BITO H, 1992, NEURON, V9, P285, DOI 10.1016/0896-6273(92)90167-C; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; CLARK GD, 1992, NEURON, V9, P1211, DOI 10.1016/0896-6273(92)90078-R; Dzenko Kirk A., 1995, Society for Neuroscience Abstracts, V21, P561; EPSTEIN LG, 1993, ANN NEUROL, V33, P429, DOI 10.1002/ana.410330502; Fine SM, 1996, J BIOL CHEM, V271, P15303, DOI 10.1074/jbc.271.26.15303; GELBARD HA, 1993, DEV NEUROSCI-BASEL, V15, P417, DOI 10.1159/000111367; GELBARD HA, 1995, NEUROPATH APPL NEURO, V21, P208, DOI 10.1111/j.1365-2990.1995.tb01052.x; GELBARD HA, 1994, J VIROL, V68, P4628, DOI 10.1128/JVI.68.7.4628-4635.1994; GENIS P, 1992, J EXP MED, V176, P1703, DOI 10.1084/jem.176.6.1703; GLASS JD, 1995, ANN NEUROL, V38, P755, DOI 10.1002/ana.410380510; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KORTH R, 1989, BRIT J PHARMACOL, V98, P653, DOI 10.1111/j.1476-5381.1989.tb12640.x; LOCARDI C, 1990, J VIROL, V64, P5874, DOI 10.1128/JVI.64.12.5874-5882.1990; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; Mori M, 1996, J NEUROSCI, V16, P3590; NOTTET HS, 1995, J IMMUNOL, V24, P3567; Perry SW, 1997, BIOTECHNIQUES, V22, P1102, DOI 10.2144/97226st01; PETITO CK, 1995, AM J PATHOL, V146, P1121; SHUKLA SD, 1992, FASEB J, V6, P2296, DOI 10.1096/fasebj.6.6.1312046; SNYDER F, 1995, BIOCHEM J, V305, P689, DOI 10.1042/bj3050689; TALLEY AK, 1995, MOL CELL BIOL, V15, P2359; VOLTERRA A, 1992, J NEUROCHEM, V59, P600, DOI 10.1111/j.1471-4159.1992.tb09411.x; VOLTERRA A, 1994, MOL PHARMACOL, V46, P986; WEISSMAN D, 1993, P NATL ACAD SCI USA, V90, P2537, DOI 10.1073/pnas.90.6.2537; WESSELINGH SL, 1993, ANN NEUROL, V33, P576, DOI 10.1002/ana.410330604; Westmoreland SV, 1996, J NEUROVIROL, V2, P118, DOI 10.3109/13550289609146545; WIERASZKO A, 1993, NEURON, V10, P553, DOI 10.1016/0896-6273(93)90342-O	33	113	117	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17660	17664		10.1074/jbc.273.28.17660	http://dx.doi.org/10.1074/jbc.273.28.17660			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651362	hybrid			2022-12-25	WOS:000074816100055
J	Waxham, MN; Tsai, AL; Putkey, JA				Waxham, MN; Tsai, AL; Putkey, JA			A mechanism for calmodulin (CaM) trapping by CaM-kinase II defined by a family of CaM-binding peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; LIGHT-CHAIN KINASE; CALCIUM-BINDING; INHIBITION; DOMAIN; AUTOPHOSPHORYLATION; COMPLEXES; FRAGMENT; SITES	Autophosphorylation of Ca2+/calmodulin (CaM)-dependent protein kinase II (CaM-kinase II) induces a striking >1,000-fold increase in its affinity for CaM, which has been called CaM trapping. Two peptides modeled after the CaM binding domain of CaM-kinase II were previously shown to kinetically resemble CaM: binding to phosphorylated and dephosphorylated forms of the enzyme, thus providing a model system with which to define the molecular basis of CaM trapping, In this report, the specific contribution of each amino acid to the rates of association and dissociation, and the overall K-d of CaM binding to CaM-kinase II was determined using an overlapping peptide family, and a fluorescently labeled CaM. The association rate constants were similar for the entire family of peptides and ranged from 8 x 10(7) to 32 x 10(7) M-1 s(-1). In contrast, the dissociation rate constants for the peptides varied by >3500-fold and ranged from 0.26 to 7 x 10(-5) s(-1). These rate constants yield overall K-d values for binding CaM to the peptides that range from 2 x 10(-9) M to 2 x 10(-13) M. Extending the low affinity CaM-binding peptide, CKII(296-312), to include (293)Phe-Asn-Ala(295) provided the single largest contribution to the decreased dissociation rate constant, 1,300-fold. It was further shown using Ala-substituted peptides that the basic residues (296)Arg-Arg-Lys(299) were also essential for slow CaM dissociation; however, their contribution was realized only when (293)Phe-Asn-Ala(295) were present, These results suggest a plausible model in which autophosphorylation of CaM-kinase II leads to a conformational change in the region of (293)Phe-Asn-Ala(295) which makes these residues accessible for binding to CaM, As a consequence of these changes, further CaM contacts with (296)Arg-Arg-Lys(299) are established leading to high affinity CaM binding or "CaM trapping.".	Univ Texas, Sch Med, Dept Neurobiol & Anat, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Internal Med, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Texas System; University of Texas System; University of Texas System	Putkey, JA (corresponding author), Univ Texas, Sch Med, Dept Neurobiol & Anat, Houston, TX 77030 USA.			Waxham, M. Neal/0000-0003-4801-1190	NHLBI NIH HHS [HL45724] Funding Source: Medline; NIGMS NIH HHS [GM44911] Funding Source: Medline; NINDS NIH HHS [NS26086] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045724] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026086, R56NS026086] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Brown SE, 1997, J BIOL CHEM, V272, P3389, DOI 10.1074/jbc.272.6.3389; Chin D, 1996, J BIOL CHEM, V271, P30465, DOI 10.1074/jbc.271.48.30465; COLBRAN RJ, 1989, J BIOL CHEM, V264, P4800; CRUZALEGUI FH, 1992, P NATL ACAD SCI USA, V89, P12127, DOI 10.1073/pnas.89.24.12127; HANLEY RM, 1988, BIOCHEM BIOPH RES CO, V152, P122, DOI 10.1016/S0006-291X(88)80688-0; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; Johnson JD, 1996, J BIOL CHEM, V271, P761, DOI 10.1074/jbc.271.2.761; KELLY PT, 1988, P NATL ACAD SCI USA, V85, P4991, DOI 10.1073/pnas.85.14.4991; KWIATKOWSKI AP, 1989, BIOCHEMISTRY-US, V28, P5380, DOI 10.1021/bi00439a010; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; OLWIN BB, 1985, BIOCHEMISTRY-US, V24, P8081, DOI 10.1021/bi00348a037; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; Persechini A, 1996, J BIOL CHEM, V271, P62, DOI 10.1074/jbc.271.1.62; Putkey JA, 1996, J BIOL CHEM, V271, P29619, DOI 10.1074/jbc.271.47.29619; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; Smith J., 1992, J MENTAL HLTH, V1, P61; TOROK K, 1994, BIOCHEMISTRY-US, V33, P12807, DOI 10.1021/bi00209a012; YAMAGATA Y, 1991, J BIOL CHEM, V266, P15391	20	56	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17579	17584		10.1074/jbc.273.28.17579	http://dx.doi.org/10.1074/jbc.273.28.17579			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651352	hybrid			2022-12-25	WOS:000074816100045
J	Kisielewski, AE; Xiao, GH; Liu, SC; Klein-Szanto, AJP; Novara, M; Sina, J; Bleicher, K; Yeung, RS; Goodrow, TL				Kisielewski, AE; Xiao, GH; Liu, SC; Klein-Szanto, AJP; Novara, M; Sina, J; Bleicher, K; Yeung, RS; Goodrow, TL			Analysis of the FHIT gene and its product in squamous cell carcinomas of the head and neck	ONCOGENE			English	Article						FHIT; squamous carcinogenesis; RT-PCR; westerns	TUMOR-SUPPRESSOR GENE; ALLELIC LOSS; LUNG-CANCER; 3P14.2; LINES; AMPLIFICATION; ONCOGENE; SITE; ALLELOTYPE; DELETIONS	The FHIT gene has been implicated as a tumor suppressor gene in human malignancies. To determine if FHIT alterations play a role in human squamous cell carcinogenesis of the head and neck (HNSCC), we examined the gene and its product by RT-PCR, SSCP, Northern, Southern, and Western blot analysis in primary HNSCC and/or HNSCC cell lines. Three of 32 tumor samples lacked detectable expression of FHIT by RT-PCR but showed amplification of a control gene of similar size. One of 29 primary tumors and 2/9 HNSCC cell lines exhibited aberrant transcripts generated by RT-PCR methods using one set of 40 cycles of amplification. FHIT mRNA expression was absent in seven HNSCC cell lines but detectable in primary keratinocytes by Northern analysis. Using specific polyclonal antiserum to the full-length I;HIT protein in immunoblot analyses, 4/9 cell lines analysed showed no expression of pFhit, two exhibited low levels of expression, and three expressed a putative truncated pFhit. One of 15 tumors analysed also exhibited an overexpressed truncated protein. PCR/SSCP and Southern analysis of one cell line DNA that expressed a truncated protein indicated that it sustained homozygous loss of FHIT exon 5. Our results suggest that alterations in FHIT at the DNA, RNA, and protein levels exist at a low but significant frequency in HNSCCs. Further studies regarding the potential biological activity of FHIT are needed to clarify the role of this gene in HIVSCC tumorigenesis.	Fox Chase Canc Ctr, Dept Pathol, Philadelphia, PA 19111 USA; Fox Chase Canc Ctr, Div Basic Sci, Philadelphia, PA 19111 USA; Merck & Co Inc, Dept Genet Toxicol, West Point, PA 19486 USA	Fox Chase Cancer Center; Fox Chase Cancer Center; Merck & Company	Goodrow, TL (corresponding author), Fox Chase Canc Ctr, Dept Pathol, Philadelphia, PA 19111 USA.		Klein-Szanto, A./E-6218-2010		NCI NIH HHS [CA61889, CA06927] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927, R29CA061889, R01CA061889] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHSEE KW, 1994, CANCER RES, V54, P1617; Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; BARTKOVA J, 1995, CANCER RES, V55, P949; BERENSON JR, 1989, ONCOGENE, V4, P1111; BRACHMAN DG, 1994, SEMIN ONCOL, V21, P320; Druck T, 1997, CANCER RES, V57, P504; Fong KM, 1997, CANCER RES, V57, P2256; Gemma A, 1997, CANCER RES, V57, P1435; Hendricks DT, 1997, CANCER RES, V57, P2112; JOVANOVIC A, 1993, J ORAL PATHOL MED, V22, P459, DOI 10.1111/j.1600-0714.1993.tb00125.x; Kastury K, 1996, CANCER RES, V56, P978; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LAMMIE GA, 1991, ONCOGENE, V6, P439; LATIF F, 1992, CANCER RES, V52, P1451; LI XH, 1994, J NATL CANCER I, V86, P1524, DOI 10.1093/jnci/86.20.1524; Mao L, 1996, CANCER RES, V56, P5128; Mau S, 1996, CANCER RES, V56, P5484; MERRITT WD, 1990, ARCH OTOLARYNGOL, V116, P1394; NAWROZ H, 1994, CANCER RES, V54, P1152; Negrini M, 1996, CANCER RES, V56, P3173; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Sakata K, 1996, J ORAL PATHOL MED, V25, P302, DOI 10.1111/j.1600-0714.1996.tb00266.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHUURING E, 1992, ONCOGENE, V7, P355; SOMERS KD, 1990, ONCOGENE, V5, P915; Sozzi G, 1996, CANCER RES, V56, P2472; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Thiagalingam S, 1996, CANCER RES, V56, P2936; Virgilio L, 1996, P NATL ACAD SCI USA, V93, P9770, DOI 10.1073/pnas.93.18.9770; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; Waber PG, 1996, ONCOGENE, V12, P365; Xiao GH, 1997, AM J PATHOL, V151, P1541; Yanagisawa K, 1996, CANCER RES, V56, P5579; ZHANG SY, 1994, CANCER RES, V54, P5050	34	31	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 9	1998	17	1					83	91		10.1038/sj.onc.1201910	http://dx.doi.org/10.1038/sj.onc.1201910			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZY936	9671317				2022-12-25	WOS:000074677800010
J	Kondo, S; Tanaka, Y; Kondo, Y; Hitomi, M; Barnett, GH; Ishizaka, Y; Liu, J; Haqqi, T; Nishiyama, A; Villeponteau, B; Cowell, JK; Barna, BP				Kondo, S; Tanaka, Y; Kondo, Y; Hitomi, M; Barnett, GH; Ishizaka, Y; Liu, J; Haqqi, T; Nishiyama, A; Villeponteau, B; Cowell, JK; Barna, BP			Antisense telomerase treatment: induction of two distinct pathways, apoptosis and differentiation	FASEB JOURNAL			English	Article						ICE; p27; CDKI; tumor cells; tumorigenicity; oligonucleotide	CISPLATIN-INDUCED APOPTOSIS; DEPENDENT KINASE INHIBITOR; PROTEIN COMPLEMENTARY-DNA; AORTIC ENDOTHELIAL-CELLS; HUMAN GLIOBLASTOMA CELLS; HUMAN ASTROCYTOMA-CELLS; DEATH GENE CED-3; INTERLEUKIN-1-BETA-CONVERTING ENZYME; IMMORTAL CELLS; POTENTIAL MEDIATOR	Telomerase, the enzyme that elongates telomeric DNA (TTAGGG)(n), may be involved in cellular immortality and oncogenesis. To investigate the effect of inhibition of telomerase on tumor cells, we transfected the antisense vector against the human telomerase RNA into human malignant glioma cells exhibiting telomerase activity. After 30 doublings, some subpopulations of transfectants expressed a high level of interleukin-lp-converting enzyme (ICE) protein and underwent apoptosis. In contrast, other subpopulations also showed enhanced ICE protein but escaped from apoptotic crisis and continued to grow, although their DNA synthesis, invasive ability, and tumorigenicity in nude mice were significantly reduced. Surviving cells demonstrated increased expression of glial fibrillary acidic protein and decreased motility, consistent with a more differentiated state. These cells also contained enhanced expression of the cyclin-dependent kinase inhibitors (CDKIs) p21 and p27. Treatment of surviving nonapoptotic cells with antisense oligonucleotides against p27, but not p21, induced apoptotic cell death, suggesting that p27 may have protected differentiating glioma cells from apoptosis. These data show that treatment with antisense telomerase inhibits telomerase activity and subsequently induces either apoptosis or differentiation. Regulation of these two distinct pathways may be dependent on the expression of ICE or CDKIs.-Kondo, S., Tanaka, Y., Kondo, Y., Hitomi, M., Barnett, G. H., Ishizaka, Y., Liu, J., Haqqi, T., Nishiyama, A., Villeponteau, B., Cowell, J. K., Barna, B. P. Antisense telomerase treatment: induction of two distinct pathways, apoptosis and differentiation.	Cleveland Clin Fdn, Dept Neurosurg, Brain Tumor Neurooncol Ctr, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Neurosci, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Mol Biol, Cleveland, OH 44195 USA; Tokyo Metropolitan Inst Med Sci, Dept Microbiol, Tokyo 113, Japan; Int Med Ctr Japan, Dept Hematol, Res Inst, Tokyo 162, Japan; Geron Corp, Menlo Park, CA USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Tokyo Metropolitan Institute of Medical Science; National Center for Global Health & Medicine - Japan; Geron Corporation	Kondo, S (corresponding author), Cleveland Clin Fdn, Dept Neurosurg S80, 9500 Euclid Ave, Cleveland, OH 44195 USA.	kondo@cesmtp.ccf.org		Cowell, John/0000-0002-2079-5950	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033932] Funding Source: NIH RePORTER; NINDS NIH HHS [R01NS-33932] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARNA BP, 1995, J NEUROIMMUNOL, V60, P75, DOI 10.1016/0165-5728(95)00055-7; BEDNAREK A, 1995, CANCER RES, V55, P4566; Bestilny LJ, 1996, CANCER RES, V56, P3796; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; Broccoli D, 1996, MOL CELL BIOL, V16, P3765; CHADENEAU C, 1995, ONCOGENE, V11, P893; CHADENEAU C, 1995, CANCER RES, V55, P2533; Chiu CP, 1996, STEM CELLS, V14, P239, DOI 10.1002/stem.140239; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COLLINS MKL, 1983, J BIOL CHEM, V258, P1689; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; FOX PL, 1994, ONCOGENE, V9, P3519; FRITSCHE M, 1993, ONCOGENE, V8, P307; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HIYAMA E, 1995, CANCER RES, V55, P3258; HIYAMA K, 1995, J NATL CANCER I, V87, P895, DOI 10.1093/jnci/87.12.895; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kondo S, 1996, ONCOGENE, V13, P1773; KONDO S, 1995, CANCER RES, V55, P6166; KONDO S, 1995, BRIT J CANCER, V71, P282, DOI 10.1038/bjc.1995.57; KONDO S, 1994, EXP CELL RES, V213, P428, DOI 10.1006/excr.1994.1219; KONDO S, 1995, ONCOGENE, V10, P2001; KONDO S, 1994, CANCER RES, V54, P2928; Kondo S, 1996, FASEB J, V10, P1192, DOI 10.1096/fasebj.10.10.8751721; KONDO S, 1998, IN PRESS ONCOGENE; KONDO Y, 1998, IN PRESS ONCOGENE; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Mehle C, 1996, ONCOGENE, V13, P161; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Okada H, 1996, INT J CANCER, V66, P255, DOI 10.1002/(SICI)1097-0215(19960410)66:2<255::AID-IJC20>3.0.CO;2-A; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; RUTKA JT, 1993, CANCER RES, V53, P3624; RUTKA JT, 1994, CANCER RES, V54, P3267; SCHOENBERG BS, 1983, ONCOLOGY NERVOUS SYS, P1; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sharma HW, 1995, P NATL ACAD SCI USA, V92, P12343, DOI 10.1073/pnas.92.26.12343; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; Strahl C, 1996, MOL CELL BIOL, V16, P53; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VAN MEIR EG, 1994, CANCER RES, V54, P649; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WYLLIE AH, 1987, INT REV CYTOL S, V17, P755; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; YIN DL, 1994, FEBS LETT, V339, P73, DOI 10.1016/0014-5793(94)80387-0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zhu XL, 1996, P NATL ACAD SCI USA, V93, P6091, DOI 10.1073/pnas.93.12.6091	68	158	184	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	1998	12	10					801	811		10.1096/fasebj.12.10.801	http://dx.doi.org/10.1096/fasebj.12.10.801			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZY035	9657520				2022-12-25	WOS:000074580100005
J	Marston, NJ; Ludwig, RL; Vousden, KH				Marston, NJ; Ludwig, RL; Vousden, KH			Activation of p53 DNA binding activity by point mutation	ONCOGENE			English	Article						p53; DNA binding; cell cycle arrest; apoptosis	HUMAN CANCER-CELLS; WILD-TYPE P53; MONOCLONAL-ANTIBODIES; TRANSCRIPTIONAL ACTIVATION; IMMUNOCHEMICAL ANALYSIS; MUTANT P53; PROTEIN; ARREST; TRANSFORMATION; APOPTOSIS	The p53 tumor suppressor protein can adopt both latent, non-DNA binding and active, DNA binding forms, and p53 activity is thought to be regulated in cells, at least in part, through a conformational shift which leads to sequence specific DNA binding. In vitro, this allosteric regulation of DNA binding by p53 has been shown to be mediated through the C-terminus of the protein. We show here that although deletion of the C-terminal 16 amino acids of p53 did not activate DNA binding, deletion of a further eight amino acids resulted in constitutive activation of DNA binding activity. Simultaneous mutation of the three lysine residues within these eight amino acids also resulted in constitutive DNA binding activity, although this was reduced when only two of these lysines were altered, The deletion or point mutants of p53 showing constitutive DNA binding activity did not display clear evidence of DNA binding site specificity, although some binding site preference was seen with the point mutants. Each of the constitutively active p53 mutants retained transcriptional activity and induced both cell cycle arrest and apoptosis in transiently transfected cells at rates comparable with the wild type protein.	NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Vousden, KH (corresponding author), NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, W 7th St, Frederick, MD 21702 USA.							ABARZUA P, 1995, CANCER RES, V55, P3490; Abarzua P, 1996, ONCOGENE, V13, P2477; Anderson ME, 1997, MOL CELL BIOL, V17, P6255, DOI 10.1128/MCB.17.11.6255; ATTARDI LD, 1996, EMBO J, V15, P3639; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BATES S, 1996, CURRENT OPIN GENET D, V6, P1; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; Crook T, 1996, VIROLOGY, V217, P285, DOI 10.1006/viro.1996.0115; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fredersdorf S, 1996, AM J PATHOL, V148, P825; FREIDLANDER P, 1996, MOL CELL BIOL, V16, P4961; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HAINAUT P, 1993, CANCER RES, V53, P4469; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; JUVEN T, 1993, ONCOGENE, V8, P3411; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lu X, 1996, ONCOGENE, V13, P413; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; MARSTON NJ, 1995, ONCOGENE, V10, P1709; MARSTON NJ, 1994, ONCOGENE, V9, P2707; MIYASHITA T, 1995, CELL, V80, P293; RENZING J, 1995, ONCOGENE, V10, P1865; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; Shaw P, 1996, ONCOGENE, V12, P921; Sun Y, 1997, ONCOGENE, V14, P385, DOI 10.1038/sj.onc.1200834; TARUNINA M, 1993, ONCOGENE, V8, P3165; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WALDMAN T, 1995, CANCER RES, V55, P5187; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WEINBERG WC, 1995, ONCOGENE, V10, P2271	50	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 18	1998	16	24					3123	3131		10.1038/sj.onc.1201856	http://dx.doi.org/10.1038/sj.onc.1201856			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671391				2022-12-25	WOS:000074261300005
J	Lee, CW; Sorensen, TS; Shikama, N; La Thangue, NB				Lee, CW; Sorensen, TS; Shikama, N; La Thangue, NB			Functional interplay between p53 and E2F through co-activator p300	ONCOGENE			English	Article						p53; E2F; p300; apoptosis; transcription	CELL-CYCLE CONTROL; TRANSCRIPTIONAL ACTIVATION; RETINOBLASTOMA-PROTEIN; P53-DEPENDENT APOPTOSIS; P53-MEDIATED APOPTOSIS; DEPENDENT KINASES; GENE-PRODUCT; HELA-CELLS; S-PHASE; EXPRESSION	Both E2F and p53 are sequence specific transcription factors that regulate early cell cycle progression. The pathway of control mediated through E2F governs the transition from G1 into S phase whereas p53 in response to genotoxic stress can facilitate cell cycle arrest or apoptosis, The mechanisms which influence the outcome of p53 induction are not clear, although transcription of the p53 target gene, encoding the cdk-inhibitor p21(Waf1/Cip1), correlates with p53-mediated cell cycle arrest. Here using a combination of biochemical and functional assays we identify p300 as a co-activator required for p53-dependent transcriptional activation of Waf1/Cip1, Furthermore, we show that the cdk-inhibitor p21(Waf1/Cip1) autoregulates in a positive fashion transcription through modulating the activity of the p53/p300 complex, whilst negatively regulating the activity of E2F by preventing cdk-dependent phosphorylation of pRb. Consistent with a role for p21(Waf1/Cip1) in, the autoregulation of p53-dependent transcription, p300 augments the ability of p53 to cause G1 arrest and, conversely, cells undergoing p53-dependent apoptosis are rescued by p300. Thus, our data suggest that the ability of p300 to interact with p53 influences the physiological consequence of p53 activation. From previous studies it is known that cells expressing aberrant levels of E2F-1 can undergo p53-dependent apoptosis, In addition, we find that E2F-1 can cause apoptosis in p53(-\-) tumour cells and further p300, which also functions as a co-activator for the E2F/DP heterodimer, enhances the apoptotic activity of E2F-1, In conditions where E2F-1 and p53 co-operate in apoptosis E2F-1. can effectively compete for p300, causing a reduction in p53-dependent transcription. Thus, a functional interaction between p300 and either p53 or E2F-1 has a profound impact on early cell cycle progression, specifically in regulating the contrasting outcomes of cell cycle arrest and apoptosis. These results suggest a critical role for p300 in integrating and coordinating the functional interplay between the pathways of growth control mediated by E2F and p53.	Univ Glasgow, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	La Thangue, NB (corresponding author), Univ Glasgow, Div Biochem & Mol Biol, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.							ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Botz J, 1996, MOL CELL BIOL, V16, P3401; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DOWDY SF, 1993, CELL, V73, P449; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; HARPER JW, 1993, CELL, V75, P805; HAUPT Y, 1995, ONCOGENE, V10, P1563; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Johnston Leland H., 1992, Trends in Cell Biology, V2, P353, DOI 10.1016/0962-8924(92)90041-K; JOOSS K, 1995, ONCOGENE, V10, P1529; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; KRAUS VB, 1992, MOL CELL BIOL, V12, P4391, DOI 10.1128/MCB.12.10.4391; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MIYASHITA T, 1995, CELL, V80, P293; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Muraoka M, 1996, ONCOGENE, V12, P1565; NEVINS JR, 1992, SCIENCE, V258, P424; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PINES J, 1995, SEMIN CANCER BIOL, V6, P63, DOI 10.1006/scbi.1995.0009; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; Sorensen TS, 1996, MOL CELL BIOL, V16, P5888; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Trouche D, 1996, NUCLEIC ACIDS RES, V24, P4139, DOI 10.1093/nar/24.21.4139; WALDMAN T, 1995, CANCER RES, V55, P5187; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x	76	88	91	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	1998	16	21					2695	2710		10.1038/sj.onc.1201818	http://dx.doi.org/10.1038/sj.onc.1201818			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ013	9652736				2022-12-25	WOS:000073812200001
J	Gough, WH; VanOoteghem, S; Sint, T; Kedishvili, NY				Gough, WH; VanOoteghem, S; Sint, T; Kedishvili, NY			cDNA cloning and characterization of a new human microsomal NAD(+)-dependent dehydrogenase that oxidizes all-trans-retinol and 3 alpha-hydroxysteroids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN; ALCOHOL-DEHYDROGENASE; MESSENGER-RNA; MEMBRANE; LIVER; ACID; ACTIVATION; REDUCTION; INVITRO	We report the cDNA sequence and catalytic properties of a new member of the short chain dehydrogenase/reductase superfamily, The 1134-base pair cDNA isolated from the human liver cDNA library encodes a 317-amino acid protein, retinol dehydrogenase 4 (RoDH-4), which exhibits the strongest similarity with rat all-trans-retinol dehydrogenases RoDH-1, RoDH-2, and RoDH-3, and mouse cis-retinol/androgen dehydrogenase (less than or equal to 73% identity). The mRNA for RoDH-4 is abundant in adult liver, where it is translated into RoDH-4 protein, which is associated with microsomal membranes, as evidenced by Western blot analysis, Significant amounts of RoDH-4 message are detected in fetal liver and lung. Recombinant RoDH-4, expressed in microsomes of Sf9 insect cells using BacoluGold Baculovirus system, oxidizes all-trans retinol and 13-cis-retinol to corresponding aldehydes and oxidizes the 3 alpha-hydroxysteroids androstane-diol and androsterone to dihydrotestosterone and androstanedione, respectively. NAD(+) and NADH are the preferred cofactors, with apparent K-m values 250-1500 times lower than those for NADP(+) and NADPH. AU-trans-retinol and 13-cis-retinol inhibit RoDH-4 catalyzed oxidation of androsterone with apparent K-i values of 5.8 and 3.5 mu M, respectively. All-trans-retinol bound to cellular retinol-binding protein (type I) exhibits a similar K-i value of 3.6 mu M, Unliganded cellular retinol-binding protein has no effect on RoDH activity. Citral and acyclic isoprenoids also act as inhibitors of RoDH-4 activity. Ethanol is not inhibitory. Thus, we have identified and characterized a sterol/retinol-oxidizing short chain dehydrogenase/reductase that prefers NAD(+) and recognizes all-trans-retinol as substrate, RoDH-4 can potentially contribute to the biosynthesis of two powerful modulators of gene expression: retinoic acid from retinol and dihydrotestosterone from 3 alpha-androstane-diol.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Kedishvili, NY (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, 635 Barnhill Dr,MS 405, Indianapolis, IN 46202 USA.			Kedishvili, Natalia/0000-0001-6917-4891	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA002342, R01AA002342] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA00221, AA02342] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Biswas MG, 1997, J BIOL CHEM, V272, P15959, DOI 10.1074/jbc.272.25.15959; BOERMAN MHEM, 1995, ARCH BIOCHEM BIOPHYS, V321, P434, DOI 10.1006/abbi.1995.1415; BOLEDA MD, 1993, ARCH BIOCHEM BIOPHYS, V307, P85, DOI 10.1006/abbi.1993.1564; Burke YD, 1997, LIPIDS, V32, P151, DOI 10.1007/s11745-997-0019-y; CAO GQ, 1994, J BIOL CHEM, V269, P26898; Chai XY, 1996, GENE, V169, P219, DOI 10.1016/0378-1119(95)00833-0; CHAI XY, 1995, J BIOL CHEM, V270, P3900, DOI 10.1074/jbc.270.8.3900; CHAI XY, 1995, J BIOL CHEM, V270, P28408, DOI 10.1074/jbc.270.47.28408; Chai XY, 1997, J BIOL CHEM, V272, P33125, DOI 10.1074/jbc.272.52.33125; CHYTIL F, 1987, ANNU REV NUTR, V7, P321, DOI 10.1146/annurev.nu.07.070187.001541; CONNOR MJ, 1987, BIOCHEM J, V244, P489, DOI 10.1042/bj2440489; CROWELL PL, 1994, CANCER CHEMOTH PHARM, V35, P31, DOI 10.1007/s002800050189; Duester G, 1996, BIOCHEMISTRY-US, V35, P12221, DOI 10.1021/bi961176+; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; Gafvelin G, 1997, J BIOL CHEM, V272, P6119, DOI 10.1074/jbc.272.10.6119; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; KAKKAD BP, 1988, J BIOL CHEM, V263, P12916; KURLANDSKY SB, 1994, J BIOL CHEM, V269, P32821; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEO MA, 1987, ARCH BIOCHEM BIOPHYS, V259, P241, DOI 10.1016/0003-9861(87)90492-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mangelsdorf David J., 1994, P319; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; Mertz JR, 1997, J BIOL CHEM, V272, P11744, DOI 10.1074/jbc.272.18.11744; NAPOLI JL, 1987, ARCH BIOCHEM BIOPHYS, V255, P95, DOI 10.1016/0003-9861(87)90298-0; ONG DE, 1978, J BIOL CHEM, V253, P828; Penning TM, 1997, ENDOCR REV, V18, P281, DOI 10.1210/er.18.3.281; POSCH KC, 1992, BIOCHEM PHARMACOL, V43, P2296; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; RUSSELL DW, 1994, ANNU REV BIOCHEM, V63, P25, DOI 10.1146/annurev.bi.63.070194.000325; SAARI JC, 1982, BIOCHIM BIOPHYS ACTA, V716, P266, DOI 10.1016/0304-4165(82)90277-X; SEGAL IH, 1975, ENZYME KINETICS, P18; SHERMAN DR, 1987, P NATL ACAD SCI USA, V84, P3209, DOI 10.1073/pnas.84.10.3209; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; VEECH RL, 1969, BIOCHEM J, V115, P609, DOI 10.1042/bj1150609a	36	101	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19778	19785		10.1074/jbc.273.31.19778	http://dx.doi.org/10.1074/jbc.273.31.19778			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677409	hybrid			2022-12-25	WOS:000075125200061
J	Jin, SLC; Bushnik, T; Lan, L; Conti, M				Jin, SLC; Bushnik, T; Lan, L; Conti, M			Subcellular localization of rolipram-sensitive, cAMP-specific phosphodiesterases - Differential targeting and activation of the splicing variants derived from the PDE4D gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; RAT SERTOLI-CELL; HORMONAL-REGULATION; ANCHORING PROTEINS; A-KINASE; IDENTIFICATION; INHIBITION; NEURONS; PHOSPHORYLATION; DROSOPHILA	Biochemical and immunofluorescence analyses revealed that phosphodiesterase variants encoded by the PDE4D gene are targeted to discrete subcellular structures. In quiescent FRTL-5 thyroid cells, the rolipram-sensitive phosphodiesterase (PDE) activity (cAMP-PDE) was recovered both in the soluble and particulate fractions of the homogenate, Although an immunoreactive 93-kDa PDE (PDE4D3) variant was recovered in both compartments, a 105-kDa variant with the properties of PDE4D4 was recovered mostly in the particulate fraction. The PDE4D3 form was readily solubilized with nonionic detergents. Conversely, the PDE4D4 form required buffers containing ionic detergents for extraction, suggesting that different mechanisms target these variants to insoluble structures. A 15-min stimulation with thyroid-stimulating hormone (TSH) led to an activation of the cAMP-PDE in both compartments and was correlated with a shift in electrophoretic mobility of the PDE4D3 polypeptide, Long term incubation with TSH caused an increase of the PDE activity in the soluble fraction and the appearance of a 68-kDa immunoreactive polypeptide with the properties of PDE4D2. Immunofluorescence analysis showed, in addition to diffuse staining, a signal localized on regions adjacent to the plasma membrane on cytoskeletal structures and in a perinuclear region of quiescent cells. Long term incubation with TSH caused an increase in the immunofluorescence signal in the soluble compartment. These data demonstrate that three PDE4D splicing variants are targeted to discrete subcellular compartments and that hormones cause the activation of these isoforms in a temporally and spatially dependent manner.	Stanford Univ, Med Ctr, Dept Gynecol & Obstet, Div Reprod Biol, Stanford, CA 94305 USA	Stanford University	Conti, M (corresponding author), Stanford Univ, Med Ctr, Dept Gynecol & Obstet, Div Reprod Biol, Stanford, CA 94305 USA.	marco.conti@forsythe.stanford.edu		Bushnik, Tamara/0000-0003-3328-257X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020788] Funding Source: NIH RePORTER; NICHD NIH HHS [HD20788] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BOLGER G, 1993, MOL CELL BIOL, V13, P6558, DOI 10.1128/MCB.13.10.6558; Bolger GB, 1997, BIOCHEM J, V328, P539; CHERRY JA, 1995, J NEUROBIOL, V28, P102, DOI 10.1002/neu.480280109; COGHLAN VM, 1993, MOL CELL BIOCHEM, V128, P309, DOI 10.1007/BF01076780; CONTI M, 1995, BIOCHEMISTRY-US, V34, P7979, DOI 10.1021/bi00025a003; CONTI M, 1995, ENDOCR REV, V16, P370, DOI 10.1210/er.16.3.370; GLANTZ SB, 1992, MOL BIOL CELL, V3, P1215, DOI 10.1091/mbc.3.11.1215; Huston E, 1996, J BIOL CHEM, V271, P31334, DOI 10.1074/jbc.271.49.31334; Iona S, 1998, MOL PHARMACOL, V53, P23, DOI 10.1124/mol.53.1.23; JIN SLC, 1992, J BIOL CHEM, V267, P18929; JOHNSON BD, 1994, P NATL ACAD SCI USA, V91, P11492, DOI 10.1073/pnas.91.24.11492; Juilfs DM, 1997, P NATL ACAD SCI USA, V94, P3388, DOI 10.1073/pnas.94.7.3388; Kelly JJ, 1996, BIOCHEM J, V318, P425, DOI 10.1042/bj3180425; KORNBERG A, 1955, METHOD ENZYMOL, V1, P441, DOI 10.1016/0076-6879(55)01072-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li Y, 1996, J BIOL CHEM, V271, P16862, DOI 10.1074/jbc.271.28.16862; MACPHEE CH, 1986, P NATL ACAD SCI USA, V83, P6660, DOI 10.1073/pnas.83.17.6660; MCPHEE I, 1995, BIOCHEM J, V310, P965, DOI 10.1042/bj3100965; MONACO L, 1994, J BIOL CHEM, V269, P347; Naro F, 1996, ENDOCRINOLOGY, V137, P2464, DOI 10.1210/en.137.6.2464; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RIOS RM, 1992, EMBO J, V11, P1723, DOI 10.1002/j.1460-2075.1992.tb05224.x; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SCHWABE U, 1976, MOL PHARMACOL, V12, P900; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SETTE C, 1994, MOL CELL ENDOCRINOL, V100, P75, DOI 10.1016/0303-7207(94)90282-8; Sette C, 1996, J BIOL CHEM, V271, P16526, DOI 10.1074/jbc.271.28.16526; SETTE C, 1994, J BIOL CHEM, V269, P9245; SETTE C, 1994, J BIOL CHEM, V269, P18271; SHAKUR Y, 1993, BIOCHEM J, V292, P677, DOI 10.1042/bj2920677; SHAKUR Y, 1995, BIOCHEM J, V306, P801, DOI 10.1042/bj3060801; SWINNEN JV, 1991, J BIOL CHEM, V266, P18370; SWINNEN JV, 1991, J BIOL CHEM, V266, P14383; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P8197, DOI 10.1073/pnas.86.21.8197; Thompson W J, 1974, Methods Enzymol, V38, P205; Vicini E, 1997, MOL ENDOCRINOL, V11, P839, DOI 10.1210/me.11.7.839	37	80	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19672	19678		10.1074/jbc.273.31.19672	http://dx.doi.org/10.1074/jbc.273.31.19672			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677395	hybrid			2022-12-25	WOS:000075125200047
J	Kowalski, JM; Parekh, RN; Mao, J; Wittrup, KD				Kowalski, JM; Parekh, RN; Mao, J; Wittrup, KD			Protein folding stability can determine the efficiency of escape from endoplasmic reticulum quality control	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC TRYPSIN-INHIBITOR; MOLECULAR CHAPERONES GROEL; SACCHAROMYCES-CEREVISIAE; THERMODYNAMIC STABILITIES; SECRETORY PATHWAY; ESCHERICHIA-COLI; MAMMALIAN-CELLS; T4 LYSOZYMES; CHO CELLS; YEAST	A fraction of each secreted protein is retained and degraded by the endoplasmic reticulum (ER) quality control apparatus that restricts export to correctly folded proteins. The intrinsic biophysical attributes that determine efficiency of escape from this proofreading process have been examined by expressing mutants of bovine pancreatic trypsin inhibitor (BPTI) in yeast. Secretion efficiency is strongly correlated with thermodynamic stability for a series of six point mutations of BPTI, No correlation of secretion efficiency with either oxidative folding or refolding rates in vitro is found; both the rapidly folded Y35L BPTI mutant and the slowly unfolded G36D BPTI mutant exhibit low secretion efficiency. Elimination of cysteines 14 and 38 by mutagenesis does not increase secretion efficiency, indicating that intramolecular thiol/disulfide rearrangements are not primarily responsible for retention and degradation of destabilized BPTI variants, Mutant yeast strains with diminished ER-associated degradation do not secrete BPTI more efficiently, indicating that retention and degradation are separable processes. These data support a model for ER quality control, wherein protein folding is functionally reversible and the relative rates of folding, unfolding, vesicular export, and retention determine secretion efficiency.	Univ Illinois, Dept Chem Engn, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Wittrup, KD (corresponding author), 600 S Mathews, Urbana, IL 61801 USA.	wittrup@uiuc.edu			NIGMS NIH HHS [GM50673] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050673, R21GM050673] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKER DM, 1991, METHOD ENZYMOL, V194, P182; DORNER AJ, 1994, BIOLOGICALS, V22, P103, DOI 10.1006/biol.1994.1016; ELLIOTT S, 1989, GENE, V79, P167, DOI 10.1016/0378-1119(89)90102-9; ElrodErickson MJ, 1996, MOL BIOL CELL, V7, P1043, DOI 10.1091/mbc.7.7.1043; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOLDENBERG DP, 1993, BIOCHEMISTRY-US, V32, P2835, DOI 10.1021/bi00062a015; GRAUSCHOPF U, 1995, CELL, V83, P947, DOI 10.1016/0092-8674(95)90210-4; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; INOUE I, 1994, J BIOL CHEM, V269, P29247; INOUE I, 1994, J BIOL CHEM, V269, P29241; JONES EW, 1991, METHOD ENZYMOL, V194, P428; KAUFMAN RJ, 1988, J BIOL CHEM, V263, P6352; KIM PS, 1993, AM J PHYSIOL, V265, pC704, DOI 10.1152/ajpcell.1993.265.3.C704; Knop M, 1996, EMBO J, V15, P753, DOI 10.1002/j.1460-2075.1996.tb00411.x; Kowalski JM, 1998, BIOCHEMISTRY-US, V37, P1264, DOI 10.1021/bi9722397; Kuehn MJ, 1997, CURR OPIN CELL BIOL, V9, P477, DOI 10.1016/S0955-0674(97)80022-1; Kwon WS, 1996, PROTEIN ENG, V9, P1197, DOI 10.1093/protein/9.12.1197; LIN TY, 1989, BIOCHEMISTRY-US, V28, P5282, DOI 10.1021/bi00438a054; Ma LC, 1997, BIOCHEMISTRY-US, V36, P3728, DOI 10.1021/bi962310t; MARQUARDT T, 1992, J CELL BIOL, V117, P505, DOI 10.1083/jcb.117.3.505; MENDOZA JA, 1994, BIOCHEMISTRY-US, V33, P1143, DOI 10.1021/bi00171a013; MOSES E, 1983, J MOL BIOL, V170, P765, DOI 10.1016/S0022-2836(83)80130-2; Muresan Z, 1997, J BIOL CHEM, V272, P26095, DOI 10.1074/jbc.272.42.26095; PAKULA AA, 1989, PROTEINS, V5, P202, DOI 10.1002/prot.340050303; PAREKH R, 1995, PROTEIN EXPRES PURIF, V6, P537, DOI 10.1006/prep.1995.1071; Parekh RN, 1997, BIOTECHNOL PROGR, V13, P117, DOI 10.1021/bp970009d; PENDSE GJ, 1992, BIOTECHNOL BIOENG, V40, P119, DOI 10.1002/bit.260400117; PUIG A, 1994, J BIOL CHEM, V269, P7764; Reff Mitchell E., 1993, Current Opinion in Biotechnology, V4, P573, DOI 10.1016/0958-1669(93)90079-C; Robinson AS, 1996, J BIOL CHEM, V271, P10017, DOI 10.1074/jbc.271.17.10017; ROBINSON AS, 1994, BIO-TECHNOL, V12, P381, DOI 10.1038/nbt0494-381; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; SCHULTZ LD, 1994, ANN NY ACAD SCI, V721, P148, DOI 10.1111/j.1749-6632.1994.tb47387.x; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Whiteley EM, 1997, J BIOL CHEM, V272, P22556, DOI 10.1074/jbc.272.36.22556; Wurm FM, 1996, ANN NY ACAD SCI, V782, P70, DOI 10.1111/j.1749-6632.1996.tb40548.x; Zahn R, 1996, SCIENCE, V271, P642, DOI 10.1126/science.271.5249.642; Zahn R, 1996, J MOL BIOL, V261, P43, DOI 10.1006/jmbi.1996.0440; Zhang JX, 1997, MOL BIOL CELL, V8, P1943, DOI 10.1091/mbc.8.10.1943; ZHANG JX, 1993, BIOCHEMISTRY-US, V32, P14075, DOI 10.1021/bi00214a001	44	98	103	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19453	19458		10.1074/jbc.273.31.19453	http://dx.doi.org/10.1074/jbc.273.31.19453			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677365	hybrid			2022-12-25	WOS:000075125200017
J	Prorok, M; Castellino, FJ				Prorok, M; Castellino, FJ			Thermodynamics of binding of calcium, magnesium, and zinc to the N-methyl-D-aspartate receptor ion channel peptidic inhibitors, conantokin-G and conantokin-T	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; PHOSPHOLIPID-BINDING; NMDA RESPONSES; PROTHROMBIN; NEURONS; TRANSITIONS; ANTAGONIST; RELEASE; BLOCK; SITE	The binding isotherms of the divalent metal cations, Ca2+, Mg2+, and Zn2+, to the synthetic gamma-carboxyglutamic acid-containing neuroactive peptides, conantokin-G (con-G) and conantokin-T (con-T), have been determined by isothermal titration calorimetry (ITC) at 25 degrees C and pH 6.5. We have previously shown by potentiometric measurements that con-G contains 2-3 equivalent Ca2+ sites with an average K-d value of 2800 mu M. With Mg2+, the ligand, two separate exothermic sites are obtained by ITC, one of K-d = 46 mu M and another of K-d = 311 mu M. Much tighter binding of Zn2+ is observed for these latter two sites (K-d values = 0.2 mu M and 1.1 mu M), and a third considerably weaker binding site is observed, characterized by a K-d value of 286 mu M and an endothermic enthalpy of binding, con-T possesses a single exothermic tight binding site for Ca2+, Mg2+, and Zn2+, with K-d values of 428 mu M, 10.2 mu M, and 0.5 mu M, respectively. Again, in the case of con-T, a weak (K-d = 410 mu M) endothermic binding site is observed for Zn2+, The binding of these cations to con-G and con-T result in an increase in the alpha-helical content of the peptides, However, this helix is somewhat destabilized in both cases by binding of Zn2+ to its weakest site. Since the differences observed in binding affinities of these three cations to the peptides are substantially greater than their comparative K-d values to malonate, we conclude that the structure of the peptide and, most likely, the steric and geometric properties imposed on the cation site as a result of peptide folding greatly influence the strength of the interaction of cations with con-G and con-T, Further, since the Zn2+ concentrations released in the synaptic cleft during excitatory synaptic activity are sufficiently high relative to the K-d of Zn2+ for con-G and con-T, this cation along with Mg2+, are most likely the most significant metal ion ligands of these peptides in neuronal cells.	Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA	University of Notre Dame	Castellino, FJ (corresponding author), Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA.	castellino.1@nd.edu			NHLBI NIH HHS [HL-19982] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019982] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANIKSZTEJN L, 1987, BRAIN RES, V404, P58, DOI 10.1016/0006-8993(87)91355-2; ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; BIEGON A, 1995, NEUROL RES, V17, P275, DOI 10.1080/01616412.1995.11740326; Blandl T, 1997, BIOCHEM J, V328, P777, DOI 10.1042/bj3280777; BOROWSKI M, 1986, J BIOL CHEM, V261, P4969; CHANDLER P, 1993, J BIOL CHEM, V268, P17173; CHEN HSV, 1992, J NEUROSCI, V12, P4427; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; Chen ZG, 1998, J BIOL CHEM, V273, P16248, DOI 10.1074/jbc.273.26.16248; CHRISTINE CW, 1990, J NEUROSCI, V10, P108; GOTTI B, 1988, J PHARMACOL EXP THER, V247, P1211; GRAHAM SH, 1993, J CEREBR BLOOD F MET, V13, P88, DOI 10.1038/jcbfm.1993.11; HAACK JA, 1990, J BIOL CHEM, V265, P6025; Kohn WD, 1998, J AM CHEM SOC, V120, P1124, DOI 10.1021/ja973673z; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCINTOSH JM, 1984, J BIOL CHEM, V259, P4343; MELDRUM BS, 1992, CURR OPIN NEUROL NEU, V5, P508; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P5648; NELSESTUEN GL, 1981, BIOCHEMISTRY-US, V20, P351, DOI 10.1021/bi00505a019; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P6886; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; PRENDERGAST FG, 1977, J BIOL CHEM, V252, P840; Prorok M, 1996, BIOCHEMISTRY-US, V35, P16528, DOI 10.1021/bi9621122; Rigby AC, 1997, BIOCHEMISTRY-US, V36, P15677, DOI 10.1021/bi9718550; RIVIER J, 1987, BIOCHEMISTRY-US, V26, P8508, DOI 10.1021/bi00400a002; SKOLNICK P, 1992, J NEUROCHEM, V59, P1516, DOI 10.1111/j.1471-4159.1992.tb08468.x; Warder SE, 1998, J BIOL CHEM, V273, P7512, DOI 10.1074/jbc.273.13.7512; Warder SE, 1997, FEBS LETT, V411, P19, DOI 10.1016/S0014-5793(97)00573-5; WESTBROOK GL, 1987, NATURE, V328, P640, DOI 10.1038/328640a0; Zhou LM, 1996, J NEUROCHEM, V66, P620	30	37	38	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19573	19578		10.1074/jbc.273.31.19573	http://dx.doi.org/10.1074/jbc.273.31.19573			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677382	hybrid			2022-12-25	WOS:000075125200034
J	Raab-Graham, KF; Vandenberg, CA				Raab-Graham, KF; Vandenberg, CA			Tetrameric subunit structure of the native brain inwardly rectifying potassium channel K-ir 2.2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; MEMBRANE PROTEINS; MOLECULAR-CLONING; ION CHANNELS; SUBSTANCE-P; RAT-BRAIN; RECTIFIER; CONDUCTANCE; BINDING; SIZE	Strongly inwardly rectifying potassium channels of the K-ir 2 subfamily (IRK1, IRK2, and IRK3) are involved in maintenance and modulation of cell excitability in brain and heart, Electrophysiological studies of channels expressed in heterologous systems have suggested that the pore-conducting pathway contains four subunits. However, inferences from electrophysiological studies have not been tested on native channels and do not address the possibility of nonconducting: auxiliary subunits, Here, we investigate the subunit stoichiometry of endogenous inwardly rectifying potassium channel K-ir 2.2 (IRK2) from rat brain. Using: chemical cross-linking, immunoprecipitiation, and velocity sedimentation, we report physical evidence demonstrating the tetrameric organization of the native channel, K-ir 2.2 was sequentially cross-linked to produce bands on SDS-polyacrylamide gel electrophoresis corresponding in size to monomer, dimer, trimer, and three forms of tetramer. Fully cross-linked channel was present as a single band of tetrameric size. Immunoprecipitation of biotinylated membranes revealed a single band corresponding to K-ir 2,2, suggesting that the channel is composed of a single type of subunit. Hydrodynamic properties of 3-[(3-cholamidopropyl)dimethylammonio]-1-propane sulfonic acid-solubilized channel were used to calculate the molecular mass of the channel. Velocity sedimentation in H2O or D2O gave a sharp peak with a sedimentation coefficient of 17.3 S. Gel filtration yielded a Stokes radius of 5.92 nm, These data indicate a multisubunit protein with a molecular mass of 193 kDa, calculated to contain 3.98 subunit's. Together, these results demonstrate that K-ir 2.2 channels are formed by the homotetrameric association of K-ir 2.2 subunits and do not contain tightly associated auxiliary subunits, These studies suggest that K-ir 2.2 channels differ in structure from related heterooctomeric ATP-sensitive K channels and heterotetrameric G-protein-regulated inward rectifier K channels.	Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Vandenberg, CA (corresponding author), Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.	vandenbe@lifesci.lscf.ucsb.edu		Raab-Graham, Kimberly/0000-0001-6502-057X	NHLBI NIH HHS [HL41656] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041656, R29HL041656] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKERS GK, 1967, J BIOL CHEM, V242, P3237; Ausubel FM, 1991, CURRENT PROTOCOLS MO; BAYER EA, 1990, METHOD ENZYMOL, V184, P138; BURGESS TL, 1995, J BIOL CHEM, V270, P19188, DOI 10.1074/jbc.270.32.19188; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; CLARKE S, 1975, J BIOL CHEM, V250, P5459; CLARKE S, 1989, METHOD ENZYMOL, V172, P696; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Coligan JE, 1995, CURRENT PROTOCOLS PR; Corey S, 1998, J BIOL CHEM, V273, P5271, DOI 10.1074/jbc.273.9.5271; DOUPNIK CA, 1995, CURR OPIN NEUROBIOL, V5, P268, DOI 10.1016/0959-4388(95)80038-7; Fahlke C, 1997, J GEN PHYSIOL, V109, P93, DOI 10.1085/jgp.109.1.93; GARFIN DE, 1990, METHOD ENZYMOL, V182, P425; GLOWATZKI E, 1995, P ROY SOC B-BIOL SCI, V261, P251, DOI 10.1098/rspb.1995.0145; Helenius A, 1979, Methods Enzymol, V56, P734; HJELMELAND LM, 1983, ANAL BIOCHEM, V130, P72, DOI 10.1016/0003-2697(83)90651-6; Inagaki N, 1997, FEBS LETT, V409, P232, DOI 10.1016/S0014-5793(97)00488-2; Inanobe A, 1995, BIOCHEM BIOPH RES CO, V217, P1238, DOI 10.1006/bbrc.1995.2901; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; Isomoto S, 1997, JPN J PHYSIOL, V47, P11, DOI 10.2170/jjphysiol.47.11; Jan LY, 1997, J PHYSIOL-LONDON, V505, P267, DOI 10.1111/j.1469-7793.1997.267bb.x; KNAUS HG, 1994, J BIOL CHEM, V269, P17274; KOFUJI P, 1995, P NATL ACAD SCI USA, V92, P6542, DOI 10.1073/pnas.92.14.6542; KOYAMA H, 1994, FEBS LETT, V341, P303, DOI 10.1016/0014-5793(94)80478-8; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUMAR KN, 1991, J BIOL CHEM, V266, P14947; LAI FA, 1989, J BIOL CHEM, V264, P16776; LAUE TM, 1990, METHOD ENZYMOL, V182, P566; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; MAKHINA EN, 1994, J BIOL CHEM, V269, P20468; MARSHALL RC, 1986, PRACTICAL PROTEIN CH, P1; MILLER C, 1992, SCIENCE, V258, P240, DOI 10.1126/science.1384128; MORISHIGE KI, 1994, FEBS LETT, V346, P251, DOI 10.1016/0014-5793(94)00483-8; NEWMAN EA, 1993, J NEUROSCI, V13, P3333; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; PARCEJ DN, 1992, BIOCHEMISTRY-US, V31, P11084, DOI 10.1021/bi00160a018; PERIER F, 1994, P NATL ACAD SCI USA, V91, P6240, DOI 10.1073/pnas.91.13.6240; Pessia M, 1996, EMBO J, V15, P2980, DOI 10.1002/j.1460-2075.1996.tb00661.x; REHM H, 1988, P NATL ACAD SCI USA, V85, P4919, DOI 10.1073/pnas.85.13.4919; Rhodes KJ, 1997, J NEUROSCI, V17, P8246; Schulteis CT, 1996, BIOCHEMISTRY-US, V35, P12133, DOI 10.1021/bi961083s; Shamotienko OG, 1997, BIOCHEMISTRY-US, V36, P8195, DOI 10.1021/bi970237g; SHARP AH, 1995, NEURON, V14, P1065, DOI 10.1016/0896-6273(95)90345-3; SHEN NV, 1993, NEURON, V11, P67; SHIMONI Y, 1992, J PHYSIOL-LONDON, V448, P709, DOI 10.1113/jphysiol.1992.sp019066; Silverman SK, 1996, J BIOL CHEM, V271, P30524, DOI 10.1074/jbc.271.48.30524; SNYNG SL, 1997, J GEN PHYSIOL, V110, P655; SOBER MA, 1970, CRC HDB BIOCH MOL BI, pC10; TAKANO K, 1995, NEURON, V14, P999, DOI 10.1016/0896-6273(95)90338-0; TAKUMI T, 1995, J BIOL CHEM, V270, P16339, DOI 10.1074/jbc.270.27.16339; TANFORD C, 1976, BIOCHIM BIOPHYS ACTA, V457, P133, DOI 10.1016/0304-4157(76)90009-5; Tinker A, 1996, CELL, V87, P857, DOI 10.1016/S0092-8674(00)81993-5; Tucker SJ, 1996, AM J PHYSIOL-HEART C, V271, pH379, DOI 10.1152/ajpheart.1996.271.1.H379; VANDENBERG CA, 1993, ION CHANNELS CARDIOV, P145; Velimirovic BM, 1996, FEBS LETT, V379, P31, DOI 10.1016/0014-5793(95)01465-9; WIMPEY TL, 1991, NEURON, V6, P281, DOI 10.1016/0896-6273(91)90363-5; YAMAGUCHI K, 1990, J PHYSIOL-LONDON, V426, P499, DOI 10.1113/jphysiol.1990.sp018151; Yang J, 1995, NEURON, V15, P1441, DOI 10.1016/0896-6273(95)90021-7	59	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19699	19707		10.1074/jbc.273.31.19699	http://dx.doi.org/10.1074/jbc.273.31.19699			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677399	hybrid			2022-12-25	WOS:000075125200051
J	Shimizu, N; Koyama, T; Ogura, K				Shimizu, N; Koyama, T; Ogura, K			Molecular cloning, expression, and purification of undecaprenyl diphosphate synthase - No sequence similarity between E- and Z-prenyl diphosphate synthases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; HEXAPRENYL PYROPHOSPHATE SYNTHETASE; MICROCOCCUS-LUTEUS B-P-26; BACILLUS-STEAROTHERMOPHILUS; ESCHERICHIA-COLI; LACTOBACILLUS-PLANTARUM; CONSERVED ASPARTATE; DOMAIN-II; RESIDUES; IDENTIFICATION	Cloning of the gene for undecaprenyl diphosphate synthase was successful, providing the first primary structure for any prenyltransferase that catalyzes Z-prenyl chain elongation, A genomic DNA library of Micrococcus luteus B-P 26 was constructed in Escherichia coli, and the recombinant clones were grown on nylon membranes. The membrane was incubated directly by floating it on a reaction mixture containing radiolabeled isopentenyl diphosphate, nonlabeled farnesyl diphosphate, and Mg2+. Only the clones harboring plasmids encoding prenyltransferases could take up the substrates to synthesize and accumulate radiolabeled products inside the cells in amounts large enough to be detectable by autoradiography. Four positive colonies were found among about 4,000 bacterial colonies of the genomic DNA library. Two of them carried the gene for undecaprenyl diphosphate synthase, which catalyzes the Z-prenyl chain elongation, and the others carried the (all-E)-hexaprenyl diphosphate synthase genes (hers-a and hexs-b; Shimizu, N., Koyama, T., and Ogura, K, (1998) J. Bacteriol. 180, 1578-1581). The undecaprenyl diphosphate synthase, which had a predicted molecular mass of 28.9 kDa, was overproduced in E. coli cells by applying a soluble expression system, and it was purified to near homogeneity. The deduced primary structure of the Z-prenyl chain-elongating enzyme is totally different from those of E-prenyl chain-elongating enzymes, which have characteristic conserved regions, including aspartate-rich motifs.	Tohoku Univ, Inst Chem React Sci, Aoba Ku, Sendai, Miyagi 9808577, Japan	Tohoku University	Koyama, T (corresponding author), Tohoku Univ, Inst Chem React Sci, Aoba Ku, Sendai, Miyagi 9808577, Japan.	koyama@icrs.tohoku.ac.jp						ALLEN CM, 1976, ARCH BIOCHEM BIOPHYS, V175, P236, DOI 10.1016/0003-9861(76)90504-X; ASAI K, 1994, BIOCHEM BIOPH RES CO, V202, P340, DOI 10.1006/bbrc.1994.1933; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; CHEN AJ, 1994, PROTEIN SCI, V3, P600; DAVISSON VJ, 1986, J ORG CHEM, V51, P4768, DOI 10.1021/jo00375a005; FUJII H, 1982, BIOCHIM BIOPHYS ACTA, V712, P716; FUJII H, 1982, J BIOL CHEM, V257, P4610; FUJII H, 1985, METHOD ENZYMOL, V110, P192; FUJISAKI S, 1990, J BIOCHEM-TOKYO, V108, P995, DOI 10.1093/oxfordjournals.jbchem.a123327; FUJISAKI S, 1984, BIOCHEM INT, V8, P779; ITO M, 1987, BIOCHEMISTRY-US, V26, P4745, DOI 10.1021/bi00389a022; JOLY A, 1993, J BIOL CHEM, V268, P26983; KOYAMA T, 1994, BIOCHEMISTRY-US, V33, P12644, DOI 10.1021/bi00208a015; KOYAMA T, 1995, BIOCHEM BIOPH RES CO, V212, P681, DOI 10.1006/bbrc.1995.2022; Koyama T, 1996, BIOCHEMISTRY-US, V35, P9533, DOI 10.1021/bi960137v; KOYAMA T, 1994, CAN J CHEM, V72, P75, DOI 10.1139/v94-012; KOYAMA T, 1993, J BIOCHEM-TOKYO, V113, P355, DOI 10.1093/oxfordjournals.jbchem.a124051; KOYAMA T, 1988, J BIOCHEM-TOKYO, V103, P867, DOI 10.1093/oxfordjournals.jbchem.a122363; MARRERO PF, 1992, J BIOL CHEM, V267, P21873; MUTH JD, 1984, ARCH BIOCHEM BIOPHYS, V230, P49, DOI 10.1016/0003-9861(84)90085-7; OGURA K, 1997, DYNAMIC ASPECTS NATU, P1; Ohnuma S, 1996, J BIOL CHEM, V271, P18831, DOI 10.1074/jbc.271.31.18831; Ohnuma S, 1996, J BIOL CHEM, V271, P30748, DOI 10.1074/jbc.271.48.30748; Ohnuma S, 1997, J BIOL CHEM, V272, P5192, DOI 10.1074/jbc.272.8.5192; Ohnuma SI, 1996, J BIOL CHEM, V271, P10087, DOI 10.1074/jbc.271.17.10087; RAETZ CRH, 1975, P NATL ACAD SCI USA, V72, P2274, DOI 10.1073/pnas.72.6.2274; SAITO H, 1963, BIOCHIM BIOPHYS ACTA, V72, P619, DOI 10.1016/0926-6550(63)90386-4; Sambrook J., 2002, MOL CLONING LAB MANU; Shimizu N, 1998, J BACTERIOL, V180, P1578, DOI 10.1128/JB.180.6.1578-1581.1998; SONG LS, 1994, P NATL ACAD SCI USA, V91, P3044, DOI 10.1073/pnas.91.8.3044; TAKATSUJI H, 1983, BIOCHEM BIOPH RES CO, V110, P187, DOI 10.1016/0006-291X(83)91278-0; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; Tarshis LC, 1996, P NATL ACAD SCI USA, V93, P15018, DOI 10.1073/pnas.93.26.15018	33	115	120	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19476	19481		10.1074/jbc.273.31.19476	http://dx.doi.org/10.1074/jbc.273.31.19476			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677368	hybrid			2022-12-25	WOS:000075125200020
J	Whitby, MC; Lloyd, RG				Whitby, MC; Lloyd, RG			Targeting Holliday junctions by the RecG branch migration protein of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							4-WAY DNA JUNCTION; BACTERIOPHAGE-T7 ENDONUCLEASE-I; IMMOBILE JUNCTION; DRUG-BINDING; SELECTIVE INTERACTION; CRUCIFORM DNA; RECOMBINATION; RESOLUTION; COMPLEX; SEQUENCE	The RecG protein of Escherichia coli is a junction-specific DNA helicase that drives branch migration of Holliday intermediates in genetic recombination and DNA repair. The reaction was investigated using synthetic X-junctions. RecG dissociates X-junctions to flayed duplex products, although DNA unwinding of the heterologous arms is limited to less than or equal to 30 base pairs. Junction unwinding requires Mg2+ and the hydrolysis of ATP. X-junction DNA stimulates the ATPase activity of RecG;, ATPase activity is also stimulated by linear duplex DNA, although to a lesser extent than by X-DNA, but not by linear single-stranded DNA. In situ 1,10-phenanthroline-copper footprinting shows that RecG binds to the strand cross-over point at the center of the X-junction. Substrate recognition by RecG was investigated using DNAs that represented the various component parts of an X-junction. The minimal DNA structure that RecG forms a stable complex with is a flayed duplex, suggesting that this is the critical feature for junction recognition by RecG. Junction binding and unwinding also depend critically on the concentration of free Mg2+, excess free cation dramatically inhibiting both processes. These inhibitory effects are not mediated specifically by Mg2+; e.g. both Ca2+ and hexamminecobalt(III) chloride also inhibit X-junction binding and unwinding by RecG. The relative abilities of these cations to inhibit RecG-junction binding is correlated with their respective abilities to stack X-junction DNA From this we conclude that RecG is unable to bind or binds very poorly to fully stacked X-junctions.	Univ Oxford, Dept Biochem, Microbiol Unit, Oxford OX6 9FS, England; Univ Nottingham, Queens Med Ctr, Dept Genet, Nottingham NG7 2UH, England	University of Oxford; University of Nottingham	Whitby, MC (corresponding author), Univ Oxford, Dept Biochem, Microbiol Unit, S Parks Rd, Oxford OX6 9FS, England.	whitby@bioch.ox.ac.uk		Whitby, Matthew/0000-0003-0951-3374				AlDeib AA, 1996, J BACTERIOL, V178, P6782, DOI 10.1128/jb.178.23.6782-6789.1996; BENNETT RJ, 1993, CELL, V74, P1021, DOI 10.1016/0092-8674(93)90724-5; BENNETT RJ, 1995, J MOL BIOL, V252, P213, DOI 10.1006/jmbi.1995.0489; BHATTACHARYYA A, 1991, J MOL BIOL, V221, P1191, DOI 10.1016/0022-2836(91)90928-Y; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; DUCKETT DR, 1995, J MOL BIOL, V246, P95, DOI 10.1006/jmbi.1994.0069; DUCKETT DR, 1990, EMBO J, V9, P583, DOI 10.1002/j.1460-2075.1990.tb08146.x; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; Fukuoh A, 1997, EMBO J, V16, P203, DOI 10.1093/emboj/16.1.203; GARTENBERG MR, 1988, NATURE, V333, P824, DOI 10.1038/333824a0; GiraudPanis MJE, 1996, J BIOL CHEM, V271, P33148, DOI 10.1074/jbc.271.51.33148; GRUBBS RD, 1987, MAGNESIUM, V6, P113; GUO Q, 1990, BIOCHEMISTRY-US, V29, P570, DOI 10.1021/bi00454a034; GUO Q, 1989, BIOCHEMISTRY-US, V28, P2355, DOI 10.1021/bi00432a001; HIOM K, 1995, CELL, V80, P787, DOI 10.1016/0092-8674(95)90357-7; HONG XK, 1995, EMBO J, V14, P2385, DOI 10.1002/j.1460-2075.1995.tb07233.x; JOHNSON RD, 1993, J MOL BIOL, V229, P812, DOI 10.1006/jmbi.1993.1087; LLOYD RG, 1991, J BACTERIOL, V173, P6837, DOI 10.1128/jb.173.21.6837-6843.1991; LLOYD RG, 1993, EMBO J, V12, P17, DOI 10.1002/j.1460-2075.1993.tb05627.x; LLOYD RG, 1993, NUCLEIC ACIDS RES, V21, P1719, DOI 10.1093/nar/21.8.1719; LOHMAN TM, 1986, CRIT REV BIOCHEM MOL, V19, P191, DOI 10.3109/10409238609084656; LU M, 1990, BIOCHEMISTRY-US, V29, P1614, DOI 10.1021/bi00458a037; LU M, 1990, BIOCHEMISTRY-US, V29, P3407, DOI 10.1021/bi00465a038; Mahdi AA, 1997, NUCLEIC ACIDS RES, V25, P3875, DOI 10.1093/nar/25.19.3875; McGlynn P, 1997, J MOL BIOL, V270, P212, DOI 10.1006/jmbi.1997.1120; Miick SM, 1997, P NATL ACAD SCI USA, V94, P9080, DOI 10.1073/pnas.94.17.9080; MOLLEGAARD NE, 1994, EMBO J, V13, P1508; MURCHIE AIH, 1989, NATURE, V341, P763, DOI 10.1038/341763a0; PANYUTIN IG, 1995, EMBO J, V14, P1819, DOI 10.1002/j.1460-2075.1995.tb07170.x; Parkinson MJ, 1997, J MOL BIOL, V270, P169, DOI 10.1006/jmbi.1997.1128; PARSONS CA, 1990, NUCLEIC ACIDS RES, V18, P4377, DOI 10.1093/nar/18.15.4377; PARSONS CA, 1990, J BIOL CHEM, V265, P9285; PARSONS CA, 1995, NATURE, V374, P375, DOI 10.1038/374375a0; PARSONS CA, 1992, P NATL ACAD SCI USA, V89, P5452, DOI 10.1073/pnas.89.12.5452; PEARSON CE, 1995, EMBO J, V14, P1571, DOI 10.1002/j.1460-2075.1995.tb07143.x; Pohler JRG, 1996, J MOL BIOL, V260, P678; PONTIGGIA A, 1993, MOL MICROBIOL, V7, P343, DOI 10.1111/j.1365-2958.1993.tb01126.x; PORSCHKE D, 1976, BIOPHYS CHEM, V4, P383, DOI 10.1016/0301-4622(76)80018-X; Rafferty JB, 1996, SCIENCE, V274, P415, DOI 10.1126/science.274.5286.415; SHARPLES GJ, 1994, EMBO J, V13, P6133, DOI 10.1002/j.1460-2075.1994.tb06960.x; SHARPLES GJ, 1994, NUCLEIC ACIDS RES, V22, P308, DOI 10.1093/nar/22.3.308; SIGMAN DS, 1991, METHOD ENZYMOL, V208, P414; Vincent SD, 1996, J MOL BIOL, V264, P713, DOI 10.1006/jmbi.1996.0671; VONKITZING E, 1990, NUCLEIC ACIDS RES, V18, P2671, DOI 10.1093/nar/18.9.2671; West SC, 1996, J BACTERIOL, V178, P1237, DOI 10.1128/jb.178.5.1237-1241.1996; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; WHITBY MC, 1995, EMBO J, V14, P3302, DOI 10.1002/j.1460-2075.1995.tb07337.x; WHITBY MC, 1993, CELL, V75, P341, DOI 10.1016/0092-8674(93)80075-P; WHITBY MC, 1994, EMBO J, V13, P5220, DOI 10.1002/j.1460-2075.1994.tb06853.x; Whitby MC, 1997, J MOL BIOL, V272, P509, DOI 10.1006/jmbi.1997.1286; White MF, 1996, J MOL BIOL, V257, P330, DOI 10.1006/jmbi.1996.0166; White MF, 1997, J MOL BIOL, V266, P122, DOI 10.1006/jmbi.1996.0795	52	74	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19729	19739		10.1074/jbc.273.31.19729	http://dx.doi.org/10.1074/jbc.273.31.19729			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677403	hybrid			2022-12-25	WOS:000075125200055
J	Krebs, S; Lamas, JR; Poenaru, S; Folkers, G; de Castro, JAL; Seebach, D; Rognan, D				Krebs, S; Lamas, JR; Poenaru, S; Folkers, G; de Castro, JAL; Seebach, D; Rognan, D			Substituting nonpeptidic spacers for the T cell receptor-binding part of class I major histocompatibility complex-binding peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; MHC; MOLECULES; HLA-B27; ANTIGEN; ASSOCIATION; HLA-A2; HLA-B-ASTERISK-2705; BIOPOLYMERS; ANTAGONISTS	X-ray diffraction studies as well as structure-activity relationships indicate that the central part of class I major histocompatibility complex (MHC)-binding nonapeptides represents the main interaction site for a T cell receptor. In order to rationally manipulate T cell epitopes, three nonpeptidic spacers have been designed from the x-ray structure of a MHC-peptide complex and substituted for the T cell receptor-binding part of several antigenic peptides. The binding of the modified epitopes to the human leukocyte antigen-B*2705 protein was studied by an in vitro stabilization assay, and the thermal stability of all complexes was examined by circular dichroism spectroscopy. Depending on their chemical nature and length, the introduced spacers may be classified into two categories. Monofunctional spacers (11-amino undecanoate, (R)-3-hydroxybutyrate trimer) simply link two anchoring peptide positions (P3 and P9) but loosely contact the MHC binding groove and thus decrease more or less the affinity of the altered epitopes to human leukocyte antigen-B*2705, A bifunctional spacer ((R)-3-hydroxybutyrate tetramer) not only bridges the two distant anchoring amino acids but also strongly interacts with the binding cleft and leads to a 5-fold increase in binding to the MRC protein. To our knowledge, this is the first report of a nonpeptidic modification of T-cell receptor binding residues that significantly enhances the binding of altered peptide Ligands to their host MHC protein. The presented modified ligands constitute interesting tools for perturbing the T cell response to the parent antigenic peptide.	Swiss Fed Inst Technol, Dept Pharm, CH-8057 Zurich, Switzerland; Swiss Fed Inst Technol, Organ Chem Lab, CH-8092 Zurich, Switzerland; Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Fac Ciencias, E-28049 Madrid, Spain	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Rognan, D (corresponding author), Swiss Fed Inst Technol, Dept Pharm, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	didier@pharma.ethz.ch	Rognan, Didier/B-9939-2014; Lamas, José Ramón/C-8318-2012	Lamas, José Ramón/0000-0003-1913-7261; Folkers, Gerd/0000-0002-3620-705X				BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004; BENJAMIN R, 1990, IMMUNOL TODAY, V11, P137, DOI 10.1016/0167-5699(90)90051-A; BOUVIER M, 1994, SCIENCE, V265, P398, DOI 10.1126/science.8023162; Bouvier M, 1996, P NATL ACAD SCI USA, V93, P4583, DOI 10.1073/pnas.93.10.4583; BREWERTON DA, 1973, LANCET, V2, P994, DOI 10.1016/S0140-6736(73)91090-8; BROOKS JM, 1993, J EXP MED, V178, P879, DOI 10.1084/jem.178.3.879; CIEPLAK P, 1995, J COMPUT CHEM, V16, P1357, DOI 10.1002/jcc.540161106; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; DEMAGISTRIS MT, 1992, CELL, V68, P625, DOI 10.1016/0092-8674(92)90139-4; ELLIS SA, 1982, HUM IMMUNOL, V5, P49, DOI 10.1016/0198-8859(82)90030-1; FAHNESTOCK ML, 1994, BIOCHEMISTRY-US, V33, P8149, DOI 10.1021/bi00192a020; FALL K, 1991, NATURE, V351, P290; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; Fox T, 1997, J AM CHEM SOC, V119, P11571, DOI 10.1021/ja964315j; Galocha B, 1996, TISSUE ANTIGENS, V48, P509, DOI 10.1111/j.1399-0039.1996.tb02664.x; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Garcia F, 1997, TISSUE ANTIGENS, V49, P215, DOI 10.1111/j.1399-0039.1997.tb02741.x; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; GUO HC, 1993, P NATL ACAD SCI USA, V90, P8053, DOI 10.1073/pnas.90.17.8053; GUO HC, 1992, NATURE, V360, P364, DOI 10.1038/360364a0; HEEMELS MT, 1995, ANNU REV BIOCHEM, V64, P643; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; HUET S, 1990, INT IMMUNOL, V2, P311, DOI 10.1093/intimm/2.4.311; ISHIOKA GY, 1994, J IMMUNOL, V152, P4310; JAMESON SC, 1993, J EXP MED, V177, P1541, DOI 10.1084/jem.177.6.1541; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KINGSLEY G, 1993, IMMUNOL TODAY, V14, P387, DOI 10.1016/0167-5699(93)90139-C; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MADDEN DR, 1995, ANNU REV IMMUNOL, V13, P587, DOI 10.1146/annurev.iy.13.040195.003103; Morgan CS, 1997, PROTEIN SCI, V6, P1771, DOI 10.1002/pro.5560060819; MULLER HM, 1993, ANGEW CHEM INT EDIT, V32, P477, DOI 10.1002/anie.199304771; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; NAGAI K, 1987, METHOD ENZYMOL, V131, P266; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PEARLMAN DA, 1995, AMBER 4 1; PLATTNER DA, 1993, HELV CHIM ACTA, V76, P2004, DOI 10.1002/hlca.19930760518; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P191; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; Reich Z, 1997, P NATL ACAD SCI USA, V94, P2495, DOI 10.1073/pnas.94.6.2495; ROGNAN D, 1994, BIOCHEMISTRY-US, V33, P11476, DOI 10.1021/bi00204a009; Rognan D, 1997, J COMPUT AID MOL DES, V11, P463, DOI 10.1023/A:1007963901092; ROGNAN D, 1995, P NATL ACAD SCI USA, V92, P753, DOI 10.1073/pnas.92.3.753; ROTZSCHKE O, 1994, IMMUNOGENETICS, V39, P74; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; Schlegel HB., 2009, GAUSSIAN 09 REVISION; SLOANLANCASTER J, 1993, NATURE, V363, P156, DOI 10.1038/363156a0; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; Stryhn A, 1996, P NATL ACAD SCI USA, V93, P10338, DOI 10.1073/pnas.93.19.10338; Weiss GA, 1996, P NATL ACAD SCI USA, V93, P10945, DOI 10.1073/pnas.93.20.10945; WEISS GA, 1995, CHEM BIOL, V2, P401, DOI 10.1016/1074-5521(95)90221-X	51	25	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19072	19079		10.1074/jbc.273.30.19072	http://dx.doi.org/10.1074/jbc.273.30.19072			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668090	hybrid			2022-12-25	WOS:000074974700057
J	Matoba, S; Ogrydziak, DM				Matoba, S; Ogrydziak, DM			Another factor besides hydrophobicity can affect signal peptide interaction with signal recognition particle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALTOSE-BINDING-PROTEIN; YEAST YARROWIA-LIPOLYTICA; EXTRACELLULAR PROTEASE; ENDOPLASMIC-RETICULUM; SECONDARY STRUCTURE; ESCHERICHIA-COLI; SEQUENCES; TRANSLOCATION; MUTATIONS; PLASMID	Translocation of alkaline extracellular protease (AEP) into the endoplasmic reticulum of Yarrowia lipolytica is cotranslational and signal recognition particle (SRP)dependent, whereas translocation of Firm AFP (proline to methionine at position 17, second amino acid in the pro-region) is posttranslational and SRP-independent. Firm signal peptide mutations that resulted in more rapid SRP-dependent translocation of AEP precursor were isolated. Most of these mutations significantly increased hydrophobicity, but the A12P/P17M mutation did not. The switch from SRP-dependent to SRP-independent translocation without a decrease in hydrophobicity (wild type to P17M) and restoration of SRP-dependent translocation without an increase in hydrophobicity (P17M to A12P/P17M) indicate that some factor(s) in addition to hydrophobicity determines selection of targeting pathway. Models of extended forms of wild type and A12P/P17M signal peptides are kinked, whereas the P17M signal peptide is relatively straight. Possibly the conformation/orientation of signal peptides at the ribosomal surface affects SRP binding and consequently the targeting route to the endoplasmic reticulum. Kinked signal peptides might approach SRP more closely more often. Most likely, these effects were only detectable because of the short length and low average hydrophobicity of the AEP signal peptide.	Univ Calif Davis, Inst Marine Resources, Davis, CA 95616 USA	University of California System; University of California Davis	Ogrydziak, DM (corresponding author), Univ Calif Davis, Inst Marine Resources, 1 Shields Ave, Davis, CA 95616 USA.	dmogrydziak@ucdavis.edu						BEDOUELLE H, 1980, NATURE, V285, P78, DOI 10.1038/285078a0; BIRD P, 1987, J CELL BIOL, V105, P2905, DOI 10.1083/jcb.105.6.2905; BIRD P, 1990, J BIOL CHEM, V265, P8420; Brasseur R, 1997, TRENDS BIOCHEM SCI, V22, P167, DOI 10.1016/S0968-0004(97)01047-5; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHOU MM, 1990, J BIOL CHEM, V265, P2873; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CORNETTE JL, 1987, J MOL BIOL, V195, P659, DOI 10.1016/0022-2836(87)90189-6; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; EMR SD, 1983, P NATL ACAD SCI-BIOL, V80, P4599, DOI 10.1073/pnas.80.15.4599; ENDERLIN CS, 1994, YEAST, V10, P67, DOI 10.1002/yea.320100107; FIKES JD, 1987, J BACTERIOL, V169, P2345, DOI 10.1128/jb.169.6.2345-2351.1987; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; Lee IH, 1997, YEAST, V13, P499, DOI 10.1002/(SICI)1097-0061(199705)13:6<499::AID-YEA100>3.0.CO;2-M; Matoba S, 1997, MICROBIOL-UK, V143, P3263, DOI 10.1099/00221287-143-10-3263; Ng DTW, 1996, J CELL BIOL, V134, P269, DOI 10.1083/jcb.134.2.269; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OGG SC, 1995, CELL, V81, P1075, DOI 10.1016/S0092-8674(05)80012-1; OGRYDZIAK DM, 1977, BIOCHIM BIOPHYS ACTA, V497, P525, DOI 10.1016/0304-4165(77)90209-4; Park CS, 1997, J BIOL CHEM, V272, P6876, DOI 10.1074/jbc.272.11.6876; RYAN JP, 1986, J BIOL CHEM, V261, P3389; Sambrook J., 2002, MOL CLONING LAB MANU; SHEEN J, 1993, CURRENT PROTOCOLS MO, V1; SIEGEL V, 1988, EMBO J, V7, P1769, DOI 10.1002/j.1460-2075.1988.tb03007.x; TOMILO M, 1994, J BIOL CHEM, V269, P32016; VANHOOF G, 1995, FASEB J, V9, P736, DOI 10.1096/fasebj.9.9.7601338; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WICKNER W, 1995, P NATL ACAD SCI USA, V92, P9433, DOI 10.1073/pnas.92.21.9433; XUAN JW, 1988, CURR GENET, V14, P15, DOI 10.1007/BF00405848; YAVER DS, 1992, J CELL BIOL, V116, P605, DOI 10.1083/jcb.116.3.605; Zheng N, 1996, CELL, V86, P849, DOI 10.1016/S0092-8674(00)80159-2	33	27	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18841	18847		10.1074/jbc.273.30.18841	http://dx.doi.org/10.1074/jbc.273.30.18841			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668059	hybrid			2022-12-25	WOS:000074974700026
J	Trybus, KM; Naroditskaya, V; Sweeney, HL				Trybus, KM; Naroditskaya, V; Sweeney, HL			The light chain-binding domain of the smooth muscle myosin heavy chain is not the only determinant of regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATION-DEPENDENT REGULATION; SCALLOP MYOSIN; RESOLUTION; MEROMYOSIN; SEQUENCE; MOTOR	Interactions between the dephosphorylated regulatory light chains (RLCs) of smooth muscle myosin are involved in maintaining the enzymatically "off" state. Expressed chimeric smooth muscle heavy meromyosins containing skeletal muscle myosin heavy chain (HC) sequences were used to assess the relative importance of the light chain-binding domain (or "neck") to regulation. Surprisingly, regulation remained intact with a skeletal RLC-binding site. A chimera with the entire cu-helical neck composed of skeletal HC sequence showed a-fold regulation of motility and nearly 5-fold regulation of actin-activated ATPase activity. Complete activation of the dephosphorylated state (i.e. complete loss of regulation) occurred when skeletal HC sequence extended from the head/rod junction to the SH1-SH2 helix. Smooth muscle-specific sequences near the motor domain may therefore position the regulatory domain in a way that optimizes RLC-rod-head interactions, thus enabling a completely off state when the RLC is dephosphorylated. Conversely, a chimera that joins the motor domain from unconventional myosin V to the smooth muscle myosin neck and rod showed only a-fold regulation. The presence of the smooth muscle light chain-binding region and rod is therefore not sufficient to confer complete phosphorylation-dependent regulation upon all motor domains of the myosin family.	Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02254 USA; Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA	Brandeis University; University of Pennsylvania	Trybus, KM (corresponding author), Univ Vermont, Dept Mol Physiol & Biophys, Given Bldg E207, Burlington, VT 05405 USA.		Sweeney, H Lee/F-1862-2010		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038113, R01HL038113] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035661] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38113] Funding Source: Medline; NIAMS NIH HHS [AR35661] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; CREMO CR, 1995, J BIOL CHEM, V270, P2171, DOI 10.1074/jbc.270.5.2171; Houdusse A, 1996, STRUCTURE, V4, P21, DOI 10.1016/S0969-2126(96)00006-8; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LOWEY S, 1993, NATURE, V365, P454, DOI 10.1038/365454a0; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; MOLINA MI, 1987, J BIOL CHEM, V262, P6478; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Rovner AS, 1995, J BIOL CHEM, V270, P30260, DOI 10.1074/jbc.270.51.30260; Sata M, 1997, P NATL ACAD SCI USA, V94, P91, DOI 10.1073/pnas.94.1.91; SELLERS JR, 1985, J BIOL CHEM, V260, P5815; TRYBUS KM, 1989, J CELL BIOL, V109, P2879, DOI 10.1083/jcb.109.6.2879; TRYBUS KM, 1993, J BIOL CHEM, V268, P4412; TRYBUS KM, 1994, J BIOL CHEM, V269, P20819; TRYBUS KM, 1997, P NATL ACAD SCI USA, V94, P46; WHITE HD, 1982, METHOD ENZYMOL, V85, P698; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0; YANAGISAWA M, 1987, J MOL BIOL, V198, P143, DOI 10.1016/0022-2836(87)90302-0	19	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18423	18428		10.1074/jbc.273.29.18423	http://dx.doi.org/10.1074/jbc.273.29.18423			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660810	hybrid			2022-12-25	WOS:000074828500065
J	Cheneval, D; Ramage, P; Kastelic, T; Szelestenyi, T; Niggli, H; Hemmig, R; Bachmann, M; MacKenzie, A				Cheneval, D; Ramage, P; Kastelic, T; Szelestenyi, T; Niggli, H; Hemmig, R; Bachmann, M; MacKenzie, A			Increased mature interleukin-1 beta (IL-1 beta) secretion from THP-1 cells induced by nigericin is a result of activation of p45 IL-1 beta-converting enzyme processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MONOCYTES; MATURATION; PRECURSOR; RELEASE	Perregaux and Gabel (Perregaux, D., and Gabel, C. A. (1994) J. Biol. Chem. 269, 15195-15203) reported that potassium depletion of lipopolysaccharide-stimulated mouse macrophages induced by the potassium ionophore, nigericin, leads to the rapid release of mature interleukin-1 beta (IL-1 beta). me have now shown a similar phenomenon in lipopolysaccharide-stimulated human monocytic leukemia THP-1 cells. Rapid secretion of mature, 17-kDa IL-1 beta occurred, in the presence of nigericin (4-16 mu M). No effects on the release of tumor necrosis factor-alpha, IL-6, or proIL-1 beta were seen. Addition of the irreversible interleukin-1 beta-converting enzyme (ICE) inhibitor, Z-Val-Ala-Asp-dichlorobenzoate, or a radicicol analog, inhibited nigericin-induced mature IL-1 beta release and activation of p45 ICE precursor. The radicicol analog itself did not inhibit ICE, but markedly, and very rapidly depleted intracellular levels of 31-kDa proIL-1 beta, By contrast, dexamethasone, cycloheximide, and the Na+/H+ antiporter inhibitor, 5-(N-ethyl-N-isopropyl)amiloride, had no effect on nigericin-induced release of IL-I beta. We have therefore shown conclusively, for the first time, that nigericin-induced release of IL-1 beta is dependent upon activation of p45 ICE processing. So far, the mechanism by which reduced intracellular potassium ion concentration triggers p45 ICE processing is not known, but further investigation in this area could lead to the discovery of novel molecular targets whereby control of IL-1 beta production might be effected.	Novartis Pharma, CH-4002 Basel, Switzerland	Novartis	Cheneval, D (corresponding author), Novartis Pharma, CH-4002 Basel, Switzerland.							AYALA JM, 1994, J IMMUNOL, V153, P2592; ELFORD PR, 1996, PHARM COMMUN, V7, P301; KAPUSCINSKI J, 1977, ANAL BIOCHEM, V83, P252, DOI 10.1016/0003-2697(77)90533-4; Kastelic T, 1996, CYTOKINE, V8, P751, DOI 10.1006/cyto.1996.0100; Loddick SA, 1996, NEUROREPORT, V7, P1465, DOI 10.1097/00001756-199606170-00004; Margolin N, 1997, J BIOL CHEM, V272, P7223, DOI 10.1074/jbc.272.11.7223; ORLINSKA U, 1992, AM J PHYSIOL, V263, pC1073, DOI 10.1152/ajpcell.1992.263.5.C1073; PERREGAUX D, 1992, J IMMUNOL, V149, P1294; PERREGAUX D, 1994, J BIOL CHEM, V269, P15195; RAMAGE P, 1995, J BIOL CHEM, V270, P9378, DOI 10.1074/jbc.270.16.9378; SCHNYDER J, 1990, AGENTS ACTIONS, V30, P350, DOI 10.1007/BF01966299; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WALEV I, 1995, EMBO J, V14, P1607, DOI 10.1002/j.1460-2075.1995.tb07149.x	13	62	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17846	17851		10.1074/jbc.273.28.17846	http://dx.doi.org/10.1074/jbc.273.28.17846			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651388	hybrid			2022-12-25	WOS:000074816100081
J	Kristensen, C; Wiberg, FC; Schaffer, L; Andersen, AS				Kristensen, C; Wiberg, FC; Schaffer, L; Andersen, AS			Expression and characterization of a 70-kDa fragment of the insulin receptor that binds insulin - Minimizing ligand binding domain of the insulin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; ALANINE-SCANNING MUTAGENESIS; EPIDERMAL GROWTH-FACTOR; ALPHA-SUBUNIT; EXTRACELLULAR DOMAIN; CRYSTAL-STRUCTURE; CROSS-LINKING; SITE; HORMONE; REGION	In order to characterize regions of the insulin receptor that are essential for ligand binding and possibly identify a smaller insulin-binding fragment of the receptor, we have used site-directed mutagenesis to construct a series of insulin receptor deletion mutants. From 112 to 246 amino acids were deleted from the alpha-subunit region comprising amino acids 469-729. The receptor constructs were expressed as soluble insulin receptor IgG fusion proteins in baby hamster kidney cells and were characterized in binding assays by immunoblotting and chemical cross-linking with radiolabeled insulin. The shortest receptor fragment identified was a free monomeric a-subunit deleted of amino acids 469-703 and 718-729 (exon 11); the mass of this receptor fragment was found by mass spectrometry to be 70 kDa. This small insulin receptor fragment bound insulin with an affinity (K-d) of 4.4 nM, which is similar to what was found for the full-length ectodomain of the insulin receptor (5.0 nM). Cross-linking experiments confirmed that the 70-kDa receptor fragment specifically bound insulin. In summary we have minimized the insulin binding domain of the insulin receptor by identifying a 70-kDa fragment of the ectodomain that retains insulin binding affinity making this an interesting candidate for detailed structural analysis.	Novo Nordisk AS, Hlth Care Discovery, Dept Insulin Res, DK-2880 Bagsvaerd, Denmark; Novo Nordisk AS, Hlth Care Discovery, Dept Cell Technol, DK-2880 Bagsvaerd, Denmark	Novo Nordisk; Novo Nordisk	Kristensen, C (corresponding author), Novo Nordisk AS, Hlth Care Discovery, Dept Insulin Res, Novo Alle 6B1-90, DK-2880 Bagsvaerd, Denmark.	clak@novo.dk	Kristensen, Claus/O-8047-2015	Kristensen, Claus/0000-0002-2594-7722				ANDERSEN AS, 1990, BIOCHEMISTRY-US, V29, P7363, DOI 10.1021/bi00484a002; ANDERSEN AS, 1992, J BIOL CHEM, V267, P13681; BAJAJ M, 1987, BIOCHIM BIOPHYS ACTA, V916, P220, DOI 10.1016/0167-4838(87)90112-9; Bass J, 1996, J BIOL CHEM, V271, P19367, DOI 10.1074/jbc.271.32.19367; CHEATHAM B, 1992, J BIOL CHEM, V267, P7108; DAmbrosio C, 1996, CANCER RES, V56, P4013; DEMEYTS P, 1994, DIABETOLOGIA, V37, pS135, DOI 10.1007/BF00400837; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FABRY M, 1992, J BIOL CHEM, V267, P8950; FUH G, 1990, J BIOL CHEM, V265, P3111; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; KADOWAKI H, 1990, J BIOL CHEM, V265, P21285; KJELDSEN T, 1991, P NATL ACAD SCI USA, V88, P4404, DOI 10.1073/pnas.88.10.4404; Kristensen C, 1997, J BIOL CHEM, V272, P12978, DOI 10.1074/jbc.272.20.12978; KUROSE T, 1994, J BIOL CHEM, V269, P29190; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; MACAULAY SL, 1994, BIOCHEM J, V303, P575, DOI 10.1042/bj3030575; MARKUSSEN J, 1991, J BIOL CHEM, V266, P18814; McKern NM, 1997, PROTEIN SCI, V6, P2663; Mynarcik DC, 1996, J BIOL CHEM, V271, P2439, DOI 10.1074/jbc.271.5.2439; PASHMFOROUSH M, 1994, J BIOL CHEM, V269, P32639; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAEFER EM, 1990, J BIOL CHEM, V265, P13248; SCHAFFER L, 1994, EUR J BIOCHEM, V221, P1127, DOI 10.1111/j.1432-1033.1994.tb18833.x; SCHAFFER L, 1992, BIOCHEM BIOPH RES CO, V189, P650, DOI 10.1016/0006-291X(92)92250-2; Sparrow LG, 1997, J BIOL CHEM, V272, P29460, DOI 10.1074/jbc.272.47.29460; SUNG CK, 1994, MOL ENDOCRINOL, V8, P315, DOI 10.1210/me.8.3.315; TAVARE JM, 1993, BIOCHIM BIOPHYS ACTA, V1178, P21, DOI 10.1016/0167-4889(93)90106-Y; TAYLOR S, 1994, ENDOCR REV, V2, P58; TAYLOR SI, 1992, ENDOCR REV, V13, P566, DOI 10.1210/er.13.3.566; WARD CW, 1995, PROTEINS, V22, P141, DOI 10.1002/prot.340220207; WAUGH SM, 1989, BIOCHEMISTRY-US, V28, P2722, DOI 10.1021/bi00432a053; WAUGH SM, 1989, BIOCHEMISTRY-US, V28, P3448, DOI 10.1021/bi00434a045; WEDEKIND F, 1989, BIOL CHEM H-S, V370, P251, DOI 10.1515/bchm3.1989.370.1.251; WILLIAMS PF, 1995, J BIOL CHEM, V270, P3012, DOI 10.1074/jbc.270.7.3012; XU QY, 1990, J BIOL CHEM, V265, P18673; YAMAGUCHI Y, 1993, ENDOCRINOLOGY, V132, P1132, DOI 10.1210/en.132.3.1132; YIP CC, 1988, BIOCHEM BIOPH RES CO, V157, P321, DOI 10.1016/S0006-291X(88)80050-0; ZHANG B, 1991, P NATL ACAD SCI USA, V88, P9858, DOI 10.1073/pnas.88.21.9858	40	52	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17780	17786		10.1074/jbc.273.28.17780	http://dx.doi.org/10.1074/jbc.273.28.17780			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651379	hybrid			2022-12-25	WOS:000074816100072
J	Bose, S; Wang, SI; Terry, MB; Hibshoosh, H; Parsons, R				Bose, S; Wang, SI; Terry, MB; Hibshoosh, H; Parsons, R			Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas	ONCOGENE			English	Article						breast carcinoma; carcinoma in situ; PTEN; chromosome 10; loss of heterozygosity	IN-SITU; CANCER; HETEROZYGOSITY; ALLELOTYPE; DELETION; REGION; FREQUENCY; 11Q13; P53	To determine the status of chromosome 10q23 in primary breast carcinomas, ill situ and invasive carcinomas were analysed for allelic loss using microsatellite markers spanning the 10q23 region. No LOH was seen in pure intraductal carcinomas (0/20 cases). On the other hand, LOH was observed in 40% (17/42) of invasive carcinomas (P=0.0005). Interestingly, in situ lesions found in invasive tumors displayed LOH. Allelic loss was also significantly associated with loss of the estrogen receptor (P=0.011). Thus, loss of the 10q23 is strongly associated with tumor progression.	Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Epidemiol, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Parsons, R (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Pathol, 630 W 168th St, New York, NY 10032 USA.			Terry, Mary Beth/0000-0002-4106-5033; Parsons, Ramon/0000-0002-6656-3514				*ACS, 1994, CANC FACTS FIG 1994; ALDAZ CM, 1995, CANCER RES, V55, P3976; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Deng GR, 1996, SCIENCE, V274, P2057, DOI 10.1126/science.274.5295.2057; DEVILEE P, 1991, ONCOGENE, V6, P1705; DEVILEE P, 1994, CRIT REV ONCOGENESIS, V5, P247, DOI 10.1615/CritRevOncog.v5.i2-3.70; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fujii H, 1996, CANCER RES, V56, P5260; GRAY IC, 1995, CANCER RES, V55, P4800; Guldberg P, 1997, CANCER RES, V57, P3660; Ittmann M, 1996, CANCER RES, V56, P2143; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; LOUIS DN, 1995, TRENDS GENET, V11, P412, DOI 10.1016/S0168-9525(00)89125-8; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; OSBORNE RJ, 1991, CANCER RES, V51, P6194; RADFORD DM, 1995, CANCER RES, V55, P3399; RADFORD DM, 1995, CANCER RES, V55, P5180; Rasheed BKA, 1997, CANCER RES, V57, P4187; RASHEED BKA, 1995, ONCOGENE, V10, P2243; Rhei E, 1997, CANCER RES, V57, P3657; SATO T, 1990, CANCER RES, V50, P7184; SCHUURING E, 1992, ONCOGENE, V7, P355; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tashiro H, 1997, CANCER RES, V57, P3935; VARLEY JM, 1991, ONCOGENE, V6, P413; Wang SI, 1997, CANCER RES, V57, P4183; Yaremko ML, 1996, GENE CHROMOSOME CANC, V16, P189, DOI 10.1002/(SICI)1098-2264(199607)16:3<189::AID-GCC6>3.0.CO;2-V; ZHUANG ZP, 1995, CANCER RES, V55, P467	32	92	107	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 9	1998	17	1					123	127		10.1038/sj.onc.1201940	http://dx.doi.org/10.1038/sj.onc.1201940			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZY936	9671321				2022-12-25	WOS:000074677800014
J	Ahmed, A; Dearn, S; Shams, M; Li, XF; Sangha, RK; Rola-Pleszczynski, M; Jiang, JQ				Ahmed, A; Dearn, S; Shams, M; Li, XF; Sangha, RK; Rola-Pleszczynski, M; Jiang, JQ			Localization, quantification, and activation of platelet-activating factor receptor in human endometrium during the menstrual cycle: PAF stimulates NO, VEGF, and FAK(pp125)	FASEB JOURNAL			English	Article						PAF receptor; uterus; nitric oxide; menstruation; implantation	ENDOTHELIAL GROWTH-FACTOR; IN-VIVO ANGIOGENESIS; MESSENGER-RNAS; NITRIC-OXIDE; CELLS; IDENTIFICATION; EXPRESSION; HYDROLYSIS; ESTROGEN; VITRO	Implantation is characterized by an inflammatory-like response with expansion of extracellular fluid volume, increased vascular permeability, and vasodilatation. These effects are believed to be mediated at the paracrine level by prostaglandin EP and platelet-activating factor (PAF), but the cellular mechanism (or mechanisms) remains largely unknown. We demonstrate that PAF receptor (PAF-R) immunoreactivity and mRNA are detected in proliferative and secretory endometrial glands, however, the responsiveness of endometrium to physiological concentrations of PAF is confined predominantly to the secretory endometrium. Semiquantitative reverse transcription-polymerase chain reaction revealed that PAF-R transcript levels were highest in the mid-late proliferative and late secretory phases of the cycle. Interaction of PAF with its receptor resulted in the rapid release of nitric oxide (NO), increased expression of vascular endothelial growth factor (VEGF), and activation of FAK(pp125), a focal adhesion kinase, demonstrating that the PAF-R is functionally active. Inhibition of NO synthesis by N-G-monomethyl-L-arginine produced dose-dependent attenuation of PAF-evoked NO release, indicating NOS activation; the dependency of PAF-evoked NO release on PKC and extracellular Ca2+ was confirmed by PRO inhibitor Ro 31-8220 and by the removal of extracellular Ca2+ PAF up-regulated VEGF gene expression in a concentration- and time-dependent fashion in human endometrial epithelial cell lysates. Transcription of VEGF was rapidly followed by secretion of the protein. These data support our premise that this auto-coid acts as an angiogenic mediator in the regeneration of the endometrium after menses and as a vasodilator to promote blastocyst attachment during the implantation process.-Ahmed, A., Dearn, S., Shams, M., Li, X. F., Sangha, R. K., Rola-Pleszczynski, M., Jiang, J. Localization, quantification, and activation of platelet-activating factor receptor in human endometriun during the menstrual cycle: PAF stimulates NO, VEGF, and FAK(pp125).	Univ Birmingham, Womens Hosp, Dept Obstet & Gynaecol, Birmingham B15 2TG, W Midlands, England	Birmingham Women's Hospital; University of Birmingham	Ahmed, A (corresponding author), Univ Birmingham, Womens Hosp, Dept Obstet & Gynaecol, Birmingham B15 2TG, W Midlands, England.	A.S.Ahmed@bham.ac.uk	Ahmed, Asif/ABE-9544-2020; Ahmed, Asif/A-7268-2010	Ahmed, Asif/0000-0002-8755-8546; Goswami, Kaushal/0000-0002-7052-4358				AHMED A, 1995, J CLIN INVEST, V96, P848, DOI 10.1172/JCI118131; AHMED A, 1994, J REPROD FERTIL, V101, P459; Ahmed A, 1997, LAB INVEST, V76, P779; AHMED A, 1992, J CELL PHYSIOL, V152, P207, DOI 10.1002/jcp.1041520126; AHMED A, 1992, BIOL REPROD, V47, P59, DOI 10.1095/biolreprod47.1.59; AHMED A, 1997, ADV EXP MED BIOL, V416, P277; AHMED A, 1995, CELL SIGNAL, V7, P1; ALECOZAY AA, 1991, J REPROD FERTIL, V91, P301; BUSSOLINO F, 1995, J CLIN INVEST, V96, P940, DOI 10.1172/JCI118142; BUSSOLINO F, 1987, J IMMUNOL, V139, P2439; CAMUSSI G, 1991, INT ARCH ALLER A IMM, V96, P84, DOI 10.1159/000235539; CAMUSSI G, 1995, J IMMUNOL, V154, P6492; CHARNOCKJONES DS, 1993, BIOL REPROD, V48, P1120, DOI 10.1095/biolreprod48.5.1120; CHAUDHURI G, 1992, STEROID HORMONES AND UTERINE BLEEDING, P241; DEARN S, 1998, IN PRESS LAB INVEST; FOX H, 1983, ATLAS GYNAECOLOGICAL, P61; GUYTON AC, 1981, TXB MED PHYSL, P1005; HEUER HO, 1990, J PHARMACOL EXP THER, V255, P962; JUNCOS LA, 1993, J CLIN INVEST, V91, P1374, DOI 10.1172/JCI116339; KAMATA K, 1989, BRIT J PHARMACOL, V98, P360; KUDOLO GB, 1991, CELL TISSUE RES, V265, P231, DOI 10.1007/BF00398071; LI XF, 1994, GROWTH FACTORS, V11, P277, DOI 10.3109/08977199409011000; LOWENSTEIN CJ, 1994, ANN INTERN MED, V120, P227, DOI 10.7326/0003-4819-120-3-199402010-00009; MCRAE AC, 1988, J REPROD FERTIL, V82, P617, DOI 10.1530/jrf.0.0820617; MONTRUCCHIO G, 1994, J EXP MED, V180, P377, DOI 10.1084/jem.180.1.377; MULLER E, 1993, P NATL ACAD SCI USA, V90, P5818, DOI 10.1073/pnas.90.12.5818; MUTOH H, 1993, FEBS LETT, V322, P129, DOI 10.1016/0014-5793(93)81552-B; MUTOH H, 1994, BIOCHEM BIOPH RES CO, V205, P1130, DOI 10.1006/bbrc.1994.2783; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; Sangha RK, 1997, LAB INVEST, V77, P389; Sato S, 1996, ADV EXP MED BIOL, V416, P95; SEYFRIED CE, 1992, GENOMICS, V13, P832, DOI 10.1016/0888-7543(92)90162-L; Shams M, 1996, MOL HUM REPROD, V2, P35, DOI 10.1093/molehr/2.1.35; SHAMS M, 1994, GROWTH FACTORS, V11, P105, DOI 10.3109/08977199409001052; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SMITH SK, 1988, J REPROD FERTIL, V82, P271; SPINKS NR, 1990, J REPROD FERTIL, V88, P241, DOI 10.1530/jrf.0.0880241; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335	38	39	39	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	1998	12	10					831	843		10.1096/fasebj.12.10.831	http://dx.doi.org/10.1096/fasebj.12.10.831			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZY035	9657523				2022-12-25	WOS:000074580100008
J	Chow, SE; Lee, RS; Shih, SH; Chen, JK				Chow, SE; Lee, RS; Shih, SH; Chen, JK			Oxidized LDL promotes vascular endothelial cell pinocytosis via a prooxidation mechanism	FASEB JOURNAL			English	Article						membrane ruffling; EC; antioxidant; ROI; pinocytotic activity; low density lipoprotein	LOW-DENSITY-LIPOPROTEIN; FLUID-PHASE PINOCYTOSIS; SMOOTH-MUSCLE CELLS; ATHEROGENIC LEVELS; HYDROGEN-PEROXIDE; GROWTH-FACTOR; ATHEROSCLEROSIS; EXPRESSION; INCREASE; TRANSCRIPTION	Human low density lipoprotein (LDL) is prepared in the presence of antioxidants and is oxidized to different levels (measured by thiobarbituric acid reactive substance) with copper ion. The effects of unoxidized LDL and oxidized LDL (ox-LDL) on stress fiber formation, cell. membrane ruffling, and pinocytosis (measured by [C-14]sucrose uptake) in cultured human umbilical cord vein endothelial cells (EC) are compared. We show that at a concentration range of 100 to 200 mu g cholesterol/ml, both unoxidized LDL and ox-LDL promote EC elongation and stress fiber formation, but the effect by the latter is more prominent when compared at the same dose range. In addition, ox-LDL also induces EC membrane ruffling and promotes pinocytosis, These effects are positively correlated with the extent of LDL oxidation and depend on the dose of ox-LDL, Ox-LDL-promoted membrane ruffling and pinocytosis are effectively blocked by brief preexposure of the cells to antioxidants, In contrast, stress fiber formation is not affected by antioxidant pretreatment. Although unoxidized LDL also promotes [C-14]sucrose uptake, it is less potent than ox-LDL and significantly higher concentrations are required to produce a detectable effect. Unlike ox-LDL, unoxidized LDL-enhanced pinocytosis is not accompanied by the appearance of membrane ruffling; therefore, they may act via different mechanisms. Elevated pinocytosis may increase transcytotic activity of the endothelium, leading to an increased influx of plasma components such as LDL into the subendothelial space.-Chow, S.-E., Lee, R.-S., Shih, S. H., Chen, J.-K. Oxidized LDL promotes vascular endothelial cell pinocytosis via a prooxidation mechanism.	Chang Gung Univ, Coll Med, Dept Physiol, Taoyuan 333, Taiwan; Natl Taiwan Normal Univ, Dept Biol, Taipei, Taiwan; Chang Gung Univ, Ctr Gen Studies, Taoyuan, Taiwan	Chang Gung University; National Taiwan Normal University; Chang Gung University	Chen, JK (corresponding author), Chang Gung Univ, Coll Med, Dept Physiol, Taoyuan 333, Taiwan.							BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BORSUM T, 1985, ATHEROSCLEROSIS, V58, P81, DOI 10.1016/0021-9150(85)90057-7; BOULANGER CM, 1992, CIRC RES, V70, P1191, DOI 10.1161/01.RES.70.6.1191; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BROWN MS, 1990, NATURE, V343, P508, DOI 10.1038/343508a0; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; CARLOS TM, 1990, IMMUNOL REV, V114, P5, DOI 10.1111/j.1600-065X.1990.tb00559.x; CHEN JK, 1986, J CELL PHYSIOL, V129, P207, DOI 10.1002/jcp.1041290212; CHIN JH, 1992, J CLIN INVEST, V89, P10, DOI 10.1172/JCI115549; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; DAVIES PF, 1980, J CELL PHYSIOL, V102, P119, DOI 10.1002/jcp.1041020204; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Holland JA, 1996, J CELL PHYSIOL, V166, P144, DOI 10.1002/(SICI)1097-4652(199601)166:1<144::AID-JCP17>3.0.CO;2-F; HOLLAND JA, 1992, AM J PATHOL, V140, P551; HOLVOET P, 1994, FASEB J, V8, P1279, DOI 10.1096/fasebj.8.15.8001740; Ishii H, 1996, J BIOL CHEM, V271, P8458, DOI 10.1074/jbc.271.14.8458; KHAN BV, 1995, J CLIN INVEST, V95, P1262, DOI 10.1172/JCI117776; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V208, P985, DOI 10.1006/bbrc.1995.1431; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LIAO JK, 1995, J BIOL CHEM, V270, P319, DOI 10.1074/jbc.270.1.319; LINDNER V, 1991, CIRC RES, V68, P106, DOI 10.1161/01.RES.68.1.106; LOWRY OH, 1951, J BIOL CHEM, V193, P265; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Ohlsson BG, 1996, J CLIN INVEST, V98, P78, DOI 10.1172/JCI118780; PARTHASARATHY S, 1989, P NATL ACAD SCI USA, V86, P1046, DOI 10.1073/pnas.86.3.1046; PHILLIPS PG, 1988, J APPL PHYSIOL, V64, P1196, DOI 10.1152/jappl.1988.64.3.1196; RAJAVASHISTH TB, 1990, NATURE, V344, P254, DOI 10.1038/344254a0; Rangaswamy S, 1997, CIRC RES, V80, P37, DOI 10.1161/01.RES.80.1.37; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Salonen JT, 1997, CIRCULATION, V95, P840; Sawamura T, 1997, NATURE, V386, P73, DOI 10.1038/386073a0; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SMITH C, 1992, BIOCHEM J, V286, P901, DOI 10.1042/bj2860901; Steinberg D, 1997, CIRCULATION, V95, P1062; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Stiko A, 1996, ARTERIOSCL THROM VAS, V16, P194, DOI 10.1161/01.ATV.16.2.194; THAKKAR K, 1993, J MED CHEM, V36, P2950, DOI 10.1021/jm00072a015; THORIN E, 1994, ARTERIOSCLER THROMB, V14, P453, DOI 10.1161/01.ATV.14.3.453; WITZTUM JL, 1994, LANCET, V344, P793, DOI 10.1016/S0140-6736(94)92346-9; Zhu WM, 1996, ARTERIOSCL THROM VAS, V16, P1104, DOI 10.1161/01.ATV.16.9.1104	41	21	22	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	1998	12	10					823	830		10.1096/fasebj.12.10.823	http://dx.doi.org/10.1096/fasebj.12.10.823			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZY035	9657522				2022-12-25	WOS:000074580100007
J	Li, YP; Schwartz, RJ; Waddell, ID; Holloway, BR; Reid, MB				Li, YP; Schwartz, RJ; Waddell, ID; Holloway, BR; Reid, MB			Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-kappa B activation in response to tumor necrosis factor alpha	FASEB JOURNAL			English	Article						cachexia; myosin; cytokines; inflammatory disease; tumor necrosis factor; ubiquitin; free radicals	UBIQUITIN-PROTEASOME PATHWAY; OXIDATIVE STRESS; GENE-EXPRESSION; TNF-ALPHA; PROSTAGLANDIN-E2 PRODUCTION; TRANSCRIPTION FACTOR; CANCER CACHEXIA; NITRIC-OXIDE; BEARING RATS; CACHECTIN	Skeletal muscle atrophy and weakness are thought to be stimulated by tumor necrosis factor a (TNF-alpha) in a variety of chronic diseases. However, little is known about the direct effects of TNF-alpha on differentiated skeletal muscle cells or the signaling mechanisms involved, We have tested the effects of TNF-alpha on the mouse-derived C2C12 muscle cell line and on primary cultures from rat skeletal muscle. TNF-alpha treatment of differentiated myotubes stimulated time- and concentration-dependent reductions in total protein content and loss of adult myosin heavy chain (MHCf) content; these changes were evident at low TNF-alpha concentrations (1-3 ng/ml) that did not alter muscle DNA content and were not associated with a decrease in MHCf synthesis. TNF-alpha activated binding of nuclear factor KB (NF-kappa B) to its targeted DNA sequence and stimulated degradation of I-kappa B alpha, an NF-kappa B inhibitory protein. TNF-alpha stimulated total ubiquitin conjugation whereas a 26S proteasome inhibitor (MG132 10-40 mu M) blocked TNF-alpha activation of NF-kappa B, Catalase 1 kU/ml inhibited NF-kappa B activation by TNF-alpha; exogenous hydrogen peroxide 200 mu M activated NF-kappa B and stimulated I-kappa B alpha degradation. These data demonstrate that TNF-alpha directly induces skeletal muscle protein loss, that NF-kappa B is rapidly activated by TNF-alpha in differentiated skeletal muscle cells, and that TNF-alpha/NF-kappa B signaling in skeletal muscle is regulated by endogenous reactive oxygen species.-Li, Y.-P., Schwartz, R. J., Waddell, I. D., Holloway, B. R., Reid, M. B. Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-kappa B activation in response to tumor necrosis factor alpha.	Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Zeneca Pharmaceut, Macclesfield SK10 4TG, Cheshire, England	Baylor College of Medicine; Baylor College of Medicine	Reid, MB (corresponding author), Baylor Coll Med, Dept Med, Suite 520B,1 Baylor Plaza, Houston, TX 77030 USA.	reid@bcm.tmc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045721] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45721] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAD S, 1994, LIFE SCI, V55, P1383, DOI 10.1016/0024-3205(94)00752-7; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Beckman J.S., 1986, PHYSL OXYGEN RADICAL, P39; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BEUTLER B, 1985, J EXP MED, V161, P984, DOI 10.1084/jem.161.5.984; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; BRENNAN P, 1995, BBA-GENE STRUCT EXPR, V1260, P167, DOI 10.1016/0167-4781(94)00186-7; Buck M, 1996, EMBO J, V15, P1753, DOI 10.1002/j.1460-2075.1996.tb00524.x; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHENG J, 1992, GENE DEV, V6, P1444, DOI 10.1101/gad.6.8.1444; DAYER JM, 1985, J EXP MED, V162, P2163, DOI 10.1084/jem.162.6.2163; DEMPLE B, 1991, CELL, V67, P837, DOI 10.1016/0092-8674(91)90355-3; ESPAT NJ, 1994, SURG ONCOL, V3, P255, DOI 10.1016/0960-7404(94)90027-2; Flohe L, 1997, FREE RADICAL BIO MED, V22, P1115, DOI 10.1016/S0891-5849(96)00501-1; GARCIAMARTINEZ C, 1993, FEBS LETT, V323, P211, DOI 10.1016/0014-5793(93)81341-V; GARCIAMARTINEZ C, 1993, MOL CELL BIOCHEM, V125, P11, DOI 10.1007/BF00926829; GarciaMartinez C, 1995, BIOCHEM BIOPH RES CO, V217, P839, DOI 10.1006/bbrc.1995.2848; GARCIAMARTINEZ C, 1994, BIOCHEM BIOPH RES CO, V201, P682, DOI 10.1006/bbrc.1994.1754; GELIN J, 1991, CANCER RES, V51, P415; GOLDBERG AL, 1988, J CLIN INVEST, V81, P1378, DOI 10.1172/JCI113466; GOODMAN MN, 1991, AM J PHYSIOL, V260, pE727, DOI 10.1152/ajpendo.1991.260.5.E727; HENNET T, 1993, BIOCHEM J, V289, P587, DOI 10.1042/bj2890587; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; ISRAEL N, 1992, J IMMUNOL, V149, P3386; KretzRemy C, 1996, J CELL BIOL, V133, P1083, DOI 10.1083/jcb.133.5.1083; LAWSON DH, 1982, ANNU REV NUTR, V2, P277, DOI 10.1146/annurev.nu.02.070182.001425; LI YP, 1995, MOL BRAIN RES, V30, P106, DOI 10.1016/0169-328X(94)00285-M; Liotta AL, 1989, INFLUENCE TUMOR DEV, P176; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Llovera M, 1996, BIOCHEM BIOPH RES CO, V221, P653, DOI 10.1006/bbrc.1996.0651; Llovera M, 1997, BIOCHEM BIOPH RES CO, V230, P238, DOI 10.1006/bbrc.1996.5827; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Makropoulos V, 1996, ARCH TOXICOL, V70, P277, DOI 10.1007/s002040050274; MEALY K, 1990, ARCH SURG-CHICAGO, V125, P42; MEYER M, 1994, MCBU, P217; MICHIE HR, 1989, ANN SURG, V209, P19, DOI 10.1097/00000658-198901000-00002; Mitch WE, 1996, NEW ENGL J MED, V335, P1897, DOI 10.1056/NEJM199612193352507; NAKASHIMA J, 1995, CANCER RES, V55, P4881; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Reid MB, 1996, NEWS PHYSIOL SCI, V11, P114, DOI 10.1152/physiologyonline.1996.11.3.114; REID MB, 1993, J APPL PHYSIOL, V75, P1081, DOI 10.1152/jappl.1993.75.3.1081; REID MB, 1992, J APPL PHYSIOL, V73, P1797, DOI 10.1152/jappl.1992.73.5.1797; REID MB, 1992, J APPL PHYSIOL, V73, P1805, DOI 10.1152/jappl.1992.73.5.1805; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROFE AM, 1987, BIOCHEM J, V247, P789, DOI 10.1042/bj2470789; SAPPEY C, 1994, AIDS RES HUM RETROV, V10, P1451, DOI 10.1089/aid.1994.10.1451; SCHMIDT KN, 1995, J BIOL CHEM, V270, P27136, DOI 10.1074/jbc.270.45.27136; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHUTZE S, 1992, SEMIN ONCOL, V19, P16; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Sen CK, 1997, BIOCHEM BIOPH RES CO, V237, P645, DOI 10.1006/bbrc.1997.7206; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHINDOH C, 1995, AM J RESP CRIT CARE, V152, P1690, DOI 10.1164/ajrccm.152.5.7582314; SHINDOH C, 1992, AM REV RESPIR DIS, V145, P1350, DOI 10.1164/ajrccm/145.6.1350; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SOCHER SH, 1988, J EXP MED, V167, P1957, DOI 10.1084/jem.167.6.1957; SUPINSKI G, 1993, AM REV RESPIR DIS, V148, P1318, DOI 10.1164/ajrccm/148.5.1318; Tawa NE, 1997, J CLIN INVEST, V100, P197, DOI 10.1172/JCI119513; TESSITORE L, 1993, BRIT J CANCER, V67, P15, DOI 10.1038/bjc.1993.4; VREUGDENHIL G, 1992, EUR J CLIN INVEST, V22, P488, DOI 10.1111/j.1365-2362.1992.tb01495.x; Zar JH, 1974, BIOSTATISTICAL ANAL	64	399	412	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1998	12	10					871	880		10.1096/fasebj.12.10.871	http://dx.doi.org/10.1096/fasebj.12.10.871			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZY035	9657527				2022-12-25	WOS:000074580100012
J	Li, Q; Jedlicka, A; Ahuja, N; Gibbons, MC; Baylin, SB; Burger, PC; Issa, JPJ				Li, Q; Jedlicka, A; Ahuja, N; Gibbons, MC; Baylin, SB; Burger, PC; Issa, JPJ			Concordant methylation of the ER and N33 genes in glioblastoma multiforme	ONCOGENE			English	Article						DNA methylation; glioblastoma multiforme; aging; estrogen receptor; N33	TUMOR-SUPPRESSOR GENE; RECEPTOR CPG ISLAND; ESTROGEN-RECEPTOR; DNA METHYLATION; EPITHELIAL-CELLS; HYPERMETHYLATION; EXPRESSION; INACTIVATION; GLIOMAS; CANCER	Methylation of promoter-associated CpG islands appears to be a potential way by which tumor suppressor genes are inactivated in cancer. Using Southern blot analysis, we have studied the methylation of several genes in glioblastoma multiforme (GBM), trying to determine their contribution to tumorigenesis. Genes studied included the estrogen receptor (ER), N33, the candidate tumor-suppressors P15, P16 and HIC1 and a control gene, c-abl, Hypermethylation of N33, ER, HIC1, P16, P15 and c-abl were found in 61%, 59%, 60%, 5%, 2% and 0% of GEM respectively. HIC1 methylation was detected in normal brain as well, but appeared to be more extensive in tumors. ER and N33 methylation were significantly more frequent in tumors from individuals over the age of 40 (70% and 88% vs 36% and 14%). In addition, there was a strong association between EX and N33 methylation, which were concordant in 81% of the cases (P< 0.01). ER and N33 methylation in GEM may therefore appear as a result of shared etiologic factors, which may relate in part to aging cell populations in the brain.	Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Anesthesia & Crit Care, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Issa, JPJ (corresponding author), Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21231 USA.		Ahuja, Nita/H-1064-2011	Issa, Jean-Pierre/0000-0003-2258-5030	NCI NIH HHS [P30CA06973, 5UO1CA64928, 5RO1CA43318] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006973, U01CA064928, R01CA043318] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baylin SB, 1998, ADV CANCER RES, V72, P141; Bondy ML, 1996, CANCER RES, V56, P1484; Costello JF, 1996, CANCER RES, V56, P2405; COUNTS JL, 1995, CELL, V83, P13, DOI 10.1016/0092-8674(95)90228-7; CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1; EDEN S, 1994, CURR OPIN GENET DEV, V4, P255, DOI 10.1016/S0959-437X(05)80052-8; Fueyo J, 1996, ONCOGENE, V13, P1615; Furnari FB, 1995, CANCER SURV, V25, P233; GARCIA M, 1992, P NATL ACAD SCI USA, V89, P11538, DOI 10.1073/pnas.89.23.11538; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; Herman JG, 1996, CANCER RES, V56, P722; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Issa JPJ, 1997, LEUKEMIA, V11, pS7; Issa JPJ, 1996, CANCER RES, V56, P973; Issa JPJ, 1997, CANCER RES, V57, P1678; Issa JPJ, 1996, P NATL ACAD SCI USA, V93, P11757, DOI 10.1073/pnas.93.21.11757; Issa JPJ, 1996, CANCER RES, V56, P3655; JIANG SY, 1992, JNCI-J NATL CANCER I, V84, P580, DOI 10.1093/jnci/84.8.580; Jones PA, 1996, CANCER RES, V56, P2463; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; Lapidus RG, 1996, CLIN CANCER RES, V2, P805; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; MA ZQ, 1993, P NATL ACAD SCI USA, V90, P3740, DOI 10.1073/pnas.90.8.3740; MacGrogan D, 1996, GENOMICS, V35, P55, DOI 10.1006/geno.1996.0322; MAKOS M, 1993, CANCER RES, V53, P2715; MAKOS M, 1993, CANCER RES, V53, P2719; MAMINTA MLD, 1991, MOL CELL ENDOCRINOL, V78, P61, DOI 10.1016/0303-7207(91)90186-V; Morton RA, 1996, J UROLOGY, V156, P512, DOI 10.1016/S0022-5347(01)65916-0; Ramirez VD, 1996, FRONT NEUROENDOCRIN, V17, P402, DOI 10.1006/frne.1996.0011; SAKAI T, 1991, AM J HUM GENET, V48, P880; SANTAGATI S, 1994, J NEUROCHEM, V63, P2058; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; VERTINO PM, 1993, CANCER RES, V53, P1684; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; ZAJCHOWSKI DA, 1993, CANCER RES, V53, P5004	37	62	65	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 18	1998	16	24					3197	3202		10.1038/sj.onc.1201831	http://dx.doi.org/10.1038/sj.onc.1201831			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671399				2022-12-25	WOS:000074261300013
